text,text_modified,label,group_label,group_label_id,original_text
"At 4 hours, losartan blocked 43% of the << Ang II >>-induced systolic blood pressure increase; [[ valsartan ]], 51%; and irbesartan, 88% (P<0.01 between drugs).","At 4 hours, losartan blocked 43% of the [ENTITY_A]-induced systolic blood pressure increase; [ENTITY_B], 51%; and irbesartan, 88% (P<0.01 between drugs).",INDIRECT-DOWNREGULATOR,CPR:4,1,"At 4 hours, losartan blocked 43% of the Ang II-induced systolic blood pressure increase; valsartan, 51%; and irbesartan, 88% (P<0.01 between drugs)."
This study thus demonstrates that the first administration of the recommended starting dose of << irbesartan >> induces a greater and longer lasting [[ Ang II receptor ]] blockade than that of valsartan and losartan in normotensive subjects.,This study thus demonstrates that the first administration of the recommended starting dose of [ENTITY_A] induces a greater and longer lasting [ENTITY_B] blockade than that of valsartan and losartan in normotensive subjects.,INHIBITOR,CPR:4,1,This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting Ang II receptor blockade than that of valsartan and losartan in normotensive subjects.
"In humans, prolonged administration of the << beta 2-adrenoceptor >> agonist [[ terbutaline ]] leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen.","In humans, prolonged administration of the [ENTITY_A] agonist [ENTITY_B] leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen.",AGONIST,CPR:5,2,"In humans, prolonged administration of the beta 2-adrenoceptor agonist terbutaline leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen."
"In a double-blind, placebo-controlled, randomized design, nine healthy male volunteers received disodium cromoglycate (4 x 200 mg/day, p.o.) or placebo for 3 weeks with terbutaline (3 x 5 mg/day, p.o.) administered concomitantly during the last 2 weeks. beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective << beta-adrenoceptor >> agonist [[ isoprenaline ]]; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia.","In a double-blind, placebo-controlled, randomized design, nine healthy male volunteers received disodium cromoglycate (4 x 200 mg/day, p.o.) or placebo for 3 weeks with terbutaline (3 x 5 mg/day, p.o.) administered concomitantly during the last 2 weeks. beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective [ENTITY_A] agonist [ENTITY_B]; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia.",AGONIST,CPR:5,2,"In a double-blind, placebo-controlled, randomized design, nine healthy male volunteers received disodium cromoglycate (4 x 200 mg/day, p.o.) or placebo for 3 weeks with terbutaline (3 x 5 mg/day, p.o.) administered concomitantly during the last 2 weeks. beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective beta-adrenoceptor agonist isoprenaline; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia."
"OBJECTIVES: This study examined the effect of a small-molecule, direct << thrombin >> inhibitor, [[ argatroban ]], on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).","OBJECTIVES: This study examined the effect of a small-molecule, direct [ENTITY_A] inhibitor, [ENTITY_B], on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).",INHIBITOR,CPR:4,1,"OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI)."
In vitro and in vivo studies have shown that << argatroban >> has advantages over heparin for the inhibition of clot-bound [[ thrombin ]] and for the enhancement of thrombolysis with TPA.,In vitro and in vivo studies have shown that [ENTITY_A] has advantages over heparin for the inhibition of clot-bound [ENTITY_B] and for the enhancement of thrombolysis with TPA.,INHIBITOR,CPR:4,1,In vitro and in vivo studies have shown that argatroban has advantages over heparin for the inhibition of clot-bound thrombin and for the enhancement of thrombolysis with TPA.
The functional inhibitory characteristics of the << angiotensin II type 1 receptor >> blockers (ARB) candesartan; [[ irbesartan ]]; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.,The functional inhibitory characteristics of the [ENTITY_A] blockers (ARB) candesartan; [ENTITY_B]; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.,INHIBITOR,CPR:4,1,The functional inhibitory characteristics of the angiotensin II type 1 receptor blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.
"In both vascular preparations, << candesartan >> caused a marked decrease in the maximal contractile response of the [[ angiotensin II ]] (Ang II) concentration-response curve.","In both vascular preparations, [ENTITY_A] caused a marked decrease in the maximal contractile response of the [ENTITY_B] (Ang II) concentration-response curve.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the angiotensin II (Ang II) concentration-response curve."
"In addition, when << candesartan >> was given to conscious rats, the inhibitory effect on [[ Ang II ]]-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of candesartan at 24 hours.","In addition, when [ENTITY_A] was given to conscious rats, the inhibitory effect on [ENTITY_B]-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of candesartan at 24 hours.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, when candesartan was given to conscious rats, the inhibitory effect on Ang II-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of candesartan at 24 hours."
"At clinically relevant concentrations, << candesartan >> is an insurmountable and long-lasting antagonist of the vascular contractile responses to [[ Ang II ]].","At clinically relevant concentrations, [ENTITY_A] is an insurmountable and long-lasting antagonist of the vascular contractile responses to [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"At clinically relevant concentrations, candesartan is an insurmountable and long-lasting antagonist of the vascular contractile responses to Ang II."
Dose-dependent inhibition of platelet << cyclooxygenase-1 >> and monocyte cyclooxygenase-2 by [[ meloxicam ]] in healthy subjects.,Dose-dependent inhibition of platelet [ENTITY_A] and monocyte cyclooxygenase-2 by [ENTITY_B] in healthy subjects.,INHIBITOR,CPR:4,1,Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
Concentration-response curves for the inhibition of monocyte << COX-2 >> and platelet COX-1 were obtained in vitro after the incubation of [[ meloxicam ]] with whole blood samples.,Concentration-response curves for the inhibition of monocyte [ENTITY_A] and platelet COX-1 were obtained in vitro after the incubation of [ENTITY_B] with whole blood samples.,INHIBITOR,CPR:4,1,Concentration-response curves for the inhibition of monocyte COX-2 and platelet COX-1 were obtained in vitro after the incubation of meloxicam with whole blood samples.
"Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram/ml) for 24 h at 37 degrees C, and << prostaglandin E2 >> was measured in plasma as an index of monocyte [[ COX-2 ]] activity.","Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram/ml) for 24 h at 37 degrees C, and [ENTITY_A] was measured in plasma as an index of monocyte [ENTITY_B] activity.",PRODUCT-OF,CPR:9,4,"Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram/ml) for 24 h at 37 degrees C, and prostaglandin E2 was measured in plasma as an index of monocyte COX-2 activity."
The production of << thromboxane B2 >> in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet [[ COX-1 ]] activity.,The production of [ENTITY_A] in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet [ENTITY_B] activity.,PRODUCT-OF,CPR:9,4,The production of thromboxane B2 in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet COX-1 activity.
"In contrast, the administration of 7.5 and 15 mg of << meloxicam >> caused dose-dependent reductions in monocyte [[ COX-2 ]] activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively.","In contrast, the administration of 7.5 and 15 mg of [ENTITY_A] caused dose-dependent reductions in monocyte [ENTITY_B] activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively.",INHIBITOR,CPR:4,1,"In contrast, the administration of 7.5 and 15 mg of meloxicam caused dose-dependent reductions in monocyte COX-2 activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively."
"Although the IC50 value of << meloxicam >> for inhibition of [[ COX-1 ]] was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.","Although the IC50 value of [ENTITY_A] for inhibition of [ENTITY_B] was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.",INHIBITOR,CPR:4,1,"Although the IC50 value of meloxicam for inhibition of COX-1 was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels."
"In distinction, the preferential << beta 1-AR >> antagonist, [[ betaxolol ]], and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT.","In distinction, the preferential [ENTITY_A] antagonist, [ENTITY_B], and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT.",ANTAGONIST,CPR:6,3,"In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT."
"The selective << 5-HT1A >> receptor antagonist, [[ WAY100,635 ]], slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.","The selective [ENTITY_A] receptor antagonist, [ENTITY_B], slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.",ANTAGONIST,CPR:6,3,"The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective."
UNLABELLED: << Entacapone >> is a potent and specific peripheral [[ catechol-O-methyltransferase ]] (COMT) inhibitor.,UNLABELLED: [ENTITY_A] is a potent and specific peripheral [ENTITY_B] (COMT) inhibitor.,INHIBITOR,CPR:4,1,UNLABELLED: Entacapone is a potent and specific peripheral catechol-O-methyltransferase (COMT) inhibitor.
<< 5-hydroxytryptamine >> evokes [[ endothelial nitric oxide synthase ]] activation in bovine aortic endothelial cell cultures.,[ENTITY_A] evokes [ENTITY_B] activation in bovine aortic endothelial cell cultures.,ACTIVATOR,CPR:3,0,5-hydroxytryptamine evokes endothelial nitric oxide synthase activation in bovine aortic endothelial cell cultures.
Activation of << endothelial nitric oxide synthase >> (eNOS) results in the production of [[ nitric oxide ]] (NO) that mediates the vasorelaxing properties of endothelial cells.,Activation of [ENTITY_A] (eNOS) results in the production of [ENTITY_B] (NO) that mediates the vasorelaxing properties of endothelial cells.,PRODUCT-OF,CPR:9,4,Activation of endothelial nitric oxide synthase (eNOS) results in the production of nitric oxide (NO) that mediates the vasorelaxing properties of endothelial cells.
"Here, we tested the hypothesis that 5-HT receptors mediate << eNOS >> activation by measuring agonist-stimulated [[ [3H]L-citrulline ]] ([3H]L-Cit) formation in BAEC cultures.","Here, we tested the hypothesis that 5-HT receptors mediate [ENTITY_A] activation by measuring agonist-stimulated [ENTITY_B] ([3H]L-Cit) formation in BAEC cultures.",PRODUCT-OF,CPR:9,4,"Here, we tested the hypothesis that 5-HT receptors mediate eNOS activation by measuring agonist-stimulated [3H]L-citrulline ([3H]L-Cit) formation in BAEC cultures."
"We found that << 5-HT >> stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating [[ eNOS ]] activation.","We found that [ENTITY_A] stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating [ENTITY_B] activation.",ACTIVATOR,CPR:3,0,"We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating eNOS activation."
"We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to << [3H]L-Cit >>, indicating [[ eNOS ]] activation.","We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [ENTITY_A], indicating [ENTITY_B] activation.",PRODUCT-OF,CPR:9,4,"We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating eNOS activation."
"The high affinity << 5-HT1B >> receptor agonist, [[ 5-nonyloxytryptamine ]] (5-NOT)-stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent.","The high affinity [ENTITY_A] receptor agonist, [ENTITY_B] (5-NOT)-stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent.",AGONIST,CPR:5,2,"The high affinity 5-HT1B receptor agonist, 5-nonyloxytryptamine (5-NOT)-stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent."
"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the << eNOS >> selective antagonists (0.01-10 microM): [[ L-Nomega -monomethyl-L-arginine ]] (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).","These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the [ENTITY_A] selective antagonists (0.01-10 microM): [ENTITY_B] (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).",ANTAGONIST,CPR:6,3,"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)."
"These findings lend evidence of a 5-HT1B receptor/eNOS pathway, accounting in part for the activation of << eNOS >> by [[ 5-HT ]].","These findings lend evidence of a 5-HT1B receptor/eNOS pathway, accounting in part for the activation of [ENTITY_A] by [ENTITY_B].",ACTIVATOR,CPR:3,0,"These findings lend evidence of a 5-HT1B receptor/eNOS pathway, accounting in part for the activation of eNOS by 5-HT."
<< Caffeine >> inhibits the checkpoint [[ kinase ]] ATM.,[ENTITY_A] inhibits the checkpoint [ENTITY_B] ATM.,INHIBITOR,CPR:4,1,Caffeine inhibits the checkpoint kinase ATM.
We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that << ATM >> kinase activity is directly inhibited by [[ caffeine ]] in vitro.,We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that [ENTITY_A] kinase activity is directly inhibited by [ENTITY_B] in vitro.,INHIBITOR,CPR:4,1,We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.
Inhibition of << ATM >> provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of [[ caffeine ]]-treated cells [6] [7] [8].,Inhibition of [ENTITY_A] provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of [ENTITY_B]-treated cells [6] [7] [8].,INHIBITOR,CPR:4,1,Inhibition of ATM provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of caffeine-treated cells [6] [7] [8].
"The turnover of << SERT >> was determined from the rate of recovery of binding after administration of [[ RTI-76 ]], an irreversible inhibitor of ligand binding.","The turnover of [ENTITY_A] was determined from the rate of recovery of binding after administration of [ENTITY_B], an irreversible inhibitor of ligand binding.",INHIBITOR,CPR:4,1,"The turnover of SERT was determined from the rate of recovery of binding after administration of RTI-76, an irreversible inhibitor of ligand binding."
"In preliminary studies, in vitro incubation of rat cerebral cortex with << RTI-76 >> produced a wash and temperature resistant inhibition of [[ SERT ]] binding densities (Bmax).","In preliminary studies, in vitro incubation of rat cerebral cortex with [ENTITY_A] produced a wash and temperature resistant inhibition of [ENTITY_B] binding densities (Bmax).",INHIBITOR,CPR:4,1,"In preliminary studies, in vitro incubation of rat cerebral cortex with RTI-76 produced a wash and temperature resistant inhibition of SERT binding densities (Bmax)."
Citalopram protected against the << RTI-76 >>-induced inhibition of [[ SERT ]] binding.,Citalopram protected against the [ENTITY_A]-induced inhibition of [ENTITY_B] binding.,INHIBITOR,CPR:4,1,Citalopram protected against the RTI-76-induced inhibition of SERT binding.
The decrease and recovery of << [3H]-5-HT >> uptake correlated highly (r = 0.93) with the recovery of [[ SERT ]] binding.,The decrease and recovery of [ENTITY_A] uptake correlated highly (r = 0.93) with the recovery of [ENTITY_B] binding.,SUBSTRATE,CPR:9,4,The decrease and recovery of [3H]-5-HT uptake correlated highly (r = 0.93) with the recovery of SERT binding.
"<< Losartan >> was the first, but by no means remained the only, [[ AT1 ]] receptor antagonist.","[ENTITY_A] was the first, but by no means remained the only, [ENTITY_B] receptor antagonist.",ANTAGONIST,CPR:6,3,"Losartan was the first, but by no means remained the only, AT1 receptor antagonist."
"Among the current << AT1 >> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of [[ losartan ]]) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Among the current [ENTITY_A] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of [ENTITY_B]) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.",ANTAGONIST,CPR:6,3,"Among the current AT1 receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280."
"The mode of (functional) << AT1 >> receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, [[ saprisartan ]], zolasartan, irbesartan, valsartan, telmisartan, E3174).","The mode of (functional) [ENTITY_A] receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, [ENTITY_B], zolasartan, irbesartan, valsartan, telmisartan, E3174).",ANTAGONIST,CPR:6,3,"The mode of (functional) AT1 receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)."
<< Quinone oxidoreductases >> are flavoproteins that catalyze two-electron reduction and detoxification of [[ quinones ]].,[ENTITY_A] are flavoproteins that catalyze two-electron reduction and detoxification of [ENTITY_B].,SUBSTRATE,CPR:9,4,Quinone oxidoreductases are flavoproteins that catalyze two-electron reduction and detoxification of quinones.
"A role of cytosolic << NQO1 >> in protection of cells from oxidative stress, cytotoxicity, and mutagenicity of [[ quinones ]] was established.","A role of cytosolic [ENTITY_A] in protection of cells from oxidative stress, cytotoxicity, and mutagenicity of [ENTITY_B] was established.",SUBSTRATE,CPR:9,4,"A role of cytosolic NQO1 in protection of cells from oxidative stress, cytotoxicity, and mutagenicity of quinones was established."
"The << mNQO >> activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of [[ 2,6-dichlorophenolindophenol ]] and menadione.",The [ENTITY_A] activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of [ENTITY_B] and menadione.,SUBSTRATE,CPR:9,4,"The mNQO activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and menadione."
"The mNQO activity was insensitive to << dicoumarol >>, a potent inhibitor of cytosolic [[ NQO1 ]].","The mNQO activity was insensitive to [ENTITY_A], a potent inhibitor of cytosolic [ENTITY_B].",INHIBITOR,CPR:4,1,"The mNQO activity was insensitive to dicoumarol, a potent inhibitor of cytosolic NQO1."
The << mu-opioid receptor >>-selective agonist [[ lofentanil ]] potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM).,The [ENTITY_A]-selective agonist [ENTITY_B] potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM).,AGONIST,CPR:5,2,The mu-opioid receptor-selective agonist lofentanil potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM).
<< Lofentanil >> exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant [[ ORL1 ]] receptors (EC(50) 50 nM).,[ENTITY_A] exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant [ENTITY_B] receptors (EC(50) 50 nM).,AGONIST-ACTIVATOR,CPR:5,2,Lofentanil exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant ORL1 receptors (EC(50) 50 nM).
The related piperidines ohmefentanyl and << sufentanil >> and the nonselective opioid receptor agonist etorphine were less potent [[ nociceptin receptor ]] agonists.,The related piperidines ohmefentanyl and [ENTITY_A] and the nonselective opioid receptor agonist etorphine were less potent [ENTITY_B] agonists.,AGONIST,CPR:5,2,The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent nociceptin receptor agonists.
The kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist << naloxone benzoylhydrazone >> was a pure antagonist at both rat brain and human [[ ORL1 ]] receptors.,The kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist [ENTITY_A] was a pure antagonist at both rat brain and human [ENTITY_B] receptors.,ANTAGONIST,CPR:6,3,The kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist naloxone benzoylhydrazone was a pure antagonist at both rat brain and human ORL1 receptors.
"The nonselective << opioid receptor >> partial agonist [[ buprenorphine ]] and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.","The nonselective [ENTITY_A] partial agonist [ENTITY_B] and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.",AGONIST,CPR:5,2,"The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors."
"The nonselective opioid receptor partial agonist buprenorphine and the nonselective << opioid receptor >> antagonist [[ (-)-quadazocine ]] exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.","The nonselective opioid receptor partial agonist buprenorphine and the nonselective [ENTITY_A] antagonist [ENTITY_B] exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.",ANTAGONIST,CPR:6,3,"The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors."
"<< Thymidylate synthase >> and thymidine kinase are key enzymes involved in the de novo and salvage pathways for [[ pyrimidine nucleotide ]] synthesis, respectively.","[ENTITY_A] and thymidine kinase are key enzymes involved in the de novo and salvage pathways for [ENTITY_B] synthesis, respectively.",PRODUCT-OF,CPR:9,4,"Thymidylate synthase and thymidine kinase are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively."
"<< Thymidylate synthase >> is inhibited by [[ 5-fluorodeoxyuridine monophosphate ]], forming an inactive ternary complex with intracellular folate.","[ENTITY_A] is inhibited by [ENTITY_B], forming an inactive ternary complex with intracellular folate.",INHIBITOR,CPR:4,1,"Thymidylate synthase is inhibited by 5-fluorodeoxyuridine monophosphate, forming an inactive ternary complex with intracellular folate."
"Thirty-week administration of << UFT >> with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of [[ thymidylate synthase ]] inhibition and the decrease of thymidine kinase activity in the tumor cells.","Thirty-week administration of [ENTITY_A] with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of [ENTITY_B] inhibition and the decrease of thymidine kinase activity in the tumor cells.",INHIBITOR,CPR:4,1,"Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of thymidine kinase activity in the tumor cells."
"Ornithine decarboxylase (<< ODC >>) catalyses the first step in the synthesis of the polyamines putrescine, [[ spermidine ]] and spermine.","Ornithine decarboxylase ([ENTITY_A]) catalyses the first step in the synthesis of the polyamines putrescine, [ENTITY_B] and spermine.",PRODUCT-OF,CPR:9,4,"Ornithine decarboxylase (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and spermine."
In << alpha(2A)-adrenoceptor >> transfected cells the rank order of agonist potency was [[ A-54741 ]] (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).,In [ENTITY_A] transfected cells the rank order of agonist potency was [ENTITY_B] (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).,AGONIST,CPR:5,2,In alpha(2A)-adrenoceptor transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).
"<< Glucocorticoid receptors >> were activated by [[ dexamethasone ]] as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT.","[ENTITY_A] were activated by [ENTITY_B] as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT.",ACTIVATOR,CPR:3,0,"Glucocorticoid receptors were activated by dexamethasone as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT."
"The << glucocorticoid receptor >> antagonist [[ RU-486 ]] (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.","The [ENTITY_A] antagonist [ENTITY_B] (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.",ANTAGONIST,CPR:6,3,"The glucocorticoid receptor antagonist RU-486 (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor."
RESULTS: << Quetiapine >> was an effective antipsychotic and improved the extrapyramidal symptoms and [[ prolactin ]] level elevation noted at baseline.,RESULTS: [ENTITY_A] was an effective antipsychotic and improved the extrapyramidal symptoms and [ENTITY_B] level elevation noted at baseline.,INDIRECT-UPREGULATOR,CPR:3,0,RESULTS: Quetiapine was an effective antipsychotic and improved the extrapyramidal symptoms and prolactin level elevation noted at baseline.
"In a physiological K(+) gradient, << TWIK-2 >> is half inhibited by 0.1 mm [[ Ba(2+) ]], quinine, and quinidine.","In a physiological K(+) gradient, [ENTITY_A] is half inhibited by 0.1 mm [ENTITY_B], quinine, and quinidine.",INHIBITOR,CPR:4,1,"In a physiological K(+) gradient, TWIK-2 is half inhibited by 0.1 mm Ba(2+), quinine, and quinidine."
"Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of << eicosapentaenoic acid >> (EPA) blocked [[ Delta-5-desaturase ]] activity, the terminal enzymatic step in AA synthesis.","Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of [ENTITY_A] (EPA) blocked [ENTITY_B] activity, the terminal enzymatic step in AA synthesis.",INHIBITOR,CPR:4,1,"Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid (EPA) blocked Delta-5-desaturase activity, the terminal enzymatic step in AA synthesis."
"BACKGROUND: This study examines the effects of << nicorandil >>, a [[ K(+) channel ]] opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS).","BACKGROUND: This study examines the effects of [ENTITY_A], a [ENTITY_B] opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS).",ACTIVATOR,CPR:3,0,"BACKGROUND: This study examines the effects of nicorandil, a K(+) channel opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS)."
"Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, << d-sotalol >> (100 micromol/L) to block [[ I(Kr) ]] (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).","Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, [ENTITY_A] (100 micromol/L) to block [ENTITY_B] (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).",INHIBITOR,CPR:4,1,"Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block I(Kr) (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model)."
"<< Peroxisome proliferator-activated receptor alpha >> (PPARalpha) activators, [[ bezafibrate ]] and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.","[ENTITY_A] (PPARalpha) activators, [ENTITY_B] and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.",ACTIVATOR,CPR:3,0,"Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes."
"<< Uncoupling proteins >> (UCPs) are inner mitochondrial membrane transporters which act as pores for [[ H(+) ]] ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.","[ENTITY_A] (UCPs) are inner mitochondrial membrane transporters which act as pores for [ENTITY_B] ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.",SUBSTRATE,CPR:9,4,"Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis."
"Thus, << bezafibrate >> treatment resulted in an 8-fold induction in [[ UCP-3 ]] mRNA levels in preadipocytes compared with the 3.5-fold induction observed in adipocytes.","Thus, [ENTITY_A] treatment resulted in an 8-fold induction in [ENTITY_B] mRNA levels in preadipocytes compared with the 3.5-fold induction observed in adipocytes.",INDIRECT-UPREGULATOR,CPR:3,0,"Thus, bezafibrate treatment resulted in an 8-fold induction in UCP-3 mRNA levels in preadipocytes compared with the 3.5-fold induction observed in adipocytes."
"The induction in << UCP-3 >> expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after [[ bezafibrate ]] or Wy-14,643 treatment.","The induction in [ENTITY_A] expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after [ENTITY_B] or Wy-14,643 treatment.",INDIRECT-UPREGULATOR,CPR:3,0,"The induction in UCP-3 expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after bezafibrate or Wy-14,643 treatment."
"Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the << UCP-3 >> induction achieved after [[ bezafibrate ]] and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.","Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the [ENTITY_A] induction achieved after [ENTITY_B] and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.",INDIRECT-UPREGULATOR,CPR:3,0,"Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the UCP-3 induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides."
<< Schisandrin B >> protects against menadione-induced hepatotoxicity by enhancing [[ DT-diaphorase ]] activity.,[ENTITY_A] protects against menadione-induced hepatotoxicity by enhancing [ENTITY_B] activity.,ACTIVATOR,CPR:3,0,Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity.
"Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against << menadione >>-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma [[ alanine aminotransferase ]] activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.","Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against [ENTITY_A]-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma [ENTITY_B] activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.",INHIBITOR,CPR:4,1,"Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control."
Hepatocytes isolated from << Sch B >> pretreated (a daily dose of 1 mmol/kg for 3 days) rats showed a significant increase (25%) in [[ DTD ]] activity.,Hepatocytes isolated from [ENTITY_A] pretreated (a daily dose of 1 mmol/kg for 3 days) rats showed a significant increase (25%) in [ENTITY_B] activity.,ACTIVATOR,CPR:3,0,Hepatocytes isolated from Sch B pretreated (a daily dose of 1 mmol/kg for 3 days) rats showed a significant increase (25%) in DTD activity.
The ensemble of results suggests that the ability of << Sch B >> pretreatment to enhance hepatocellular [[ DTD ]] activity may at least in part be attributed to the protection against menadione hepatotoxicity.,The ensemble of results suggests that the ability of [ENTITY_A] pretreatment to enhance hepatocellular [ENTITY_B] activity may at least in part be attributed to the protection against menadione hepatotoxicity.,ACTIVATOR,CPR:3,0,The ensemble of results suggests that the ability of Sch B pretreatment to enhance hepatocellular DTD activity may at least in part be attributed to the protection against menadione hepatotoxicity.
"The group treated with << pyridostigmine >> alone showed decreased plasma [[ butyrylcholinesterase ]] (BChE) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.","The group treated with [ENTITY_A] alone showed decreased plasma [ENTITY_B] (BChE) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.",INHIBITOR,CPR:4,1,"The group treated with pyridostigmine alone showed decreased plasma butyrylcholinesterase (BChE) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination."
"However, << AChE >> activity in triceps muscle decreased significantly (78% of control) in the group treated with [[ pyridostigmine ]] plus exercise.","However, [ENTITY_A] activity in triceps muscle decreased significantly (78% of control) in the group treated with [ENTITY_B] plus exercise.",INHIBITOR,CPR:4,1,"However, AChE activity in triceps muscle decreased significantly (78% of control) in the group treated with pyridostigmine plus exercise."
"<< Creatine phosphokinase >> activity in plasma increased slightly (compared to control, [[ pyridostigmine ]] or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.","[ENTITY_A] activity in plasma increased slightly (compared to control, [ENTITY_B] or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.",ACTIVATOR,CPR:3,0,"Creatine phosphokinase activity in plasma increased slightly (compared to control, pyridostigmine or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination."
"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas << danazol >> (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on [[ MCP-1 ]] expression.","RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas [ENTITY_A] (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on [ENTITY_B] expression.",INHIBITOR,CPR:4,1,"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression."
"RESULT(S): << Buserelin acetate >>, a [[ GnRH ]] agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.","RESULT(S): [ENTITY_A], a [ENTITY_B] agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.",AGONIST,CPR:5,2,"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression."
"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (<< CB1093 >>) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce [[ NGF ]] synthesis in vivo.","The present studies were undertaken to compare two compounds, a vitamin D(3) analogue ([ENTITY_A]) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce [ENTITY_B] synthesis in vivo.",INDIRECT-UPREGULATOR,CPR:3,0,"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce NGF synthesis in vivo."
"The present studies were undertaken to compare two compounds, a << vitamin D(3) >> analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce [[ NGF ]] synthesis in vivo.","The present studies were undertaken to compare two compounds, a [ENTITY_A] analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce [ENTITY_B] synthesis in vivo.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce NGF synthesis in vivo."
"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and << clenbuterol >>, a long-acting [[ beta(2)-adrenoceptor ]] agonist, both of which induce NGF synthesis in vivo.","The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and [ENTITY_A], a long-acting [ENTITY_B] agonist, both of which induce NGF synthesis in vivo.",AGONIST,CPR:5,2,"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce NGF synthesis in vivo."
<< Clenbuterol >> caused significant increases in both [[ NGF ]] mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure.,[ENTITY_A] caused significant increases in both [ENTITY_B] mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure.,INDIRECT-UPREGULATOR,CPR:3,0,Clenbuterol caused significant increases in both NGF mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure.
Mobility shift assays on whole cell extracts showed that << clenbuterol >> increased AP1 binding in 3T3 cells prior to increasing [[ NGF ]] synthesis.,Mobility shift assays on whole cell extracts showed that [ENTITY_A] increased AP1 binding in 3T3 cells prior to increasing [ENTITY_B] synthesis.,INDIRECT-UPREGULATOR,CPR:3,0,Mobility shift assays on whole cell extracts showed that clenbuterol increased AP1 binding in 3T3 cells prior to increasing NGF synthesis.
"Clenbuterol was without effect on NGF mRNA levels in L929 cells, whereas << CB1093 >> caused significant increases in both [[ NGF ]] mRNA and protein levels in both 3T3 and L929 cells.","Clenbuterol was without effect on NGF mRNA levels in L929 cells, whereas [ENTITY_A] caused significant increases in both [ENTITY_B] mRNA and protein levels in both 3T3 and L929 cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Clenbuterol was without effect on NGF mRNA levels in L929 cells, whereas CB1093 caused significant increases in both NGF mRNA and protein levels in both 3T3 and L929 cells."
This study demonstrates that << CB1093 >> and clenbuterol stimulate [[ NGF ]] levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds.,This study demonstrates that [ENTITY_A] and clenbuterol stimulate [ENTITY_B] levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds.,INDIRECT-UPREGULATOR,CPR:3,0,This study demonstrates that CB1093 and clenbuterol stimulate NGF levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds.
Protective effect of << halothane >> anesthesia on retinal light damage: inhibition of metabolic [[ rhodopsin ]] regeneration.,Protective effect of [ENTITY_A] anesthesia on retinal light damage: inhibition of metabolic [ENTITY_B] regeneration.,INDIRECT-DOWNREGULATOR,CPR:4,1,Protective effect of halothane anesthesia on retinal light damage: inhibition of metabolic rhodopsin regeneration.
RESULTS: << Halothane >> anesthesia reversibly inhibited metabolic [[ rhodopsin ]] regeneration and thus prevented rhodopsin from absorbing high numbers of photons during light exposure.,RESULTS: [ENTITY_A] anesthesia reversibly inhibited metabolic [ENTITY_B] regeneration and thus prevented rhodopsin from absorbing high numbers of photons during light exposure.,INDIRECT-DOWNREGULATOR,CPR:4,1,RESULTS: Halothane anesthesia reversibly inhibited metabolic rhodopsin regeneration and thus prevented rhodopsin from absorbing high numbers of photons during light exposure.
"CONCLUSIONS: After the initial bleach, << halothane >> impeded photon absorption by rhodopsin by inhibiting metabolic [[ rhodopsin ]] regeneration.","CONCLUSIONS: After the initial bleach, [ENTITY_A] impeded photon absorption by rhodopsin by inhibiting metabolic [ENTITY_B] regeneration.",INDIRECT-DOWNREGULATOR,CPR:4,1,"CONCLUSIONS: After the initial bleach, halothane impeded photon absorption by rhodopsin by inhibiting metabolic rhodopsin regeneration."
"METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [<< buspirone >> (partial [[ 5-HT1A ]] agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.","METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [[ENTITY_A] (partial [ENTITY_B] agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.",AGONIST,CPR:5,2,"METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test."
"<< Pemetrexed disodium >> (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, [[ dihydrofolate reductase ]], and glycinamide ribonucleotide formyl transferase.","[ENTITY_A] (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, [ENTITY_B], and glycinamide ribonucleotide formyl transferase.",INHIBITOR,CPR:4,1,"Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase."
"To mechanistically evaluate this regional selectivity, we assessed << cyclo-oxygenase-2 >> (COX-2) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and [[ AOM ]]-treated rats.","To mechanistically evaluate this regional selectivity, we assessed [ENTITY_A] (COX-2) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and [ENTITY_B]-treated rats.",INDIRECT-UPREGULATOR,CPR:3,0,"To mechanistically evaluate this regional selectivity, we assessed cyclo-oxygenase-2 (COX-2) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and AOM-treated rats."
"<< Diacylglycerol kinase >> (DGK) catalyzes the conversion of diacylglycerol to [[ phosphatidic acid ]], making it an attractive candidate for a signal transduction component.","[ENTITY_A] (DGK) catalyzes the conversion of diacylglycerol to [ENTITY_B], making it an attractive candidate for a signal transduction component.",PRODUCT-OF,CPR:9,4,"Diacylglycerol kinase (DGK) catalyzes the conversion of diacylglycerol to phosphatidic acid, making it an attractive candidate for a signal transduction component."
"We took advantage of the previous observations that << phosphatidylserine >> inhibits [[ DGK-delta ]] (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H. (1996) J. Biol. Chem. 271, 8394-8401), and constitutively active RhoA inhibits DGK-theta (reviewed by Houssa, B., de Widt, J., Kranenburg, O., Moolenaar, W. H., and van Blitterswijk, W. J. (1999) J. Biol. Chem. 274, 6820-6822) to identify the activity induced by alpha-thrombin.","We took advantage of the previous observations that [ENTITY_A] inhibits [ENTITY_B] (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H. (1996) J. Biol. Chem. 271, 8394-8401), and constitutively active RhoA inhibits DGK-theta (reviewed by Houssa, B., de Widt, J., Kranenburg, O., Moolenaar, W. H., and van Blitterswijk, W. J. (1999) J. Biol. Chem. 274, 6820-6822) to identify the activity induced by alpha-thrombin.",INHIBITOR,CPR:4,1,"We took advantage of the previous observations that phosphatidylserine inhibits DGK-delta (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H. (1996) J. Biol. Chem. 271, 8394-8401), and constitutively active RhoA inhibits DGK-theta (reviewed by Houssa, B., de Widt, J., Kranenburg, O., Moolenaar, W. H., and van Blitterswijk, W. J. (1999) J. Biol. Chem. 274, 6820-6822) to identify the activity induced by alpha-thrombin."
<< Nordihydroguaiaretic acid >> (NDGA) has been shown to inhibit both 5-lipoxygenase and [[ ornithine decarboxylase ]] and is active against several cancer cell lines and at least one mouse tumor model.,[ENTITY_A] (NDGA) has been shown to inhibit both 5-lipoxygenase and [ENTITY_B] and is active against several cancer cell lines and at least one mouse tumor model.,INHIBITOR,CPR:4,1,Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.
<< Carbonic anhydrase >> (CA) is a zinc enzyme that catalyses the reversible hydration reaction of [[ CO2 ]] and plays a major role in the acid-base balance.,[ENTITY_A] (CA) is a zinc enzyme that catalyses the reversible hydration reaction of [ENTITY_B] and plays a major role in the acid-base balance.,SUBSTRATE_PRODUCT-OF,CPR:9,4,Carbonic anhydrase (CA) is a zinc enzyme that catalyses the reversible hydration reaction of CO2 and plays a major role in the acid-base balance.
The temporal profile of butyrylcholinesterase (BuChE) and in vitro << pralidoxime >>-reactivated [[ BuChE ]] was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.,The temporal profile of butyrylcholinesterase (BuChE) and in vitro [ENTITY_A]-reactivated [ENTITY_B] was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.,ACTIVATOR,CPR:3,0,The temporal profile of butyrylcholinesterase (BuChE) and in vitro pralidoxime-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.
Reactivation potentials of << BuChE >> (the difference between [[ oxime ]]-reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion.,Reactivation potentials of [ENTITY_A] (the difference between [ENTITY_B]-reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion.,ACTIVATOR,CPR:3,0,Reactivation potentials of BuChE (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion.
Reactivation potentials of << BuChE >> (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after [[ organophosphate ]] ingestion.,Reactivation potentials of [ENTITY_A] (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after [ENTITY_B] ingestion.,DOWNREGULATOR,CPR:4,1,Reactivation potentials of BuChE (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion.
Patients who received << oxime >> prior to hospitalization had a higher rate of intermediate syndrome and lower levels of [[ BuChE ]] at admission than those who had not.,Patients who received [ENTITY_A] prior to hospitalization had a higher rate of intermediate syndrome and lower levels of [ENTITY_B] at admission than those who had not.,INDIRECT-DOWNREGULATOR,CPR:4,1,Patients who received oxime prior to hospitalization had a higher rate of intermediate syndrome and lower levels of BuChE at admission than those who had not.
"The segments were contracted with the << alpha(2)-adrenoceptor >> agonists [[ brimonidine ]], apraclonidine, and oxymetazoline.","The segments were contracted with the [ENTITY_A] agonists [ENTITY_B], apraclonidine, and oxymetazoline.",AGONIST,CPR:5,2,"The segments were contracted with the alpha(2)-adrenoceptor agonists brimonidine, apraclonidine, and oxymetazoline."
"The following alpha(2)-adrenoceptor antagonists were applied: << BRL44408 >> ([[ alpha(2A) ]]-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).","The following alpha(2)-adrenoceptor antagonists were applied: [ENTITY_A] ([ENTITY_B]-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).",ANTAGONIST,CPR:6,3,"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective)."
"RESULTS: The << alpha(2)-adrenoceptor >> agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: [[ brimonidine ]] 2.11, oxymetazoline 5.26, and apraclonidine 13.0.","RESULTS: The [ENTITY_A] agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: [ENTITY_B] 2.11, oxymetazoline 5.26, and apraclonidine 13.0.",AGONIST,CPR:5,2,"RESULTS: The alpha(2)-adrenoceptor agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, oxymetazoline 5.26, and apraclonidine 13.0."
"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for << BRL44408 >> (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional [[ alpha(2A)-adrenoceptors ]].","Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for [ENTITY_A] (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional [ENTITY_B].",ANTAGONIST,CPR:6,3,"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional alpha(2A)-adrenoceptors."
"CONCLUSIONS: The << alpha(2)-adrenoceptor >> agonists [[ brimonidine ]], apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery.","CONCLUSIONS: The [ENTITY_A] agonists [ENTITY_B], apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery.",AGONIST,CPR:5,2,"CONCLUSIONS: The alpha(2)-adrenoceptor agonists brimonidine, apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery."
"<< Pemetrexed disodium >> (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, [[ thymidylate synthase ]], dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.","[ENTITY_A] (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, [ENTITY_B], dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.",INHIBITOR,CPR:4,1,"Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase."
"<< DHFS >> is present exclusively in the mitochondria, making this compartment the sole site of synthesis of [[ dihydrofolate ]] in the plant cell.","[ENTITY_A] is present exclusively in the mitochondria, making this compartment the sole site of synthesis of [ENTITY_B] in the plant cell.",PRODUCT-OF,CPR:9,4,"DHFS is present exclusively in the mitochondria, making this compartment the sole site of synthesis of dihydrofolate in the plant cell."
UNLABELLED: << Rabeprazole >> is an inhibitor of the [[ gastric proton pump ]].,UNLABELLED: [ENTITY_A] is an inhibitor of the [ENTITY_B].,INHIBITOR,CPR:4,1,UNLABELLED: Rabeprazole is an inhibitor of the gastric proton pump.
CONCLUSION: << Rabeprazole >> is a well tolerated [[ proton pump ]] inhibitor.,CONCLUSION: [ENTITY_A] is a well tolerated [ENTITY_B] inhibitor.,INHIBITOR,CPR:4,1,CONCLUSION: Rabeprazole is a well tolerated proton pump inhibitor.
<< Angiotensin II >> suppression in humans by the orally active renin inhibitor [[ Aliskiren ]] (SPP100): comparison with enalapril.,[ENTITY_A] suppression in humans by the orally active renin inhibitor [ENTITY_B] (SPP100): comparison with enalapril.,INDIRECT-DOWNREGULATOR,CPR:4,1,Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
"We tested the new orally active nonpeptidic << renin >> inhibitor [[ SPP100 ]] (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.","We tested the new orally active nonpeptidic [ENTITY_A] inhibitor [ENTITY_B] (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.",INHIBITOR,CPR:4,1,"We tested the new orally active nonpeptidic renin inhibitor SPP100 (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol."
"There was a dose-dependent decrease in plasma renin activity, << Ang I >>, and Ang II following single doses of [[ Aliskiren ]] starting with 40 mg.","There was a dose-dependent decrease in plasma renin activity, [ENTITY_A], and Ang II following single doses of [ENTITY_B] starting with 40 mg.",INDIRECT-DOWNREGULATOR,CPR:4,1,"There was a dose-dependent decrease in plasma renin activity, Ang I, and Ang II following single doses of Aliskiren starting with 40 mg."
"Inhibition was still marked and significant after repeated dosing with maximal decreases in << Ang II >> levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of [[ Aliskiren ]] was compared with placebo.","Inhibition was still marked and significant after repeated dosing with maximal decreases in [ENTITY_A] levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of [ENTITY_B] was compared with placebo.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Inhibition was still marked and significant after repeated dosing with maximal decreases in Ang II levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared with placebo."
"At the same time, mean plasma active << renin >> was increased 16- and 34-fold at the highest dose of [[ Aliskiren ]].","At the same time, mean plasma active [ENTITY_A] was increased 16- and 34-fold at the highest dose of [ENTITY_B].",ACTIVATOR,CPR:3,0,"At the same time, mean plasma active renin was increased 16- and 34-fold at the highest dose of Aliskiren."
"In conclusion, the renin inhibitor << Aliskiren >> dose-dependently decreases [[ Ang II ]] levels in humans following oral administration.","In conclusion, the renin inhibitor [ENTITY_A] dose-dependently decreases [ENTITY_B] levels in humans following oral administration.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In conclusion, the renin inhibitor Aliskiren dose-dependently decreases Ang II levels in humans following oral administration."
<< Aliskiren >> has the potential to become the first orally active [[ renin ]] inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.,[ENTITY_A] has the potential to become the first orally active [ENTITY_B] inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.,INHIBITOR,CPR:4,1,Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.
<< Aliskiren >> has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and [[ Ang II receptor ]] antagonists in therapy for hypertension and other cardiovascular and renal diseases.,[ENTITY_A] has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and [ENTITY_B] antagonists in therapy for hypertension and other cardiovascular and renal diseases.,ANTAGONIST,CPR:6,3,Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.
"The earliest known << AChE >> inhibitors, namely, [[ physostigmine ]] and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).","The earliest known [ENTITY_A] inhibitors, namely, [ENTITY_B] and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).",INHIBITOR,CPR:4,1,"The earliest known AChE inhibitors, namely, physostigmine and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability)."
<< Donepezil hydrochloride >> inaugurates a new class of [[ AChE ]] inhibitors with longer and more selective action and with manageable adverse effects.,[ENTITY_A] inaugurates a new class of [ENTITY_B] inhibitors with longer and more selective action and with manageable adverse effects.,INHIBITOR,CPR:4,1,Donepezil hydrochloride inaugurates a new class of AChE inhibitors with longer and more selective action and with manageable adverse effects.
"<< Thalidomide >>--removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of [[ TNF alpha ]].","[ENTITY_A]--removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of [ENTITY_B].",INHIBITOR,CPR:4,1,"Thalidomide--removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of TNF alpha."
"As a prodrug << leflunomide >> is completely converted to its active metabolite A 77 1726 (M1) which blocks the [[ dihydroorotate dehydrogenase ]], a key enzyme of the pyrimidine de novo synthesis.","As a prodrug [ENTITY_A] is completely converted to its active metabolite A 77 1726 (M1) which blocks the [ENTITY_B], a key enzyme of the pyrimidine de novo synthesis.",INHIBITOR,CPR:4,1,"As a prodrug leflunomide is completely converted to its active metabolite A 77 1726 (M1) which blocks the dihydroorotate dehydrogenase, a key enzyme of the pyrimidine de novo synthesis."
"A recent study showed that << anastrozole >>, an [[ aromatase ]] inhibitor, is as effective or even superior to tamoxifen when used as a first-line therapy.","A recent study showed that [ENTITY_A], an [ENTITY_B] inhibitor, is as effective or even superior to tamoxifen when used as a first-line therapy.",INHIBITOR,CPR:4,1,"A recent study showed that anastrozole, an aromatase inhibitor, is as effective or even superior to tamoxifen when used as a first-line therapy."
"<< Fulvestrant >>, the first agent in this new class, not only induces the degradation of the [[ estrogen receptor ]] but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile.","[ENTITY_A], the first agent in this new class, not only induces the degradation of the [ENTITY_B] but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile.",DOWNREGULATOR,CPR:4,1,"Fulvestrant, the first agent in this new class, not only induces the degradation of the estrogen receptor but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile."
"<< Lovastatin >>, a specific inhibitor of [[ HMG-CoA reductase ]], induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC.","[ENTITY_A], a specific inhibitor of [ENTITY_B], induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC.",INHIBITOR,CPR:4,1,"Lovastatin, a specific inhibitor of HMG-CoA reductase, induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC."
"Chronic treatment with the NET inhibitor, << desipramine >> (DMI), reduced [[ NET ]] levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.","Chronic treatment with the NET inhibitor, [ENTITY_A] (DMI), reduced [ENTITY_B] levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Chronic treatment with the NET inhibitor, desipramine (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs."
"Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific << alpha(4)beta(2*) nAChR >> agonist [[ metanicotine ]], or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates.","Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific [ENTITY_A] agonist [ENTITY_B], or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates.",AGONIST,CPR:5,2,"Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific alpha(4)beta(2*) nAChR agonist metanicotine, or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates."
<< Cilostazol >> decreases levels of serum triglycerides and causes some increase in [[ HDL ]]-cholesterol levels.,[ENTITY_A] decreases levels of serum triglycerides and causes some increase in [ENTITY_B]-cholesterol levels.,INDIRECT-UPREGULATOR,CPR:3,0,Cilostazol decreases levels of serum triglycerides and causes some increase in HDL-cholesterol levels.
<< Cilostazol >> undergoes intensive and finally complete hepatic metabolism via the [[ cytochrome P450 ]] systems.,[ENTITY_A] undergoes intensive and finally complete hepatic metabolism via the [ENTITY_B] systems.,SUBSTRATE,CPR:9,4,Cilostazol undergoes intensive and finally complete hepatic metabolism via the cytochrome P450 systems.
"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by << milrinone >> and cilostazol, specific inhibitors of [[ PDE3 ]].","We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by [ENTITY_A] and cilostazol, specific inhibitors of [ENTITY_B].",INHIBITOR,CPR:4,1,"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and cilostazol, specific inhibitors of PDE3."
"Mutants << Y751A >>, D950A, and F1004A had reduced sensitivity to [[ milrinone ]] (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).","Mutants [ENTITY_A], D950A, and F1004A had reduced sensitivity to [ENTITY_B] (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).",INHIBITOR,CPR:4,1,"Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)."
"In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for << cilostazol >> but no difference for milrinone from the recombinant [[ PDE3A ]].","In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for [ENTITY_A] but no difference for milrinone from the recombinant [ENTITY_B].",INHIBITOR,CPR:4,1,"In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A."
"Molecular models show that the << PDE3 >> inhibitors [[ cilostazol ]] and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.","Molecular models show that the [ENTITY_A] inhibitors [ENTITY_B] and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.",INHIBITOR,CPR:4,1,"Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site."
"Our study implies that highly conserved residuals Y751, D950 and F1004 in the << PDE >> families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the [[ cilostazol ]] selectivity of PDE3A.","Our study implies that highly conserved residuals Y751, D950 and F1004 in the [ENTITY_A] families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the [ENTITY_B] selectivity of PDE3A.",INHIBITOR,CPR:4,1,"Our study implies that highly conserved residuals Y751, D950 and F1004 in the PDE families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the cilostazol selectivity of PDE3A."
"The bacterial enzyme << maltodextrin phosphorylase >> (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as [[ glucose-1-phosphate ]] (Glc1P).","The bacterial enzyme [ENTITY_A] (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as [ENTITY_B] (Glc1P).",PRODUCT-OF,CPR:9,4,"The bacterial enzyme maltodextrin phosphorylase (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (Glc1P)."
OBJECTIVE: << Fondaparinux sodium >> is the first in a new class of synthetic [[ factor Xa ]] inhibitors that binds reversibly with high affinity to antithrombin III.,OBJECTIVE: [ENTITY_A] is the first in a new class of synthetic [ENTITY_B] inhibitors that binds reversibly with high affinity to antithrombin III.,INHIBITOR,CPR:4,1,OBJECTIVE: Fondaparinux sodium is the first in a new class of synthetic factor Xa inhibitors that binds reversibly with high affinity to antithrombin III.
"It is caused by a deficiency of << propionyl-CoA carboxylase >> (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of [[ propionyl-CoA ]] to D-methylmalonyl-CoA.","It is caused by a deficiency of [ENTITY_A] (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of [ENTITY_B] to D-methylmalonyl-CoA.",SUBSTRATE,CPR:9,4,"It is caused by a deficiency of propionyl-CoA carboxylase (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA."
"Although only << clozapine >> and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined [[ 5-HT(2A) ]] and D(2) blockade.","Although only [ENTITY_A] and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined [ENTITY_B] and D(2) blockade.",INHIBITOR,CPR:4,1,"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade."
"Although only << clozapine >> and ziprasidone are directly acting [[ 5-HT(1A) ]] agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.","Although only [ENTITY_A] and ziprasidone are directly acting [ENTITY_B] agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.",AGONIST,CPR:5,2,"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade."
"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, << WAY100635 >>, a selective [[ 5-HT(1A) ]] antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.","Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, [ENTITY_A], a selective [ENTITY_B] antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.",ANTAGONIST,CPR:6,3,"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade."
"However, << 5-HT(1A) >> agonism may be important only for [[ quetiapine ]]-induced ACh release.","However, [ENTITY_A] agonism may be important only for [ENTITY_B]-induced ACh release.",AGONIST,CPR:5,2,"However, 5-HT(1A) agonism may be important only for quetiapine-induced ACh release."
BACKGROUND: The novel antiepileptic drug << retigabine >> is the first selective M-current potassium channel opener for [[ KCNQ2/3 ]] and KCNQ3/5 channels.,BACKGROUND: The novel antiepileptic drug [ENTITY_A] is the first selective M-current potassium channel opener for [ENTITY_B] and KCNQ3/5 channels.,ACTIVATOR,CPR:3,0,BACKGROUND: The novel antiepileptic drug retigabine is the first selective M-current potassium channel opener for KCNQ2/3 and KCNQ3/5 channels.
"OBJECTIVE: Because of these physiological effects and the widespread use of the selective << COX-2 >> inhibitor, [[ celecoxib ]], we wanted to determine if inhibition of COX-2 would affect incisional skin wound healing.","OBJECTIVE: Because of these physiological effects and the widespread use of the selective [ENTITY_A] inhibitor, [ENTITY_B], we wanted to determine if inhibition of COX-2 would affect incisional skin wound healing.",INHIBITOR,CPR:4,1,"OBJECTIVE: Because of these physiological effects and the widespread use of the selective COX-2 inhibitor, celecoxib, we wanted to determine if inhibition of COX-2 would affect incisional skin wound healing."
"METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of COX-2 in the wound healing process by comparing the effects of a nonselective << COX >> inhibitor, [[ diclofenac ]], with a selective COX-2 inhibitor, SC-791.","METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of COX-2 in the wound healing process by comparing the effects of a nonselective [ENTITY_A] inhibitor, [ENTITY_B], with a selective COX-2 inhibitor, SC-791.",INHIBITOR,CPR:4,1,"METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of COX-2 in the wound healing process by comparing the effects of a nonselective COX inhibitor, diclofenac, with a selective COX-2 inhibitor, SC-791."
"<< Histamine H1-receptor >> antagonists, [[ promethazine ]] and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.","[ENTITY_A] antagonists, [ENTITY_B] and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.",ANTAGONIST,CPR:6,3,"Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol."
"The effects of histamine H1-receptor antagonists, << promethazine >> and homochlorcyclizine, both of which are inhibitors of [[ CYP2D6 ]], on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.","The effects of histamine H1-receptor antagonists, [ENTITY_A] and homochlorcyclizine, both of which are inhibitors of [ENTITY_B], on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.",INHIBITOR,CPR:4,1,"The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks."
"The effects of << histamine H1-receptor >> antagonists, [[ promethazine ]] and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.","The effects of [ENTITY_A] antagonists, [ENTITY_B] and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.",ANTAGONIST,CPR:6,3,"The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks."
"Thus, the current study suggests that coadministration of clinical doses of << promethazine >> and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the [[ CYP2D6 ]]-catalyzed metabolism of haloperidol and reduced haloperidol.","Thus, the current study suggests that coadministration of clinical doses of [ENTITY_A] and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the [ENTITY_B]-catalyzed metabolism of haloperidol and reduced haloperidol.",INHIBITOR,CPR:4,1,"Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the CYP2D6-catalyzed metabolism of haloperidol and reduced haloperidol."
"Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the << CYP2D6 >>-catalyzed metabolism of haloperidol and reduced [[ haloperidol ]].","Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the [ENTITY_A]-catalyzed metabolism of haloperidol and reduced [ENTITY_B].",SUBSTRATE,CPR:9,4,"Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the CYP2D6-catalyzed metabolism of haloperidol and reduced haloperidol."
"The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of << OTCase >> to [[ ornithine ]] and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.","The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of [ENTITY_A] to [ENTITY_B] and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.",INHIBITOR,CPR:4,1,"The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain."
"Inhibition of binding of both << plasminogen >> and plasmin to gp330 by [[ benzamidine ]] was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.","Inhibition of binding of both [ENTITY_A] and plasmin to gp330 by [ENTITY_B] was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.",INHIBITOR,CPR:4,1,"Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330."
"Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective << alpha-adrenoceptor >> antagonists, [[ phentolamine ]] (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).","Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective [ENTITY_A] antagonists, [ENTITY_B] (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).",ANTAGONIST,CPR:6,3,"Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg)."
"The << alpha(2)-adrenoceptor >> antagonist, [[ rauwolscine ]] (0.5 mg/kg), was without antagonistic effects.","The [ENTITY_A] antagonist, [ENTITY_B] (0.5 mg/kg), was without antagonistic effects.",ANTAGONIST,CPR:6,3,"The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects."
"<< alpha(1A)-Adrenoceptor >> selective antagonists, [[ 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane ]] (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.","[ENTITY_A] selective antagonists, [ENTITY_B] (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.",ANTAGONIST,CPR:6,3,"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved."
"To further investigate this positive correlation and its possible therapeutic implications, a selective << COX-2 >> inhibitor, [[ etodolac ]], was tested on three variants of HT-29 colon cancer cell lines, HT-29/Inv1, HT-29/Inv2 and HT-29/Inv3, with graded increases of in vitro Matrigel invasive potential and COX-2 expression levels.","To further investigate this positive correlation and its possible therapeutic implications, a selective [ENTITY_A] inhibitor, [ENTITY_B], was tested on three variants of HT-29 colon cancer cell lines, HT-29/Inv1, HT-29/Inv2 and HT-29/Inv3, with graded increases of in vitro Matrigel invasive potential and COX-2 expression levels.",INHIBITOR,CPR:4,1,"To further investigate this positive correlation and its possible therapeutic implications, a selective COX-2 inhibitor, etodolac, was tested on three variants of HT-29 colon cancer cell lines, HT-29/Inv1, HT-29/Inv2 and HT-29/Inv3, with graded increases of in vitro Matrigel invasive potential and COX-2 expression levels."
"However, other << alpha(1)-adrenoceptor >> antagonists ([[ tamsulosin ]], WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.","However, other [ENTITY_A] antagonists ([ENTITY_B], WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.",ANTAGONIST,CPR:6,3,"However, other alpha(1)-adrenoceptor antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding."
"The potency of MrIA was greater for inhibition of uptake by << hNET >> of [[ [3H]norepinephrine ]] (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).","The potency of MrIA was greater for inhibition of uptake by [ENTITY_A] of [ENTITY_B] (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).",SUBSTRATE,CPR:9,4,"The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM)."
A comparison of the results with previous data for desipramine and cocaine inhibition of << norepinephrine >> uptake by the mutant [[ hNETs ]] reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.,A comparison of the results with previous data for desipramine and cocaine inhibition of [ENTITY_A] uptake by the mutant [ENTITY_B] reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.,SUBSTRATE,CPR:9,4,A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant hNETs reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.
"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, << ACY-1 >>) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of [[ N-acylated L-amino acids ]] except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, [ENTITY_A]) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of [ENTITY_B] except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",SUBSTRATE,CPR:9,4,"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced."
"Patients stable on warfarin therapy and concurrently taking a << cyclooxygenase-2 >> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, [[ salsalate ]], or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.","Patients stable on warfarin therapy and concurrently taking a [ENTITY_A] (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, [ENTITY_B], or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.",INHIBITOR,CPR:4,1,"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks."
<< AT1 >> antagonism by [[ eprosartan ]] lowers heart rate variability and baroreflex gain.,[ENTITY_A] antagonism by [ENTITY_B] lowers heart rate variability and baroreflex gain.,ANTAGONIST,CPR:6,3,AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.
We sought to assess the effects of the << angiotensin type 1 (AT1) receptor >> blocker [[ eprosartan ]] on HRV and BRG.,We sought to assess the effects of the [ENTITY_A] blocker [ENTITY_B] on HRV and BRG.,INHIBITOR,CPR:4,1,We sought to assess the effects of the angiotensin type 1 (AT1) receptor blocker eprosartan on HRV and BRG.
"RESULTS: << Eprosartan >> tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating [[ Ang-II ]] levels (p<0.01).","RESULTS: [ENTITY_A] tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating [ENTITY_B] levels (p<0.01).",INDIRECT-UPREGULATOR,CPR:3,0,"RESULTS: Eprosartan tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating Ang-II levels (p<0.01)."
CONCLUSIONS: << AT1 >> antagonism by [[ eprosartan ]] lowers heart rate variability and baroreflex gain.,CONCLUSIONS: [ENTITY_A] antagonism by [ENTITY_B] lowers heart rate variability and baroreflex gain.,ANTAGONIST,CPR:6,3,CONCLUSIONS: AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.
The antinociceptive activity of the << alpha 2-adrenoceptor >> agonist [[ clonidine ]] was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31).,The antinociceptive activity of the [ENTITY_A] agonist [ENTITY_B] was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31).,AGONIST,CPR:5,2,The antinociceptive activity of the alpha 2-adrenoceptor agonist clonidine was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31).
"<< Loperamide >>, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress [[ ACTH ]] and cortisol levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease.","[ENTITY_A], an opiate agonist of high specificity for mu-receptors, was recently reported to suppress [ENTITY_B] and cortisol levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Loperamide, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress ACTH and cortisol levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease."
"In seven normal subjects, basal << ACTH >> plasma levels were significantly suppressed 3 h after [[ loperamide ]] administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).","In seven normal subjects, basal [ENTITY_A] plasma levels were significantly suppressed 3 h after [ENTITY_B] administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).",INDIRECT-DOWNREGULATOR,CPR:4,1,"In seven normal subjects, basal ACTH plasma levels were significantly suppressed 3 h after loperamide administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001)."
"After the combined pituitary stimulation test (100 micrograms << human CRH >>, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by [[ loperamide ]] from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).","After the combined pituitary stimulation test (100 micrograms [ENTITY_A], 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by [ENTITY_B] from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).",DOWNREGULATOR,CPR:4,1,"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05)."
"In summary, << loperamide >> is able to reduce basal and [[ CRH ]]-induced ACTH and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.","In summary, [ENTITY_A] is able to reduce basal and [ENTITY_B]-induced ACTH and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In summary, loperamide is able to reduce basal and CRH-induced ACTH and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin."
"We also examined the effects of << WEB 2086 >>, a [[ platelet-activating factor (PAF) receptor ]] antagonist, in parallel.","We also examined the effects of [ENTITY_A], a [ENTITY_B] antagonist, in parallel.",ANTAGONIST,CPR:6,3,"We also examined the effects of WEB 2086, a platelet-activating factor (PAF) receptor antagonist, in parallel."
The unique role of the enzyme << 5-lipoxygenase >> (5-LO) in the production of [[ leukotrienes ]] (LTs) makes it a likely target for biochemical manipulation.,The unique role of the enzyme [ENTITY_A] (5-LO) in the production of [ENTITY_B] (LTs) makes it a likely target for biochemical manipulation.,PRODUCT-OF,CPR:9,4,The unique role of the enzyme 5-lipoxygenase (5-LO) in the production of leukotrienes (LTs) makes it a likely target for biochemical manipulation.
"The compounds identified as 5-LO inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where << hydroxamic acids >> are potent and more selective inhibitors of [[ 5-LO ]].","The compounds identified as 5-LO inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where [ENTITY_A] are potent and more selective inhibitors of [ENTITY_B].",INHIBITOR,CPR:4,1,"The compounds identified as 5-LO inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where hydroxamic acids are potent and more selective inhibitors of 5-LO."
"The << benzothiophene hydroxyurea >>, zileuton, is the first selective [[ 5-LO ]] inhibitor evaluated for the treatment of patients with IBD.","The [ENTITY_A], zileuton, is the first selective [ENTITY_B] inhibitor evaluated for the treatment of patients with IBD.",INHIBITOR,CPR:4,1,"The benzothiophene hydroxyurea, zileuton, is the first selective 5-LO inhibitor evaluated for the treatment of patients with IBD."
"Ribonucleotide reductase (<< RR >>) is responsible for the de novo conversion of the ribonucleoside diphosphates to [[ deoxyribonucleoside diphosphates ]], which are essential for DNA synthesis and repair.","Ribonucleotide reductase ([ENTITY_A]) is responsible for the de novo conversion of the ribonucleoside diphosphates to [ENTITY_B], which are essential for DNA synthesis and repair.",PRODUCT-OF,CPR:9,4,"Ribonucleotide reductase (RR) is responsible for the de novo conversion of the ribonucleoside diphosphates to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair."
"In PC3 cells, << hydroxyurea >> inhibited [[ hRRM2 ]] and resulted in increased sensitivity to UV irradiation.","In PC3 cells, [ENTITY_A] inhibited [ENTITY_B] and resulted in increased sensitivity to UV irradiation.",INHIBITOR,CPR:4,1,"In PC3 cells, hydroxyurea inhibited hRRM2 and resulted in increased sensitivity to UV irradiation."
"In addition, << minocycline >> treatment significantly reduced the specific [[ caspase-3 ]] activity after SCI as compared to that of vehicle control.","In addition, [ENTITY_A] treatment significantly reduced the specific [ENTITY_B] activity after SCI as compared to that of vehicle control.",INHIBITOR,CPR:4,1,"In addition, minocycline treatment significantly reduced the specific caspase-3 activity after SCI as compared to that of vehicle control."
"Furthermore, RT-PCR analyses revealed that << minocycline >> treatment increased expression of [[ interleukin-10 ]] mRNA but decreased tumor necrosis factor-alpha expression.","Furthermore, RT-PCR analyses revealed that [ENTITY_A] treatment increased expression of [ENTITY_B] mRNA but decreased tumor necrosis factor-alpha expression.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, RT-PCR analyses revealed that minocycline treatment increased expression of interleukin-10 mRNA but decreased tumor necrosis factor-alpha expression."
"Furthermore, RT-PCR analyses revealed that << minocycline >> treatment increased expression of interleukin-10 mRNA but decreased [[ tumor necrosis factor-alpha ]] expression.","Furthermore, RT-PCR analyses revealed that [ENTITY_A] treatment increased expression of interleukin-10 mRNA but decreased [ENTITY_B] expression.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, RT-PCR analyses revealed that minocycline treatment increased expression of interleukin-10 mRNA but decreased tumor necrosis factor-alpha expression."
RESULTS: The density of << AR >> in liver tissue in [[ NP ]] group was higher than that in control group (P < 0.05).,RESULTS: The density of [ENTITY_A] in liver tissue in [ENTITY_B] group was higher than that in control group (P < 0.05).,INDIRECT-UPREGULATOR,CPR:3,0,RESULTS: The density of AR in liver tissue in NP group was higher than that in control group (P < 0.05).
"CONCLUSION: << Nandrolone phenylpropionate >> up-regulated the density of [[ AR ]] in liver tissue, whereas it had no significant effects on the density of AR in testis and ovary tissues.","CONCLUSION: [ENTITY_A] up-regulated the density of [ENTITY_B] in liver tissue, whereas it had no significant effects on the density of AR in testis and ovary tissues.",INDIRECT-UPREGULATOR,CPR:3,0,"CONCLUSION: Nandrolone phenylpropionate up-regulated the density of AR in liver tissue, whereas it had no significant effects on the density of AR in testis and ovary tissues."
"Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective << beta(2)-adrenoceptor >> agonist [[ salbutamol ]] (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.","Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective [ENTITY_A] agonist [ENTITY_B] (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.",AGONIST,CPR:5,2,"Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization."
"Rats received a concomitant treatment with the selective << beta(1)-adrenoceptor >> antagonist, [[ bisoprolol ]] (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.","Rats received a concomitant treatment with the selective [ENTITY_A] antagonist, [ENTITY_B] (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.",ANTAGONIST,CPR:6,3,"Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization."
The pretreatment with << salbutamol >> induced a 59% down-regulation of left ventricular [[ beta(2)-adrenoceptors ]] compared to control.,The pretreatment with [ENTITY_A] induced a 59% down-regulation of left ventricular [ENTITY_B] compared to control.,DOWNREGULATOR,CPR:4,1,The pretreatment with salbutamol induced a 59% down-regulation of left ventricular beta(2)-adrenoceptors compared to control.
"TRPM8 (<< CMR1 >>) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, [[ eucalyptol ]] and icilin.","TRPM8 ([ENTITY_A]) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, [ENTITY_B] and icilin.",ACTIVATOR,CPR:3,0,"TRPM8 (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin."
"Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of << TRPM8 >> to [[ menthol ]] (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).","Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of [ENTITY_A] to [ENTITY_B] (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).",ACTIVATOR,CPR:3,0,"Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively)."
"Known VR1 antagonists (<< BCTC >>, thio-BCTC and capsazepine) were also able to block the response of [[ TRPM8 ]] to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).","Known VR1 antagonists ([ENTITY_A], thio-BCTC and capsazepine) were also able to block the response of [ENTITY_B] to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).",INHIBITOR,CPR:4,1,"Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively)."
"Known << VR1 >> antagonists ([[ BCTC ]], thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).","Known [ENTITY_A] antagonists ([ENTITY_B], thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).",ANTAGONIST,CPR:6,3,"Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively)."
The Ca(2+) response of << hVR1 >>-transfected HEK293 cells to the endogenous VR1 agonist [[ N-arachidonoyl-dopamine ]] was potentiated by low pH.,The Ca(2+) response of [ENTITY_A]-transfected HEK293 cells to the endogenous VR1 agonist [ENTITY_B] was potentiated by low pH.,ACTIVATOR,CPR:3,0,The Ca(2+) response of hVR1-transfected HEK293 cells to the endogenous VR1 agonist N-arachidonoyl-dopamine was potentiated by low pH.
The Ca(2+) response of hVR1-transfected HEK293 cells to the endogenous << VR1 >> agonist [[ N-arachidonoyl-dopamine ]] was potentiated by low pH.,The Ca(2+) response of hVR1-transfected HEK293 cells to the endogenous [ENTITY_A] agonist [ENTITY_B] was potentiated by low pH.,AGONIST,CPR:5,2,The Ca(2+) response of hVR1-transfected HEK293 cells to the endogenous VR1 agonist N-arachidonoyl-dopamine was potentiated by low pH.
"In contrast, << menthol >>- and icilin-activated [[ TRPM8 ]] currents were suppressed by low pH.","In contrast, [ENTITY_A]- and icilin-activated [ENTITY_B] currents were suppressed by low pH.",ACTIVATOR,CPR:3,0,"In contrast, menthol- and icilin-activated TRPM8 currents were suppressed by low pH."
"Inhibitory effects of the << monoamine oxidase >> inhibitor [[ tranylcypromine ]] on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.","Inhibitory effects of the [ENTITY_A] inhibitor [ENTITY_B] on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.",INHIBITOR,CPR:4,1,"Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6."
"The inhibitory effects of << tranylcypromine >>, a nonselective irreversible inhibitor of [[ monoamine oxidase ]] (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.","The inhibitory effects of [ENTITY_A], a nonselective irreversible inhibitor of [ENTITY_B] (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.",INHIBITOR,CPR:4,1,"The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro."
The results demonstrated that << tranylcypromine >> is a competitive inhibitor of [[ CYP2C19 ]] (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM).,The results demonstrated that [ENTITY_A] is a competitive inhibitor of [ENTITY_B] (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM).,INHIBITOR,CPR:4,1,The results demonstrated that tranylcypromine is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM).
"Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than << atorvastatin >>, a compound that blocks [[ HMG-CoA reductase ]].","Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than [ENTITY_A], a compound that blocks [ENTITY_B].",INHIBITOR,CPR:4,1,"Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks HMG-CoA reductase."
"Although highly homologous to other class III RTKs, Flt3 is resistant to the << phenylaminopyrimidine >> STI571 (Gleevec, Imatinib), a potent inhibitor of other [[ RTKs ]] in the family, such as the PDGFbeta-receptor or c-Kit.","Although highly homologous to other class III RTKs, Flt3 is resistant to the [ENTITY_A] STI571 (Gleevec, Imatinib), a potent inhibitor of other [ENTITY_B] in the family, such as the PDGFbeta-receptor or c-Kit.",INHIBITOR,CPR:4,1,"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit."
STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding << Flt3 >> mutant sensitive to [[ STI571 ]].,STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding [ENTITY_A] mutant sensitive to [ENTITY_B].,INHIBITOR,CPR:4,1,STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571.
"Compounds of several other structural families, including the << quinoxaline >> AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [[ Flt3 ]] kinase.","Compounds of several other structural families, including the [ENTITY_A] AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [ENTITY_B] kinase.",INHIBITOR,CPR:4,1,"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase."
"Novel mechanism of action for << hydralazine >>: induction of hypoxia-inducible factor-1alpha, [[ vascular endothelial growth factor ]], and angiogenesis by inhibition of prolyl hydroxylases.","Novel mechanism of action for [ENTITY_A]: induction of hypoxia-inducible factor-1alpha, [ENTITY_B], and angiogenesis by inhibition of prolyl hydroxylases.",INDIRECT-UPREGULATOR,CPR:3,0,"Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases."
"Novel mechanism of action for << hydralazine >>: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of [[ prolyl hydroxylases ]].","Novel mechanism of action for [ENTITY_A]: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of [ENTITY_B].",INHIBITOR,CPR:4,1,"Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases."
"<< Hydralazine >> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF ([[ endothelin-1 ]], adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.","[ENTITY_A] induced rapid and transient expression of HIF-1alpha and downstream targets of HIF ([ENTITY_B], adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.",INDIRECT-UPREGULATOR,CPR:3,0,"Hydralazine induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation."
"<< Hydralazine >> dose-dependently inhibited PHD activity and induced nonhydroxylated [[ HIF-1alpha ]], evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.","[ENTITY_A] dose-dependently inhibited PHD activity and induced nonhydroxylated [ENTITY_B], evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.",UPREGULATOR,CPR:3,0,"Hydralazine dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity."
"<< Hydralazine >> dose-dependently inhibited [[ PHD ]] activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.","[ENTITY_A] dose-dependently inhibited [ENTITY_B] activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.",INHIBITOR,CPR:4,1,"Hydralazine dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity."
"In vivo, << hydralazine >> induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma [[ VEGF ]] levels.","In vivo, [ENTITY_A] induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma [ENTITY_B] levels.",INDIRECT-UPREGULATOR,CPR:3,0,"In vivo, hydralazine induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma VEGF levels."
"Thus, << hydralazine >> activates the [[ HIF ]] pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype.","Thus, [ENTITY_A] activates the [ENTITY_B] pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype.",ACTIVATOR,CPR:3,0,"Thus, hydralazine activates the HIF pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype."
"Thus, << hydralazine >> activates the HIF pathway through inhibition of [[ PHD ]] activity and initiates a pro-angiogenic phenotype.","Thus, [ENTITY_A] activates the HIF pathway through inhibition of [ENTITY_B] activity and initiates a pro-angiogenic phenotype.",INHIBITOR,CPR:4,1,"Thus, hydralazine activates the HIF pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype."
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas << NS398 >>, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting [[ COX-2 ]] than COX-1.","RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas [ENTITY_A], carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting [ENTITY_B] than COX-1.",INHIBITOR,CPR:4,1,"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1."
"CONCLUSIONS AND CLINICAL RELEVANCE: << Canine COX-2 >> was selectively inhibited by [[ etodolac ]], nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.","CONCLUSIONS AND CLINICAL RELEVANCE: [ENTITY_A] was selectively inhibited by [ENTITY_B], nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.",INHIBITOR,CPR:4,1,"CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs."
"<< Acarbose >> served as inhibitor of an interfering [[ acid alpha-glucosidase ]] present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed.","[ENTITY_A] served as inhibitor of an interfering [ENTITY_B] present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed.",INHIBITOR,CPR:4,1,"Acarbose served as inhibitor of an interfering acid alpha-glucosidase present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed."
"After 12 months of treatment, << carvedilol >> significantly improved all end points (plasma concentration of [[ B-type natriuretic peptide ]] [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).","After 12 months of treatment, [ENTITY_A] significantly improved all end points (plasma concentration of [ENTITY_B] [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).",INDIRECT-DOWNREGULATOR,CPR:4,1,"After 12 months of treatment, carvedilol significantly improved all end points (plasma concentration of B-type natriuretic peptide [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs)."
Univariate regression analyses showed that only the use of << carvedilol >> was correlated with the decrease in [[ plasma BNP ]] concentration (p <0.03).,Univariate regression analyses showed that only the use of [ENTITY_A] was correlated with the decrease in [ENTITY_B] concentration (p <0.03).,INDIRECT-DOWNREGULATOR,CPR:4,1,Univariate regression analyses showed that only the use of carvedilol was correlated with the decrease in plasma BNP concentration (p <0.03).
<< Terbinafine >>: mode of action and properties of the [[ squalene epoxidase ]] inhibition.,[ENTITY_A]: mode of action and properties of the [ENTITY_B] inhibition.,INHIBITOR,CPR:4,1,Terbinafine: mode of action and properties of the squalene epoxidase inhibition.
<< Terbinafine >> (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of [[ squalene epoxidase ]] inhibition.,[ENTITY_A] (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of [ENTITY_B] inhibition.,INHIBITOR,CPR:4,1,Terbinafine (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of squalene epoxidase inhibition.
<< Terbinafine >> is a potent non-competitive inhibitor of [[ squalene epoxidase ]] from Candida (Ki = 30 nM).,[ENTITY_A] is a potent non-competitive inhibitor of [ENTITY_B] from Candida (Ki = 30 nM).,INHIBITOR,CPR:4,1,Terbinafine is a potent non-competitive inhibitor of squalene epoxidase from Candida (Ki = 30 nM).
"In contrast, inhibition of << rat liver squalene epoxidase >> only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with [[ squalene ]].","In contrast, inhibition of [ENTITY_A] only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with [ENTITY_B].",INHIBITOR,CPR:4,1,"In contrast, inhibition of rat liver squalene epoxidase only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with squalene."
Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the << apoA-I >> induction [[ pitavastatin ]] (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).,Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the [ENTITY_A] induction [ENTITY_B] (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).,INDIRECT-UPREGULATOR,CPR:3,0,Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).
"The induction of << apoA-I >> by statins disappeared with addition of [[ mevalonate ]], which indicates that the effect is HMG-CoA reductase inhibition-dependent.","The induction of [ENTITY_A] by statins disappeared with addition of [ENTITY_B], which indicates that the effect is HMG-CoA reductase inhibition-dependent.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The induction of apoA-I by statins disappeared with addition of mevalonate, which indicates that the effect is HMG-CoA reductase inhibition-dependent."
"Based on HMG-CoA reductase inhibition, pitavastatin-induced << apoA-I >> more efficiently than [[ simvastatin ]] and atorvastatin.","Based on HMG-CoA reductase inhibition, pitavastatin-induced [ENTITY_A] more efficiently than [ENTITY_B] and atorvastatin.",INDIRECT-UPREGULATOR,CPR:3,0,"Based on HMG-CoA reductase inhibition, pitavastatin-induced apoA-I more efficiently than simvastatin and atorvastatin."
Further study revealed that << pitavastatin >> increased [[ ABCA1 ]] mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.,Further study revealed that [ENTITY_A] increased [ENTITY_B] mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.,INDIRECT-UPREGULATOR,CPR:3,0,Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.
Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that << Rho >> and Rho kinase inhibitor (C3T and [[ Y27632 ]]) increased apoA-I production in the HepG2 cells.,Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that [ENTITY_A] and Rho kinase inhibitor (C3T and [ENTITY_B]) increased apoA-I production in the HepG2 cells.,INHIBITOR,CPR:4,1,Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.
These results suggest that << pitavastatin >> efficiently increases [[ apoA-I ]] in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.,These results suggest that [ENTITY_A] efficiently increases [ENTITY_B] in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.,INDIRECT-UPREGULATOR,CPR:3,0,These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.
These results suggest that << pitavastatin >> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of [[ HMG-CoA reductase ]] and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.,These results suggest that [ENTITY_A] efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of [ENTITY_B] and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.,INHIBITOR,CPR:4,1,These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.
"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two << receptor tyrosine kinase >> inhibitors, [[ imatinib ]] and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.","MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two [ENTITY_A] inhibitors, [ENTITY_B] and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.",INHIBITOR,CPR:4,1,"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition."
"RESULTS: << Imatinib >>, despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or [[ VEGFR ]] inhibition.","RESULTS: [ENTITY_A], despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or [ENTITY_B] inhibition.",INHIBITOR,CPR:4,1,"RESULTS: Imatinib, despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or VEGFR inhibition."
The objective of the present study was to compare the anti-inflammatory effects of the preferential COX-2 inhibitor etodolac with the non-selective << COX >> inhibitor [[ phenylbutazone ]] in horses with lipopolysaccharide (LPS)-induced synovitis.,The objective of the present study was to compare the anti-inflammatory effects of the preferential COX-2 inhibitor etodolac with the non-selective [ENTITY_A] inhibitor [ENTITY_B] in horses with lipopolysaccharide (LPS)-induced synovitis.,INHIBITOR,CPR:4,1,The objective of the present study was to compare the anti-inflammatory effects of the preferential COX-2 inhibitor etodolac with the non-selective COX inhibitor phenylbutazone in horses with lipopolysaccharide (LPS)-induced synovitis.
"In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable << COX-1 >> prostanoid TXB2 was significantly reduced by [[ phenylbutazone ]] (P<0.05), but not etodolac.","In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable [ENTITY_A] prostanoid TXB2 was significantly reduced by [ENTITY_B] (P<0.05), but not etodolac.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable COX-1 prostanoid TXB2 was significantly reduced by phenylbutazone (P<0.05), but not etodolac."
Effect of << bosentan >> ([[ ETA ]]/ETB receptor antagonist) on metabolic changes during stress and diabetes.,Effect of [ENTITY_A] ([ENTITY_B]/ETB receptor antagonist) on metabolic changes during stress and diabetes.,ANTAGONIST,CPR:6,3,Effect of bosentan (ETA/ETB receptor antagonist) on metabolic changes during stress and diabetes.
"To test this, we studied the possible effect of the << endothelin receptor >> antagonist, [[ bosentan ]] (50 and 100 mg kg(-1)) on serum glucose and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals.","To test this, we studied the possible effect of the [ENTITY_A] antagonist, [ENTITY_B] (50 and 100 mg kg(-1)) on serum glucose and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals.",ANTAGONIST,CPR:6,3,"To test this, we studied the possible effect of the endothelin receptor antagonist, bosentan (50 and 100 mg kg(-1)) on serum glucose and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals."
"Pre-irradiation administration of RP-1 enhanced levels of << GSH >> induced increase in [[ complex I ]] (upto 16 h), complex I/III (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).","Pre-irradiation administration of RP-1 enhanced levels of [ENTITY_A] induced increase in [ENTITY_B] (upto 16 h), complex I/III (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).",ACTIVATOR,CPR:3,0,"Pre-irradiation administration of RP-1 enhanced levels of GSH induced increase in complex I (upto 16 h), complex I/III (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01)."
"Moreover, << minocycline >> efficiently suppressed the release of [[ cytochrome c ]] from mitochondria of the liver tissues from Jo2-challenged mice.","Moreover, [ENTITY_A] efficiently suppressed the release of [ENTITY_B] from mitochondria of the liver tissues from Jo2-challenged mice.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, minocycline efficiently suppressed the release of cytochrome c from mitochondria of the liver tissues from Jo2-challenged mice."
"Our results suggest that easing of Fas-triggered fulminant hepatitis by << minocycline >> may involve a mitochondrial apoptotic pathway, probably through preventing [[ cytochrome c ]] release and thereby blocking downstream caspase activation.","Our results suggest that easing of Fas-triggered fulminant hepatitis by [ENTITY_A] may involve a mitochondrial apoptotic pathway, probably through preventing [ENTITY_B] release and thereby blocking downstream caspase activation.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Our results suggest that easing of Fas-triggered fulminant hepatitis by minocycline may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream caspase activation."
Cystathionine-gamma-lyase (<< CSE >>) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form [[ H2S ]].,Cystathionine-gamma-lyase ([ENTITY_A]) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form [ENTITY_B].,PRODUCT-OF,CPR:9,4,Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S.
"Of these two enzymes, << cystathionine-gamma-lyase >> (CSE) is believed to be the key enzyme that forms [[ H2S ]] in the cardiovascular system.","Of these two enzymes, [ENTITY_A] (CSE) is believed to be the key enzyme that forms [ENTITY_B] in the cardiovascular system.",PRODUCT-OF,CPR:9,4,"Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system."
"Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic << myeloperoxidase oxidase >> (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; [[ PAG ]], 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.","Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic [ENTITY_A] (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; [ENTITY_B], 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.",ACTIVATOR,CPR:3,0,"Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury."
"Also, prophylactic, as well as therapeutic, treatment with the << CSE >> inhibitor, [[ DL-propargylglycine ]] (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.","Also, prophylactic, as well as therapeutic, treatment with the [ENTITY_A] inhibitor, [ENTITY_B] (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.",INHIBITOR,CPR:4,1,"Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury."
"ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (<< LXRs >>), which are also activated by oxysterols and some derivatives of plant [[ sterols ]].","ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors ([ENTITY_A]), which are also activated by oxysterols and some derivatives of plant [ENTITY_B].",ACTIVATOR,CPR:3,0,"ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols."
<< NPC1L1 >> could recently be identified as a major sterol transporter for the intestinal uptake of [[ cholesterol ]] as well as plant sterols.,[ENTITY_A] could recently be identified as a major sterol transporter for the intestinal uptake of [ENTITY_B] as well as plant sterols.,SUBSTRATE,CPR:9,4,NPC1L1 could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant sterols.
<< Bupropion >> has an antidepressant effect through blocking the [[ dopamine transporter ]].,[ENTITY_A] has an antidepressant effect through blocking the [ENTITY_B].,INHIBITOR,CPR:4,1,Bupropion has an antidepressant effect through blocking the dopamine transporter.
"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, << bexarotene >>, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the [[ p55 ]] and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.","In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, [ENTITY_A], at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the [ENTITY_B] and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.",INDIRECT-UPREGULATOR,CPR:3,0,"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, bexarotene, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox."
Our results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and that even low doses (150 mg/day) of << bexarotene >> are capable of in vivo upregulation of [[ CD25 ]] expression on circulating leukemia cells.,Our results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and that even low doses (150 mg/day) of [ENTITY_A] are capable of in vivo upregulation of [ENTITY_B] expression on circulating leukemia cells.,INDIRECT-UPREGULATOR,CPR:3,0,Our results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and that even low doses (150 mg/day) of bexarotene are capable of in vivo upregulation of CD25 expression on circulating leukemia cells.
"<< PSMA >> acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including [[ folate ]], the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.","[ENTITY_A] acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including [ENTITY_B], the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.",SUBSTRATE,CPR:9,4,"PSMA acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate."
Elucidation of the << PSMA >> structure combined with docking studies and a proposed catalytic mechanism provides insight into the recognition of inhibitors and the natural substrate [[ N-acetyl-l-aspartyl-l-glutamate ]].,Elucidation of the [ENTITY_A] structure combined with docking studies and a proposed catalytic mechanism provides insight into the recognition of inhibitors and the natural substrate [ENTITY_B].,SUBSTRATE,CPR:9,4,Elucidation of the PSMA structure combined with docking studies and a proposed catalytic mechanism provides insight into the recognition of inhibitors and the natural substrate N-acetyl-l-aspartyl-l-glutamate.
"A number of selective << 5-HT3 >> antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and [[ zacopride ]].","A number of selective [ENTITY_A] antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and [ENTITY_B].",ANTAGONIST,CPR:6,3,"A number of selective 5-HT3 antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and zacopride."
"While the substituted << benzamide >> prokinetics (for example, metoclopramide, cisapride) also block [[ 5-HT3 ]] receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.","While the substituted [ENTITY_A] prokinetics (for example, metoclopramide, cisapride) also block [ENTITY_B] receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.",INHIBITOR,CPR:4,1,"While the substituted benzamide prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor."
"While the substituted << benzamide >> prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative [[ 5-HT4 ]] receptor.","While the substituted [ENTITY_A] prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative [ENTITY_B] receptor.",AGONIST,CPR:5,2,"While the substituted benzamide prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor."
"Some 5-HT3 antagonists have << 5-HT4 >> agonist activity (for example, [[ renzapride ]], zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.","Some 5-HT3 antagonists have [ENTITY_A] agonist activity (for example, [ENTITY_B], zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.",AGONIST,CPR:5,2,"Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist."
"Some << 5-HT3 >> antagonists have 5-HT4 agonist activity (for example, [[ renzapride ]], zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.","Some [ENTITY_A] antagonists have 5-HT4 agonist activity (for example, [ENTITY_B], zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.",ANTAGONIST,CPR:6,3,"Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist."
"We present our studies to demonstrate that HM74A, but not HM74, binds << niacin >> at high affinities and effectively mediates [[ Gi ]] signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.","We present our studies to demonstrate that HM74A, but not HM74, binds [ENTITY_A] at high affinities and effectively mediates [ENTITY_B] signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.",INDIRECT-UPREGULATOR,CPR:3,0,"We present our studies to demonstrate that HM74A, but not HM74, binds niacin at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A."
"When cultured in YPD medium containing 15% glucose under aerobic conditions, the << KGD1 >> (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of [[ succinate ]] than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.","When cultured in YPD medium containing 15% glucose under aerobic conditions, the [ENTITY_A] (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of [ENTITY_B] than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.",PRODUCT-OF,CPR:9,4,"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate."
"On the other hand, the << FUM1 >> (fumarase) gene disrupted mutant produced significantly higher levels of [[ fumarate ]] but did not form malate at all.","On the other hand, the [ENTITY_A] (fumarase) gene disrupted mutant produced significantly higher levels of [ENTITY_B] but did not form malate at all.",PRODUCT-OF,CPR:9,4,"On the other hand, the FUM1 (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form malate at all."
"When the growth condition was shifted from aerobic to anaerobic, the increased level of << succinate >> in [[ SDH1 ]] disruptants was no longer observed, whereas the decreased level of succinate in the KGD1 diruptant was still observed.","When the growth condition was shifted from aerobic to anaerobic, the increased level of [ENTITY_A] in [ENTITY_B] disruptants was no longer observed, whereas the decreased level of succinate in the KGD1 diruptant was still observed.",PRODUCT-OF,CPR:9,4,"When the growth condition was shifted from aerobic to anaerobic, the increased level of succinate in SDH1 disruptants was no longer observed, whereas the decreased level of succinate in the KGD1 diruptant was still observed."
A double mutant of the two << fumarate reductase >> isozyme genes (OSM1 and FRDS) showed a [[ succinate ]] productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.,A double mutant of the two [ENTITY_A] isozyme genes (OSM1 and FRDS) showed a [ENTITY_B] productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.,PRODUCT-OF,CPR:9,4,A double mutant of the two fumarate reductase isozyme genes (OSM1 and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.
<< Vitamin E >> and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and [[ low-density lipoprotein ]] cholesterol compared to HC-control group.,[ENTITY_A] and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and [ENTITY_B] cholesterol compared to HC-control group.,INDIRECT-DOWNREGULATOR,CPR:4,1,Vitamin E and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and low-density lipoprotein cholesterol compared to HC-control group.
"However, plasma high-density lipoprotein-cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma << paraoxonase >> activity were only significantly higher in [[ vitamin E ]] group after 8 weeks.","However, plasma high-density lipoprotein-cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma [ENTITY_A] activity were only significantly higher in [ENTITY_B] group after 8 weeks.",ACTIVATOR,CPR:3,0,"However, plasma high-density lipoprotein-cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks."
"Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while << HMG-CoA reductase >> activity was the highest only in the [[ probucol ]] group.","Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while [ENTITY_A] activity was the highest only in the [ENTITY_B] group.",ACTIVATOR,CPR:3,0,"Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group."
"Hepatic << ACAT >> activity was significantly lower in both [[ vitamin E ]] and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group.","Hepatic [ENTITY_A] activity was significantly lower in both [ENTITY_B] and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group.",INHIBITOR,CPR:4,1,"Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group."
Hepatic mRNA expressions of << apo B-100 >> and apo C-III were significantly lower in [[ probucol ]] group than in other groups.,Hepatic mRNA expressions of [ENTITY_A] and apo C-III were significantly lower in [ENTITY_B] group than in other groups.,INDIRECT-DOWNREGULATOR,CPR:4,1,Hepatic mRNA expressions of apo B-100 and apo C-III were significantly lower in probucol group than in other groups.
"Vitamin E supplementation was found to alter the plasma HDL-C-related factors; meanwhile, << probucol >> supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma [[ HDL ]]-C concentration.","Vitamin E supplementation was found to alter the plasma HDL-C-related factors; meanwhile, [ENTITY_A] supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma [ENTITY_B]-C concentration.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Vitamin E supplementation was found to alter the plasma HDL-C-related factors; meanwhile, probucol supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma HDL-C concentration."
"The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel << CCR5 >> antagonists, such as [[ maraviroc ]] (UK-427,857).","The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel [ENTITY_A] antagonists, such as [ENTITY_B] (UK-427,857).",ANTAGONIST,CPR:6,3,"The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel CCR5 antagonists, such as maraviroc (UK-427,857)."
"<< Maraviroc >> inhibited binding of [125I]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through [[ CCR5 ]] from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).","[ENTITY_A] inhibited binding of [125I]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through [ENTITY_B] from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).",ANTAGONIST,CPR:6,3,"Maraviroc inhibited binding of [125I]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively)."
"However, as with the human receptor, << maraviroc >> was shown to be a high affinity, potent functional antagonist of [[ macaque CCR5 ]] thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists.","However, as with the human receptor, [ENTITY_A] was shown to be a high affinity, potent functional antagonist of [ENTITY_B] thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists.",ANTAGONIST,CPR:6,3,"However, as with the human receptor, maraviroc was shown to be a high affinity, potent functional antagonist of macaque CCR5 thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists."
"Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of << CRABPI >> for localized sequestration of [[ retinoids ]] that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.","Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of [ENTITY_A] for localized sequestration of [ENTITY_B] that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.",INDIRECT-UPREGULATOR,CPR:3,0,"Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of retinoids that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta."
"Its special profile of actions, especially the rise in << HDL >>-cholesterol levels induced by [[ nicotinic acid ]], is unique among the currently available pharmacological tools to treat lipid disorders.","Its special profile of actions, especially the rise in [ENTITY_A]-cholesterol levels induced by [ENTITY_B], is unique among the currently available pharmacological tools to treat lipid disorders.",INDIRECT-UPREGULATOR,CPR:3,0,"Its special profile of actions, especially the rise in HDL-cholesterol levels induced by nicotinic acid, is unique among the currently available pharmacological tools to treat lipid disorders."
<< Valproic acid >> selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by [[ brain microsomal long-chain fatty acyl-CoA synthetases ]]: relevance to bipolar disorder.,[ENTITY_A] selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by [ENTITY_B]: relevance to bipolar disorder.,INHIBITOR,CPR:4,1,Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder.
Valproic acid selectively inhibits conversion of arachidonic acid to << arachidonoyl-CoA >> by [[ brain microsomal long-chain fatty acyl-CoA synthetases ]]: relevance to bipolar disorder.,Valproic acid selectively inhibits conversion of arachidonic acid to [ENTITY_A] by [ENTITY_B]: relevance to bipolar disorder.,PRODUCT-OF,CPR:9,4,Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder.
"RATIONALE: Several drugs used to treat bipolar disorder (<< lithium >> and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective [[ phospholipase A(2) ]].","RATIONALE: Several drugs used to treat bipolar disorder ([ENTITY_A] and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective [ENTITY_B].",INHIBITOR,CPR:4,1,"RATIONALE: Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective phospholipase A(2)."
"MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (Acsl), we show in vitro that << valproic acid >> is a non-competitive inhibitor of [[ Acsl ]], as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.","MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (Acsl), we show in vitro that [ENTITY_A] is a non-competitive inhibitor of [ENTITY_B], as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.",INHIBITOR,CPR:4,1,"MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (Acsl), we show in vitro that valproic acid is a non-competitive inhibitor of Acsl, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme."
"CONCLUSIONS: This study shows that << valproic acid >> acts as a non-competitive inhibitor of [[ brain microsomal Acsl ]], and that inhibition is substrate-selective.","CONCLUSIONS: This study shows that [ENTITY_A] acts as a non-competitive inhibitor of [ENTITY_B], and that inhibition is substrate-selective.",INHIBITOR,CPR:4,1,"CONCLUSIONS: This study shows that valproic acid acts as a non-competitive inhibitor of brain microsomal Acsl, and that inhibition is substrate-selective."
"On the other hand, holocarboxylase synthetase (<< HCS >>) mRNA levels were markedly low in the deficient animals, and increased upon [[ biotin ]] injection.","On the other hand, holocarboxylase synthetase ([ENTITY_A]) mRNA levels were markedly low in the deficient animals, and increased upon [ENTITY_B] injection.",INDIRECT-UPREGULATOR,CPR:3,0,"On the other hand, holocarboxylase synthetase (HCS) mRNA levels were markedly low in the deficient animals, and increased upon biotin injection."
Involvement of << COX-1 >> and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced [[ prostaglandin E2 ]] production by microglia.,Involvement of [ENTITY_A] and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced [ENTITY_B] production by microglia.,PRODUCT-OF,CPR:9,4,Involvement of COX-1 and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced prostaglandin E2 production by microglia.
"Furthermore, PS liposome-induced PGE2 production was significantly suppressed by << indomethacin >>, a preferential [[ COX-1 ]] inhibitor, but not by NS-398, a selective COX-2 inhibitor.","Furthermore, PS liposome-induced PGE2 production was significantly suppressed by [ENTITY_A], a preferential [ENTITY_B] inhibitor, but not by NS-398, a selective COX-2 inhibitor.",INHIBITOR,CPR:4,1,"Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin, a preferential COX-1 inhibitor, but not by NS-398, a selective COX-2 inhibitor."
"These observations strongly suggest that the up-regulation of terminal << PGESs >> that are preferentially coupled with COX-1, especially mPGES-2, plays the pivotal role in PS liposome-induced [[ PGE2 ]] production by microglia.","These observations strongly suggest that the up-regulation of terminal [ENTITY_A] that are preferentially coupled with COX-1, especially mPGES-2, plays the pivotal role in PS liposome-induced [ENTITY_B] production by microglia.",PRODUCT-OF,CPR:9,4,"These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with COX-1, especially mPGES-2, plays the pivotal role in PS liposome-induced PGE2 production by microglia."
"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-<< kinase >> inhibitors (MKIs) [[ sorafenib ]], sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta.","Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-[ENTITY_A] inhibitors (MKIs) [ENTITY_B], sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta.",INHIBITOR,CPR:4,1,"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta."
"<< Sorafenib >> has the added advantage of inhibiting multiple different [[ Raf ]] isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.","[ENTITY_A] has the added advantage of inhibiting multiple different [ENTITY_B] isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.",INHIBITOR,CPR:4,1,"Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta."
"Low << TS >> expression levels, cytoplasmic expression pattern and C SNP arose as variables associated to longer progression-free survival (PFS) in patients treated with [[ 5FU ]].","Low [ENTITY_A] expression levels, cytoplasmic expression pattern and C SNP arose as variables associated to longer progression-free survival (PFS) in patients treated with [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Low TS expression levels, cytoplasmic expression pattern and C SNP arose as variables associated to longer progression-free survival (PFS) in patients treated with 5FU."
"Therefore, in the present studies, animals were rendered tolerant to the << delta-opioid receptor >>-selective agonist [D-Pen2,D-Pen5]enkephalin ([[ DPDPE ]]), and receptor binding activities were measured.","Therefore, in the present studies, animals were rendered tolerant to the [ENTITY_A]-selective agonist [D-Pen2,D-Pen5]enkephalin ([ENTITY_B]), and receptor binding activities were measured.",AGONIST,CPR:5,2,"Therefore, in the present studies, animals were rendered tolerant to the delta-opioid receptor-selective agonist [D-Pen2,D-Pen5]enkephalin (DPDPE), and receptor binding activities were measured."
Our conclusion is that chronic << DPDPE >> treatment preferentially reduces [[ delta-opioid receptor ]] binding activity.,Our conclusion is that chronic [ENTITY_A] treatment preferentially reduces [ENTITY_B] binding activity.,INHIBITOR,CPR:4,1,Our conclusion is that chronic DPDPE treatment preferentially reduces delta-opioid receptor binding activity.
"Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that << amoxapine >> really acts in vivo as a [[ 5-HT3 ]] antagonist (IC50 = 50 micrograms/kg i.v.), whereas amitriptyline is essentially inactive on 5-HT3 receptors.","Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that [ENTITY_A] really acts in vivo as a [ENTITY_B] antagonist (IC50 = 50 micrograms/kg i.v.), whereas amitriptyline is essentially inactive on 5-HT3 receptors.",ANTAGONIST,CPR:6,3,"Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that amoxapine really acts in vivo as a 5-HT3 antagonist (IC50 = 50 micrograms/kg i.v.), whereas amitriptyline is essentially inactive on 5-HT3 receptors."
"Competitive radioligand binding assays were performed using cells expressing either the << human serotonin (5-HT) transporter >> (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for [[ DVS ]] of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.","Competitive radioligand binding assays were performed using cells expressing either the [ENTITY_A] (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for [ENTITY_B] of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.",INHIBITOR,CPR:4,1,"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively."
"Inhibition of << [3H]5-HT >> or [3H]NE uptake by DVS for the [[ hSERT ]] or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.","Inhibition of [ENTITY_A] or [3H]NE uptake by DVS for the [ENTITY_B] or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.",SUBSTRATE,CPR:9,4,"Inhibition of [3H]5-HT or [3H]NE uptake by DVS for the hSERT or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively."
"To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a << 5-HT(1A) >> antagonist, [[ N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt ]] (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).","To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a [ENTITY_A] antagonist, [ENTITY_B] (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).",ANTAGONIST,CPR:6,3,"To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a 5-HT(1A) antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally)."
"The tissue RA level is maintained through a cascade of metabolic reactions where << retinal dehydrogenases >> (RALDHs) catalyze the terminal reaction of [[ RA ]] biosynthesis from retinal, a rate-limiting step.","The tissue RA level is maintained through a cascade of metabolic reactions where [ENTITY_A] (RALDHs) catalyze the terminal reaction of [ENTITY_B] biosynthesis from retinal, a rate-limiting step.",PRODUCT-OF,CPR:9,4,"The tissue RA level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (RALDHs) catalyze the terminal reaction of RA biosynthesis from retinal, a rate-limiting step."
"Further, << cholesterol >> metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of [[ sterol regulatory element binding protein-1c ]] (SREBP-1c) that bound to the regulatory regions of these genes.","Further, [ENTITY_A] metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of [ENTITY_B] (SREBP-1c) that bound to the regulatory regions of these genes.",INDIRECT-UPREGULATOR,CPR:3,0,"Further, cholesterol metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes."
"Hypermethlyation of << RELN and GAD67 promoters >> can be induced by treating mice with [[ methionine ]], and these mice display brain and behavioral abnormalities similar to +/rl.","Hypermethlyation of [ENTITY_A] can be induced by treating mice with [ENTITY_B], and these mice display brain and behavioral abnormalities similar to +/rl.",UPREGULATOR,CPR:3,0,"Hypermethlyation of RELN and GAD67 promoters can be induced by treating mice with methionine, and these mice display brain and behavioral abnormalities similar to +/rl."
Functional and bioenergetic consequences of << AT1 >> antagonist [[ olmesartan medoxomil ]] in hearts with postinfarction LV remodeling.,Functional and bioenergetic consequences of [ENTITY_A] antagonist [ENTITY_B] in hearts with postinfarction LV remodeling.,ANTAGONIST,CPR:6,3,Functional and bioenergetic consequences of AT1 antagonist olmesartan medoxomil in hearts with postinfarction LV remodeling.
"Thus, severe LV dysfunction and accompanying abnormal myocardial bioenergetic phenotype were prevented by the << AT1 >> antagonist [[ olmesartan medoxomil ]].","Thus, severe LV dysfunction and accompanying abnormal myocardial bioenergetic phenotype were prevented by the [ENTITY_A] antagonist [ENTITY_B].",ANTAGONIST,CPR:6,3,"Thus, severe LV dysfunction and accompanying abnormal myocardial bioenergetic phenotype were prevented by the AT1 antagonist olmesartan medoxomil."
"We evaluated << imatinib >>, a [[ tyrosine kinase ]] inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors.","We evaluated [ENTITY_A], a [ENTITY_B] inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors.",INHIBITOR,CPR:4,1,"We evaluated imatinib, a tyrosine kinase inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors."
RESULTS: << Imatinib >> inhibited [[ RET ]] Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure.,RESULTS: [ENTITY_A] inhibited [ENTITY_B] Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure.,INHIBITOR,CPR:4,1,RESULTS: Imatinib inhibited RET Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure.
CONCLUSIONS: << Imatinib >> inhibits RET-mediated MTC cell growth affecting [[ RET ]] protein levels in vitro in a dose-dependent manner.,CONCLUSIONS: [ENTITY_A] inhibits RET-mediated MTC cell growth affecting [ENTITY_B] protein levels in vitro in a dose-dependent manner.,INDIRECT-DOWNREGULATOR,CPR:4,1,CONCLUSIONS: Imatinib inhibits RET-mediated MTC cell growth affecting RET protein levels in vitro in a dose-dependent manner.
"The concentration of << imatinib >> necessary to inhibit [[ RET ]] in vitro, however, makes it impossible to conclude that imatinib monotherapy will be a good option for systemic therapy of MTC.","The concentration of [ENTITY_A] necessary to inhibit [ENTITY_B] in vitro, however, makes it impossible to conclude that imatinib monotherapy will be a good option for systemic therapy of MTC.",INHIBITOR,CPR:4,1,"The concentration of imatinib necessary to inhibit RET in vitro, however, makes it impossible to conclude that imatinib monotherapy will be a good option for systemic therapy of MTC."
"In eukaryotes, the most prominent Mo-enzymes are (1) << sulfite oxidase >>, which catalyzes the final step in the degradation of [[ sulfur ]]-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.","In eukaryotes, the most prominent Mo-enzymes are (1) [ENTITY_A], which catalyzes the final step in the degradation of [ENTITY_B]-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.",SUBSTRATE,CPR:9,4,"In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation."
"<< Retinoid >> is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of [[ nuclear hormone receptor ]] superfamily.","[ENTITY_A] is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of [ENTITY_B] superfamily.",ACTIVATOR,CPR:3,0,"Retinoid is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily."
"The cholesterol-lowering drug << simvastatin >> inhibits [[ LFA-1 ]] signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation.","The cholesterol-lowering drug [ENTITY_A] inhibits [ENTITY_B] signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The cholesterol-lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation."
<< Simvastatin >> abolished these anti-[[ CD11a ]] mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.,[ENTITY_A] abolished these anti-[ENTITY_B] mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.,INDIRECT-DOWNREGULATOR,CPR:4,1,Simvastatin abolished these anti-CD11a mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.
"<< Menthol >>, popularly known for its cooling effect, activates [[ TRPM8 ]]--a cold-activated thermoTRP ion channel.","[ENTITY_A], popularly known for its cooling effect, activates [ENTITY_B]--a cold-activated thermoTRP ion channel.",ACTIVATOR,CPR:3,0,"Menthol, popularly known for its cooling effect, activates TRPM8--a cold-activated thermoTRP ion channel."
"However, human physiological studies demonstrate a paradoxical role of menthol in modulation of warm sensation, and here, we show that << menthol >> also activates heat-activated [[ TRPV3 ]].","However, human physiological studies demonstrate a paradoxical role of menthol in modulation of warm sensation, and here, we show that [ENTITY_A] also activates heat-activated [ENTITY_B].",ACTIVATOR,CPR:3,0,"However, human physiological studies demonstrate a paradoxical role of menthol in modulation of warm sensation, and here, we show that menthol also activates heat-activated TRPV3."
"We further show that << menthol >> inhibits [[ TRPA1 ]], potentially explaining the use of menthol as an analgesic.","We further show that [ENTITY_A] inhibits [ENTITY_B], potentially explaining the use of menthol as an analgesic.",INHIBITOR,CPR:4,1,"We further show that menthol inhibits TRPA1, potentially explaining the use of menthol as an analgesic."
"Similar to << menthol >>, both camphor and cinnamaldehyde (initially reported to be specific activators of [[ TRPV3 ]] and TRPA1, respectively) also modulate other thermoTRPs.","Similar to [ENTITY_A], both camphor and cinnamaldehyde (initially reported to be specific activators of [ENTITY_B] and TRPA1, respectively) also modulate other thermoTRPs.",ACTIVATOR,CPR:3,0,"Similar to menthol, both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other thermoTRPs."
The glutamate-aspartate transporter << GLAST >> mediates [[ glutamate ]] uptake at inner hair cell afferent synapses in the mammalian cochlea.,The glutamate-aspartate transporter [ENTITY_A] mediates [ENTITY_B] uptake at inner hair cell afferent synapses in the mammalian cochlea.,SUBSTRATE,CPR:9,4,The glutamate-aspartate transporter GLAST mediates glutamate uptake at inner hair cell afferent synapses in the mammalian cochlea.
"Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated << anion channel >> and blocked by the transporter antagonist [[ D,L-threo-beta-benzyloxyaspartate ]].","Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated [ENTITY_A] and blocked by the transporter antagonist [ENTITY_B].",ANTAGONIST,CPR:6,3,"Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated anion channel and blocked by the transporter antagonist D,L-threo-beta-benzyloxyaspartate."
"These currents were produced by << glutamate-aspartate transporters >> (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by [[ dihydrokainate ]], an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.","These currents were produced by [ENTITY_A] (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by [ENTITY_B], an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.",INHIBITOR,CPR:4,1,"These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas."
"These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by << dihydrokainate >>, an antagonist of [[ glutamate transporter-1 ]] (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.","These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by [ENTITY_A], an antagonist of [ENTITY_B] (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.",ANTAGONIST,CPR:6,3,"These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas."
"Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by << L-glutamate >>, a prominent feature of [[ GLAST ]], and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.","Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by [ENTITY_A], a prominent feature of [ENTITY_B], and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.",SUBSTRATE,CPR:9,4,"Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by L-glutamate, a prominent feature of GLAST, and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs."
Overexpression of << proline oxidase >> induces [[ proline ]]-dependent and mitochondria-mediated apoptosis.,Overexpression of [ENTITY_A] induces [ENTITY_B]-dependent and mitochondria-mediated apoptosis.,SUBSTRATE,CPR:9,4,Overexpression of proline oxidase induces proline-dependent and mitochondria-mediated apoptosis.
"<< Proline oxidase >> (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to [[ pyrroline- 5-carboxylate ]] (P5C).","[ENTITY_A] (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to [ENTITY_B] (P5C).",PRODUCT-OF,CPR:9,4,"Proline oxidase (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C)."
"To further investigate the molecular basis of POX-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing << POX >> exhibit an [[ L-proline ]]-dependent apoptotic response.","To further investigate the molecular basis of POX-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing [ENTITY_A] exhibit an [ENTITY_B]-dependent apoptotic response.",SUBSTRATE,CPR:9,4,"To further investigate the molecular basis of POX-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing POX exhibit an L-proline-dependent apoptotic response."
"The apoptotic effect is specific for L-proline, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of << L-proline >> to cells with maximally induced [[ POX ]].","The apoptotic effect is specific for L-proline, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of [ENTITY_A] to cells with maximally induced [ENTITY_B].",SUBSTRATE,CPR:9,4,"The apoptotic effect is specific for L-proline, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of L-proline to cells with maximally induced POX."
"We conclude that in the presence of << proline >>, high [[ POX ]] activity is sufficient to induce mitochondria-mediated apoptosis.","We conclude that in the presence of [ENTITY_A], high [ENTITY_B] activity is sufficient to induce mitochondria-mediated apoptosis.",SUBSTRATE,CPR:9,4,"We conclude that in the presence of proline, high POX activity is sufficient to induce mitochondria-mediated apoptosis."
"The exception was << bupropion >>, a dual [[ norepinephrine transporter ]]/dopamine transporter blocker, which tended to increase spontaneous locomotor activity.","The exception was [ENTITY_A], a dual [ENTITY_B]/dopamine transporter blocker, which tended to increase spontaneous locomotor activity.",INHIBITOR,CPR:4,1,"The exception was bupropion, a dual norepinephrine transporter/dopamine transporter blocker, which tended to increase spontaneous locomotor activity."
Coadministration of reboxetine and the << dopamine transporter >> blocker [[ GBR 12909 ]] also increased spontaneous locomotor activity.,Coadministration of reboxetine and the [ENTITY_A] blocker [ENTITY_B] also increased spontaneous locomotor activity.,INHIBITOR,CPR:4,1,Coadministration of reboxetine and the dopamine transporter blocker GBR 12909 also increased spontaneous locomotor activity.
"<< Tamoxifen >> blocks the action of estrogen by binding to the ER, and possesses both [[ ER ]]-agonist and antagonist properties.","[ENTITY_A] blocks the action of estrogen by binding to the ER, and possesses both [ENTITY_B]-agonist and antagonist properties.",AGONIST,CPR:5,2,"Tamoxifen blocks the action of estrogen by binding to the ER, and possesses both ER-agonist and antagonist properties."
"<< Tamoxifen >> blocks the action of estrogen by binding to the ER, and possesses both [[ ER ]]-agonist and antagonist properties.","[ENTITY_A] blocks the action of estrogen by binding to the ER, and possesses both [ENTITY_B]-agonist and antagonist properties.",ANTAGONIST,CPR:6,3,"Tamoxifen blocks the action of estrogen by binding to the ER, and possesses both ER-agonist and antagonist properties."
<< Fulvestrant >> is a novel ER antagonist that destroys the [[ ER ]] and its signaling pathway and is not associated with tamoxifen-like agonist effects.,[ENTITY_A] is a novel ER antagonist that destroys the [ENTITY_B] and its signaling pathway and is not associated with tamoxifen-like agonist effects.,INHIBITOR,CPR:4,1,Fulvestrant is a novel ER antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects.
<< Fulvestrant >> is a novel [[ ER ]] antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects.,[ENTITY_A] is a novel [ENTITY_B] antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects.,ANTAGONIST,CPR:6,3,Fulvestrant is a novel ER antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects.
"<< Phosphodiesterase-5 >> (PDE5) contains a catalytic domain (C domain) that hydrolyzes [[ cGMP ]] and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).","[ENTITY_A] (PDE5) contains a catalytic domain (C domain) that hydrolyzes [ENTITY_B] and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).",SUBSTRATE,CPR:9,4,"Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs)."
Binding of << cGMP >> to GAF-A increases [[ cNPK ]] phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors.,Binding of [ENTITY_A] to GAF-A increases [ENTITY_B] phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors.,INDIRECT-UPREGULATOR,CPR:3,0,Binding of cGMP to GAF-A increases cNPK phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors.
K(m) values of the mutants for << cGMP >> were similar to that of full-length [[ PDE5 ]].,K(m) values of the mutants for [ENTITY_A] were similar to that of full-length [ENTITY_B].,SUBSTRATE,CPR:9,4,K(m) values of the mutants for cGMP were similar to that of full-length PDE5.
<< Telmisartan >> downregulates angiotensin II type 1 receptor through activation of [[ peroxisome proliferator-activated receptor gamma ]].,[ENTITY_A] downregulates angiotensin II type 1 receptor through activation of [ENTITY_B].,ACTIVATOR,CPR:3,0,Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
<< Telmisartan >> downregulates [[ angiotensin II type 1 receptor ]] through activation of peroxisome proliferator-activated receptor gamma.,[ENTITY_A] downregulates [ENTITY_B] through activation of peroxisome proliferator-activated receptor gamma.,DOWNREGULATOR,CPR:4,1,Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
"OBJECTIVE: << Telmisartan >>, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of [[ peroxisome proliferator-activated receptor gamma ]] (PPARgamma).","OBJECTIVE: [ENTITY_A], an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of [ENTITY_B] (PPARgamma).",AGONIST,CPR:5,2,"OBJECTIVE: Telmisartan, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma)."
"OBJECTIVE: << Telmisartan >>, an [[ angiotensin II type 1 receptor ]] (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).","OBJECTIVE: [ENTITY_A], an [ENTITY_B] (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).",ANTAGONIST,CPR:6,3,"OBJECTIVE: Telmisartan, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma)."
RESULTS: << Telmisartan >> decreased the expression of [[ AT1R ]] at the mRNA and protein levels in a dose- and time-dependent manner.,RESULTS: [ENTITY_A] decreased the expression of [ENTITY_B] at the mRNA and protein levels in a dose- and time-dependent manner.,INDIRECT-DOWNREGULATOR,CPR:4,1,RESULTS: Telmisartan decreased the expression of AT1R at the mRNA and protein levels in a dose- and time-dependent manner.
Decreased AT1R promoter activity with unchanged mRNA stability suggested that << telmisartan >> suppressed [[ AT1R ]] gene expression at the transcriptional level.,Decreased AT1R promoter activity with unchanged mRNA stability suggested that [ENTITY_A] suppressed [ENTITY_B] gene expression at the transcriptional level.,INDIRECT-DOWNREGULATOR,CPR:4,1,Decreased AT1R promoter activity with unchanged mRNA stability suggested that telmisartan suppressed AT1R gene expression at the transcriptional level.
"However, the expression of AT1R was not suppressed by other << AT1R >> antagonists such as [[ candesartan ]] or olmesartan.","However, the expression of AT1R was not suppressed by other [ENTITY_A] antagonists such as [ENTITY_B] or olmesartan.",ANTAGONIST,CPR:6,3,"However, the expression of AT1R was not suppressed by other AT1R antagonists such as candesartan or olmesartan."
"Since the suppression of << AT1R >> expression was prevented by pretreatment with [[ GW9662 ]], a PPARgamma antagonist, PPARgamma should have participated in the process.","Since the suppression of [ENTITY_A] expression was prevented by pretreatment with [ENTITY_B], a PPARgamma antagonist, PPARgamma should have participated in the process.",INDIRECT-UPREGULATOR,CPR:3,0,"Since the suppression of AT1R expression was prevented by pretreatment with GW9662, a PPARgamma antagonist, PPARgamma should have participated in the process."
"Since the suppression of AT1R expression was prevented by pretreatment with << GW9662 >>, a [[ PPARgamma ]] antagonist, PPARgamma should have participated in the process.","Since the suppression of AT1R expression was prevented by pretreatment with [ENTITY_A], a [ENTITY_B] antagonist, PPARgamma should have participated in the process.",ANTAGONIST,CPR:6,3,"Since the suppression of AT1R expression was prevented by pretreatment with GW9662, a PPARgamma antagonist, PPARgamma should have participated in the process."
The deletion and mutation analysis of the << AT1R >> gene promoter indicated that a GC box located in the proximal promoter region is responsible for the [[ telmisartan ]]-induced downregulation.,The deletion and mutation analysis of the [ENTITY_A] gene promoter indicated that a GC box located in the proximal promoter region is responsible for the [ENTITY_B]-induced downregulation.,INDIRECT-DOWNREGULATOR,CPR:4,1,The deletion and mutation analysis of the AT1R gene promoter indicated that a GC box located in the proximal promoter region is responsible for the telmisartan-induced downregulation.
CONCLUSION: Our data provides a novel insight into an effect of telmisartan: << telmisartan >> inhibits AT1R gene expression through [[ PPARgamma ]] activation.,CONCLUSION: Our data provides a novel insight into an effect of telmisartan: [ENTITY_A] inhibits AT1R gene expression through [ENTITY_B] activation.,ACTIVATOR,CPR:3,0,CONCLUSION: Our data provides a novel insight into an effect of telmisartan: telmisartan inhibits AT1R gene expression through PPARgamma activation.
CONCLUSION: Our data provides a novel insight into an effect of telmisartan: << telmisartan >> inhibits [[ AT1R ]] gene expression through PPARgamma activation.,CONCLUSION: Our data provides a novel insight into an effect of telmisartan: [ENTITY_A] inhibits [ENTITY_B] gene expression through PPARgamma activation.,INDIRECT-DOWNREGULATOR,CPR:4,1,CONCLUSION: Our data provides a novel insight into an effect of telmisartan: telmisartan inhibits AT1R gene expression through PPARgamma activation.
"Upon differentiation, osteoclasts express << vesicular glutamate transporter 1 >> (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of [[ glutamate ]] in neurons.","Upon differentiation, osteoclasts express [ENTITY_A] (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of [ENTITY_B] in neurons.",SUBSTRATE,CPR:9,4,"Upon differentiation, osteoclasts express vesicular glutamate transporter 1 (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of glutamate in neurons."
<< VGLUT1 >> is localized in transcytotic vesicles and accumulates [[ L-glutamate ]].,[ENTITY_A] is localized in transcytotic vesicles and accumulates [ENTITY_B].,SUBSTRATE,CPR:9,4,VGLUT1 is localized in transcytotic vesicles and accumulates L-glutamate.
"Synthesis, << dihydrofolate reductase >> inhibition, antitumor testing, and molecular modeling study of some new [[ 4(3H)-quinazolinone ]] analogs.","Synthesis, [ENTITY_A] inhibition, antitumor testing, and molecular modeling study of some new [ENTITY_B] analogs.",INHIBITOR,CPR:4,1,"Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs."
"In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble << methotrexate >> (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of [[ mammalian DHFR ]] activity.","In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble [ENTITY_A] (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of [ENTITY_B] activity.",INHIBITOR,CPR:4,1,"In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of mammalian DHFR activity."
"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of << linoleic acid >> (LA) and alpha-linolenic acid (LNA) and the expression of PBMC [[ D6D ]] and D5D genes.","A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of [ENTITY_A] (LA) and alpha-linolenic acid (LNA) and the expression of PBMC [ENTITY_B] and D5D genes.",INDIRECT-DOWNREGULATOR,CPR:4,1,"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes."
"CONCLUSION: Intake of high << SFAs >> and MUFAs appears to increase expression of PBMC [[ D6D ]] and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.","CONCLUSION: Intake of high [ENTITY_A] and MUFAs appears to increase expression of PBMC [ENTITY_B] and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.",INDIRECT-UPREGULATOR,CPR:3,0,"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes."
"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high << EFAs >> intake appears to decrease expression of PBMC [[ D6D ]] and D5D genes.","CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high [ENTITY_A] intake appears to decrease expression of PBMC [ENTITY_B] and D5D genes.",INDIRECT-DOWNREGULATOR,CPR:4,1,"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes."
<< Decitabine >> inhibits [[ DNA methyltransferase ]] and has shown therapeutic effects in patients with hematologic malignancies.,[ENTITY_A] inhibits [ENTITY_B] and has shown therapeutic effects in patients with hematologic malignancies.,INHIBITOR,CPR:4,1,Decitabine inhibits DNA methyltransferase and has shown therapeutic effects in patients with hematologic malignancies.
"Our data suggest that << l-arginine >> is taken up by Sertoli cells and peritubular cells, principally via system y(+)L ([[ SLC3A2 ]]/SLC7A6) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution.","Our data suggest that [ENTITY_A] is taken up by Sertoli cells and peritubular cells, principally via system y(+)L ([ENTITY_B]/SLC7A6) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution.",SUBSTRATE,CPR:9,4,"Our data suggest that l-arginine is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (SLC3A2/SLC7A6) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution."
KIEs were measured on the arsenolysis of << 5'-methylthioadenosine >> (MTA) catalyzed by [[ MTAP ]] and were corrected for the forward commitment to catalysis.,KIEs were measured on the arsenolysis of [ENTITY_A] (MTA) catalyzed by [ENTITY_B] and were corrected for the forward commitment to catalysis.,SUBSTRATE,CPR:9,4,KIEs were measured on the arsenolysis of 5'-methylthioadenosine (MTA) catalyzed by MTAP and were corrected for the forward commitment to catalysis.
"During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to << retinal dehydrogenase 2 >> (raldh2), the key enzyme for [[ retinoic acid ]] synthesis.","During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to [ENTITY_A] (raldh2), the key enzyme for [ENTITY_B] synthesis.",PRODUCT-OF,CPR:9,4,"During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (raldh2), the key enzyme for retinoic acid synthesis."
"Blocking << retinyl ester >> formation by a targeted knock down of [[ Lratb ]] results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects.","Blocking [ENTITY_A] formation by a targeted knock down of [ENTITY_B] results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects.",PRODUCT-OF,CPR:9,4,"Blocking retinyl ester formation by a targeted knock down of Lratb results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects."
"<< ADP >> initiates platelet aggregation by 'simultaneous activation of two [[ G protein-coupled receptors ]], P2Y1 and P2Y12.","[ENTITY_A] initiates platelet aggregation by 'simultaneous activation of two [ENTITY_B], P2Y1 and P2Y12.",ACTIVATOR,CPR:3,0,"ADP initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, P2Y1 and P2Y12."
"Our results imply that << P2Y12 >> has the potential to be inhibited by [[ ADP ]]/ATP analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation.","Our results imply that [ENTITY_A] has the potential to be inhibited by [ENTITY_B]/ATP analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation.",INHIBITOR,CPR:4,1,"Our results imply that P2Y12 has the potential to be inhibited by ADP/ATP analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation."
"<< Cd >> decreased [[ ERalpha ]] expression, but not ERbeta.","[ENTITY_A] decreased [ENTITY_B] expression, but not ERbeta.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Cd decreased ERalpha expression, but not ERbeta."
"<< Cd >> also increased ERK1/2, [[ Akt ]] and PDGFRalpha phosphorylation while ICI blocked it.","[ENTITY_A] also increased ERK1/2, [ENTITY_B] and PDGFRalpha phosphorylation while ICI blocked it.",ACTIVATOR,CPR:3,0,"Cd also increased ERK1/2, Akt and PDGFRalpha phosphorylation while ICI blocked it."
"<< Cd >> rapidly increased [[ c-jun ]], c-fos and PDGFA expression.","[ENTITY_A] rapidly increased [ENTITY_B], c-fos and PDGFA expression.",INDIRECT-UPREGULATOR,CPR:3,0,"Cd rapidly increased c-jun, c-fos and PDGFA expression."
"In conclusion, our results indicate that << Cd >> increases BC cell proliferation in vitro by stimulating [[ Akt ]], ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.","In conclusion, our results indicate that [ENTITY_A] increases BC cell proliferation in vitro by stimulating [ENTITY_B], ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.",ACTIVATOR,CPR:3,0,"In conclusion, our results indicate that Cd increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism."
Gonadotropin-releasing hormone functionally antagonizes << testosterone >> activation of the [[ human androgen receptor ]] in prostate cells through focal adhesion complexes involving Hic-5.,Gonadotropin-releasing hormone functionally antagonizes [ENTITY_A] activation of the [ENTITY_B] in prostate cells through focal adhesion complexes involving Hic-5.,ACTIVATOR,CPR:3,0,Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5.
<< Gonadotropin-releasing hormone >> functionally antagonizes testosterone activation of the [[ human androgen receptor ]] in prostate cells through focal adhesion complexes involving Hic-5.,[ENTITY_A] functionally antagonizes testosterone activation of the [ENTITY_B] in prostate cells through focal adhesion complexes involving Hic-5.,ANTAGONIST,CPR:6,3,Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5.
<< GnRH >>-induced [[ Pyk2 ]] activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.,[ENTITY_A]-induced [ENTITY_B] activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.,ACTIVATOR,CPR:3,0,GnRH-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.
<< GnRH >>-induced Pyk2 activation opposed the association of [[ Hic-5 ]] with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.,[ENTITY_A]-induced Pyk2 activation opposed the association of [ENTITY_B] with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.,DOWNREGULATOR,CPR:4,1,GnRH-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.
<< GnRH >>-induced [[ c-Src ]] activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor.,[ENTITY_A]-induced [ENTITY_B] activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor.,ACTIVATOR,CPR:3,0,GnRH-induced c-Src activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor.
"In contrast to << testosterone >>, GnRH-induced nuclear translocation did not transcriptionally activate the [[ androgen receptor ]].","In contrast to [ENTITY_A], GnRH-induced nuclear translocation did not transcriptionally activate the [ENTITY_B].",ACTIVATOR,CPR:3,0,"In contrast to testosterone, GnRH-induced nuclear translocation did not transcriptionally activate the androgen receptor."
The discovery that << METH >> and AMPH activate the [[ rTAAR1 ]] motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1).,The discovery that [ENTITY_A] and AMPH activate the [ENTITY_B] motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1).,ACTIVATOR,CPR:3,0,The discovery that METH and AMPH activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1).
"Furthermore, because S-(+)-isomers of << METH >> and AMPH are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of [[ TAAR1 ]].","Furthermore, because S-(+)-isomers of [ENTITY_A] and AMPH are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of [ENTITY_B].",ACTIVATOR,CPR:3,0,"Furthermore, because S-(+)-isomers of METH and AMPH are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of TAAR1."
"EC50 values for << S-(+)-METH >> were 0.89, 0.92, and 4.44 microM for [[ rTAAR1 ]], mTAAR1, and h-rChTAAR1, respectively.","EC50 values for [ENTITY_A] were 0.89, 0.92, and 4.44 microM for [ENTITY_B], mTAAR1, and h-rChTAAR1, respectively.",ACTIVATOR,CPR:3,0,"EC50 values for S-(+)-METH were 0.89, 0.92, and 4.44 microM for rTAAR1, mTAAR1, and h-rChTAAR1, respectively."
"<< PEA >> was a potent and full agonist at each species of [[ TAAR1 ]], whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1.","[ENTITY_A] was a potent and full agonist at each species of [ENTITY_B], whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1.",AGONIST-ACTIVATOR,CPR:5,2,"PEA was a potent and full agonist at each species of TAAR1, whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1."
"Interestingly, both isomers of << METH >> were full agonists at [[ mTAAR1 ]] and h-rChTAAR1, whereas both were partial agonists at rTAAR1.","Interestingly, both isomers of [ENTITY_A] were full agonists at [ENTITY_B] and h-rChTAAR1, whereas both were partial agonists at rTAAR1.",AGONIST-ACTIVATOR,CPR:5,2,"Interestingly, both isomers of METH were full agonists at mTAAR1 and h-rChTAAR1, whereas both were partial agonists at rTAAR1."
"Finally, we showed that << chlorate >> activated endocrine cell development by inducing [[ neurogenin 3 ]] (Neurog3) expression in early endocrine progenitor cells.","Finally, we showed that [ENTITY_A] activated endocrine cell development by inducing [ENTITY_B] (Neurog3) expression in early endocrine progenitor cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Finally, we showed that chlorate activated endocrine cell development by inducing neurogenin 3 (Neurog3) expression in early endocrine progenitor cells."
"DNA cloning, characterization, and inhibition studies of the << human secretory isoform VI >>, a new target for [[ sulfonamide ]] and sulfamate inhibitors.","DNA cloning, characterization, and inhibition studies of the [ENTITY_A], a new target for [ENTITY_B] and sulfamate inhibitors.",INHIBITOR,CPR:4,1,"DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors."
"The kinetic parameters for the << CO2 >> hydration reaction proved [[ hCA VI ]] to possess a kcat of 3.4 x 10(5) s-1 and kcat/KM of 4.9 x 10(7) M-1 s-1 (at pH 7.5 and 20 degrees C). hCA VI has a significant catalytic activity for the physiological reaction on the same order of magnitude as the ubiquitous isoform CA I or the transmembrane, tumor-associated isozyme CA IX.","The kinetic parameters for the [ENTITY_A] hydration reaction proved [ENTITY_B] to possess a kcat of 3.4 x 10(5) s-1 and kcat/KM of 4.9 x 10(7) M-1 s-1 (at pH 7.5 and 20 degrees C). hCA VI has a significant catalytic activity for the physiological reaction on the same order of magnitude as the ubiquitous isoform CA I or the transmembrane, tumor-associated isozyme CA IX.",SUBSTRATE_PRODUCT-OF,CPR:9,4,"The kinetic parameters for the CO2 hydration reaction proved hCA VI to possess a kcat of 3.4 x 10(5) s-1 and kcat/KM of 4.9 x 10(7) M-1 s-1 (at pH 7.5 and 20 degrees C). hCA VI has a significant catalytic activity for the physiological reaction on the same order of magnitude as the ubiquitous isoform CA I or the transmembrane, tumor-associated isozyme CA IX."
"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, << dichlorophenamide >>, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective [[ hCA VI ]] inhibitory activity, with inhibition constants of 0.8-79 nM.","Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, [ENTITY_A], dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective [ENTITY_B] inhibitory activity, with inhibition constants of 0.8-79 nM.",INHIBITOR,CPR:4,1,"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM."
"The best inhibitors were << brinzolamide >> and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a [[ CA VI ]]-selective inhibitor.","The best inhibitors were [ENTITY_A] and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a [ENTITY_B]-selective inhibitor.",INHIBITOR,CPR:4,1,"The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor."
The metallic taste reported as a side effect after the treatment with systemic << sulfonamides >> may be due to the inhibition of the [[ salivary CA VI ]].,The metallic taste reported as a side effect after the treatment with systemic [ENTITY_A] may be due to the inhibition of the [ENTITY_B].,INHIBITOR,CPR:4,1,The metallic taste reported as a side effect after the treatment with systemic sulfonamides may be due to the inhibition of the salivary CA VI.
"Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant << CO2 >> hydrase activity of enamel [[ CA VI ]], which leads to the formation of protons and bicarbonate and may have a role in cariogenesis.","Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant [ENTITY_A] hydrase activity of enamel [ENTITY_B], which leads to the formation of protons and bicarbonate and may have a role in cariogenesis.",SUBSTRATE_PRODUCT-OF,CPR:9,4,"Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel CA VI, which leads to the formation of protons and bicarbonate and may have a role in cariogenesis."
Transmembrane isoforms of << adenylate cyclases >> (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate [[ cAMP ]] production in response to calcium entry.,Transmembrane isoforms of [ENTITY_A] (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate [ENTITY_B] production in response to calcium entry.,PRODUCT-OF,CPR:9,4,Transmembrane isoforms of adenylate cyclases (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate cAMP production in response to calcium entry.
<< Pirfenidone >> inhibits [[ TGF-beta ]] expression in malignant glioma cells.,[ENTITY_A] inhibits [ENTITY_B] expression in malignant glioma cells.,INDIRECT-DOWNREGULATOR,CPR:4,1,Pirfenidone inhibits TGF-beta expression in malignant glioma cells.
"Here, we report that the antifibrotic drug << 5-methyl-1-phenyl-2-(1H)-pyridone >> (pirfenidone, PFD) elicits growth-inhibitory effects and reduces [[ TGF-beta2 ]] protein levels in human glioma cell lines.","Here, we report that the antifibrotic drug [ENTITY_A] (pirfenidone, PFD) elicits growth-inhibitory effects and reduces [ENTITY_B] protein levels in human glioma cell lines.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, PFD) elicits growth-inhibitory effects and reduces TGF-beta2 protein levels in human glioma cell lines."
This reduction in << TGF-beta2 >> is biologically relevant since [[ PFD ]] treatment reduces the growth inhibition of TGF-beta-sensitive CCL-64 cells mediated by conditioned media of glioma cells.,This reduction in [ENTITY_A] is biologically relevant since [ENTITY_B] treatment reduces the growth inhibition of TGF-beta-sensitive CCL-64 cells mediated by conditioned media of glioma cells.,INDIRECT-DOWNREGULATOR,CPR:4,1,This reduction in TGF-beta2 is biologically relevant since PFD treatment reduces the growth inhibition of TGF-beta-sensitive CCL-64 cells mediated by conditioned media of glioma cells.
<< PFD >> leads to a reduction of [[ TGF-beta2 ]] mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin.,[ENTITY_A] leads to a reduction of [ENTITY_B] mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin.,INDIRECT-DOWNREGULATOR,CPR:4,1,PFD leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin.
"In addition, << PFD >> reduces the protein levels of the [[ matrix metalloproteinase (MMP)-11 ]], a TGF-beta target gene and furin substrate involved in carcinogenesis.","In addition, [ENTITY_A] reduces the protein levels of the [ENTITY_B], a TGF-beta target gene and furin substrate involved in carcinogenesis.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, PFD reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and furin substrate involved in carcinogenesis."
UNLABELLED: << Bile acid-coenzyme A:amino acid N-acyltransferase >> (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to [[ taurine ]] and glycine.,UNLABELLED: [ENTITY_A] (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to [ENTITY_B] and glycine.,PRODUCT-OF,CPR:9,4,UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.
The absence or presence of a cytosolic pool of << BAAT >> has important implications for the intracellular transport of unconjugated/deconjugated [[ bile salts ]].,The absence or presence of a cytosolic pool of [ENTITY_A] has important implications for the intracellular transport of unconjugated/deconjugated [ENTITY_B].,SUBSTRATE,CPR:9,4,The absence or presence of a cytosolic pool of BAAT has important implications for the intracellular transport of unconjugated/deconjugated bile salts.
"The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the << riboflavin kinase >>, enzyme that converts riboflavin to [[ flavinmononucleotide ]]) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.","The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the [ENTITY_A], enzyme that converts riboflavin to [ENTITY_B]) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.",PRODUCT-OF,CPR:9,4,"The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the riboflavin kinase, enzyme that converts riboflavin to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated."
Mechanism of the irreversible inactivation of << mouse ornithine decarboxylase >> by [[ alpha-difluoromethylornithine ]].,Mechanism of the irreversible inactivation of [ENTITY_A] by [ENTITY_B].,INHIBITOR,CPR:4,1,Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha-difluoromethylornithine.
"<< Mouse ornithine decarboxylase >> (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, [[ alpha-difluoromethylornithine ]] (DFMO).","[ENTITY_A] (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, [ENTITY_B] (DFMO).",INHIBITOR,CPR:4,1,"Mouse ornithine decarboxylase (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO)."
"Na+-Dependent transmembrane transport of small neutral << amino acids >>, such as glutamine and alanine, is mediated, among others, by the [[ neutral amino acid transporters ]] of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Na+-Dependent transmembrane transport of small neutral [ENTITY_A], such as glutamine and alanine, is mediated, among others, by the [ENTITY_B] of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",SUBSTRATE,CPR:9,4,"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]."
"Here, we describe a new photolabile << alanine >> derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by [[ ASCT2 ]], SNAT1, and SNAT2.","Here, we describe a new photolabile [ENTITY_A] derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by [ENTITY_B], SNAT1, and SNAT2.",SUBSTRATE,CPR:9,4,"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and SNAT2."
Stimulated << P-selectin >> and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after [[ aspirin ]].,Stimulated [ENTITY_A] and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,Stimulated P-selectin and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after aspirin.
"At least 4 h of estrogen pre-treatment was required to elicit protection, an effect that was blocked by the << ER >> antagonist, [[ ICI 182,780 ]].","At least 4 h of estrogen pre-treatment was required to elicit protection, an effect that was blocked by the [ENTITY_A] antagonist, [ENTITY_B].",ANTAGONIST,CPR:6,3,"At least 4 h of estrogen pre-treatment was required to elicit protection, an effect that was blocked by the ER antagonist, ICI 182,780."
"Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the << ERbeta >> agonist, [[ DPN ]], protected against dopamine cell loss.","Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the [ENTITY_A] agonist, [ENTITY_B], protected against dopamine cell loss.",AGONIST,CPR:5,2,"Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the ERbeta agonist, DPN, protected against dopamine cell loss."
Differential activation of << cAMP response element binding protein >> in discrete nucleus accumbens subregions during early and late [[ cocaine ]] sensitization.,Differential activation of [ENTITY_A] in discrete nucleus accumbens subregions during early and late [ENTITY_B] sensitization.,ACTIVATOR,CPR:3,0,Differential activation of cAMP response element binding protein in discrete nucleus accumbens subregions during early and late cocaine sensitization.
The present study examined the differential << cocaine >>-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein ([[ CREB ]]) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.,The present study examined the differential [ENTITY_A]-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein ([ENTITY_B]) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.,ACTIVATOR,CPR:3,0,The present study examined the differential cocaine-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.
"Using immunohistochemistry, the authors analyzed changes in << CREB >> phosphorylation in the NAc after 5 days of [[ cocaine ]], a short or long drug-free period, and a subsequent challenge injection.","Using immunohistochemistry, the authors analyzed changes in [ENTITY_A] phosphorylation in the NAc after 5 days of [ENTITY_B], a short or long drug-free period, and a subsequent challenge injection.",ACTIVATOR,CPR:3,0,"Using immunohistochemistry, the authors analyzed changes in CREB phosphorylation in the NAc after 5 days of cocaine, a short or long drug-free period, and a subsequent challenge injection."
"Repeated << cocaine >> resulted in [[ CREB ]] phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated cocaine, but rats challenged after 2 drug-free days yielded a more localized activation of CREB in the 3 most dorsomedial zones of the shell.","Repeated [ENTITY_A] resulted in [ENTITY_B] phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated cocaine, but rats challenged after 2 drug-free days yielded a more localized activation of CREB in the 3 most dorsomedial zones of the shell.",ACTIVATOR,CPR:3,0,"Repeated cocaine resulted in CREB phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated cocaine, but rats challenged after 2 drug-free days yielded a more localized activation of CREB in the 3 most dorsomedial zones of the shell."
The temporal and anatomical determinants of << cocaine >>-induced [[ CREB ]] activity may indicate functional differences among NAc shell subregions and suggest the involvement of CREB in early and late cocaine effects.,The temporal and anatomical determinants of [ENTITY_A]-induced [ENTITY_B] activity may indicate functional differences among NAc shell subregions and suggest the involvement of CREB in early and late cocaine effects.,ACTIVATOR,CPR:3,0,The temporal and anatomical determinants of cocaine-induced CREB activity may indicate functional differences among NAc shell subregions and suggest the involvement of CREB in early and late cocaine effects.
"The carboxylation of glutamic acid residues to << gamma-carboxyglutamic acid >> (Gla) by the [[ vitamin K-dependent gamma-glutamyl carboxylase ]] (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.","The carboxylation of glutamic acid residues to [ENTITY_A] (Gla) by the [ENTITY_B] (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.",PRODUCT-OF,CPR:9,4,"The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation."
"We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of << (R)-(alpha)-(-)-methylhistamine dihydrobromide >> (RAMH) ([[ H3R ]] agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats.","We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of [ENTITY_A] (RAMH) ([ENTITY_B] agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats.",AGONIST,CPR:5,2,"We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats."
"We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), << thioperamide maleate >> ([[ H3R ]] antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats.","We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), [ENTITY_A] ([ENTITY_B] antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats.",ANTAGONIST,CPR:6,3,"We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats."
<< RAMH >> inhibition of cholangiocyte growth was associated with decreased cAMP levels and [[ PKA ]]/ERK1/2/Elk-1 phosphorylation.,[ENTITY_A] inhibition of cholangiocyte growth was associated with decreased cAMP levels and [ENTITY_B]/ERK1/2/Elk-1 phosphorylation.,INHIBITOR,CPR:4,1,RAMH inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA/ERK1/2/Elk-1 phosphorylation.
<< Proline dehydrogenase >> (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to [[ glutamate ]].,[ENTITY_A] (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to [ENTITY_B].,PRODUCT-OF,CPR:9,4,Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate.
"Finally, we demonstrate that << T. thermophilus PRODH >> reacts with O(2) producing [[ superoxide ]].","Finally, we demonstrate that [ENTITY_A] reacts with O(2) producing [ENTITY_B].",PRODUCT-OF,CPR:9,4,"Finally, we demonstrate that T. thermophilus PRODH reacts with O(2) producing superoxide."
"This is significant because << superoxide >> production underlies the role of [[ human PRODH ]] in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.","This is significant because [ENTITY_A] production underlies the role of [ENTITY_B] in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.",PRODUCT-OF,CPR:9,4,"This is significant because superoxide production underlies the role of human PRODH in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs."
"The << phosphodiesterase (PDE) 4 >> is the predominant [[ cyclic AMP ]] degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes.","The [ENTITY_A] is the predominant [ENTITY_B] degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes.",SUBSTRATE,CPR:9,4,"The phosphodiesterase (PDE) 4 is the predominant cyclic AMP degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes."
"Consequently, << PDE4 >> inhibitors including [[ cilomilast ]] and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation.","Consequently, [ENTITY_A] inhibitors including [ENTITY_B] and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation.",INHIBITOR,CPR:4,1,"Consequently, PDE4 inhibitors including cilomilast and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation."
"Results of early clinical trials with both topically (<< cipamfylline >>, CP80,633) and systemically (CC-10004) active [[ PDE4 ]] inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.","Results of early clinical trials with both topically ([ENTITY_A], CP80,633) and systemically (CC-10004) active [ENTITY_B] inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.",INHIBITOR,CPR:4,1,"Results of early clinical trials with both topically (cipamfylline, CP80,633) and systemically (CC-10004) active PDE4 inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis."
"Although considerable functional diversity exists, most << C2 domains >> are activated by [[ Ca2+ ]] binding and then dock to a specific cellular membrane.","Although considerable functional diversity exists, most [ENTITY_A] are activated by [ENTITY_B] binding and then dock to a specific cellular membrane.",ACTIVATOR,CPR:3,0,"Although considerable functional diversity exists, most C2 domains are activated by Ca2+ binding and then dock to a specific cellular membrane."
<< Bile acid coenzyme A:amino acid N-acyltransferase >> (BAT) is responsible for the amidation of [[ bile acids ]] with the amino acids glycine and taurine.,[ENTITY_A] (BAT) is responsible for the amidation of [ENTITY_B] with the amino acids glycine and taurine.,SUBSTRATE,CPR:9,4,Bile acid coenzyme A:amino acid N-acyltransferase (BAT) is responsible for the amidation of bile acids with the amino acids glycine and taurine.
"Because of their low asparagine synthetase (<< ASNS >>) expression and [[ asparagine ]] biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.","Because of their low asparagine synthetase ([ENTITY_A]) expression and [ENTITY_B] biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.",PRODUCT-OF,CPR:9,4,"Because of their low asparagine synthetase (ASNS) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion."
"<< Asparagine >> secretion by MSCs was directly related to their [[ ASNS ]] expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed.","[ENTITY_A] secretion by MSCs was directly related to their [ENTITY_B] expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed.",PRODUCT-OF,CPR:9,4,"Asparagine secretion by MSCs was directly related to their ASNS expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed."
"<< MK-801 >> ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive [[ NMDA receptor ]] antagonist, partially prevented the decrease in cell viability and the energy impairment.","[ENTITY_A] ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive [ENTITY_B] antagonist, partially prevented the decrease in cell viability and the energy impairment.",ANTAGONIST,CPR:6,3,"MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment."
The use of << Delta 6 desaturase >> (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of [[ DHA ]] from ALA.,The use of [ENTITY_A] (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of [ENTITY_B] from ALA.,PRODUCT-OF,CPR:9,4,The use of Delta 6 desaturase (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.
"The accumulation of the post-<< D6D >> products of 22:5n-3, 24:6n-3 and [[ DHA ]], in cell phospholipids was saturated at concentrations of >18 microM ALA.","The accumulation of the post-[ENTITY_A] products of 22:5n-3, 24:6n-3 and [ENTITY_B], in cell phospholipids was saturated at concentrations of >18 microM ALA.",PRODUCT-OF,CPR:9,4,"The accumulation of the post-D6D products of 22:5n-3, 24:6n-3 and DHA, in cell phospholipids was saturated at concentrations of >18 microM ALA."
The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for << D6D >> may contribute to the limited accumulation of [[ DHA ]] in cell membranes.,The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for [ENTITY_A] may contribute to the limited accumulation of [ENTITY_B] in cell membranes.,PRODUCT-OF,CPR:9,4,The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for D6D may contribute to the limited accumulation of DHA in cell membranes.
<< Dopamine D1 receptor >> agonist and D2 receptor antagonist effects of the natural product [[ (-)-stepholidine ]]: molecular modeling and dynamics simulations.,[ENTITY_A] agonist and D2 receptor antagonist effects of the natural product [ENTITY_B]: molecular modeling and dynamics simulations.,AGONIST,CPR:5,2,Dopamine D1 receptor agonist and D2 receptor antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations.
Dopamine D1 receptor agonist and << D2 receptor >> antagonist effects of the natural product [[ (-)-stepholidine ]]: molecular modeling and dynamics simulations.,Dopamine D1 receptor agonist and [ENTITY_A] antagonist effects of the natural product [ENTITY_B]: molecular modeling and dynamics simulations.,ANTAGONIST,CPR:6,3,Dopamine D1 receptor agonist and D2 receptor antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations.
"<< (-)-Stepholidine >> (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a [[ dopamine receptor D1 ]] agonist and D2 antagonist.","[ENTITY_A] (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a [ENTITY_B] agonist and D2 antagonist.",AGONIST,CPR:5,2,"(-)-Stepholidine (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and D2 antagonist."
"<< (-)-Stepholidine >> (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and [[ D2 ]] antagonist.","[ENTITY_A] (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"(-)-Stepholidine (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and D2 antagonist."
"The Ki for << mycophenolic acid >> inhibition of the [[ L263F ]] variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and nicotinamide adenine dinucleotide did not change significantly.","The Ki for [ENTITY_A] inhibition of the [ENTITY_B] variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and nicotinamide adenine dinucleotide did not change significantly.",INHIBITOR,CPR:4,1,"The Ki for mycophenolic acid inhibition of the L263F variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and nicotinamide adenine dinucleotide did not change significantly."
"<< L-BOAA >> causes loss of GSH and inhibition of [[ mitochondrial complex I ]] in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.","[ENTITY_A] causes loss of GSH and inhibition of [ENTITY_B] in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.",INHIBITOR,CPR:4,1,"L-BOAA causes loss of GSH and inhibition of mitochondrial complex I in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant."
Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to << L-BOAA >> toxicity seen as [[ mitochondrial complex I ]] loss.,Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to [ENTITY_A] toxicity seen as [ENTITY_B] loss.,DOWNREGULATOR,CPR:4,1,Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to L-BOAA toxicity seen as mitochondrial complex I loss.
"Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to << L-BOAA >> toxicity as evidenced by activation of [[ AP1 ]], loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection.","Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to [ENTITY_A] toxicity as evidenced by activation of [ENTITY_B], loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection.",ACTIVATOR,CPR:3,0,"Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of AP1, loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection."
<< Estrogen >> protects against mitochondrial dysfunction caused by excitotoxicity by maintaining cellular redox status through higher constitutive expression of [[ glutaredoxin ]] in the CNS.,[ENTITY_A] protects against mitochondrial dysfunction caused by excitotoxicity by maintaining cellular redox status through higher constitutive expression of [ENTITY_B] in the CNS.,INDIRECT-UPREGULATOR,CPR:3,0,Estrogen protects against mitochondrial dysfunction caused by excitotoxicity by maintaining cellular redox status through higher constitutive expression of glutaredoxin in the CNS.
"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, << glycine >> and GABA, share the same [[ vesicular inhibitory amino acid transporter ]] (VIAAT) and are both present in neurons during postnatal development.","The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, [ENTITY_A] and GABA, share the same [ENTITY_B] (VIAAT) and are both present in neurons during postnatal development.",SUBSTRATE,CPR:9,4,"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and GABA, share the same vesicular inhibitory amino acid transporter (VIAAT) and are both present in neurons during postnatal development."
We have expressed << VIAAT >> and the plasmalemmal transporters for glycine and [[ GABA ]] in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.,We have expressed [ENTITY_A] and the plasmalemmal transporters for glycine and [ENTITY_B] in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.,SUBSTRATE,CPR:9,4,We have expressed VIAAT and the plasmalemmal transporters for glycine and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.
We found that << glycine >> is released from vesicles when [[ VIAAT ]] is coexpressed with either the neuronal transporter GlyT2 or the glial transporter GlyT1.,We found that [ENTITY_A] is released from vesicles when [ENTITY_B] is coexpressed with either the neuronal transporter GlyT2 or the glial transporter GlyT1.,SUBSTRATE,CPR:9,4,We found that glycine is released from vesicles when VIAAT is coexpressed with either the neuronal transporter GlyT2 or the glial transporter GlyT1.
"However, GlyT2 was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic << glycine >> concentration required for efficient vesicular loading by [[ VIAAT ]].","However, GlyT2 was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic [ENTITY_A] concentration required for efficient vesicular loading by [ENTITY_B].",SUBSTRATE,CPR:9,4,"However, GlyT2 was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic glycine concentration required for efficient vesicular loading by VIAAT."
The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when << GABA >> is introduced into the secretory cell and competes for uptake by [[ VIAAT ]].,The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when [ENTITY_A] is introduced into the secretory cell and competes for uptake by [ENTITY_B].,SUBSTRATE,CPR:9,4,The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when GABA is introduced into the secretory cell and competes for uptake by VIAAT.
"Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports << glycine >> exocytosis in the presence of [[ GlyT2 ]], and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity.","Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports [ENTITY_A] exocytosis in the presence of [ENTITY_B], and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity.",SUBSTRATE,CPR:9,4,"Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity."
"Together, these results suggest that an increased cytosolic availability of << glycine >> in [[ VIAAT ]]-containing terminals was crucial for the emergence of glycinergic transmission in vertebrates.","Together, these results suggest that an increased cytosolic availability of [ENTITY_A] in [ENTITY_B]-containing terminals was crucial for the emergence of glycinergic transmission in vertebrates.",SUBSTRATE,CPR:9,4,"Together, these results suggest that an increased cytosolic availability of glycine in VIAAT-containing terminals was crucial for the emergence of glycinergic transmission in vertebrates."
<< Na+ >>/Cl- dipole couples agonist binding to [[ kainate receptor ]] activation.,[ENTITY_A]/Cl- dipole couples agonist binding to [ENTITY_B] activation.,ACTIVATOR,CPR:3,0,Na+/Cl- dipole couples agonist binding to kainate receptor activation.
<< Kainate-selective ionotropic glutamate receptors >> (GluRs) require external Na+ and Cl- as well as the neurotransmitter [[ L-glutamate ]] for activation.,[ENTITY_A] (GluRs) require external Na+ and Cl- as well as the neurotransmitter [ENTITY_B] for activation.,ACTIVATOR,CPR:3,0,Kainate-selective ionotropic glutamate receptors (GluRs) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation.
"Additionally, << Na+ >> and Cl- ions coactivate [[ GluR6 ]] receptors by establishing a dipole, accounting for their common effect on KARs.","Additionally, [ENTITY_A] and Cl- ions coactivate [ENTITY_B] receptors by establishing a dipole, accounting for their common effect on KARs.",ACTIVATOR,CPR:3,0,"Additionally, Na+ and Cl- ions coactivate GluR6 receptors by establishing a dipole, accounting for their common effect on KARs."
"Phenserine. << Phenserine >>, a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase ([[ AChE ]]) and was shown to improve cognition in various experimental paradigms in rodents and dogs.","Phenserine. [ENTITY_A], a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase ([ENTITY_B]) and was shown to improve cognition in various experimental paradigms in rodents and dogs.",INHIBITOR,CPR:4,1,"Phenserine. Phenserine, a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs."
"<< Phenserine >> deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing [[ APP ]] translation.","[ENTITY_A] deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing [ENTITY_B] translation.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Phenserine deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing APP translation."
"<< Phenserine >> apparently reduces translational efficiency of [[ APP ]] mRNA into protein, a process that may involve an interaction with iron and/or an iron-responsive element.","[ENTITY_A] apparently reduces translational efficiency of [ENTITY_B] mRNA into protein, a process that may involve an interaction with iron and/or an iron-responsive element.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Phenserine apparently reduces translational efficiency of APP mRNA into protein, a process that may involve an interaction with iron and/or an iron-responsive element."
"As a consequence, << phenserine >> reduces [[ beta-amyloid ]] peptide (Abeta) formation in vitro and in vivo.","As a consequence, [ENTITY_A] reduces [ENTITY_B] peptide (Abeta) formation in vitro and in vivo.",INDIRECT-DOWNREGULATOR,CPR:4,1,"As a consequence, phenserine reduces beta-amyloid peptide (Abeta) formation in vitro and in vivo."
"Phenserine is also unique because of differing actions of its enantiomers: << (-)-phenserine >> is the active enantiomer for inhibition of [[ AChE ]], whereas (+)-phenserine ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher.","Phenserine is also unique because of differing actions of its enantiomers: [ENTITY_A] is the active enantiomer for inhibition of [ENTITY_B], whereas (+)-phenserine ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher.",INHIBITOR,CPR:4,1,"Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas (+)-phenserine ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher."
"BACKGROUND AND PURPOSE: << AMP-activated protein kinase >> (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside ([[ AICAR ]]).","BACKGROUND AND PURPOSE: [ENTITY_A] (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside ([ENTITY_B]).",ACTIVATOR,CPR:3,0,"BACKGROUND AND PURPOSE: AMP-activated protein kinase (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)."
"KEY RESULTS: << Phenformin >>, AICAR and metformin increased [[ AMPK (alpha1) ]] activity and decreased I(amiloride).","KEY RESULTS: [ENTITY_A], AICAR and metformin increased [ENTITY_B] activity and decreased I(amiloride).",ACTIVATOR,CPR:3,0,"KEY RESULTS: Phenformin, AICAR and metformin increased AMPK (alpha1) activity and decreased I(amiloride)."
The << AMPK >> inhibitor Compound C prevented the action of metformin and AICAR but not [[ phenformin ]].,The [ENTITY_A] inhibitor Compound C prevented the action of metformin and AICAR but not [ENTITY_B].,ACTIVATOR,CPR:3,0,The AMPK inhibitor Compound C prevented the action of metformin and AICAR but not phenformin.
"Additional pharmacological effects evoked by << AICAR >> and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of [[ AMPK ]] in cell systems where Na+K+ATPase is an important component.","Additional pharmacological effects evoked by [ENTITY_A] and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of [ENTITY_B] in cell systems where Na+K+ATPase is an important component.",ACTIVATOR,CPR:3,0,"Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component."
"Neuroprotective effect of << nimesulide >>, a preferential [[ COX-2 ]] inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice.","Neuroprotective effect of [ENTITY_A], a preferential [ENTITY_B] inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice.",INHIBITOR,CPR:4,1,"Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice."
"Brain cyclooxygenases (<< COX >>), the rate-limiting enzyme in [[ prostaglandin ]] synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.","Brain cyclooxygenases ([ENTITY_A]), the rate-limiting enzyme in [ENTITY_B] synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.",PRODUCT-OF,CPR:9,4,"Brain cyclooxygenases (COX), the rate-limiting enzyme in prostaglandin synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons."
Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or << rofecoxib >> (selective [[ COX-2 ]] inhibitor) against chemical kindling in mice.,Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or [ENTITY_A] (selective [ENTITY_B] inhibitor) against chemical kindling in mice.,INHIBITOR,CPR:4,1,Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) against chemical kindling in mice.
"With this background, the present study was designed to explore the possible effect of << nimesulide >> (a preferential [[ COX-2 ]] inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice.","With this background, the present study was designed to explore the possible effect of [ENTITY_A] (a preferential [ENTITY_B] inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice.",INHIBITOR,CPR:4,1,"With this background, the present study was designed to explore the possible effect of nimesulide (a preferential COX-2 inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice."
"Compared with normal control group, << PTZ >>-kindled mice had significantly higher levels of malondialdehyde, nitrite, [[ myeloperoxidase ]] but had lower levels of reduced glutathione in the whole brain homogenate.","Compared with normal control group, [ENTITY_A]-kindled mice had significantly higher levels of malondialdehyde, nitrite, [ENTITY_B] but had lower levels of reduced glutathione in the whole brain homogenate.",INDIRECT-UPREGULATOR,CPR:3,0,"Compared with normal control group, PTZ-kindled mice had significantly higher levels of malondialdehyde, nitrite, myeloperoxidase but had lower levels of reduced glutathione in the whole brain homogenate."
"These results suggested that << nimesulide >>, a preferential [[ COX-2 ]] inhibitor offered neuroprotection against PTZ-induced kindling in mice.","These results suggested that [ENTITY_A], a preferential [ENTITY_B] inhibitor offered neuroprotection against PTZ-induced kindling in mice.",INHIBITOR,CPR:4,1,"These results suggested that nimesulide, a preferential COX-2 inhibitor offered neuroprotection against PTZ-induced kindling in mice."
"While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and << gallic acid >> or n-propyl gallate efficiently inhibited the activity of all three [[ PHDs ]], demonstrating different functions of these antioxidants.","While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and [ENTITY_A] or n-propyl gallate efficiently inhibited the activity of all three [ENTITY_B], demonstrating different functions of these antioxidants.",INHIBITOR,CPR:4,1,"While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three PHDs, demonstrating different functions of these antioxidants."
"<< LTC4 synthase >> (LTC4S), the pivotal enzyme for the biosynthesis of [[ LTC4 ]] (ref. 10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref. 13).","[ENTITY_A] (LTC4S), the pivotal enzyme for the biosynthesis of [ENTITY_B] (ref. 10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref. 13).",PRODUCT-OF,CPR:9,4,"LTC4 synthase (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref. 10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref. 13)."
<< Phenelzine >> causes an increase in brain ornithine that is prevented by prior [[ monoamine oxidase ]] inhibition.,[ENTITY_A] causes an increase in brain ornithine that is prevented by prior [ENTITY_B] inhibition.,INHIBITOR,CPR:4,1,Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition.
"<< Phenelzine >> (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase ([[ GABA-T ]]), markedly increasing brain GABA levels.","[ENTITY_A] (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase ([ENTITY_B]), markedly increasing brain GABA levels.",INHIBITOR,CPR:4,1,"Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels."
"<< PLZ >> is also a substrate for [[ MAO ]], and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in GABA observed.","[ENTITY_A] is also a substrate for [ENTITY_B], and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in GABA observed.",SUBSTRATE,CPR:9,4,"PLZ is also a substrate for MAO, and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in GABA observed."
"To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the << MAO >> inhibitor [[ tranylcypromine ]] (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.","To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the [ENTITY_A] inhibitor [ENTITY_B] (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.",INHIBITOR,CPR:4,1,"To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the MAO inhibitor tranylcypromine (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later."
"Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of << PLZ >> formed by the action of [[ MAO ]] is responsible for the elevation of brain ORN observed.","Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of [ENTITY_A] formed by the action of [ENTITY_B] is responsible for the elevation of brain ORN observed.",SUBSTRATE,CPR:9,4,"Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of PLZ formed by the action of MAO is responsible for the elevation of brain ORN observed."
Nitric oxide (<< NO >>) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by [[ endothelial nitric oxide synthase ]] (eNOS).,Nitric oxide ([ENTITY_A]) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by [ENTITY_B] (eNOS).,PRODUCT-OF,CPR:9,4,Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (eNOS).
"As further support, << alpha-methyl-DL-aspartate >>, an inhibitor of [[ argininosuccinate synthase ]] (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.","As further support, [ENTITY_A], an inhibitor of [ENTITY_B] (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.",INHIBITOR,CPR:4,1,"As further support, alpha-methyl-DL-aspartate, an inhibitor of argininosuccinate synthase (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner."
"Caution is necessary only when it is coadministered with drugs metabolised by << CYP2D6 >>, such as [[ metoprolol ]], or administered to the elderly or patients with severe hepatic or renal impairment.","Caution is necessary only when it is coadministered with drugs metabolised by [ENTITY_A], such as [ENTITY_B], or administered to the elderly or patients with severe hepatic or renal impairment.",SUBSTRATE,CPR:9,4,"Caution is necessary only when it is coadministered with drugs metabolised by CYP2D6, such as metoprolol, or administered to the elderly or patients with severe hepatic or renal impairment."
"Inhibition of platelet aggregation by AZD6140, a reversible oral << P2Y12 >> receptor antagonist, compared with [[ clopidogrel ]] in patients with acute coronary syndromes.","Inhibition of platelet aggregation by AZD6140, a reversible oral [ENTITY_A] receptor antagonist, compared with [ENTITY_B] in patients with acute coronary syndromes.",ANTAGONIST,CPR:6,3,"Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes."
<< AZD6140 >> is a reversible oral [[ P2Y(12) ]] receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study).,[ENTITY_A] is a reversible oral [ENTITY_B] receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study).,ANTAGONIST,CPR:6,3,AZD6140 is a reversible oral P2Y(12) receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study).
<< Oxybutynin >> (1) is a non-selective [[ muscarinic receptor ]] antagonist that is used clinically for the treatment of urinary incontinence.,[ENTITY_A] (1) is a non-selective [ENTITY_B] antagonist that is used clinically for the treatment of urinary incontinence.,ANTAGONIST,CPR:6,3,Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence.
"Degradation of submandibular gland << AQP5 >> by parasympathetic denervation of chorda tympani and its recovery by [[ cevimeline ]], an M3 muscarinic receptor agonist.","Degradation of submandibular gland [ENTITY_A] by parasympathetic denervation of chorda tympani and its recovery by [ENTITY_B], an M3 muscarinic receptor agonist.",INDIRECT-UPREGULATOR,CPR:3,0,"Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor agonist."
"Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by << cevimeline >>, an [[ M3 muscarinic receptor ]] agonist.","Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by [ENTITY_A], an [ENTITY_B] agonist.",AGONIST,CPR:5,2,"Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor agonist."
"Administration of << cevimeline hydrochloride >>, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the [[ AQP5 ]] protein level reduced by CTD and increased the AQP1 protein level above the control one.","Administration of [ENTITY_A], an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the [ENTITY_B] protein level reduced by CTD and increased the AQP1 protein level above the control one.",INDIRECT-UPREGULATOR,CPR:3,0,"Administration of cevimeline hydrochloride, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one."
"Administration of << cevimeline hydrochloride >>, an [[ M3 muscarinic receptor ]] agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one.","Administration of [ENTITY_A], an [ENTITY_B] agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one.",AGONIST,CPR:5,2,"Administration of cevimeline hydrochloride, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one."
"Administration of << chloroquine >> (50 mg/kg for 7 days po), a denaturant of lysosomes, increased the [[ AQP5 ]] protein level reduced by CTD.","Administration of [ENTITY_A] (50 mg/kg for 7 days po), a denaturant of lysosomes, increased the [ENTITY_B] protein level reduced by CTD.",INDIRECT-UPREGULATOR,CPR:3,0,"Administration of chloroquine (50 mg/kg for 7 days po), a denaturant of lysosomes, increased the AQP5 protein level reduced by CTD."
"Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? d,l-threo-methylphenidate (MPH) is an effective first-line treatment for the symptoms associated with attention-deficit/hyperactivity disorder. << threo-methylphenidate >> inhibits the [[ dopamine transporter ]] and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release.","Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? d,l-threo-methylphenidate (MPH) is an effective first-line treatment for the symptoms associated with attention-deficit/hyperactivity disorder. [ENTITY_A] inhibits the [ENTITY_B] and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release.",INHIBITOR,CPR:4,1,"Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? d,l-threo-methylphenidate (MPH) is an effective first-line treatment for the symptoms associated with attention-deficit/hyperactivity disorder. threo-methylphenidate inhibits the dopamine transporter and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release."
"Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? d,l-threo-methylphenidate (MPH) is an effective first-line treatment for the symptoms associated with attention-deficit/hyperactivity disorder. threo-methylphenidate inhibits the << dopamine transporter >> and the norepinephrine transporter, resulting in elevations of these [[ monoamines ]] after impulse release.","Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? d,l-threo-methylphenidate (MPH) is an effective first-line treatment for the symptoms associated with attention-deficit/hyperactivity disorder. threo-methylphenidate inhibits the [ENTITY_A] and the norepinephrine transporter, resulting in elevations of these [ENTITY_B] after impulse release.",SUBSTRATE,CPR:9,4,"Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? d,l-threo-methylphenidate (MPH) is an effective first-line treatment for the symptoms associated with attention-deficit/hyperactivity disorder. threo-methylphenidate inhibits the dopamine transporter and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release."
The direct inhibition of << stathmin >> by [[ CCNU ]] is likely a contributing factor.,The direct inhibition of [ENTITY_A] by [ENTITY_B] is likely a contributing factor.,INHIBITOR,CPR:4,1,The direct inhibition of stathmin by CCNU is likely a contributing factor.
The principal aim of the study was to find << amiodarone >> analogues that retained [[ human ether-a-go-go-related protein (hERG) channel ]] inhibition but with reduced cytotoxicity.,The principal aim of the study was to find [ENTITY_A] analogues that retained [ENTITY_B] inhibition but with reduced cytotoxicity.,INHIBITOR,CPR:4,1,The principal aim of the study was to find amiodarone analogues that retained human ether-a-go-go-related protein (hERG) channel inhibition but with reduced cytotoxicity.
"CONCLUSIONS AND IMPLICATIONS: << Amiodarone >> analogues with better [[ hERG ]] channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and hERG channel interaction are mechanistically distinct and separable properties of the compounds.","CONCLUSIONS AND IMPLICATIONS: [ENTITY_A] analogues with better [ENTITY_B] channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and hERG channel interaction are mechanistically distinct and separable properties of the compounds.",INHIBITOR,CPR:4,1,"CONCLUSIONS AND IMPLICATIONS: Amiodarone analogues with better hERG channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and hERG channel interaction are mechanistically distinct and separable properties of the compounds."
"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as << carbetocin >> ([[ OT ]] agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.","In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as [ENTITY_A] ([ENTITY_B] agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.",AGONIST,CPR:5,2,"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use."
"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and << atosiban >> (Tractocile [[ OT ]] antagonist) are also in clinical use.","In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and [ENTITY_A] (Tractocile [ENTITY_B] antagonist) are also in clinical use.",ANTAGONIST,CPR:6,3,"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use."
"While a number of orally active non-peptide << V(2) >> antagonists (Vaptans); notably, [[ Tolvaptan ]], Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.","While a number of orally active non-peptide [ENTITY_A] antagonists (Vaptans); notably, [ENTITY_B], Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.",ANTAGONIST,CPR:6,3,"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients."
"Absorbable drugs (<< fibric acids >>, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce [[ plasma very-low-density lipoproteins ]] (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.","Absorbable drugs ([ENTITY_A], nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce [ENTITY_B] (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Absorbable drugs (fibric acids, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms."
"<< Fibric acids >>, in particular, act by stimulating the catabolism of [[ VLDL ]] and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake.","[ENTITY_A], in particular, act by stimulating the catabolism of [ENTITY_B] and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Fibric acids, in particular, act by stimulating the catabolism of VLDL and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake."
"Probucol acts by a newly described mechanism, i.e. accelerating reverse transport of << cholesteryl esters >> from [[ high-density lipoproteins ]] to lower-density lipoproteins.","Probucol acts by a newly described mechanism, i.e. accelerating reverse transport of [ENTITY_A] from [ENTITY_B] to lower-density lipoproteins.",SUBSTRATE,CPR:9,4,"Probucol acts by a newly described mechanism, i.e. accelerating reverse transport of cholesteryl esters from high-density lipoproteins to lower-density lipoproteins."
<< Lapatinib >>: a dual inhibitor of [[ human epidermal growth factor receptor ]] tyrosine kinases.,[ENTITY_A]: a dual inhibitor of [ENTITY_B] tyrosine kinases.,INHIBITOR,CPR:4,1,Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
"BACKGROUND: << Lapatinib >>, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 ([[ HER2 ]]) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.","BACKGROUND: [ENTITY_A], the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 ([ENTITY_B]) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.",INHIBITOR,CPR:4,1,"BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007."
"<< Lapatinib >> is metabolized primarily by the [[ cytochrome P450 3A4 ]] isozyme, with 1 metabolite remaining active against EGFR but not HER2.","[ENTITY_A] is metabolized primarily by the [ENTITY_B] isozyme, with 1 metabolite remaining active against EGFR but not HER2.",SUBSTRATE,CPR:9,4,"Lapatinib is metabolized primarily by the cytochrome P450 3A4 isozyme, with 1 metabolite remaining active against EGFR but not HER2."
CONCLUSIONS: << Lapatinib >> is a dual inhibitor of the [[ EGFR ]] and HER2 tyrosine kinases.,CONCLUSIONS: [ENTITY_A] is a dual inhibitor of the [ENTITY_B] and HER2 tyrosine kinases.,INHIBITOR,CPR:4,1,CONCLUSIONS: Lapatinib is a dual inhibitor of the EGFR and HER2 tyrosine kinases.
Phenelzine is a more potent << monoamine oxidase >> inhibitor than is [[ N2-acetylphenelzine ]].,Phenelzine is a more potent [ENTITY_A] inhibitor than is [ENTITY_B].,INHIBITOR,CPR:4,1,Phenelzine is a more potent monoamine oxidase inhibitor than is N2-acetylphenelzine.
Acetylation of << phenelzine >> at the N2 position presumably interferes with the inhibition of the [[ transaminase ]] enzymes for gamma-aminobutyric acid and alanine.,Acetylation of [ENTITY_A] at the N2 position presumably interferes with the inhibition of the [ENTITY_B] enzymes for gamma-aminobutyric acid and alanine.,INHIBITOR,CPR:4,1,Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the transaminase enzymes for gamma-aminobutyric acid and alanine.
All neurotrophic effects were blocked by the unselective D2/D3 receptor antagonist sulpiride (5 microm) and by the selective << D3 receptor >> antagonist [[ SB-277011-A ]] at a low dose (50 nm).,All neurotrophic effects were blocked by the unselective D2/D3 receptor antagonist sulpiride (5 microm) and by the selective [ENTITY_A] antagonist [ENTITY_B] at a low dose (50 nm).,ANTAGONIST,CPR:6,3,All neurotrophic effects were blocked by the unselective D2/D3 receptor antagonist sulpiride (5 microm) and by the selective D3 receptor antagonist SB-277011-A at a low dose (50 nm).
"<< Quinpirole >> and 7-OH-DPAT also increased the phosphorylation of [[ extracellular signal-regulated kinase ]] (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A.","[ENTITY_A] and 7-OH-DPAT also increased the phosphorylation of [ENTITY_B] (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A.",ACTIVATOR,CPR:3,0,"Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A."
"Quinpirole and 7-OH-DPAT also increased the phosphorylation of << extracellular signal-regulated kinase >> (ERK) within minutes, an effect blocked by pretreatment with [[ SB-277011-A ]].","Quinpirole and 7-OH-DPAT also increased the phosphorylation of [ENTITY_A] (ERK) within minutes, an effect blocked by pretreatment with [ENTITY_B].",INHIBITOR,CPR:4,1,"Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A."
"This study identified four clinically approved antihypertensive drugs (<< efonidipine >>, felodipine, isradipine, and nitrendipine) as potent [[ T-channel ]] blockers (IC(50) < 3 microM).","This study identified four clinically approved antihypertensive drugs ([ENTITY_A], felodipine, isradipine, and nitrendipine) as potent [ENTITY_B] blockers (IC(50) < 3 microM).",INHIBITOR,CPR:4,1,"This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, isradipine, and nitrendipine) as potent T-channel blockers (IC(50) < 3 microM)."
"We found compounds that inhibited << Panx1 >> currents with a rank order of potency: [[ carbenoxolone ]] > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.","We found compounds that inhibited [ENTITY_A] currents with a rank order of potency: [ENTITY_B] > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.",INHIBITOR,CPR:4,1,"We found compounds that inhibited Panx1 currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid."
"Triphosphate nucleotides (ATP, GTP, and << UTP >>) rapidly and reversibly inhibited [[ Panx1 ]] currents via mechanism(s) independent of purine receptors.","Triphosphate nucleotides (ATP, GTP, and [ENTITY_A]) rapidly and reversibly inhibited [ENTITY_B] currents via mechanism(s) independent of purine receptors.",INHIBITOR,CPR:4,1,"Triphosphate nucleotides (ATP, GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of purine receptors."
"When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), << DIDS >> was found to act as a [[ P2X(7)R ]] antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.","When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), [ENTITY_A] was found to act as a [ENTITY_B] antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.",ANTAGONIST,CPR:6,3,"When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), DIDS was found to act as a P2X(7)R antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents."
"We investigated the effect of << captopril >>, an [[ ACE ]] inhibitor, on MMP-2 and MMP-9 in monocrotaline-induced right ventricular hypertrophy.","We investigated the effect of [ENTITY_A], an [ENTITY_B] inhibitor, on MMP-2 and MMP-9 in monocrotaline-induced right ventricular hypertrophy.",INHIBITOR,CPR:4,1,"We investigated the effect of captopril, an ACE inhibitor, on MMP-2 and MMP-9 in monocrotaline-induced right ventricular hypertrophy."
<< MMP-2 >> and MMP-9 expressions and activities in right ventricles increased significantly in [[ monocrotaline ]]-injected rats and captopril inhibited them.,[ENTITY_A] and MMP-9 expressions and activities in right ventricles increased significantly in [ENTITY_B]-injected rats and captopril inhibited them.,ACTIVATOR,CPR:3,0,MMP-2 and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and captopril inhibited them.
<< MMP-2 >> and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and [[ captopril ]] inhibited them.,[ENTITY_A] and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and [ENTITY_B] inhibited them.,INDIRECT-DOWNREGULATOR,CPR:4,1,MMP-2 and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and captopril inhibited them.
These findings indicate that captopril attenuates the development of << monocrotaline >>-induced right ventricular hypertrophy in association with inhibition of [[ MMP-2 ]] and MMP-9 in rats.,These findings indicate that captopril attenuates the development of [ENTITY_A]-induced right ventricular hypertrophy in association with inhibition of [ENTITY_B] and MMP-9 in rats.,ACTIVATOR,CPR:3,0,These findings indicate that captopril attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of MMP-2 and MMP-9 in rats.
These findings indicate that << captopril >> attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of [[ MMP-2 ]] and MMP-9 in rats.,These findings indicate that [ENTITY_A] attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of [ENTITY_B] and MMP-9 in rats.,INHIBITOR,CPR:4,1,These findings indicate that captopril attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of MMP-2 and MMP-9 in rats.
"<< Thiazide >> and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase ([[ CA ]], EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.","[ENTITY_A] and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase ([ENTITY_B], EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.",INHIBITOR,CPR:4,1,"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide."
"Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with << chlorthalidone >>, trichloromethiazide, and furosemide being efficient inhibitors against [[ CA II ]] (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).","Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with [ENTITY_A], trichloromethiazide, and furosemide being efficient inhibitors against [ENTITY_B] (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).",INHIBITOR,CPR:4,1,"Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)."
"<< Sergliflozin etabonate >>, a selective [[ SGLT2 ]] inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.","[ENTITY_A], a selective [ENTITY_B] inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.",INHIBITOR,CPR:4,1,"Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats."
The low-affinity << sodium glucose cotransporter >> (SGLT2) is responsible for most of the [[ glucose ]] reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.,The low-affinity [ENTITY_A] (SGLT2) is responsible for most of the [ENTITY_B] reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.,SUBSTRATE,CPR:9,4,The low-affinity sodium glucose cotransporter (SGLT2) is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.
"We discovered << sergliflozin etabonate >>, a novel selective [[ SGLT2 ]] inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels.","We discovered [ENTITY_A], a novel selective [ENTITY_B] inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels.",INHIBITOR,CPR:4,1,"We discovered sergliflozin etabonate, a novel selective SGLT2 inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels."
"In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an << alpha-glucosidase >> inhibitor ([[ voglibose ]]).","In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an [ENTITY_A] inhibitor ([ENTITY_B]).",INHIBITOR,CPR:4,1,"In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an alpha-glucosidase inhibitor (voglibose)."
"Chronic treatment with << sergliflozin etabonate >> reduced the levels of [[ glycated hemoglobin ]] and fasting plasma glucose, and improved the glycemic response after glucose loading in Zucker fatty rats.","Chronic treatment with [ENTITY_A] reduced the levels of [ENTITY_B] and fasting plasma glucose, and improved the glycemic response after glucose loading in Zucker fatty rats.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Chronic treatment with sergliflozin etabonate reduced the levels of glycated hemoglobin and fasting plasma glucose, and improved the glycemic response after glucose loading in Zucker fatty rats."
"Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with << fenoldopam >>, a D1-like receptor agonist, inhibited the stimulatory effect of [[ insulin ]].","Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with [ENTITY_A], a D1-like receptor agonist, inhibited the stimulatory effect of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with fenoldopam, a D1-like receptor agonist, inhibited the stimulatory effect of insulin."
"Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with << fenoldopam >>, a [[ D1-like receptor ]] agonist, inhibited the stimulatory effect of insulin.","Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with [ENTITY_A], a [ENTITY_B] agonist, inhibited the stimulatory effect of insulin.",AGONIST,CPR:5,2,"Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with fenoldopam, a D1-like receptor agonist, inhibited the stimulatory effect of insulin."
"The inhibitory effect of << fenoldopam >> on [[ insulin ]]-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist.","The inhibitory effect of [ENTITY_A] on [ENTITY_B]-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist."
"The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by << SCH23390 >>, a [[ D1-like receptor ]] antagonist.","The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by [ENTITY_A], a [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist."
"<< Fenoldopam >> also inhibited [[ insulin receptor ]] mRNA and protein expression, which was time dependent and concentration dependent.","[ENTITY_A] also inhibited [ENTITY_B] mRNA and protein expression, which was time dependent and concentration dependent.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Fenoldopam also inhibited insulin receptor mRNA and protein expression, which was time dependent and concentration dependent."
"A PKC or MAP kinase inhibitor blocked the inhibitory effect of << fenoldopam >> on [[ insulin receptor ]] expression, indicating that PKC and MAP kinase were involved in the signaling pathway.","A PKC or MAP kinase inhibitor blocked the inhibitory effect of [ENTITY_A] on [ENTITY_B] expression, indicating that PKC and MAP kinase were involved in the signaling pathway.",INDIRECT-DOWNREGULATOR,CPR:4,1,"A PKC or MAP kinase inhibitor blocked the inhibitory effect of fenoldopam on insulin receptor expression, indicating that PKC and MAP kinase were involved in the signaling pathway."
The progress of the enzymatic reaction of the hydrolysis of << acetylthiocholine >> at pH 8 in the presence of [[ AChE ]] and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh).,The progress of the enzymatic reaction of the hydrolysis of [ENTITY_A] at pH 8 in the presence of [ENTITY_B] and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh).,SUBSTRATE,CPR:9,4,The progress of the enzymatic reaction of the hydrolysis of acetylthiocholine at pH 8 in the presence of AChE and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh).
The mechanism of << OP >> poisoning involves inhibition of [[ acetylcholinesterase ]] (AChE) leading to inactivation of the enzyme which has an important role in neurotransmission.,The mechanism of [ENTITY_A] poisoning involves inhibition of [ENTITY_B] (AChE) leading to inactivation of the enzyme which has an important role in neurotransmission.,INHIBITOR,CPR:4,1,The mechanism of OP poisoning involves inhibition of acetylcholinesterase (AChE) leading to inactivation of the enzyme which has an important role in neurotransmission.
They act by reactivation of << AChE >> inhibited by [[ OP ]].,They act by reactivation of [ENTITY_A] inhibited by [ENTITY_B].,INHIBITOR,CPR:4,1,They act by reactivation of AChE inhibited by OP.
"Presently, a combination of an antimuscarinic agent, e.g. atropine, << AChE >> reactivator such as one of the recommended pyridinium oximes (pralidoxime, [[ trimedoxime ]], obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.","Presently, a combination of an antimuscarinic agent, e.g. atropine, [ENTITY_A] reactivator such as one of the recommended pyridinium oximes (pralidoxime, [ENTITY_B], obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.",ACTIVATOR,CPR:3,0,"Presently, a combination of an antimuscarinic agent, e.g. atropine, AChE reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans."
"Presently, a combination of an antimuscarinic agent, e.g. atropine, << AChE >> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of [[ OP ]] poisoning in humans.","Presently, a combination of an antimuscarinic agent, e.g. atropine, [ENTITY_A] reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of [ENTITY_B] poisoning in humans.",INHIBITOR,CPR:4,1,"Presently, a combination of an antimuscarinic agent, e.g. atropine, AChE reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans."
"<< Palonosetron >> is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation [[ 5-HT3 receptor ]] antagonists.","[ENTITY_A] is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation [ENTITY_B] antagonists.",ANTAGONIST,CPR:6,3,"Palonosetron is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists."
Oral << palonosetron >> is likely to be a useful addition to oral formulations of other [[ 5-HT3 recepto ]]r antagonists in preventing CINV in patients receiving MEC.,Oral [ENTITY_A] is likely to be a useful addition to oral formulations of other [ENTITY_B]r antagonists in preventing CINV in patients receiving MEC.,ANTAGONIST,CPR:6,3,Oral palonosetron is likely to be a useful addition to oral formulations of other 5-HT3 receptor antagonists in preventing CINV in patients receiving MEC.
"Luteinizing hormone-releasing hormone (LHRH) agonists, such as << buserelin >>, goserelin, leuprorelin and triptorelin, stimulate the pituitary's [[ gonadotrophin-releasing hormone (GnRH) receptor ]], ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Luteinizing hormone-releasing hormone (LHRH) agonists, such as [ENTITY_A], goserelin, leuprorelin and triptorelin, stimulate the pituitary's [ENTITY_B], ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",ACTIVATOR,CPR:3,0,"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels."
"Luteinizing hormone-releasing hormone (LHRH) agonists, such as << buserelin >>, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of [[ LH ]] and testosterone levels.","Luteinizing hormone-releasing hormone (LHRH) agonists, such as [ENTITY_A], goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of [ENTITY_B] and testosterone levels.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels."
"<< Luteinizing hormone-releasing hormone >> (LHRH) agonists, such as [[ buserelin ]], goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","[ENTITY_A] (LHRH) agonists, such as [ENTITY_B], goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",AGONIST,CPR:5,2,"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels."
"Two pure << GnRH >> antagonists have been developed, [[ abarelix ]] and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.","Two pure [ENTITY_A] antagonists have been developed, [ENTITY_B] and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.",ANTAGONIST,CPR:6,3,"Two pure GnRH antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare."
"<< Abarelix >> was the first [[ GnRH ]] antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary.","[ENTITY_A] was the first [ENTITY_B] antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary.",ANTAGONIST,CPR:6,3,"Abarelix was the first GnRH antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary."
"<< Fulvestrant >>, a pure [[ estrogen receptor ]] downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002.","[ENTITY_A], a pure [ENTITY_B] downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002.",DOWNREGULATOR,CPR:4,1,"Fulvestrant, a pure estrogen receptor downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002."
The concentration of << estramustine phosphate >> required to inhibit the assembly or to induce the disassembly of [[ chick brain MAP2 ]]:tubulin microtubules is markedly dependent upon the microtubule protein concentration.,The concentration of [ENTITY_A] required to inhibit the assembly or to induce the disassembly of [ENTITY_B]:tubulin microtubules is markedly dependent upon the microtubule protein concentration.,ACTIVATOR,CPR:3,0,The concentration of estramustine phosphate required to inhibit the assembly or to induce the disassembly of chick brain MAP2:tubulin microtubules is markedly dependent upon the microtubule protein concentration.
The concentration of << estramustine phosphate >> required to inhibit the assembly or to induce the disassembly of [[ chick brain MAP2 ]]:tubulin microtubules is markedly dependent upon the microtubule protein concentration.,The concentration of [ENTITY_A] required to inhibit the assembly or to induce the disassembly of [ENTITY_B]:tubulin microtubules is markedly dependent upon the microtubule protein concentration.,INHIBITOR,CPR:4,1,The concentration of estramustine phosphate required to inhibit the assembly or to induce the disassembly of chick brain MAP2:tubulin microtubules is markedly dependent upon the microtubule protein concentration.
It is proposed that two molecules of << estramustine phosphate >> interact with each of the three tubulin-binding sites of MAP2 and inhibit the [[ MAP2 ]]:tubulin interaction by neutralising two highly conserved basic residues.,It is proposed that two molecules of [ENTITY_A] interact with each of the three tubulin-binding sites of MAP2 and inhibit the [ENTITY_B]:tubulin interaction by neutralising two highly conserved basic residues.,INHIBITOR,CPR:4,1,It is proposed that two molecules of estramustine phosphate interact with each of the three tubulin-binding sites of MAP2 and inhibit the MAP2:tubulin interaction by neutralising two highly conserved basic residues.
"Activity of << XL184 >> (Cabozantinib), an oral [[ tyrosine kinase ]] inhibitor, in patients with medullary thyroid cancer.","Activity of [ENTITY_A] (Cabozantinib), an oral [ENTITY_B] inhibitor, in patients with medullary thyroid cancer.",INHIBITOR,CPR:4,1,"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer."
"PURPOSE: XL184 (<< cabozantinib >>) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 ([[ VEGFR2 ]]), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.","PURPOSE: XL184 ([ENTITY_A]) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 ([ENTITY_B]), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.",INHIBITOR,CPR:4,1,"PURPOSE: XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models."
"Further, we used this model to test the efficacy of << GDC-0941 >>, a [[ PI3K ]] inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition.","Further, we used this model to test the efficacy of [ENTITY_A], a [ENTITY_B] inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition.",INHIBITOR,CPR:4,1,"Further, we used this model to test the efficacy of GDC-0941, a PI3K inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition."
"Inhibitory effect of synthetic << progestins >>, 4-MA and cyanoketone on [[ human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase ]] activity.","Inhibitory effect of synthetic [ENTITY_A], 4-MA and cyanoketone on [ENTITY_B] activity.",INHIBITOR,CPR:4,1,"Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase activity."
"<< Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase >> (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding [[ 3-keto-4-ene-steroids ]] and is thus involved in the biosynthesis of all classes of hormonal steroids.","[ENTITY_A] (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding [ENTITY_B] and is thus involved in the biosynthesis of all classes of hormonal steroids.",PRODUCT-OF,CPR:9,4,"Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids."
"<< Trilostane >>, epostane and cyanoketone are potent inhibitors of [[ 3 beta-HSD ]] with Ki values of approximately 50 nM.","[ENTITY_A], epostane and cyanoketone are potent inhibitors of [ENTITY_B] with Ki values of approximately 50 nM.",INHIBITOR,CPR:4,1,"Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM."
"<< 4-MA >>, a well known [[ 5 alpha-reductase ]] inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM.","[ENTITY_A], a well known [ENTITY_B] inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM.",INHIBITOR,CPR:4,1,"4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM."
"<< Cyproterone acetate >>, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit [[ 3 beta-HSD ]] activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.","[ENTITY_A], a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit [ENTITY_B] activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.",INHIBITOR,CPR:4,1,"Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit 3 beta-HSD activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively."
"However, chronic treatment of cLH rats with << MPEP >> did not reverse learned helplessness, indicating that the enhanced [[ mGlu5 receptor ]] function is not the only player in the behavioral phenotype of this genetic model of depression.","However, chronic treatment of cLH rats with [ENTITY_A] did not reverse learned helplessness, indicating that the enhanced [ENTITY_B] function is not the only player in the behavioral phenotype of this genetic model of depression.",ACTIVATOR,CPR:3,0,"However, chronic treatment of cLH rats with MPEP did not reverse learned helplessness, indicating that the enhanced mGlu5 receptor function is not the only player in the behavioral phenotype of this genetic model of depression."
"Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or << MS-275 >> ([[ histone deacetylase ]] (HDAC) inhibitor), applied after extinction training.","Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or [ENTITY_A] ([ENTITY_B] (HDAC) inhibitor), applied after extinction training.",INHIBITOR,CPR:4,1,"Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or MS-275 (histone deacetylase (HDAC) inhibitor), applied after extinction training."
"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while << MS-275 >> or PEPA ([[ AMPA receptor ]] potentiator) failed to affect extinction acquisition in S1 mice.","Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while [ENTITY_A] or PEPA ([ENTITY_B] potentiator) failed to affect extinction acquisition in S1 mice.",ACTIVATOR,CPR:3,0,"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice."
"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of << valproic acid >> (a GABAergic enhancer and [[ HDAC ]] inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.","Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of [ENTITY_A] (a GABAergic enhancer and [ENTITY_B] inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.",INHIBITOR,CPR:4,1,"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice."
"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or << AMN082 >> [[[ metabotropic glutamate receptor 7 ]] (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.","Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or [ENTITY_A] [[ENTITY_B] (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.",AGONIST,CPR:5,2,"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice."
Electroencephalographic recordings during substance consumption showed reduced alpha activity and << P300 >> latencies in the [[ nicotine ]] group compared to the control group.,Electroencephalographic recordings during substance consumption showed reduced alpha activity and [ENTITY_A] latencies in the [ENTITY_B] group compared to the control group.,INDIRECT-DOWNREGULATOR,CPR:4,1,Electroencephalographic recordings during substance consumption showed reduced alpha activity and P300 latencies in the nicotine group compared to the control group.
These findings suggest that oral consumption of << nicotine >> enhances the efficacy of [[ nicotinic acetylcholine receptors ]].,These findings suggest that oral consumption of [ENTITY_A] enhances the efficacy of [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,These findings suggest that oral consumption of nicotine enhances the efficacy of nicotinic acetylcholine receptors.
Toxicity profile of small-molecule << IAP >> antagonist [[ GDC-0152 ]] is linked to TNF-α pharmacology.,Toxicity profile of small-molecule [ENTITY_A] antagonist [ENTITY_B] is linked to TNF-α pharmacology.,ANTAGONIST,CPR:6,3,Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-α pharmacology.
<< GDC-0152 >> is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing [[ IAPs ]].,[ENTITY_A] is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing [ENTITY_B].,ANTAGONIST,CPR:6,3,GDC-0152 is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing IAPs.
"<< GDC-0152 >> induces [[ NF-κB ]] transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-α) is the most important for single-agent tumor activity.","[ENTITY_A] induces [ENTITY_B] transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-α) is the most important for single-agent tumor activity.",ACTIVATOR,CPR:3,0,"GDC-0152 induces NF-κB transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-α) is the most important for single-agent tumor activity."
"The << PARP >> inhibitor [[ PJ34 ]] modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.","The [ENTITY_A] inhibitor [ENTITY_B] modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.",INHIBITOR,CPR:4,1,"The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines."
"Since PARP-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the << PARP >> inhibitor [[ PJ34 ]] on several properties of thyroid cancer cell lines was investigated.","Since PARP-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the [ENTITY_A] inhibitor [ENTITY_B] on several properties of thyroid cancer cell lines was investigated.",INHIBITOR,CPR:4,1,"Since PARP-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the PARP inhibitor PJ34 on several properties of thyroid cancer cell lines was investigated."
"In TPC1, BCPAP, FRO, WRO cell lines << PJ34 >> induced a strong increase in [[ NIS ]] mRNA levels.","In TPC1, BCPAP, FRO, WRO cell lines [ENTITY_A] induced a strong increase in [ENTITY_B] mRNA levels.",INDIRECT-UPREGULATOR,CPR:3,0,"In TPC1, BCPAP, FRO, WRO cell lines PJ34 induced a strong increase in NIS mRNA levels."
"Accordingly, in transfection experiments performed in TPC1 cells, treatment with << PJ34 >> increased [[ NIS promoter ]] activity without affecting PARP-1 binding to the promoter sequence.","Accordingly, in transfection experiments performed in TPC1 cells, treatment with [ENTITY_A] increased [ENTITY_B] activity without affecting PARP-1 binding to the promoter sequence.",ACTIVATOR,CPR:3,0,"Accordingly, in transfection experiments performed in TPC1 cells, treatment with PJ34 increased NIS promoter activity without affecting PARP-1 binding to the promoter sequence."
"We also investigated the epigenetic status of NIS promoter after << PJ34 >> treatment in TPC1 cell line: in addition to an increase of [[ histone modification activation marks ]] (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.","We also investigated the epigenetic status of NIS promoter after [ENTITY_A] treatment in TPC1 cell line: in addition to an increase of [ENTITY_B] (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.",INDIRECT-UPREGULATOR,CPR:3,0,"We also investigated the epigenetic status of NIS promoter after PJ34 treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark."
"Both << apo-lycopenoic acids >> also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in [[ NOX-4 ]] and COX-2 expressions caused by CSE.","Both [ENTITY_A] also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in [ENTITY_B] and COX-2 expressions caused by CSE.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Both apo-lycopenoic acids also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in NOX-4 and COX-2 expressions caused by CSE."
"Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme << butyrylcholinesterase >> (BChE), which is capable of breaking down naturally occurring [[ (-)-cocaine ]] before the drug can influence the reward centers of the brain or affect other areas of the body.","Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme [ENTITY_A] (BChE), which is capable of breaking down naturally occurring [ENTITY_B] before the drug can influence the reward centers of the brain or affect other areas of the body.",SUBSTRATE,CPR:9,4,"Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme butyrylcholinesterase (BChE), which is capable of breaking down naturally occurring (-)-cocaine before the drug can influence the reward centers of the brain or affect other areas of the body."
This prompted the design of variants of << BChE >> which exhibit significantly improved catalytic activity against [[ (-)-cocaine ]].,This prompted the design of variants of [ENTITY_A] which exhibit significantly improved catalytic activity against [ENTITY_B].,SUBSTRATE,CPR:9,4,This prompted the design of variants of BChE which exhibit significantly improved catalytic activity against (-)-cocaine.
"Here, in expressing << cocaine >>-hydrolyzing mutants of [[ BChE ]] in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered BChE proteins with desired properties.","Here, in expressing [ENTITY_A]-hydrolyzing mutants of [ENTITY_B] in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered BChE proteins with desired properties.",SUBSTRATE,CPR:9,4,"Here, in expressing cocaine-hydrolyzing mutants of BChE in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered BChE proteins with desired properties."
"We examined in cats the 1) ulcerogenic effects of selective << COX-1 >> ([[ SC-560 ]], ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.","We examined in cats the 1) ulcerogenic effects of selective [ENTITY_A] ([ENTITY_B], ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.",INHIBITOR,CPR:4,1,"We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum."
"Second, feeding increased both the expression of << COX >> isoforms and PGE(2) level in the duodenum, and the effects were markedly inhibited by pretreatment with [[ cimetidine ]].","Second, feeding increased both the expression of [ENTITY_A] isoforms and PGE(2) level in the duodenum, and the effects were markedly inhibited by pretreatment with [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Second, feeding increased both the expression of COX isoforms and PGE(2) level in the duodenum, and the effects were markedly inhibited by pretreatment with cimetidine."
Reversal of inhibition by << D2 >> agonist quinpirole was produced by serotonin (50 µM) and by [[ neurotensin ]] (5-10 nM).,Reversal of inhibition by [ENTITY_A] agonist quinpirole was produced by serotonin (50 µM) and by [ENTITY_B] (5-10 nM).,ACTIVATOR,CPR:3,0,Reversal of inhibition by D2 agonist quinpirole was produced by serotonin (50 µM) and by neurotensin (5-10 nM).
Reversal of inhibition by << D2 >> agonist [[ quinpirole ]] was produced by serotonin (50 µM) and by neurotensin (5-10 nM).,Reversal of inhibition by [ENTITY_A] agonist [ENTITY_B] was produced by serotonin (50 µM) and by neurotensin (5-10 nM).,AGONIST,CPR:5,2,Reversal of inhibition by D2 agonist quinpirole was produced by serotonin (50 µM) and by neurotensin (5-10 nM).
"Serotonin-induced or neurotensin-induced reversal was blocked by β-ARK1 inhibitor, dynasore, or << cPKC >> antagonist [[ 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile ]] (Gö6976).","Serotonin-induced or neurotensin-induced reversal was blocked by β-ARK1 inhibitor, dynasore, or [ENTITY_A] antagonist [ENTITY_B] (Gö6976).",ANTAGONIST,CPR:6,3,"Serotonin-induced or neurotensin-induced reversal was blocked by β-ARK1 inhibitor, dynasore, or cPKC antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (Gö6976)."
"<< RSV >> targets and activates the [[ NAD(+)-dependent protein deacetylase SIRT1 ]]; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).","[ENTITY_A] targets and activates the [ENTITY_B]; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).",ACTIVATOR,CPR:3,0,"RSV targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2)."
"However, << 4'G-RSV >>, but not 3G-RSV, induced [[ SIRT1 ]]-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.","However, [ENTITY_A], but not 3G-RSV, induced [ENTITY_B]-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.",ACTIVATOR,CPR:3,0,"However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects."
Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting << cholesterol >> efflux by the [[ ABCA1 ]] transporter.,Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting [ENTITY_A] efflux by the [ENTITY_B] transporter.,SUBSTRATE,CPR:9,4,Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter.
The bihelical << apolipoprotein mimetic peptide 5A >> effluxes [[ cholesterol ]] from cells and reduces inflammation and atherosclerosis in animal models.,The bihelical [ENTITY_A] effluxes [ENTITY_B] from cells and reduces inflammation and atherosclerosis in animal models.,SUBSTRATE,CPR:9,4,The bihelical apolipoprotein mimetic peptide 5A effluxes cholesterol from cells and reduces inflammation and atherosclerosis in animal models.
"Compared with active peptides containing F or W, peptides containing E in either of these two positions were more than 10-fold less effective in effluxing << cholesterol >> by the [[ ABCA1 ]] transporter.","Compared with active peptides containing F or W, peptides containing E in either of these two positions were more than 10-fold less effective in effluxing [ENTITY_A] by the [ENTITY_B] transporter.",SUBSTRATE,CPR:9,4,"Compared with active peptides containing F or W, peptides containing E in either of these two positions were more than 10-fold less effective in effluxing cholesterol by the ABCA1 transporter."
These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the << ABCA1 >> transporter during the [[ cholesterol ]] efflux process.,These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the [ENTITY_A] transporter during the [ENTITY_B] efflux process.,SUBSTRATE,CPR:9,4,These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the ABCA1 transporter during the cholesterol efflux process.
Efficacy of the << GluK1 >>/AMPA receptor antagonist [[ LY293558 ]] against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.,Efficacy of the [ENTITY_A]/AMPA receptor antagonist [ENTITY_B] against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.,ANTAGONIST,CPR:6,3,Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.
"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the << GluK1 >> (GluR5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist [[ (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid ]] (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.","To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the [ENTITY_A] (GluR5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist [ENTITY_B] (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.",ANTAGONIST,CPR:6,3,"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman."
"Although acetylcholinesterase (<< AChE >>) is primarily a hydrolytic enzyme, metabolising the neurotransmitter [[ acetylcholine ]] in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised.","Although acetylcholinesterase ([ENTITY_A]) is primarily a hydrolytic enzyme, metabolising the neurotransmitter [ENTITY_B] in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised.",SUBSTRATE,CPR:9,4,"Although acetylcholinesterase (AChE) is primarily a hydrolytic enzyme, metabolising the neurotransmitter acetylcholine in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised."
"Cellular release of << AChE >> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists [[ carbachol ]] or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.","Cellular release of [ENTITY_A] by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists [ENTITY_B] or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.",INDIRECT-UPREGULATOR,CPR:3,0,"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine."
"Cellular release of << AChE >> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist [[ atropine ]].","Cellular release of [ENTITY_A] by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine."
"Cellular release of AChE by SH-SY5Y is significantly enhanced by the << muscarinic acetylcholine receptor >> (mAChR) agonists [[ carbachol ]] or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.","Cellular release of AChE by SH-SY5Y is significantly enhanced by the [ENTITY_A] (mAChR) agonists [ENTITY_B] or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.",AGONIST,CPR:5,2,"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine."
"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the << mAChR >> antagonist [[ atropine ]].","Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the [ENTITY_A] antagonist [ENTITY_B].",ANTAGONIST,CPR:6,3,"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine."
<< L-BMAA >> induced ER stress and enhanced [[ caspase 12 ]] cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations.,[ENTITY_A] induced ER stress and enhanced [ENTITY_B] cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations.,INDIRECT-UPREGULATOR,CPR:3,0,L-BMAA induced ER stress and enhanced caspase 12 cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations.
"Nevertheless, low << L-BMAA >> concentrations (≥ 0.1mM, 48 h) increased protein ubiquitination, [[ 20S proteasomal ]] and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2α in SH-SY5Y cells.","Nevertheless, low [ENTITY_A] concentrations (≥ 0.1mM, 48 h) increased protein ubiquitination, [ENTITY_B] and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2α in SH-SY5Y cells.",ACTIVATOR,CPR:3,0,"Nevertheless, low L-BMAA concentrations (≥ 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2α in SH-SY5Y cells."
<< Ribavirin >>-induced intracellular GTP depletion activates transcription elongation in [[ coagulation factor VII ]] gene expression.,[ENTITY_A]-induced intracellular GTP depletion activates transcription elongation in [ENTITY_B] gene expression.,INDIRECT-UPREGULATOR,CPR:3,0,Ribavirin-induced intracellular GTP depletion activates transcription elongation in coagulation factor VII gene expression.
"It was reported previously that << FVII >> gene (F7) expression was up-regulated by [[ ribavirin ]] treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.","It was reported previously that [ENTITY_A] gene (F7) expression was up-regulated by [ENTITY_B] treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.",INDIRECT-UPREGULATOR,CPR:3,0,"It was reported previously that FVII gene (F7) expression was up-regulated by ribavirin treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown."
"In the present study, we investigated the molecular mechanism of << ribavirin >>-induced up-regulation of [[ F7 ]] expression in HepG2 (human hepatoma cell line).","In the present study, we investigated the molecular mechanism of [ENTITY_A]-induced up-regulation of [ENTITY_B] expression in HepG2 (human hepatoma cell line).",INDIRECT-UPREGULATOR,CPR:3,0,"In the present study, we investigated the molecular mechanism of ribavirin-induced up-regulation of F7 expression in HepG2 (human hepatoma cell line)."
"We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as << mycophenolic acid >> and 6-mercaptopurine, up-regulated [[ F7 ]] expression.","We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as [ENTITY_A] and 6-mercaptopurine, up-regulated [ENTITY_B] expression.",INDIRECT-UPREGULATOR,CPR:3,0,"We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression."
<< Ribavirin >> unregulated [[ ELL ]] (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation.,[ENTITY_A] unregulated [ENTITY_B] (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation.,INDIRECT-UPREGULATOR,CPR:3,0,Ribavirin unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation.
"We observed that << ribavirin >> enhanced [[ ELL3 ]] recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation.","We observed that [ENTITY_A] enhanced [ENTITY_B] recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation.",INDIRECT-UPREGULATOR,CPR:3,0,"We observed that ribavirin enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation."
<< Ribavirin >> also enhanced recruitment of [[ CDK9 ]] (cyclin-dependent kinase 9) and AFF4 to F7.,[ENTITY_A] also enhanced recruitment of [ENTITY_B] (cyclin-dependent kinase 9) and AFF4 to F7.,INDIRECT-UPREGULATOR,CPR:3,0,Ribavirin also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to F7.
"These data suggest that << ribavirin >>-induced intracellular GTP depletion recruits a super elongation complex containing [[ P-TEFb ]], AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation.","These data suggest that [ENTITY_A]-induced intracellular GTP depletion recruits a super elongation complex containing [ENTITY_B], AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation.",INDIRECT-UPREGULATOR,CPR:3,0,"These data suggest that ribavirin-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation."
"Collectively, we have elucidated a basal mechanism for << ribavirin >>-induced [[ FVII ]] mRNA up-regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions in vivo.","Collectively, we have elucidated a basal mechanism for [ENTITY_A]-induced [ENTITY_B] mRNA up-regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions in vivo.",INDIRECT-UPREGULATOR,CPR:3,0,"Collectively, we have elucidated a basal mechanism for ribavirin-induced FVII mRNA up-regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions in vivo."
"The potentiation of heteromeric << KARs >> by mGlu1 activation was attenuated by GDPβS, blocked by an inhibitor of phospholipase C or the calcium chelator [[ 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid ]] (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.","The potentiation of heteromeric [ENTITY_A] by mGlu1 activation was attenuated by GDPβS, blocked by an inhibitor of phospholipase C or the calcium chelator [ENTITY_B] (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.",INHIBITOR,CPR:4,1,"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPβS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A."
"Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of << PKC >> by [[ phorbol 12-myristate,13-acetate ]] potentiated GluK2/GluK5.","Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of [ENTITY_A] by [ENTITY_B] potentiated GluK2/GluK5.",ACTIVATOR,CPR:3,0,"Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5."
"<< Fingolimod >> (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different [[ sphingosine-1-phosphate receptor ]] (S1PR) subtypes.","[ENTITY_A] (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different [ENTITY_B] (S1PR) subtypes.",ACTIVATOR,CPR:3,0,"Fingolimod (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (S1PR) subtypes."
"Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective << type-1 S1PR >> (S1P1R) antagonist, [[ W146 ]], and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.","Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective [ENTITY_A] (S1P1R) antagonist, [ENTITY_B], and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.",ANTAGONIST,CPR:6,3,"Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways."
"Pharmacokinetics and metabolism of << [(14)C]anagliptin >>, a novel [[ dipeptidyl peptidase-4 ]] inhibitor, in humans.","Pharmacokinetics and metabolism of [ENTITY_A], a novel [ENTITY_B] inhibitor, in humans.",INHIBITOR,CPR:4,1,"Pharmacokinetics and metabolism of [(14)C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans."
"1. The disposition of << anagliptin >>, an orally active, highly selective [[ dipeptidyl peptidase-4 ]] inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq [(14)C]anagliptin to six healthy men.","1. The disposition of [ENTITY_A], an orally active, highly selective [ENTITY_B] inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq [(14)C]anagliptin to six healthy men.",INHIBITOR,CPR:4,1,"1. The disposition of anagliptin, an orally active, highly selective dipeptidyl peptidase-4 inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq [(14)C]anagliptin to six healthy men."
"Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that << anagliptin >> may be a substrate of [[ OAT1 ]], OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.","Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that [ENTITY_A] may be a substrate of [ENTITY_B], OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.",SUBSTRATE,CPR:9,4,"Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4."
Antiretroviral << protease >> inhibitors [[ lopinavir ]] (LPV) and ritonavir (RTV) are reported BSEP inhibitors.,Antiretroviral [ENTITY_A] inhibitors [ENTITY_B] (LPV) and ritonavir (RTV) are reported BSEP inhibitors.,INHIBITOR,CPR:4,1,Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir (RTV) are reported BSEP inhibitors.
<< GHRP-6 >> is a [[ growth hormone ]] secretagogue that also enhances tissue viability in different organs.,[ENTITY_A] is a [ENTITY_B] secretagogue that also enhances tissue viability in different organs.,INDIRECT-UPREGULATOR,CPR:3,0,GHRP-6 is a growth hormone secretagogue that also enhances tissue viability in different organs.
"The altered activities of key enzymes such as << glucose-6-phosphatase >> and fructose-1,6-bisphosphatase of [[ carbohydrate ]] metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).","The altered activities of key enzymes such as [ENTITY_A] and fructose-1,6-bisphosphatase of [ENTITY_B] metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).",PRODUCT-OF,CPR:9,4,"The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP)."
<< Ibandronate >> increases the expression of the pro-apoptotic gene [[ FAS ]] by epigenetic mechanisms in tumor cells.,[ENTITY_A] increases the expression of the pro-apoptotic gene [ENTITY_B] by epigenetic mechanisms in tumor cells.,INDIRECT-UPREGULATOR,CPR:3,0,Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells.
"Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of << DNMT1 >>, which was rescued by re-isoprenylation by both [[ geranylgeranyl-pyrophosphate ]] and farnesylpyrophosphate.","Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of [ENTITY_A], which was rescued by re-isoprenylation by both [ENTITY_B] and farnesylpyrophosphate.",UPREGULATOR,CPR:3,0,"Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and farnesylpyrophosphate."
Data suggest that << bisphosphonates >> via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of [[ FAS ]]-expression.,Data suggest that [ENTITY_A] via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of [ENTITY_B]-expression.,INDIRECT-UPREGULATOR,CPR:3,0,Data suggest that bisphosphonates via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of FAS-expression.
"The AhR target gene << CYP1A1 >> mRNA expression was induced by [[ TCDD ]], but was not affected by the AR CAG length.","The AhR target gene [ENTITY_A] mRNA expression was induced by [ENTITY_B], but was not affected by the AR CAG length.",INDIRECT-UPREGULATOR,CPR:3,0,"The AhR target gene CYP1A1 mRNA expression was induced by TCDD, but was not affected by the AR CAG length."
"TCDD had no effect on AR activity in PC-3 cells, whereas the shortest << AR >> variant was induced by [[ TCDD ]] in PNT1A cells.","TCDD had no effect on AR activity in PC-3 cells, whereas the shortest [ENTITY_A] variant was induced by [ENTITY_B] in PNT1A cells.",ACTIVATOR,CPR:3,0,"TCDD had no effect on AR activity in PC-3 cells, whereas the shortest AR variant was induced by TCDD in PNT1A cells."
"Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several cytokines in mice and replacement of plasmid by << polyglutamate >> reduced the elevation of all assayed [[ cytokines ]].","Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several cytokines in mice and replacement of plasmid by [ENTITY_A] reduced the elevation of all assayed [ENTITY_B].",DOWNREGULATOR,CPR:4,1,"Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several cytokines in mice and replacement of plasmid by polyglutamate reduced the elevation of all assayed cytokines."
"We found that << helenalin >> markedly induced endoplasmic reticulum (ER) stress-related genes, such as [[ regulated in development and DNA damage responses (REDD) 1 ]], activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).","We found that [ENTITY_A] markedly induced endoplasmic reticulum (ER) stress-related genes, such as [ENTITY_B], activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).",INDIRECT-UPREGULATOR,CPR:3,0,"We found that helenalin markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP)."
Contributions of << rat Ctr1 >> to the uptake and toxicity of [[ copper ]] and platinum anticancer drugs in dorsal root ganglion neurons.,Contributions of [ENTITY_A] to the uptake and toxicity of [ENTITY_B] and platinum anticancer drugs in dorsal root ganglion neurons.,SUBSTRATE,CPR:9,4,Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons.
"Heterologous expression of << rCtr1 >> in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of [[ copper ]], oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.","Heterologous expression of [ENTITY_A] in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of [ENTITY_B], oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.",SUBSTRATE,CPR:9,4,"Heterologous expression of rCtr1 in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells."
"Cultured rat DRG neurons endogenously expressed << rCtr1 >> protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up [[ copper ]], but were resistant to copper toxicity.","Cultured rat DRG neurons endogenously expressed [ENTITY_A] protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up [ENTITY_B], but were resistant to copper toxicity.",SUBSTRATE,CPR:9,4,"Cultured rat DRG neurons endogenously expressed rCtr1 protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up copper, but were resistant to copper toxicity."
"The uptake of << copper >> by both cultured rat DRG neurons and HEK/[[ rCtr1 ]] cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by rCtr1.","The uptake of [ENTITY_A] by both cultured rat DRG neurons and HEK/[ENTITY_B] cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by rCtr1.",SUBSTRATE,CPR:9,4,"The uptake of copper by both cultured rat DRG neurons and HEK/rCtr1 cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by rCtr1."
"In conclusion, << rCtr1 >> can transport copper and [[ platinum ]] drugs, and sensitizes cells to their cytotoxicities.","In conclusion, [ENTITY_A] can transport copper and [ENTITY_B] drugs, and sensitizes cells to their cytotoxicities.",SUBSTRATE,CPR:9,4,"In conclusion, rCtr1 can transport copper and platinum drugs, and sensitizes cells to their cytotoxicities."
"DRG neurons display substantial capacity for accumulating << copper >> via a transport process mediated by [[ rCtr1 ]], but appear able to resist copper toxicity and use alternative mechanisms to take up oxaliplatin.","DRG neurons display substantial capacity for accumulating [ENTITY_A] via a transport process mediated by [ENTITY_B], but appear able to resist copper toxicity and use alternative mechanisms to take up oxaliplatin.",SUBSTRATE,CPR:9,4,"DRG neurons display substantial capacity for accumulating copper via a transport process mediated by rCtr1, but appear able to resist copper toxicity and use alternative mechanisms to take up oxaliplatin."
"Examination of phosphorylation in << retinoblastoma (Rb) protein >>, we found an inhibitory effect by [[ glucosamine ]] at 20 and 50 mM.","Examination of phosphorylation in [ENTITY_A], we found an inhibitory effect by [ENTITY_B] at 20 and 50 mM.",INHIBITOR,CPR:4,1,"Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM."
"<< Glucosamine >> at 50 mM was demonstrated to elevate both the mRNA and protein expression of [[ p53 ]] and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.","[ENTITY_A] at 50 mM was demonstrated to elevate both the mRNA and protein expression of [ENTITY_B] and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.",INDIRECT-UPREGULATOR,CPR:3,0,"Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression."
"<< Glucosamine >> at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in [[ p21 ]] protein expression.","[ENTITY_A] at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in [ENTITY_B] protein expression.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression."
"In addition, << glucosamine >> attenuated p21 protein stability via the proteasomal proteolytic pathway, as well as inducing [[ p21 ]] nuclear accumulation.","In addition, [ENTITY_A] attenuated p21 protein stability via the proteasomal proteolytic pathway, as well as inducing [ENTITY_B] nuclear accumulation.",INDIRECT-UPREGULATOR,CPR:3,0,"In addition, glucosamine attenuated p21 protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation."
"In addition, << glucosamine >> attenuated [[ p21 ]] protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation.","In addition, [ENTITY_A] attenuated [ENTITY_B] protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, glucosamine attenuated p21 protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation."
"Altogether, our results suggest that a high dose of << glucosamine >> may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear [[ p21 ]] accumulation.","Altogether, our results suggest that a high dose of [ENTITY_A] may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear [ENTITY_B] accumulation.",INDIRECT-UPREGULATOR,CPR:3,0,"Altogether, our results suggest that a high dose of glucosamine may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation."
"Altogether, our results suggest that a high dose of << glucosamine >> may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in [[ Rb ]] phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation.","Altogether, our results suggest that a high dose of [ENTITY_A] may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in [ENTITY_B] phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation.",INHIBITOR,CPR:4,1,"Altogether, our results suggest that a high dose of glucosamine may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation."
Characterization of substituted << phenylpropylamides >> as highly selective agonists at the [[ melatonin MT2 receptor ]].,Characterization of substituted [ENTITY_A] as highly selective agonists at the [ENTITY_B].,AGONIST,CPR:5,2,Characterization of substituted phenylpropylamides as highly selective agonists at the melatonin MT2 receptor.
We show that the expression of PIM-1 is induced in response to << estradiol >> in MCF-7 cells and that the induction is mediated by [[ ERα ]]-regulated enhancers located distally upstream from the gene.,We show that the expression of PIM-1 is induced in response to [ENTITY_A] in MCF-7 cells and that the induction is mediated by [ENTITY_B]-regulated enhancers located distally upstream from the gene.,ACTIVATOR,CPR:3,0,We show that the expression of PIM-1 is induced in response to estradiol in MCF-7 cells and that the induction is mediated by ERα-regulated enhancers located distally upstream from the gene.
"In this work, the metabolism of four frequently prescribed inhaled GCs, << triamcinolone acetonide >>, flunisolide, budesonide, and fluticasone propionate, by the [[ CYP3A ]] family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.","In this work, the metabolism of four frequently prescribed inhaled GCs, [ENTITY_A], flunisolide, budesonide, and fluticasone propionate, by the [ENTITY_B] family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.",SUBSTRATE,CPR:9,4,"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide, and fluticasone propionate, by the CYP3A family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites."
"<< CYP3A5 >>, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize [[ triamcinolone acetonide ]], budesonide, and fluticasone propionate.","[ENTITY_A], which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize [ENTITY_B], budesonide, and fluticasone propionate.",SUBSTRATE,CPR:9,4,"CYP3A5, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, budesonide, and fluticasone propionate."
"In contrast, << flunisolide >> was only metabolized via [[ CYP3A4 ]], with no significant turnover by CYP3A5 or CYP3A7.","In contrast, [ENTITY_A] was only metabolized via [ENTITY_B], with no significant turnover by CYP3A5 or CYP3A7.",SUBSTRATE,CPR:9,4,"In contrast, flunisolide was only metabolized via CYP3A4, with no significant turnover by CYP3A5 or CYP3A7."
"Distinct roles of << methamphetamine >> in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of [[ ERK ]] and CREB activation in hippocampus and prefrontal cortex.","Distinct roles of [ENTITY_A] in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of [ENTITY_B] and CREB activation in hippocampus and prefrontal cortex.",ACTIVATOR,CPR:3,0,"Distinct roles of methamphetamine in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of ERK and CREB activation in hippocampus and prefrontal cortex."
"In contrast, activation of both << ERK >> and CREB in the PFC was found following memory retrieval but not other processes in [[ METH ]]-treated mouse groups.","In contrast, activation of both [ENTITY_A] and CREB in the PFC was found following memory retrieval but not other processes in [ENTITY_B]-treated mouse groups.",ACTIVATOR,CPR:3,0,"In contrast, activation of both ERK and CREB in the PFC was found following memory retrieval but not other processes in METH-treated mouse groups."
"Moreover, activation of the << ERK >> and CREB signaling pathway in the hippocampus might be involved in [[ METH ]]-induced spatial memory changes.","Moreover, activation of the [ENTITY_A] and CREB signaling pathway in the hippocampus might be involved in [ENTITY_B]-induced spatial memory changes.",ACTIVATOR,CPR:3,0,"Moreover, activation of the ERK and CREB signaling pathway in the hippocampus might be involved in METH-induced spatial memory changes."
"A reporter construct driven by 4 kb of the << chicken ras-dva >> 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by [[ corticosterone ]].","A reporter construct driven by 4 kb of the [ENTITY_A] 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by corticosterone."
"However, mutating putative << GR binding sites >> did not substantially reduce induction of ras-dva promoter activity by [[ corticosterone ]], suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation.","However, mutating putative [ENTITY_A] did not substantially reduce induction of ras-dva promoter activity by [ENTITY_B], suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation.",INDIRECT-UPREGULATOR,CPR:3,0,"However, mutating putative GR binding sites did not substantially reduce induction of ras-dva promoter activity by corticosterone, suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation."
"To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the << mGluR8 >>-specific orthosteric agonist [[ (S)-3,4-dicarboxyphenylglycine ]] (DCPG).","To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the [ENTITY_A]-specific orthosteric agonist [ENTITY_B] (DCPG).",AGONIST,CPR:5,2,"To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG)."
"UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the << NMDA receptor >> antagonist [[ MK-801 ]].","UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the [ENTITY_A] antagonist [ENTITY_B].",ANTAGONIST,CPR:6,3,"UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the NMDA receptor antagonist MK-801."
"Here, we compared the effects of a dimeric << PSD-95 >> inhibitor, [[ UCCB01-125 ]], and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.","Here, we compared the effects of a dimeric [ENTITY_A] inhibitor, [ENTITY_B], and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.",INHIBITOR,CPR:4,1,"Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain."
"Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the << NMDAR >> antagonist, [[ MK-801 ]], on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.","Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the [ENTITY_A] antagonist, [ENTITY_B], on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.",ANTAGONIST,CPR:6,3,"Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain."
"The treatment also prevented the high << cholesterol >> diet-induced increase in serum [[ creatine kinase ]], total and isoforms, markers of neurological, cardiac and muscular damage.","The treatment also prevented the high [ENTITY_A] diet-induced increase in serum [ENTITY_B], total and isoforms, markers of neurological, cardiac and muscular damage.",INDIRECT-UPREGULATOR,CPR:3,0,"The treatment also prevented the high cholesterol diet-induced increase in serum creatine kinase, total and isoforms, markers of neurological, cardiac and muscular damage."
"GIP potentiates << glucose >>-stimulated [[ insulin ]] secretion and induces energy accumulation into adipose tissue, resulting in obesity.","GIP potentiates [ENTITY_A]-stimulated [ENTITY_B] secretion and induces energy accumulation into adipose tissue, resulting in obesity.",INDIRECT-UPREGULATOR,CPR:3,0,"GIP potentiates glucose-stimulated insulin secretion and induces energy accumulation into adipose tissue, resulting in obesity."
"Diet, physical exercise and << Orlistat >> administration increase serum [[ Anti-Müllerian Hormone ]] (AMH) levels in women with polycystic ovary syndrome (PCOS).","Diet, physical exercise and [ENTITY_A] administration increase serum [ENTITY_B] (AMH) levels in women with polycystic ovary syndrome (PCOS).",INDIRECT-UPREGULATOR,CPR:3,0,"Diet, physical exercise and Orlistat administration increase serum Anti-Müllerian Hormone (AMH) levels in women with polycystic ovary syndrome (PCOS)."
"We concluded that in overweight and obese women with PCOS << Orlistat >> administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and insulin sensitivity, and increased serum [[ AMH ]] levels.","We concluded that in overweight and obese women with PCOS [ENTITY_A] administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and insulin sensitivity, and increased serum [ENTITY_B] levels.",INDIRECT-UPREGULATOR,CPR:3,0,"We concluded that in overweight and obese women with PCOS Orlistat administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and insulin sensitivity, and increased serum AMH levels."
"Moreover, << 1,25(OH)(2)D(3) >> decreased expression of [[ Oat1 ]] and Oat3 in rat kidney.","Moreover, [ENTITY_A] decreased expression of [ENTITY_B] and Oat3 in rat kidney.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, 1,25(OH)(2)D(3) decreased expression of Oat1 and Oat3 in rat kidney."
"The mechanism of interaction between JBP485 and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of << 1,25(OH)(2)D(3) >> on expression of [[ Oats ]] in rat kidney.","The mechanism of interaction between JBP485 and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of [ENTITY_A] on expression of [ENTITY_B] in rat kidney.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The mechanism of interaction between JBP485 and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of 1,25(OH)(2)D(3) on expression of Oats in rat kidney."
"<< ISO >> is able to induce apoptosis through mitochondrial dysfunction and inhibition of [[ PI3K ]]/Akt signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown.","[ENTITY_A] is able to induce apoptosis through mitochondrial dysfunction and inhibition of [ENTITY_B]/Akt signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown.",INHIBITOR,CPR:4,1,"ISO is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown."
<< ISO >> significantly inhibited the levels of ERK1/2 kinase and increased the expression of [[ JNK ]] and p38 kinases.,[ENTITY_A] significantly inhibited the levels of ERK1/2 kinase and increased the expression of [ENTITY_B] and p38 kinases.,INDIRECT-UPREGULATOR,CPR:3,0,ISO significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and p38 kinases.
"Furthermore, << U0126 >> (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the [[ Bax ]]/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.","Furthermore, [ENTITY_A] (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the [ENTITY_B]/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3."
While SP600125 (a << JNK >> inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by [[ ISO ]].,While SP600125 (a [ENTITY_A] inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,While SP600125 (a JNK inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.
While << SP600125 >> (a [[ JNK ]] inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.,While [ENTITY_A] (a [ENTITY_B] inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.,INHIBITOR,CPR:4,1,While SP600125 (a JNK inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.
"<< NAC >> also suppressed the p-[[ JNK ]] and p-p38, but failed to reverse the effects of ISO.","[ENTITY_A] also suppressed the p-[ENTITY_B] and p-p38, but failed to reverse the effects of ISO.",INHIBITOR,CPR:4,1,"NAC also suppressed the p-JNK and p-p38, but failed to reverse the effects of ISO."
"These results demonstrated for the first time that << ISO >> induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating [[ JNK ]] and p38 kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.","These results demonstrated for the first time that [ENTITY_A] induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating [ENTITY_B] and p38 kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.",ACTIVATOR,CPR:3,0,"These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules."
"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and << IMG >> or hyperoside inhibited production of [[ thrombin ]] and FXa in HUVECs.","Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and [ENTITY_A] or hyperoside inhibited production of [ENTITY_B] and FXa in HUVECs.",INDIRECT-UPREGULATOR,CPR:3,0,"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs."
"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and << IMG >> or hyperoside inhibited production of thrombin and [[ FXa ]] in HUVECs.","Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and [ENTITY_A] or hyperoside inhibited production of thrombin and [ENTITY_B] in HUVECs.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs."
"In addition, treatment with << IMG >> and hyperoside resulted in inhibition of TNF-α-induced production of [[ PAI-1 ]], and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.","In addition, treatment with [ENTITY_A] and hyperoside resulted in inhibition of TNF-α-induced production of [ENTITY_B], and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-α-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio."
Optimization of << 5-hydroxytryptamines >> as dual function inhibitors targeting [[ phospholipase A2 ]] and leukotriene A4 hydrolase.,Optimization of [ENTITY_A] as dual function inhibitors targeting [ENTITY_B] and leukotriene A4 hydrolase.,INHIBITOR,CPR:4,1,Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase.
Dual function inhibitors targeting phospholipase A(2) (<< PLA(2) >>) and leukotriene A(4) hydrolase (LTA(4)H) may balance the [[ arachidonic acid ]] (AA) metabolic network and be used as new anti-inflammatory drugs.,Dual function inhibitors targeting phospholipase A(2) ([ENTITY_A]) and leukotriene A(4) hydrolase (LTA(4)H) may balance the [ENTITY_B] (AA) metabolic network and be used as new anti-inflammatory drugs.,PRODUCT-OF,CPR:9,4,Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the arachidonic acid (AA) metabolic network and be used as new anti-inflammatory drugs.
"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<< JMC08-4 >>) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and [[ human leukotriene A(4) hydrolase ]] (LTA(4)H-h) was found.","In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor ([ENTITY_A]) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and [ENTITY_B] (LTA(4)H-h) was found.",INHIBITOR,CPR:4,1,"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (JMC08-4) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found."
"Whereas the addition of << apomorphine >> in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed [[ TRPA1 ]] channels, resulting from a reduction of single-channel open times.","Whereas the addition of [ENTITY_A] in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed [ENTITY_B] channels, resulting from a reduction of single-channel open times.",INHIBITOR,CPR:4,1,"Whereas the addition of apomorphine in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed TRPA1 channels, resulting from a reduction of single-channel open times."
"In addition, we provide evidence that << apomorphine >> also acts on endogenous TRPA1 in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of [[ TRPA1 ]].","In addition, we provide evidence that [ENTITY_A] also acts on endogenous TRPA1 in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of [ENTITY_B].",ACTIVATOR,CPR:3,0,"In addition, we provide evidence that apomorphine also acts on endogenous TRPA1 in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of TRPA1."
"Our study shows that human TRPA1 is a target for << apomorphine >>, suggesting that an activation of [[ TRPA1 ]] might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.","Our study shows that human TRPA1 is a target for [ENTITY_A], suggesting that an activation of [ENTITY_B] might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.",ACTIVATOR,CPR:3,0,"Our study shows that human TRPA1 is a target for apomorphine, suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine."
<< Human stearoyl-CoA desaturase 1 >> (SCD-1) gene expression is negatively regulated by [[ thyroid hormone ]] without direct binding of thyroid hormone receptor to the gene promoter.,[ENTITY_A] (SCD-1) gene expression is negatively regulated by [ENTITY_B] without direct binding of thyroid hormone receptor to the gene promoter.,INDIRECT-DOWNREGULATOR,CPR:4,1,Human stearoyl-CoA desaturase 1 (SCD-1) gene expression is negatively regulated by thyroid hormone without direct binding of thyroid hormone receptor to the gene promoter.
Dietary << carbohydrates >> increase [[ SCD-1 ]] gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways.,Dietary [ENTITY_A] increase [ENTITY_B] gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways.,INDIRECT-UPREGULATOR,CPR:3,0,Dietary carbohydrates increase SCD-1 gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways.
Previous report demonstrated that << thyroid hormone >> (TH) negatively regulates [[ mouse SCD-1 gene promoter ]] before SREBP-1c was revealed.,Previous report demonstrated that [ENTITY_A] (TH) negatively regulates [ENTITY_B] before SREBP-1c was revealed.,INDIRECT-DOWNREGULATOR,CPR:4,1,Previous report demonstrated that thyroid hormone (TH) negatively regulates mouse SCD-1 gene promoter before SREBP-1c was revealed.
"Exposure of H9c2 cells to high << glucose >> reduced AMPK activity, inhibited [[ Jun NH2-terminal kinase 1 ]] (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.","Exposure of H9c2 cells to high [ENTITY_A] reduced AMPK activity, inhibited [ENTITY_B] (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2."
"Finally, chronic administration of << metformin >> in diabetic mice restored cardiac autophagy by activating [[ JNK1 ]]-Bcl-2 pathways and dissociating Beclin1 and Bcl-2.","Finally, chronic administration of [ENTITY_A] in diabetic mice restored cardiac autophagy by activating [ENTITY_B]-Bcl-2 pathways and dissociating Beclin1 and Bcl-2.",ACTIVATOR,CPR:3,0,"Finally, chronic administration of metformin in diabetic mice restored cardiac autophagy by activating JNK1-Bcl-2 pathways and dissociating Beclin1 and Bcl-2."
<< Metformin >>-mediated downregulation of [[ p38 ]] mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.,[ENTITY_A]-mediated downregulation of [ENTITY_B] mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.,DOWNREGULATOR,CPR:4,1,Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.
"In this current study, << paclitaxel >> was found to increase phosphorylation of [[ mitogen-activated protein kinase ]] (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.","In this current study, [ENTITY_A] was found to increase phosphorylation of [ENTITY_B] (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.",ACTIVATOR,CPR:3,0,"In this current study, paclitaxel was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells."
"Moreover, << paclitaxel >>-induced [[ ERCC1 ]] protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).","Moreover, [ENTITY_A]-induced [ENTITY_B] protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).",INDIRECT-UPREGULATOR,CPR:3,0,"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA)."
"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of << p38 >> activity by either a p38 MAPK inhibitor [[ SB202190 ]] or p38 knockdown with specific small interfering RNA (siRNA).","Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of [ENTITY_A] activity by either a p38 MAPK inhibitor [ENTITY_B] or p38 knockdown with specific small interfering RNA (siRNA).",INHIBITOR,CPR:4,1,"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA)."
"Furthermore, metformin was able to not only decrease the << paclitaxel >>-induced [[ p38 ]] MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.","Furthermore, metformin was able to not only decrease the [ENTITY_A]-induced [ENTITY_B] MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.",ACTIVATOR,CPR:3,0,"Furthermore, metformin was able to not only decrease the paclitaxel-induced p38 MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel."
"Furthermore, << metformin >> was able to not only decrease the paclitaxel-induced p38 MAPK-mediated [[ ERCC1 ]] expression, but also augment the cytotoxic effect induced by paclitaxel.","Furthermore, [ENTITY_A] was able to not only decrease the paclitaxel-induced p38 MAPK-mediated [ENTITY_B] expression, but also augment the cytotoxic effect induced by paclitaxel.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, metformin was able to not only decrease the paclitaxel-induced p38 MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel."
"Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate << ERCC1 >> downregulation by [[ metformin ]] and paclitaxel as well as cell viability and DNA repair capacity.","Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate [ENTITY_A] downregulation by [ENTITY_B] and paclitaxel as well as cell viability and DNA repair capacity.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and paclitaxel as well as cell viability and DNA repair capacity."
"Overall, our results suggest that inhibition of the << p38 >> MAPK signaling by [[ metformin ]] coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.","Overall, our results suggest that inhibition of the [ENTITY_A] MAPK signaling by [ENTITY_B] coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.",INHIBITOR,CPR:4,1,"Overall, our results suggest that inhibition of the p38 MAPK signaling by metformin coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation."
<< Orlistat >> has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal [[ lipases ]].,[ENTITY_A] has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal [ENTITY_B].,INHIBITOR,CPR:4,1,Orlistat has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal lipases.
"This study was designed to test the hypothesis that << orlistat >> inhibits [[ CESs ]] with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity.","This study was designed to test the hypothesis that [ENTITY_A] inhibits [ENTITY_B] with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity.",INHIBITOR,CPR:4,1,"This study was designed to test the hypothesis that orlistat inhibits CESs with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity."
"Contrary to the hypothesis, orlistat at 1 nM inhibited << CES2 >> activity by 75% but no inhibition on CES1, placing CES2 one of the most sensitive targets of [[ orlistat ]].","Contrary to the hypothesis, orlistat at 1 nM inhibited [ENTITY_A] activity by 75% but no inhibition on CES1, placing CES2 one of the most sensitive targets of [ENTITY_B].",INHIBITOR,CPR:4,1,"Contrary to the hypothesis, orlistat at 1 nM inhibited CES2 activity by 75% but no inhibition on CES1, placing CES2 one of the most sensitive targets of orlistat."
Inhibition of this << carboxylesterase >> probably presents a major source for altered therapeutic activity of these medicines if co-administered with [[ orlistat ]].,Inhibition of this [ENTITY_A] probably presents a major source for altered therapeutic activity of these medicines if co-administered with [ENTITY_B].,INHIBITOR,CPR:4,1,Inhibition of this carboxylesterase probably presents a major source for altered therapeutic activity of these medicines if co-administered with orlistat.
"Regulation of multiple << adenylyl cyclases >> (AC) provides unique inputs to mediate the synthesis of [[ cAMP ]], a ubiquitous second messenger that controls many aspects of cellular function.","Regulation of multiple [ENTITY_A] (AC) provides unique inputs to mediate the synthesis of [ENTITY_B], a ubiquitous second messenger that controls many aspects of cellular function.",PRODUCT-OF,CPR:9,4,"Regulation of multiple adenylyl cyclases (AC) provides unique inputs to mediate the synthesis of cAMP, a ubiquitous second messenger that controls many aspects of cellular function."
"On stimulation by G(s), the activities of << ACs >> can be further selectively modulated by other pathways to ensure precise control of intracellular [[ cAMP ]] responses to specific stimuli.","On stimulation by G(s), the activities of [ENTITY_A] can be further selectively modulated by other pathways to ensure precise control of intracellular [ENTITY_B] responses to specific stimuli.",PRODUCT-OF,CPR:9,4,"On stimulation by G(s), the activities of ACs can be further selectively modulated by other pathways to ensure precise control of intracellular cAMP responses to specific stimuli."
"We identified one compound, << E235 >> (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide), that activated the ISR and dose-dependently increased levels of [[ ATF4 ]] in transformed cells.","We identified one compound, [ENTITY_A] (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide), that activated the ISR and dose-dependently increased levels of [ENTITY_B] in transformed cells.",INDIRECT-UPREGULATOR,CPR:3,0,"We identified one compound, E235 (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide), that activated the ISR and dose-dependently increased levels of ATF4 in transformed cells."
"<< E235 >> also activated DNA damage response signaling, resulting in increased levels of Ser15-[[ phosphorylated p53 ]], γ-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.","[ENTITY_A] also activated DNA damage response signaling, resulting in increased levels of Ser15-[ENTITY_B], γ-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.",INDIRECT-UPREGULATOR,CPR:3,0,"E235 also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, γ-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage."
Cell culture studies demonstrated that << PKAA >> is capable of delivering anti-TNF (tumor necrosis factor)-α siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of [[ TNF-α ]].,Cell culture studies demonstrated that [ENTITY_A] is capable of delivering anti-TNF (tumor necrosis factor)-α siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of [ENTITY_B].,INDIRECT-DOWNREGULATOR,CPR:4,1,Cell culture studies demonstrated that PKAA is capable of delivering anti-TNF (tumor necrosis factor)-α siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of TNF-α.
<< PKAA >>/anti-TNF-α siRNA nanocomplexes significantly reduced the [[ ALT ]] (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.,[ENTITY_A]/anti-TNF-α siRNA nanocomplexes significantly reduced the [ENTITY_B] (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.,INDIRECT-DOWNREGULATOR,CPR:4,1,PKAA/anti-TNF-α siRNA nanocomplexes significantly reduced the ALT (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.
Wogonin inhibits << H2O2 >>-induced vascular permeability through suppressing the phosphorylation of [[ caveolin-1 ]].,Wogonin inhibits [ENTITY_A]-induced vascular permeability through suppressing the phosphorylation of [ENTITY_B].,ACTIVATOR,CPR:3,0,Wogonin inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of caveolin-1.
<< Wogonin >> inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of [[ caveolin-1 ]].,[ENTITY_A] inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of [ENTITY_B].,INHIBITOR,CPR:4,1,Wogonin inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of caveolin-1.
"We found that wogonin can suppress the << H2O2 >>-stimulated [[ actin ]] remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.","We found that wogonin can suppress the [ENTITY_A]-stimulated [ENTITY_B] remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.",INDIRECT-UPREGULATOR,CPR:3,0,"We found that wogonin can suppress the H2O2-stimulated actin remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231."
"We found that << wogonin >> can suppress the H2O2-stimulated [[ actin ]] remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.","We found that [ENTITY_A] can suppress the H2O2-stimulated [ENTITY_B] remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.",INDIRECT-DOWNREGULATOR,CPR:4,1,"We found that wogonin can suppress the H2O2-stimulated actin remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231."
The mechanism revealed that wogonin inhibited << H2O2 >>-induced phosphorylation of [[ caveolin-1 ]] (cav-1) associating with the suppression of stabilization of VE-cadherin and β-catenin.,The mechanism revealed that wogonin inhibited [ENTITY_A]-induced phosphorylation of [ENTITY_B] (cav-1) associating with the suppression of stabilization of VE-cadherin and β-catenin.,ACTIVATOR,CPR:3,0,The mechanism revealed that wogonin inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and β-catenin.
The mechanism revealed that << wogonin >> inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of [[ VE-cadherin ]] and β-catenin.,The mechanism revealed that [ENTITY_A] inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of [ENTITY_B] and β-catenin.,INDIRECT-DOWNREGULATOR,CPR:4,1,The mechanism revealed that wogonin inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and β-catenin.
"Moreover, wogonin repressed << anisomycin >>-induced phosphorylation of [[ p38 ]], cav-1 and vascular permeability.","Moreover, wogonin repressed [ENTITY_A]-induced phosphorylation of [ENTITY_B], cav-1 and vascular permeability.",ACTIVATOR,CPR:3,0,"Moreover, wogonin repressed anisomycin-induced phosphorylation of p38, cav-1 and vascular permeability."
"Moreover, << wogonin >> repressed anisomycin-induced phosphorylation of [[ p38 ]], cav-1 and vascular permeability.","Moreover, [ENTITY_A] repressed anisomycin-induced phosphorylation of [ENTITY_B], cav-1 and vascular permeability.",INHIBITOR,CPR:4,1,"Moreover, wogonin repressed anisomycin-induced phosphorylation of p38, cav-1 and vascular permeability."
"These results suggested that wogonin could inhibit << H2O2 >>-induced vascular permeability by downregulating the phosphorylation of [[ cav-1 ]], and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.","These results suggested that wogonin could inhibit [ENTITY_A]-induced vascular permeability by downregulating the phosphorylation of [ENTITY_B], and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.",ACTIVATOR,CPR:3,0,"These results suggested that wogonin could inhibit H2O2-induced vascular permeability by downregulating the phosphorylation of cav-1, and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability."
"These results suggested that << wogonin >> could inhibit H2O2-induced vascular permeability by downregulating the phosphorylation of [[ cav-1 ]], and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.","These results suggested that [ENTITY_A] could inhibit H2O2-induced vascular permeability by downregulating the phosphorylation of [ENTITY_B], and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.",INHIBITOR,CPR:4,1,"These results suggested that wogonin could inhibit H2O2-induced vascular permeability by downregulating the phosphorylation of cav-1, and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability."
"In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the hERG activity, conformational modifications of the core structure resulted in the identification of fused << oxadiazepines >> such as 7i which had an improved [[ hERG ]] inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.","In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the hERG activity, conformational modifications of the core structure resulted in the identification of fused [ENTITY_A] such as 7i which had an improved [ENTITY_B] inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.",INHIBITOR,CPR:4,1,"In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the hERG activity, conformational modifications of the core structure resulted in the identification of fused oxadiazepines such as 7i which had an improved hERG inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats."
"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors << survivin >>, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by [[ BZA ]].","Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors [ENTITY_A], Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by BZA."
"We used << nutlin-3 >>, a well-known disruptor of [[ p53 ]]-Mdm2 interaction, to validate the specificity of the assay.","We used [ENTITY_A], a well-known disruptor of [ENTITY_B]-Mdm2 interaction, to validate the specificity of the assay.",INHIBITOR,CPR:4,1,"We used nutlin-3, a well-known disruptor of p53-Mdm2 interaction, to validate the specificity of the assay."
"The reduction of BiFC signal mediated by << nutlin-3 >> was correlated with an increase in [[ Puma ]] transactivation, PARP cleavage, and cell death.","The reduction of BiFC signal mediated by [ENTITY_A] was correlated with an increase in [ENTITY_B] transactivation, PARP cleavage, and cell death.",ACTIVATOR,CPR:3,0,"The reduction of BiFC signal mediated by nutlin-3 was correlated with an increase in Puma transactivation, PARP cleavage, and cell death."
"<< Sal >> toxicity coincided with reduced [[ pAkt ]] level and its downstream effectors: pCREB, pGSK-3β, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.","[ENTITY_A] toxicity coincided with reduced [ENTITY_B] level and its downstream effectors: pCREB, pGSK-3β, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Sal toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3β, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling."
This was confirmed on adding << LY294002 >> the [[ PI3K ]] inhibitor which abolished the protection.,This was confirmed on adding [ENTITY_A] the [ENTITY_B] inhibitor which abolished the protection.,INHIBITOR,CPR:4,1,This was confirmed on adding LY294002 the PI3K inhibitor which abolished the protection.
"<< Isoproterenol >> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial [[ glutathione peroxidase ]], glutathione reductase, reduced glutathione, isocitrate, succinate, malate, α-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.","[ENTITY_A] induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial [ENTITY_B], glutathione reductase, reduced glutathione, isocitrate, succinate, malate, α-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, α-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate."
"Increased urinary excretion of << albumin >>, hemopexin, transferrin and VDBP correlates with chronic sensitization to [[ gentamicin ]] nephrotoxicity in rats.","Increased urinary excretion of [ENTITY_A], hemopexin, transferrin and VDBP correlates with chronic sensitization to [ENTITY_B] nephrotoxicity in rats.",INDIRECT-UPREGULATOR,CPR:3,0,"Increased urinary excretion of albumin, hemopexin, transferrin and VDBP correlates with chronic sensitization to gentamicin nephrotoxicity in rats."
"Design and synthesis of novel << 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one >> derivatives as [[ telomerase ]] inhibitors.",Design and synthesis of novel [ENTITY_A] derivatives as [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,"Design and synthesis of novel 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one derivatives as telomerase inhibitors."
<< DPEP >> induced dose-dependent reduction of the protein levels of [[ inducible nitric oxide synthase ]] (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).,[ENTITY_A] induced dose-dependent reduction of the protein levels of [ENTITY_B] (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).,INDIRECT-DOWNREGULATOR,CPR:4,1,DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).
"Additionally, << DPEP >> suppressed the production of inflammatory [[ cytokines ]], including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6.","Additionally, [ENTITY_A] suppressed the production of inflammatory [ENTITY_B], including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Additionally, DPEP suppressed the production of inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6."
"<< DPEP >> inhibited LPS-induced phosphorylation of [[ ERK ]], JNK, and p38.","[ENTITY_A] inhibited LPS-induced phosphorylation of [ENTITY_B], JNK, and p38.",INHIBITOR,CPR:4,1,"DPEP inhibited LPS-induced phosphorylation of ERK, JNK, and p38."
"Furthermore, << DPEP >> inhibited the LPS-induced phosphorylation of inhibitor κB (IκB)-α and NF-κB [[ p50 ]].","Furthermore, [ENTITY_A] inhibited the LPS-induced phosphorylation of inhibitor κB (IκB)-α and NF-κB [ENTITY_B].",INHIBITOR,CPR:4,1,"Furthermore, DPEP inhibited the LPS-induced phosphorylation of inhibitor κB (IκB)-α and NF-κB p50."
"Taken together, the results of this study demonstrate that << DPEP >> inhibits LPS-stimulated inflammation by blocking the [[ NF-κB ]] and MAPK pathways in macrophages.","Taken together, the results of this study demonstrate that [ENTITY_A] inhibits LPS-stimulated inflammation by blocking the [ENTITY_B] and MAPK pathways in macrophages.",INHIBITOR,CPR:4,1,"Taken together, the results of this study demonstrate that DPEP inhibits LPS-stimulated inflammation by blocking the NF-κB and MAPK pathways in macrophages."
"This leads to decreased expression of << glutamate aspartate transporter >>, which in turn reduces [[ glutamate ]] transport.","This leads to decreased expression of [ENTITY_A], which in turn reduces [ENTITY_B] transport.",SUBSTRATE,CPR:9,4,"This leads to decreased expression of glutamate aspartate transporter, which in turn reduces glutamate transport."
<< Tetrahydropyrroloquinolinone >> type dual inhibitors of [[ aromatase ]]/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.,[ENTITY_A] type dual inhibitors of [ENTITY_B]/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.,INHIBITOR,CPR:4,1,Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.
"Furthermore, << MDZ >> caused mechanism-based inactivation of [[ cytochrome P450 3A ]]-dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.","Furthermore, [ENTITY_A] caused mechanism-based inactivation of [ENTITY_B]-dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.",INHIBITOR,CPR:4,1,"Furthermore, MDZ caused mechanism-based inactivation of cytochrome P450 3A-dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies."
"Furthermore, MDZ caused mechanism-based inactivation of << cytochrome P450 3A >>-dependent [[ TRZ ]] 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.","Furthermore, MDZ caused mechanism-based inactivation of [ENTITY_A]-dependent [ENTITY_B] 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.",SUBSTRATE,CPR:9,4,"Furthermore, MDZ caused mechanism-based inactivation of cytochrome P450 3A-dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies."
<< Tamoxifen >> represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating [[ c-Myc ]] in endometrial carcinoma cell lines.,[ENTITY_A] represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating [ENTITY_B] in endometrial carcinoma cell lines.,UPREGULATOR,CPR:3,0,Tamoxifen represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines.
<< Tamoxifen >> represses [[ miR-200 ]] microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines.,[ENTITY_A] represses [ENTITY_B] microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines.,INDIRECT-DOWNREGULATOR,CPR:4,1,Tamoxifen represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines.
"When treated with TAM, ECC-1 and Ishikawa cells were characterized by higher invasiveness and motility and underwent EMT. << miR-200 >>, a miRNA family with tumor suppressive functions in a wide range of cancers, was found reduced in response to [[ TAM ]] treatment.","When treated with TAM, ECC-1 and Ishikawa cells were characterized by higher invasiveness and motility and underwent EMT. [ENTITY_A], a miRNA family with tumor suppressive functions in a wide range of cancers, was found reduced in response to [ENTITY_B] treatment.",INDIRECT-DOWNREGULATOR,CPR:4,1,"When treated with TAM, ECC-1 and Ishikawa cells were characterized by higher invasiveness and motility and underwent EMT. miR-200, a miRNA family with tumor suppressive functions in a wide range of cancers, was found reduced in response to TAM treatment."
"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as << Snail >> and N-cadherin increased, whereas E-cadherin decreased in the [[ TAM ]]-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.","Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as [ENTITY_A] and N-cadherin increased, whereas E-cadherin decreased in the [ENTITY_B]-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells."
"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas << E-cadherin >> decreased in the [[ TAM ]]-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.","Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas [ENTITY_A] decreased in the [ENTITY_B]-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells."
"In addition, we showed that c-Myc directly binds to and represses the promoter of miR-200 miRNAs, and its up-regulation in << TAM >>-treated endometrial cancer cells leads to the down-regulation of [[ miR-200 ]] and eventually to EMT.","In addition, we showed that c-Myc directly binds to and represses the promoter of miR-200 miRNAs, and its up-regulation in [ENTITY_A]-treated endometrial cancer cells leads to the down-regulation of [ENTITY_B] and eventually to EMT.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, we showed that c-Myc directly binds to and represses the promoter of miR-200 miRNAs, and its up-regulation in TAM-treated endometrial cancer cells leads to the down-regulation of miR-200 and eventually to EMT."
"Collectively, our data suggest that << TAM >> can repress the miR-200 family and induce EMT via the up-regulation of [[ c-Myc ]] in endometrial cancer cells.","Collectively, our data suggest that [ENTITY_A] can repress the miR-200 family and induce EMT via the up-regulation of [ENTITY_B] in endometrial cancer cells.",UPREGULATOR,CPR:3,0,"Collectively, our data suggest that TAM can repress the miR-200 family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells."
"Collectively, our data suggest that << TAM >> can repress the [[ miR-200 ]] family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells.","Collectively, our data suggest that [ENTITY_A] can repress the [ENTITY_B] family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Collectively, our data suggest that TAM can repress the miR-200 family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells."
"Here, we show that oral administration of << resveratrol >>, which leads to activation of an [[ NAD(+)-dependent protein deacetylase SIRT1 ]], suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice.","Here, we show that oral administration of [ENTITY_A], which leads to activation of an [ENTITY_B], suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice.",ACTIVATOR,CPR:3,0,"Here, we show that oral administration of resveratrol, which leads to activation of an NAD(+)-dependent protein deacetylase SIRT1, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice."
"The pro-hypertrophic co-activator p300 protein but not p300 mRNA was up-regulated in the mdx heart, and << resveratrol >> administration down-regulated the [[ p300 ]] protein level.","The pro-hypertrophic co-activator p300 protein but not p300 mRNA was up-regulated in the mdx heart, and [ENTITY_A] administration down-regulated the [ENTITY_B] protein level.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The pro-hypertrophic co-activator p300 protein but not p300 mRNA was up-regulated in the mdx heart, and resveratrol administration down-regulated the p300 protein level."
"In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the α(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as << resveratrol >>, both of which down-regulated [[ p300 ]] protein levels but not p300 mRNA levels.","In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the α(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as [ENTITY_A], both of which down-regulated [ENTITY_B] protein levels but not p300 mRNA levels.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the α(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as resveratrol, both of which down-regulated p300 protein levels but not p300 mRNA levels."
Synthesis and dual biological effects of << hydroxycinnamoyl phenylalanyl >>/prolyl hydroxamic acid derivatives as [[ tyrosinase ]] inhibitor and antioxidant.,Synthesis and dual biological effects of [ENTITY_A]/prolyl hydroxamic acid derivatives as [ENTITY_B] inhibitor and antioxidant.,INHIBITOR,CPR:4,1,Synthesis and dual biological effects of hydroxycinnamoyl phenylalanyl/prolyl hydroxamic acid derivatives as tyrosinase inhibitor and antioxidant.
"We previously reported that caffeoyl-amino acidyl-hydroxamic acid (<< CA-Xaa-NHOH >>) acted as both a good antioxidant and [[ tyrosinase ]] inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine.","We previously reported that caffeoyl-amino acidyl-hydroxamic acid ([ENTITY_A]) acted as both a good antioxidant and [ENTITY_B] inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine.",INHIBITOR,CPR:4,1,"We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and tyrosinase inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine."
"In addition, derivatives of << caffeic acid >> and sinapic acid efficiently inhibited [[ tyrosinase ]] activity and reduced melanin content in melanocytes Mel-Ab cell.","In addition, derivatives of [ENTITY_A] and sinapic acid efficiently inhibited [ENTITY_B] activity and reduced melanin content in melanocytes Mel-Ab cell.",INHIBITOR,CPR:4,1,"In addition, derivatives of caffeic acid and sinapic acid efficiently inhibited tyrosinase activity and reduced melanin content in melanocytes Mel-Ab cell."
<< Ruxolitinib >> is a small-molecule inhibitor of [[ JAK1 ]] and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.,[ENTITY_A] is a small-molecule inhibitor of [ENTITY_B] and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.,INHIBITOR,CPR:4,1,Ruxolitinib is a small-molecule inhibitor of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.
<< Pb >> and BaP treatments significantly increased active [[ caspase-3 ]] levels in a time-dependent manner.,[ENTITY_A] and BaP treatments significantly increased active [ENTITY_B] levels in a time-dependent manner.,INDIRECT-UPREGULATOR,CPR:3,0,Pb and BaP treatments significantly increased active caspase-3 levels in a time-dependent manner.
<< TAA >> increased the number and area of [[ glutathione S-transferase placental form ]] (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.,[ENTITY_A] increased the number and area of [ENTITY_B] (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.,INDIRECT-UPREGULATOR,CPR:3,0,TAA increased the number and area of glutathione S-transferase placental form (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.
"<< TAA >> also increased the numbers of ED2(+), [[ cyclooxygenase-2 ]](+), and heme oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes.","[ENTITY_A] also increased the numbers of ED2(+), [ENTITY_B](+), and heme oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes.",INDIRECT-DOWNREGULATOR,CPR:4,1,"TAA also increased the numbers of ED2(+), cyclooxygenase-2(+), and heme oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes."
<< ICA-105574 >> interacts with a common binding site to elicit opposite effects on inactivation gating of [[ EAG ]] and ERG potassium channels.,[ENTITY_A] interacts with a common binding site to elicit opposite effects on inactivation gating of [ENTITY_B] and ERG potassium channels.,ACTIVATOR,CPR:3,0,ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG potassium channels.
"Although << ICA >> greatly attenuates [[ ERG ]] inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence.","Although [ENTITY_A] greatly attenuates [ENTITY_B] inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence.",ACTIVATOR,CPR:3,0,"Although ICA greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence."
"Although << ICA >> greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of [[ EAG ]] inactivation without altering its voltage dependence.","Although [ENTITY_A] greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of [ENTITY_B] inactivation without altering its voltage dependence.",INHIBITOR,CPR:4,1,"Although ICA greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence."
<< ICA >> is a mixed agonist of mutant [[ EAG ]] and EAG/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.,[ENTITY_A] is a mixed agonist of mutant [ENTITY_B] and EAG/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.,AGONIST,CPR:5,2,ICA is a mixed agonist of mutant EAG and EAG/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.
PNU-282987 on the other hand displayed an increase in anxiety-like behavior at a higher dose (10 mg/kg) that was significantly reduced by the << serotonin 5-HT1a receptor >> antagonist [[ WAY-100135 ]].,PNU-282987 on the other hand displayed an increase in anxiety-like behavior at a higher dose (10 mg/kg) that was significantly reduced by the [ENTITY_A] antagonist [ENTITY_B].,ANTAGONIST,CPR:6,3,PNU-282987 on the other hand displayed an increase in anxiety-like behavior at a higher dose (10 mg/kg) that was significantly reduced by the serotonin 5-HT1a receptor antagonist WAY-100135.
However the << α7 receptor >> antagonist [[ methyllycaconitine ]] was unable to reverse these anxiety-like effects seen with PNU-282987.,However the [ENTITY_A] antagonist [ENTITY_B] was unable to reverse these anxiety-like effects seen with PNU-282987.,ANTAGONIST,CPR:6,3,However the α7 receptor antagonist methyllycaconitine was unable to reverse these anxiety-like effects seen with PNU-282987.
<< Carnitine palmitoyltransferase 2 >> and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of [[ acylcarnitines ]].,[ENTITY_A] and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of [ENTITY_B].,PRODUCT-OF,CPR:9,4,Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
"This shows that << CPT2 >> and CACT are crucial for mitochondrial [[ acylcarnitine ]] formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R.","This shows that [ENTITY_A] and CACT are crucial for mitochondrial [ENTITY_B] formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R.",PRODUCT-OF,CPR:9,4,"This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R."
"As a result of this study, << microgrewiapine A >> (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit [[ nicotinic receptor ]] antagonistic activity for both the hα3β4 and hα4β2 receptor subtypes.","As a result of this study, [ENTITY_A] (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit [ENTITY_B] antagonistic activity for both the hα3β4 and hα4β2 receptor subtypes.",ANTAGONIST,CPR:6,3,"As a result of this study, microgrewiapine A (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit nicotinic receptor antagonistic activity for both the hα3β4 and hα4β2 receptor subtypes."
PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual << orexin receptor >> antagonist [[ almorexant ]].,PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual [ENTITY_A] antagonist [ENTITY_B].,ANTAGONIST,CPR:6,3,PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual orexin receptor antagonist almorexant.
"Commercially-available << 5-HT2C >> agonists ([[ CP 809101 ]], Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.","Commercially-available [ENTITY_A] agonists ([ENTITY_B], Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.",AGONIST,CPR:5,2,"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR."
"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for << 5-HT2A >> ([[ M100907 ]]), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.","Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for [ENTITY_A] ([ENTITY_B]), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.",ANTAGONIST,CPR:6,3,"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR."
In vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the DOI-elicited-HTR also reduced the efficacy of << DOI >> to activate [[ mouse 5-HT2C ]] receptor-mediated PLC signaling in HEK cells.,In vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the DOI-elicited-HTR also reduced the efficacy of [ENTITY_A] to activate [ENTITY_B] receptor-mediated PLC signaling in HEK cells.,ACTIVATOR,CPR:3,0,In vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the DOI-elicited-HTR also reduced the efficacy of DOI to activate mouse 5-HT2C receptor-mediated PLC signaling in HEK cells.
"<< Methadone >> N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to [[ CYP3A4 ]].","[ENTITY_A] N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to [ENTITY_B].",SUBSTRATE,CPR:9,4,"Methadone N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4."
"This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based << CYP2B6 >> inhibitor [[ ticlopidine ]], given orally for 4 days.","This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based [ENTITY_A] inhibitor [ENTITY_B], given orally for 4 days.",INHIBITOR,CPR:4,1,"This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days."
"This investigation tested the hypothesis that << CYP2B6 >> is a prominent CYP isoform responsible for clinical [[ methadone ]] N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.","This investigation tested the hypothesis that [ENTITY_A] is a prominent CYP isoform responsible for clinical [ENTITY_B] N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.",SUBSTRATE,CPR:9,4,"This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days."
"CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for << CYP2B6 >> in clinical [[ methadone ]] disposition.","CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for [ENTITY_A] in clinical [ENTITY_B] disposition.",SUBSTRATE,CPR:9,4,"CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition."
"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, << quinpirole >>, triggered an increase in the expression of [[ GDNF ]] that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.","We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, [ENTITY_A], triggered an increase in the expression of [ENTITY_B] that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.",INDIRECT-UPREGULATOR,CPR:3,0,"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene."
"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the << dopamine D2 receptor >> (D2R) agonist, [[ quinpirole ]], triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.","We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the [ENTITY_A] (D2R) agonist, [ENTITY_B], triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.",AGONIST,CPR:5,2,"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene."
"Moreover, the D2R inhibitor << raclopride >> blocked the increase of both [[ GDNF ]] and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.","Moreover, the D2R inhibitor [ENTITY_A] blocked the increase of both [ENTITY_B] and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, the D2R inhibitor raclopride blocked the increase of both GDNF and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells."
"Synthesis and biological evaluation of << 1,3,4-thiadiazole >> analogues as novel [[ AChE ]] and BuChE inhibitors.",Synthesis and biological evaluation of [ENTITY_A] analogues as novel [ENTITY_B] and BuChE inhibitors.,INHIBITOR,CPR:4,1,"Synthesis and biological evaluation of 1,3,4-thiadiazole analogues as novel AChE and BuChE inhibitors."
"In this paper a series of new << 1,3,4-thiadiazole >> derivatives has been designed, synthesized and evaluated as the [[ acetyl- and butyrylcholinesterase ]] inhibitors.","In this paper a series of new [ENTITY_A] derivatives has been designed, synthesized and evaluated as the [ENTITY_B] inhibitors.",INHIBITOR,CPR:4,1,"In this paper a series of new 1,3,4-thiadiazole derivatives has been designed, synthesized and evaluated as the acetyl- and butyrylcholinesterase inhibitors."
"<< LY294002 >>, a specific PI3K/AKT inhibitor, selectively activated the [[ p38 ]] MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.","[ENTITY_A], a specific PI3K/AKT inhibitor, selectively activated the [ENTITY_B] MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.",ACTIVATOR,CPR:3,0,"LY294002, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK."
"<< LY294002 >>, a specific [[ PI3K ]]/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.","[ENTITY_A], a specific [ENTITY_B]/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.",INHIBITOR,CPR:4,1,"LY294002, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK."
The pharmacological inhibitors << SB203580 >> ([[ p38 ]] inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.,The pharmacological inhibitors [ENTITY_A] ([ENTITY_B] inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.,INHIBITOR,CPR:4,1,The pharmacological inhibitors SB203580 (p38 inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.
"Today, we used << cobalt chloride >>, a hypoxia mimetic that inhibits proteasomal [[ HIF-1 ]] degradation and generates reactive oxygen species (ROS).","Today, we used [ENTITY_A], a hypoxia mimetic that inhibits proteasomal [ENTITY_B] degradation and generates reactive oxygen species (ROS).",INDIRECT-UPREGULATOR,CPR:3,0,"Today, we used cobalt chloride, a hypoxia mimetic that inhibits proteasomal HIF-1 degradation and generates reactive oxygen species (ROS)."
"An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and LC3-II expression whereas the << p53 >>(mut) presence decreased with [[ CoCl2 ]] time exposure.","An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and LC3-II expression whereas the [ENTITY_A](mut) presence decreased with [ENTITY_B] time exposure.",INDIRECT-DOWNREGULATOR,CPR:4,1,"An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and LC3-II expression whereas the p53(mut) presence decreased with CoCl2 time exposure."
Cellular responses to DNA damage induced by << etoposide >> or doxorubicin include down-regulation of endogenous supervillin coincident with increases in [[ p53 ]].,Cellular responses to DNA damage induced by [ENTITY_A] or doxorubicin include down-regulation of endogenous supervillin coincident with increases in [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,Cellular responses to DNA damage induced by etoposide or doxorubicin include down-regulation of endogenous supervillin coincident with increases in p53.
Cellular responses to DNA damage induced by << etoposide >> or doxorubicin include down-regulation of endogenous [[ supervillin ]] coincident with increases in p53.,Cellular responses to DNA damage induced by [ENTITY_A] or doxorubicin include down-regulation of endogenous [ENTITY_B] coincident with increases in p53.,INDIRECT-DOWNREGULATOR,CPR:4,1,Cellular responses to DNA damage induced by etoposide or doxorubicin include down-regulation of endogenous supervillin coincident with increases in p53.
Novel << acylethanolamide >> derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin ([[ POMC ]]) and/or decreased neuropeptide Y (NPY).,Novel [ENTITY_A] derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin ([ENTITY_B]) and/or decreased neuropeptide Y (NPY).,UPREGULATOR,CPR:3,0,Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
Novel << acylethanolamide >> derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased [[ neuropeptide Y ]] (NPY).,Novel [ENTITY_A] derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased [ENTITY_B] (NPY).,DOWNREGULATOR,CPR:4,1,Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
"<< Dexamethasone >> suppressed [[ IL-11 ]] gene transcription enhanced by PTH(1-34) without affecting ΔFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with ΔFosB.","[ENTITY_A] suppressed [ENTITY_B] gene transcription enhanced by PTH(1-34) without affecting ΔFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with ΔFosB.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting ΔFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with ΔFosB."
Number and area of preneoplastic foci positive for << glutathione S-transferase placental form >> (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with [[ HEP ]] or HCB alone.,Number and area of preneoplastic foci positive for [ENTITY_A] (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with [ENTITY_B] or HCB alone.,INDIRECT-UPREGULATOR,CPR:3,0,Number and area of preneoplastic foci positive for glutathione S-transferase placental form (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone.
"On the basis of these findings, we conclude that << HEP >> and HCB have additive and synergistic effects on the development of [[ GST-P ]]-positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.","On the basis of these findings, we conclude that [ENTITY_A] and HCB have additive and synergistic effects on the development of [ENTITY_B]-positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.",INDIRECT-UPREGULATOR,CPR:3,0,"On the basis of these findings, we conclude that HEP and HCB have additive and synergistic effects on the development of GST-P-positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides."
The food contaminant << deoxynivalenol >> activates the [[ mitogen activated protein kinases ]] in the intestine: interest of ex vivo models as an alternative to in vivo experiments.,The food contaminant [ENTITY_A] activates the [ENTITY_B] in the intestine: interest of ex vivo models as an alternative to in vivo experiments.,ACTIVATOR,CPR:3,0,The food contaminant deoxynivalenol activates the mitogen activated protein kinases in the intestine: interest of ex vivo models as an alternative to in vivo experiments.
Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to << DON >> lead to similar intestinal lesions and activation of [[ MAPK ]].,Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to [ENTITY_A] lead to similar intestinal lesions and activation of [ENTITY_B].,ACTIVATOR,CPR:3,0,Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to DON lead to similar intestinal lesions and activation of MAPK.
<< Paeoniflorin >> protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the [[ NF-E2-related factor 2 ]]/heme oxygenase-1 pathway.,[ENTITY_A] protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the [ENTITY_B]/heme oxygenase-1 pathway.,ACTIVATOR,CPR:3,0,Paeoniflorin protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2/heme oxygenase-1 pathway.
"In particular, we showed that << Paeoniflorin >> significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and [[ superoxide dismutase ]] (SOD) in EA.hy926 cells.","In particular, we showed that [ENTITY_A] significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and [ENTITY_B] (SOD) in EA.hy926 cells.",INDIRECT-UPREGULATOR,CPR:3,0,"In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells."
"In particular, we showed that << Paeoniflorin >> significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and [[ lactate dehydrogenase ]] (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.","In particular, we showed that [ENTITY_A] significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and [ENTITY_B] (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells."
Treatment of these cells with << Paeoniflorin >> significantly induced [[ HO-1 ]] expression.,Treatment of these cells with [ENTITY_A] significantly induced [ENTITY_B] expression.,INDIRECT-UPREGULATOR,CPR:3,0,Treatment of these cells with Paeoniflorin significantly induced HO-1 expression.
The << Paeoniflorin >>-induced [[ HO-1 ]] expression was abrogated by Nrf2 siRNA.,The [ENTITY_A]-induced [ENTITY_B] expression was abrogated by Nrf2 siRNA.,INDIRECT-UPREGULATOR,CPR:3,0,The Paeoniflorin-induced HO-1 expression was abrogated by Nrf2 siRNA.
"Furthermore, inhibition of << HO-1 >> with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of [[ Paeoniflorin ]] against radiation-induced damage in EA.hy926 cells.","Furthermore, inhibition of [ENTITY_A] with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of [ENTITY_B] against radiation-induced damage in EA.hy926 cells.",ACTIVATOR,CPR:3,0,"Furthermore, inhibition of HO-1 with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells."
"Furthermore, inhibition of << HO-1 >> with [[ zinc protoporphyrin IX ]] (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells.","Furthermore, inhibition of [ENTITY_A] with [ENTITY_B] (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells.",INHIBITOR,CPR:4,1,"Furthermore, inhibition of HO-1 with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells."
Our findings confirmed that << Paeoniflorin >> protected EA.hy926 cells against radiation-induced injury through the [[ Nrf2 ]]/HO-1 pathway.,Our findings confirmed that [ENTITY_A] protected EA.hy926 cells against radiation-induced injury through the [ENTITY_B]/HO-1 pathway.,ACTIVATOR,CPR:3,0,Our findings confirmed that Paeoniflorin protected EA.hy926 cells against radiation-induced injury through the Nrf2/HO-1 pathway.
"<< Palonosetron >>, a second-generation [[ 5-HT3 ]] receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in its class.","[ENTITY_A], a second-generation [ENTITY_B] receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in its class.",ANTAGONIST,CPR:6,3,"Palonosetron, a second-generation 5-HT3 receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in its class."
"<< Aprepitant >>, the first and only agent clinically available in the [[ NK1 receptor ]] antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV.","[ENTITY_A], the first and only agent clinically available in the [ENTITY_B] antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV.",ANTAGONIST,CPR:6,3,"Aprepitant, the first and only agent clinically available in the NK1 receptor antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV."
<< Rolapitant >> and netupitant are other [[ NK1 receptor ]] antagonists that are currently in phase III clinical trials.,[ENTITY_A] and netupitant are other [ENTITY_B] antagonists that are currently in phase III clinical trials.,ANTAGONIST,CPR:6,3,Rolapitant and netupitant are other NK1 receptor antagonists that are currently in phase III clinical trials.
Moderate inhibitory effect of << LDL >>-C oxidation by [[ phytosteryl phenolates ]] was observed.,Moderate inhibitory effect of [ENTITY_A]-C oxidation by [ENTITY_B] was observed.,INDIRECT-DOWNREGULATOR,CPR:4,1,Moderate inhibitory effect of LDL-C oxidation by phytosteryl phenolates was observed.
"Aqueous << ethanol >> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting [[ 15-LOX ]] (IC(50), 55 μg/ml), with moderate COX-1 (IC(50), 66 μg/ml) and COX-2 (IC(50), 119 μg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.","Aqueous [ENTITY_A] (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting [ENTITY_B] (IC(50), 55 μg/ml), with moderate COX-1 (IC(50), 66 μg/ml) and COX-2 (IC(50), 119 μg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.",INHIBITOR,CPR:4,1,"Aqueous ethanol (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 μg/ml), with moderate COX-1 (IC(50), 66 μg/ml) and COX-2 (IC(50), 119 μg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity."
"<< Histidine decarboxylase >> (HDC) catalyses the formation of histamine, a bioactive [[ amine ]].","[ENTITY_A] (HDC) catalyses the formation of histamine, a bioactive [ENTITY_B].",PRODUCT-OF,CPR:9,4,"Histidine decarboxylase (HDC) catalyses the formation of histamine, a bioactive amine."
"We searched for inhibitors of << HDC >> from the [[ ethyl acetate ]] extract of the petal of Filipendula ulmaria, also called meadowsweet.","We searched for inhibitors of [ENTITY_A] from the [ENTITY_B] extract of the petal of Filipendula ulmaria, also called meadowsweet.",INHIBITOR,CPR:4,1,"We searched for inhibitors of HDC from the ethyl acetate extract of the petal of Filipendula ulmaria, also called meadowsweet."
Discovery of a novel series of << quinolone >> [[ α7 nicotinic acetylcholine receptor ]] agonists.,Discovery of a novel series of [ENTITY_A] [ENTITY_B] agonists.,AGONIST,CPR:5,2,Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists.
High throughput screening led to the identification of a novel series of << quinolone >> α7 nicotinic acetylcholine receptor ([[ nAChR ]]) agonists.,High throughput screening led to the identification of a novel series of [ENTITY_A] α7 nicotinic acetylcholine receptor ([ENTITY_B]) agonists.,AGONIST,CPR:5,2,High throughput screening led to the identification of a novel series of quinolone α7 nicotinic acetylcholine receptor (nAChR) agonists.
<< Amino acid >> derived quinazolines as [[ Rock ]]/PKA inhibitors.,[ENTITY_A] derived quinazolines as [ENTITY_B]/PKA inhibitors.,INHIBITOR,CPR:4,1,Amino acid derived quinazolines as Rock/PKA inhibitors.
SAR and lead optimization studies for << Rock >> inhibitors based on [[ amino acid ]]-derived quinazolines are described.,SAR and lead optimization studies for [ENTITY_A] inhibitors based on [ENTITY_B]-derived quinazolines are described.,INHIBITOR,CPR:4,1,SAR and lead optimization studies for Rock inhibitors based on amino acid-derived quinazolines are described.
"This is distinct from << Rock >> inhibitors based on non-[[ amino acid ]] derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.","This is distinct from [ENTITY_A] inhibitors based on non-[ENTITY_B] derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.",INHIBITOR,CPR:4,1,"This is distinct from Rock inhibitors based on non-amino acid derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability."
"The << cyclooxygenase-2 >> inhibitor, [[ diflunisal ]], is used in the clinic for its anti-inflammatory activity.","The [ENTITY_A] inhibitor, [ENTITY_B], is used in the clinic for its anti-inflammatory activity.",INHIBITOR,CPR:4,1,"The cyclooxygenase-2 inhibitor, diflunisal, is used in the clinic for its anti-inflammatory activity."
"Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, << BPA >> significantly decreased the IR, [[ Akt ]] and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.","Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, [ENTITY_A] significantly decreased the IR, [ENTITY_B] and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle."
"In conclusion, << BPA >> has adverse effects on phosphorylation of Akt, [[ GLUT4 ]] translocation and (14)C-glucose oxidation.","In conclusion, [ENTITY_A] has adverse effects on phosphorylation of Akt, [ENTITY_B] translocation and (14)C-glucose oxidation.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In conclusion, BPA has adverse effects on phosphorylation of Akt, GLUT4 translocation and (14)C-glucose oxidation."
"The obtained results showed that << Cd >> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, [[ lactate dehydrogenase ]], acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3β-hydroxysteroid dehydrogenase (HSD), 17β-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.","The obtained results showed that [ENTITY_A] increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, [ENTITY_B], acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3β-hydroxysteroid dehydrogenase (HSD), 17β-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.",INHIBITOR,CPR:4,1,"The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3β-hydroxysteroid dehydrogenase (HSD), 17β-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values."
"Acute intoxication with << Cd >> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase ([[ GST ]])).","Acute intoxication with [ENTITY_A] was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase ([ENTITY_B])).",INHIBITOR,CPR:4,1,"Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))."
"The << tyrosine hydroxylase >> inhibitor [[ α-methyltyrosine ]] (300µM, 24h) completely abolished MeHg-induced DA release.","The [ENTITY_A] inhibitor [ENTITY_B] (300µM, 24h) completely abolished MeHg-induced DA release.",INHIBITOR,CPR:4,1,"The tyrosine hydroxylase inhibitor α-methyltyrosine (300µM, 24h) completely abolished MeHg-induced DA release."
"MeHg significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10µM), revealing that << MeHg >> increases [[ tyrosine hydroxylase ]] activity.","MeHg significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10µM), revealing that [ENTITY_A] increases [ENTITY_B] activity.",ACTIVATOR,CPR:3,0,"MeHg significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10µM), revealing that MeHg increases tyrosine hydroxylase activity."
"The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of << benzoxazinyl-oxazolidinone >> analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low [[ hERG ]] inhibition.","The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of [ENTITY_A] analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low [ENTITY_B] inhibition.",INHIBITOR,CPR:4,1,"The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of benzoxazinyl-oxazolidinone analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low hERG inhibition."
Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the << FLT3 >> inhibitors [[ AC220 ]] (quizartinib) and sorafenib.,Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the [ENTITY_A] inhibitors [ENTITY_B] (quizartinib) and sorafenib.,INHIBITOR,CPR:4,1,Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib.
"<< Ponatinib >> (AP24534) is a [[ multikinase ]] inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.","[ENTITY_A] (AP24534) is a [ENTITY_B] inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.",INHIBITOR,CPR:4,1,"Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation."
"However, the involvement of the caspase-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan<< caspase >> inhibitor [[ z-VAD-fmk ]].","However, the involvement of the caspase-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan[ENTITY_A] inhibitor [ENTITY_B].",INHIBITOR,CPR:4,1,"However, the involvement of the caspase-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pancaspase inhibitor z-VAD-fmk."
"Moreover, since reduced levels of << p21CIP1 >> and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after [[ BSC ]] 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.","Moreover, since reduced levels of [ENTITY_A] and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after [ENTITY_B] 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis."
A one-pot domino synthesis and discovery of highly functionalized << dihydrobenzo[b]thiophenes >> as [[ AChE ]] inhibitors.,A one-pot domino synthesis and discovery of highly functionalized [ENTITY_A] as [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,A one-pot domino synthesis and discovery of highly functionalized dihydrobenzo[b]thiophenes as AChE inhibitors.
"These compounds were evaluated for their acetylcholinesterase (AChE) inhibitory activity and << 5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile >> was found to be the most potent against [[ AChE ]] with IC50 4.16 μmol/L.",These compounds were evaluated for their acetylcholinesterase (AChE) inhibitory activity and [ENTITY_A] was found to be the most potent against [ENTITY_B] with IC50 4.16 μmol/L.,INHIBITOR,CPR:4,1,"These compounds were evaluated for their acetylcholinesterase (AChE) inhibitory activity and 5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile was found to be the most potent against AChE with IC50 4.16 μmol/L."
"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including << paclitaxel >>, doxorubicin, actinomycin-D, and rapamycin, which are also [[ P-gp ]] substrates.","Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including [ENTITY_A], doxorubicin, actinomycin-D, and rapamycin, which are also [ENTITY_B] substrates.",SUBSTRATE,CPR:9,4,"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and rapamycin, which are also P-gp substrates."
"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-<< MMC >> rats showed higher [[ quinone reductase ]] and depleted xanthine oxidase activities.","Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-[ENTITY_A] rats showed higher [ENTITY_B] and depleted xanthine oxidase activities.",ACTIVATOR,CPR:3,0,"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities."
"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-<< MMC >> rats showed higher quinone reductase and depleted [[ xanthine oxidase ]] activities.","Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-[ENTITY_A] rats showed higher quinone reductase and depleted [ENTITY_B] activities.",INHIBITOR,CPR:4,1,"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities."
"Conclusively, protein malnutrition alters CP, FU and << MMC >> metabolism in rat stomach by enhancing [[ CCBL ]] pathway for CP activation, delaying FU elimination and activating two-electron reduction of MMC, potentiating their gastrotoxicity.","Conclusively, protein malnutrition alters CP, FU and [ENTITY_A] metabolism in rat stomach by enhancing [ENTITY_B] pathway for CP activation, delaying FU elimination and activating two-electron reduction of MMC, potentiating their gastrotoxicity.",SUBSTRATE,CPR:9,4,"Conclusively, protein malnutrition alters CP, FU and MMC metabolism in rat stomach by enhancing CCBL pathway for CP activation, delaying FU elimination and activating two-electron reduction of MMC, potentiating their gastrotoxicity."
"N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase (<< JNK >>) inhibitor ([[ SP600125 ]], 33 μM) further decreased the viability in the presence of DEP (200 μg/ml) and 3.3% FCS.","N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase ([ENTITY_A]) inhibitor ([ENTITY_B], 33 μM) further decreased the viability in the presence of DEP (200 μg/ml) and 3.3% FCS.",INHIBITOR,CPR:4,1,"N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase (JNK) inhibitor (SP600125, 33 μM) further decreased the viability in the presence of DEP (200 μg/ml) and 3.3% FCS."
<< HENA >> activated the [[ BK (cbv1 + β1) channels ]] cloned from rat cerebral artery myocytes with a potency (EC50 = 53 μM) similar to and an efficacy (×2.5 potentiation) significantly greater than that of LCA.,[ENTITY_A] activated the [ENTITY_B] cloned from rat cerebral artery myocytes with a potency (EC50 = 53 μM) similar to and an efficacy (×2.5 potentiation) significantly greater than that of LCA.,ACTIVATOR,CPR:3,0,HENA activated the BK (cbv1 + β1) channels cloned from rat cerebral artery myocytes with a potency (EC50 = 53 μM) similar to and an efficacy (×2.5 potentiation) significantly greater than that of LCA.
"<< HENA >> failed to activate the channels made of cbv1 + β2, β3, β4, or β1T169A, indicating that this drug selectively targets [[ β1-containing BK channels ]] via the BK β1 steroid-sensing site.","[ENTITY_A] failed to activate the channels made of cbv1 + β2, β3, β4, or β1T169A, indicating that this drug selectively targets [ENTITY_B] via the BK β1 steroid-sensing site.",ACTIVATOR,CPR:3,0,"HENA failed to activate the channels made of cbv1 + β2, β3, β4, or β1T169A, indicating that this drug selectively targets β1-containing BK channels via the BK β1 steroid-sensing site."
"Assessment of the abuse liability of << ABT-288 >>, a novel [[ histamine H3 receptor ]] antagonist.","Assessment of the abuse liability of [ENTITY_A], a novel [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"Assessment of the abuse liability of ABT-288, a novel histamine H3 receptor antagonist."
"RATIONALE: << Histamine H3 receptor >> antagonists, such as [[ ABT-288 ]], have been shown to possess cognitive-enhancing and wakefulness-promoting effects.","RATIONALE: [ENTITY_A] antagonists, such as [ENTITY_B], have been shown to possess cognitive-enhancing and wakefulness-promoting effects.",ANTAGONIST,CPR:6,3,"RATIONALE: Histamine H3 receptor antagonists, such as ABT-288, have been shown to possess cognitive-enhancing and wakefulness-promoting effects."
"CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to H3 antagonists, indicates that << ABT-288 >> is unlikely to possess a high potential for abuse in the human population and suggests that [[ H3 ]] antagonists, as a class, are similar in this regard.","CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to H3 antagonists, indicates that [ENTITY_A] is unlikely to possess a high potential for abuse in the human population and suggests that [ENTITY_B] antagonists, as a class, are similar in this regard.",ANTAGONIST,CPR:6,3,"CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to H3 antagonists, indicates that ABT-288 is unlikely to possess a high potential for abuse in the human population and suggests that H3 antagonists, as a class, are similar in this regard."
Uptake of << estrone-3-sulfate >> (5 nM) by [[ OATP1B1 ]] was reduced by 82%-95%.,Uptake of [ENTITY_A] (5 nM) by [ENTITY_B] was reduced by 82%-95%.,SUBSTRATE,CPR:9,4,Uptake of estrone-3-sulfate (5 nM) by OATP1B1 was reduced by 82%-95%.
"This methodology was subsequently used to assess the relative contribution of << OATP1B1 >> uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), [[ pitavastatin ]] (84%-98%) and lopinavir (64%-89%).","This methodology was subsequently used to assess the relative contribution of [ENTITY_A] uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), [ENTITY_B] (84%-98%) and lopinavir (64%-89%).",SUBSTRATE,CPR:9,4,"This methodology was subsequently used to assess the relative contribution of OATP1B1 uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)."
Oral << l-glutamine >> increases active [[ GLP-1 ]] (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.,Oral [ENTITY_A] increases active [ENTITY_B] (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.,INDIRECT-UPREGULATOR,CPR:3,0,Oral l-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.
The objective of the present investigation was to evaluate << l-glutamine >> increases [[ glucagon like peptide-1 ]] (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.,The objective of the present investigation was to evaluate [ENTITY_A] increases [ENTITY_B] (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.,INDIRECT-UPREGULATOR,CPR:3,0,The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.
"<< l-glutamine >> decreased plasma glucose, increased plasma and pancreatic [[ insulin ]], increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.","[ENTITY_A] decreased plasma glucose, increased plasma and pancreatic [ENTITY_B], increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.",INDIRECT-UPREGULATOR,CPR:3,0,"l-glutamine decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats."
"In the present study, << hinokitiol >> (1 and 2μM) inhibited the [[ collagen ]]-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP.","In the present study, [ENTITY_A] (1 and 2μM) inhibited the [ENTITY_B]-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP.",INHIBITOR,CPR:4,1,"In the present study, hinokitiol (1 and 2μM) inhibited the collagen-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP."
"<< Hinokitiol >> inhibited the phosphorylation of [[ phospholipase C (PLC)γ2 ]], protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.","[ENTITY_A] inhibited the phosphorylation of [ENTITY_B], protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.",INHIBITOR,CPR:4,1,"Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)γ2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation."
<< Hinokitiol >> also reduced the [[ PKC ]] activation and platelet aggregation stimulated by PDBu.,[ENTITY_A] also reduced the [ENTITY_B] activation and platelet aggregation stimulated by PDBu.,INHIBITOR,CPR:4,1,Hinokitiol also reduced the PKC activation and platelet aggregation stimulated by PDBu.
"In conclusion, << hinokitiol >> may inhibit platelet activation by inhibiting the [[ PLCγ2 ]]-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt.","In conclusion, [ENTITY_A] may inhibit platelet activation by inhibiting the [ENTITY_B]-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt.",INHIBITOR,CPR:4,1,"In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLCγ2-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt."
Novel << 5-(benzyloxy)pyridin-2(1H)-one >> derivatives as potent [[ c-Met ]] inhibitors.,Novel [ENTITY_A] derivatives as potent [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.
"Design, Synthesis, and Pharmacological Characterization of Novel << Endomorphin-1 >> Analogues as Extremely Potent [[ μ-Opioid ]] Agonists.","Design, Synthesis, and Pharmacological Characterization of Novel [ENTITY_A] Analogues as Extremely Potent [ENTITY_B] Agonists.",AGONIST,CPR:5,2,"Design, Synthesis, and Pharmacological Characterization of Novel Endomorphin-1 Analogues as Extremely Potent μ-Opioid Agonists."
"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFα levels) was seen in LPS-stimulated human PBMCs, except with << JWH-210 >> and JWH-122 which caused a decrease of [[ TNFα ]] and IL-12/23p40.","Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFα levels) was seen in LPS-stimulated human PBMCs, except with [ENTITY_A] and JWH-122 which caused a decrease of [ENTITY_B] and IL-12/23p40.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFα levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and JWH-122 which caused a decrease of TNFα and IL-12/23p40."
<< AlCl3 >> markedly reduced AA performance and activities of [[ cytochrome c oxidase ]] (COX) and acetylcholinesterase (AChE) in all regions.,[ENTITY_A] markedly reduced AA performance and activities of [ENTITY_B] (COX) and acetylcholinesterase (AChE) in all regions.,INHIBITOR,CPR:4,1,AlCl3 markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (AChE) in all regions.
"GTLE pretreatment completely reversed the damaging effects of << AlCl3 >> on AA and [[ superoxide dismutase ]] activity, markedly corrected COX and AChE activities, and moderately improved TGC.","GTLE pretreatment completely reversed the damaging effects of [ENTITY_A] on AA and [ENTITY_B] activity, markedly corrected COX and AChE activities, and moderately improved TGC.",INHIBITOR,CPR:4,1,"GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and superoxide dismutase activity, markedly corrected COX and AChE activities, and moderately improved TGC."
Our study demonstrated that << curcumin >> inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased [[ IL-10 ]] level in bronchoalveolar lavage fluid.,Our study demonstrated that [ENTITY_A] inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased [ENTITY_B] level in bronchoalveolar lavage fluid.,INDIRECT-UPREGULATOR,CPR:3,0,Our study demonstrated that curcumin inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.
Our study demonstrated that << curcumin >> inhibited [[ OVA ]]-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.,Our study demonstrated that [ENTITY_A] inhibited [ENTITY_B]-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.,INHIBITOR,CPR:4,1,Our study demonstrated that curcumin inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.
Histological studies demonstrated that << curcumin >> substantially inhibited [[ OVA ]]-induced eosinophilia in lung tissue.,Histological studies demonstrated that [ENTITY_A] substantially inhibited [ENTITY_B]-induced eosinophilia in lung tissue.,INHIBITOR,CPR:4,1,Histological studies demonstrated that curcumin substantially inhibited OVA-induced eosinophilia in lung tissue.
The results in vivo show << ovalbumin >>-induced significantly broke Treg/Th17 balance; [[ curcumin ]] treatments markedly attenuated the inflammatory in asthma model by regulating Treg/Th17 balance.,The results in vivo show [ENTITY_A]-induced significantly broke Treg/Th17 balance; [ENTITY_B] treatments markedly attenuated the inflammatory in asthma model by regulating Treg/Th17 balance.,INHIBITOR,CPR:4,1,The results in vivo show ovalbumin-induced significantly broke Treg/Th17 balance; curcumin treatments markedly attenuated the inflammatory in asthma model by regulating Treg/Th17 balance.
Synthesis of a << DOTA >> (Gd(3+))-conjugate of [[ proton-pump ]] inhibitor pantoprazole for gastric wall imaging studies.,Synthesis of a [ENTITY_A] (Gd(3+))-conjugate of [ENTITY_B] inhibitor pantoprazole for gastric wall imaging studies.,INHIBITOR,CPR:4,1,Synthesis of a DOTA (Gd(3+))-conjugate of proton-pump inhibitor pantoprazole for gastric wall imaging studies.
"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a << Gd >>-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used [[ proton pump ]] inhibitor that binds to proton pumps in the stomach and colon.","To overcome this limitation, we de novo synthesized a conjugate that covalently combines a [ENTITY_A]-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used [ENTITY_B] inhibitor that binds to proton pumps in the stomach and colon.",INHIBITOR,CPR:4,1,"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used proton pump inhibitor that binds to proton pumps in the stomach and colon."
"Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible << AChE >> inhibitor [[ donepezil ]] (100nM).","Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible [ENTITY_A] inhibitor [ENTITY_B] (100nM).",INHIBITOR,CPR:4,1,"Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible AChE inhibitor donepezil (100nM)."
A Nanogram Dose of the << CYP3A >> Probe Substrate [[ Midazolam ]] to Evaluate Drug Interactions.,A Nanogram Dose of the [ENTITY_A] Probe Substrate [ENTITY_B] to Evaluate Drug Interactions.,SUBSTRATE,CPR:9,4,A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions.
We then evaluated the interactions with the << CYP3A >> inhibitor [[ ketoconazole ]] (400 mg q.d.) after nanogram and regular doses of midazolam.,We then evaluated the interactions with the [ENTITY_A] inhibitor [ENTITY_B] (400 mg q.d.) after nanogram and regular doses of midazolam.,INHIBITOR,CPR:4,1,We then evaluated the interactions with the CYP3A inhibitor ketoconazole (400 mg q.d.) after nanogram and regular doses of midazolam.
<< CYP3A5 >> carrier status had no influence on midazolam oral clearance or its inhibition by [[ ketoconazole ]].,[ENTITY_A] carrier status had no influence on midazolam oral clearance or its inhibition by [ENTITY_B].,INHIBITOR,CPR:4,1,CYP3A5 carrier status had no influence on midazolam oral clearance or its inhibition by ketoconazole.
<< CYP3A5 >> carrier status had no influence on [[ midazolam ]] oral clearance or its inhibition by ketoconazole.,[ENTITY_A] carrier status had no influence on [ENTITY_B] oral clearance or its inhibition by ketoconazole.,SUBSTRATE,CPR:9,4,CYP3A5 carrier status had no influence on midazolam oral clearance or its inhibition by ketoconazole.
Metabolism of << Beclomethasone Dipropionate >> by [[ Cytochrome P450 3A ]] Enzymes.,Metabolism of [ENTITY_A] by [ENTITY_B] Enzymes.,SUBSTRATE,CPR:9,4,Metabolism of Beclomethasone Dipropionate by Cytochrome P450 3A Enzymes.
It is possible that variations in << cytochrome P450 3A >> enzyme-mediated metabolism of [[ BDP ]] may contribute to this phenomenon.,It is possible that variations in [ENTITY_A] enzyme-mediated metabolism of [ENTITY_B] may contribute to this phenomenon.,SUBSTRATE,CPR:9,4,It is possible that variations in cytochrome P450 3A enzyme-mediated metabolism of BDP may contribute to this phenomenon.
"This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and << esterase >> enzymes in the metabolism of [[ BDP ]] in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.","This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and [ENTITY_A] enzymes in the metabolism of [ENTITY_B] in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.",SUBSTRATE,CPR:9,4,"This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and esterase enzymes in the metabolism of BDP in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells."
<< CYP3A4 >> and CYP3A5 metabolized [[ BDP ]] via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP.,[ENTITY_A] and CYP3A5 metabolized [ENTITY_B] via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP.,SUBSTRATE,CPR:9,4,CYP3A4 and CYP3A5 metabolized BDP via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP.
These studies show that << CYP3A4 >> and CYP3A5 metabolize [[ BDP ]] to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence BDP disposition in humans.,These studies show that [ENTITY_A] and CYP3A5 metabolize [ENTITY_B] to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence BDP disposition in humans.,SUBSTRATE,CPR:9,4,These studies show that CYP3A4 and CYP3A5 metabolize BDP to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence BDP disposition in humans.
"In macrophages, levels of << TNF-α >>, IFN-γ, NO, IL-6 and IL-10 were increased by [[ CDM ]] used alone or in combination with HSV-2.","In macrophages, levels of [ENTITY_A], IFN-γ, NO, IL-6 and IL-10 were increased by [ENTITY_B] used alone or in combination with HSV-2.",INDIRECT-UPREGULATOR,CPR:3,0,"In macrophages, levels of TNF-α, IFN-γ, NO, IL-6 and IL-10 were increased by CDM used alone or in combination with HSV-2."
"Besides, << CDM >> not only synergized [[ TNF-α ]] production combined with IFN-γ, but also prolonged its expression in time.","Besides, [ENTITY_A] not only synergized [ENTITY_B] production combined with IFN-γ, but also prolonged its expression in time.",INDIRECT-UPREGULATOR,CPR:3,0,"Besides, CDM not only synergized TNF-α production combined with IFN-γ, but also prolonged its expression in time."
"Results indicate that << CDM >> inhibits HSV-2 multiplication in epithelial cells and also increases [[ cytokine ]] production in macrophages, both important actions to the clearance of infecting virus in the mouse vagina.","Results indicate that [ENTITY_A] inhibits HSV-2 multiplication in epithelial cells and also increases [ENTITY_B] production in macrophages, both important actions to the clearance of infecting virus in the mouse vagina.",INDIRECT-UPREGULATOR,CPR:3,0,"Results indicate that CDM inhibits HSV-2 multiplication in epithelial cells and also increases cytokine production in macrophages, both important actions to the clearance of infecting virus in the mouse vagina."
Intestinal and hepatic first-pass extraction of the << 11β-HSD1 >> inhibitor [[ AMG 221 ]] in rats with chronic vascular catheters.,Intestinal and hepatic first-pass extraction of the [ENTITY_A] inhibitor [ENTITY_B] in rats with chronic vascular catheters.,INHIBITOR,CPR:4,1,Intestinal and hepatic first-pass extraction of the 11β-HSD1 inhibitor AMG 221 in rats with chronic vascular catheters.
"A catheterized rat model was used to define the intestinal and hepatic components of oral bioavailability for an << 11β-HSD1 >> inhibitor, [[ AMG 221 ]].","A catheterized rat model was used to define the intestinal and hepatic components of oral bioavailability for an [ENTITY_A] inhibitor, [ENTITY_B].",INHIBITOR,CPR:4,1,"A catheterized rat model was used to define the intestinal and hepatic components of oral bioavailability for an 11β-HSD1 inhibitor, AMG 221."
"In DU-PM cells with acquired resistance to << elisidepsin >>, ErbB3 expression was decreased, while [[ Bcl2 ]] was increased.","In DU-PM cells with acquired resistance to [ENTITY_A], ErbB3 expression was decreased, while [ENTITY_B] was increased.",INDIRECT-UPREGULATOR,CPR:3,0,"In DU-PM cells with acquired resistance to elisidepsin, ErbB3 expression was decreased, while Bcl2 was increased."
"In DU-PM cells with acquired resistance to << elisidepsin >>, [[ ErbB3 ]] expression was decreased, while Bcl2 was increased.","In DU-PM cells with acquired resistance to [ENTITY_A], [ENTITY_B] expression was decreased, while Bcl2 was increased.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In DU-PM cells with acquired resistance to elisidepsin, ErbB3 expression was decreased, while Bcl2 was increased."
"Administration of << bicuculline >>, a [[ GABAA ]] inhibitor, isolated a single response to ω-agatoxin, which was characterized by a reduction in network activity.","Administration of [ENTITY_A], a [ENTITY_B] inhibitor, isolated a single response to ω-agatoxin, which was characterized by a reduction in network activity.",INHIBITOR,CPR:4,1,"Administration of bicuculline, a GABAA inhibitor, isolated a single response to ω-agatoxin, which was characterized by a reduction in network activity."
"<< tert-Butylcarbamate >>-Containing [[ Histone Deacetylase ]] Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells.","[ENTITY_A]-Containing [ENTITY_B] Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells.",INHIBITOR,CPR:4,1,"tert-Butylcarbamate-Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells."
"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the << tert-butylcarbamate >> group at the CAP moiety as [[ histone deacetylase ]] (HDAC) inhibitors.","Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the [ENTITY_A] group at the CAP moiety as [ENTITY_B] (HDAC) inhibitors.",INHIBITOR,CPR:4,1,"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors."
"Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other << hydroxamates >> effected an increase in [[ acetyl-α-tubulin ]] levels in human acute myeloid leukemia U937 cells.","Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other [ENTITY_A] effected an increase in [ENTITY_B] levels in human acute myeloid leukemia U937 cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-α-tubulin levels in human acute myeloid leukemia U937 cells."
Discovery of a synthetic << Aminopeptidase N >> inhibitor [[ LB-4b ]] as a potential anticancer agent.,Discovery of a synthetic [ENTITY_A] inhibitor [ENTITY_B] as a potential anticancer agent.,INHIBITOR,CPR:4,1,Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.
<< LB-4b >> is the first synthetic [[ APN ]] inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects.,[ENTITY_A] is the first synthetic [ENTITY_B] inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects.,INHIBITOR,CPR:4,1,LB-4b is the first synthetic APN inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects.
"As a potent synthetic << APN >> inhibitor (IC50=850nM, versus [[ bestatin ]] of 8.1μM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin.","As a potent synthetic [ENTITY_A] inhibitor (IC50=850nM, versus [ENTITY_B] of 8.1μM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin.",INHIBITOR,CPR:4,1,"As a potent synthetic APN inhibitor (IC50=850nM, versus bestatin of 8.1μM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin."
Both types of granules contain << catechol oxidase >> that catalyzes oxidative cross-linking of [[ L-DOPA ]].,Both types of granules contain [ENTITY_A] that catalyzes oxidative cross-linking of [ENTITY_B].,SUBSTRATE,CPR:9,4,Both types of granules contain catechol oxidase that catalyzes oxidative cross-linking of L-DOPA.
"Under << NaCl >> and sorbitol stresses, [[ catalase ]] (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.","Under [ENTITY_A] and sorbitol stresses, [ENTITY_B] (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.",ACTIVATOR,CPR:3,0,"Under NaCl and sorbitol stresses, catalase (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively."
Immunofluorescence staining and western blotting demonstrated that << cilostazol >> treatment reduced GFAP and [[ VEGF ]] expression in the retinas of OLETF rats.,Immunofluorescence staining and western blotting demonstrated that [ENTITY_A] treatment reduced GFAP and [ENTITY_B] expression in the retinas of OLETF rats.,INDIRECT-DOWNREGULATOR,CPR:4,1,Immunofluorescence staining and western blotting demonstrated that cilostazol treatment reduced GFAP and VEGF expression in the retinas of OLETF rats.
"Other dams received 1.8ng/kg/day of a mixture of << aryl hydrocarbon receptor >> (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and [[ PC-dibenzofurans ]]) without or with 0.5M (0.5MAhR).","Other dams received 1.8ng/kg/day of a mixture of [ENTITY_A] (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and [ENTITY_B]) without or with 0.5M (0.5MAhR).",AGONIST,CPR:5,2,"Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR)."
"Discovery of a series of novel << 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers >>, as potent [[ JAK3 ]] kinase inhibitors.","Discovery of a series of novel [ENTITY_A], as potent [ENTITY_B] kinase inhibitors.",INHIBITOR,CPR:4,1,"Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors."
"We report the discovery of a novel series of ATP-competitive << Janus kinase 3 >> (JAK3) inhibitors based on the [[ 5H-pyrrolo[2,3-b]pyrazine ]] scaffold.",We report the discovery of a novel series of ATP-competitive [ENTITY_A] (JAK3) inhibitors based on the [ENTITY_B] scaffold.,INHIBITOR,CPR:4,1,"We report the discovery of a novel series of ATP-competitive Janus kinase 3 (JAK3) inhibitors based on the 5H-pyrrolo[2,3-b]pyrazine scaffold."
<< Arsenic trioxide >> depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of [[ Notch ]] pathway.,[ENTITY_A] depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of [ENTITY_B] pathway.,INHIBITOR,CPR:4,1,Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway.
<< ATO >> inhibited the phosphorylation and activation of AKT and STAT3 through [[ Notch ]] signaling blockade.,[ENTITY_A] inhibited the phosphorylation and activation of AKT and STAT3 through [ENTITY_B] signaling blockade.,INDIRECT-DOWNREGULATOR,CPR:4,1,ATO inhibited the phosphorylation and activation of AKT and STAT3 through Notch signaling blockade.
These data show that the << ATO >> is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of [[ Notch ]] pathway.,These data show that the [ENTITY_A] is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of [ENTITY_B] pathway.,INHIBITOR,CPR:4,1,These data show that the ATO is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of Notch pathway.
"The high fat diet significantly increased hepatic mRNA expressions of << PPARγ >>, SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with [[ fisetin ]].","The high fat diet significantly increased hepatic mRNA expressions of [ENTITY_A], SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"The high fat diet significantly increased hepatic mRNA expressions of PPARγ, SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with fisetin."
"In addition, << fisetin >> supplementation significantly reduced hepatic mRNA abundance of [[ FAS ]], ATPCL and G6Pase compared to the control group.","In addition, [ENTITY_A] supplementation significantly reduced hepatic mRNA abundance of [ENTITY_B], ATPCL and G6Pase compared to the control group.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, fisetin supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group."
"Finally, epididymal mRNA abundance of << GLUT4 >> was significantly increased by [[ fisetin ]] supplementation, compared to levels in the control and HF groups.","Finally, epididymal mRNA abundance of [ENTITY_A] was significantly increased by [ENTITY_B] supplementation, compared to levels in the control and HF groups.",INDIRECT-UPREGULATOR,CPR:3,0,"Finally, epididymal mRNA abundance of GLUT4 was significantly increased by fisetin supplementation, compared to levels in the control and HF groups."
Enhancement of << GLUT4 >> expression by [[ fisetin ]] was further confirmed in differentiated 3T3-L1 adipocytes.,Enhancement of [ENTITY_A] expression by [ENTITY_B] was further confirmed in differentiated 3T3-L1 adipocytes.,INDIRECT-UPREGULATOR,CPR:3,0,Enhancement of GLUT4 expression by fisetin was further confirmed in differentiated 3T3-L1 adipocytes.
Western blot assay demonstrated that << DICO >> decreased Bcl-2 level and induced [[ Bax ]] translocation to cause cytochrome c release.,Western blot assay demonstrated that [ENTITY_A] decreased Bcl-2 level and induced [ENTITY_B] translocation to cause cytochrome c release.,INDIRECT-UPREGULATOR,CPR:3,0,Western blot assay demonstrated that DICO decreased Bcl-2 level and induced Bax translocation to cause cytochrome c release.
Western blot assay demonstrated that << DICO >> decreased [[ Bcl-2 ]] level and induced Bax translocation to cause cytochrome c release.,Western blot assay demonstrated that [ENTITY_A] decreased [ENTITY_B] level and induced Bax translocation to cause cytochrome c release.,INDIRECT-DOWNREGULATOR,CPR:4,1,Western blot assay demonstrated that DICO decreased Bcl-2 level and induced Bax translocation to cause cytochrome c release.
<< Quercetin >> and rutin also increased [[ alkaline phosphatase ]] activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).,[ENTITY_A] and rutin also increased [ENTITY_B] activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).,ACTIVATOR,CPR:3,0,Quercetin and rutin also increased alkaline phosphatase activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).
"Further, both the << flavonoids >> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like [[ osteopontin ]], osterix, RunX2, osteoprotegerin and osteocalcin.","Further, both the [ENTITY_A] were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like [ENTITY_B], osterix, RunX2, osteoprotegerin and osteocalcin.",INDIRECT-UPREGULATOR,CPR:3,0,"Further, both the flavonoids were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, osteoprotegerin and osteocalcin."
"<< Cytochrome P450 2E1 >> (CYP 450 2E1), activity was determined as hydroxylation of [[ aniline ]] in liver microsomes.","[ENTITY_A] (CYP 450 2E1), activity was determined as hydroxylation of [ENTITY_B] in liver microsomes.",SUBSTRATE,CPR:9,4,"Cytochrome P450 2E1 (CYP 450 2E1), activity was determined as hydroxylation of aniline in liver microsomes."
"Serum markers of liver damage (<< AST >>, ALT, ALP and Bilirubin) were increased by [[ CCl4 ]] and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).","Serum markers of liver damage ([ENTITY_A], ALT, ALP and Bilirubin) were increased by [ENTITY_B] and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).",INDIRECT-UPREGULATOR,CPR:3,0,"Serum markers of liver damage (AST, ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)."
"Serum markers of liver damage (<< AST >>, ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with [[ NAC ]] reversed such changes (p<0.001).","Serum markers of liver damage ([ENTITY_A], ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with [ENTITY_B] reversed such changes (p<0.001).",INDIRECT-DOWNREGULATOR,CPR:4,1,"Serum markers of liver damage (AST, ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)."
"LPO was increased while as GSH, << CAT >> and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of [[ NAC ]] restored these liver markers to normal levels (p<0.001).","LPO was increased while as GSH, [ENTITY_A] and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of [ENTITY_B] restored these liver markers to normal levels (p<0.001).",INDIRECT-UPREGULATOR,CPR:3,0,"LPO was increased while as GSH, CAT and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of NAC restored these liver markers to normal levels (p<0.001)."
"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory << interleukins >>, IL-6 and IL-8, caused by a mixture of [[ oxysterols ]] representative of a high cholesterol diet.","This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory [ENTITY_A], IL-6 and IL-8, caused by a mixture of [ENTITY_B] representative of a high cholesterol diet.",INDIRECT-UPREGULATOR,CPR:3,0,"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and IL-8, caused by a mixture of oxysterols representative of a high cholesterol diet."
"<< Oxysterol >>-dependent [[ NOX1 ]] activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.","[ENTITY_A]-dependent [ENTITY_B] activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.",ACTIVATOR,CPR:3,0,"Oxysterol-dependent NOX1 activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids."
"Oxysterol-dependent NOX1 activation, as well as << interleukin >> synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular [[ phenolic acids ]] and flavonoids.","Oxysterol-dependent NOX1 activation, as well as [ENTITY_A] synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular [ENTITY_B] and flavonoids.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Oxysterol-dependent NOX1 activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids."
"Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in << interleukin >> synthesis induced by dietary [[ oxysterols ]].","Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in [ENTITY_A] synthesis induced by dietary [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in interleukin synthesis induced by dietary oxysterols."
"Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking << oxysterol >>-related [[ NOX1 ]] induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.","Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking [ENTITY_A]-related [ENTITY_B] induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.",ACTIVATOR,CPR:3,0,"Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related NOX1 induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols."
"Besides this direct activity, an excess of << phenolic >> compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related [[ NOX1 ]] induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.","Besides this direct activity, an excess of [ENTITY_A] compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related [ENTITY_B] induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.",INHIBITOR,CPR:4,1,"Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related NOX1 induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols."
<< Arsenic >> inhibits autophagic flux activating the [[ Nrf2 ]]-Keap1 pathway in a p62-dependent manner.,[ENTITY_A] inhibits autophagic flux activating the [ENTITY_B]-Keap1 pathway in a p62-dependent manner.,ACTIVATOR,CPR:3,0,Arsenic inhibits autophagic flux activating the Nrf2-Keap1 pathway in a p62-dependent manner.
"<< Arsenic >> deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of [[ p62 ]], Keap1, and LC3.","[ENTITY_A] deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of [ENTITY_B], Keap1, and LC3.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Arsenic deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, Keap1, and LC3."
"Thus, << arsenic >> activates [[ Nrf2 ]] through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of Nrf2.","Thus, [ENTITY_A] activates [ENTITY_B] through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of Nrf2.",ACTIVATOR,CPR:3,0,"Thus, arsenic activates Nrf2 through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of Nrf2."
"In contrast, activation of << Nrf2 >> by [[ sulforaphane ]] and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism).","In contrast, activation of [ENTITY_A] by [ENTITY_B] and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism).",ACTIVATOR,CPR:3,0,"In contrast, activation of Nrf2 by sulforaphane and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism)."
"Collectively, these findings provide evidence that << arsenic >> causes prolonged activation of [[ Nrf2 ]] through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of Nrf2 found in certain human cancers.","Collectively, these findings provide evidence that [ENTITY_A] causes prolonged activation of [ENTITY_B] through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of Nrf2 found in certain human cancers.",ACTIVATOR,CPR:3,0,"Collectively, these findings provide evidence that arsenic causes prolonged activation of Nrf2 through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of Nrf2 found in certain human cancers."
"Ovarian AR was not influenced by either treatment, and oviduct << AR >> was reduced after [[ ethanol ]]-melatonin combination.","Ovarian AR was not influenced by either treatment, and oviduct [ENTITY_A] was reduced after [ENTITY_B]-melatonin combination.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Ovarian AR was not influenced by either treatment, and oviduct AR was reduced after ethanol-melatonin combination."
"Oviduct << ER-α >>, ER-β and uterine ER-β were down-regulated by either [[ ethanol ]] or melatonin.","Oviduct [ENTITY_A], ER-β and uterine ER-β were down-regulated by either [ENTITY_B] or melatonin.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Oviduct ER-α, ER-β and uterine ER-β were down-regulated by either ethanol or melatonin."
"Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas << PRA >> was down-regulated in the uterus and oviduct after [[ ethanol ]] consumption.","Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas [ENTITY_A] was down-regulated in the uterus and oviduct after [ENTITY_B] consumption.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption."
<< MT1R >> was increased in ovaries and uteri of [[ melatonin ]]-treated rats.,[ENTITY_A] was increased in ovaries and uteri of [ENTITY_B]-treated rats.,INDIRECT-UPREGULATOR,CPR:3,0,MT1R was increased in ovaries and uteri of melatonin-treated rats.
"Intraplantar or intrathecal administered Phα1β reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with << SB366791 >>, a specific [[ TRPV1 ]] antagonist.","Intraplantar or intrathecal administered Phα1β reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with [ENTITY_A], a specific [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"Intraplantar or intrathecal administered Phα1β reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with SB366791, a specific TRPV1 antagonist."
"Recently, the << c-Abl >> kinase inhibitor [[ imatinib mesylate ]] (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.","Recently, the [ENTITY_A] kinase inhibitor [ENTITY_B] (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.",INHIBITOR,CPR:4,1,"Recently, the c-Abl kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin."
"We found that, before apoptosis, << cisplatin >> induces [[ c-Abl ]] and TAp73 expression in the oocyte.","We found that, before apoptosis, [ENTITY_A] induces [ENTITY_B] and TAp73 expression in the oocyte.",INDIRECT-UPREGULATOR,CPR:3,0,"We found that, before apoptosis, cisplatin induces c-Abl and TAp73 expression in the oocyte."
"While imatinib was unable to block << cisplatin >>-induced DNA damage and damage response, such as the upregulation of [[ p53 ]], imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.","While imatinib was unable to block [ENTITY_A]-induced DNA damage and damage response, such as the upregulation of [ENTITY_B], imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.",INDIRECT-UPREGULATOR,CPR:3,0,"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death."
"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, << imatinib >> inhibited the cisplatin-induced nuclear accumulation of [[ c-Abl ]]/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.","While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, [ENTITY_A] inhibited the cisplatin-induced nuclear accumulation of [ENTITY_B]/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.",INDIRECT-DOWNREGULATOR,CPR:4,1,"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death."
"Surprisingly, the conditional deletion of Trp63, but not ΔNp63, in oocytes inhibited apoptosis, as well as the accumulation of << c-Abl >> and TAp73 caused by [[ cisplatin ]].","Surprisingly, the conditional deletion of Trp63, but not ΔNp63, in oocytes inhibited apoptosis, as well as the accumulation of [ENTITY_A] and TAp73 caused by [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"Surprisingly, the conditional deletion of Trp63, but not ΔNp63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by cisplatin."
"The expression kinetics of TAp63, c-Abl and TAp73 suggest that << cisplatin >> activates [[ TAp63 ]]-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.","The expression kinetics of TAp63, c-Abl and TAp73 suggest that [ENTITY_A] activates [ENTITY_B]-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.",ACTIVATOR,CPR:3,0,"The expression kinetics of TAp63, c-Abl and TAp73 suggest that cisplatin activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression."
"Our findings indicate that << imatinib >> protects oocytes from cisplatin-induced cell death by inhibiting c-Abl [[ kinase ]], which would otherwise activate TAp73-BAX-mediated apoptosis.","Our findings indicate that [ENTITY_A] protects oocytes from cisplatin-induced cell death by inhibiting c-Abl [ENTITY_B], which would otherwise activate TAp73-BAX-mediated apoptosis.",ACTIVATOR,CPR:3,0,"Our findings indicate that imatinib protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-BAX-mediated apoptosis."
"Our findings indicate that << imatinib >> protects oocytes from cisplatin-induced cell death by inhibiting [[ c-Abl ]] kinase, which would otherwise activate TAp73-BAX-mediated apoptosis.","Our findings indicate that [ENTITY_A] protects oocytes from cisplatin-induced cell death by inhibiting [ENTITY_B] kinase, which would otherwise activate TAp73-BAX-mediated apoptosis.",INHIBITOR,CPR:4,1,"Our findings indicate that imatinib protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-BAX-mediated apoptosis."
"Thus, << imatinib >> and other [[ c-Abl ]] kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.","Thus, [ENTITY_A] and other [ENTITY_B] kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.",INHIBITOR,CPR:4,1,"Thus, imatinib and other c-Abl kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31."
"Among the possible transporters involved in the uptake of << Cd(2+) >> and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by [[ Slc39a8 ]], showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.","Among the possible transporters involved in the uptake of [ENTITY_A] and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by [ENTITY_B], showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.",SUBSTRATE,CPR:9,4,"Among the possible transporters involved in the uptake of Cd(2+) and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells."
These results suggest that << ZIP8 >> plays a pivotal role in the transport and toxicity of [[ Cd(2+) ]] and Mn(2+) in RBL-2H3 cells.,These results suggest that [ENTITY_A] plays a pivotal role in the transport and toxicity of [ENTITY_B] and Mn(2+) in RBL-2H3 cells.,SUBSTRATE,CPR:9,4,These results suggest that ZIP8 plays a pivotal role in the transport and toxicity of Cd(2+) and Mn(2+) in RBL-2H3 cells.
"Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of << HIV capsid >> assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-[[ phenyl ]] moiety.","Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of [ENTITY_A] assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-[ENTITY_B] moiety.",INHIBITOR,CPR:4,1,"Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-phenyl moiety."
"Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of << 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione >> inhibitors of [[ HIV capsid ]] (CA) assembly are described.",Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of [ENTITY_A] inhibitors of [ENTITY_B] (CA) assembly are described.,INHIBITOR,CPR:4,1,"Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione inhibitors of HIV capsid (CA) assembly are described."
<< Arsenic >> upregulates the expression of [[ angiotensin II Type I receptor ]] in mouse aortic endothelial cells.,[ENTITY_A] upregulates the expression of [ENTITY_B] in mouse aortic endothelial cells.,INDIRECT-UPREGULATOR,CPR:3,0,Arsenic upregulates the expression of angiotensin II Type I receptor in mouse aortic endothelial cells.
"Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 << AT1R >> subtypes, AT1AR and AT1BR following [[ sodium arsenite ]] (SA) treatment.","Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 [ENTITY_A] subtypes, AT1AR and AT1BR following [ENTITY_B] (SA) treatment.",INDIRECT-UPREGULATOR,CPR:3,0,"Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following sodium arsenite (SA) treatment."
"Finally, SA-induced << AT1R >> expression was found to be prevented both by NAC and specific JNK inhibitor, [[ SP6001325 ]], strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.","Finally, SA-induced [ENTITY_A] expression was found to be prevented both by NAC and specific JNK inhibitor, [ENTITY_B], strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific JNK inhibitor, SP6001325, strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway."
"Taken together, our results indicate that << arsenic >> indeed upregulates the [[ AT1R ]] expression, thus highlighting a role of arsenic-induced aberrant AT1R signaling in the pathogenesis of hypertension.","Taken together, our results indicate that [ENTITY_A] indeed upregulates the [ENTITY_B] expression, thus highlighting a role of arsenic-induced aberrant AT1R signaling in the pathogenesis of hypertension.",INDIRECT-UPREGULATOR,CPR:3,0,"Taken together, our results indicate that arsenic indeed upregulates the AT1R expression, thus highlighting a role of arsenic-induced aberrant AT1R signaling in the pathogenesis of hypertension."
"The mRNA levels of << SOD1 >>, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined [[ Na2SeO3 ]]+NaAsO2 treatment group.","The mRNA levels of [ENTITY_A], CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined [ENTITY_B]+NaAsO2 treatment group.",INDIRECT-UPREGULATOR,CPR:3,0,"The mRNA levels of SOD1, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+NaAsO2 treatment group."
"The mRNA levels of << SOD1 >>, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+[[ NaAsO2 ]] treatment group.","The mRNA levels of [ENTITY_A], CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+[ENTITY_B] treatment group.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The mRNA levels of SOD1, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+NaAsO2 treatment group."
The expressions of << HSP70 >> and HO-1 were significantly (P<0.05) increased in the [[ NaAsO2 ]] group and reduced in the combined treatment group.,The expressions of [ENTITY_A] and HO-1 were significantly (P<0.05) increased in the [ENTITY_B] group and reduced in the combined treatment group.,INDIRECT-UPREGULATOR,CPR:3,0,The expressions of HSP70 and HO-1 were significantly (P<0.05) increased in the NaAsO2 group and reduced in the combined treatment group.
"From the 10 isolated compounds, << methyl-3,5-di-O-caffeoylquinate >> showed the most potent inhibition, with IC50 values of 0.30 and 0.67 μM for [[ rAR ]] and rhAR, respectively.","From the 10 isolated compounds, [ENTITY_A] showed the most potent inhibition, with IC50 values of 0.30 and 0.67 μM for [ENTITY_B] and rhAR, respectively.",INHIBITOR,CPR:4,1,"From the 10 isolated compounds, methyl-3,5-di-O-caffeoylquinate showed the most potent inhibition, with IC50 values of 0.30 and 0.67 μM for rAR and rhAR, respectively."
"In the kinetic analyses using Lineweaver-Burk plots of 1/velocity and 1/substrate, << methyl-3,5-di-O-caffeoylquinate >> showed competitive inhibition of [[ rhAR ]].","In the kinetic analyses using Lineweaver-Burk plots of 1/velocity and 1/substrate, [ENTITY_A] showed competitive inhibition of [ENTITY_B].",INHIBITOR,CPR:4,1,"In the kinetic analyses using Lineweaver-Burk plots of 1/velocity and 1/substrate, methyl-3,5-di-O-caffeoylquinate showed competitive inhibition of rhAR."
Recent observations revealed that << human UDP-glucuronosyltransferase (UGT) 2B10 >> catalyzes N-glucuronidation of [[ amine ]]-containing compounds.,Recent observations revealed that [ENTITY_A] catalyzes N-glucuronidation of [ENTITY_B]-containing compounds.,SUBSTRATE,CPR:9,4,Recent observations revealed that human UDP-glucuronosyltransferase (UGT) 2B10 catalyzes N-glucuronidation of amine-containing compounds.
"Using recombinant << UGT2B10 >>, we found that it catalyzes the N-glucuronidation of [[ amitriptyline ]], imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.","Using recombinant [ENTITY_A], we found that it catalyzes the N-glucuronidation of [ENTITY_B], imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.",SUBSTRATE,CPR:9,4,"Using recombinant UGT2B10, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam."
"This group of drugs contains secondary or primary amines, and these results suggest that << UGT2B10 >> preferably conjugates [[ tertiary amines ]].","This group of drugs contains secondary or primary amines, and these results suggest that [ENTITY_A] preferably conjugates [ENTITY_B].",SUBSTRATE,CPR:9,4,"This group of drugs contains secondary or primary amines, and these results suggest that UGT2B10 preferably conjugates tertiary amines."
"Kinetic analyses revealed that the affinity and clearance of << UGT2B10 >> for [[ amitriptyline ]], imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Kinetic analyses revealed that the affinity and clearance of [ENTITY_A] for [ENTITY_B], imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.",SUBSTRATE,CPR:9,4,"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher."
"In conclusion, this study expands the understanding of the substrate specificity of << UGT2B10 >>, highlighting its preference for [[ tertiary amines ]] with higher affinities and clearance values than those of UGT1A4 and UGT1A3.","In conclusion, this study expands the understanding of the substrate specificity of [ENTITY_A], highlighting its preference for [ENTITY_B] with higher affinities and clearance values than those of UGT1A4 and UGT1A3.",SUBSTRATE,CPR:9,4,"In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for tertiary amines with higher affinities and clearance values than those of UGT1A4 and UGT1A3."
"<< SB225002 >> (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit [[ IL-8 ]]-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.","[ENTITY_A] (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit [ENTITY_B]-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.",INHIBITOR,CPR:4,1,"SB225002 (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects."
"<< SB225002 >> (SB) is an [[ IL-8 receptor B ]] (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.","[ENTITY_A] (SB) is an [ENTITY_B] (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.",ANTAGONIST,CPR:6,3,"SB225002 (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects."
"Of note, << SB265610 >> which is a close structural analogue of SB225002 with a potent [[ IL-8RB ]] antagonistic activity did not exhibit a similar antimitotic activity.","Of note, [ENTITY_A] which is a close structural analogue of SB225002 with a potent [ENTITY_B] antagonistic activity did not exhibit a similar antimitotic activity.",ANTAGONIST,CPR:6,3,"Of note, SB265610 which is a close structural analogue of SB225002 with a potent IL-8RB antagonistic activity did not exhibit a similar antimitotic activity."
"In support of this observation, elongation can be reversed by the << tyrosine kinase >> inhibitor [[ SU5402 ]], mRNA for the FGFR antagonist sprouty4, or FGF8 morpholino.","In support of this observation, elongation can be reversed by the [ENTITY_A] inhibitor [ENTITY_B], mRNA for the FGFR antagonist sprouty4, or FGF8 morpholino.",INHIBITOR,CPR:4,1,"In support of this observation, elongation can be reversed by the tyrosine kinase inhibitor SU5402, mRNA for the FGFR antagonist sprouty4, or FGF8 morpholino."
<< Caffeic Acid Phenethyl Ester >> Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of [[ Akt ]] Signaling.,[ENTITY_A] Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of [ENTITY_B] Signaling.,INDIRECT-DOWNREGULATOR,CPR:4,1,Caffeic Acid Phenethyl Ester Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of Akt Signaling.
"Treatment with << CAPE >> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3β, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-κB, phospho-NF-κB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor [[ p27Kip ]].","Treatment with [ENTITY_A] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3β, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-κB, phospho-NF-κB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3β, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-κB, phospho-NF-κB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip."
"Treatment with << CAPE >> decreased protein abundance of [[ Akt ]], Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3β, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-κB, phospho-NF-κB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Treatment with [ENTITY_A] decreased protein abundance of [ENTITY_B], Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3β, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-κB, phospho-NF-κB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3β, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-κB, phospho-NF-κB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip."
Here we show that << fisetin >> rapidly increases the levels of both [[ Nrf2 ]] and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.,Here we show that [ENTITY_A] rapidly increases the levels of both [ENTITY_B] and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.,INDIRECT-UPREGULATOR,CPR:3,0,Here we show that fisetin rapidly increases the levels of both Nrf2 and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.
"Although << fisetin >> greatly increases the stability of both [[ Nrf2 ]] and ATF4, only the effect on ATF4 is dependent on protein kinase activity.","Although [ENTITY_A] greatly increases the stability of both [ENTITY_B] and ATF4, only the effect on ATF4 is dependent on protein kinase activity.",INDIRECT-UPREGULATOR,CPR:3,0,"Although fisetin greatly increases the stability of both Nrf2 and ATF4, only the effect on ATF4 is dependent on protein kinase activity."
"<< Cynomolgus FMO1 >>, FMO2, FMO3, and FMO5 metabolized [[ benzydamine ]], and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.","[ENTITY_A], FMO2, FMO3, and FMO5 metabolized [ENTITY_B], and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.",SUBSTRATE,CPR:9,4,"Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively."
"Rates of << benzydamine >> N-oxygenation (catalyzed by [[ FMO3 ]]) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.","Rates of [ENTITY_A] N-oxygenation (catalyzed by [ENTITY_B]) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.",SUBSTRATE,CPR:9,4,"Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression."
"<< Cynomolgus FMO6 >> metabolized [[ benzydamine ]] only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional.","[ENTITY_A] metabolized [ENTITY_B] only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional.",SUBSTRATE,CPR:9,4,"Cynomolgus FMO6 metabolized benzydamine only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional."
Activation of << AMPK >> using [[ AICAR ]] resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.,Activation of [ENTITY_A] using [ENTITY_B] resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.,ACTIVATOR,CPR:3,0,Activation of AMPK using AICAR resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.
Activation of AMPK using << AICAR >> resulted in STIM1 phosphorylation on serine residues and prevented [[ PAR-1 ]]-induced Ca2+ entry.,Activation of AMPK using [ENTITY_A] resulted in STIM1 phosphorylation on serine residues and prevented [ENTITY_B]-induced Ca2+ entry.,INDIRECT-DOWNREGULATOR,CPR:4,1,Activation of AMPK using AICAR resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.
"Further, << AICAR >> pretreatment blocked [[ PAR-1 ]]-induced increase in permeability of mouse-lung microvessels.","Further, [ENTITY_A] pretreatment blocked [ENTITY_B]-induced increase in permeability of mouse-lung microvessels.",INHIBITOR,CPR:4,1,"Further, AICAR pretreatment blocked PAR-1-induced increase in permeability of mouse-lung microvessels."
"Interestingly, << SB203580 >>, a selective inhibitor of [[ p38 ]] MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.","Interestingly, [ENTITY_A], a selective inhibitor of [ENTITY_B] MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.",INHIBITOR,CPR:4,1,"Interestingly, SB203580, a selective inhibitor of p38 MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry."
"Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the << cholesterol >> side-chain cleavage enzyme, [[ P450scc ]], and its two electron-transfer partners, ferredoxin reductase and ferredoxin.","Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the [ENTITY_A] side-chain cleavage enzyme, [ENTITY_B], and its two electron-transfer partners, ferredoxin reductase and ferredoxin.",SUBSTRATE,CPR:9,4,"Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the cholesterol side-chain cleavage enzyme, P450scc, and its two electron-transfer partners, ferredoxin reductase and ferredoxin."
"The precise fashion in which these proteins interact and move << cholesterol >> from the OMM to [[ P450scc ]], and the means by which cholesterol is loaded into the OMM, remain unclear.","The precise fashion in which these proteins interact and move [ENTITY_A] from the OMM to [ENTITY_B], and the means by which cholesterol is loaded into the OMM, remain unclear.",SUBSTRATE,CPR:9,4,"The precise fashion in which these proteins interact and move cholesterol from the OMM to P450scc, and the means by which cholesterol is loaded into the OMM, remain unclear."
<< Matrix Metalloproteinase >> Inhibitors Based on the [[ 3-Mercaptopyrrolidine ]] Core.,[ENTITY_A] Inhibitors Based on the [ENTITY_B] Core.,INHIBITOR,CPR:4,1,Matrix Metalloproteinase Inhibitors Based on the 3-Mercaptopyrrolidine Core.
"New series of << pyrrolidine mercaptosulfide >>, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine [[ matrix metalloproteinase ]] inhibitors (MMPIs) were designed, synthesized, and evaluated.","New series of [ENTITY_A], 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine [ENTITY_B] inhibitors (MMPIs) were designed, synthesized, and evaluated.",INHIBITOR,CPR:4,1,"New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated."
"Exhibiting unique properties over other MMPIs (e.g., << hydroxamates >>), these newly reported compounds are capable of modulating activities of several [[ MMPs ]] in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM).","Exhibiting unique properties over other MMPIs (e.g., [ENTITY_A]), these newly reported compounds are capable of modulating activities of several [ENTITY_B] in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM).",INHIBITOR,CPR:4,1,"Exhibiting unique properties over other MMPIs (e.g., hydroxamates), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM)."
"Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in glucosinolates, which upon << myrosinase >> hydrolysis release the corresponding [[ isothiocyanates ]].","Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in glucosinolates, which upon [ENTITY_A] hydrolysis release the corresponding [ENTITY_B].",PRODUCT-OF,CPR:9,4,"Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in glucosinolates, which upon myrosinase hydrolysis release the corresponding isothiocyanates."
"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive << RS -GRA >> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as [[ interleukin-1β ]] (IL-1β), and apoptosis (Bax and caspase 3 expression).","RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive [ENTITY_A] significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as [ENTITY_B] (IL-1β), and apoptosis (Bax and caspase 3 expression).",INDIRECT-DOWNREGULATOR,CPR:4,1,"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive RS -GRA significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1β (IL-1β), and apoptosis (Bax and caspase 3 expression)."
"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on << H2O2 >>-induced disruption of [[ phase II detoxifying enzyme ]] system and cAMP response element binding protein (CREB) phosphorylation.","Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on [ENTITY_A]-induced disruption of [ENTITY_B] system and cAMP response element binding protein (CREB) phosphorylation.",DOWNREGULATOR,CPR:4,1,"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (CREB) phosphorylation."
"In H2O2-treated cells, << calycopterin >> also suppressed [[ cytochrome C ]] release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells.","In H2O2-treated cells, [ENTITY_A] also suppressed [ENTITY_B] release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In H2O2-treated cells, calycopterin also suppressed cytochrome C release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells."
"Moreover, << calycopterin >>, in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, [[ CREB ]] and Nrf2, which play an important role in antioxidant capacity of the cell.","Moreover, [ENTITY_A], in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, [ENTITY_B] and Nrf2, which play an important role in antioxidant capacity of the cell.",INDIRECT-UPREGULATOR,CPR:3,0,"Moreover, calycopterin, in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and Nrf2, which play an important role in antioxidant capacity of the cell."
There was also an increase in << γ-GCS >> and HO-1 levels in [[ calycopterin ]] pretreated cells.,There was also an increase in [ENTITY_A] and HO-1 levels in [ENTITY_B] pretreated cells.,INDIRECT-UPREGULATOR,CPR:3,0,There was also an increase in γ-GCS and HO-1 levels in calycopterin pretreated cells.
"In the presence of H2O2, << calycopterin >> inhibited decrease in GSH level and [[ SOD ]] activity.","In the presence of H2O2, [ENTITY_A] inhibited decrease in GSH level and [ENTITY_B] activity.",ACTIVATOR,CPR:3,0,"In the presence of H2O2, calycopterin inhibited decrease in GSH level and SOD activity."
<< Indoxyl 3-sulfate >> stimulates Th17 differentiation enhancing phosphorylation of [[ c-Src ]] and STAT3 to worsen experimental autoimmune encephalomyelitis.,[ENTITY_A] stimulates Th17 differentiation enhancing phosphorylation of [ENTITY_B] and STAT3 to worsen experimental autoimmune encephalomyelitis.,ACTIVATOR,CPR:3,0,Indoxyl 3-sulfate stimulates Th17 differentiation enhancing phosphorylation of c-Src and STAT3 to worsen experimental autoimmune encephalomyelitis.
"In the present study, using in vitro Th17 differentiation model, we examined effects of << AhR >> activation by [[ indoxyl 3-sulfate ]] (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.","In the present study, using in vitro Th17 differentiation model, we examined effects of [ENTITY_A] activation by [ENTITY_B] (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.",ACTIVATOR,CPR:3,0,"In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms."
"<< I3S >> increased expression of [[ RORγt ]], the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.","[ENTITY_A] increased expression of [ENTITY_B], the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.",INDIRECT-UPREGULATOR,CPR:3,0,"I3S increased expression of RORγt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand."
"Activation of << STAT3 >>, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and [[ TCDD ]].","Activation of [ENTITY_A], which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and [ENTITY_B].",ACTIVATOR,CPR:3,0,"Activation of STAT3, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and TCDD."
"Phosphorylation of << c-Src >>, which was shown to be activated by AhR ligands, was also increased by [[ I3S ]] and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.","Phosphorylation of [ENTITY_A], which was shown to be activated by AhR ligands, was also increased by [ENTITY_B] and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.",ACTIVATOR,CPR:3,0,"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation."
"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of << c-Src >> activity by [[ 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine ]] (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.","Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of [ENTITY_A] activity by [ENTITY_B] (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.",INHIBITOR,CPR:4,1,"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation."
"Finally, we found that << I3S >> worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of [[ IL-17 ]]-producing cells in draining lymph nodes.","Finally, we found that [ENTITY_A] worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of [ENTITY_B]-producing cells in draining lymph nodes.",INDIRECT-UPREGULATOR,CPR:3,0,"Finally, we found that I3S worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of IL-17-producing cells in draining lymph nodes."
<< TCDD >> induces the expression of [[ insulin-like growth factor binding protein 4 ]] in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on dioxin toxicity.,[ENTITY_A] induces the expression of [ENTITY_B] in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on dioxin toxicity.,INDIRECT-UPREGULATOR,CPR:3,0,TCDD induces the expression of insulin-like growth factor binding protein 4 in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on dioxin toxicity.
"By ""working upwards"" from mTOR, we observed that << TCDD >> inhibited endogenous and IGF-I-induced [[ AKT ]] and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.","By ""working upwards"" from mTOR, we observed that [ENTITY_A] inhibited endogenous and IGF-I-induced [ENTITY_B] and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.",INDIRECT-DOWNREGULATOR,CPR:4,1,"By ""working upwards"" from mTOR, we observed that TCDD inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1."
This inhibition was mediated by a << TCDD >>-induced secreted factor which was identified as [[ insulin-like growth factor binding protein 4 ]] (IGFBP-4).,This inhibition was mediated by a [ENTITY_A]-induced secreted factor which was identified as [ENTITY_B] (IGFBP-4).,UPREGULATOR,CPR:3,0,This inhibition was mediated by a TCDD-induced secreted factor which was identified as insulin-like growth factor binding protein 4 (IGFBP-4).
The induction of IGFBP-4 protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of << IGFBP-4 >> mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of [[ TCDD ]] in 5L cells.,The induction of IGFBP-4 protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of [ENTITY_A] mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of [ENTITY_B] in 5L cells.,INDIRECT-DOWNREGULATOR,CPR:4,1,The induction of IGFBP-4 protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of TCDD in 5L cells.
The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of << IGFBP-4 >> by [[ TCDD ]].,The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of [ENTITY_A] by [ENTITY_B].,UPREGULATOR,CPR:3,0,The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of IGFBP-4 by TCDD.
"Although numerous mechanisms of action of << pimozide >> and thioridazine have been identified, both drugs are [[ calmodulin ]] antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.","Although numerous mechanisms of action of [ENTITY_A] and thioridazine have been identified, both drugs are [ENTITY_B] antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.",ANTAGONIST,CPR:6,3,"Although numerous mechanisms of action of pimozide and thioridazine have been identified, both drugs are calmodulin antagonists at drug concentrations that inhibit breast cancer cell growth in vitro."
Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and W-12 is consistent with a role for << calmodulin >> antagonism in the broad growth-inhibitory properties of [[ pimozide ]].,Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and W-12 is consistent with a role for [ENTITY_A] antagonism in the broad growth-inhibitory properties of [ENTITY_B].,INHIBITOR,CPR:4,1,Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide.
Inhibition of MCF-7 cell growth by the selective << calmodulin >> antagonists [[ W-13 ]] and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide.,Inhibition of MCF-7 cell growth by the selective [ENTITY_A] antagonists [ENTITY_B] and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide.,ANTAGONIST,CPR:6,3,Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide.
"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), << MAO-B >> by [[ (-)deprenyl ]] (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).","Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), [ENTITY_A] by [ENTITY_B] (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).",INHIBITOR,CPR:4,1,"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.)."
The results suggest that most of the << HVA >> in plasma is derived from deamination of DA by [[ MAO-A ]] in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.,The results suggest that most of the [ENTITY_A] in plasma is derived from deamination of DA by [ENTITY_B] in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.,PRODUCT-OF,CPR:9,4,The results suggest that most of the HVA in plasma is derived from deamination of DA by MAO-A in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.
"After << loperamide >> administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an [[ ACTH ]] increase; the pattern of ACTH response to CRH was slightly delayed.","After [ENTITY_A] administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an [ENTITY_B] increase; the pattern of ACTH response to CRH was slightly delayed.",INDIRECT-UPREGULATOR,CPR:3,0,"After loperamide administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an ACTH increase; the pattern of ACTH response to CRH was slightly delayed."
"After << loperamide >> administration [[ ACTH ]] levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an ACTH increase; the pattern of ACTH response to CRH was slightly delayed.","After [ENTITY_A] administration [ENTITY_B] levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an ACTH increase; the pattern of ACTH response to CRH was slightly delayed.",INDIRECT-DOWNREGULATOR,CPR:4,1,"After loperamide administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an ACTH increase; the pattern of ACTH response to CRH was slightly delayed."
"<< Ambenonium >> is known to be an inhibitor of [[ acetylcholinesterase ]], and recent data have shown this drug to antagonize muscarinic receptors as well.","[ENTITY_A] is known to be an inhibitor of [ENTITY_B], and recent data have shown this drug to antagonize muscarinic receptors as well.",INHIBITOR,CPR:4,1,"Ambenonium is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize muscarinic receptors as well."
"<< Ambenonium >> is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize [[ muscarinic receptors ]] as well.","[ENTITY_A] is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize [ENTITY_B] as well.",ANTAGONIST,CPR:6,3,"Ambenonium is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize muscarinic receptors as well."
"Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the << acetylcholinesterase >> inhibitor [[ neostigmine ]].","Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the [ENTITY_A] inhibitor [ENTITY_B].",INHIBITOR,CPR:4,1,"Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the acetylcholinesterase inhibitor neostigmine."
These data suggested that << ambenonium >> had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of [[ acetylcholinesterase ]] and concomitant antagonism by blockade of muscarinic receptors.,These data suggested that [ENTITY_A] had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of [ENTITY_B] and concomitant antagonism by blockade of muscarinic receptors.,INHIBITOR,CPR:4,1,These data suggested that ambenonium had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of muscarinic receptors.
These data suggested that ambenonium had a dual effect on tissue responses to << acetylcholine >>-producing potentiation by blockade of [[ acetylcholinesterase ]] and concomitant antagonism by blockade of muscarinic receptors.,These data suggested that ambenonium had a dual effect on tissue responses to [ENTITY_A]-producing potentiation by blockade of [ENTITY_B] and concomitant antagonism by blockade of muscarinic receptors.,AGONIST,CPR:5,2,These data suggested that ambenonium had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of muscarinic receptors.
These data suggested that << ambenonium >> had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of [[ muscarinic receptors ]].,These data suggested that [ENTITY_A] had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of [ENTITY_B].,ANTAGONIST,CPR:6,3,These data suggested that ambenonium had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of muscarinic receptors.
"However, << betaxolol >> produces less systemic beta 2- and possibly [[ beta 1-adrenergic receptor ]] blockade than either timolol or levobunolol.","However, [ENTITY_A] produces less systemic beta 2- and possibly [ENTITY_B] blockade than either timolol or levobunolol.",INHIBITOR,CPR:4,1,"However, betaxolol produces less systemic beta 2- and possibly beta 1-adrenergic receptor blockade than either timolol or levobunolol."
"<< Tyrosinase >> catalyzes an unusual oxidative decarboxylation of [[ 3,4-dihydroxymandelate ]].",[ENTITY_A] catalyzes an unusual oxidative decarboxylation of [ENTITY_B].,SUBSTRATE,CPR:9,4,"Tyrosinase catalyzes an unusual oxidative decarboxylation of 3,4-dihydroxymandelate."
<< Tyrosinase >> usually catalyzes the conversion of [[ monophenols ]] to o-diphenols and oxidation of diphenols to the corresponding quinones.,[ENTITY_A] usually catalyzes the conversion of [ENTITY_B] to o-diphenols and oxidation of diphenols to the corresponding quinones.,SUBSTRATE,CPR:9,4,Tyrosinase usually catalyzes the conversion of monophenols to o-diphenols and oxidation of diphenols to the corresponding quinones.
"<< Phenol oxidase >> inhibitors such as [[ phenylthiourea ]], potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.","[ENTITY_A] inhibitors such as [ENTITY_B], potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.",INHIBITOR,CPR:4,1,"Phenol oxidase inhibitors such as phenylthiourea, potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis."
"<< Mimosine >>, a well-known competitive inhibitor of [[ tyrosinase ]], competitively inhibited the new reaction also.","[ENTITY_A], a well-known competitive inhibitor of [ENTITY_B], competitively inhibited the new reaction also.",INHIBITOR,CPR:4,1,"Mimosine, a well-known competitive inhibitor of tyrosinase, competitively inhibited the new reaction also."
"Present studies demonstrate that << mushroom tyrosinase >> will also catalyze [[ quinone methide ]] production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided.","Present studies demonstrate that [ENTITY_A] will also catalyze [ENTITY_B] production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided.",PRODUCT-OF,CPR:9,4,"Present studies demonstrate that mushroom tyrosinase will also catalyze quinone methide production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided."
"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (<< t-PA >>) is inhibited by Cl-, at physiological concentrations, and stimulated by [[ epsilon-aminocaproic acid ]] (EACA), as well as fibrin(ogen).","The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator ([ENTITY_A]) is inhibited by Cl-, at physiological concentrations, and stimulated by [ENTITY_B] (EACA), as well as fibrin(ogen).",ACTIVATOR,CPR:3,0,"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)."
"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (<< t-PA >>) is inhibited by [[ Cl- ]], at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).","The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator ([ENTITY_A]) is inhibited by [ENTITY_B], at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).",INHIBITOR,CPR:4,1,"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)."
"The presence of << Cl- >> inhibits the stimulation of [[ [Glu1]Pg ]] activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator.","The presence of [ENTITY_A] inhibits the stimulation of [ENTITY_B] activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator.",INHIBITOR,CPR:4,1,"The presence of Cl- inhibits the stimulation of [Glu1]Pg activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator."
Sodium-dependent << norepinephrine >>-induced currents in [[ norepinephrine-transporter ]]-transfected HEK-293 cells blocked by cocaine and antidepressants.,Sodium-dependent [ENTITY_A]-induced currents in [ENTITY_B]-transfected HEK-293 cells blocked by cocaine and antidepressants.,ACTIVATOR,CPR:3,0,Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants.
Sodium-dependent norepinephrine-induced currents in << norepinephrine-transporter >>-transfected HEK-293 cells blocked by [[ cocaine ]] and antidepressants.,Sodium-dependent norepinephrine-induced currents in [ENTITY_A]-transfected HEK-293 cells blocked by [ENTITY_B] and antidepressants.,INHIBITOR,CPR:4,1,Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants.
"Whole-cell voltage-clamp of << hNET >>-293 cells reveals [[ NE ]]-induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells.","Whole-cell voltage-clamp of [ENTITY_A]-293 cells reveals [ENTITY_B]-induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells.",ACTIVATOR,CPR:3,0,"Whole-cell voltage-clamp of hNET-293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells."
"Whole-cell voltage-clamp of << hNET >>-293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and [[ cocaine ]] that are absent in parental cells.","Whole-cell voltage-clamp of [ENTITY_A]-293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and [ENTITY_B] that are absent in parental cells.",INHIBITOR,CPR:4,1,"Whole-cell voltage-clamp of hNET-293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells."
"To explain our observations, we propose that << hNETs >> function as ion-gated ligand channels with an indefinite stoichiometry relating ion flux to [[ NE ]] transport.","To explain our observations, we propose that [ENTITY_A] function as ion-gated ligand channels with an indefinite stoichiometry relating ion flux to [ENTITY_B] transport.",SUBSTRATE,CPR:9,4,"To explain our observations, we propose that hNETs function as ion-gated ligand channels with an indefinite stoichiometry relating ion flux to NE transport."
BACKGROUND: The active metabolite of the anti-inflammatory drug << nabumetone >> has been characterized as a selective inhibitor of the inducible [[ prostaglandin H synthase ]] (PGHS).,BACKGROUND: The active metabolite of the anti-inflammatory drug [ENTITY_A] has been characterized as a selective inhibitor of the inducible [ENTITY_B] (PGHS).,INHIBITOR,CPR:4,1,BACKGROUND: The active metabolite of the anti-inflammatory drug nabumetone has been characterized as a selective inhibitor of the inducible prostaglandin H synthase (PGHS).
"Moreover, the production of << TXB2 >> during whole blood clotting was assessed as an index of the [[ cyclooxygenase ]] activity of platelet PGHS-1 ex vivo.","Moreover, the production of [ENTITY_A] during whole blood clotting was assessed as an index of the [ENTITY_B] activity of platelet PGHS-1 ex vivo.",PRODUCT-OF,CPR:9,4,"Moreover, the production of TXB2 during whole blood clotting was assessed as an index of the cyclooxygenase activity of platelet PGHS-1 ex vivo."
"The daily administration of low-dose << aspirin >> (40 mg), a selective inhibitor of platelet [[ PGHS-1 ]], caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.","The daily administration of low-dose [ENTITY_A] (40 mg), a selective inhibitor of platelet [ENTITY_B], caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.",INHIBITOR,CPR:4,1,"The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet PGHS-1, caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover."
"The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet << PGHS-1 >>, caused a cumulative inhibition of urinary [[ 11-dehydro-TXB2 ]] and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.","The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet [ENTITY_A], caused a cumulative inhibition of urinary [ENTITY_B] and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.",PRODUCT-OF,CPR:9,4,"The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet PGHS-1, caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover."
CONCLUSIONS: << Nabumetone >> does dose-dependently inhibit the [[ cyclooxygenase ]] activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo.,CONCLUSIONS: [ENTITY_A] does dose-dependently inhibit the [ENTITY_B] activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo.,INHIBITOR,CPR:4,1,CONCLUSIONS: Nabumetone does dose-dependently inhibit the cyclooxygenase activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo.
"Preclinical efficacy of << emedastine >>, a potent, selective [[ histamine H1 ]] antagonist for topical ocular use.","Preclinical efficacy of [ENTITY_A], a potent, selective [ENTITY_B] antagonist for topical ocular use.",ANTAGONIST,CPR:6,3,"Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use."
"(2) Exposure histories vary in secondary 11q23 leukemia, as the only << topoisomerase II >> inhibitor was [[ dactinomycin ]] in one case, and, in another case, no topoisomerase II inhibitor was administered.","(2) Exposure histories vary in secondary 11q23 leukemia, as the only [ENTITY_A] inhibitor was [ENTITY_B] in one case, and, in another case, no topoisomerase II inhibitor was administered.",INHIBITOR,CPR:4,1,"(2) Exposure histories vary in secondary 11q23 leukemia, as the only topoisomerase II inhibitor was dactinomycin in one case, and, in another case, no topoisomerase II inhibitor was administered."
"<< Indomethacin >>, piroxicam, and sulindac sulfide were found to preferentially inhibit [[ PGHS-1 ]].","[ENTITY_A], piroxicam, and sulindac sulfide were found to preferentially inhibit [ENTITY_B].",INHIBITOR,CPR:4,1,"Indomethacin, piroxicam, and sulindac sulfide were found to preferentially inhibit PGHS-1."
"<< 6-Methoxy-2-naphthylacetic acid >>, the active metabolite of Relafen, inhibits murine [[ PGHS-2 ]] preferentially.","[ENTITY_A], the active metabolite of Relafen, inhibits murine [ENTITY_B] preferentially.",INHIBITOR,CPR:4,1,"6-Methoxy-2-naphthylacetic acid, the active metabolite of Relafen, inhibits murine PGHS-2 preferentially."
"<< Aspirin >> irreversibly inhibits [[ PGHS-1 ]], preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.","[ENTITY_A] irreversibly inhibits [ENTITY_B], preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.",INHIBITOR,CPR:4,1,"Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2."
"Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of << PGHS-2 >> causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid ([[ 15-HETE ]]) instead of PGH2.","Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of [ENTITY_A] causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid ([ENTITY_B]) instead of PGH2.",PRODUCT-OF,CPR:9,4,"Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2."
"Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of << phenylpropanolamine >>, to stimulate directly [[ alpha 1-adrenoceptors ]].","Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of [ENTITY_A], to stimulate directly [ENTITY_B].",ACTIVATOR,CPR:3,0,"Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly alpha 1-adrenoceptors."
"Under these conditions, blockade of << monoamine oxidase >> with [[ pargyline ]] (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine.","Under these conditions, blockade of [ENTITY_A] with [ENTITY_B] (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine.",INHIBITOR,CPR:4,1,"Under these conditions, blockade of monoamine oxidase with pargyline (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine."
"In addition several ligands known to act as agonists at either << 5-HT2A >> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), [[ Ru 24969 ]], MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.","In addition several ligands known to act as agonists at either [ENTITY_A] or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), [ENTITY_B], MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",AGONIST,CPR:5,2,"In addition several ligands known to act as agonists at either 5-HT2A or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive."
Phorbol esters and << norepinephrine >> destabilize [[ alpha 1B-adrenergic receptor ]] mRNA in vascular smooth muscle cells.,Phorbol esters and [ENTITY_A] destabilize [ENTITY_B] mRNA in vascular smooth muscle cells.,INDIRECT-DOWNREGULATOR,CPR:4,1,Phorbol esters and norepinephrine destabilize alpha 1B-adrenergic receptor mRNA in vascular smooth muscle cells.
The mechanism by which << norepinephrine >> (NE) down-regulates [[ alpha 1B-adrenergic receptor ]] (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.,The mechanism by which [ENTITY_A] (NE) down-regulates [ENTITY_B] (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.,INDIRECT-DOWNREGULATOR,CPR:4,1,The mechanism by which norepinephrine (NE) down-regulates alpha 1B-adrenergic receptor (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.
"<< NE >>, phorbol esters, and bradykinin each decreased [[ alpha-AR ]] mRNA levels by 70-80%.","[ENTITY_A], phorbol esters, and bradykinin each decreased [ENTITY_B] mRNA levels by 70-80%.",INDIRECT-DOWNREGULATOR,CPR:4,1,"NE, phorbol esters, and bradykinin each decreased alpha-AR mRNA levels by 70-80%."
The << protein kinase C >> inhibitor [[ (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride ]] (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.,The [ENTITY_A] inhibitor [ENTITY_B] (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.,INHIBITOR,CPR:4,1,The protein kinase C inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.
Neither ryanodine nor << EGTA >> inhibited down-regulation of [[ alpha-AR ]] mRNA by NE.,Neither ryanodine nor [ENTITY_A] inhibited down-regulation of [ENTITY_B] mRNA by NE.,INDIRECT-UPREGULATOR,CPR:3,0,Neither ryanodine nor EGTA inhibited down-regulation of alpha-AR mRNA by NE.
Neither ryanodine nor EGTA inhibited down-regulation of << alpha-AR >> mRNA by [[ NE ]].,Neither ryanodine nor EGTA inhibited down-regulation of [ENTITY_A] mRNA by [ENTITY_B].,INDIRECT-DOWNREGULATOR,CPR:4,1,Neither ryanodine nor EGTA inhibited down-regulation of alpha-AR mRNA by NE.
<< Actinomycin D >> caused [[ alpha-AR ]] mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level.,[ENTITY_A] caused [ENTITY_B] mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level.,INDIRECT-DOWNREGULATOR,CPR:4,1,Actinomycin D caused alpha-AR mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level.
Both << NE >> and phorbol esters increased the rate of [[ alpha-AR ]] mRNA degradation.,Both [ENTITY_A] and phorbol esters increased the rate of [ENTITY_B] mRNA degradation.,INDIRECT-DOWNREGULATOR,CPR:4,1,Both NE and phorbol esters increased the rate of alpha-AR mRNA degradation.
"In << NE >>-desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of [[ alpha-AR ]] mRNA.","In [ENTITY_A]-desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of [ENTITY_B] mRNA.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In NE-desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of alpha-AR mRNA."
The << protein phosphatase >> inhibitor [[ okadaic acid ]] prolonged the normally transient effect of NE for at least 24 h.,The [ENTITY_A] inhibitor [ENTITY_B] prolonged the normally transient effect of NE for at least 24 h.,INHIBITOR,CPR:4,1,The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of NE for at least 24 h.
The specific binding is displaced by the selective << 5-HT1D >> agonist [[ sumatriptan ]] but not by the mixed 5-HT1A/1D agonist 5-carboxyamidotryptamine.,The specific binding is displaced by the selective [ENTITY_A] agonist [ENTITY_B] but not by the mixed 5-HT1A/1D agonist 5-carboxyamidotryptamine.,AGONIST,CPR:5,2,The specific binding is displaced by the selective 5-HT1D agonist sumatriptan but not by the mixed 5-HT1A/1D agonist 5-carboxyamidotryptamine.
HeLa cells transfected with the MR77 gene exhibited inhibition of << adenylate cyclase >> in response to [[ serotonin ]].,HeLa cells transfected with the MR77 gene exhibited inhibition of [ENTITY_A] in response to [ENTITY_B].,INHIBITOR,CPR:4,1,HeLa cells transfected with the MR77 gene exhibited inhibition of adenylate cyclase in response to serotonin.
"The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous << adenosine >> may modulate VT through alterations in autonomic tone by activation of arterial [[ chemoreceptors ]], and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.","The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous [ENTITY_A] may modulate VT through alterations in autonomic tone by activation of arterial [ENTITY_B], and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.",ACTIVATOR,CPR:3,0,"The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous adenosine may modulate VT through alterations in autonomic tone by activation of arterial chemoreceptors, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch."
"VT recurred with the addition of << aminophylline >>, a competitive [[ adenosine A1-receptor ]] antagonist.","VT recurred with the addition of [ENTITY_A], a competitive [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"VT recurred with the addition of aminophylline, a competitive adenosine A1-receptor antagonist."
"Edrophonium (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the << muscarinic cholinergic receptor >>, terminated VT in four of four patients, an effect that was reversed by [[ atropine ]].","Edrophonium (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the [ENTITY_A], terminated VT in four of four patients, an effect that was reversed by [ENTITY_B].",DOWNREGULATOR,CPR:4,1,"Edrophonium (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by atropine."
<< Amantadine >> induces [[ c-fos ]] in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists.,[ENTITY_A] induces [ENTITY_B] in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists.,INDIRECT-UPREGULATOR,CPR:3,0,Amantadine induces c-fos in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists.
"<< Amantadine >> (1-aminoadamantane) induced [[ Fos ]] expression in the central, dorsal-medial and ventral-medial part of the striatum.","[ENTITY_A] (1-aminoadamantane) induced [ENTITY_B] expression in the central, dorsal-medial and ventral-medial part of the striatum.",INDIRECT-UPREGULATOR,CPR:3,0,"Amantadine (1-aminoadamantane) induced Fos expression in the central, dorsal-medial and ventral-medial part of the striatum."
The distribution pattern of << Fos >> induced by [[ amantadine ]] was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists.,The distribution pattern of [ENTITY_A] induced by [ENTITY_B] was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists.,INDIRECT-UPREGULATOR,CPR:3,0,The distribution pattern of Fos induced by amantadine was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists.
"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked << amantadine >> induction of [[ Fos ]] in the striatum.","Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked [ENTITY_A] induction of [ENTITY_B] in the striatum.",INDIRECT-UPREGULATOR,CPR:3,0,"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum."
"Pretreatment with the dopamine D1 receptor antagonist, << SCH23390 >>, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of [[ Fos ]] in the striatum.","Pretreatment with the dopamine D1 receptor antagonist, [ENTITY_A], and the NMDA receptor antagonist, MK-801, blocked amantadine induction of [ENTITY_B] in the striatum.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum."
"Pretreatment with the << dopamine D1 receptor >> antagonist, [[ SCH23390 ]], and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum.","Pretreatment with the [ENTITY_A] antagonist, [ENTITY_B], and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum.",ANTAGONIST,CPR:6,3,"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum."
"However, << amantadine >> induction of [[ Fos ]] in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride.","However, [ENTITY_A] induction of [ENTITY_B] in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride.",INDIRECT-UPREGULATOR,CPR:3,0,"However, amantadine induction of Fos in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride."
"However, amantadine induction of Fos in the striatum was unaffected by the << dopamine D2 receptor >> antagonist, [[ sulpiride ]].","However, amantadine induction of Fos in the striatum was unaffected by the [ENTITY_A] antagonist, [ENTITY_B].",ANTAGONIST,CPR:6,3,"However, amantadine induction of Fos in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride."
These results suggest that << amantadine >> induction of [[ Fos ]] in the rat striatum is related to dopamine D1 and NMDA receptors.,These results suggest that [ENTITY_A] induction of [ENTITY_B] in the rat striatum is related to dopamine D1 and NMDA receptors.,INDIRECT-UPREGULATOR,CPR:3,0,These results suggest that amantadine induction of Fos in the rat striatum is related to dopamine D1 and NMDA receptors.
"After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received << aurintrycarboxilic acid >> (ATA), an inhibitor of platelet [[ glycoprotein Ib ]]/von Willebrand factor interaction (10 mg/kg i.v. bolus).","After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received [ENTITY_A] (ATA), an inhibitor of platelet [ENTITY_B]/von Willebrand factor interaction (10 mg/kg i.v. bolus).",INHIBITOR,CPR:4,1,"After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (ATA), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus)."
"These events are stimulated by NE and by guanethidine, an << hNET >> substrate, and they are blocked by [[ cocaine ]] and the antidepressant desipramine.","These events are stimulated by NE and by guanethidine, an [ENTITY_A] substrate, and they are blocked by [ENTITY_B] and the antidepressant desipramine.",INHIBITOR,CPR:4,1,"These events are stimulated by NE and by guanethidine, an hNET substrate, and they are blocked by cocaine and the antidepressant desipramine."
"These events are stimulated by << NE >> and by guanethidine, an [[ hNET ]] substrate, and they are blocked by cocaine and the antidepressant desipramine.","These events are stimulated by [ENTITY_A] and by guanethidine, an [ENTITY_B] substrate, and they are blocked by cocaine and the antidepressant desipramine.",SUBSTRATE,CPR:9,4,"These events are stimulated by NE and by guanethidine, an hNET substrate, and they are blocked by cocaine and the antidepressant desipramine."
Voltage-clamp data combined with << NE >> uptake data from these same cells indicate that [[ hNETs ]] have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode).,Voltage-clamp data combined with [ENTITY_A] uptake data from these same cells indicate that [ENTITY_B] have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode).,SUBSTRATE,CPR:9,4,Voltage-clamp data combined with NE uptake data from these same cells indicate that hNETs have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode).
"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the << mineralocorticoid receptor >> (MR) antagonist [[ RU28318 ]]; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.","In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the [ENTITY_A] (MR) antagonist [ENTITY_B]; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.",ANTAGONIST,CPR:6,3,"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting."
<< Amezinium >> and debrisoquine are substrates of uptake1 and potent inhibitors of [[ monoamine oxidase ]] in perfused lungs of rats.,[ENTITY_A] and debrisoquine are substrates of uptake1 and potent inhibitors of [ENTITY_B] in perfused lungs of rats.,INHIBITOR,CPR:4,1,Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of monoamine oxidase in perfused lungs of rats.
<< Amezinium >> and debrisoquine are substrates of [[ uptake1 ]] and potent inhibitors of monoamine oxidase in perfused lungs of rats.,[ENTITY_A] and debrisoquine are substrates of [ENTITY_B] and potent inhibitors of monoamine oxidase in perfused lungs of rats.,SUBSTRATE,CPR:9,4,Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of monoamine oxidase in perfused lungs of rats.
"Previous studies have resulted in the classification of << amezinium >> as a selective inhibitor of neuronal [[ monoamine oxidase ]] (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.","Previous studies have resulted in the classification of [ENTITY_A] as a selective inhibitor of neuronal [ENTITY_B] (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.",INHIBITOR,CPR:4,1,"Previous studies have resulted in the classification of amezinium as a selective inhibitor of neuronal monoamine oxidase (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates."
"In addition, another drug that is both a substrate of uptake1 and a << MAO >> inhibitor, [[ debrisoquine ]], was investigated in the study.","In addition, another drug that is both a substrate of uptake1 and a [ENTITY_A] inhibitor, [ENTITY_B], was investigated in the study.",INHIBITOR,CPR:4,1,"In addition, another drug that is both a substrate of uptake1 and a MAO inhibitor, debrisoquine, was investigated in the study."
"In addition, another drug that is both a substrate of << uptake1 >> and a MAO inhibitor, [[ debrisoquine ]], was investigated in the study.","In addition, another drug that is both a substrate of [ENTITY_A] and a MAO inhibitor, [ENTITY_B], was investigated in the study.",SUBSTRATE,CPR:9,4,"In addition, another drug that is both a substrate of uptake1 and a MAO inhibitor, debrisoquine, was investigated in the study."
"When MAO-B was also inhibited, 10 nmol/l << amezinium >> caused 84% inhibition of the deamination of noradrenaline by [[ MAO-A ]] in the lungs.","When MAO-B was also inhibited, 10 nmol/l [ENTITY_A] caused 84% inhibition of the deamination of noradrenaline by [ENTITY_B] in the lungs.",INHIBITOR,CPR:4,1,"When MAO-B was also inhibited, 10 nmol/l amezinium caused 84% inhibition of the deamination of noradrenaline by MAO-A in the lungs."
"The results when considered with previous reports in the literature show that << amezinium >> is about 1000 times more potent and debrisoquine is about 20 times more potent for [[ MAO ]] inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1.","The results when considered with previous reports in the literature show that [ENTITY_A] is about 1000 times more potent and debrisoquine is about 20 times more potent for [ENTITY_B] inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1.",INHIBITOR,CPR:4,1,"The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1."
"The results when considered with previous reports in the literature show that << amezinium >> is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by [[ uptake1 ]].","The results when considered with previous reports in the literature show that [ENTITY_A] is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by [ENTITY_B].",SUBSTRATE,CPR:9,4,"The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1."
"<< Amezinium >> is much less potent as a [[ MAO ]] inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart.","[ENTITY_A] is much less potent as a [ENTITY_B] inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart.",INHIBITOR,CPR:4,1,"Amezinium is much less potent as a MAO inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart."
"<< Amezinium >> is much less potent as a MAO inhibitor in cells with the [[ uptake2 transporter ]], such as the myocardial cells of the heart.","[ENTITY_A] is much less potent as a MAO inhibitor in cells with the [ENTITY_B], such as the myocardial cells of the heart.",SUBSTRATE,CPR:9,4,"Amezinium is much less potent as a MAO inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart."
The results also confirmed previous reports that << amezinium >> is highly selective for [[ MAO-A ]].,The results also confirmed previous reports that [ENTITY_A] is highly selective for [ENTITY_B].,INHIBITOR,CPR:4,1,The results also confirmed previous reports that amezinium is highly selective for MAO-A.
"We have investigated the effects of << CP-99,994 >> [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a [[ tachykinin NK1 receptor ]] antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.","We have investigated the effects of [ENTITY_A] [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a [ENTITY_B] antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.",ANTAGONIST,CPR:6,3,"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde."
Molecular determinants of << dofetilide >> block of [[ HERG ]] K+ channels.,Molecular determinants of [ENTITY_A] block of [ENTITY_B] K+ channels.,INHIBITOR,CPR:4,1,Molecular determinants of dofetilide block of HERG K+ channels.
"<< HERG >>/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, [[ E4031 ]], and MK-499, at submicromolar concentrations.","[ENTITY_A]/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, [ENTITY_B], and MK-499, at submicromolar concentrations.",INHIBITOR,CPR:4,1,"HERG/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations."
Treatment using a combination of testosterone and the << aromatase >> inhibitor [[ testolactone ]] may have significantly better effects on sexual function and also seizure frequency than testosterone alone.,Treatment using a combination of testosterone and the [ENTITY_A] inhibitor [ENTITY_B] may have significantly better effects on sexual function and also seizure frequency than testosterone alone.,INHIBITOR,CPR:4,1,Treatment using a combination of testosterone and the aromatase inhibitor testolactone may have significantly better effects on sexual function and also seizure frequency than testosterone alone.
"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with << DNA-topoisomerase II >> inhibitors, [[ etoposide ]] and mitoxantrone, and the alkylating agent, cyclophosphamide.","A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with [ENTITY_A] inhibitors, [ENTITY_B] and mitoxantrone, and the alkylating agent, cyclophosphamide.",INHIBITOR,CPR:4,1,"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide."
"A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with << DNA-topoisomerase II >> inhibitors, [[ etoposide ]] and mitoxantrone, and an alkylating agent, cyclophosphamide.","A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with [ENTITY_A] inhibitors, [ENTITY_B] and mitoxantrone, and an alkylating agent, cyclophosphamide.",INHIBITOR,CPR:4,1,"A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and an alkylating agent, cyclophosphamide."
"<< Selegiline >> (deprenyl), a selective, irreversible inhibitor of [[ monoamine oxidase type B ]] (MAO-B) is widely used in the treatment of Parkinson's disease.","[ENTITY_A] (deprenyl), a selective, irreversible inhibitor of [ENTITY_B] (MAO-B) is widely used in the treatment of Parkinson's disease.",INHIBITOR,CPR:4,1,"Selegiline (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B) is widely used in the treatment of Parkinson's disease."
"Unlike the nonselective << MAO >> inhibitors, [[ selegiline ]] does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.","Unlike the nonselective [ENTITY_A] inhibitors, [ENTITY_B] does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.",INHIBITOR,CPR:4,1,"Unlike the nonselective MAO inhibitors, selegiline does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease."
"A low tyramine diet is recommended if << selegiline >> is used together with nonselective [[ MAO ]] inhibitors or the selective, reversible MAO-A inhibitor, moclobemide.","A low tyramine diet is recommended if [ENTITY_A] is used together with nonselective [ENTITY_B] inhibitors or the selective, reversible MAO-A inhibitor, moclobemide.",INHIBITOR,CPR:4,1,"A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible MAO-A inhibitor, moclobemide."
<< Ibuprofen >> inhibits [[ cystic fibrosis transmembrane conductance regulator ]]-mediated Cl- secretion.,[ENTITY_A] inhibits [ENTITY_B]-mediated Cl- secretion.,INHIBITOR,CPR:4,1,Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator-mediated Cl- secretion.
<< Ibuprofen >> (300 microM) reduced [[ CFTR ]] Cl- current by 60+/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+/-0.04 pA to 0.59+/-0.04 pA (n = 3).,[ENTITY_A] (300 microM) reduced [ENTITY_B] Cl- current by 60+/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+/-0.04 pA to 0.59+/-0.04 pA (n = 3).,INHIBITOR,CPR:4,1,Ibuprofen (300 microM) reduced CFTR Cl- current by 60+/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+/-0.04 pA to 0.59+/-0.04 pA (n = 3).
"Similarly, << salicylic acid >> (3 mM) reduced [[ CFTR ]] Cl- current by 50+/-8% with an apparent reduction in single channel amplitude from 1.08+/-0.03 pA to 0.48+/-0.06 pA (n = 4).","Similarly, [ENTITY_A] (3 mM) reduced [ENTITY_B] Cl- current by 50+/-8% with an apparent reduction in single channel amplitude from 1.08+/-0.03 pA to 0.48+/-0.06 pA (n = 4).",INHIBITOR,CPR:4,1,"Similarly, salicylic acid (3 mM) reduced CFTR Cl- current by 50+/-8% with an apparent reduction in single channel amplitude from 1.08+/-0.03 pA to 0.48+/-0.06 pA (n = 4)."
"Based on these results, we conclude that the NSAIDs << ibuprofen >> and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of [[ CFTR ]] Cl- channels as well as basolateral membrane K+ channels.","Based on these results, we conclude that the NSAIDs [ENTITY_A] and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of [ENTITY_B] Cl- channels as well as basolateral membrane K+ channels.",INHIBITOR,CPR:4,1,"Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane K+ channels."
"Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in << plasma prolactin >> and ACTH levels after i.v. [[ mCPP ]], pointing to a general state of arousal in these mCPP-treated animals.","Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in [ENTITY_A] and ACTH levels after i.v. [ENTITY_B], pointing to a general state of arousal in these mCPP-treated animals.",INDIRECT-UPREGULATOR,CPR:3,0,"Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in plasma prolactin and ACTH levels after i.v. mCPP, pointing to a general state of arousal in these mCPP-treated animals."
"These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective << 5-HT2A >>/5-HT2C antagonist [[ ritanserin ]].","These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective [ENTITY_A]/5-HT2C antagonist [ENTITY_B].",ANTAGONIST,CPR:6,3,"These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin."
"The cardiovascular effects of three different << acetylcholinesterase >> inhibitors: [[ physostigmine ]], tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats.","The cardiovascular effects of three different [ENTITY_A] inhibitors: [ENTITY_B], tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats.",INHIBITOR,CPR:4,1,"The cardiovascular effects of three different acetylcholinesterase inhibitors: physostigmine, tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats."
<< Tacrine >> was chosen as a model to study the mechanisms underlying the cardiovascular effects of i.v. [[ cholinesterase ]] inhibitors.,[ENTITY_A] was chosen as a model to study the mechanisms underlying the cardiovascular effects of i.v. [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Tacrine was chosen as a model to study the mechanisms underlying the cardiovascular effects of i.v. cholinesterase inhibitors.
"The << alpha1-adrenoceptor >> antagonist [[ prazosin ]] or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.","The [ENTITY_A] antagonist [ENTITY_B] or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.",ANTAGONIST,CPR:6,3,"The alpha1-adrenoceptor antagonist prazosin or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly."
"The tacrine pressor response was inhibited in a dose-dependent manner by the i.c.v. administration of the non-selective << muscarinic receptor >> antagonist [[ atropine ]] (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).","The tacrine pressor response was inhibited in a dose-dependent manner by the i.c.v. administration of the non-selective [ENTITY_A] antagonist [ENTITY_B] (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).",ANTAGONIST,CPR:6,3,"The tacrine pressor response was inhibited in a dose-dependent manner by the i.c.v. administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)."
"State-dependent << cocaine >> block of [[ sodium channel ]] isoforms, chimeras, and channels coexpressed with the beta1 subunit.","State-dependent [ENTITY_A] block of [ENTITY_B] isoforms, chimeras, and channels coexpressed with the beta1 subunit.",INHIBITOR,CPR:4,1,"State-dependent cocaine block of sodium channel isoforms, chimeras, and channels coexpressed with the beta1 subunit."
<< Cocaine >> block of [[ human cardiac (hH1) ]] and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.,[ENTITY_A] block of [ENTITY_B] and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.,INHIBITOR,CPR:4,1,Cocaine block of human cardiac (hH1) and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.
"<< Cocaine >> block of [[ hH1 channels ]] was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.","[ENTITY_A] block of [ENTITY_B] was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.",INHIBITOR,CPR:4,1,"Cocaine block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block."
<< Androgen >> antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated [[ androgen receptor ]].,[ENTITY_A] antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated [ENTITY_B].,ANTAGONIST,CPR:6,3,Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.
"Down-regulation of << prostate-specific antigen >> (PSA) expression, an AR-target gene, by [[ estramustine ]] and bicalutamide was accompanied by the blockade of the mutated androgen receptor.","Down-regulation of [ENTITY_A] (PSA) expression, an AR-target gene, by [ENTITY_B] and bicalutamide was accompanied by the blockade of the mutated androgen receptor.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated androgen receptor."
Exposure of LNCaP cells to << estramustine >> for 24 hr caused transcriptional inhibition of [[ PSA ]] in a concentration-dependent manner.,Exposure of LNCaP cells to [ENTITY_A] for 24 hr caused transcriptional inhibition of [ENTITY_B] in a concentration-dependent manner.,INHIBITOR,CPR:4,1,Exposure of LNCaP cells to estramustine for 24 hr caused transcriptional inhibition of PSA in a concentration-dependent manner.
"The levels of << PSA >> mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of [[ estramustine ]], respectively (IC50 = 10.97 +/- 1.68 microM).","The levels of [ENTITY_A] mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of [ENTITY_B], respectively (IC50 = 10.97 +/- 1.68 microM).",INDIRECT-DOWNREGULATOR,CPR:4,1,"The levels of PSA mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of estramustine, respectively (IC50 = 10.97 +/- 1.68 microM)."
"Binding of << hydroxyflutamide >> to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of [[ PSA ]] expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR.","Binding of [ENTITY_A] to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of [ENTITY_B] expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR.",INDIRECT-UPREGULATOR,CPR:3,0,"Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR."
"Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that << hydroxyflutamide >> acted as an agonist of the m-[[ AR ]].","Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that [ENTITY_A] acted as an agonist of the m-[ENTITY_B].",AGONIST,CPR:5,2,"Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR."
"Our data indicate that << estramustine phosphate >> metabolites perform as androgen antagonists of [[ AR ]], an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.","Our data indicate that [ENTITY_A] metabolites perform as androgen antagonists of [ENTITY_B], an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.",ANTAGONIST,CPR:6,3,"Our data indicate that estramustine phosphate metabolites perform as androgen antagonists of AR, an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer."
"In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of << Torpedo californica AChE >> soaked with the reversible inhibitor [[ edrophonium ]], using a total X-ray exposure time of 24 ms.","In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of [ENTITY_A] soaked with the reversible inhibitor [ENTITY_B], using a total X-ray exposure time of 24 ms.",INHIBITOR,CPR:4,1,"In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of Torpedo californica AChE soaked with the reversible inhibitor edrophonium, using a total X-ray exposure time of 24 ms."
Selective inhibition of << cyclooxygenase 2 >> spares renal function and [[ prostaglandin ]] synthesis in cirrhotic rats with ascites.,Selective inhibition of [ENTITY_A] spares renal function and [ENTITY_B] synthesis in cirrhotic rats with ascites.,PRODUCT-OF,CPR:9,4,Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites.
The current study evaluates the effects of a selective << COX-2 >> inhibitor ([[ SC-236 ]]) on renal function in cirrhotic rats with ascites.,The current study evaluates the effects of a selective [ENTITY_A] inhibitor ([ENTITY_B]) on renal function in cirrhotic rats with ascites.,INHIBITOR,CPR:4,1,The current study evaluates the effects of a selective COX-2 inhibitor (SC-236) on renal function in cirrhotic rats with ascites.
"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective << COX-1 >>/COX-2 inhibitor, [[ ketorolac ]], resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism.","RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective [ENTITY_A]/COX-2 inhibitor, [ENTITY_B], resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism.",INHIBITOR,CPR:4,1,"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism."
"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective << COX-1 >>/COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of [[ prostaglandins ]], and glomerular filtration rate and in a significant impairment in renal water metabolism.","RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective [ENTITY_A]/COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of [ENTITY_B], and glomerular filtration rate and in a significant impairment in renal water metabolism.",PRODUCT-OF,CPR:9,4,"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism."
Inhibition of << cPLA2 >> translocation and leukotriene C4 secretion by [[ fluticasone propionate ]] in exogenously activated human eosinophils.,Inhibition of [ENTITY_A] translocation and leukotriene C4 secretion by [ENTITY_B] in exogenously activated human eosinophils.,INDIRECT-DOWNREGULATOR,CPR:4,1,Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils.
FMLP/CB-stimulated translocation of << cPLA2 >> to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by [[ FP ]].,FMLP/CB-stimulated translocation of [ENTITY_A] to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by [ENTITY_B].,INDIRECT-DOWNREGULATOR,CPR:4,1,FMLP/CB-stimulated translocation of cPLA2 to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by FP.
We find that << FP >> causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by [[ phospholipase A2 ]] (PLA2).,We find that [ENTITY_A] causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by [ENTITY_B] (PLA2).,INDIRECT-DOWNREGULATOR,CPR:4,1,We find that FP causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by phospholipase A2 (PLA2).
We find that FP causes a decrease in stimulated eosinophil secretion of << LTC4 >> that is regulated by [[ phospholipase A2 ]] (PLA2).,We find that FP causes a decrease in stimulated eosinophil secretion of [ENTITY_A] that is regulated by [ENTITY_B] (PLA2).,PRODUCT-OF,CPR:9,4,We find that FP causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by phospholipase A2 (PLA2).
Inhibition of LTC4 synthesis precedes the global cytotoxic effects of << FP >> as indicated by the simultaneous upregulation of [[ annexin-1 ]] expression.,Inhibition of LTC4 synthesis precedes the global cytotoxic effects of [ENTITY_A] as indicated by the simultaneous upregulation of [ENTITY_B] expression.,INDIRECT-UPREGULATOR,CPR:3,0,Inhibition of LTC4 synthesis precedes the global cytotoxic effects of FP as indicated by the simultaneous upregulation of annexin-1 expression.
<< Desipramine >> treatment decreases 3H-nisoxetine binding and [[ norepinephrine transporter ]] mRNA in SK-N-SHSY5Y cells.,[ENTITY_A] treatment decreases 3H-nisoxetine binding and [ENTITY_B] mRNA in SK-N-SHSY5Y cells.,INDIRECT-DOWNREGULATOR,CPR:4,1,Desipramine treatment decreases 3H-nisoxetine binding and norepinephrine transporter mRNA in SK-N-SHSY5Y cells.
"The antidepressant << desipramine >> has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter ([[ NET ]]) in vivo and in vitro, on both an acute and a chronic basis.","The antidepressant [ENTITY_A] has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter ([ENTITY_B]) in vivo and in vitro, on both an acute and a chronic basis.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The antidepressant desipramine has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter (NET) in vivo and in vitro, on both an acute and a chronic basis."
"We conclude that decreased NET synthesis may contribute to the chronic, but not acute, effect of << desipramine >> to downregulate the [[ NET ]].","We conclude that decreased NET synthesis may contribute to the chronic, but not acute, effect of [ENTITY_A] to downregulate the [ENTITY_B].",DOWNREGULATOR,CPR:4,1,"We conclude that decreased NET synthesis may contribute to the chronic, but not acute, effect of desipramine to downregulate the NET."
Inhibition of the << human ether-a-go-go-related gene (HERG) potassium channel >> by [[ cisapride ]]: affinity for open and inactivated states.,Inhibition of the [ENTITY_A] by [ENTITY_B]: affinity for open and inactivated states.,INHIBITOR,CPR:4,1,Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states.
"2 In a chronic transfection model using CHO-K1 cells, << cisapride >> inhibited [[ HERG ]] tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16. 4 nM at 20-22 degrees C and 23.6 nM at 37 degrees C).","2 In a chronic transfection model using CHO-K1 cells, [ENTITY_A] inhibited [ENTITY_B] tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16. 4 nM at 20-22 degrees C and 23.6 nM at 37 degrees C).",INHIBITOR,CPR:4,1,"2 In a chronic transfection model using CHO-K1 cells, cisapride inhibited HERG tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16. 4 nM at 20-22 degrees C and 23.6 nM at 37 degrees C)."
"6 In conclusion, << HERG >> channel inhibition by [[ cisapride ]] exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration.","6 In conclusion, [ENTITY_A] channel inhibition by [ENTITY_B] exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration.",INHIBITOR,CPR:4,1,"6 In conclusion, HERG channel inhibition by cisapride exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration."
"While it is an antagonist at these latter receptors, << ziprasidone >> behaves as a [[ 5-HT1A ]] agonist in vitro in adenylate cyclase measurements.","While it is an antagonist at these latter receptors, [ENTITY_A] behaves as a [ENTITY_B] agonist in vitro in adenylate cyclase measurements.",AGONIST,CPR:5,2,"While it is an antagonist at these latter receptors, ziprasidone behaves as a 5-HT1A agonist in vitro in adenylate cyclase measurements."
"Pretreatment with the << 5-HT1A >> antagonist [[ WAY-100,635 ]] (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine.","Pretreatment with the [ENTITY_A] antagonist [ENTITY_B] (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine.",ANTAGONIST,CPR:6,3,"Pretreatment with the 5-HT1A antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine."
"These profiles suggest a mechanism of action for each agent, << 5-HT1A >> agonism for [[ ziprasidone ]] and alpha 1 antagonism for clozapine and olanzapine.","These profiles suggest a mechanism of action for each agent, [ENTITY_A] agonism for [ENTITY_B] and alpha 1 antagonism for clozapine and olanzapine.",AGONIST,CPR:5,2,"These profiles suggest a mechanism of action for each agent, 5-HT1A agonism for ziprasidone and alpha 1 antagonism for clozapine and olanzapine."
The << 5-HT1A >> agonist activity reported here clearly distinguishes [[ ziprasidone ]] from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.,The [ENTITY_A] agonist activity reported here clearly distinguishes [ENTITY_B] from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.,AGONIST,CPR:5,2,The 5-HT1A agonist activity reported here clearly distinguishes ziprasidone from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.
"The nonselective and irreversible << MAO >> inhibitors, [[ phenelzine ]] (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement.","The nonselective and irreversible [ENTITY_A] inhibitors, [ENTITY_B] (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement.",INHIBITOR,CPR:4,1,"The nonselective and irreversible MAO inhibitors, phenelzine (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement."
"The reversible << MAO-A >> inhibitor, [[ befloxatone ]] (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration.","The reversible [ENTITY_A] inhibitor, [ENTITY_B] (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration.",INHIBITOR,CPR:4,1,"The reversible MAO-A inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration."
"The irreversible << MAO-B >> inhibitors, [[ pargyline ]] (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice.","The irreversible [ENTITY_A] inhibitors, [ENTITY_B] (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice.",INHIBITOR,CPR:4,1,"The irreversible MAO-B inhibitors, pargyline (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice."
"<< Dicumarol >>, a potent inhibitor of [[ quinone oxidoreductase ]], at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin.","[ENTITY_A], a potent inhibitor of [ENTITY_B], at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin.",INHIBITOR,CPR:4,1,"Dicumarol, a potent inhibitor of quinone oxidoreductase, at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin."
"Activity of the mutant << delta-aminolevulinate synthase >> protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of [[ pyridoxal 5'-phosphate ]], consistent with the clinical response of the patient to pyridoxine treatment.","Activity of the mutant [ENTITY_A] protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of [ENTITY_B], consistent with the clinical response of the patient to pyridoxine treatment.",ACTIVATOR,CPR:3,0,"Activity of the mutant delta-aminolevulinate synthase protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of pyridoxal 5'-phosphate, consistent with the clinical response of the patient to pyridoxine treatment."
Preferential cerebrospinal fluid << acetylcholinesterase >> inhibition by [[ rivastigmine ]] in humans.,Preferential cerebrospinal fluid [ENTITY_A] inhibition by [ENTITY_B] in humans.,INHIBITOR,CPR:4,1,Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.
Inhibition of << AChE >> in the CSF after [[ rivastigmine ]] administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours.,Inhibition of [ENTITY_A] in the CSF after [ENTITY_B] administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours.,INHIBITOR,CPR:4,1,Inhibition of AChE in the CSF after rivastigmine administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours.
"Plasma << BuChE >> activity was significantly lower after [[ rivastigmine ]] than after placebo, but this was not clinically relevant.","Plasma [ENTITY_A] activity was significantly lower after [ENTITY_B] than after placebo, but this was not clinically relevant.",INHIBITOR,CPR:4,1,"Plasma BuChE activity was significantly lower after rivastigmine than after placebo, but this was not clinically relevant."
"<< BuChE >> activity in CSF was significantly lower after [[ rivastigmine ]] than after placebo for up to 3.6 hours after dosing, but this difference was not sustained.","[ENTITY_A] activity in CSF was significantly lower after [ENTITY_B] than after placebo for up to 3.6 hours after dosing, but this difference was not sustained.",INHIBITOR,CPR:4,1,"BuChE activity in CSF was significantly lower after rivastigmine than after placebo for up to 3.6 hours after dosing, but this difference was not sustained."
"This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that << rivastigmine >> markedly inhibits CSF [[ AChE ]] after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE.","This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that [ENTITY_A] markedly inhibits CSF [ENTITY_B] after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE.",INHIBITOR,CPR:4,1,"This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that rivastigmine markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE."
"Agonist and antagonist actions of << yohimbine >> as compared to fluparoxan at alpha(2)-adrenergic receptors [[ (AR)s ]], serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.","Agonist and antagonist actions of [ENTITY_A] as compared to fluparoxan at alpha(2)-adrenergic receptors [ENTITY_B], serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",AGONIST,CPR:5,2,"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors."
"Agonist and antagonist actions of << yohimbine >> as compared to fluparoxan at alpha(2)-adrenergic receptors [[ (AR)s ]], serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.","Agonist and antagonist actions of [ENTITY_A] as compared to fluparoxan at alpha(2)-adrenergic receptors [ENTITY_B], serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",ANTAGONIST,CPR:6,3,"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors."
"Herein, we evaluate the interaction of the << alpha(2)-AR antagonist >>, [[ yohimbine ]], as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.","Herein, we evaluate the interaction of the [ENTITY_A], [ENTITY_B], as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.",ANTAGONIST,CPR:6,3,"Herein, we evaluate the interaction of the alpha(2)-AR antagonist, yohimbine, as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats."
"In [(35)S]GTPgammaS binding protocols, << yohimbine >> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at [[ h5-HT(1A) ]] sites.","In [(35)S]GTPgammaS binding protocols, [ENTITY_A] exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at [ENTITY_B] sites.",AGONIST,CPR:5,2,"In [(35)S]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites."
"In [(35)S]GTPgammaS binding protocols, << yohimbine >> exerts antagonist actions at [[ halpha(2A)-AR ]], h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.","In [(35)S]GTPgammaS binding protocols, [ENTITY_A] exerts antagonist actions at [ENTITY_B], h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.",ANTAGONIST,CPR:6,3,"In [(35)S]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites."
"In vivo, agonist actions of << yohimbine >> at [[ 5-HT(1A) ]] sites are revealed by WAY100,635-reversible induction of hypothermia in the rat.","In vivo, agonist actions of [ENTITY_A] at [ENTITY_B] sites are revealed by WAY100,635-reversible induction of hypothermia in the rat.",AGONIST,CPR:5,2,"In vivo, agonist actions of yohimbine at 5-HT(1A) sites are revealed by WAY100,635-reversible induction of hypothermia in the rat."
"In vivo, agonist actions of yohimbine at << 5-HT(1A) >> sites are revealed by [[ WAY100,635 ]]-reversible induction of hypothermia in the rat.","In vivo, agonist actions of yohimbine at [ENTITY_A] sites are revealed by [ENTITY_B]-reversible induction of hypothermia in the rat.",ANTAGONIST,CPR:6,3,"In vivo, agonist actions of yohimbine at 5-HT(1A) sites are revealed by WAY100,635-reversible induction of hypothermia in the rat."
"In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the << 5-HT(1B) >> agonist, [[ GR46,611 ]].","In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the [ENTITY_A] agonist, [ENTITY_B].",AGONIST,CPR:5,2,"In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611."
"In guinea pigs, antagonist actions of << yohimbine >> at [[ 5-HT(1B) ]] receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611.","In guinea pigs, antagonist actions of [ENTITY_A] at [ENTITY_B] receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611.",ANTAGONIST,CPR:6,3,"In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611."
"In distinction to << yohimbine >>, fluparoxan shows only modest partial agonist actions at [[ h5-HT(1A) ]] sites versus marked antagonist actions at halpha(2)-ARs.","In distinction to [ENTITY_A], fluparoxan shows only modest partial agonist actions at [ENTITY_B] sites versus marked antagonist actions at halpha(2)-ARs.",AGONIST,CPR:5,2,"In distinction to yohimbine, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at halpha(2)-ARs."
"In distinction to << yohimbine >>, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at [[ halpha(2)-ARs ]].","In distinction to [ENTITY_A], fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at [ENTITY_B].",ANTAGONIST,CPR:6,3,"In distinction to yohimbine, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at halpha(2)-ARs."
"In conclusion, the << alpha(2)-AR >> antagonist properties of [[ yohimbine ]] increase DA and NAD levels both alone and in association with fluoxetine.","In conclusion, the [ENTITY_A] antagonist properties of [ENTITY_B] increase DA and NAD levels both alone and in association with fluoxetine.",ANTAGONIST,CPR:6,3,"In conclusion, the alpha(2)-AR antagonist properties of yohimbine increase DA and NAD levels both alone and in association with fluoxetine."
"However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the << 5-HT(1A) >> agonist actions of [[ yohimbine ]] suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.","However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the [ENTITY_A] agonist actions of [ENTITY_B] suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.",AGONIST,CPR:5,2,"However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels."
"However, in contrast to the selective << alpha(2)-AR >> antagonist, [[ fluparoxan ]], the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.","However, in contrast to the selective [ENTITY_A] antagonist, [ENTITY_B], the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.",ANTAGONIST,CPR:6,3,"However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels."
"In this study, the activity of the << delta-opioid receptor >> subtype-selective agonist, [[ SB 227122 ]], was investigated in a guinea pig model of citric acid-induced cough.","In this study, the activity of the [ENTITY_A] subtype-selective agonist, [ENTITY_B], was investigated in a guinea pig model of citric acid-induced cough.",AGONIST,CPR:5,2,"In this study, the activity of the delta-opioid receptor subtype-selective agonist, SB 227122, was investigated in a guinea pig model of citric acid-induced cough."
"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and << kappa-opioid receptor >> ([[ BRL 52974 ]]) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.","Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and [ENTITY_A] ([ENTITY_B]) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.",AGONIST,CPR:5,2,"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively."
"The nonselective << opioid receptor >> antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of [[ codeine ]] or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated.","The nonselective [ENTITY_A] antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of [ENTITY_B] or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated.",AGONIST,CPR:5,2,"The nonselective opioid receptor antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated."
"The nonselective << opioid receptor >> antagonist, [[ naloxone ]] (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated.","The nonselective [ENTITY_A] antagonist, [ENTITY_B] (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated.",ANTAGONIST,CPR:6,3,"The nonselective opioid receptor antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated."
"The << delta-receptor >> antagonist, SB 244525 (10 mg/kg, i.p.), inhibited the antitussive effect of [[ SB 227122 ]] (20 mg/kg, i.p.).","The [ENTITY_A] antagonist, SB 244525 (10 mg/kg, i.p.), inhibited the antitussive effect of [ENTITY_B] (20 mg/kg, i.p.).",AGONIST,CPR:5,2,"The delta-receptor antagonist, SB 244525 (10 mg/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg/kg, i.p.)."
"The << delta-receptor >> antagonist, [[ SB 244525 ]] (10 mg/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg/kg, i.p.).","The [ENTITY_A] antagonist, [ENTITY_B] (10 mg/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg/kg, i.p.).",ANTAGONIST,CPR:6,3,"The delta-receptor antagonist, SB 244525 (10 mg/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg/kg, i.p.)."
"In contrast, combined pretreatment with << beta-funaltrexamine >> ([[ mu-receptor ]] antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).","In contrast, combined pretreatment with [ENTITY_A] ([ENTITY_B] antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).",ANTAGONIST,CPR:6,3,"In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.)."
"The << sigma-receptor >> antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of [[ dextromethorphan ]] (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122.","The [ENTITY_A] antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of [ENTITY_B] (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122.",AGONIST,CPR:5,2,"The sigma-receptor antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122."
"The << sigma-receptor >> antagonist [[ rimcazole ]] (3 mg/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122.","The [ENTITY_A] antagonist [ENTITY_B] (3 mg/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122.",ANTAGONIST,CPR:6,3,"The sigma-receptor antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122."
These studies provide compelling evidence that the antitussive effects of << SB 227122 >> in this guinea pig cough model are mediated by agonist activity at the [[ delta-opioid receptor ]].,These studies provide compelling evidence that the antitussive effects of [ENTITY_A] in this guinea pig cough model are mediated by agonist activity at the [ENTITY_B].,AGONIST,CPR:5,2,These studies provide compelling evidence that the antitussive effects of SB 227122 in this guinea pig cough model are mediated by agonist activity at the delta-opioid receptor.
"New modes of therapy have recently been introduced, and data on the << cyclooxygenase-2 >> (COX-2)-specific inhibitors [[ celecoxib ]] and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.","New modes of therapy have recently been introduced, and data on the [ENTITY_A] (COX-2)-specific inhibitors [ENTITY_B] and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.",INHIBITOR,CPR:4,1,"New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (COX-2)-specific inhibitors celecoxib and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs."
"Kinetics of inhibition of << human and rat dihydroorotate dehydrogenase >> by atovaquone, lawsone derivatives, [[ brequinar sodium ]] and polyporic acid.","Kinetics of inhibition of [ENTITY_A] by atovaquone, lawsone derivatives, [ENTITY_B] and polyporic acid.",INHIBITOR,CPR:4,1,"Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid."
Mitochondrially-bound << dihydroorotate dehydrogenase >> (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of [[ uridine monophosphate ]].,Mitochondrially-bound [ENTITY_A] (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of [ENTITY_B].,PRODUCT-OF,CPR:9,4,Mitochondrially-bound dihydroorotate dehydrogenase (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of uridine monophosphate.
"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, << atovaquone >> (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of [[ human dihydroorotate dehydrogenase ]].","With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, [ENTITY_A] (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of [ENTITY_B].",INHIBITOR,CPR:4,1,"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase."
"With respect to the << quinone >> co-substrate of the [[ dihydroorotate dehydrogenase ]], atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase.","With respect to the [ENTITY_A] co-substrate of the [ENTITY_B], atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase.",SUBSTRATE,CPR:9,4,"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase."
"<< Dichloroally]-lawsone >> was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for [[ mammalian dihydroorotate dehydrogenases ]].","[ENTITY_A] was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for [ENTITY_B].",INHIBITOR,CPR:4,1,"Dichloroally]-lawsone was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for mammalian dihydroorotate dehydrogenases."
"Another inhibitor, << brequinar >> was previously reported to be a slow-binding inhibitor of the [[ human dihydroorotate dehydrogenase ]] [W. Knecht, M. Loffler, Species-related inhibition of human and rat dihyroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem. Pharmacol. 56 (1998) 1259-1264].","Another inhibitor, [ENTITY_A] was previously reported to be a slow-binding inhibitor of the [ENTITY_B] [W. Knecht, M. Loffler, Species-related inhibition of human and rat dihyroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem. Pharmacol. 56 (1998) 1259-1264].",INHIBITOR,CPR:4,1,"Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W. Knecht, M. Loffler, Species-related inhibition of human and rat dihyroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem. Pharmacol. 56 (1998) 1259-1264]."
"With respect to the substrate << dihydroorotate >>, atovaquone was an uncompetitive inhibitor of [[ human dihydroorotate dehydrogenase ]] (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM).","With respect to the substrate [ENTITY_A], atovaquone was an uncompetitive inhibitor of [ENTITY_B] (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM).",INHIBITOR,CPR:4,1,"With respect to the substrate dihydroorotate, atovaquone was an uncompetitive inhibitor of human dihydroorotate dehydrogenase (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM)."
Determinants of voltage-dependent inactivation affect << Mibefradil >> block of [[ calcium channels ]].,Determinants of voltage-dependent inactivation affect [ENTITY_A] block of [ENTITY_B].,INHIBITOR,CPR:4,1,Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels.
<< Mibefradil >> (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block [[ T-type Ca2+ channels ]].,[ENTITY_A] (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block [ENTITY_B].,INHIBITOR,CPR:4,1,Mibefradil (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block T-type Ca2+ channels.
"<< Mibefradil >> blocked alpha1A and alpha1E with a Kd comparable to that reported for [[ T-type channels ]], but had a lower affinity (approximately 30-fold) for alpha1C.","[ENTITY_A] blocked alpha1A and alpha1E with a Kd comparable to that reported for [ENTITY_B], but had a lower affinity (approximately 30-fold) for alpha1C.",INHIBITOR,CPR:4,1,"Mibefradil blocked alpha1A and alpha1E with a Kd comparable to that reported for T-type channels, but had a lower affinity (approximately 30-fold) for alpha1C."
Postoperative concentrations of << plasminogen >> were decreased significantly in the [[ tranexamic acid ]] group (P < 0.001).,Postoperative concentrations of [ENTITY_A] were decreased significantly in the [ENTITY_B] group (P < 0.001).,INDIRECT-DOWNREGULATOR,CPR:4,1,Postoperative concentrations of plasminogen were decreased significantly in the tranexamic acid group (P < 0.001).
"Iontophoresis of << +/- propranolol >>, whose serotonergic actions include antagonism and partial agonism at [[ 5-HT1 ]] receptors, also increased serotonin and decreased firing (n=4).","Iontophoresis of [ENTITY_A], whose serotonergic actions include antagonism and partial agonism at [ENTITY_B] receptors, also increased serotonin and decreased firing (n=4).",AGONIST,CPR:5,2,"Iontophoresis of +/- propranolol, whose serotonergic actions include antagonism and partial agonism at 5-HT1 receptors, also increased serotonin and decreased firing (n=4)."
"Iontophoresis of << +/- propranolol >>, whose serotonergic actions include antagonism and partial agonism at [[ 5-HT1 ]] receptors, also increased serotonin and decreased firing (n=4).","Iontophoresis of [ENTITY_A], whose serotonergic actions include antagonism and partial agonism at [ENTITY_B] receptors, also increased serotonin and decreased firing (n=4).",ANTAGONIST,CPR:6,3,"Iontophoresis of +/- propranolol, whose serotonergic actions include antagonism and partial agonism at 5-HT1 receptors, also increased serotonin and decreased firing (n=4)."
"<< Methiothepin >> (intravenous, 1 mg/kg), whose serotonergic actions include [[ 5-HT1 ]] and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).","[ENTITY_A] (intravenous, 1 mg/kg), whose serotonergic actions include [ENTITY_B] and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).",ANTAGONIST,CPR:6,3,"Methiothepin (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)."
The << Hsp90 >>-specific inhibitor [[ geldanamycin ]] selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.,The [ENTITY_A]-specific inhibitor [ENTITY_B] selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.,INHIBITOR,CPR:4,1,The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.
Improper function of these proteins can be induced by selective disruption of their complexes with << Hsp90 >> using the [[ benzoquinonoid ansamycin ]] geldanamycin.,Improper function of these proteins can be induced by selective disruption of their complexes with [ENTITY_A] using the [ENTITY_B] geldanamycin.,INHIBITOR,CPR:4,1,Improper function of these proteins can be induced by selective disruption of their complexes with Hsp90 using the benzoquinonoid ansamycin geldanamycin.
"In this study, we demonstrate that << geldanamycin >> treatment blocks [[ interleukin (IL)-2 ]] secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes.","In this study, we demonstrate that [ENTITY_A] treatment blocks [ENTITY_B] secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In this study, we demonstrate that geldanamycin treatment blocks interleukin (IL)-2 secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes."
"Moreover, << geldanamycin >> decreases the amount and phosphorylation of [[ Lck ]] and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.","Moreover, [ENTITY_A] decreases the amount and phosphorylation of [ENTITY_B] and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, geldanamycin decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase."
<< Geldanamycin >> also disrupts the [[ T-cell receptor ]]-mediated activation of nuclear factor of activated T-cells (NF-AT).,[ENTITY_A] also disrupts the [ENTITY_B]-mediated activation of nuclear factor of activated T-cells (NF-AT).,INHIBITOR,CPR:4,1,Geldanamycin also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells (NF-AT).
"Through demonstrating the selective inhibition of << kinase >>-related T-lymphocyte responses by [[ geldanamycin ]], our results emphasize the substantial role of Hsp90-kinase complexes in T-cell activation.","Through demonstrating the selective inhibition of [ENTITY_A]-related T-lymphocyte responses by [ENTITY_B], our results emphasize the substantial role of Hsp90-kinase complexes in T-cell activation.",INHIBITOR,CPR:4,1,"Through demonstrating the selective inhibition of kinase-related T-lymphocyte responses by geldanamycin, our results emphasize the substantial role of Hsp90-kinase complexes in T-cell activation."
"<< gamma-Butyrobetaine hydroxylase >> catalyse the last step in [[ carnitine ]] biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.","[ENTITY_A] catalyse the last step in [ENTITY_B] biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.",PRODUCT-OF,CPR:9,4,"gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen."
Inhibition of the actions of << ET-1 >> by [[ salicylates ]] is apparently competitive.,Inhibition of the actions of [ENTITY_A] by [ENTITY_B] is apparently competitive.,INHIBITOR,CPR:4,1,Inhibition of the actions of ET-1 by salicylates is apparently competitive.
A unique cytosolic activity related but distinct from << NQO1 >> catalyses metabolic activation of [[ mitomycin C ]].,A unique cytosolic activity related but distinct from [ENTITY_A] catalyses metabolic activation of [ENTITY_B].,SUBSTRATE,CPR:9,4,A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C.
"Among the various enzymes, << dicoumarol >> inhibitable cytosolic [[ NAD(P)H:quinone oxidoreductase1 ]] (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.","Among the various enzymes, [ENTITY_A] inhibitable cytosolic [ENTITY_B] (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.",INHIBITOR,CPR:4,1,"Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity."
"Among the various enzymes, dicoumarol inhibitable cytosolic << NAD(P)H:quinone oxidoreductase1 >> (NQO1) was shown to catalyse bioreductive activation of [[ MMC ]] leading to cross-linking of the DNA and cytotoxicity.","Among the various enzymes, dicoumarol inhibitable cytosolic [ENTITY_A] (NQO1) was shown to catalyse bioreductive activation of [ENTITY_B] leading to cross-linking of the DNA and cytotoxicity.",SUBSTRATE,CPR:9,4,"Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity."
"However, the role of << NQO1 >> in metabolic activation of [[ MMC ]] has been disputed.","However, the role of [ENTITY_A] in metabolic activation of [ENTITY_B] has been disputed.",SUBSTRATE,CPR:9,4,"However, the role of NQO1 in metabolic activation of MMC has been disputed."
"In this report, we present cellular and animal models to demonstrate that << NQO1 >> may play only a minor role in metabolic activation of [[ MMC ]].","In this report, we present cellular and animal models to demonstrate that [ENTITY_A] may play only a minor role in metabolic activation of [ENTITY_B].",SUBSTRATE,CPR:9,4,"In this report, we present cellular and animal models to demonstrate that NQO1 may play only a minor role in metabolic activation of MMC."
"This activity, like << NQO1 >>, was inhibited by [[ dicoumarol ]] and immunologically related to NQO1.","This activity, like [ENTITY_A], was inhibited by [ENTITY_B] and immunologically related to NQO1.",INHIBITOR,CPR:4,1,"This activity, like NQO1, was inhibited by dicoumarol and immunologically related to NQO1."
<< Troglitazone >> reduces [[ plasminogen activator inhibitor-1 ]] expression and secretion in cultured human adipocytes.,[ENTITY_A] reduces [ENTITY_B] expression and secretion in cultured human adipocytes.,INDIRECT-DOWNREGULATOR,CPR:4,1,Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes.
RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml << troglitazone >> for 72 h caused a reduction of both [[ PAI-1 ]] secretion (by 29 +/- 5%; p < 0.01) and PAI-1 mRNA expression (by 26 +/- 3%; p < 0.05).,RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml [ENTITY_A] for 72 h caused a reduction of both [ENTITY_B] secretion (by 29 +/- 5%; p < 0.01) and PAI-1 mRNA expression (by 26 +/- 3%; p < 0.05).,INDIRECT-DOWNREGULATOR,CPR:4,1,RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml troglitazone for 72 h caused a reduction of both PAI-1 secretion (by 29 +/- 5%; p < 0.01) and PAI-1 mRNA expression (by 26 +/- 3%; p < 0.05).
"In cultures from severely obese subjects, << troglitazone >> induced a decrease of [[ PAI-1 ]] antigen secretion from newly differentiated omental adipocytes by 49 +/- 8% (p < 0.01) and from subcutaneous adipocytes by 30 +/- 7% (p < 0.05).","In cultures from severely obese subjects, [ENTITY_A] induced a decrease of [ENTITY_B] antigen secretion from newly differentiated omental adipocytes by 49 +/- 8% (p < 0.01) and from subcutaneous adipocytes by 30 +/- 7% (p < 0.05).",INDIRECT-DOWNREGULATOR,CPR:4,1,"In cultures from severely obese subjects, troglitazone induced a decrease of PAI-1 antigen secretion from newly differentiated omental adipocytes by 49 +/- 8% (p < 0.01) and from subcutaneous adipocytes by 30 +/- 7% (p < 0.05)."
"Exposure of freshly isolated subcutaneous and omental adipocytes in suspension culture to << troglitazone >> induced a similar reduction of [[ PAI-1 ]] concentration in the culture medium (by 35 +/- 11%, p < 0.05, and 33 +/- 8%, p < 0.05 compared with control, respectively).","Exposure of freshly isolated subcutaneous and omental adipocytes in suspension culture to [ENTITY_A] induced a similar reduction of [ENTITY_B] concentration in the culture medium (by 35 +/- 11%, p < 0.05, and 33 +/- 8%, p < 0.05 compared with control, respectively).",INDIRECT-DOWNREGULATOR,CPR:4,1,"Exposure of freshly isolated subcutaneous and omental adipocytes in suspension culture to troglitazone induced a similar reduction of PAI-1 concentration in the culture medium (by 35 +/- 11%, p < 0.05, and 33 +/- 8%, p < 0.05 compared with control, respectively)."
"CONCLUSION/INTERPRETATION: This study provides evidence that << troglitazone >> reduces [[ PAI-1 ]] production in human adipocytes, probably at the transcriptional level.","CONCLUSION/INTERPRETATION: This study provides evidence that [ENTITY_A] reduces [ENTITY_B] production in human adipocytes, probably at the transcriptional level.",INDIRECT-DOWNREGULATOR,CPR:4,1,"CONCLUSION/INTERPRETATION: This study provides evidence that troglitazone reduces PAI-1 production in human adipocytes, probably at the transcriptional level."
"We examined the effect of JTH-601 (3- inverted question mark<< N-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom >> ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new [[ alpha(1L)-adrenoceptor ]] antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.","We examined the effect of JTH-601 (3- inverted question mark[ENTITY_A] ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new [ENTITY_B] antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.",ANTAGONIST,CPR:6,3,"We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new alpha(1L)-adrenoceptor antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs."
"In these tissues, << JTH-601 >>, prazosin (a non-selective [[ alpha(1)-adrenoceptor ]] antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.","In these tissues, [ENTITY_A], prazosin (a non-selective [ENTITY_B] antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.",ANTAGONIST,CPR:6,3,"In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner."
<< JTH-601 >> is expected to be an effective [[ alpha(1)-adrenoceptor ]] antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.,[ENTITY_A] is expected to be an effective [ENTITY_B] antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.,ANTAGONIST,CPR:6,3,JTH-601 is expected to be an effective alpha(1)-adrenoceptor antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.
The salivary fluid secretory mechanism is thought to require << Na(+)/K(+)/2Cl(-) cotransporter >>-mediated [[ Cl(-) ]] uptake.,The salivary fluid secretory mechanism is thought to require [ENTITY_A]-mediated [ENTITY_B] uptake.,SUBSTRATE,CPR:9,4,The salivary fluid secretory mechanism is thought to require Na(+)/K(+)/2Cl(-) cotransporter-mediated Cl(-) uptake.
These data directly demonstrate that << NKCC1 >> is the major [[ Cl(-) ]] uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.,These data directly demonstrate that [ENTITY_A] is the major [ENTITY_B] uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.,SUBSTRATE,CPR:9,4,These data directly demonstrate that NKCC1 is the major Cl(-) uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.
"UNLABELLED: Apparent << muscarinic acetylcholine (mAch) receptor >> occupancy in mouse cerebral cortex, hippocampus, and striatum by [[ scopolamine ]], an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).","UNLABELLED: Apparent [ENTITY_A] occupancy in mouse cerebral cortex, hippocampus, and striatum by [ENTITY_B], an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).",ANTAGONIST,CPR:6,3,"UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)."
Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and << troglitazone >> reverse lactation-induced downregulation of the [[ uncoupling protein-3 ]] gene.,Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and [ENTITY_A] reverse lactation-induced downregulation of the [ENTITY_B] gene.,INDIRECT-UPREGULATOR,CPR:3,0,Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and troglitazone reverse lactation-induced downregulation of the uncoupling protein-3 gene.
"Treatment of lactating mice with a single injection of << bezafibrate >>, an activator of the [[ peroxisome proliferator-activated receptor ]] (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.","Treatment of lactating mice with a single injection of [ENTITY_A], an activator of the [ENTITY_B] (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.",ACTIVATOR,CPR:3,0,"Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice."
"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas << troglitazone >>, a specific activator of [[ PPAR-gamma ]], also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.","4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas [ENTITY_A], a specific activator of [ENTITY_B], also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.",ACTIVATOR,CPR:3,0,"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice."
It is proposed that the UCP-3 gene is regulated in skeletal muscle during lactation in response to changes in circulating free << fatty acids >> by mechanisms involving activation of [[ PPARs ]].,It is proposed that the UCP-3 gene is regulated in skeletal muscle during lactation in response to changes in circulating free [ENTITY_A] by mechanisms involving activation of [ENTITY_B].,ACTIVATOR,CPR:3,0,It is proposed that the UCP-3 gene is regulated in skeletal muscle during lactation in response to changes in circulating free fatty acids by mechanisms involving activation of PPARs.
"<< Retigabine >>, a novel anti-convulsant, enhances activation of KCNQ2/Q3 [[ potassium channels ]].","[ENTITY_A], a novel anti-convulsant, enhances activation of KCNQ2/Q3 [ENTITY_B].",ACTIVATOR,CPR:3,0,"Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels."
Suppression of << NF-kappaB >> activity by [[ sulfasalazine ]] is mediated by direct inhibition of IkappaB kinases alpha and beta.,Suppression of [ENTITY_A] activity by [ENTITY_B] is mediated by direct inhibition of IkappaB kinases alpha and beta.,INHIBITOR,CPR:4,1,Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta.
The aim of this study was to define the molecular mechanism by which << sulfasalazine >> inhibits [[ NF-kappaB ]] activation.,The aim of this study was to define the molecular mechanism by which [ENTITY_A] inhibits [ENTITY_B] activation.,INHIBITOR,CPR:4,1,The aim of this study was to define the molecular mechanism by which sulfasalazine inhibits NF-kappaB activation.
"RESULTS: << NF-kappaB >>/Rel activity induced by tumor necrosis factor alpha, [[ 12-O-tetradecanoylphorbol-13-acetate ]], or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.","RESULTS: [ENTITY_A]/Rel activity induced by tumor necrosis factor alpha, [ENTITY_B], or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.",ACTIVATOR,CPR:3,0,"RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine."
"RESULTS: << NF-kappaB >>/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by [[ sulfasalazine ]].","RESULTS: [ENTITY_A]/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by [ENTITY_B].",INHIBITOR,CPR:4,1,"RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine."
"<< Sulfasalazine >> inhibited [[ tumor necrosis factor alpha ]]-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro.","[ENTITY_A] inhibited [ENTITY_B]-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro.",INHIBITOR,CPR:4,1,"Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro."
The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of << IKKs >> and can be antagonized by excess [[ adenosine triphosphate ]].,The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of [ENTITY_A] and can be antagonized by excess [ENTITY_B].,INHIBITOR,CPR:4,1,The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of IKKs and can be antagonized by excess adenosine triphosphate.
The suppression of << NF-kappaB >> activation by inhibition of the IKKs contributes to the well-known anti-inflammatory and immunosuppressive effects of [[ sulfasalazine ]].,The suppression of [ENTITY_A] activation by inhibition of the IKKs contributes to the well-known anti-inflammatory and immunosuppressive effects of [ENTITY_B].,INHIBITOR,CPR:4,1,The suppression of NF-kappaB activation by inhibition of the IKKs contributes to the well-known anti-inflammatory and immunosuppressive effects of sulfasalazine.
<< COX-2 >> produces [[ prostaglandins ]] that inhibit apoptosis and stimulate angiogenesis and invasiveness.,[ENTITY_A] produces [ENTITY_B] that inhibit apoptosis and stimulate angiogenesis and invasiveness.,PRODUCT-OF,CPR:9,4,COX-2 produces prostaglandins that inhibit apoptosis and stimulate angiogenesis and invasiveness.
"In contrast, aspirin-like nonselective NSAIDs such as sulindac and << indomethacin >> inhibit not only the enzymatic action of the highly inducible, proinflammatory [[ COX-2 ]] but the constitutively expressed, cytoprotective COX-1 as well.","In contrast, aspirin-like nonselective NSAIDs such as sulindac and [ENTITY_A] inhibit not only the enzymatic action of the highly inducible, proinflammatory [ENTITY_B] but the constitutively expressed, cytoprotective COX-1 as well.",INHIBITOR,CPR:4,1,"In contrast, aspirin-like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective COX-1 as well."
"Selective COX-2 inhibitors, such as << meloxicam >>, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit [[ COX-2 ]] but not COX-1.","Selective COX-2 inhibitors, such as [ENTITY_A], celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit [ENTITY_B] but not COX-1.",INHIBITOR,CPR:4,1,"Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1."
"For instance, << meloxicam >> inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express [[ COX-2 ]] but has no effect on HCT-116 tumor cells that do not express COX-2.","For instance, [ENTITY_A] inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express [ENTITY_B] but has no effect on HCT-116 tumor cells that do not express COX-2.",INHIBITOR,CPR:4,1,"For instance, meloxicam inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express COX-2 but has no effect on HCT-116 tumor cells that do not express COX-2."
"This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of << Bcl-2 >>, as has been demonstrated for some nonselective NSAIDs, for instance, [[ flurbiprofen ]].","This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of [ENTITY_A], as has been demonstrated for some nonselective NSAIDs, for instance, [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of Bcl-2, as has been demonstrated for some nonselective NSAIDs, for instance, flurbiprofen."
"To assess the feasibility of targeting these high AAAD levels for chemotherapy, << AAAD >> inhibitors [[ carbidopa ]] (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.","To assess the feasibility of targeting these high AAAD levels for chemotherapy, [ENTITY_A] inhibitors [ENTITY_B] (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.",INHIBITOR,CPR:4,1,"To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells."
"<< Hexahydrochromeno[4,3-b]pyrrole >> derivatives as [[ acetylcholinesterase ]] inhibitors.",[ENTITY_A] derivatives as [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,"Hexahydrochromeno[4,3-b]pyrrole derivatives as acetylcholinesterase inhibitors."
"Since this compound retains good << AChE >> inhibitory activity and its [[ hexahydrochromeno[4,3-b]pyrrole ]] moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE.","Since this compound retains good [ENTITY_A] inhibitory activity and its [ENTITY_B] moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE.",INHIBITOR,CPR:4,1,"Since this compound retains good AChE inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE."
"When the anti-corticosterone drug << aminoglutethimide >> (CYP11A1 inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and [[ CYP11A1 ]] mRNA expression were decreased at 14 days after tumor inoculation.","When the anti-corticosterone drug [ENTITY_A] (CYP11A1 inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and [ENTITY_B] mRNA expression were decreased at 14 days after tumor inoculation.",INDIRECT-DOWNREGULATOR,CPR:4,1,"When the anti-corticosterone drug aminoglutethimide (CYP11A1 inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation."
"We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of << topoisomerase I >> inhibitor [[ irinotecan hydrochloride ]] or the antimetabolite 5-fluorouracil.","We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of [ENTITY_A] inhibitor [ENTITY_B] or the antimetabolite 5-fluorouracil.",INHIBITOR,CPR:4,1,"We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil."
"Furthermore, h[<< Gly2 >>]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited [[ poly(ADP-ribose) polymerase ]] cleavage in heterologous cells transfected with the GLP-2 receptor.","Furthermore, h[[ENTITY_A]]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited [ENTITY_B] cleavage in heterologous cells transfected with the GLP-2 receptor.",INHIBITOR,CPR:4,1,"Furthermore, h[Gly2]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited poly(ADP-ribose) polymerase cleavage in heterologous cells transfected with the GLP-2 receptor."
OBJECTIVES: The hypothesis of the present study was that differences among << dopamine transporter >> (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as [[ DA ]] uptake inhibitors.,OBJECTIVES: The hypothesis of the present study was that differences among [ENTITY_A] (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as [ENTITY_B] uptake inhibitors.,SUBSTRATE,CPR:9,4,OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as DA uptake inhibitors.
"Accordingly, self-administration of a group of local anesthetics that are << DAT >> ligands was compared to their effects as [[ DA ]] uptake blockers in vitro in brain tissue.","Accordingly, self-administration of a group of local anesthetics that are [ENTITY_A] ligands was compared to their effects as [ENTITY_B] uptake blockers in vitro in brain tissue.",SUBSTRATE,CPR:9,4,"Accordingly, self-administration of a group of local anesthetics that are DAT ligands was compared to their effects as DA uptake blockers in vitro in brain tissue."
Contribution of the << Na+-K+-2Cl- cotransporter >> NKCC1 to [[ Cl- ]] secretion in rat OMCD.,Contribution of the [ENTITY_A] NKCC1 to [ENTITY_B] secretion in rat OMCD.,SUBSTRATE,CPR:9,4,Contribution of the Na+-K+-2Cl- cotransporter NKCC1 to Cl- secretion in rat OMCD.
"The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through << Cl- >> uptake across the basolateral membrane mediated by [[ NKCC1 ]] in series with Cl- efflux across the apical membrane.","The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through [ENTITY_A] uptake across the basolateral membrane mediated by [ENTITY_B] in series with Cl- efflux across the apical membrane.",SUBSTRATE,CPR:9,4,"The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through Cl- uptake across the basolateral membrane mediated by NKCC1 in series with Cl- efflux across the apical membrane."
"Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of << NKCC1 >>-mediated [[ Cl- ]] transport.","Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of [ENTITY_A]-mediated [ENTITY_B] transport.",SUBSTRATE,CPR:9,4,"Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of NKCC1-mediated Cl- transport."
"In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete << Cl- >> into the luminal fluid through [[ NKCC1 ]]-mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane.","In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete [ENTITY_A] into the luminal fluid through [ENTITY_B]-mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane.",SUBSTRATE,CPR:9,4,"In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through NKCC1-mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane."
The physiological role of << NKCC1 >>-mediated [[ Cl- ]] uptake remains to be determined.,The physiological role of [ENTITY_A]-mediated [ENTITY_B] uptake remains to be determined.,SUBSTRATE,CPR:9,4,The physiological role of NKCC1-mediated Cl- uptake remains to be determined.
"The broad-spectrum anti-emetic activity of << AS-8112 >>, a novel dopamine D2, D3 and [[ 5-HT3 receptors ]] antagonist.","The broad-spectrum anti-emetic activity of [ENTITY_A], a novel dopamine D2, D3 and [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist."
"In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of << 2-methyl-5HT >>, a [[ 5-HT3 receptor ]] agonist (pA2 value of 7.04).","In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of [ENTITY_A], a [ENTITY_B] agonist (pA2 value of 7.04).",AGONIST,CPR:5,2,"In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a 5-HT3 receptor agonist (pA2 value of 7.04)."
"In guinea-pig isolated colon, << AS-8112 >> produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a [[ 5-HT3 receptor ]] agonist (pA2 value of 7.04).","In guinea-pig isolated colon, [ENTITY_A] produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a [ENTITY_B] agonist (pA2 value of 7.04).",ANTAGONIST,CPR:6,3,"In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a 5-HT3 receptor agonist (pA2 value of 7.04)."
Other << 5-HT3 receptor >> antagonists also produced such a shift in the following antagonistic-potency order: [[ granisetron ]]> ondansetron=AS-8112>>metoclopramide.,Other [ENTITY_A] antagonists also produced such a shift in the following antagonistic-potency order: [ENTITY_B]> ondansetron=AS-8112>>metoclopramide.,ANTAGONIST,CPR:6,3,Other 5-HT3 receptor antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=AS-8112>>metoclopramide.
"In mice, << AS-8112 >> (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the [[ dopamine D3 receptor ]] agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).","In mice, [ENTITY_A] (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the [ENTITY_B] agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).",INHIBITOR,CPR:4,1,"In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the dopamine D3 receptor agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)."
"In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the << dopamine D3 receptor >> agonist; [[ R(+)-7-OH-DPAT ]] (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).","In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the [ENTITY_A] agonist; [ENTITY_B] (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).",AGONIST,CPR:5,2,"In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the dopamine D3 receptor agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)."
"In conclusion, << AS-8112 >> is a potent dopamine D2, D3 and [[ 5-HT3 receptors ]] antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity.","In conclusion, [ENTITY_A] is a potent dopamine D2, D3 and [ENTITY_B] antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity.",ANTAGONIST,CPR:6,3,"In conclusion, AS-8112 is a potent dopamine D2, D3 and 5-HT3 receptors antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity."
<< Rofecoxib >> is a selective [[ cyclo-oxygenase (COX)-2 ]] inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day.,[ENTITY_A] is a selective [ENTITY_B] inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day.,INHIBITOR,CPR:4,1,Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day.
"<< Rofecoxib >> has greater selectivity for [[ COX-2 ]] than celecoxib, meloxicam, diclofenac and indomethacin.","[ENTITY_A] has greater selectivity for [ENTITY_B] than celecoxib, meloxicam, diclofenac and indomethacin.",INHIBITOR,CPR:4,1,"Rofecoxib has greater selectivity for COX-2 than celecoxib, meloxicam, diclofenac and indomethacin."
<< Fenofibrate >> and GW2331 induced expression of [[ acyl-coenzyme A (CoA) oxidase ]] and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.,[ENTITY_A] and GW2331 induced expression of [ENTITY_B] and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.,INDIRECT-UPREGULATOR,CPR:3,0,Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.
<< Fenofibrate >> and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced [[ apolipoprotein C-III ]] and phosphoenolpyruvate carboxykinase mRNAs.,[ENTITY_A] and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced [ENTITY_B] and phosphoenolpyruvate carboxykinase mRNAs.,INDIRECT-DOWNREGULATOR,CPR:4,1,Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.
<< Rosiglitazone >> modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of [[ glucose transporter 4 ]] and phosphoenolpyruvate carboxykinase in adipose tissue.,[ENTITY_A] modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of [ENTITY_B] and phosphoenolpyruvate carboxykinase in adipose tissue.,INDIRECT-UPREGULATOR,CPR:3,0,Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue.
<< Long-chain alkanols >> are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral [[ nicotinic acetylcholine receptor ]] (AChR) by binding to one or more specific sites on the AChR.,[ENTITY_A] are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral [ENTITY_B] (AChR) by binding to one or more specific sites on the AChR.,INHIBITOR,CPR:4,1,Long-chain alkanols are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic acetylcholine receptor (AChR) by binding to one or more specific sites on the AChR.
"<< Cembranoids >> are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal [[ AChRs ]], which have no demonstrable general anesthetic activity in vivo.","[ENTITY_A] are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal [ENTITY_B], which have no demonstrable general anesthetic activity in vivo.",INHIBITOR,CPR:4,1,"Cembranoids are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal AChRs, which have no demonstrable general anesthetic activity in vivo."
"<< Sulfasalazine >>, a potent suppressor of lymphoma growth by inhibition of the [[ x(c)- cystine transporter ]]: a new action for an old drug.","[ENTITY_A], a potent suppressor of lymphoma growth by inhibition of the [ENTITY_B]: a new action for an old drug.",INHIBITOR,CPR:4,1,"Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug."
"<< Sulfasalazine >> was fortuitously found to be a novel, potent inhibitor of the [[ x(c)- transporter ]].","[ENTITY_A] was fortuitously found to be a novel, potent inhibitor of the [ENTITY_B].",INHIBITOR,CPR:4,1,"Sulfasalazine was fortuitously found to be a novel, potent inhibitor of the x(c)- transporter."
"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of << x(c) >>--mediated cystine uptake, in contrast to its colonic metabolites, [[ sulfapyridine ]] and 5-aminosalicylic acid.","It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of [ENTITY_A]--mediated cystine uptake, in contrast to its colonic metabolites, [ENTITY_B] and 5-aminosalicylic acid.",INHIBITOR,CPR:4,1,"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of x(c)--mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid."
"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of << x(c) >>--mediated [[ cystine ]] uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid.","It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of [ENTITY_A]--mediated [ENTITY_B] uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid.",SUBSTRATE,CPR:9,4,"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of x(c)--mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid."
The << x(c)- cystine transporter >> represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular [[ cyst(e)ine ]].,The [ENTITY_A] represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular [ENTITY_B].,SUBSTRATE,CPR:9,4,The x(c)- cystine transporter represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular cyst(e)ine.
"Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with << omapatrilat >>, a [[ vasopeptidase ]] inhibitor.","Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with [ENTITY_A], a [ENTITY_B] inhibitor.",INHIBITOR,CPR:4,1,"Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with omapatrilat, a vasopeptidase inhibitor."
"<< Omapatrilat >>, the prototypical [[ vasopeptidase ]] inhibitor, inhibits not only ACE but also neutral endopeptidase.","[ENTITY_A], the prototypical [ENTITY_B] inhibitor, inhibits not only ACE but also neutral endopeptidase.",INHIBITOR,CPR:4,1,"Omapatrilat, the prototypical vasopeptidase inhibitor, inhibits not only ACE but also neutral endopeptidase."
"Like conventional ACE inhibitors, << omapatrilat >> causes extracellular volume reduction and vasodilatation; moreover, it increases levels of [[ atrial and brain natriuretic peptides ]] and bradykinin.","Like conventional ACE inhibitors, [ENTITY_A] causes extracellular volume reduction and vasodilatation; moreover, it increases levels of [ENTITY_B] and bradykinin.",INDIRECT-UPREGULATOR,CPR:3,0,"Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin."
"Like conventional << ACE >> inhibitors, [[ omapatrilat ]] causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin.","Like conventional [ENTITY_A] inhibitors, [ENTITY_B] causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin.",INHIBITOR,CPR:4,1,"Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin."
"The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to << Na+ >>-H+ exchange ([[ NHE1 ]] isoform).","The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to [ENTITY_A]-H+ exchange ([ENTITY_B] isoform).",SUBSTRATE,CPR:9,4,"The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+-H+ exchange (NHE1 isoform)."
<< Aspirin >> and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its [[ ATPase ]] activity in human fibroblasts.,[ENTITY_A] and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its [ENTITY_B] activity in human fibroblasts.,INHIBITOR,CPR:4,1,Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its ATPase activity in human fibroblasts.
<< Salicylates >> inhibited [[ ATPase ]] activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression.,[ENTITY_A] inhibited [ENTITY_B] activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression.,INHIBITOR,CPR:4,1,Salicylates inhibited ATPase activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression.
"The specific activity of only << ornithine aminotransferase >> (OAT), the rate-limiting enzyme in the conversion of ornithine to [[ proline ]], increased in 2 weeks of hypertrophy.","The specific activity of only [ENTITY_A] (OAT), the rate-limiting enzyme in the conversion of ornithine to [ENTITY_B], increased in 2 weeks of hypertrophy.",PRODUCT-OF,CPR:9,4,"The specific activity of only ornithine aminotransferase (OAT), the rate-limiting enzyme in the conversion of ornithine to proline, increased in 2 weeks of hypertrophy."
"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective << cyclooxygenase (COX)-2 >> inhibitor ([[ celecoxib ]]) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac).","A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective [ENTITY_A] inhibitor ([ENTITY_B]) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac).",INHIBITOR,CPR:4,1,"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac)."
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of << prostaglandin E2 >> (PGE2; a product of both [[ COX-1 ]] and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.,Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of [ENTITY_A] (PGE2; a product of both [ENTITY_B] and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.,PRODUCT-OF,CPR:9,4,Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2; a product of both COX-1 and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.
"The time course of << PGE2 >> production was consistent with early release due to [[ COX-1 ]] activity followed by increased production 2-3 hours after surgery, consistent with COX-2 expression.","The time course of [ENTITY_A] production was consistent with early release due to [ENTITY_B] activity followed by increased production 2-3 hours after surgery, consistent with COX-2 expression.",PRODUCT-OF,CPR:9,4,"The time course of PGE2 production was consistent with early release due to COX-1 activity followed by increased production 2-3 hours after surgery, consistent with COX-2 expression."
"<< Celecoxib >> selectively suppressed PGE2 but not TxB2 at time points consistent with [[ COX-2 ]] activity, while producing analgesia.","[ENTITY_A] selectively suppressed PGE2 but not TxB2 at time points consistent with [ENTITY_B] activity, while producing analgesia.",INHIBITOR,CPR:4,1,"Celecoxib selectively suppressed PGE2 but not TxB2 at time points consistent with COX-2 activity, while producing analgesia."
"Celecoxib selectively suppressed << PGE2 >> but not TxB2 at time points consistent with [[ COX-2 ]] activity, while producing analgesia.","Celecoxib selectively suppressed [ENTITY_A] but not TxB2 at time points consistent with [ENTITY_B] activity, while producing analgesia.",PRODUCT-OF,CPR:9,4,"Celecoxib selectively suppressed PGE2 but not TxB2 at time points consistent with COX-2 activity, while producing analgesia."
These studies demonstrate the ability to assess the time course and selective effects of COX-2 inhibitors in vivo and suggest that suppression of << COX-2 >> mediated [[ PGE2 ]] is temporally related to NSAID analgesia.,These studies demonstrate the ability to assess the time course and selective effects of COX-2 inhibitors in vivo and suggest that suppression of [ENTITY_A] mediated [ENTITY_B] is temporally related to NSAID analgesia.,PRODUCT-OF,CPR:9,4,These studies demonstrate the ability to assess the time course and selective effects of COX-2 inhibitors in vivo and suggest that suppression of COX-2 mediated PGE2 is temporally related to NSAID analgesia.
"Acute and chronic << PLZ >> administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, [[ GABA transaminase ]] (GABA-T).","Acute and chronic [ENTITY_A] administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, [ENTITY_B] (GABA-T).",INHIBITOR,CPR:4,1,"Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (GABA-T)."
"Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the << GABA >> metabolizing enzyme, [[ GABA transaminase ]] (GABA-T).","Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the [ENTITY_A] metabolizing enzyme, [ENTITY_B] (GABA-T).",SUBSTRATE,CPR:9,4,"Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (GABA-T)."
"As with GABA, the metabolism of << alanine >> involves a [[ pyridoxal phosphate-dependent transaminase ]].","As with GABA, the metabolism of [ENTITY_A] involves a [ENTITY_B].",SUBSTRATE,CPR:9,4,"As with GABA, the metabolism of alanine involves a pyridoxal phosphate-dependent transaminase."
"In the study reported here, the effects of acute PLZ treatment on the levels of various << amino acids >>, some of which are also metabolized by [[ pyridoxal phosphate-dependent transaminases ]] were compared in rat whole brain.","In the study reported here, the effects of acute PLZ treatment on the levels of various [ENTITY_A], some of which are also metabolized by [ENTITY_B] were compared in rat whole brain.",SUBSTRATE,CPR:9,4,"In the study reported here, the effects of acute PLZ treatment on the levels of various amino acids, some of which are also metabolized by pyridoxal phosphate-dependent transaminases were compared in rat whole brain."
"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of << PLZ >> on [[ alanine transaminase ]] (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.","The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of [ENTITY_A] on [ENTITY_B] (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.",INHIBITOR,CPR:4,1,"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced."
"The elevation in brain << alanine >> levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on [[ alanine transaminase ]] (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.","The elevation in brain [ENTITY_A] levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on [ENTITY_B] (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.",SUBSTRATE,CPR:9,4,"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced."
"In addition, we also showed that the elevation in alanine levels and the inhibition of << alanine transaminase >> in the brain are retained after 14 days of [[ PLZ ]] treatment, and that PLZ produces a marked increase in extracellular levels of alanine.","In addition, we also showed that the elevation in alanine levels and the inhibition of [ENTITY_A] in the brain are retained after 14 days of [ENTITY_B] treatment, and that PLZ produces a marked increase in extracellular levels of alanine.",INHIBITOR,CPR:4,1,"In addition, we also showed that the elevation in alanine levels and the inhibition of alanine transaminase in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine."
"In addition, we also showed that the elevation in << alanine >> levels and the inhibition of [[ alanine transaminase ]] in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine.","In addition, we also showed that the elevation in [ENTITY_A] levels and the inhibition of [ENTITY_B] in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine.",SUBSTRATE,CPR:9,4,"In addition, we also showed that the elevation in alanine levels and the inhibition of alanine transaminase in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine."
"<< Cyclooxygenase-1 >> (COX-1) inhibitors ([[ flurbiprofen ]], ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.","[ENTITY_A] (COX-1) inhibitors ([ENTITY_B], ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.",INHIBITOR,CPR:4,1,"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction."
A << TXA2 synthetase >> inhibitor ([[ OKY-046 ]]) attenuated the contraction to a small extent only at high concentrations.,A [ENTITY_A] inhibitor ([ENTITY_B]) attenuated the contraction to a small extent only at high concentrations.,INHIBITOR,CPR:4,1,A TXA2 synthetase inhibitor (OKY-046) attenuated the contraction to a small extent only at high concentrations.
A << TXA2 receptor >> antagonist ([[ S-1452 ]]) attenuated the contraction in a concentration-dependent manner.,A [ENTITY_A] antagonist ([ENTITY_B]) attenuated the contraction in a concentration-dependent manner.,ANTAGONIST,CPR:6,3,A TXA2 receptor antagonist (S-1452) attenuated the contraction in a concentration-dependent manner.
A << nicotinic receptor >> antagonist ([[ hexamethonium ]]) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction.,A [ENTITY_A] antagonist ([ENTITY_B]) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction.,ANTAGONIST,CPR:6,3,A nicotinic receptor antagonist (hexamethonium) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction.
"Non-<< steroidal >> anti-inflammatory drugs (NSAIDs) are competitive inhibitors of [[ cyclooxygenase ]] (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid.","Non-[ENTITY_A] anti-inflammatory drugs (NSAIDs) are competitive inhibitors of [ENTITY_B] (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid.",INHIBITOR,CPR:4,1,"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid."
"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of << cyclooxygenase >> (COX), the enzyme that mediates biosynthesis of [[ prostaglandins ]] and thromboxanes from arachidonic acid.","Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of [ENTITY_A] (COX), the enzyme that mediates biosynthesis of [ENTITY_B] and thromboxanes from arachidonic acid.",PRODUCT-OF,CPR:9,4,"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid."
"Accordingly, docking of different << COX >> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, [[ zomepirac ]], indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.","Accordingly, docking of different [ENTITY_A] inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, [ENTITY_B], indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.",INHIBITOR,CPR:4,1,"Accordingly, docking of different COX inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program."
"Olopatadine hydrochloride (<< olopatadine >>, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/[[ histamine H1-receptor ]] antagonistic drug that was synthesized and evaluated in our laboratories.","Olopatadine hydrochloride ([ENTITY_A], 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/[ENTITY_B] antagonistic drug that was synthesized and evaluated in our laboratories.",ANTAGONIST,CPR:6,3,"Olopatadine hydrochloride (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/histamine H1-receptor antagonistic drug that was synthesized and evaluated in our laboratories."
<< Olopatadine >> is a selective [[ histamine H1-receptor ]] antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils.,[ENTITY_A] is a selective [ENTITY_B] antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils.,ANTAGONIST,CPR:6,3,Olopatadine is a selective histamine H1-receptor antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils.
A molecular mechanism of action of << theophylline >>: Induction of [[ histone deacetylase ]] activity to decrease inflammatory gene expression.,A molecular mechanism of action of [ENTITY_A]: Induction of [ENTITY_B] activity to decrease inflammatory gene expression.,ACTIVATOR,CPR:3,0,A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression.
We show both in vitro and in vivo that low-dose << theophylline >> enhances [[ HDAC ]] activity in epithelial cells and macrophages.,We show both in vitro and in vivo that low-dose [ENTITY_A] enhances [ENTITY_B] activity in epithelial cells and macrophages.,ACTIVATOR,CPR:3,0,We show both in vitro and in vivo that low-dose theophylline enhances HDAC activity in epithelial cells and macrophages.
Thus we have shown that low-dose << theophylline >> exerts an anti-asthma effect through increasing activation of [[ HDAC ]] which is subsequently recruited by corticosteroids to suppress inflammatory genes.,Thus we have shown that low-dose [ENTITY_A] exerts an anti-asthma effect through increasing activation of [ENTITY_B] which is subsequently recruited by corticosteroids to suppress inflammatory genes.,ACTIVATOR,CPR:3,0,Thus we have shown that low-dose theophylline exerts an anti-asthma effect through increasing activation of HDAC which is subsequently recruited by corticosteroids to suppress inflammatory genes.
"In rats, << rifamycin SV >> and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the [[ organic anion transporting polypeptides ]] Oatp1 and Oatp2.","In rats, [ENTITY_A] and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the [ENTITY_B] Oatp1 and Oatp2.",INHIBITOR,CPR:4,1,"In rats, rifamycin SV and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and Oatp2."
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, << rifamycin SV >> (10 micromol/L) cis-inhibited [[ human organic anion transporting polypeptide C ]] (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","In complementary RNA (cRNA)-injected Xenopus laevis oocytes, [ENTITY_A] (10 micromol/L) cis-inhibited [ENTITY_B] (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.",INHIBITOR,CPR:4,1,"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes."
"<< Rifampicin >> (10 micromol/L) inhibited [[ OATP8 ]]-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.","[ENTITY_A] (10 micromol/L) inhibited [ENTITY_B]-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.",INHIBITOR,CPR:4,1,"Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%."
"Rifampicin (10 micromol/L) inhibited << OATP8 >>-mediated [[ BSP ]] uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.","Rifampicin (10 micromol/L) inhibited [ENTITY_A]-mediated [ENTITY_B] uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.",SUBSTRATE,CPR:9,4,"Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%."
"100 micromol/L << rifampicin >> inhibited [[ OATP-C ]]- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.","100 micromol/L [ENTITY_A] inhibited [ENTITY_B]- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.",INHIBITOR,CPR:4,1,"100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively."
"100 micromol/L rifampicin inhibited << OATP-C >>- and OATP8-, OATP-B- and OATP-A-mediated [[ BSP ]] uptake by 66%, 96%, 25%, and 49%, respectively.","100 micromol/L rifampicin inhibited [ENTITY_A]- and OATP8-, OATP-B- and OATP-A-mediated [ENTITY_B] uptake by 66%, 96%, 25%, and 49%, respectively.",SUBSTRATE,CPR:9,4,"100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively."
Direct transport of << rifampicin >> could be shown for [[ OATP-C ]] (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L).,Direct transport of [ENTITY_A] could be shown for [ENTITY_B] (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L).,SUBSTRATE,CPR:9,4,Direct transport of rifampicin could be shown for OATP-C (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L).
Inhibition of << human liver OATPs >> can explain the previously observed effects of [[ rifamycin SV ]] and rifampicin on hepatic organic anion elimination.,Inhibition of [ENTITY_A] can explain the previously observed effects of [ENTITY_B] and rifampicin on hepatic organic anion elimination.,INHIBITOR,CPR:4,1,Inhibition of human liver OATPs can explain the previously observed effects of rifamycin SV and rifampicin on hepatic organic anion elimination.
<< Metformin >> increases [[ AMP-activated protein kinase ]] activity in skeletal muscle of subjects with type 2 diabetes.,[ENTITY_A] increases [ENTITY_B] activity in skeletal muscle of subjects with type 2 diabetes.,ACTIVATOR,CPR:3,0,Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes.
"<< AMP-activated protein kinase >> (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of [[ glucose ]] uptake into skeletal muscle and the inhibition of liver gluconeogenesis.","[ENTITY_A] (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of [ENTITY_B] uptake into skeletal muscle and the inhibition of liver gluconeogenesis.",SUBSTRATE,CPR:9,4,"AMP-activated protein kinase (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis."
"We recently reported that << AMPK >> is activated by [[ metformin ]] in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production.","We recently reported that [ENTITY_A] is activated by [ENTITY_B] in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production.",ACTIVATOR,CPR:3,0,"We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production."
"In the present study, we evaluated whether therapeutic doses of << metformin >> increase [[ AMPK ]] activity in vivo in subjects with type 2 diabetes.","In the present study, we evaluated whether therapeutic doses of [ENTITY_A] increase [ENTITY_B] activity in vivo in subjects with type 2 diabetes.",ACTIVATOR,CPR:3,0,"In the present study, we evaluated whether therapeutic doses of metformin increase AMPK activity in vivo in subjects with type 2 diabetes."
"<< Metformin >> treatment for 10 weeks significantly increased [[ AMPK alpha2 ]] activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity.","[ENTITY_A] treatment for 10 weeks significantly increased [ENTITY_B] activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity.",ACTIVATOR,CPR:3,0,"Metformin treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity."
"<< Metformin >> treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased [[ acetyl-CoA carboxylase-2 ]] activity.","[ENTITY_A] treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased [ENTITY_B] activity.",INHIBITOR,CPR:4,1,"Metformin treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity."
The increase in << AMPK alpha2 >> activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after [[ metformin ]] treatment.,The increase in [ENTITY_A] activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after [ENTITY_B] treatment.,ACTIVATOR,CPR:3,0,The increase in AMPK alpha2 activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after metformin treatment.
<< Metformin >>-induced increases in [[ AMPK ]] activity were associated with higher rates of glucose disposal and muscle glycogen concentrations.,[ENTITY_A]-induced increases in [ENTITY_B] activity were associated with higher rates of glucose disposal and muscle glycogen concentrations.,ACTIVATOR,CPR:3,0,Metformin-induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle glycogen concentrations.
<< Thalidomide >> prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and [[ TNF-alpha ]] production.,[ENTITY_A] prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and [ENTITY_B] production.,INDIRECT-DOWNREGULATOR,CPR:4,1,Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production.
<< Thalidomide >> has been shown to suppress [[ TNF-alpha ]] production from macrophages.,[ENTITY_A] has been shown to suppress [ENTITY_B] production from macrophages.,INDIRECT-DOWNREGULATOR,CPR:4,1,Thalidomide has been shown to suppress TNF-alpha production from macrophages.
"Furthermore, << thalidomide >> abolished the LPS-induced increase in [[ CD14 ]] expression and [Ca2+]i elevation in KCs.","Furthermore, [ENTITY_A] abolished the LPS-induced increase in [ENTITY_B] expression and [Ca2+]i elevation in KCs.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, thalidomide abolished the LPS-induced increase in CD14 expression and [Ca2+]i elevation in KCs."
"Moreover, << thalidomide >> reduced the LPS-induced [[ TNF-alpha ]] production by KCs by decreasing TNF-alpha messenger RNA.","Moreover, [ENTITY_A] reduced the LPS-induced [ENTITY_B] production by KCs by decreasing TNF-alpha messenger RNA.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, thalidomide reduced the LPS-induced TNF-alpha production by KCs by decreasing TNF-alpha messenger RNA."
CONCLUSIONS: These results collectively indicate that << thalidomide >> prevents alcoholic liver injury through suppression of [[ TNF-alpha ]] production and abolishment of KC sensitization.,CONCLUSIONS: These results collectively indicate that [ENTITY_A] prevents alcoholic liver injury through suppression of [ENTITY_B] production and abolishment of KC sensitization.,INDIRECT-DOWNREGULATOR,CPR:4,1,CONCLUSIONS: These results collectively indicate that thalidomide prevents alcoholic liver injury through suppression of TNF-alpha production and abolishment of KC sensitization.
"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by << polyamine oxidase >> (PAO) to produce [[ spermidine ]] and putrescine, respectively.","During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by [ENTITY_A] (PAO) to produce [ENTITY_B] and putrescine, respectively.",PRODUCT-OF,CPR:9,4,"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively."
"In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves << spermine >> in the absence of prior acetylation by [[ SSAT ]].","In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves [ENTITY_A] in the absence of prior acetylation by [ENTITY_B].",SUBSTRATE,CPR:9,4,"In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves spermine in the absence of prior acetylation by SSAT."
"Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified << oxidase >> strongly favoured [[ spermine ]] over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.","Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified [ENTITY_A] strongly favoured [ENTITY_B] over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.",SUBSTRATE,CPR:9,4,"Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine."
"The << PAO >> inhibitor, [[ MDL-72,527 ]], only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction.","The [ENTITY_A] inhibitor, [ENTITY_B], only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction.",INHIBITOR,CPR:4,1,"The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction."
"The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported << PAO >> substrate, [[ N (1)-( n -octanesulphonyl)spermine ]], potently inhibited the reaction.","The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported [ENTITY_A] substrate, [ENTITY_B], potently inhibited the reaction.",SUBSTRATE,CPR:9,4,"The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction."
"Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or << ADP >>-induced [[ CD62P ]] expression.","Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or [ENTITY_A]-induced [ENTITY_B] expression.",INDIRECT-UPREGULATOR,CPR:3,0,"Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or ADP-induced CD62P expression."
In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or << ADP >>-stimulated [[ CD62P ]] expression.,In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or [ENTITY_A]-stimulated [ENTITY_B] expression.,INDIRECT-UPREGULATOR,CPR:3,0,In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or ADP-stimulated CD62P expression.
"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate << beta-lyases >> to [[ pyruvate ]], ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.","Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate [ENTITY_A] to [ENTITY_B], ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.",PRODUCT-OF,CPR:9,4,"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate beta-lyases to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins."
"The juvenile visceral steatosis (jvs) mouse, having a mutation in the << carnitine >> transporter gene [[ Octn2 ]], is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140).","The juvenile visceral steatosis (jvs) mouse, having a mutation in the [ENTITY_A] transporter gene [ENTITY_B], is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140).",SUBSTRATE,CPR:9,4,"The juvenile visceral steatosis (jvs) mouse, having a mutation in the carnitine transporter gene Octn2, is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140)."
"Reuptake of extracellular << noradrenaline >> (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the [[ noradrenaline transporter ]] (NAT, uptake 1).","Reuptake of extracellular [ENTITY_A] (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the [ENTITY_B] (NAT, uptake 1).",SUBSTRATE,CPR:9,4,"Reuptake of extracellular noradrenaline (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (NAT, uptake 1)."
"The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the << OCT3 >> inhibitors cyanine 863, [[ oestradiol ]] and corticosterone.","The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the [ENTITY_A] inhibitors cyanine 863, [ENTITY_B] and corticosterone.",INHIBITOR,CPR:4,1,"The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the OCT3 inhibitors cyanine 863, oestradiol and corticosterone."
"The outflow of << [3H]-MPP+ >> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for [[ OCT ]]-related transmembrane transporters.","The outflow of [ENTITY_A] was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for [ENTITY_B]-related transmembrane transporters.",SUBSTRATE,CPR:9,4,"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related transmembrane transporters."
"However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of << MPP+ >>, indicating the [[ NAT ]] and not an OCT as their primary site of action.","However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of [ENTITY_A], indicating the [ENTITY_B] and not an OCT as their primary site of action.",SUBSTRATE,CPR:9,4,"However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action."
Our observations indicate an << OCT >>-mediated transmembrane transport of [[ [3H]-MPP+ ]].,Our observations indicate an [ENTITY_A]-mediated transmembrane transport of [ENTITY_B].,SUBSTRATE,CPR:9,4,Our observations indicate an OCT-mediated transmembrane transport of [3H]-MPP+.
"Amongst the three << OCTs >> expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of [[ [3H]-MPP+ ]] release.","Amongst the three [ENTITY_A] expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of [ENTITY_B] release.",SUBSTRATE,CPR:9,4,"Amongst the three OCTs expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of [3H]-MPP+ release."
"An inhibitor of << type B monoamine oxidase >> (MAO-B), [[ (-)deprenyl ]] (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it.","An inhibitor of [ENTITY_A] (MAO-B), [ENTITY_B] (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it.",INHIBITOR,CPR:4,1,"An inhibitor of type B monoamine oxidase (MAO-B), (-)deprenyl (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it."
"<< Rasagiline >> prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic [[ Bcl-2 ]] and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF).","[ENTITY_A] prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic [ENTITY_B] and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF).",INDIRECT-UPREGULATOR,CPR:3,0,"Rasagiline prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF)."
Long-term administration of << propargylamines >> to rats increased the activities of antioxidative enzymes [[ superoxide dismutase ]] (SOD) and catalase in the brain regions containing dopamine neurons.,Long-term administration of [ENTITY_A] to rats increased the activities of antioxidative enzymes [ENTITY_B] (SOD) and catalase in the brain regions containing dopamine neurons.,ACTIVATOR,CPR:3,0,Long-term administration of propargylamines to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD) and catalase in the brain regions containing dopamine neurons.
"Practical asymmetric synthesis of << aprepitant >>, a potent human [[ NK-1 receptor ]] antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction.","Practical asymmetric synthesis of [ENTITY_A], a potent human [ENTITY_B] antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction.",ANTAGONIST,CPR:6,3,"Practical asymmetric synthesis of aprepitant, a potent human NK-1 receptor antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction."
"A streamlined and high-yielding synthesis of << aprepitant >> (1), a potent [[ substance P (SP) receptor ]] antagonist, is described.","A streamlined and high-yielding synthesis of [ENTITY_A] (1), a potent [ENTITY_B] antagonist, is described.",ANTAGONIST,CPR:6,3,"A streamlined and high-yielding synthesis of aprepitant (1), a potent substance P (SP) receptor antagonist, is described."
Pentosan polysulfate << sodium >> (PPS) has been shown to exert antitumor activity by antagonizing the binding of [[ bFGF ]] to cell surface receptors.,Pentosan polysulfate [ENTITY_A] (PPS) has been shown to exert antitumor activity by antagonizing the binding of [ENTITY_B] to cell surface receptors.,ANTAGONIST,CPR:6,3,Pentosan polysulfate sodium (PPS) has been shown to exert antitumor activity by antagonizing the binding of bFGF to cell surface receptors.
These findings suggest that << RhBG >> and RhCG may play important and cell-specific roles in [[ ammonium ]] transport and signaling in these regions of the kidney.,These findings suggest that [ENTITY_A] and RhCG may play important and cell-specific roles in [ENTITY_B] transport and signaling in these regions of the kidney.,SUBSTRATE,CPR:9,4,These findings suggest that RhBG and RhCG may play important and cell-specific roles in ammonium transport and signaling in these regions of the kidney.
"<< PDE5 >> is the predominant PDE in the corpus cavernosum, and [[ cGMP ]] is its primary substrate.","[ENTITY_A] is the predominant PDE in the corpus cavernosum, and [ENTITY_B] is its primary substrate.",SUBSTRATE,CPR:9,4,"PDE5 is the predominant PDE in the corpus cavernosum, and cGMP is its primary substrate."
"Therefore, in men with ED, elevation of cGMP in corpus cavernosal tissue via selective inhibition of << cGMP >>-specific [[ PDE5 ]] is a means of improving erectile function at minimal risk of adverse events.","Therefore, in men with ED, elevation of cGMP in corpus cavernosal tissue via selective inhibition of [ENTITY_A]-specific [ENTITY_B] is a means of improving erectile function at minimal risk of adverse events.",INHIBITOR,CPR:4,1,"Therefore, in men with ED, elevation of cGMP in corpus cavernosal tissue via selective inhibition of cGMP-specific PDE5 is a means of improving erectile function at minimal risk of adverse events."
"This approach is validated by the clinical efficacy and safety of << sildenafil >>, the pioneering drug for selective [[ PDE5 ]] inhibitor therapy for ED.","This approach is validated by the clinical efficacy and safety of [ENTITY_A], the pioneering drug for selective [ENTITY_B] inhibitor therapy for ED.",INHIBITOR,CPR:4,1,"This approach is validated by the clinical efficacy and safety of sildenafil, the pioneering drug for selective PDE5 inhibitor therapy for ED."
"<< Sildenafil >> exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant [[ PDE ]] in the phototransduction cascade in rods.","[ENTITY_A] exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant [ENTITY_B] in the phototransduction cascade in rods.",INHIBITOR,CPR:4,1,"Sildenafil exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods."
"As free << sildenafil >> plasma concentrations approach concentrations sufficient to inhibit retinal [[ PDE6 ]], usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently.","As free [ENTITY_A] plasma concentrations approach concentrations sufficient to inhibit retinal [ENTITY_B], usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently.",INHIBITOR,CPR:4,1,"As free sildenafil plasma concentrations approach concentrations sufficient to inhibit retinal PDE6, usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently."
"Selective inhibition of << PDE5 >> is a rational therapeutic approach in ED, as proved by the clinical success of [[ sildenafil ]].","Selective inhibition of [ENTITY_A] is a rational therapeutic approach in ED, as proved by the clinical success of [ENTITY_B].",INHIBITOR,CPR:4,1,"Selective inhibition of PDE5 is a rational therapeutic approach in ED, as proved by the clinical success of sildenafil."
"However, when coapplied with 10 micro m GABA, << ivermectin >> potentiated the GABA-evoked current of the [[ GAB-1 ]]/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.","However, when coapplied with 10 micro m GABA, [ENTITY_A] potentiated the GABA-evoked current of the [ENTITY_B]/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.",UPREGULATOR,CPR:3,0,"However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor."
"However, when coapplied with 10 micro m GABA, << ivermectin >> potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the [[ GAB-1 ]]/HG1E receptor.","However, when coapplied with 10 micro m GABA, [ENTITY_A] potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the [ENTITY_B]/HG1E receptor.",DOWNREGULATOR,CPR:4,1,"However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor."
<< Yohimbine >> is a potent and selective [[ alpha2- versus alpha1-adrenoceptor ]] antagonist.,[ENTITY_A] is a potent and selective [ENTITY_B] antagonist.,ANTAGONIST,CPR:6,3,Yohimbine is a potent and selective alpha2- versus alpha1-adrenoceptor antagonist.
"Plasmacytoid dendritic cells produce cytokines and mature in response to the << TLR7 >> agonists, imiquimod and [[ resiquimod ]].","Plasmacytoid dendritic cells produce cytokines and mature in response to the [ENTITY_A] agonists, imiquimod and [ENTITY_B].",AGONIST,CPR:5,2,"Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod."
"The immune response modifiers, << imiquimod >> and resiquimod, are TLR7 agonists that induce [[ type I interferon ]] in numerous species, including humans.","The immune response modifiers, [ENTITY_A] and resiquimod, are TLR7 agonists that induce [ENTITY_B] in numerous species, including humans.",INDIRECT-UPREGULATOR,CPR:3,0,"The immune response modifiers, imiquimod and resiquimod, are TLR7 agonists that induce type I interferon in numerous species, including humans."
"The immune response modifiers, << imiquimod >> and resiquimod, are [[ TLR7 ]] agonists that induce type I interferon in numerous species, including humans.","The immune response modifiers, [ENTITY_A] and resiquimod, are [ENTITY_B] agonists that induce type I interferon in numerous species, including humans.",AGONIST,CPR:5,2,"The immune response modifiers, imiquimod and resiquimod, are TLR7 agonists that induce type I interferon in numerous species, including humans."
"Here, we characterize the activation of human pDC with the << TLR7 >> agonists [[ imiquimod ]] and resiquimod.","Here, we characterize the activation of human pDC with the [ENTITY_A] agonists [ENTITY_B] and resiquimod.",AGONIST,CPR:5,2,"Here, we characterize the activation of human pDC with the TLR7 agonists imiquimod and resiquimod."
"Results indicate that << imiquimod >> and resiquimod induce [[ IFN-alpha ]] and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood.","Results indicate that [ENTITY_A] and resiquimod induce [ENTITY_B] and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood.",INDIRECT-UPREGULATOR,CPR:3,0,"Results indicate that imiquimod and resiquimod induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood."
<< Resiquimod >>-stimulated pDC also produce a number of other [[ cytokines ]] including TNF-alpha and IP-10.,[ENTITY_A]-stimulated pDC also produce a number of other [ENTITY_B] including TNF-alpha and IP-10.,INDIRECT-UPREGULATOR,CPR:3,0,Resiquimod-stimulated pDC also produce a number of other cytokines including TNF-alpha and IP-10.
"<< Resiquimod >> enhances co-stimulatory marker expression, [[ CCR7 ]] expression, and pDC viability.","[ENTITY_A] enhances co-stimulatory marker expression, [ENTITY_B] expression, and pDC viability.",INDIRECT-UPREGULATOR,CPR:3,0,"Resiquimod enhances co-stimulatory marker expression, CCR7 expression, and pDC viability."
"These results demonstrate that << imidazoquinoline >> molecules directly induce pDC maturation as determined by [[ cytokine ]] induction, CCR7 and co-stimulatory marker expression and prolonging viability.","These results demonstrate that [ENTITY_A] molecules directly induce pDC maturation as determined by [ENTITY_B] induction, CCR7 and co-stimulatory marker expression and prolonging viability.",INDIRECT-UPREGULATOR,CPR:3,0,"These results demonstrate that imidazoquinoline molecules directly induce pDC maturation as determined by cytokine induction, CCR7 and co-stimulatory marker expression and prolonging viability."
Induction of << heat shock proteins >> (HSPs) by [[ sodium arsenite ]] in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.,Induction of [ENTITY_A] (HSPs) by [ENTITY_B] in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.,UPREGULATOR,CPR:3,0,Induction of heat shock proteins (HSPs) by sodium arsenite in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.
"<< Arsenite >> triggered strong induction of [[ HSPs ]], which was prevented by 1 micro g/mL cycloheximide (CXH).","[ENTITY_A] triggered strong induction of [ENTITY_B], which was prevented by 1 micro g/mL cycloheximide (CXH).",UPREGULATOR,CPR:3,0,"Arsenite triggered strong induction of HSPs, which was prevented by 1 micro g/mL cycloheximide (CXH)."
"Arsenite triggered strong induction of << HSPs >>, which was prevented by 1 micro g/mL [[ cycloheximide ]] (CXH).","Arsenite triggered strong induction of [ENTITY_A], which was prevented by 1 micro g/mL [ENTITY_B] (CXH).",DOWNREGULATOR,CPR:4,1,"Arsenite triggered strong induction of HSPs, which was prevented by 1 micro g/mL cycloheximide (CXH)."
"<< H2O2 >> caused cell loss and increased cell death with features of apoptosis, i.e. TdT-mediated dUTP nick-end labelling (TUNEL) reaction and [[ caspase-3 ]] activation.","[ENTITY_A] caused cell loss and increased cell death with features of apoptosis, i.e. TdT-mediated dUTP nick-end labelling (TUNEL) reaction and [ENTITY_B] activation.",ACTIVATOR,CPR:3,0,"H2O2 caused cell loss and increased cell death with features of apoptosis, i.e. TdT-mediated dUTP nick-end labelling (TUNEL) reaction and caspase-3 activation."
Pre-treatment with arsenite increased << protein kinase B >> (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after [[ H2O2 ]].,Pre-treatment with arsenite increased [ENTITY_A] (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after [ENTITY_B].,ACTIVATOR,CPR:3,0,Pre-treatment with arsenite increased protein kinase B (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after H2O2.
"However, while << Akt >> phosphorylation was prevented by CHX, Erk1/2 phosphorylation was further enhanced by [[ CHX ]].","However, while [ENTITY_A] phosphorylation was prevented by CHX, Erk1/2 phosphorylation was further enhanced by [ENTITY_B].",INHIBITOR,CPR:4,1,"However, while Akt phosphorylation was prevented by CHX, Erk1/2 phosphorylation was further enhanced by CHX."
"The results show that transient << arsenite >> pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of [[ Akt ]] following H2O2.","The results show that transient [ENTITY_A] pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of [ENTITY_B] following H2O2.",ACTIVATOR,CPR:3,0,"The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2."
Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual << ACE >>/NEP inhibitors [[ GW660511X ]] and omapatrilat.,Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual [ENTITY_A]/NEP inhibitors [ENTITY_B] and omapatrilat.,INHIBITOR,CPR:4,1,Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and omapatrilat.
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual << ACE >>/NEP inhibitors ([[ GW660511X ]] and omapatrilat) currently under clinical trial.,In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual [ENTITY_A]/NEP inhibitors ([ENTITY_B] and omapatrilat) currently under clinical trial.,INHIBITOR,CPR:4,1,In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial.
"Unlike GW660511X, << omapatrilat >> abolished the production of [[ BrBK1-5 ]] and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.","Unlike GW660511X, [ENTITY_A] abolished the production of [ENTITY_B] and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found."
In addition the production of << BrBK1-8 >> was enhanced in the presence of these inhibitors with a greater accumulation being observed with [[ omapatrilat ]].,In addition the production of [ENTITY_A] was enhanced in the presence of these inhibitors with a greater accumulation being observed with [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,In addition the production of BrBK1-8 was enhanced in the presence of these inhibitors with a greater accumulation being observed with omapatrilat.
The production of << Br-Phe5 >> was reduced with [[ GW660511X ]] while no significant change was observed with omapatrilat after 4 h of incubation.,The production of [ENTITY_A] was reduced with [ENTITY_B] while no significant change was observed with omapatrilat after 4 h of incubation.,INDIRECT-DOWNREGULATOR,CPR:4,1,The production of Br-Phe5 was reduced with GW660511X while no significant change was observed with omapatrilat after 4 h of incubation.
<< GW660511X >> and omapatrilat reduced the production of [[ BrBK1-5 ]] and BrBK1-7 with more effect being observed with omapatrilat.,[ENTITY_A] and omapatrilat reduced the production of [ENTITY_B] and BrBK1-7 with more effect being observed with omapatrilat.,INDIRECT-DOWNREGULATOR,CPR:4,1,GW660511X and omapatrilat reduced the production of BrBK1-5 and BrBK1-7 with more effect being observed with omapatrilat.
<< GW660511X >> and omapatrilat increased the production of both [[ BrBK1-8 ]] and Br-Phe5 but not that of BrBK4-8 and BrBK2-8.,[ENTITY_A] and omapatrilat increased the production of both [ENTITY_B] and Br-Phe5 but not that of BrBK4-8 and BrBK2-8.,INDIRECT-UPREGULATOR,CPR:3,0,GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8.
"This study shows that the potency of << GW660511X >> in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of [[ ACE ]]/NEP inhibition in relation to effects in humans.","This study shows that the potency of [ENTITY_A] in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of [ENTITY_B]/NEP inhibition in relation to effects in humans.",INHIBITOR,CPR:4,1,"This study shows that the potency of GW660511X in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE/NEP inhibition in relation to effects in humans."
"Acetylcholinesterase (<< AChE >>) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain [[ acetylcholine ]] (ACh) levels.","Acetylcholinesterase ([ENTITY_A]) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain [ENTITY_B] (ACh) levels.",SUBSTRATE,CPR:9,4,"Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels."
"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both << AChE >> and BuChE, [[ rivastigmine ]], indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.","Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both [ENTITY_A] and BuChE, [ENTITY_B], indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.",INHIBITOR,CPR:4,1,"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias."
The development of specific << BuChE >> inhibitors and further experience with the dual enzyme inhibitor [[ rivastigmine ]] will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.,The development of specific [ENTITY_A] inhibitors and further experience with the dual enzyme inhibitor [ENTITY_B] will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.,INHIBITOR,CPR:4,1,The development of specific BuChE inhibitors and further experience with the dual enzyme inhibitor rivastigmine will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.
"Agents which have recently been shown to block << cyclin D1 >> translation by regulating calcium levels are the [[ unsaturated essential fatty acid ]], eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole.","Agents which have recently been shown to block [ENTITY_A] translation by regulating calcium levels are the [ENTITY_B], eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Agents which have recently been shown to block cyclin D1 translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole."
<< Angiotensin AT1 receptor >> antagonist [[ losartan ]] and the defence reaction in the anaesthetised rat.,[ENTITY_A] antagonist [ENTITY_B] and the defence reaction in the anaesthetised rat.,ANTAGONIST,CPR:6,3,Angiotensin AT1 receptor antagonist losartan and the defence reaction in the anaesthetised rat.
We investigated the effect of << AT1 receptor >> blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent [[ pancuronium bromide ]].,We investigated the effect of [ENTITY_A] blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent [ENTITY_B].,INHIBITOR,CPR:4,1,We investigated the effect of AT1 receptor blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent pancuronium bromide.
Blockade of << LTC4 >> synthesis caused by additive inhibition of [[ gIV-PLA2 ]] phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils.,Blockade of [ENTITY_A] synthesis caused by additive inhibition of [ENTITY_B] phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils.,PRODUCT-OF,CPR:9,4,Blockade of LTC4 synthesis caused by additive inhibition of gIV-PLA2 phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils.
"OBJECTIVE: To determine (a) whether << PDE4 >> inhibition alone with [[ rolipram ]] blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.","OBJECTIVE: To determine (a) whether [ENTITY_A] inhibition alone with [ENTITY_B] blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.",INHIBITOR,CPR:4,1,"OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP."
RESULTS: Rolipram unmasked the inhibitory effect of << beta(2)-adrenoceptor >> stimulation with [[ salmeterol ]] and significantly attenuated the stimulated release of AA and subsequent LTC(4).,RESULTS: Rolipram unmasked the inhibitory effect of [ENTITY_A] stimulation with [ENTITY_B] and significantly attenuated the stimulated release of AA and subsequent LTC(4).,ACTIVATOR,CPR:3,0,RESULTS: Rolipram unmasked the inhibitory effect of beta(2)-adrenoceptor stimulation with salmeterol and significantly attenuated the stimulated release of AA and subsequent LTC(4).
Inhibition corresponded to increased cAMP production caused by rolipram alone or << rolipram >> plus salmeterol and blocked proportionately the phosphorylation and activation of [[ gIV-PLA(2) ]] in FMLP/B-activated eosinophils.,Inhibition corresponded to increased cAMP production caused by rolipram alone or [ENTITY_A] plus salmeterol and blocked proportionately the phosphorylation and activation of [ENTITY_B] in FMLP/B-activated eosinophils.,INHIBITOR,CPR:4,1,Inhibition corresponded to increased cAMP production caused by rolipram alone or rolipram plus salmeterol and blocked proportionately the phosphorylation and activation of gIV-PLA(2) in FMLP/B-activated eosinophils.
CONCLUSIONS: Inhibition of << PDE4 >> by [[ rolipram ]] unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP/B.,CONCLUSIONS: Inhibition of [ENTITY_A] by [ENTITY_B] unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP/B.,INHIBITOR,CPR:4,1,CONCLUSIONS: Inhibition of PDE4 by rolipram unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP/B.
Anabolic effects of << clenbuterol >> on skeletal muscle are mediated by [[ beta 2-adrenoceptor ]] activation.,Anabolic effects of [ENTITY_A] on skeletal muscle are mediated by [ENTITY_B] activation.,ACTIVATOR,CPR:3,0,Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation.
The potent anabolic effects of the << beta 2-adrenoceptor >> agonist [[ clenbuterol ]] on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors.,The potent anabolic effects of the [ENTITY_A] agonist [ENTITY_B] on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors.,AGONIST,CPR:5,2,The potent anabolic effects of the beta 2-adrenoceptor agonist clenbuterol on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors.
"These effects were not mimicked by oral administration of the << beta 2-adrenoceptor >> agonist [[ salbutamol ]] even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg/kg diet).","These effects were not mimicked by oral administration of the [ENTITY_A] agonist [ENTITY_B] even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg/kg diet).",AGONIST,CPR:5,2,"These effects were not mimicked by oral administration of the beta 2-adrenoceptor agonist salbutamol even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg/kg diet)."
"In the hot-plate test in mice, the antinociceptive action of the << alpha 2-adrenoceptor >> agonist, [[ UK 14,304 ]], was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.","In the hot-plate test in mice, the antinociceptive action of the [ENTITY_A] agonist, [ENTITY_B], was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.",AGONIST,CPR:5,2,"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408."
"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the << alpha 2-adrenoceptor >> antagonist, [[ idazoxan ]], the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.","In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the [ENTITY_A] antagonist, [ENTITY_B], the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.",ANTAGONIST,CPR:6,3,"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408."
"The preferential << alpha 2A-adrenoceptor >> partial agonist, [[ guanfacine ]], partially inhibited UK 14,304-induced antinociception.","The preferential [ENTITY_A] partial agonist, [ENTITY_B], partially inhibited UK 14,304-induced antinociception.",AGONIST,CPR:5,2,"The preferential alpha 2A-adrenoceptor partial agonist, guanfacine, partially inhibited UK 14,304-induced antinociception."
"<< SDH >> (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield [[ pyruvate ]] and ammonia.","[ENTITY_A] (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield [ENTITY_B] and ammonia.",PRODUCT-OF,CPR:9,4,"SDH (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia."
"Formation of << pyruvate >> by [[ SDH ]] is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.","Formation of [ENTITY_A] by [ENTITY_B] is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.",PRODUCT-OF,CPR:9,4,"Formation of pyruvate by SDH is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate."
Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) << GW572016 >> decreased the postradiation survival of irradiated [[ Ras ]]-transformed cells and normal cells but had no effect on the survival of unirradiated cells.,Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) [ENTITY_A] decreased the postradiation survival of irradiated [ENTITY_B]-transformed cells and normal cells but had no effect on the survival of unirradiated cells.,INDIRECT-DOWNREGULATOR,CPR:4,1,Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) GW572016 decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.
"Ras-CM and TGF-alpha also increase << PI3-K >> activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by [[ GW572016 ]].","Ras-CM and TGF-alpha also increase [ENTITY_A] activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by [ENTITY_B].",INHIBITOR,CPR:4,1,"Ras-CM and TGF-alpha also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by GW572016."
"Thus, << Ras >> utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI [[ GW572016 ]] acts as a radiosensitizer.","Thus, [ENTITY_A] utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI [ENTITY_B] acts as a radiosensitizer.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW572016 acts as a radiosensitizer."
The observation that << Ras >>-transformed cells can be sensitized to killing by ionizing radiation with [[ GW572016 ]] demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.,The observation that [ENTITY_A]-transformed cells can be sensitized to killing by ionizing radiation with [ENTITY_B] demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.,INDIRECT-DOWNREGULATOR,CPR:4,1,The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with GW572016 demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.
"(-)-Isoprenaline and a nonconventional << beta(3)-adrenoceptor >> agonist, [[ (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ]] ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.","(-)-Isoprenaline and a nonconventional [ENTITY_A] agonist, [ENTITY_B] ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.",AGONIST,CPR:5,2,"(-)-Isoprenaline and a nonconventional beta(3)-adrenoceptor agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations."
"Pretreatment with a combination of << (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate >> (CGP20712A, a selective [[ beta(1)-adrenoceptor ]] antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.","Pretreatment with a combination of [ENTITY_A] (CGP20712A, a selective [ENTITY_B] antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.",ANTAGONIST,CPR:6,3,"Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors."
The specificity of tracer uptake was determined by adding the << NET >> inhibitor [[ imipramine ]].,The specificity of tracer uptake was determined by adding the [ENTITY_A] inhibitor [ENTITY_B].,INHIBITOR,CPR:4,1,The specificity of tracer uptake was determined by adding the NET inhibitor imipramine.
"<< [(131)I]MIBG >> uptake in PC12 cells, which express the [[ NET ]] endogenously, was 20- to 28-fold lower than in transduced cells.","[ENTITY_A] uptake in PC12 cells, which express the [ENTITY_B] endogenously, was 20- to 28-fold lower than in transduced cells.",SUBSTRATE,CPR:9,4,"[(131)I]MIBG uptake in PC12 cells, which express the NET endogenously, was 20- to 28-fold lower than in transduced cells."
"In vivo, A431<< NET >> tumors demonstrated a 33-fold higher [[ [(123)I]MIBG ]] uptake than parental tumors.","In vivo, A431[ENTITY_A] tumors demonstrated a 33-fold higher [ENTITY_B] uptake than parental tumors.",SUBSTRATE,CPR:9,4,"In vivo, A431NET tumors demonstrated a 33-fold higher [(123)I]MIBG uptake than parental tumors."
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, << formoterol >>, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [[ human beta-adrenergic receptors ]] in an identical cellular background.","The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, [ENTITY_A], broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [ENTITY_B] in an identical cellular background.",AGONIST,CPR:5,2,"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background."
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (<< propranolol >>, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [[ human beta-adrenergic receptors ]] in an identical cellular background.","The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists ([ENTITY_A], alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [ENTITY_B] in an identical cellular background.",ANTAGONIST,CPR:6,3,"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background."
Manipulation of kinetic profiles in << 2-aryl propionic acid >> [[ cyclooxygenase ]] inhibitors.,Manipulation of kinetic profiles in [ENTITY_A] [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors.
"Effects of the << EGFR >>/HER2 kinase inhibitor [[ GW572016 ]] on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.","Effects of the [ENTITY_A]/HER2 kinase inhibitor [ENTITY_B] on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.",INHIBITOR,CPR:4,1,"Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance."
"To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual << EGFR >>/HER2 inhibitor, [[ GW572016 ]], on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines.","To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual [ENTITY_A]/HER2 inhibitor, [ENTITY_B], on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines.",INHIBITOR,CPR:4,1,"To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR/HER2 inhibitor, GW572016, on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines."
"RESULTS: << GW572016 >> inhibited constitutive and/or ligand-induced [[ EGFR ]] or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.","RESULTS: [ENTITY_A] inhibited constitutive and/or ligand-induced [ENTITY_B] or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.",INHIBITOR,CPR:4,1,"RESULTS: GW572016 inhibited constitutive and/or ligand-induced EGFR or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line."
"Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of << GW572016 >> to inhibit downstream ERK and Akt activation, despite inhibition of [[ HER2 ]] phosphorylation.","Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of [ENTITY_A] to inhibit downstream ERK and Akt activation, despite inhibition of [ENTITY_B] phosphorylation.",INHIBITOR,CPR:4,1,"Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of GW572016 to inhibit downstream ERK and Akt activation, despite inhibition of HER2 phosphorylation."
CONCLUSION: << GW572016 >> potently inhibits receptor phosphorylation in either [[ EGFR ]]- or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects.,CONCLUSION: [ENTITY_A] potently inhibits receptor phosphorylation in either [ENTITY_B]- or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects.,INHIBITOR,CPR:4,1,CONCLUSION: GW572016 potently inhibits receptor phosphorylation in either EGFR- or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects.
"Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on << glucose >>-stimulated [[ insulin ]] secretion.","Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on [ENTITY_A]-stimulated [ENTITY_B] secretion.",INDIRECT-UPREGULATOR,CPR:3,0,"Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion."
"<< Metformin >>, a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of [[ AMP-activated protein kinase ]] (AMPK).","[ENTITY_A], a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of [ENTITY_B] (AMPK).",ACTIVATOR,CPR:3,0,"Metformin, a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of AMP-activated protein kinase (AMPK)."
"Whether << metformin >> or the satiety factor leptin, which also stimulates [[ AMPK ]] in muscle, regulates this enzyme in pancreatic islets is unknown.","Whether [ENTITY_A] or the satiety factor leptin, which also stimulates [ENTITY_B] in muscle, regulates this enzyme in pancreatic islets is unknown.",ACTIVATOR,CPR:3,0,"Whether metformin or the satiety factor leptin, which also stimulates AMPK in muscle, regulates this enzyme in pancreatic islets is unknown."
"Increases in << glucose >> concentration from 0 to 3 and from 3 to 17 mM inhibited [[ AMPK ]] activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells.","Increases in [ENTITY_A] concentration from 0 to 3 and from 3 to 17 mM inhibited [ENTITY_B] activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells.",INHIBITOR,CPR:4,1,"Increases in glucose concentration from 0 to 3 and from 3 to 17 mM inhibited AMPK activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells."
"Incubation with << metformin >> (0.2-1 mM) activated [[ AMPK ]] in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells.","Incubation with [ENTITY_A] (0.2-1 mM) activated [ENTITY_B] in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells.",ACTIVATOR,CPR:3,0,"Incubation with metformin (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells."
"Incubation with << metformin >> (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of [[ insulin ]] secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells.","Incubation with [ENTITY_A] (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of [ENTITY_B] secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Incubation with metformin (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells."
The inhibitory effects of << metformin >> on [[ insulin ]] secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes.,The inhibitory effects of [ENTITY_A] on [ENTITY_B] secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes.,INDIRECT-DOWNREGULATOR,CPR:4,1,The inhibitory effects of metformin on insulin secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes.
A novel retinoic acid-responsive element regulates << retinoic acid >>-induced [[ BLR1 ]] expression.,A novel retinoic acid-responsive element regulates [ENTITY_A]-induced [ENTITY_B] expression.,INDIRECT-UPREGULATOR,CPR:3,0,A novel retinoic acid-responsive element regulates retinoic acid-induced BLR1 expression.
"RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of << blr1 >> expression by [[ RA ]].","RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of [ENTITY_A] expression by [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA."
A 5'-flanking region capable of supporting << RA >>-induced [[ blr1 ]] activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA.,A 5'-flanking region capable of supporting [ENTITY_A]-induced [ENTITY_B] activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA.,ACTIVATOR,CPR:3,0,A 5'-flanking region capable of supporting RA-induced blr1 activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA.
"The ability of this cis-acting RAR-RXR binding element to activate transcription in response to << RA >> also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a [[ nuclear factor of activated T cells ]] (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.","The ability of this cis-acting RAR-RXR binding element to activate transcription in response to [ENTITY_A] also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a [ENTITY_B] (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary."
In sum the results of the present study indicate that << RA >>-induced expression of [[ blr1 ]] expression depends on a novel RA response element.,In sum the results of the present study indicate that [ENTITY_A]-induced expression of [ENTITY_B] expression depends on a novel RA response element.,INDIRECT-UPREGULATOR,CPR:3,0,In sum the results of the present study indicate that RA-induced expression of blr1 expression depends on a novel RA response element.
The persistent membrane retention of << desipramine >> causes lasting inhibition of [[ norepinephrine transporter ]] function.,The persistent membrane retention of [ENTITY_A] causes lasting inhibition of [ENTITY_B] function.,INHIBITOR,CPR:4,1,The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function.
"[3H]DMI trapped in membranes was displaceable by the structurally unrelated << NET >> inhibitor, [[ nisoxetine ]], in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET.","[3H]DMI trapped in membranes was displaceable by the structurally unrelated [ENTITY_A] inhibitor, [ENTITY_B], in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET.",INHIBITOR,CPR:4,1,"[3H]DMI trapped in membranes was displaceable by the structurally unrelated NET inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET."
<< Irbesartan >> is a long-acting [[ angiotensin II ]] antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor).,[ENTITY_A] is a long-acting [ENTITY_B] antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor).,ANTAGONIST,CPR:6,3,Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor).
<< Irbesartan >> may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of [[ angiotensin II ]].,[ENTITY_A] may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of [ENTITY_B].,DOWNREGULATOR,CPR:4,1,Irbesartan may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II.
"To verify the hypothesis that the non-conventional partial agonist << (-)-CGP12177 >> binds at two beta(1)-adrenoceptor sites, [[ human beta(1)-adrenoceptors ]], expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.","To verify the hypothesis that the non-conventional partial agonist [ENTITY_A] binds at two beta(1)-adrenoceptor sites, [ENTITY_B], expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.",AGONIST,CPR:5,2,"To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two beta(1)-adrenoceptor sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177."
"<< Imiquimod >>, a Toll-like receptor-7 agonist, induces [[ perforin ]] in cytotoxic T lymphocytes in vitro.","[ENTITY_A], a Toll-like receptor-7 agonist, induces [ENTITY_B] in cytotoxic T lymphocytes in vitro.",UPREGULATOR,CPR:3,0,"Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro."
"<< Imiquimod >>, a [[ Toll-like receptor-7 ]] agonist, induces perforin in cytotoxic T lymphocytes in vitro.","[ENTITY_A], a [ENTITY_B] agonist, induces perforin in cytotoxic T lymphocytes in vitro.",AGONIST,CPR:5,2,"Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro."
"<< Imiquimod >> (IMQ), an activator of [[ Toll-like receptor-7 ]] (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo.","[ENTITY_A] (IMQ), an activator of [ENTITY_B] (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo.",ACTIVATOR,CPR:3,0,"Imiquimod (IMQ), an activator of Toll-like receptor-7 (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo."
"In peripheral lymphocytes of healthy and diseased subjects, << IMQ >> induced a significant increase of [[ perforin ]](+) CTLs within 12h in all experiments performed.","In peripheral lymphocytes of healthy and diseased subjects, [ENTITY_A] induced a significant increase of [ENTITY_B](+) CTLs within 12h in all experiments performed.",INDIRECT-UPREGULATOR,CPR:3,0,"In peripheral lymphocytes of healthy and diseased subjects, IMQ induced a significant increase of perforin(+) CTLs within 12h in all experiments performed."
"This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of << perforin >>(+) CTLs were induced by 2.5 microg/ml [corrected] [[ IMQ ]].","This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of [ENTITY_A](+) CTLs were induced by 2.5 microg/ml [corrected] [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of perforin(+) CTLs were induced by 2.5 microg/ml [corrected] IMQ."
"Thus, the biological activity of << IMQ >> appears to exceed its previously known functions, inasmuch as it boosts up significantly the [[ perforin ]]-granule system.","Thus, the biological activity of [ENTITY_A] appears to exceed its previously known functions, inasmuch as it boosts up significantly the [ENTITY_B]-granule system.",INDIRECT-UPREGULATOR,CPR:3,0,"Thus, the biological activity of IMQ appears to exceed its previously known functions, inasmuch as it boosts up significantly the perforin-granule system."
"<< Ang II >> level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in [[ irbesartan ]] group and lower in imidapril group.","[ENTITY_A] level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in [ENTITY_B] group and lower in imidapril group.",INDIRECT-UPREGULATOR,CPR:3,0,"Ang II level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in imidapril group."
"<< Ang II >> level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in [[ imidapril ]] group.","[ENTITY_A] level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in [ENTITY_B] group.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Ang II level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in imidapril group."
"The ratio of << TGF-beta1 >> absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, [[ imidapril ]] group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01).","The ratio of [ENTITY_A] absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, [ENTITY_B] group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01).",INDIRECT-UPREGULATOR,CPR:3,0,"The ratio of TGF-beta1 absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, imidapril group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01)."
<< Ang II >> level in plasma and mesenteric arteries in imidapril group was significantly lower than that in [[ irbesartan ]] group (P<0.05).,[ENTITY_A] level in plasma and mesenteric arteries in imidapril group was significantly lower than that in [ENTITY_B] group (P<0.05).,INDIRECT-UPREGULATOR,CPR:3,0,Ang II level in plasma and mesenteric arteries in imidapril group was significantly lower than that in irbesartan group (P<0.05).
<< Ang II >> level in plasma and mesenteric arteries in [[ imidapril ]] group was significantly lower than that in irbesartan group (P<0.05).,[ENTITY_A] level in plasma and mesenteric arteries in [ENTITY_B] group was significantly lower than that in irbesartan group (P<0.05).,INDIRECT-DOWNREGULATOR,CPR:4,1,Ang II level in plasma and mesenteric arteries in imidapril group was significantly lower than that in irbesartan group (P<0.05).
"The << c-Jun >> absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, [[ imidapril ]], and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05).","The [ENTITY_A] absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, [ENTITY_B], and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05).",INDIRECT-UPREGULATOR,CPR:3,0,"The c-Jun absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, imidapril, and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05)."
"CONCLUSION: << Imidapril >> and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of [[ TGF-beta1 ]], c-Jun in SHR.","CONCLUSION: [ENTITY_A] and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of [ENTITY_B], c-Jun in SHR.",INDIRECT-DOWNREGULATOR,CPR:4,1,"CONCLUSION: Imidapril and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, c-Jun in SHR."
"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized << NET >> by a range of doses of [[ duloxetine ]] [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.","BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized [ENTITY_A] by a range of doses of [ENTITY_B] [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.",ANTAGONIST,CPR:6,3,"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process."
"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized << NET >> by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the [[ NE ]] reuptake process.","BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized [ENTITY_A] by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the [ENTITY_B] reuptake process.",SUBSTRATE,CPR:9,4,"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process."
"<< Auranofin >>, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and [[ glutathione peroxidase ]].","[ENTITY_A], an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and [ENTITY_B].",INHIBITOR,CPR:4,1,"Auranofin, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and glutathione peroxidase."
"There was significantly less << thioredoxin reductase >> activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of [[ auranofin ]] used was able to selectively inhibit one of these enzyme systems.","There was significantly less [ENTITY_A] activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of [ENTITY_B] used was able to selectively inhibit one of these enzyme systems.",INHIBITOR,CPR:4,1,"There was significantly less thioredoxin reductase activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of auranofin used was able to selectively inhibit one of these enzyme systems."
"Furthermore, << gallium >> also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on [[ vacuolar-type H(+)-ATPases ]].","Furthermore, [ENTITY_A] also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on [ENTITY_B].",INHIBITOR,CPR:4,1,"Furthermore, gallium also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on vacuolar-type H(+)-ATPases."
"However, some experimental findings raise the question whether these effects resulting from the << iron >>-mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting [[ tubulin ]] polymerization.","However, some experimental findings raise the question whether these effects resulting from the [ENTITY_A]-mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting [ENTITY_B] polymerization.",INHIBITOR,CPR:4,1,"However, some experimental findings raise the question whether these effects resulting from the iron-mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting tubulin polymerization."
"GABA-evoked currents were completely and reversibly blocked by the competitive << GABAA receptor >> antagonist [[ bicuculline ]] (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors.","GABA-evoked currents were completely and reversibly blocked by the competitive [ENTITY_A] antagonist [ENTITY_B] (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors.",ANTAGONIST,CPR:6,3,"GABA-evoked currents were completely and reversibly blocked by the competitive GABAA receptor antagonist bicuculline (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors."
"<< Histamine H1-receptor >> (H1R) antagonists, or [[ antihistamines ]], often induce sedative side effects when used for the treatment of allergic disorders.","[ENTITY_A] (H1R) antagonists, or [ENTITY_B], often induce sedative side effects when used for the treatment of allergic disorders.",ANTAGONIST,CPR:6,3,"Histamine H1-receptor (H1R) antagonists, or antihistamines, often induce sedative side effects when used for the treatment of allergic disorders."
"A novel membrane sensor for << histamine H1-receptor >> antagonist ""[[ fexofenadine ]]"".","A novel membrane sensor for [ENTITY_A] antagonist ""[ENTITY_B]"".",ANTAGONIST,CPR:6,3,"A novel membrane sensor for histamine H1-receptor antagonist ""fexofenadine""."
"<< Thymidylate synthase >> (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of [[ 2-deoxythymidine-5-monophosphate ]], a precursor for DNA synthesis.","[ENTITY_A] (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of [ENTITY_B], a precursor for DNA synthesis.",PRODUCT-OF,CPR:9,4,"Thymidylate synthase (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis."
"While fluoropyrimidine antimetabolites have other sites of action, antifolates << ZD1694 >> (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent [[ TS ]] inhibitors.","While fluoropyrimidine antimetabolites have other sites of action, antifolates [ENTITY_A] (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent [ENTITY_B] inhibitors.",INHIBITOR,CPR:4,1,"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent TS inhibitors."
"The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that << thymidine phosphorylase >>, the activating enzyme for [[ 5-FU ]], is expressed at a higher level in tumor tissue compared with normal tissue counterparts.","The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that [ENTITY_A], the activating enzyme for [ENTITY_B], is expressed at a higher level in tumor tissue compared with normal tissue counterparts.",SUBSTRATE,CPR:9,4,"The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that thymidine phosphorylase, the activating enzyme for 5-FU, is expressed at a higher level in tumor tissue compared with normal tissue counterparts."
<< Orlistat >> is an inhibitor of [[ pancreatic lipase ]] which is able to block the absorption of 30% of ingested fat.,[ENTITY_A] is an inhibitor of [ENTITY_B] which is able to block the absorption of 30% of ingested fat.,INHIBITOR,CPR:4,1,Orlistat is an inhibitor of pancreatic lipase which is able to block the absorption of 30% of ingested fat.
"<< Troglitazone >>, bosentan and glibenclamide inhibit the [[ bile salt export pump ]] (Bsep) which transports taurocholate into bile.","[ENTITY_A], bosentan and glibenclamide inhibit the [ENTITY_B] (Bsep) which transports taurocholate into bile.",INHIBITOR,CPR:4,1,"Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (Bsep) which transports taurocholate into bile."
"Troglitazone, bosentan and glibenclamide inhibit the << bile salt export pump >> (Bsep) which transports [[ taurocholate ]] into bile.","Troglitazone, bosentan and glibenclamide inhibit the [ENTITY_A] (Bsep) which transports [ENTITY_B] into bile.",SUBSTRATE,CPR:9,4,"Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (Bsep) which transports taurocholate into bile."
The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing << prostaglandin >> formation from [[ COX-1 ]].,The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing [ENTITY_A] formation from [ENTITY_B].,PRODUCT-OF,CPR:9,4,The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing prostaglandin formation from COX-1.
"We report here the pharmacological properties of a third selective << COX-2 >> inhibitor, [[ valdecoxib ]], which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied.","We report here the pharmacological properties of a third selective [ENTITY_A] inhibitor, [ENTITY_B], which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied.",INHIBITOR,CPR:4,1,"We report here the pharmacological properties of a third selective COX-2 inhibitor, valdecoxib, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied."
"<< Valdecoxib >> potently inhibits recombinant [[ COX-2 ]], with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib.","[ENTITY_A] potently inhibits recombinant [ENTITY_B], with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib.",INHIBITOR,CPR:4,1,"Valdecoxib potently inhibits recombinant COX-2, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib."
"Unique binding interactions of << valdecoxib >> with COX-2 translate into a fast rate of inactivation of [[ COX-2 ]] (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib).","Unique binding interactions of [ENTITY_A] with COX-2 translate into a fast rate of inactivation of [ENTITY_B] (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib).",DOWNREGULATOR,CPR:4,1,"Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib)."
<< Valdecoxib >> inhibits [[ COX-1 ]] in a competitive fashion only at very high concentrations (IC(50) = 150 microM).,[ENTITY_A] inhibits [ENTITY_B] in a competitive fashion only at very high concentrations (IC(50) = 150 microM).,INHIBITOR,CPR:4,1,Valdecoxib inhibits COX-1 in a competitive fashion only at very high concentrations (IC(50) = 150 microM).
<< Valdecoxib >> showed similar activity in the [[ human whole-blood COX ]] assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM).,[ENTITY_A] showed similar activity in the [ENTITY_B] assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM).,INHIBITOR,CPR:4,1,Valdecoxib showed similar activity in the human whole-blood COX assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM).
"An angiotensin II AT1 receptor antagonist, << telmisartan >> augments glucose uptake and [[ GLUT4 ]] protein expression in 3T3-L1 adipocytes.","An angiotensin II AT1 receptor antagonist, [ENTITY_A] augments glucose uptake and [ENTITY_B] protein expression in 3T3-L1 adipocytes.",INDIRECT-UPREGULATOR,CPR:3,0,"An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes."
"An << angiotensin II AT1 receptor >> antagonist, [[ telmisartan ]] augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.","An [ENTITY_A] antagonist, [ENTITY_B] augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.",ANTAGONIST,CPR:6,3,"An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes."
"An angiotensin II AT1 receptor antagonist, telmisartan augments << glucose >> uptake and [[ GLUT4 ]] protein expression in 3T3-L1 adipocytes.","An angiotensin II AT1 receptor antagonist, telmisartan augments [ENTITY_A] uptake and [ENTITY_B] protein expression in 3T3-L1 adipocytes.",SUBSTRATE,CPR:9,4,"An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes."
Treatment of both differentiating adipocytes and fully differentiated adipocytes with << telmisartan >> caused a dose-dependent increase in mRNA levels for [[ PPARgamma ]] target genes such as aP2 and adiponectin.,Treatment of both differentiating adipocytes and fully differentiated adipocytes with [ENTITY_A] caused a dose-dependent increase in mRNA levels for [ENTITY_B] target genes such as aP2 and adiponectin.,INDIRECT-UPREGULATOR,CPR:3,0,Treatment of both differentiating adipocytes and fully differentiated adipocytes with telmisartan caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as aP2 and adiponectin.
"By contrast, << telmisartan >> attenuated [[ 11beta-hydroxysteroid dehydrogenase type 1 ]] mRNA level in differentiated adipocytes.","By contrast, [ENTITY_A] attenuated [ENTITY_B] mRNA level in differentiated adipocytes.",INDIRECT-UPREGULATOR,CPR:3,0,"By contrast, telmisartan attenuated 11beta-hydroxysteroid dehydrogenase type 1 mRNA level in differentiated adipocytes."
"Of note, we demonstrated for the first time that << telmisartan >> augmented [[ GLUT4 ]] protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.","Of note, we demonstrated for the first time that [ENTITY_A] augmented [ENTITY_B] protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.",INDIRECT-UPREGULATOR,CPR:3,0,"Of note, we demonstrated for the first time that telmisartan augmented GLUT4 protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability."
"Of note, we demonstrated for the first time that telmisartan augmented << GLUT4 >> protein expression and [[ 2-deoxy glucose ]] uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.","Of note, we demonstrated for the first time that telmisartan augmented [ENTITY_A] protein expression and [ENTITY_B] uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.",SUBSTRATE,CPR:9,4,"Of note, we demonstrated for the first time that telmisartan augmented GLUT4 protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability."
"Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme << tyrosinase >>, as compared to the standard tyrosinase inhibitors [[ kojic acid ]] (IC50=16.67 microM) and L-mimosine (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.","Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme [ENTITY_A], as compared to the standard tyrosinase inhibitors [ENTITY_B] (IC50=16.67 microM) and L-mimosine (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.",INHIBITOR,CPR:4,1,"Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme tyrosinase, as compared to the standard tyrosinase inhibitors kojic acid (IC50=16.67 microM) and L-mimosine (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes."
"Oxytocin antagonist (OTA), << TT-235 >>, was developed by our group and shown to inhibit either spontaneous or [[ oxytocin ]]-induced uterine contractions in primates.","Oxytocin antagonist (OTA), [ENTITY_A], was developed by our group and shown to inhibit either spontaneous or [ENTITY_B]-induced uterine contractions in primates.",INHIBITOR,CPR:4,1,"Oxytocin antagonist (OTA), TT-235, was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates."
"<< Oxytocin >> antagonist (OTA), [[ TT-235 ]], was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates.","[ENTITY_A] antagonist (OTA), [ENTITY_B], was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates.",ANTAGONIST,CPR:6,3,"Oxytocin antagonist (OTA), TT-235, was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates."
The purpose of the present study was to confirm the duration of << TT-235 >> to block [[ oxytocin ]]-induced uterine contractions in estrous rats.,The purpose of the present study was to confirm the duration of [ENTITY_A] to block [ENTITY_B]-induced uterine contractions in estrous rats.,INHIBITOR,CPR:4,1,The purpose of the present study was to confirm the duration of TT-235 to block oxytocin-induced uterine contractions in estrous rats.
"In Experiment 1, << Antag I >>, Antag II and TT-235 inhibited the integrated uterine response to [[ oxytocin ]] at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).","In Experiment 1, [ENTITY_A], Antag II and TT-235 inhibited the integrated uterine response to [ENTITY_B] at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).",INHIBITOR,CPR:4,1,"In Experiment 1, Antag I, Antag II and TT-235 inhibited the integrated uterine response to oxytocin at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)."
"In Experiment 2, << TT-235 >> induced a significant decrease (p<0.05) in [[ oxytocin receptor ]] number and binding affinity at both 0.5 and 4 hours compared with controls.","In Experiment 2, [ENTITY_A] induced a significant decrease (p<0.05) in [ENTITY_B] number and binding affinity at both 0.5 and 4 hours compared with controls.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In Experiment 2, TT-235 induced a significant decrease (p<0.05) in oxytocin receptor number and binding affinity at both 0.5 and 4 hours compared with controls."
"In conclusion, << TT-235 >> may inhibit the uterine response to oxytocin by decreasing [[ oxytocin receptor ]] numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.","In conclusion, [ENTITY_A] may inhibit the uterine response to oxytocin by decreasing [ENTITY_B] numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235."
"In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged << oxytocin >> antagonist activity of [[ TT-235 ]].","In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged [ENTITY_A] antagonist activity of [ENTITY_B].",ANTAGONIST,CPR:6,3,"In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235."
Preclinical pharmacology of << lumiracoxib >>: a novel selective inhibitor of [[ cyclooxygenase-2 ]].,Preclinical pharmacology of [ENTITY_A]: a novel selective inhibitor of [ENTITY_B].,INHIBITOR,CPR:4,1,Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
"This manuscript presents the preclinical profile of << lumiracoxib >>, a novel [[ cyclooxygenase-2 ]] (COX-2) selective inhibitor.","This manuscript presents the preclinical profile of [ENTITY_A], a novel [ENTITY_B] (COX-2) selective inhibitor.",INHIBITOR,CPR:4,1,"This manuscript presents the preclinical profile of lumiracoxib, a novel cyclooxygenase-2 (COX-2) selective inhibitor."
"<< Lumiracoxib >> inhibited purified [[ COX-1 ]] and COX-2 with K(i) values of 3 and 0.06 microM, respectively.","[ENTITY_A] inhibited purified [ENTITY_B] and COX-2 with K(i) values of 3 and 0.06 microM, respectively.",INHIBITOR,CPR:4,1,"Lumiracoxib inhibited purified COX-1 and COX-2 with K(i) values of 3 and 0.06 microM, respectively."
"In cellular assays, << lumiracoxib >> had an IC(50) of 0.14 microM in [[ COX-2 ]]-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).","In cellular assays, [ENTITY_A] had an IC(50) of 0.14 microM in [ENTITY_B]-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).",INHIBITOR,CPR:4,1,"In cellular assays, lumiracoxib had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1)."
"In a human whole blood assay, IC(50) values for << lumiracoxib >> were 0.13 microM for [[ COX-2 ]] and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).","In a human whole blood assay, IC(50) values for [ENTITY_A] were 0.13 microM for [ENTITY_B] and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).",INHIBITOR,CPR:4,1,"In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515)."
"Ex vivo, << lumiracoxib >> inhibited [[ COX-1 ]]-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).","Ex vivo, [ENTITY_A] inhibited [ENTITY_B]-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",INHIBITOR,CPR:4,1,"Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)."
"Ex vivo, lumiracoxib inhibited << COX-1 >>-derived [[ thromboxane B(2) ]] (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).","Ex vivo, lumiracoxib inhibited [ENTITY_A]-derived [ENTITY_B] (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",PRODUCT-OF,CPR:9,4,"Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)."
"However, consistent with its low << COX-1 >> inhibitory activity, [[ lumiracoxib ]] at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05).","However, consistent with its low [ENTITY_A] inhibitory activity, [ENTITY_B] at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05).",INHIBITOR,CPR:4,1,"However, consistent with its low COX-1 inhibitory activity, lumiracoxib at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05)."
"<< Lumiracoxib >> is a highly selective [[ COX-2 ]] inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety.","[ENTITY_A] is a highly selective [ENTITY_B] inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety.",INHIBITOR,CPR:4,1,"Lumiracoxib is a highly selective COX-2 inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety."
"As << thiamine >> metabolism deficiencies have been seen in placental infarcts previously, these indicate that [[ PP20 ]]/hTPK may have a role in placental diseases.","As [ENTITY_A] metabolism deficiencies have been seen in placental infarcts previously, these indicate that [ENTITY_B]/hTPK may have a role in placental diseases.",SUBSTRATE,CPR:9,4,"As thiamine metabolism deficiencies have been seen in placental infarcts previously, these indicate that PP20/hTPK may have a role in placental diseases."
"Safety and tolerability of << denufosol tetrasodium >> inhalation solution, a novel [[ P2Y2 receptor ]] agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.","Safety and tolerability of [ENTITY_A] inhalation solution, a novel [ENTITY_B] agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.",AGONIST,CPR:5,2,"Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis."
"<< Denufosol tetrasodium >> (INS37217) is a selective [[ P2Y(2) ]] agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.","[ENTITY_A] (INS37217) is a selective [ENTITY_B] agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.",AGONIST,CPR:5,2,"Denufosol tetrasodium (INS37217) is a selective P2Y(2) agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF."
"The << Cl(-) >> secretory response is mediated via a non-[[ CFTR ]] pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport.","The [ENTITY_A] secretory response is mediated via a non-[ENTITY_B] pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport.",SUBSTRATE,CPR:9,4,"The Cl(-) secretory response is mediated via a non-CFTR pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport."
"<< Denufosol >> is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated [[ P2Y(2) ]] agonists.","[ENTITY_A] is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated [ENTITY_B] agonists.",AGONIST,CPR:5,2,"Denufosol is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated P2Y(2) agonists."
The dextromethorphan analog << dimemorfan >> attenuates kainate-induced seizures via [[ sigma1 receptor ]] activation: comparison with the effects of dextromethorphan.,The dextromethorphan analog [ENTITY_A] attenuates kainate-induced seizures via [ENTITY_B] activation: comparison with the effects of dextromethorphan.,ACTIVATOR,CPR:3,0,The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan.
"Dimemorfan pre-treatment also attenuated the << KA >>-induced increases in c-fos/c-jun expression, [[ activator protein (AP)-1 ]] DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.","Dimemorfan pre-treatment also attenuated the [ENTITY_A]-induced increases in c-fos/c-jun expression, [ENTITY_B] DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.",ACTIVATOR,CPR:3,0,"Dimemorfan pre-treatment also attenuated the KA-induced increases in c-fos/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus."
"<< Dimemorfan >> pre-treatment also attenuated the KA-induced increases in [[ c-fos ]]/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.","[ENTITY_A] pre-treatment also attenuated the KA-induced increases in [ENTITY_B]/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Dimemorfan pre-treatment also attenuated the KA-induced increases in c-fos/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus."
"The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective << sigma1 receptor >> antagonist [[ BD 1047 ]], suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.","The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective [ENTITY_A] antagonist [ENTITY_B], suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.",ANTAGONIST,CPR:6,3,"The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors."
Binding domains of the oxytocin receptor for the selective << oxytocin receptor >> antagonist barusiban in comparison to the agonists [[ oxytocin ]] and carbetocin.,Binding domains of the oxytocin receptor for the selective [ENTITY_A] antagonist barusiban in comparison to the agonists [ENTITY_B] and carbetocin.,AGONIST,CPR:5,2,Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.
Binding domains of the oxytocin receptor for the selective << oxytocin receptor >> antagonist [[ barusiban ]] in comparison to the agonists oxytocin and carbetocin.,Binding domains of the oxytocin receptor for the selective [ENTITY_A] antagonist [ENTITY_B] in comparison to the agonists oxytocin and carbetocin.,ANTAGONIST,CPR:6,3,Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.
"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined << vasopressin V1A/oxytocin receptor >> antagonist atosiban and the agonists [[ oxytocin ]] and carbetocin.","We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined [ENTITY_A] antagonist atosiban and the agonists [ENTITY_B] and carbetocin.",AGONIST,CPR:5,2,"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin."
"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined << vasopressin V1A/oxytocin receptor >> antagonist [[ atosiban ]] and the agonists oxytocin and carbetocin.","We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined [ENTITY_A] antagonist [ENTITY_B] and the agonists oxytocin and carbetocin.",ANTAGONIST,CPR:6,3,"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin."
"For the << vasopressin V1A/oxytocin receptor >> antagonist [[ atosiban ]], none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor.","For the [ENTITY_A] antagonist [ENTITY_B], none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor.",ANTAGONIST,CPR:6,3,"For the vasopressin V1A/oxytocin receptor antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor."
"The binding domain of barusiban differs from the binding domain of the agonists and the nonselective << oxytocin receptor >> antagonist [[ d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin ]] that has been used in previous studies.",The binding domain of barusiban differs from the binding domain of the agonists and the nonselective [ENTITY_A] antagonist [ENTITY_B] that has been used in previous studies.,ANTAGONIST,CPR:6,3,"The binding domain of barusiban differs from the binding domain of the agonists and the nonselective oxytocin receptor antagonist d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin that has been used in previous studies."
"The compounds << 5'-azacytidine >> (AZC) and procainamide (PCA) belong to inhibitors of [[ DNMT1 ]], whose low activity correlates with increase in transcription of various genes.","The compounds [ENTITY_A] (AZC) and procainamide (PCA) belong to inhibitors of [ENTITY_B], whose low activity correlates with increase in transcription of various genes.",INHIBITOR,CPR:4,1,"The compounds 5'-azacytidine (AZC) and procainamide (PCA) belong to inhibitors of DNMT1, whose low activity correlates with increase in transcription of various genes."
"However, the flowcytometric analysis revealed that << AZC >> and PCA decreased intracellular contents of [[ CD3-zeta chain ]] in these cells in dose dependent manner.","However, the flowcytometric analysis revealed that [ENTITY_A] and PCA decreased intracellular contents of [ENTITY_B] in these cells in dose dependent manner.",INDIRECT-DOWNREGULATOR,CPR:4,1,"However, the flowcytometric analysis revealed that AZC and PCA decreased intracellular contents of CD3-zeta chain in these cells in dose dependent manner."
"Clinical studies in cancer patients treated with the new << fluoropyrimidine >> analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of [[ thymidylate synthase ]] (TS).","Clinical studies in cancer patients treated with the new [ENTITY_A] analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of [ENTITY_B] (TS).",INHIBITOR,CPR:4,1,"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (TS)."
These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to << TS >> inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate ([[ FdUMP ]]).,These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to [ENTITY_A] inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate ([ENTITY_B]).,INHIBITOR,CPR:4,1,These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to TS inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (FdUMP).
Induction of heparin-binding EGF-like growth factor and activation of << EGF receptor >> in [[ imatinib mesylate ]]-treated squamous carcinoma cells.,Induction of heparin-binding EGF-like growth factor and activation of [ENTITY_A] in [ENTITY_B]-treated squamous carcinoma cells.,ACTIVATOR,CPR:3,0,Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
"<< Imatinib mesylate >> is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor ([[ PDGFR ]]), and c-kit kinases.","[ENTITY_A] is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor ([ENTITY_B]), and c-kit kinases.",INHIBITOR,CPR:4,1,"Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases."
Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of << imatinib >>-induced changes in cell morphology and growth similar to changes associated with [[ epidermal growth factor receptor ]] (EGFR) activation.,Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of [ENTITY_A]-induced changes in cell morphology and growth similar to changes associated with [ENTITY_B] (EGFR) activation.,ACTIVATOR,CPR:3,0,Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of imatinib-induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (EGFR) activation.
"<< Imatinib >>-induced changes were blocked with the EGFR antagonist cetuximab, which suggested direct involvement of [[ EGFR ]] in this process.","[ENTITY_A]-induced changes were blocked with the EGFR antagonist cetuximab, which suggested direct involvement of [ENTITY_B] in this process.",ACTIVATOR,CPR:3,0,"Imatinib-induced changes were blocked with the EGFR antagonist cetuximab, which suggested direct involvement of EGFR in this process."
"Western blot analysis of cells incubated with << imatinib >> demonstrated activation of [[ EGFR ]] and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2/ErbB2.","Western blot analysis of cells incubated with [ENTITY_A] demonstrated activation of [ENTITY_B] and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2/ErbB2.",ACTIVATOR,CPR:3,0,"Western blot analysis of cells incubated with imatinib demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2/ErbB2."
"Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced << imatinib >>-mediated [[ mitogen activated protein kinase ]] (MAPK) activation.","Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced [ENTITY_A]-mediated [ENTITY_B] (MAPK) activation.",ACTIVATOR,CPR:3,0,"Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced imatinib-mediated mitogen activated protein kinase (MAPK) activation."
"<< Imatinib >> stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic [[ MAPK ]] activation.","[ENTITY_A] stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic [ENTITY_B] activation.",ACTIVATOR,CPR:3,0,"Imatinib stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic MAPK activation."
"Together, these results suggested that << imatinib >> affects EGFR activation and signaling pathways through rapid release and increased expression of endogenous [[ EGFR ]]-activating ligands.","Together, these results suggested that [ENTITY_A] affects EGFR activation and signaling pathways through rapid release and increased expression of endogenous [ENTITY_B]-activating ligands.",INDIRECT-UPREGULATOR,CPR:3,0,"Together, these results suggested that imatinib affects EGFR activation and signaling pathways through rapid release and increased expression of endogenous EGFR-activating ligands."
"Although, << imatinib >> primarily inhibits tyrosine kinases, it also stimulates the activity of [[ EGFR ]] tyrosine kinase in head and neck squamous tumors.","Although, [ENTITY_A] primarily inhibits tyrosine kinases, it also stimulates the activity of [ENTITY_B] tyrosine kinase in head and neck squamous tumors.",ACTIVATOR,CPR:3,0,"Although, imatinib primarily inhibits tyrosine kinases, it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors."
"Although, << imatinib >> primarily inhibits [[ tyrosine kinases ]], it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors.","Although, [ENTITY_A] primarily inhibits [ENTITY_B], it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors.",INHIBITOR,CPR:4,1,"Although, imatinib primarily inhibits tyrosine kinases, it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors."
"The identity of the lung << beta-ADHs >> was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by [[ 4-methylpyrazole ]] or 1,10-phenanthroline.","The identity of the lung [ENTITY_A] was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by [ENTITY_B] or 1,10-phenanthroline.",INHIBITOR,CPR:4,1,"The identity of the lung beta-ADHs was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline."
"The identity of the lung << beta-ADHs >> was further demonstrated by their characteristic pH-activity profiles for [[ ethanol ]] oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline.","The identity of the lung [ENTITY_A] was further demonstrated by their characteristic pH-activity profiles for [ENTITY_B] oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline.",SUBSTRATE,CPR:9,4,"The identity of the lung beta-ADHs was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline."
These findings indicate that human pulmonary << ethanol >>-metabolizing activities differ significantly with respect to genetic polymorphism at both the [[ ADH2 ]] and the ALDH2 loci.,These findings indicate that human pulmonary [ENTITY_A]-metabolizing activities differ significantly with respect to genetic polymorphism at both the [ENTITY_B] and the ALDH2 loci.,SUBSTRATE,CPR:9,4,These findings indicate that human pulmonary ethanol-metabolizing activities differ significantly with respect to genetic polymorphism at both the ADH2 and the ALDH2 loci.
"The results suggest that individuals with high Vmax << beta 2-ADH >> and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with [[ acetaldehyde ]] accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.","The results suggest that individuals with high Vmax [ENTITY_A] and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with [ENTITY_B] accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.",PRODUCT-OF,CPR:9,4,"The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite."
<< Simvastatin >> induces [[ interleukin-18 ]] production in human peripheral blood mononuclear cells.,[ENTITY_A] induces [ENTITY_B] production in human peripheral blood mononuclear cells.,INDIRECT-UPREGULATOR,CPR:3,0,Simvastatin induces interleukin-18 production in human peripheral blood mononuclear cells.
"<< Simvastatin >>, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of [[ interleukin (IL)-18 ]], tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).","[ENTITY_A], an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of [ENTITY_B], tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).",INDIRECT-UPREGULATOR,CPR:3,0,"Simvastatin, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)."
"<< Simvastatin >>, an [[ HMG-CoA reductase ]] inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).","[ENTITY_A], an [ENTITY_B] inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).",INHIBITOR,CPR:4,1,"Simvastatin, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)."
The IL-18 production is located upstream of the << cytokine >> cascade activated by [[ simvastatin ]].,The IL-18 production is located upstream of the [ENTITY_A] cascade activated by [ENTITY_B].,ACTIVATOR,CPR:3,0,The IL-18 production is located upstream of the cytokine cascade activated by simvastatin.
"Moreover, << simvastatin >> concentration-dependently inhibited the expression of ICAM-1 and induced the expression of [[ CD40 ]] on monocytes.","Moreover, [ENTITY_A] concentration-dependently inhibited the expression of ICAM-1 and induced the expression of [ENTITY_B] on monocytes.",INDIRECT-UPREGULATOR,CPR:3,0,"Moreover, simvastatin concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes."
"Moreover, << simvastatin >> concentration-dependently inhibited the expression of [[ ICAM-1 ]] and induced the expression of CD40 on monocytes.","Moreover, [ENTITY_A] concentration-dependently inhibited the expression of [ENTITY_B] and induced the expression of CD40 on monocytes.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, simvastatin concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes."
"In the presence of IL-18, << simvastatin >> suppressed the expression of ICAM-1 and CD40 as well as the production of [[ IL-12 ]], TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.","In the presence of IL-18, [ENTITY_A] suppressed the expression of ICAM-1 and CD40 as well as the production of [ENTITY_B], TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.",INDIRECT-UPREGULATOR,CPR:3,0,"In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin."
"In the presence of IL-18, << simvastatin >> suppressed the expression of [[ ICAM-1 ]] and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.","In the presence of IL-18, [ENTITY_A] suppressed the expression of [ENTITY_B] and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin."
"The effects of simvastatin were abolished by the addition of the product of the << HMG-CoA reductase >>, [[ mevalonate ]], indicating the involvement of HMG-CoA reductase in the action of simvastatin.","The effects of simvastatin were abolished by the addition of the product of the [ENTITY_A], [ENTITY_B], indicating the involvement of HMG-CoA reductase in the action of simvastatin.",PRODUCT-OF,CPR:9,4,"The effects of simvastatin were abolished by the addition of the product of the HMG-CoA reductase, mevalonate, indicating the involvement of HMG-CoA reductase in the action of simvastatin."
"<< COX-1 >> and COX-2 inhibition in horse blood by [[ phenylbutazone ]], flunixin, carprofen and meloxicam: an in vitro analysis.","[ENTITY_A] and COX-2 inhibition in horse blood by [ENTITY_B], flunixin, carprofen and meloxicam: an in vitro analysis.",INHIBITOR,CPR:4,1,"COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis."
"We report on the inhibitory activity of the NSAIDs meloxicam, << carprofen >>, phenylbutazone and flunixin, on blood [[ cyclooxygenases ]] in the horse using in vitro enzyme-linked assays.","We report on the inhibitory activity of the NSAIDs meloxicam, [ENTITY_A], phenylbutazone and flunixin, on blood [ENTITY_B] in the horse using in vitro enzyme-linked assays.",INHIBITOR,CPR:4,1,"We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, phenylbutazone and flunixin, on blood cyclooxygenases in the horse using in vitro enzyme-linked assays."
"As expected, comparison of IC50 indicated that << meloxicam >> and carprofen are more selective inhibitors of [[ COX-2 ]] than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined.","As expected, comparison of IC50 indicated that [ENTITY_A] and carprofen are more selective inhibitors of [ENTITY_B] than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined.",INHIBITOR,CPR:4,1,"As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of COX-2 than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined."
"However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and << carprofen >> (-12.9%) had lower [[ COX-2 ]] selectivity than at IC50.","However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and [ENTITY_A] (-12.9%) had lower [ENTITY_B] selectivity than at IC50.",INHIBITOR,CPR:4,1,"However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50."
<< Carvedilol >> prevents cardiac hypertrophy and overexpression of [[ hypoxia-inducible factor-1alpha ]] and vascular endothelial growth factor in pressure-overloaded rat heart.,[ENTITY_A] prevents cardiac hypertrophy and overexpression of [ENTITY_B] and vascular endothelial growth factor in pressure-overloaded rat heart.,INDIRECT-DOWNREGULATOR,CPR:4,1,Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.
"Treatment with << carvedilol >> reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and [[ NGF-beta ]] to the baseline values.","Treatment with [ENTITY_A] reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and [ENTITY_B] to the baseline values.",INDIRECT-UPREGULATOR,CPR:3,0,"Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values."
"Treatment with << carvedilol >> reversed both protein and mRNA of [[ HIF-1alpha ]], VEGF, BNP, and NGF-beta to the baseline values.","Treatment with [ENTITY_A] reversed both protein and mRNA of [ENTITY_B], VEGF, BNP, and NGF-beta to the baseline values.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values."
"Increased immunohistochemical labeling of << HIF-1alpha >>, VEGF, and BNP in the ventricular myocardium was observed in the banding group and [[ carvedilol ]] again normalized the labeling.","Increased immunohistochemical labeling of [ENTITY_A], VEGF, and BNP in the ventricular myocardium was observed in the banding group and [ENTITY_B] again normalized the labeling.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Increased immunohistochemical labeling of HIF-1alpha, VEGF, and BNP in the ventricular myocardium was observed in the banding group and carvedilol again normalized the labeling."
"Treatment with << carvedilol >> is associated with a reversal of abnormal regulation of [[ HIF-1alpha ]], VEGF, BNP, and NGF-beta in the hypertrophic myocardium.","Treatment with [ENTITY_A] is associated with a reversal of abnormal regulation of [ENTITY_B], VEGF, BNP, and NGF-beta in the hypertrophic myocardium.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF, BNP, and NGF-beta in the hypertrophic myocardium."
"<< Imatinib >> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of [[ KIT ]], ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","[ENTITY_A] (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of [ENTITY_B], ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",INHIBITOR,CPR:4,1,"Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs."
"Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of << 4-methylhistamine >> as the first potent and selective [[ H4 receptor ]] agonist.","Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of [ENTITY_A] as the first potent and selective [ENTITY_B] agonist.",AGONIST,CPR:5,2,"Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist."
"Most of the tested H(2)R agonists and << imidazole >>-based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic [[ hH(4)R ]] activities, ranging from full agonists to inverse agonists.","Most of the tested H(2)R agonists and [ENTITY_A]-based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic [ENTITY_B] activities, ranging from full agonists to inverse agonists.",AGONIST-ACTIVATOR,CPR:5,2,"Most of the tested H(2)R agonists and imidazole-based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists."
"Moreover, << 4-methylhistamine >> potently activated the [[ hH(4)R ]] (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).","Moreover, [ENTITY_A] potently activated the [ENTITY_B] (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).",ACTIVATOR,CPR:3,0,"Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8)."
"Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective << H(4)R >> antagonist [[ JNJ 7777120 ]] [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).","Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective [ENTITY_A] antagonist [ENTITY_B] [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).",ANTAGONIST,CPR:6,3,"Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8)."
The identification of << 4-methylhistamine >> as a potent [[ H(4)R ]] agonist is of major importance for future studies to unravel the physiological roles of the H(4)R.,The identification of [ENTITY_A] as a potent [ENTITY_B] agonist is of major importance for future studies to unravel the physiological roles of the H(4)R.,AGONIST,CPR:5,2,The identification of 4-methylhistamine as a potent H(4)R agonist is of major importance for future studies to unravel the physiological roles of the H(4)R.
"Irinotecan (CPT-11, << 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin >>) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting [[ DNA topoisomerase I ]] (Topo I).","Irinotecan (CPT-11, [ENTITY_A]) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting [ENTITY_B] (Topo I).",INHIBITOR,CPR:4,1,"Irinotecan (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (Topo I)."
"Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of << acetylcholinesterase >> activity, which can be eliminated by administration of [[ atropine ]].","Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of [ENTITY_A] activity, which can be eliminated by administration of [ENTITY_B].",ACTIVATOR,CPR:3,0,"Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of acetylcholinesterase activity, which can be eliminated by administration of atropine."
"Early-onset diarrhea is observed immediately after << CPT-11 >> infusion and probably due to the inhibition of [[ acetylcholinesterase ]] activity, which can be eliminated by administration of atropine.","Early-onset diarrhea is observed immediately after [ENTITY_A] infusion and probably due to the inhibition of [ENTITY_B] activity, which can be eliminated by administration of atropine.",INHIBITOR,CPR:4,1,"Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of acetylcholinesterase activity, which can be eliminated by administration of atropine."
"<< CPT-11 >> and SN-38 may also stimulate the production of pro-inflammatory [[ cytokines ]] and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-).","[ENTITY_A] and SN-38 may also stimulate the production of pro-inflammatory [ENTITY_B] and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-).",INDIRECT-UPREGULATOR,CPR:3,0,"CPT-11 and SN-38 may also stimulate the production of pro-inflammatory cytokines and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)."
"<< Pyridoxal kinase >> (PDXK) catalyzes the phosphorylation of [[ pyridoxal ]], pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.","[ENTITY_A] (PDXK) catalyzes the phosphorylation of [ENTITY_B], pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.",SUBSTRATE,CPR:9,4,"Pyridoxal kinase (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+."
"<< (R)-Roscovitine >> (CYC202, Seliciclib) is a relatively selective inhibitor of [[ cyclin-dependent kinases ]] (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.","[ENTITY_A] (CYC202, Seliciclib) is a relatively selective inhibitor of [ENTITY_B] (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.",INHIBITOR,CPR:4,1,"(R)-Roscovitine (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections."
"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on << mucin >> secretion was inhibited by EGFR kinase inhibitor, [[ PD153035 ]], as well as wortmannin, a specific inhibitor of PI3K.","Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on [ENTITY_A] secretion was inhibited by EGFR kinase inhibitor, [ENTITY_B], as well as wortmannin, a specific inhibitor of PI3K.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K."
"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as << adenylate cyclase >> activator, [[ forskolin ]].","Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as [ENTITY_A] activator, [ENTITY_B].",ACTIVATOR,CPR:3,0,"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, forskolin."
"Both inhibitors, moreover, blunted the << mucin >> secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, [[ forskolin ]].","Both inhibitors, moreover, blunted the [ENTITY_A] secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, forskolin."
"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, << cAMP >> as well as [[ adenylate cyclase ]] activator, forskolin.","Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, [ENTITY_A] as well as [ENTITY_B] activator, forskolin.",SUBSTRATE,CPR:9,4,"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, forskolin."
"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by << PP2 >>, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent [[ EGFR ]] autophosphorylation, but not by ERK inhibitor, PD98059.","The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by [ENTITY_A], a selective inhibitor of tyrosine kinase Src responsible for ligand-independent [ENTITY_B] autophosphorylation, but not by ERK inhibitor, PD98059.",ACTIVATOR,CPR:3,0,"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059."
"The << gastric mucin >> secretory responses to isoproterenol, furthermore, were inhibited by [[ PP2 ]], a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.","The [ENTITY_A] secretory responses to isoproterenol, furthermore, were inhibited by [ENTITY_B], a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059."
"The inhibition of << ERK >>, moreover, did not cause attenuation in mucin secretion in response to [[ cAMP ]] and forskolin.","The inhibition of [ENTITY_A], moreover, did not cause attenuation in mucin secretion in response to [ENTITY_B] and forskolin.",INHIBITOR,CPR:4,1,"The inhibition of ERK, moreover, did not cause attenuation in mucin secretion in response to cAMP and forskolin."
<< Losartan >>: a selective [[ angiotensin II type 1 (AT1) receptor ]] antagonist for the treatment of heart failure.,[ENTITY_A]: a selective [ENTITY_B] antagonist for the treatment of heart failure.,ANTAGONIST,CPR:6,3,Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure.
<< Losartan >> (COZAAR) is the prototype of a new class of potent and selective [[ angiotensin II (AII) type 1 (AT(1)) receptor ]] antagonists with the largest published preclinical and clinical data base.,[ENTITY_A] (COZAAR) is the prototype of a new class of potent and selective [ENTITY_B] antagonists with the largest published preclinical and clinical data base.,ANTAGONIST,CPR:6,3,Losartan (COZAAR) is the prototype of a new class of potent and selective angiotensin II (AII) type 1 (AT(1)) receptor antagonists with the largest published preclinical and clinical data base.
<< Losartan >> is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the [[ AT(1) receptor ]] (non-competitive inhibition).,[ENTITY_A] is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the [ENTITY_B] (non-competitive inhibition).,INHIBITOR,CPR:4,1,Losartan is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the AT(1) receptor (non-competitive inhibition).
"Clinical experience in heart failure is growing, and recent data suggest an improved survival with << losartan >> versus captopril, a drug from the [[ angiotensin-converting-enzyme ]] inhibitor class with proven benefit in this population.","Clinical experience in heart failure is growing, and recent data suggest an improved survival with [ENTITY_A] versus captopril, a drug from the [ENTITY_B] inhibitor class with proven benefit in this population.",INHIBITOR,CPR:4,1,"Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus captopril, a drug from the angiotensin-converting-enzyme inhibitor class with proven benefit in this population."
"The current comprehensive losartan clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the << AT(1) receptor >> with [[ losartan ]] compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.","The current comprehensive losartan clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the [ENTITY_A] with [ENTITY_B] compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.",INHIBITOR,CPR:4,1,"The current comprehensive losartan clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the AT(1) receptor with losartan compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL."
"We now demonstrate that << amrinone >>, a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced [[ TNF ]] production at concentrations readily achieved in vivo.","We now demonstrate that [ENTITY_A], a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced [ENTITY_B] production at concentrations readily achieved in vivo.",INDIRECT-DOWNREGULATOR,CPR:4,1,"We now demonstrate that amrinone, a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced TNF production at concentrations readily achieved in vivo."
Combined application of << dexamethasone >> and amrinone caused additive inhibition of [[ TNF ]] biosynthesis in vitro.,Combined application of [ENTITY_A] and amrinone caused additive inhibition of [ENTITY_B] biosynthesis in vitro.,INHIBITOR,CPR:4,1,Combined application of dexamethasone and amrinone caused additive inhibition of TNF biosynthesis in vitro.
"Abrupt removal of << amrinone >> or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented [[ TNF ]] production.","Abrupt removal of [ENTITY_A] or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented [ENTITY_B] production.",INDIRECT-UPREGULATOR,CPR:3,0,"Abrupt removal of amrinone or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented TNF production."
"In the present study, age-related changes of << pyridoxal 5'-phosphate >> (PLP) synthesizing enzymes, pyridoxal kinase ([[ PLK ]]) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.","In the present study, age-related changes of [ENTITY_A] (PLP) synthesizing enzymes, pyridoxal kinase ([ENTITY_B]) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.",PRODUCT-OF,CPR:9,4,"In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper."
"Therefore, decreases of << PLK >> and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with [[ gamma-aminobutyric acid ]] (GABA) function.","Therefore, decreases of [ENTITY_A] and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with [ENTITY_B] (GABA) function.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Therefore, decreases of PLK and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid (GABA) function."
"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical << monocarboxylate transporter >> (MCT) inhibitor, [[ alpha-cyano-4-hydroxycinnamic acid ]], suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.","This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical [ENTITY_A] (MCT) inhibitor, [ENTITY_B], suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.",INHIBITOR,CPR:4,1,"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system."
"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that << nicotinate >> uptake by rat astrocytes is mediated by H(+)-coupled [[ monocarboxylate transport system ]].","This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that [ENTITY_A] uptake by rat astrocytes is mediated by H(+)-coupled [ENTITY_B].",SUBSTRATE,CPR:9,4,"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system."
"Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that << nicotinate >> uptake in rat astrocytes is mediated by [[ MCT1 ]] and/or MCT2.","Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that [ENTITY_A] uptake in rat astrocytes is mediated by [ENTITY_B] and/or MCT2.",SUBSTRATE,CPR:9,4,"Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by MCT1 and/or MCT2."
"These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a << low-affinity monocarboxylate transporter >> MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for [[ nicotinate ]] in rat cerebrocortical astrocytes.","These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a [ENTITY_A] MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for [ENTITY_B] in rat cerebrocortical astrocytes.",SUBSTRATE,CPR:9,4,"These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes."
"A review of the structural and functional features of << olmesartan medoxomil >>, an [[ angiotensin receptor ]] blocker.","A review of the structural and functional features of [ENTITY_A], an [ENTITY_B] blocker.",INHIBITOR,CPR:4,1,"A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker."
"The marked antihypertensive efficacy of << olmesartan medoxomil >> may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of [[ A-II ]].","The marked antihypertensive efficacy of [ENTITY_A] may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of [ENTITY_B].",INHIBITOR,CPR:4,1,"The marked antihypertensive efficacy of olmesartan medoxomil may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of A-II."
Effects of << granulocyte colony-stimulating factor >> (G-CSF) and neutrophil elastase inhibitor ([[ ONO-5046 ]]) on acid-induced lung injury in rats.,Effects of [ENTITY_A] (G-CSF) and neutrophil elastase inhibitor ([ENTITY_B]) on acid-induced lung injury in rats.,INHIBITOR,CPR:4,1,Effects of granulocyte colony-stimulating factor (G-CSF) and neutrophil elastase inhibitor (ONO-5046) on acid-induced lung injury in rats.
"We examined the effects of the high dose of granulocyte-colony stimulating factor (G-CSF), which is capable of increasing peripheral neutrophils, and a specific << neutrophil elastase >> inhibitor ([[ ONO-5046 ]]) on acid lung injury in rats.","We examined the effects of the high dose of granulocyte-colony stimulating factor (G-CSF), which is capable of increasing peripheral neutrophils, and a specific [ENTITY_A] inhibitor ([ENTITY_B]) on acid lung injury in rats.",INHIBITOR,CPR:4,1,"We examined the effects of the high dose of granulocyte-colony stimulating factor (G-CSF), which is capable of increasing peripheral neutrophils, and a specific neutrophil elastase inhibitor (ONO-5046) on acid lung injury in rats."
"<< Miglustat >>, an imino sugar that reversibly inhibits [[ glucosylceramide synthase ]] and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option.","[ENTITY_A], an imino sugar that reversibly inhibits [ENTITY_B] and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option.",INHIBITOR,CPR:4,1,"Miglustat, an imino sugar that reversibly inhibits glucosylceramide synthase and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option."
"Nicotinic-receptor potentiator drugs, huprine X and << galantamine >>, increase ACh release by blocking [[ AChE ]] activity but not acting on nicotinic receptors.","Nicotinic-receptor potentiator drugs, huprine X and [ENTITY_A], increase ACh release by blocking [ENTITY_B] activity but not acting on nicotinic receptors.",INHIBITOR,CPR:4,1,"Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors."
"This effect was reverted in the presence of << atropine >> (ATR; 0.1 microM), which blocks the pre-synaptic [[ muscarinic M2 receptor ]].","This effect was reverted in the presence of [ENTITY_A] (ATR; 0.1 microM), which blocks the pre-synaptic [ENTITY_B].",INHIBITOR,CPR:4,1,"This effect was reverted in the presence of atropine (ATR; 0.1 microM), which blocks the pre-synaptic muscarinic M2 receptor."
"After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of << haloperidol >> (HAL; 0.01 microM), a [[ dopamine D2 ]] antagonist.","After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of [ENTITY_A] (HAL; 0.01 microM), a [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a dopamine D2 antagonist."
"To test the role of << nicotinic receptors >> in the drugs' effects on [3H]-ACh release, [[ mecamylamine ]] (MEC) 100 microM was used to block such receptors.","To test the role of [ENTITY_A] in the drugs' effects on [3H]-ACh release, [ENTITY_B] (MEC) 100 microM was used to block such receptors.",INHIBITOR,CPR:4,1,"To test the role of nicotinic receptors in the drugs' effects on [3H]-ACh release, mecamylamine (MEC) 100 microM was used to block such receptors."
"mRNA levels for << RAR-alpha >>, RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with [[ retinoid ]] supplementation.","mRNA levels for [ENTITY_A], RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with [ENTITY_B] supplementation.",INDIRECT-DOWNREGULATOR,CPR:4,1,"mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation."
"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of << fenoterol >> decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the [[ beta(2)-adrenoceptor ]].","Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of [ENTITY_A] decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the [ENTITY_B].",DOWNREGULATOR,CPR:4,1,"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the beta(2)-adrenoceptor."
"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased << isoprenaline >>-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the [[ beta(2)-adrenoceptor ]].","Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased [ENTITY_A]-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the [ENTITY_B].",AGONIST,CPR:5,2,"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the beta(2)-adrenoceptor."
"Preincubation with 1 microM of the << protein kinase C >> (PKC) activator phorbol 12-myristate 13-acetate ([[ PMA ]]) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.","Preincubation with 1 microM of the [ENTITY_A] (PKC) activator phorbol 12-myristate 13-acetate ([ENTITY_B]) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.",ACTIVATOR,CPR:3,0,"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization."
"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (<< PMA >>) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous [[ beta(2)-adrenoceptor ]] desensitization.","Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate ([ENTITY_A]) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous [ENTITY_B] desensitization.",DOWNREGULATOR,CPR:4,1,"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization."
"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in << isoprenaline >>-induced E(max), indicating activated PKC-mediated heterologous [[ beta(2)-adrenoceptor ]] desensitization.","Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in [ENTITY_A]-induced E(max), indicating activated PKC-mediated heterologous [ENTITY_B] desensitization.",AGONIST,CPR:5,2,"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization."
"Moreover, the specific << PKC >>-inhibitor [[ 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide ]] (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented.","Moreover, the specific [ENTITY_A]-inhibitor [ENTITY_B] (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented.",INHIBITOR,CPR:4,1,"Moreover, the specific PKC-inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented."
"Tyrosine kinase inhibitors are << quinazoline >>-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of [[ EGFR ]] signaling.","Tyrosine kinase inhibitors are [ENTITY_A]-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of [ENTITY_B] signaling.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Tyrosine kinase inhibitors are quinazoline-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling."
"When expressed heterologously in a mammalian cell line, << rabbit PAT1 >> mediates pH-dependent, Na(+)-independent uptake of [[ proline ]], glycine, l-alanine and alpha-(methylamino)isobutyric acid.","When expressed heterologously in a mammalian cell line, [ENTITY_A] mediates pH-dependent, Na(+)-independent uptake of [ENTITY_B], glycine, l-alanine and alpha-(methylamino)isobutyric acid.",SUBSTRATE,CPR:9,4,"When expressed heterologously in a mammalian cell line, rabbit PAT1 mediates pH-dependent, Na(+)-independent uptake of proline, glycine, l-alanine and alpha-(methylamino)isobutyric acid."
"In the presence of Na+ and under conditions in which << PAT1 >> transport function was suppressed, a second [[ proline ]] uptake system was detected that exhibited functional characteristics similar to those of the IMINO system.","In the presence of Na+ and under conditions in which [ENTITY_A] transport function was suppressed, a second [ENTITY_B] uptake system was detected that exhibited functional characteristics similar to those of the IMINO system.",SUBSTRATE,CPR:9,4,"In the presence of Na+ and under conditions in which PAT1 transport function was suppressed, a second proline uptake system was detected that exhibited functional characteristics similar to those of the IMINO system."
"The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that << PAT1 >> is the low-affinity transporter of [[ proline ]], glycine and hydroxyproline believed to be defective in patients with iminoglycinuria.","The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that [ENTITY_A] is the low-affinity transporter of [ENTITY_B], glycine and hydroxyproline believed to be defective in patients with iminoglycinuria.",SUBSTRATE,CPR:9,4,"The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that PAT1 is the low-affinity transporter of proline, glycine and hydroxyproline believed to be defective in patients with iminoglycinuria."
The fact that << trimipramine >> also suppressed [[ IFN-gamma ]] production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake.,The fact that [ENTITY_A] also suppressed [ENTITY_B] production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake.,INDIRECT-DOWNREGULATOR,CPR:4,1,The fact that trimipramine also suppressed IFN-gamma production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake.
"The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean << leptin >> level after 1 week of treatment with [[ cyproheptadine ]] (3.14 ng/mL) was 14.2% higher than that at baseline (2.75 ng/mL; P < .05).","The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean [ENTITY_A] level after 1 week of treatment with [ENTITY_B] (3.14 ng/mL) was 14.2% higher than that at baseline (2.75 ng/mL; P < .05).",INDIRECT-UPREGULATOR,CPR:3,0,"The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean leptin level after 1 week of treatment with cyproheptadine (3.14 ng/mL) was 14.2% higher than that at baseline (2.75 ng/mL; P < .05)."
Comparison of << captopril >> and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with [[ ACE ]] inhibitors in high dieted methionine mice.,Comparison of [ENTITY_A] and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with [ENTITY_B] inhibitors in high dieted methionine mice.,INHIBITOR,CPR:4,1,Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in high dieted methionine mice.
"We compared the effects of << Captopril >> (an [[ ACE ]] inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.","We compared the effects of [ENTITY_A] (an [ENTITY_B] inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.",INHIBITOR,CPR:4,1,"We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats."
"It was found that a single intragastric gavage by << L-methionine >> resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of [[ PON1 ]] and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.","It was found that a single intragastric gavage by [ENTITY_A] resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of [ENTITY_B] and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.",INHIBITOR,CPR:4,1,"It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group."
"Given the treatment with three doses of << Captopril >> (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of [[ PON1 ]] and SOD in serum by single intragastric gavaged L-methionine.","Given the treatment with three doses of [ENTITY_A] (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of [ENTITY_B] and SOD in serum by single intragastric gavaged L-methionine.",ACTIVATOR,CPR:3,0,"Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and SOD in serum by single intragastric gavaged L-methionine."
"These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of << Captopril >> may be related to attenuating the decrease in [[ PON1 ]] activity and NO levels.","These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of [ENTITY_A] may be related to attenuating the decrease in [ENTITY_B] activity and NO levels.",ACTIVATOR,CPR:3,0,"These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in PON1 activity and NO levels."
"These results suggested that Captopril can protect the vascular endothelium against the damages induced by << L-methionine >> in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in [[ PON1 ]] activity and NO levels.","These results suggested that Captopril can protect the vascular endothelium against the damages induced by [ENTITY_A] in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in [ENTITY_B] activity and NO levels.",INHIBITOR,CPR:4,1,"These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in PON1 activity and NO levels."
"<< Sorafenib >>, which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of [[ Raf-1 ]] and its favorable kinase selectivity profile.","[ENTITY_A], which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of [ENTITY_B] and its favorable kinase selectivity profile.",INHIBITOR,CPR:4,1,"Sorafenib, which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable kinase selectivity profile."
Further characterization showed that << sorafenib >> suppresses both wild-type and [[ V599E ]] mutant B-Raf activity in vitro.,Further characterization showed that [ENTITY_A] suppresses both wild-type and [ENTITY_B] mutant B-Raf activity in vitro.,INHIBITOR,CPR:4,1,Further characterization showed that sorafenib suppresses both wild-type and V599E mutant B-Raf activity in vitro.
"In addition, << sorafenib >> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, [[ VEGFR-3 ]], platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.","In addition, [ENTITY_A] demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, [ENTITY_B], platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.",UPREGULATOR,CPR:3,0,"In addition, sorafenib demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT."
"A selective << retinoid X receptor >> agonist [[ bexarotene ]] (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.","A selective [ENTITY_A] agonist [ENTITY_B] (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.",AGONIST,CPR:5,2,"A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours."
The present study determined the influence of a << retinoid X receptor >> agonist [[ bexarotene ]] on angiogenesis and metastasis in solid tumours.,The present study determined the influence of a [ENTITY_A] agonist [ENTITY_B] on angiogenesis and metastasis in solid tumours.,AGONIST,CPR:5,2,The present study determined the influence of a retinoid X receptor agonist bexarotene on angiogenesis and metastasis in solid tumours.
Analysis of tumour-conditioned medium indicated that << bexarotene >> decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of [[ matrix metalloproteinases ]].,Analysis of tumour-conditioned medium indicated that [ENTITY_A] decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,Analysis of tumour-conditioned medium indicated that bexarotene decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of matrix metalloproteinases.
Analysis of tumour-conditioned medium indicated that << bexarotene >> decreased the secretion of angiogenic factors and [[ matrix metalloproteinases ]] and increased the tissue inhibitor of matrix metalloproteinases.,Analysis of tumour-conditioned medium indicated that [ENTITY_A] decreased the secretion of angiogenic factors and [ENTITY_B] and increased the tissue inhibitor of matrix metalloproteinases.,INDIRECT-DOWNREGULATOR,CPR:4,1,Analysis of tumour-conditioned medium indicated that bexarotene decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of matrix metalloproteinases.
The ability of << bexarotene >> to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner [[ peroxisome proliferator-activated receptor gamma ]].,The ability of [ENTITY_A] to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner [ENTITY_B].,ACTIVATOR,CPR:3,0,The ability of bexarotene to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner peroxisome proliferator-activated receptor gamma.
In subjects with dysmenorrhea the increase in pain following the administration of << vasopressin >> was significantly lower during [[ atosiban ]] than during placebo infusion.,In subjects with dysmenorrhea the increase in pain following the administration of [ENTITY_A] was significantly lower during [ENTITY_B] than during placebo infusion.,INDIRECT-DOWNREGULATOR,CPR:4,1,In subjects with dysmenorrhea the increase in pain following the administration of vasopressin was significantly lower during atosiban than during placebo infusion.
"CONCLUSIONS: << Atosiban >> reduces [[ vasopressin ]]-induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea.","CONCLUSIONS: [ENTITY_A] reduces [ENTITY_B]-induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea.",INDIRECT-DOWNREGULATOR,CPR:4,1,"CONCLUSIONS: Atosiban reduces vasopressin-induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea."
"Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the << acetylcholinesterase >> inhibitor [[ tacrine ]].","Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the [ENTITY_A] inhibitor [ENTITY_B].",INHIBITOR,CPR:4,1,"Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor tacrine."
"Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main << histamine >> metabolizing enzyme in the brain, [[ N-methyltransferase ]], chemically show structural elements of the acetylcholinesterase inhibitor tacrine.","Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main [ENTITY_A] metabolizing enzyme in the brain, [ENTITY_B], chemically show structural elements of the acetylcholinesterase inhibitor tacrine.",SUBSTRATE,CPR:9,4,"Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor tacrine."
Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of << acetylcholinesterase >> and of butyrylcholinesterase which is another catalytic enzyme hydrolysing [[ acetylcholine ]].,Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of [ENTITY_A] and of butyrylcholinesterase which is another catalytic enzyme hydrolysing [ENTITY_B].,SUBSTRATE,CPR:9,4,Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of acetylcholinesterase and of butyrylcholinesterase which is another catalytic enzyme hydrolysing acetylcholine.
"For some, pharmacologic inhibitors are available, including << sorafenib >> for [[ BRAF ]], farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.","For some, pharmacologic inhibitors are available, including [ENTITY_A] for [ENTITY_B], farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.",INHIBITOR,CPR:4,1,"For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors."
"This aminophospholipid ""<< flippase >>"" selectively transports [[ PS ]] to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents.","This aminophospholipid ""[ENTITY_A]"" selectively transports [ENTITY_B] to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents.",SUBSTRATE,CPR:9,4,"This aminophospholipid ""flippase"" selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents."
"The purified << Atp8a1 >> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by [[ phosphatidylglycerol ]] or phosphatidylethanolamine (PE), and is maximally activated by PS.","The purified [ENTITY_A] is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by [ENTITY_B] or phosphatidylethanolamine (PE), and is maximally activated by PS.",ACTIVATOR,CPR:3,0,"The purified Atp8a1 is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS."
"Similar to the << plasma membrane PS transporter >>, Atp8a1 is activated only by the naturally occurring [[ sn-1,2-glycerol ]] isomer of PS and not the sn-2,3-glycerol stereoisomer.","Similar to the [ENTITY_A], Atp8a1 is activated only by the naturally occurring [ENTITY_B] isomer of PS and not the sn-2,3-glycerol stereoisomer.",ACTIVATOR,CPR:3,0,"Similar to the plasma membrane PS transporter, Atp8a1 is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the sn-2,3-glycerol stereoisomer."
"Activation of << Atp8a1 >> is also reduced by these modifications; [[ phosphatidylserine-O-methyl ester ]], lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.","Activation of [ENTITY_A] is also reduced by these modifications; [ENTITY_B], lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.",DOWNREGULATOR,CPR:4,1,"Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1."
"Weakly translocated lipids (<< PE >>, phosphatidylhydroxypropionate, and phosphatidylhomoserine) are also weak [[ Atp8a1 ]] activators.","Weakly translocated lipids ([ENTITY_A], phosphatidylhydroxypropionate, and phosphatidylhomoserine) are also weak [ENTITY_B] activators.",ACTIVATOR,CPR:3,0,"Weakly translocated lipids (PE, phosphatidylhydroxypropionate, and phosphatidylhomoserine) are also weak Atp8a1 activators."
"However, << N-methyl-phosphatidylserine >>, which is transported by the plasma membrane [[ flippase ]] at a rate equivalent to PS, is incapable of activating Atp8a1 activity.","However, [ENTITY_A], which is transported by the plasma membrane [ENTITY_B] at a rate equivalent to PS, is incapable of activating Atp8a1 activity.",SUBSTRATE,CPR:9,4,"However, N-methyl-phosphatidylserine, which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating Atp8a1 activity."
"These results indicate that the << ATPase >> activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties ([[ PS ]] selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.","These results indicate that the [ENTITY_A] activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties ([ENTITY_B] selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.",ACTIVATOR,CPR:3,0,"These results indicate that the ATPase activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties (PS selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase."
<< Sorafenib >> (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of [[ tyrosine kinases ]] that are known to be involved in tumor cell proliferation and tumor angiogenesis.,[ENTITY_A] (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of [ENTITY_B] that are known to be involved in tumor cell proliferation and tumor angiogenesis.,INHIBITOR,CPR:4,1,Sorafenib (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of tyrosine kinases that are known to be involved in tumor cell proliferation and tumor angiogenesis.
<< Hydrogen sulfide >> inhibits nitric oxide production and [[ nuclear factor-kappaB ]] via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide.,[ENTITY_A] inhibits nitric oxide production and [ENTITY_B] via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide.,INHIBITOR,CPR:4,1,Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide.
"Hydrogen sulfide (<< H(2)S >>), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ([[ CSE ]]) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Hydrogen sulfide ([ENTITY_A]), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ([ENTITY_B]) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",PRODUCT-OF,CPR:9,4,"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored."
"Here, we show that at noncytotoxic concentrations, << H(2)S >> was able to inhibit NO production and [[ inducible NO synthase ]] (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Here, we show that at noncytotoxic concentrations, [ENTITY_A] was able to inhibit NO production and [ENTITY_B] (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).",INDIRECT-DOWNREGULATOR,CPR:4,1,"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible NO synthase (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)."
"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit << NO >> production and [[ inducible NO synthase ]] (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit [ENTITY_A] production and [ENTITY_B] (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).",PRODUCT-OF,CPR:9,4,"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible NO synthase (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)."
"Both << H(2)S >> solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the [[ extracellular signal-regulated kinase ]] (ERK).","Both [ENTITY_A] solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the [ENTITY_B] (ERK).",ACTIVATOR,CPR:3,0,"Both H(2)S solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase (ERK)."
Pretreatment with << H(2)S >> or NaHS significantly inhibited LPS-induced [[ iNOS ]] expression and NO production.,Pretreatment with [ENTITY_A] or NaHS significantly inhibited LPS-induced [ENTITY_B] expression and NO production.,INDIRECT-DOWNREGULATOR,CPR:4,1,Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced iNOS expression and NO production.
Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced << iNOS >> expression and [[ NO ]] production.,Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced [ENTITY_A] expression and [ENTITY_B] production.,PRODUCT-OF,CPR:9,4,Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced iNOS expression and NO production.
"Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective << CSE >> inhibitor [[ beta-cyano-L-alanine ]] but not by the CBS inhibitor aminooxyacetic acid.","Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective [ENTITY_A] inhibitor [ENTITY_B] but not by the CBS inhibitor aminooxyacetic acid.",INHIBITOR,CPR:4,1,"Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid."
"Moreover, NO production in LPS-stimulated macrophages that are expressing << CSE >> mRNA was significantly reduced by the addition of [[ L-Cys ]], a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid.","Moreover, NO production in LPS-stimulated macrophages that are expressing [ENTITY_A] mRNA was significantly reduced by the addition of [ENTITY_B], a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid.",SUBSTRATE,CPR:9,4,"Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid."
"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of << H(2)S >> on [[ iNOS ]] expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S.","While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of [ENTITY_A] on [ENTITY_B] expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S.",INDIRECT-DOWNREGULATOR,CPR:4,1,"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S."
"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on << iNOS >> expression and [[ NO ]] production, HO-1 overexpression produced the same inhibitory effects of H(2)S.","While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on [ENTITY_A] expression and [ENTITY_B] production, HO-1 overexpression produced the same inhibitory effects of H(2)S.",PRODUCT-OF,CPR:9,4,"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S."
"In addition, LPS-induced nuclear factor << (NF)-kappaB >> activation was diminished in RAW264.7 macrophages preincubated with [[ H(2)S ]].","In addition, LPS-induced nuclear factor [ENTITY_A] activation was diminished in RAW264.7 macrophages preincubated with [ENTITY_B].",INHIBITOR,CPR:4,1,"In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S."
"Interestingly, the inhibitory effect of << H(2)S >> on [[ NF-kappaB ]] activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.","Interestingly, the inhibitory effect of [ENTITY_A] on [ENTITY_B] activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.",INHIBITOR,CPR:4,1,"Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1."
"Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with << carbon monoxide >> (CO), an end product of [[ HO-1 ]].","Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with [ENTITY_A] (CO), an end product of [ENTITY_B].",PRODUCT-OF,CPR:9,4,"Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1."
<< CO >> treatment also inhibited LPS-induced NO production and [[ iNOS ]] expression via its inactivation of NF-kappaB.,[ENTITY_A] treatment also inhibited LPS-induced NO production and [ENTITY_B] expression via its inactivation of NF-kappaB.,INDIRECT-DOWNREGULATOR,CPR:4,1,CO treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB.
CO treatment also inhibited LPS-induced << NO >> production and [[ iNOS ]] expression via its inactivation of NF-kappaB.,CO treatment also inhibited LPS-induced [ENTITY_A] production and [ENTITY_B] expression via its inactivation of NF-kappaB.,PRODUCT-OF,CPR:9,4,CO treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB.
"Collectively, our results suggest that << H(2)S >> can inhibit NO production and [[ NF-kappaB ]] activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/CO.","Collectively, our results suggest that [ENTITY_A] can inhibit NO production and [ENTITY_B] activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/CO.",INHIBITOR,CPR:4,1,"Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/CO."
"Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of << HO-1 >>/[[ CO ]].","Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of [ENTITY_A]/[ENTITY_B].",PRODUCT-OF,CPR:9,4,"Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/CO."
Sources of << L-arg >> include dietary proteins and endogenous synthesis by [[ argininosuccinate synthetase ]] and argininosuccinate lyase.,Sources of [ENTITY_A] include dietary proteins and endogenous synthesis by [ENTITY_B] and argininosuccinate lyase.,PRODUCT-OF,CPR:9,4,Sources of L-arg include dietary proteins and endogenous synthesis by argininosuccinate synthetase and argininosuccinate lyase.
L-arg is converted to << urea >> by [[ arginase I ]] in the liver and arginase II in the kidney.,L-arg is converted to [ENTITY_A] by [ENTITY_B] in the liver and arginase II in the kidney.,PRODUCT-OF,CPR:9,4,L-arg is converted to urea by arginase I in the liver and arginase II in the kidney.
"We hypothesized that preservation of plasma << L-arg >> in CRF may be, partly, due to downregulation/inhibition of [[ arginase ]].","We hypothesized that preservation of plasma [ENTITY_A] in CRF may be, partly, due to downregulation/inhibition of [ENTITY_B].",SUBSTRATE,CPR:9,4,"We hypothesized that preservation of plasma L-arg in CRF may be, partly, due to downregulation/inhibition of arginase."
"However, in vitro experiments simulating a uremic milieu revealed a marked concentration-dependent inhibition of << arginase >> activity by [[ urea ]] in the tissue lysates.","However, in vitro experiments simulating a uremic milieu revealed a marked concentration-dependent inhibition of [ENTITY_A] activity by [ENTITY_B] in the tissue lysates.",INHIBITOR,CPR:4,1,"However, in vitro experiments simulating a uremic milieu revealed a marked concentration-dependent inhibition of arginase activity by urea in the tissue lysates."
"CONCLUSIONS: Although CRF does not change the abundance or intrinsic properties of << arginase >>, the inherent rise in [[ urea ]] concentration inhibits its enzymatic activity.","CONCLUSIONS: Although CRF does not change the abundance or intrinsic properties of [ENTITY_A], the inherent rise in [ENTITY_B] concentration inhibits its enzymatic activity.",INHIBITOR,CPR:4,1,"CONCLUSIONS: Although CRF does not change the abundance or intrinsic properties of arginase, the inherent rise in urea concentration inhibits its enzymatic activity."
"However, several promising nonpeptide, << vasopressin receptor >> antagonists have been described; these agents are [[ VPA-985 ]] (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.","However, several promising nonpeptide, [ENTITY_A] antagonists have been described; these agents are [ENTITY_B] (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.",ANTAGONIST,CPR:6,3,"However, several promising nonpeptide, vasopressin receptor antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463."
Sedation and << histamine H1-receptor >> antagonism: studies in man with the enantiomers of chlorpheniramine and [[ dimethindene ]].,Sedation and [ENTITY_A] antagonism: studies in man with the enantiomers of chlorpheniramine and [ENTITY_B].,ANTAGONIST,CPR:6,3,Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene.
"BG also showed a protective effect in the presence of a << DNA polymerase beta >> inhibitor ([[ cytosine arabinoside-3-phosphate ]], Ara-C), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta.","BG also showed a protective effect in the presence of a [ENTITY_A] inhibitor ([ENTITY_B], Ara-C), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta.",INHIBITOR,CPR:4,1,"BG also showed a protective effect in the presence of a DNA polymerase beta inhibitor (cytosine arabinoside-3-phosphate, Ara-C), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta."
"Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the << HMG-CoA reductase >> inhibitor [[ rosuvastatin ]] and their combination.","Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the [ENTITY_A] inhibitor [ENTITY_B] and their combination.",INHIBITOR,CPR:4,1,"Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination."
Our purpose was to test the impact of single and/or combined treatment with the << AT(1) >>-receptor blocker [[ candesartan ]] and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats.,Our purpose was to test the impact of single and/or combined treatment with the [ENTITY_A]-receptor blocker [ENTITY_B] and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats.,INHIBITOR,CPR:4,1,Our purpose was to test the impact of single and/or combined treatment with the AT(1)-receptor blocker candesartan and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats.
Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to << phosphatidic acid >> by [[ DAG kinase ]] (DGK).,Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to [ENTITY_A] by [ENTITY_B] (DGK).,PRODUCT-OF,CPR:9,4,Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (DGK).
Monoclonal antibody 25B1 generated against << diisopropyl phosphorofluoridate >> inhibited fetal [[ bovine serum acetylcholinesterase ]] has been extensively characterized with respect to its anticholinesterase properties.,Monoclonal antibody 25B1 generated against [ENTITY_A] inhibited fetal [ENTITY_B] has been extensively characterized with respect to its anticholinesterase properties.,INHIBITOR,CPR:4,1,Monoclonal antibody 25B1 generated against diisopropyl phosphorofluoridate inhibited fetal bovine serum acetylcholinesterase has been extensively characterized with respect to its anticholinesterase properties.
Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of << acetylcholinesterase >> against denaturation by heat or [[ guanidine ]] following phosphorylation by organophosphorus anticholinesterase compounds.,Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of [ENTITY_A] against denaturation by heat or [ENTITY_B] following phosphorylation by organophosphorus anticholinesterase compounds.,DOWNREGULATOR,CPR:4,1,Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of acetylcholinesterase against denaturation by heat or guanidine following phosphorylation by organophosphorus anticholinesterase compounds.
The << sordarins >> group are protein synthesis inhibitors that work by blocking the function of [[ fungal translation elongation factor 2 ]].,The [ENTITY_A] group are protein synthesis inhibitors that work by blocking the function of [ENTITY_B].,INHIBITOR,CPR:4,1,The sordarins group are protein synthesis inhibitors that work by blocking the function of fungal translation elongation factor 2.
"Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by << D-myo-inositol 1,4,5-trisphosphate >> (IP3), a [[ PLC-beta ]] hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.","Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by [ENTITY_A] (IP3), a [ENTITY_B] hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.",PRODUCT-OF,CPR:9,4,"Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays."
"It has been known for decades that << lithium chloride >> (LiCl) leads to D-myo-inositol 1-phosphate accumulation on [[ GPCR ]] activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade.","It has been known for decades that [ENTITY_A] (LiCl) leads to D-myo-inositol 1-phosphate accumulation on [ENTITY_B] activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade.",ACTIVATOR,CPR:3,0,"It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade."
"It has been known for decades that << lithium chloride >> (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting [[ inositol monophosphatase ]], the final enzyme of the IP3 metabolic cascade.","It has been known for decades that [ENTITY_A] (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting [ENTITY_B], the final enzyme of the IP3 metabolic cascade.",INHIBITOR,CPR:4,1,"It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade."
"It has been known for decades that lithium chloride (LiCl) leads to << D-myo-inositol 1-phosphate >> accumulation on GPCR activation by inhibiting [[ inositol monophosphatase ]], the final enzyme of the IP3 metabolic cascade.","It has been known for decades that lithium chloride (LiCl) leads to [ENTITY_A] accumulation on GPCR activation by inhibiting [ENTITY_B], the final enzyme of the IP3 metabolic cascade.",SUBSTRATE,CPR:9,4,"It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade."
"Once formed, the molecule can be converted to << glycine >> by [[ alanine-glyoxylate aminotransferase ]] (AGAT).","Once formed, the molecule can be converted to [ENTITY_A] by [ENTITY_B] (AGAT).",PRODUCT-OF,CPR:9,4,"Once formed, the molecule can be converted to glycine by alanine-glyoxylate aminotransferase (AGAT)."
<< 11Beta-HSD1 >> activates cortisone to [[ cortisol ]] to facilitate glucocorticoid receptor (GR)-mediated action.,[ENTITY_A] activates cortisone to [ENTITY_B] to facilitate glucocorticoid receptor (GR)-mediated action.,PRODUCT-OF,CPR:9,4,11Beta-HSD1 activates cortisone to cortisol to facilitate glucocorticoid receptor (GR)-mediated action.
"By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the << mineralocorticoid receptor >> (MR) by [[ cortisol ]].","By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the [ENTITY_A] (MR) by [ENTITY_B].",ACTIVATOR,CPR:3,0,"By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor (MR) by cortisol."
"By contrast, << 11beta-HSD2 >> plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to [[ cortisone ]]) to prevent activation of the mineralocorticoid receptor (MR) by cortisol.","By contrast, [ENTITY_A] plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to [ENTITY_B]) to prevent activation of the mineralocorticoid receptor (MR) by cortisol.",PRODUCT-OF,CPR:9,4,"By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor (MR) by cortisol."
"Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which << cortisol >> activates the [[ MR ]] resulting in severe hypertension and hypokalemia.","Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which [ENTITY_A] activates the [ENTITY_B] resulting in severe hypertension and hypokalemia.",ACTIVATOR,CPR:3,0,"Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which cortisol activates the MR resulting in severe hypertension and hypokalemia."
Ingestion of competitive inhibitors of << 11beta-HSD2 >> such as liquorice and [[ carbenoxolone ]] result in a similar but milder clinical phenotype.,Ingestion of competitive inhibitors of [ENTITY_A] such as liquorice and [ENTITY_B] result in a similar but milder clinical phenotype.,INHIBITOR,CPR:4,1,Ingestion of competitive inhibitors of 11beta-HSD2 such as liquorice and carbenoxolone result in a similar but milder clinical phenotype.
"Here we demonstrate that PPARgamma, turns on << retinoic acid >> synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as [[ retinol dehydrogenase 10 ]] and retinaldehyde dehydrogenase type 2 (RALDH2).","Here we demonstrate that PPARgamma, turns on [ENTITY_A] synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as [ENTITY_B] and retinaldehyde dehydrogenase type 2 (RALDH2).",PRODUCT-OF,CPR:9,4,"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2)."
"<< ATRA >> regulates gene expression via the activation of the [[ retinoic acid receptor (RAR)alpha ]] in human DCs, and RARalpha acutely regulates CD1d expression.","[ENTITY_A] regulates gene expression via the activation of the [ENTITY_B] in human DCs, and RARalpha acutely regulates CD1d expression.",ACTIVATOR,CPR:3,0,"ATRA regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and RARalpha acutely regulates CD1d expression."
The << retinoic acid >>-induced elevated expression of [[ CD1d ]] is coupled to enhanced iNKT cell activation.,The [ENTITY_A]-induced elevated expression of [ENTITY_B] is coupled to enhanced iNKT cell activation.,INDIRECT-UPREGULATOR,CPR:3,0,The retinoic acid-induced elevated expression of CD1d is coupled to enhanced iNKT cell activation.
"Furthermore, in vivo relevant lipids such as oxidized low-density lipoprotein can also elicit << retinoid >> signaling leading to [[ CD1d ]] up-regulation.","Furthermore, in vivo relevant lipids such as oxidized low-density lipoprotein can also elicit [ENTITY_A] signaling leading to [ENTITY_B] up-regulation.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, in vivo relevant lipids such as oxidized low-density lipoprotein can also elicit retinoid signaling leading to CD1d up-regulation."
CONTEXT: << Ramelteon >> is a novel [[ MT1 ]] and MT2 melatonin receptor selective agonist recently approved for insomnia treatment.,CONTEXT: [ENTITY_A] is a novel [ENTITY_B] and MT2 melatonin receptor selective agonist recently approved for insomnia treatment.,AGONIST,CPR:5,2,CONTEXT: Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for insomnia treatment.
Late INa induced by the << VGSC >> long QT mutant R1623Q was reduced by [[ resveratrol ]] and quercetin.,Late INa induced by the [ENTITY_A] long QT mutant R1623Q was reduced by [ENTITY_B] and quercetin.,INDIRECT-DOWNREGULATOR,CPR:4,1,Late INa induced by the VGSC long QT mutant R1623Q was reduced by resveratrol and quercetin.
"Enhancement of radiosensitivity by << topoisomerase II >> inhibitor, [[ amrubicin ]] and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.","Enhancement of radiosensitivity by [ENTITY_A] inhibitor, [ENTITY_B] and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.",INHIBITOR,CPR:4,1,"Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction."
"Similar to << AMR >> and AMROH, adriamycin and etoposide (VP-16) are [[ DNA topoisomerase II ]] inhibitors.","Similar to [ENTITY_A] and AMROH, adriamycin and etoposide (VP-16) are [ENTITY_B] inhibitors.",INHIBITOR,CPR:4,1,"Similar to AMR and AMROH, adriamycin and etoposide (VP-16) are DNA topoisomerase II inhibitors."
"Accumulated evidence in humans and animals shows that both << aspirin >> and H. pylori upregulate the expression of [[ cyclooxygenase (COX)-2 ]] both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of COX-1.","Accumulated evidence in humans and animals shows that both [ENTITY_A] and H. pylori upregulate the expression of [ENTITY_B] both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of COX-1.",INDIRECT-UPREGULATOR,CPR:3,0,"Accumulated evidence in humans and animals shows that both aspirin and H. pylori upregulate the expression of cyclooxygenase (COX)-2 both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of COX-1."
"It was, therefore, proposed that H. pylori may in fact, antagonize, << aspirin >>-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from [[ COX-2 ]] expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.","It was, therefore, proposed that H. pylori may in fact, antagonize, [ENTITY_A]-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from [ENTITY_B] expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.",ACTIVATOR,CPR:3,0,"It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF."
"It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in << PGE(2) >> possibly derived from [[ COX-2 ]] expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.","It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in [ENTITY_A] possibly derived from [ENTITY_B] expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.",PRODUCT-OF,CPR:9,4,"It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF."
<< Methylthioadenosine phosphorylase >> (MTAP) salvages purines by releasing [[ adenine ]] from methylthioadenosine and is often deleted in mesothelioma.,[ENTITY_A] (MTAP) salvages purines by releasing [ENTITY_B] from methylthioadenosine and is often deleted in mesothelioma.,PRODUCT-OF,CPR:9,4,Methylthioadenosine phosphorylase (MTAP) salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma.
"Based on selective nucleoside protection, TS was found to be the primary pemetrexed target in both cell lines with << GARFT >> inhibition requiring 20- to 30-fold higher [[ pemetrexed ]] concentrations.","Based on selective nucleoside protection, TS was found to be the primary pemetrexed target in both cell lines with [ENTITY_A] inhibition requiring 20- to 30-fold higher [ENTITY_B] concentrations.",INHIBITOR,CPR:4,1,"Based on selective nucleoside protection, TS was found to be the primary pemetrexed target in both cell lines with GARFT inhibition requiring 20- to 30-fold higher pemetrexed concentrations."
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating << insulin >> release ([[ sulfonylureas ]], glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).","Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating [ENTITY_A] release ([ENTITY_B], glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).",INDIRECT-UPREGULATOR,CPR:3,0,"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones)."
Our work shows that << sulfonylureas >> and glinides additionally bind to PPARgamma and exhibit [[ PPARgamma ]] agonistic activity.,Our work shows that [ENTITY_A] and glinides additionally bind to PPARgamma and exhibit [ENTITY_B] agonistic activity.,AGONIST,CPR:5,2,Our work shows that sulfonylureas and glinides additionally bind to PPARgamma and exhibit PPARgamma agonistic activity.
"Among the measured compounds, << gliquidone >> and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit [[ PPARgamma ]] agonistic activity at concentrations comparable with those reached under pharmacological treatment.","Among the measured compounds, [ENTITY_A] and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit [ENTITY_B] agonistic activity at concentrations comparable with those reached under pharmacological treatment.",AGONIST,CPR:5,2,"Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit PPARgamma agonistic activity at concentrations comparable with those reached under pharmacological treatment."
"The most active of these compounds, << gliquidone >>, is shown to be as potent as pioglitazone at inducing [[ PPARgamma ]] target gene expression.","The most active of these compounds, [ENTITY_A], is shown to be as potent as pioglitazone at inducing [ENTITY_B] target gene expression.",INDIRECT-UPREGULATOR,CPR:3,0,"The most active of these compounds, gliquidone, is shown to be as potent as pioglitazone at inducing PPARgamma target gene expression."
"<< Glinides >>, sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new [[ PPARgamma ]] agonists.","[ENTITY_A], sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new [ENTITY_B] agonists.",AGONIST,CPR:5,2,"Glinides, sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new PPARgamma agonists."
"Such organization results in the local activation of << PKA >> subsets through the generation of confined intracellular gradients of [[ cAMP ]], but the mechanisms responsible for limiting the diffusion of cAMP largely remain to be clarified.","Such organization results in the local activation of [ENTITY_A] subsets through the generation of confined intracellular gradients of [ENTITY_B], but the mechanisms responsible for limiting the diffusion of cAMP largely remain to be clarified.",ACTIVATOR,CPR:3,0,"Such organization results in the local activation of PKA subsets through the generation of confined intracellular gradients of cAMP, but the mechanisms responsible for limiting the diffusion of cAMP largely remain to be clarified."
"By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized << PDE4B >> and PDE4D are responsible for selectively modulating the concentration of [[ cAMP ]] in individual subcellular compartments.","By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized [ENTITY_A] and PDE4D are responsible for selectively modulating the concentration of [ENTITY_B] in individual subcellular compartments.",SUBSTRATE,CPR:9,4,"By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized PDE4B and PDE4D are responsible for selectively modulating the concentration of cAMP in individual subcellular compartments."
"We propose a model whereby compartmentalized << PDEs >>, rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different [[ cAMP ]] concentrations irrespective of their distance from the site of cAMP synthesis.","We propose a model whereby compartmentalized [ENTITY_A], rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different [ENTITY_B] concentrations irrespective of their distance from the site of cAMP synthesis.",SUBSTRATE,CPR:9,4,"We propose a model whereby compartmentalized PDEs, rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different cAMP concentrations irrespective of their distance from the site of cAMP synthesis."
SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors << doxorubicin >> and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in [[ FAS promoter ]] activity when compared with control cells growing in drug-free culture conditions.,SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors [ENTITY_A] and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in [ENTITY_B] activity when compared with control cells growing in drug-free culture conditions.,ACTIVATOR,CPR:3,0,SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.
SK-Br3 cells cultured in the presence of << topoisomerase IIalpha >> (TOP2A) inhibitors [[ doxorubicin ]] and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.,SK-Br3 cells cultured in the presence of [ENTITY_A] (TOP2A) inhibitors [ENTITY_B] and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.,INHIBITOR,CPR:4,1,SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.
"RESULT(S): The expression of endometrial << ERalpha >>, PRAB, PRB, and SRC-1 was increased significantly after 1 week of [[ mifepristone ]], but the increase was no longer seen after 10 weeks.","RESULT(S): The expression of endometrial [ENTITY_A], PRAB, PRB, and SRC-1 was increased significantly after 1 week of [ENTITY_B], but the increase was no longer seen after 10 weeks.",INDIRECT-UPREGULATOR,CPR:3,0,"RESULT(S): The expression of endometrial ERalpha, PRAB, PRB, and SRC-1 was increased significantly after 1 week of mifepristone, but the increase was no longer seen after 10 weeks."
"CONCLUSION(S): Short-term exposure of << mifepristone >> in new starters of DMPA increases the expression of endometrial [[ ERalpha ]], PRAB, PRB, and SRC-1 and promotes cell proliferation.","CONCLUSION(S): Short-term exposure of [ENTITY_A] in new starters of DMPA increases the expression of endometrial [ENTITY_B], PRAB, PRB, and SRC-1 and promotes cell proliferation.",INDIRECT-UPREGULATOR,CPR:3,0,"CONCLUSION(S): Short-term exposure of mifepristone in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, PRB, and SRC-1 and promotes cell proliferation."
"In the present study, << glucose >>-stimulated [[ insulin ]] secretion was significantly increased in GalN-treated rats compared to controls.","In the present study, [ENTITY_A]-stimulated [ENTITY_B] secretion was significantly increased in GalN-treated rats compared to controls.",INDIRECT-UPREGULATOR,CPR:3,0,"In the present study, glucose-stimulated insulin secretion was significantly increased in GalN-treated rats compared to controls."
"Levels of mRNA encoding << insulin 1 >>, ICA512, and PC1/3 were increased in the pancreatic islets of [[ GalN ]]-treated rats.","Levels of mRNA encoding [ENTITY_A], ICA512, and PC1/3 were increased in the pancreatic islets of [ENTITY_B]-treated rats.",INDIRECT-UPREGULATOR,CPR:3,0,"Levels of mRNA encoding insulin 1, ICA512, and PC1/3 were increased in the pancreatic islets of GalN-treated rats."
"When the << PTB-binding site >> in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from [[ GalN ]]-treated rats compared to the level in control rats.","When the [ENTITY_A] in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from [ENTITY_B]-treated rats compared to the level in control rats.",INDIRECT-UPREGULATOR,CPR:3,0,"When the PTB-binding site in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from GalN-treated rats compared to the level in control rats."
The cytosolic fraction obtained from pancreatic islets obtained from << GalN >>-treated rats had an increased [[ PTB ]] level compared to the levels obtained from the pancreatic islets of control rats.,The cytosolic fraction obtained from pancreatic islets obtained from [ENTITY_A]-treated rats had an increased [ENTITY_B] level compared to the levels obtained from the pancreatic islets of control rats.,INDIRECT-UPREGULATOR,CPR:3,0,The cytosolic fraction obtained from pancreatic islets obtained from GalN-treated rats had an increased PTB level compared to the levels obtained from the pancreatic islets of control rats.
"The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a << CysLT1 receptor >> antagonist, [[ pranlukast ]] (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.","The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a [ENTITY_A] antagonist, [ENTITY_B] (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.",ANTAGONIST,CPR:6,3,"The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed."
"RESULTS: In the << NMDA >>-injured brain, the [[ CysLT1 receptor ]] mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes.","RESULTS: In the [ENTITY_A]-injured brain, the [ENTITY_B] mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes.",INDIRECT-UPREGULATOR,CPR:3,0,"RESULTS: In the NMDA-injured brain, the CysLT1 receptor mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes."
"Pranlukast, ketamine and edaravone decreased NMDA-induced injury; << pranlukast >> (0.1 mg/kg) and ketamine inhibited the upregulated expression of the [[ CysLT1 receptor ]].","Pranlukast, ketamine and edaravone decreased NMDA-induced injury; [ENTITY_A] (0.1 mg/kg) and ketamine inhibited the upregulated expression of the [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and ketamine inhibited the upregulated expression of the CysLT1 receptor."
"CONCLUSION: << CysLT1 receptor >> expression in neurons is upregulated after [[ NMDA ]] injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.","CONCLUSION: [ENTITY_A] expression in neurons is upregulated after [ENTITY_B] injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.",INDIRECT-UPREGULATOR,CPR:3,0,"CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity."
"We have previously demonstrated that phosphorylation of << Fas-associated death domain-containing protein >> (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by [[ paclitaxel ]].","We have previously demonstrated that phosphorylation of [ENTITY_A] (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by [ENTITY_B].",ACTIVATOR,CPR:3,0,"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel."
"The mechanism(s) responsible for arterial vasodilation observed following acute administration of << racemic carvedilol >>, a novel vasodilator/[[ beta adrenoceptor ]] antagonist, has been investigated in rats.","The mechanism(s) responsible for arterial vasodilation observed following acute administration of [ENTITY_A], a novel vasodilator/[ENTITY_B] antagonist, has been investigated in rats.",ANTAGONIST,CPR:6,3,"The mechanism(s) responsible for arterial vasodilation observed following acute administration of racemic carvedilol, a novel vasodilator/beta adrenoceptor antagonist, has been investigated in rats."
"Carvedilol (0.3 mg/kg, iv) produced a significant inhibition of the << beta 1 adrenoceptor >> mediated positive chronotropic response to [[ isoproterenol ]].","Carvedilol (0.3 mg/kg, iv) produced a significant inhibition of the [ENTITY_A] mediated positive chronotropic response to [ENTITY_B].",ACTIVATOR,CPR:3,0,"Carvedilol (0.3 mg/kg, iv) produced a significant inhibition of the beta 1 adrenoceptor mediated positive chronotropic response to isoproterenol."
"<< Carvedilol >> (0.3 mg/kg, iv) produced a significant inhibition of the [[ beta 1 adrenoceptor ]] mediated positive chronotropic response to isoproterenol.","[ENTITY_A] (0.3 mg/kg, iv) produced a significant inhibition of the [ENTITY_B] mediated positive chronotropic response to isoproterenol.",INHIBITOR,CPR:4,1,"Carvedilol (0.3 mg/kg, iv) produced a significant inhibition of the beta 1 adrenoceptor mediated positive chronotropic response to isoproterenol."
"This same dose of << carvedilol >> also inhibited, but to a lesser degree, the [[ beta 2 adrenoceptor ]] mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II.","This same dose of [ENTITY_A] also inhibited, but to a lesser degree, the [ENTITY_B] mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II.",INHIBITOR,CPR:4,1,"This same dose of carvedilol also inhibited, but to a lesser degree, the beta 2 adrenoceptor mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II."
"Thus, << carvedilol >> blocks both beta 1 and beta 2 adrenoceptors at antihypertensive doses, with modest selectivity being observed for the [[ beta 1 adrenoceptor ]] subtype.","Thus, [ENTITY_A] blocks both beta 1 and beta 2 adrenoceptors at antihypertensive doses, with modest selectivity being observed for the [ENTITY_B] subtype.",INHIBITOR,CPR:4,1,"Thus, carvedilol blocks both beta 1 and beta 2 adrenoceptors at antihypertensive doses, with modest selectivity being observed for the beta 1 adrenoceptor subtype."
"<< Carvedilol >> produced significant inhibition of the [[ alpha 1 adrenoceptor ]] mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.","[ENTITY_A] produced significant inhibition of the [ENTITY_B] mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.",INHIBITOR,CPR:4,1,"Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses."
"Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that << carvedilol >> is also an [[ alpha 1 adrenoceptor ]] antagonist at antihypertensive doses.","Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that [ENTITY_A] is also an [ENTITY_B] antagonist at antihypertensive doses.",ANTAGONIST,CPR:6,3,"Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses."
"The vasopressor response to the << calcium channel >> activator, [[ BAY-K-8644 ]], which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.","The vasopressor response to the [ENTITY_A] activator, [ENTITY_B], which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.",ACTIVATOR,CPR:3,0,"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies."
"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of << voltage dependent calcium channels >> and the subsequent translocation of extracellular calcium, was significantly inhibited by [[ carvedilol ]] (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.","The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of [ENTITY_A] and the subsequent translocation of extracellular calcium, was significantly inhibited by [ENTITY_B] (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.",INHIBITOR,CPR:4,1,"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies."
"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that << carvedilol >> is also a [[ calcium channel ]] antagonist, consistent with our previous in vitro studies.","The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that [ENTITY_A] is also a [ENTITY_B] antagonist, consistent with our previous in vitro studies.",ANTAGONIST,CPR:6,3,"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies."
"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of << voltage dependent calcium channels >> and the subsequent translocation of extracellular [[ calcium ]], was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.","The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of [ENTITY_A] and the subsequent translocation of extracellular [ENTITY_B], was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.",SUBSTRATE,CPR:9,4,"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies."
"In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the << alpha 1 adrenoceptor >> antagonist, [[ prazosin ]] (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.","In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the [ENTITY_A] antagonist, [ENTITY_B] (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.",ANTAGONIST,CPR:6,3,"In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors."
"We therefore conclude that << carvedilol >>, at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of [[ calcium channels ]] in vascular smooth muscle.(ABSTRACT TRUNCATED AT 400 WORDS)","We therefore conclude that [ENTITY_A], at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of [ENTITY_B] in vascular smooth muscle.(ABSTRACT TRUNCATED AT 400 WORDS)",ANTAGONIST,CPR:6,3,"We therefore conclude that carvedilol, at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of calcium channels in vascular smooth muscle.(ABSTRACT TRUNCATED AT 400 WORDS)"
<< 5-HT3 receptor >> antagonism with [[ alosetron ]] reduced responses to 5-HT in controls but not during inflammation.,[ENTITY_A] antagonism with [ENTITY_B] reduced responses to 5-HT in controls but not during inflammation.,ANTAGONIST,CPR:6,3,5-HT3 receptor antagonism with alosetron reduced responses to 5-HT in controls but not during inflammation.
"<< Progestin >> activation of [[ Src ]]/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.","[ENTITY_A] activation of [ENTITY_B]/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.",ACTIVATOR,CPR:3,0,"Progestin activation of Src/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear."
"<< Progestin >> induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on [[ PR ]] activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.","[ENTITY_A] induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on [ENTITY_B] activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.",ACTIVATOR,CPR:3,0,"Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src."
These results highlight the importance of << PR >> activation of the Src/MAPK signaling pathway for [[ progesterone ]]-induced transcription of select target genes and cell cycle progression.,These results highlight the importance of [ENTITY_A] activation of the Src/MAPK signaling pathway for [ENTITY_B]-induced transcription of select target genes and cell cycle progression.,ACTIVATOR,CPR:3,0,These results highlight the importance of PR activation of the Src/MAPK signaling pathway for progesterone-induced transcription of select target genes and cell cycle progression.
"i.p. injection of a subthreshold dose of << picrotoxin >>, a use-dependent [[ gamma-aminobutyric acid receptor ]] antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice.","i.p. injection of a subthreshold dose of [ENTITY_A], a use-dependent [ENTITY_B] antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice.",ANTAGONIST,CPR:6,3,"i.p. injection of a subthreshold dose of picrotoxin, a use-dependent gamma-aminobutyric acid receptor antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice."
MicroPET imaging in nonhuman primates with [<< 11C >>]1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the [[ SERT ]]-rich brain regions and peak uptake being achieved in about 55 min postinjection.,MicroPET imaging in nonhuman primates with [[ENTITY_A]]1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the [ENTITY_B]-rich brain regions and peak uptake being achieved in about 55 min postinjection.,SUBSTRATE,CPR:9,4,MicroPET imaging in nonhuman primates with [11C]1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the SERT-rich brain regions and peak uptake being achieved in about 55 min postinjection.
This trial investigated the possibility of pharmacokinetic interactions between the << AT1 receptor >> antagonist [[ olmesartan medoxomil ]] and the thiazide diuretic hydrochlorothiazide in healthy subjects.,This trial investigated the possibility of pharmacokinetic interactions between the [ENTITY_A] antagonist [ENTITY_B] and the thiazide diuretic hydrochlorothiazide in healthy subjects.,ANTAGONIST,CPR:6,3,This trial investigated the possibility of pharmacokinetic interactions between the AT1 receptor antagonist olmesartan medoxomil and the thiazide diuretic hydrochlorothiazide in healthy subjects.
<< SecS >> required selenophosphate and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate [[ selenocysteyl ]]-tRNA([Ser]Sec).,[ENTITY_A] required selenophosphate and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate [ENTITY_B]-tRNA([Ser]Sec).,PRODUCT-OF,CPR:9,4,SecS required selenophosphate and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec).
"In addition, we found that << selenophosphate synthetase 2 >> could synthesize [[ monoselenophosphate ]] in vitro but selenophosphate synthetase 1 could not.","In addition, we found that [ENTITY_A] could synthesize [ENTITY_B] in vitro but selenophosphate synthetase 1 could not.",PRODUCT-OF,CPR:9,4,"In addition, we found that selenophosphate synthetase 2 could synthesize monoselenophosphate in vitro but selenophosphate synthetase 1 could not."
<< Triflusal >> (30 mg/kg) also significantly decreased the protein levels of [[ IL-Ibeta ]] but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion.,[ENTITY_A] (30 mg/kg) also significantly decreased the protein levels of [ENTITY_B] but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion.,INDIRECT-DOWNREGULATOR,CPR:4,1,Triflusal (30 mg/kg) also significantly decreased the protein levels of IL-Ibeta but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion.
<< Glutamate >> stimulates [[ glutamate receptor interacting protein 1 ]] degradation by ubiquitin-proteasome system to regulate surface expression of GluR2.,[ENTITY_A] stimulates [ENTITY_B] degradation by ubiquitin-proteasome system to regulate surface expression of GluR2.,DOWNREGULATOR,CPR:4,1,Glutamate stimulates glutamate receptor interacting protein 1 degradation by ubiquitin-proteasome system to regulate surface expression of GluR2.
"Here we report that << glutamate >> stimulation caused a rapid reduction in protein levels of [[ GRIP1 ]], but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures.","Here we report that [ENTITY_A] stimulation caused a rapid reduction in protein levels of [ENTITY_B], but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Here we report that glutamate stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures."
"Down-regulation of << GRIP1 >> by [[ glutamate ]] was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.","Down-regulation of [ENTITY_A] by [ENTITY_B] was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.",DOWNREGULATOR,CPR:4,1,"Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin."
"The << GRIP1 >> reduction was inhibited by [[ MK-801 ]], an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.","The [ENTITY_A] reduction was inhibited by [ENTITY_B], an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.",ACTIVATOR,CPR:3,0,"The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist."
"The GRIP1 reduction was inhibited by << MK-801 >>, an [[ N-methyl-d-aspartate (NMDA) receptor ]] antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.","The GRIP1 reduction was inhibited by [ENTITY_A], an [ENTITY_B] antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.",ANTAGONIST,CPR:6,3,"The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist."
"<< EGTA >> and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented [[ GRIP1 ]] degradation.","[ENTITY_A] and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented [ENTITY_B] degradation.",UPREGULATOR,CPR:3,0,"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented GRIP1 degradation."
"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not << nifedipine >>, an [[ L-type Ca2+ channel ]] blocker, prevented GRIP1 degradation.","EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not [ENTITY_A], an [ENTITY_B] blocker, prevented GRIP1 degradation.",INHIBITOR,CPR:4,1,"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented GRIP1 degradation."
"Furthermore, MG132 prevented << glutamate >>-stimulated reduction in surface amount of [[ GluR2 ]], and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons.","Furthermore, MG132 prevented [ENTITY_A]-stimulated reduction in surface amount of [ENTITY_B], and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, MG132 prevented glutamate-stimulated reduction in surface amount of GluR2, and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons."
Our results suggest that << glutamate >> induces [[ GRIP1 ]] degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.,Our results suggest that [ENTITY_A] induces [ENTITY_B] degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.,DOWNREGULATOR,CPR:4,1,Our results suggest that glutamate induces GRIP1 degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.
The inhibitory effect of the leukotriene receptor antagonist on << leukotriene D4 >>-induced MUC2/5AC gene expression and [[ mucin ]] secretion in human airway epithelial cells.,The inhibitory effect of the leukotriene receptor antagonist on [ENTITY_A]-induced MUC2/5AC gene expression and [ENTITY_B] secretion in human airway epithelial cells.,INDIRECT-UPREGULATOR,CPR:3,0,The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells.
"METHODS: The effect of leukotriene D(4) and the << leukotriene receptor >> antagonist, [[ pranlukast hydrate ]] (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.","METHODS: The effect of leukotriene D(4) and the [ENTITY_A] antagonist, [ENTITY_B] (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.",ANTAGONIST,CPR:6,3,"METHODS: The effect of leukotriene D(4) and the leukotriene receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells."
RESULTS: << Leukotriene D(4) >> upregulated [[ MUC2/5AC ]] gene expression and mucin secretion in a dose dependent pattern.,RESULTS: [ENTITY_A] upregulated [ENTITY_B] gene expression and mucin secretion in a dose dependent pattern.,INDIRECT-UPREGULATOR,CPR:3,0,RESULTS: Leukotriene D(4) upregulated MUC2/5AC gene expression and mucin secretion in a dose dependent pattern.
"Pranlukast hydrate (ONO-1078, 100 microM) downregulated the << leukotriene D(4) >>-induced [[ MUC2/5AC ]] gene expression and mucin secretion.","Pranlukast hydrate (ONO-1078, 100 microM) downregulated the [ENTITY_A]-induced [ENTITY_B] gene expression and mucin secretion.",INDIRECT-UPREGULATOR,CPR:3,0,"Pranlukast hydrate (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and mucin secretion."
"<< Pranlukast hydrate >> (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced [[ MUC2/5AC ]] gene expression and mucin secretion.","[ENTITY_A] (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced [ENTITY_B] gene expression and mucin secretion.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Pranlukast hydrate (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and mucin secretion."
"We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by << adenosine triphosphate-binding cassette A1 >>- (ABCA1), dependent [[ cholesterol ]] efflux from macrophages.","We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by [ENTITY_A]- (ABCA1), dependent [ENTITY_B] efflux from macrophages.",SUBSTRATE,CPR:9,4,"We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1- (ABCA1), dependent cholesterol efflux from macrophages."
"[H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and << ABCA1 >>-dependent [[ cholesterol ]] efflux and serum lipid and lipoprotein levels were assessed.","[H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and [ENTITY_A]-dependent [ENTITY_B] efflux and serum lipid and lipoprotein levels were assessed.",SUBSTRATE,CPR:9,4,"[H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and ABCA1-dependent cholesterol efflux and serum lipid and lipoprotein levels were assessed."
"Thus, isoflavone supplementation did not affect << ABCA1 >>-dependent [[ cholesterol ]] efflux to serum.","Thus, isoflavone supplementation did not affect [ENTITY_A]-dependent [ENTITY_B] efflux to serum.",SUBSTRATE,CPR:9,4,"Thus, isoflavone supplementation did not affect ABCA1-dependent cholesterol efflux to serum."
"However, as a novel finding, << isoflavone >> treatment increased a subclass of [[ high-density lipoprotein ]], the pre-beta high-density lipoprotein levels by 18% without affecting any other serum lipid concentrations.","However, as a novel finding, [ENTITY_A] treatment increased a subclass of [ENTITY_B], the pre-beta high-density lipoprotein levels by 18% without affecting any other serum lipid concentrations.",INDIRECT-UPREGULATOR,CPR:3,0,"However, as a novel finding, isoflavone treatment increased a subclass of high-density lipoprotein, the pre-beta high-density lipoprotein levels by 18% without affecting any other serum lipid concentrations."
<< ABCA1 >>-facilitated [[ cholesterol ]] efflux and lipid parameters did not differ between equol-producing and non-equol-producing women.,[ENTITY_A]-facilitated [ENTITY_B] efflux and lipid parameters did not differ between equol-producing and non-equol-producing women.,SUBSTRATE,CPR:9,4,ABCA1-facilitated cholesterol efflux and lipid parameters did not differ between equol-producing and non-equol-producing women.
"CONCLUSION: In postmenopausal women, isolated << isoflavone >> treatment does not affect ABCA1-dependent cholesterol efflux potential from macrophages but increases circulating [[ pre-beta high-density lipoprotein ]] level, which could provide beneficial vascular effects.","CONCLUSION: In postmenopausal women, isolated [ENTITY_A] treatment does not affect ABCA1-dependent cholesterol efflux potential from macrophages but increases circulating [ENTITY_B] level, which could provide beneficial vascular effects.",INDIRECT-UPREGULATOR,CPR:3,0,"CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect ABCA1-dependent cholesterol efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects."
"CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect << ABCA1 >>-dependent [[ cholesterol ]] efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.","CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect [ENTITY_A]-dependent [ENTITY_B] efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.",SUBSTRATE,CPR:9,4,"CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect ABCA1-dependent cholesterol efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects."
The ability of << sorafenib >> to inhibit oncogenic [[ PDGFRbeta ]] and FLT3 mutants and overcome resistance to other small molecule inhibitors.,The ability of [ENTITY_A] to inhibit oncogenic [ENTITY_B] and FLT3 mutants and overcome resistance to other small molecule inhibitors.,INHIBITOR,CPR:4,1,The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
"<< Sorafenib >> (BAY43-9006, Nexavar) is a small molecule [[ B-RAF ]] inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.","[ENTITY_A] (BAY43-9006, Nexavar) is a small molecule [ENTITY_B] inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.",INHIBITOR,CPR:4,1,"Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families."
"We investigated the efficacy of << sorafenib >> at inhibiting mutants of the [[ receptor tyrosine kinases ]] PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.","We investigated the efficacy of [ENTITY_A] at inhibiting mutants of the [ENTITY_B] PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.",INHIBITOR,CPR:4,1,"We investigated the efficacy of sorafenib at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies."
"RESULTS: We show that << sorafenib >> is a potent inhibitor of [[ ETV6 ]]-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors.","RESULTS: We show that [ENTITY_A] is a potent inhibitor of [ENTITY_B]-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors.",INHIBITOR,CPR:4,1,"RESULTS: We show that sorafenib is a potent inhibitor of ETV6-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors."
"<< Sorafenib >> induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing [[ FLT3 ]] with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines.","[ENTITY_A] induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing [ENTITY_B] with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines.",INHIBITOR,CPR:4,1,"Sorafenib induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing FLT3 with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines."
INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of << sorafenib >> for the treatment of myeloid malignancies expressing activated forms of [[ PDGFRbeta ]] and FLT3.,INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of [ENTITY_A] for the treatment of myeloid malignancies expressing activated forms of [ENTITY_B] and FLT3.,INHIBITOR,CPR:4,1,INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of sorafenib for the treatment of myeloid malignancies expressing activated forms of PDGFRbeta and FLT3.
"Exposure to << mifepristone >> (a [[ glucocorticoid receptor ]] antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.","Exposure to [ENTITY_A] (a [ENTITY_B] antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.",ANTAGONIST,CPR:6,3,"Exposure to mifepristone (a glucocorticoid receptor antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA."
Oral << aspirin >> (as a representative of the salicylate family) inhibited diabetes-induced increase in [[ NF-kappaB ]] DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina.,Oral [ENTITY_A] (as a representative of the salicylate family) inhibited diabetes-induced increase in [ENTITY_B] DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina.,INHIBITOR,CPR:4,1,Oral aspirin (as a representative of the salicylate family) inhibited diabetes-induced increase in NF-kappaB DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina.
"All three << salicylates >> inhibited the diabetes-induced translocation of [[ p50 ]] (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.","All three [ENTITY_A] inhibited the diabetes-induced translocation of [ENTITY_B] (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.",INDIRECT-DOWNREGULATOR,CPR:4,1,"All three salicylates inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections."
"<< Sulfasalazine >> (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by [[ NF-kappaB ]], including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate.","[ENTITY_A] (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by [ENTITY_B], including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate.",INHIBITOR,CPR:4,1,"Sulfasalazine (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate."
"<< Salicylates >>, in doses administrated in our experiments, inhibited [[ NF-kappa ]]B and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy.","[ENTITY_A], in doses administrated in our experiments, inhibited [ENTITY_B]B and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy.",INHIBITOR,CPR:4,1,"Salicylates, in doses administrated in our experiments, inhibited NF-kappaB and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy."
"Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (<< ACh >>); [[ choline acetyltransferase ]] (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).","Lymphocytes possess the essential components of a cholinergic system, including acetylcholine ([ENTITY_A]); [ENTITY_B] (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).",PRODUCT-OF,CPR:9,4,"Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)."
"In addition, activation of protein kinase C and increases in intracellular << cAMP >> also enhance cholinergic activity in T cells, and [[ lymphocyte function associated antigen-1 ]] (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation.","In addition, activation of protein kinase C and increases in intracellular [ENTITY_A] also enhance cholinergic activity in T cells, and [ENTITY_B] (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation.",INDIRECT-UPREGULATOR,CPR:3,0,"In addition, activation of protein kinase C and increases in intracellular cAMP also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation."
We found that << simvastatin >> abolishes anti-[[ CD11a ]] mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.,We found that [ENTITY_A] abolishes anti-[ENTITY_B] mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.,DOWNREGULATOR,CPR:4,1,We found that simvastatin abolishes anti-CD11a mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.
INTRODUCTION: Medroxyprogesterone acetate (<< MPA >>) induces estrogen receptor (ER)-positive and progesterone receptor ([[ PR ]])-positive ductal invasive mammary carcinomas in BALB/c mice.,INTRODUCTION: Medroxyprogesterone acetate ([ENTITY_A]) induces estrogen receptor (ER)-positive and progesterone receptor ([ENTITY_B])-positive ductal invasive mammary carcinomas in BALB/c mice.,UPREGULATOR,CPR:3,0,INTRODUCTION: Medroxyprogesterone acetate (MPA) induces estrogen receptor (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.
"The expression of << ER-alpha >> and PR isoform A in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in [[ progestin ]]-treated BALB/c mice (P < 0.05).","The expression of [ENTITY_A] and PR isoform A in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in [ENTITY_B]-treated BALB/c mice (P < 0.05).",INDIRECT-DOWNREGULATOR,CPR:4,1,"The expression of ER-alpha and PR isoform A in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in progestin-treated BALB/c mice (P < 0.05)."
<< PR isoform B >> levels were low in virgin control mice and increased after [[ progestin ]] treatment in both strains.,[ENTITY_A] levels were low in virgin control mice and increased after [ENTITY_B] treatment in both strains.,INDIRECT-UPREGULATOR,CPR:3,0,PR isoform B levels were low in virgin control mice and increased after progestin treatment in both strains.
"Various genes controlled by << estrogen >>, including [[ X-inactive-specific transcript ]], anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.","Various genes controlled by [ENTITY_A], including [ENTITY_B], anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.",INDIRECT-UPREGULATOR,CPR:3,0,"Various genes controlled by estrogen, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed."
"<< Estrogen >>-regulated genes including cytokeratin 1-19 and [[ Cyp2a4 ]] were over-expressed, although Cyp3a25 was suppressed.","[ENTITY_A]-regulated genes including cytokeratin 1-19 and [ENTITY_B] were over-expressed, although Cyp3a25 was suppressed.",INDIRECT-UPREGULATOR,CPR:3,0,"Estrogen-regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed."
"<< Estrogen >>-regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although [[ Cyp3a25 ]] was suppressed.","[ENTITY_A]-regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although [ENTITY_B] was suppressed.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Estrogen-regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed."
"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of << 17beta-hydroxysteroid dehydrogenase-7 >> (HSD17beta7; involved in [[ estradiol ]] production) and decreased expression of HSD17beta5 (involved in testosterone production).","Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of [ENTITY_A] (HSD17beta7; involved in [ENTITY_B] production) and decreased expression of HSD17beta5 (involved in testosterone production).",PRODUCT-OF,CPR:9,4,"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production)."
"The expression of key genes important in << methionine >> metabolism, such as [[ methionine adenosyltransferase-1a ]], betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed.","The expression of key genes important in [ENTITY_A] metabolism, such as [ENTITY_B], betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed.",PRODUCT-OF,CPR:9,4,"The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed."
<< Monosodium urate >> crystals stimulate monocytes and macrophages to release [[ IL-1beta ]] through the NALP3 component of the inflammasome.,[ENTITY_A] crystals stimulate monocytes and macrophages to release [ENTITY_B] through the NALP3 component of the inflammasome.,INDIRECT-UPREGULATOR,CPR:3,0,Monosodium urate crystals stimulate monocytes and macrophages to release IL-1beta through the NALP3 component of the inflammasome.
Structural basis of inhibition of the << human NAD+-dependent deacetylase SIRT5 >> by [[ suramin ]].,Structural basis of inhibition of the [ENTITY_A] by [ENTITY_B].,INHIBITOR,CPR:4,1,Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin.
We identified << suramin >> as a compound that binds to human SIRT5 and showed that it inhibits [[ SIRT5 NAD(+)-dependent deacetylase ]] activity with an IC(50) value of 22 microM.,We identified [ENTITY_A] as a compound that binds to human SIRT5 and showed that it inhibits [ENTITY_B] activity with an IC(50) value of 22 microM.,INHIBITOR,CPR:4,1,We identified suramin as a compound that binds to human SIRT5 and showed that it inhibits SIRT5 NAD(+)-dependent deacetylase activity with an IC(50) value of 22 microM.
"In humans, << methionine synthase >> deficiency results in the accumulation of [[ methyltetrahydrofolate ]] at the expense of folate derivatives required for purine and thymidylate biosynthesis.","In humans, [ENTITY_A] deficiency results in the accumulation of [ENTITY_B] at the expense of folate derivatives required for purine and thymidylate biosynthesis.",SUBSTRATE,CPR:9,4,"In humans, methionine synthase deficiency results in the accumulation of methyltetrahydrofolate at the expense of folate derivatives required for purine and thymidylate biosynthesis."
<< Metformin >> and phenformin activate [[ AMP-activated protein kinase ]] in the heart by increasing cytosolic AMP concentration.,[ENTITY_A] and phenformin activate [ENTITY_B] in the heart by increasing cytosolic AMP concentration.,ACTIVATOR,CPR:3,0,Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration.
"<< Metformin >> and phenformin, which are biguanides, have been reported to increase [[ AMPK ]] activity without increasing AMP/ATP.","[ENTITY_A] and phenformin, which are biguanides, have been reported to increase [ENTITY_B] activity without increasing AMP/ATP.",ACTIVATOR,CPR:3,0,"Metformin and phenformin, which are biguanides, have been reported to increase AMPK activity without increasing AMP/ATP."
"In hearts treated with << phenformin >> for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and [[ AMPK ]] activity was elevated at 36 min.","In hearts treated with [ENTITY_A] for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and [ENTITY_B] activity was elevated at 36 min.",ACTIVATOR,CPR:3,0,"In hearts treated with phenformin for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and AMPK activity was elevated at 36 min."
"In hearts treated with << metformin >>, [AMP] was increased at 50 min and [[ AMPK ]] activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min.","In hearts treated with [ENTITY_A], [AMP] was increased at 50 min and [ENTITY_B] activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min.",ACTIVATOR,CPR:3,0,"In hearts treated with metformin, [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min."
"In summary, << phenformin >> and metformin increase [[ AMPK ]] activity and phosphorylation in the isolated heart.","In summary, [ENTITY_A] and metformin increase [ENTITY_B] activity and phosphorylation in the isolated heart.",ACTIVATOR,CPR:3,0,"In summary, phenformin and metformin increase AMPK activity and phosphorylation in the isolated heart."
"Cytosolic [AMP] reported metabolically active << AMP >>, which triggered increased [[ AMPK ]] activity, but measures of total AMP did not.","Cytosolic [AMP] reported metabolically active [ENTITY_A], which triggered increased [ENTITY_B] activity, but measures of total AMP did not.",ACTIVATOR,CPR:3,0,"Cytosolic [AMP] reported metabolically active AMP, which triggered increased AMPK activity, but measures of total AMP did not."
<< Histamine H(1) >> blockade is one of the more prominent actions of the multi-receptor acting antipsychotic [[ clozapine ]].,[ENTITY_A] blockade is one of the more prominent actions of the multi-receptor acting antipsychotic [ENTITY_B].,INHIBITOR,CPR:4,1,Histamine H(1) blockade is one of the more prominent actions of the multi-receptor acting antipsychotic clozapine.
It is currently not known how much this << H(1) >> antagonism of [[ clozapine ]] contributes to the therapeutic or adverse side effects of clozapine.,It is currently not known how much this [ENTITY_A] antagonism of [ENTITY_B] contributes to the therapeutic or adverse side effects of clozapine.,ANTAGONIST,CPR:6,3,It is currently not known how much this H(1) antagonism of clozapine contributes to the therapeutic or adverse side effects of clozapine.
"In the current project, we found that the selective << H(1) >> antagonist pyrilamine also reversed the [[ dizocilpine ]]-induced impairment in PPI of tactile startle with an auditory prepulse.","In the current project, we found that the selective [ENTITY_A] antagonist pyrilamine also reversed the [ENTITY_B]-induced impairment in PPI of tactile startle with an auditory prepulse.",UPREGULATOR,CPR:3,0,"In the current project, we found that the selective H(1) antagonist pyrilamine also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse."
"In the current project, we found that the selective << H(1) >> antagonist [[ pyrilamine ]] also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse.","In the current project, we found that the selective [ENTITY_A] antagonist [ENTITY_B] also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse.",ANTAGONIST,CPR:6,3,"In the current project, we found that the selective H(1) antagonist pyrilamine also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse."
"In summary, the therapeutic effect of << clozapine >> in reversing PPI impairment was mimicked by the [[ H(1) ]] antagonist pyrilamine, while pyrilamine had a mixed effect on cognition.","In summary, the therapeutic effect of [ENTITY_A] in reversing PPI impairment was mimicked by the [ENTITY_B] antagonist pyrilamine, while pyrilamine had a mixed effect on cognition.",DOWNREGULATOR,CPR:4,1,"In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the H(1) antagonist pyrilamine, while pyrilamine had a mixed effect on cognition."
"In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the << H(1) >> antagonist [[ pyrilamine ]], while pyrilamine had a mixed effect on cognition.","In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the [ENTITY_A] antagonist [ENTITY_B], while pyrilamine had a mixed effect on cognition.",ANTAGONIST,CPR:6,3,"In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the H(1) antagonist pyrilamine, while pyrilamine had a mixed effect on cognition."
"Thus, << H(1) >> antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as [[ clozapine ]].","Thus, [ENTITY_A] antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as [ENTITY_B].",ANTAGONIST,CPR:6,3,"Thus, H(1) antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as clozapine."
"Furthermore, the enzymatic activity of << alanine aminotransferase >> (ALT), which converts the critical gluconeogenic amino acid alanine into [[ pyruvate ]], is decreased (approximately 50%) in KLF15-/- hepatocytes.","Furthermore, the enzymatic activity of [ENTITY_A] (ALT), which converts the critical gluconeogenic amino acid alanine into [ENTITY_B], is decreased (approximately 50%) in KLF15-/- hepatocytes.",PRODUCT-OF,CPR:9,4,"Furthermore, the enzymatic activity of alanine aminotransferase (ALT), which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes."
<< D-glucose >> stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and [[ Smad2 ]] requiring functional type II TGF-beta receptors in human umbilical vein endothelium.,[ENTITY_A] stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and [ENTITY_B] requiring functional type II TGF-beta receptors in human umbilical vein endothelium.,ACTIVATOR,CPR:3,0,D-glucose stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium.
Elevated extracellular << D-glucose >> increases [[ transforming growth factor beta1 ]] (TGF-beta1) release from human umbilical vein endothelium (HUVEC).,Elevated extracellular [ENTITY_A] increases [ENTITY_B] (TGF-beta1) release from human umbilical vein endothelium (HUVEC).,INDIRECT-UPREGULATOR,CPR:3,0,Elevated extracellular D-glucose increases transforming growth factor beta1 (TGF-beta1) release from human umbilical vein endothelium (HUVEC).
<< TGF-beta1 >> release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal) [[ D-glucose ]].,[ENTITY_A] release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal) [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,TGF-beta1 release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal) D-glucose.
"TGF-beta1 and high << D-glucose >> increased [[ hCAT-1 ]] mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.","TGF-beta1 and high [ENTITY_A] increased [ENTITY_B] mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.",INDIRECT-UPREGULATOR,CPR:3,0,"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation."
"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of << NO >> synthesis) and [[ endothelial NO synthase ]] (eNOS) protein abundance, but did not alter eNOS phosphorylation.","TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of [ENTITY_A] synthesis) and [ENTITY_B] (eNOS) protein abundance, but did not alter eNOS phosphorylation.",PRODUCT-OF,CPR:9,4,"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation."
"TGF-beta1 and high << D-glucose >> increased p42/44(mapk) and [[ Smad2 ]] phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor).","TGF-beta1 and high [ENTITY_A] increased p42/44(mapk) and [ENTITY_B] phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor).",ACTIVATOR,CPR:3,0,"TGF-beta1 and high D-glucose increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor)."
"TGF-beta1 and high D-glucose increased p42/44(mapk) and << Smad2 >> phosphorylation, an effect blocked by [[ PD-98059 ]] (MEK1/2 inhibitor).","TGF-beta1 and high D-glucose increased p42/44(mapk) and [ENTITY_A] phosphorylation, an effect blocked by [ENTITY_B] (MEK1/2 inhibitor).",INHIBITOR,CPR:4,1,"TGF-beta1 and high D-glucose increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor)."
High << D-glucose >> increases L-arginine transport and eNOS expression following [[ TbetaRII ]] activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC.,High [ENTITY_A] increases L-arginine transport and eNOS expression following [ENTITY_B] activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC.,ACTIVATOR,CPR:3,0,High D-glucose increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC.
<< n-3 and n-6 polyunsaturated fatty acids >> induce the expression of COX-2 via [[ PPARgamma ]] activation in human keratinocyte HaCaT cells.,[ENTITY_A] induce the expression of COX-2 via [ENTITY_B] activation in human keratinocyte HaCaT cells.,ACTIVATOR,CPR:3,0,n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells.
"We demonstrate that only treatment of HaCaT with << GLA >> and EPA or a PPARgamma ligand (roziglitazone), induced [[ COX-2 ]] expression (protein and mRNA).","We demonstrate that only treatment of HaCaT with [ENTITY_A] and EPA or a PPARgamma ligand (roziglitazone), induced [ENTITY_B] expression (protein and mRNA).",INDIRECT-UPREGULATOR,CPR:3,0,"We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand (roziglitazone), induced COX-2 expression (protein and mRNA)."
Moreover stimulation of << COX-2 promoter >> activity was increased by those [[ PUFAs ]] or rosiglitazone.,Moreover stimulation of [ENTITY_A] activity was increased by those [ENTITY_B] or rosiglitazone.,ACTIVATOR,CPR:3,0,Moreover stimulation of COX-2 promoter activity was increased by those PUFAs or rosiglitazone.
"The inhibitory effects of << GW9662 >> and T0070907 ([[ PPARgamma ]] antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.","The inhibitory effects of [ENTITY_A] and T0070907 ([ENTITY_B] antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.",ANTAGONIST,CPR:6,3,"The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction."
"Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of << AA >> metabolites in [[ PPAR ]] activation.","Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of [ENTITY_A] metabolites in [ENTITY_B] activation.",ACTIVATOR,CPR:3,0,"Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation."
"Finally, << PLA2 >> inhibitor methyl [[ arachidonyl fluorophosphonate ]] blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation.","Finally, [ENTITY_A] inhibitor methyl [ENTITY_B] blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation.",INHIBITOR,CPR:4,1,"Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation."
These findings demonstrate that << n-3 and n-6 PUFA >> increased [[ PPARgamma ]] activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells.,These findings demonstrate that [ENTITY_A] increased [ENTITY_B] activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells.,ACTIVATOR,CPR:3,0,These findings demonstrate that n-3 and n-6 PUFA increased PPARgamma activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells.
"Given the anti-inflammatory properties of EPA, we suggest that induction of << COX-2 >> in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of [[ PUFAs n-3 ]] or n-6.","Given the anti-inflammatory properties of EPA, we suggest that induction of [ENTITY_A] in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of [ENTITY_B] or n-6.",ACTIVATOR,CPR:3,0,"Given the anti-inflammatory properties of EPA, we suggest that induction of COX-2 in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of PUFAs n-3 or n-6."
"OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting << beta(2)-adrenergic >> agonist that is the [[ [R,R] isomer of formoterol ]]) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD).","OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting [ENTITY_A] agonist that is the [ENTITY_B]) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD).",AGONIST,CPR:5,2,"OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting beta(2)-adrenergic agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD)."
"<< Acetyl-coenzyme A carboxylase >> (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in [[ fatty acid ]] biosynthesis and oxidation.","[ENTITY_A] (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in [ENTITY_B] biosynthesis and oxidation.",PRODUCT-OF,CPR:9,4,"Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in fatty acid biosynthesis and oxidation."
"The cytosolic << ACC1 >> is expressed primarily in liver and adipose tissue, and uses malonyl-coenzyme A as a key building block in [[ fatty acid ]] biosynthesis.","The cytosolic [ENTITY_A] is expressed primarily in liver and adipose tissue, and uses malonyl-coenzyme A as a key building block in [ENTITY_B] biosynthesis.",PRODUCT-OF,CPR:9,4,"The cytosolic ACC1 is expressed primarily in liver and adipose tissue, and uses malonyl-coenzyme A as a key building block in fatty acid biosynthesis."
"The mitochondrial << ACC2 >> is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of [[ fatty acid ]] oxidation.","The mitochondrial [ENTITY_A] is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of [ENTITY_B] oxidation.",PRODUCT-OF,CPR:9,4,"The mitochondrial ACC2 is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of fatty acid oxidation."
"In contrast, the << RA >> catabolising enzymes [[ Cyp26A1 ]] and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye.","In contrast, the [ENTITY_A] catabolising enzymes [ENTITY_B] and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye.",SUBSTRATE,CPR:9,4,"In contrast, the RA catabolising enzymes Cyp26A1 and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye."
"Incretin-receptor activation leads to << glucose >>-dependent [[ insulin ]] secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis.","Incretin-receptor activation leads to [ENTITY_A]-dependent [ENTITY_B] secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis.",INDIRECT-UPREGULATOR,CPR:3,0,"Incretin-receptor activation leads to glucose-dependent insulin secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis."
This report reviews published and unpublished data that suggest that << aripiprazole >> acts as a selective partial agonist at the [[ dopamine D(2) receptor ]] and does not affect 5-HT receptors at therapeutic doses.,This report reviews published and unpublished data that suggest that [ENTITY_A] acts as a selective partial agonist at the [ENTITY_B] and does not affect 5-HT receptors at therapeutic doses.,AGONIST,CPR:5,2,This report reviews published and unpublished data that suggest that aripiprazole acts as a selective partial agonist at the dopamine D(2) receptor and does not affect 5-HT receptors at therapeutic doses.
<< Mifepriston'e >> blocks [[ glucocorticoid receptor ]] activation without modifying cortisol synthesis.,[ENTITY_A] blocks [ENTITY_B] activation without modifying cortisol synthesis.,INHIBITOR,CPR:4,1,Mifepriston'e blocks glucocorticoid receptor activation without modifying cortisol synthesis.
"[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (<< SR 141716A >>), a selective [[ cannabinoid CB1 receptor ]] antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.","[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] ([ENTITY_A]), a selective [ENTITY_B] antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.",ANTAGONIST,CPR:6,3,"[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (SR 141716A), a selective cannabinoid CB1 receptor antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection."
"The present findings confirm that PVN CB1 receptors, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of << CB1 receptors >> by [[ SR 141716A ]] increases the density of these receptors in the PVN.","The present findings confirm that PVN CB1 receptors, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of [ENTITY_A] by [ENTITY_B] increases the density of these receptors in the PVN.",INHIBITOR,CPR:4,1,"The present findings confirm that PVN CB1 receptors, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of CB1 receptors by SR 141716A increases the density of these receptors in the PVN."
"Modulation of the function of CD36 (CD36-/- mice), << p38 >>(MAPK) ([[ SB203580 ]]), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.","Modulation of the function of CD36 (CD36-/- mice), [ENTITY_A](MAPK) ([ENTITY_B]), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.",INHIBITOR,CPR:4,1,"Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition."
"We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that << human type 12 RDH >> reduces dihydrotestosterone to [[ androstanediol ]], and is thus also involved in steroid metabolism.","We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that [ENTITY_A] reduces dihydrotestosterone to [ENTITY_B], and is thus also involved in steroid metabolism.",PRODUCT-OF,CPR:9,4,"We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that human type 12 RDH reduces dihydrotestosterone to androstanediol, and is thus also involved in steroid metabolism."
"The << sibutramine >> group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial [[ peptide YY ]] compared with the placebo group.","The [ENTITY_A] group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial [ENTITY_B] compared with the placebo group.",INDIRECT-UPREGULATOR,CPR:3,0,"The sibutramine group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial peptide YY compared with the placebo group."
CONCLUSIONS: Weight reduction with << sibutramine >> is associated with altered gastric functions and increased [[ peptide YY ]] and is significantly associated with SLC6A4 genotype.,CONCLUSIONS: Weight reduction with [ENTITY_A] is associated with altered gastric functions and increased [ENTITY_B] and is significantly associated with SLC6A4 genotype.,INDIRECT-UPREGULATOR,CPR:3,0,CONCLUSIONS: Weight reduction with sibutramine is associated with altered gastric functions and increased peptide YY and is significantly associated with SLC6A4 genotype.
An investigation of the absolute configuration of the potent << histamine H3 receptor >> antagonist [[ GT-2331 ]] using vibrational circular dichroism.,An investigation of the absolute configuration of the potent [ENTITY_A] antagonist [ENTITY_B] using vibrational circular dichroism.,ANTAGONIST,CPR:6,3,An investigation of the absolute configuration of the potent histamine H3 receptor antagonist GT-2331 using vibrational circular dichroism.
"In this study the neuromuscular blocking drug << vecuronium >> and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant [[ human muscarinic M2 receptors ]] K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).","In this study the neuromuscular blocking drug [ENTITY_A] and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant [ENTITY_B] K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).",DOWNREGULATOR,CPR:4,1,"In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant human muscarinic M2 receptors K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01)."
Patients with acute vitiligo have low epidermal << catalase >> expression/activities and accumulate 10(-3) M [[ H(2)O(2) ]].,Patients with acute vitiligo have low epidermal [ENTITY_A] expression/activities and accumulate 10(-3) M [ENTITY_B].,SUBSTRATE,CPR:9,4,Patients with acute vitiligo have low epidermal catalase expression/activities and accumulate 10(-3) M H(2)O(2).
<< Mammalian cysteine dioxygenase >> (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative [[ cysteine ]] catabolism.,[ENTITY_A] (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative [ENTITY_B] catabolism.,SUBSTRATE,CPR:9,4,Mammalian cysteine dioxygenase (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism.
"However, upon addition of NO to << CDO >> in the presence of substrate [[ l-cysteine ]], a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops.","However, upon addition of NO to [ENTITY_A] in the presence of substrate [ENTITY_B], a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops.",SUBSTRATE,CPR:9,4,"However, upon addition of NO to CDO in the presence of substrate l-cysteine, a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops."
"The transcriptional activity of torafugu << PPARalpha1 >> was enhanced 4.5- and 11.5-fold by [[ Wy-14643 ]] and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.","The transcriptional activity of torafugu [ENTITY_A] was enhanced 4.5- and 11.5-fold by [ENTITY_B] and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.",ACTIVATOR,CPR:3,0,"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively."
"Furthermore, the activities of the two << torafugu PPARalphas >> were enhanced 4.3- and 7.6-fold by [[ arachidonic acid ]], 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively.","Furthermore, the activities of the two [ENTITY_A] were enhanced 4.3- and 7.6-fold by [ENTITY_B], 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively.",ACTIVATOR,CPR:3,0,"Furthermore, the activities of the two torafugu PPARalphas were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively."
Combination chemotherapy with a << substance P receptor >> antagonist ([[ aprepitant ]]) and melarsoprol in a mouse model of human African trypanosomiasis.,Combination chemotherapy with a [ENTITY_A] antagonist ([ENTITY_B]) and melarsoprol in a mouse model of human African trypanosomiasis.,ANTAGONIST,CPR:6,3,Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis.
In this study we investigated the effects of combination chemotherapy with melarsoprol and a << humanised SP receptor >> antagonist [[ aprepitant ]] (EMEND) in this mouse model.,In this study we investigated the effects of combination chemotherapy with melarsoprol and a [ENTITY_A] antagonist [ENTITY_B] (EMEND) in this mouse model.,ANTAGONIST,CPR:6,3,In this study we investigated the effects of combination chemotherapy with melarsoprol and a humanised SP receptor antagonist aprepitant (EMEND) in this mouse model.
It is thought to play a critical role in the visual cycle by functioning as an acceptor of << 11-cis-retinol >> from the [[ isomerohydrolase ]] reaction.,It is thought to play a critical role in the visual cycle by functioning as an acceptor of [ENTITY_A] from the [ENTITY_B] reaction.,PRODUCT-OF,CPR:9,4,It is thought to play a critical role in the visual cycle by functioning as an acceptor of 11-cis-retinol from the isomerohydrolase reaction.
<< Dimethylarginine dimethylaminohydrolase >> (DDAH) metabolizes asymmetric dimethylarginine to generate [[ L-citrulline ]] and is present in large quantities in the kidney.,[ENTITY_A] (DDAH) metabolizes asymmetric dimethylarginine to generate [ENTITY_B] and is present in large quantities in the kidney.,PRODUCT-OF,CPR:9,4,Dimethylarginine dimethylaminohydrolase (DDAH) metabolizes asymmetric dimethylarginine to generate L-citrulline and is present in large quantities in the kidney.
We present a new study that optimizes the Prescott-Jones colorimetric assay to measure << DDAH >>-dependent [[ L-citrulline ]] generation in kidney homogenates.,We present a new study that optimizes the Prescott-Jones colorimetric assay to measure [ENTITY_A]-dependent [ENTITY_B] generation in kidney homogenates.,PRODUCT-OF,CPR:9,4,We present a new study that optimizes the Prescott-Jones colorimetric assay to measure DDAH-dependent L-citrulline generation in kidney homogenates.
We found that the removal of << urea >> with [[ urease ]] is necessary since urea also produces a positive reaction.,We found that the removal of [ENTITY_A] with [ENTITY_B] is necessary since urea also produces a positive reaction.,SUBSTRATE,CPR:9,4,We found that the removal of urea with urease is necessary since urea also produces a positive reaction.
Our optimized << L-citrulline >> production assay to measure [[ DDAH ]] activity correlated closely with the direct measure of the rate of asymmetric dimethylarginine consumption.,Our optimized [ENTITY_A] production assay to measure [ENTITY_B] activity correlated closely with the direct measure of the rate of asymmetric dimethylarginine consumption.,PRODUCT-OF,CPR:9,4,Our optimized L-citrulline production assay to measure DDAH activity correlated closely with the direct measure of the rate of asymmetric dimethylarginine consumption.
"Using this assay, we found that both << superoxide >> and nitric oxide inhibit renal cortical [[ DDAH ]] activity in vitro.","Using this assay, we found that both [ENTITY_A] and nitric oxide inhibit renal cortical [ENTITY_B] activity in vitro.",INHIBITOR,CPR:4,1,"Using this assay, we found that both superoxide and nitric oxide inhibit renal cortical DDAH activity in vitro."
"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting << HER2 >>/neu as well as the epidermal growth factor receptor (EGFR), [[ lapatinib ]].","The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting [ENTITY_A]/neu as well as the epidermal growth factor receptor (EGFR), [ENTITY_B].",INHIBITOR,CPR:4,1,"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/neu as well as the epidermal growth factor receptor (EGFR), lapatinib."
"Exposure of Jurkat cells to either << (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine >> [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective [[ NMDA receptor ]] antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.","Exposure of Jurkat cells to either [ENTITY_A] [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective [ENTITY_B] antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.",ANTAGONIST,CPR:6,3,"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin."
<< Desvenlafaxine succinate >> identifies novel antagonist binding determinants in the [[ human norepinephrine transporter ]].,[ENTITY_A] identifies novel antagonist binding determinants in the [ENTITY_B].,ANTAGONIST,CPR:6,3,Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter.
"<< Desvenlafaxine succinate >> (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters ([[ hNET ]] and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.","[ENTITY_A] (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters ([ENTITY_B] and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.",ANTAGONIST,CPR:6,3,"Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause."
"Using << hNET >> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the [[ DVS ]] analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.","Using [ENTITY_A] in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the [ENTITY_B] analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",ANTAGONIST,CPR:6,3,"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine."
"<< Sorafenib >> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 ([[ VEGFR-2 ]], VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.","[ENTITY_A] and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 ([ENTITY_B], VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.",INHIBITOR,CPR:4,1,"Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor."
"One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas << tazarotene >> preferentially binds to and activates RAR-beta and -gamma in preference to [[ RAR-alpha ]].","One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas [ENTITY_A] preferentially binds to and activates RAR-beta and -gamma in preference to [ENTITY_B].",ACTIVATOR,CPR:3,0,"One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha."
"Comprehensive review of << rasagiline >>, a second-generation [[ monoamine oxidase ]] inhibitor, for the treatment of Parkinson's disease.","Comprehensive review of [ENTITY_A], a second-generation [ENTITY_B] inhibitor, for the treatment of Parkinson's disease.",INHIBITOR,CPR:4,1,"Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease."
Rasagiline [<< N-propargyl-l(R)-aminoindan >>] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain [[ MAO-B ]] and is specifically designed for the treatment of Parkinson's disease (PD).,Rasagiline [[ENTITY_A]] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain [ENTITY_B] and is specifically designed for the treatment of Parkinson's disease (PD).,INHIBITOR,CPR:4,1,Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain MAO-B and is specifically designed for the treatment of Parkinson's disease (PD).
"Based on the results from those studies, we concluded that << rasagiline >> PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited [[ MAO-B ]].","Based on the results from those studies, we concluded that [ENTITY_A] PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited [ENTITY_B].",INHIBITOR,CPR:4,1,"Based on the results from those studies, we concluded that rasagiline PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited MAO-B."
This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to << factor Xa >> ([[ rivaroxaban ]] and apixaban) and IIa (dabigatran).,This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to [ENTITY_A] ([ENTITY_B] and apixaban) and IIa (dabigatran).,INHIBITOR,CPR:4,1,This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban) and IIa (dabigatran).
"INTERVENTIONS: In the 8-week run-in period, all participants received the << ACE >> inhibitor [[ cilazapril ]] (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg.","INTERVENTIONS: In the 8-week run-in period, all participants received the [ENTITY_A] inhibitor [ENTITY_B] (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg.",INHIBITOR,CPR:4,1,"INTERVENTIONS: In the 8-week run-in period, all participants received the ACE inhibitor cilazapril (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg."
"Porcine TLR8 and << TLR7 >> are both activated by a selective TLR7 ligand, [[ imiquimod ]].","Porcine TLR8 and [ENTITY_A] are both activated by a selective TLR7 ligand, [ENTITY_B].",ACTIVATOR,CPR:3,0,"Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod."
"Two << imidazoquinoline >> molecules, imiquimod and gardiquimod, markedly activated both [[ porcine TLR7 ]] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.","Two [ENTITY_A] molecules, imiquimod and gardiquimod, markedly activated both [ENTITY_B] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.",ACTIVATOR,CPR:3,0,"Two imidazoquinoline molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands."
"Moreover, activation of transfected cells and porcine PBMC by << TLR7 >> ligands was inhibited by [[ bafilomycin A(1) ]] indicating the requirement of endosomal/lysosomal acidification for activation of the receptors.","Moreover, activation of transfected cells and porcine PBMC by [ENTITY_A] ligands was inhibited by [ENTITY_B] indicating the requirement of endosomal/lysosomal acidification for activation of the receptors.",INHIBITOR,CPR:4,1,"Moreover, activation of transfected cells and porcine PBMC by TLR7 ligands was inhibited by bafilomycin A(1) indicating the requirement of endosomal/lysosomal acidification for activation of the receptors."
High-affinity blockade of << voltage-operated skeletal muscle and neuronal sodium channels >> by [[ halogenated propofol ]] analogues.,High-affinity blockade of [ENTITY_A] by [ENTITY_B] analogues.,INHIBITOR,CPR:4,1,High-affinity blockade of voltage-operated skeletal muscle and neuronal sodium channels by halogenated propofol analogues.
"The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for << 4-chloropropofol >> in [[ Na(V)1.2 ]].","The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for [ENTITY_A] in [ENTITY_B].",INHIBITOR,CPR:4,1,"The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for 4-chloropropofol in Na(V)1.2."
"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for << 4-iodopropofol >>, 4-bromopropofol and 4-chloropropofol in [[ Na(V)1.4 ]], and 450 nM for 4-chloropropofol in Na(V)1.2.","Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for [ENTITY_A], 4-bromopropofol and 4-chloropropofol in [ENTITY_B], and 450 nM for 4-chloropropofol in Na(V)1.2.",INHIBITOR,CPR:4,1,"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in Na(V)1.4, and 450 nM for 4-chloropropofol in Na(V)1.2."
CONCLUSIONS AND IMPLICATIONS: << Halogenated propofol >> analogues constitute a novel class of [[ sodium channel ]]-blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug lidocaine.,CONCLUSIONS AND IMPLICATIONS: [ENTITY_A] analogues constitute a novel class of [ENTITY_B]-blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug lidocaine.,INHIBITOR,CPR:4,1,CONCLUSIONS AND IMPLICATIONS: Halogenated propofol analogues constitute a novel class of sodium channel-blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug lidocaine.
"<< Irbesartan >> (Aprovel, Avapro, Irbetan, Karvea), an [[ angiotensin II receptor type 1 ]] antagonist, is approved in many countries worldwide for the treatment of hypertension.","[ENTITY_A] (Aprovel, Avapro, Irbetan, Karvea), an [ENTITY_B] antagonist, is approved in many countries worldwide for the treatment of hypertension.",ANTAGONIST,CPR:6,3,"Irbesartan (Aprovel, Avapro, Irbetan, Karvea), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension."
"DNA damage is accepted as a consequence of << thymidylate >> deprivation induced by chemotherapeutic inhibitors of [[ thymidylate synthase ]] (TS), but the types of damage and signaling responses remain incompletely understood.","DNA damage is accepted as a consequence of [ENTITY_A] deprivation induced by chemotherapeutic inhibitors of [ENTITY_B] (TS), but the types of damage and signaling responses remain incompletely understood.",PRODUCT-OF,CPR:9,4,"DNA damage is accepted as a consequence of thymidylate deprivation induced by chemotherapeutic inhibitors of thymidylate synthase (TS), but the types of damage and signaling responses remain incompletely understood."
"When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed (<< RTX >>), which specifically inhibits [[ TS ]].","When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed ([ENTITY_A]), which specifically inhibits [ENTITY_B].",INHIBITOR,CPR:4,1,"When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed (RTX), which specifically inhibits TS."
"<< RTX >> treatment also induced foci of [[ RAD51 ]], gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied.","[ENTITY_A] treatment also induced foci of [ENTITY_B], gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied.",INDIRECT-UPREGULATOR,CPR:3,0,"RTX treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied."
<< Nicotinamide N-methyltransferase >> (NNMT) catalyses the conversion of nicotinamide to [[ 1-methylnicotinamide ]] and plays an important role in hepatic detoxification reactions.,[ENTITY_A] (NNMT) catalyses the conversion of nicotinamide to [ENTITY_B] and plays an important role in hepatic detoxification reactions.,PRODUCT-OF,CPR:9,4,Nicotinamide N-methyltransferase (NNMT) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.
"<< Homocysteine >>, the atherogenic product of the [[ NNMT ]]-catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures.","[ENTITY_A], the atherogenic product of the [ENTITY_B]-catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures.",PRODUCT-OF,CPR:9,4,"Homocysteine, the atherogenic product of the NNMT-catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures."
Homocysteine release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the << NNMT >> inhibitor [[ 1-methylnicotinamide ]].,Homocysteine release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the [ENTITY_A] inhibitor [ENTITY_B].,INHIBITOR,CPR:4,1,Homocysteine release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the NNMT inhibitor 1-methylnicotinamide.
"Nicotinic acid (<< NA >>), a widely used drug to lower elevated plasma lipid levels, induced [[ NNMT ]] enzyme activity in white adipose tissue of mice.","Nicotinic acid ([ENTITY_A]), a widely used drug to lower elevated plasma lipid levels, induced [ENTITY_B] enzyme activity in white adipose tissue of mice.",ACTIVATOR,CPR:3,0,"Nicotinic acid (NA), a widely used drug to lower elevated plasma lipid levels, induced NNMT enzyme activity in white adipose tissue of mice."
These data support the concept that adipose tissue << NNMT >> contributes to the increased plasma [[ homocysteine ]] levels in patients treated with NA.,These data support the concept that adipose tissue [ENTITY_A] contributes to the increased plasma [ENTITY_B] levels in patients treated with NA.,PRODUCT-OF,CPR:9,4,These data support the concept that adipose tissue NNMT contributes to the increased plasma homocysteine levels in patients treated with NA.
Global target profile of the << kinase >> inhibitor [[ bosutinib ]] in primary chronic myeloid leukemia cells.,Global target profile of the [ENTITY_A] inhibitor [ENTITY_B] in primary chronic myeloid leukemia cells.,INHIBITOR,CPR:4,1,Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
"Here, we characterized the target profile of the dual << SRC >>/ABL inhibitor [[ bosutinib ]] employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.","Here, we characterized the target profile of the dual [ENTITY_A]/ABL inhibitor [ENTITY_B] employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.",INHIBITOR,CPR:4,1,"Here, we characterized the target profile of the dual SRC/ABL inhibitor bosutinib employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel."
"A comparison of bosutinib with << dasatinib >> across the whole [[ kinase ]] panel revealed overlapping, but distinct, inhibition profiles.","A comparison of bosutinib with [ENTITY_A] across the whole [ENTITY_B] panel revealed overlapping, but distinct, inhibition profiles.",INHIBITOR,CPR:4,1,"A comparison of bosutinib with dasatinib across the whole kinase panel revealed overlapping, but distinct, inhibition profiles."
"Finally, << bosutinib >> is the first [[ kinase ]] inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.","Finally, [ENTITY_A] is the first [ENTITY_B] inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.",INHIBITOR,CPR:4,1,"Finally, bosutinib is the first kinase inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation."
Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the << dehydrogenase >> and isomerase substrate [[ steroids ]] bind at different sites on the same protein.,Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the [ENTITY_A] and isomerase substrate [ENTITY_B] bind at different sites on the same protein.,SUBSTRATE,CPR:9,4,Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the dehydrogenase and isomerase substrate steroids bind at different sites on the same protein.
"The affinity labeling << nucleotide >> analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the [[ dehydrogenase ]] and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).","The affinity labeling [ENTITY_A] analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the [ENTITY_B] and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).",INHIBITOR,CPR:4,1,"The affinity labeling nucleotide analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the dehydrogenase and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)."
"The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as << dehydrogenase >> from inactivation by [[ FSA ]].","The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as [ENTITY_A] from inactivation by [ENTITY_B].",INHIBITOR,CPR:4,1,"The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as dehydrogenase from inactivation by FSA."
"The most successful example of << kinase >> blockers is [[ Imatinib ]] (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.","The most successful example of [ENTITY_A] blockers is [ENTITY_B] (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.",INHIBITOR,CPR:4,1,"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia."
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (<< SU 11248 >>, Sutent) specific for [[ VEGF receptor ]] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib ([ENTITY_A], Sutent) specific for [ENTITY_B] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",INHIBITOR,CPR:4,1,"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase."
"The following << TK >> blockers for treatment of various human tumors are in clinical development: [[ Lapatinib ]] (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).","The following [ENTITY_A] blockers for treatment of various human tumors are in clinical development: [ENTITY_B] (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).",INHIBITOR,CPR:4,1,"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)."
"Currently, the use of orally administered << MAO >> inhibitor antidepressants (eg, [[ phenelzine ]], tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the ""cheese reaction"") when combined with dietary tyramine.","Currently, the use of orally administered [ENTITY_A] inhibitor antidepressants (eg, [ENTITY_B], tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the ""cheese reaction"") when combined with dietary tyramine.",INHIBITOR,CPR:4,1,"Currently, the use of orally administered MAO inhibitor antidepressants (eg, phenelzine, tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the ""cheese reaction"") when combined with dietary tyramine."
"It undergoes extensive biotransformation, which is affected by poor metabolism by << cytochrome P450 (CYP) 2D6 >> in a small percentage of the population; these patients have greater exposure to and slower elimination of [[ atomoxetine ]] than extensive metabolizers.","It undergoes extensive biotransformation, which is affected by poor metabolism by [ENTITY_A] in a small percentage of the population; these patients have greater exposure to and slower elimination of [ENTITY_B] than extensive metabolizers.",SUBSTRATE,CPR:9,4,"It undergoes extensive biotransformation, which is affected by poor metabolism by cytochrome P450 (CYP) 2D6 in a small percentage of the population; these patients have greater exposure to and slower elimination of atomoxetine than extensive metabolizers."
"<< CYP2D6 >> inhibitors, such as [[ paroxetine ]], are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers.","[ENTITY_A] inhibitors, such as [ENTITY_B], are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers.",INHIBITOR,CPR:4,1,"CYP2D6 inhibitors, such as paroxetine, are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers."
"CYP2D6 inhibitors, such as paroxetine, are associated with changes in << atomoxetine >> pharmacokinetics similar to those observed among poor [[ CYP2D6 ]] metabolizers.","CYP2D6 inhibitors, such as paroxetine, are associated with changes in [ENTITY_A] pharmacokinetics similar to those observed among poor [ENTITY_B] metabolizers.",SUBSTRATE,CPR:9,4,"CYP2D6 inhibitors, such as paroxetine, are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers."
<< Atomoxetine >> appeared better tolerated among extensive [[ CYP2D6 ]] metabolizers than among poor metabolizers.,[ENTITY_A] appeared better tolerated among extensive [ENTITY_B] metabolizers than among poor metabolizers.,SUBSTRATE,CPR:9,4,Atomoxetine appeared better tolerated among extensive CYP2D6 metabolizers than among poor metabolizers.
<< Mammalian glutamate dehydrogenase >> (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to [[ 2-oxoglutarate ]] using NAD(P)(+) as coenzyme.,[ENTITY_A] (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to [ENTITY_B] using NAD(P)(+) as coenzyme.,PRODUCT-OF,CPR:9,4,Mammalian glutamate dehydrogenase (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using NAD(P)(+) as coenzyme.
The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by << GTP >> causes excessive secretion of [[ insulin ]].,The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by [ENTITY_A] causes excessive secretion of [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by GTP causes excessive secretion of insulin.
"Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of << GDH >> are inhibited by the green tea polyphenols, [[ epigallocatechin gallate ]] and epicatechin gallate.","Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of [ENTITY_A] are inhibited by the green tea polyphenols, [ENTITY_B] and epicatechin gallate.",INHIBITOR,CPR:4,1,"Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of GDH are inhibited by the green tea polyphenols, epigallocatechin gallate and epicatechin gallate."
"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord << COX-2 >> (cyclooxygenase-2), with a subsequent increase in central [[ prostaglandin E2 ]] (PGE2) levels associated with the development of hyperalgesia.","BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord [ENTITY_A] (cyclooxygenase-2), with a subsequent increase in central [ENTITY_B] (PGE2) levels associated with the development of hyperalgesia.",PRODUCT-OF,CPR:9,4,"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 (cyclooxygenase-2), with a subsequent increase in central prostaglandin E2 (PGE2) levels associated with the development of hyperalgesia."
"Using the << alpha 1-adrenoceptor >> subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and [[ 5-methyl-urapidil ]], we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.","Using the [ENTITY_A] subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and [ENTITY_B], we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.",ANTAGONIST,CPR:6,3,"Using the alpha 1-adrenoceptor subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta."
Radioligand binding studies with the nonselective << alpha 1-adrenoceptor >> antagonist radioligand [[ 125I-BE2254 ]] showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).,Radioligand binding studies with the nonselective [ENTITY_A] antagonist radioligand [ENTITY_B] showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).,ANTAGONIST,CPR:6,3,Radioligand binding studies with the nonselective alpha 1-adrenoceptor antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).
"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against << alpha 1a-adrenoceptor >>-selective agonist [[ methoxamine ]]-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.","The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against [ENTITY_A]-selective agonist [ENTITY_B]-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",AGONIST,CPR:5,2,"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against alpha 1a-adrenoceptor-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil."
"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against << alpha 1a-adrenoceptor >>-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for [[ WB4101 ]] and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.","The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against [ENTITY_A]-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for [ENTITY_B] and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",ANTAGONIST,CPR:6,3,"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against alpha 1a-adrenoceptor-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil."
"Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that << alpha 1-adrenoceptor >> populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for [[ WB4101 ]] and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)","Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that [ENTITY_A] populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for [ENTITY_B] and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)",ANTAGONIST,CPR:6,3,"Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that alpha 1-adrenoceptor populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)"
<< Ambrisentan >> is an [[ endothelin receptor ]] antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH).,[ENTITY_A] is an [ENTITY_B] antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH).,ANTAGONIST,CPR:6,3,Ambrisentan is an endothelin receptor antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH).
<< Ambrisentan >> is the first [[ ET(A) ]] selective ERA approved for use in the US.,[ENTITY_A] is the first [ENTITY_B] selective ERA approved for use in the US.,ANTAGONIST,CPR:6,3,Ambrisentan is the first ET(A) selective ERA approved for use in the US.
"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, << promegestone >>, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking [[ sulfatase ]] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.","As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, [ENTITY_A], nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking [ENTITY_B] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.",INHIBITOR,CPR:4,1,"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities."
"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of << estradiol >> in breast cancer by blocking [[ sulfatase ]] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.","As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of [ENTITY_A] in breast cancer by blocking [ENTITY_B] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.",SUBSTRATE,CPR:9,4,"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities."
<< Mitiglinide >> reduced fasting plasma glucose and [[ GA ]] levels after 4 weeks and Hb(A1c) levels after 8 weeks.,[ENTITY_A] reduced fasting plasma glucose and [ENTITY_B] levels after 4 weeks and Hb(A1c) levels after 8 weeks.,INDIRECT-DOWNREGULATOR,CPR:4,1,Mitiglinide reduced fasting plasma glucose and GA levels after 4 weeks and Hb(A1c) levels after 8 weeks.
A molecular mechanism for << ibuprofen >>-mediated [[ RhoA ]] inhibition in neurons.,A molecular mechanism for [ENTITY_A]-mediated [ENTITY_B] inhibition in neurons.,INHIBITOR,CPR:4,1,A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons.
<< Ibuprofen >> is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of [[ cyclooxygenases ]].,[ENTITY_A] is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of [ENTITY_B].,INHIBITOR,CPR:4,1,Ibuprofen is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of cyclooxygenases.
"Recently, we have demonstrated that << ibuprofen >> inhibits intracellular signaling of [[ RhoA ]] and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents.","Recently, we have demonstrated that [ENTITY_A] inhibits intracellular signaling of [ENTITY_B] and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Recently, we have demonstrated that ibuprofen inhibits intracellular signaling of RhoA and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents."
"In addition, another study suggests that << ibuprofen >> reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate [[ amyloid-beta42 ]] formation by direct inhibition of the gamma-secretase complex.","In addition, another study suggests that [ENTITY_A] reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate [ENTITY_B] formation by direct inhibition of the gamma-secretase complex.",INDIRECT-UPREGULATOR,CPR:3,0,"In addition, another study suggests that ibuprofen reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex."
"In addition, another study suggests that << ibuprofen >> reduces generation of [[ amyloid-beta42 ]] peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex.","In addition, another study suggests that [ENTITY_A] reduces generation of [ENTITY_B] peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, another study suggests that ibuprofen reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex."
"The molecular mechanisms by which << ibuprofen >> inhibits the [[ RhoA ]] signal in neurons, however, remain unclear.","The molecular mechanisms by which [ENTITY_A] inhibits the [ENTITY_B] signal in neurons, however, remain unclear.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The molecular mechanisms by which ibuprofen inhibits the RhoA signal in neurons, however, remain unclear."
"Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is essential for coupling << ibuprofen >> to [[ RhoA ]] inhibition and subsequent neurite growth promotion in neurons.","Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is essential for coupling [ENTITY_A] to [ENTITY_B] inhibition and subsequent neurite growth promotion in neurons.",INHIBITOR,CPR:4,1,"Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is essential for coupling ibuprofen to RhoA inhibition and subsequent neurite growth promotion in neurons."
<< Ibuprofen >> activates [[ PPARgamma ]] in neuron-like PC12 and B104 cells.,[ENTITY_A] activates [ENTITY_B] in neuron-like PC12 and B104 cells.,ACTIVATOR,CPR:3,0,Ibuprofen activates PPARgamma in neuron-like PC12 and B104 cells.
"Activation of PPARgamma with traditional agonists mimics the << RhoA >>-inhibiting properties of [[ ibuprofen ]] in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors.","Activation of PPARgamma with traditional agonists mimics the [ENTITY_A]-inhibiting properties of [ENTITY_B] in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors.",INHIBITOR,CPR:4,1,"Activation of PPARgamma with traditional agonists mimics the RhoA-inhibiting properties of ibuprofen in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors."
These findings support that PPARgamma plays an essential role in mediating the << RhoA >>-inhibiting effect of [[ ibuprofen ]].,These findings support that PPARgamma plays an essential role in mediating the [ENTITY_A]-inhibiting effect of [ENTITY_B].,INHIBITOR,CPR:4,1,These findings support that PPARgamma plays an essential role in mediating the RhoA-inhibiting effect of ibuprofen.
"Elucidation of the novel molecular mechanisms linking << ibuprofen >> to [[ RhoA ]] inhibition may provide additional therapeutic targets to the disorders characterized by RhoA activation, including spinal cord injuries and Alzheimer's disease.","Elucidation of the novel molecular mechanisms linking [ENTITY_A] to [ENTITY_B] inhibition may provide additional therapeutic targets to the disorders characterized by RhoA activation, including spinal cord injuries and Alzheimer's disease.",INHIBITOR,CPR:4,1,"Elucidation of the novel molecular mechanisms linking ibuprofen to RhoA inhibition may provide additional therapeutic targets to the disorders characterized by RhoA activation, including spinal cord injuries and Alzheimer's disease."
"Of these, the << thrombin >> inhibitor [[ dabigatran ]] and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.","Of these, the [ENTITY_A] inhibitor [ENTITY_B] and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.",INHIBITOR,CPR:4,1,"Of these, the thrombin inhibitor dabigatran and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe."
"In addition, the << factor Xa >> inhibitor [[ apixaban ]] is in late-stage clinical development.","In addition, the [ENTITY_A] inhibitor [ENTITY_B] is in late-stage clinical development.",INHIBITOR,CPR:4,1,"In addition, the factor Xa inhibitor apixaban is in late-stage clinical development."
<< Captopril >> directly inhibits [[ matrix metalloproteinase-2 ]] activity in continuous ambulatory peritoneal dialysis therapy.,[ENTITY_A] directly inhibits [ENTITY_B] activity in continuous ambulatory peritoneal dialysis therapy.,INHIBITOR,CPR:4,1,Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy.
"We determined whether an << angiotensin-converting enzyme >> (ACE) inhibitor, [[ captopril ]], inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.","We determined whether an [ENTITY_A] (ACE) inhibitor, [ENTITY_B], inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.",INHIBITOR,CPR:4,1,"We determined whether an angiotensin-converting enzyme (ACE) inhibitor, captopril, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex."
METHODS: The inhibitory effect of << captopril >> on [[ MMP-2 ]] activity was measured in peritoneal effluents from 17 patients on CAPD.,METHODS: The inhibitory effect of [ENTITY_A] on [ENTITY_B] activity was measured in peritoneal effluents from 17 patients on CAPD.,INHIBITOR,CPR:4,1,METHODS: The inhibitory effect of captopril on MMP-2 activity was measured in peritoneal effluents from 17 patients on CAPD.
"RESULTS: << Captopril >> directly inhibited [[ MMP-2 ]] activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that captopril binding to the MMP-2 active site could be formed in each complex model without molecular distortion.","RESULTS: [ENTITY_A] directly inhibited [ENTITY_B] activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that captopril binding to the MMP-2 active site could be formed in each complex model without molecular distortion.",INHIBITOR,CPR:4,1,"RESULTS: Captopril directly inhibited MMP-2 activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that captopril binding to the MMP-2 active site could be formed in each complex model without molecular distortion."
"CONCLUSION: ACE inhibitors, such as << captopril >>, may be applied as important compounds for [[ MMP-2 ]] inhibition in inflammation caused by CAPD.","CONCLUSION: ACE inhibitors, such as [ENTITY_A], may be applied as important compounds for [ENTITY_B] inhibition in inflammation caused by CAPD.",INHIBITOR,CPR:4,1,"CONCLUSION: ACE inhibitors, such as captopril, may be applied as important compounds for MMP-2 inhibition in inflammation caused by CAPD."
<< Phenformin >> has a direct inhibitory effect on the [[ ATP-sensitive potassium channel ]].,[ENTITY_A] has a direct inhibitory effect on the [ENTITY_B].,INHIBITOR,CPR:4,1,Phenformin has a direct inhibitory effect on the ATP-sensitive potassium channel.
<< Phenformin >> but not metformin inhibits a number of variants of [[ K(ATP) ]] including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).,[ENTITY_A] but not metformin inhibits a number of variants of [ENTITY_B] including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).,INHIBITOR,CPR:4,1,Phenformin but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).
The extent and rate of inhibition are similar to that seen with the known << K(ATP) >> blocker [[ PNU 37883A ]].,The extent and rate of inhibition are similar to that seen with the known [ENTITY_A] blocker [ENTITY_B].,INHIBITOR,CPR:4,1,The extent and rate of inhibition are similar to that seen with the known K(ATP) blocker PNU 37883A.
"Additionally, << phenformin >> inhibited the current elicited through the [[ Kir6.2DeltaC26 ]] (functional without SUR) channel with an IC50 of 1.78 mM.","Additionally, [ENTITY_A] inhibited the current elicited through the [ENTITY_B] (functional without SUR) channel with an IC50 of 1.78 mM.",INHIBITOR,CPR:4,1,"Additionally, phenformin inhibited the current elicited through the Kir6.2DeltaC26 (functional without SUR) channel with an IC50 of 1.78 mM."
<< Phenformin >> reduced the open probability of [[ Kir6.1 ]]/SUR2B channels by approximately 90% in inside-out patches.,[ENTITY_A] reduced the open probability of [ENTITY_B]/SUR2B channels by approximately 90% in inside-out patches.,DOWNREGULATOR,CPR:4,1,Phenformin reduced the open probability of Kir6.1/SUR2B channels by approximately 90% in inside-out patches.
"Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum << Ca >> regulates [[ PTH ]] secretion mediated by the Ca-sensing receptor (CaSR).","Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum [ENTITY_A] regulates [ENTITY_B] secretion mediated by the Ca-sensing receptor (CaSR).",INDIRECT-UPREGULATOR,CPR:3,0,"Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (CaSR)."
"Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum << PTH >> effectively in the 5/6 NX rats, but [[ paricalcitol ]] was less potent in raising serum Ca than doxercalciferol.","Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum [ENTITY_A] effectively in the 5/6 NX rats, but [ENTITY_B] was less potent in raising serum Ca than doxercalciferol.",DOWNREGULATOR,CPR:4,1,"Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum PTH effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than doxercalciferol."
"In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although << paricalcitol >> induced the expression of [[ CaSR ]] mRNA more effectively.","In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although [ENTITY_A] induced the expression of [ENTITY_B] mRNA more effectively.",INDIRECT-UPREGULATOR,CPR:3,0,"In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively."
"In pig parathyroid cells, << paricalcitol >> and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed [[ PTH ]] mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively.","In pig parathyroid cells, [ENTITY_A] and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed [ENTITY_B] mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively."
<< Thalidomide >> initiates its teratogenic effects by binding to CRBN and inhibiting the associated [[ ubiquitin ligase ]] activity.,[ENTITY_A] initiates its teratogenic effects by binding to CRBN and inhibiting the associated [ENTITY_B] activity.,INHIBITOR,CPR:4,1,Thalidomide initiates its teratogenic effects by binding to CRBN and inhibiting the associated ubiquitin ligase activity.
"<< Telmisartan >> is an [[ angiotensin II receptor ]] blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure.","[ENTITY_A] is an [ENTITY_B] blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure.",INHIBITOR,CPR:4,1,"Telmisartan is an angiotensin II receptor blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure."
"Recent studies indicate that << tamoxifen >> initially acts as an antagonist, but later functions as an [[ ER ]] agonist, promoting tumor growth.","Recent studies indicate that [ENTITY_A] initially acts as an antagonist, but later functions as an [ENTITY_B] agonist, promoting tumor growth.",AGONIST,CPR:5,2,"Recent studies indicate that tamoxifen initially acts as an antagonist, but later functions as an ER agonist, promoting tumor growth."
"Recent studies indicate that << tamoxifen >> initially acts as an antagonist, but later functions as an [[ ER ]] agonist, promoting tumor growth.","Recent studies indicate that [ENTITY_A] initially acts as an antagonist, but later functions as an [ENTITY_B] agonist, promoting tumor growth.",ANTAGONIST,CPR:6,3,"Recent studies indicate that tamoxifen initially acts as an antagonist, but later functions as an ER agonist, promoting tumor growth."
"With the pentapeptide linked through the C7alpha position of << estradiol >>, the resulting PROTAC shows the most effective [[ ER ]] degradation and highest affinity for the estrogen receptor.","With the pentapeptide linked through the C7alpha position of [ENTITY_A], the resulting PROTAC shows the most effective [ENTITY_B] degradation and highest affinity for the estrogen receptor.",DOWNREGULATOR,CPR:4,1,"With the pentapeptide linked through the C7alpha position of estradiol, the resulting PROTAC shows the most effective ER degradation and highest affinity for the estrogen receptor."
"KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. << salmeterol >> and formoterol, for the [[ beta(2)-adrenoceptor ]] over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity.","KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. [ENTITY_A] and formoterol, for the [ENTITY_B] over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity.",AGONIST,CPR:5,2,"KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the beta(2)-adrenoceptor over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity."
<< Rasagiline >>: a novel anti-Parkinsonian [[ monoamine oxidase-B ]] inhibitor with neuroprotective activity.,[ENTITY_A]: a novel anti-Parkinsonian [ENTITY_B] inhibitor with neuroprotective activity.,INHIBITOR,CPR:4,1,Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
"<< Rasagiline >> (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible [[ monoamine oxidase (MAO)-B ]] inhibitor, anti-Parkinsonian drug.","[ENTITY_A] (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible [ENTITY_B] inhibitor, anti-Parkinsonian drug.",INHIBITOR,CPR:4,1,"Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug."
"Its S-isomer, << TVP1022 >> is thousand times less potent as an [[ MAO-B ]] inhibitor.","Its S-isomer, [ENTITY_A] is thousand times less potent as an [ENTITY_B] inhibitor.",INHIBITOR,CPR:4,1,"Its S-isomer, TVP1022 is thousand times less potent as an MAO-B inhibitor."
"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the << N-propargyl >> moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating [[ Bcl-2 ]] family proteins.","However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the [ENTITY_A] moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating [ENTITY_B] family proteins.",INDIRECT-UPREGULATOR,CPR:3,0,"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins."
"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of << rasagiline >> does not depend on inhibition of [[ MAO-B ]], but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins.","However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of [ENTITY_A] does not depend on inhibition of [ENTITY_B], but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins.",INHIBITOR,CPR:4,1,"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins."
"Our findings suggest that R316C causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum << TSH >> level with high dose of [[ levothyroxine ]] might be optimum for normal growth.","Our findings suggest that R316C causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum [ENTITY_A] level with high dose of [ENTITY_B] might be optimum for normal growth.",INDIRECT-UPREGULATOR,CPR:3,0,"Our findings suggest that R316C causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum TSH level with high dose of levothyroxine might be optimum for normal growth."
BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-<< steroidal >> anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of [[ cyclooxygenase-2 ]] (COX-2).,BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-[ENTITY_A] anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of [ENTITY_B] (COX-2).,INHIBITOR,CPR:4,1,BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 (COX-2).
"METHODS: We conducted a case-control study to measure the association between selective << cox-2 >> inhibitors, particularly [[ celecoxib ]], rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk.","METHODS: We conducted a case-control study to measure the association between selective [ENTITY_A] inhibitors, particularly [ENTITY_B], rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk.",INHIBITOR,CPR:4,1,"METHODS: We conducted a case-control study to measure the association between selective cox-2 inhibitors, particularly celecoxib, rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk."
"With exposure to << rofecoxib >>, a selective [[ COX-2 ]] inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.","With exposure to [ENTITY_A], a selective [ENTITY_B] inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.",INHIBITOR,CPR:4,1,"With exposure to rofecoxib, a selective COX-2 inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis."
"The suppressive effect of << ceruletide >> on barrel rotation could be partially countered by MK-329, a selective peripheral [[ CCK ]] (CCK-A) receptor antagonist.","The suppressive effect of [ENTITY_A] on barrel rotation could be partially countered by MK-329, a selective peripheral [ENTITY_B] (CCK-A) receptor antagonist.",DOWNREGULATOR,CPR:4,1,"The suppressive effect of ceruletide on barrel rotation could be partially countered by MK-329, a selective peripheral CCK (CCK-A) receptor antagonist."
"The suppressive effect of ceruletide on barrel rotation could be partially countered by << MK-329 >>, a selective peripheral [[ CCK ]] (CCK-A) receptor antagonist.","The suppressive effect of ceruletide on barrel rotation could be partially countered by [ENTITY_A], a selective peripheral [ENTITY_B] (CCK-A) receptor antagonist.",ANTAGONIST,CPR:6,3,"The suppressive effect of ceruletide on barrel rotation could be partially countered by MK-329, a selective peripheral CCK (CCK-A) receptor antagonist."
These findings suggest that << ceruletide >> specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through [[ CCK-A receptor ]].,These findings suggest that [ENTITY_A] specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through [ENTITY_B].,DOWNREGULATOR,CPR:4,1,These findings suggest that ceruletide specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through CCK-A receptor.
Effects of the << histamine H1 >> antagonist [[ chlorcyclizine ]] on rat fetal palate development.,Effects of the [ENTITY_A] antagonist [ENTITY_B] on rat fetal palate development.,ANTAGONIST,CPR:6,3,Effects of the histamine H1 antagonist chlorcyclizine on rat fetal palate development.
BACKGROUND: The effects of << histamine H1 >> antagonist [[ chlorcyclizine ]] on rat palate development were characterized following in utero exposure.,BACKGROUND: The effects of [ENTITY_A] antagonist [ENTITY_B] on rat palate development were characterized following in utero exposure.,ANTAGONIST,CPR:6,3,BACKGROUND: The effects of histamine H1 antagonist chlorcyclizine on rat palate development were characterized following in utero exposure.
"Removing medium Ca2+, blocking << Ca2+ channels >> with 50 mumol/l [[ verapamil ]], or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.","Removing medium Ca2+, blocking [ENTITY_A] with 50 mumol/l [ENTITY_B], or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.",INHIBITOR,CPR:4,1,"Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion."
"The smooth muscle relaxant, << W-7 >>, which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced [[ PRL ]] secretion in a dose-dependent manner (r = -0.991, p less than 0.01).","The smooth muscle relaxant, [ENTITY_A], which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced [ENTITY_B] secretion in a dose-dependent manner (r = -0.991, p less than 0.01).",INDIRECT-DOWNREGULATOR,CPR:4,1,"The smooth muscle relaxant, W-7, which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced PRL secretion in a dose-dependent manner (r = -0.991, p less than 0.01)."
An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement << spermine >> and this can be accomplished by breeding with CAG-[[ SMS ]] mice that express SpmS from a ubiquitous promoter.,An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement [ENTITY_A] and this can be accomplished by breeding with CAG-[ENTITY_B] mice that express SpmS from a ubiquitous promoter.,PRODUCT-OF,CPR:9,4,An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement spermine and this can be accomplished by breeding with CAG-SMS mice that express SpmS from a ubiquitous promoter.
"<< Cabozantinib >> (XL184), a novel [[ MET ]] and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.","[ENTITY_A] (XL184), a novel [ENTITY_B] and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.",INHIBITOR,CPR:4,1,"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth."
"<< Cabozantinib >> (XL184) is a small-molecule [[ kinase ]] inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.","[ENTITY_A] (XL184) is a small-molecule [ENTITY_B] inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.",INHIBITOR,CPR:4,1,"Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3."
Treatment with << cabozantinib >> inhibited [[ MET ]] and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.,Treatment with [ENTITY_A] inhibited [ENTITY_B] and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.,INHIBITOR,CPR:4,1,Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.
"Importantly, treatment with << cabozantinib >> did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of [[ VEGF ]] signaling that do not target MET.","Importantly, treatment with [ENTITY_A] did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of [ENTITY_B] signaling that do not target MET.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Importantly, treatment with cabozantinib did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of VEGF signaling that do not target MET."
"Collectively, these data suggest that << cabozantinib >> is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated [[ MET ]] and VEGFR signaling.","Collectively, these data suggest that [ENTITY_A] is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated [ENTITY_B] and VEGFR signaling.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling."
"Inhibition of the NF-kappaB pathway was responsible for this effect since the << colchicoside >> inhibited RANKL-induced [[ NF-kappaB ]] activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.","Inhibition of the NF-kappaB pathway was responsible for this effect since the [ENTITY_A] inhibited RANKL-induced [ENTITY_B] activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.",INHIBITOR,CPR:4,1,"Inhibition of the NF-kappaB pathway was responsible for this effect since the colchicoside inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB."
"CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that << thiocolchicoside >> significantly suppressed osteoclastogenesis induced by [[ RANKL ]] and tumour cells via the NF-kappaB signalling pathway.","CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that [ENTITY_A] significantly suppressed osteoclastogenesis induced by [ENTITY_B] and tumour cells via the NF-kappaB signalling pathway.",INHIBITOR,CPR:4,1,"CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that thiocolchicoside significantly suppressed osteoclastogenesis induced by RANKL and tumour cells via the NF-kappaB signalling pathway."
"Although genetic polymorphisms in the endothelial nitric oxide synthase (<< eNOS >>) gene may impair endogenous [[ NO ]] formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil.","Although genetic polymorphisms in the endothelial nitric oxide synthase ([ENTITY_A]) gene may impair endogenous [ENTITY_B] formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil.",PRODUCT-OF,CPR:9,4,"Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil."
<< Mercury >> induces the expression of [[ cyclooxygenase-2 ]] and inducible nitric oxide synthase.,[ENTITY_A] induces the expression of [ENTITY_B] and inducible nitric oxide synthase.,INDIRECT-UPREGULATOR,CPR:3,0,Mercury induces the expression of cyclooxygenase-2 and inducible nitric oxide synthase.
"Here, we report biochemical evidence that << mercury >> alone induces [[ NF-κB ]] activation, resulting in the induced expression of COX-2 and iNOS.","Here, we report biochemical evidence that [ENTITY_A] alone induces [ENTITY_B] activation, resulting in the induced expression of COX-2 and iNOS.",ACTIVATOR,CPR:3,0,"Here, we report biochemical evidence that mercury alone induces NF-κB activation, resulting in the induced expression of COX-2 and iNOS."
"Unexpectedly, both the << mGluR(5) >>specific agonist, [[ CHPG ]], and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization.","Unexpectedly, both the [ENTITY_A]specific agonist, [ENTITY_B], and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization.",AGONIST,CPR:5,2,"Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization."
Both outward currents were significantly reduced by the << mGluR >> antagonist [[ MCPG ]] and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP.,Both outward currents were significantly reduced by the [ENTITY_A] antagonist [ENTITY_B] and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP.,ANTAGONIST,CPR:6,3,Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP.
"We have examined the effectiveness of two novel << Chk1 >> selective inhibitors, [[ AR323 ]] and AR678, in a panel of melanoma cell lines and normal cell types.","We have examined the effectiveness of two novel [ENTITY_A] selective inhibitors, [ENTITY_B] and AR678, in a panel of melanoma cell lines and normal cell types.",INHIBITOR,CPR:4,1,"We have examined the effectiveness of two novel Chk1 selective inhibitors, AR323 and AR678, in a panel of melanoma cell lines and normal cell types."
"<< Aspirin >> inhibits mTOR signaling, activates [[ AMP-activated protein kinase ]], and induces autophagy in colorectal cancer cells.","[ENTITY_A] inhibits mTOR signaling, activates [ENTITY_B], and induces autophagy in colorectal cancer cells.",ACTIVATOR,CPR:3,0,"Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells."
"<< Aspirin >> inhibits [[ mTOR ]] signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.","[ENTITY_A] inhibits [ENTITY_B] signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells."
RESULTS: << Aspirin >> reduced [[ mTOR ]] signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1.,RESULTS: [ENTITY_A] reduced [ENTITY_B] signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1.,INDIRECT-DOWNREGULATOR,CPR:4,1,RESULTS: Aspirin reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1.
<< Aspirin >> changed nucleotide ratios and activated [[ AMPK ]] in CRC cells.,[ENTITY_A] changed nucleotide ratios and activated [ENTITY_B] in CRC cells.,ACTIVATOR,CPR:3,0,Aspirin changed nucleotide ratios and activated AMPK in CRC cells.
"<< mTOR >> was still inhibited by [[ aspirin ]] in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR.","[ENTITY_A] was still inhibited by [ENTITY_B] in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR.",INHIBITOR,CPR:4,1,"mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR."
"<< Aspirin >> induced autophagy, a feature of [[ mTOR ]] inhibition.","[ENTITY_A] induced autophagy, a feature of [ENTITY_B] inhibition.",INHIBITOR,CPR:4,1,"Aspirin induced autophagy, a feature of mTOR inhibition."
"Aspirin and << metformin >> (an activator of [[ AMPK ]]) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells.","Aspirin and [ENTITY_A] (an activator of [ENTITY_B]) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells.",ACTIVATOR,CPR:3,0,"Aspirin and metformin (an activator of AMPK) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells."
"Aspirin and << metformin >> (an activator of AMPK) increased inhibition of [[ mTOR ]] and Akt, as well as autophagy in CRC cells.","Aspirin and [ENTITY_A] (an activator of AMPK) increased inhibition of [ENTITY_B] and Akt, as well as autophagy in CRC cells.",INHIBITOR,CPR:4,1,"Aspirin and metformin (an activator of AMPK) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells."
Rectal mucosal samples from patients given << aspirin >> had reduced phosphorylation of [[ S6K1 ]] and S6.,Rectal mucosal samples from patients given [ENTITY_A] had reduced phosphorylation of [ENTITY_B] and S6.,INHIBITOR,CPR:4,1,Rectal mucosal samples from patients given aspirin had reduced phosphorylation of S6K1 and S6.
"CONCLUSIONS: << Aspirin >> is an inhibitor of mTOR and an activator of [[ AMPK ]], targeting regulators of intracellular energy homeostasis and metabolism.","CONCLUSIONS: [ENTITY_A] is an inhibitor of mTOR and an activator of [ENTITY_B], targeting regulators of intracellular energy homeostasis and metabolism.",ACTIVATOR,CPR:3,0,"CONCLUSIONS: Aspirin is an inhibitor of mTOR and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism."
"CONCLUSIONS: << Aspirin >> is an inhibitor of [[ mTOR ]] and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism.","CONCLUSIONS: [ENTITY_A] is an inhibitor of [ENTITY_B] and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism.",INHIBITOR,CPR:4,1,"CONCLUSIONS: Aspirin is an inhibitor of mTOR and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism."
"Exogenous stimulation of << PKA >> activity, achieved by [[ forskolin ]] treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.","Exogenous stimulation of [ENTITY_A] activity, achieved by [ENTITY_B] treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.",ACTIVATOR,CPR:3,0,"Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels."
"Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected << K-ras >>-transformed cells from apoptosis induced by [[ glucose ]] deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.","Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected [ENTITY_A]-transformed cells from apoptosis induced by [ENTITY_B] deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels."
"In << TGF-β1 >>-induced NPDFs, [[ berberine ]] significantly inhibited the expression of α-SMA and collagen type I mRNA and reduced α-SMA and collagen protein levels.","In [ENTITY_A]-induced NPDFs, [ENTITY_B] significantly inhibited the expression of α-SMA and collagen type I mRNA and reduced α-SMA and collagen protein levels.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In TGF-β1-induced NPDFs, berberine significantly inhibited the expression of α-SMA and collagen type I mRNA and reduced α-SMA and collagen protein levels."
<< Berberine >> only suppressed the expression of [[ pp38 ]] among the evaluated signaling molecules.,[ENTITY_A] only suppressed the expression of [ENTITY_B] among the evaluated signaling molecules.,INDIRECT-DOWNREGULATOR,CPR:4,1,Berberine only suppressed the expression of pp38 among the evaluated signaling molecules.
<< SB203580 >> (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of [[ collagen type I ]] and α-SMA in TGF-β1-induced NPDFs.,[ENTITY_A] (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of [ENTITY_B] and α-SMA in TGF-β1-induced NPDFs.,INDIRECT-DOWNREGULATOR,CPR:4,1,SB203580 (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and α-SMA in TGF-β1-induced NPDFs.
"CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as << lenalidomide >>- and pomalidomide-induced [[ cytokine ]] production in T cells.","CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as [ENTITY_A]- and pomalidomide-induced [ENTITY_B] production in T cells.",INDIRECT-UPREGULATOR,CPR:3,0,"CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide-induced cytokine production in T cells."
"<< Lenalidomide >> and pomalidomide inhibited autoubiquitination of [[ CRBN ]] in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA).","[ENTITY_A] and pomalidomide inhibited autoubiquitination of [ENTITY_B] in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA).",INHIBITOR,CPR:4,1,"Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA)."
"Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified << pomalidomide >>-mediated reductions in c-myc and IRF4 expression and increases in p21([[ WAF-1 ]]) expression.","Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified [ENTITY_A]-mediated reductions in c-myc and IRF4 expression and increases in p21([ENTITY_B]) expression.",INDIRECT-UPREGULATOR,CPR:3,0,"Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression."
"Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified << pomalidomide >>-mediated reductions in [[ c-myc ]] and IRF4 expression and increases in p21(WAF-1) expression.","Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified [ENTITY_A]-mediated reductions in [ENTITY_B] and IRF4 expression and increases in p21(WAF-1) expression.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression."
"Long-term selection for << lenalidomide >> resistance in H929 myeloma cell lines was accompanied by a reduction in [[ CRBN ]], while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable.","Long-term selection for [ENTITY_A] resistance in H929 myeloma cell lines was accompanied by a reduction in [ENTITY_B], while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Long-term selection for lenalidomide resistance in H929 myeloma cell lines was accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable."
"These << polyphenols >>, but not GvEx, showed a certain level of inhibition of human-cDNA-expressed [[ CYPs ]].","These [ENTITY_A], but not GvEx, showed a certain level of inhibition of human-cDNA-expressed [ENTITY_B].",INHIBITOR,CPR:4,1,"These polyphenols, but not GvEx, showed a certain level of inhibition of human-cDNA-expressed CYPs."
"<< Crizotinib >> is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the [[ ALK ]] fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK.","[ENTITY_A] is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the [ENTITY_B] fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Crizotinib is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK."
"To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. << adenosine >> agonists, [[ N6-(R-phenylisopropyl)adenosine ]] (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.","To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. [ENTITY_A] agonists, [ENTITY_B] (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",AGONIST,CPR:5,2,"To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod."
"To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. << adenosine >> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, [[ theophylline ]] and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.","To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. [ENTITY_A] agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, [ENTITY_B] and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",ANTAGONIST,CPR:6,3,"To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod."
"<< Enprofylline >>, a weak adenosine antagonist but potent inhibitor of [[ cyclic AMP phosphodiesterase ]], did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.","[ENTITY_A], a weak adenosine antagonist but potent inhibitor of [ENTITY_B], did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.",INHIBITOR,CPR:4,1,"Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions."
"<< Enprofylline >>, a weak [[ adenosine ]] antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.","[ENTITY_A], a weak [ENTITY_B] antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.",ANTAGONIST,CPR:6,3,"Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions."
"<< Celastrol >>, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased [[ TGF-β1 ]]-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.","[ENTITY_A], a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased [ENTITY_B]-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.",DOWNREGULATOR,CPR:4,1,"Celastrol, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity."
"<< Celastrol >> also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and [[ Annexin V ]] markers of apoptosis.","[ENTITY_A] also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and [ENTITY_B] markers of apoptosis.",INDIRECT-UPREGULATOR,CPR:3,0,"Celastrol also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and Annexin V markers of apoptosis."
<< Celastrol >> highlights the therapeutic potential of agents targeting [[ TAK1 ]] as a key node in this pro-oncogenic TGF-β-NF-κB signal pathway.,[ENTITY_A] highlights the therapeutic potential of agents targeting [ENTITY_B] as a key node in this pro-oncogenic TGF-β-NF-κB signal pathway.,INHIBITOR,CPR:4,1,Celastrol highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic TGF-β-NF-κB signal pathway.
The atypical antidepressant << mianserin >> exhibits agonist activity at [[ kappa-opioid receptors ]].,The atypical antidepressant [ENTITY_A] exhibits agonist activity at [ENTITY_B].,AGONIST,CPR:5,2,The atypical antidepressant mianserin exhibits agonist activity at kappa-opioid receptors.
We previously reported that << tricyclic >> antidepressants act as agonists at distinct [[ opioid receptors ]].,We previously reported that [ENTITY_A] antidepressants act as agonists at distinct [ENTITY_B].,AGONIST,CPR:5,2,We previously reported that tricyclic antidepressants act as agonists at distinct opioid receptors.
"In [(35)S]GTPgammaS assays, << mianserin >> selectively activated [[ kappa-opioid receptors ]].","In [(35)S]GTPgammaS assays, [ENTITY_A] selectively activated [ENTITY_B].",ACTIVATOR,CPR:3,0,"In [(35)S]GTPgammaS assays, mianserin selectively activated kappa-opioid receptors."
The agonist activity was antagonized by the selective << kappa-opioid >> blocker [[ nor-binaltorphimine ]] (nor-BNI).,The agonist activity was antagonized by the selective [ENTITY_A] blocker [ENTITY_B] (nor-BNI).,INHIBITOR,CPR:4,1,The agonist activity was antagonized by the selective kappa-opioid blocker nor-binaltorphimine (nor-BNI).
The agonist activity was antagonized by the selective << kappa-opioid >> blocker [[ nor-binaltorphimine ]] (nor-BNI).,The agonist activity was antagonized by the selective [ENTITY_A] blocker [ENTITY_B] (nor-BNI).,ANTAGONIST,CPR:6,3,The agonist activity was antagonized by the selective kappa-opioid blocker nor-binaltorphimine (nor-BNI).
The << mianserin >> analogue mirtazapine also displayed [[ kappa-opioid ]] agonist activity.,The [ENTITY_A] analogue mirtazapine also displayed [ENTITY_B] agonist activity.,AGONIST,CPR:5,2,The mianserin analogue mirtazapine also displayed kappa-opioid agonist activity.
"In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full << kappa-opioid >> agonists [[ (-)-U50,488 ]] and dynorphin A.","In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full [ENTITY_A] agonists [ENTITY_B] and dynorphin A.",AGONIST,CPR:5,2,"In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and dynorphin A."
"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of << p38 >> MAPK and ERK1/2 phosphorylation by [[ dynorphin A ]].","When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of [ENTITY_A] MAPK and ERK1/2 phosphorylation by [ENTITY_B].",ACTIVATOR,CPR:3,0,"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A."
"When combined, << mianserin >> antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of [[ p38 ]] MAPK and ERK1/2 phosphorylation by dynorphin A.","When combined, [ENTITY_A] antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of [ENTITY_B] MAPK and ERK1/2 phosphorylation by dynorphin A.",INHIBITOR,CPR:4,1,"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A."
"When combined, << mianserin >> antagonized the effects of the full [[ kappa-opioid receptor ]] agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A.","When combined, [ENTITY_A] antagonized the effects of the full [ENTITY_B] agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A.",ANTAGONIST,CPR:6,3,"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A."
"CONCLUSIONS AND IMPLICATIONS: In different cell systems, << mianserin >> directly activates [[ kappa-opioid receptors ]], displaying partial agonist activity at brain receptors.","CONCLUSIONS AND IMPLICATIONS: In different cell systems, [ENTITY_A] directly activates [ENTITY_B], displaying partial agonist activity at brain receptors.",ACTIVATOR,CPR:3,0,"CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors, displaying partial agonist activity at brain receptors."
"CONCLUSIONS AND IMPLICATIONS: In different cell systems, << mianserin >> directly activates [[ kappa-opioid receptors ]], displaying partial agonist activity at brain receptors.","CONCLUSIONS AND IMPLICATIONS: In different cell systems, [ENTITY_A] directly activates [ENTITY_B], displaying partial agonist activity at brain receptors.",AGONIST,CPR:5,2,"CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors, displaying partial agonist activity at brain receptors."
"In the present study we tested whether << propranolol >>, a [[ β-receptor ]] antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8).","In the present study we tested whether [ENTITY_A], a [ENTITY_B] antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8).",ANTAGONIST,CPR:6,3,"In the present study we tested whether propranolol, a β-receptor antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8)."
<< LXRs >> are thought to be activated predominantly by [[ oxysterols ]] generated enzymatically from cholesterol in different cell organelles.,[ENTITY_A] are thought to be activated predominantly by [ENTITY_B] generated enzymatically from cholesterol in different cell organelles.,ACTIVATOR,CPR:3,0,LXRs are thought to be activated predominantly by oxysterols generated enzymatically from cholesterol in different cell organelles.
Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in << sterol-27-hydroxylase >> activity lead to specific blocks in [[ oxysterol ]] production and impaired LXR-dependent gene activation.,Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in [ENTITY_A] activity lead to specific blocks in [ENTITY_B] production and impaired LXR-dependent gene activation.,PRODUCT-OF,CPR:9,4,Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in sterol-27-hydroxylase activity lead to specific blocks in oxysterol production and impaired LXR-dependent gene activation.
"The purpose of this review is to summarize current knowledge about << oxysterol >>-dependent activation by [[ LXR ]] of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of oxysterol generation for expression of LXR-dependent genes.","The purpose of this review is to summarize current knowledge about [ENTITY_A]-dependent activation by [ENTITY_B] of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of oxysterol generation for expression of LXR-dependent genes.",ACTIVATOR,CPR:3,0,"The purpose of this review is to summarize current knowledge about oxysterol-dependent activation by LXR of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of oxysterol generation for expression of LXR-dependent genes."
<< CBDP >> irreversibly inhibits [[ butyrylcholinesterase ]] (BChE) in human plasma by forming adducts on the active site serine (Ser-198).,[ENTITY_A] irreversibly inhibits [ENTITY_B] (BChE) in human plasma by forming adducts on the active site serine (Ser-198).,INHIBITOR,CPR:4,1,CBDP irreversibly inhibits butyrylcholinesterase (BChE) in human plasma by forming adducts on the active site serine (Ser-198).
"Mass spectral analysis of << CBDP >>-inhibited [[ BChE ]] digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438.","Mass spectral analysis of [ENTITY_A]-inhibited [ENTITY_B] digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438.",INHIBITOR,CPR:4,1,"Mass spectral analysis of CBDP-inhibited BChE digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438."
"We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by << α-tocopherol >> in the rat dentate gyrus, increasing [[ cyclic adenosine monophosphate response element binding protein ]] phosphorylation.","We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by [ENTITY_A] in the rat dentate gyrus, increasing [ENTITY_B] phosphorylation.",ACTIVATOR,CPR:3,0,"We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by α-tocopherol in the rat dentate gyrus, increasing cyclic adenosine monophosphate response element binding protein phosphorylation."
"<< Galantamine >> is a reversible, competitive [[ acetylcholinesterase ]] (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids.","[ENTITY_A] is a reversible, competitive [ENTITY_B] (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids.",INHIBITOR,CPR:4,1,"Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids."
Modulation of the << nitric oxide >> producing system (demonstrated via the [[ NADPH-diaphorase ]] histochemical reaction) by oestradiol has been established in several structures of the rat brain.,Modulation of the [ENTITY_A] producing system (demonstrated via the [ENTITY_B] histochemical reaction) by oestradiol has been established in several structures of the rat brain.,PRODUCT-OF,CPR:9,4,Modulation of the nitric oxide producing system (demonstrated via the NADPH-diaphorase histochemical reaction) by oestradiol has been established in several structures of the rat brain.
"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective << ERβ >> agonist-[[ DPN ]] [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).","Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective [ENTITY_A] agonist-[ENTITY_B] [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",AGONIST,CPR:5,2,"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)."
"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective << ERα >> antagonist-[[ MPP ]] [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).","Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective [ENTITY_A] antagonist-[ENTITY_B] [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",ANTAGONIST,CPR:6,3,"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)."
<< Verrucarin A >> sensitizes TRAIL-induced apoptosis via the upregulation of [[ DR5 ]] in an eIF2α/CHOP-dependent manner.,[ENTITY_A] sensitizes TRAIL-induced apoptosis via the upregulation of [ENTITY_B] in an eIF2α/CHOP-dependent manner.,INDIRECT-UPREGULATOR,CPR:3,0,Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2α/CHOP-dependent manner.
"Furthermore, << salubrinal >>, a specific [[ eIF2α ]] phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA.","Furthermore, [ENTITY_A], a specific [ENTITY_B] phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA.",ACTIVATOR,CPR:3,0,"Furthermore, salubrinal, a specific eIF2α phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA."
"Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface << glucose transporter isoform 4 >> (GLUT4) and [[ glucose ]] uptake.","Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface [ENTITY_A] (GLUT4) and [ENTITY_B] uptake.",SUBSTRATE,CPR:9,4,"Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and glucose uptake."
"Other groups received either an infusion of the selective << NMDA receptor >> antagonist ([[ AP7 ]]; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).","Other groups received either an infusion of the selective [ENTITY_A] antagonist ([ENTITY_B]; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).",ANTAGONIST,CPR:6,3,"Other groups received either an infusion of the selective NMDA receptor antagonist (AP7; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900)."
"Our data also indicate that << NMDA receptor >> pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since [[ AP7 ]] microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO.","Our data also indicate that [ENTITY_A] pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since [ENTITY_B] microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO.",INHIBITOR,CPR:4,1,"Our data also indicate that NMDA receptor pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO."
"Metabolism of << triethylenetetramine >> and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and [[ thialysine acetyltransferase ]].","Metabolism of [ENTITY_A] and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and [ENTITY_B].",SUBSTRATE,CPR:9,4,"Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase."
We recently showed that << TETA >> is metabolized in vitro by polyamine catabolic enzyme [[ spermidine/spermine-N(1)-acetyltransferase ]] (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).,We recently showed that [ENTITY_A] is metabolized in vitro by polyamine catabolic enzyme [ENTITY_B] (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).,SUBSTRATE,CPR:9,4,We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).
The acetylation of << TETA >> is increased in [[ SSAT1 ]]-overexpressing mice compared with wild-type mice.,The acetylation of [ENTITY_A] is increased in [ENTITY_B]-overexpressing mice compared with wild-type mice.,SUBSTRATE,CPR:9,4,The acetylation of TETA is increased in SSAT1-overexpressing mice compared with wild-type mice.
"However, SSAT1-deficient mice metabolize << TETA >> at the same rate as the wild-type mice, indicating the existence of another [[ N-acetylase ]] respons 2ible for its metabolism in mice.","However, SSAT1-deficient mice metabolize [ENTITY_A] at the same rate as the wild-type mice, indicating the existence of another [ENTITY_B] respons 2ible for its metabolism in mice.",SUBSTRATE,CPR:9,4,"However, SSAT1-deficient mice metabolize TETA at the same rate as the wild-type mice, indicating the existence of another N-acetylase respons 2ible for its metabolism in mice."
"Here, we show that siRNA-mediated knockdown of << SSAT2 >> in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of [[ TETA ]] to MAT.","Here, we show that siRNA-mediated knockdown of [ENTITY_A] in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of [ENTITY_B] to MAT.",SUBSTRATE,CPR:9,4,"Here, we show that siRNA-mediated knockdown of SSAT2 in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of TETA to MAT."
"By contrast, << 1,12-diamino-3,6,9-triazadodecane >>(SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by [[ SSAT1 ]] in HEPG2 cells and in wild-type primary hepatocytes.","By contrast, [ENTITY_A](SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by [ENTITY_B] in HEPG2 cells and in wild-type primary hepatocytes.",SUBSTRATE,CPR:9,4,"By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes."
"Thus, despite the similar structures of TETA and SpmTrien, << SSAT2 >> is the main acetylator of [[ TETA ]], whereas SpmTrien is primarily acetylated by SSAT1.","Thus, despite the similar structures of TETA and SpmTrien, [ENTITY_A] is the main acetylator of [ENTITY_B], whereas SpmTrien is primarily acetylated by SSAT1.",SUBSTRATE,CPR:9,4,"Thus, despite the similar structures of TETA and SpmTrien, SSAT2 is the main acetylator of TETA, whereas SpmTrien is primarily acetylated by SSAT1."
In vitro metabolism of the << 5-hydroxytryptamine1B >> receptor antagonist [[ elzasonan ]].,In vitro metabolism of the [ENTITY_A] receptor antagonist [ENTITY_B].,ANTAGONIST,CPR:6,3,In vitro metabolism of the 5-hydroxytryptamine1B receptor antagonist elzasonan.
The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each << rCYP >> in the metabolism of [[ elzasonan ]].,The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each [ENTITY_A] in the metabolism of [ENTITY_B].,SUBSTRATE,CPR:9,4,The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each rCYP in the metabolism of elzasonan.
Cytochrome b5 has shown to be an essential component in << P450 3A4 >> catalyzed [[ 5-hydroxyelzasonan ]] formation and provides insights on the disconnect between human liver microsomes data and that of rCYP.,Cytochrome b5 has shown to be an essential component in [ENTITY_A] catalyzed [ENTITY_B] formation and provides insights on the disconnect between human liver microsomes data and that of rCYP.,PRODUCT-OF,CPR:9,4,Cytochrome b5 has shown to be an essential component in P450 3A4 catalyzed 5-hydroxyelzasonan formation and provides insights on the disconnect between human liver microsomes data and that of rCYP.
"In utero exposure to << valproic acid >> (VPA), a [[ histone deacetylase ]] (HDAC) inhibitor, causes neural tube, heart, and limb defects.","In utero exposure to [ENTITY_A] (VPA), a [ENTITY_B] (HDAC) inhibitor, causes neural tube, heart, and limb defects.",INHIBITOR,CPR:4,1,"In utero exposure to valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, causes neural tube, heart, and limb defects."
"<< VPA >> caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its [[ HDAC ]] inhibitory effect.","[ENTITY_A] caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its [ENTITY_B] inhibitory effect.",INHIBITOR,CPR:4,1,"VPA caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its HDAC inhibitory effect."
"The signaling of both << Sox9 >> and Runx2, key regulators of chondrogenesis, was downregulated by [[ VPA ]].","The signaling of both [ENTITY_A] and Runx2, key regulators of chondrogenesis, was downregulated by [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"The signaling of both Sox9 and Runx2, key regulators of chondrogenesis, was downregulated by VPA."
<< α-TOCO >> plus a [[ pancaspase ]] inhibitor completely abolished AMD/TNF-induced cytotoxicity.,[ENTITY_A] plus a [ENTITY_B] inhibitor completely abolished AMD/TNF-induced cytotoxicity.,INHIBITOR,CPR:4,1,α-TOCO plus a pancaspase inhibitor completely abolished AMD/TNF-induced cytotoxicity.
"In summary, activation of << caspases >> and oxidative stress were observed after [[ AMD ]]/TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated AMD/TNF-induced cytotoxicity.","In summary, activation of [ENTITY_A] and oxidative stress were observed after [ENTITY_B]/TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated AMD/TNF-induced cytotoxicity.",ACTIVATOR,CPR:3,0,"In summary, activation of caspases and oxidative stress were observed after AMD/TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated AMD/TNF-induced cytotoxicity."
Human serum butyrylcholinesterase (<< HuBChE >>) is currently the most suitable bioscavenger for the prophylaxis of highly toxic [[ organophosphate ]] (OP) nerve agents.,Human serum butyrylcholinesterase ([ENTITY_A]) is currently the most suitable bioscavenger for the prophylaxis of highly toxic [ENTITY_B] (OP) nerve agents.,SUBSTRATE,CPR:9,4,Human serum butyrylcholinesterase (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic organophosphate (OP) nerve agents.
Cu-dependent << tyrosinase >> activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate [[ l-DOPA ]].,Cu-dependent [ENTITY_A] activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate [ENTITY_B].,SUBSTRATE,CPR:9,4,Cu-dependent tyrosinase activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate l-DOPA.
Protein expression of << Ugt1a6 >> also decreased and corresponded with reduced in vitro glucuronidation of [[ bisphenol A ]] in S9 fractions from livers of pregnant mice.,Protein expression of [ENTITY_A] also decreased and corresponded with reduced in vitro glucuronidation of [ENTITY_B] in S9 fractions from livers of pregnant mice.,INDIRECT-DOWNREGULATOR,CPR:4,1,Protein expression of Ugt1a6 also decreased and corresponded with reduced in vitro glucuronidation of bisphenol A in S9 fractions from livers of pregnant mice.
<< Dimethylfumarate >> attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/[[ Smad ]] signaling.,[ENTITY_A] attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/[ENTITY_B] signaling.,INDIRECT-DOWNREGULATOR,CPR:4,1,Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/Smad signaling.
"Results showed that << DMF >> increased nuclear levels of [[ Nrf2 ]], and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).","Results showed that [ENTITY_A] increased nuclear levels of [ENTITY_B], and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).",INDIRECT-UPREGULATOR,CPR:3,0,"Results showed that DMF increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)."
"Results showed that DMF increased nuclear levels of Nrf2, and both << DMF >> and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased [[ PAI-1 ]], alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).","Results showed that DMF increased nuclear levels of Nrf2, and both [ENTITY_A] and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased [ENTITY_B], alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).",INDIRECT-DOWNREGULATOR,CPR:4,1,"Results showed that DMF increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)."
"Additionally, << DMF >> and Ad-Nrf2 repressed [[ TGF-beta ]]-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.","Additionally, [ENTITY_A] and Ad-Nrf2 repressed [ENTITY_B]-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.",DOWNREGULATOR,CPR:4,1,"Additionally, DMF and Ad-Nrf2 repressed TGF-beta-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression."
"However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of << DMF >> on [[ TGF-beta ]]-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.","However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of [ENTITY_A] on [ENTITY_B]-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.",DOWNREGULATOR,CPR:4,1,"However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF."
"Finally, << DMF >> suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of [[ Nrf2 ]] and phospho-Smad3, respectively.","Finally, [ENTITY_A] suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of [ENTITY_B] and phospho-Smad3, respectively.",INDIRECT-UPREGULATOR,CPR:3,0,"Finally, DMF suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively."
"Finally, << DMF >> suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and [[ alpha-SMA ]], fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively.","Finally, [ENTITY_A] suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and [ENTITY_B], fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Finally, DMF suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively."
"In summary, << DMF >> attenuated renal fibrosis via the Nrf2-mediated inhibition of [[ TGF-beta ]]/Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.","In summary, [ENTITY_A] attenuated renal fibrosis via the Nrf2-mediated inhibition of [ENTITY_B]/Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In summary, DMF attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta/Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis."
Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with << Met >>-RANTES (an antagonist of [[ CCR5 ]] and CCR1).,Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with [ENTITY_A]-RANTES (an antagonist of [ENTITY_B] and CCR1).,ANTAGONIST,CPR:6,3,Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1).
"mRNA levels of << receptor activator of nuclear factor kappa-B >> (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with [[ Met ]]-RANTES.","mRNA levels of [ENTITY_A] (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with [ENTITY_B]-RANTES.",INDIRECT-DOWNREGULATOR,CPR:4,1,"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES."
<< Met >>-RANTES treatment also reduced the levels of [[ cathepsin K ]] and metalloproteinase 13 (MMP13).,[ENTITY_A]-RANTES treatment also reduced the levels of [ENTITY_B] and metalloproteinase 13 (MMP13).,INDIRECT-DOWNREGULATOR,CPR:4,1,Met-RANTES treatment also reduced the levels of cathepsin K and metalloproteinase 13 (MMP13).
"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while << osteocalcin >> (OCN) was augmented in CCL3(-/-) and [[ Met ]]-RANTES-treated mice.","The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while [ENTITY_A] (OCN) was augmented in CCL3(-/-) and [ENTITY_B]-RANTES-treated mice.",INDIRECT-UPREGULATOR,CPR:3,0,"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and Met-RANTES-treated mice."
"The expression of the osteoblast markers runt-related transcription factor 2 (<< RUNX2 >>) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and [[ Met ]]-RANTES-treated mice.","The expression of the osteoblast markers runt-related transcription factor 2 ([ENTITY_A]) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and [ENTITY_B]-RANTES-treated mice.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and Met-RANTES-treated mice."
"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and << matrine >> carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and [[ hERG ]] blocking activity.","The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and [ENTITY_A] carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and [ENTITY_B] blocking activity.",INHIBITOR,CPR:4,1,"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and hERG blocking activity."
"Several effects of << polyphenols >> are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, [[ AMPK ]] activators, calorie-restriction mimetics or epigenetic regulators.","Several effects of [ENTITY_A] are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, [ENTITY_B] activators, calorie-restriction mimetics or epigenetic regulators.",ACTIVATOR,CPR:3,0,"Several effects of polyphenols are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators."
"Several effects of << polyphenols >> are useful in this scenario, including a reduction in the activities of [[ cytokines ]] and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators.","Several effects of [ENTITY_A] are useful in this scenario, including a reduction in the activities of [ENTITY_B] and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators.",INHIBITOR,CPR:4,1,"Several effects of polyphenols are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators."
"Inhibition of << EGF >>/EGFR activation with [[ naphtho[1,2-b]furan-4,5-dione ]] blocks migration and invasion of MDA-MB-231 cells.",Inhibition of [ENTITY_A]/EGFR activation with [ENTITY_B] blocks migration and invasion of MDA-MB-231 cells.,INHIBITOR,CPR:4,1,"Inhibition of EGF/EGFR activation with naphtho[1,2-b]furan-4,5-dione blocks migration and invasion of MDA-MB-231 cells."
"<< NFD >> suppressed [[ EGF ]]-mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.","[ENTITY_A] suppressed [ENTITY_B]-mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.",DOWNREGULATOR,CPR:4,1,"NFD suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity."
<< NFD >> abrogated [[ EGF ]]-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt.,[ENTITY_A] abrogated [ENTITY_B]-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt.,DOWNREGULATOR,CPR:4,1,NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt.
"The specific << PI3K >> inhibitor, [[ wortmannin ]], blocked significantly EGF-induced cell migration and invasion.","The specific [ENTITY_A] inhibitor, [ENTITY_B], blocked significantly EGF-induced cell migration and invasion.",INHIBITOR,CPR:4,1,"The specific PI3K inhibitor, wortmannin, blocked significantly EGF-induced cell migration and invasion."
"Furthermore, the EGFR inhibitor << AG1478 >> inhibited EGF-induced [[ MMP-9 ]] expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.","Furthermore, the EGFR inhibitor [ENTITY_A] inhibited EGF-induced [ENTITY_B] expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, the EGFR inhibitor AG1478 inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation."
"These findings suggest that << NFD >> inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent [[ PI3K ]]/Akt signaling, leading to the down-regulation of MMP-9 expression.","These findings suggest that [ENTITY_A] inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent [ENTITY_B]/Akt signaling, leading to the down-regulation of MMP-9 expression.",INDIRECT-DOWNREGULATOR,CPR:4,1,"These findings suggest that NFD inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K/Akt signaling, leading to the down-regulation of MMP-9 expression."
"Herein, we report the identification and characterization of << 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile >> (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated [[ insulin ]] secretion in pancreatic β cells.","Herein, we report the identification and characterization of [ENTITY_A] (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated [ENTITY_B] secretion in pancreatic β cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells."
"Herein, we report the identification and characterization of << 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile >> (ESI-09), a novel noncyclic nucleotide [[ EPAC ]] antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Herein, we report the identification and characterization of [ENTITY_A] (ESI-09), a novel noncyclic nucleotide [ENTITY_B] antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.",ANTAGONIST,CPR:6,3,"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells."
<< Metformin >> directly inhibits [[ ghrelin ]] secretion through AMP-activated protein kinase in rat primary gastric cells.,[ENTITY_A] directly inhibits [ENTITY_B] secretion through AMP-activated protein kinase in rat primary gastric cells.,INDIRECT-DOWNREGULATOR,CPR:4,1,Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells.
<< Metformin >> treatment is also associated with lower circulating levels of the [[ orexigenic hormone ]] ghrelin.,[ENTITY_A] treatment is also associated with lower circulating levels of the [ENTITY_B] ghrelin.,INDIRECT-DOWNREGULATOR,CPR:4,1,Metformin treatment is also associated with lower circulating levels of the orexigenic hormone ghrelin.
Metformin significantly reduced << ghrelin >> secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor [[ compound C ]].,Metformin significantly reduced [ENTITY_A] secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C.
<< Metformin >> significantly reduced [[ ghrelin ]] secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C.,[ENTITY_A] significantly reduced [ENTITY_B] secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C.,INDIRECT-DOWNREGULATOR,CPR:4,1,Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C.
"Furthermore, the << AMPK >> activator [[ 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide ]] (AICAR) significantly inhibited ghrelin secretion.","Furthermore, the [ENTITY_A] activator [ENTITY_B] (AICAR) significantly inhibited ghrelin secretion.",ACTIVATOR,CPR:3,0,"Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion."
"Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (<< AICAR >>) significantly inhibited [[ ghrelin ]] secretion.","Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide ([ENTITY_A]) significantly inhibited [ENTITY_B] secretion.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion."
"Finally, << Metformin >> treatment caused a significant increase in the level of [[ phosphorylated (active) AMPK ]].","Finally, [ENTITY_A] treatment caused a significant increase in the level of [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"Finally, Metformin treatment caused a significant increase in the level of phosphorylated (active) AMPK."
Our results show that << Metformin >> directly inhibits stomach [[ ghrelin ]] production and secretion through AMPK.,Our results show that [ENTITY_A] directly inhibits stomach [ENTITY_B] production and secretion through AMPK.,INDIRECT-DOWNREGULATOR,CPR:4,1,Our results show that Metformin directly inhibits stomach ghrelin production and secretion through AMPK.
Fungicide << prochloraz >> and environmental pollutant dioxin induce the [[ ABCG2 ]] transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.,Fungicide [ENTITY_A] and environmental pollutant dioxin induce the [ENTITY_B] transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.,UPREGULATOR,CPR:3,0,Fungicide prochloraz and environmental pollutant dioxin induce the ABCG2 transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.
"As these regulatory motifs mediate regulation of target genes by << AhR >> agonists including [[ TCDD ]] and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.","As these regulatory motifs mediate regulation of target genes by [ENTITY_A] agonists including [ENTITY_B] and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.",AGONIST,CPR:5,2,"As these regulatory motifs mediate regulation of target genes by AhR agonists including TCDD and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells."
TCDD or prochloraz doubled << ABCG2 >>-mediated [[ Hoechst H33342 ]] secretion.,TCDD or prochloraz doubled [ENTITY_A]-mediated [ENTITY_B] secretion.,SUBSTRATE,CPR:9,4,TCDD or prochloraz doubled ABCG2-mediated Hoechst H33342 secretion.
This effect was almost completely reversed by specific << ABCG2 >> inhibitor [[ Ko143 ]].,This effect was almost completely reversed by specific [ENTITY_A] inhibitor [ENTITY_B].,INHIBITOR,CPR:4,1,This effect was almost completely reversed by specific ABCG2 inhibitor Ko143.
Receptor binding was significantly reduced by specific << AhR >> antagonist [[ salicyl amide ]].,Receptor binding was significantly reduced by specific [ENTITY_A] antagonist [ENTITY_B].,ANTAGONIST,CPR:6,3,Receptor binding was significantly reduced by specific AhR antagonist salicyl amide.
Induction of AhR by << TCDD >> and prochloraz resulted in a time- and dose-dependent increase of [[ ABCG2 ]] gene expression and transporter protein levels.,Induction of AhR by [ENTITY_A] and prochloraz resulted in a time- and dose-dependent increase of [ENTITY_B] gene expression and transporter protein levels.,INDIRECT-UPREGULATOR,CPR:3,0,Induction of AhR by TCDD and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels.
We found that << Ag >> NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing [[ albumin ]] release.,We found that [ENTITY_A] NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing [ENTITY_B] release.,INDIRECT-DOWNREGULATOR,CPR:4,1,We found that Ag NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing albumin release.
"We observed similar effects of << Ag >> NPs on inflammatory mediator expression in vitro and in vivo with increase of [[ interleukin-8 ]] (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro.","We observed similar effects of [ENTITY_A] NPs on inflammatory mediator expression in vitro and in vivo with increase of [ENTITY_B] (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro.",INDIRECT-UPREGULATOR,CPR:3,0,"We observed similar effects of Ag NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro."
"Blood pressure was increased in rats exposed to IH, and treatment with the << PDK-1 >> inhibitor [[ OSU-03012 ]] [2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide] (33 mg/day) lowered blood pressure in IH but not sham group rats.","Blood pressure was increased in rats exposed to IH, and treatment with the [ENTITY_A] inhibitor [ENTITY_B] [2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide] (33 mg/day) lowered blood pressure in IH but not sham group rats.",INHIBITOR,CPR:4,1,"Blood pressure was increased in rats exposed to IH, and treatment with the PDK-1 inhibitor OSU-03012 [2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide] (33 mg/day) lowered blood pressure in IH but not sham group rats."
"Following << CdCl₂ >> treatment, [[ ICAM2 ]] was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h.","Following [ENTITY_A] treatment, [ENTITY_B] was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h.",UPREGULATOR,CPR:3,0,"Following CdCl₂ treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h."
"Interestingly, there was a loss in the binding of ICAM2 to << actin >> during [[ CdCl₂ ]]-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.","Interestingly, there was a loss in the binding of ICAM2 to [ENTITY_A] during [ENTITY_B]-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.",INHIBITOR,CPR:4,1,"Interestingly, there was a loss in the binding of ICAM2 to actin during CdCl₂-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring."
The catalytic competence of << cytochrome P450 >> in the synthesis of [[ serotonin ]] from 5-methoxytryptamine in the brain: an in vitro study.,The catalytic competence of [ENTITY_A] in the synthesis of [ENTITY_B] from 5-methoxytryptamine in the brain: an in vitro study.,PRODUCT-OF,CPR:9,4,The catalytic competence of cytochrome P450 in the synthesis of serotonin from 5-methoxytryptamine in the brain: an in vitro study.
"Of the rat CYP isoforms studied, << CYP2D >> isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to [[ serotonin ]], but they were less effective than the human isoform CYP2D6.","Of the rat CYP isoforms studied, [ENTITY_A] isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to [ENTITY_B], but they were less effective than the human isoform CYP2D6.",PRODUCT-OF,CPR:9,4,"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6."
The reaction was inhibited by the specific << CYP2D >> inhibitors [[ quinine ]] and fluoxetine.,The reaction was inhibited by the specific [ENTITY_A] inhibitors [ENTITY_B] and fluoxetine.,INHIBITOR,CPR:4,1,The reaction was inhibited by the specific CYP2D inhibitors quinine and fluoxetine.
Human liver microsomes of the wild-type << CYP2D6 >> metabolized 5-methoxytryptamine to [[ serotonin ]] more effectively than did the defective CYP2D6*4*4 ones.,Human liver microsomes of the wild-type [ENTITY_A] metabolized 5-methoxytryptamine to [ENTITY_B] more effectively than did the defective CYP2D6*4*4 ones.,PRODUCT-OF,CPR:9,4,Human liver microsomes of the wild-type CYP2D6 metabolized 5-methoxytryptamine to serotonin more effectively than did the defective CYP2D6*4*4 ones.
"The obtained results indicate that << rat brain CYP2D >> isoforms catalyze the formation of [[ serotonin ]] from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain.","The obtained results indicate that [ENTITY_A] isoforms catalyze the formation of [ENTITY_B] from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain.",PRODUCT-OF,CPR:9,4,"The obtained results indicate that rat brain CYP2D isoforms catalyze the formation of serotonin from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain."
<< Toosendanin >> induces apoptosis through suppression of [[ JNK ]] signaling pathway in HL-60 cells.,[ENTITY_A] induces apoptosis through suppression of [ENTITY_B] signaling pathway in HL-60 cells.,INDIRECT-DOWNREGULATOR,CPR:4,1,Toosendanin induces apoptosis through suppression of JNK signaling pathway in HL-60 cells.
Western blot analysis indicated that << TSN >> inhibits the [[ CDC42 ]]/MEKK1/JNK pathway.,Western blot analysis indicated that [ENTITY_A] inhibits the [ENTITY_B]/MEKK1/JNK pathway.,INHIBITOR,CPR:4,1,Western blot analysis indicated that TSN inhibits the CDC42/MEKK1/JNK pathway.
"Administration of low, but not high, doses of oral << nicotine >> in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of [[ tumor necrosis factor-α ]].","Administration of low, but not high, doses of oral [ENTITY_A] in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"Administration of low, but not high, doses of oral nicotine in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of tumor necrosis factor-α."
"Small interfering RNA directed BDNF, orexin-A, and << SB334867 >> [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific [[ orexin-1 receptor ]] antagonist] were administered directly into the hypothalamus.","Small interfering RNA directed BDNF, orexin-A, and [ENTITY_A] [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific [ENTITY_B] antagonist] were administered directly into the hypothalamus.",ANTAGONIST,CPR:6,3,"Small interfering RNA directed BDNF, orexin-A, and SB334867 [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus."
"The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of << orexin-A >> was reversed by the administration of [[ SB334867 ]] as well as by hypothalamic BDNF knockdown.","The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of [ENTITY_A] was reversed by the administration of [ENTITY_B] as well as by hypothalamic BDNF knockdown.",DOWNREGULATOR,CPR:4,1,"The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of SB334867 as well as by hypothalamic BDNF knockdown."
<< Mesalamine >> modulates intercellular adhesion through inhibition of [[ p-21 activated kinase-1 ]].,[ENTITY_A] modulates intercellular adhesion through inhibition of [ENTITY_B].,INHIBITOR,CPR:4,1,Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1.
"Moreover, << 5-ASA >> treatment restored membranous expression of adhesion molecules [[ E-cadherin ]] and β-catenin.","Moreover, [ENTITY_A] treatment restored membranous expression of adhesion molecules [ENTITY_B] and β-catenin.",INDIRECT-UPREGULATOR,CPR:3,0,"Moreover, 5-ASA treatment restored membranous expression of adhesion molecules E-cadherin and β-catenin."
<< PAK1 >> expression was elevated in APC(min) polyps and [[ 5-ASA ]] treatment reduced its expression.,[ENTITY_A] expression was elevated in APC(min) polyps and [ENTITY_B] treatment reduced its expression.,INDIRECT-DOWNREGULATOR,CPR:4,1,PAK1 expression was elevated in APC(min) polyps and 5-ASA treatment reduced its expression.
We propose that inhibition of << PAK1 >> expression by [[ 5-ASA ]] can impede with neoplastic progression in colorectal carcinogenesis.,We propose that inhibition of [ENTITY_A] expression by [ENTITY_B] can impede with neoplastic progression in colorectal carcinogenesis.,INDIRECT-DOWNREGULATOR,CPR:4,1,We propose that inhibition of PAK1 expression by 5-ASA can impede with neoplastic progression in colorectal carcinogenesis.
The mechanism of << PAK1 >> inhibition and induction of membranous translocation of adhesion proteins by [[ 5-ASA ]] might be independent of its known anti-inflammatory action.,The mechanism of [ENTITY_A] inhibition and induction of membranous translocation of adhesion proteins by [ENTITY_B] might be independent of its known anti-inflammatory action.,INHIBITOR,CPR:4,1,The mechanism of PAK1 inhibition and induction of membranous translocation of adhesion proteins by 5-ASA might be independent of its known anti-inflammatory action.
"In contrast, << EGCG >> markedly downregulated major [[ bile acid transporters ]] (Asbt and Ostα) and regulatory molecules (Shp and Fgf15) in the ileum.","In contrast, [ENTITY_A] markedly downregulated major [ENTITY_B] (Asbt and Ostα) and regulatory molecules (Shp and Fgf15) in the ileum.",DOWNREGULATOR,CPR:4,1,"In contrast, EGCG markedly downregulated major bile acid transporters (Asbt and Ostα) and regulatory molecules (Shp and Fgf15) in the ileum."
"This study shows ability of << EGCG >> to raise plasma bile acid concentrations, mainly through [[ Cyp7a1 ]] upregulation, and to decrease bile production through reduction in Mrp2-mediated bile acid-independent bile flow.","This study shows ability of [ENTITY_A] to raise plasma bile acid concentrations, mainly through [ENTITY_B] upregulation, and to decrease bile production through reduction in Mrp2-mediated bile acid-independent bile flow.",INDIRECT-UPREGULATOR,CPR:3,0,"This study shows ability of EGCG to raise plasma bile acid concentrations, mainly through Cyp7a1 upregulation, and to decrease bile production through reduction in Mrp2-mediated bile acid-independent bile flow."
<< Catalpol >> inhibits LPS plus [[ IFN-γ ]]-induced inflammatory response in astrocytes primary cultures.,[ENTITY_A] inhibits LPS plus [ENTITY_B]-induced inflammatory response in astrocytes primary cultures.,INHIBITOR,CPR:4,1,Catalpol inhibits LPS plus IFN-γ-induced inflammatory response in astrocytes primary cultures.
Biochemical analyses showed that NO and ROS production and << iNOS >> activity were significantly reduced by [[ catalpol ]].,Biochemical analyses showed that NO and ROS production and [ENTITY_A] activity were significantly reduced by [ENTITY_B].,INHIBITOR,CPR:4,1,Biochemical analyses showed that NO and ROS production and iNOS activity were significantly reduced by catalpol.
"Data at transcriptional level also demonstrated that << catalpol >> potently attenuated gene expressions involved in inflammation, such as [[ iNOS ]], COX-2 and TLR4.","Data at transcriptional level also demonstrated that [ENTITY_A] potently attenuated gene expressions involved in inflammation, such as [ENTITY_B], COX-2 and TLR4.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Data at transcriptional level also demonstrated that catalpol potently attenuated gene expressions involved in inflammation, such as iNOS, COX-2 and TLR4."
"In addition, our exploration further revealed that the suppressive action of << catalpol >> on inflammation was mediated via inhibiting nuclear factor-κB ([[ NF-κB ]]) activation.","In addition, our exploration further revealed that the suppressive action of [ENTITY_A] on inflammation was mediated via inhibiting nuclear factor-κB ([ENTITY_B]) activation.",INHIBITOR,CPR:4,1,"In addition, our exploration further revealed that the suppressive action of catalpol on inflammation was mediated via inhibiting nuclear factor-κB (NF-κB) activation."
"Collectively, these results suggest that << catalpol >> can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of [[ NF-κB ]] could be the major determinant for its anti-inflammatory mechanism.","Collectively, these results suggest that [ENTITY_A] can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of [ENTITY_B] could be the major determinant for its anti-inflammatory mechanism.",INHIBITOR,CPR:4,1,"Collectively, these results suggest that catalpol can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of NF-κB could be the major determinant for its anti-inflammatory mechanism."
<< Protein tyrosine phosphatase 1B >> inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum [[ saponins ]].,[ENTITY_A] inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum [ENTITY_B].,INHIBITOR,CPR:4,1,Protein tyrosine phosphatase 1B inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins.
"Also, reactive astrogliosis takes part of the early responses to the insult with << (PhTe)(2) >>, evidenced by upregulated [[ GFAP ]] in Western blot, PCR and immunofluorescence analysis.","Also, reactive astrogliosis takes part of the early responses to the insult with [ENTITY_A], evidenced by upregulated [ENTITY_B] in Western blot, PCR and immunofluorescence analysis.",INDIRECT-UPREGULATOR,CPR:3,0,"Also, reactive astrogliosis takes part of the early responses to the insult with (PhTe)(2), evidenced by upregulated GFAP in Western blot, PCR and immunofluorescence analysis."
"Six days after (PhTe)(2) injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for << NeuN >>, suggesting that the in vivo exposure to [[ (PhTe)(2) ]] progressed to neuronal death.","Six days after (PhTe)(2) injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for [ENTITY_A], suggesting that the in vivo exposure to [ENTITY_B] progressed to neuronal death.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Six days after (PhTe)(2) injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for NeuN, suggesting that the in vivo exposure to (PhTe)(2) progressed to neuronal death."
"Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased << Akt >> immunoreactivity, however phospho-GSK-3-β (Ser9) was not altered in [[ (PhTe)(2) ]] injected rat.","Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased [ENTITY_A] immunoreactivity, however phospho-GSK-3-β (Ser9) was not altered in [ENTITY_B] injected rat.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased Akt immunoreactivity, however phospho-GSK-3-β (Ser9) was not altered in (PhTe)(2) injected rat."
"Therefore, the present results show that the earlier cerebellar responses to << (PhTe)(2) >> include disruption of cytoskeletal homeostasis that could be related with [[ MAPK ]] and PKA activation and reactive astrogliosis.","Therefore, the present results show that the earlier cerebellar responses to [ENTITY_A] include disruption of cytoskeletal homeostasis that could be related with [ENTITY_B] and PKA activation and reactive astrogliosis.",ACTIVATOR,CPR:3,0,"Therefore, the present results show that the earlier cerebellar responses to (PhTe)(2) include disruption of cytoskeletal homeostasis that could be related with MAPK and PKA activation and reactive astrogliosis."
"Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted << quinone >> substrate by the cancer-associated [[ human NAD(P)H:quinone oxidoreductase isozyme 1 ]] (hNQO1).","Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted [ENTITY_A] substrate by the cancer-associated [ENTITY_B] (hNQO1).",SUBSTRATE,CPR:9,4,"Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated human NAD(P)H:quinone oxidoreductase isozyme 1 (hNQO1)."
"Synthesis, biological evaluation, and molecular modeling of << glycyrrhizin >> derivatives as potent [[ high-mobility group box-1 ]] inhibitors with anti-heart-failure activity in vivo.","Synthesis, biological evaluation, and molecular modeling of [ENTITY_A] derivatives as potent [ENTITY_B] inhibitors with anti-heart-failure activity in vivo.",INHIBITOR,CPR:4,1,"Synthesis, biological evaluation, and molecular modeling of glycyrrhizin derivatives as potent high-mobility group box-1 inhibitors with anti-heart-failure activity in vivo."
"Within the << TPBP >> scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan-[[ mAChR ]] antagonism, which was demonstrated to be mediated via the orthosteric site.","Within the [ENTITY_A] scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan-[ENTITY_B] antagonism, which was demonstrated to be mediated via the orthosteric site.",ANTAGONIST,CPR:6,3,"Within the TPBP scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan-mAChR antagonism, which was demonstrated to be mediated via the orthosteric site."
"Additional SAR around a related M(1) allosteric agonist family (<< VU0357017 >>) identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan-[[ mAChR ]] orthosteric antagonism.","Additional SAR around a related M(1) allosteric agonist family ([ENTITY_A]) identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan-[ENTITY_B] orthosteric antagonism.",ANTAGONIST,CPR:6,3,"Additional SAR around a related M(1) allosteric agonist family (VU0357017) identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan-mAChR orthosteric antagonism."
"2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a << P-gp >> substrate, [[ risperidone ]], and its major metabolite, 9-hydroxyrisperidone, in rats.","2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a [ENTITY_A] substrate, [ENTITY_B], and its major metabolite, 9-hydroxyrisperidone, in rats.",SUBSTRATE,CPR:9,4,"2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats."
"On the other hand, peptides modified with << (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid >>, apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to [[ arginine vasopressin ]].","On the other hand, peptides modified with [ENTITY_A], apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to [ENTITY_B].",ANTAGONIST,CPR:6,3,"On the other hand, peptides modified with (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid, apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to arginine vasopressin."
"<< Liver X Receptor (LXR) α >> and LXR β are nuclear receptors activated by [[ oxysterols ]], oxidized derivatives of cholesterol.","[ENTITY_A] and LXR β are nuclear receptors activated by [ENTITY_B], oxidized derivatives of cholesterol.",ACTIVATOR,CPR:3,0,"Liver X Receptor (LXR) α and LXR β are nuclear receptors activated by oxysterols, oxidized derivatives of cholesterol."
β-catenin regulates << GnRH >>-induced [[ FSHβ ]] gene expression.,β-catenin regulates [ENTITY_A]-induced [ENTITY_B] gene expression.,INDIRECT-UPREGULATOR,CPR:3,0,β-catenin regulates GnRH-induced FSHβ gene expression.
"<< GnRH >> caused a sustained increase in nuclear [[ β-catenin ]] levels, which was significantly reduced by c-Jun N-terminal kinase (JNK) inhibition.","[ENTITY_A] caused a sustained increase in nuclear [ENTITY_B] levels, which was significantly reduced by c-Jun N-terminal kinase (JNK) inhibition.",INDIRECT-UPREGULATOR,CPR:3,0,"GnRH caused a sustained increase in nuclear β-catenin levels, which was significantly reduced by c-Jun N-terminal kinase (JNK) inhibition."
Small interfering RNA-mediated knockdown of β-catenin mRNA demonstrated that induction of << FSHβ >> mRNA by [[ GnRH ]] depended on β-catenin and that regulation of FSHβ by β-catenin occurred independently of the JNK-c-jun pathway.,Small interfering RNA-mediated knockdown of β-catenin mRNA demonstrated that induction of [ENTITY_A] mRNA by [ENTITY_B] depended on β-catenin and that regulation of FSHβ by β-catenin occurred independently of the JNK-c-jun pathway.,INDIRECT-UPREGULATOR,CPR:3,0,Small interfering RNA-mediated knockdown of β-catenin mRNA demonstrated that induction of FSHβ mRNA by GnRH depended on β-catenin and that regulation of FSHβ by β-catenin occurred independently of the JNK-c-jun pathway.
"Furthermore, knockdown of Brms1L significantly attenuated << GnRH >>-induced [[ FSHβ ]] expression.","Furthermore, knockdown of Brms1L significantly attenuated [ENTITY_A]-induced [ENTITY_B] expression.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, knockdown of Brms1L significantly attenuated GnRH-induced FSHβ expression."
"Thus, our findings indicate that the expression of Brms1L depends on β-catenin activity and contributes to << FSHβ >> induction by [[ GnRH ]].","Thus, our findings indicate that the expression of Brms1L depends on β-catenin activity and contributes to [ENTITY_A] induction by [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"Thus, our findings indicate that the expression of Brms1L depends on β-catenin activity and contributes to FSHβ induction by GnRH."
The herbicide << paraquat >> (PQ) is a [[ P-gp ]] substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote.,The herbicide [ENTITY_A] (PQ) is a [ENTITY_B] substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote.,SUBSTRATE,CPR:9,4,The herbicide paraquat (PQ) is a P-gp substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote.
"The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether << doxorubicin >> (DOX), a known [[ P-gp ]] inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario.","The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether [ENTITY_A] (DOX), a known [ENTITY_B] inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario.",ACTIVATOR,CPR:3,0,"The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (DOX), a known P-gp inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario."
"In conclusion, in this cellular model, << DOX >> effectively protects against PQ toxicity by inducing [[ P-gp ]] and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.","In conclusion, in this cellular model, [ENTITY_A] effectively protects against PQ toxicity by inducing [ENTITY_B] and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.",ACTIVATOR,CPR:3,0,"In conclusion, in this cellular model, DOX effectively protects against PQ toxicity by inducing P-gp and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications."
The selective << SYK >> inhibitor [[ P505-15 ]] (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.,The selective [ENTITY_A] inhibitor [ENTITY_B] (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.,INHIBITOR,CPR:4,1,The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
"<< P505-15 >> (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule [[ SYK ]] inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.","[ENTITY_A] (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule [ENTITY_B] inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.",INHIBITOR,CPR:4,1,"P505-15 (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases."
<< P505-15 >> successfully inhibited SYK-mediated [[ B-cell receptor ]] signaling and decreased cell viability in NHL and CLL.,[ENTITY_A] successfully inhibited SYK-mediated [ENTITY_B] signaling and decreased cell viability in NHL and CLL.,INDIRECT-DOWNREGULATOR,CPR:4,1,P505-15 successfully inhibited SYK-mediated B-cell receptor signaling and decreased cell viability in NHL and CLL.
"<< 17-Allylamino-17-demethoxygeldanamycin >> (17-AAG), an [[ Hsp90 ]] inhibitor, is currently under evaluation for its anticancer activity in clinical trials.","[ENTITY_A] (17-AAG), an [ENTITY_B] inhibitor, is currently under evaluation for its anticancer activity in clinical trials.",INHIBITOR,CPR:4,1,"17-Allylamino-17-demethoxygeldanamycin (17-AAG), an Hsp90 inhibitor, is currently under evaluation for its anticancer activity in clinical trials."
"Although treatment with << 17-AAG >> reduced [[ AhR ]] levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG.","Although treatment with [ENTITY_A] reduced [ENTITY_B] levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Although treatment with 17-AAG reduced AhR levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG."
"In addition, << 17-AAG >> treatment reduced cell viability, [[ CDK2 ]], CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells.","In addition, [ENTITY_A] treatment reduced cell viability, [ENTITY_B], CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, 17-AAG treatment reduced cell viability, CDK2, CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells."
"<< Gemcitabine >> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ([[ DCK ]]), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","[ENTITY_A] (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ([ENTITY_B]), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",SUBSTRATE,CPR:9,4,"Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear."
"Wild-type enzymes and variants of << CDA >> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ([[ Ara-C ]]), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Wild-type enzymes and variants of [ENTITY_A] (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ([ENTITY_B]), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",SUBSTRATE,CPR:9,4,"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates."
"All three << CDA >> proteins showed similar K(m) and V(max) for [[ Ara-C ]] and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination.","All three [ENTITY_A] proteins showed similar K(m) and V(max) for [ENTITY_B] and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination.",SUBSTRATE,CPR:9,4,"All three CDA proteins showed similar K(m) and V(max) for Ara-C and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination."
"All four << DCK >> proteins yielded comparable metabolic activity for [[ Ara-C ]] and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).","All four [ENTITY_A] proteins yielded comparable metabolic activity for [ENTITY_B] and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).",SUBSTRATE,CPR:9,4,"All four DCK proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05)."
"In conclusion, the << Lys27Gln >> substitution does not significantly modulate CDA activity toward [[ dFdC ]], and therefore would not contribute to interindividual variability in response to gemcitabine.","In conclusion, the [ENTITY_A] substitution does not significantly modulate CDA activity toward [ENTITY_B], and therefore would not contribute to interindividual variability in response to gemcitabine.",SUBSTRATE,CPR:9,4,"In conclusion, the Lys27Gln substitution does not significantly modulate CDA activity toward dFdC, and therefore would not contribute to interindividual variability in response to gemcitabine."
The higher in vitro catalytic efficiency of << DCK >>24Val toward [[ dFdC ]] monophosphorylation may be relevant to dFdC clinical response.,The higher in vitro catalytic efficiency of [ENTITY_A]24Val toward [ENTITY_B] monophosphorylation may be relevant to dFdC clinical response.,SUBSTRATE,CPR:9,4,The higher in vitro catalytic efficiency of DCK24Val toward dFdC monophosphorylation may be relevant to dFdC clinical response.
Discovery of << 4-phenyl-2-phenylaminopyridine >> based [[ TNIK ]] inhibitors.,Discovery of [ENTITY_A] based [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors.
A series of compounds based on a << 4-phenyl-2-phenylaminopyridine >> scaffold that are potent and selective inhibitors of [[ Traf2- and Nck-interacting kinase ]] (TNIK) activity are described.,A series of compounds based on a [ENTITY_A] scaffold that are potent and selective inhibitors of [ENTITY_B] (TNIK) activity are described.,INHIBITOR,CPR:4,1,A series of compounds based on a 4-phenyl-2-phenylaminopyridine scaffold that are potent and selective inhibitors of Traf2- and Nck-interacting kinase (TNIK) activity are described.
<< Boron >>-based inhibitors of [[ acyl protein thioesterases 1 and 2 ]].,[ENTITY_A]-based inhibitors of [ENTITY_B].,INHIBITOR,CPR:4,1,Boron-based inhibitors of acyl protein thioesterases 1 and 2.
Here we present << boronic >> and borinic acid derivatives as a new class of potent and nontoxic [[ APT ]] inhibitors.,Here we present [ENTITY_A] and borinic acid derivatives as a new class of potent and nontoxic [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Here we present boronic and borinic acid derivatives as a new class of potent and nontoxic APT inhibitors.
"Here, we report that << genistein >> at physiologically relevant concentrations (0.1-10 μM) significantly inhibited [[ thrombin ]]-induced increase in endothelial monolayer permeability.","Here, we report that [ENTITY_A] at physiologically relevant concentrations (0.1-10 μM) significantly inhibited [ENTITY_B]-induced increase in endothelial monolayer permeability.",INHIBITOR,CPR:4,1,"Here, we report that genistein at physiologically relevant concentrations (0.1-10 μM) significantly inhibited thrombin-induced increase in endothelial monolayer permeability."
<< Genistein >> also reduced the formation of stress fibers by [[ thrombin ]] and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs).,[ENTITY_A] also reduced the formation of stress fibers by [ENTITY_B] and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs).,INHIBITOR,CPR:4,1,Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs).
"Furthermore, << thrombin >> diminished cAMP production in ECs, which were prevented by treatment with [[ genistein ]].","Furthermore, [ENTITY_A] diminished cAMP production in ECs, which were prevented by treatment with [ENTITY_B].",INHIBITOR,CPR:4,1,"Furthermore, thrombin diminished cAMP production in ECs, which were prevented by treatment with genistein."
Evaluation of drug interactions of << GSK1292263 >> (a [[ GPR119 ]] agonist) with statins: from in vitro data to clinical study design.,Evaluation of drug interactions of [ENTITY_A] (a [ENTITY_B] agonist) with statins: from in vitro data to clinical study design.,AGONIST,CPR:5,2,Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
"1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the << HMG-coA reductase >> inhibitors [[ simvastatin ]] and rosuvastatin.","1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the [ENTITY_A] inhibitors [ENTITY_B] and rosuvastatin.",INHIBITOR,CPR:4,1,"1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin."
"1. This work investigated the drug interaction potential of << GSK1292263 >>, a novel [[ GPR119 ]] agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin.","1. This work investigated the drug interaction potential of [ENTITY_A], a novel [ENTITY_B] agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin.",AGONIST,CPR:5,2,"1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin."
"2. In vitro experiments assessed the inhibition of << transporters >> and CYP enzymes by [[ GSK1292263 ]], and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose).","2. In vitro experiments assessed the inhibition of [ENTITY_A] and CYP enzymes by [ENTITY_B], and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose).",INHIBITOR,CPR:4,1,"2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose)."
"3. In vitro, << GSK1292263 >> demonstrated little/weak inhibition (IC50 values >30 μM) towards [[ CYPs ]] (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2.","3. In vitro, [ENTITY_A] demonstrated little/weak inhibition (IC50 values >30 μM) towards [ENTITY_B] (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2.",INHIBITOR,CPR:4,1,"3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2."
"However, << GSK1292263 >> inhibited [[ BCRP ]] and OATP1B1, which are transporters involved in statin disposition.","However, [ENTITY_A] inhibited [ENTITY_B] and OATP1B1, which are transporters involved in statin disposition.",INHIBITOR,CPR:4,1,"However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition."
"4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with << GSK1292263 >>, which is consistent with an inhibitory effect on intestinal BCRP and [[ CYP3A4 ]].","4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with [ENTITY_A], which is consistent with an inhibitory effect on intestinal BCRP and [ENTITY_B].",INHIBITOR,CPR:4,1,"4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and CYP3A4."
This study provides a mechanistic understanding of the in vivo inhibition of << transporters >> and enzymes by [[ GSK1292263 ]].,This study provides a mechanistic understanding of the in vivo inhibition of [ENTITY_A] and enzymes by [ENTITY_B].,INHIBITOR,CPR:4,1,This study provides a mechanistic understanding of the in vivo inhibition of transporters and enzymes by GSK1292263.
The presence of << steroid >> hormones most probably causes the degradation of the [[ Tat2 ]] permease and impairment of tryptophan import.,The presence of [ENTITY_A] hormones most probably causes the degradation of the [ENTITY_B] permease and impairment of tryptophan import.,INDIRECT-DOWNREGULATOR,CPR:4,1,The presence of steroid hormones most probably causes the degradation of the Tat2 permease and impairment of tryptophan import.
Inhibition of Th1/Th17 responses via suppression of << STAT1 >> and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside [[ icariin ]].,Inhibition of Th1/Th17 responses via suppression of [ENTITY_A] and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside [ENTITY_B].,INHIBITOR,CPR:4,1,Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin.
"Further study showed that << icariin >> dose-dependently inhibited the proliferation and activation of T lymphocytes, and suppressed pro-inflammatory [[ cytokine ]] levels of activated T cells.","Further study showed that [ENTITY_A] dose-dependently inhibited the proliferation and activation of T lymphocytes, and suppressed pro-inflammatory [ENTITY_B] levels of activated T cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Further study showed that icariin dose-dependently inhibited the proliferation and activation of T lymphocytes, and suppressed pro-inflammatory cytokine levels of activated T cells."
"Moreover, << icariin >> treatment inhibited the phosphorylations of [[ STAT1 ]] and STAT3 in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively.","Moreover, [ENTITY_A] treatment inhibited the phosphorylations of [ENTITY_B] and STAT3 in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively.",INHIBITOR,CPR:4,1,"Moreover, icariin treatment inhibited the phosphorylations of STAT1 and STAT3 in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively."
"Pharmacological inhibition of MTORC1 with << rapamycin >> abrogated the [[ insulin ]]-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6.","Pharmacological inhibition of MTORC1 with [ENTITY_A] abrogated the [ENTITY_B]-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6.",DOWNREGULATOR,CPR:4,1,"Pharmacological inhibition of MTORC1 with rapamycin abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6."
"Furthermore, << insulin >>-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by [[ rapamycin ]].","Furthermore, [ENTITY_A]-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by rapamycin."
Synthesis and evaluation of << 8-oxoadenine >> derivatives as potent [[ Toll-like receptor 7 ]] agonists with high water solubility.,Synthesis and evaluation of [ENTITY_A] derivatives as potent [ENTITY_B] agonists with high water solubility.,AGONIST,CPR:5,2,Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility.
"We report the discovery of novel series of highly potent << TLR7 >> agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various [[ tertiary amines ]] onto the N(9)-position of the adenine moiety.","We report the discovery of novel series of highly potent [ENTITY_A] agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various [ENTITY_B] onto the N(9)-position of the adenine moiety.",AGONIST,CPR:5,2,"We report the discovery of novel series of highly potent TLR7 agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety."
The introduction of the << amino >> group resulted in not only improved water solubility but also enhanced [[ TLR7 ]] agonistic activity.,The introduction of the [ENTITY_A] group resulted in not only improved water solubility but also enhanced [ENTITY_B] agonistic activity.,AGONIST,CPR:5,2,The introduction of the amino group resulted in not only improved water solubility but also enhanced TLR7 agonistic activity.
Inhibitors based on a << benzo-fused spirocyclic oxazepine >> scaffold were discovered for stearoyl-coenzyme A (CoA) desaturase 1 ([[ SCD1 ]]) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.,Inhibitors based on a [ENTITY_A] scaffold were discovered for stearoyl-coenzyme A (CoA) desaturase 1 ([ENTITY_B]) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.,INHIBITOR,CPR:4,1,Inhibitors based on a benzo-fused spirocyclic oxazepine scaffold were discovered for stearoyl-coenzyme A (CoA) desaturase 1 (SCD1) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.
The porcine heart malate dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited << human Hsp60 >> chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of [[ ETB ]] (IC(50): 10.9 ± 0.63 μM).,The porcine heart malate dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited [ENTITY_A] chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of [ENTITY_B] (IC(50): 10.9 ± 0.63 μM).,INHIBITOR,CPR:4,1,The porcine heart malate dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited human Hsp60 chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of ETB (IC(50): 10.9 ± 0.63 μM).
<< Apocynin >> and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated [[ p66Shc ]] in rat testes.,[ENTITY_A] and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated [ENTITY_B] in rat testes.,INHIBITOR,CPR:4,1,Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.
Apocynin and << raisanberine >> alleviate intermittent hypoxia induced abnormal StAR and [[ 3β-HSD ]] and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.,Apocynin and [ENTITY_A] alleviate intermittent hypoxia induced abnormal StAR and [ENTITY_B] and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.,SUBSTRATE,CPR:9,4,Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.
"We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, << APO >> (apocynin) an inhibitor of [[ NOX ]] and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.","We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, [ENTITY_A] (apocynin) an inhibitor of [ENTITY_B] and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.",INHIBITOR,CPR:4,1,"We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis."
"<< APO >> and RS at least partially normalize hypoxia caused male hypogonadism by suppressing ER stress, and [[ p66Shc ]] in testes.","[ENTITY_A] and RS at least partially normalize hypoxia caused male hypogonadism by suppressing ER stress, and [ENTITY_B] in testes.",INHIBITOR,CPR:4,1,"APO and RS at least partially normalize hypoxia caused male hypogonadism by suppressing ER stress, and p66Shc in testes."
"Here we found that << arsenic trioxide >>, a frontline agent for acute promyelocytic leukemia, inhibits [[ ΔNp63 ]] but not TAp63 expression in time- and dose-dependent manners.","Here we found that [ENTITY_A], a frontline agent for acute promyelocytic leukemia, inhibits [ENTITY_B] but not TAp63 expression in time- and dose-dependent manners.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Here we found that arsenic trioxide, a frontline agent for acute promyelocytic leukemia, inhibits ΔNp63 but not TAp63 expression in time- and dose-dependent manners."
"In addition, we found that << arsenic trioxide >> decreases the stability of [[ ΔNp63 ]] protein via a proteasome-dependent pathway but has little effect on the level of ΔNp63 transcript.","In addition, we found that [ENTITY_A] decreases the stability of [ENTITY_B] protein via a proteasome-dependent pathway but has little effect on the level of ΔNp63 transcript.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, we found that arsenic trioxide decreases the stability of ΔNp63 protein via a proteasome-dependent pathway but has little effect on the level of ΔNp63 transcript."
"Furthermore, we found that << arsenic trioxide >> activates the [[ Pirh2 promoter ]] and consequently induces Pirh2 expression.","Furthermore, we found that [ENTITY_A] activates the [ENTITY_B] and consequently induces Pirh2 expression.",ACTIVATOR,CPR:3,0,"Furthermore, we found that arsenic trioxide activates the Pirh2 promoter and consequently induces Pirh2 expression."
"Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances, << arsenic >>-induced degradation of [[ ΔNp63 ]] protein.","Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances, [ENTITY_A]-induced degradation of [ENTITY_B] protein.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances, arsenic-induced degradation of ΔNp63 protein."
"Together, these data suggest that << arsenic >> degrades [[ ΔNp63 ]] protein at least in part via Pirh2-dependent proteolysis and that inhibition of ΔNp63 expression facilitates tumor cells to arsenic-induced death.","Together, these data suggest that [ENTITY_A] degrades [ENTITY_B] protein at least in part via Pirh2-dependent proteolysis and that inhibition of ΔNp63 expression facilitates tumor cells to arsenic-induced death.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Together, these data suggest that arsenic degrades ΔNp63 protein at least in part via Pirh2-dependent proteolysis and that inhibition of ΔNp63 expression facilitates tumor cells to arsenic-induced death."
"<< Jaceosidin >>, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via [[ ATM ]]-Chk1/2 activation.","[ENTITY_A], isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via [ENTITY_B]-Chk1/2 activation.",ACTIVATOR,CPR:3,0,"Jaceosidin, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via ATM-Chk1/2 activation."
"<< Jaceosidin >>, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating [[ cdc25C ]]-cdc2 via ATM-Chk1/2 activation.","[ENTITY_A], isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating [ENTITY_B]-cdc2 via ATM-Chk1/2 activation.",INHIBITOR,CPR:4,1,"Jaceosidin, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via ATM-Chk1/2 activation."
Additional mechanistic studies revealed that << jaceosidin >> treatment resulted in an increase in phosphorylation of [[ Cdc25C ]] and ATM-Chk1/2.,Additional mechanistic studies revealed that [ENTITY_A] treatment resulted in an increase in phosphorylation of [ENTITY_B] and ATM-Chk1/2.,ACTIVATOR,CPR:3,0,Additional mechanistic studies revealed that jaceosidin treatment resulted in an increase in phosphorylation of Cdc25C and ATM-Chk1/2.
"Moreover, jaceosidin treatment resulted in phosphorylation of ERK, and pretreatment with the << ERK >> inhibitor, [[ PD98059 ]], attenuated cell growth inhibition by jaceosidin.","Moreover, jaceosidin treatment resulted in phosphorylation of ERK, and pretreatment with the [ENTITY_A] inhibitor, [ENTITY_B], attenuated cell growth inhibition by jaceosidin.",INHIBITOR,CPR:4,1,"Moreover, jaceosidin treatment resulted in phosphorylation of ERK, and pretreatment with the ERK inhibitor, PD98059, attenuated cell growth inhibition by jaceosidin."
"These data suggest that << jaceosidin >>, isolated from Japanese mugwort, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the [[ Cdc2 ]]-cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells.","These data suggest that [ENTITY_A], isolated from Japanese mugwort, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the [ENTITY_B]-cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells.",INHIBITOR,CPR:4,1,"These data suggest that jaceosidin, isolated from Japanese mugwort, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the Cdc2-cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells."
Electrical Stimuli Release ATP to Increase << GLUT4 >> Translocation and [[ Glucose ]] Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.,Electrical Stimuli Release ATP to Increase [ENTITY_A] Translocation and [ENTITY_B] Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.,SUBSTRATE,CPR:9,4,Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.
"Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by << adenosine-phosphate phosphatase >> and by purinergic receptor blockade ([[ suramin ]]).","Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by [ENTITY_A] and by purinergic receptor blockade ([ENTITY_B]).",INHIBITOR,CPR:4,1,"Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin)."
Electrical stimulation transiently elevated extracellular ATP and caused << Akt >> phosphorylation that was additive to insulin and inhibited by [[ suramin ]].,Electrical stimulation transiently elevated extracellular ATP and caused [ENTITY_A] phosphorylation that was additive to insulin and inhibited by [ENTITY_B].,INHIBITOR,CPR:4,1,Electrical stimulation transiently elevated extracellular ATP and caused Akt phosphorylation that was additive to insulin and inhibited by suramin.
"Exogenous << ATP >> transiently activated [[ Akt ]] and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation.","Exogenous [ENTITY_A] transiently activated [ENTITY_B] and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation.",ACTIVATOR,CPR:3,0,"Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation."
ATP-dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the << phosphatidylinositol 3-kinase-γ >> (PI3Kγ) inhibitor [[ AS605240 ]].,ATP-dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the [ENTITY_A] (PI3Kγ) inhibitor [ENTITY_B].,INHIBITOR,CPR:4,1,ATP-dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ (PI3Kγ) inhibitor AS605240.
"Structure-based design, synthesis and evaluation of novel << anthra[1,2-d]imidazole-6,11-dione >> derivatives as [[ telomerase ]] inhibitors and potential for cancer polypharmacology.","Structure-based design, synthesis and evaluation of novel [ENTITY_A] derivatives as [ENTITY_B] inhibitors and potential for cancer polypharmacology.",INHIBITOR,CPR:4,1,"Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology."
"A series of << anthra[1,2-d]imidazole-6,11-dione >> derivatives were synthesized and evaluated for [[ telomerase ]] inhibition, hTERT expression and suppression of cancer cell growth in vitro.","A series of [ENTITY_A] derivatives were synthesized and evaluated for [ENTITY_B] inhibition, hTERT expression and suppression of cancer cell growth in vitro.",INHIBITOR,CPR:4,1,"A series of anthra[1,2-d]imidazole-6,11-dione derivatives were synthesized and evaluated for telomerase inhibition, hTERT expression and suppression of cancer cell growth in vitro."
<< Trichostatin A >> inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced [[ NF-E2-related factor 2 ]]-antioxidant response element signaling.,[ENTITY_A] inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced [ENTITY_B]-antioxidant response element signaling.,INDIRECT-UPREGULATOR,CPR:3,0,Trichostatin A inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling.
<< Trichostatin A >> inhibits [[ transforming growth factor-β ]]-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling.,[ENTITY_A] inhibits [ENTITY_B]-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling.,INHIBITOR,CPR:4,1,Trichostatin A inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling.
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the << NF-E2-related factor 2 >>-antioxidant response element (Nrf2-ARE) activator [[ sulforaphane ]], or small interfering RNA.","Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the [ENTITY_A]-antioxidant response element (Nrf2-ARE) activator [ENTITY_B], or small interfering RNA.",ACTIVATOR,CPR:3,0,"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA."
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the << NAD(P)H oxidase >> inhibitor [[ diphenyleneiodonium ]] (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.","Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the [ENTITY_A] inhibitor [ENTITY_B] (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.",INHIBITOR,CPR:4,1,"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA."
Treatment with << TSA >> and the Nrf2-ARE activator resulted in increased inhibition of the [[ TGF-β ]]-induced myofibroblast differentiation as compared with treatment with DPI or NAC.,Treatment with [ENTITY_A] and the Nrf2-ARE activator resulted in increased inhibition of the [ENTITY_B]-induced myofibroblast differentiation as compared with treatment with DPI or NAC.,INHIBITOR,CPR:4,1,Treatment with TSA and the Nrf2-ARE activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or NAC.
"Furthermore, << TSA >> also decreased cellular ROS and H(2)O(2) accumulation induced by [[ TGF-β ]], whereas it elevated intracellular GSH level and cellular total antioxidant capacity.","Furthermore, [ENTITY_A] also decreased cellular ROS and H(2)O(2) accumulation induced by [ENTITY_B], whereas it elevated intracellular GSH level and cellular total antioxidant capacity.",INHIBITOR,CPR:4,1,"Furthermore, TSA also decreased cellular ROS and H(2)O(2) accumulation induced by TGF-β, whereas it elevated intracellular GSH level and cellular total antioxidant capacity."
"In addition, << TSA >> induced Nrf2 nuclear translocation and up-regulated the expression of [[ Nrf2 ]]-ARE downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation.","In addition, [ENTITY_A] induced Nrf2 nuclear translocation and up-regulated the expression of [ENTITY_B]-ARE downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation.",INDIRECT-UPREGULATOR,CPR:3,0,"In addition, TSA induced Nrf2 nuclear translocation and up-regulated the expression of Nrf2-ARE downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation."
"In conclusion, this study provides the first evidence implicating that << TSA >> inhibits TGF-β-induced ROS accumulation and myofibroblast differentiation via enhanced [[ Nrf2 ]]-ARE signaling.","In conclusion, this study provides the first evidence implicating that [ENTITY_A] inhibits TGF-β-induced ROS accumulation and myofibroblast differentiation via enhanced [ENTITY_B]-ARE signaling.",INDIRECT-UPREGULATOR,CPR:3,0,"In conclusion, this study provides the first evidence implicating that TSA inhibits TGF-β-induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-ARE signaling."
"In conclusion, this study provides the first evidence implicating that << TSA >> inhibits [[ TGF-β ]]-induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-ARE signaling.","In conclusion, this study provides the first evidence implicating that [ENTITY_A] inhibits [ENTITY_B]-induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-ARE signaling.",INHIBITOR,CPR:4,1,"In conclusion, this study provides the first evidence implicating that TSA inhibits TGF-β-induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-ARE signaling."
"<< Cannabinoid receptor 1 >> (CB(1)) inverse agonists (e.g., [[ rimonabant ]]) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.","[ENTITY_A] (CB(1)) inverse agonists (e.g., [ENTITY_B]) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.",AGONIST-INHIBITOR,CPR:5,2,"Cannabinoid receptor 1 (CB(1)) inverse agonists (e.g., rimonabant) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications."
"In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel << CB(1) >> full agonist [[ AM4054 ]].","In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel [ENTITY_A] full agonist [ENTITY_B].",AGONIST-ACTIVATOR,CPR:5,2,"In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054."
"In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the << CB(1) >> neutral antagonist [[ AM4113 ]] were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.","In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the [ENTITY_A] neutral antagonist [ENTITY_B] were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.",ANTAGONIST,CPR:6,3,"In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054."
"Results indicate that << AM4054 >> serves as an effective [[ CB(1) ]] discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.","Results indicate that [ENTITY_A] serves as an effective [ENTITY_B] discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.",ACTIVATOR,CPR:3,0,"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054."
"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the << CB(1) >> agonist [[ Δ(9)-tetrahydrocannabinol ]], and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.","Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the [ENTITY_A] agonist [ENTITY_B], and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.",AGONIST,CPR:5,2,"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054."
"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the << CB(1) >> agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist [[ AM4113 ]] produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.","Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the [ENTITY_A] agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist [ENTITY_B] produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.",ANTAGONIST,CPR:6,3,"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054."
"<< FXa >> inhibitors, e.g. [[ rivaroxaban ]] and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free FXa.","[ENTITY_A] inhibitors, e.g. [ENTITY_B] and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free FXa.",INHIBITOR,CPR:4,1,"FXa inhibitors, e.g. rivaroxaban and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free FXa."
"Although parenteral oral direct << thrombin >> inhibitors (DTIs), such as [[ argatroban ]] and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists.","Although parenteral oral direct [ENTITY_A] inhibitors (DTIs), such as [ENTITY_B] and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists.",INHIBITOR,CPR:4,1,"Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists."
"Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as << dabigatran >> are novel synthetic [[ thrombin ]] antagonists.","Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as [ENTITY_A] are novel synthetic [ENTITY_B] antagonists.",ANTAGONIST,CPR:6,3,"Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists."
"<< Dabigatran >> has an advantage over the indirect [[ thrombin ]] inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin.","[ENTITY_A] has an advantage over the indirect [ENTITY_B] inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin.",INHIBITOR,CPR:4,1,"Dabigatran has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin."
"The reversible binding of << dabigatran >> may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent [[ thrombin ]] inhibitors, e.g. hirudin.","The reversible binding of [ENTITY_A] may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent [ENTITY_B] inhibitors, e.g. hirudin.",INHIBITOR,CPR:4,1,"The reversible binding of dabigatran may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent thrombin inhibitors, e.g. hirudin."
<< Aldehyde dehydrogenase 1 >> (ALDH1A1) catalyzes the oxidation of toxic aldehydes to [[ carboxylic acids ]].,[ENTITY_A] (ALDH1A1) catalyzes the oxidation of toxic aldehydes to [ENTITY_B].,PRODUCT-OF,CPR:9,4,Aldehyde dehydrogenase 1 (ALDH1A1) catalyzes the oxidation of toxic aldehydes to carboxylic acids.
Physiologic levels of << Mg(2+) >> ions decrease [[ ALDH1 ]] activity in part by increasing NADH binding affinity to the enzyme.,Physiologic levels of [ENTITY_A] ions decrease [ENTITY_B] activity in part by increasing NADH binding affinity to the enzyme.,INHIBITOR,CPR:4,1,Physiologic levels of Mg(2+) ions decrease ALDH1 activity in part by increasing NADH binding affinity to the enzyme.
"As the << Mg(2+) >> ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the [[ ALDH1 ]]-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).","As the [ENTITY_A] ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the [ENTITY_B]-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).",DOWNREGULATOR,CPR:4,1,"As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)."
This shift in conformational population at higher << Mg(2+) >> ion concentrations and to lower enzyme activity may be due to longer residence time of the NADH in the [[ ALDH1 ]] pocket.,This shift in conformational population at higher [ENTITY_A] ion concentrations and to lower enzyme activity may be due to longer residence time of the NADH in the [ENTITY_B] pocket.,DOWNREGULATOR,CPR:4,1,This shift in conformational population at higher Mg(2+) ion concentrations and to lower enzyme activity may be due to longer residence time of the NADH in the ALDH1 pocket.
"Interestingly, << Acrolein >> increased proteins' levels of [[ amyloid precursor protein ]] (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.","Interestingly, [ENTITY_A] increased proteins' levels of [ENTITY_B] (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.",INDIRECT-UPREGULATOR,CPR:3,0,"Interestingly, Acrolein increased proteins' levels of amyloid precursor protein (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels."
"Interestingly, << Acrolein >> increased proteins' levels of amyloid precursor protein (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased [[ A-disintegrin and metalloprotease (ADAM) 10 ]] levels.","Interestingly, [ENTITY_A] increased proteins' levels of amyloid precursor protein (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased [ENTITY_B] levels.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Interestingly, Acrolein increased proteins' levels of amyloid precursor protein (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels."
"Moreover, << Acrolein >> resulted in activation of astrocytes, up-regulation of [[ BACE-1 ]] in cortex and down-regulation of ADAM-10 in hippocampus and cortex.","Moreover, [ENTITY_A] resulted in activation of astrocytes, up-regulation of [ENTITY_B] in cortex and down-regulation of ADAM-10 in hippocampus and cortex.",INDIRECT-UPREGULATOR,CPR:3,0,"Moreover, Acrolein resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of ADAM-10 in hippocampus and cortex."
"Moreover, << Acrolein >> resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of [[ ADAM-10 ]] in hippocampus and cortex.","Moreover, [ENTITY_A] resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of [ENTITY_B] in hippocampus and cortex.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, Acrolein resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of ADAM-10 in hippocampus and cortex."
Regulation of sexual reproduction by << estradiol >> involves the activation of [[ estrogen receptors ]] (ERs) in the hypothalamus.,Regulation of sexual reproduction by [ENTITY_A] involves the activation of [ENTITY_B] (ERs) in the hypothalamus.,ACTIVATOR,CPR:3,0,Regulation of sexual reproduction by estradiol involves the activation of estrogen receptors (ERs) in the hypothalamus.
"Using surface biotinylation, we observed that treatment of N-38 neurons with estradiol or with a membrane impermeant << estradiol >> elevated plasma membrane [[ ERα ]] protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane.","Using surface biotinylation, we observed that treatment of N-38 neurons with estradiol or with a membrane impermeant [ENTITY_A] elevated plasma membrane [ENTITY_B] protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane.",INDIRECT-UPREGULATOR,CPR:3,0,"Using surface biotinylation, we observed that treatment of N-38 neurons with estradiol or with a membrane impermeant estradiol elevated plasma membrane ERα protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane."
"Insertion of << ERα >> was blocked by the ER antagonist [[ ICI 182,780 ]] or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS).",Insertion of [ENTITY_A] was blocked by the ER antagonist [ENTITY_B] or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS).,INHIBITOR,CPR:4,1,"Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)."
"Insertion of ERα was blocked by the << ER >> antagonist [[ ICI 182,780 ]] or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS).",Insertion of ERα was blocked by the [ENTITY_A] antagonist [ENTITY_B] or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS).,ANTAGONIST,CPR:6,3,"Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)."
These results indicate that membrane << ERα >> levels in N-38 neurons are dynamically autoregulated by [[ estradiol ]].,These results indicate that membrane [ENTITY_A] levels in N-38 neurons are dynamically autoregulated by [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,These results indicate that membrane ERα levels in N-38 neurons are dynamically autoregulated by estradiol.
Reductions in striatal dopamine and << tyrosine hydroxylase >> content were also less pronounced with [[ EHT ]] treatment.,Reductions in striatal dopamine and [ENTITY_A] content were also less pronounced with [ENTITY_B] treatment.,INDIRECT-UPREGULATOR,CPR:3,0,Reductions in striatal dopamine and tyrosine hydroxylase content were also less pronounced with EHT treatment.
"The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and << JNK >> activation were significantly prevented with [[ EHT ]].","The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and [ENTITY_A] activation were significantly prevented with [ENTITY_B].",INHIBITOR,CPR:4,1,"The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and JNK activation were significantly prevented with EHT."
"In cultured primary microglia and astrocytes, << EHT >> had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced [[ NFκB ]] activation, iNOS induction, and nitric oxide production.","In cultured primary microglia and astrocytes, [ENTITY_A] had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced [ENTITY_B] activation, iNOS induction, and nitric oxide production.",INHIBITOR,CPR:4,1,"In cultured primary microglia and astrocytes, EHT had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NFκB activation, iNOS induction, and nitric oxide production."
"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of << phosphoprotein phosphatase 2A >> (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by [[ EHT ]].","Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of [ENTITY_A] (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by [ENTITY_B].",UPREGULATOR,CPR:3,0,"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT."
"Additionally, in SH-SY5Y cells, << MPP(+) >>-induced demethylation of [[ phosphoprotein phosphatase 2A ]] (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT.","Additionally, in SH-SY5Y cells, [ENTITY_A]-induced demethylation of [ENTITY_B] (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT.",DOWNREGULATOR,CPR:4,1,"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT."
"Substantial evidence shows that << H(2)S >> is involved in aging by inhibiting free-radical reactions, activating [[ SIRT1 ]], and probably interacting with the age-related gene Klotho.","Substantial evidence shows that [ENTITY_A] is involved in aging by inhibiting free-radical reactions, activating [ENTITY_B], and probably interacting with the age-related gene Klotho.",ACTIVATOR,CPR:3,0,"Substantial evidence shows that H(2)S is involved in aging by inhibiting free-radical reactions, activating SIRT1, and probably interacting with the age-related gene Klotho."
Induction of << HO-1 >> through p38 MAPK/Nrf2 signaling pathway by [[ ethanol ]] extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.,Induction of [ENTITY_A] through p38 MAPK/Nrf2 signaling pathway by [ENTITY_B] extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.,ACTIVATOR,CPR:3,0,Induction of HO-1 through p38 MAPK/Nrf2 signaling pathway by ethanol extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.
"The induction of << HO-1 >> by EIH was inhibited by [[ SB203580 ]] but not by SP600125, PD98059, nor LY294002.","The induction of [ENTITY_A] by EIH was inhibited by [ENTITY_B] but not by SP600125, PD98059, nor LY294002.",INHIBITOR,CPR:4,1,"The induction of HO-1 by EIH was inhibited by SB203580 but not by SP600125, PD98059, nor LY294002."
"We demonstrate that two << flavin mono-oxygenase >> family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to [[ TMAO ]].","We demonstrate that two [ENTITY_A] family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to [ENTITY_B].",PRODUCT-OF,CPR:9,4,"We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO."
FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing << FMO3 >> decreases [[ TMAO ]] levels.,FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing [ENTITY_A] decreases [ENTITY_B] levels.,SUBSTRATE,CPR:9,4,FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing FMO3 decreases TMAO levels.
"In mice, this reduction in << FMO3 >> expression is due primarily to downregulation by [[ androgens ]].","In mice, this reduction in [ENTITY_A] expression is due primarily to downregulation by [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"In mice, this reduction in FMO3 expression is due primarily to downregulation by androgens."
"FMO3 expression is induced by dietary bile acids by a mechanism that involves the << farnesoid X receptor >> (FXR), a [[ bile acid ]]-activated nuclear receptor.","FMO3 expression is induced by dietary bile acids by a mechanism that involves the [ENTITY_A] (FXR), a [ENTITY_B]-activated nuclear receptor.",ACTIVATOR,CPR:3,0,"FMO3 expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor."
"Analysis of natural genetic variation among inbred strains of mice indicates that << FMO3 >> and [[ TMAO ]] are significantly correlated, and TMAO levels explain 11% of the variation in atherosclerosis.","Analysis of natural genetic variation among inbred strains of mice indicates that [ENTITY_A] and [ENTITY_B] are significantly correlated, and TMAO levels explain 11% of the variation in atherosclerosis.",PRODUCT-OF,CPR:9,4,"Analysis of natural genetic variation among inbred strains of mice indicates that FMO3 and TMAO are significantly correlated, and TMAO levels explain 11% of the variation in atherosclerosis."
Synthesis of << quinoline >> derivatives: discovery of a potent and selective [[ phosphodiesterase 5 ]] inhibitor for the treatment of Alzheimer's disease.,Synthesis of [ENTITY_A] derivatives: discovery of a potent and selective [ENTITY_B] inhibitor for the treatment of Alzheimer's disease.,INHIBITOR,CPR:4,1,Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.
Phosphodiesterase type 5 (<< PDE5 >>) mediates the degradation of [[ cGMP ]] in a variety of tissues including brain.,Phosphodiesterase type 5 ([ENTITY_A]) mediates the degradation of [ENTITY_B] in a variety of tissues including brain.,SUBSTRATE,CPR:9,4,Phosphodiesterase type 5 (PDE5) mediates the degradation of cGMP in a variety of tissues including brain.
"Fragment-based design, synthesis, and biological evaluation of << N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide >> derivatives as novel [[ Mcl-1 ]] inhibitors.","Fragment-based design, synthesis, and biological evaluation of [ENTITY_A] derivatives as novel [ENTITY_B] inhibitors.",INHIBITOR,CPR:4,1,"Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors."
"We have previously reported a nanomolar inhibitor of antiapoptotic << Mcl-1 >> protein, [[ 3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile ]] (S1).","We have previously reported a nanomolar inhibitor of antiapoptotic [ENTITY_A] protein, [ENTITY_B] (S1).",INHIBITOR,CPR:4,1,"We have previously reported a nanomolar inhibitor of antiapoptotic Mcl-1 protein, 3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1)."
"A novel potent compound, << N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide >> (12c), which binds [[ Mcl-1 ]] with an IC(50) value of 54 nM was obtained.","A novel potent compound, [ENTITY_A] (12c), which binds [ENTITY_B] with an IC(50) value of 54 nM was obtained.",INHIBITOR,CPR:4,1,"A novel potent compound, N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide (12c), which binds Mcl-1 with an IC(50) value of 54 nM was obtained."
"<< Peginesatide >>, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the [[ erythropoietin receptor ]] dimer that governs erythropoiesis.","[ENTITY_A], a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the [ENTITY_B] dimer that governs erythropoiesis.",ACTIVATOR,CPR:3,0,"Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis."
"LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of << LPA >> by driving MRTF-dependent [[ CTGF ]] expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A.","LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of [ENTITY_A] by driving MRTF-dependent [ENTITY_B] expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A.",INDIRECT-UPREGULATOR,CPR:3,0,"LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of LPA by driving MRTF-dependent CTGF expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A."
"<< Bile acids >> are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, [[ constitutive androstane receptor ]], and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.","[ENTITY_A] are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, [ENTITY_B], and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.",ACTIVATOR,CPR:3,0,"Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism."
"The peptide << YR-11 >> (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and [[ RANKL ]] induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.","The peptide [ENTITY_A] (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and [ENTITY_B] induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.",INHIBITOR,CPR:4,1,"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity."
Results confirmed that << YR-11 >> peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of [[ NF-κB ]].,Results confirmed that [ENTITY_A] peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of [ENTITY_B].,INDIRECT-DOWNREGULATOR,CPR:4,1,Results confirmed that YR-11 peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of NF-κB.
The activation of << Rac1 >> was induced by [[ silica ]] nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation.,The activation of [ENTITY_A] was induced by [ENTITY_B] nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation.,ACTIVATOR,CPR:3,0,The activation of Rac1 was induced by silica nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation.
Osteoblasts survive the << arsenic trioxide >> treatment by activation of [[ ATM ]]-mediated pathway.,Osteoblasts survive the [ENTITY_A] treatment by activation of [ENTITY_B]-mediated pathway.,ACTIVATOR,CPR:3,0,Osteoblasts survive the arsenic trioxide treatment by activation of ATM-mediated pathway.
"Additionally, these effects of << ATO >> on γ-H2AX, Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an [[ ATM ]] inhibitor.","Additionally, these effects of [ENTITY_A] on γ-H2AX, Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an [ENTITY_B] inhibitor.",ACTIVATOR,CPR:3,0,"Additionally, these effects of ATO on γ-H2AX, Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an ATM inhibitor."
"Furthermore, a mixture of << isoflavonoid >> parent compounds, and a mixture of isoflavonoid metabolites were found to have [[ PPARγ ]] activating abilities.","Furthermore, a mixture of [ENTITY_A] parent compounds, and a mixture of isoflavonoid metabolites were found to have [ENTITY_B] activating abilities.",ACTIVATOR,CPR:3,0,"Furthermore, a mixture of isoflavonoid parent compounds, and a mixture of isoflavonoid metabolites were found to have PPARγ activating abilities."
"Both << fatty acids >>, but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of [[ cytokine ]]-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.","Both [ENTITY_A], but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of [ENTITY_B]-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Both fatty acids, but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells."
"In monocytes, both << EPA >> and DHA increased [[ interleukin (IL)-10 ]] without affecting tumor necrosis factor (TNF)-α and IL-6.","In monocytes, both [ENTITY_A] and DHA increased [ENTITY_B] without affecting tumor necrosis factor (TNF)-α and IL-6.",UPREGULATOR,CPR:3,0,"In monocytes, both EPA and DHA increased interleukin (IL)-10 without affecting tumor necrosis factor (TNF)-α and IL-6."
"In the in vitro model we observed high permeability of << imperatorin >> and isoimperatorin with the [[ P-gp ]]-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82.","In the in vitro model we observed high permeability of [ENTITY_A] and isoimperatorin with the [ENTITY_B]-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82.",SUBSTRATE,CPR:9,4,"In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the P-gp-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82."
"Treatment with << adenosine dialdehyde >> (AdOx), an inhibitor of transmethylation-suppressive [[ adenosylhomocysteine (SAH) hydrolase ]] (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.","Treatment with [ENTITY_A] (AdOx), an inhibitor of transmethylation-suppressive [ENTITY_B] (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.",INHIBITOR,CPR:4,1,"Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner."
"Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive << adenosylhomocysteine (SAH) hydrolase >> (SAHH), enhanced the level of [[ SAH ]] and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.","Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive [ENTITY_A] (SAHH), enhanced the level of [ENTITY_B] and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.",SUBSTRATE,CPR:9,4,"Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner."
"Through immunoblotting analysis, it was found that << AdOx >> was capable of indirectly diminishing the phosphorylation of oncogenic [[ Src ]] and its kinase activity.","Through immunoblotting analysis, it was found that [ENTITY_A] was capable of indirectly diminishing the phosphorylation of oncogenic [ENTITY_B] and its kinase activity.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Through immunoblotting analysis, it was found that AdOx was capable of indirectly diminishing the phosphorylation of oncogenic Src and its kinase activity."
"Interestingly, << AdOx >> disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of [[ Src ]] and p85/PI3K, which is linked to various tumorigenic responses.","Interestingly, [ENTITY_A] disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of [ENTITY_B] and p85/PI3K, which is linked to various tumorigenic responses.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Interestingly, AdOx disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85/PI3K, which is linked to various tumorigenic responses."
"In agreement with these data, the exogenous treatment of << SAH >> or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on [[ Src ]], the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.","In agreement with these data, the exogenous treatment of [ENTITY_A] or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on [ENTITY_B], the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.",DOWNREGULATOR,CPR:4,1,"In agreement with these data, the exogenous treatment of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src."
Synthesis of derivatives of << methyl rosmarinate >> and their inhibitory activities against matrix metalloproteinase-1 ([[ MMP-1 ]]).,Synthesis of derivatives of [ENTITY_A] and their inhibitory activities against matrix metalloproteinase-1 ([ENTITY_B]).,INHIBITOR,CPR:4,1,Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).
A series of << MMP-1 >> inhibitors have been identified based upon a [[ methyl rosmarinate ]] scaffold using structure-based drug design methods.,A series of [ENTITY_A] inhibitors have been identified based upon a [ENTITY_B] scaffold using structure-based drug design methods.,INHIBITOR,CPR:4,1,A series of MMP-1 inhibitors have been identified based upon a methyl rosmarinate scaffold using structure-based drug design methods.
"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as << cyclooxygenase-2 >> (COX-2)-derived [[ prostaglandin E2 ]] (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line.","All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as [ENTITY_A] (COX-2)-derived [ENTITY_B] (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line.",PRODUCT-OF,CPR:9,4,"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (COX-2)-derived prostaglandin E2 (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line."
"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the << lipoxygenase >> (LOX)-pathway (one having as precursors the [[ polyunsaturated fatty acids ]] containing a cis-cis-1,4-pentadiene system).","Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the [ENTITY_A] (LOX)-pathway (one having as precursors the [ENTITY_B] containing a cis-cis-1,4-pentadiene system).",SUBSTRATE,CPR:9,4,"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (LOX)-pathway (one having as precursors the polyunsaturated fatty acids containing a cis-cis-1,4-pentadiene system)."
"In general, antiproliferative activity is greatly enhanced by low levels of the << glutathione synthase >> inhibitor [[ l-buthionine sulfoxime ]].","In general, antiproliferative activity is greatly enhanced by low levels of the [ENTITY_A] inhibitor [ENTITY_B].",INHIBITOR,CPR:4,1,"In general, antiproliferative activity is greatly enhanced by low levels of the glutathione synthase inhibitor l-buthionine sulfoxime."
Cellular << zinc >> is controlled by [[ zinc-chelating proteins ]] and by zinc transporters.,Cellular [ENTITY_A] is controlled by [ENTITY_B] and by zinc transporters.,SUBSTRATE,CPR:9,4,Cellular zinc is controlled by zinc-chelating proteins and by zinc transporters.
"The recent identification of << zinc >> permeability of the lysosomal ion channel [[ TRPML1 ]] (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport.","The recent identification of [ENTITY_A] permeability of the lysosomal ion channel [ENTITY_B] (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport.",SUBSTRATE,CPR:9,4,"The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport."
These results underscore a role for << TRPML1 >> in [[ zinc ]] metabolism.,These results underscore a role for [ENTITY_A] in [ENTITY_B] metabolism.,SUBSTRATE,CPR:9,4,These results underscore a role for TRPML1 in zinc metabolism.
"Furthermore, they suggest that << TRPML1 >> works in concert with ZnT4 to regulate [[ zinc ]] translocation between the cytoplasm and lysosomes.","Furthermore, they suggest that [ENTITY_A] works in concert with ZnT4 to regulate [ENTITY_B] translocation between the cytoplasm and lysosomes.",SUBSTRATE,CPR:9,4,"Furthermore, they suggest that TRPML1 works in concert with ZnT4 to regulate zinc translocation between the cytoplasm and lysosomes."
<< Serum amyloid A >> upsurge precedes standard biomarkers of hepatotoxicity in [[ ritodrine ]]-injected mice.,[ENTITY_A] upsurge precedes standard biomarkers of hepatotoxicity in [ENTITY_B]-injected mice.,INDIRECT-UPREGULATOR,CPR:3,0,Serum amyloid A upsurge precedes standard biomarkers of hepatotoxicity in ritodrine-injected mice.
"Importantly, expression of the acute-phase reactant << serum amyloid A >> (SAA) significantly increased after [[ ritodrine ]] injection, with values indicating the largest fold-change.","Importantly, expression of the acute-phase reactant [ENTITY_A] (SAA) significantly increased after [ENTITY_B] injection, with values indicating the largest fold-change.",INDIRECT-UPREGULATOR,CPR:3,0,"Importantly, expression of the acute-phase reactant serum amyloid A (SAA) significantly increased after ritodrine injection, with values indicating the largest fold-change."
"The increase in << SAA >> expression is specific to [[ ritodrine ]]-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin.","The increase in [ENTITY_A] expression is specific to [ENTITY_B]-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin.",INDIRECT-UPREGULATOR,CPR:3,0,"The increase in SAA expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin."
"Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate (cAMP) accumulation was not a primary cause of the << ritodrine >>-induced [[ SAA ]] increase.","Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate (cAMP) accumulation was not a primary cause of the [ENTITY_A]-induced [ENTITY_B] increase.",INDIRECT-UPREGULATOR,CPR:3,0,"Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate (cAMP) accumulation was not a primary cause of the ritodrine-induced SAA increase."
<< Ceftazidime >>-avibactam: a novel cephalosporin/[[ β-lactamase ]] inhibitor combination.,[ENTITY_A]-avibactam: a novel cephalosporin/[ENTITY_B] inhibitor combination.,INHIBITOR,CPR:4,1,Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
"Avibactam (formerly << NXL104 >>, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some [[ Ambler class D ]] enzymes.","Avibactam (formerly [ENTITY_A], AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some [ENTITY_B] enzymes.",INHIBITOR,CPR:4,1,"Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes."
The addition of << avibactam >> greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of [[ β-lactamase ]] enzyme(s).,The addition of [ENTITY_A] greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of [ENTITY_B] enzyme(s).,INHIBITOR,CPR:4,1,The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of β-lactamase enzyme(s).
"Pharmacodynamic data suggest that << ceftazidime >>-avibactam is rapidly bactericidal versus [[ β-lactamase ]]-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates.","Pharmacodynamic data suggest that [ENTITY_A]-avibactam is rapidly bactericidal versus [ENTITY_B]-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates.",INHIBITOR,CPR:4,1,"Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus β-lactamase-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates."
"Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, << avibactam >> serves to broaden the spectrum of ceftazidime versus [[ ß-lactamase ]]-producing Gram-negative bacilli.","Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, [ENTITY_A] serves to broaden the spectrum of ceftazidime versus [ENTITY_B]-producing Gram-negative bacilli.",INHIBITOR,CPR:4,1,"Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of ceftazidime versus ß-lactamase-producing Gram-negative bacilli."
"Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective << cyclooxygenase-2 >> inhibitor, [[ celecoxib ]], improved vascular function, and also attenuated obesity.","Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective [ENTITY_A] inhibitor, [ENTITY_B], improved vascular function, and also attenuated obesity.",INHIBITOR,CPR:4,1,"Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective cyclooxygenase-2 inhibitor, celecoxib, improved vascular function, and also attenuated obesity."
<< Upamostat >> (Mesupron®) is a new small molecule [[ serine protease ]] inhibitor.,[ENTITY_A] (Mesupron®) is a new small molecule [ENTITY_B] inhibitor.,INHIBITOR,CPR:4,1,Upamostat (Mesupron®) is a new small molecule serine protease inhibitor.
"Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas << GPx1b1 >> and GPx1b2 were highly induced by exposure to [[ selenium ]] levels that had some toxic effects on the cells.","Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas [ENTITY_A] and GPx1b2 were highly induced by exposure to [ENTITY_B] levels that had some toxic effects on the cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas GPx1b1 and GPx1b2 were highly induced by exposure to selenium levels that had some toxic effects on the cells."
"<< Mn >> exposure (20 mg/kg) increased [[ p38 ]](MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation.","[ENTITY_A] exposure (20 mg/kg) increased [ENTITY_B](MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation.",ACTIVATOR,CPR:3,0,"Mn exposure (20 mg/kg) increased p38(MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation."
"<< Mn >> exposure (20 mg/kg) increased p38(MAPK) and Akt phosphorylation, but decreased [[ DARPP-32 ]]-Thr-34 phosphorylation.","[ENTITY_A] exposure (20 mg/kg) increased p38(MAPK) and Akt phosphorylation, but decreased [ENTITY_B]-Thr-34 phosphorylation.",INHIBITOR,CPR:4,1,"Mn exposure (20 mg/kg) increased p38(MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation."
<< Mn >> (10 and 20 mg/kg) increased [[ caspase ]] activity and F(2)-isoprostane production (a biological marker of lipid peroxidation).,[ENTITY_A] (10 and 20 mg/kg) increased [ENTITY_B] activity and F(2)-isoprostane production (a biological marker of lipid peroxidation).,ACTIVATOR,CPR:3,0,Mn (10 and 20 mg/kg) increased caspase activity and F(2)-isoprostane production (a biological marker of lipid peroxidation).
"Notably, the antioxidant Trolox™ reversed the << Mn >> (20 mg/kg)-dependent augmentation in [[ p38 ]](MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production.","Notably, the antioxidant Trolox™ reversed the [ENTITY_A] (20 mg/kg)-dependent augmentation in [ENTITY_B](MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production.",ACTIVATOR,CPR:3,0,"Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production."
"Notably, the antioxidant << Trolox >>™ reversed the Mn (20 mg/kg)-dependent augmentation in [[ p38 ]](MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production.","Notably, the antioxidant [ENTITY_A]™ reversed the Mn (20 mg/kg)-dependent augmentation in [ENTITY_B](MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production.",INHIBITOR,CPR:4,1,"Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production."
"These findings are the first to show that long-term exposure to << Mn >> during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, [[ p38 ]](MAPK) phosphorylation and caspase activity in the striatum.","These findings are the first to show that long-term exposure to [ENTITY_A] during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, [ENTITY_B](MAPK) phosphorylation and caspase activity in the striatum.",ACTIVATOR,CPR:3,0,"These findings are the first to show that long-term exposure to Mn during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38(MAPK) phosphorylation and caspase activity in the striatum."
"<< Nocapyrone H >> (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and [[ interleukin-1β ]] (IL-1β).","[ENTITY_A] (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and [ENTITY_B] (IL-1β).",INDIRECT-DOWNREGULATOR,CPR:4,1,"Nocapyrone H (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and interleukin-1β (IL-1β)."
"Investigating the enteroenteric recirculation of << apixaban >>, a [[ factor Xa ]] inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.","Investigating the enteroenteric recirculation of [ENTITY_A], a [ENTITY_B] inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.",INHIBITOR,CPR:4,1,"Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats."
"The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with << GF-120918 >>, a dual [[ BCRP ]] and P-gp inhibitor).","The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with [ENTITY_A], a dual [ENTITY_B] and P-gp inhibitor).",INHIBITOR,CPR:4,1,"The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with GF-120918, a dual BCRP and P-gp inhibitor)."
"<< BCRP >> appeared to play a more important role for absorption and intestinal and renal elimination of [[ apixaban ]] than P-gp in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species.","[ENTITY_A] appeared to play a more important role for absorption and intestinal and renal elimination of [ENTITY_B] than P-gp in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species.",SUBSTRATE,CPR:9,4,"BCRP appeared to play a more important role for absorption and intestinal and renal elimination of apixaban than P-gp in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species."
"Cloning, Characterization, and << Sulfonamide >> and Thiol Inhibition Studies of an [[ α-Carbonic Anhydrase ]] from Trypanosoma cruzi, the Causative Agent of Chagas Disease.","Cloning, Characterization, and [ENTITY_A] and Thiol Inhibition Studies of an [ENTITY_B] from Trypanosoma cruzi, the Causative Agent of Chagas Disease.",INHIBITOR,CPR:4,1,"Cloning, Characterization, and Sulfonamide and Thiol Inhibition Studies of an α-Carbonic Anhydrase from Trypanosoma cruzi, the Causative Agent of Chagas Disease."
"The enzyme (TcCA) has a very high catalytic activity for the << CO(2) >> hydration reaction, being similar kinetically to the human (h) isoform [[ hCA II ]], although it is devoid of the His64 proton shuttle.","The enzyme (TcCA) has a very high catalytic activity for the [ENTITY_A] hydration reaction, being similar kinetically to the human (h) isoform [ENTITY_B], although it is devoid of the His64 proton shuttle.",SUBSTRATE,CPR:9,4,"The enzyme (TcCA) has a very high catalytic activity for the CO(2) hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the His64 proton shuttle."
"A large number of << aromatic/heterocyclic sulfonamides >> and some 5-mercapto-1,3,4-thiadiazoles were investigated as [[ TcCA ]] inhibitors.","A large number of [ENTITY_A] and some 5-mercapto-1,3,4-thiadiazoles were investigated as [ENTITY_B] inhibitors.",INHIBITOR,CPR:4,1,"A large number of aromatic/heterocyclic sulfonamides and some 5-mercapto-1,3,4-thiadiazoles were investigated as TcCA inhibitors."
"The mRNA level for << nestin >> (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-[[ EDS ]], but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.","The mRNA level for [ENTITY_A] (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-[ENTITY_B], but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.",INDIRECT-UPREGULATOR,CPR:3,0,"The mRNA level for nestin (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-EDS, but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes."
<< GnRH >> pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of PKA and [[ CREB ]].,[ENTITY_A] pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of PKA and [ENTITY_B].,ACTIVATOR,CPR:3,0,GnRH pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of PKA and CREB.
"cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile << GnRH >> regulates [[ CREB ]] activation remain poorly understood.","cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile [ENTITY_A] regulates [ENTITY_B] activation remain poorly understood.",ACTIVATOR,CPR:3,0,"cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood."
We hypothesized that << CREB >> is activated by a distinct signaling pathway in response to pulsatile [[ GnRH ]] in a frequency-dependent manner to dictate the FSHβ transcriptional response.,We hypothesized that [ENTITY_A] is activated by a distinct signaling pathway in response to pulsatile [ENTITY_B] in a frequency-dependent manner to dictate the FSHβ transcriptional response.,ACTIVATOR,CPR:3,0,We hypothesized that CREB is activated by a distinct signaling pathway in response to pulsatile GnRH in a frequency-dependent manner to dictate the FSHβ transcriptional response.
"<< GnRH >> stimulation of [[ CREB ]] phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89.","[ENTITY_A] stimulation of [ENTITY_B] phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89.",ACTIVATOR,CPR:3,0,"GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89."
"GnRH stimulation of << CREB >> phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, [[ H89 ]].","GnRH stimulation of [ENTITY_A] phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, [ENTITY_B].",INHIBITOR,CPR:4,1,"GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89."
"A dominant negative PKA (DNPKA) reduced << GnRH >>-stimulated [[ pCREB ]] and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.","A dominant negative PKA (DNPKA) reduced [ENTITY_A]-stimulated [ENTITY_B] and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.",ACTIVATOR,CPR:3,0,"A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway."
"In perifusion studies, FSHβ mRNA levels and << FSHβ >>LUC activities were increased by pulsatile [[ GnRH ]], with significantly greater increases at low compared with high pulse frequencies.","In perifusion studies, FSHβ mRNA levels and [ENTITY_A]LUC activities were increased by pulsatile [ENTITY_B], with significantly greater increases at low compared with high pulse frequencies.",ACTIVATOR,CPR:3,0,"In perifusion studies, FSHβ mRNA levels and FSHβLUC activities were increased by pulsatile GnRH, with significantly greater increases at low compared with high pulse frequencies."
DNPKA markedly reduced these << GnRH >>-stimulated [[ FSHβ ]] responses at both low and high pulse frequencies.,DNPKA markedly reduced these [ENTITY_A]-stimulated [ENTITY_B] responses at both low and high pulse frequencies.,INDIRECT-UPREGULATOR,CPR:3,0,DNPKA markedly reduced these GnRH-stimulated FSHβ responses at both low and high pulse frequencies.
"Correlating with << FSHβ >> activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high [[ GnRH ]] pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies.","Correlating with [ENTITY_A] activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high [ENTITY_B] pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies.",ACTIVATOR,CPR:3,0,"Correlating with FSHβ activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies."
"Taken together, these data indicate that a PKA-mediated signaling pathway mediates << GnRH >> activation of [[ CREB ]] at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic GnRH signal to result in frequency-dependent FSHβ activation.","Taken together, these data indicate that a PKA-mediated signaling pathway mediates [ENTITY_A] activation of [ENTITY_B] at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic GnRH signal to result in frequency-dependent FSHβ activation.",ACTIVATOR,CPR:3,0,"Taken together, these data indicate that a PKA-mediated signaling pathway mediates GnRH activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic GnRH signal to result in frequency-dependent FSHβ activation."
<< Sophocarpine >> alleviates hepatocyte steatosis through activating [[ AMPK ]] signaling pathway.,[ENTITY_A] alleviates hepatocyte steatosis through activating [ENTITY_B] signaling pathway.,ACTIVATOR,CPR:3,0,Sophocarpine alleviates hepatocyte steatosis through activating AMPK signaling pathway.
"While << sophocarpine >> treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of [[ adiponectin ]] expression (>1.48-fold).","While [ENTITY_A] treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of [ENTITY_B] expression (>1.48-fold).",INDIRECT-UPREGULATOR,CPR:3,0,"While sophocarpine treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold)."
"While << sophocarpine >> treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of [[ leptin ]] expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold).","While [ENTITY_A] treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of [ENTITY_B] expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold).",INDIRECT-DOWNREGULATOR,CPR:4,1,"While sophocarpine treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold)."
"Moreover, compared with the model group, << sophocarpine >> could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and [[ ACC ]] (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.","Moreover, compared with the model group, [ENTITY_A] could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and [ENTITY_B] (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.",INDIRECT-UPREGULATOR,CPR:3,0,"Moreover, compared with the model group, sophocarpine could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression."
"Moreover, compared with the model group, << sophocarpine >> could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce [[ P-ACC ]] (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.","Moreover, compared with the model group, [ENTITY_A] could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce [ENTITY_B] (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, compared with the model group, sophocarpine could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression."
We concluded that << sophocarpine >> could alleviate hepatocyte steatosis and the potential mechanism might be the activated signaling pathway of [[ AMPK ]].,We concluded that [ENTITY_A] could alleviate hepatocyte steatosis and the potential mechanism might be the activated signaling pathway of [ENTITY_B].,ACTIVATOR,CPR:3,0,We concluded that sophocarpine could alleviate hepatocyte steatosis and the potential mechanism might be the activated signaling pathway of AMPK.
"To evaluate to what extent the regional differences in expression of << P-gp >> and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of [[ darunavir ]] across different small intestinal segments (duodenum, proximal jejunum and ileum).","To evaluate to what extent the regional differences in expression of [ENTITY_A] and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of [ENTITY_B] across different small intestinal segments (duodenum, proximal jejunum and ileum).",SUBSTRATE,CPR:9,4,"To evaluate to what extent the regional differences in expression of P-gp and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of darunavir across different small intestinal segments (duodenum, proximal jejunum and ileum)."
The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of darunavir with the << P-gp >> inhibitor [[ zosuquidar ]].,The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of darunavir with the [ENTITY_A] inhibitor [ENTITY_B].,INHIBITOR,CPR:4,1,The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar.
The involvement of << P-gp >> in the absorption of [[ darunavir ]] was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar.,The involvement of [ENTITY_A] in the absorption of [ENTITY_B] was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar.,SUBSTRATE,CPR:9,4,The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar.
Involvement of << P450 >> mediated metabolism in the absorption of [[ darunavir ]] could not be demonstrated in this rat model.,Involvement of [ENTITY_A] mediated metabolism in the absorption of [ENTITY_B] could not be demonstrated in this rat model.,SUBSTRATE,CPR:9,4,Involvement of P450 mediated metabolism in the absorption of darunavir could not be demonstrated in this rat model.
"Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of << ketoconazole >> on [[ P-gp ]] as the main mechanism for the increased transport of darunavir across the small intestine.","Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of [ENTITY_A] on [ENTITY_B] as the main mechanism for the increased transport of darunavir across the small intestine.",INHIBITOR,CPR:4,1,"Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on P-gp as the main mechanism for the increased transport of darunavir across the small intestine."
"Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on << P-gp >> as the main mechanism for the increased transport of [[ darunavir ]] across the small intestine.","Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on [ENTITY_A] as the main mechanism for the increased transport of [ENTITY_B] across the small intestine.",SUBSTRATE,CPR:9,4,"Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on P-gp as the main mechanism for the increased transport of darunavir across the small intestine."
"In HaCaT cells, << buthanol >> and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including [[ cyclooxygenase-2 ]] (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).","In HaCaT cells, [ENTITY_A] and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including [ENTITY_B] (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).",INDIRECT-DOWNREGULATOR,CPR:4,1,"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α)."
"In another experiment, topical application of CFB, CFE or << CLS >> prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of [[ COX-2 ]], iNOS, and TNF-α.","In another experiment, topical application of CFB, CFE or [ENTITY_A] prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of [ENTITY_B], iNOS, and TNF-α.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In another experiment, topical application of CFB, CFE or CLS prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of COX-2, iNOS, and TNF-α."
"In overexpressing cell lines, << OATP1B1 >>- and OATP1B3-mediated estradiol-17β-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin [[ flavonolignans ]] investigated.","In overexpressing cell lines, [ENTITY_A]- and OATP1B3-mediated estradiol-17β-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin [ENTITY_B] investigated.",INHIBITOR,CPR:4,1,"In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17β-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated."
"In overexpressing cell lines, << OATP1B1 >>- and OATP1B3-mediated [[ estradiol-17β-glucuronide ]] uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated.","In overexpressing cell lines, [ENTITY_A]- and OATP1B3-mediated [ENTITY_B] uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated.",SUBSTRATE,CPR:9,4,"In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17β-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated."
"<< OATP1B1 >>-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), [[ silybin A ]] (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).","[ENTITY_A]-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), [ENTITY_B] (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).",INHIBITOR,CPR:4,1,"OATP1B1-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively)."
"Furthermore, silymarin, << silybin A >>, and silybin B (100 µM) significantly inhibited [[ OATP ]]-mediated estradiol-17β-glucuronide and rosuvastatin uptake into human hepatocytes.","Furthermore, silymarin, [ENTITY_A], and silybin B (100 µM) significantly inhibited [ENTITY_B]-mediated estradiol-17β-glucuronide and rosuvastatin uptake into human hepatocytes.",INHIBITOR,CPR:4,1,"Furthermore, silymarin, silybin A, and silybin B (100 µM) significantly inhibited OATP-mediated estradiol-17β-glucuronide and rosuvastatin uptake into human hepatocytes."
"Furthermore, silymarin, silybin A, and silybin B (100 µM) significantly inhibited << OATP >>-mediated [[ estradiol-17β-glucuronide ]] and rosuvastatin uptake into human hepatocytes.","Furthermore, silymarin, silybin A, and silybin B (100 µM) significantly inhibited [ENTITY_A]-mediated [ENTITY_B] and rosuvastatin uptake into human hepatocytes.",SUBSTRATE,CPR:9,4,"Furthermore, silymarin, silybin A, and silybin B (100 µM) significantly inhibited OATP-mediated estradiol-17β-glucuronide and rosuvastatin uptake into human hepatocytes."
Further investigation demonstrated that 8k reduced << H2O2 >>-induced activation of mitochondrial apoptosis by inhibiting the expression of [[ Bax ]] and elevating the expression of Bcl-2.,Further investigation demonstrated that 8k reduced [ENTITY_A]-induced activation of mitochondrial apoptosis by inhibiting the expression of [ENTITY_B] and elevating the expression of Bcl-2.,INDIRECT-UPREGULATOR,CPR:3,0,Further investigation demonstrated that 8k reduced H2O2-induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of Bcl-2.
Further investigation demonstrated that 8k reduced << H2O2 >>-induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of [[ Bcl-2 ]].,Further investigation demonstrated that 8k reduced [ENTITY_A]-induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of [ENTITY_B].,INDIRECT-DOWNREGULATOR,CPR:4,1,Further investigation demonstrated that 8k reduced H2O2-induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of Bcl-2.
"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of << insulin >> (achieved by administering insulin plus [[ glucose ]], glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine).","Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of [ENTITY_A] (achieved by administering insulin plus [ENTITY_B], glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine).",INDIRECT-UPREGULATOR,CPR:3,0,"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine)."
The << CRF(1) receptor >> antagonist [[ SSR125543 ]] prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine.,The [ENTITY_A] antagonist [ENTITY_B] prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine.,ANTAGONIST,CPR:6,3,The CRF(1) receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine.
RATIONALE: The selective << CRF(1) (corticotropin releasing factor type 1) receptor >> antagonist [[ SSR125543 ]] has been previously shown to attenuate the long-term cognitive deficit produced by traumatic stress exposure.,RATIONALE: The selective [ENTITY_A] antagonist [ENTITY_B] has been previously shown to attenuate the long-term cognitive deficit produced by traumatic stress exposure.,ANTAGONIST,CPR:6,3,RATIONALE: The selective CRF(1) (corticotropin releasing factor type 1) receptor antagonist SSR125543 has been previously shown to attenuate the long-term cognitive deficit produced by traumatic stress exposure.
"Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10 mg/kg/day), and the partial << N-methyl-D-aspartate (NMDA) receptor >> agonist, [[ D-cycloserine ]] (10 mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD.","Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10 mg/kg/day), and the partial [ENTITY_A] agonist, [ENTITY_B] (10 mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD.",AGONIST,CPR:5,2,"Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10 mg/kg/day), and the partial N-methyl-D-aspartate (NMDA) receptor agonist, D-cycloserine (10 mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD."
CONCLUSIONS: These findings confirm that the << CRF(1) receptor >> antagonist [[ SSR125543 ]] is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress.,CONCLUSIONS: These findings confirm that the [ENTITY_A] antagonist [ENTITY_B] is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress.,ANTAGONIST,CPR:6,3,CONCLUSIONS: These findings confirm that the CRF(1) receptor antagonist SSR125543 is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress.
A series of << indazole arylsulfonamides >> were synthesized and examined as [[ human CCR4 ]] antagonists.,A series of [ENTITY_A] were synthesized and examined as [ENTITY_B] antagonists.,ANTAGONIST,CPR:6,3,A series of indazole arylsulfonamides were synthesized and examined as human CCR4 antagonists.
Repeated Low Dose Administration of the << Monoacylglycerol Lipase >> Inhibitor [[ JZL184 ]] Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects.,Repeated Low Dose Administration of the [ENTITY_A] Inhibitor [ENTITY_B] Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects.,INHIBITOR,CPR:4,1,Repeated Low Dose Administration of the Monoacylglycerol Lipase Inhibitor JZL184 Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects.
The monoacylglycerol lipase (<< MAGL >>) inhibitor [[ JZL184 ]] produces antinociceptive and anti-inflammatory effects.,The monoacylglycerol lipase ([ENTITY_A]) inhibitor [ENTITY_B] produces antinociceptive and anti-inflammatory effects.,INHIBITOR,CPR:4,1,The monoacylglycerol lipase (MAGL) inhibitor JZL184 produces antinociceptive and anti-inflammatory effects.
"Mice given daily injections of high dose << JZL184 >> (≥16 mg/kg) for six days displayed decreased [[ CB(1) ]] receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTPγS binding assays, respectively.","Mice given daily injections of high dose [ENTITY_A] (≥16 mg/kg) for six days displayed decreased [ENTITY_B] receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTPγS binding assays, respectively.",DOWNREGULATOR,CPR:4,1,"Mice given daily injections of high dose JZL184 (≥16 mg/kg) for six days displayed decreased CB(1) receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTPγS binding assays, respectively."
Design and synthesis of << bicyclic pyrazinone and pyrimidinone amides >> as potent [[ TF ]]-FVIIa inhibitors.,Design and synthesis of [ENTITY_A] as potent [ENTITY_B]-FVIIa inhibitors.,INHIBITOR,CPR:4,1,Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitors.
<< Bicyclic pyrazinone and pyrimidinone amides >> were designed and synthesized as potent TF-[[ FVIIa ]] inhibitors.,[ENTITY_A] were designed and synthesized as potent TF-[ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Bicyclic pyrazinone and pyrimidinone amides were designed and synthesized as potent TF-FVIIa inhibitors.
"Fragment-based drug design and identification of << HJC0123 >>, a novel orally bioavailable [[ STAT3 ]] inhibitor for cancer therapy.","Fragment-based drug design and identification of [ENTITY_A], a novel orally bioavailable [ENTITY_B] inhibitor for cancer therapy.",INHIBITOR,CPR:4,1,"Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy."
"The most potent compound 5 (<< HJC0123 >>) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved [[ caspase-3 ]], inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.","The most potent compound 5 ([ENTITY_A]) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved [ENTITY_B], inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.",INDIRECT-UPREGULATOR,CPR:3,0,"The most potent compound 5 (HJC0123) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values."
"The most potent compound 5 (<< HJC0123 >>) has demonstrated to inhibit [[ STAT3 promoter ]] activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.","The most potent compound 5 ([ENTITY_A]) has demonstrated to inhibit [ENTITY_B] activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.",INHIBITOR,CPR:4,1,"The most potent compound 5 (HJC0123) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values."
The effects of the << phosphodiesterase type 5 >> inhibitor [[ vardenafil ]] on cognitive performance in healthy adults: a behavioral- electroencephalography study.,The effects of the [ENTITY_A] inhibitor [ENTITY_B] on cognitive performance in healthy adults: a behavioral- electroencephalography study.,INHIBITOR,CPR:4,1,The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral- electroencephalography study.
"Therefore, we examined whether the << PDE5 >>-I [[ vardenafil ]] improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults.","Therefore, we examined whether the [ENTITY_A]-I [ENTITY_B] improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults.",INHIBITOR,CPR:4,1,"Therefore, we examined whether the PDE5-I vardenafil improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults."
"Statins are inhibitors of the enzyme << 3-hydroxy-3-methylglutaryl coenzyme A reductase >>, the rate-limiting step in [[ cholesterol ]] biosynthesis.","Statins are inhibitors of the enzyme [ENTITY_A], the rate-limiting step in [ENTITY_B] biosynthesis.",PRODUCT-OF,CPR:9,4,"Statins are inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting step in cholesterol biosynthesis."
"We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased << NADPH oxidase >> activity and immunoreactivity for the protein nitration marker [[ 3-nitrotyrosine ]] in the cerebral cortex.","We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased [ENTITY_A] activity and immunoreactivity for the protein nitration marker [ENTITY_B] in the cerebral cortex.",ACTIVATOR,CPR:3,0,"We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased NADPH oxidase activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex."
"Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8 μg/100 g body weight (BW), i.p.) for 15 days or along with a << peroxisome proliferator-activated receptor alpha >> agonist [[ bezafibrate ]] (Bzf; 30 μg/100 g BW, oral) and were found to improve in the Bzf co-treated condition.","Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8 μg/100 g body weight (BW), i.p.) for 15 days or along with a [ENTITY_A] agonist [ENTITY_B] (Bzf; 30 μg/100 g BW, oral) and were found to improve in the Bzf co-treated condition.",AGONIST,CPR:5,2,"Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8 μg/100 g body weight (BW), i.p.) for 15 days or along with a peroxisome proliferator-activated receptor alpha agonist bezafibrate (Bzf; 30 μg/100 g BW, oral) and were found to improve in the Bzf co-treated condition."
"Moreover, the effects of the << DRD3 >> agonist [[ 7-hydroxy-N,N-dipropyl-2-aminotetralin ]] (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.","Moreover, the effects of the [ENTITY_A] agonist [ENTITY_B] (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.",AGONIST,CPR:5,2,"Moreover, the effects of the DRD3 agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant."
"Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid << (AMPA) receptor >> antagonist [[ IKM-159 ]]: asymmetric synthesis, neuroactivity, and structural characterization.","Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid [ENTITY_A] antagonist [ENTITY_B]: asymmetric synthesis, neuroactivity, and structural characterization.",ANTAGONIST,CPR:6,3,"Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptor antagonist IKM-159: asymmetric synthesis, neuroactivity, and structural characterization."
<< IKM-159 >> was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as [[ AMPA receptor ]]-selective antagonists.,[ENTITY_A] was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as [ENTITY_B]-selective antagonists.,ANTAGONIST,CPR:6,3,IKM-159 was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as AMPA receptor-selective antagonists.
"<< (2R)-IKM-159 >> locks the [[ GluA2 ]] in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors.","[ENTITY_A] locks the [ENTITY_B] in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors.",INHIBITOR,CPR:4,1,"(2R)-IKM-159 locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors."
"<< (2R)-IKM-159 >> locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of [[ AMPA receptors ]].","[ENTITY_A] locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of [ENTITY_B].",ANTAGONIST,CPR:6,3,"(2R)-IKM-159 locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors."
"Coumarin 7-hydroxylation, catalyzed by << P450 2A13 >>, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, [[ flavanone ]], chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.","Coumarin 7-hydroxylation, catalyzed by [ENTITY_A], was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, [ENTITY_B], chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.",INHIBITOR,CPR:4,1,"Coumarin 7-hydroxylation, catalyzed by P450 2A13, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values."
"<< Coumarin >> 7-hydroxylation, catalyzed by [[ P450 2A13 ]], was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.","[ENTITY_A] 7-hydroxylation, catalyzed by [ENTITY_B], was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.",SUBSTRATE,CPR:9,4,"Coumarin 7-hydroxylation, catalyzed by P450 2A13, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values."
"Full agonists to the << peroxisome proliferator-activated receptor (PPAR)γ >>, such as [[ Rosiglitazone ]], have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity.","Full agonists to the [ENTITY_A], such as [ENTITY_B], have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity.",AGONIST-ACTIVATOR,CPR:5,2,"Full agonists to the peroxisome proliferator-activated receptor (PPAR)γ, such as Rosiglitazone, have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity."
The << (R)-omeprazole >> hydroxylation index reflects [[ CYP2C19 ]] activity in healthy Japanese volunteers.,The [ENTITY_A] hydroxylation index reflects [ENTITY_B] activity in healthy Japanese volunteers.,SUBSTRATE,CPR:9,4,The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.
"PURPOSE: << Omeprazole >> has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with [[ cytochrome P450 (CYP) 2C19 ]] genotype groups.","PURPOSE: [ENTITY_A] has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with [ENTITY_B] genotype groups.",SUBSTRATE,CPR:9,4,"PURPOSE: Omeprazole has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with cytochrome P450 (CYP) 2C19 genotype groups."
"Additionally, there was a significant difference in plasma concentrations of << (R)-5-hydroxyomeprazole >> among [[ CYP2C19 ]] genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole.","Additionally, there was a significant difference in plasma concentrations of [ENTITY_A] among [ENTITY_B] genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole.",SUBSTRATE,CPR:9,4,"Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among CYP2C19 genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole."
"CONCLUSION: Our findings demonstrate that << (R)-omeprazole >> HI correlated better with [[ CYP2C19 ]] genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.","CONCLUSION: Our findings demonstrate that [ENTITY_A] HI correlated better with [ENTITY_B] genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.",SUBSTRATE,CPR:9,4,"CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with CYP2C19 genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment."
"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, << all-trans retinoic acid >> (atRA), which regulates the expression of a battery of target genes through several families of [[ nuclear receptors ]] (RARs, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.","The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, [ENTITY_A] (atRA), which regulates the expression of a battery of target genes through several families of [ENTITY_B] (RARs, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.",INDIRECT-UPREGULATOR,CPR:3,0,"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators."
"Interestingly, << miR-21 >> expression positively correlated with urine albumin [[ creatine ]] ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein.","Interestingly, [ENTITY_A] expression positively correlated with urine albumin [ENTITY_B] ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein.",INDIRECT-UPREGULATOR,CPR:3,0,"Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein."
"Interestingly, << miR-21 >> expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with [[ creatine ]] clearance ratio (Ccr) and MMP-9 protein.","Interestingly, [ENTITY_A] expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with [ENTITY_B] clearance ratio (Ccr) and MMP-9 protein.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein."
"The << human cytosolic sulfotransferase hSULT2A1 >> catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous [[ hydroxysteroids ]] and bile acids.","The [ENTITY_A] catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous [ENTITY_B] and bile acids.",SUBSTRATE,CPR:9,4,"The human cytosolic sulfotransferase hSULT2A1 catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous hydroxysteroids and bile acids."
Studies on the kinetics of the << hSULT2A1 >>-catalyzed sulfation of [[ dehydroepiandrosterone ]] (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme.,Studies on the kinetics of the [ENTITY_A]-catalyzed sulfation of [ENTITY_B] (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme.,SUBSTRATE,CPR:9,4,Studies on the kinetics of the hSULT2A1-catalyzed sulfation of dehydroepiandrosterone (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme.
"Computational docking analysis was conducted to model the interaction of these antagonists with the human ERα and showed that they could tightly bind to the ERα in a manner similar to that of << ICI-182,780 >>, a pure [[ ER ]] antagonist.","Computational docking analysis was conducted to model the interaction of these antagonists with the human ERα and showed that they could tightly bind to the ERα in a manner similar to that of [ENTITY_A], a pure [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"Computational docking analysis was conducted to model the interaction of these antagonists with the human ERα and showed that they could tightly bind to the ERα in a manner similar to that of ICI-182,780, a pure ER antagonist."
"These results provide an example that attachment of a bulky side chain to the C-7α position of E2 can produce ER antagonists with << ER >> affinity comparable to that of [[ ICI-182,780 ]].",These results provide an example that attachment of a bulky side chain to the C-7α position of E2 can produce ER antagonists with [ENTITY_A] affinity comparable to that of [ENTITY_B].,ANTAGONIST,CPR:6,3,"These results provide an example that attachment of a bulky side chain to the C-7α position of E2 can produce ER antagonists with ER affinity comparable to that of ICI-182,780."
"Discovery of << 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole >> (TASP0382088): a potent and selective [[ transforming growth factor-β type I receptor ]] inhibitor as a topical drug for alopecia.",Discovery of [ENTITY_A] (TASP0382088): a potent and selective [ENTITY_B] inhibitor as a topical drug for alopecia.,INHIBITOR,CPR:4,1,"Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia."
"<< 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole >> 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as [[ activin receptor-like kinase 5 ]] or ALK5) inhibitor.",[ENTITY_A] 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as [ENTITY_B] or ALK5) inhibitor.,INHIBITOR,CPR:4,1,"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitor."
"In non-pre-treated cells, only << efflux transporters >> were down-regulated by [[ 7-ketosterols ]], showing a greater influence upon ABCG5 expression.","In non-pre-treated cells, only [ENTITY_A] were down-regulated by [ENTITY_B], showing a greater influence upon ABCG5 expression.",DOWNREGULATOR,CPR:4,1,"In non-pre-treated cells, only efflux transporters were down-regulated by 7-ketosterols, showing a greater influence upon ABCG5 expression."
"Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced << NPC1L1 >> expression only in [[ 7-ketocholesterol ]]-incubated cells.","Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced [ENTITY_A] expression only in [ENTITY_B]-incubated cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells."
"In non-pre-treated cells, << HMG-CoA >> was up-regulated by both [[ 7-ketosterols ]].","In non-pre-treated cells, [ENTITY_A] was up-regulated by both [ENTITY_B].",UPREGULATOR,CPR:3,0,"In non-pre-treated cells, HMG-CoA was up-regulated by both 7-ketosterols."
"In lymphocytes, the NTPDase and << ADA >> activities were increased in all groups treated with [[ caffeic acid ]] when compared to control (P<0.05).","In lymphocytes, the NTPDase and [ENTITY_A] activities were increased in all groups treated with [ENTITY_B] when compared to control (P<0.05).",ACTIVATOR,CPR:3,0,"In lymphocytes, the NTPDase and ADA activities were increased in all groups treated with caffeic acid when compared to control (P<0.05)."
"Currently, the most important insecticides are << neonicotinoids >>, which are metabolized in vitro by [[ AOX ]] on reduction of the nitroimino group and by CYPs via oxidation reactions.","Currently, the most important insecticides are [ENTITY_A], which are metabolized in vitro by [ENTITY_B] on reduction of the nitroimino group and by CYPs via oxidation reactions.",SUBSTRATE,CPR:9,4,"Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by AOX on reduction of the nitroimino group and by CYPs via oxidation reactions."
The procedure was to reduce liver << AOX >> activity by providing [[ tungsten ]] or hydralazine in the drinking water or to use the AOX-deficient DBA/2 mouse strain.,The procedure was to reduce liver [ENTITY_A] activity by providing [ENTITY_B] or hydralazine in the drinking water or to use the AOX-deficient DBA/2 mouse strain.,INHIBITOR,CPR:4,1,The procedure was to reduce liver AOX activity by providing tungsten or hydralazine in the drinking water or to use the AOX-deficient DBA/2 mouse strain.
Liver << AOX >> activity was reduced by 45% with [[ tungsten ]] and 61% with hydralazine and 81% in AOX-deficient mice relative to controls.,Liver [ENTITY_A] activity was reduced by 45% with [ENTITY_B] and 61% with hydralazine and 81% in AOX-deficient mice relative to controls.,INHIBITOR,CPR:4,1,Liver AOX activity was reduced by 45% with tungsten and 61% with hydralazine and 81% in AOX-deficient mice relative to controls.
"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the << AOX >>-generated nitrosoguanidine metabolite was decreased by 30% with [[ tungsten ]] and 56% with hydralazine and 86% in the AOX-deficient mice.","When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the [ENTITY_A]-generated nitrosoguanidine metabolite was decreased by 30% with [ENTITY_B] and 56% with hydralazine and 86% in the AOX-deficient mice.",INHIBITOR,CPR:4,1,"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice."
"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the << AOX >>-generated [[ nitrosoguanidine ]] metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.","When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the [ENTITY_A]-generated [ENTITY_B] metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.",PRODUCT-OF,CPR:9,4,"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice."
"Thus, decreasing liver << AOX >> activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of [[ IMI ]]-treated mice.","Thus, decreasing liver [ENTITY_A] activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of [ENTITY_B]-treated mice.",SUBSTRATE,CPR:9,4,"Thus, decreasing liver AOX activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of IMI-treated mice."
"Possible << AOX >> involvement in [[ IMI ]] metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains.","Possible [ENTITY_A] involvement in [ENTITY_B] metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains.",SUBSTRATE,CPR:9,4,"Possible AOX involvement in IMI metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains."
This is the first study to establish the in vivo relevance of << AOX >> in [[ neonicotinoid ]] metabolism in mammals and one of the first for xenobiotics in general.,This is the first study to establish the in vivo relevance of [ENTITY_A] in [ENTITY_B] metabolism in mammals and one of the first for xenobiotics in general.,SUBSTRATE,CPR:9,4,This is the first study to establish the in vivo relevance of AOX in neonicotinoid metabolism in mammals and one of the first for xenobiotics in general.
Recommended management may include use of << acetylcholinesterase >> inhibitors (e.g. [[ neostigmine ]]) and wound care on a case-by-case basis.,Recommended management may include use of [ENTITY_A] inhibitors (e.g. [ENTITY_B]) and wound care on a case-by-case basis.,INHIBITOR,CPR:4,1,Recommended management may include use of acetylcholinesterase inhibitors (e.g. neostigmine) and wound care on a case-by-case basis.
"Of the compounds active in the present assay system, the most potent compound 7, << platyphyllonol-5-O-β-d-xylopyranoside >>, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and [[ CCAAT/enhancer binding protein α ]] (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist.","Of the compounds active in the present assay system, the most potent compound 7, [ENTITY_A], significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and [ENTITY_B] (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-β-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist."
"Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-β-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by << troglitazone >>, a [[ PPARγ ]] agonist.","Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-β-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by [ENTITY_A], a [ENTITY_B] agonist.",AGONIST,CPR:5,2,"Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-β-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist."
<< Benzenesulfonamides >>: a unique class of [[ chemokine receptor type 4 ]] inhibitors.,[ENTITY_A]: a unique class of [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Benzenesulfonamides: a unique class of chemokine receptor type 4 inhibitors.
"Based on our previously published work on CXCR4 antagonists, we have synthesized a series of << aryl sulfonamides >> that inhibit the [[ CXCR4 ]]/CXCL12 interaction.","Based on our previously published work on CXCR4 antagonists, we have synthesized a series of [ENTITY_A] that inhibit the [ENTITY_B]/CXCL12 interaction.",INHIBITOR,CPR:4,1,"Based on our previously published work on CXCR4 antagonists, we have synthesized a series of aryl sulfonamides that inhibit the CXCR4/CXCL12 interaction."
These data demonstrate that << benzenesulfonamides >> are a unique class of [[ CXCR4 ]] inhibitors with high potency.,These data demonstrate that [ENTITY_A] are a unique class of [ENTITY_B] inhibitors with high potency.,INHIBITOR,CPR:4,1,These data demonstrate that benzenesulfonamides are a unique class of CXCR4 inhibitors with high potency.
Measurement of Transport Activities of << 3β-Hydroxy-Δ(5)-bile Acids >> in [[ Bile Salt Export Pump ]] and Multidrug Resistance-Associated Proteins Using LC-MS/MS.,Measurement of Transport Activities of [ENTITY_A] in [ENTITY_B] and Multidrug Resistance-Associated Proteins Using LC-MS/MS.,SUBSTRATE,CPR:9,4,Measurement of Transport Activities of 3β-Hydroxy-Δ(5)-bile Acids in Bile Salt Export Pump and Multidrug Resistance-Associated Proteins Using LC-MS/MS.
"The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and << human bile salt export pump >>-expressing Sf9 cells for conjugated [[ 3β-hydroxy-Δ(5)-bile acids ]].","The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and [ENTITY_A]-expressing Sf9 cells for conjugated [ENTITY_B].",SUBSTRATE,CPR:9,4,"The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and human bile salt export pump-expressing Sf9 cells for conjugated 3β-hydroxy-Δ(5)-bile acids."
The present study demonstrated that << human multidrug resistance-associated protein 3 >> vesicles accepted conjugated [[ 3β-hydroxy-Δ(5)-bile acids ]] along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.,The present study demonstrated that [ENTITY_A] vesicles accepted conjugated [ENTITY_B] along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.,SUBSTRATE,CPR:9,4,The present study demonstrated that human multidrug resistance-associated protein 3 vesicles accepted conjugated 3β-hydroxy-Δ(5)-bile acids along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.
"Synthesis and evaluation of << 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines >> as [[ Bcl-2 ]] inhibitory anticancer agents.",Synthesis and evaluation of [ENTITY_A] as [ENTITY_B] inhibitory anticancer agents.,INHIBITOR,CPR:4,1,"Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents."
"A series of substituted << 3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines >> has been synthesised and tested in vitro as potential pro-apoptotic [[ Bcl-2 ]]-inhibitory anticancer agents.",A series of substituted [ENTITY_A] has been synthesised and tested in vitro as potential pro-apoptotic [ENTITY_B]-inhibitory anticancer agents.,INHIBITOR,CPR:4,1,"A series of substituted 3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines has been synthesised and tested in vitro as potential pro-apoptotic Bcl-2-inhibitory anticancer agents."
"Active compounds, such as the << nitrobenzyl >> analogue 6c, were found to exhibit sub-micromolar IC50 values in [[ Bcl-2 ]] expressing human cancer cell lines.","Active compounds, such as the [ENTITY_A] analogue 6c, were found to exhibit sub-micromolar IC50 values in [ENTITY_B] expressing human cancer cell lines.",INHIBITOR,CPR:4,1,"Active compounds, such as the nitrobenzyl analogue 6c, were found to exhibit sub-micromolar IC50 values in Bcl-2 expressing human cancer cell lines."
"<< Glutathione-S-transferase >>, a phase II enzyme, was inhibited by both [[ arsenic ]] and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine.","[ENTITY_A], a phase II enzyme, was inhibited by both [ENTITY_B] and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine.",INHIBITOR,CPR:4,1,"Glutathione-S-transferase, a phase II enzyme, was inhibited by both arsenic and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine."
"Upon << nicotine >> pre-exposure, brain [[ acetylcholinesterase ]] increased, while monoamine oxidase (MAO) decreased.","Upon [ENTITY_A] pre-exposure, brain [ENTITY_B] increased, while monoamine oxidase (MAO) decreased.",UPREGULATOR,CPR:3,0,"Upon nicotine pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase (MAO) decreased."
"Upon << nicotine >> pre-exposure, brain acetylcholinesterase increased, while [[ monoamine oxidase ]] (MAO) decreased.","Upon [ENTITY_A] pre-exposure, brain acetylcholinesterase increased, while [ENTITY_B] (MAO) decreased.",DOWNREGULATOR,CPR:4,1,"Upon nicotine pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase (MAO) decreased."
The toxic effects of << MAO >> significantly attenuated with [[ nicotine ]] pre-exposure.,The toxic effects of [ENTITY_A] significantly attenuated with [ENTITY_B] pre-exposure.,DOWNREGULATOR,CPR:4,1,The toxic effects of MAO significantly attenuated with nicotine pre-exposure.
"We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the << aromatase >> inhibitor, [[ fadrozole ]] (FAD).","We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the [ENTITY_A] inhibitor, [ENTITY_B] (FAD).",INHIBITOR,CPR:4,1,"We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the aromatase inhibitor, fadrozole (FAD)."
"Although naturally occurring electrophilic plant compounds, such as mustard oil and << cinnamaldehyde >>, are [[ TRPA1 ]] agonists, it is unknown whether arthropod-produced electrophiles activate mammalian TRPA1.","Although naturally occurring electrophilic plant compounds, such as mustard oil and [ENTITY_A], are [ENTITY_B] agonists, it is unknown whether arthropod-produced electrophiles activate mammalian TRPA1.",AGONIST,CPR:5,2,"Although naturally occurring electrophilic plant compounds, such as mustard oil and cinnamaldehyde, are TRPA1 agonists, it is unknown whether arthropod-produced electrophiles activate mammalian TRPA1."
We found that << pBQN >> activates [[ TRPA1 ]] starting at 10 nM and peaking at 300 nM; higher concentrations caused rapid activation followed by a fast decline.,We found that [ENTITY_A] activates [ENTITY_B] starting at 10 nM and peaking at 300 nM; higher concentrations caused rapid activation followed by a fast decline.,ACTIVATOR,CPR:3,0,We found that pBQN activates TRPA1 starting at 10 nM and peaking at 300 nM; higher concentrations caused rapid activation followed by a fast decline.
"Interestingly, following pBQN desensitization, wild-type TRPA1 had dramatically reduced response to the nonelectrophile agonist << carvacrol >>, whereas the triple cysteine mutant [[ TRPA1 ]] retained its full response.","Interestingly, following pBQN desensitization, wild-type TRPA1 had dramatically reduced response to the nonelectrophile agonist [ENTITY_A], whereas the triple cysteine mutant [ENTITY_B] retained its full response.",AGONIST-ACTIVATOR,CPR:5,2,"Interestingly, following pBQN desensitization, wild-type TRPA1 had dramatically reduced response to the nonelectrophile agonist carvacrol, whereas the triple cysteine mutant TRPA1 retained its full response."
Synthesis and in-silico studies of some << diaryltriazole >> derivatives as potential [[ cyclooxygenase ]] inhibitors.,Synthesis and in-silico studies of some [ENTITY_A] derivatives as potential [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Synthesis and in-silico studies of some diaryltriazole derivatives as potential cyclooxygenase inhibitors.
A highly potent inhibition of the << peroxidase >> catalytic reaction by [[ NO ]]/SNO was seen in assays employing the coupled Prx-Trx system.,A highly potent inhibition of the [ENTITY_A] catalytic reaction by [ENTITY_B]/SNO was seen in assays employing the coupled Prx-Trx system.,INHIBITOR,CPR:4,1,A highly potent inhibition of the peroxidase catalytic reaction by NO/SNO was seen in assays employing the coupled Prx-Trx system.
"In this setting, << S-nitrosocysteine >> (10 μm) effectively blocked the [[ Trx ]]-mediated regeneration of oxidized Prx1.","In this setting, [ENTITY_A] (10 μm) effectively blocked the [ENTITY_B]-mediated regeneration of oxidized Prx1.",INHIBITOR,CPR:4,1,"In this setting, S-nitrosocysteine (10 μm) effectively blocked the Trx-mediated regeneration of oxidized Prx1."
"CK significantly inhibited << DMN >>-induced increases in serum [[ alanine aminotransferase ]] (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.","CK significantly inhibited [ENTITY_A]-induced increases in serum [ENTITY_B] (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.",ACTIVATOR,CPR:3,0,"CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content."
"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited << DMN >>-induced increases in [[ matrix metalloproteinase-13 ]] (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein.","Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited [ENTITY_A]-induced increases in [ENTITY_B] (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein.",INDIRECT-UPREGULATOR,CPR:3,0,"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited DMN-induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein."
<< DMN >>-induced cyclooxygenase-2 (COX-2) expression and [[ nuclear factor-kappa B ]] (NF-κB) activation was reduced by CK treatment.,[ENTITY_A]-induced cyclooxygenase-2 (COX-2) expression and [ENTITY_B] (NF-κB) activation was reduced by CK treatment.,ACTIVATOR,CPR:3,0,DMN-induced cyclooxygenase-2 (COX-2) expression and nuclear factor-kappa B (NF-κB) activation was reduced by CK treatment.
Extrinsic apoptotic pathway markers such as Fas levels and << caspase-8 >> activity increased as a result of [[ CdTe ]]-QD exposure.,Extrinsic apoptotic pathway markers such as Fas levels and [ENTITY_A] activity increased as a result of [ENTITY_B]-QD exposure.,ACTIVATOR,CPR:3,0,Extrinsic apoptotic pathway markers such as Fas levels and caspase-8 activity increased as a result of CdTe-QD exposure.
"Our findings reveal that << CdTe >>-QDs cause oxidative stress, interfere with antioxidant defenses and activate protein [[ kinases ]], leading to apoptosis via both extrinsic and intrinsic pathways.","Our findings reveal that [ENTITY_A]-QDs cause oxidative stress, interfere with antioxidant defenses and activate protein [ENTITY_B], leading to apoptosis via both extrinsic and intrinsic pathways.",ACTIVATOR,CPR:3,0,"Our findings reveal that CdTe-QDs cause oxidative stress, interfere with antioxidant defenses and activate protein kinases, leading to apoptosis via both extrinsic and intrinsic pathways."
"<< Puerarin >> administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and [[ PI3K ]]/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.","[ENTITY_A] administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and [ENTITY_B]/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.",ACTIVATOR,CPR:3,0,"Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice."
"In addition to the effect on ROS, << puerarin >> ameliorated MPTP-reduced lysosome-associated membrane protein type 2A ([[ Lamp 2A ]]) expression.","In addition to the effect on ROS, [ENTITY_A] ameliorated MPTP-reduced lysosome-associated membrane protein type 2A ([ENTITY_B]) expression.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition to the effect on ROS, puerarin ameliorated MPTP-reduced lysosome-associated membrane protein type 2A (Lamp 2A) expression."
"Taken together, our data demonstrate that << puerarin >> attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of [[ Lamp 2A ]] expression.","Taken together, our data demonstrate that [ENTITY_A] attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of [ENTITY_B] expression.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression."
"Instead, radiolabeled << nucleosides >> resulting from [[ nuclease ]] hydrolysis were observed.","Instead, radiolabeled [ENTITY_A] resulting from [ENTITY_B] hydrolysis were observed.",PRODUCT-OF,CPR:9,4,"Instead, radiolabeled nucleosides resulting from nuclease hydrolysis were observed."
A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the << vesicular monoamine transporter >> and for their inhibition of vesicular [[ [(3)H]dopamine ]] uptake.,A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the [ENTITY_A] and for their inhibition of vesicular [ENTITY_B] uptake.,SUBSTRATE,CPR:9,4,A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the vesicular monoamine transporter and for their inhibition of vesicular [(3)H]dopamine uptake.
<< IPI-926 >> is both a substrate and inhibitor (IC50 = 1.9 µM) of [[ P-glycoprotein ]].,[ENTITY_A] is both a substrate and inhibitor (IC50 = 1.9 µM) of [ENTITY_B].,INHIBITOR,CPR:4,1,IPI-926 is both a substrate and inhibitor (IC50 = 1.9 µM) of P-glycoprotein.
<< IPI-926 >> is both a substrate and inhibitor (IC50 = 1.9 µM) of [[ P-glycoprotein ]].,[ENTITY_A] is both a substrate and inhibitor (IC50 = 1.9 µM) of [ENTITY_B].,SUBSTRATE,CPR:9,4,IPI-926 is both a substrate and inhibitor (IC50 = 1.9 µM) of P-glycoprotein.
"Oral << lorcaserin >> (BELVIQ(®)), a selective serotonin [[ 5-HT2C ]] receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes).","Oral [ENTITY_A] (BELVIQ(®)), a selective serotonin [ENTITY_B] receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes).",AGONIST,CPR:5,2,"Oral lorcaserin (BELVIQ(®)), a selective serotonin 5-HT2C receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes)."
"Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a << 2-Cyanopyrrolidine >> Moiety as Potent [[ Dipeptidyl Peptidase 4 ]] Inhibitors.","Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a [ENTITY_A] Moiety as Potent [ENTITY_B] Inhibitors.",INHIBITOR,CPR:4,1,"Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a 2-Cyanopyrrolidine Moiety as Potent Dipeptidyl Peptidase 4 Inhibitors."
"Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (DPP-4) inhibitors, among them, the << cyclopropyl-substituted phenylalanine >> derivative 11h displayed the most potent [[ DPP-4 ]] inhibitory activity with an IC50 value of 0.247 μM.","Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (DPP-4) inhibitors, among them, the [ENTITY_A] derivative 11h displayed the most potent [ENTITY_B] inhibitory activity with an IC50 value of 0.247 μM.",INHIBITOR,CPR:4,1,"Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (DPP-4) inhibitors, among them, the cyclopropyl-substituted phenylalanine derivative 11h displayed the most potent DPP-4 inhibitory activity with an IC50 value of 0.247 μM."
"<< TCPOBOP >>, a CAR ligand, modestly induced [[ mdr1a ]].fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation.","[ENTITY_A], a CAR ligand, modestly induced [ENTITY_B].fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation.",INDIRECT-UPREGULATOR,CPR:3,0,"TCPOBOP, a CAR ligand, modestly induced mdr1a.fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation."
"<< Galangin >> decreased expression of pro-inflammatory [[ cytokines ]], such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and IL-8.","[ENTITY_A] decreased expression of pro-inflammatory [ENTITY_B], such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and IL-8.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Galangin decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and IL-8."
"The inhibitory effect of << galangin >> on theses pro-inflammatory [[ cytokines ]] was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.","The inhibitory effect of [ENTITY_A] on theses pro-inflammatory [ENTITY_B] was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1."
"Furthermore, << galangin >> attenuated [[ IgE ]]-mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue.","Furthermore, [ENTITY_A] attenuated [ENTITY_B]-mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue.",DOWNREGULATOR,CPR:4,1,"Furthermore, galangin attenuated IgE-mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue."
Our results showed that << galangin >> down-regulates mast cell-derived allergic inflammatory reactions by blocking histamine release and expression of pro-inflammatory [[ cytokines ]].,Our results showed that [ENTITY_A] down-regulates mast cell-derived allergic inflammatory reactions by blocking histamine release and expression of pro-inflammatory [ENTITY_B].,INDIRECT-DOWNREGULATOR,CPR:4,1,Our results showed that galangin down-regulates mast cell-derived allergic inflammatory reactions by blocking histamine release and expression of pro-inflammatory cytokines.
<< Nobiletin >> attenuates metastasis via both [[ ERK ]] and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells.,[ENTITY_A] attenuates metastasis via both [ENTITY_B] and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells.,INHIBITOR,CPR:4,1,Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells.
"Among them, << nobiletin >> markedly inhibited [[ HGF ]]-induced the abilities of the adhesion, invasion, and migration by cell-matrix adhesion assay and transwell-chamber invasion/migration assay under non-cytotoxic concentrations.","Among them, [ENTITY_A] markedly inhibited [ENTITY_B]-induced the abilities of the adhesion, invasion, and migration by cell-matrix adhesion assay and transwell-chamber invasion/migration assay under non-cytotoxic concentrations.",INHIBITOR,CPR:4,1,"Among them, nobiletin markedly inhibited HGF-induced the abilities of the adhesion, invasion, and migration by cell-matrix adhesion assay and transwell-chamber invasion/migration assay under non-cytotoxic concentrations."
Data also showed << nobiletin >> inhibited [[ HGF ]]-induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia.,Data also showed [ENTITY_A] inhibited [ENTITY_B]-induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia.,INHIBITOR,CPR:4,1,Data also showed nobiletin inhibited HGF-induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia.
"Furthermore, << nobiletin >> could inhibit [[ HGF ]]-induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1/2 and p38.","Furthermore, [ENTITY_A] could inhibit [ENTITY_B]-induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1/2 and p38.",INHIBITOR,CPR:4,1,"Furthermore, nobiletin could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1/2 and p38."
"Next, << nobiletin >> significantly decreased the levels of [[ phospho-ERK2 ]] and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.","Next, [ENTITY_A] significantly decreased the levels of [ENTITY_B] and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Next, nobiletin significantly decreased the levels of phospho-ERK2 and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration."
"In conclusion, << nobiletin >> attenuates [[ HGF ]]-induced HepG2 cells metastasis involving both ERK and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.","In conclusion, [ENTITY_A] attenuates [ENTITY_B]-induced HepG2 cells metastasis involving both ERK and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.",INHIBITOR,CPR:4,1,"In conclusion, nobiletin attenuates HGF-induced HepG2 cells metastasis involving both ERK and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma."
<< Cholesterol >> also increases [[ Amyloid β ]] (Aβ) deposition and tau pathology.,[ENTITY_A] also increases [ENTITY_B] (Aβ) deposition and tau pathology.,DOWNREGULATOR,CPR:4,1,Cholesterol also increases Amyloid β (Aβ) deposition and tau pathology.
Excess of << cholesterol >> converted into 24OHC may up-regulate [[ ApoE ]] synthesis which is a scavenger for Aβ and Tau.,Excess of [ENTITY_A] converted into 24OHC may up-regulate [ENTITY_B] synthesis which is a scavenger for Aβ and Tau.,INDIRECT-UPREGULATOR,CPR:3,0,Excess of cholesterol converted into 24OHC may up-regulate ApoE synthesis which is a scavenger for Aβ and Tau.
"In the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular << glutamate >> is reduced when [[ CaMKII ]] is inhibited.","In the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular [ENTITY_A] is reduced when [ENTITY_B] is inhibited.",SUBSTRATE,CPR:9,4,"In the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular glutamate is reduced when CaMKII is inhibited."
<< 3-Hydroxypyridin-2-thione >> as Novel Zinc Binding Group for Selective [[ Histone Deacetylase ]] Inhibition.,[ENTITY_A] as Novel Zinc Binding Group for Selective [ENTITY_B] Inhibition.,INHIBITOR,CPR:4,1,3-Hydroxypyridin-2-thione as Novel Zinc Binding Group for Selective Histone Deacetylase Inhibition.
Small molecules bearing hydroxamic acid as the << zinc >> binding group (ZBG) have been the most effective [[ histone deacetylase ]] inhibitors (HDACi) to date.,Small molecules bearing hydroxamic acid as the [ENTITY_A] binding group (ZBG) have been the most effective [ENTITY_B] inhibitors (HDACi) to date.,INHIBITOR,CPR:4,1,Small molecules bearing hydroxamic acid as the zinc binding group (ZBG) have been the most effective histone deacetylase inhibitors (HDACi) to date.
We have identified << 3-hydroxypyridin-2-thione >> (3-HPT) as a novel ZBG that is compatible with [[ HDAC ]] inhibition.,We have identified [ENTITY_A] (3-HPT) as a novel ZBG that is compatible with [ENTITY_B] inhibition.,INHIBITOR,CPR:4,1,We have identified 3-hydroxypyridin-2-thione (3-HPT) as a novel ZBG that is compatible with HDAC inhibition.
"<< 3-HPT >> inhibits [[ HDAC 6 ]] and HDAC 8 with an IC50 of 681 and 3675 nM, respectively.","[ENTITY_A] inhibits [ENTITY_B] and HDAC 8 with an IC50 of 681 and 3675 nM, respectively.",INHIBITOR,CPR:4,1,"3-HPT inhibits HDAC 6 and HDAC 8 with an IC50 of 681 and 3675 nM, respectively."
Subsequent optimization led to several novel << 3HPT >>-based [[ HDAC ]]i that are selective for HDAC 6 and HDAC 8.,Subsequent optimization led to several novel [ENTITY_A]-based [ENTITY_B]i that are selective for HDAC 6 and HDAC 8.,INHIBITOR,CPR:4,1,Subsequent optimization led to several novel 3HPT-based HDACi that are selective for HDAC 6 and HDAC 8.
Maqui berry (Aristotelia chilensis) and the constituent << delphinidin glycoside >> inhibit [[ photoreceptor ]] cell death induced by visible light.,Maqui berry (Aristotelia chilensis) and the constituent [ENTITY_A] inhibit [ENTITY_B] cell death induced by visible light.,ACTIVATOR,CPR:3,0,Maqui berry (Aristotelia chilensis) and the constituent delphinidin glycoside inhibit photoreceptor cell death induced by visible light.
"These findings indicate that MBE and its << anthocyanidins >> suppress the light-induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of [[ phosphorylated-p38 ]] may be involved in the underlying mechanism.","These findings indicate that MBE and its [ENTITY_A] suppress the light-induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of [ENTITY_B] may be involved in the underlying mechanism.",INHIBITOR,CPR:4,1,"These findings indicate that MBE and its anthocyanidins suppress the light-induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of phosphorylated-p38 may be involved in the underlying mechanism."
"Moreover, << curcumin >> could also down-regulate the expression and activity of [[ matrix metalloproteinase-9 ]] (MMP-9).","Moreover, [ENTITY_A] could also down-regulate the expression and activity of [ENTITY_B] (MMP-9).",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, curcumin could also down-regulate the expression and activity of matrix metalloproteinase-9 (MMP-9)."
"Treatment with << EVn-50 >> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of [[ Histone 3 ]] at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.","Treatment with [ENTITY_A] or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of [ENTITY_B] at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.",ACTIVATOR,CPR:3,0,"Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c."
"Treatment with << EVn-50 >> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of [[ Cdc25c ]].","Treatment with [ENTITY_A] or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c."
<< Xanthohumol >> and 2-hydroxychalcone induced apoptosis by [[ Bcl-2 ]] downregulation.,[ENTITY_A] and 2-hydroxychalcone induced apoptosis by [ENTITY_B] downregulation.,INDIRECT-DOWNREGULATOR,CPR:4,1,Xanthohumol and 2-hydroxychalcone induced apoptosis by Bcl-2 downregulation.
"Importantly, << 2-hydroxychalcone >> and xanthohumol exerted more potent inhibitory effects on the proliferation, [[ MMP-9 ]] expression and invasive phenotype of MDA-MB-231 than chalcone.","Importantly, [ENTITY_A] and xanthohumol exerted more potent inhibitory effects on the proliferation, [ENTITY_B] expression and invasive phenotype of MDA-MB-231 than chalcone.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Importantly, 2-hydroxychalcone and xanthohumol exerted more potent inhibitory effects on the proliferation, MMP-9 expression and invasive phenotype of MDA-MB-231 than chalcone."
"<< 4-Hydroxypyridazin-3(2H)-one >> Derivatives as Novel [[ d-Amino Acid Oxidase ]] Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor.","[ENTITY_A] Derivatives as Novel [ENTITY_B] Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor.",INHIBITOR,CPR:4,1,"4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor."
"4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including << d-serine >>, a coagonist of the [[ N-methyl-d-aspartate receptor ]].","4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including [ENTITY_A], a coagonist of the [ENTITY_B].",AGONIST,CPR:5,2,"4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor."
"4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. << d-Amino acid oxidase >> (DAAO) catalyzes the oxidation of d-amino acids including [[ d-serine ]], a coagonist of the N-methyl-d-aspartate receptor.","4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. [ENTITY_A] (DAAO) catalyzes the oxidation of d-amino acids including [ENTITY_B], a coagonist of the N-methyl-d-aspartate receptor.",SUBSTRATE,CPR:9,4,"4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor."
We identified a series of << 4-hydroxypyridazin-3(2H)-one >> derivatives as novel [[ DAAO ]] inhibitors with high potency and substantial cell permeability using fragment-based drug design.,We identified a series of [ENTITY_A] derivatives as novel [ENTITY_B] inhibitors with high potency and substantial cell permeability using fragment-based drug design.,INHIBITOR,CPR:4,1,We identified a series of 4-hydroxypyridazin-3(2H)-one derivatives as novel DAAO inhibitors with high potency and substantial cell permeability using fragment-based drug design.
<< 3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one >> exhibited the predicted binding mode and demonstrated high inhibitory activity for [[ human DAAO ]] in enzyme- and cell-based assays.,[ENTITY_A] exhibited the predicted binding mode and demonstrated high inhibitory activity for [ENTITY_B] in enzyme- and cell-based assays.,INHIBITOR,CPR:4,1,3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one exhibited the predicted binding mode and demonstrated high inhibitory activity for human DAAO in enzyme- and cell-based assays.
"Fourteen of 17 << parabens >> exhibited [[ hERα ]] and/or hERβ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity.","Fourteen of 17 [ENTITY_A] exhibited [ENTITY_B] and/or hERβ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity.",AGONIST,CPR:5,2,"Fourteen of 17 parabens exhibited hERα and/or hERβ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity."
"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, << heptylparaben >> (C7) and pentylparaben (C5) showed the most potent [[ ERα ]] and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.","Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, [ENTITY_A] (C7) and pentylparaben (C5) showed the most potent [ENTITY_B] and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",AGONIST,CPR:5,2,"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ERα and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12."
Most << parabens >> showing estrogenic activity exhibited [[ ERβ ]]-agonistic activity at lower concentrations than those inducing ERα-agonistic activity.,Most [ENTITY_A] showing estrogenic activity exhibited [ENTITY_B]-agonistic activity at lower concentrations than those inducing ERα-agonistic activity.,AGONIST,CPR:5,2,Most parabens showing estrogenic activity exhibited ERβ-agonistic activity at lower concentrations than those inducing ERα-agonistic activity.
"These results indicate that << parabens >> are selective agonists for [[ ERβ ]] over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.","These results indicate that [ENTITY_A] are selective agonists for [ENTITY_B] over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.",AGONIST,CPR:5,2,"These results indicate that parabens are selective agonists for ERβ over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity."
"These results indicate that << parabens >> are selective agonists for ERβ over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by [[ carboxylesterases ]], leading to attenuation of their estrogenic activity.","These results indicate that [ENTITY_A] are selective agonists for ERβ over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by [ENTITY_B], leading to attenuation of their estrogenic activity.",SUBSTRATE,CPR:9,4,"These results indicate that parabens are selective agonists for ERβ over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity."
Wattakaka volubilis << steroidal glycoside >> mixture (WVSM) and PPG (1-50μM) significantly inhibited the [[ COX-2 ]] and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.,Wattakaka volubilis [ENTITY_A] mixture (WVSM) and PPG (1-50μM) significantly inhibited the [ENTITY_B] and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.,INHIBITOR,CPR:4,1,Wattakaka volubilis steroidal glycoside mixture (WVSM) and PPG (1-50μM) significantly inhibited the COX-2 and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.
<< Quercetin >> suppressed [[ CYP2E1 ]]-dependent ethanol hepatotoxicity via depleting heme pool and releasing CO.,[ENTITY_A] suppressed [ENTITY_B]-dependent ethanol hepatotoxicity via depleting heme pool and releasing CO.,DOWNREGULATOR,CPR:4,1,Quercetin suppressed CYP2E1-dependent ethanol hepatotoxicity via depleting heme pool and releasing CO.
"However, the precise mechanism by which << quercetin >> counteracts [[ CYP2E1 ]]-mediated ethanol hepatotoxicity through HO-1 system is still remained unclear.","However, the precise mechanism by which [ENTITY_A] counteracts [ENTITY_B]-mediated ethanol hepatotoxicity through HO-1 system is still remained unclear.",DOWNREGULATOR,CPR:4,1,"However, the precise mechanism by which quercetin counteracts CYP2E1-mediated ethanol hepatotoxicity through HO-1 system is still remained unclear."
"Our data showed that chronic << ethanol >> over-activated [[ CYP2E1 ]] but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.).","Our data showed that chronic [ENTITY_A] over-activated [ENTITY_B] but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.).",ACTIVATOR,CPR:3,0,"Our data showed that chronic ethanol over-activated CYP2E1 but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.)."
"Our data showed that chronic << ethanol >> over-activated CYP2E1 but suppressed [[ HO-1 ]] with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.).","Our data showed that chronic [ENTITY_A] over-activated CYP2E1 but suppressed [ENTITY_B] with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.).",DOWNREGULATOR,CPR:4,1,"Our data showed that chronic ethanol over-activated CYP2E1 but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.)."
<< Quercetin >> (100μM) induced [[ HO-1 ]] and depleted heme pool when incubated to human hepatocytes.,[ENTITY_A] (100μM) induced [ENTITY_B] and depleted heme pool when incubated to human hepatocytes.,UPREGULATOR,CPR:3,0,Quercetin (100μM) induced HO-1 and depleted heme pool when incubated to human hepatocytes.
<< Ethanol >>-stimulated (100mM) [[ CYP2E1 ]] upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation.,[ENTITY_A]-stimulated (100mM) [ENTITY_B] upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation.,UPREGULATOR,CPR:3,0,Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation.
Ethanol-stimulated (100mM) << CYP2E1 >> upregulation was suppressed by [[ quercetin ]] but further enhanced by HO-1 inhibition with resultant heme accumulation.,Ethanol-stimulated (100mM) [ENTITY_A] upregulation was suppressed by [ENTITY_B] but further enhanced by HO-1 inhibition with resultant heme accumulation.,DOWNREGULATOR,CPR:4,1,Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation.
Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by << HO-1 >> inhibition with resultant [[ heme ]] accumulation.,Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by [ENTITY_A] inhibition with resultant [ENTITY_B] accumulation.,SUBSTRATE,CPR:9,4,Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation.
<< CO >> scavenging blocked the suppression of quercetin only on [[ CYP2E1 ]] activity.,[ENTITY_A] scavenging blocked the suppression of quercetin only on [ENTITY_B] activity.,DOWNREGULATOR,CPR:4,1,CO scavenging blocked the suppression of quercetin only on CYP2E1 activity.
"CO donor dose-dependently inactivated << CYP2E1 >> of [[ ethanol ]]-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger.","CO donor dose-dependently inactivated [ENTITY_A] of [ENTITY_B]-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger.",UPREGULATOR,CPR:3,0,"CO donor dose-dependently inactivated CYP2E1 of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger."
"<< CO >> donor dose-dependently inactivated [[ CYP2E1 ]] of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger.","[ENTITY_A] donor dose-dependently inactivated [ENTITY_B] of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger.",DOWNREGULATOR,CPR:4,1,"CO donor dose-dependently inactivated CYP2E1 of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger."
"Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by << quercetin >> through [[ HO-1 ]] induction.","Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by [ENTITY_A] through [ENTITY_B] induction.",UPREGULATOR,CPR:3,0,"Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by quercetin through HO-1 induction."
"Depleted heme pool and << CO >> releasing limited protein synthesis and inhibited enzymatic activity of [[ CYP2E1 ]], respectively.","Depleted heme pool and [ENTITY_A] releasing limited protein synthesis and inhibited enzymatic activity of [ENTITY_B], respectively.",INHIBITOR,CPR:4,1,"Depleted heme pool and CO releasing limited protein synthesis and inhibited enzymatic activity of CYP2E1, respectively."
Novel racemic << tetrahydrocurcuminoid dihydropyrimidinone >> analogues as potent [[ acetylcholinesterase ]] inhibitors.,Novel racemic [ENTITY_A] analogues as potent [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Novel racemic tetrahydrocurcuminoid dihydropyrimidinone analogues as potent acetylcholinesterase inhibitors.
Agonistic activity of << ICI 182 780 >> on activation of GSK 3β/[[ AKT ]] pathway in the rat uterus during the estrous cycle.,Agonistic activity of [ENTITY_A] on activation of GSK 3β/[ENTITY_B] pathway in the rat uterus during the estrous cycle.,ACTIVATOR,CPR:3,0,Agonistic activity of ICI 182 780 on activation of GSK 3β/AKT pathway in the rat uterus during the estrous cycle.
Agonistic activity of << ICI 182 780 >> on activation of [[ GSK 3β ]]/AKT pathway in the rat uterus during the estrous cycle.,Agonistic activity of [ENTITY_A] on activation of [ENTITY_B]/AKT pathway in the rat uterus during the estrous cycle.,AGONIST,CPR:5,2,Agonistic activity of ICI 182 780 on activation of GSK 3β/AKT pathway in the rat uterus during the estrous cycle.
"Both << ICI >> treatments, induced a significant decrease (p<0.01) in uterine [[ estrogen receptor alpha ]] (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.","Both [ENTITY_A] treatments, induced a significant decrease (p<0.01) in uterine [ENTITY_B] (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Both ICI treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals."
"Furthermore, we detected that << ICI >> treatment induced [[ glycogen synthase kinase ]] (Gsk3-β) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization.","Furthermore, we detected that [ENTITY_A] treatment induced [ENTITY_B] (Gsk3-β) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization.",ACTIVATOR,CPR:3,0,"Furthermore, we detected that ICI treatment induced glycogen synthase kinase (Gsk3-β) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization."
"We observed that the administration of << ICI >> at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of [[ Akt ]] phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters.","We observed that the administration of [ENTITY_A] at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of [ENTITY_B] phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters.",INHIBITOR,CPR:4,1,"We observed that the administration of ICI at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of Akt phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters."
"The overall results indicate that << ICI >> may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the [[ Akt ]] pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model.","The overall results indicate that [ENTITY_A] may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the [ENTITY_B] pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model.",ACTIVATOR,CPR:3,0,"The overall results indicate that ICI may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the Akt pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model."
<< Aminopropylindenes >> derived from Grundmann's ketone as a novel chemotype of [[ oxidosqualene cyclase ]] inhibitors.,[ENTITY_A] derived from Grundmann's ketone as a novel chemotype of [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Aminopropylindenes derived from Grundmann's ketone as a novel chemotype of oxidosqualene cyclase inhibitors.
"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (<< OSC >>)-mediated cyclization of 2,3-oxidosqualen to [[ lanosterol ]] was prepared from Grundmann's ketone.","A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) ([ENTITY_A])-mediated cyclization of 2,3-oxidosqualen to [ENTITY_B] was prepared from Grundmann's ketone.",PRODUCT-OF,CPR:9,4,"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone."
"A << N,N-dimethylaminopropyl >> derivative showed promising inhibition of [[ Trypanosoma cruzi OSC ]] in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line.","A [ENTITY_A] derivative showed promising inhibition of [ENTITY_B] in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line.",INHIBITOR,CPR:4,1,"A N,N-dimethylaminopropyl derivative showed promising inhibition of Trypanosoma cruzi OSC in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line."
"A N,N-dimethylaminopropyl derivative showed promising inhibition of << Trypanosoma cruzi OSC >> in combination with low cytotoxicity, and showed significant reduction of [[ cholesterol ]] biosynthesis in a human cell line.","A N,N-dimethylaminopropyl derivative showed promising inhibition of [ENTITY_A] in combination with low cytotoxicity, and showed significant reduction of [ENTITY_B] biosynthesis in a human cell line.",PRODUCT-OF,CPR:9,4,"A N,N-dimethylaminopropyl derivative showed promising inhibition of Trypanosoma cruzi OSC in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line."
The << ATP >> required for potentiation of skeletal muscle contraction is released via [[ pannexin ]] hemichannels.,The [ENTITY_A] required for potentiation of skeletal muscle contraction is released via [ENTITY_B] hemichannels.,SUBSTRATE,CPR:9,4,The ATP required for potentiation of skeletal muscle contraction is released via pannexin hemichannels.
"During repetitive stimulation of skeletal muscle, extracellular << ATP >> levels raise, activating [[ purinergic receptors ]], increasing Ca(2+) influx, and enhancing contractile force, a response called potentiation.","During repetitive stimulation of skeletal muscle, extracellular [ENTITY_A] levels raise, activating [ENTITY_B], increasing Ca(2+) influx, and enhancing contractile force, a response called potentiation.",ACTIVATOR,CPR:3,0,"During repetitive stimulation of skeletal muscle, extracellular ATP levels raise, activating purinergic receptors, increasing Ca(2+) influx, and enhancing contractile force, a response called potentiation."
"Consistent with two << glucose >> uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or [[ glucose transporter ]] (GLUT4), and blocked by dual blockade.","Consistent with two [ENTITY_A] uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or [ENTITY_B] (GLUT4), and blocked by dual blockade.",SUBSTRATE,CPR:9,4,"Consistent with two glucose uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (GLUT4), and blocked by dual blockade."
"MRS2179, a P2Y1R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles << ATP >> activates [[ P2Y1 ]] but not P2X receptors.","MRS2179, a P2Y1R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles [ENTITY_A] activates [ENTITY_B] but not P2X receptors.",ACTIVATOR,CPR:3,0,"MRS2179, a P2Y1R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles ATP activates P2Y1 but not P2X receptors."
"Opening of << Panx1 >> HCs during repetitive activation allows efflux of [[ ATP ]], influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction.","Opening of [ENTITY_A] HCs during repetitive activation allows efflux of [ENTITY_B], influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction.",SUBSTRATE,CPR:9,4,"Opening of Panx1 HCs during repetitive activation allows efflux of ATP, influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction."
The rate limiting enzyme of beta-oxidation (<< ACOX1 >>) was significantly over-expressed in the liver with [[ tBHQ ]] treatment.,The rate limiting enzyme of beta-oxidation ([ENTITY_A]) was significantly over-expressed in the liver with [ENTITY_B] treatment.,INDIRECT-UPREGULATOR,CPR:3,0,The rate limiting enzyme of beta-oxidation (ACOX1) was significantly over-expressed in the liver with tBHQ treatment.
"These results indicate that << tBHQ >> suppresses body weight gain in mice, possibly at least related to the up-regulation of [[ ACOX1 ]] gene expression.","These results indicate that [ENTITY_A] suppresses body weight gain in mice, possibly at least related to the up-regulation of [ENTITY_B] gene expression.",INDIRECT-UPREGULATOR,CPR:3,0,"These results indicate that tBHQ suppresses body weight gain in mice, possibly at least related to the up-regulation of ACOX1 gene expression."
"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the << VEGF >> release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core [[ PLGA ]] and more than 45% with HMW core PLGA.","When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the [ENTITY_A] release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core [ENTITY_B] and more than 45% with HMW core PLGA.",INDIRECT-UPREGULATOR,CPR:3,0,"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA."
"Potency switch between CHK1 and << MK2 >>: Discovery of [[ imidazo[1,2-a]pyrazine ]]- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.","Potency switch between CHK1 and [ENTITY_A]: Discovery of [ENTITY_B]- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.",INHIBITOR,CPR:4,1,"Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors."
Discovery of << aryl ureas >> and aryl amides as potent and selective [[ histamine H3 receptor ]] antagonists for the treatment of obesity (Part I).,Discovery of [ENTITY_A] and aryl amides as potent and selective [ENTITY_B] antagonists for the treatment of obesity (Part I).,ANTAGONIST,CPR:6,3,Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (Part I).
A series of structurally novel << aryl ureas >> was derived from optimization of the HTS lead as selective [[ histamine H3 receptor ]] (H3R) antagonists.,A series of structurally novel [ENTITY_A] was derived from optimization of the HTS lead as selective [ENTITY_B] (H3R) antagonists.,ANTAGONIST,CPR:6,3,A series of structurally novel aryl ureas was derived from optimization of the HTS lead as selective histamine H3 receptor (H3R) antagonists.
"In terms of the mechanisms, we found that fatty acid amide hydrolase (<< FAAH >>) which degrades [[ anandamide ]], was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.","In terms of the mechanisms, we found that fatty acid amide hydrolase ([ENTITY_A]) which degrades [ENTITY_B], was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.",SUBSTRATE,CPR:9,4,"In terms of the mechanisms, we found that fatty acid amide hydrolase (FAAH) which degrades anandamide, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences."
"However, enzymes contributing to oxidative metabolism of << anandamide >>, namely [[ cyclooxygenase-1 ]] and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.","However, enzymes contributing to oxidative metabolism of [ENTITY_A], namely [ENTITY_B] and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.",SUBSTRATE,CPR:9,4,"However, enzymes contributing to oxidative metabolism of anandamide, namely cyclooxygenase-1 and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide."
<< 24(S)-hydroxycholesterol >> is actively eliminated from neuronal cells by [[ ABCA1 ]].,[ENTITY_A] is actively eliminated from neuronal cells by [ENTITY_B].,SUBSTRATE,CPR:9,4,24(S)-hydroxycholesterol is actively eliminated from neuronal cells by ABCA1.
"High << cholesterol >> turnover catalyzed by [[ cholesterol 24-hydroxylase ]] is essential for neural functions, especially learning.","High [ENTITY_A] turnover catalyzed by [ENTITY_B] is essential for neural functions, especially learning.",SUBSTRATE,CPR:9,4,"High cholesterol turnover catalyzed by cholesterol 24-hydroxylase is essential for neural functions, especially learning."
"Because << 24(S)-hydroxycholesterol >> (24-OHC), produced by [[ 24-hydroxylase ]], induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells.","Because [ENTITY_A] (24-OHC), produced by [ENTITY_B], induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells.",PRODUCT-OF,CPR:9,4,"Because 24(S)-hydroxycholesterol (24-OHC), produced by 24-hydroxylase, induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells."
"The expression of << ABCA1 >> and ABCG1 was induced by 24-OHC, as well as TO901317 and [[ retinoic acid ]], which are ligands of the nuclear receptors LXR/RXR.","The expression of [ENTITY_A] and ABCG1 was induced by 24-OHC, as well as TO901317 and [ENTITY_B], which are ligands of the nuclear receptors LXR/RXR.",INDIRECT-UPREGULATOR,CPR:3,0,"The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR."
"To confirm the role of each transporter, we analyzed HEK293 cells stably expressing << human ABCA1 >> or ABCG1; we clearly observed [[ 24-OHC ]] efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal.","To confirm the role of each transporter, we analyzed HEK293 cells stably expressing [ENTITY_A] or ABCG1; we clearly observed [ENTITY_B] efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal.",SUBSTRATE,CPR:9,4,"To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or ABCG1; we clearly observed 24-OHC efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal."
These results suggest that << ABCA1 >> actively eliminates [[ 24-OHC ]] in the presence of HDL as a lipid acceptor and protects neuronal cells.,These results suggest that [ENTITY_A] actively eliminates [ENTITY_B] in the presence of HDL as a lipid acceptor and protects neuronal cells.,SUBSTRATE,CPR:9,4,These results suggest that ABCA1 actively eliminates 24-OHC in the presence of HDL as a lipid acceptor and protects neuronal cells.
The selective << CaMKIIα >> inhibitor [[ KN-62 ]] reversed the blockade produced by ionomycin and K(+)-depolarization.,The selective [ENTITY_A] inhibitor [ENTITY_B] reversed the blockade produced by ionomycin and K(+)-depolarization.,INHIBITOR,CPR:4,1,The selective CaMKIIα inhibitor KN-62 reversed the blockade produced by ionomycin and K(+)-depolarization.
"In K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when << CaMKIIα >> was blocked with [[ KN-62 ]].","In K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when [ENTITY_A] was blocked with [ENTITY_B].",INHIBITOR,CPR:4,1,"In K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when CaMKIIα was blocked with KN-62."
"In the presence of this inhibitor, the selective << D3 >> agonist [[ PD 128,907 ]] reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4 nM.","In the presence of this inhibitor, the selective [ENTITY_A] agonist [ENTITY_B] reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4 nM.",AGONIST,CPR:5,2,"In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4 nM."
The << Bcl2 >>/Bax ratio increased and Mfn2 expression decreased in MIN6 cells after [[ glucose ]] stimulation.,The [ENTITY_A]/Bax ratio increased and Mfn2 expression decreased in MIN6 cells after [ENTITY_B] stimulation.,INDIRECT-UPREGULATOR,CPR:3,0,The Bcl2/Bax ratio increased and Mfn2 expression decreased in MIN6 cells after glucose stimulation.
The Bcl2/Bax ratio increased and << Mfn2 >> expression decreased in MIN6 cells after [[ glucose ]] stimulation.,The Bcl2/Bax ratio increased and [ENTITY_A] expression decreased in MIN6 cells after [ENTITY_B] stimulation.,INDIRECT-DOWNREGULATOR,CPR:4,1,The Bcl2/Bax ratio increased and Mfn2 expression decreased in MIN6 cells after glucose stimulation.
"Additionally, treatment with << glucose >>/iron showed a higher [[ HO ]] activity.","Additionally, treatment with [ENTITY_A]/iron showed a higher [ENTITY_B] activity.",ACTIVATOR,CPR:3,0,"Additionally, treatment with glucose/iron showed a higher HO activity."
"Our study revealed that high << glucose >>/Fe concentrations in MIN6 cells induced an increase of the [[ Bcl2 ]]/Bax ratio, an indicator of increased cell apoptosis.","Our study revealed that high [ENTITY_A]/Fe concentrations in MIN6 cells induced an increase of the [ENTITY_B]/Bax ratio, an indicator of increased cell apoptosis.",INDIRECT-UPREGULATOR,CPR:3,0,"Our study revealed that high glucose/Fe concentrations in MIN6 cells induced an increase of the Bcl2/Bax ratio, an indicator of increased cell apoptosis."
"This includes << nonribosomal peptide synthetases >> (NRPS) and polyketide synthases (PKS) required for the formation of the [[ benzopyranopyrrole ]] core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.","This includes [ENTITY_A] (NRPS) and polyketide synthases (PKS) required for the formation of the [ENTITY_B] core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.",PRODUCT-OF,CPR:9,4,"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure."
"Targeted disruption of the gene encoding the << N-glycosyltransferase >>, prlH, abolished [[ pyralomicin ]] production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.","Targeted disruption of the gene encoding the [ENTITY_A], prlH, abolished [ENTITY_B] production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.",PRODUCT-OF,CPR:9,4,"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety."
"To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the << ERα >>-selective agonist [[ PPT ]] or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates.","To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the [ENTITY_A]-selective agonist [ENTITY_B] or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates.",AGONIST,CPR:5,2,"To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates."
The << Intermediate-conductance Calcium-activated Potassium Channel KCa3.1 >> Regulates Vascular Smooth Muscle Cell Proliferation via Controlling [[ Calcium ]]-dependent Signaling.,The [ENTITY_A] Regulates Vascular Smooth Muscle Cell Proliferation via Controlling [ENTITY_B]-dependent Signaling.,SUBSTRATE,CPR:9,4,The Intermediate-conductance Calcium-activated Potassium Channel KCa3.1 Regulates Vascular Smooth Muscle Cell Proliferation via Controlling Calcium-dependent Signaling.
"Reactive Metabolite Trapping Studies on << Imidazo- and 2-Methylimidazo[2,1-b]thiazole >>-based Inverse Agonists of the [[ Ghrelin Receptor ]].",Reactive Metabolite Trapping Studies on [ENTITY_A]-based Inverse Agonists of the [ENTITY_B].,AGONIST-INHIBITOR,CPR:5,2,"Reactive Metabolite Trapping Studies on Imidazo- and 2-Methylimidazo[2,1-b]thiazole-based Inverse Agonists of the Ghrelin Receptor."
"The current study examined the bioactivation potential of << ghrelin receptor >> inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and [[ 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone ]] (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure.","The current study examined the bioactivation potential of [ENTITY_A] inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and [ENTITY_B] (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure.",AGONIST-INHIBITOR,CPR:5,2,"The current study examined the bioactivation potential of ghrelin receptor inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure."
Processing of polysialylated NCAM was reproduced in a mouse model by << bleomycin >> administration leading to an activation of the inflammasome and secretion of [[ interleukin (IL)-1β ]].,Processing of polysialylated NCAM was reproduced in a mouse model by [ENTITY_A] administration leading to an activation of the inflammasome and secretion of [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,Processing of polysialylated NCAM was reproduced in a mouse model by bleomycin administration leading to an activation of the inflammasome and secretion of interleukin (IL)-1β.
<< 4-Hydroxytamoxifen >>-stimulated processing of [[ cyclin E ]] is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.,[ENTITY_A]-stimulated processing of [ENTITY_B] is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.,INDIRECT-UPREGULATOR,CPR:3,0,4-Hydroxytamoxifen-stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.
<< 17β-Estradiol >> (E2) has been recently shown to induce [[ cyclin E ]] processing in breast cancer cells.,[ENTITY_A] (E2) has been recently shown to induce [ENTITY_B] processing in breast cancer cells.,INDIRECT-UPREGULATOR,CPR:3,0,17β-Estradiol (E2) has been recently shown to induce cyclin E processing in breast cancer cells.
"Collectively, our data indicate that << OHT >> contributes to the production of proteolyzed [[ cyclin E ]] via GPR30 with augmented migration in MCF-7 cells.","Collectively, our data indicate that [ENTITY_A] contributes to the production of proteolyzed [ENTITY_B] via GPR30 with augmented migration in MCF-7 cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Collectively, our data indicate that OHT contributes to the production of proteolyzed cyclin E via GPR30 with augmented migration in MCF-7 cells."
We have recently reported that a mono-hydroxylated metabolite of the synthetic << aminoalkylindole >> cannabinoid JHW-073 (3) exhibits neutral antagonist activity at [[ CB1Rs ]] and thus may serve as a promising lead for the development of novel alcohol abuse therapies.,We have recently reported that a mono-hydroxylated metabolite of the synthetic [ENTITY_A] cannabinoid JHW-073 (3) exhibits neutral antagonist activity at [ENTITY_B] and thus may serve as a promising lead for the development of novel alcohol abuse therapies.,ANTAGONIST,CPR:6,3,We have recently reported that a mono-hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid JHW-073 (3) exhibits neutral antagonist activity at CB1Rs and thus may serve as a promising lead for the development of novel alcohol abuse therapies.
"In the current study, we show that systematic modification of an << aminoalkylindole >> scaffold identifies two new compounds with dual CB1R antagonist/[[ CB2R ]] agonist activity.","In the current study, we show that systematic modification of an [ENTITY_A] scaffold identifies two new compounds with dual CB1R antagonist/[ENTITY_B] agonist activity.",AGONIST,CPR:5,2,"In the current study, we show that systematic modification of an aminoalkylindole scaffold identifies two new compounds with dual CB1R antagonist/CB2R agonist activity."
"In the current study, we show that systematic modification of an << aminoalkylindole >> scaffold identifies two new compounds with dual [[ CB1R ]] antagonist/CB2R agonist activity.","In the current study, we show that systematic modification of an [ENTITY_A] scaffold identifies two new compounds with dual [ENTITY_B] antagonist/CB2R agonist activity.",ANTAGONIST,CPR:6,3,"In the current study, we show that systematic modification of an aminoalkylindole scaffold identifies two new compounds with dual CB1R antagonist/CB2R agonist activity."
"Collectively, these initial findings suggest that design and systematic modification of << aminoalkylindoles >> such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/[[ CB2R ]] agonist activity with potential for use as treatments of alcohol abuse.","Collectively, these initial findings suggest that design and systematic modification of [ENTITY_A] such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/[ENTITY_B] agonist activity with potential for use as treatments of alcohol abuse.",AGONIST,CPR:5,2,"Collectively, these initial findings suggest that design and systematic modification of aminoalkylindoles such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse."
"Collectively, these initial findings suggest that design and systematic modification of << aminoalkylindoles >> such as 3 may lead to development of novel cannabinoid ligands with dual [[ CB1R ]] antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse.","Collectively, these initial findings suggest that design and systematic modification of [ENTITY_A] such as 3 may lead to development of novel cannabinoid ligands with dual [ENTITY_B] antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse.",ANTAGONIST,CPR:6,3,"Collectively, these initial findings suggest that design and systematic modification of aminoalkylindoles such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse."
Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the << dipeptidyl peptidase-4 >> inhibitor [[ vildagliptin ]] in an advanced-aged diet-induced obesity mouse model.,Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the [ENTITY_A] inhibitor [ENTITY_B] in an advanced-aged diet-induced obesity mouse model.,INHIBITOR,CPR:4,1,Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model.
"METHODS: After 1 month of HFD alone, the mice were given the << DPP4 >> inhibitor [[ vildagliptin ]] for a further 11 months.","METHODS: After 1 month of HFD alone, the mice were given the [ENTITY_A] inhibitor [ENTITY_B] for a further 11 months.",INHIBITOR,CPR:4,1,"METHODS: After 1 month of HFD alone, the mice were given the DPP4 inhibitor vildagliptin for a further 11 months."
"The improved survival rates for obese mice chronically treated with << vildagliptin >> suggest that chronic [[ DPP4 ]] inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy.","The improved survival rates for obese mice chronically treated with [ENTITY_A] suggest that chronic [ENTITY_B] inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy.",INHIBITOR,CPR:4,1,"The improved survival rates for obese mice chronically treated with vildagliptin suggest that chronic DPP4 inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy."
Protein levels of the << glucose transporter >> (GLUT4) involved in [[ glucose ]] transport via these two pathways were also increased.,Protein levels of the [ENTITY_A] (GLUT4) involved in [ENTITY_B] transport via these two pathways were also increased.,SUBSTRATE,CPR:9,4,Protein levels of the glucose transporter (GLUT4) involved in glucose transport via these two pathways were also increased.
<< Puerarin >> stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent [[ MEK ]]/ERK and PI3K/Akt activation.,[ENTITY_A] stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent [ENTITY_B]/ERK and PI3K/Akt activation.,ACTIVATOR,CPR:3,0,Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/Akt activation.
Puerarin promotes proliferation by altering cell cycle distribution whereas << puerarin >>-mediated survival may be associated with up-regulation of [[ Bcl-xL ]] expression.,Puerarin promotes proliferation by altering cell cycle distribution whereas [ENTITY_A]-mediated survival may be associated with up-regulation of [ENTITY_B] expression.,INDIRECT-UPREGULATOR,CPR:3,0,Puerarin promotes proliferation by altering cell cycle distribution whereas puerarin-mediated survival may be associated with up-regulation of Bcl-xL expression.
"Treatment with the << ER >> antagonist [[ ICI 182,780 ]] abolishes the above actions of puerarin on osteoblast-derived cells.",Treatment with the [ENTITY_A] antagonist [ENTITY_B] abolishes the above actions of puerarin on osteoblast-derived cells.,ANTAGONIST,CPR:6,3,"Treatment with the ER antagonist ICI 182,780 abolishes the above actions of puerarin on osteoblast-derived cells."
"Moreover, we also demonstrate that << puerarin >> functions at least partially through activation of [[ MEK ]]/ERK and PI3K/Akt signaling.","Moreover, we also demonstrate that [ENTITY_A] functions at least partially through activation of [ENTITY_B]/ERK and PI3K/Akt signaling.",ACTIVATOR,CPR:3,0,"Moreover, we also demonstrate that puerarin functions at least partially through activation of MEK/ERK and PI3K/Akt signaling."
"RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the << phosphatidylinositol 3-kinase >> (PI3-kinase) inhibitor, [[ wortmannin ]].","RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the [ENTITY_A] (PI3-kinase) inhibitor, [ENTITY_B].",INHIBITOR,CPR:4,1,"RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, wortmannin."
"In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150μgL(-1) << oxyfluorfen >> showed a higher [[ CAT ]] activity than controls.","In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150μgL(-1) [ENTITY_A] showed a higher [ENTITY_B] activity than controls.",ACTIVATOR,CPR:3,0,"In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150μgL(-1) oxyfluorfen showed a higher CAT activity than controls."
"The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using << D1 >>/D5 ([[ SCH23390 ]]), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.","The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using [ENTITY_A]/D5 ([ENTITY_B]), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.",ANTAGONIST,CPR:6,3,"The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice."
<< Haloperidol >> promotes mTORC1-dependent phosphorylation of [[ ribosomal protein S6 ]] via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.,[ENTITY_A] promotes mTORC1-dependent phosphorylation of [ENTITY_B] via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.,ACTIVATOR,CPR:3,0,Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.
<< Haloperidol >> promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of [[ protein phosphatase-1 ]].,[ENTITY_A] promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of [ENTITY_B].,INHIBITOR,CPR:4,1,Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.
"This effect was prevented by << rapamycin >>, an inhibitor of the [[ mammalian target of rapamycin complex 1 ]] (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).","This effect was prevented by [ENTITY_A], an inhibitor of the [ENTITY_B] (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).",INHIBITOR,CPR:4,1,"This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)."
"In line with this observation, incubation of striatal slices with << okadaic acid >> and calyculin A, two inhibitors of [[ PP-1 ]], increased Ser240/244 phosphorylation.","In line with this observation, incubation of striatal slices with [ENTITY_A] and calyculin A, two inhibitors of [ENTITY_B], increased Ser240/244 phosphorylation.",INHIBITOR,CPR:4,1,"In line with this observation, incubation of striatal slices with okadaic acid and calyculin A, two inhibitors of PP-1, increased Ser240/244 phosphorylation."
"These results show that << haloperidol >> promotes mTORC1- and S6K1-dependent phosphorylation of [[ rpS6 ]] at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs.","These results show that [ENTITY_A] promotes mTORC1- and S6K1-dependent phosphorylation of [ENTITY_B] at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs.",ACTIVATOR,CPR:3,0,"These results show that haloperidol promotes mTORC1- and S6K1-dependent phosphorylation of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs."
These compounds resulted from our efforts to merge the pharmacophores of selective << factor Xa >> inhibitor [[ rivaroxaban ]] with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity.,These compounds resulted from our efforts to merge the pharmacophores of selective [ENTITY_A] inhibitor [ENTITY_B] with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity.,INHIBITOR,CPR:4,1,These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity.
"Resulting from this study, a structurally novel class of submicromolar fibrinogen << GPIIb/IIIa >> binding inhibitor bearing [[ 1,2,4-oxadiazol-5(4H)-one ]] moiety is also described.","Resulting from this study, a structurally novel class of submicromolar fibrinogen [ENTITY_A] binding inhibitor bearing [ENTITY_B] moiety is also described.",INHIBITOR,CPR:4,1,"Resulting from this study, a structurally novel class of submicromolar fibrinogen GPIIb/IIIa binding inhibitor bearing 1,2,4-oxadiazol-5(4H)-one moiety is also described."
"Rats intoxicated with << Cd >> for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants [[ superoxide dismutase ]], glutathione peroxidase and catalase in the frontal cortex tissue.","Rats intoxicated with [ENTITY_A] for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants [ENTITY_B], glutathione peroxidase and catalase in the frontal cortex tissue.",DOWNREGULATOR,CPR:4,1,"Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and catalase in the frontal cortex tissue."
The << caspase-3 >> immunopositivity was increased in degenerating neurons of the [[ Cd ]] group.,The [ENTITY_A] immunopositivity was increased in degenerating neurons of the [ENTITY_B] group.,INDIRECT-UPREGULATOR,CPR:3,0,The caspase-3 immunopositivity was increased in degenerating neurons of the Cd group.
"In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the << sodium iodide symporter >>, was significantly inhibited by [[ 17beta-oestradiol ]].In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem/progenitor cells.","In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the [ENTITY_A], was significantly inhibited by [ENTITY_B].In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem/progenitor cells.",INHIBITOR,CPR:4,1,"In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the sodium iodide symporter, was significantly inhibited by 17beta-oestradiol.In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem/progenitor cells."
"Drug-drug interactions are dependent on statins' pharmacokinetic profile: << simvastatin >>, lovastatin and atorvastatin are metabolized through [[ cytochrome P450 (CYP) 3A ]], while the metabolism of the other statins is independent of this CYP.","Drug-drug interactions are dependent on statins' pharmacokinetic profile: [ENTITY_A], lovastatin and atorvastatin are metabolized through [ENTITY_B], while the metabolism of the other statins is independent of this CYP.",SUBSTRATE,CPR:9,4,"Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and atorvastatin are metabolized through cytochrome P450 (CYP) 3A, while the metabolism of the other statins is independent of this CYP."
"All HIV PIs except nelfinavir are coadministered with a low dose of << ritonavir >>, a potent [[ CYP3A ]] inhibitor to improve their pharmacokinetic properties.","All HIV PIs except nelfinavir are coadministered with a low dose of [ENTITY_A], a potent [ENTITY_B] inhibitor to improve their pharmacokinetic properties.",INHIBITOR,CPR:4,1,"All HIV PIs except nelfinavir are coadministered with a low dose of ritonavir, a potent CYP3A inhibitor to improve their pharmacokinetic properties."
"The HCV-PIs << boceprevir >> and telaprevir are both, to different extents, inhibitors of [[ CYP3A ]].","The HCV-PIs [ENTITY_A] and telaprevir are both, to different extents, inhibitors of [ENTITY_B].",INHIBITOR,CPR:4,1,"The HCV-PIs boceprevir and telaprevir are both, to different extents, inhibitors of CYP3A."
"Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent << CYP3A >> inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or [[ boceprevir ]], and therefore their coadministration is contraindicated.","Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent [ENTITY_A] inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or [ENTITY_B], and therefore their coadministration is contraindicated.",INHIBITOR,CPR:4,1,"Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated."
"<< Simvastatin >> and lovastatin metabolized through [[ CYP3A ]] have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.","[ENTITY_A] and lovastatin metabolized through [ENTITY_B] have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.",SUBSTRATE,CPR:9,4,"Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated."
"<< Atorvastatin >> is also a [[ CYP3A ]] substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors.","[ENTITY_A] is also a [ENTITY_B] substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors.",SUBSTRATE,CPR:9,4,"Atorvastatin is also a CYP3A substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors."
"The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective << anaplastic lymphoma kinase >> inhibitor 15b ([[ LDK378 ]]) are described.","The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective [ENTITY_A] inhibitor 15b ([ENTITY_B]) are described.",INHIBITOR,CPR:4,1,"The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described."
"In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation << ALK >> inhibitor 4 ([[ TAE684 ]]).","In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation [ENTITY_A] inhibitor 4 ([ENTITY_B]).",INHIBITOR,CPR:4,1,"In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684)."
"Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a << BDZ receptor >> weak partial agonist ([[ Ro 15-1788 ]]) at micromolar concentrations.","Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a [ENTITY_A] weak partial agonist ([ENTITY_B]) at micromolar concentrations.",AGONIST,CPR:5,2,"Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations."
"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the << BDZ receptor >>, including [[ Ro 15-1788 ]] and the beta CCs.","The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the [ENTITY_A], including [ENTITY_B] and the beta CCs.",AGONIST,CPR:5,2,"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the BDZ receptor, including Ro 15-1788 and the beta CCs."
"These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that << BDZs >> limit SRF by slowing recovery of [[ sodium channels ]] from inactivation.","These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that [ENTITY_A] limit SRF by slowing recovery of [ENTITY_B] from inactivation.",ACTIVATOR,CPR:3,0,"These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation."
"In addition to effects on cell proliferation, << DHT >> increased the percentage of [[ alkaline phosphatase ]] (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens.","In addition to effects on cell proliferation, [ENTITY_A] increased the percentage of [ENTITY_B] (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens.",INDIRECT-UPREGULATOR,CPR:3,0,"In addition to effects on cell proliferation, DHT increased the percentage of alkaline phosphatase (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens."
"We conclude that << androgens >> can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the [[ osteoblast-line differentiation marker ]] ALP, presumably by an androgen receptor mediated mechanism.","We conclude that [ENTITY_A] can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the [ENTITY_B] ALP, presumably by an androgen receptor mediated mechanism.",INDIRECT-UPREGULATOR,CPR:3,0,"We conclude that androgens can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker ALP, presumably by an androgen receptor mediated mechanism."
The effect of << histamine-H1 receptor >> antagonism with [[ terfenadine ]] on concentration-related AMP-induced bronchoconstriction in asthma.,The effect of [ENTITY_A] antagonism with [ENTITY_B] on concentration-related AMP-induced bronchoconstriction in asthma.,ANTAGONIST,CPR:6,3,The effect of histamine-H1 receptor antagonism with terfenadine on concentration-related AMP-induced bronchoconstriction in asthma.
"<< Ibrutinib >> (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits [[ B-cell antigen receptor ]] signalling downstream of BTK.","[ENTITY_A] (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits [ENTITY_B] signalling downstream of BTK.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK."
"To study the mechanism underlying this phenomenon, the effects of the nonselective << beta-adrenoceptor >> antagonists [[ propranolol ]] [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.","To study the mechanism underlying this phenomenon, the effects of the nonselective [ENTITY_A] antagonists [ENTITY_B] [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.",ANTAGONIST,CPR:6,3,"To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years."
<< Propranolol >> treatment (4 X 40 mg/day) increased the density of [[ beta 2-adrenoceptors ]] by 25% after 2 days; concomitantly PRA and heart rate were reduced.,[ENTITY_A] treatment (4 X 40 mg/day) increased the density of [ENTITY_B] by 25% after 2 days; concomitantly PRA and heart rate were reduced.,INDIRECT-UPREGULATOR,CPR:3,0,Propranolol treatment (4 X 40 mg/day) increased the density of beta 2-adrenoceptors by 25% after 2 days; concomitantly PRA and heart rate were reduced.
<< Mepindolol >> treatment (2 X 5 mg/day) caused a 30% decrease of [[ beta 2-adrenoceptor ]] density and PRA after 2 days; both parameters remained reduced during treatment.,[ENTITY_A] treatment (2 X 5 mg/day) caused a 30% decrease of [ENTITY_B] density and PRA after 2 days; both parameters remained reduced during treatment.,INDIRECT-DOWNREGULATOR,CPR:4,1,Mepindolol treatment (2 X 5 mg/day) caused a 30% decrease of beta 2-adrenoceptor density and PRA after 2 days; both parameters remained reduced during treatment.
Inhibition of << 5-lipoxygenase >> pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and [[ 5-aminosalicylic acid ]].,Inhibition of [ENTITY_A] pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and [ENTITY_B].,INHIBITOR,CPR:4,1,Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.
Inhibition of << 5-lipoxygenase >> pathway of [[ arachidonic acid ]] metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.,Inhibition of [ENTITY_A] pathway of [ENTITY_B] metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.,SUBSTRATE,CPR:9,4,Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.
"Interference with << lipoxygenase >> enzymes, rather than a [[ steroid ]]-like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action.","Interference with [ENTITY_A] enzymes, rather than a [ENTITY_B]-like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action.",INHIBITOR,CPR:4,1,"Interference with lipoxygenase enzymes, rather than a steroid-like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action."
"Interference with << lipoxygenase >> enzymes, rather than a steroid-like inhibition of [[ arachidonic acid ]] release from intracellular phospholipids, seems to be the mode of action.","Interference with [ENTITY_A] enzymes, rather than a steroid-like inhibition of [ENTITY_B] release from intracellular phospholipids, seems to be the mode of action.",SUBSTRATE,CPR:9,4,"Interference with lipoxygenase enzymes, rather than a steroid-like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action."
<< Bevantolol >>: a [[ beta-1 adrenoceptor ]] antagonist with unique additional actions.,[ENTITY_A]: a [ENTITY_B] antagonist with unique additional actions.,ANTAGONIST,CPR:6,3,Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions.
UNLABELLED: << Bevantolol >> is a [[ beta-1 adrenoceptor ]] antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.,UNLABELLED: [ENTITY_A] is a [ENTITY_B] antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.,ANTAGONIST,CPR:6,3,UNLABELLED: Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.
It is suggested that all the additional actions of << bevantolol >> can be attributed to a partial agonist action on [[ alpha-adrenoceptors ]].,It is suggested that all the additional actions of [ENTITY_A] can be attributed to a partial agonist action on [ENTITY_B].,AGONIST,CPR:5,2,It is suggested that all the additional actions of bevantolol can be attributed to a partial agonist action on alpha-adrenoceptors.
"The apparent affinity of << benzodiazepine receptors >> for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of [[ alprazolam ]] increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)","The apparent affinity of [ENTITY_A] for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of [ENTITY_B] increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)",ACTIVATOR,CPR:3,0,"The apparent affinity of benzodiazepine receptors for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)"
"When menadione was omitted from the diet, however, << 4HPR >>-dosed animals had elevated [[ prothrombin ]] times.","When menadione was omitted from the diet, however, [ENTITY_A]-dosed animals had elevated [ENTITY_B] times.",INDIRECT-UPREGULATOR,CPR:3,0,"When menadione was omitted from the diet, however, 4HPR-dosed animals had elevated prothrombin times."
"In the high-dose << ROAc >> group, there was a twofold increase in [[ prothrombin ]] times but only after prolonged dosing.","In the high-dose [ENTITY_A] group, there was a twofold increase in [ENTITY_B] times but only after prolonged dosing.",INDIRECT-UPREGULATOR,CPR:3,0,"In the high-dose ROAc group, there was a twofold increase in prothrombin times but only after prolonged dosing."
"The order of effect was << 4HPR >> greater than ROAc greater than 13cisRA, with increases in [[ prothrombin ]] times correlating with increases in hemorrhagic deaths.","The order of effect was [ENTITY_A] greater than ROAc greater than 13cisRA, with increases in [ENTITY_B] times correlating with increases in hemorrhagic deaths.",INDIRECT-UPREGULATOR,CPR:3,0,"The order of effect was 4HPR greater than ROAc greater than 13cisRA, with increases in prothrombin times correlating with increases in hemorrhagic deaths."
"<< 13cisRA >> and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma [[ osteocalcin ]], an effect that correlated with retinoid-induced bone effects.","[ENTITY_A] and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma [ENTITY_B], an effect that correlated with retinoid-induced bone effects.",INDIRECT-DOWNREGULATOR,CPR:4,1,"13cisRA and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma osteocalcin, an effect that correlated with retinoid-induced bone effects."
"In contrast, serum << alkaline phosphatase >> was elevated in animals dosed with [[ 13cisRA ]] or 4HPR but not in those dose with ROAc.","In contrast, serum [ENTITY_A] was elevated in animals dosed with [ENTITY_B] or 4HPR but not in those dose with ROAc.",INDIRECT-UPREGULATOR,CPR:3,0,"In contrast, serum alkaline phosphatase was elevated in animals dosed with 13cisRA or 4HPR but not in those dose with ROAc."
"However, in the presence of 100 mM << Na+ >>, which is required for opiate inhibition of [[ adenylate cyclase ]] activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +/- 110 nM.","However, in the presence of 100 mM [ENTITY_A], which is required for opiate inhibition of [ENTITY_B] activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +/- 110 nM.",INHIBITOR,CPR:4,1,"However, in the presence of 100 mM Na+, which is required for opiate inhibition of adenylate cyclase activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +/- 110 nM."
"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between << diethylcarbamazine >> and piriprost, a [[ 5-lipoxygenase ]] inhibitor.","Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between [ENTITY_A] and piriprost, a [ENTITY_B] inhibitor.",INHIBITOR,CPR:4,1,"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor."
"Similar concentrations also inhibited the formation of << leukotriene C4 >> (LTC4) by [[ LTC synthetase ]], a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione.","Similar concentrations also inhibited the formation of [ENTITY_A] (LTC4) by [ENTITY_B], a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione.",PRODUCT-OF,CPR:9,4,"Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by LTC synthetase, a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione."
"The EC50 for inhibition of the << leukotriene C synthetase >> of RBL cells was directly proportional to the [[ LTA4 ]] concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4.","The EC50 for inhibition of the [ENTITY_A] of RBL cells was directly proportional to the [ENTITY_B] concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4.",SUBSTRATE,CPR:9,4,"The EC50 for inhibition of the leukotriene C synthetase of RBL cells was directly proportional to the LTA4 concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4."
Kinetic analysis revealed that the inhibition of the << leukotriene C synthetase >> reaction by [[ diethylcarbamazine ]] was competitive with respect to LTA4.,Kinetic analysis revealed that the inhibition of the [ENTITY_A] reaction by [ENTITY_B] was competitive with respect to LTA4.,INHIBITOR,CPR:4,1,Kinetic analysis revealed that the inhibition of the leukotriene C synthetase reaction by diethylcarbamazine was competitive with respect to LTA4.
"In contrast to << diethylcarbamazine >>, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the [[ 5-lipoxygenase ]] step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.","In contrast to [ENTITY_A], piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the [ENTITY_B] step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.",INHIBITOR,CPR:4,1,"In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells."
"In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of << sulfidopeptide leuktrienes >> in RBL cells at the [[ 5-lipoxygenase ]] step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.","In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of [ENTITY_A] in RBL cells at the [ENTITY_B] step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.",PRODUCT-OF,CPR:9,4,"In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells."
These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of << LTA4 >> in the [[ leukotriene C synthetase ]] reaction.,These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of [ENTITY_A] in the [ENTITY_B] reaction.,SUBSTRATE,CPR:9,4,These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of LTA4 in the leukotriene C synthetase reaction.
The test procedure was verified with respect to intestinal << lactose >> hydrolysis by demonstrating a linear relationship between lactose/lactulose excretion and log jejunal mucosal [[ lactase ]] activity by in vitro assay (R2 = 0.95) in a further group of subjects.,The test procedure was verified with respect to intestinal [ENTITY_A] hydrolysis by demonstrating a linear relationship between lactose/lactulose excretion and log jejunal mucosal [ENTITY_B] activity by in vitro assay (R2 = 0.95) in a further group of subjects.,SUBSTRATE,CPR:9,4,The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose/lactulose excretion and log jejunal mucosal lactase activity by in vitro assay (R2 = 0.95) in a further group of subjects.
Differential << lactose >>/lactulose/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal [[ lactase ]] deficiency.,Differential [ENTITY_A]/lactulose/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal [ENTITY_B] deficiency.,SUBSTRATE,CPR:9,4,Differential lactose/lactulose/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal lactase deficiency.
The irreversible complex between << phenoxybenzamine >> and calmodulin may be useful for inhibiting certain [[ calmodulin ]]-dependent reactions and for studying the various biological functions of calmodulin.,The irreversible complex between [ENTITY_A] and calmodulin may be useful for inhibiting certain [ENTITY_B]-dependent reactions and for studying the various biological functions of calmodulin.,INHIBITOR,CPR:4,1,The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.
<< Xanthines >> are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of [[ adenosine receptors ]].,[ENTITY_A] are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of [ENTITY_B].,INHIBITOR,CPR:4,1,Xanthines are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of adenosine receptors.
<< Xanthines >> are classical antagonists for [[ adenosine receptors ]] for many of their pharmacological actions may be due to blockade of adenosine receptors.,[ENTITY_A] are classical antagonists for [ENTITY_B] for many of their pharmacological actions may be due to blockade of adenosine receptors.,ANTAGONIST,CPR:6,3,Xanthines are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of adenosine receptors.
Inhibition of testicular << LDH-X >> from laboratory animals and man by [[ gossypol ]] and its isomers.,Inhibition of testicular [ENTITY_A] from laboratory animals and man by [ENTITY_B] and its isomers.,INHIBITOR,CPR:4,1,Inhibition of testicular LDH-X from laboratory animals and man by gossypol and its isomers.
"The inhibitory effect of << (+)-, (-)-, (+/-)-gossypol >> and (+/-)-gossypol acetic acid upon testicular cytosolic [[ LDH-X ]] was measured in vitro.",The inhibitory effect of [ENTITY_A] and (+/-)-gossypol acetic acid upon testicular cytosolic [ENTITY_B] was measured in vitro.,INHIBITOR,CPR:4,1,"The inhibitory effect of (+)-, (-)-, (+/-)-gossypol and (+/-)-gossypol acetic acid upon testicular cytosolic LDH-X was measured in vitro."
<< Gossypol acetic acid >> (0-100 mumol/l) inhibited [[ LDH-X ]] prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster.,[ENTITY_A] (0-100 mumol/l) inhibited [ENTITY_B] prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster.,INHIBITOR,CPR:4,1,Gossypol acetic acid (0-100 mumol/l) inhibited LDH-X prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster.
"<< Gossypol >> and its isomers were non-competitive inhibitors of [[ human and hamster LDH-X ]] with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate.","[ENTITY_A] and its isomers were non-competitive inhibitors of [ENTITY_B] with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate.",INHIBITOR,CPR:4,1,"Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate."
"Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of << hamster LDH-X >> with respect to the substrate [[ alpha-ketobutyrate ]].","Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of [ENTITY_A] with respect to the substrate [ENTITY_B].",SUBSTRATE,CPR:9,4,"Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate."
Inactivation of << prostaglandin H synthase >> and prostacyclin synthase by [[ phenylbutazone ]].,Inactivation of [ENTITY_A] and prostacyclin synthase by [ENTITY_B].,INHIBITOR,CPR:4,1,Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone.
Most reducing cofactors for the peroxidase protect << PHS >> and prostacyclin synthase from inactivation by [[ hydroperoxides ]].,Most reducing cofactors for the peroxidase protect [ENTITY_A] and prostacyclin synthase from inactivation by [ENTITY_B].,INHIBITOR,CPR:4,1,Most reducing cofactors for the peroxidase protect PHS and prostacyclin synthase from inactivation by hydroperoxides.
Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of << PHS >> is markedly increased in the presence of 100 microM [[ H2O2 ]].,Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of [ENTITY_A] is markedly increased in the presence of 100 microM [ENTITY_B].,INHIBITOR,CPR:4,1,Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of PHS is markedly increased in the presence of 100 microM H2O2.
Chromatographic analysis of the metabolism of << 14C-labeled arachidonic acid >> in this system revealed that PB-dependent inactivation of [[ PHS ]] is markedly increased in the presence of 100 microM H2O2.,Chromatographic analysis of the metabolism of [ENTITY_A] in this system revealed that PB-dependent inactivation of [ENTITY_B] is markedly increased in the presence of 100 microM H2O2.,SUBSTRATE,CPR:9,4,Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of PHS is markedly increased in the presence of 100 microM H2O2.
"In plasma membranes prepared from these isolated brown fat cells by << borate >> extraction there was a similar enrichment of activity of [[ SSAO ]] and of the plasma membrane marker enzyme, phosphodiesterase I.","In plasma membranes prepared from these isolated brown fat cells by [ENTITY_A] extraction there was a similar enrichment of activity of [ENTITY_B] and of the plasma membrane marker enzyme, phosphodiesterase I.",ACTIVATOR,CPR:3,0,"In plasma membranes prepared from these isolated brown fat cells by borate extraction there was a similar enrichment of activity of SSAO and of the plasma membrane marker enzyme, phosphodiesterase I."
"Positive staining of mitochondria was achieved in the presence of the << MAO >> substrate, [[ tryptamine ]].","Positive staining of mitochondria was achieved in the presence of the [ENTITY_A] substrate, [ENTITY_B].",SUBSTRATE,CPR:9,4,"Positive staining of mitochondria was achieved in the presence of the MAO substrate, tryptamine."
"Staining around the edges of the brown fat cells was observed with the << SSAO >> substrates, [[ tyramine ]] and benzylamine.","Staining around the edges of the brown fat cells was observed with the [ENTITY_A] substrates, [ENTITY_B] and benzylamine.",SUBSTRATE,CPR:9,4,"Staining around the edges of the brown fat cells was observed with the SSAO substrates, tyramine and benzylamine."
"Staining was largely absent when substrate was omitted or after pretreatment with the irreversible << SSAO >> inhibitor, [[ hydralazine ]] and the slowly reversible inhibitor, semicarbazide.","Staining was largely absent when substrate was omitted or after pretreatment with the irreversible [ENTITY_A] inhibitor, [ENTITY_B] and the slowly reversible inhibitor, semicarbazide.",INHIBITOR,CPR:4,1,"Staining was largely absent when substrate was omitted or after pretreatment with the irreversible SSAO inhibitor, hydralazine and the slowly reversible inhibitor, semicarbazide."
"This agent acts synergistically with many << penicillins >>, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the [[ peptidoglycan ]] of the bacterial cell wall.","This agent acts synergistically with many [ENTITY_A], such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the [ENTITY_B] of the bacterial cell wall.",INDIRECT-UPREGULATOR,CPR:3,0,"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the peptidoglycan of the bacterial cell wall."
"Since both << TFP >> and W-7 are potent inhibitors of [[ calmodulin ]], we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors.","Since both [ENTITY_A] and W-7 are potent inhibitors of [ENTITY_B], we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors.",INHIBITOR,CPR:4,1,"Since both TFP and W-7 are potent inhibitors of calmodulin, we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors."
"Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) << Promethazine >>, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several [[ calmodulin ]] functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.","Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) [ENTITY_A], a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several [ENTITY_B] functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.",INHIBITOR,CPR:4,1,"Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin."
"From these results, it is proposed that << tyrosine hydroxylase >> activity determines p-HPAA concentrations by regulating [[ p-tyrosine ]] availability.","From these results, it is proposed that [ENTITY_A] activity determines p-HPAA concentrations by regulating [ENTITY_B] availability.",SUBSTRATE,CPR:9,4,"From these results, it is proposed that tyrosine hydroxylase activity determines p-HPAA concentrations by regulating p-tyrosine availability."
The binding of << FHA >>-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists [[ diphenhydramine ]] and clemastine.,The binding of [ENTITY_A]-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists [ENTITY_B] and clemastine.,INHIBITOR,CPR:4,1,The binding of FHA-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and clemastine.
The binding of FHA-HIS was inhibited on 35-79% of the platelets by the << histamine H1 receptor >> antagonists [[ diphenhydramine ]] and clemastine.,The binding of FHA-HIS was inhibited on 35-79% of the platelets by the [ENTITY_A] antagonists [ENTITY_B] and clemastine.,ANTAGONIST,CPR:6,3,The binding of FHA-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and clemastine.
The histamine H2 receptor antagonist << cimetidine >> blocked the [[ FHA ]]-HIS binding on 14-37% of the platelets.,The histamine H2 receptor antagonist [ENTITY_A] blocked the [ENTITY_B]-HIS binding on 14-37% of the platelets.,INHIBITOR,CPR:4,1,The histamine H2 receptor antagonist cimetidine blocked the FHA-HIS binding on 14-37% of the platelets.
The << histamine H2 receptor >> antagonist [[ cimetidine ]] blocked the FHA-HIS binding on 14-37% of the platelets.,The [ENTITY_A] antagonist [ENTITY_B] blocked the FHA-HIS binding on 14-37% of the platelets.,ANTAGONIST,CPR:6,3,The histamine H2 receptor antagonist cimetidine blocked the FHA-HIS binding on 14-37% of the platelets.
"<< Alanine:glyoxylate aminotransferase >> (AGT) in the liver catalyzes most of the [[ glyoxylate ]] transamination in mammalian tissues (E. V. Rowsell, K. Snell, J. A. Carnie, and K. V. Rowsell (1972) Biochem. J. 127, 155-165).","[ENTITY_A] (AGT) in the liver catalyzes most of the [ENTITY_B] transamination in mammalian tissues (E. V. Rowsell, K. Snell, J. A. Carnie, and K. V. Rowsell (1972) Biochem. J. 127, 155-165).",SUBSTRATE,CPR:9,4,"Alanine:glyoxylate aminotransferase (AGT) in the liver catalyzes most of the glyoxylate transamination in mammalian tissues (E. V. Rowsell, K. Snell, J. A. Carnie, and K. V. Rowsell (1972) Biochem. J. 127, 155-165)."
"The holo activity of combined peroxisomal and mitochondrial << AGT 1 >> with a low Km for [[ L-alanine ]] rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days).","The holo activity of combined peroxisomal and mitochondrial [ENTITY_A] with a low Km for [ENTITY_B] rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days).",SUBSTRATE,CPR:9,4,"The holo activity of combined peroxisomal and mitochondrial AGT 1 with a low Km for L-alanine rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days)."
"The holo activity of AGT 2 with a high Km for << L-alanine >> decreased more slowly than [[ AGT 1 ]] (by 33% in 14 days, by 60% in 28 days).","The holo activity of AGT 2 with a high Km for [ENTITY_A] decreased more slowly than [ENTITY_B] (by 33% in 14 days, by 60% in 28 days).",SUBSTRATE,CPR:9,4,"The holo activity of AGT 2 with a high Km for L-alanine decreased more slowly than AGT 1 (by 33% in 14 days, by 60% in 28 days)."
"<< Triclosan >> inhibited both [[ cyclooxygenase 1 ]] and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively.","[ENTITY_A] inhibited both [ENTITY_B] and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively.",INHIBITOR,CPR:4,1,"Triclosan inhibited both cyclooxygenase 1 and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively."
<< Triclosan >> also inhibited [[ 5-lipoxygenase ]] with an IC-50 of 43 microM.,[ENTITY_A] also inhibited [ENTITY_B] with an IC-50 of 43 microM.,INHIBITOR,CPR:4,1,Triclosan also inhibited 5-lipoxygenase with an IC-50 of 43 microM.
The << 15-lipoxygenase >> was similarly inhibited by [[ triclosan ]] with an IC-50 of 61 microM.,The [ENTITY_A] was similarly inhibited by [ENTITY_B] with an IC-50 of 61 microM.,INHIBITOR,CPR:4,1,The 15-lipoxygenase was similarly inhibited by triclosan with an IC-50 of 61 microM.
"Hence, << triclosan >> has the ability to inhibit both the [[ cyclo-oxygenase ]] and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy.","Hence, [ENTITY_A] has the ability to inhibit both the [ENTITY_B] and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy.",INHIBITOR,CPR:4,1,"Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy."
"Hence, triclosan has the ability to inhibit both the << cyclo-oxygenase >> and lipoxygenase pathways of [[ arachidonic acid ]] metabolism with similar efficacy.","Hence, triclosan has the ability to inhibit both the [ENTITY_A] and lipoxygenase pathways of [ENTITY_B] metabolism with similar efficacy.",SUBSTRATE,CPR:9,4,"Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy."
"In cell culture experiments, it was found that << triclosan >> inhibited [[ IL-1 beta ]] induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.","In cell culture experiments, it was found that [ENTITY_A] inhibited [ENTITY_B] induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.",INHIBITOR,CPR:4,1,"In cell culture experiments, it was found that triclosan inhibited IL-1 beta induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations."
"In cell culture experiments, it was found that triclosan inhibited << IL-1 beta >> induced [[ prostaglandin E2 ]] production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.","In cell culture experiments, it was found that triclosan inhibited [ENTITY_A] induced [ENTITY_B] production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.",PRODUCT-OF,CPR:9,4,"In cell culture experiments, it was found that triclosan inhibited IL-1 beta induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations."
Cells propagated in medium containing << N5-methyltetrahydrofolate >> and homocysteine showed a substantial increase in [[ MS ]] activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.,Cells propagated in medium containing [ENTITY_A] and homocysteine showed a substantial increase in [ENTITY_B] activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.,ACTIVATOR,CPR:3,0,Cells propagated in medium containing N5-methyltetrahydrofolate and homocysteine showed a substantial increase in MS activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.
<< Ergovaline >> binding and activation of [[ D2 dopamine receptors ]] in GH4ZR7 cells.,[ENTITY_A] binding and activation of [ENTITY_B] in GH4ZR7 cells.,ACTIVATOR,CPR:3,0,Ergovaline binding and activation of D2 dopamine receptors in GH4ZR7 cells.
"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and << ergot alkaloid >> inhibition of [[ vasoactive intestinal peptide ]] (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.","Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and [ENTITY_A] inhibition of [ENTITY_B] (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.",INHIBITOR,CPR:4,1,"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated."
"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of << vasoactive intestinal peptide >> (VIP)-stimulated [[ cyclic AMP ]] production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.","Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of [ENTITY_A] (VIP)-stimulated [ENTITY_B] production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.",PRODUCT-OF,CPR:9,4,"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated."
"<< Ergot alkaloids >> were also effective in inhibiting [[ VIP ]]-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.","[ENTITY_A] were also effective in inhibiting [ENTITY_B]-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.",INHIBITOR,CPR:4,1,"Ergot alkaloids were also effective in inhibiting VIP-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively."
"Ergot alkaloids were also effective in inhibiting << VIP >>-stimulated [[ cyclic AMP ]] production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.","Ergot alkaloids were also effective in inhibiting [ENTITY_A]-stimulated [ENTITY_B] production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.",PRODUCT-OF,CPR:9,4,"Ergot alkaloids were also effective in inhibiting VIP-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively."
"Inhibition of cyclic AMP production by ergovaline was blocked by the << dopamine receptor >> antagonist, [[ (-)-sulpiride ]] (IC50, 300 +/- 150 nM).","Inhibition of cyclic AMP production by ergovaline was blocked by the [ENTITY_A] antagonist, [ENTITY_B] (IC50, 300 +/- 150 nM).",ANTAGONIST,CPR:6,3,"Inhibition of cyclic AMP production by ergovaline was blocked by the dopamine receptor antagonist, (-)-sulpiride (IC50, 300 +/- 150 nM)."
"These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several << ergot alkaloids >> including ergovaline, may be due to [[ D2 dopamine receptor ]] activation.","These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several [ENTITY_A] including ergovaline, may be due to [ENTITY_B] activation.",ACTIVATOR,CPR:3,0,"These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several ergot alkaloids including ergovaline, may be due to D2 dopamine receptor activation."
"Incubation of rat aortic membranes with the irreversible << alpha 1B-adrenoceptor >> antagonist, [[ chloroethylclonidine ]] (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).","Incubation of rat aortic membranes with the irreversible [ENTITY_A] antagonist, [ENTITY_B] (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).",ANTAGONIST,CPR:6,3,"Incubation of rat aortic membranes with the irreversible alpha 1B-adrenoceptor antagonist, chloroethylclonidine (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax)."
"Intraperitoneal administration of << (+/- )propranolol HCl >> (2.5-10 mg/kg), a nonselective [[ beta-adrenoceptor ]] antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses.","Intraperitoneal administration of [ENTITY_A] (2.5-10 mg/kg), a nonselective [ENTITY_B] antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses.",ANTAGONIST,CPR:6,3,"Intraperitoneal administration of (+/- )propranolol HCl (2.5-10 mg/kg), a nonselective beta-adrenoceptor antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses."
"<< ICI118,551 HCl >> (1.25-5 mg/kg, IP), a selective [[ beta 2-adrenoceptor ]] antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it.","[ENTITY_A] (1.25-5 mg/kg, IP), a selective [ENTITY_B] antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it.",ANTAGONIST,CPR:6,3,"ICI118,551 HCl (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it."
"Moreover, << clenbuterol HCl >> (0.1-0.5 mg/kg, IP), a lipophilic [[ beta 2-adrenoceptor ]] agonist, significantly increased the duration of basal aggressive behavior.","Moreover, [ENTITY_A] (0.1-0.5 mg/kg, IP), a lipophilic [ENTITY_B] agonist, significantly increased the duration of basal aggressive behavior.",AGONIST,CPR:5,2,"Moreover, clenbuterol HCl (0.1-0.5 mg/kg, IP), a lipophilic beta 2-adrenoceptor agonist, significantly increased the duration of basal aggressive behavior."
"Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by << yohimbine >>, an [[ alpha 2-adrenoceptor ]] antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.","Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by [ENTITY_A], an [ENTITY_B] antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.",ANTAGONIST,CPR:6,3,"Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by yohimbine, an alpha 2-adrenoceptor antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice."
"In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective << alpha 1A-adrenoceptor >> antagonist [[ WB 4101 ]] (100 nM).","In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective [ENTITY_A] antagonist [ENTITY_B] (100 nM).",ANTAGONIST,CPR:6,3,"In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective alpha 1A-adrenoceptor antagonist WB 4101 (100 nM)."
"Furthermore, the phosphorylation of << myosin light chain >> produced by [[ norepinephrine ]] was greater than that produced by clonidine.","Furthermore, the phosphorylation of [ENTITY_A] produced by [ENTITY_B] was greater than that produced by clonidine.",ACTIVATOR,CPR:3,0,"Furthermore, the phosphorylation of myosin light chain produced by norepinephrine was greater than that produced by clonidine."
"The drug had a potent cytotoxic effect on RIN cells expressing << GLUT2 >>, but had no effect on cells lacking GLUT2 expression, as indicated by histological analysis and measurement of the blood [[ glucose ]] levels of treated animals.","The drug had a potent cytotoxic effect on RIN cells expressing [ENTITY_A], but had no effect on cells lacking GLUT2 expression, as indicated by histological analysis and measurement of the blood [ENTITY_B] levels of treated animals.",SUBSTRATE,CPR:9,4,"The drug had a potent cytotoxic effect on RIN cells expressing GLUT2, but had no effect on cells lacking GLUT2 expression, as indicated by histological analysis and measurement of the blood glucose levels of treated animals."
"Consistent with these data, only << GLUT2 >>-expressing RIN or AtT-20ins cells transported [[ STZ ]] efficiently.","Consistent with these data, only [ENTITY_A]-expressing RIN or AtT-20ins cells transported [ENTITY_B] efficiently.",SUBSTRATE,CPR:9,4,"Consistent with these data, only GLUT2-expressing RIN or AtT-20ins cells transported STZ efficiently."
"We conclude that expression of << GLUT2 >> is required for efficient killing of neuroendocrine cells by [[ STZ ]], and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1.","We conclude that expression of [ENTITY_A] is required for efficient killing of neuroendocrine cells by [ENTITY_B], and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1.",SUBSTRATE,CPR:9,4,"We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by STZ, and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1."
Inhibitory effects of << lysine >> analogues on [[ t-PA ]] induced whole blood clot lysis.,Inhibitory effects of [ENTITY_A] analogues on [ENTITY_B] induced whole blood clot lysis.,INHIBITOR,CPR:4,1,Inhibitory effects of lysine analogues on t-PA induced whole blood clot lysis.
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of << lysine >> analogues required for inhibition of clot lysis induced by exogenous [[ t-PA ]].,The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of [ENTITY_A] analogues required for inhibition of clot lysis induced by exogenous [ENTITY_B].,INHIBITOR,CPR:4,1,The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA.
<< AMCA >> (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous [[ t-PA ]] or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.,[ENTITY_A] (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous [ENTITY_B] or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.,INHIBITOR,CPR:4,1,AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.
"However, their inhibitory effect was markedly reduced if clots were formed in the presence of << t-PA >> and then exposed to either of the [[ lysine ]] analogues.","However, their inhibitory effect was markedly reduced if clots were formed in the presence of [ENTITY_A] and then exposed to either of the [ENTITY_B] analogues.",INHIBITOR,CPR:4,1,"However, their inhibitory effect was markedly reduced if clots were formed in the presence of t-PA and then exposed to either of the lysine analogues."
"The data suggest that << lysine >> analogues, even at low concentrations, reduce the rate of [[ t-PA ]] induced whole blood clot lysis by several mechanisms.","The data suggest that [ENTITY_A] analogues, even at low concentrations, reduce the rate of [ENTITY_B] induced whole blood clot lysis by several mechanisms.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The data suggest that lysine analogues, even at low concentrations, reduce the rate of t-PA induced whole blood clot lysis by several mechanisms."
<< Histamine >> enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via [[ H1-receptor ]] activation.,[ENTITY_A] enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via [ENTITY_B] activation.,ACTIVATOR,CPR:3,0,Histamine enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via H1-receptor activation.
"The enhancement of the depolarizing afterpotential by histamine was mimicked by the << histamine H1-receptor >> agonist [[ 2-thiazolylethylamine ]] and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.","The enhancement of the depolarizing afterpotential by histamine was mimicked by the [ENTITY_A] agonist [ENTITY_B] and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.",AGONIST,CPR:5,2,"The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine."
"The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the << H1-receptor >> antagonist [[ promethazine ]], but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.","The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the [ENTITY_A] antagonist [ENTITY_B], but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.",ANTAGONIST,CPR:6,3,"The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine."
"In summary, these results show that the excitatory effect of << histamine >> on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the [[ H1-receptor ]]-mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.","In summary, these results show that the excitatory effect of [ENTITY_A] on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the [ENTITY_B]-mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.",ACTIVATOR,CPR:3,0,"In summary, these results show that the excitatory effect of histamine on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the H1-receptor-mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential."
"The goal of the present study was to compare the effects of three potent reference << renin >> inhibitors ([[ remikiren ]], CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys.","The goal of the present study was to compare the effects of three potent reference [ENTITY_A] inhibitors ([ENTITY_B], CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys.",INHIBITOR,CPR:4,1,"The goal of the present study was to compare the effects of three potent reference renin inhibitors (remikiren, CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys."
"Finally, the three drugs were compared with the << angiotensin converting enzyme >> inhibitor [[ cilazapril ]].","Finally, the three drugs were compared with the [ENTITY_A] inhibitor [ENTITY_B].",INHIBITOR,CPR:4,1,"Finally, the three drugs were compared with the angiotensin converting enzyme inhibitor cilazapril."
"One possible explanation is that, in our model, << remikiren >> in contrast to CGP 38560A and enalkiren is able to inhibit [[ renin ]] in a functionally important extraplasmatic compartment.","One possible explanation is that, in our model, [ENTITY_A] in contrast to CGP 38560A and enalkiren is able to inhibit [ENTITY_B] in a functionally important extraplasmatic compartment.",INHIBITOR,CPR:4,1,"One possible explanation is that, in our model, remikiren in contrast to CGP 38560A and enalkiren is able to inhibit renin in a functionally important extraplasmatic compartment."
Inhibition of << cytokine >>-primed eosinophil chemotaxis by [[ nedocromil sodium ]].,Inhibition of [ENTITY_A]-primed eosinophil chemotaxis by [ENTITY_B].,INHIBITOR,CPR:4,1,Inhibition of cytokine-primed eosinophil chemotaxis by nedocromil sodium.
"RESULTS: << Nedocromil sodium >> inhibited the chemotactic response toward FMLP and NAF/IL-8 of [[ GM-CSF ]] primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).","RESULTS: [ENTITY_A] inhibited the chemotactic response toward FMLP and NAF/IL-8 of [ENTITY_B] primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).",INDIRECT-DOWNREGULATOR,CPR:4,1,"RESULTS: Nedocromil sodium inhibited the chemotactic response toward FMLP and NAF/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L)."
CONCLUSIONS: The chemotactic responses toward << C5a >> were inhibited by [[ nedocromil sodium ]] at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol/L).,CONCLUSIONS: The chemotactic responses toward [ENTITY_A] were inhibited by [ENTITY_B] at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol/L).,INHIBITOR,CPR:4,1,CONCLUSIONS: The chemotactic responses toward C5a were inhibited by nedocromil sodium at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol/L).
"Glutathione-independent prostaglandin D synthase [<< prostaglandin-H2 D-isomerase >>; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of [[ prostaglandin D2 ]] in the central nervous system.","Glutathione-independent prostaglandin D synthase [[ENTITY_A]; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of [ENTITY_B] in the central nervous system.",PRODUCT-OF,CPR:9,4,"Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system."
Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-<< N-methyl-D-aspartate (NMDA) receptor >> antagonist [[ CNQX ]] (6-cyano-7-nitro-quinoxalinedione).,Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-[ENTITY_A] antagonist [ENTITY_B] (6-cyano-7-nitro-quinoxalinedione).,ANTAGONIST,CPR:6,3,Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione).
"One group of experimental animals was treated with << 5-lipoxygenase >> (5-LO) inhibitor, [[ diethylcarbamazine ]] (DEC, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.), immediately before blast.","One group of experimental animals was treated with [ENTITY_A] (5-LO) inhibitor, [ENTITY_B] (DEC, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.), immediately before blast.",INHIBITOR,CPR:4,1,"One group of experimental animals was treated with 5-lipoxygenase (5-LO) inhibitor, diethylcarbamazine (DEC, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.), immediately before blast."
"Although << DEC >> exerts local antioxidant activity with beneficial effects on lung tissue, this [[ 5-LO ]] inhibitor intensifies the blast overpressure caused hemodynamic insufficiency.","Although [ENTITY_A] exerts local antioxidant activity with beneficial effects on lung tissue, this [ENTITY_B] inhibitor intensifies the blast overpressure caused hemodynamic insufficiency.",INHIBITOR,CPR:4,1,"Although DEC exerts local antioxidant activity with beneficial effects on lung tissue, this 5-LO inhibitor intensifies the blast overpressure caused hemodynamic insufficiency."
"<< Tamsulosin >>, the first prostate-selective [[ alpha 1A-adrenoceptor ]] antagonist.","[ENTITY_A], the first prostate-selective [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist."
"Expressions of << insulin >> and PC3, but not PC2, are coordinately regulated by [[ glucose ]], consistent with the important role of PC3 in regulating proinsulin processing.","Expressions of [ENTITY_A] and PC3, but not PC2, are coordinately regulated by [ENTITY_B], consistent with the important role of PC3 in regulating proinsulin processing.",INDIRECT-UPREGULATOR,CPR:3,0,"Expressions of insulin and PC3, but not PC2, are coordinately regulated by glucose, consistent with the important role of PC3 in regulating proinsulin processing."
After 7 days of << DMI >> administration the number of [[ beta-adrenoceptors ]] was lower in frontal and occipital cortex and hippocampus.,After 7 days of [ENTITY_A] administration the number of [ENTITY_B] was lower in frontal and occipital cortex and hippocampus.,INHIBITOR,CPR:4,1,After 7 days of DMI administration the number of beta-adrenoceptors was lower in frontal and occipital cortex and hippocampus.
The << DMI >> induced reduction in [[ beta-adrenoceptors ]] did not differ in OB and sham-operated control rats.,The [ENTITY_A] induced reduction in [ENTITY_B] did not differ in OB and sham-operated control rats.,INHIBITOR,CPR:4,1,The DMI induced reduction in beta-adrenoceptors did not differ in OB and sham-operated control rats.
"<< DMI >> administration for up to 21 days produced a progressive reduction in the number of [[ 5-HT2A ]] receptors in frontal cortex, without significant alterations in occipital cortex.","[ENTITY_A] administration for up to 21 days produced a progressive reduction in the number of [ENTITY_B] receptors in frontal cortex, without significant alterations in occipital cortex.",INHIBITOR,CPR:4,1,"DMI administration for up to 21 days produced a progressive reduction in the number of 5-HT2A receptors in frontal cortex, without significant alterations in occipital cortex."
The time course of the reduction in the number of << 5-HT2A >> receptors was similar to that of the [[ DMI ]]-induced behavioural changes whereas that for the reduction in beta-adrenoceptors was clearly different.,The time course of the reduction in the number of [ENTITY_A] receptors was similar to that of the [ENTITY_B]-induced behavioural changes whereas that for the reduction in beta-adrenoceptors was clearly different.,INHIBITOR,CPR:4,1,The time course of the reduction in the number of 5-HT2A receptors was similar to that of the DMI-induced behavioural changes whereas that for the reduction in beta-adrenoceptors was clearly different.
The present results suggest that the action of << DMI >> in this animal model is unlikely to be directly related to a reduction in [[ beta-adrenoceptors ]] but may be related to a reduction in frontal cortical 5-HT2A receptors.,The present results suggest that the action of [ENTITY_A] in this animal model is unlikely to be directly related to a reduction in [ENTITY_B] but may be related to a reduction in frontal cortical 5-HT2A receptors.,INDIRECT-DOWNREGULATOR,CPR:4,1,The present results suggest that the action of DMI in this animal model is unlikely to be directly related to a reduction in beta-adrenoceptors but may be related to a reduction in frontal cortical 5-HT2A receptors.
Binding of << thalidomide >> to alpha1-acid glycoprotein may be involved in its inhibition of [[ tumor necrosis factor alpha ]] production.,Binding of [ENTITY_A] to alpha1-acid glycoprotein may be involved in its inhibition of [ENTITY_B] production.,INDIRECT-DOWNREGULATOR,CPR:4,1,Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production.
The immunomodulatory activity of << thalidomide >> has been ascribed to the selective inhibition of [[ tumor necrosis factor alpha ]] from monocytes.,The immunomodulatory activity of [ENTITY_A] has been ascribed to the selective inhibition of [ENTITY_B] from monocytes.,INHIBITOR,CPR:4,1,The immunomodulatory activity of thalidomide has been ascribed to the selective inhibition of tumor necrosis factor alpha from monocytes.
"We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both << thalidomide >> and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of [[ tumor necrosis factor alpha ]] from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.","We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both [ENTITY_A] and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of [ENTITY_B] from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.",INDIRECT-DOWNREGULATOR,CPR:4,1,"We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide."
"In conclusion, our data suggest that chronic << cocaine >> use is associated with modestly reduced levels of striatal DA and the [[ DA transporter ]] in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.","In conclusion, our data suggest that chronic [ENTITY_A] use is associated with modestly reduced levels of striatal DA and the [ENTITY_B] in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.",DOWNREGULATOR,CPR:4,1,"In conclusion, our data suggest that chronic cocaine use is associated with modestly reduced levels of striatal DA and the DA transporter in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug."
It appears likely that the << histamine H2 receptor >> blocked by [[ cimetidine ]] obviated the pulmonary vasodilator effect of tolazoline therapy.,It appears likely that the [ENTITY_A] blocked by [ENTITY_B] obviated the pulmonary vasodilator effect of tolazoline therapy.,INHIBITOR,CPR:4,1,It appears likely that the histamine H2 receptor blocked by cimetidine obviated the pulmonary vasodilator effect of tolazoline therapy.
<< GYKI 52466 >> decreased the peak amplitude of hippocampal area CA1 [[ AMPA receptor ]]-mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics.,[ENTITY_A] decreased the peak amplitude of hippocampal area CA1 [ENTITY_B]-mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics.,DOWNREGULATOR,CPR:4,1,GYKI 52466 decreased the peak amplitude of hippocampal area CA1 AMPA receptor-mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics.
<< Cyclothiazide >> prolonged the decay time constant of [[ AMPA receptor ]]-mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c. onset kinetics and increasing e.p.s.c. amplitude.,[ENTITY_A] prolonged the decay time constant of [ENTITY_B]-mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c. onset kinetics and increasing e.p.s.c. amplitude.,DOWNREGULATOR,CPR:4,1,Cyclothiazide prolonged the decay time constant of AMPA receptor-mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c. onset kinetics and increasing e.p.s.c. amplitude.
Activation of cytoprotective << prostaglandin synthase-1 >> by [[ minoxidil ]] as a possible explanation for its hair growth-stimulating effect.,Activation of cytoprotective [ENTITY_A] by [ENTITY_B] as a possible explanation for its hair growth-stimulating effect.,ACTIVATOR,CPR:3,0,Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect.
"We thus speculated that activation of << PGHS-1 >> might be a mechanism by which [[ minoxidil ]] (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo.","We thus speculated that activation of [ENTITY_A] might be a mechanism by which [ENTITY_B] (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo.",ACTIVATOR,CPR:3,0,"We thus speculated that activation of PGHS-1 might be a mechanism by which minoxidil (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo."
"We demonstrate here that << minoxidil >> is a potent activator of purified [[ PGHS-1 ]] (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production.","We demonstrate here that [ENTITY_A] is a potent activator of purified [ENTITY_B] (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production.",ACTIVATOR,CPR:3,0,"We demonstrate here that minoxidil is a potent activator of purified PGHS-1 (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production."
"This study was designed to determine the gastroprotective properties of << cinitapride >> (CNT), a novel prokinetic benzamide derivative agonist of [[ 5-HT4 ]] and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.","This study was designed to determine the gastroprotective properties of [ENTITY_A] (CNT), a novel prokinetic benzamide derivative agonist of [ENTITY_B] and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",AGONIST,CPR:5,2,"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol."
"This study was designed to determine the gastroprotective properties of << cinitapride >> (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and [[ 5-HT2 ]] antagonist, on mucosal injury produced by 50% (v/v) ethanol.","This study was designed to determine the gastroprotective properties of [ENTITY_A] (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and [ENTITY_B] antagonist, on mucosal injury produced by 50% (v/v) ethanol.",ANTAGONIST,CPR:6,3,"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol."
"We have identified << adenosine deaminase >>, an enzyme involved in [[ purine ]] metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2.","We have identified [ENTITY_A], an enzyme involved in [ENTITY_B] metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2.",SUBSTRATE,CPR:9,4,"We have identified adenosine deaminase, an enzyme involved in purine metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2."
<< Alendronate >> inhibition of [[ protein-tyrosine-phosphatase-meg1 ]].,[ENTITY_A] inhibition of [ENTITY_B].,INHIBITOR,CPR:4,1,Alendronate inhibition of protein-tyrosine-phosphatase-meg1.
Here we report that << alendronate >> is a potent inhibitor of the [[ protein-tyrosine-phosphatase-meg1 ]] (PTPmeg1).,Here we report that [ENTITY_A] is a potent inhibitor of the [ENTITY_B] (PTPmeg1).,INHIBITOR,CPR:4,1,Here we report that alendronate is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (PTPmeg1).
"With either substrate, << alendronate >> was a slow binding inhibitor of [[ PTPmeg1 ]].","With either substrate, [ENTITY_A] was a slow binding inhibitor of [ENTITY_B].",INHIBITOR,CPR:4,1,"With either substrate, alendronate was a slow binding inhibitor of PTPmeg1."
"Among the other << bisphosphonates >> studied, alendronate was more potent and selective for [[ PTPmeg1 ]].","Among the other [ENTITY_A] studied, alendronate was more potent and selective for [ENTITY_B].",INHIBITOR,CPR:4,1,"Among the other bisphosphonates studied, alendronate was more potent and selective for PTPmeg1."
"The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; << PTPsigma >>, however, under the same conditions, was inhibited by only 50% with 141 microM [[ alendronate ]].","The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; [ENTITY_A], however, under the same conditions, was inhibited by only 50% with 141 microM [ENTITY_B].",INHIBITOR,CPR:4,1,"The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate."
"The hydrolysis of fluorescein << diphosphate >> by [[ PTP epsilon ]] and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.","The hydrolysis of fluorescein [ENTITY_A] by [ENTITY_B] and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.",SUBSTRATE,CPR:9,4,"The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate."
"<< Alendronate >> inhibited [[ PTPmeg1 ]] with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM.","[ENTITY_A] inhibited [ENTITY_B] with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM.",INHIBITOR,CPR:4,1,"Alendronate inhibited PTPmeg1 with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM."
"The << alendronate >> inhibition of these three [[ PTPs ]] and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor.","The [ENTITY_A] inhibition of these three [ENTITY_B] and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor.",INHIBITOR,CPR:4,1,"The alendronate inhibition of these three PTPs and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor."
"<< PTP >> inhibition by [[ hisphosphonates ]] or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.","[ENTITY_A] inhibition by [ENTITY_B] or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.",INHIBITOR,CPR:4,1,"PTP inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition."
These observations show substrate- and enzyme-specific << PTP >> inhibition by [[ alendronate ]] and support the possibility that a certain PTP(s) may be the molecular target for alendronate action.,These observations show substrate- and enzyme-specific [ENTITY_A] inhibition by [ENTITY_B] and support the possibility that a certain PTP(s) may be the molecular target for alendronate action.,INHIBITOR,CPR:4,1,These observations show substrate- and enzyme-specific PTP inhibition by alendronate and support the possibility that a certain PTP(s) may be the molecular target for alendronate action.
"16,16-dimethyl-PGE2 and two putative << EP1 >> antagonists, [[ AH6809 ]] and SC-19220, did not show any significant binding to this receptor.","16,16-dimethyl-PGE2 and two putative [ENTITY_A] antagonists, [ENTITY_B] and SC-19220, did not show any significant binding to this receptor.",ANTAGONIST,CPR:6,3,"16,16-dimethyl-PGE2 and two putative EP1 antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor."
"<< M&B-28767 >>, a putative [[ EP3 ]] agonist, and misoprostol, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM.","[ENTITY_A], a putative [ENTITY_B] agonist, and misoprostol, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM.",AGONIST,CPR:5,2,"M&B-28767, a putative EP3 agonist, and misoprostol, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM."
Blockage of the << HERG human cardiac K+ channel >> by the gastrointestinal prokinetic agent [[ cisapride ]].,Blockage of the [ENTITY_A] by the gastrointestinal prokinetic agent [ENTITY_B].,INHIBITOR,CPR:4,1,Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride.
We tested the hypothesis that << cisapride >> blocks [[ HERG ]].,We tested the hypothesis that [ENTITY_A] blocks [ENTITY_B].,INHIBITOR,CPR:4,1,We tested the hypothesis that cisapride blocks HERG.
"Under voltage-clamp conditions, << cisapride >> block of [[ HERG ]] is dose dependent with a half-maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells).","Under voltage-clamp conditions, [ENTITY_A] block of [ENTITY_B] is dose dependent with a half-maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells).",INHIBITOR,CPR:4,1,"Under voltage-clamp conditions, cisapride block of HERG is dose dependent with a half-maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells)."
Block of << HERG >> with [[ cisapride ]] after channel activation was voltage dependent.,Block of [ENTITY_A] with [ENTITY_B] after channel activation was voltage dependent.,INHIBITOR,CPR:4,1,Block of HERG with cisapride after channel activation was voltage dependent.
"At -20 mV, 10 nM << cisapride >> reduced [[ HERG ]] tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells).","At -20 mV, 10 nM [ENTITY_A] reduced [ENTITY_B] tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells).",INDIRECT-DOWNREGULATOR,CPR:4,1,"At -20 mV, 10 nM cisapride reduced HERG tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells)."
We conclude that << cisapride >> is a potent blocker of [[ HERG ]] channels expressed in HEK293 cells.,We conclude that [ENTITY_A] is a potent blocker of [ENTITY_B] channels expressed in HEK293 cells.,INHIBITOR,CPR:4,1,We conclude that cisapride is a potent blocker of HERG channels expressed in HEK293 cells.
"Intravenous (I.V.) cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the << dopamine receptor >> antagonist, [[ SCH 23390 ]].","Intravenous (I.V.) cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the [ENTITY_A] antagonist, [ENTITY_B].",ANTAGONIST,CPR:6,3,"Intravenous (I.V.) cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the dopamine receptor antagonist, SCH 23390."
"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse << monoamine transporter >> selectivities ([[ BTCP ]], indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.","Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse [ENTITY_A] selectivities ([ENTITY_B], indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.",INHIBITOR,CPR:4,1,"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse monoamine transporter selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response."
"At nonconvulsant doses, the << sodium channel >> blockers [[ acetylprocainamide ]], dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.","At nonconvulsant doses, the [ENTITY_A] blockers [ENTITY_B], dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.",INHIBITOR,CPR:4,1,"At nonconvulsant doses, the sodium channel blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP."
The << sodium channel >>-blocking action of [[ cocaine ]] per se does not appear to be involved in the rapid pressor response to cocaine.,The [ENTITY_A]-blocking action of [ENTITY_B] per se does not appear to be involved in the rapid pressor response to cocaine.,INHIBITOR,CPR:4,1,The sodium channel-blocking action of cocaine per se does not appear to be involved in the rapid pressor response to cocaine.
"Characterization of binding sites of a new << neurotensin receptor >> antagonist, [[ [3H]SR 142948A ]], in the rat brain.","Characterization of binding sites of a new [ENTITY_A] antagonist, [ENTITY_B], in the rat brain.",ANTAGONIST,CPR:6,3,"Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain."
"The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of << neurotensin receptors >>, [[ [3H]SR 142948A ]] (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain.","The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of [ENTITY_A], [ENTITY_B] (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain.",ANTAGONIST,CPR:6,3,"The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of neurotensin receptors, [3H]SR 142948A (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain."
"Saturation and competition studies in the presence or absence of the << histamine H1 receptor >> antagonist, [[ levocabastine ]], revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).","Saturation and competition studies in the presence or absence of the [ENTITY_A] antagonist, [ENTITY_B], revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).",ANTAGONIST,CPR:6,3,"Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)."
"In conclusion, these findings indicate that << [3H]SR 142948A >> is a new potent antagonist radioligand which recognizes with high affinity both [[ neurotensin NT1 ]] and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.","In conclusion, these findings indicate that [ENTITY_A] is a new potent antagonist radioligand which recognizes with high affinity both [ENTITY_B] and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.",ANTAGONIST,CPR:6,3,"In conclusion, these findings indicate that [3H]SR 142948A is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain."
Isoform-specific inhibition of << L-type calcium channels >> by [[ dihydropyridines ]] is independent of isoform-specific gating properties.,Isoform-specific inhibition of [ENTITY_A] by [ENTITY_B] is independent of isoform-specific gating properties.,INHIBITOR,CPR:4,1,Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties.
"<< Dihydropyridines >> (DHPs) block [[ L-type Ca2+ channels ]] more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state.","[ENTITY_A] (DHPs) block [ENTITY_B] more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state.",INHIBITOR,CPR:4,1,"Dihydropyridines (DHPs) block L-type Ca2+ channels more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state."
"<< Nisoldipine >> (a DHP antagonist) blocks the [[ smooth muscle channel ]] more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels.","[ENTITY_A] (a DHP antagonist) blocks the [ENTITY_B] more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels.",INHIBITOR,CPR:4,1,"Nisoldipine (a DHP antagonist) blocks the smooth muscle channel more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels."
We thus conclude that the more potent << nisoldipine >> inhibition of smooth muscle versus [[ cardiac L-type Ca2+ channels ]] is not attributable to differences in channel inactivation or activation.,We thus conclude that the more potent [ENTITY_A] inhibition of smooth muscle versus [ENTITY_B] is not attributable to differences in channel inactivation or activation.,INHIBITOR,CPR:4,1,We thus conclude that the more potent nisoldipine inhibition of smooth muscle versus cardiac L-type Ca2+ channels is not attributable to differences in channel inactivation or activation.
"<< Methylenetetrahydrofolate reductase >> deficiency impairs [[ methyltetrahydrofolate ]] synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis.","[ENTITY_A] deficiency impairs [ENTITY_B] synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis.",PRODUCT-OF,CPR:9,4,"Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis."
Increased << Cat3 >>-mediated cationic [[ amino acid ]] transport functionally compensates in Cat1 knockout cell lines.,Increased [ENTITY_A]-mediated cationic [ENTITY_B] transport functionally compensates in Cat1 knockout cell lines.,SUBSTRATE,CPR:9,4,Increased Cat3-mediated cationic amino acid transport functionally compensates in Cat1 knockout cell lines.
"The majority of << L-Arg >> transport is mediated by [[ System y+ ]], although several other carriers have been kinetically defined.","The majority of [ENTITY_A] transport is mediated by [ENTITY_B], although several other carriers have been kinetically defined.",SUBSTRATE,CPR:9,4,"The majority of L-Arg transport is mediated by System y+, although several other carriers have been kinetically defined."
"<< System y+ >> cationic [[ amino acid ]] transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3.","[ENTITY_A] cationic [ENTITY_B] transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3.",SUBSTRATE,CPR:9,4,"System y+ cationic amino acid transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3."
"However, the apparent affinity for << lysine >> transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of [[ Cat3 ]]-mediated transport.","However, the apparent affinity for [ENTITY_A] transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of [ENTITY_B]-mediated transport.",SUBSTRATE,CPR:9,4,"However, the apparent affinity for lysine transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of Cat3-mediated transport."
These results suggest that << Cat3 >> compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity [[ arginine ]] transport.,These results suggest that [ENTITY_A] compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity [ENTITY_B] transport.,SUBSTRATE,CPR:9,4,These results suggest that Cat3 compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity arginine transport.
"Effect of << lintitript >>, a new [[ CCK-A receptor ]] antagonist, on gastric emptying of a solid-liquid meal in humans.","Effect of [ENTITY_A], a new [ENTITY_B] antagonist, on gastric emptying of a solid-liquid meal in humans.",ANTAGONIST,CPR:6,3,"Effect of lintitript, a new CCK-A receptor antagonist, on gastric emptying of a solid-liquid meal in humans."
"We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent << CCK-A receptor >> antagonist [[ lintitript ]].","We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent [ENTITY_A] antagonist [ENTITY_B].",ANTAGONIST,CPR:6,3,"We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent CCK-A receptor antagonist lintitript."
<< Lintitript >> markedly increased postprandial plasma [[ CCK ]] release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo.,[ENTITY_A] markedly increased postprandial plasma [ENTITY_B] release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo.,INDIRECT-UPREGULATOR,CPR:3,0,Lintitript markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo.
<< Lintitript >> markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial [[ PP ]] levels (P<0.01) as compared to placebo.,[ENTITY_A] markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial [ENTITY_B] levels (P<0.01) as compared to placebo.,INDIRECT-DOWNREGULATOR,CPR:4,1,Lintitript markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo.
The study demonstrates for the first time the marked gastrokinetic properties of the new << CCK-A receptor >> antagonist [[ lintitript ]] in humans.,The study demonstrates for the first time the marked gastrokinetic properties of the new [ENTITY_A] antagonist [ENTITY_B] in humans.,ANTAGONIST,CPR:6,3,The study demonstrates for the first time the marked gastrokinetic properties of the new CCK-A receptor antagonist lintitript in humans.
"Concanavalin A (Con A)-induced << IFN-gamma >>, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist [[ isoproterenol ]] and by the selective beta2AR agonist fenoterol.","Concanavalin A (Con A)-induced [ENTITY_A], GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist [ENTITY_B] and by the selective beta2AR agonist fenoterol.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol."
"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective << betaAR >> agonist [[ isoproterenol ]] and by the selective beta2AR agonist fenoterol.","Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective [ENTITY_A] agonist [ENTITY_B] and by the selective beta2AR agonist fenoterol.",AGONIST,CPR:5,2,"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol."
"The observed inhibition on << IFN-gamma >>, GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist [[ ICI 118,551 ]] (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.","The observed inhibition on [ENTITY_A], GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist [ENTITY_B] (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.",INDIRECT-UPREGULATOR,CPR:3,0,"The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist."
"The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective << beta2AR >> antagonist [[ ICI 118,551 ]] (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.","The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective [ENTITY_A] antagonist [ENTITY_B] (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.",ANTAGONIST,CPR:6,3,"The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist."
The selective << beta1AR >> antagonist [[ atenolol ]] (0.3 x 10(-6) M) did not have any effect.,The selective [ENTITY_A] antagonist [ENTITY_B] (0.3 x 10(-6) M) did not have any effect.,ANTAGONIST,CPR:6,3,The selective beta1AR antagonist atenolol (0.3 x 10(-6) M) did not have any effect.
Secretion of << GM-CSF >> protein in the presence of increasing concentrations of [[ isoproterenol ]] followed a similar pattern as observed for GM-CSF mRNA.,Secretion of [ENTITY_A] protein in the presence of increasing concentrations of [ENTITY_B] followed a similar pattern as observed for GM-CSF mRNA.,INDIRECT-UPREGULATOR,CPR:3,0,Secretion of GM-CSF protein in the presence of increasing concentrations of isoproterenol followed a similar pattern as observed for GM-CSF mRNA.
"Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the << beta3AR >> agonist [[ BRL 37344 ]] had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels.","Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the [ENTITY_A] agonist [ENTITY_B] had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels.",AGONIST,CPR:5,2,"Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the beta3AR agonist BRL 37344 had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels."
"All three compounds displayed antagonistic properties against << oxytocin >> in vitro, with [[ carbetocin ]] being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81).","All three compounds displayed antagonistic properties against [ENTITY_A] in vitro, with [ENTITY_B] being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81).",INHIBITOR,CPR:4,1,"All three compounds displayed antagonistic properties against oxytocin in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81)."
These results indicate that << carbetocin >> is a partial agonist/antagonist to the [[ oxytocin receptor ]] while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.,These results indicate that [ENTITY_A] is a partial agonist/antagonist to the [ENTITY_B] while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.,AGONIST,CPR:5,2,These results indicate that carbetocin is a partial agonist/antagonist to the oxytocin receptor while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.
These results indicate that << carbetocin >> is a partial agonist/antagonist to the [[ oxytocin receptor ]] while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.,These results indicate that [ENTITY_A] is a partial agonist/antagonist to the [ENTITY_B] while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.,ANTAGONIST,CPR:6,3,These results indicate that carbetocin is a partial agonist/antagonist to the oxytocin receptor while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.
Crystallographic analysis of the << human phenylalanine hydroxylase catalytic domain >> with bound [[ catechol ]] inhibitors at 2.0 A resolution.,Crystallographic analysis of the [ENTITY_A] with bound [ENTITY_B] inhibitors at 2.0 A resolution.,INHIBITOR,CPR:4,1,Crystallographic analysis of the human phenylalanine hydroxylase catalytic domain with bound catechol inhibitors at 2.0 A resolution.
"The << aromatic amino acid hydroxylases >> represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by [[ catechol ]] derivatives.","The [ENTITY_A] represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by [ENTITY_B] derivatives.",INHIBITOR,CPR:4,1,"The aromatic amino acid hydroxylases represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by catechol derivatives."
"Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of << human phenylalanine hydroxylase >> (hPheOH), cocrystallized with various potent and well-known [[ catechol ]] inhibitors and refined at a resolution of 2.0 A.","Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of [ENTITY_A] (hPheOH), cocrystallized with various potent and well-known [ENTITY_B] inhibitors and refined at a resolution of 2.0 A.",INHIBITOR,CPR:4,1,"Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human phenylalanine hydroxylase (hPheOH), cocrystallized with various potent and well-known catechol inhibitors and refined at a resolution of 2.0 A."
"Crystallographic comparison with the structurally related << rat tyrosine hydroxylase >> binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the [[ catechols ]] versus BH4.","Crystallographic comparison with the structurally related [ENTITY_A] binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the [ENTITY_B] versus BH4.",INHIBITOR,CPR:4,1,"Crystallographic comparison with the structurally related rat tyrosine hydroxylase binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4."
"All GCs including the antagonistic compound << RU486 >> efficiently reduced [[ NF-kappaB ]]-mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression.","All GCs including the antagonistic compound [ENTITY_A] efficiently reduced [ENTITY_B]-mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression.",DOWNREGULATOR,CPR:4,1,"All GCs including the antagonistic compound RU486 efficiently reduced NF-kappaB-mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression."
The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of << glucose >>-induced [[ insulin ]] secretion.,The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of [ENTITY_A]-induced [ENTITY_B] secretion.,INDIRECT-UPREGULATOR,CPR:3,0,The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of glucose-induced insulin secretion.
"These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound << MgATP >> at [[ NBF2 ]], stabilizes prebound 8-azido-ATP binding at NBF1.","These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound [ENTITY_A] at [ENTITY_B], stabilizes prebound 8-azido-ATP binding at NBF1.",SUBSTRATE,CPR:9,4,"These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1."
"<< Epidermal growth factor receptor >> inhibitors currently under investigation include the small molecules [[ gefitinib ]] (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).","[ENTITY_A] inhibitors currently under investigation include the small molecules [ENTITY_B] (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).",INHIBITOR,CPR:4,1,"Epidermal growth factor receptor inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)."
"Agents that have only begun to undergo clinical evaluation include << CI-1033 >>, an irreversible pan-[[ erbB ]] tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2).","Agents that have only begun to undergo clinical evaluation include [ENTITY_A], an irreversible pan-[ENTITY_B] tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2).",INHIBITOR,CPR:4,1,"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)."
<< Alprenolol >> and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the [[ beta 1-adrenoceptors ]] of rat left atria.,[ENTITY_A] and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the [ENTITY_B] of rat left atria.,ANTAGONIST,CPR:6,3,Alprenolol and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the beta 1-adrenoceptors of rat left atria.
"<< Alprenolol >> and BAAM at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of [[ beta-adrenoceptor ]] blockade.","[ENTITY_A] and BAAM at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of [ENTITY_B] blockade.",INHIBITOR,CPR:4,1,"Alprenolol and BAAM at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of beta-adrenoceptor blockade."
"Alprenolol and BAAM also caused surmountable antagonism of << isoprenaline >> responses, and this [[ beta 1-adrenoceptor ]] antagonism was slowly reversible.","Alprenolol and BAAM also caused surmountable antagonism of [ENTITY_A] responses, and this [ENTITY_B] antagonism was slowly reversible.",AGONIST,CPR:5,2,"Alprenolol and BAAM also caused surmountable antagonism of isoprenaline responses, and this beta 1-adrenoceptor antagonism was slowly reversible."
"<< Alprenolol >> and BAAM also caused surmountable antagonism of isoprenaline responses, and this [[ beta 1-adrenoceptor ]] antagonism was slowly reversible.","[ENTITY_A] and BAAM also caused surmountable antagonism of isoprenaline responses, and this [ENTITY_B] antagonism was slowly reversible.",ANTAGONIST,CPR:6,3,"Alprenolol and BAAM also caused surmountable antagonism of isoprenaline responses, and this beta 1-adrenoceptor antagonism was slowly reversible."
We conclude that << alprenolol >> and BAAM are competitive slowly reversible [[ beta 1-adrenoceptor ]] antagonists on rat left atria.,We conclude that [ENTITY_A] and BAAM are competitive slowly reversible [ENTITY_B] antagonists on rat left atria.,ANTAGONIST,CPR:6,3,We conclude that alprenolol and BAAM are competitive slowly reversible beta 1-adrenoceptor antagonists on rat left atria.
Discovery and optimization of << anthranilic acid sulfonamides >> as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of [[ albumin ]] binding.,Discovery and optimization of [ENTITY_A] as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of [ENTITY_B] binding.,DOWNREGULATOR,CPR:4,1,Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding.
<< Adenine phosphoribosyltransferase >> plays a role in purine salvage by catalyzing the direct conversion of adenine to [[ adenosine monophosphate ]].,[ENTITY_A] plays a role in purine salvage by catalyzing the direct conversion of adenine to [ENTITY_B].,PRODUCT-OF,CPR:9,4,Adenine phosphoribosyltransferase plays a role in purine salvage by catalyzing the direct conversion of adenine to adenosine monophosphate.
"BACKGROUND: Since the introduction of the first << cholinesterase >> inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, [[ donepezil ]], galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.","BACKGROUND: Since the introduction of the first [ENTITY_A] inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, [ENTITY_B], galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.",INHIBITOR,CPR:4,1,"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase."
"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of << acetylcholine >>, an important neurotransmitter associated with memory, by blocking the enzyme [[ acetylcholinesterase ]].","BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of [ENTITY_A], an important neurotransmitter associated with memory, by blocking the enzyme [ENTITY_B].",SUBSTRATE,CPR:9,4,"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase."
"Mitiglinide (<< KAD-1229 >>), a new anti-diabetic drug, is thought to stimulate [[ insulin ]] secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells.","Mitiglinide ([ENTITY_A]), a new anti-diabetic drug, is thought to stimulate [ENTITY_B] secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Mitiglinide (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells."
"Mitiglinide (<< KAD-1229 >>), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the [[ ATP-sensitive K+ (K(ATP)) channels ]] in pancreatic beta-cells.","Mitiglinide ([ENTITY_A]), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the [ENTITY_B] in pancreatic beta-cells.",INHIBITOR,CPR:4,1,"Mitiglinide (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells."
"Patch-clamp analysis using inside-out recording configuration showed that << mitiglinide >> inhibits the [[ Kir6.2 ]]/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 microM).","Patch-clamp analysis using inside-out recording configuration showed that [ENTITY_A] inhibits the [ENTITY_B]/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 microM).",INHIBITOR,CPR:4,1,"Patch-clamp analysis using inside-out recording configuration showed that mitiglinide inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 microM)."
"<< Nateglinide >> inhibits [[ Kir6.2 ]]/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM).","[ENTITY_A] inhibits [ENTITY_B]/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM).",INHIBITOR,CPR:4,1,"Nateglinide inhibits Kir6.2/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM)."
"These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the Kir6.2/SUR1 complex, i.e., the pancreatic beta-cell << K(ATP) channel >>, and suggest that [[ mitiglinide ]] may be a clinically useful anti-diabetic drug.","These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the Kir6.2/SUR1 complex, i.e., the pancreatic beta-cell [ENTITY_A], and suggest that [ENTITY_B] may be a clinically useful anti-diabetic drug.",AGONIST,CPR:5,2,"These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the Kir6.2/SUR1 complex, i.e., the pancreatic beta-cell K(ATP) channel, and suggest that mitiglinide may be a clinically useful anti-diabetic drug."
"Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly << telmisartan >>, are partial agonists at [[ peroxisome proliferator-activated receptor-γ ]].","Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly [ENTITY_A], are partial agonists at [ENTITY_B].",AGONIST,CPR:5,2,"Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly telmisartan, are partial agonists at peroxisome proliferator-activated receptor-γ."
"Although generally highly specific for << angiotensin II type 1 receptors >>, some ARBs, particularly [[ telmisartan ]], are partial agonists at peroxisome proliferator-activated receptor-γ.","Although generally highly specific for [ENTITY_A], some ARBs, particularly [ENTITY_B], are partial agonists at peroxisome proliferator-activated receptor-γ.",ANTAGONIST,CPR:6,3,"Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly telmisartan, are partial agonists at peroxisome proliferator-activated receptor-γ."
"Direct-acting << CB1 >> agonists, including [[ Δ(9)-tetrahydrocannabinol ]], WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.","Direct-acting [ENTITY_A] agonists, including [ENTITY_B], WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",AGONIST,CPR:5,2,"Direct-acting CB1 agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia."
"Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the << CB2 >> agonist [[ AM1241 ]] [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects.","Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the [ENTITY_A] agonist [ENTITY_B] [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects.",AGONIST,CPR:5,2,"Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the CB2 agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects."
"In further studies, the diuretic effects of the << CB1 >> agonist [[ AM4054 ]] were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].","In further studies, the diuretic effects of the [ENTITY_A] agonist [ENTITY_B] were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",AGONIST,CPR:5,2,"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]."
"In further studies, the diuretic effects of the << CB1 >> agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with [[ rimonabant ]], but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].","In further studies, the diuretic effects of the [ENTITY_A] agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with [ENTITY_B], but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",ANTAGONIST,CPR:6,3,"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]."
"<< N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide >> (NS-398), a selective [[ cyclooxygenase-2 ]] inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis.","[ENTITY_A] (NS-398), a selective [ENTITY_B] inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis.",INHIBITOR,CPR:4,1,"N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis."
"Mutation of arginine 228 to << lysine >> enhances the [[ glucosyltransferase ]] activity of bovine beta-1,4-galactosyltransferase I.","Mutation of arginine 228 to [ENTITY_A] enhances the [ENTITY_B] activity of bovine beta-1,4-galactosyltransferase I.",UPREGULATOR,CPR:3,0,"Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I."
"Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from << UDP-Glc >> to GlcNAc ([[ Glc-T ]] activity), albeit at only 0.3% efficiency.","Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from [ENTITY_A] to GlcNAc ([ENTITY_B] activity), albeit at only 0.3% efficiency.",SUBSTRATE,CPR:9,4,"Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency."
Discovery of novel << 2-hydroxydiarylamide >> derivatives as [[ TMPRSS4 ]] inhibitors.,Discovery of novel [ENTITY_A] derivatives as [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Discovery of novel 2-hydroxydiarylamide derivatives as TMPRSS4 inhibitors.
"In this study, a novel series of << 2-hydroxydiarylamide >> derivatives were synthesized and evaluated for inhibiting [[ TMPRSS4 ]] serine protease activity and suppressing cancer cell invasion.","In this study, a novel series of [ENTITY_A] derivatives were synthesized and evaluated for inhibiting [ENTITY_B] serine protease activity and suppressing cancer cell invasion.",INHIBITOR,CPR:4,1,"In this study, a novel series of 2-hydroxydiarylamide derivatives were synthesized and evaluated for inhibiting TMPRSS4 serine protease activity and suppressing cancer cell invasion."
"The selective << betaAR >> agonist [[ isoproterenol ]] caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region.","The selective [ENTITY_A] agonist [ENTITY_B] caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region.",AGONIST,CPR:5,2,"The selective betaAR agonist isoproterenol caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region."
"The selective << beta1AR >> antagonists atenolol and metoprolol blocked [[ isoproterenol ]]-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.","The selective [ENTITY_A] antagonists atenolol and metoprolol blocked [ENTITY_B]-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.",AGONIST,CPR:5,2,"The selective beta1AR antagonists atenolol and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively."
"The selective << beta1AR >> antagonists [[ atenolol ]] and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.","The selective [ENTITY_A] antagonists [ENTITY_B] and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.",ANTAGONIST,CPR:6,3,"The selective beta1AR antagonists atenolol and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively."
"In contrast, the selective << beta2AR >> antagonists ICI-118,551 and butoxamine inhibited [[ isoproterenol ]]-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).","In contrast, the selective [ENTITY_A] antagonists ICI-118,551 and butoxamine inhibited [ENTITY_B]-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).",AGONIST,CPR:5,2,"In contrast, the selective beta2AR antagonists ICI-118,551 and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively)."
"In contrast, the selective << beta2AR >> antagonists ICI-118,551 and [[ butoxamine ]] inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).","In contrast, the selective [ENTITY_A] antagonists ICI-118,551 and [ENTITY_B] inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).",ANTAGONIST,CPR:6,3,"In contrast, the selective beta2AR antagonists ICI-118,551 and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively)."
"Together, this pharmacological profile of subtype-selective betaAR antagonists indicates that in this model, << beta1AR >> activation is responsible for the enhanced hippocampal CA3 network activity initiated by [[ isoproterenol ]].","Together, this pharmacological profile of subtype-selective betaAR antagonists indicates that in this model, [ENTITY_A] activation is responsible for the enhanced hippocampal CA3 network activity initiated by [ENTITY_B].",AGONIST,CPR:5,2,"Together, this pharmacological profile of subtype-selective betaAR antagonists indicates that in this model, beta1AR activation is responsible for the enhanced hippocampal CA3 network activity initiated by isoproterenol."
<< P2Y(2) receptor >> agonist [[ INS37217 ]] enhances functional recovery after detachment caused by subretinal injection in normal and rds mice.,[ENTITY_A] agonist [ENTITY_B] enhances functional recovery after detachment caused by subretinal injection in normal and rds mice.,AGONIST,CPR:5,2,P2Y(2) receptor agonist INS37217 enhances functional recovery after detachment caused by subretinal injection in normal and rds mice.
Selective antagonism of << GluR5 >> kainate-receptor-mediated synaptic currents by [[ topiramate ]] in rat basolateral amygdala neurons.,Selective antagonism of [ENTITY_A] kainate-receptor-mediated synaptic currents by [ENTITY_B] in rat basolateral amygdala neurons.,ANTAGONIST,CPR:6,3,Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons.
"In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, << topiramate >> at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by [[ kainate receptors ]] containing the GluR5 subunit.","In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, [ENTITY_A] at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by [ENTITY_B] containing the GluR5 subunit.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, topiramate at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by kainate receptors containing the GluR5 subunit."
"<< Topiramate >> also partially depressed predominantly [[ AMPA-receptor ]]-mediated EPSCs, but with lower efficacy.","[ENTITY_A] also partially depressed predominantly [ENTITY_B]-mediated EPSCs, but with lower efficacy.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Topiramate also partially depressed predominantly AMPA-receptor-mediated EPSCs, but with lower efficacy."
Inhibition of << GluR5 >> kainate receptors could represent a key mechanism underlying the anticonvulsant activity of [[ topiramate ]].,Inhibition of [ENTITY_A] kainate receptors could represent a key mechanism underlying the anticonvulsant activity of [ENTITY_B].,INHIBITOR,CPR:4,1,Inhibition of GluR5 kainate receptors could represent a key mechanism underlying the anticonvulsant activity of topiramate.
Density functional theory calculations using the hybrid functional B3LYP have been performed to study the << methyl >> transfer step in [[ glycine N-methyltransferase ]] (GNMT).,Density functional theory calculations using the hybrid functional B3LYP have been performed to study the [ENTITY_A] transfer step in [ENTITY_B] (GNMT).,SUBSTRATE,CPR:9,4,Density functional theory calculations using the hybrid functional B3LYP have been performed to study the methyl transfer step in glycine N-methyltransferase (GNMT).
The starting point for the calculations is the recent X-ray crystal structure of << GNMT >> complexed with [[ SAM ]] and acetate.,The starting point for the calculations is the recent X-ray crystal structure of [ENTITY_A] complexed with [ENTITY_B] and acetate.,SUBSTRATE,CPR:9,4,The starting point for the calculations is the recent X-ray crystal structure of GNMT complexed with SAM and acetate.
"<< Dasatinib >> (BMS-354825) inhibits [[ KIT ]]D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.","[ENTITY_A] (BMS-354825) inhibits [ENTITY_B]D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.",INHIBITOR,CPR:4,1,"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis."
<< Dasatinib >> (BMS-354825) is a novel orally bioavailable [[ SRC ]]/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).,[ENTITY_A] (BMS-354825) is a novel orally bioavailable [ENTITY_B]/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).,INHIBITOR,CPR:4,1,Dasatinib (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).
"In this study, we demonstrate significant inhibitory activity of << dasatinib >> against both wild-type [[ KIT ]] and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays.","In this study, we demonstrate significant inhibitory activity of [ENTITY_A] against both wild-type [ENTITY_B] and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays.",INHIBITOR,CPR:4,1,"In this study, we demonstrate significant inhibitory activity of dasatinib against both wild-type KIT and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays."
"Additionally, << dasatinib >> leads to growth inhibition of a [[ KIT ]]D816V-harboring human masto-cytosis cell line.","Additionally, [ENTITY_A] leads to growth inhibition of a [ENTITY_B]D816V-harboring human masto-cytosis cell line.",INHIBITOR,CPR:4,1,"Additionally, dasatinib leads to growth inhibition of a KITD816V-harboring human masto-cytosis cell line."
Dopamine D(2) receptor-induced << COX-2 >>-mediated production of [[ prostaglandin E(2) ]] in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent.,Dopamine D(2) receptor-induced [ENTITY_A]-mediated production of [ENTITY_B] in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent.,SUBSTRATE,CPR:9,4,Dopamine D(2) receptor-induced COX-2-mediated production of prostaglandin E(2) in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent.
"The effect was counteracted by the << D(2) >> antagonist [[ eticlopride ]], pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA.","The effect was counteracted by the [ENTITY_A] antagonist [ENTITY_B], pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA.",ANTAGONIST,CPR:6,3,"The effect was counteracted by the D(2) antagonist eticlopride, pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA."
"It was also antagonized by the non-specific << cyclooxygenase >> (COX) inhibitor, [[ indomethacin ]], and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate.","It was also antagonized by the non-specific [ENTITY_A] (COX) inhibitor, [ENTITY_B], and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate.",INHIBITOR,CPR:4,1,"It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate."
"Both the non-specific << phospholipase A(2) >> inhibitor, [[ quinacrine ]], and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective.","Both the non-specific [ENTITY_A] inhibitor, [ENTITY_B], and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective.",INHIBITOR,CPR:4,1,"Both the non-specific phospholipase A(2) inhibitor, quinacrine, and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective."
"The results reinforce previous assumptions that << dopamine >> may interact with eicosanoid metabolism by means of [[ D(2) receptor ]] activation, and implicate an involvement of cPLA(2) and COX-2 in this effect.","The results reinforce previous assumptions that [ENTITY_A] may interact with eicosanoid metabolism by means of [ENTITY_B] activation, and implicate an involvement of cPLA(2) and COX-2 in this effect.",ACTIVATOR,CPR:3,0,"The results reinforce previous assumptions that dopamine may interact with eicosanoid metabolism by means of D(2) receptor activation, and implicate an involvement of cPLA(2) and COX-2 in this effect."
A high throughput assay for the glucuronidation of << 7-hydroxy-4-trifluoromethylcoumarin >> by recombinant [[ human UDP-glucuronosyltransferases ]] and liver microsomes.,A high throughput assay for the glucuronidation of [ENTITY_A] by recombinant [ENTITY_B] and liver microsomes.,SUBSTRATE,CPR:9,4,A high throughput assay for the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin by recombinant human UDP-glucuronosyltransferases and liver microsomes.
2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of << 7-hydroxy-4-trifluoromethylcoumarin >> (HFC) for several [[ UGTs ]].,2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of [ENTITY_A] (HFC) for several [ENTITY_B].,SUBSTRATE,CPR:9,4,2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs.
3.  We have used this method to screen 11 recombinant << human UGTs >> for [[ HFC ]] glucuronidation activity and studied the reaction kinetics with the most active enzymes.,3.  We have used this method to screen 11 recombinant [ENTITY_A] for [ENTITY_B] glucuronidation activity and studied the reaction kinetics with the most active enzymes.,SUBSTRATE,CPR:9,4,3.  We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes.
"4.  At a substrate concentration of 20 µM, the most active << HFC >> glucuronidation catalysts were [[ UGT1A10 ]] followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.","4.  At a substrate concentration of 20 µM, the most active [ENTITY_A] glucuronidation catalysts were [ENTITY_B] followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.",SUBSTRATE,CPR:9,4,"4.  At a substrate concentration of 20 µM, the most active HFC glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs."
UGT1A6 exhibited a significantly higher Vmax and Km values toward both << HFC >> and UDP-glucuronic acid than the other [[ UGTs ]].,UGT1A6 exhibited a significantly higher Vmax and Km values toward both [ENTITY_A] and UDP-glucuronic acid than the other [ENTITY_B].,SUBSTRATE,CPR:9,4,UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs.
This inhibition was blocked when mice were pretreated with the selective << H3R >> agonist [[ R-(alpha)-methyl-histamine ]] (10 mg/kg).,This inhibition was blocked when mice were pretreated with the selective [ENTITY_A] agonist [ENTITY_B] (10 mg/kg).,AGONIST,CPR:5,2,This inhibition was blocked when mice were pretreated with the selective H3R agonist R-(alpha)-methyl-histamine (10 mg/kg).
"The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the << 5-HT(1A/1B)-receptor >> antagonist [[ (-)-propranolol ]] and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it.","The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the [ENTITY_A] antagonist [ENTITY_B] and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it.",ANTAGONIST,CPR:6,3,"The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it."
"The << 5-HT(2B/2C)-receptor >> antagonist [[ SB 206553 ]] facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect.","The [ENTITY_A] antagonist [ENTITY_B] facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect.",ANTAGONIST,CPR:6,3,"The 5-HT(2B/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect."
"These results suggest that << clomipramine >> induces hyperglycemia in mice by blocking the [[ 5-HT(2B ) ]]and/or 5-HT(2C) receptors, which results in facilitation of adrenaline release.","These results suggest that [ENTITY_A] induces hyperglycemia in mice by blocking the [ENTITY_B]and/or 5-HT(2C) receptors, which results in facilitation of adrenaline release.",INHIBITOR,CPR:4,1,"These results suggest that clomipramine induces hyperglycemia in mice by blocking the 5-HT(2B )and/or 5-HT(2C) receptors, which results in facilitation of adrenaline release."
"<< Phosphatidylserine >> (PtdSer) is made in mammalian cells by two [[ PtdSer synthases ]], PSS1 and PSS2.","[ENTITY_A] (PtdSer) is made in mammalian cells by two [ENTITY_B], PSS1 and PSS2.",PRODUCT-OF,CPR:9,4,"Phosphatidylserine (PtdSer) is made in mammalian cells by two PtdSer synthases, PSS1 and PSS2."
"Moreover, a normal level of expression of << PSS1 >> and/or PSS2 is not required for generating the pool of [[ PtdSer ]] externalized during apoptosis.","Moreover, a normal level of expression of [ENTITY_A] and/or PSS2 is not required for generating the pool of [ENTITY_B] externalized during apoptosis.",PRODUCT-OF,CPR:9,4,"Moreover, a normal level of expression of PSS1 and/or PSS2 is not required for generating the pool of PtdSer externalized during apoptosis."
"<< PKC >> isoforms did show different sensitivity and selectivity for down-regulation by [[ I3A ]] and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-92, and Colo-205 cells.","[ENTITY_A] isoforms did show different sensitivity and selectivity for down-regulation by [ENTITY_B] and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-92, and Colo-205 cells.",DOWNREGULATOR,CPR:4,1,"PKC isoforms did show different sensitivity and selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-92, and Colo-205 cells."
<< I3A >> induced a higher level of secretion of the inflammatory cytokine [[ interleukin 6 ]] compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.,[ENTITY_A] induced a higher level of secretion of the inflammatory cytokine [ENTITY_B] compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.,INDIRECT-UPREGULATOR,CPR:3,0,I3A induced a higher level of secretion of the inflammatory cytokine interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.
The in vitro kinase activity of << PKC-alpha >> induced by [[ I3A ]] was lower than that induced by PMA.,The in vitro kinase activity of [ENTITY_A] induced by [ENTITY_B] was lower than that induced by PMA.,ACTIVATOR,CPR:3,0,The in vitro kinase activity of PKC-alpha induced by I3A was lower than that induced by PMA.
"<< Type I deiodinase >>, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by [[ TCPP ]], while TDCPP induced CYP3A37 and CYP2H1.","[ENTITY_A], liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by [ENTITY_B], while TDCPP induced CYP3A37 and CYP2H1.",INDIRECT-UPREGULATOR,CPR:3,0,"Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while TDCPP induced CYP3A37 and CYP2H1."
"The results suggested that both the << EtOAc >> extract and berberine were able to activate [[ PPARα/β/γ ]], and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine.","The results suggested that both the [ENTITY_A] extract and berberine were able to activate [ENTITY_B], and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine.",AGONIST-ACTIVATOR,CPR:5,2,"The results suggested that both the EtOAc extract and berberine were able to activate PPARα/β/γ, and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine."
"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific << renin >>-angiotensin-aldosterone system (RAAS) blockade by renin-inhibitor [[ remikiren ]] could be predicted from pretreatment renal vascular tone.","This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific [ENTITY_A]-angiotensin-aldosterone system (RAAS) blockade by renin-inhibitor [ENTITY_B] could be predicted from pretreatment renal vascular tone.",INHIBITOR,CPR:4,1,"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin-angiotensin-aldosterone system (RAAS) blockade by renin-inhibitor remikiren could be predicted from pretreatment renal vascular tone."
TREK-1 currents are insensitive to pharmacological agents that block << TWIK-1 >> activity such as [[ quinine ]] and quinidine.,TREK-1 currents are insensitive to pharmacological agents that block [ENTITY_A] activity such as [ENTITY_B] and quinidine.,INHIBITOR,CPR:4,1,TREK-1 currents are insensitive to pharmacological agents that block TWIK-1 activity such as quinine and quinidine.
"<< CGP 12177A >> mediates cardiostimulation by activation of the 'putative' [[ beta(4)-adrenoceptor ]]; however, it has recently been reported that disruption of the beta(1)-adrenoceptor gene abolishes this effect.","[ENTITY_A] mediates cardiostimulation by activation of the 'putative' [ENTITY_B]; however, it has recently been reported that disruption of the beta(1)-adrenoceptor gene abolishes this effect.",ACTIVATOR,CPR:3,0,"CGP 12177A mediates cardiostimulation by activation of the 'putative' beta(4)-adrenoceptor; however, it has recently been reported that disruption of the beta(1)-adrenoceptor gene abolishes this effect."
<< CGP 12177A >> but not isoprenaline initiated arrhythmias at lower concentrations following [[ beta(1)-adrenoceptor ]] overexpression.,[ENTITY_A] but not isoprenaline initiated arrhythmias at lower concentrations following [ENTITY_B] overexpression.,INDIRECT-UPREGULATOR,CPR:3,0,CGP 12177A but not isoprenaline initiated arrhythmias at lower concentrations following beta(1)-adrenoceptor overexpression.
<< (125)I-Cyanopindolol >> saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in [[ beta(1)-adrenoceptors ]].,[ENTITY_A] saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,(125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in beta(1)-adrenoceptors.
"(3)H-CGP 12177A saturation binding, in the presence of << propranolol >>, increased approximately 5-fold following overexpression of [[ beta(1)-adrenoceptors ]].","(3)H-CGP 12177A saturation binding, in the presence of [ENTITY_A], increased approximately 5-fold following overexpression of [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"(3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of beta(1)-adrenoceptors."
"In contrast, in the presence of << Ca >> UFH accelerated the inhibition of [[ factor Xa ]] by antithrombin 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin.","In contrast, in the presence of [ENTITY_A] UFH accelerated the inhibition of [ENTITY_B] by antithrombin 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin.",INHIBITOR,CPR:4,1,"In contrast, in the presence of Ca UFH accelerated the inhibition of factor Xa by antithrombin 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin."
"INTRODUCTION: The principal aim of this study was to assess the efficacy of << quinidine >> in suppressing [[ IKr ]] in vitro and in modulating the rate dependence of the QT interval in the ""SQT1"" form of the short QT syndrome.","INTRODUCTION: The principal aim of this study was to assess the efficacy of [ENTITY_A] in suppressing [ENTITY_B] in vitro and in modulating the rate dependence of the QT interval in the ""SQT1"" form of the short QT syndrome.",INDIRECT-DOWNREGULATOR,CPR:4,1,"INTRODUCTION: The principal aim of this study was to assess the efficacy of quinidine in suppressing IKr in vitro and in modulating the rate dependence of the QT interval in the ""SQT1"" form of the short QT syndrome."
CONCLUSION: Oral << quinidine >> is effective in suppressing the gain of function in [[ IKr ]] responsible for some cases of short QT syndrome with a mutation in HERG and thus restoring normal rate dependence of the QT interval and rendering ventricular tachycardia/ventricular fibrillation noninducible.,CONCLUSION: Oral [ENTITY_A] is effective in suppressing the gain of function in [ENTITY_B] responsible for some cases of short QT syndrome with a mutation in HERG and thus restoring normal rate dependence of the QT interval and rendering ventricular tachycardia/ventricular fibrillation noninducible.,INDIRECT-DOWNREGULATOR,CPR:4,1,CONCLUSION: Oral quinidine is effective in suppressing the gain of function in IKr responsible for some cases of short QT syndrome with a mutation in HERG and thus restoring normal rate dependence of the QT interval and rendering ventricular tachycardia/ventricular fibrillation noninducible.
"The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of prostaglandin E2 (PGE2) reflecting << cyclooxygenase (COX)-2 >>-mediated [[ PGE2 ]] release were 47 microg/ml and 0.6 microg/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively.","The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of prostaglandin E2 (PGE2) reflecting [ENTITY_A]-mediated [ENTITY_B] release were 47 microg/ml and 0.6 microg/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively.",PRODUCT-OF,CPR:9,4,"The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of prostaglandin E2 (PGE2) reflecting cyclooxygenase (COX)-2-mediated PGE2 release were 47 microg/ml and 0.6 microg/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively."
Our results indicate that Salix extract 1520L inhibits << COX-2 >>-mediated [[ PGE2 ]] release through compounds other than salicin or salicylate.,Our results indicate that Salix extract 1520L inhibits [ENTITY_A]-mediated [ENTITY_B] release through compounds other than salicin or salicylate.,PRODUCT-OF,CPR:9,4,Our results indicate that Salix extract 1520L inhibits COX-2-mediated PGE2 release through compounds other than salicin or salicylate.
"<< Follicle-stimulating hormone >> (FSH), a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex [[ steroids ]] and gametes.","[ENTITY_A] (FSH), a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex [ENTITY_B] and gametes.",PRODUCT-OF,CPR:9,4,"Follicle-stimulating hormone (FSH), a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex steroids and gametes."
"Humans with << FSH beta >> gene mutations tend to have a more severe phenotype than those with FSHR gene mutations, although infertility and varying degrees of impaired sex [[ steroid ]] production occur in both types of mutations.","Humans with [ENTITY_A] gene mutations tend to have a more severe phenotype than those with FSHR gene mutations, although infertility and varying degrees of impaired sex [ENTITY_B] production occur in both types of mutations.",PRODUCT-OF,CPR:9,4,"Humans with FSH beta gene mutations tend to have a more severe phenotype than those with FSHR gene mutations, although infertility and varying degrees of impaired sex steroid production occur in both types of mutations."
"OBJECTIVES: The aim of the current study was to assess the activity of << rolipram >>, a nonsubtype-selective [[ PDE4 ]] inhibitor, in several animal models predictive of antipsychotic-like efficacy and side-effect liability and to use PDE4B wild-type and knockout mice to begin to understand the subtypes involved in the activity of rolipram.","OBJECTIVES: The aim of the current study was to assess the activity of [ENTITY_A], a nonsubtype-selective [ENTITY_B] inhibitor, in several animal models predictive of antipsychotic-like efficacy and side-effect liability and to use PDE4B wild-type and knockout mice to begin to understand the subtypes involved in the activity of rolipram.",INHIBITOR,CPR:4,1,"OBJECTIVES: The aim of the current study was to assess the activity of rolipram, a nonsubtype-selective PDE4 inhibitor, in several animal models predictive of antipsychotic-like efficacy and side-effect liability and to use PDE4B wild-type and knockout mice to begin to understand the subtypes involved in the activity of rolipram."
These results suggest that PDE4B mediates the antipsychotic effects of rolipram in CAR and that the << PDE4B >>-regulated [[ cyclic adenosine monophosphate ]] signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.,These results suggest that PDE4B mediates the antipsychotic effects of rolipram in CAR and that the [ENTITY_A]-regulated [ENTITY_B] signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.,SUBSTRATE,CPR:9,4,These results suggest that PDE4B mediates the antipsychotic effects of rolipram in CAR and that the PDE4B-regulated cyclic adenosine monophosphate signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.
"<< Cat-1 >>, the transporter for the essential [[ amino acids ]], arginine and lysine, is one of the up-regulated genes.","[ENTITY_A], the transporter for the essential [ENTITY_B], arginine and lysine, is one of the up-regulated genes.",SUBSTRATE,CPR:9,4,"Cat-1, the transporter for the essential amino acids, arginine and lysine, is one of the up-regulated genes."
RESULTS: Fractionated bulb extracts and the two isolated << steroidal glycoalkaloids >> (1) and (2) induced NO production and [[ TGF-β receptor I ]] mRNA expression in fibroblast cell culture.,RESULTS: Fractionated bulb extracts and the two isolated [ENTITY_A] (1) and (2) induced NO production and [ENTITY_B] mRNA expression in fibroblast cell culture.,INDIRECT-UPREGULATOR,CPR:3,0,RESULTS: Fractionated bulb extracts and the two isolated steroidal glycoalkaloids (1) and (2) induced NO production and TGF-β receptor I mRNA expression in fibroblast cell culture.
"On the basis of data obtained in rabbits, the imidazoline receptor ligand << rilmenidine >> has been suggested to decrease blood pressure in humans by activating central [[ alpha(2A)-adrenoceptors ]].","On the basis of data obtained in rabbits, the imidazoline receptor ligand [ENTITY_A] has been suggested to decrease blood pressure in humans by activating central [ENTITY_B].",UPREGULATOR,CPR:3,0,"On the basis of data obtained in rabbits, the imidazoline receptor ligand rilmenidine has been suggested to decrease blood pressure in humans by activating central alpha(2A)-adrenoceptors."
A prerequisite for this hypothesis was the unproved assumption that rabbit and human << alpha(2A)-adrenoceptors >> are equally activated by [[ rilmenidine ]].,A prerequisite for this hypothesis was the unproved assumption that rabbit and human [ENTITY_A] are equally activated by [ENTITY_B].,ACTIVATOR,CPR:3,0,A prerequisite for this hypothesis was the unproved assumption that rabbit and human alpha(2A)-adrenoceptors are equally activated by rilmenidine.
Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of alpha(2)-adrenoceptor agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the << alpha(2)-adrenoceptor >>-mediated inhibition induced by [[ moxonidine ]].,Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of alpha(2)-adrenoceptor agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the [ENTITY_A]-mediated inhibition induced by [ENTITY_B].,INHIBITOR,CPR:4,1,Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of alpha(2)-adrenoceptor agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the alpha(2)-adrenoceptor-mediated inhibition induced by moxonidine.
"In the rabbit pulmonary artery, << rilmenidine >> and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the [[ alpha(2)-autoreceptors ]], sharing this property with rauwolscine, phentolamine, and idazoxan.","In the rabbit pulmonary artery, [ENTITY_A] and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the [ENTITY_B], sharing this property with rauwolscine, phentolamine, and idazoxan.",ANTAGONIST,CPR:6,3,"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the alpha(2)-autoreceptors, sharing this property with rauwolscine, phentolamine, and idazoxan."
"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with << alpha(2A)-autoreceptors >>, at which, however, both rilmenidine and [[ oxymetazoline ]] exhibit different properties (antagonism and agonism, respectively).","The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with [ENTITY_A], at which, however, both rilmenidine and [ENTITY_B] exhibit different properties (antagonism and agonism, respectively).",AGONIST,CPR:5,2,"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with alpha(2A)-autoreceptors, at which, however, both rilmenidine and oxymetazoline exhibit different properties (antagonism and agonism, respectively)."
"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with << alpha(2A)-autoreceptors >>, at which, however, both [[ rilmenidine ]] and oxymetazoline exhibit different properties (antagonism and agonism, respectively).","The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with [ENTITY_A], at which, however, both [ENTITY_B] and oxymetazoline exhibit different properties (antagonism and agonism, respectively).",ANTAGONIST,CPR:6,3,"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with alpha(2A)-autoreceptors, at which, however, both rilmenidine and oxymetazoline exhibit different properties (antagonism and agonism, respectively)."
"The antagonistic property of << rilmenidine >> at [[ human alpha(2A)-adrenoceptors ]] indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of alpha(2A)-adrenoceptors but other, presumably I(1)-imidazoline receptors, are probably involved.","The antagonistic property of [ENTITY_A] at [ENTITY_B] indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of alpha(2A)-adrenoceptors but other, presumably I(1)-imidazoline receptors, are probably involved.",ANTAGONIST,CPR:6,3,"The antagonistic property of rilmenidine at human alpha(2A)-adrenoceptors indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of alpha(2A)-adrenoceptors but other, presumably I(1)-imidazoline receptors, are probably involved."
"<< Cetrorelix >> completely blocked the rise of levels of the two most abundant species, 5.0 kb and 4.5 kb, of the [[ GnRH-R ]] mRNA, during both the infantile and the juvenile periods.","[ENTITY_A] completely blocked the rise of levels of the two most abundant species, 5.0 kb and 4.5 kb, of the [ENTITY_B] mRNA, during both the infantile and the juvenile periods.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Cetrorelix completely blocked the rise of levels of the two most abundant species, 5.0 kb and 4.5 kb, of the GnRH-R mRNA, during both the infantile and the juvenile periods."
<< Cetrorelix >> also abolished the developmental rise of the [[ gonadotropin beta ]] subunit mRNAs during the two periods of the study.,[ENTITY_A] also abolished the developmental rise of the [ENTITY_B] subunit mRNAs during the two periods of the study.,INDIRECT-DOWNREGULATOR,CPR:4,1,Cetrorelix also abolished the developmental rise of the gonadotropin beta subunit mRNAs during the two periods of the study.
"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating << histamine H1-receptor >> antagonists [[ terfenadine ]], astemizole, loratadine, and acrivastine are reviewed.","The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating [ENTITY_A] antagonists [ENTITY_B], astemizole, loratadine, and acrivastine are reviewed.",ANTAGONIST,CPR:6,3,"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating histamine H1-receptor antagonists terfenadine, astemizole, loratadine, and acrivastine are reviewed."
<< Terfenadine >> and astemizole are chemically unrelated to [[ histamine H1-receptor ]] antagonists such as diphenhydramine and chlorpheniramine.,[ENTITY_A] and astemizole are chemically unrelated to [ENTITY_B] antagonists such as diphenhydramine and chlorpheniramine.,ANTAGONIST,CPR:6,3,Terfenadine and astemizole are chemically unrelated to histamine H1-receptor antagonists such as diphenhydramine and chlorpheniramine.
Anti-inflammatory effect of << prunetin >> via the suppression of [[ NF-κB ]] pathway.,Anti-inflammatory effect of [ENTITY_A] via the suppression of [ENTITY_B] pathway.,INHIBITOR,CPR:4,1,Anti-inflammatory effect of prunetin via the suppression of NF-κB pathway.
Promoter assay revealed that << prunetin >> inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of [[ iNOS ]] and COX-2 at the transcriptional level.,Promoter assay revealed that [ENTITY_A] inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of [ENTITY_B] and COX-2 at the transcriptional level.,INDIRECT-DOWNREGULATOR,CPR:4,1,Promoter assay revealed that prunetin inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of iNOS and COX-2 at the transcriptional level.
"In addition, << prunetin >> inhibits [[ NF-κB ]]-dependent inflammatory responses by modulating IκB kinase (IKK)-inhibitor κBα (IκBα)-NF-κB signaling.","In addition, [ENTITY_A] inhibits [ENTITY_B]-dependent inflammatory responses by modulating IκB kinase (IKK)-inhibitor κBα (IκBα)-NF-κB signaling.",INHIBITOR,CPR:4,1,"In addition, prunetin inhibits NF-κB-dependent inflammatory responses by modulating IκB kinase (IKK)-inhibitor κBα (IκBα)-NF-κB signaling."
"Consistent with these results, << prunetin >> significantly reduced serum levels of inflammatory [[ cytokines ]] and mortality in mice challenged with lipopolysaccharide.","Consistent with these results, [ENTITY_A] significantly reduced serum levels of inflammatory [ENTITY_B] and mortality in mice challenged with lipopolysaccharide.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Consistent with these results, prunetin significantly reduced serum levels of inflammatory cytokines and mortality in mice challenged with lipopolysaccharide."
G6PC2: A Negative Regulator of Basal << Glucose >>-Stimulated [[ Insulin ]] Secretion.,G6PC2: A Negative Regulator of Basal [ENTITY_A]-Stimulated [ENTITY_B] Secretion.,UPREGULATOR,CPR:3,0,G6PC2: A Negative Regulator of Basal Glucose-Stimulated Insulin Secretion.
G6pc2 deletion resulted in a leftward shift in the dose-response curve for << glucose >>-stimulated [[ insulin ]] secretion (GSIS).,G6pc2 deletion resulted in a leftward shift in the dose-response curve for [ENTITY_A]-stimulated [ENTITY_B] secretion (GSIS).,UPREGULATOR,CPR:3,0,G6pc2 deletion resulted in a leftward shift in the dose-response curve for glucose-stimulated insulin secretion (GSIS).
"These data suggest that << G6pc2 >> represents a novel, negative regulator of basal GSIS that acts by hydrolyzing [[ glucose-6-phosphate ]], thereby reducing glycolytic flux.","These data suggest that [ENTITY_A] represents a novel, negative regulator of basal GSIS that acts by hydrolyzing [ENTITY_B], thereby reducing glycolytic flux.",SUBSTRATE,CPR:9,4,"These data suggest that G6pc2 represents a novel, negative regulator of basal GSIS that acts by hydrolyzing glucose-6-phosphate, thereby reducing glycolytic flux."
"Using the << mTOR >> inhibitor [[ PP242, ]] we found that TGFβ-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression.",Using the [ENTITY_A] inhibitor [ENTITY_B] we found that TGFβ-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression.,INHIBITOR,CPR:4,1,"Using the mTOR inhibitor PP242, we found that TGFβ-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression."
<< PP242 >>-induced reversal of [[ deptor ]] suppression by TGFβ was associated with a significant inhibition of TGFβ-stimulated protein synthesis and hypertrophy.,[ENTITY_A]-induced reversal of [ENTITY_B] suppression by TGFβ was associated with a significant inhibition of TGFβ-stimulated protein synthesis and hypertrophy.,ACTIVATOR,CPR:3,0,PP242-induced reversal of deptor suppression by TGFβ was associated with a significant inhibition of TGFβ-stimulated protein synthesis and hypertrophy.
METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of << [(3)H] dopamine >> (DA) uptake and [(3)H]WIN 35428 binding in [[ human dopamine transporter ]] (DAT) wild-type and mutants with altered conformational equilibria.,METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [ENTITY_A] (DA) uptake and [(3)H]WIN 35428 binding in [ENTITY_B] (DAT) wild-type and mutants with altered conformational equilibria.,SUBSTRATE,CPR:9,4,METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA) uptake and [(3)H]WIN 35428 binding in human dopamine transporter (DAT) wild-type and mutants with altered conformational equilibria.
"RESULTS: (+/-)-, R-, and S-modafinil bind to the << DAT >> and inhibit [[ DA ]] uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer.","RESULTS: (+/-)-, R-, and S-modafinil bind to the [ENTITY_A] and inhibit [ENTITY_B] uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer.",SUBSTRATE,CPR:9,4,"RESULTS: (+/-)-, R-, and S-modafinil bind to the DAT and inhibit DA uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer."
Apple << polyphenols >> suppress antigen presentation of [[ ovalbumin ]] by THP-1-derived dendritic cells.,Apple [ENTITY_A] suppress antigen presentation of [ENTITY_B] by THP-1-derived dendritic cells.,DOWNREGULATOR,CPR:4,1,Apple polyphenols suppress antigen presentation of ovalbumin by THP-1-derived dendritic cells.
"A significant decrease in << HLA-DR >> expression was observed in the AP and fractionated [[ procyanidin ]]-treated cells in the presence of ovalbumin (OVA), but no effect on CD86 expression was observed.","A significant decrease in [ENTITY_A] expression was observed in the AP and fractionated [ENTITY_B]-treated cells in the presence of ovalbumin (OVA), but no effect on CD86 expression was observed.",INDIRECT-DOWNREGULATOR,CPR:4,1,"A significant decrease in HLA-DR expression was observed in the AP and fractionated procyanidin-treated cells in the presence of ovalbumin (OVA), but no effect on CD86 expression was observed."
"Furthermore, the up-regulation of << IL-12 >> and TNF-α was found in the [[ procyanidin ]] trimers-treated cells in the presence of OVA.","Furthermore, the up-regulation of [ENTITY_A] and TNF-α was found in the [ENTITY_B] trimers-treated cells in the presence of OVA.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, the up-regulation of IL-12 and TNF-α was found in the procyanidin trimers-treated cells in the presence of OVA."
"The acute toxicity of << organophosphorus >> (OP) compounds in mammals is due to their irreversible inhibition of [[ acetylcholinesterase ]] (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels.","The acute toxicity of [ENTITY_A] (OP) compounds in mammals is due to their irreversible inhibition of [ENTITY_B] (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels.",INHIBITOR,CPR:4,1,"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels."
"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of << acetylcholinesterase >> (AChE) in the nervous system, which leads to increased synaptic [[ acetylcholine ]] levels.","The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of [ENTITY_A] (AChE) in the nervous system, which leads to increased synaptic [ENTITY_B] levels.",SUBSTRATE,CPR:9,4,"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels."
"In phosphotriesterase and physostigmine-treated mice, a 4- and 2-fold higher << sarin >> dose, respectively, was needed to cause a 50% inhibition of brain [[ AChE ]] activity.","In phosphotriesterase and physostigmine-treated mice, a 4- and 2-fold higher [ENTITY_A] dose, respectively, was needed to cause a 50% inhibition of brain [ENTITY_B] activity.",INHIBITOR,CPR:4,1,"In phosphotriesterase and physostigmine-treated mice, a 4- and 2-fold higher sarin dose, respectively, was needed to cause a 50% inhibition of brain AChE activity."
"The << CYP3A4 >> activity could be induced 2-fold by [[ rifampicin ]], whereas CYP2C9 activity remained equally high.","The [ENTITY_A] activity could be induced 2-fold by [ENTITY_B], whereas CYP2C9 activity remained equally high.",ACTIVATOR,CPR:3,0,"The CYP3A4 activity could be induced 2-fold by rifampicin, whereas CYP2C9 activity remained equally high."
<< PF-04859989 >> as a template for structure-based drug design: identification of new pyrazole series of irreversible [[ KAT II ]] inhibitors with improved lipophilic efficiency.,[ENTITY_A] as a template for structure-based drug design: identification of new pyrazole series of irreversible [ENTITY_B] inhibitors with improved lipophilic efficiency.,INHIBITOR,CPR:4,1,PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency.
"The structure-based design, synthesis, and biological evaluation of a new << pyrazole >> series of irreversible [[ KAT II ]] inhibitors are described herein.","The structure-based design, synthesis, and biological evaluation of a new [ENTITY_A] series of irreversible [ENTITY_B] inhibitors are described herein.",INHIBITOR,CPR:4,1,"The structure-based design, synthesis, and biological evaluation of a new pyrazole series of irreversible KAT II inhibitors are described herein."
The modification of the inhibitor scaffold of 1 and 2 from a << dihydroquinolinone >> core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent [[ KAT II ]] inhibitors with excellent physicochemical properties.,The modification of the inhibitor scaffold of 1 and 2 from a [ENTITY_A] core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent [ENTITY_B] inhibitors with excellent physicochemical properties.,INHIBITOR,CPR:4,1,The modification of the inhibitor scaffold of 1 and 2 from a dihydroquinolinone core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent KAT II inhibitors with excellent physicochemical properties.
"The capacity of << acetylcholinesterase >> inhibitors, with the exception of [[ tacrine ]] and ambenonium, to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors.","The capacity of [ENTITY_A] inhibitors, with the exception of [ENTITY_B] and ambenonium, to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors.",INHIBITOR,CPR:4,1,"The capacity of acetylcholinesterase inhibitors, with the exception of tacrine and ambenonium, to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors."
"Moreover, the rank order for potency in inhibiting << acetylcholinesterase >> (ambenonium>neostigmine=physostigmine =tacrine>[[ pyridostigmine ]]=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.","Moreover, the rank order for potency in inhibiting [ENTITY_A] (ambenonium>neostigmine=physostigmine =tacrine>[ENTITY_B]=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.",INHIBITOR,CPR:4,1,"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent."
"CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired << pyridoxal kinase >> for the conversion of pyridoxine and pyridoxal to [[ PLP ]].","CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired [ENTITY_A] for the conversion of pyridoxine and pyridoxal to [ENTITY_B].",PRODUCT-OF,CPR:9,4,"CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired pyridoxal kinase for the conversion of pyridoxine and pyridoxal to PLP."
"Synthesis, molecular modeling and evaluation of novel << N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone >> derivatives as dual inhibitors for [[ cholinesterases ]] and Aβ aggregation.","Synthesis, molecular modeling and evaluation of novel [ENTITY_A] derivatives as dual inhibitors for [ENTITY_B] and Aβ aggregation.",INHIBITOR,CPR:4,1,"Synthesis, molecular modeling and evaluation of novel N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone derivatives as dual inhibitors for cholinesterases and Aβ aggregation."
"To develop new drugs for treatment of Alzheimer's disease, a group of << N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones >> was designed, synthesized and tested for their ability to inhibit [[ acetylcholinesterase ]], butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42).","To develop new drugs for treatment of Alzheimer's disease, a group of [ENTITY_A] was designed, synthesized and tested for their ability to inhibit [ENTITY_B], butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42).",INHIBITOR,CPR:4,1,"To develop new drugs for treatment of Alzheimer's disease, a group of N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones was designed, synthesized and tested for their ability to inhibit acetylcholinesterase, butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42)."
"β-Amyloid aggregation results showed that all compounds exhibited remarkable << Aβ >> fibril aggregation inhibition activity with a nearly similar potential as the reference compound [[ rifampicin ]], which makes them promising anti-Alzheimer drug candidates.","β-Amyloid aggregation results showed that all compounds exhibited remarkable [ENTITY_A] fibril aggregation inhibition activity with a nearly similar potential as the reference compound [ENTITY_B], which makes them promising anti-Alzheimer drug candidates.",INHIBITOR,CPR:4,1,"β-Amyloid aggregation results showed that all compounds exhibited remarkable Aβ fibril aggregation inhibition activity with a nearly similar potential as the reference compound rifampicin, which makes them promising anti-Alzheimer drug candidates."
"Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic << steroids >> (AAS) were activating [[ hAR ]] and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR.","Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic [ENTITY_A] (AAS) were activating [ENTITY_B] and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR.",ACTIVATOR,CPR:3,0,"Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic steroids (AAS) were activating hAR and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR."
"<< Licofelone >>, a balanced inhibitor of [[ cyclooxygenase ]] and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.","[ENTITY_A], a balanced inhibitor of [ENTITY_B] and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.",INHIBITOR,CPR:4,1,"Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis."
"<< Licofelone >>, a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to [[ cycloxygenase-1 ]] blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.","[ENTITY_A], a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to [ENTITY_B] blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.",INHIBITOR,CPR:4,1,"Licofelone, a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability."
"We examined the anti-inflammatory effect of licofelone on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of << COX-2 >>, [[ rofecoxib ]].","We examined the anti-inflammatory effect of licofelone on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of [ENTITY_A], [ENTITY_B].",INHIBITOR,CPR:4,1,"We examined the anti-inflammatory effect of licofelone on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of COX-2, rofecoxib."
"<< Licofelone >> reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, [[ monocyte chemoattractant protein-1 ]] (MCP-1) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma.","[ENTITY_A] reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, [ENTITY_B] (MCP-1) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Licofelone reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 (MCP-1) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma."
"Moreover, << licofelone >> inhibited [[ COX-2 ]] and 5-LOX protein expression in vascular lesions.","Moreover, [ENTITY_A] inhibited [ENTITY_B] and 5-LOX protein expression in vascular lesions.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, licofelone inhibited COX-2 and 5-LOX protein expression in vascular lesions."
<< Rofecoxib >> only diminished [[ COX-2 ]] protein expression and MCP-1 gene expression in vascular atheroma.,[ENTITY_A] only diminished [ENTITY_B] protein expression and MCP-1 gene expression in vascular atheroma.,INDIRECT-DOWNREGULATOR,CPR:4,1,Rofecoxib only diminished COX-2 protein expression and MCP-1 gene expression in vascular atheroma.
<< Licofelone >> almost abolished [[ 5-LOX ]] activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.,[ENTITY_A] almost abolished [ENTITY_B] activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.,INHIBITOR,CPR:4,1,Licofelone almost abolished 5-LOX activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.
Licofelone almost abolished << 5-LOX >> activity by inhibiting [[ leukotriene B4 ]] generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.,Licofelone almost abolished [ENTITY_A] activity by inhibiting [ENTITY_B] generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.,PRODUCT-OF,CPR:9,4,Licofelone almost abolished 5-LOX activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.
"No influence of moderate hepatic impairment on the pharmacokinetics of << lumiracoxib >>, an oral [[ COX-2 ]] selective inhibitor.","No influence of moderate hepatic impairment on the pharmacokinetics of [ENTITY_A], an oral [ENTITY_B] selective inhibitor.",INHIBITOR,CPR:4,1,"No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor."
"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel << cyclooxygenase-2 >> (COX-2) selective inhibitor [[ lumiracoxib ]] (Prexige), so that dose recommendations for clinical use can be provided.","The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel [ENTITY_A] (COX-2) selective inhibitor [ENTITY_B] (Prexige), so that dose recommendations for clinical use can be provided.",INHIBITOR,CPR:4,1,"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 (COX-2) selective inhibitor lumiracoxib (Prexige), so that dose recommendations for clinical use can be provided."
"In addition, << ethanol >> induced degradation of [[ DNA methyltransferases ]] (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.","In addition, [ENTITY_A] induced degradation of [ENTITY_B] (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",DOWNREGULATOR,CPR:4,1,"In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway."
"Comparison of the << monoamine oxidase >> inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors [[ moclobemide ]] and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.","Comparison of the [ENTITY_A] inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors [ENTITY_B] and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.",INHIBITOR,CPR:4,1,"Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects."
"The effects of two reversible, predominantly << monoamine oxidase-A >> (MAO-A) inhibitors, [[ moclobemide ]] (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects.","The effects of two reversible, predominantly [ENTITY_A] (MAO-A) inhibitors, [ENTITY_B] (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects.",INHIBITOR,CPR:4,1,"The effects of two reversible, predominantly monoamine oxidase-A (MAO-A) inhibitors, moclobemide (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects."
"Before the next drug intake, << MAO-A >> inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with [[ moclobemide ]] but not with toloxatone.","Before the next drug intake, [ENTITY_A] inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with [ENTITY_B] but not with toloxatone.",INHIBITOR,CPR:4,1,"Before the next drug intake, MAO-A inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with moclobemide but not with toloxatone."
"Previously, we have found that << BRN-103 >>, a nicotinamide derivative, inhibits vascular endothelial growth factor ([[ VEGF ]])-mediated angiogenesis signaling in human endothelial cells.","Previously, we have found that [ENTITY_A], a nicotinamide derivative, inhibits vascular endothelial growth factor ([ENTITY_B])-mediated angiogenesis signaling in human endothelial cells.",INHIBITOR,CPR:4,1,"Previously, we have found that BRN-103, a nicotinamide derivative, inhibits vascular endothelial growth factor (VEGF)-mediated angiogenesis signaling in human endothelial cells."
"Furthermore, << BRN-250 >> inhibited the [[ VEGF ]]-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway.","Furthermore, [ENTITY_A] inhibited the [ENTITY_B]-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway.",INHIBITOR,CPR:4,1,"Furthermore, BRN-250 inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway."
Inhibition of << gelatinase A >> (MMP-2) by [[ batimastat ]] and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.,Inhibition of [ENTITY_A] (MMP-2) by [ENTITY_B] and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.,INHIBITOR,CPR:4,1,Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.
"We have examined the effects of the synthetic << matrix metalloproteinase >> inhibitor, [[ batimastat ]] (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.","We have examined the effects of the synthetic [ENTITY_A] inhibitor, [ENTITY_B] (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.",INHIBITOR,CPR:4,1,"We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice."
Here we report that << captopril >> treatment resulted in decreased transcription and protein levels of [[ gelatinase A ]] by 3LL cells.,Here we report that [ENTITY_A] treatment resulted in decreased transcription and protein levels of [ENTITY_B] by 3LL cells.,INDIRECT-DOWNREGULATOR,CPR:4,1,Here we report that captopril treatment resulted in decreased transcription and protein levels of gelatinase A by 3LL cells.
Both << BB-94 >> and captopril also prevented substrate degradation by [[ gelatinase A and B ]] released in conditioned medium by cultured cells.,Both [ENTITY_A] and captopril also prevented substrate degradation by [ENTITY_B] released in conditioned medium by cultured cells.,INDIRECT-DOWNREGULATOR,CPR:4,1,Both BB-94 and captopril also prevented substrate degradation by gelatinase A and B released in conditioned medium by cultured cells.
Methionine synthase reductase (<< MTRR >>) is an enzyme involved in the conversion of Hcy to [[ methionine ]].,Methionine synthase reductase ([ENTITY_A]) is an enzyme involved in the conversion of Hcy to [ENTITY_B].,PRODUCT-OF,CPR:9,4,Methionine synthase reductase (MTRR) is an enzyme involved in the conversion of Hcy to methionine.
<< GPxs >> reduce hydroperoxides to the corresponding [[ alcohols ]] by means of glutathione (GSH).,[ENTITY_A] reduce hydroperoxides to the corresponding [ENTITY_B] by means of glutathione (GSH).,PRODUCT-OF,CPR:9,4,GPxs reduce hydroperoxides to the corresponding alcohols by means of glutathione (GSH).
"<< TCDD >> decreased the expression of the [[ glucose transporter ]], SLC2A1, and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate.","[ENTITY_A] decreased the expression of the [ENTITY_B], SLC2A1, and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate.",INDIRECT-DOWNREGULATOR,CPR:4,1,"TCDD decreased the expression of the glucose transporter, SLC2A1, and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate."
"Mitochondrial << glutathione (GSH) reductase >> activity and the GSH/glutathione disulfide ratio were decreased by [[ TCDD ]], ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide.","Mitochondrial [ENTITY_A] activity and the GSH/glutathione disulfide ratio were decreased by [ENTITY_B], ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide.",INHIBITOR,CPR:4,1,"Mitochondrial glutathione (GSH) reductase activity and the GSH/glutathione disulfide ratio were decreased by TCDD, ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide."
<< ATP-binding cassette transporter A1 >> is involved in hepatic [[ alpha-tocopherol ]] secretion.,[ENTITY_A] is involved in hepatic [ENTITY_B] secretion.,PRODUCT-OF,CPR:9,4,ATP-binding cassette transporter A1 is involved in hepatic alpha-tocopherol secretion.
"alpha-Tocopherol transfer protein (<< alpha-TTP >>), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma [[ alpha-tocopherol ]] level by mediating the secretion of alpha-tocopherol by the liver.","alpha-Tocopherol transfer protein ([ENTITY_A]), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma [ENTITY_B] level by mediating the secretion of alpha-tocopherol by the liver.",SUBSTRATE,CPR:9,4,"alpha-Tocopherol transfer protein (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of alpha-tocopherol by the liver."
"First, addition of << apolipoprotein A-I >> (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased [[ alpha-tocopherol ]] secretion in a dose-dependent manner.","First, addition of [ENTITY_A] (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased [ENTITY_B] secretion in a dose-dependent manner.",PRODUCT-OF,CPR:9,4,"First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased alpha-tocopherol secretion in a dose-dependent manner."
"Second, << probucol >>, an antiatherogenic compound reported to be an inactivator of [[ ABCA1 ]] reduced hepatic alpha-tocopherol secretion.","Second, [ENTITY_A], an antiatherogenic compound reported to be an inactivator of [ENTITY_B] reduced hepatic alpha-tocopherol secretion.",DOWNREGULATOR,CPR:4,1,"Second, probucol, an antiatherogenic compound reported to be an inactivator of ABCA1 reduced hepatic alpha-tocopherol secretion."
"Third, << ABCA1 >>-RNAi suppressed hepatic [[ alpha-tocopherol ]] secretion.","Third, [ENTITY_A]-RNAi suppressed hepatic [ENTITY_B] secretion.",PRODUCT-OF,CPR:9,4,"Third, ABCA1-RNAi suppressed hepatic alpha-tocopherol secretion."
These results strongly suggest that << ABCA1 >> is substantially involved in hepatic [[ alpha-tocopherol ]] secretion.,These results strongly suggest that [ENTITY_A] is substantially involved in hepatic [ENTITY_B] secretion.,PRODUCT-OF,CPR:9,4,These results strongly suggest that ABCA1 is substantially involved in hepatic alpha-tocopherol secretion.
"<< 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid >> (1) is a potent [[ AMPA receptor ]] agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors.","[ENTITY_A] (1) is a potent [ENTITY_B] agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors.",AGONIST,CPR:5,2,"2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors."
"<< Pranlukast >>, a leukotriene receptor antagonist, inhibits [[ interleukin-5 ]] production via a mechanism distinct from leukotriene receptor antagonism.","[ENTITY_A], a leukotriene receptor antagonist, inhibits [ENTITY_B] production via a mechanism distinct from leukotriene receptor antagonism.",INHIBITOR,CPR:4,1,"Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism."
"<< Pranlukast >>, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from [[ leukotriene receptor ]] antagonism.","[ENTITY_A], a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from [ENTITY_B] antagonism.",ANTAGONIST,CPR:6,3,"Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism."
"BACKGROUND: << Pranlukast >>, a [[ cysteinyl leukotriene receptor 1 ]] (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.","BACKGROUND: [ENTITY_A], a [ENTITY_B] (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.",ANTAGONIST,CPR:6,3,"BACKGROUND: Pranlukast, a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation."
The aim of this study was to determine the mechanism of << pranlukast >>-induced [[ interleukin-5 ]] (IL-5) inhibition in allergic inflammation.,The aim of this study was to determine the mechanism of [ENTITY_A]-induced [ENTITY_B] (IL-5) inhibition in allergic inflammation.,INHIBITOR,CPR:4,1,The aim of this study was to determine the mechanism of pranlukast-induced interleukin-5 (IL-5) inhibition in allergic inflammation.
RESULTS: Pretreatment of lung tissues with << pranlukast >> alone significantly decreased the amount of [[ IL-5 ]] protein in the culture medium by 40%.,RESULTS: Pretreatment of lung tissues with [ENTITY_A] alone significantly decreased the amount of [ENTITY_B] protein in the culture medium by 40%.,INDIRECT-DOWNREGULATOR,CPR:4,1,RESULTS: Pretreatment of lung tissues with pranlukast alone significantly decreased the amount of IL-5 protein in the culture medium by 40%.
"<< Pranlukast >>-induced inhibition of [[ IL-5 ]] mRNA expression was noted in various cells, irrespective of their CysLTR1 mRNA expression status.","[ENTITY_A]-induced inhibition of [ENTITY_B] mRNA expression was noted in various cells, irrespective of their CysLTR1 mRNA expression status.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Pranlukast-induced inhibition of IL-5 mRNA expression was noted in various cells, irrespective of their CysLTR1 mRNA expression status."
CONCLUSION: Our results indicate that << pranlukast >> inhibits [[ IL-5 ]] synthesis via a mechanism distinct from CysLTR1 antagonism.,CONCLUSION: Our results indicate that [ENTITY_A] inhibits [ENTITY_B] synthesis via a mechanism distinct from CysLTR1 antagonism.,INHIBITOR,CPR:4,1,CONCLUSION: Our results indicate that pranlukast inhibits IL-5 synthesis via a mechanism distinct from CysLTR1 antagonism.
CONCLUSION: Our results indicate that << pranlukast >> inhibits IL-5 synthesis via a mechanism distinct from [[ CysLTR1 ]] antagonism.,CONCLUSION: Our results indicate that [ENTITY_A] inhibits IL-5 synthesis via a mechanism distinct from [ENTITY_B] antagonism.,ANTAGONIST,CPR:6,3,CONCLUSION: Our results indicate that pranlukast inhibits IL-5 synthesis via a mechanism distinct from CysLTR1 antagonism.
<< Thiazolidinediones >> are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of [[ insulin ]]-responsive genes involved in glucose and lipid metabolism.,[ENTITY_A] are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of [ENTITY_B]-responsive genes involved in glucose and lipid metabolism.,INDIRECT-UPREGULATOR,CPR:3,0,Thiazolidinediones are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism.
The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that << troglitazone >> was a competitive inhibitor of [[ ENT1 ]].,The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that [ENTITY_A] was a competitive inhibitor of [ENTITY_B].,INHIBITOR,CPR:4,1,The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that troglitazone was a competitive inhibitor of ENT1.
The difference in structure of << troglitazone >> did not account for its inhibitory effect on [[ ENT1 ]] because Vitamin E did not inhibit [3H]adenosine uptake by HASMCs.,The difference in structure of [ENTITY_A] did not account for its inhibitory effect on [ENTITY_B] because Vitamin E did not inhibit [3H]adenosine uptake by HASMCs.,INHIBITOR,CPR:4,1,The difference in structure of troglitazone did not account for its inhibitory effect on ENT1 because Vitamin E did not inhibit [3H]adenosine uptake by HASMCs.
"Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that << troglitazone >> inhibited [[ ENT1 ]] but had no effect on ENT2.","Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that [ENTITY_A] inhibited [ENTITY_B] but had no effect on ENT2.",INHIBITOR,CPR:4,1,"Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that troglitazone inhibited ENT1 but had no effect on ENT2."
"From these results, it is suggested that << troglitazone >> may enhance the vasodilatory effect of adenosine by inhibiting [[ ENT1 ]].","From these results, it is suggested that [ENTITY_A] may enhance the vasodilatory effect of adenosine by inhibiting [ENTITY_B].",INHIBITOR,CPR:4,1,"From these results, it is suggested that troglitazone may enhance the vasodilatory effect of adenosine by inhibiting ENT1."
"Pharmacologically, << troglitazone >> is a novel inhibitor of [[ ENT1 ]].","Pharmacologically, [ENTITY_A] is a novel inhibitor of [ENTITY_B].",INHIBITOR,CPR:4,1,"Pharmacologically, troglitazone is a novel inhibitor of ENT1."
"<< Phenytoin >> is principally metabolized by [[ CYP2C9 ]], and both are probable substrates of the drug transporter P-glycoprotein.","[ENTITY_A] is principally metabolized by [ENTITY_B], and both are probable substrates of the drug transporter P-glycoprotein.",SUBSTRATE,CPR:9,4,"Phenytoin is principally metabolized by CYP2C9, and both are probable substrates of the drug transporter P-glycoprotein."
<< Fisetin >> treatment of preadipocytes reduced the phosphorylation of [[ S6K1 ]] and mTORC1 in a time- and concentration-dependent manner.,[ENTITY_A] treatment of preadipocytes reduced the phosphorylation of [ENTITY_B] and mTORC1 in a time- and concentration-dependent manner.,INHIBITOR,CPR:4,1,Fisetin treatment of preadipocytes reduced the phosphorylation of S6K1 and mTORC1 in a time- and concentration-dependent manner.
"To further our understanding of how << fisetin >> negatively regulates [[ mTORC1 ]] signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in fisetin-treated TSC2-knockdown cells.","To further our understanding of how [ENTITY_A] negatively regulates [ENTITY_B] signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in fisetin-treated TSC2-knockdown cells.",DOWNREGULATOR,CPR:4,1,"To further our understanding of how fisetin negatively regulates mTORC1 signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in fisetin-treated TSC2-knockdown cells."
The results suggested that << fisetin >> treatment inhibits [[ mTORC1 ]] activity in an Akt-dependent manner.,The results suggested that [ENTITY_A] treatment inhibits [ENTITY_B] activity in an Akt-dependent manner.,INHIBITOR,CPR:4,1,The results suggested that fisetin treatment inhibits mTORC1 activity in an Akt-dependent manner.
"Fisetin treatment inhibited adipocyte differentiation, consistent with the negative effect of << fisetin >> on [[ mTOR ]].","Fisetin treatment inhibited adipocyte differentiation, consistent with the negative effect of [ENTITY_A] on [ENTITY_B].",DOWNREGULATOR,CPR:4,1,"Fisetin treatment inhibited adipocyte differentiation, consistent with the negative effect of fisetin on mTOR."
"We also observed that << fisetin >> efficiently suppressed the phosphorylation of [[ Akt ]], S6K1 and mTORC1 in adipose tissue.","We also observed that [ENTITY_A] efficiently suppressed the phosphorylation of [ENTITY_B], S6K1 and mTORC1 in adipose tissue.",INHIBITOR,CPR:4,1,"We also observed that fisetin efficiently suppressed the phosphorylation of Akt, S6K1 and mTORC1 in adipose tissue."
"Collectively, these results suggest that inhibition of << mTORC1 >> signaling by [[ fisetin ]] prevents adipocyte differentiation of 3T3-L1 preadipocytes and obesity in HFD-fed mice.","Collectively, these results suggest that inhibition of [ENTITY_A] signaling by [ENTITY_B] prevents adipocyte differentiation of 3T3-L1 preadipocytes and obesity in HFD-fed mice.",INHIBITOR,CPR:4,1,"Collectively, these results suggest that inhibition of mTORC1 signaling by fisetin prevents adipocyte differentiation of 3T3-L1 preadipocytes and obesity in HFD-fed mice."
Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the << thymidylate synthase >> inhibitor [[ Tomudex ]].,Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the [ENTITY_A] inhibitor [ENTITY_B].,INHIBITOR,CPR:4,1,Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
<< Tomudex >> (ZD1694) is a specific antifolate-based [[ thymidylate synthase ]] inhibitor active in a variety of solid tumor malignancies.,[ENTITY_A] (ZD1694) is a specific antifolate-based [ENTITY_B] inhibitor active in a variety of solid tumor malignancies.,INHIBITOR,CPR:4,1,Tomudex (ZD1694) is a specific antifolate-based thymidylate synthase inhibitor active in a variety of solid tumor malignancies.
Studies were carried out in vitro to evaluate downstream molecular alterations induced as a consequence of the potent and sustained inhibition of << thymidylate synthase >> by [[ Tomudex ]].,Studies were carried out in vitro to evaluate downstream molecular alterations induced as a consequence of the potent and sustained inhibition of [ENTITY_A] by [ENTITY_B].,INHIBITOR,CPR:4,1,Studies were carried out in vitro to evaluate downstream molecular alterations induced as a consequence of the potent and sustained inhibition of thymidylate synthase by Tomudex.
"<< Tomudex >> treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and [[ kinase ]] activities 24 h after a 2-h exposure.","[ENTITY_A] treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and [ENTITY_B] activities 24 h after a 2-h exposure.",ACTIVATOR,CPR:3,0,"Tomudex treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure."
"<< Tomudex >> treatment resulted in the decrease in [[ p27(kip1) ]] expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure.","[ENTITY_A] treatment resulted in the decrease in [ENTITY_B] expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Tomudex treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure."
The studies with dThyd rescue from << cyclin E >>-cdk2 protein overexpression and growth inhibition by [[ Tomudex ]] indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.,The studies with dThyd rescue from [ENTITY_A]-cdk2 protein overexpression and growth inhibition by [ENTITY_B] indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.,INDIRECT-UPREGULATOR,CPR:3,0,The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.
The studies with dThyd rescue from << cyclin E >>-cdk2 protein overexpression and growth inhibition by [[ Tomudex ]] indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.,The studies with dThyd rescue from [ENTITY_A]-cdk2 protein overexpression and growth inhibition by [ENTITY_B] indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.,INHIBITOR,CPR:4,1,The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.
These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by << Tomudex >> and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in [[ cyclin E ]] and cdk2 kinase activities.,These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by [ENTITY_A] and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in [ENTITY_B] and cdk2 kinase activities.,ACTIVATOR,CPR:3,0,These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 kinase activities.
These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by << Tomudex >> and kilobase DNA fragmentation may correlate with the reduction of [[ p27(kip1) ]] expression and the increase in cyclin E and cdk2 kinase activities.,These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by [ENTITY_A] and kilobase DNA fragmentation may correlate with the reduction of [ENTITY_B] expression and the increase in cyclin E and cdk2 kinase activities.,INDIRECT-DOWNREGULATOR,CPR:4,1,These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 kinase activities.
"Cells were also evaluated in the presence of << wortmannin >>, an inhibitor of phosphatidylinositol 3-kinases and thus [[ AKt ]] (0-100 nM).","Cells were also evaluated in the presence of [ENTITY_A], an inhibitor of phosphatidylinositol 3-kinases and thus [ENTITY_B] (0-100 nM).",INDIRECT-DOWNREGULATOR,CPR:4,1,"Cells were also evaluated in the presence of wortmannin, an inhibitor of phosphatidylinositol 3-kinases and thus AKt (0-100 nM)."
"Saturated << palmitic and stearic acids >> increased ceramides, up-regulated PTP1B, and had AKt and [[ PTP1B ]] phosphorylation at Ser 50 impaired.","Saturated [ENTITY_A] increased ceramides, up-regulated PTP1B, and had AKt and [ENTITY_B] phosphorylation at Ser 50 impaired.",ACTIVATOR,CPR:3,0,"Saturated palmitic and stearic acids increased ceramides, up-regulated PTP1B, and had AKt and PTP1B phosphorylation at Ser 50 impaired."
Only FFAs that increased << ceramides >> caused impairment of [[ AKt ]] and PTP1B phosphorylation at Ser 50.,Only FFAs that increased [ENTITY_A] caused impairment of [ENTITY_B] and PTP1B phosphorylation at Ser 50.,INDIRECT-DOWNREGULATOR,CPR:4,1,Only FFAs that increased ceramides caused impairment of AKt and PTP1B phosphorylation at Ser 50.
"Indoleamine 2,3-dioxygenase (<< IDO >>), a [[ tryptophan ]] catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders.","Indoleamine 2,3-dioxygenase ([ENTITY_A]), a [ENTITY_B] catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders.",SUBSTRATE,CPR:9,4,"Indoleamine 2,3-dioxygenase (IDO), a tryptophan catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders."
"To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of << SIRT1 >> ([[ nicotinamide ]], sirtinol, EX527) in aorta segments isolated from young Wistar rats.","To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of [ENTITY_A] ([ENTITY_B], sirtinol, EX527) in aorta segments isolated from young Wistar rats.",INHIBITOR,CPR:4,1,"To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats."
"To determine whether dysregulation of SIRT1 promotes << NADPH oxidase >>-dependent production of reactive [[ oxygen ]] species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats.","To determine whether dysregulation of SIRT1 promotes [ENTITY_A]-dependent production of reactive [ENTITY_B] species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats.",PRODUCT-OF,CPR:9,4,"To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats."
Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the << NADPH oxidase >> inhibitor [[ apocynin ]] or superoxide dismutase.,Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the [ENTITY_A] inhibitor [ENTITY_B] or superoxide dismutase.,INHIBITOR,CPR:4,1,Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the NADPH oxidase inhibitor apocynin or superoxide dismutase.
"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced << NADPH oxidase >> activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by [[ resveratrol ]].","Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced [ENTITY_A] activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by [ENTITY_B].",DOWNREGULATOR,CPR:4,1,"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol."
"Inhibition of << SIRT1 >> significantly increased vascular [[ superoxide ]] production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol.","Inhibition of [ENTITY_A] significantly increased vascular [ENTITY_B] production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol.",PRODUCT-OF,CPR:9,4,"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol."
Peroxisome proliferator-activated receptor-α (PPARα) activation mimicked the effects of << resveratrol >> while PPARα inhibition prevented the effects of this [[ SIRT1 ]] activator.,Peroxisome proliferator-activated receptor-α (PPARα) activation mimicked the effects of [ENTITY_A] while PPARα inhibition prevented the effects of this [ENTITY_B] activator.,ACTIVATOR,CPR:3,0,Peroxisome proliferator-activated receptor-α (PPARα) activation mimicked the effects of resveratrol while PPARα inhibition prevented the effects of this SIRT1 activator.
"SIRT1 co-precipitated with PPARα and << nicotinamide >> increased the acetylation of the PPARα coactivator [[ PGC-1α ]], which was suppressed by resveratrol.","SIRT1 co-precipitated with PPARα and [ENTITY_A] increased the acetylation of the PPARα coactivator [ENTITY_B], which was suppressed by resveratrol.",ACTIVATOR,CPR:3,0,"SIRT1 co-precipitated with PPARα and nicotinamide increased the acetylation of the PPARα coactivator PGC-1α, which was suppressed by resveratrol."
"SIRT1 co-precipitated with PPARα and nicotinamide increased the acetylation of the PPARα coactivator << PGC-1α >>, which was suppressed by [[ resveratrol ]].","SIRT1 co-precipitated with PPARα and nicotinamide increased the acetylation of the PPARα coactivator [ENTITY_A], which was suppressed by [ENTITY_B].",INHIBITOR,CPR:4,1,"SIRT1 co-precipitated with PPARα and nicotinamide increased the acetylation of the PPARα coactivator PGC-1α, which was suppressed by resveratrol."
"<< EROD >> activity induction in peripheral blood lymphocytes, liver and brain tissues of rats orally exposed to [[ polycyclic aromatic hydrocarbons ]].","[ENTITY_A] activity induction in peripheral blood lymphocytes, liver and brain tissues of rats orally exposed to [ENTITY_B].",ACTIVATOR,CPR:3,0,"EROD activity induction in peripheral blood lymphocytes, liver and brain tissues of rats orally exposed to polycyclic aromatic hydrocarbons."
"Little is known in terms of multi-matrix << cytochrome P450 >> activity induction under repeated oral exposure to planar [[ halogenated and polycyclic aromatic hydrocarbons ]] (PHH, PAH).","Little is known in terms of multi-matrix [ENTITY_A] activity induction under repeated oral exposure to planar [ENTITY_B] (PHH, PAH).",ACTIVATOR,CPR:3,0,"Little is known in terms of multi-matrix cytochrome P450 activity induction under repeated oral exposure to planar halogenated and polycyclic aromatic hydrocarbons (PHH, PAH)."
Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor << manumycin A >> caused elevation of [[ ApoA-I ]] secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.,Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor [ENTITY_A] caused elevation of [ENTITY_B] secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.,INDIRECT-UPREGULATOR,CPR:3,0,Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor manumycin A caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.
Repression of << farnesyltransferase >> (FNTA) by siRNA and the enzyme inhibitor [[ manumycin A ]] caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.,Repression of [ENTITY_A] (FNTA) by siRNA and the enzyme inhibitor [ENTITY_B] caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.,INHIBITOR,CPR:4,1,Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor manumycin A caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.
<< Estrogens >> are biosynthesised from androgens by the [[ CYP450 ]] enzyme complex called aromatase.,[ENTITY_A] are biosynthesised from androgens by the [ENTITY_B] enzyme complex called aromatase.,PRODUCT-OF,CPR:9,4,Estrogens are biosynthesised from androgens by the CYP450 enzyme complex called aromatase.
"In breast cancer, intratumoural << aromatase >> is the source for local [[ estrogen ]] production in the tissue.","In breast cancer, intratumoural [ENTITY_A] is the source for local [ENTITY_B] production in the tissue.",PRODUCT-OF,CPR:9,4,"In breast cancer, intratumoural aromatase is the source for local estrogen production in the tissue."
"The potent and selective third-generation << aromatase >> inhibitors anastrozole, [[ letrozole ]] and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies.","The potent and selective third-generation [ENTITY_A] inhibitors anastrozole, [ENTITY_B] and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies.",INHIBITOR,CPR:4,1,"The potent and selective third-generation aromatase inhibitors anastrozole, letrozole and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies."
<< Anastrozole >> and letrozole are both non-steroidal [[ aromatase ]] inhibitors that compete with the substrate for binding to the enzyme active site.,[ENTITY_A] and letrozole are both non-steroidal [ENTITY_B] inhibitors that compete with the substrate for binding to the enzyme active site.,INHIBITOR,CPR:4,1,Anastrozole and letrozole are both non-steroidal aromatase inhibitors that compete with the substrate for binding to the enzyme active site.
Identification and synthesis of << N-(thiophen-2-yl) benzamide >> derivatives as [[ BRAF ]](V600E) inhibitors.,Identification and synthesis of [ENTITY_A] derivatives as [ENTITY_B](V600E) inhibitors.,INHIBITOR,CPR:4,1,Identification and synthesis of N-(thiophen-2-yl) benzamide derivatives as BRAF(V600E) inhibitors.
"In this study, we employed virtual screening and chemical synthesis to identify a series of << N-(thiophen-2-yl) benzamide >> derivatives as potent [[ BRAF ]](V600E) inhibitors.","In this study, we employed virtual screening and chemical synthesis to identify a series of [ENTITY_A] derivatives as potent [ENTITY_B](V600E) inhibitors.",INHIBITOR,CPR:4,1,"In this study, we employed virtual screening and chemical synthesis to identify a series of N-(thiophen-2-yl) benzamide derivatives as potent BRAF(V600E) inhibitors."
"Exposure of cells to 4mM << NaF >> for 24h induced [[ caspase-3 ]] activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent.","Exposure of cells to 4mM [ENTITY_A] for 24h induced [ENTITY_B] activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent.",ACTIVATOR,CPR:3,0,"Exposure of cells to 4mM NaF for 24h induced caspase-3 activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent."
"<< Fluoride >> treatment also increased phosphorylation of [[ JNK ]] and ERK, but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively.","[ENTITY_A] treatment also increased phosphorylation of [ENTITY_B] and ERK, but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively.",ACTIVATOR,CPR:3,0,"Fluoride treatment also increased phosphorylation of JNK and ERK, but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively."
"Furthermore, the << Panx1 >> channel blockers [[ carbenoxolone ]] and Probenecid were less effective in inhibiting Panx1 currents when Kvbeta3 was co-expressed.","Furthermore, the [ENTITY_A] channel blockers [ENTITY_B] and Probenecid were less effective in inhibiting Panx1 currents when Kvbeta3 was co-expressed.",INHIBITOR,CPR:4,1,"Furthermore, the Panx1 channel blockers carbenoxolone and Probenecid were less effective in inhibiting Panx1 currents when Kvbeta3 was co-expressed."
"<< (-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one >> (KCA-1490) exhibits moderate dual [[ PDE3/4 ]]-inhibitory activity and promises as a combined bronchodilatory/anti-inflammatory agent.",[ENTITY_A] (KCA-1490) exhibits moderate dual [ENTITY_B]-inhibitory activity and promises as a combined bronchodilatory/anti-inflammatory agent.,INHIBITOR,CPR:4,1,"(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one (KCA-1490) exhibits moderate dual PDE3/4-inhibitory activity and promises as a combined bronchodilatory/anti-inflammatory agent."
<< N >>-alkylation of the pyridazinone ring markedly enhances potency against [[ PDE4 ]] but suppresses PDE3 inhibition.,[ENTITY_A]-alkylation of the pyridazinone ring markedly enhances potency against [ENTITY_B] but suppresses PDE3 inhibition.,INHIBITOR,CPR:4,1,N-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition.
"Addition of a << 6-aryl-4,5-dihydropyridazin-3(2H)-one >> extension to the N-alkyl group facilitates both enhancement of [[ PDE4 ]]-inhibitory activity and restoration of potent PDE3 inhibition.",Addition of a [ENTITY_A] extension to the N-alkyl group facilitates both enhancement of [ENTITY_B]-inhibitory activity and restoration of potent PDE3 inhibition.,INHIBITOR,CPR:4,1,"Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent PDE3 inhibition."
Fumarate reductase (<< FRD >>) is the key enzyme in [[ fumarate ]] respiration induced by anaerobic growth of bacteria.,Fumarate reductase ([ENTITY_A]) is the key enzyme in [ENTITY_B] respiration induced by anaerobic growth of bacteria.,SUBSTRATE,CPR:9,4,Fumarate reductase (FRD) is the key enzyme in fumarate respiration induced by anaerobic growth of bacteria.
"The frdA gene coding for subunit A of FRD, and two control genes, << copA >> and copP associated with the export of [[ copper ]] out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes.","The frdA gene coding for subunit A of FRD, and two control genes, [ENTITY_A] and copP associated with the export of [ENTITY_B] out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes.",SUBSTRATE,CPR:9,4,"The frdA gene coding for subunit A of FRD, and two control genes, copA and copP associated with the export of copper out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes."
"Given that << FRD >>, present in all H. pylori strains, is immunogenic in H. pylori -infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics ([[ morantel ]], oxantel and thiabendazole), this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.","Given that [ENTITY_A], present in all H. pylori strains, is immunogenic in H. pylori -infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics ([ENTITY_B], oxantel and thiabendazole), this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.",INHIBITOR,CPR:4,1,"Given that FRD, present in all H. pylori strains, is immunogenic in H. pylori -infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics (morantel, oxantel and thiabendazole), this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication."
"To begin to examine whether these changes are mediated by alterations in gene expression for << tryptophan hydroxylase >> (TPH), the rate-limiting enzyme in [[ 5-HT ]] biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR).","To begin to examine whether these changes are mediated by alterations in gene expression for [ENTITY_A] (TPH), the rate-limiting enzyme in [ENTITY_B] biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR).",PRODUCT-OF,CPR:9,4,"To begin to examine whether these changes are mediated by alterations in gene expression for tryptophan hydroxylase (TPH), the rate-limiting enzyme in 5-HT biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR)."
"In contrast, there was little change in mRNA levels for << GTP cyclohydrolase I >> (GTPCH), the rate limiting enzyme in synthesis of the [[ tetrahydrobiopterin ]] (BH4), the obligate cofactor for TPH.","In contrast, there was little change in mRNA levels for [ENTITY_A] (GTPCH), the rate limiting enzyme in synthesis of the [ENTITY_B] (BH4), the obligate cofactor for TPH.",PRODUCT-OF,CPR:9,4,"In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (GTPCH), the rate limiting enzyme in synthesis of the tetrahydrobiopterin (BH4), the obligate cofactor for TPH."
"In relation to zinc bioavailability, << α-CPPs >>, β-CPPs, α(s1)-CN(64-74)4P and β-CN(1-25)4P increased [[ zinc ]] uptake.","In relation to zinc bioavailability, [ENTITY_A], β-CPPs, α(s1)-CN(64-74)4P and β-CN(1-25)4P increased [ENTITY_B] uptake.",SUBSTRATE,CPR:9,4,"In relation to zinc bioavailability, α-CPPs, β-CPPs, α(s1)-CN(64-74)4P and β-CN(1-25)4P increased zinc uptake."
"In contrast to parenteral delivery of rBChE, which currently requires posttranslational modification for good plasma stability, an unmodified aer-rBChE pretreatment given 1-40h prior to >1 LD50 of aer-<< paraoxon >> (Px) was able to prevent inhibition of circulating [[ cholinesterase ]] in a dose-dependent manner.","In contrast to parenteral delivery of rBChE, which currently requires posttranslational modification for good plasma stability, an unmodified aer-rBChE pretreatment given 1-40h prior to >1 LD50 of aer-[ENTITY_A] (Px) was able to prevent inhibition of circulating [ENTITY_B] in a dose-dependent manner.",ACTIVATOR,CPR:3,0,"In contrast to parenteral delivery of rBChE, which currently requires posttranslational modification for good plasma stability, an unmodified aer-rBChE pretreatment given 1-40h prior to >1 LD50 of aer-paraoxon (Px) was able to prevent inhibition of circulating cholinesterase in a dose-dependent manner."
"Next to << Glut-4 >>, the predominant protein influencing [[ glucose ]] metabolism is PPARα and γ whose expressions were also positively modulated.","Next to [ENTITY_A], the predominant protein influencing [ENTITY_B] metabolism is PPARα and γ whose expressions were also positively modulated.",SUBSTRATE,CPR:9,4,"Next to Glut-4, the predominant protein influencing glucose metabolism is PPARα and γ whose expressions were also positively modulated."
"Both the << 5 alpha-reductase >> inhibitor [[ finasteride ]] and alpha 1-adrenoceptor antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.","Both the [ENTITY_A] inhibitor [ENTITY_B] and alpha 1-adrenoceptor antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",INHIBITOR,CPR:4,1,"Both the 5 alpha-reductase inhibitor finasteride and alpha 1-adrenoceptor antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials."
"Both the 5 alpha-reductase inhibitor finasteride and << alpha 1-adrenoceptor >> antagonists (e.g. [[ alfuzosin ]], doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.","Both the 5 alpha-reductase inhibitor finasteride and [ENTITY_A] antagonists (e.g. [ENTITY_B], doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",ANTAGONIST,CPR:6,3,"Both the 5 alpha-reductase inhibitor finasteride and alpha 1-adrenoceptor antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials."
Central << 5-HT3 >> receptor stimulation by [[ m-CPBG ]] increases blood glucose in rats.,Central [ENTITY_A] receptor stimulation by [ENTITY_B] increases blood glucose in rats.,ACTIVATOR,CPR:3,0,Central 5-HT3 receptor stimulation by m-CPBG increases blood glucose in rats.
"Injections of << m-CPBG >>, a selective [[ 5-HT3 ]] receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states.","Injections of [ENTITY_A], a selective [ENTITY_B] receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states.",AGONIST,CPR:5,2,"Injections of m-CPBG, a selective 5-HT3 receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states."
"The hyperglycemic effect of << m-CPBG >> central administration was blocked by pretreatment with ondansetron, a specific [[ 5-HT3 ]] receptor antagonist, indicating that the effects here obtained with m-CPBG were a result of its interaction with 5-HT3 receptors.","The hyperglycemic effect of [ENTITY_A] central administration was blocked by pretreatment with ondansetron, a specific [ENTITY_B] receptor antagonist, indicating that the effects here obtained with m-CPBG were a result of its interaction with 5-HT3 receptors.",AGONIST,CPR:5,2,"The hyperglycemic effect of m-CPBG central administration was blocked by pretreatment with ondansetron, a specific 5-HT3 receptor antagonist, indicating that the effects here obtained with m-CPBG were a result of its interaction with 5-HT3 receptors."
"<< 3'-R/S-Hydroxyvoacamine >>, a potent [[ acetylcholinesterase ]] inhibitor from Tabernaemontana divaricata.","[ENTITY_A], a potent [ENTITY_B] inhibitor from Tabernaemontana divaricata.",INHIBITOR,CPR:4,1,"3'-R/S-Hydroxyvoacamine, a potent acetylcholinesterase inhibitor from Tabernaemontana divaricata."
"Guided by the << acetylcholinesterase >> inhibiting activity, the [[ bisindole alkaloid ]] 3'-R/S-hydroxyvoacamine was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory.","Guided by the [ENTITY_A] inhibiting activity, the [ENTITY_B] 3'-R/S-hydroxyvoacamine was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory.",INHIBITOR,CPR:4,1,"Guided by the acetylcholinesterase inhibiting activity, the bisindole alkaloid 3'-R/S-hydroxyvoacamine was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory."
<< α-Amino-α´-Halomethylketones >>: Synthetic Methodologies and Pharmaceutical Applications as [[ Serine and Cysteine Protease ]] Inhibitors.,[ENTITY_A]: Synthetic Methodologies and Pharmaceutical Applications as [ENTITY_B] Inhibitors.,INHIBITOR,CPR:4,1,α-Amino-α´-Halomethylketones: Synthetic Methodologies and Pharmaceutical Applications as Serine and Cysteine Protease Inhibitors.
"Introduction: 5-Lipoxygenase (<< 5-LO >>) is a crucial enzyme of the [[ arachidonic acid ]] (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein.","Introduction: 5-Lipoxygenase ([ENTITY_A]) is a crucial enzyme of the [ENTITY_B] (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein.",SUBSTRATE,CPR:9,4,"Introduction: 5-Lipoxygenase (5-LO) is a crucial enzyme of the arachidonic acid (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein."
"Using a transient heterologous cell expression system, we find that the transport activities of the << short OATP2B1 >> variant towards substrates [[ estrone sulfate ]] and rosuvastatin are similar to the well-characterized full length variant.","Using a transient heterologous cell expression system, we find that the transport activities of the [ENTITY_A] variant towards substrates [ENTITY_B] and rosuvastatin are similar to the well-characterized full length variant.",SUBSTRATE,CPR:9,4,"Using a transient heterologous cell expression system, we find that the transport activities of the short OATP2B1 variant towards substrates estrone sulfate and rosuvastatin are similar to the well-characterized full length variant."
<< Memantine >> is an uncompetitive (channel blocking) [[ NMDA receptor ]] antagonist.,[ENTITY_A] is an uncompetitive (channel blocking) [ENTITY_B] antagonist.,ANTAGONIST,CPR:6,3,Memantine is an uncompetitive (channel blocking) NMDA receptor antagonist.
"Like other << NMDA receptor >> antagonists, [[ memantine ]] at high concentrations can inhibit mechanisms of synaptic plasticity that are believed to underlie learning and memory.","Like other [ENTITY_A] antagonists, [ENTITY_B] at high concentrations can inhibit mechanisms of synaptic plasticity that are believed to underlie learning and memory.",ANTAGONIST,CPR:6,3,"Like other NMDA receptor antagonists, memantine at high concentrations can inhibit mechanisms of synaptic plasticity that are believed to underlie learning and memory."
"Blockade of << NMDA receptors >> by [[ memantine ]] could theoretically confer disease-modifying activity in AD by inhibiting the ""weak"" NMDA receptor-dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia.","Blockade of [ENTITY_A] by [ENTITY_B] could theoretically confer disease-modifying activity in AD by inhibiting the ""weak"" NMDA receptor-dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia.",INHIBITOR,CPR:4,1,"Blockade of NMDA receptors by memantine could theoretically confer disease-modifying activity in AD by inhibiting the ""weak"" NMDA receptor-dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia."
"Moreover, recent in vitro studies suggest that << memantine >> abrogates [[ beta-amyloid ]] (Abeta) toxicity and possibly inhibits Abeta production.","Moreover, recent in vitro studies suggest that [ENTITY_A] abrogates [ENTITY_B] (Abeta) toxicity and possibly inhibits Abeta production.",DOWNREGULATOR,CPR:4,1,"Moreover, recent in vitro studies suggest that memantine abrogates beta-amyloid (Abeta) toxicity and possibly inhibits Abeta production."
"Considerable attention has focused on the investigation of theories to explain the better tolerability of << memantine >> over other [[ NMDA receptor ]] antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801).","Considerable attention has focused on the investigation of theories to explain the better tolerability of [ENTITY_A] over other [ENTITY_B] antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801).",ANTAGONIST,CPR:6,3,"Considerable attention has focused on the investigation of theories to explain the better tolerability of memantine over other NMDA receptor antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801)."
The concomitantly administered effects of << rifampicin >> on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by [[ p-glycoprotein ]] in the gastrointestinal tract and liver.,The concomitantly administered effects of [ENTITY_A] on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by [ENTITY_B] in the gastrointestinal tract and liver.,SUBSTRATE,CPR:9,4,The concomitantly administered effects of rifampicin on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by p-glycoprotein in the gastrointestinal tract and liver.
"In general, rifampicin can act on a pattern: << rifampicin >> activates the [[ nuclear pregnane X receptor ]] that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities.","In general, rifampicin can act on a pattern: [ENTITY_A] activates the [ENTITY_B] that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities.",ACTIVATOR,CPR:3,0,"In general, rifampicin can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities."
"In general, << rifampicin >> can act on a pattern: rifampicin activates the [[ nuclear pregnane X receptor ]] that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities.","In general, [ENTITY_A] can act on a pattern: rifampicin activates the [ENTITY_B] that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities.",AGONIST-ACTIVATOR,CPR:5,2,"In general, rifampicin can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities."
We describe here the isolation and biochemical characterization of the marine natural << sesquiterpene >> palinurin as a [[ GSK-3β ]] inhibitor.,We describe here the isolation and biochemical characterization of the marine natural [ENTITY_A] palinurin as a [ENTITY_B] inhibitor.,INHIBITOR,CPR:4,1,We describe here the isolation and biochemical characterization of the marine natural sesquiterpene palinurin as a GSK-3β inhibitor.
Experimental studies performed for characterizing the inhibitory mechanism indicate that << GSK-3β >> inhibition by [[ palinurin ]] cannot be competed out by ATP nor peptide substrate.,Experimental studies performed for characterizing the inhibitory mechanism indicate that [ENTITY_A] inhibition by [ENTITY_B] cannot be competed out by ATP nor peptide substrate.,INHIBITOR,CPR:4,1,Experimental studies performed for characterizing the inhibitory mechanism indicate that GSK-3β inhibition by palinurin cannot be competed out by ATP nor peptide substrate.
"Moreover, molecular dynamics simulations have identified an allosteric mechanism by which binding of << palinurin >> leads to [[ GSK-3β ]] inhibition.","Moreover, molecular dynamics simulations have identified an allosteric mechanism by which binding of [ENTITY_A] leads to [ENTITY_B] inhibition.",INHIBITOR,CPR:4,1,"Moreover, molecular dynamics simulations have identified an allosteric mechanism by which binding of palinurin leads to GSK-3β inhibition."
<< Cyclooxygenase(COX)-2 >>-derived [[ prostanoids ]] can influence several processes that are linked to carcinogenesis.,[ENTITY_A]-derived [ENTITY_B] can influence several processes that are linked to carcinogenesis.,PRODUCT-OF,CPR:9,4,Cyclooxygenase(COX)-2-derived prostanoids can influence several processes that are linked to carcinogenesis.
"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of << p21 >>(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by [[ rofecoxib ]](a selective COX-2 inhibitor) and rescued by exogenous PGE2.","Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of [ENTITY_A](WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by [ENTITY_B](a selective COX-2 inhibitor) and rescued by exogenous PGE2.",INDIRECT-UPREGULATOR,CPR:3,0,"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2."
"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of << cyclinB1 >>, since these effects were prevented by [[ rofecoxib ]](a selective COX-2 inhibitor) and rescued by exogenous PGE2.","Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of [ENTITY_A], since these effects were prevented by [ENTITY_B](a selective COX-2 inhibitor) and rescued by exogenous PGE2.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2."
"Platelet-induced << COX-2 >>-dependent [[ PGE2 ]] synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2.","Platelet-induced [ENTITY_A]-dependent [ENTITY_B] synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2.",PRODUCT-OF,CPR:9,4,"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2."
"Previous studies demonstrated that the << Group III mGlu receptor >>-selective orthosteric agonist, [[ LSP1-2111 ]] produced anxiolytic- but not antidepressant-like effects upon peripheral administration.","Previous studies demonstrated that the [ENTITY_A]-selective orthosteric agonist, [ENTITY_B] produced anxiolytic- but not antidepressant-like effects upon peripheral administration.",AGONIST,CPR:5,2,"Previous studies demonstrated that the Group III mGlu receptor-selective orthosteric agonist, LSP1-2111 produced anxiolytic- but not antidepressant-like effects upon peripheral administration."
"The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either << 5-HT(1A) >> receptors by [[ WAY100635 ]], or 5-HT(2A/2C) receptors by ritanserin.","The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either [ENTITY_A] receptors by [ENTITY_B], or 5-HT(2A/2C) receptors by ritanserin.",INHIBITOR,CPR:4,1,"The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin."
"The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the << benzodiazepine receptor >> antagonist [[ flumazenil ]] (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin.","The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the [ENTITY_A] antagonist [ENTITY_B] (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin.",ANTAGONIST,CPR:6,3,"The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin."
"Catalytic-site affinities for cGMP, vardenafil, sildenafil, << tadalafil >>, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for [[ Q817A ]]; and 59-, 448-, 71-, 137-, and 93-fold for F820A.","Catalytic-site affinities for cGMP, vardenafil, sildenafil, [ENTITY_A], or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for [ENTITY_B]; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",SUBSTRATE,CPR:9,4,"Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for F820A."
<< Allicin >> treatment showed reduced production of pro-inflammatory cytokines and NO and increased [[ HO-1 ]] activity.,[ENTITY_A] treatment showed reduced production of pro-inflammatory cytokines and NO and increased [ENTITY_B] activity.,ACTIVATOR,CPR:3,0,Allicin treatment showed reduced production of pro-inflammatory cytokines and NO and increased HO-1 activity.
<< Allicin >> treatment showed reduced production of pro-inflammatory [[ cytokines ]] and NO and increased HO-1 activity.,[ENTITY_A] treatment showed reduced production of pro-inflammatory [ENTITY_B] and NO and increased HO-1 activity.,INDIRECT-DOWNREGULATOR,CPR:4,1,Allicin treatment showed reduced production of pro-inflammatory cytokines and NO and increased HO-1 activity.
"Recently, it has been shown that the activation of particular << T2R >> bitter taste receptors is partially involved with the bitter aftertaste sensation of [[ saccharin ]] and acesulfame-K.","Recently, it has been shown that the activation of particular [ENTITY_A] bitter taste receptors is partially involved with the bitter aftertaste sensation of [ENTITY_B] and acesulfame-K.",ACTIVATOR,CPR:3,0,"Recently, it has been shown that the activation of particular T2R bitter taste receptors is partially involved with the bitter aftertaste sensation of saccharin and acesulfame-K."
"We also found that << TRPV1 >> receptors are activated by [[ CuSO(4) ]], ZnSO(4), and FeSO(4), three salts known to produce a metallic taste sensation.","We also found that [ENTITY_A] receptors are activated by [ENTITY_B], ZnSO(4), and FeSO(4), three salts known to produce a metallic taste sensation.",ACTIVATOR,CPR:3,0,"We also found that TRPV1 receptors are activated by CuSO(4), ZnSO(4), and FeSO(4), three salts known to produce a metallic taste sensation."
<< 2-Arylpropionic >> CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive [[ CXCL8 ]] inhibitors.,[ENTITY_A] CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
<< (R)-Ketoprofen >> (1) was previously reported to be a potent and specific noncompetitive inhibitor of [[ CXCL8 ]]-induced human PMNs chemotaxis.,[ENTITY_A] (1) was previously reported to be a potent and specific noncompetitive inhibitor of [ENTITY_B]-induced human PMNs chemotaxis.,INHIBITOR,CPR:4,1,(R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCL8-induced human PMNs chemotaxis.
Role of organic cation/carnitine transporter 1 in uptake of << phenformin >> and inhibitory effect on [[ complex I ]] respiration in mitochondria.,Role of organic cation/carnitine transporter 1 in uptake of [ENTITY_A] and inhibitory effect on [ENTITY_B] respiration in mitochondria.,INHIBITOR,CPR:4,1,Role of organic cation/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria.
Role of << organic cation/carnitine transporter 1 >> in uptake of [[ phenformin ]] and inhibitory effect on complex I respiration in mitochondria.,Role of [ENTITY_A] in uptake of [ENTITY_B] and inhibitory effect on complex I respiration in mitochondria.,SUBSTRATE,CPR:9,4,Role of organic cation/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria.
<< Phenformin >> causes lactic acidosis in clinical situations due to inhibition of [[ mitochondrial respiratory chain complex I ]].,[ENTITY_A] causes lactic acidosis in clinical situations due to inhibition of [ENTITY_B].,INHIBITOR,CPR:4,1,Phenformin causes lactic acidosis in clinical situations due to inhibition of mitochondrial respiratory chain complex I.
"In this study, uptake of phenformin and [(14)C]tetraethylammonium (TEA) and << complex I >> inhibition by [[ phenformin ]] were examined in isolated liver and heart mitochondria.","In this study, uptake of phenformin and [(14)C]tetraethylammonium (TEA) and [ENTITY_A] inhibition by [ENTITY_B] were examined in isolated liver and heart mitochondria.",INHIBITOR,CPR:4,1,"In this study, uptake of phenformin and [(14)C]tetraethylammonium (TEA) and complex I inhibition by phenformin were examined in isolated liver and heart mitochondria."
"Inhibition by << phenformin >> of oxygen consumption via [[ complex I ]] respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of phenformin on complex I respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts.","Inhibition by [ENTITY_A] of oxygen consumption via [ENTITY_B] respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of phenformin on complex I respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts.",INHIBITOR,CPR:4,1,"Inhibition by phenformin of oxygen consumption via complex I respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of phenformin on complex I respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts."
These observations suggest that uptake of << phenformin >> into liver mitochondria is at least partly mediated by OCTN1 and functionally relevant to its inhibition potential of [[ complex I ]] respiration.,These observations suggest that uptake of [ENTITY_A] into liver mitochondria is at least partly mediated by OCTN1 and functionally relevant to its inhibition potential of [ENTITY_B] respiration.,INHIBITOR,CPR:4,1,These observations suggest that uptake of phenformin into liver mitochondria is at least partly mediated by OCTN1 and functionally relevant to its inhibition potential of complex I respiration.
These observations suggest that uptake of << phenformin >> into liver mitochondria is at least partly mediated by [[ OCTN1 ]] and functionally relevant to its inhibition potential of complex I respiration.,These observations suggest that uptake of [ENTITY_A] into liver mitochondria is at least partly mediated by [ENTITY_B] and functionally relevant to its inhibition potential of complex I respiration.,SUBSTRATE,CPR:9,4,These observations suggest that uptake of phenformin into liver mitochondria is at least partly mediated by OCTN1 and functionally relevant to its inhibition potential of complex I respiration.
A series of << xanthine >> derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of [[ dipeptidyl peptidase 4 ]] (DPP-4) for the treatment of type 2 diabetes.,A series of [ENTITY_A] derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of [ENTITY_B] (DPP-4) for the treatment of type 2 diabetes.,INHIBITOR,CPR:4,1,A series of xanthine derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (DPP-4) for the treatment of type 2 diabetes.
"The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists << SB224289 >> (300 microg/kg; [[ 5-HT1B ]]), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C).","The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists [ENTITY_A] (300 microg/kg; [ENTITY_B]), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C).",ANTAGONIST,CPR:6,3,"The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)."
"In an earlier report, DRD2 E8 A/A genotype was associated with reduced responsiveness to the << dopamine D2 >> agonist [[ apomorphine ]]; however, it is not clear whether both findings share the same biological basis.","In an earlier report, DRD2 E8 A/A genotype was associated with reduced responsiveness to the [ENTITY_A] agonist [ENTITY_B]; however, it is not clear whether both findings share the same biological basis.",AGONIST,CPR:5,2,"In an earlier report, DRD2 E8 A/A genotype was associated with reduced responsiveness to the dopamine D2 agonist apomorphine; however, it is not clear whether both findings share the same biological basis."
"As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and << xanthine oxidase >> was identified as the likely source of [[ TES ]]-stimulated superoxide production.","As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and [ENTITY_A] was identified as the likely source of [ENTITY_B]-stimulated superoxide production.",PRODUCT-OF,CPR:9,4,"As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and xanthine oxidase was identified as the likely source of TES-stimulated superoxide production."
Functional and biochemical studies indicated that << TES >> signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the [[ androgen receptor ]] and culminated in enhanced production of cGMP and microvascular vasodilation.,Functional and biochemical studies indicated that [ENTITY_A] signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the [ENTITY_B] and culminated in enhanced production of cGMP and microvascular vasodilation.,ACTIVATOR,CPR:3,0,Functional and biochemical studies indicated that TES signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation.
"These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by << peroxynitrite >> formed from [[ xanthine oxidase ]]-generated superoxide and NO.","These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by [ENTITY_A] formed from [ENTITY_B]-generated superoxide and NO.",PRODUCT-OF,CPR:9,4,"These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from xanthine oxidase-generated superoxide and NO."
<< Mouse brain serine racemase >> catalyzes specific elimination of L-serine to [[ pyruvate ]].,[ENTITY_A] catalyzes specific elimination of L-serine to [ENTITY_B].,PRODUCT-OF,CPR:9,4,Mouse brain serine racemase catalyzes specific elimination of L-serine to pyruvate.
<< D-Serine >> was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the [[ N-methyl-D-aspartate (NMDA)-type receptors ]].,[ENTITY_A] was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the [ENTITY_B].,AGONIST,CPR:5,2,D-Serine was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the N-methyl-D-aspartate (NMDA)-type receptors.
"Racemization of << serine >> is catalyzed by [[ serine racemase ]], a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver.","Racemization of [ENTITY_A] is catalyzed by [ENTITY_B], a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver.",SUBSTRATE,CPR:9,4,"Racemization of serine is catalyzed by serine racemase, a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver."
"Pharmacogenetic analysis of two genes, the << warfarin >> metabolic enzyme [[ CYP2C9 ]] and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose.","Pharmacogenetic analysis of two genes, the [ENTITY_A] metabolic enzyme [ENTITY_B] and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose.",SUBSTRATE,CPR:9,4,"Pharmacogenetic analysis of two genes, the warfarin metabolic enzyme CYP2C9 and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose."
"Possession of << CYP2C9 >>*2 or CYP2C9*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean [[ warfarin ]] dose.","Possession of [ENTITY_A]*2 or CYP2C9*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean [ENTITY_B] dose.",SUBSTRATE,CPR:9,4,"Possession of CYP2C9*2 or CYP2C9*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean warfarin dose."
"<< Pseudoephedrine >> inhibits T-cell activation by targeting [[ NF-kappaB ]], NFAT and AP-1 signaling pathways.","[ENTITY_A] inhibits T-cell activation by targeting [ENTITY_B], NFAT and AP-1 signaling pathways.",INHIBITOR,CPR:4,1,"Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways."
"We found that << PSE >> inhibits interleukin-2 (IL-2) and [[ tumor necrosis factor (TNF) alpha ]]-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.","We found that [ENTITY_A] inhibits interleukin-2 (IL-2) and [ENTITY_B]-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.",INDIRECT-UPREGULATOR,CPR:3,0,"We found that PSE inhibits interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line."
"We found that << PSE >> inhibits [[ interleukin-2 ]] (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.","We found that [ENTITY_A] inhibits [ENTITY_B] (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.",INDIRECT-DOWNREGULATOR,CPR:4,1,"We found that PSE inhibits interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line."
"To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that << PSE >> inhibited [[ NF-kappaB ]]-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity.","To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that [ENTITY_A] inhibited [ENTITY_B]-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity.",INHIBITOR,CPR:4,1,"To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity."
"However, phosphorylation of the << p65 >>/RelA subunit was clearly inhibited by [[ PSE ]] in stimulated cells.","However, phosphorylation of the [ENTITY_A]/RelA subunit was clearly inhibited by [ENTITY_B] in stimulated cells.",INHIBITOR,CPR:4,1,"However, phosphorylation of the p65/RelA subunit was clearly inhibited by PSE in stimulated cells."
"In addition, PSE inhibited the transcriptional activity of NFAT without interfering with the << calcium >>-induced [[ NFAT ]] dephosphorylation event, which represents the major signaling pathway for its activation.","In addition, PSE inhibited the transcriptional activity of NFAT without interfering with the [ENTITY_A]-induced [ENTITY_B] dephosphorylation event, which represents the major signaling pathway for its activation.",ACTIVATOR,CPR:3,0,"In addition, PSE inhibited the transcriptional activity of NFAT without interfering with the calcium-induced NFAT dephosphorylation event, which represents the major signaling pathway for its activation."
"In addition, << PSE >> inhibited the transcriptional activity of [[ NFAT ]] without interfering with the calcium-induced NFAT dephosphorylation event, which represents the major signaling pathway for its activation.","In addition, [ENTITY_A] inhibited the transcriptional activity of [ENTITY_B] without interfering with the calcium-induced NFAT dephosphorylation event, which represents the major signaling pathway for its activation.",INHIBITOR,CPR:4,1,"In addition, PSE inhibited the transcriptional activity of NFAT without interfering with the calcium-induced NFAT dephosphorylation event, which represents the major signaling pathway for its activation."
"NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that << PSE >> inhibited both [[ JNK ]] activation and AP-1 transcriptional activity.","NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that [ENTITY_A] inhibited both [ENTITY_B] activation and AP-1 transcriptional activity.",INHIBITOR,CPR:4,1,"NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that PSE inhibited both JNK activation and AP-1 transcriptional activity."
"Furthermore, experiments showed that treatment with << DEC >> results in a reduction in the amount of [[ COX-1 ]] protein in peritoneal exudate cells.","Furthermore, experiments showed that treatment with [ENTITY_A] results in a reduction in the amount of [ENTITY_B] protein in peritoneal exudate cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, experiments showed that treatment with DEC results in a reduction in the amount of COX-1 protein in peritoneal exudate cells."
"Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the << ATP >> inhibition of [[ K(IR)6.2 ]]/SUR1, but had no effect on homomeric K(IR)6.2 channels.","Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the [ENTITY_A] inhibition of [ENTITY_B]/SUR1, but had no effect on homomeric K(IR)6.2 channels.",INHIBITOR,CPR:4,1,"Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the ATP inhibition of K(IR)6.2/SUR1, but had no effect on homomeric K(IR)6.2 channels."
"These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to << DeltaNK(ATP) channels >> decreased their P(O(max)) and apparent IC(50) for [[ ATP ]] in the absence of Mg(2+).","These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to [ENTITY_A] decreased their P(O(max)) and apparent IC(50) for [ENTITY_B] in the absence of Mg(2+).",INHIBITOR,CPR:4,1,"These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to DeltaNK(ATP) channels decreased their P(O(max)) and apparent IC(50) for ATP in the absence of Mg(2+)."
"<< Monocarboxylate transporters >> (MCTs) are proton-linked membrane carriers involved in the transport of [[ monocarboxylates ]] such as lactate, pyruvate, as well as ketone bodies.","[ENTITY_A] (MCTs) are proton-linked membrane carriers involved in the transport of [ENTITY_B] such as lactate, pyruvate, as well as ketone bodies.",SUBSTRATE,CPR:9,4,"Monocarboxylate transporters (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as ketone bodies."
"Interestingly, part of << MCT2 >> immunoreactivity is located at postsynaptic sites, suggesting a particular role of [[ monocarboxylates ]] and their transporters in synaptic transmission.","Interestingly, part of [ENTITY_A] immunoreactivity is located at postsynaptic sites, suggesting a particular role of [ENTITY_B] and their transporters in synaptic transmission.",SUBSTRATE,CPR:9,4,"Interestingly, part of MCT2 immunoreactivity is located at postsynaptic sites, suggesting a particular role of monocarboxylates and their transporters in synaptic transmission."
"Differentiating the roles of mGlu2 and mGlu3 receptors using << LY541850 >>, an [[ mGlu2 ]] agonist/mGlu3 antagonist.","Differentiating the roles of mGlu2 and mGlu3 receptors using [ENTITY_A], an [ENTITY_B] agonist/mGlu3 antagonist.",AGONIST,CPR:5,2,"Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist."
"Differentiating the roles of mGlu2 and mGlu3 receptors using << LY541850 >>, an mGlu2 agonist/[[ mGlu3 ]] antagonist.","Differentiating the roles of mGlu2 and mGlu3 receptors using [ENTITY_A], an mGlu2 agonist/[ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist."
<< LY541850 >> was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric [[ mGlu2 ]] agonist and mGlu3 antagonist.,[ENTITY_A] was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric [ENTITY_B] agonist and mGlu3 antagonist.,AGONIST,CPR:5,2,LY541850 was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and mGlu3 antagonist.
<< LY541850 >> was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and [[ mGlu3 ]] antagonist.,[ENTITY_A] was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and [ENTITY_B] antagonist.,ANTAGONIST,CPR:6,3,LY541850 was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and mGlu3 antagonist.
These results confirm the selective << mGlu2 >> agonist and mGlu3 antagonist actions of [[ LY541850 ]].,These results confirm the selective [ENTITY_A] agonist and mGlu3 antagonist actions of [ENTITY_B].,AGONIST,CPR:5,2,These results confirm the selective mGlu2 agonist and mGlu3 antagonist actions of LY541850.
These results confirm the selective mGlu2 agonist and << mGlu3 >> antagonist actions of [[ LY541850 ]].,These results confirm the selective mGlu2 agonist and [ENTITY_A] antagonist actions of [ENTITY_B].,ANTAGONIST,CPR:6,3,These results confirm the selective mGlu2 agonist and mGlu3 antagonist actions of LY541850.
Selective precipitation of cytosol receptors with 36% << (NH4)2SO4 >> reduced [[ CBG ]] concentrations to negligible levels.,Selective precipitation of cytosol receptors with 36% [ENTITY_A] reduced [ENTITY_B] concentrations to negligible levels.,INDIRECT-DOWNREGULATOR,CPR:4,1,Selective precipitation of cytosol receptors with 36% (NH4)2SO4 reduced CBG concentrations to negligible levels.
"The activity of the human nasal mucosa microsomes was inhibited by << 8-methoxypsoralen >>, a known [[ CYP2A ]] inhibitor.","The activity of the human nasal mucosa microsomes was inhibited by [ENTITY_A], a known [ENTITY_B] inhibitor.",INHIBITOR,CPR:4,1,"The activity of the human nasal mucosa microsomes was inhibited by 8-methoxypsoralen, a known CYP2A inhibitor."
Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of << soman >>-inhibited [[ human acetylcholinesterase ]] in vitro.,Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of [ENTITY_A]-inhibited [ENTITY_B] in vitro.,INHIBITOR,CPR:4,1,Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of soman-inhibited human acetylcholinesterase in vitro.
"<< Acetylcholinesterase >> (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by [[ oximes ]] due to dealkylation of the soman-enzyme complex.","[ENTITY_A] (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by [ENTITY_B] due to dealkylation of the soman-enzyme complex.",ACTIVATOR,CPR:3,0,"Acetylcholinesterase (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex."
"<< Acetylcholinesterase >> (AChE) inhibited by the [[ organophosphate ]] soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.","[ENTITY_A] (AChE) inhibited by the [ENTITY_B] soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.",INHIBITOR,CPR:4,1,"Acetylcholinesterase (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex."
"The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium (TMA), hexamethonium, decamethonium and suxamethonium on the reactivatability of << soman >>-inhibited, solubilized [[ AChE ]] from human erythrocytes was investigated in vitro.","The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium (TMA), hexamethonium, decamethonium and suxamethonium on the reactivatability of [ENTITY_A]-inhibited, solubilized [ENTITY_B] from human erythrocytes was investigated in vitro.",INHIBITOR,CPR:4,1,"The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium (TMA), hexamethonium, decamethonium and suxamethonium on the reactivatability of soman-inhibited, solubilized AChE from human erythrocytes was investigated in vitro."
"If the effectors were added after 5 min of aging they increased the activity of << soman >>-inhibited [[ AChE ]], but to a considerably smaller extent than HI 6.","If the effectors were added after 5 min of aging they increased the activity of [ENTITY_A]-inhibited [ENTITY_B], but to a considerably smaller extent than HI 6.",INHIBITOR,CPR:4,1,"If the effectors were added after 5 min of aging they increased the activity of soman-inhibited AChE, but to a considerably smaller extent than HI 6."
"First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, << TOP2 >>-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. [[ doxorubicin ]], etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected.","First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, [ENTITY_A]-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. [ENTITY_B], etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected.",INHIBITOR,CPR:4,1,"First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected."
"In addition, ADP was shown to strongly antagonize << TOP2 >>-mediated DNA cleavage induced by [[ ATP ]]-sensitive but not ATP-insensitive TOP2 poisons.","In addition, ADP was shown to strongly antagonize [ENTITY_A]-mediated DNA cleavage induced by [ENTITY_B]-sensitive but not ATP-insensitive TOP2 poisons.",INDIRECT-UPREGULATOR,CPR:3,0,"In addition, ADP was shown to strongly antagonize TOP2-mediated DNA cleavage induced by ATP-sensitive but not ATP-insensitive TOP2 poisons."
"Second, C427A mutant human TOP2alpha, which exhibits reduced << ATPase >> activity, was shown to exhibit cross-resistance to all ATP-sensitive but not [[ ATP ]]-insensitive TOP2 poisons.","Second, C427A mutant human TOP2alpha, which exhibits reduced [ENTITY_A] activity, was shown to exhibit cross-resistance to all ATP-sensitive but not [ENTITY_B]-insensitive TOP2 poisons.",DOWNREGULATOR,CPR:4,1,"Second, C427A mutant human TOP2alpha, which exhibits reduced ATPase activity, was shown to exhibit cross-resistance to all ATP-sensitive but not ATP-insensitive TOP2 poisons."
Activation of << ALDH2 >> with [[ ethanol ]] attenuates diabetes induced myocardial injury in rats.,Activation of [ENTITY_A] with [ENTITY_B] attenuates diabetes induced myocardial injury in rats.,ACTIVATOR,CPR:3,0,Activation of ALDH2 with ethanol attenuates diabetes induced myocardial injury in rats.
"This study assessed changes in myocardial ALDH2 expression in the diabetic rat, in particular the diabetic rat pretreated with << ALDH2 >> activator [[ ethanol ]] (EtOH).","This study assessed changes in myocardial ALDH2 expression in the diabetic rat, in particular the diabetic rat pretreated with [ENTITY_A] activator [ENTITY_B] (EtOH).",ACTIVATOR,CPR:3,0,"This study assessed changes in myocardial ALDH2 expression in the diabetic rat, in particular the diabetic rat pretreated with ALDH2 activator ethanol (EtOH)."
"HbA1c level in DM12W group was higher than in DM4W group, << HbA1c >> level in [[ EtOH ]]+DM8W group was lower than in DM8W group.","HbA1c level in DM12W group was higher than in DM4W group, [ENTITY_A] level in [ENTITY_B]+DM8W group was lower than in DM8W group.",INDIRECT-DOWNREGULATOR,CPR:4,1,"HbA1c level in DM12W group was higher than in DM4W group, HbA1c level in EtOH+DM8W group was lower than in DM8W group."
"Compared with DM8W group, << SOD >> and ALDH2 in [[ EtOH ]]+DM8W group was increased, MDA was decreased.","Compared with DM8W group, [ENTITY_A] and ALDH2 in [ENTITY_B]+DM8W group was increased, MDA was decreased.",INDIRECT-UPREGULATOR,CPR:3,0,"Compared with DM8W group, SOD and ALDH2 in EtOH+DM8W group was increased, MDA was decreased."
Kinetic mechanism of << quinone oxidoreductase 2 >> and its inhibition by the antimalarial [[ quinolines ]].,Kinetic mechanism of [ENTITY_A] and its inhibition by the antimalarial [ENTITY_B].,INHIBITOR,CPR:4,1,Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines.
<< QR2 >> catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or [[ N-ribosylated nicotinamides ]].,[ENTITY_A] catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or [ENTITY_B].,SUBSTRATE,CPR:9,4,QR2 catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or N-ribosylated nicotinamides.
"To investigate the mechanism and consequences of inhibition of << QR2 >> by the [[ quinolines ]] further, we have used steady-state and transient-state kinetics to define the mechanism of QR2.","To investigate the mechanism and consequences of inhibition of [ENTITY_A] by the [ENTITY_B] further, we have used steady-state and transient-state kinetics to define the mechanism of QR2.",INHIBITOR,CPR:4,1,"To investigate the mechanism and consequences of inhibition of QR2 by the quinolines further, we have used steady-state and transient-state kinetics to define the mechanism of QR2."
Our studies shed light on the possible in vivo potency of the << quinolines >> and provide a foundation for future studies aimed at creating more potent [[ QR2 ]] inhibitors and at understanding the physiological significance of QR2.,Our studies shed light on the possible in vivo potency of the [ENTITY_A] and provide a foundation for future studies aimed at creating more potent [ENTITY_B] inhibitors and at understanding the physiological significance of QR2.,INHIBITOR,CPR:4,1,Our studies shed light on the possible in vivo potency of the quinolines and provide a foundation for future studies aimed at creating more potent QR2 inhibitors and at understanding the physiological significance of QR2.
Methods: Stabilized anaplastic thyroid cancer cell lines (BHT-101 and CAL-62) and primary cultures from patients who underwent thyroidectomy for anaplastic thyroid cancer were treated with the << histone deacetylase >> inhibitor [[ LBH589 ]].,Methods: Stabilized anaplastic thyroid cancer cell lines (BHT-101 and CAL-62) and primary cultures from patients who underwent thyroidectomy for anaplastic thyroid cancer were treated with the [ENTITY_A] inhibitor [ENTITY_B].,INHIBITOR,CPR:4,1,Methods: Stabilized anaplastic thyroid cancer cell lines (BHT-101 and CAL-62) and primary cultures from patients who underwent thyroidectomy for anaplastic thyroid cancer were treated with the histone deacetylase inhibitor LBH589.
"Results: Our results demonstrate that treatment with << LBH589 >> leads to [[ NIS ]] RNA expression as shown by RT-PCR and luciferase assay, and to protein expression as determined by immunofluorescence in vitro and by immunohistochemistry in xenograft tumors.","Results: Our results demonstrate that treatment with [ENTITY_A] leads to [ENTITY_B] RNA expression as shown by RT-PCR and luciferase assay, and to protein expression as determined by immunofluorescence in vitro and by immunohistochemistry in xenograft tumors.",INDIRECT-UPREGULATOR,CPR:3,0,"Results: Our results demonstrate that treatment with LBH589 leads to NIS RNA expression as shown by RT-PCR and luciferase assay, and to protein expression as determined by immunofluorescence in vitro and by immunohistochemistry in xenograft tumors."
"Pharmacokinetic Interactions between << Monoamine Oxidase A >> Inhibitor [[ Harmaline ]] and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status.","Pharmacokinetic Interactions between [ENTITY_A] Inhibitor [ENTITY_B] and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status.",INHIBITOR,CPR:4,1,"Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status."
Our recent study has demonstrated that coadministration of << monoamine oxidase A >> (MAO-A) inhibitor [[ harmaline ]] (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine.,Our recent study has demonstrated that coadministration of [ENTITY_A] (MAO-A) inhibitor [ENTITY_B] (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine.,INHIBITOR,CPR:4,1,Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine.
"Our data revealed that inhibition of << MAO-A >>-mediated metabolic elimination by [[ harmaline ]] (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations.","Our data revealed that inhibition of [ENTITY_A]-mediated metabolic elimination by [ENTITY_B] (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations.",INHIBITOR,CPR:4,1,"Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations."
The in vivo inhibitory effect of << harmaline >> on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified [[ CYP2D6 ]].,The in vivo inhibitory effect of [ENTITY_A] on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified [ENTITY_B].,DOWNREGULATOR,CPR:4,1,The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6.
The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed << bufotenine >> formation was confirmed by in vitro study using purified [[ CYP2D6 ]].,The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed [ENTITY_A] formation was confirmed by in vitro study using purified [ENTITY_B].,PRODUCT-OF,CPR:9,4,The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6.
"Given these findings, a unified PK model including the inhibition of << MAO-A >>- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood [[ harmaline ]], 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.","Given these findings, a unified PK model including the inhibition of [ENTITY_A]- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood [ENTITY_B], 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",INHIBITOR,CPR:4,1,"Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models."
"Given these findings, a unified PK model including the inhibition of << MAO-A >>- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, [[ 5-MeO-DMT ]], and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.","Given these findings, a unified PK model including the inhibition of [ENTITY_A]- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, [ENTITY_B], and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",SUBSTRATE,CPR:9,4,"Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models."
"Compared pharmacological characteristics in humans of racemic << cetirizine >> and levocetirizine, two [[ histamine H1-receptor ]] antagonists.","Compared pharmacological characteristics in humans of racemic [ENTITY_A] and levocetirizine, two [ENTITY_B] antagonists.",ANTAGONIST,CPR:6,3,"Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists."
The potent << histamine H(1)-receptor >> antagonist [[ cetirizine ]] (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine.,The potent [ENTITY_A] antagonist [ENTITY_B] (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine.,ANTAGONIST,CPR:6,3,The potent histamine H(1)-receptor antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine.
"<< Vegfrecine >>, an Inhibitor of [[ VEGF Receptor Tyrosine Kinases ]] Isolated from the Culture Broth of Streptomyces sp.","[ENTITY_A], an Inhibitor of [ENTITY_B] Isolated from the Culture Broth of Streptomyces sp.",INHIBITOR,CPR:4,1,"Vegfrecine, an Inhibitor of VEGF Receptor Tyrosine Kinases Isolated from the Culture Broth of Streptomyces sp."
"A new inhibitor of << VEGF receptor tyrosine kinases >>, [[ vegfrecine ]] (1), was isolated from the culture broth of Streptomyces sp.","A new inhibitor of [ENTITY_A], [ENTITY_B] (1), was isolated from the culture broth of Streptomyces sp.",INHIBITOR,CPR:4,1,"A new inhibitor of VEGF receptor tyrosine kinases, vegfrecine (1), was isolated from the culture broth of Streptomyces sp."
"As opposed to the rat and flounder orthologs, << hNaDC-3 >> was hardly inhibited by [[ lithium ]] concentrations up to 5 mM.","As opposed to the rat and flounder orthologs, [ENTITY_A] was hardly inhibited by [ENTITY_B] concentrations up to 5 mM.",INHIBITOR,CPR:4,1,"As opposed to the rat and flounder orthologs, hNaDC-3 was hardly inhibited by lithium concentrations up to 5 mM."
Effects of inhibition of << urokinase-type plasminogen activator >> (u-PA) by [[ amiloride ]] in the cornea and tear fluid of eyes irradiated with UVB.,Effects of inhibition of [ENTITY_A] (u-PA) by [ENTITY_B] in the cornea and tear fluid of eyes irradiated with UVB.,INHIBITOR,CPR:4,1,Effects of inhibition of urokinase-type plasminogen activator (u-PA) by amiloride in the cornea and tear fluid of eyes irradiated with UVB.
"The purpose of the present study was to test our hypothesis that << amiloride >>, a specific [[ u-PA ]] inhibitor, effectively decreases u-PA activity in cornea as well as in tear fluid and favourably affects corneal healing.","The purpose of the present study was to test our hypothesis that [ENTITY_A], a specific [ENTITY_B] inhibitor, effectively decreases u-PA activity in cornea as well as in tear fluid and favourably affects corneal healing.",INHIBITOR,CPR:4,1,"The purpose of the present study was to test our hypothesis that amiloride, a specific u-PA inhibitor, effectively decreases u-PA activity in cornea as well as in tear fluid and favourably affects corneal healing."
"Therefore, comparative histochemical and biochemical studies of << u-PA >> and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate [[ Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin ]].","Therefore, comparative histochemical and biochemical studies of [ENTITY_A] and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate [ENTITY_B].",SUBSTRATE,CPR:9,4,"Therefore, comparative histochemical and biochemical studies of u-PA and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin."
"When << amiloride >> was dropped on the eye surface on the first day of irradiation and subsequently daily until the end of the experiment, [[ u-PA ]] activity in both cornea and tear fluid was strongly inhibited.","When [ENTITY_A] was dropped on the eye surface on the first day of irradiation and subsequently daily until the end of the experiment, [ENTITY_B] activity in both cornea and tear fluid was strongly inhibited.",INHIBITOR,CPR:4,1,"When amiloride was dropped on the eye surface on the first day of irradiation and subsequently daily until the end of the experiment, u-PA activity in both cornea and tear fluid was strongly inhibited."
"In conclusion, early application of << amiloride >> inhibited [[ u-PA ]] activity in UVB-irradiated corneas as well as in tear fluid and diminished the development of corneal pathology.","In conclusion, early application of [ENTITY_A] inhibited [ENTITY_B] activity in UVB-irradiated corneas as well as in tear fluid and diminished the development of corneal pathology.",INHIBITOR,CPR:4,1,"In conclusion, early application of amiloride inhibited u-PA activity in UVB-irradiated corneas as well as in tear fluid and diminished the development of corneal pathology."
"<< Prednisolone >> also inhibited ACTH and cortisol secretion in response to exogenous [[ CRH ]] stimulation, inferring rapid feedback inhibition at the anterior pituitary.","[ENTITY_A] also inhibited ACTH and cortisol secretion in response to exogenous [ENTITY_B] stimulation, inferring rapid feedback inhibition at the anterior pituitary.",DOWNREGULATOR,CPR:4,1,"Prednisolone also inhibited ACTH and cortisol secretion in response to exogenous CRH stimulation, inferring rapid feedback inhibition at the anterior pituitary."
"Prednisolone also inhibited ACTH and << cortisol >> secretion in response to exogenous [[ CRH ]] stimulation, inferring rapid feedback inhibition at the anterior pituitary.","Prednisolone also inhibited ACTH and [ENTITY_A] secretion in response to exogenous [ENTITY_B] stimulation, inferring rapid feedback inhibition at the anterior pituitary.",PRODUCT-OF,CPR:9,4,"Prednisolone also inhibited ACTH and cortisol secretion in response to exogenous CRH stimulation, inferring rapid feedback inhibition at the anterior pituitary."
Pharmacophore identification of << c-Myc >> inhibitor [[ 10074-G5 ]].,Pharmacophore identification of [ENTITY_A] inhibitor [ENTITY_B].,INHIBITOR,CPR:4,1,Pharmacophore identification of c-Myc inhibitor 10074-G5.
"A structure-activity relationship (SAR) study of the << c-Myc >> (Myc) inhibitor [[ 10074-G5 ]] (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore.","A structure-activity relationship (SAR) study of the [ENTITY_A] (Myc) inhibitor [ENTITY_B] (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore.",INHIBITOR,CPR:4,1,"A structure-activity relationship (SAR) study of the c-Myc (Myc) inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore."
"Importantly, the carboxylic acid of << JY-3-094 >> improves the physicochemical properties of the lead compound, which will facilitate the incorporation of additional hydrophobicity that might enhance [[ Myc ]] inhibitory activity further still.","Importantly, the carboxylic acid of [ENTITY_A] improves the physicochemical properties of the lead compound, which will facilitate the incorporation of additional hydrophobicity that might enhance [ENTITY_B] inhibitory activity further still.",INHIBITOR,CPR:4,1,"Importantly, the carboxylic acid of JY-3-094 improves the physicochemical properties of the lead compound, which will facilitate the incorporation of additional hydrophobicity that might enhance Myc inhibitory activity further still."
"<< Miglustat >>, a small iminosugar molecule approved for the treatment of Gaucher disease, reversibly inhibits [[ glucosylceramide synthase ]], which catalyses the first committed step in glycosphingolipid synthesis.","[ENTITY_A], a small iminosugar molecule approved for the treatment of Gaucher disease, reversibly inhibits [ENTITY_B], which catalyses the first committed step in glycosphingolipid synthesis.",INHIBITOR,CPR:4,1,"Miglustat, a small iminosugar molecule approved for the treatment of Gaucher disease, reversibly inhibits glucosylceramide synthase, which catalyses the first committed step in glycosphingolipid synthesis."
"Furthermore, compared with control groups, the plaque endothelium level of << p75(NTR) >> was 3-fold increased and the liver level of p75(NTR) was 17.4-fold increased by [[ SFO ]]-HD.","Furthermore, compared with control groups, the plaque endothelium level of [ENTITY_A] was 3-fold increased and the liver level of p75(NTR) was 17.4-fold increased by [ENTITY_B]-HD.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, compared with control groups, the plaque endothelium level of p75(NTR) was 3-fold increased and the liver level of p75(NTR) was 17.4-fold increased by SFO-HD."
"Meanwhile, the serum level of KC (a functional homolog of << IL-8 >> and the main proinflammatory alpha chemokine in mice) in apoE(-/-) mice was up to 357pg/ml in [[ SFO ]]-HD treated group.","Meanwhile, the serum level of KC (a functional homolog of [ENTITY_A] and the main proinflammatory alpha chemokine in mice) in apoE(-/-) mice was up to 357pg/ml in [ENTITY_B]-HD treated group.",INDIRECT-UPREGULATOR,CPR:3,0,"Meanwhile, the serum level of KC (a functional homolog of IL-8 and the main proinflammatory alpha chemokine in mice) in apoE(-/-) mice was up to 357pg/ml in SFO-HD treated group."
"Thus, << SFO >> contributes to the instability of atherosclerotic plaque in apoE(-/-) mice through activating [[ p75(NTR) ]] and IL-8 and cell apoptosis in plaque.","Thus, [ENTITY_A] contributes to the instability of atherosclerotic plaque in apoE(-/-) mice through activating [ENTITY_B] and IL-8 and cell apoptosis in plaque.",ACTIVATOR,CPR:3,0,"Thus, SFO contributes to the instability of atherosclerotic plaque in apoE(-/-) mice through activating p75(NTR) and IL-8 and cell apoptosis in plaque."
<< Levodopa >> is absorbed in the small bowel and is rapidly catabolized by [[ aromatic-L-amino-acid decarboxylase ]] (AADC) and catechol-O-methyltransferase (COMT).,[ENTITY_A] is absorbed in the small bowel and is rapidly catabolized by [ENTITY_B] (AADC) and catechol-O-methyltransferase (COMT).,SUBSTRATE,CPR:9,4,Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol-O-methyltransferase (COMT).
"Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of << AADC >> (carbidopa or [[ benserazide ]]), and inhibitors of COMT will also enter clinical use.","Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of [ENTITY_A] (carbidopa or [ENTITY_B]), and inhibitors of COMT will also enter clinical use.",INHIBITOR,CPR:4,1,"Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use."
"Because gastric << AADC >> and COMT degrade [[ levodopa ]], the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use.","Because gastric [ENTITY_A] and COMT degrade [ENTITY_B], the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use.",SUBSTRATE,CPR:9,4,"Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use."
Rats were fed experimental diets containing SPI or << casein >> as a [[ nitrogen ]] source.,Rats were fed experimental diets containing SPI or [ENTITY_A] as a [ENTITY_B] source.,PRODUCT-OF,CPR:9,4,Rats were fed experimental diets containing SPI or casein as a nitrogen source.
"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of << L-arginine >> for [[ aminopeptidase B ]].","Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of [ENTITY_A] for [ENTITY_B].",SUBSTRATE,CPR:9,4,"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B."
The inhibition of << aminopeptidase >> activity in the presence of [[ bestatin ]] and puromycin inhibitors was also investigated.,The inhibition of [ENTITY_A] activity in the presence of [ENTITY_B] and puromycin inhibitors was also investigated.,INHIBITOR,CPR:4,1,The inhibition of aminopeptidase activity in the presence of bestatin and puromycin inhibitors was also investigated.
"Here, we demonstrate that << peptidyl-prolyl cis/trans-isomerase A1 >> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of [[ pSer ]]/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.","Here, we demonstrate that [ENTITY_A] (Pin1), an enzyme that catalyzes the conversion of the peptide bond of [ENTITY_B]/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",SUBSTRATE,CPR:9,4,"Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification."
Withdrawal from free-choice << ethanol >> consumption results in increased packing density of [[ glutamine synthetase ]]-immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats.,Withdrawal from free-choice [ENTITY_A] consumption results in increased packing density of [ENTITY_B]-immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats.,UPREGULATOR,CPR:3,0,Withdrawal from free-choice ethanol consumption results in increased packing density of glutamine synthetase-immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats.
Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to << glutamine >> through the enzyme [[ glutamine synthetase ]] (GS).,Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to [ENTITY_A] through the enzyme [ENTITY_B] (GS).,PRODUCT-OF,CPR:9,4,Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to glutamine through the enzyme glutamine synthetase (GS).
<< All-trans retinoic acid >> protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating [[ collagen 8A2 ]].,[ENTITY_A] protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating [ENTITY_B].,UPREGULATOR,CPR:3,0,All-trans retinoic acid protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating collagen 8A2.
"The protein exhibited modest << H(2)O(2) >>-dependent [[ peroxidase ]] activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).","The protein exhibited modest [ENTITY_A]-dependent [ENTITY_B] activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).",ACTIVATOR,CPR:3,0,"The protein exhibited modest H(2)O(2)-dependent peroxidase activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)."
"The protein exhibited modest H(2)O(2)-dependent << peroxidase >> activities with [[ guaiacol ]], potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).","The protein exhibited modest H(2)O(2)-dependent [ENTITY_A] activities with [ENTITY_B], potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).",SUBSTRATE,CPR:9,4,"The protein exhibited modest H(2)O(2)-dependent peroxidase activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)."
"Ferredoxin 1 (<< FDX1 >>; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including [[ steroid ]] hormone synthesis in mammalian tissues.","Ferredoxin 1 ([ENTITY_A]; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including [ENTITY_B] hormone synthesis in mammalian tissues.",PRODUCT-OF,CPR:9,4,"Ferredoxin 1 (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues."
"Luciferase reporter assays showed that transcription of << FDX1 >> was synergistically activated by the NR5A family and [[ 8Br-cAMP ]] treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN.","Luciferase reporter assays showed that transcription of [ENTITY_A] was synergistically activated by the NR5A family and [ENTITY_B] treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN.",INDIRECT-UPREGULATOR,CPR:3,0,"Luciferase reporter assays showed that transcription of FDX1 was synergistically activated by the NR5A family and 8Br-cAMP treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN."
"These results indicate transcription of << FDX1 >> is regulated by the NR5A family and [[ cAMP ]] signaling, and participates in steroid hormone production in ovarian granulosa cells.","These results indicate transcription of [ENTITY_A] is regulated by the NR5A family and [ENTITY_B] signaling, and participates in steroid hormone production in ovarian granulosa cells.",INDIRECT-UPREGULATOR,CPR:3,0,"These results indicate transcription of FDX1 is regulated by the NR5A family and cAMP signaling, and participates in steroid hormone production in ovarian granulosa cells."
"These results indicate transcription of << FDX1 >> is regulated by the NR5A family and cAMP signaling, and participates in [[ steroid ]] hormone production in ovarian granulosa cells.","These results indicate transcription of [ENTITY_A] is regulated by the NR5A family and cAMP signaling, and participates in [ENTITY_B] hormone production in ovarian granulosa cells.",PRODUCT-OF,CPR:9,4,"These results indicate transcription of FDX1 is regulated by the NR5A family and cAMP signaling, and participates in steroid hormone production in ovarian granulosa cells."
"<< Flutamide >>, an effective competitive inhibitor of the [[ androgen receptor ]] used orally for palliative treatment of prostatic carcinoma and regulation of prostatic hyperplasia was evaluated for its genotoxic effects in the intact rat and in primary cultures of human hepatocytes.","[ENTITY_A], an effective competitive inhibitor of the [ENTITY_B] used orally for palliative treatment of prostatic carcinoma and regulation of prostatic hyperplasia was evaluated for its genotoxic effects in the intact rat and in primary cultures of human hepatocytes.",INHIBITOR,CPR:4,1,"Flutamide, an effective competitive inhibitor of the androgen receptor used orally for palliative treatment of prostatic carcinoma and regulation of prostatic hyperplasia was evaluated for its genotoxic effects in the intact rat and in primary cultures of human hepatocytes."
"In the liver of rats given << flutamide >> as initiating agent at the dose of 500 mg/kg/week for 6 successive weeks, [[ gamma-glutamyltraspeptidase ]]-positive foci were detected only in 3 of 10 rats.","In the liver of rats given [ENTITY_A] as initiating agent at the dose of 500 mg/kg/week for 6 successive weeks, [ENTITY_B]-positive foci were detected only in 3 of 10 rats.",INDIRECT-UPREGULATOR,CPR:3,0,"In the liver of rats given flutamide as initiating agent at the dose of 500 mg/kg/week for 6 successive weeks, gamma-glutamyltraspeptidase-positive foci were detected only in 3 of 10 rats."
<< Cycloxygenase-2 >> (COX-2)-derived [[ prostaglandin E2 ]] (PGE2) has been shown to be important in esophageal tumorigenesis.,[ENTITY_A] (COX-2)-derived [ENTITY_B] (PGE2) has been shown to be important in esophageal tumorigenesis.,PRODUCT-OF,CPR:9,4,Cycloxygenase-2 (COX-2)-derived prostaglandin E2 (PGE2) has been shown to be important in esophageal tumorigenesis.
We have shown that << COX-2 >> mediates acid-induced [[ PGE2 ]] production.,We have shown that [ENTITY_A] mediates acid-induced [ENTITY_B] production.,PRODUCT-OF,CPR:9,4,We have shown that COX-2 mediates acid-induced PGE2 production.
We conclude that << mPGES1 >> mediates acid-induced increase in [[ PGE2 ]] production and cell proliferation.,We conclude that [ENTITY_A] mediates acid-induced increase in [ENTITY_B] production and cell proliferation.,PRODUCT-OF,CPR:9,4,We conclude that mPGES1 mediates acid-induced increase in PGE2 production and cell proliferation.
<< Butein >> also increased [[ heme oxygenase-1 ]] (HO-1) protein expression and HO activity.,[ENTITY_A] also increased [ENTITY_B] (HO-1) protein expression and HO activity.,INDIRECT-UPREGULATOR,CPR:3,0,Butein also increased heme oxygenase-1 (HO-1) protein expression and HO activity.
"Furthermore, << butein >> treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of [[ antioxidant response elements ]] (AREs).","Furthermore, [ENTITY_A] treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of [ENTITY_B] (AREs).",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, butein treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of antioxidant response elements (AREs)."
"Treatment of HDP cells with a c-Jun NH2-terminal kinase (JNK) inhibitor also reduced butein-induced HO-1 expression, and << butein >> treatment led to increased [[ JNK ]] phosphorylation.","Treatment of HDP cells with a c-Jun NH2-terminal kinase (JNK) inhibitor also reduced butein-induced HO-1 expression, and [ENTITY_A] treatment led to increased [ENTITY_B] phosphorylation.",ACTIVATOR,CPR:3,0,"Treatment of HDP cells with a c-Jun NH2-terminal kinase (JNK) inhibitor also reduced butein-induced HO-1 expression, and butein treatment led to increased JNK phosphorylation."
The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its << proline-42-to-alanine >> mutant (Pro42Ala) have been studied by monitoring tyrosine burial and [[ 2'-cytidine monophosphate ]] (2'CMP) inhibitor binding.,The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its [ENTITY_A] mutant (Pro42Ala) have been studied by monitoring tyrosine burial and [ENTITY_B] (2'CMP) inhibitor binding.,INHIBITOR,CPR:4,1,The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.
"The folding rate for wild-type << RNase A >> is faster in the presence of the inhibitor [[ 2'CMP ]] than in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by 2'CMP.","The folding rate for wild-type [ENTITY_A] is faster in the presence of the inhibitor [ENTITY_B] than in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by 2'CMP.",INHIBITOR,CPR:4,1,"The folding rate for wild-type RNase A is faster in the presence of the inhibitor 2'CMP than in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by 2'CMP."
"During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce << prostaglandins >> (PG) via [[ PG synthase 2 ]] (PTGS2) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1).","During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce [ENTITY_A] (PG) via [ENTITY_B] (PTGS2) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1).",PRODUCT-OF,CPR:9,4,"During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1)."
The primary aim of these studies was to test the hypothesis that << HSD11B1 >>-derived [[ cortisol ]] has a biological role in endometrial function and conceptus development during early pregnancy in sheep.,The primary aim of these studies was to test the hypothesis that [ENTITY_A]-derived [ENTITY_B] has a biological role in endometrial function and conceptus development during early pregnancy in sheep.,PRODUCT-OF,CPR:9,4,The primary aim of these studies was to test the hypothesis that HSD11B1-derived cortisol has a biological role in endometrial function and conceptus development during early pregnancy in sheep.
"In study 1, cyclic ewes received vehicle, cortisol, << PF 915275 >> (PF; a selective inhibitor of [[ HSD11B1 ]]), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus.","In study 1, cyclic ewes received vehicle, cortisol, [ENTITY_A] (PF; a selective inhibitor of [ENTITY_B]), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus.",INHIBITOR,CPR:4,1,"In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus."
"<< Cortisol >> and IFNT stimulated endometrial [[ HSD11B1 ]] expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium.","[ENTITY_A] and IFNT stimulated endometrial [ENTITY_B] expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium.",ACTIVATOR,CPR:3,0,"Cortisol and IFNT stimulated endometrial HSD11B1 expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium."
"These results suggest that << HSD11B1 >>-derived [[ cortisol ]] mediates, in part, actions of ovarian progesterone and the conceptus on endometrial function and support the hypothesis that IFNT, PG, and cortisol coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep.","These results suggest that [ENTITY_A]-derived [ENTITY_B] mediates, in part, actions of ovarian progesterone and the conceptus on endometrial function and support the hypothesis that IFNT, PG, and cortisol coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep.",PRODUCT-OF,CPR:9,4,"These results suggest that HSD11B1-derived cortisol mediates, in part, actions of ovarian progesterone and the conceptus on endometrial function and support the hypothesis that IFNT, PG, and cortisol coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep."
<< 2-(2-Aminoethyl)-quinoline >> (D-1997): a novel agonist at [[ 5-hydroxytryptamine1-like receptors ]] in the canine basilar artery.,[ENTITY_A] (D-1997): a novel agonist at [ENTITY_B] in the canine basilar artery.,AGONIST,CPR:5,2,2-(2-Aminoethyl)-quinoline (D-1997): a novel agonist at 5-hydroxytryptamine1-like receptors in the canine basilar artery.
"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the << beta-adrenoceptor >> blocker with high affinity for 5-HT1A and 5-HT1B binding sites [[ (+/-)-pindolol ]] (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).","The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the [ENTITY_A] blocker with high affinity for 5-HT1A and 5-HT1B binding sites [ENTITY_B] (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",INHIBITOR,CPR:4,1,"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)."
"The effects of D-1997 in the basilar artery were not modified by incubation with either the << 5-HT2 receptor >> antagonist [[ ketanserin ]] (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).","The effects of D-1997 in the basilar artery were not modified by incubation with either the [ENTITY_A] antagonist [ENTITY_B] (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",ANTAGONIST,CPR:6,3,"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)."
"In contrast, the << D-1997 >>-induced responses were potently and concentration-dependently antagonized by the mixed [[ 5-HT1-like ]] and 5-HT2 receptor antagonist methiothepin (0.01-1 microM).","In contrast, the [ENTITY_A]-induced responses were potently and concentration-dependently antagonized by the mixed [ENTITY_B] and 5-HT2 receptor antagonist methiothepin (0.01-1 microM).",AGONIST,CPR:5,2,"In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and 5-HT2 receptor antagonist methiothepin (0.01-1 microM)."
"In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed << 5-HT1-like >> and 5-HT2 receptor antagonist [[ methiothepin ]] (0.01-1 microM).","In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed [ENTITY_A] and 5-HT2 receptor antagonist [ENTITY_B] (0.01-1 microM).",ANTAGONIST,CPR:6,3,"In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and 5-HT2 receptor antagonist methiothepin (0.01-1 microM)."
It is concluded that << D-1997 >> contracts the canine basilar artery by stimulating [[ 5-HT1-like receptors ]] unrelated to either the 5-HT1A or 5-HT1B receptor subtypes.,It is concluded that [ENTITY_A] contracts the canine basilar artery by stimulating [ENTITY_B] unrelated to either the 5-HT1A or 5-HT1B receptor subtypes.,ACTIVATOR,CPR:3,0,It is concluded that D-1997 contracts the canine basilar artery by stimulating 5-HT1-like receptors unrelated to either the 5-HT1A or 5-HT1B receptor subtypes.
"Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for << VK2 >>-induced [[ cytochrome c ]] (cyt c) release and cell death.","Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for [ENTITY_A]-induced [ENTITY_B] (cyt c) release and cell death.",INDIRECT-UPREGULATOR,CPR:3,0,"Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for VK2-induced cytochrome c (cyt c) release and cell death."
"In muscle and liver, << TCDD >> (10 ng/kg/day) induced increases in methylation and decreases in mRNA expression of [[ Igf2r ]].","In muscle and liver, [ENTITY_A] (10 ng/kg/day) induced increases in methylation and decreases in mRNA expression of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"In muscle and liver, TCDD (10 ng/kg/day) induced increases in methylation and decreases in mRNA expression of Igf2r."
<< Rasagiline >> is a propargylamine and irreversible [[ monoamine oxidase (MAO) B ]] inhibitor used for the treatment of Parkinson's disease (PD).,[ENTITY_A] is a propargylamine and irreversible [ENTITY_B] inhibitor used for the treatment of Parkinson's disease (PD).,INHIBITOR,CPR:4,1,Rasagiline is a propargylamine and irreversible monoamine oxidase (MAO) B inhibitor used for the treatment of Parkinson's disease (PD).
<< Tolvaptan >> is a selective [[ arginine vasopressin (AVP) V(2) receptor ]] blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia.,[ENTITY_A] is a selective [ENTITY_B] blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia.,INHIBITOR,CPR:4,1,Tolvaptan is a selective arginine vasopressin (AVP) V(2) receptor blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia.
Prolonged use of << tolvaptan >> leads to increased endogenous levels of AVP and perhaps over-stimulation of [[ V(1A) receptors ]].,Prolonged use of [ENTITY_A] leads to increased endogenous levels of AVP and perhaps over-stimulation of [ENTITY_B].,ACTIVATOR,CPR:3,0,Prolonged use of tolvaptan leads to increased endogenous levels of AVP and perhaps over-stimulation of V(1A) receptors.
"In addition, << tolvaptan >> is metabolized by the [[ CYP3A4 ]] system; thus physicians should be aware of the potential for increased interactions with other medications.","In addition, [ENTITY_A] is metabolized by the [ENTITY_B] system; thus physicians should be aware of the potential for increased interactions with other medications.",SUBSTRATE,CPR:9,4,"In addition, tolvaptan is metabolized by the CYP3A4 system; thus physicians should be aware of the potential for increased interactions with other medications."
"<< Fisetin >> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma [[ insulin ]].","[ENTITY_A] treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin."
"<< Fisetin >> treatment showed a significant decline in the levels of blood glucose, [[ glycosylated hemoglobin ]] (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin.","[ENTITY_A] treatment showed a significant decline in the levels of blood glucose, [ENTITY_B] (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin."
High-<< glucose >> environment enhanced oxidative stress and increased [[ interleukin-8 ]] secretion from keratinocytes: New insights on impaired diabetic wound healing.,High-[ENTITY_A] environment enhanced oxidative stress and increased [ENTITY_B] secretion from keratinocytes: New insights on impaired diabetic wound healing.,INDIRECT-UPREGULATOR,CPR:3,0,High-glucose environment enhanced oxidative stress and increased interleukin-8 secretion from keratinocytes: New insights on impaired diabetic wound healing.
"Using cultured human keratinocytes and diabetic rat model, the current study showed that high-<< glucose >> environment enhanced [[ IL-8 ]] production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.","Using cultured human keratinocytes and diabetic rat model, the current study showed that high-[ENTITY_A] environment enhanced [ENTITY_B] production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.",INDIRECT-UPREGULATOR,CPR:3,0,"Using cultured human keratinocytes and diabetic rat model, the current study showed that high-glucose environment enhanced IL-8 production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes."
"In conclusion, << IL-8 >> production and neutrophil infiltration are increased in high-[[ glucose ]] environment due to elevated ROS level and contributed to impaired wound healing in diabetic skin.","In conclusion, [ENTITY_A] production and neutrophil infiltration are increased in high-[ENTITY_B] environment due to elevated ROS level and contributed to impaired wound healing in diabetic skin.",INDIRECT-UPREGULATOR,CPR:3,0,"In conclusion, IL-8 production and neutrophil infiltration are increased in high-glucose environment due to elevated ROS level and contributed to impaired wound healing in diabetic skin."
"The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) << PhIP >> (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased [[ catalase ]] (CAT) activity compared with the control.","The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) [ENTITY_A] (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased [ENTITY_B] (CAT) activity compared with the control.",UPREGULATOR,CPR:3,0,"The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control."
"The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) << PhIP >> (10 and/or 15mg/kg) significantly decreased [[ superoxide dismutase ]] (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control.","The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) [ENTITY_A] (10 and/or 15mg/kg) significantly decreased [ENTITY_B] (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control.",DOWNREGULATOR,CPR:4,1,"The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control."
"With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) << PhIP >> at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and [[ c-jun ]] expression relative to control.","With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) [ENTITY_A] at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and [ENTITY_B] expression relative to control.",INDIRECT-UPREGULATOR,CPR:3,0,"With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) PhIP at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control."
"With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) << PhIP >> at the doses of 10mg/kg and/or 15mg/kg significantly inhibited [[ p16 ]] mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control.","With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) [ENTITY_A] at the doses of 10mg/kg and/or 15mg/kg significantly inhibited [ENTITY_B] mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control.",INDIRECT-DOWNREGULATOR,CPR:4,1,"With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) PhIP at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control."
"The data indicated that << PhIP >> could cause stomach injury, oxidative stress in rat stomachs as well as the activation of [[ c-fos ]] and c-jun and inactivation of p16, which may play a role in the pathogenesis of PhIP-associated stomach cancer.","The data indicated that [ENTITY_A] could cause stomach injury, oxidative stress in rat stomachs as well as the activation of [ENTITY_B] and c-jun and inactivation of p16, which may play a role in the pathogenesis of PhIP-associated stomach cancer.",ACTIVATOR,CPR:3,0,"The data indicated that PhIP could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of p16, which may play a role in the pathogenesis of PhIP-associated stomach cancer."
"The data indicated that << PhIP >> could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of [[ p16 ]], which may play a role in the pathogenesis of PhIP-associated stomach cancer.","The data indicated that [ENTITY_A] could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of [ENTITY_B], which may play a role in the pathogenesis of PhIP-associated stomach cancer.",INHIBITOR,CPR:4,1,"The data indicated that PhIP could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of p16, which may play a role in the pathogenesis of PhIP-associated stomach cancer."
"We also shortly discuss the ongoing debate on whether << NO >> is the actual reaction product of [[ NOS ]] catalysis, as well as the phenomenon of NO-mediated autoinhibition.","We also shortly discuss the ongoing debate on whether [ENTITY_A] is the actual reaction product of [ENTITY_B] catalysis, as well as the phenomenon of NO-mediated autoinhibition.",PRODUCT-OF,CPR:9,4,"We also shortly discuss the ongoing debate on whether NO is the actual reaction product of NOS catalysis, as well as the phenomenon of NO-mediated autoinhibition."
<< Prostacyclin >> analogues inhibit [[ tissue factor ]] expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism.,[ENTITY_A] analogues inhibit [ENTITY_B] expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism.,INDIRECT-DOWNREGULATOR,CPR:4,1,Prostacyclin analogues inhibit tissue factor expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism.
"The present studies were undertaken to determine whether stable analogues of << prostacyclin >>, a potent endothelium-derived platelet inhibitor and vasodilator, could inhibit [[ tissue factor ]] expression by human monocytic cells.","The present studies were undertaken to determine whether stable analogues of [ENTITY_A], a potent endothelium-derived platelet inhibitor and vasodilator, could inhibit [ENTITY_B] expression by human monocytic cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The present studies were undertaken to determine whether stable analogues of prostacyclin, a potent endothelium-derived platelet inhibitor and vasodilator, could inhibit tissue factor expression by human monocytic cells."
"Preincubation for 30 minutes with << iloprost >>, ciprostene, and carbacyclin led to a dose-dependent inhibition of [[ tissue factor ]] expression induced by all three challenging agents.","Preincubation for 30 minutes with [ENTITY_A], ciprostene, and carbacyclin led to a dose-dependent inhibition of [ENTITY_B] expression induced by all three challenging agents.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Preincubation for 30 minutes with iloprost, ciprostene, and carbacyclin led to a dose-dependent inhibition of tissue factor expression induced by all three challenging agents."
"This effect was potentiated by << isobutylmethylxanthine >>, an inhibitor of [[ phosphodiesterase ]].","This effect was potentiated by [ENTITY_A], an inhibitor of [ENTITY_B].",INHIBITOR,CPR:4,1,"This effect was potentiated by isobutylmethylxanthine, an inhibitor of phosphodiesterase."
The inhibitory effects of iloprost on << tissue factor >> expression were also potentiated by [[ isobutylmethylxanthine ]] and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP.,The inhibitory effects of iloprost on [ENTITY_A] expression were also potentiated by [ENTITY_B] and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP.,INHIBITOR,CPR:4,1,The inhibitory effects of iloprost on tissue factor expression were also potentiated by isobutylmethylxanthine and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP.
"These results suggest that prostacyclin may play a role in downregulating << tissue factor >> expression in monocytes, at least in part via elevation of intracellular levels of [[ cyclic AMP ]].","These results suggest that prostacyclin may play a role in downregulating [ENTITY_A] expression in monocytes, at least in part via elevation of intracellular levels of [ENTITY_B].",DOWNREGULATOR,CPR:4,1,"These results suggest that prostacyclin may play a role in downregulating tissue factor expression in monocytes, at least in part via elevation of intracellular levels of cyclic AMP."
PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to << 5-fluorouracil >> (5-FU) by thymidine phosphorylase ([[ TP ]]) inside target tissues.,PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to [ENTITY_A] (5-FU) by thymidine phosphorylase ([ENTITY_B]) inside target tissues.,PRODUCT-OF,CPR:9,4,PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues.
<< 5-FU >> interferes with DNA synthesis by blocking [[ thymidylate synthase ]] (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD).,[ENTITY_A] interferes with DNA synthesis by blocking [ENTITY_B] (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD).,INHIBITOR,CPR:4,1,5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD).
"Favorable enzyme profiles (high << TP >> and low DPD) generate high intratumor levels of [[ 5-FU ]] that are effective against many tumors, especially those with low TS.","Favorable enzyme profiles (high [ENTITY_A] and low DPD) generate high intratumor levels of [ENTITY_B] that are effective against many tumors, especially those with low TS.",PRODUCT-OF,CPR:9,4,"Favorable enzyme profiles (high TP and low DPD) generate high intratumor levels of 5-FU that are effective against many tumors, especially those with low TS."
"Previous studies by this research team proved that vasodilating << prostaglandins >> (PGs) E1, E2 and I2 inhibit [[ carbonic anhydrase ]] (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs.","Previous studies by this research team proved that vasodilating [ENTITY_A] (PGs) E1, E2 and I2 inhibit [ENTITY_B] (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs.",INHIBITOR,CPR:4,1,"Previous studies by this research team proved that vasodilating prostaglandins (PGs) E1, E2 and I2 inhibit carbonic anhydrase (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs."
Histamine and << Ca >> added to NSAIDs amplified the activating effect of the latter on [[ CA II ]].,Histamine and [ENTITY_A] added to NSAIDs amplified the activating effect of the latter on [ENTITY_B].,UPREGULATOR,CPR:3,0,Histamine and Ca added to NSAIDs amplified the activating effect of the latter on CA II.
Association of PGE2 or << acetazolamide >> to NSAIDs reduced NSAID-induced activation of [[ CA I ]] and CA II.,Association of PGE2 or [ENTITY_A] to NSAIDs reduced NSAID-induced activation of [ENTITY_B] and CA II.,DOWNREGULATOR,CPR:4,1,Association of PGE2 or acetazolamide to NSAIDs reduced NSAID-induced activation of CA I and CA II.
<< Indomethacin >> abolished the inhibitory effect of acetazolamide on [[ CA I ]] and CA II.,[ENTITY_A] abolished the inhibitory effect of acetazolamide on [ENTITY_B] and CA II.,ACTIVATOR,CPR:3,0,Indomethacin abolished the inhibitory effect of acetazolamide on CA I and CA II.
Indomethacin abolished the inhibitory effect of << acetazolamide >> on [[ CA I ]] and CA II.,Indomethacin abolished the inhibitory effect of [ENTITY_A] on [ENTITY_B] and CA II.,INHIBITOR,CPR:4,1,Indomethacin abolished the inhibitory effect of acetazolamide on CA I and CA II.
"<< COX-1 >> inhibition was measured as percentage inhibition of serum [[ TXB2 ]] generation in clotting whole blood, and as closure time with use of the platelet function analyser PFA-100.","[ENTITY_A] inhibition was measured as percentage inhibition of serum [ENTITY_B] generation in clotting whole blood, and as closure time with use of the platelet function analyser PFA-100.",PRODUCT-OF,CPR:9,4,"COX-1 inhibition was measured as percentage inhibition of serum TXB2 generation in clotting whole blood, and as closure time with use of the platelet function analyser PFA-100."
"CONCLUSIONS: In the maximum registered dosage, << nabumetone >> inhibits thromboxane production much more than meloxicam, signifying less [[ COX-2 ]] selectivity of the former.","CONCLUSIONS: In the maximum registered dosage, [ENTITY_A] inhibits thromboxane production much more than meloxicam, signifying less [ENTITY_B] selectivity of the former.",DOWNREGULATOR,CPR:4,1,"CONCLUSIONS: In the maximum registered dosage, nabumetone inhibits thromboxane production much more than meloxicam, signifying less COX-2 selectivity of the former."
"Treatment with << diclofenac >> resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated [[ caspase-3 ]] after 6 hr, indicating that diclofenac may cause apoptosis of neuronal cells via activation of the caspase cascade.","Treatment with [ENTITY_A] resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated [ENTITY_B] after 6 hr, indicating that diclofenac may cause apoptosis of neuronal cells via activation of the caspase cascade.",ACTIVATOR,CPR:3,0,"Treatment with diclofenac resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated caspase-3 after 6 hr, indicating that diclofenac may cause apoptosis of neuronal cells via activation of the caspase cascade."
Correlation between activation of << PPARγ >> and resistin downregulation in a mouse adipocyte cell line by a series of [[ thiazolidinediones ]].,Correlation between activation of [ENTITY_A] and resistin downregulation in a mouse adipocyte cell line by a series of [ENTITY_B].,ACTIVATOR,CPR:3,0,Correlation between activation of PPARγ and resistin downregulation in a mouse adipocyte cell line by a series of thiazolidinediones.
Correlation between activation of PPARγ and << resistin >> downregulation in a mouse adipocyte cell line by a series of [[ thiazolidinediones ]].,Correlation between activation of PPARγ and [ENTITY_A] downregulation in a mouse adipocyte cell line by a series of [ENTITY_B].,DOWNREGULATOR,CPR:4,1,Correlation between activation of PPARγ and resistin downregulation in a mouse adipocyte cell line by a series of thiazolidinediones.
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported << NRF2 >> target genes in response to NRF2 inducers ([[ sulforaphane ]], tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.","Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported [ENTITY_A] target genes in response to NRF2 inducers ([ENTITY_B], tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.",ACTIVATOR,CPR:3,0,"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments."
"The treatment of U937 cells with << NRF2 >> inducers including [[ sulforaphane ]] effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3.","The treatment of U937 cells with [ENTITY_A] inducers including [ENTITY_B] effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3.",ACTIVATOR,CPR:3,0,"The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3."
"Whereas, the levels of both the basal and << sulforaphane >>-inducible expression of [[ AKR1C1 ]] were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells.","Whereas, the levels of both the basal and [ENTITY_A]-inducible expression of [ENTITY_B] were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells."
"<< Human and rat renin >> and angiotensinogen genes were downregulated in dTGR and were increased by [[ losartan ]] and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.","[ENTITY_A] and angiotensinogen genes were downregulated in dTGR and were increased by [ENTITY_B] and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.",INDIRECT-UPREGULATOR,CPR:3,0,"Human and rat renin and angiotensinogen genes were downregulated in dTGR and were increased by losartan and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed."
<< Endothelial NO synthase >> expression was increased by [[ cilazapril ]] but not by losartan.,[ENTITY_A] expression was increased by [ENTITY_B] but not by losartan.,INDIRECT-UPREGULATOR,CPR:3,0,Endothelial NO synthase expression was increased by cilazapril but not by losartan.
"In addition to this pronounced loss of function, << M1766L >> also showed a 10-fold increase in the persistent late [[ sodium ]] current.","In addition to this pronounced loss of function, [ENTITY_A] also showed a 10-fold increase in the persistent late [ENTITY_B] current.",UPREGULATOR,CPR:3,0,"In addition to this pronounced loss of function, M1766L also showed a 10-fold increase in the persistent late sodium current."
Western blot analysis revealed that << OMT >> decreased the expression of [[ Bax ]] and repaired the balance of pro- and anti-apoptotic proteins.,Western blot analysis revealed that [ENTITY_A] decreased the expression of [ENTITY_B] and repaired the balance of pro- and anti-apoptotic proteins.,INDIRECT-DOWNREGULATOR,CPR:4,1,Western blot analysis revealed that OMT decreased the expression of Bax and repaired the balance of pro- and anti-apoptotic proteins.
"Furthermore, << OMT >> significantly reversed the up-regulation of [[ NR2B ]] and inhibited the calcium overload in the cultured neurons after challenging the NMDA.","Furthermore, [ENTITY_A] significantly reversed the up-regulation of [ENTITY_B] and inhibited the calcium overload in the cultured neurons after challenging the NMDA.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, OMT significantly reversed the up-regulation of NR2B and inhibited the calcium overload in the cultured neurons after challenging the NMDA."
<< OMT >> showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of [[ Bcl-2 ]] family.,[ENTITY_A] showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of [ENTITY_B] family.,INDIRECT-UPREGULATOR,CPR:3,0,OMT showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of Bcl-2 family.
<< OMT >> showed partial protection in the cortical neurons via down-regulation of NR2B containing [[ NMDA receptors ]] and up-regulation of Bcl-2 family.,[ENTITY_A] showed partial protection in the cortical neurons via down-regulation of NR2B containing [ENTITY_B] and up-regulation of Bcl-2 family.,DOWNREGULATOR,CPR:4,1,OMT showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of Bcl-2 family.
<< Emodin-6-O-β-D-glucoside >> inhibits [[ HMGB1 ]]-induced inflammatory responses in vitro and in vivo.,[ENTITY_A] inhibits [ENTITY_B]-induced inflammatory responses in vitro and in vivo.,INHIBITOR,CPR:4,1,Emodin-6-O-β-D-glucoside inhibits HMGB1-induced inflammatory responses in vitro and in vivo.
"Pharmacology of << ramelteon >>, a selective [[ MT1 ]]/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.","Pharmacology of [ENTITY_A], a selective [ENTITY_B]/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.",AGONIST,CPR:5,2,"Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders."
"<< Ramelteon >> (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin [[ MT(1) ]]/MT(2) receptor agonist.","[ENTITY_A] (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin [ENTITY_B]/MT(2) receptor agonist.",AGONIST,CPR:5,2,"Ramelteon (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin MT(1)/MT(2) receptor agonist."
"Unlike the sedative hypnotics that target GABA(A) receptor complexes, << ramelteon >> is a chronohypnotic that acts on the melatonin [[ MT(1) ]] and MT(2) receptors, which are primarily located in the suprachiasmatic nucleus, the body's ""master clock."" As such, ramelteon possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades.","Unlike the sedative hypnotics that target GABA(A) receptor complexes, [ENTITY_A] is a chronohypnotic that acts on the melatonin [ENTITY_B] and MT(2) receptors, which are primarily located in the suprachiasmatic nucleus, the body's ""master clock."" As such, ramelteon possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades.",AGONIST,CPR:5,2,"Unlike the sedative hypnotics that target GABA(A) receptor complexes, ramelteon is a chronohypnotic that acts on the melatonin MT(1) and MT(2) receptors, which are primarily located in the suprachiasmatic nucleus, the body's ""master clock."" As such, ramelteon possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades."
"<< Am80 >> slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by [[ VEGF ]].","[ENTITY_A] slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by [ENTITY_B].",INHIBITOR,CPR:4,1,"Am80 slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by VEGF."
<< Am80 >> inhibited VEGF-induced phosphorylation of [[ VEGF receptor ]].,[ENTITY_A] inhibited VEGF-induced phosphorylation of [ENTITY_B].,INHIBITOR,CPR:4,1,Am80 inhibited VEGF-induced phosphorylation of VEGF receptor.
"In addition, << VEGF >>-induced formation of tube-like structures in vitro and neovascularization in mouse corneas were significantly inhibited by [[ Am80 ]].","In addition, [ENTITY_A]-induced formation of tube-like structures in vitro and neovascularization in mouse corneas were significantly inhibited by [ENTITY_B].",INHIBITOR,CPR:4,1,"In addition, VEGF-induced formation of tube-like structures in vitro and neovascularization in mouse corneas were significantly inhibited by Am80."
We have examined the effect of dihydropyridine << Ca2+-channel >> blockers [[ felodipine ]] and nicardipine on CaMPDE.,We have examined the effect of dihydropyridine [ENTITY_A] blockers [ENTITY_B] and nicardipine on CaMPDE.,INHIBITOR,CPR:4,1,We have examined the effect of dihydropyridine Ca2+-channel blockers felodipine and nicardipine on CaMPDE.
The results suggest that the 63-kDa (<< PDE 1B1 >>) and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by [[ felodipine ]] and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other.,The results suggest that the 63-kDa ([ENTITY_A]) and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by [ENTITY_B] and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other.,INHIBITOR,CPR:4,1,The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by felodipine and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other.
"Felodipine and nicardipine have similar affinities for 60-kDa << CaMPDE >> isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by [[ dihydropyridine ]] Ca2+-channel blockers.","Felodipine and nicardipine have similar affinities for 60-kDa [ENTITY_A] isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by [ENTITY_B] Ca2+-channel blockers.",INHIBITOR,CPR:4,1,"Felodipine and nicardipine have similar affinities for 60-kDa CaMPDE isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by dihydropyridine Ca2+-channel blockers."
"Several inhibitors of << Lp-PLA(2) >> have been described, including [[ darapladib ]], which is currently in phase 3 clinical development for the treatment of atherosclerosis.","Several inhibitors of [ENTITY_A] have been described, including [ENTITY_B], which is currently in phase 3 clinical development for the treatment of atherosclerosis.",INHIBITOR,CPR:4,1,"Several inhibitors of Lp-PLA(2) have been described, including darapladib, which is currently in phase 3 clinical development for the treatment of atherosclerosis."
We show that both << darapladib >> and a novel class of structurally distinct carbamate inhibitors inactivate [[ Lp-PLA(2) ]] in mouse tissues and human cell lines with high selectivity.,We show that both [ENTITY_A] and a novel class of structurally distinct carbamate inhibitors inactivate [ENTITY_B] in mouse tissues and human cell lines with high selectivity.,INHIBITOR,CPR:4,1,We show that both darapladib and a novel class of structurally distinct carbamate inhibitors inactivate Lp-PLA(2) in mouse tissues and human cell lines with high selectivity.
"Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the << beta(2)-adrenoceptor >> agonist [[ formoterol ]] [eformoterol].","Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the [ENTITY_A] agonist [ENTITY_B] [eformoterol].",AGONIST,CPR:5,2,"Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the beta(2)-adrenoceptor agonist formoterol [eformoterol]."
Nitric oxide products of << VP-16 >> displayed significantly diminished [[ topoisomerase II ]]-dependent cleavage of DNA and cytotoxicity to human HL-60 leukemia cells.,Nitric oxide products of [ENTITY_A] displayed significantly diminished [ENTITY_B]-dependent cleavage of DNA and cytotoxicity to human HL-60 leukemia cells.,INHIBITOR,CPR:4,1,Nitric oxide products of VP-16 displayed significantly diminished topoisomerase II-dependent cleavage of DNA and cytotoxicity to human HL-60 leukemia cells.
"Consistent with these locations, << N-ethylmaleimide >>, an inhibitor of [[ ACS4 ]], inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum.","Consistent with these locations, [ENTITY_A], an inhibitor of [ENTITY_B], inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum.",INHIBITOR,CPR:4,1,"Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum."
"<< Troglitazone >>, a second [[ ACS4 ]] inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM.","[ENTITY_A], a second [ENTITY_B] inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM.",INHIBITOR,CPR:4,1,"Troglitazone, a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM."
"<< Triacsin C >>, a competitive inhibitor of both [[ ACS1 ]] and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria.","[ENTITY_A], a competitive inhibitor of both [ENTITY_B] and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria.",INHIBITOR,CPR:4,1,"Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria."
"Re-feeding normal chow or a high << sucrose >> diet for 24 h after a 48-h fast increased both [[ ACS1 ]] and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies.","Re-feeding normal chow or a high [ENTITY_A] diet for 24 h after a 48-h fast increased both [ENTITY_B] and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies.",INDIRECT-UPREGULATOR,CPR:3,0,"Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies."
These results suggest that << ACS1 >> and ACS4 may be linked to [[ triacylglycerol ]] synthesis.,These results suggest that [ENTITY_A] and ACS4 may be linked to [ENTITY_B] synthesis.,PRODUCT-OF,CPR:9,4,These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis.
"The << tyrosine kinase >> inhibitor [[ ZD1839 ]] (""Iressa"") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.","The [ENTITY_A] inhibitor [ENTITY_B] (""Iressa"") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.",INHIBITOR,CPR:4,1,"The tyrosine kinase inhibitor ZD1839 (""Iressa"") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells."
"The << tyrosine kinase >>[[ tyrosine ]] kinase inhibitor ZD1839 (""Iressa"") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.","The [ENTITY_A][ENTITY_B] kinase inhibitor ZD1839 (""Iressa"") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.",SUBSTRATE,CPR:9,4,"The tyrosine kinasetyrosine kinase inhibitor ZD1839 (""Iressa"") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells."
"<< ZD1839 >> (""Iressa""), a quinazoline [[ tyrosine kinase ]] inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.","[ENTITY_A] (""Iressa""), a quinazoline [ENTITY_B] inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.",INHIBITOR,CPR:4,1,"ZD1839 (""Iressa""), a quinazoline tyrosine kinase inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials."
"ZD1839 (""Iressa""), a << quinazoline tyrosine >>[[ tyrosine kinase ]] inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.","ZD1839 (""Iressa""), a [ENTITY_A][ENTITY_B] inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.",SUBSTRATE,CPR:9,4,"ZD1839 (""Iressa""), a quinazoline tyrosinetyrosine kinase inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials."
"Growth inhibition of these tumor cell lines was associated with the dephosphorylation of EGFR, HER2, and HER3, accompanied by the loss of association of HER3 with << phosphatidylinositol 3-kinase >>[[ phosphatidylinositol ]] 3-kinase, and down-regulation of Akt activity.","Growth inhibition of these tumor cell lines was associated with the dephosphorylation of EGFR, HER2, and HER3, accompanied by the loss of association of HER3 with [ENTITY_A][ENTITY_B] 3-kinase, and down-regulation of Akt activity.",SUBSTRATE,CPR:9,4,"Growth inhibition of these tumor cell lines was associated with the dephosphorylation of EGFR, HER2, and HER3, accompanied by the loss of association of HER3 with phosphatidylinositol 3-kinasephosphatidylinositol 3-kinase, and down-regulation of Akt activity."
These studies suggest that HER2-overexpressing tumors are particularly susceptible to the inhibition of HER family << tyrosine kinase >>[[ tyrosine ]] kinase signaling and suggest novel strategies to treat these particularly aggressive tumors.,These studies suggest that HER2-overexpressing tumors are particularly susceptible to the inhibition of HER family [ENTITY_A][ENTITY_B] kinase signaling and suggest novel strategies to treat these particularly aggressive tumors.,SUBSTRATE,CPR:9,4,These studies suggest that HER2-overexpressing tumors are particularly susceptible to the inhibition of HER family tyrosine kinasetyrosine kinase signaling and suggest novel strategies to treat these particularly aggressive tumors.
[Pharmacological effects of a << mu-opioid receptor >> antagonist [[ naltrexone ]] on alcohol dependence].,[Pharmacological effects of a [ENTITY_A] antagonist [ENTITY_B] on alcohol dependence].,ANTAGONIST,CPR:6,3,[Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence].
"In many countries, a << mu-opioid receptor >> antagonist [[ naltrexone ]] has been used in the treatment of alcohol dependence.","In many countries, a [ENTITY_A] antagonist [ENTITY_B] has been used in the treatment of alcohol dependence.",ANTAGONIST,CPR:6,3,"In many countries, a mu-opioid receptor antagonist naltrexone has been used in the treatment of alcohol dependence."
"RESULTS: In drug discrimination studies, << lisuride >> fully mimicked the [[ 5-HT(1A) ]] agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine.","RESULTS: In drug discrimination studies, [ENTITY_A] fully mimicked the [ENTITY_B] agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine.",AGONIST,CPR:5,2,"RESULTS: In drug discrimination studies, lisuride fully mimicked the 5-HT(1A) agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine."
"Only pMPPI [<< 4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride >>], a selective [[ 5-HT(1A) ]] antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD.","Only pMPPI [[ENTITY_A]], a selective [ENTITY_B] antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD.",ANTAGONIST,CPR:6,3,"Only pMPPI [4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride], a selective 5-HT(1A) antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD."
Lisuride dose dependently decreased body temperature in rats with a potency similar to that of the selective << 5-HT(1A) >> agonist [[ LY 293284 ]].,Lisuride dose dependently decreased body temperature in rats with a potency similar to that of the selective [ENTITY_A] agonist [ENTITY_B].,AGONIST,CPR:5,2,Lisuride dose dependently decreased body temperature in rats with a potency similar to that of the selective 5-HT(1A) agonist LY 293284.
"<< Bupropion >>, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters ([[ DAT ]] and NET, respectively).","[ENTITY_A], an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters ([ENTITY_B] and NET, respectively).",INHIBITOR,CPR:4,1,"Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively)."
"To eliminate the interaction of << bupropion >> with [[ DAT ]] or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer.","To eliminate the interaction of [ENTITY_A] with [ENTITY_B] or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer.",INHIBITOR,CPR:4,1,"To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer."
"Thus, << bupropion >> acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits [[ DAT ]] and NET function.","Thus, [ENTITY_A] acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits [ENTITY_B] and NET function.",INHIBITOR,CPR:4,1,"Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function."
The combination of << nAChR >> and transporter inhibition produced by [[ bupropion ]] may contribute to its clinical efficacy as a smoking cessation agent.,The combination of [ENTITY_A] and transporter inhibition produced by [ENTITY_B] may contribute to its clinical efficacy as a smoking cessation agent.,INHIBITOR,CPR:4,1,The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent.
<< Nitrogen >>-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and [[ Bim ]]-mediated activation of the intrinsic apoptotic pathway.,[ENTITY_A]-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and [ENTITY_B]-mediated activation of the intrinsic apoptotic pathway.,ACTIVATOR,CPR:3,0,Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.
<< Nitrogen >>-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of [[ Ras ]] signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.,[ENTITY_A]-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of [ENTITY_B] signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.,INHIBITOR,CPR:4,1,Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.
<< Nitrogen >>-containing bisphosphonates (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small [[ G-proteins ]].,[ENTITY_A]-containing bisphosphonates (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small [ENTITY_B].,INHIBITOR,CPR:4,1,Nitrogen-containing bisphosphonates (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small G-proteins.
"Furthermore, << N >>-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced [[ Bim ]] expression.","Furthermore, [ENTITY_A]-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced [ENTITY_B] expression.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, N-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression."
"Furthermore, << N >>-BPs decreased the levels of [[ phosphorylated extracellular signal-regulated kinase ]] (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression.","Furthermore, [ENTITY_A]-BPs decreased the levels of [ENTITY_B] (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, N-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression."
"The present results indicated that << N >>-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of [[ caspase-9 ]] and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways.","The present results indicated that [ENTITY_A]-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of [ENTITY_B] and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways.",ACTIVATOR,CPR:3,0,"The present results indicated that N-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways."
"The present results indicated that << N >>-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the [[ Ras ]]/MEK/ERK and Ras/mTOR pathways.","The present results indicated that [ENTITY_A]-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the [ENTITY_B]/MEK/ERK and Ras/mTOR pathways.",INHIBITOR,CPR:4,1,"The present results indicated that N-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways."
The reduction of << P2X3 >> expression levels was reversed by the proteasomal inhibitor [[ MG-132 ]].,The reduction of [ENTITY_A] expression levels was reversed by the proteasomal inhibitor [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,The reduction of P2X3 expression levels was reversed by the proteasomal inhibitor MG-132.
"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the << chenodeoxycholic acid >> (CDCA)-induced expression of [[ Cdx2 ]] and MUC2 in normal rat gastric epithelial cells (RGM-1 cells).","We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the [ENTITY_A] (CDCA)-induced expression of [ENTITY_B] and MUC2 in normal rat gastric epithelial cells (RGM-1 cells).",INDIRECT-UPREGULATOR,CPR:3,0,"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (CDCA)-induced expression of Cdx2 and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)."
"RGM-1 cells were treated with << CDCA >> or GW4064, an [[ FXR ]] agonist, in the presence or absence of guggulsterone, an FXR antagonist.","RGM-1 cells were treated with [ENTITY_A] or GW4064, an [ENTITY_B] agonist, in the presence or absence of guggulsterone, an FXR antagonist.",AGONIST,CPR:5,2,"RGM-1 cells were treated with CDCA or GW4064, an FXR agonist, in the presence or absence of guggulsterone, an FXR antagonist."
"RGM-1 cells were treated with CDCA or GW4064, an FXR agonist, in the presence or absence of << guggulsterone >>, an [[ FXR ]] antagonist.","RGM-1 cells were treated with CDCA or GW4064, an FXR agonist, in the presence or absence of [ENTITY_A], an [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"RGM-1 cells were treated with CDCA or GW4064, an FXR agonist, in the presence or absence of guggulsterone, an FXR antagonist."
<< CDCA >> induced dose-dependent expression of [[ Cdx2 ]] and MUC2 at both the mRNA and protein levels.,[ENTITY_A] induced dose-dependent expression of [ENTITY_B] and MUC2 at both the mRNA and protein levels.,INDIRECT-UPREGULATOR,CPR:3,0,CDCA induced dose-dependent expression of Cdx2 and MUC2 at both the mRNA and protein levels.
"The maximum stimulation of << Cdx2 >> and MUC2 mRNA induced by [[ CDCA ]] was observed at 3 h and by 6 h, respectively.","The maximum stimulation of [ENTITY_A] and MUC2 mRNA induced by [ENTITY_B] was observed at 3 h and by 6 h, respectively.",INDIRECT-UPREGULATOR,CPR:3,0,"The maximum stimulation of Cdx2 and MUC2 mRNA induced by CDCA was observed at 3 h and by 6 h, respectively."
The effects of CDCA and GW4064 on expression of << Cdx2 >> and MUC2 were abolished by [[ guggulsterone ]].,The effects of CDCA and GW4064 on expression of [ENTITY_A] and MUC2 were abolished by [ENTITY_B].,INDIRECT-DOWNREGULATOR,CPR:4,1,The effects of CDCA and GW4064 on expression of Cdx2 and MUC2 were abolished by guggulsterone.
<< Mazindol >> analogues as potential inhibitors of the [[ cocaine binding site ]] at the dopamine transporter.,[ENTITY_A] analogues as potential inhibitors of the [ENTITY_B] at the dopamine transporter.,INHIBITOR,CPR:4,1,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.
Mazindol analogues as potential inhibitors of the cocaine binding site at the << dopamine transporter >>[[ dopamine ]] transporter.,Mazindol analogues as potential inhibitors of the cocaine binding site at the [ENTITY_A][ENTITY_B] transporter.,SUBSTRATE,CPR:9,4,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporterdopamine transporter.
"Several active analogues were also evaluated for their ability to block uptake of DA, << 5-HT >>, and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-[[ hSERT ]], and HEK-hNET cells.","Several active analogues were also evaluated for their ability to block uptake of DA, [ENTITY_A], and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-[ENTITY_B], and HEK-hNET cells.",SUBSTRATE,CPR:9,4,"Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-hSERT, and HEK-hNET cells."
<< Glyphosate >> affects aromatic amino acid biosynthesis by inhibiting [[ 5-enolpyruvylshikimate-3-phosphate synthase ]] (EPSPS).,[ENTITY_A] affects aromatic amino acid biosynthesis by inhibiting [ENTITY_B] (EPSPS).,INHIBITOR,CPR:4,1,Glyphosate affects aromatic amino acid biosynthesis by inhibiting 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS).
<< Glufosinate >> inhibits [[ glutamine synthetase ]] and blocks biosynthesis of glutamine.,[ENTITY_A] inhibits [ENTITY_B] and blocks biosynthesis of glutamine.,INHIBITOR,CPR:4,1,Glufosinate inhibits glutamine synthetase and blocks biosynthesis of glutamine.
Glufosinate inhibits << glutamine synthetase >> and blocks biosynthesis of [[ glutamine ]].,Glufosinate inhibits [ENTITY_A] and blocks biosynthesis of [ENTITY_B].,PRODUCT-OF,CPR:9,4,Glufosinate inhibits glutamine synthetase and blocks biosynthesis of glutamine.
Mechanisms of Glucose Lowering of << Dipeptidyl Peptidase-4 >> Inhibitor [[ Sitagliptin ]] When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study.,Mechanisms of Glucose Lowering of [ENTITY_A] Inhibitor [ENTITY_B] When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study.,INHIBITOR,CPR:4,1,Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study.
"Upon co-exposure to V(5+) and << TCDD >>, V(5+) significantly potentiated the TCDD-mediated induction of the [[ Cyp1a1 ]], Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24 h.","Upon co-exposure to V(5+) and [ENTITY_A], V(5+) significantly potentiated the TCDD-mediated induction of the [ENTITY_B], Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24 h.",ACTIVATOR,CPR:3,0,"Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24 h."
"In vitro, V(5+) decreased the << TCDD >>-mediated induction of [[ Cyp1a1 ]] mRNA, protein, and catalytic activity levels.","In vitro, V(5+) decreased the [ENTITY_A]-mediated induction of [ENTITY_B] mRNA, protein, and catalytic activity levels.",INDIRECT-UPREGULATOR,CPR:3,0,"In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels."
"In vitro, << V(5+) >> decreased the TCDD-mediated induction of [[ Cyp1a1 ]] mRNA, protein, and catalytic activity levels.","In vitro, [ENTITY_A] decreased the TCDD-mediated induction of [ENTITY_B] mRNA, protein, and catalytic activity levels.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels."
"Furthermore, V(5+) significantly inhibited the << TCDD >>-induced [[ AhR ]]-dependent luciferase activity.","Furthermore, V(5+) significantly inhibited the [ENTITY_A]-induced [ENTITY_B]-dependent luciferase activity.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, V(5+) significantly inhibited the TCDD-induced AhR-dependent luciferase activity."
"Furthermore, << V(5+) >> significantly inhibited the TCDD-induced [[ AhR ]]-dependent luciferase activity.","Furthermore, [ENTITY_A] significantly inhibited the TCDD-induced [ENTITY_B]-dependent luciferase activity.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, V(5+) significantly inhibited the TCDD-induced AhR-dependent luciferase activity."
<< V(5+) >> also increased [[ serum hemoglobin ]] (Hb) levels in animals treated for 24 h.,[ENTITY_A] also increased [ENTITY_B] (Hb) levels in animals treated for 24 h.,INDIRECT-UPREGULATOR,CPR:3,0,V(5+) also increased serum hemoglobin (Hb) levels in animals treated for 24 h.
"Upon treatment of isolated hepatocytes with Hb alone or in the presence of << TCDD >>, there was an increase in the [[ AhR ]]-dependent luciferase activity.","Upon treatment of isolated hepatocytes with Hb alone or in the presence of [ENTITY_A], there was an increase in the [ENTITY_B]-dependent luciferase activity.",INDIRECT-UPREGULATOR,CPR:3,0,"Upon treatment of isolated hepatocytes with Hb alone or in the presence of TCDD, there was an increase in the AhR-dependent luciferase activity."
<< GCS >> therapy results in reduced mRNA expression of [[ interleukin-4 ]] (IL-4) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma.,[ENTITY_A] therapy results in reduced mRNA expression of [ENTITY_B] (IL-4) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma.,INDIRECT-DOWNREGULATOR,CPR:4,1,GCS therapy results in reduced mRNA expression of interleukin-4 (IL-4) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma.
"In vitro studies with blood-derived T cells, however, show inhibition of all three << cytokines >> by [[ GCS ]].","In vitro studies with blood-derived T cells, however, show inhibition of all three [ENTITY_A] by [ENTITY_B].",INHIBITOR,CPR:4,1,"In vitro studies with blood-derived T cells, however, show inhibition of all three cytokines by GCS."
"Dexamethasone (<< DEX >>) inhibited the anti-CD3-induced production of [[ IL-4 ]], IL-5 and IFN-gamma in all 20 clones tested.","Dexamethasone ([ENTITY_A]) inhibited the anti-CD3-induced production of [ENTITY_B], IL-5 and IFN-gamma in all 20 clones tested.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Dexamethasone (DEX) inhibited the anti-CD3-induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested."
"<< DEX >> enhanced the ratio [[ IFN-gamma ]]/IL-4 (mean +/- SEM: control, 28.7 +/- 17.6; with 10-7 M DEX, 55.0 +/- 27.5, P<0.005).","[ENTITY_A] enhanced the ratio [ENTITY_B]/IL-4 (mean +/- SEM: control, 28.7 +/- 17.6; with 10-7 M DEX, 55.0 +/- 27.5, P<0.005).",UPREGULATOR,CPR:3,0,"DEX enhanced the ratio IFN-gamma/IL-4 (mean +/- SEM: control, 28.7 +/- 17.6; with 10-7 M DEX, 55.0 +/- 27.5, P<0.005)."
"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers << DEX >> inhibited IL-2 production partially and enhanced [[ IL-2R alpha ]] expression and proliferation.","Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers [ENTITY_A] inhibited IL-2 production partially and enhanced [ENTITY_B] expression and proliferation.",INDIRECT-UPREGULATOR,CPR:3,0,"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation."
"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers << DEX >> blocked [[ IL-2 ]] production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.","Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers [ENTITY_A] blocked [ENTITY_B] production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation."
"In conclusion, the production of << IL-4 >> and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by [[ DEX ]] than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma.","In conclusion, the production of [ENTITY_A] and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by [ENTITY_B] than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In conclusion, the production of IL-4 and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by DEX than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma."
Pregnane X Receptor Mediates Dyslipidemia Induced by the << HIV Protease >> Inhibitor [[ Amprenavir ]] in Mice.,Pregnane X Receptor Mediates Dyslipidemia Induced by the [ENTITY_A] Inhibitor [ENTITY_B] in Mice.,INHIBITOR,CPR:4,1,Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice.
"In the present study, we identified << amprenavir >>, a widely used HIV PI, as a potent [[ PXR ]]-selective agonist.","In the present study, we identified [ENTITY_A], a widely used HIV PI, as a potent [ENTITY_B]-selective agonist.",AGONIST,CPR:5,2,"In the present study, we identified amprenavir, a widely used HIV PI, as a potent PXR-selective agonist."
<< Amprenavir >> efficiently activated [[ PXR ]] and induced PXR target gene expression in vitro and in vivo.,[ENTITY_A] efficiently activated [ENTITY_B] and induced PXR target gene expression in vitro and in vivo.,ACTIVATOR,CPR:3,0,Amprenavir efficiently activated PXR and induced PXR target gene expression in vitro and in vivo.
<< Amprenavir >>-mediated [[ PXR ]] activation stimulated the expression of several key intestinal genes involved in lipid homeostasis.,[ENTITY_A]-mediated [ENTITY_B] activation stimulated the expression of several key intestinal genes involved in lipid homeostasis.,ACTIVATOR,CPR:3,0,Amprenavir-mediated PXR activation stimulated the expression of several key intestinal genes involved in lipid homeostasis.
"Anti-diabetic Activity of Swertiamarin is due to an Active Metabolite, << Gentianine >>, that Upregulates [[ PPAR-γ ]] Gene Expression in 3T3-L1 cells.","Anti-diabetic Activity of Swertiamarin is due to an Active Metabolite, [ENTITY_A], that Upregulates [ENTITY_B] Gene Expression in 3T3-L1 cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Anti-diabetic Activity of Swertiamarin is due to an Active Metabolite, Gentianine, that Upregulates PPAR-γ Gene Expression in 3T3-L1 cells."
"<< Swertiamarin >> treatment had no significant effect on adipogenesis, or the mRNA expression of PPAR-γ and GLUT-4; however, there was a significant increase in the mRNA expression of [[ adiponectin ]].","[ENTITY_A] treatment had no significant effect on adipogenesis, or the mRNA expression of PPAR-γ and GLUT-4; however, there was a significant increase in the mRNA expression of [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"Swertiamarin treatment had no significant effect on adipogenesis, or the mRNA expression of PPAR-γ and GLUT-4; however, there was a significant increase in the mRNA expression of adiponectin."
"On the other hand, treatment with << gentianine >> significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of [[ PPAR-γ ]], GLUT-4 and adiponectin.","On the other hand, treatment with [ENTITY_A] significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of [ENTITY_B], GLUT-4 and adiponectin.",INDIRECT-UPREGULATOR,CPR:3,0,"On the other hand, treatment with gentianine significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-γ, GLUT-4 and adiponectin."
"<< Jaspamide >> also inhibited other channels including [[ Cav1.2 ]], Cav3.2, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected.","[ENTITY_A] also inhibited other channels including [ENTITY_B], Cav3.2, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected.",INHIBITOR,CPR:4,1,"Jaspamide also inhibited other channels including Cav1.2, Cav3.2, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected."
"Increased immunohistochemical labeling of << HIF-1alpha >>, VEGF, and BNP in the ventricular myocardium was observed in the shunt group and [[ carvedilol ]] again normalized the labeling.","Increased immunohistochemical labeling of [ENTITY_A], VEGF, and BNP in the ventricular myocardium was observed in the shunt group and [ENTITY_B] again normalized the labeling.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Increased immunohistochemical labeling of HIF-1alpha, VEGF, and BNP in the ventricular myocardium was observed in the shunt group and carvedilol again normalized the labeling."
Treatment with << carvedilol >> is associated with a reversal of abnormal regulation of [[ HIF-1alpha ]] and VEGF in the failing ventricular myocardium.,Treatment with [ENTITY_A] is associated with a reversal of abnormal regulation of [ENTITY_B] and VEGF in the failing ventricular myocardium.,INDIRECT-DOWNREGULATOR,CPR:4,1,Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1alpha and VEGF in the failing ventricular myocardium.
"These effects were fully counteracted by dietary << phenolics >> which inhibited ROS overproduction and GSH consumption, rendered the reactive transcription of glutathione-associated enzymes unnecessary and blocked the intracellular signals leading to the overexpression and rearrangement of [[ p66Shc ]] signalling molecule.","These effects were fully counteracted by dietary [ENTITY_A] which inhibited ROS overproduction and GSH consumption, rendered the reactive transcription of glutathione-associated enzymes unnecessary and blocked the intracellular signals leading to the overexpression and rearrangement of [ENTITY_B] signalling molecule.",INDIRECT-DOWNREGULATOR,CPR:4,1,"These effects were fully counteracted by dietary phenolics which inhibited ROS overproduction and GSH consumption, rendered the reactive transcription of glutathione-associated enzymes unnecessary and blocked the intracellular signals leading to the overexpression and rearrangement of p66Shc signalling molecule."
"The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not ATP, whereas mammalian << serine racemase >> activity is increased by [[ ATP ]].","The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not ATP, whereas mammalian [ENTITY_A] activity is increased by [ENTITY_B].",ACTIVATOR,CPR:3,0,"The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not ATP, whereas mammalian serine racemase activity is increased by ATP."
"In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to << AMP >> by ecto-[[ phosphodiesterase ]], and metabolism of AMP to adenosine by ecto-5'-nucleotidase.","In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to [ENTITY_A] by ecto-[ENTITY_B], and metabolism of AMP to adenosine by ecto-5'-nucleotidase.",PRODUCT-OF,CPR:9,4,"In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by ecto-5'-nucleotidase."
"A broad-spectrum << phosphodiesterase >> (PDE) inhibitor ([[ 1,3-isobutyl-1-methylxanthine ]], 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively.","A broad-spectrum [ENTITY_A] (PDE) inhibitor ([ENTITY_B], 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively.",INHIBITOR,CPR:4,1,"A broad-spectrum phosphodiesterase (PDE) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively."
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], << PDE3 >> ([[ milrinone ]], 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.","Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], [ENTITY_A] ([ENTITY_B], 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.",INHIBITOR,CPR:4,1,"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity."
Administration of a concentration (100 microM) of << dipyridamole >> that blocks [[ PDE8 ]] inhibited ecto-phosphodiesterase activity (by 44%).,Administration of a concentration (100 microM) of [ENTITY_A] that blocks [ENTITY_B] inhibited ecto-phosphodiesterase activity (by 44%).,INHIBITOR,CPR:4,1,Administration of a concentration (100 microM) of dipyridamole that blocks PDE8 inhibited ecto-phosphodiesterase activity (by 44%).
"However, a lower concentration of << dipyridamole >> (3 microM) that blocks [[ PDE9 ]], PDE10, and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity.","However, a lower concentration of [ENTITY_A] (3 microM) that blocks [ENTITY_B], PDE10, and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity.",INHIBITOR,CPR:4,1,"However, a lower concentration of dipyridamole (3 microM) that blocks PDE9, PDE10, and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity."
"These data support the conclusion that renal ecto-<< phosphodiesterase >> activity is not mediated by PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE9, PDE10, or PDE11 and is inhibited by high concentrations of [[ dipyridamole ]].","These data support the conclusion that renal ecto-[ENTITY_A] activity is not mediated by PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE9, PDE10, or PDE11 and is inhibited by high concentrations of [ENTITY_B].",INHIBITOR,CPR:4,1,"These data support the conclusion that renal ecto-phosphodiesterase activity is not mediated by PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE9, PDE10, or PDE11 and is inhibited by high concentrations of dipyridamole."
<< Ambrisentan >> is an [[ endothelin type A (ET(A))-selective receptor ]] antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4.,[ENTITY_A] is an [ENTITY_B] antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4.,ANTAGONIST,CPR:6,3,Ambrisentan is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4.
<< Ambrisentan >> is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by [[ CYP3A4 ]].,[ENTITY_A] is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by [ENTITY_B].,SUBSTRATE,CPR:9,4,Ambrisentan is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4.
"The potential for << ketoconazole >>, the archetypal strong inhibitor of [[ CYP3A4 ]], to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men.","The potential for [ENTITY_A], the archetypal strong inhibitor of [ENTITY_B], to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men.",INHIBITOR,CPR:4,1,"The potential for ketoconazole, the archetypal strong inhibitor of CYP3A4, to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men."
"In summary, << ketoconazole >> had no clinically significant effect on the pharmacokinetics or safety profile of ambrisentan; therefore, no changes in ambrisentan dose should be necessary when the drug is administered concomitantly with known [[ CYP3A4 ]] inhibitors.","In summary, [ENTITY_A] had no clinically significant effect on the pharmacokinetics or safety profile of ambrisentan; therefore, no changes in ambrisentan dose should be necessary when the drug is administered concomitantly with known [ENTITY_B] inhibitors.",INHIBITOR,CPR:4,1,"In summary, ketoconazole had no clinically significant effect on the pharmacokinetics or safety profile of ambrisentan; therefore, no changes in ambrisentan dose should be necessary when the drug is administered concomitantly with known CYP3A4 inhibitors."
"Although << glutathione S-transferase omega 1 >> (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze [[ DMAs(V) ]] reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain.","Although [ENTITY_A] (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze [ENTITY_B] reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain.",SUBSTRATE,CPR:9,4,"Although glutathione S-transferase omega 1 (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain."
"Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect << methyltransferase >> inhibitor periodate-oxidized [[ adenosine ]] was without effect.","Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect [ENTITY_A] inhibitor periodate-oxidized [ENTITY_B] was without effect.",INHIBITOR,CPR:4,1,"Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect methyltransferase inhibitor periodate-oxidized adenosine was without effect."
"Although << thioredoxin reductase >> (TRR) inhibitors ([[ aurothioglucose ]] and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.","Although [ENTITY_A] (TRR) inhibitors ([ENTITY_B] and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.",INHIBITOR,CPR:4,1,"Although thioredoxin reductase (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction."
The << kinase >> activity of EGFR was little inhibited by [[ TT-B ]] in a cell-free system.,The [ENTITY_A] activity of EGFR was little inhibited by [ENTITY_B] in a cell-free system.,INHIBITOR,CPR:4,1,The kinase activity of EGFR was little inhibited by TT-B in a cell-free system.
"<< Sorafenib >> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and [[ tyrosine kinases ]] VEGFR/PDGFR in tumor vasculature.","[ENTITY_A] (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and [ENTITY_B] VEGFR/PDGFR in tumor vasculature.",INHIBITOR,CPR:4,1,"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature."
A novel class of << biaryl urea >> that inhibits [[ C-RAF ]] kinase was discovered using a combination of medicinal and combinatorial chemistry approaches.,A novel class of [ENTITY_A] that inhibits [ENTITY_B] kinase was discovered using a combination of medicinal and combinatorial chemistry approaches.,INHIBITOR,CPR:4,1,A novel class of biaryl urea that inhibits C-RAF kinase was discovered using a combination of medicinal and combinatorial chemistry approaches.
<< Sorafenib >> inhibited the [[ kinase ]] activity of both C-RAF and B-RAF (wild type and V600E mutant).,[ENTITY_A] inhibited the [ENTITY_B] activity of both C-RAF and B-RAF (wild type and V600E mutant).,INHIBITOR,CPR:4,1,Sorafenib inhibited the kinase activity of both C-RAF and B-RAF (wild type and V600E mutant).
"Further characterization of << sorafenib >> revealed that this molecule was a multikinase inhibitor that targeted the [[ vascular endothelial growth factor receptor ]] family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis.","Further characterization of [ENTITY_A] revealed that this molecule was a multikinase inhibitor that targeted the [ENTITY_B] family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis.",INHIBITOR,CPR:4,1,"Further characterization of sorafenib revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis."
"Thus, << sorafenib >> may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of [[ Raf ]] and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling).","Thus, [ENTITY_A] may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of [ENTITY_B] and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling).",INDIRECT-DOWNREGULATOR,CPR:4,1,"Thus, sorafenib may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling)."
<< Rapamycin >> inhibits [[ proteinase ]] and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations.,[ENTITY_A] inhibits [ENTITY_B] and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations.,INHIBITOR,CPR:4,1,Rapamycin inhibits proteinase and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations.
"Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor << chloramine T >> (CT), to destroy [[ plasmatic PAI-1 ]] and alpha2-antiplasmin.","Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor [ENTITY_A] (CT), to destroy [ENTITY_B] and alpha2-antiplasmin.",DOWNREGULATOR,CPR:4,1,"Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (CT), to destroy plasmatic PAI-1 and alpha2-antiplasmin."
"For determination of << plasmin >> activity, 10 microL thereof was incubated with 150 microL 1.5 M [[ arginine ]], pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C).","For determination of [ENTITY_A] activity, 10 microL thereof was incubated with 150 microL 1.5 M [ENTITY_B], pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C).",SUBSTRATE,CPR:9,4,"For determination of plasmin activity, 10 microL thereof was incubated with 150 microL 1.5 M arginine, pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C)."
"For determination of [<< PA >>+Pli]-activity, [[ arginine ]] was added after this incubation.","For determination of [[ENTITY_A]+Pli]-activity, [ENTITY_B] was added after this incubation.",SUBSTRATE,CPR:9,4,"For determination of [PA+Pli]-activity, arginine was added after this incubation."
"<< KCNK1 >>, a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after [[ phenobarbital ]] treatment.","[ENTITY_A], a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after [ENTITY_B] treatment.",ACTIVATOR,CPR:3,0,"KCNK1, a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after phenobarbital treatment."
"Here, we have determined the molecular mechanism of this male-specific activation of the Kcnk1 gene and characterized << KCNK1 >> as a [[ phenobarbital ]]-inducible antihyperplasia factor.","Here, we have determined the molecular mechanism of this male-specific activation of the Kcnk1 gene and characterized [ENTITY_A] as a [ENTITY_B]-inducible antihyperplasia factor.",ACTIVATOR,CPR:3,0,"Here, we have determined the molecular mechanism of this male-specific activation of the Kcnk1 gene and characterized KCNK1 as a phenobarbital-inducible antihyperplasia factor."
"Upon activation by << phenobarbital >>, [[ nuclear receptor ]] CAR binds the 97-bp response element (-2441/-2345) within the Kcnk1 promoter.","Upon activation by [ENTITY_A], [ENTITY_B] CAR binds the 97-bp response element (-2441/-2345) within the Kcnk1 promoter.",ACTIVATOR,CPR:3,0,"Upon activation by phenobarbital, nuclear receptor CAR binds the 97-bp response element (-2441/-2345) within the Kcnk1 promoter."
These results indicate that << phenobarbital >> treatment induces [[ KCNK1 ]] to elicit a male-specific and growth-suppressing signal.,These results indicate that [ENTITY_A] treatment induces [ENTITY_B] to elicit a male-specific and growth-suppressing signal.,ACTIVATOR,CPR:3,0,These results indicate that phenobarbital treatment induces KCNK1 to elicit a male-specific and growth-suppressing signal.
"<< Methylphenidate >>, an inhibitor of [[ dopamine and norepinephrine transporters ]] (DAT and NET, respectively), is a standard treatment for ADHD.","[ENTITY_A], an inhibitor of [ENTITY_B] (DAT and NET, respectively), is a standard treatment for ADHD.",INHIBITOR,CPR:4,1,"Methylphenidate, an inhibitor of dopamine and norepinephrine transporters (DAT and NET, respectively), is a standard treatment for ADHD."
<< Methylphenidate >> increased [[ DAT ]] Vmax in SHR mPFC and decreased DAT Vmax in WKY OFC.,[ENTITY_A] increased [ENTITY_B] Vmax in SHR mPFC and decreased DAT Vmax in WKY OFC.,ACTIVATOR,CPR:3,0,Methylphenidate increased DAT Vmax in SHR mPFC and decreased DAT Vmax in WKY OFC.
<< Methylphenidate >> increased DAT Vmax in SHR mPFC and decreased [[ DAT ]] Vmax in WKY OFC.,[ENTITY_A] increased DAT Vmax in SHR mPFC and decreased [ENTITY_B] Vmax in WKY OFC.,INHIBITOR,CPR:4,1,Methylphenidate increased DAT Vmax in SHR mPFC and decreased DAT Vmax in WKY OFC.
"Also, << methylphenidate >> decreased [[ DAT ]] Km in WIS OFC.","Also, [ENTITY_A] decreased [ENTITY_B] Km in WIS OFC.",INHIBITOR,CPR:4,1,"Also, methylphenidate decreased DAT Km in WIS OFC."
"Thus, the increase in mPFC << DAT >> function was an SHR-specific long term consequence of [[ methylphenidate ]] treatment during adolescence, which may be responsible for the treatment-induced alterations in behavior including the observed increases in cocaine self-administration.","Thus, the increase in mPFC [ENTITY_A] function was an SHR-specific long term consequence of [ENTITY_B] treatment during adolescence, which may be responsible for the treatment-induced alterations in behavior including the observed increases in cocaine self-administration.",UPREGULATOR,CPR:3,0,"Thus, the increase in mPFC DAT function was an SHR-specific long term consequence of methylphenidate treatment during adolescence, which may be responsible for the treatment-induced alterations in behavior including the observed increases in cocaine self-administration."
"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by << meloxicam >>, which has been reported to preferentially inhibit [[ cyclooxygenase-2 ]] (COX-2).","OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by [ENTITY_A], which has been reported to preferentially inhibit [ENTITY_B] (COX-2).",INHIBITOR,CPR:4,1,"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by meloxicam, which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2)."
"The effects of << meloxicam >> were compared with those of diclofenac, a nonselective [[ COX ]] inhibitor.","The effects of [ENTITY_A] were compared with those of diclofenac, a nonselective [ENTITY_B] inhibitor.",INHIBITOR,CPR:4,1,"The effects of meloxicam were compared with those of diclofenac, a nonselective COX inhibitor."
METHODS: << COX-1 >> inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg [[ meloxicam ]] and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily).,METHODS: [ENTITY_A] inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg [ENTITY_B] and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily).,INHIBITOR,CPR:4,1,METHODS: COX-1 inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily).
Thus our data suggest that the << COX-2 >> preference of [[ meloxicam ]] observed in vitro may not result in clinical advantages when the higher dose of 15 mg is needed.,Thus our data suggest that the [ENTITY_A] preference of [ENTITY_B] observed in vitro may not result in clinical advantages when the higher dose of 15 mg is needed.,INHIBITOR,CPR:4,1,Thus our data suggest that the COX-2 preference of meloxicam observed in vitro may not result in clinical advantages when the higher dose of 15 mg is needed.
Inhibition of angiogenesis and invasion by << DMBT >> is mediated by downregulation of [[ VEGF ]] and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells.,Inhibition of angiogenesis and invasion by [ENTITY_A] is mediated by downregulation of [ENTITY_B] and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells.,DOWNREGULATOR,CPR:4,1,Inhibition of angiogenesis and invasion by DMBT is mediated by downregulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells.
Gelatin zymography showed that << DMBT >> inhibited secretion and activity of [[ MMP-9 ]].,Gelatin zymography showed that [ENTITY_A] inhibited secretion and activity of [ENTITY_B].,INHIBITOR,CPR:4,1,Gelatin zymography showed that DMBT inhibited secretion and activity of MMP-9.
"Western blotting demonstrated that << DMBT >> effectively suppressed the expression of [[ VEGF ]], p-VEGFR-2, p-EGFR, and p-Akt.","Western blotting demonstrated that [ENTITY_A] effectively suppressed the expression of [ENTITY_B], p-VEGFR-2, p-EGFR, and p-Akt.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Western blotting demonstrated that DMBT effectively suppressed the expression of VEGF, p-VEGFR-2, p-EGFR, and p-Akt."
"These results suggested that << DMBT >> could inhibit invasion and angiogenesis by downregulation of [[ VEGF ]]and MMP-9, resulting from the inhibition of Akt pathway.","These results suggested that [ENTITY_A] could inhibit invasion and angiogenesis by downregulation of [ENTITY_B]and MMP-9, resulting from the inhibition of Akt pathway.",DOWNREGULATOR,CPR:4,1,"These results suggested that DMBT could inhibit invasion and angiogenesis by downregulation of VEGFand MMP-9, resulting from the inhibition of Akt pathway."
Expression of L-type pyruvate kinase (<< L-PK >>) is upregulated in the liver by dietary [[ carbohydrate ]].,Expression of L-type pyruvate kinase ([ENTITY_A]) is upregulated in the liver by dietary [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,Expression of L-type pyruvate kinase (L-PK) is upregulated in the liver by dietary carbohydrate.
<< Felbamate >> block of recombinant [[ N-methyl-D-aspartate receptors ]]: selectivity for the NR2B subunit.,[ENTITY_A] block of recombinant [ENTITY_B]: selectivity for the NR2B subunit.,INHIBITOR,CPR:4,1,Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit.
The anticonvulsant << felbamate >> blocks [[ N-methyl-D-asparate (NMDA) receptors ]] but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists.,The anticonvulsant [ENTITY_A] blocks [ENTITY_B] but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists.,INHIBITOR,CPR:4,1,The anticonvulsant felbamate blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists.
The anticonvulsant << felbamate >> blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other [[ NMDA receptor ]] antagonists.,The anticonvulsant [ENTITY_A] blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other [ENTITY_B] antagonists.,ANTAGONIST,CPR:6,3,The anticonvulsant felbamate blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists.
"To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of << felbamate >> block of recombinant [[ NMDA receptors ]] composed of the NR1a subunit and various NR2 subunits.","To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of [ENTITY_A] block of recombinant [ENTITY_B] composed of the NR1a subunit and various NR2 subunits.",INHIBITOR,CPR:4,1,"To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant NMDA receptors composed of the NR1a subunit and various NR2 subunits."
"<< Felbamate >> produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the [[ rat NR1a ]] subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV).","[ENTITY_A] produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the [ENTITY_B] subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV).",INHIBITOR,CPR:4,1,"Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)."
The higher affinity of << felbamate >> block of [[ NMDA receptors ]] containing the NR2B subunit could be accounted for by more rapid association and slower dissociation from these sites.,The higher affinity of [ENTITY_A] block of [ENTITY_B] containing the NR2B subunit could be accounted for by more rapid association and slower dissociation from these sites.,INHIBITOR,CPR:4,1,The higher affinity of felbamate block of NMDA receptors containing the NR2B subunit could be accounted for by more rapid association and slower dissociation from these sites.
We conclude that << felbamate >> exhibits modest selectivity for [[ NMDA receptors ]] composed of NR1a/NR2B subunits.,We conclude that [ENTITY_A] exhibits modest selectivity for [ENTITY_B] composed of NR1a/NR2B subunits.,INHIBITOR,CPR:4,1,We conclude that felbamate exhibits modest selectivity for NMDA receptors composed of NR1a/NR2B subunits.
"This selectivity could, in part, account for the more favorable clinical profile of << felbamate >> in comparison with [[ NMDA receptor ]] antagonists that do not show subunit selectivity.","This selectivity could, in part, account for the more favorable clinical profile of [ENTITY_A] in comparison with [ENTITY_B] antagonists that do not show subunit selectivity.",ANTAGONIST,CPR:6,3,"This selectivity could, in part, account for the more favorable clinical profile of felbamate in comparison with NMDA receptor antagonists that do not show subunit selectivity."
In four (10 %) patients the peak << ACTH >>-stimulated [[ cortisol ]] values were lower than 18 μg/dL.,In four (10 %) patients the peak [ENTITY_A]-stimulated [ENTITY_B] values were lower than 18 μg/dL.,PRODUCT-OF,CPR:9,4,In four (10 %) patients the peak ACTH-stimulated cortisol values were lower than 18 μg/dL.
"<< ACTH >>-stimulated peak [[ cortisol ]], delta cortisol, and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover.","[ENTITY_A]-stimulated peak [ENTITY_B], delta cortisol, and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover.",PRODUCT-OF,CPR:9,4,"ACTH-stimulated peak cortisol, delta cortisol, and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover."
"Previously, we showed that the << human kappa-opioid receptor >> (hkor) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged [[ U50,488H ]] treatment.","Previously, we showed that the [ENTITY_A] (hkor) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged [ENTITY_B] treatment.",DOWNREGULATOR,CPR:4,1,"Previously, we showed that the human kappa-opioid receptor (hkor) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged U50,488H treatment."
"<< U50, 488H >> caused a significant down-regulation of the [[ hkor ]], although etorphine did not.","[ENTITY_A] caused a significant down-regulation of the [ENTITY_B], although etorphine did not.",DOWNREGULATOR,CPR:4,1,"U50, 488H caused a significant down-regulation of the hkor, although etorphine did not."
"Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced << U50,488H >>-induced down-regulation of the [[ hkor ]].",Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced [ENTITY_A]-induced down-regulation of the [ENTITY_B].,DOWNREGULATOR,CPR:4,1,"Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced U50,488H-induced down-regulation of the hkor."
"Coexpression of GRK2 or GRK2 and arrestin-2 permitted << etorphine >> to induce down-regulation of the [[ hkor ]], although expression of arrestin-2 or dynamin I alone did not.","Coexpression of GRK2 or GRK2 and arrestin-2 permitted [ENTITY_A] to induce down-regulation of the [ENTITY_B], although expression of arrestin-2 or dynamin I alone did not.",DOWNREGULATOR,CPR:4,1,"Coexpression of GRK2 or GRK2 and arrestin-2 permitted etorphine to induce down-regulation of the hkor, although expression of arrestin-2 or dynamin I alone did not."
"Expression of the dominant negative mutants << rab5A >>-N133I or rab7-N125I blunted [[ U50,488H ]]-induced down-regulation.",Expression of the dominant negative mutants [ENTITY_A]-N133I or rab7-N125I blunted [ENTITY_B]-induced down-regulation.,DOWNREGULATOR,CPR:4,1,"Expression of the dominant negative mutants rab5A-N133I or rab7-N125I blunted U50,488H-induced down-regulation."
"Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors (<< proteasome >> inhibitor I, [[ MG-132 ]], or lactacystin) decreased the extent of U50,488H-induced down-regulation.","Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors ([ENTITY_A] inhibitor I, [ENTITY_B], or lactacystin) decreased the extent of U50,488H-induced down-regulation.",INHIBITOR,CPR:4,1,"Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors (proteasome inhibitor I, MG-132, or lactacystin) decreased the extent of U50,488H-induced down-regulation."
"These results indicate that << U50,488H >>-induced down-regulation of the [[ hkor ]] involves GRK-, arrestin-2-, dynamin-, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation.","These results indicate that [ENTITY_A]-induced down-regulation of the [ENTITY_B] involves GRK-, arrestin-2-, dynamin-, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation.",DOWNREGULATOR,CPR:4,1,"These results indicate that U50,488H-induced down-regulation of the hkor involves GRK-, arrestin-2-, dynamin-, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation."
"Thus, << U50,488H >>-induced internalization and down-regulation of the [[ hkor ]] share initial common mechanisms.","Thus, [ENTITY_A]-induced internalization and down-regulation of the [ENTITY_B] share initial common mechanisms.",DOWNREGULATOR,CPR:4,1,"Thus, U50,488H-induced internalization and down-regulation of the hkor share initial common mechanisms."
"In Alexander cells, only when they were transfected with FXR+RXR, << GW4064 >> caused up-regulation of [[ SHP ]] and OSTβ, and a down-regulation of CYP27A1.","In Alexander cells, only when they were transfected with FXR+RXR, [ENTITY_A] caused up-regulation of [ENTITY_B] and OSTβ, and a down-regulation of CYP27A1.",INDIRECT-UPREGULATOR,CPR:3,0,"In Alexander cells, only when they were transfected with FXR+RXR, GW4064 caused up-regulation of SHP and OSTβ, and a down-regulation of CYP27A1."
"In Alexander cells, only when they were transfected with FXR+RXR, << GW4064 >> caused up-regulation of SHP and OSTβ, and a down-regulation of [[ CYP27A1 ]].","In Alexander cells, only when they were transfected with FXR+RXR, [ENTITY_A] caused up-regulation of SHP and OSTβ, and a down-regulation of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"In Alexander cells, only when they were transfected with FXR+RXR, GW4064 caused up-regulation of SHP and OSTβ, and a down-regulation of CYP27A1."
"Moreover, GCs have a synergistic effect on << GW4064 >>-induced [[ FXR ]] activation, whereas chenodeoxycholate and GW4064 have an additive effect.","Moreover, GCs have a synergistic effect on [ENTITY_A]-induced [ENTITY_B] activation, whereas chenodeoxycholate and GW4064 have an additive effect.",ACTIVATOR,CPR:3,0,"Moreover, GCs have a synergistic effect on GW4064-induced FXR activation, whereas chenodeoxycholate and GW4064 have an additive effect."
Kinetic parameters for << PAM >> inactivation by [[ 4-oxo-5-acetamido-6-phenyl-hex-2-enoic acid and 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid ]] were obtained by using both the conventional dilution assay method and the more complex progress curve method.,Kinetic parameters for [ENTITY_A] inactivation by [ENTITY_B] were obtained by using both the conventional dilution assay method and the more complex progress curve method.,INHIBITOR,CPR:4,1,Kinetic parameters for PAM inactivation by 4-oxo-5-acetamido-6-phenyl-hex-2-enoic acid and 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid were obtained by using both the conventional dilution assay method and the more complex progress curve method.
"Stereochemical studies established that << PAM >> inactivation by [[ 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid ]] is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous results with substrates and reversible inhibitors.","Stereochemical studies established that [ENTITY_A] inactivation by [ENTITY_B] is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous results with substrates and reversible inhibitors.",INHIBITOR,CPR:4,1,"Stereochemical studies established that PAM inactivation by 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous results with substrates and reversible inhibitors."
"In contrast, << 2, 4-dioxo-5-acetamido-6-phenylhexanoic acid >>, which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both [[ PAM ]] and dopamine-beta-hydroxylase.","In contrast, [ENTITY_A], which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both [ENTITY_B] and dopamine-beta-hydroxylase.",INHIBITOR,CPR:4,1,"In contrast, 2, 4-dioxo-5-acetamido-6-phenylhexanoic acid, which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both PAM and dopamine-beta-hydroxylase."
Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of << [(3)H]estradiol glucuronide >> (E217βG) (a prototypical [[ MRP ]] substrate) into MRP-enriched inside-out membrane vesicles.,Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [ENTITY_A] (E217βG) (a prototypical [ENTITY_B] substrate) into MRP-enriched inside-out membrane vesicles.,SUBSTRATE,CPR:9,4,Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide (E217βG) (a prototypical MRP substrate) into MRP-enriched inside-out membrane vesicles.
Sixteen of 34 << CGPs >> inhibited [[ MRP1 ]]-mediated E217βG uptake by >50% (IC50's 0.7-7.6 μM).,Sixteen of 34 [ENTITY_A] inhibited [ENTITY_B]-mediated E217βG uptake by >50% (IC50's 0.7-7.6 μM).,INHIBITOR,CPR:4,1,Sixteen of 34 CGPs inhibited MRP1-mediated E217βG uptake by >50% (IC50's 0.7-7.6 μM).
Sixteen of 34 CGPs inhibited << MRP1 >>-mediated [[ E217βG ]] uptake by >50% (IC50's 0.7-7.6 μM).,Sixteen of 34 CGPs inhibited [ENTITY_A]-mediated [ENTITY_B] uptake by >50% (IC50's 0.7-7.6 μM).,SUBSTRATE,CPR:9,4,Sixteen of 34 CGPs inhibited MRP1-mediated E217βG uptake by >50% (IC50's 0.7-7.6 μM).
"When tested in the intact cells, only 4 of 16 << CGPs >> (at 10 μM) inhibited [[ MRP1 ]]-mediated calcein efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%.","When tested in the intact cells, only 4 of 16 [ENTITY_A] (at 10 μM) inhibited [ENTITY_B]-mediated calcein efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%.",INHIBITOR,CPR:4,1,"When tested in the intact cells, only 4 of 16 CGPs (at 10 μM) inhibited MRP1-mediated calcein efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%."
"When tested in the intact cells, only 4 of 16 CGPs (at 10 μM) inhibited << MRP1 >>-mediated [[ calcein ]] efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%.","When tested in the intact cells, only 4 of 16 CGPs (at 10 μM) inhibited [ENTITY_A]-mediated [ENTITY_B] efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%.",SUBSTRATE,CPR:9,4,"When tested in the intact cells, only 4 of 16 CGPs (at 10 μM) inhibited MRP1-mediated calcein efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%."
These five << CGPs >> also inhibited [(3)H]E217βG uptake by [[ MRP4 ]].,These five [ENTITY_A] also inhibited [(3)H]E217βG uptake by [ENTITY_B].,INHIBITOR,CPR:4,1,These five CGPs also inhibited [(3)H]E217βG uptake by MRP4.
These five CGPs also inhibited << [(3)H]E217βG >> uptake by [[ MRP4 ]].,These five CGPs also inhibited [ENTITY_A] uptake by [ENTITY_B].,SUBSTRATE,CPR:9,4,These five CGPs also inhibited [(3)H]E217βG uptake by MRP4.
"<< Gemfibrozil >>, a lipid-lowering drug, inhibits the induction of [[ nitric-oxide synthase ]] in human astrocytes.","[ENTITY_A], a lipid-lowering drug, inhibits the induction of [ENTITY_B] in human astrocytes.",INHIBITOR,CPR:4,1,"Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes."
"Gemfibrozil, a lipid-lowering drug, inhibits the induction of << nitric-oxide synthase >>[[ nitric-oxide ]] synthase in human astrocytes.","Gemfibrozil, a lipid-lowering drug, inhibits the induction of [ENTITY_A][ENTITY_B] synthase in human astrocytes.",PRODUCT-OF,CPR:9,4,"Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthasenitric-oxide synthase in human astrocytes."
"<< Gemfibrozil >>, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of [[ inducible nitric-oxide synthase ]] (iNOS) in human U373MG astroglial cells and primary astrocytes.","[ENTITY_A], a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of [ENTITY_B] (iNOS) in human U373MG astroglial cells and primary astrocytes.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes."
"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of << NO >> and the expression of [[ inducible nitric-oxide synthase ]] (iNOS) in human U373MG astroglial cells and primary astrocytes.","Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of [ENTITY_A] and the expression of [ENTITY_B] (iNOS) in human U373MG astroglial cells and primary astrocytes.",PRODUCT-OF,CPR:9,4,"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes."
"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of << inducible nitric-oxide synthase >>[[ nitric-oxide ]] synthase (iNOS) in human U373MG astroglial cells and primary astrocytes.","Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of [ENTITY_A][ENTITY_B] synthase (iNOS) in human U373MG astroglial cells and primary astrocytes.",PRODUCT-OF,CPR:9,4,"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthasenitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes."
"Similar to << gemfibrozil >>, clofibrate, another fibrate drug, also inhibited the expression of [[ iNOS ]].","Similar to [ENTITY_A], clofibrate, another fibrate drug, also inhibited the expression of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Similar to gemfibrozil, clofibrate, another fibrate drug, also inhibited the expression of iNOS."
Inhibition of human iNOS promoter-driven luciferase activity by << gemfibrozil >> in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of [[ iNOS ]].,Inhibition of human iNOS promoter-driven luciferase activity by [ENTITY_A] in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of [ENTITY_B].,INDIRECT-DOWNREGULATOR,CPR:4,1,Inhibition of human iNOS promoter-driven luciferase activity by gemfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS.
"Since << gemfibrozil >> is known to activate [[ peroxisome proliferator-activated receptor-alpha ]] (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS.","Since [ENTITY_A] is known to activate [ENTITY_B] (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS.",ACTIVATOR,CPR:3,0,"Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS."
"Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in << gemfibrozil >>-mediated inhibition of [[ iNOS ]].","Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in [ENTITY_A]-mediated inhibition of [ENTITY_B].",INHIBITOR,CPR:4,1,"Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS."
"<< Gemfibrozil >> induced [[ peroxisome proliferator-responsive element ]] (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha.","[ENTITY_A] induced [ENTITY_B] (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha.",ACTIVATOR,CPR:3,0,"Gemfibrozil induced peroxisome proliferator-responsive element (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha."
"However, DeltahPPAR-alpha was unable to abrogate << gemfibrozil >>-mediated inhibition of [[ iNOS ]] suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha.","However, DeltahPPAR-alpha was unable to abrogate [ENTITY_A]-mediated inhibition of [ENTITY_B] suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha.",INHIBITOR,CPR:4,1,"However, DeltahPPAR-alpha was unable to abrogate gemfibrozil-mediated inhibition of iNOS suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha."
"Interestingly, << gemfibrozil >> strongly inhibited the activation of [[ NF-kappaB ]], AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells.","Interestingly, [ENTITY_A] strongly inhibited the activation of [ENTITY_B], AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells.",INHIBITOR,CPR:4,1,"Interestingly, gemfibrozil strongly inhibited the activation of NF-kappaB, AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells."
"These results suggest that << gemfibrozil >> inhibits the induction of [[ iNOS ]] probably by inhibiting the activation of NF-kappaB, AP-1, and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.","These results suggest that [ENTITY_A] inhibits the induction of [ENTITY_B] probably by inhibiting the activation of NF-kappaB, AP-1, and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.",INHIBITOR,CPR:4,1,"These results suggest that gemfibrozil inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, AP-1, and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases."
OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting << alpha2 adrenergic receptor >> (AR) agonist ([[ dexmedetomidine ]]).,OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting [ENTITY_A] (AR) agonist ([ENTITY_B]).,AGONIST,CPR:5,2,OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting alpha2 adrenergic receptor (AR) agonist (dexmedetomidine).
The inhibitory effect of << sodium nitroprusside >> on [[ HIF-1 ]] activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway.,The inhibitory effect of [ENTITY_A] on [ENTITY_B] activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway.,INHIBITOR,CPR:4,1,The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway.
"We demonstrate that among the three nitrates, only << SNP >> inhibits [[ HIF-1 ]] activation in response to hypoxia.","We demonstrate that among the three nitrates, only [ENTITY_A] inhibits [ENTITY_B] activation in response to hypoxia.",INHIBITOR,CPR:4,1,"We demonstrate that among the three nitrates, only SNP inhibits HIF-1 activation in response to hypoxia."
"<< SNP >> inhibits the accumulation of HIF-1alpha, the regulatory subunit of HIF-1, and the transcriptional activation of [[ HIF-1alpha ]] via a mechanism that is not dependent on either NO or soluble guanylate cyclase.","[ENTITY_A] inhibits the accumulation of HIF-1alpha, the regulatory subunit of HIF-1, and the transcriptional activation of [ENTITY_B] via a mechanism that is not dependent on either NO or soluble guanylate cyclase.",INDIRECT-DOWNREGULATOR,CPR:4,1,"SNP inhibits the accumulation of HIF-1alpha, the regulatory subunit of HIF-1, and the transcriptional activation of HIF-1alpha via a mechanism that is not dependent on either NO or soluble guanylate cyclase."
"<< Indomethacin >> activates [[ carbonic anhydrase ]] and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action.","[ENTITY_A] activates [ENTITY_B] and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action.",ACTIVATOR,CPR:3,0,"Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action."
"Indomethacin activates << carbonic anhydrase >> and antagonizes the effect of the specific carbonic anhydrase inhibitor [[ acetazolamide ]], by a direct mechanism of action.","Indomethacin activates [ENTITY_A] and antagonizes the effect of the specific carbonic anhydrase inhibitor [ENTITY_B], by a direct mechanism of action.",INHIBITOR,CPR:4,1,"Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action."
"RESULTS: << Indomethacin >>, in vitro and in vivo. induces an increase in erythorcyte [[ CA I ]] and CA II activity.","RESULTS: [ENTITY_A], in vitro and in vivo. induces an increase in erythorcyte [ENTITY_B] and CA II activity.",ACTIVATOR,CPR:3,0,"RESULTS: Indomethacin, in vitro and in vivo. induces an increase in erythorcyte CA I and CA II activity."
"<< Acetazolamide >>, a specific inhibitor of [[ CA ]], reduces the activity of CA I and CA II from red cells.","[ENTITY_A], a specific inhibitor of [ENTITY_B], reduces the activity of CA I and CA II from red cells.",INHIBITOR,CPR:4,1,"Acetazolamide, a specific inhibitor of CA, reduces the activity of CA I and CA II from red cells."
"<< Indomethacin >> completely antagonizes [[ CA ]] activity, i.e. abolishes the inhibitory effect of acetazolamide on CA.","[ENTITY_A] completely antagonizes [ENTITY_B] activity, i.e. abolishes the inhibitory effect of acetazolamide on CA.",ACTIVATOR,CPR:3,0,"Indomethacin completely antagonizes CA activity, i.e. abolishes the inhibitory effect of acetazolamide on CA."
"Indomethacin completely antagonizes << CA >> activity, i.e. abolishes the inhibitory effect of [[ acetazolamide ]] on CA.","Indomethacin completely antagonizes [ENTITY_A] activity, i.e. abolishes the inhibitory effect of [ENTITY_B] on CA.",INHIBITOR,CPR:4,1,"Indomethacin completely antagonizes CA activity, i.e. abolishes the inhibitory effect of acetazolamide on CA."
"CONCLUSIONS: Our results show that << indomethacin >>, a known cyclooxygenase (COX) inhibitor, is also an activator of [[ CA ]].","CONCLUSIONS: Our results show that [ENTITY_A], a known cyclooxygenase (COX) inhibitor, is also an activator of [ENTITY_B].",ACTIVATOR,CPR:3,0,"CONCLUSIONS: Our results show that indomethacin, a known cyclooxygenase (COX) inhibitor, is also an activator of CA."
"CONCLUSIONS: Our results show that << indomethacin >>, a known [[ cyclooxygenase ]] (COX) inhibitor, is also an activator of CA.","CONCLUSIONS: Our results show that [ENTITY_A], a known [ENTITY_B] (COX) inhibitor, is also an activator of CA.",INHIBITOR,CPR:4,1,"CONCLUSIONS: Our results show that indomethacin, a known cyclooxygenase (COX) inhibitor, is also an activator of CA."
"Our data also prove that << indomethacin >> is not only an activator of [[ CA ]] but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme.","Our data also prove that [ENTITY_A] is not only an activator of [ENTITY_B] but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme.",ACTIVATOR,CPR:3,0,"Our data also prove that indomethacin is not only an activator of CA but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme."
"Our data also prove that indomethacin is not only an activator of << CA >> but also antagonizes the effect of [[ acetazolamide ]], a specific inhibitor of this enzyme.","Our data also prove that indomethacin is not only an activator of [ENTITY_A] but also antagonizes the effect of [ENTITY_B], a specific inhibitor of this enzyme.",INHIBITOR,CPR:4,1,"Our data also prove that indomethacin is not only an activator of CA but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme."
"In view of the role of CA in acid-base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra- and extracellular pH, our results suggest that: firstly, << CA >> activation induced by [[ indomethacin ]] might cause changes in COX activity; secondly, PGs are synthetized as a consequence of the changes in COX activity, a hypothesis that requires further study.","In view of the role of CA in acid-base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra- and extracellular pH, our results suggest that: firstly, [ENTITY_A] activation induced by [ENTITY_B] might cause changes in COX activity; secondly, PGs are synthetized as a consequence of the changes in COX activity, a hypothesis that requires further study.",ACTIVATOR,CPR:3,0,"In view of the role of CA in acid-base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra- and extracellular pH, our results suggest that: firstly, CA activation induced by indomethacin might cause changes in COX activity; secondly, PGs are synthetized as a consequence of the changes in COX activity, a hypothesis that requires further study."
"The acetylcholinesterase (<< AChE >>) and butyrylcholinesterase (BuChE) inhibitory activities of a series of [[ pyrano[2,3-b]quinolines ]] (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","The acetylcholinesterase ([ENTITY_A]) and butyrylcholinesterase (BuChE) inhibitory activities of a series of [ENTITY_B] (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",INHIBITOR,CPR:4,1,"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described."
"These compounds are competitive and, in a few cases, non-competitive inhibitors for << AChE >>, the most potent being compound (14), though three-fold less active than [[ tacrine ]].","These compounds are competitive and, in a few cases, non-competitive inhibitors for [ENTITY_A], the most potent being compound (14), though three-fold less active than [ENTITY_B].",INHIBITOR,CPR:4,1,"These compounds are competitive and, in a few cases, non-competitive inhibitors for AChE, the most potent being compound (14), though three-fold less active than tacrine."
"The << BuChE >> inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than [[ tacrine ]].","The [ENTITY_A] inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than [ENTITY_B].",INHIBITOR,CPR:4,1,"The BuChE inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than tacrine."
"<< Juglone >>, isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of [[ AR ]] expression in human prostate cancer LNCaP cells.","[ENTITY_A], isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of [ENTITY_B] expression in human prostate cancer LNCaP cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Juglone, isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of AR expression in human prostate cancer LNCaP cells."
"Moreover, we found that << juglone >> significantly inhibited the expression levels of [[ androgen receptor ]] (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT).","Moreover, we found that [ENTITY_A] significantly inhibited the expression levels of [ENTITY_B] (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT).",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)."
"Take together, our results demonstrated that << juglone >> might induce the apoptosis in LNCaP cell via down-regulation of [[ AR ]] expression.","Take together, our results demonstrated that [ENTITY_A] might induce the apoptosis in LNCaP cell via down-regulation of [ENTITY_B] expression.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Take together, our results demonstrated that juglone might induce the apoptosis in LNCaP cell via down-regulation of AR expression."
"<< Astemizole >>, a potent [[ histamine H1-receptor ]] antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels.","[ENTITY_A], a potent [ENTITY_B] antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels.",ANTAGONIST,CPR:6,3,"Astemizole, a potent histamine H1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels."
"The efficacy of << astemizole >>, a new, long acting, oral [[ histamine H1-receptor ]] antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982.","The efficacy of [ENTITY_A], a new, long acting, oral [ENTITY_B] antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982.",ANTAGONIST,CPR:6,3,"The efficacy of astemizole, a new, long acting, oral histamine H1-receptor antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982."
"<< Tacrine >>, the first of the [[ cholinesterase ]] inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity.","[ENTITY_A], the first of the [ENTITY_B] inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity.",INHIBITOR,CPR:4,1,"Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity."
"Other << cholinesterase >> inhibitors, including [[ rivastigmine ]], with superior properties in terms of specificity of action and low risk of adverse effects, have now been introduced.","Other [ENTITY_A] inhibitors, including [ENTITY_B], with superior properties in terms of specificity of action and low risk of adverse effects, have now been introduced.",INHIBITOR,CPR:4,1,"Other cholinesterase inhibitors, including rivastigmine, with superior properties in terms of specificity of action and low risk of adverse effects, have now been introduced."
"<< 5-(N,N-dimethyl)-amiloride >> (50 microM; DMA), a concentration that selectively inhibits the [[ NHE ]] isoforms NHE1 and NHE2, but not NHE3, did not affect DBS.","[ENTITY_A] (50 microM; DMA), a concentration that selectively inhibits the [ENTITY_B] isoforms NHE1 and NHE2, but not NHE3, did not affect DBS.",INHIBITOR,CPR:4,1,"5-(N,N-dimethyl)-amiloride (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not NHE3, did not affect DBS."
"Nevertheless, 3 mM << DMA >>, a higher concentration that inhibits [[ NHE1 ]], NHE2, and NHE3, significantly increased DBS.","Nevertheless, 3 mM [ENTITY_A], a higher concentration that inhibits [ENTITY_B], NHE2, and NHE3, significantly increased DBS.",INHIBITOR,CPR:4,1,"Nevertheless, 3 mM DMA, a higher concentration that inhibits NHE1, NHE2, and NHE3, significantly increased DBS."
"Moreover, << S1611 >> and S3226, both specific inhibitors of [[ NHE3 ]] only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH.","Moreover, [ENTITY_A] and S3226, both specific inhibitors of [ENTITY_B] only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH.",INHIBITOR,CPR:4,1,"Moreover, S1611 and S3226, both specific inhibitors of NHE3 only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH."
"Nevertheless, coperfusion with 0.1 and 0.3 mM << 5-nitro-2-(3-phenylpropylamino) benzoic acid >>, which inhibits the [[ cystic fibrosis transmembrane conductor regulator ]] (CFTR), dose dependently inhibited S3226-induced DBS.","Nevertheless, coperfusion with 0.1 and 0.3 mM [ENTITY_A], which inhibits the [ENTITY_B] (CFTR), dose dependently inhibited S3226-induced DBS.",INHIBITOR,CPR:4,1,"Nevertheless, coperfusion with 0.1 and 0.3 mM 5-nitro-2-(3-phenylpropylamino) benzoic acid, which inhibits the cystic fibrosis transmembrane conductor regulator (CFTR), dose dependently inhibited S3226-induced DBS."
"In conclusion, only specific apical NHE3 inhibition increased DBS, whereas prostaglandin synthesis, Na+-HCO3- cotransporter activation, or intracellular << HCO3 >>- formation by [[ carbonic anhydrase ]] was not involved.","In conclusion, only specific apical NHE3 inhibition increased DBS, whereas prostaglandin synthesis, Na+-HCO3- cotransporter activation, or intracellular [ENTITY_A]- formation by [ENTITY_B] was not involved.",PRODUCT-OF,CPR:9,4,"In conclusion, only specific apical NHE3 inhibition increased DBS, whereas prostaglandin synthesis, Na+-HCO3- cotransporter activation, or intracellular HCO3- formation by carbonic anhydrase was not involved."
Mechanisms limiting distribution of the << threonine-protein kinase B-RaF >>(V600E) inhibitor [[ dabrafenib ]] to the brain: implications for the treatment of melanoma brain metastases.,Mechanisms limiting distribution of the [ENTITY_A](V600E) inhibitor [ENTITY_B] to the brain: implications for the treatment of melanoma brain metastases.,INHIBITOR,CPR:4,1,Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.
In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that << dabrafenib >> is an avid substrate for both [[ P-gp ]] and BCRP.,In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that [ENTITY_A] is an avid substrate for both [ENTITY_B] and BCRP.,SUBSTRATE,CPR:9,4,In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that dabrafenib is an avid substrate for both P-gp and BCRP.
"Further, compared with << vemurafenib >>, another [[ BRAF ]](V600E) inhibitor, dabrafenib showed greater brain penetration with a similar dose.","Further, compared with [ENTITY_A], another [ENTITY_B](V600E) inhibitor, dabrafenib showed greater brain penetration with a similar dose.",INHIBITOR,CPR:4,1,"Further, compared with vemurafenib, another BRAF(V600E) inhibitor, dabrafenib showed greater brain penetration with a similar dose."
"Since the original discovery of << azoles >> analogs as [[ PXR ]] antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists.","Since the original discovery of [ENTITY_A] analogs as [ENTITY_B] antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists.",ANTAGONIST,CPR:6,3,"Since the original discovery of azoles analogs as PXR antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists."
Activation of endogenous << somatostatin receptor subtype 2 >> (sst2) by [[ somatostatin-14 ]] or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect.,Activation of endogenous [ENTITY_A] (sst2) by [ENTITY_B] or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect.,ACTIVATOR,CPR:3,0,Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect.
"In contrast, in the same system, << N >>-type currents, formed from transiently transfected alpha(1B)/alpha(2)delta-1/beta(3), showed strong [[ G-protein ]]-mediated inhibition.","In contrast, in the same system, [ENTITY_A]-type currents, formed from transiently transfected alpha(1B)/alpha(2)delta-1/beta(3), showed strong [ENTITY_B]-mediated inhibition.",INHIBITOR,CPR:4,1,"In contrast, in the same system, N-type currents, formed from transiently transfected alpha(1B)/alpha(2)delta-1/beta(3), showed strong G-protein-mediated inhibition."
Levels of << Cx43 >> protein were also decreased in a dose- and time-dependent manner following [[ antofine ]] treatment.,Levels of [ENTITY_A] protein were also decreased in a dose- and time-dependent manner following [ENTITY_B] treatment.,INDIRECT-DOWNREGULATOR,CPR:4,1,Levels of Cx43 protein were also decreased in a dose- and time-dependent manner following antofine treatment.
Co-treatment of astrocytes with antofine and the intracellular Ca(2+) chelator << BAPTA-AM >> prevented downregulation of [[ Cx43 ]] and inhibition of GJIC.,Co-treatment of astrocytes with antofine and the intracellular Ca(2+) chelator [ENTITY_A] prevented downregulation of [ENTITY_B] and inhibition of GJIC.,INDIRECT-UPREGULATOR,CPR:3,0,Co-treatment of astrocytes with antofine and the intracellular Ca(2+) chelator BAPTA-AM prevented downregulation of Cx43 and inhibition of GJIC.
Co-treatment of astrocytes with << antofine >> and the intracellular Ca(2+) chelator BAPTA-AM prevented downregulation of [[ Cx43 ]] and inhibition of GJIC.,Co-treatment of astrocytes with [ENTITY_A] and the intracellular Ca(2+) chelator BAPTA-AM prevented downregulation of [ENTITY_B] and inhibition of GJIC.,INDIRECT-DOWNREGULATOR,CPR:4,1,Co-treatment of astrocytes with antofine and the intracellular Ca(2+) chelator BAPTA-AM prevented downregulation of Cx43 and inhibition of GJIC.
"Moreover, co-treatment with << antofine >> and a specific PKCβ inhibitor prevented endocytosis of gap junctions, downregulation of [[ Cx43 ]], and inhibition of GJIC.","Moreover, co-treatment with [ENTITY_A] and a specific PKCβ inhibitor prevented endocytosis of gap junctions, downregulation of [ENTITY_B], and inhibition of GJIC.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, co-treatment with antofine and a specific PKCβ inhibitor prevented endocytosis of gap junctions, downregulation of Cx43, and inhibition of GJIC."
"Taken together, these findings indicate that << antofine >> induces Cx43 gap junction disassembly by the [[ PKCβ ]] signaling pathway.","Taken together, these findings indicate that [ENTITY_A] induces Cx43 gap junction disassembly by the [ENTITY_B] signaling pathway.",ACTIVATOR,CPR:3,0,"Taken together, these findings indicate that antofine induces Cx43 gap junction disassembly by the PKCβ signaling pathway."
<< Torasemide >> inhibits [[ angiotensin II ]]-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats.,[ENTITY_A] inhibits [ENTITY_B]-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats.,INHIBITOR,CPR:4,1,Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats.
Isometric contraction induced by a submaximal concentration of << Ang II >> (10(-7) mol/L) was reduced in a dose-dependent way by [[ torasemide ]] (IC(50)=0.5+/-0.04 micromol/L).,Isometric contraction induced by a submaximal concentration of [ENTITY_A] (10(-7) mol/L) was reduced in a dose-dependent way by [ENTITY_B] (IC(50)=0.5+/-0.04 micromol/L).,INHIBITOR,CPR:4,1,Isometric contraction induced by a submaximal concentration of Ang II (10(-7) mol/L) was reduced in a dose-dependent way by torasemide (IC(50)=0.5+/-0.04 micromol/L).
The stimulatory effect of [Ca(2+)](i) induced by a submaximal concentration of << Ang II >> (10(-7) mol/L) was blocked by [[ torasemide ]] (IC(50)=0.5+/-0.3 nmol/L).,The stimulatory effect of [Ca(2+)](i) induced by a submaximal concentration of [ENTITY_A] (10(-7) mol/L) was blocked by [ENTITY_B] (IC(50)=0.5+/-0.3 nmol/L).,INHIBITOR,CPR:4,1,The stimulatory effect of [Ca(2+)](i) induced by a submaximal concentration of Ang II (10(-7) mol/L) was blocked by torasemide (IC(50)=0.5+/-0.3 nmol/L).
Our findings suggest that << torasemide >> blocks the vasoconstrictor action of [[ Ang II ]] in vitro.,Our findings suggest that [ENTITY_A] blocks the vasoconstrictor action of [ENTITY_B] in vitro.,INHIBITOR,CPR:4,1,Our findings suggest that torasemide blocks the vasoconstrictor action of Ang II in vitro.
This action can be related to the ability of << torasemide >> to block the increase of [Ca(2+)](i) induced by [[ Ang II ]] in VSMCs.,This action can be related to the ability of [ENTITY_A] to block the increase of [Ca(2+)](i) induced by [ENTITY_B] in VSMCs.,INHIBITOR,CPR:4,1,This action can be related to the ability of torasemide to block the increase of [Ca(2+)](i) induced by Ang II in VSMCs.
"Among the isolated compounds, << trans-dihydromorin >> (8), oxyresveratrol (9), and steppogenin (12) were found to exhibit significant [[ tyrosinase ]] inhibition activities.","Among the isolated compounds, [ENTITY_A] (8), oxyresveratrol (9), and steppogenin (12) were found to exhibit significant [ENTITY_B] inhibition activities.",INHIBITOR,CPR:4,1,"Among the isolated compounds, trans-dihydromorin (8), oxyresveratrol (9), and steppogenin (12) were found to exhibit significant tyrosinase inhibition activities."
"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), << 17-phenyl-trinor-PGE2 >> (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit [[ HVA Ca2+ channels ]] was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.","Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), [ENTITY_A] (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit [ENTITY_B] was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.",DOWNREGULATOR,CPR:4,1,"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2."
"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), << 17-phenyl-trinor-PGE2 >> (an [[ EP1 ]]-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.","Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), [ENTITY_A] (an [ENTITY_B]-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.",AGONIST,CPR:5,2,"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2."
"SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that << PGE1 >>- and PGE2-induced inhibition of the [[ HVA Ca2+ channels ]] is possibly mediated by the EP3 receptor.","SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that [ENTITY_A]- and PGE2-induced inhibition of the [ENTITY_B] is possibly mediated by the EP3 receptor.",INHIBITOR,CPR:4,1,"SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor."
"<< SC-51089 >> (10(-5) M), a selective [[ EP1-receptor ]] antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor.","[ENTITY_A] (10(-5) M), a selective [ENTITY_B] antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor.",ANTAGONIST,CPR:6,3,"SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor."
"The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the << protein kinase C >> (PKC) inhibitor [[ chelerythrine ]] blocked the action of PMA.","The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the [ENTITY_A] (PKC) inhibitor [ENTITY_B] blocked the action of PMA.",INHIBITOR,CPR:4,1,"The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the protein kinase C (PKC) inhibitor chelerythrine blocked the action of PMA."
It was concluded that << PGE1 >> selectively reduces both N- and R-type Ca2+ currents by activating a [[ G-protein ]] probably through the EP3 receptor in paratracheal ganglion cells.,It was concluded that [ENTITY_A] selectively reduces both N- and R-type Ca2+ currents by activating a [ENTITY_B] probably through the EP3 receptor in paratracheal ganglion cells.,ACTIVATOR,CPR:3,0,It was concluded that PGE1 selectively reduces both N- and R-type Ca2+ currents by activating a G-protein probably through the EP3 receptor in paratracheal ganglion cells.
Inhibition of << MCP-1 >> and MIP-2 transcription and translation by [[ mimosine ]] in muscle tissue infected with the parasite Trichinella spiralis.,Inhibition of [ENTITY_A] and MIP-2 transcription and translation by [ENTITY_B] in muscle tissue infected with the parasite Trichinella spiralis.,INDIRECT-DOWNREGULATOR,CPR:4,1,Inhibition of MCP-1 and MIP-2 transcription and translation by mimosine in muscle tissue infected with the parasite Trichinella spiralis.
"In addition, we found that << MCP-1 >> transcription and translation was completely inhibited by [[ mimosine ]], while MIP-2 transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T. spiralis.","In addition, we found that [ENTITY_A] transcription and translation was completely inhibited by [ENTITY_B], while MIP-2 transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T. spiralis.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, we found that MCP-1 transcription and translation was completely inhibited by mimosine, while MIP-2 transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T. spiralis."
"This is described in a case study of the expedited review and approval of << peramivir >>, a novel [[ neuraminidase ]] inhibitor, in Japan in the context of the emergence of new strain of influenza in 2009.","This is described in a case study of the expedited review and approval of [ENTITY_A], a novel [ENTITY_B] inhibitor, in Japan in the context of the emergence of new strain of influenza in 2009.",INHIBITOR,CPR:4,1,"This is described in a case study of the expedited review and approval of peramivir, a novel neuraminidase inhibitor, in Japan in the context of the emergence of new strain of influenza in 2009."
"The influence of sex, ethnicity, and << CYP2B6 >> genotype on [[ bupropion ]] metabolism as an index of hepatic CYP2B6 activity in humans.","The influence of sex, ethnicity, and [ENTITY_A] genotype on [ENTITY_B] metabolism as an index of hepatic CYP2B6 activity in humans.",SUBSTRATE,CPR:9,4,"The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans."
"To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using << bupropion >> (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a [[ CYP2B6 ]] probe substrate.","To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using [ENTITY_A] (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a [ENTITY_B] probe substrate.",SUBSTRATE,CPR:9,4,"To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using bupropion (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a CYP2B6 probe substrate."
"These results suggest that << CYP2B6 >> genotype is the most important patient variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of [[ bupropion ]].","These results suggest that [ENTITY_A] genotype is the most important patient variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of [ENTITY_B].",SUBSTRATE,CPR:9,4,"These results suggest that CYP2B6 genotype is the most important patient variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of bupropion."
"The << bupropion >> metabolic ratio appears to detect known differences in [[ CYP2B6 ]] activity associated with genetic polymorphism, across different ethnic groups.","The [ENTITY_A] metabolic ratio appears to detect known differences in [ENTITY_B] activity associated with genetic polymorphism, across different ethnic groups.",SUBSTRATE,CPR:9,4,"The bupropion metabolic ratio appears to detect known differences in CYP2B6 activity associated with genetic polymorphism, across different ethnic groups."
"The identification of the << succinate receptor >> SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of [[ succinate ]] were shown to potentiate the effect of low doses of a variety of platelet agonists.","The identification of the [ENTITY_A] SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of [ENTITY_B] were shown to potentiate the effect of low doses of a variety of platelet agonists.",AGONIST,CPR:5,2,"The identification of the succinate receptor SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of succinate were shown to potentiate the effect of low doses of a variety of platelet agonists."
<< β-ionone >> was also shown to induce the expression of cleaved-[[ caspase-3 ]] and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner.,[ENTITY_A] was also shown to induce the expression of cleaved-[ENTITY_B] and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner.,INDIRECT-UPREGULATOR,CPR:3,0,β-ionone was also shown to induce the expression of cleaved-caspase-3 and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner.
<< β-ionone >> was also shown to induce the expression of cleaved-caspase-3 and inhibit [[ bcl-2 ]] expression in SGC-7901 cells in a dose-dependent manner.,[ENTITY_A] was also shown to induce the expression of cleaved-caspase-3 and inhibit [ENTITY_B] expression in SGC-7901 cells in a dose-dependent manner.,INDIRECT-DOWNREGULATOR,CPR:4,1,β-ionone was also shown to induce the expression of cleaved-caspase-3 and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner.
The significantly decreased levels of << p-PI3K >> and p-AKT expression were observed in SGC-7901 cells after [[ β-ionone ]] treatments in a time- and dose-dependent manner (P < 0.01).,The significantly decreased levels of [ENTITY_A] and p-AKT expression were observed in SGC-7901 cells after [ENTITY_B] treatments in a time- and dose-dependent manner (P < 0.01).,INDIRECT-DOWNREGULATOR,CPR:4,1,The significantly decreased levels of p-PI3K and p-AKT expression were observed in SGC-7901 cells after β-ionone treatments in a time- and dose-dependent manner (P < 0.01).
"However, AII receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as substance P. Within the class of << AII >> blockers, [[ eprosartan ]] differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non-tetrazole, non-peptide antagonist with a dual pharmacological mode of action.","However, AII receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as substance P. Within the class of [ENTITY_A] blockers, [ENTITY_B] differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non-tetrazole, non-peptide antagonist with a dual pharmacological mode of action.",INHIBITOR,CPR:4,1,"However, AII receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as substance P. Within the class of AII blockers, eprosartan differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non-tetrazole, non-peptide antagonist with a dual pharmacological mode of action."
"In clinical trials, eprosartan has been demonstrated to be at least as effective in reducing blood pressure as the << ACE >> inhibitor [[ enalapril ]], and has significantly lower side effects.","In clinical trials, eprosartan has been demonstrated to be at least as effective in reducing blood pressure as the [ENTITY_A] inhibitor [ENTITY_B], and has significantly lower side effects.",INHIBITOR,CPR:4,1,"In clinical trials, eprosartan has been demonstrated to be at least as effective in reducing blood pressure as the ACE inhibitor enalapril, and has significantly lower side effects."
Reductive detoxification of << arylhydroxylamine >> carcinogens by human NADH cytochrome b5 reductase and [[ cytochrome b5 ]].,Reductive detoxification of [ENTITY_A] carcinogens by human NADH cytochrome b5 reductase and [ENTITY_B].,SUBSTRATE,CPR:9,4,Reductive detoxification of arylhydroxylamine carcinogens by human NADH cytochrome b5 reductase and cytochrome b5.
"On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of << arylhydroxylamine >> carcinogens was catalyzed by [[ NADH cytochrome b5 reductase ]] (b5R) and cytochrome b5 (cyt b5).","On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of [ENTITY_A] carcinogens was catalyzed by [ENTITY_B] (b5R) and cytochrome b5 (cyt b5).",SUBSTRATE,CPR:9,4,"On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and cytochrome b5 (cyt b5)."
"We found that reduction of the carcinogenic << hydroxylamines >> of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [[ human b5R ]] and cyt b5.","We found that reduction of the carcinogenic [ENTITY_A] of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [ENTITY_B] and cyt b5.",SUBSTRATE,CPR:9,4,"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5."
"Polyclonal antisera to either << b5R >> or cyt b5 significantly inhibited [[ N-hydroxy-4-aminobiphenyl ]] (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).","Polyclonal antisera to either [ENTITY_A] or cyt b5 significantly inhibited [ENTITY_B] (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).",SUBSTRATE,CPR:9,4,"Polyclonal antisera to either b5R or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)."
"Clinical effects of << pranlukast >>, an oral [[ leukotriene receptor ]] antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial.","Clinical effects of [ENTITY_A], an oral [ENTITY_B] antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial.",ANTAGONIST,CPR:6,3,"Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial."
"<< Pranlukast >> is a new, orally active, selective inhibitor of [[ CysLt1 ]] leukotriene receptor.","[ENTITY_A] is a new, orally active, selective inhibitor of [ENTITY_B] leukotriene receptor.",INHIBITOR,CPR:4,1,"Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor."
"We used mutagenesis of these residues, combined with an investigation of << hERG >> block by close analogs of [[ clofilium ]] and ibutilide, to assess how specific alterations in drug structure affected potency and binding interactions.","We used mutagenesis of these residues, combined with an investigation of [ENTITY_A] block by close analogs of [ENTITY_B] and ibutilide, to assess how specific alterations in drug structure affected potency and binding interactions.",INHIBITOR,CPR:4,1,"We used mutagenesis of these residues, combined with an investigation of hERG block by close analogs of clofilium and ibutilide, to assess how specific alterations in drug structure affected potency and binding interactions."
"<< Parathion >> is a [[ cholinesterase ]] inhibitor that induces the hydrolysis of body choline esters, including acetylcholine at cholinergic synapses.","[ENTITY_A] is a [ENTITY_B] inhibitor that induces the hydrolysis of body choline esters, including acetylcholine at cholinergic synapses.",INHIBITOR,CPR:4,1,"Parathion is a cholinesterase inhibitor that induces the hydrolysis of body choline esters, including acetylcholine at cholinergic synapses."
"There was also an increase in << c-kit >>, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the [[ parathion ]]-treated cells.","There was also an increase in [ENTITY_A], Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the [ENTITY_B]-treated cells.",INDIRECT-UPREGULATOR,CPR:3,0,"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the parathion-treated cells."
<< N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase >> (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the [[ mannose 6-phosphate ]] determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.,[ENTITY_A] (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the [ENTITY_B] determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.,PRODUCT-OF,CPR:9,4,N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.
The purified << phosphodiester alpha-GlcNAcase >> has a specific activity of 498 micromol of [[ [3H]GlcNAc-alpha-phosphomannose-alpha-methyl ]] cleaved per h per mg of protein using 0.5 mM [3H]GlcNAc-alpha-phosphomannose-alpha-methyl as substrate.,The purified [ENTITY_A] has a specific activity of 498 micromol of [ENTITY_B] cleaved per h per mg of protein using 0.5 mM [3H]GlcNAc-alpha-phosphomannose-alpha-methyl as substrate.,SUBSTRATE,CPR:9,4,The purified phosphodiester alpha-GlcNAcase has a specific activity of 498 micromol of [3H]GlcNAc-alpha-phosphomannose-alpha-methyl cleaved per h per mg of protein using 0.5 mM [3H]GlcNAc-alpha-phosphomannose-alpha-methyl as substrate.
"In the in vitro assay, << kinsenoside >> (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), [[ lactic dehydrogenase ]] (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","In the in vitro assay, [ENTITY_A] (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), [ENTITY_B] (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system."
The vascular protective effects of << kinsenoside >> were speculated to be attributed to oxidative stress inhibition and the reduction of [[ nuclear factor kappa B ]] (NF-κB) mRNA expression levels in high glucose conditions.,The vascular protective effects of [ENTITY_A] were speculated to be attributed to oxidative stress inhibition and the reduction of [ENTITY_B] (NF-κB) mRNA expression levels in high glucose conditions.,INDIRECT-DOWNREGULATOR,CPR:4,1,The vascular protective effects of kinsenoside were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (NF-κB) mRNA expression levels in high glucose conditions.
"<< Tolbutamide >> and gliclazide block the K(ATP) channel K(ir)6.2/Sur1, causing membrane depolarization and stimulating [[ insulin ]] secretion in pancreatic beta cells.","[ENTITY_A] and gliclazide block the K(ATP) channel K(ir)6.2/Sur1, causing membrane depolarization and stimulating [ENTITY_B] secretion in pancreatic beta cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Tolbutamide and gliclazide block the K(ATP) channel K(ir)6.2/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells."
"<< Tolbutamide >> and gliclazide block the [[ K(ATP) channel ]] K(ir)6.2/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells.","[ENTITY_A] and gliclazide block the [ENTITY_B] K(ir)6.2/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells.",INHIBITOR,CPR:4,1,"Tolbutamide and gliclazide block the K(ATP) channel K(ir)6.2/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells."
"<< Insulin >> secretion stimulated by both 200 μM [[ tolbutamide ]] and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the L-type Ca(2+) channel blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells.","[ENTITY_A] secretion stimulated by both 200 μM [ENTITY_B] and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the L-type Ca(2+) channel blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Insulin secretion stimulated by both 200 μM tolbutamide and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the L-type Ca(2+) channel blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells."
"<< Insulin >> secretion stimulated by both 200 μM tolbutamide and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by [[ thapsigargin ]] (1 μM) or the L-type Ca(2+) channel blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells.","[ENTITY_A] secretion stimulated by both 200 μM tolbutamide and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by [ENTITY_B] (1 μM) or the L-type Ca(2+) channel blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Insulin secretion stimulated by both 200 μM tolbutamide and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the L-type Ca(2+) channel blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells."
"Both << tolbutamide >> and gliclazide stimulated [[ phospholipase C ]] activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin.","Both [ENTITY_A] and gliclazide stimulated [ENTITY_B] activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin.",ACTIVATOR,CPR:3,0,"Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin."
8-pCPT-2'-O-Me-cAMP-AM potentiation of << insulin >> secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor [[ bisindolylmaleimide I ]] (1 μM).,8-pCPT-2'-O-Me-cAMP-AM potentiation of [ENTITY_A] secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor [ENTITY_B] (1 μM).,INDIRECT-UPREGULATOR,CPR:3,0,8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM).
8-pCPT-2'-O-Me-cAMP-AM potentiation of << insulin >> secretion stimulated by tolbutamide was markedly inhibited by [[ 2-APB ]] (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM).,8-pCPT-2'-O-Me-cAMP-AM potentiation of [ENTITY_A] secretion stimulated by tolbutamide was markedly inhibited by [ENTITY_B] (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM).,INDIRECT-DOWNREGULATOR,CPR:4,1,8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM).
"Our data demonstrate that the actions of both tolbutamide and gliclazide are strongly potentiated by 8-pCPT-2'-O-Me-cAMP-AM, that << gliclazide >> can stimulate [[ phospholipase C ]] activity via a partially pertussis toxin-sensitive mechanism, and that 8-pCPT-2'-O-Me-cAMP-AM potentiation of tolbutamide action may involve activation of a 2-APB-sensitive Ca(2+) influx.","Our data demonstrate that the actions of both tolbutamide and gliclazide are strongly potentiated by 8-pCPT-2'-O-Me-cAMP-AM, that [ENTITY_A] can stimulate [ENTITY_B] activity via a partially pertussis toxin-sensitive mechanism, and that 8-pCPT-2'-O-Me-cAMP-AM potentiation of tolbutamide action may involve activation of a 2-APB-sensitive Ca(2+) influx.",ACTIVATOR,CPR:3,0,"Our data demonstrate that the actions of both tolbutamide and gliclazide are strongly potentiated by 8-pCPT-2'-O-Me-cAMP-AM, that gliclazide can stimulate phospholipase C activity via a partially pertussis toxin-sensitive mechanism, and that 8-pCPT-2'-O-Me-cAMP-AM potentiation of tolbutamide action may involve activation of a 2-APB-sensitive Ca(2+) influx."
"Phosphorylation of << AMPK >> at Thr172 increased by 1.4-fold within 5 min, and remained elevated throughout a 30-min time course, in response to [[ 2-deoxyglucose ]].","Phosphorylation of [ENTITY_A] at Thr172 increased by 1.4-fold within 5 min, and remained elevated throughout a 30-min time course, in response to [ENTITY_B].",ACTIVATOR,CPR:3,0,"Phosphorylation of AMPK at Thr172 increased by 1.4-fold within 5 min, and remained elevated throughout a 30-min time course, in response to 2-deoxyglucose."
Phosphorylation of ER-stress marker << eIF2α >> was also increased but only at 30 min of [[ 2-deoxyglucose ]] exposure.,Phosphorylation of ER-stress marker [ENTITY_A] was also increased but only at 30 min of [ENTITY_B] exposure.,ACTIVATOR,CPR:3,0,Phosphorylation of ER-stress marker eIF2α was also increased but only at 30 min of 2-deoxyglucose exposure.
<< 2-Deoxyglucose >> increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to [[ TSC2 ]].,[ENTITY_A] increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to [ENTITY_B].,ACTIVATOR,CPR:3,0,2-Deoxyglucose increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2.
<< Conivaptan >>: a dual [[ vasopressin receptor v1a/v2 ]] antagonist [corrected].,[ENTITY_A]: a dual [ENTITY_B] antagonist [corrected].,ANTAGONIST,CPR:6,3,Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
<< Conivaptan >> is a nonpeptide dual [[ V1a/V2 AVP receptor ]] antagonist.,[ENTITY_A] is a nonpeptide dual [ENTITY_B] antagonist.,ANTAGONIST,CPR:6,3,Conivaptan is a nonpeptide dual V1a/V2 AVP receptor antagonist.
"<< H1-receptor >> antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which histamine is considered to be of pathogenic importance and conversely to help elucidate the role of [[ histamine ]] in disease, through an evaluation of their influence on disease expression.","[ENTITY_A] antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which histamine is considered to be of pathogenic importance and conversely to help elucidate the role of [ENTITY_B] in disease, through an evaluation of their influence on disease expression.",AGONIST,CPR:5,2,"H1-receptor antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which histamine is considered to be of pathogenic importance and conversely to help elucidate the role of histamine in disease, through an evaluation of their influence on disease expression."
"While there is considerable indirect evidence to implicate << histamine >> in the pathogenesis of asthma, a critical evaluation of [[ H1-receptor ]] antagonism in this condition has, until recently, proved difficult, as many of the early H1-receptor antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity.","While there is considerable indirect evidence to implicate [ENTITY_A] in the pathogenesis of asthma, a critical evaluation of [ENTITY_B] antagonism in this condition has, until recently, proved difficult, as many of the early H1-receptor antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity.",AGONIST,CPR:5,2,"While there is considerable indirect evidence to implicate histamine in the pathogenesis of asthma, a critical evaluation of H1-receptor antagonism in this condition has, until recently, proved difficult, as many of the early H1-receptor antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity."
"The recent development of << H1-receptor >> antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of H1-receptor blockade within the airways, thus permitting a better appraisal of the role of [[ histamine ]] in this condition.","The recent development of [ENTITY_A] antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of H1-receptor blockade within the airways, thus permitting a better appraisal of the role of [ENTITY_B] in this condition.",AGONIST,CPR:5,2,"The recent development of H1-receptor antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of H1-receptor blockade within the airways, thus permitting a better appraisal of the role of histamine in this condition."
<< Cholesterol esterase >> (CE) induced surface erosion of poly(ethylene carbonate) ([[ PEC ]]) and drug release from PEC under mild physiological environment was investigated.,[ENTITY_A] (CE) induced surface erosion of poly(ethylene carbonate) ([ENTITY_B]) and drug release from PEC under mild physiological environment was investigated.,SUBSTRATE,CPR:9,4,Cholesterol esterase (CE) induced surface erosion of poly(ethylene carbonate) (PEC) and drug release from PEC under mild physiological environment was investigated.
"Intravenous << arginine >> significantly increased the acute [[ glucagon ]] response (129 +/- 12 vs 36 +/- 6 ng/l in controls; p < 0.01), notably without affecting plasma glucose.","Intravenous [ENTITY_A] significantly increased the acute [ENTITY_B] response (129 +/- 12 vs 36 +/- 6 ng/l in controls; p < 0.01), notably without affecting plasma glucose.",INDIRECT-UPREGULATOR,CPR:3,0,"Intravenous arginine significantly increased the acute glucagon response (129 +/- 12 vs 36 +/- 6 ng/l in controls; p < 0.01), notably without affecting plasma glucose."
"Isolated islets displayed improved << glucose >>-stimulated [[ insulin ]] secretion after GRA treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), without affecting islet glucose oxidation.","Isolated islets displayed improved [ENTITY_A]-stimulated [ENTITY_B] secretion after GRA treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), without affecting islet glucose oxidation.",INDIRECT-UPREGULATOR,CPR:3,0,"Isolated islets displayed improved glucose-stimulated insulin secretion after GRA treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), without affecting islet glucose oxidation."
"<< PIP5K1B >> encodes phosphatidylinositol 4-phosphate 5-kinase β type I (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate [[ phosphatidylinositol-4,5-bisphosphate ]] [PI(4,5)P2].","[ENTITY_A] encodes phosphatidylinositol 4-phosphate 5-kinase β type I (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate [ENTITY_B] [PI(4,5)P2].",PRODUCT-OF,CPR:9,4,"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase β type I (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]."
"Accordingly, loss of << pip5k1β >> function in FRDA cells was accompanied by decreased [[ PI(4,5)P2 ]] levels and was shown instrumental for destabilization of the actin network and delayed cell spreading.","Accordingly, loss of [ENTITY_A] function in FRDA cells was accompanied by decreased [ENTITY_B] levels and was shown instrumental for destabilization of the actin network and delayed cell spreading.",PRODUCT-OF,CPR:9,4,"Accordingly, loss of pip5k1β function in FRDA cells was accompanied by decreased PI(4,5)P2 levels and was shown instrumental for destabilization of the actin network and delayed cell spreading."
The expression of << regucalcin >> is stimulated through the action of insulin in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by [[ streptozotocin ]] administration in vivo.,The expression of [ENTITY_A] is stimulated through the action of insulin in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by [ENTITY_B] administration in vivo.,INDIRECT-DOWNREGULATOR,CPR:4,1,The expression of regucalcin is stimulated through the action of insulin in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by streptozotocin administration in vivo.
"<< AMPK >> activators [[ metformin ]] and AICAR partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C.","[ENTITY_A] activators [ENTITY_B] and AICAR partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C.",ACTIVATOR,CPR:3,0,"AMPK activators metformin and AICAR partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C."
"<< Indomethacin >> treatment led to an increase in lipid peroxidation, [[ glutathione peroxidase ]] and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa.","[ENTITY_A] treatment led to an increase in lipid peroxidation, [ENTITY_B] and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa.",ACTIVATOR,CPR:3,0,"Indomethacin treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa."
"<< Indomethacin >> treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in [[ catalase ]] activity and glutathione levels in gastric mucosa.","[ENTITY_A] treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in [ENTITY_B] activity and glutathione levels in gastric mucosa.",INHIBITOR,CPR:4,1,"Indomethacin treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa."
Reversible inhibition of << human carboxylesterases >> by [[ acyl glucuronides ]].,Reversible inhibition of [ENTITY_A] by [ENTITY_B].,INHIBITOR,CPR:4,1,Reversible inhibition of human carboxylesterases by acyl glucuronides.
"<< Carboxylesterases >> hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting [[ alcohols ]], amines, and thiols, respectively.","[ENTITY_A] hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting [ENTITY_B], amines, and thiols, respectively.",PRODUCT-OF,CPR:9,4,"Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively."
"<< Uridine 5'-diphosphate- glucuronosyltransferases >> are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to [[ acyl glucuronides ]], but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.","[ENTITY_A] are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to [ENTITY_B], but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.",PRODUCT-OF,CPR:9,4,"Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases."
Objective: This study explores the ability of << acyl glucuronides >> to act as substrates or inhibitors of [[ human carboxylesterases 1 ]] (hCES1) and 2 (hCES2).,Objective: This study explores the ability of [ENTITY_A] to act as substrates or inhibitors of [ENTITY_B] (hCES1) and 2 (hCES2).,INHIBITOR,CPR:4,1,Objective: This study explores the ability of acyl glucuronides to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (hCES2).
Objective: This study explores the ability of << acyl glucuronides >> to act as substrates or inhibitors of [[ human carboxylesterases 1 ]] (hCES1) and 2 (hCES2).,Objective: This study explores the ability of [ENTITY_A] to act as substrates or inhibitors of [ENTITY_B] (hCES1) and 2 (hCES2).,SUBSTRATE,CPR:9,4,Objective: This study explores the ability of acyl glucuronides to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (hCES2).
"Methods: The stability of six << acyl glucuronides >> in the presence of [[ hCES1 ]], hCES2, and buffer alone (100 mM potassium phosphate, pH 7.4, 37°C) were investigated.","Methods: The stability of six [ENTITY_A] in the presence of [ENTITY_B], hCES2, and buffer alone (100 mM potassium phosphate, pH 7.4, 37°C) were investigated.",SUBSTRATE,CPR:9,4,"Methods: The stability of six acyl glucuronides in the presence of hCES1, hCES2, and buffer alone (100 mM potassium phosphate, pH 7.4, 37°C) were investigated."
"Diclofenac-β-d-glucuronide, << clopidogrel-β-d-glucuronide >>, ibuprofen-β-d-glucuronide, (R)-naproxen-β-d-glucuronide, and (S)-naproxen-β-d-glucuronide selectively inhibited [[ hCES1 ]], with Ki values of 4.32 ± 0.47, 24.8 ± 4.2, 355 ± 38, 468 ± 21, 707 ± 64 µM, respectively, but did not significantly inhibit hCES2.","Diclofenac-β-d-glucuronide, [ENTITY_A], ibuprofen-β-d-glucuronide, (R)-naproxen-β-d-glucuronide, and (S)-naproxen-β-d-glucuronide selectively inhibited [ENTITY_B], with Ki values of 4.32 ± 0.47, 24.8 ± 4.2, 355 ± 38, 468 ± 21, 707 ± 64 µM, respectively, but did not significantly inhibit hCES2.",INHIBITOR,CPR:4,1,"Diclofenac-β-d-glucuronide, clopidogrel-β-d-glucuronide, ibuprofen-β-d-glucuronide, (R)-naproxen-β-d-glucuronide, and (S)-naproxen-β-d-glucuronide selectively inhibited hCES1, with Ki values of 4.32 ± 0.47, 24.8 ± 4.2, 355 ± 38, 468 ± 21, 707 ± 64 µM, respectively, but did not significantly inhibit hCES2."
Conclusion: Drug-drug interaction studies may be warranted for drugs that metabolize to << acyl glucuronides >> due to the potential inhibition of [[ hCESs ]].,Conclusion: Drug-drug interaction studies may be warranted for drugs that metabolize to [ENTITY_A] due to the potential inhibition of [ENTITY_B].,INHIBITOR,CPR:4,1,Conclusion: Drug-drug interaction studies may be warranted for drugs that metabolize to acyl glucuronides due to the potential inhibition of hCESs.
"Furthermore, << DOX >>-treated WT and p65(-/-) MEFs differed in their expression of various apoptosis-associated molecules, when the former demonstrated a decrease in the percentage of [[ p65 ]]-positive and a more prominent decrease in the percentage of p53-positive cells, while a decreased percentage of IκBα-positive and a more prominent decrease in the percentage of bcl-2-positive cells was detected among the latter.","Furthermore, [ENTITY_A]-treated WT and p65(-/-) MEFs differed in their expression of various apoptosis-associated molecules, when the former demonstrated a decrease in the percentage of [ENTITY_B]-positive and a more prominent decrease in the percentage of p53-positive cells, while a decreased percentage of IκBα-positive and a more prominent decrease in the percentage of bcl-2-positive cells was detected among the latter.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, DOX-treated WT and p65(-/-) MEFs differed in their expression of various apoptosis-associated molecules, when the former demonstrated a decrease in the percentage of p65-positive and a more prominent decrease in the percentage of p53-positive cells, while a decreased percentage of IκBα-positive and a more prominent decrease in the percentage of bcl-2-positive cells was detected among the latter."
RESULTS: << DZN >> induced histophatological damages and elevated the level of cardiac marker [[ CK-MB ]].,RESULTS: [ENTITY_A] induced histophatological damages and elevated the level of cardiac marker [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,RESULTS: DZN induced histophatological damages and elevated the level of cardiac marker CK-MB.
"Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of << caspase 3 >> and release of cytochrome c to the cytosol induced by [[ DZN ]].","Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of [ENTITY_A] and release of cytochrome c to the cytosol induced by [ENTITY_B].",ACTIVATOR,CPR:3,0,"Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN."
"<< Crocin >> (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of [[ cytochrome c ]] to the cytosol induced by DZN.","[ENTITY_A] (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of [ENTITY_B] to the cytosol induced by DZN.",DOWNREGULATOR,CPR:4,1,"Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN."
Effect of << fenoterol >>-induced constitutive [[ beta(2)-adrenoceptor ]] activity on contractile receptor function in airway smooth muscle.,Effect of [ENTITY_A]-induced constitutive [ENTITY_B] activity on contractile receptor function in airway smooth muscle.,ACTIVATOR,CPR:3,0,Effect of fenoterol-induced constitutive beta(2)-adrenoceptor activity on contractile receptor function in airway smooth muscle.
"In the present study, we investigated the effect of << fenoterol >>-induced constitutive [[ beta(2)-adrenoceptor ]] activity on muscarinic receptor agonist- and histamine-induced bovine tracheal smooth muscle contractions.","In the present study, we investigated the effect of [ENTITY_A]-induced constitutive [ENTITY_B] activity on muscarinic receptor agonist- and histamine-induced bovine tracheal smooth muscle contractions.",ACTIVATOR,CPR:3,0,"In the present study, we investigated the effect of fenoterol-induced constitutive beta(2)-adrenoceptor activity on muscarinic receptor agonist- and histamine-induced bovine tracheal smooth muscle contractions."
"After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial << muscarinic receptor >> agonist [[ 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium ]] (McN-A-343) and histamine.","After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial [ENTITY_A] agonist [ENTITY_B] (McN-A-343) and histamine.",AGONIST,CPR:5,2,"After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine."
"In conclusion, << fenoterol >>-induced constitutive [[ beta(2)-adrenoceptor ]] activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist timolol.","In conclusion, [ENTITY_A]-induced constitutive [ENTITY_B] activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist timolol.",ACTIVATOR,CPR:3,0,"In conclusion, fenoterol-induced constitutive beta(2)-adrenoceptor activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist timolol."
"In conclusion, fenoterol-induced constitutive << beta(2)-adrenoceptor >> activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist [[ timolol ]].","In conclusion, fenoterol-induced constitutive [ENTITY_A] activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist [ENTITY_B].",AGONIST-INHIBITOR,CPR:5,2,"In conclusion, fenoterol-induced constitutive beta(2)-adrenoceptor activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist timolol."
<< Beta-glucogallin >> reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of [[ aldose reductase ]] in murine macrophages and ocular tissues.,[ENTITY_A] reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of [ENTITY_B] in murine macrophages and ocular tissues.,INHIBITOR,CPR:4,1,Beta-glucogallin reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of aldose reductase in murine macrophages and ocular tissues.
<< Aldose reductase >> (AR) catalyzes the reduction of toxic lipid aldehydes to their [[ alcohol ]] products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).,[ENTITY_A] (AR) catalyzes the reduction of toxic lipid aldehydes to their [ENTITY_B] products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).,PRODUCT-OF,CPR:9,4,Aldose reductase (AR) catalyzes the reduction of toxic lipid aldehydes to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).
"<< Beta-glucogallin >> (BGG), a recently described [[ AR ]] inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis).","[ENTITY_A] (BGG), a recently described [ENTITY_B] inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis).",INHIBITOR,CPR:4,1,"Beta-glucogallin (BGG), a recently described AR inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis)."
"In this study, we found that << BGG >> showed low cytotoxicity in Raw264.7 murine macrophages and effectively inhibited [[ AR ]] activity as measured by a decrease in sorbitol accumulation.","In this study, we found that [ENTITY_A] showed low cytotoxicity in Raw264.7 murine macrophages and effectively inhibited [ENTITY_B] activity as measured by a decrease in sorbitol accumulation.",INHIBITOR,CPR:4,1,"In this study, we found that BGG showed low cytotoxicity in Raw264.7 murine macrophages and effectively inhibited AR activity as measured by a decrease in sorbitol accumulation."
"In addition, << BGG >>-mediated inhibition of AR prevented LPS-induced activation of [[ JNK ]] and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis.","In addition, [ENTITY_A]-mediated inhibition of AR prevented LPS-induced activation of [ENTITY_B] and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, BGG-mediated inhibition of AR prevented LPS-induced activation of JNK and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis."
Exogenous << C2-ceramide >> activates [[ c-fos serum response element ]] via Rac-dependent signalling pathway.,Exogenous [ENTITY_A] activates [ENTITY_B] via Rac-dependent signalling pathway.,ACTIVATOR,CPR:3,0,Exogenous C2-ceramide activates c-fos serum response element via Rac-dependent signalling pathway.
Treatment of Rat-2 fibroblast cells with << C2-ceramide >> caused the stimulation of [[ c-fos SRE ]]-dependent reporter gene activity in a dose- and time-dependent manner by transient transfection analysis.,Treatment of Rat-2 fibroblast cells with [ENTITY_A] caused the stimulation of [ENTITY_B]-dependent reporter gene activity in a dose- and time-dependent manner by transient transfection analysis.,ACTIVATOR,CPR:3,0,Treatment of Rat-2 fibroblast cells with C2-ceramide caused the stimulation of c-fos SRE-dependent reporter gene activity in a dose- and time-dependent manner by transient transfection analysis.
"Next, we examined the role of Rho family GTPases in the << ceramide >>-induced signalling to [[ SRE ]] activation.","Next, we examined the role of Rho family GTPases in the [ENTITY_A]-induced signalling to [ENTITY_B] activation.",ACTIVATOR,CPR:3,0,"Next, we examined the role of Rho family GTPases in the ceramide-induced signalling to SRE activation."
"By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA, << C2-ceramide >>-induced [[ SRE ]] activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus.","By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA, [ENTITY_A]-induced [ENTITY_B] activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus.",ACTIVATOR,CPR:3,0,"By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA, C2-ceramide-induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus."
"In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the << C2-ceramide >>-induced [[ SRE ]] activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus.","In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the [ENTITY_A]-induced [ENTITY_B] activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus.",ACTIVATOR,CPR:3,0,"In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus."
"Consistent with these results, the translocation of cPLA2 protein as well as the release of << arachidonic acid >>, a principal product of [[ phospholipase A2 ]], was rapidly induced by the addition of C2-ceramide in a Rac-dependent manner.","Consistent with these results, the translocation of cPLA2 protein as well as the release of [ENTITY_A], a principal product of [ENTITY_B], was rapidly induced by the addition of C2-ceramide in a Rac-dependent manner.",PRODUCT-OF,CPR:9,4,"Consistent with these results, the translocation of cPLA2 protein as well as the release of arachidonic acid, a principal product of phospholipase A2, was rapidly induced by the addition of C2-ceramide in a Rac-dependent manner."
"Together, our findings suggest the critical role of 'Rac and subsequent activation of << phospholipase A2 >>' in [[ ceramide ]]-signalling to nucleus.","Together, our findings suggest the critical role of 'Rac and subsequent activation of [ENTITY_A]' in [ENTITY_B]-signalling to nucleus.",ACTIVATOR,CPR:3,0,"Together, our findings suggest the critical role of 'Rac and subsequent activation of phospholipase A2' in ceramide-signalling to nucleus."
"Effect of << ramelteon >> (TAK-375), a selective [[ MT1/MT2 receptor ]] agonist, on motor performance in mice.","Effect of [ENTITY_A] (TAK-375), a selective [ENTITY_B] agonist, on motor performance in mice.",AGONIST,CPR:5,2,"Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice."
"Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (<< ramelteon >>, TAK-375), a selective [[ MT1/MT2 receptor ]] agonist, on motor coordination was studied using rota-rod performance in mice.","Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide ([ENTITY_A], TAK-375), a selective [ENTITY_B] agonist, on motor coordination was studied using rota-rod performance in mice.",AGONIST,CPR:5,2,"Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (ramelteon, TAK-375), a selective MT1/MT2 receptor agonist, on motor coordination was studied using rota-rod performance in mice."
"Synthesis and cancer stem cell-based activity of substituted << 5-morpholino-7H-thieno[3,2-b]pyran-7-ones >> designed as next generation [[ PI3K ]] inhibitors.",Synthesis and cancer stem cell-based activity of substituted [ENTITY_A] designed as next generation [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,"Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors."
"Our previous work, built on the early pioneering multikinase inhibitor << LY294002 >>, resulted in the only [[ PI3K ]] vascular-targeted PI3K inhibitor prodrug, SF1126, which has now completed Phase I clinical trials.","Our previous work, built on the early pioneering multikinase inhibitor [ENTITY_A], resulted in the only [ENTITY_B] vascular-targeted PI3K inhibitor prodrug, SF1126, which has now completed Phase I clinical trials.",INHIBITOR,CPR:4,1,"Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only PI3K vascular-targeted PI3K inhibitor prodrug, SF1126, which has now completed Phase I clinical trials."
"This work resulted in the discovery of the << 5-morpholino-7H-thieno[3,2-b]pyran-7-one >> system as the foundation of a new compound class of potential [[ PI3K ]] inhibitors having improved potency toward PI3K.",This work resulted in the discovery of the [ENTITY_A] system as the foundation of a new compound class of potential [ENTITY_B] inhibitors having improved potency toward PI3K.,INHIBITOR,CPR:4,1,"This work resulted in the discovery of the 5-morpholino-7H-thieno[3,2-b]pyran-7-one system as the foundation of a new compound class of potential PI3K inhibitors having improved potency toward PI3K."
"<< CP-690550 >>, a [[ JAK3 ]] inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials.","[ENTITY_A], a [ENTITY_B] inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials.",INHIBITOR,CPR:4,1,"CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials."
"Firstly, the V(max) of << GAD >> was increased when ApoCaM was present whereas the affinity for the substrate, [[ glutamate ]], was not affected.","Firstly, the V(max) of [ENTITY_A] was increased when ApoCaM was present whereas the affinity for the substrate, [ENTITY_B], was not affected.",SUBSTRATE,CPR:9,4,"Firstly, the V(max) of GAD was increased when ApoCaM was present whereas the affinity for the substrate, glutamate, was not affected."
Hydrogen sulphide (<< H(2)S >>) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase ([[ CSE ]]) and cystathionine-beta-synthase (CBS).,Hydrogen sulphide ([ENTITY_A]) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase ([ENTITY_B]) and cystathionine-beta-synthase (CBS).,PRODUCT-OF,CPR:9,4,Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS).
"In this study, we investigated the presence of H(2)S and the expression of << H(2)S >> synthesizing enzymes, [[ CSE ]] and CBS, in isolated mouse pancreatic acini.","In this study, we investigated the presence of H(2)S and the expression of [ENTITY_A] synthesizing enzymes, [ENTITY_B] and CBS, in isolated mouse pancreatic acini.",PRODUCT-OF,CPR:9,4,"In this study, we investigated the presence of H(2)S and the expression of H(2)S synthesizing enzymes, CSE and CBS, in isolated mouse pancreatic acini."
<< Caerulein >> increased the levels of H(2)S and [[ CSE ]] mRNA expression while CBS mRNA expression was decreased.,[ENTITY_A] increased the levels of H(2)S and [ENTITY_B] mRNA expression while CBS mRNA expression was decreased.,INDIRECT-UPREGULATOR,CPR:3,0,Caerulein increased the levels of H(2)S and CSE mRNA expression while CBS mRNA expression was decreased.
<< Caerulein >> increased the levels of H(2)S and CSE mRNA expression while [[ CBS ]] mRNA expression was decreased.,[ENTITY_A] increased the levels of H(2)S and CSE mRNA expression while [ENTITY_B] mRNA expression was decreased.,INDIRECT-DOWNREGULATOR,CPR:4,1,Caerulein increased the levels of H(2)S and CSE mRNA expression while CBS mRNA expression was decreased.
"In addition, cells pre-treated with << DL-propargylglycine >> (PAG, 3 mM), a [[ CSE ]] inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells.","In addition, cells pre-treated with [ENTITY_A] (PAG, 3 mM), a [ENTITY_B] inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells.",INHIBITOR,CPR:4,1,"In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells."
"In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that << CSE >> may be the main enzyme involved in [[ H(2)S ]] formation in mouse acinar cells.","In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that [ENTITY_A] may be the main enzyme involved in [ENTITY_B] formation in mouse acinar cells.",PRODUCT-OF,CPR:9,4,"In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells."
"Furthermore, << substance P >> (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue [[ caerulein ]]-treated acinar cells.","Furthermore, [ENTITY_A] (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue [ENTITY_B]-treated acinar cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells."
"Inhibition of endogenous production of << H(2)S >> by PAG significantly suppressed [[ SP ]] concentration, PPT-A expression and NK1-R expression in the acini.","Inhibition of endogenous production of [ENTITY_A] by PAG significantly suppressed [ENTITY_B] concentration, PPT-A expression and NK1-R expression in the acini.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Inhibition of endogenous production of H(2)S by PAG significantly suppressed SP concentration, PPT-A expression and NK1-R expression in the acini."
"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, << sodium hydrosulphide >> (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in [[ SP ]] concentration and expression of PPT-A and NK1-R in acinar cells.","To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, [ENTITY_A] (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in [ENTITY_B] concentration and expression of PPT-A and NK1-R in acinar cells.",INDIRECT-UPREGULATOR,CPR:3,0,"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and NK1-R in acinar cells."
These results suggest that the pro-inflammatory effect of << H(2)S >> may be mediated by [[ SP ]]-NK-1R related pathway in mouse pancreatic acinar cells.,These results suggest that the pro-inflammatory effect of [ENTITY_A] may be mediated by [ENTITY_B]-NK-1R related pathway in mouse pancreatic acinar cells.,PRODUCT-OF,CPR:9,4,These results suggest that the pro-inflammatory effect of H(2)S may be mediated by SP-NK-1R related pathway in mouse pancreatic acinar cells.
"The results showed that administration of << AlCl3 >> resulted in a significant elevation in the levels of AchE activity, [[ CRP ]], NF-κB, and MCP-1 accompanied with a significant depletion in the Ach level.","The results showed that administration of [ENTITY_A] resulted in a significant elevation in the levels of AchE activity, [ENTITY_B], NF-κB, and MCP-1 accompanied with a significant depletion in the Ach level.",INDIRECT-UPREGULATOR,CPR:3,0,"The results showed that administration of AlCl3 resulted in a significant elevation in the levels of AchE activity, CRP, NF-κB, and MCP-1 accompanied with a significant depletion in the Ach level."
"6-DHSG was metabolised by GSH to form a GSH conjugate (<< GS-6-DHSG >>) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of [[ glutathione-S-transferase ]] (GST).","6-DHSG was metabolised by GSH to form a GSH conjugate ([ENTITY_A]) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of [ENTITY_B] (GST).",PRODUCT-OF,CPR:9,4,"6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase (GST)."
"The concentration response to << levcromakalim >> (LEVC), a [[ K(ATP) channel ]] opener, was significantly shifted to the left in the inflamed smooth-muscle cells.","The concentration response to [ENTITY_A] (LEVC), a [ENTITY_B] opener, was significantly shifted to the left in the inflamed smooth-muscle cells.",ACTIVATOR,CPR:3,0,"The concentration response to levcromakalim (LEVC), a K(ATP) channel opener, was significantly shifted to the left in the inflamed smooth-muscle cells."
Sulfhydration of << sulfonylurea receptor 2B >> (SUR2B) was induced by [[ NaHS ]] and colonic inflammation.,Sulfhydration of [ENTITY_A] (SUR2B) was induced by [ENTITY_B] and colonic inflammation.,ACTIVATOR,CPR:3,0,Sulfhydration of sulfonylurea receptor 2B (SUR2B) was induced by NaHS and colonic inflammation.
"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., << sotalol >> or ibutilide in patients with a mutation in the [[ IKr ]]-coding gene KCNH2 (HERG).","Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., [ENTITY_A] or ibutilide in patients with a mutation in the [ENTITY_B]-coding gene KCNH2 (HERG).",INHIBITOR,CPR:4,1,"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or ibutilide in patients with a mutation in the IKr-coding gene KCNH2 (HERG)."
"Although inhibition of << LH >> release can be achieved by [[ estrogen ]] and progestins, an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an LHRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the LH responsiveness to LHRH.","Although inhibition of [ENTITY_A] release can be achieved by [ENTITY_B] and progestins, an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an LHRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the LH responsiveness to LHRH.",INHIBITOR,CPR:4,1,"Although inhibition of LH release can be achieved by estrogen and progestins, an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an LHRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the LH responsiveness to LHRH."
Mechanisms of << cefadroxil >> uptake in the choroid plexus: studies in wild-type and [[ PEPT2 ]] knockout mice.,Mechanisms of [ENTITY_A] uptake in the choroid plexus: studies in wild-type and [ENTITY_B] knockout mice.,SUBSTRATE,CPR:9,4,Mechanisms of cefadroxil uptake in the choroid plexus: studies in wild-type and PEPT2 knockout mice.
"The choroid plexus uptake of << [(3)H]cefadroxil >> was studied in [[ peptide transporter 2 ]] (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability.","The choroid plexus uptake of [ENTITY_A] was studied in [ENTITY_B] (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability.",SUBSTRATE,CPR:9,4,"The choroid plexus uptake of [(3)H]cefadroxil was studied in peptide transporter 2 (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability."
"At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM << cefadroxil >> was reduced by 83% in [[ PEPT2 ]](-/-) mice as compared with PEPT2(+/+) mice (p < 0.001).","At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM [ENTITY_A] was reduced by 83% in [ENTITY_B](-/-) mice as compared with PEPT2(+/+) mice (p < 0.001).",SUBSTRATE,CPR:9,4,"At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM cefadroxil was reduced by 83% in PEPT2(-/-) mice as compared with PEPT2(+/+) mice (p < 0.001)."
Glycylsarcosine coadministration could inhibit the uptake of << cefadroxil >> in [[ PEPT2 ]](+/+) mice (p < 0.01) but not PEPT2(-/-) mice.,Glycylsarcosine coadministration could inhibit the uptake of [ENTITY_A] in [ENTITY_B](+/+) mice (p < 0.01) but not PEPT2(-/-) mice.,SUBSTRATE,CPR:9,4,Glycylsarcosine coadministration could inhibit the uptake of cefadroxil in PEPT2(+/+) mice (p < 0.01) but not PEPT2(-/-) mice.
"Although a proton-stimulated uptake of << cefadroxil >> was demonstrated in [[ PEPT2 ]](+/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in PEPT2(-/-) mice.","Although a proton-stimulated uptake of [ENTITY_A] was demonstrated in [ENTITY_B](+/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in PEPT2(-/-) mice.",SUBSTRATE,CPR:9,4,"Although a proton-stimulated uptake of cefadroxil was demonstrated in PEPT2(+/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in PEPT2(-/-) mice."
These findings demonstrate that << PEPT2 >> is the primary transporter responsible for [[ cefadroxil ]] uptake in the choroid plexus.,These findings demonstrate that [ENTITY_A] is the primary transporter responsible for [ENTITY_B] uptake in the choroid plexus.,SUBSTRATE,CPR:9,4,These findings demonstrate that PEPT2 is the primary transporter responsible for cefadroxil uptake in the choroid plexus.
The effects of the << adenosine A3 receptor >> agonist [[ IB-MECA ]] on sodium taurocholate-induced experimental acute pancreatitis.,The effects of the [ENTITY_A] agonist [ENTITY_B] on sodium taurocholate-induced experimental acute pancreatitis.,AGONIST,CPR:5,2,The effects of the adenosine A3 receptor agonist IB-MECA on sodium taurocholate-induced experimental acute pancreatitis.
"The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the << adenosine A3 receptor >> agonist [[ IB-MECA ]] (1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75 mg/kg b.w.","The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the [ENTITY_A] agonist [ENTITY_B] (1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75 mg/kg b.w.",AGONIST,CPR:5,2,"The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the adenosine A3 receptor agonist IB-MECA (1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75 mg/kg b.w."
"In the << IB-MECA >> group, [[ α-amylase ]] activity was decreased with statistically high significance compared to group I.","In the [ENTITY_A] group, [ENTITY_B] activity was decreased with statistically high significance compared to group I.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In the IB-MECA group, α-amylase activity was decreased with statistically high significance compared to group I."
The use of << A3 receptor >> agonist [[ IB-MECA ]] attenuates EAP.,The use of [ENTITY_A] agonist [ENTITY_B] attenuates EAP.,AGONIST,CPR:5,2,The use of A3 receptor agonist IB-MECA attenuates EAP.
<< Pyrrolopyrazines >> as Selective [[ Spleen Tyrosine Kinase ]] Inhibitors.,[ENTITY_A] as Selective [ENTITY_B] Inhibitors.,INHIBITOR,CPR:4,1,Pyrrolopyrazines as Selective Spleen Tyrosine Kinase Inhibitors.
We describe the discovery of several << pyrrolopyrazines >> as potent and selective [[ Syk ]] inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies.,We describe the discovery of several [ENTITY_A] as potent and selective [ENTITY_B] inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies.,INHIBITOR,CPR:4,1,We describe the discovery of several pyrrolopyrazines as potent and selective Syk inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies.
"<< Ozone >> plus PM(2.5) exposure, however, induced [[ CRP ]], IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way.","[ENTITY_A] plus PM(2.5) exposure, however, induced [ENTITY_B], IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way.",INDIRECT-UPREGULATOR,CPR:3,0,"Ozone plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way."
"<< Ozone >> plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and MDA increase, [[ SOD ]] and HRV decrease significantly in a dose-response way.","[ENTITY_A] plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and MDA increase, [ENTITY_B] and HRV decrease significantly in a dose-response way.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Ozone plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way."
"<< Flavopiridol >>, a [[ cyclin-dependent kinase ]] inhibitor, arrests cell division and causes apoptosis in non-small lung cancer cells [283660].","[ENTITY_A], a [ENTITY_B] inhibitor, arrests cell division and causes apoptosis in non-small lung cancer cells [283660].",INHIBITOR,CPR:4,1,"Flavopiridol, a cyclin-dependent kinase inhibitor, arrests cell division and causes apoptosis in non-small lung cancer cells [283660]."
"In ex vivo experiments with tumor cells from refractory chronic lymphoblastic leukemia, dose-dependent << CDK2 >> inhibition associated with apoptotic changes was seen at concentrations greater than 100 nM of [[ flavopiridol ]].","In ex vivo experiments with tumor cells from refractory chronic lymphoblastic leukemia, dose-dependent [ENTITY_A] inhibition associated with apoptotic changes was seen at concentrations greater than 100 nM of [ENTITY_B].",INHIBITOR,CPR:4,1,"In ex vivo experiments with tumor cells from refractory chronic lymphoblastic leukemia, dose-dependent CDK2 inhibition associated with apoptotic changes was seen at concentrations greater than 100 nM of flavopiridol."
<< Flavopiridol >> inhibits [[ CDK ]] with an IC50 value of 0.4 mM [285707].,[ENTITY_A] inhibits [ENTITY_B] with an IC50 value of 0.4 mM [285707].,INHIBITOR,CPR:4,1,Flavopiridol inhibits CDK with an IC50 value of 0.4 mM [285707].
<< Carbonic anhydrase >> inhibitors: [[ aromatic and heterocyclic sulfonamides ]] incorporating adamantyl moieties with strong anticonvulsant activity.,[ENTITY_A] inhibitors: [ENTITY_B] incorporating adamantyl moieties with strong anticonvulsant activity.,INHIBITOR,CPR:4,1,Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity.
"Some of these derivatives showed good inhibitory potency against two << human CA >> isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and [[ methazolamide ]].","Some of these derivatives showed good inhibitory potency against two [ENTITY_A] isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and [ENTITY_B].",INHIBITOR,CPR:4,1,"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and methazolamide."
"BACKGROUND AND AIMS: << Glutamic acid decarboxylase >> (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to [[ gamma-aminobutyric acid ]] (GABA).","BACKGROUND AND AIMS: [ENTITY_A] (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to [ENTITY_B] (GABA).",PRODUCT-OF,CPR:9,4,"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (GABA)."
"FCEO significantly inhibited << nitric oxide >> (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of [[ inducible nitric oxide synthase ]] (iNOS) and cyclooxygenase (COX)-2, respectively.","FCEO significantly inhibited [ENTITY_A] (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of [ENTITY_B] (iNOS) and cyclooxygenase (COX)-2, respectively.",INDIRECT-DOWNREGULATOR,CPR:4,1,"FCEO significantly inhibited nitric oxide (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2, respectively."
"<< Amrinone >> and milrinone, selective PDE3 inhibitors, suppressed [[ TNF ]] secretion to a lesser extent.","[ENTITY_A] and milrinone, selective PDE3 inhibitors, suppressed [ENTITY_B] secretion to a lesser extent.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Amrinone and milrinone, selective PDE3 inhibitors, suppressed TNF secretion to a lesser extent."
"The effects of << theophylline >> (unspecific [[ PDE ]] inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak.","The effects of [ENTITY_A] (unspecific [ENTITY_B] inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak.",INHIBITOR,CPR:4,1,"The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak."
"In human blood, the tested glucocorticoids << beclomethasone >>, dexamethasone and fluticasone inhibited the LPS induced [[ TNF ]] release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced.","In human blood, the tested glucocorticoids [ENTITY_A], dexamethasone and fluticasone inhibited the LPS induced [ENTITY_B] release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In human blood, the tested glucocorticoids beclomethasone, dexamethasone and fluticasone inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced."
"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and << milrinone >>, reduced the [[ GM-CSF ]] release in a concentration dependent manner.","The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and [ENTITY_A], reduced the [ENTITY_B] release in a concentration dependent manner.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and milrinone, reduced the GM-CSF release in a concentration dependent manner."
Activating << glucocorticoid receptor >>-ERK signaling pathway contributes to [[ ginsenoside Rg1 ]] protection against β-amyloid peptide-induced human endothelial cells apoptosis.,Activating [ENTITY_A]-ERK signaling pathway contributes to [ENTITY_B] protection against β-amyloid peptide-induced human endothelial cells apoptosis.,ACTIVATOR,CPR:3,0,Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis.
Activating glucocorticoid receptor-ERK signaling pathway contributes to << ginsenoside Rg1 >> protection against [[ β-amyloid peptide ]]-induced human endothelial cells apoptosis.,Activating glucocorticoid receptor-ERK signaling pathway contributes to [ENTITY_A] protection against [ENTITY_B]-induced human endothelial cells apoptosis.,INHIBITOR,CPR:4,1,Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis.
"<< Rg1 >> attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting [[ HIF-1α ]] expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.","[ENTITY_A] attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting [ENTITY_B] expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination."
"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or << p-ERK >> inhibitor [[ U0126 ]] rather than estrogen receptor α antagonist ICI 82,780.","These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or [ENTITY_A] inhibitor [ENTITY_B] rather than estrogen receptor α antagonist ICI 82,780.",INHIBITOR,CPR:4,1,"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780."
"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than << estrogen receptor α >> antagonist [[ ICI 82,780 ]].",These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than [ENTITY_A] antagonist [ENTITY_B].,ANTAGONIST,CPR:6,3,"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780."
"Taken together, our results suggested that << Rg1 >> protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent [[ ERK ]] phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.","Taken together, our results suggested that [ENTITY_A] protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent [ENTITY_B] phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.",ACTIVATOR,CPR:3,0,"Taken together, our results suggested that Rg1 protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades."
"Taken together, our results suggested that << Rg1 >> protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating [[ HIF-1α ]] initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.","Taken together, our results suggested that [ENTITY_A] protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating [ENTITY_B] initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Taken together, our results suggested that Rg1 protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades."
"These data provided a novel insight to the mechanisms of << Rg1 >>protective effects on [[ Aβ25-35 ]]-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it.","These data provided a novel insight to the mechanisms of [ENTITY_A]protective effects on [ENTITY_B]-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it.",INHIBITOR,CPR:4,1,"These data provided a novel insight to the mechanisms of Rg1protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it."
Effectiveness of << endopeptidase >> inhibition ([[ candoxatril ]]) in congestive heart failure.,Effectiveness of [ENTITY_A] inhibition ([ENTITY_B]) in congestive heart failure.,INHIBITOR,CPR:4,1,Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure.
"<< Candoxatril >> is a novel, orally active inhibitor of [[ neutral endopeptidase ]] EC 3.4.24.11, the enzyme that degrades atrial natriuretic peptide (ANP).","[ENTITY_A] is a novel, orally active inhibitor of [ENTITY_B] EC 3.4.24.11, the enzyme that degrades atrial natriuretic peptide (ANP).",INHIBITOR,CPR:4,1,"Candoxatril is a novel, orally active inhibitor of neutral endopeptidase EC 3.4.24.11, the enzyme that degrades atrial natriuretic peptide (ANP)."
"On study day 1, << candoxatril >> acutely increased plasma [[ ANP ]] levels, suppressed aldosterone and decreased right atrial and pulmonary capillary wedge pressures.","On study day 1, [ENTITY_A] acutely increased plasma [ENTITY_B] levels, suppressed aldosterone and decreased right atrial and pulmonary capillary wedge pressures.",INDIRECT-UPREGULATOR,CPR:3,0,"On study day 1, candoxatril acutely increased plasma ANP levels, suppressed aldosterone and decreased right atrial and pulmonary capillary wedge pressures."
"On study day 10, the acute effects of << candoxatril >> were similar to those on day 1 (i.e., [[ ANP ]] was further increased, aldosterone was suppressed, and right and left ventricular filling pressures were decreased).","On study day 10, the acute effects of [ENTITY_A] were similar to those on day 1 (i.e., [ENTITY_B] was further increased, aldosterone was suppressed, and right and left ventricular filling pressures were decreased).",INDIRECT-UPREGULATOR,CPR:3,0,"On study day 10, the acute effects of candoxatril were similar to those on day 1 (i.e., ANP was further increased, aldosterone was suppressed, and right and left ventricular filling pressures were decreased)."
"<< Type 2 11β-hydroxysteroid dehydrogenase >> encoded by the HSD11B2 gene converts [[ cortisol ]] to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids.","[ENTITY_A] encoded by the HSD11B2 gene converts [ENTITY_B] to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids.",SUBSTRATE_PRODUCT-OF,CPR:9,4,"Type 2 11β-hydroxysteroid dehydrogenase encoded by the HSD11B2 gene converts cortisol to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids."
"The << alpha(1)-adrenoceptor >> antagonist, [[ tamsulosin ]], is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors.","The [ENTITY_A] antagonist, [ENTITY_B], is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors.",ANTAGONIST,CPR:6,3,"The alpha(1)-adrenoceptor antagonist, tamsulosin, is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors."
"The obtained results showed that << pioglitazone >> improved the renal function, structural changes, renal malondialdehyde (MDA), [[ tumor necrosis factor alpha ]] (TNF-α), nuclear factor kappa B (NF-κB) genes expression in cisplatin injected rats.","The obtained results showed that [ENTITY_A] improved the renal function, structural changes, renal malondialdehyde (MDA), [ENTITY_B] (TNF-α), nuclear factor kappa B (NF-κB) genes expression in cisplatin injected rats.",INDIRECT-UPREGULATOR,CPR:3,0,"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-α), nuclear factor kappa B (NF-κB) genes expression in cisplatin injected rats."
"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), << tumor necrosis factor alpha >> (TNF-α), nuclear factor kappa B (NF-κB) genes expression in [[ cisplatin ]] injected rats.","The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), [ENTITY_A] (TNF-α), nuclear factor kappa B (NF-κB) genes expression in [ENTITY_B] injected rats.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-α), nuclear factor kappa B (NF-κB) genes expression in cisplatin injected rats."
<< Sulindac >> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate [[ cyclic GMP-dependent protein kinase ]] (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis.,[ENTITY_A] metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate [ENTITY_B] (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis.,ACTIVATOR,CPR:3,0,Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis.
<< Sulindac >> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease [[ beta-catenin ]] protein expression at times and doses consistent with apoptosis.,[ENTITY_A] metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease [ENTITY_B] protein expression at times and doses consistent with apoptosis.,INDIRECT-DOWNREGULATOR,CPR:4,1,Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis.
"Cotreatment with << U0126 >> and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, [[ JNK ]], and beta-catenin.","Cotreatment with [ENTITY_A] and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, [ENTITY_B], and beta-catenin.",ACTIVATOR,CPR:3,0,"Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, JNK, and beta-catenin."
"Cotreatment with << U0126 >> and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, JNK, and [[ beta-catenin ]].","Cotreatment with [ENTITY_A] and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, JNK, and [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, JNK, and beta-catenin."
Synthesis and antagonistic activity at << muscarinic receptor >> subtypes of some 2-carbonyl derivatives of [[ diphenidol ]].,Synthesis and antagonistic activity at [ENTITY_A] subtypes of some 2-carbonyl derivatives of [ENTITY_B].,ANTAGONIST,CPR:6,3,Synthesis and antagonistic activity at muscarinic receptor subtypes of some 2-carbonyl derivatives of diphenidol.
"A series of 2-carbonyl analogues of the muscarinic antagonist << diphenidol >> bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the [[ M2 and M3 muscarinic receptor ]] subtypes was evaluated by functional tests.","A series of 2-carbonyl analogues of the muscarinic antagonist [ENTITY_A] bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the [ENTITY_B] subtypes was evaluated by functional tests.",ANTAGONIST,CPR:6,3,"A series of 2-carbonyl analogues of the muscarinic antagonist diphenidol bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the M2 and M3 muscarinic receptor subtypes was evaluated by functional tests."
This work showed that appropriate structural modification of << diphenidol >> can lead to [[ M2 ]]-selective muscarinic antagonists of possible interest in the field of Alzheimer's disease.,This work showed that appropriate structural modification of [ENTITY_A] can lead to [ENTITY_B]-selective muscarinic antagonists of possible interest in the field of Alzheimer's disease.,ANTAGONIST,CPR:6,3,This work showed that appropriate structural modification of diphenidol can lead to M2-selective muscarinic antagonists of possible interest in the field of Alzheimer's disease.
Activation of an apoptotic signal transduction pathway involved in the upregulation of << calpain >> and apoptosis-inducing factor in [[ aldosterone ]]-induced primary cultured cardiomyocytes.,Activation of an apoptotic signal transduction pathway involved in the upregulation of [ENTITY_A] and apoptosis-inducing factor in [ENTITY_B]-induced primary cultured cardiomyocytes.,INDIRECT-UPREGULATOR,CPR:3,0,Activation of an apoptotic signal transduction pathway involved in the upregulation of calpain and apoptosis-inducing factor in aldosterone-induced primary cultured cardiomyocytes.
"In this study, aldosterone (<< ALD >>)-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of [[ calpain ]] signaling were clarified.","In this study, aldosterone ([ENTITY_A])-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of [ENTITY_B] signaling were clarified.",INDIRECT-UPREGULATOR,CPR:3,0,"In this study, aldosterone (ALD)-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of calpain signaling were clarified."
<< ALD >> increased calpain expression and [[ caspase-3 ]] activity and promoted Bid cleavage.,[ENTITY_A] increased calpain expression and [ENTITY_B] activity and promoted Bid cleavage.,ACTIVATOR,CPR:3,0,ALD increased calpain expression and caspase-3 activity and promoted Bid cleavage.
"The upregulation of calpain, tBid and << caspase-3 >> activity were further inhibited by treatment with EGTA in the presence of [[ ALD ]].","The upregulation of calpain, tBid and [ENTITY_A] activity were further inhibited by treatment with EGTA in the presence of [ENTITY_B].",ACTIVATOR,CPR:3,0,"The upregulation of calpain, tBid and caspase-3 activity were further inhibited by treatment with EGTA in the presence of ALD."
"The upregulation of << calpain >>, tBid and caspase-3 activity were further inhibited by treatment with [[ EGTA ]] in the presence of ALD.","The upregulation of [ENTITY_A], tBid and caspase-3 activity were further inhibited by treatment with [ENTITY_B] in the presence of ALD.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The upregulation of calpain, tBid and caspase-3 activity were further inhibited by treatment with EGTA in the presence of ALD."
"Additionally, << AIF >> levels in the cytosol decreased due to [[ EGTA ]] but not due to calpeptin.","Additionally, [ENTITY_A] levels in the cytosol decreased due to [ENTITY_B] but not due to calpeptin.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Additionally, AIF levels in the cytosol decreased due to EGTA but not due to calpeptin."
"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the << ALD >>-induced increase of [[ calpain ]] and AIF levels.","Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the [ENTITY_A]-induced increase of [ENTITY_B] and AIF levels.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of calpain and AIF levels."
"Furthermore, treatment with << spironoclactone >> not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of [[ calpain ]] and AIF levels.","Furthermore, treatment with [ENTITY_A] not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of [ENTITY_B] and AIF levels.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of calpain and AIF levels."
<< Loperamide >> is a peripheral opiate agonist able to inhibit [[ ACTH ]] secretion.,[ENTITY_A] is a peripheral opiate agonist able to inhibit [ENTITY_B] secretion.,INDIRECT-DOWNREGULATOR,CPR:4,1,Loperamide is a peripheral opiate agonist able to inhibit ACTH secretion.
In all patients << loperamide >> induced a significant fall in plasma [[ ACTH ]] levels.,In all patients [ENTITY_A] induced a significant fall in plasma [ENTITY_B] levels.,INDIRECT-DOWNREGULATOR,CPR:4,1,In all patients loperamide induced a significant fall in plasma ACTH levels.
"CRH caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of << CRH >>-induced ACTH secretion was significantly lower after [[ loperamide ]].","CRH caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of [ENTITY_A]-induced ACTH secretion was significantly lower after [ENTITY_B].",DOWNREGULATOR,CPR:4,1,"CRH caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of CRH-induced ACTH secretion was significantly lower after loperamide."
<< CCl(4) >> intoxication caused hepatic necrosis and increased serum [[ ALT ]] activity.,[ENTITY_A] intoxication caused hepatic necrosis and increased serum [ENTITY_B] activity.,ACTIVATOR,CPR:3,0,CCl(4) intoxication caused hepatic necrosis and increased serum ALT activity.
"<< CCl(4) >> administration triggered inflammatory response in mice livers by activating [[ nuclear factor-kappaB ]] (NF-κB), which coincided with the induction of tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (COX-2).","[ENTITY_A] administration triggered inflammatory response in mice livers by activating [ENTITY_B] (NF-κB), which coincided with the induction of tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (COX-2).",ACTIVATOR,CPR:3,0,"CCl(4) administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-κB), which coincided with the induction of tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (COX-2)."
"Furthermore, RA significantly inhibited the << CCl(4) >>-induced apoptosis, which was evident from decreased cleavage of [[ caspase-3 ]].","Furthermore, RA significantly inhibited the [ENTITY_A]-induced apoptosis, which was evident from decreased cleavage of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, RA significantly inhibited the CCl(4)-induced apoptosis, which was evident from decreased cleavage of caspase-3."
"Pre-clinical pharmacology of << zolmitriptan >> (Zomig; formerly 311C90), a centrally and peripherally acting [[ 5HT1B/1D ]] agonist for migraine.","Pre-clinical pharmacology of [ENTITY_A] (Zomig; formerly 311C90), a centrally and peripherally acting [ENTITY_B] agonist for migraine.",AGONIST,CPR:5,2,"Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine."
Zolmitriptan (Zomig; formerly << 311C90 >>) is a novel [[ 5-hydroxytryptamine (5HT)1B/1D ]] receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.,Zolmitriptan (Zomig; formerly [ENTITY_A]) is a novel [ENTITY_B] receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.,AGONIST,CPR:5,2,Zolmitriptan (Zomig; formerly 311C90) is a novel 5-hydroxytryptamine (5HT)1B/1D receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.
"These actions are consistent with a pre-junctional inhibition of neuropeptide release from perivascular afferents of the trigeminal nerve, as confirmed by independent studies showing that << zolmitriptan >> blocks elevations of [[ calcitonin-gene-related peptide ]] in jugular venous blood during electrical stimulation of the trigeminal ganglion.","These actions are consistent with a pre-junctional inhibition of neuropeptide release from perivascular afferents of the trigeminal nerve, as confirmed by independent studies showing that [ENTITY_A] blocks elevations of [ENTITY_B] in jugular venous blood during electrical stimulation of the trigeminal ganglion.",INDIRECT-DOWNREGULATOR,CPR:4,1,"These actions are consistent with a pre-junctional inhibition of neuropeptide release from perivascular afferents of the trigeminal nerve, as confirmed by independent studies showing that zolmitriptan blocks elevations of calcitonin-gene-related peptide in jugular venous blood during electrical stimulation of the trigeminal ganglion."
It has been reported that oligomeric << procyanidins >> of lotus seedpod (LSOPC) is effective in the alleviation of Alzheimer's disease and diabetes through its antioxidant and [[ insulin ]]-potentiating activities.,It has been reported that oligomeric [ENTITY_A] of lotus seedpod (LSOPC) is effective in the alleviation of Alzheimer's disease and diabetes through its antioxidant and [ENTITY_B]-potentiating activities.,UPREGULATOR,CPR:3,0,It has been reported that oligomeric procyanidins of lotus seedpod (LSOPC) is effective in the alleviation of Alzheimer's disease and diabetes through its antioxidant and insulin-potentiating activities.
"They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with << rhArg >>, to [[ citrulline ]], which is converted back to arginine via ASS.","They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with [ENTITY_A], to [ENTITY_B], which is converted back to arginine via ASS.",PRODUCT-OF,CPR:9,4,"They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS."
This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to << rhArg >>-mediated [[ arginine ]] depletion.,This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to [ENTITY_A]-mediated [ENTITY_B] depletion.,SUBSTRATE,CPR:9,4,This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to rhArg-mediated arginine depletion.
"Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to << arginine >> depletion with [[ arginine-depleting enzymes ]].","Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to [ENTITY_A] depletion with [ENTITY_B].",SUBSTRATE,CPR:9,4,"Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to arginine depletion with arginine-depleting enzymes."
"To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective << 5-HT1F >> receptor agonist ([[ LY 344864 ]]) on c-fos protein expression in the trigeminal nucleus caudalis.","To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective [ENTITY_A] receptor agonist ([ENTITY_B]) on c-fos protein expression in the trigeminal nucleus caudalis.",AGONIST,CPR:5,2,"To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective 5-HT1F receptor agonist (LY 344864) on c-fos protein expression in the trigeminal nucleus caudalis."
<< c-fos >> expression was induced in urethane-anaesthetized rats by intracisternal [[ capsaicin ]] administration.,[ENTITY_A] expression was induced in urethane-anaesthetized rats by intracisternal [ENTITY_B] administration.,INDIRECT-UPREGULATOR,CPR:3,0,c-fos expression was induced in urethane-anaesthetized rats by intracisternal capsaicin administration.
Sumatriptan and LY 344864 decreased the number of << capsaicin >>-induced [[ c-fos ]]-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).,Sumatriptan and LY 344864 decreased the number of [ENTITY_A]-induced [ENTITY_B]-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).,INDIRECT-UPREGULATOR,CPR:3,0,Sumatriptan and LY 344864 decreased the number of capsaicin-induced c-fos-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).
<< Sumatriptan >> and LY 344864 decreased the number of capsaicin-induced [[ c-fos ]]-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).,[ENTITY_A] and LY 344864 decreased the number of capsaicin-induced [ENTITY_B]-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).,INDIRECT-DOWNREGULATOR,CPR:4,1,Sumatriptan and LY 344864 decreased the number of capsaicin-induced c-fos-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).
"The effect of sumatriptan, but not of LY 344864, was prevented by pretreatment with the antagonist << SDZ 21-009 >>, which displays high affinity for [[ rat 5-HT1B ]] receptors.","The effect of sumatriptan, but not of LY 344864, was prevented by pretreatment with the antagonist [ENTITY_A], which displays high affinity for [ENTITY_B] receptors.",ANTAGONIST,CPR:6,3,"The effect of sumatriptan, but not of LY 344864, was prevented by pretreatment with the antagonist SDZ 21-009, which displays high affinity for rat 5-HT1B receptors."
"The involvement of << EP1 >> and EP2 receptors is indicated by studies with the EP1 selective agonist [[ 17-phenyl trinor PGE2 ]], and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).","The involvement of [ENTITY_A] and EP2 receptors is indicated by studies with the EP1 selective agonist [ENTITY_B], and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).",AGONIST,CPR:5,2,"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)."
"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and << AH 6809 >> ([[ EP1 ]] and EP2 specific).","The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and [ENTITY_A] ([ENTITY_B] and EP2 specific).",ANTAGONIST,CPR:6,3,"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)."
"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the << PGE1 >> mediated stimulation of [[ Na,K-ATPase beta ]] subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089.","In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the [ENTITY_A] mediated stimulation of [ENTITY_B] subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089.",INDIRECT-UPREGULATOR,CPR:3,0,"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089."
"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of << Na,K-ATPase beta >> subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of [[ SC-51089 ]].","In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of [ENTITY_A] subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089."
"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the << PKC >> inhibitor Go 6976, [[ thapsigargin ]], as well as the calmodulin antagonists W7 and W13.","Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the [ENTITY_A] inhibitor Go 6976, [ENTITY_B], as well as the calmodulin antagonists W7 and W13.",INHIBITOR,CPR:4,1,"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13."
"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the << calmodulin >> antagonists [[ W7 ]] and W13.","Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the [ENTITY_A] antagonists [ENTITY_B] and W13.",ANTAGONIST,CPR:6,3,"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13."
"Spiro heterocycles as potential inhibitors of << SIRT1 >>: Pd/C-mediated synthesis of novel [[ N-indolylmethyl spiroindoline-3,2'-quinazolines ]].",Spiro heterocycles as potential inhibitors of [ENTITY_A]: Pd/C-mediated synthesis of novel [ENTITY_B].,INHIBITOR,CPR:4,1,"Spiro heterocycles as potential inhibitors of SIRT1: Pd/C-mediated synthesis of novel N-indolylmethyl spiroindoline-3,2'-quinazolines."
"Novel << N-indolylmethyl substituted spiroindoline-3,2'-quinazolines >> were designed as potential inhibitiors of [[ SIRT1 ]].",Novel [ENTITY_A] were designed as potential inhibitiors of [ENTITY_B].,INHIBITOR,CPR:4,1,"Novel N-indolylmethyl substituted spiroindoline-3,2'-quinazolines were designed as potential inhibitiors of SIRT1."
"Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of << inducible nitric-oxide synthase >> by [[ 15-deoxy-Delta12,14-prostaglandin J2 ]].",Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of [ENTITY_A] by [ENTITY_B].,DOWNREGULATOR,CPR:4,1,"Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2."
"<< Cyclopentenone prostaglandins >> were potent inhibitors of [[ iNOS ]] induction and were more effective than their precursors, prostaglandins E2 and D2.","[ENTITY_A] were potent inhibitors of [ENTITY_B] induction and were more effective than their precursors, prostaglandins E2 and D2.",INHIBITOR,CPR:4,1,"Cyclopentenone prostaglandins were potent inhibitors of iNOS induction and were more effective than their precursors, prostaglandins E2 and D2."
"In activated microglia, << 15d-PGJ2 >> suppressed iNOS promoter activity, [[ iNOS ]] mRNA, and protein levels.","In activated microglia, [ENTITY_A] suppressed iNOS promoter activity, [ENTITY_B] mRNA, and protein levels.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In activated microglia, 15d-PGJ2 suppressed iNOS promoter activity, iNOS mRNA, and protein levels."
"<< 15d-PGJ2 >> did not block nuclear translocation or DNA-binding activity of the transcription factor NFkappaB, but it did inhibit the activity of an [[ NFkappaB ]] reporter construct, suggesting that the mechanism of suppression of microglial iNOS by 15d-PGJ2 may involve interference with NFkappaB transcriptional activity in the nucleus.","[ENTITY_A] did not block nuclear translocation or DNA-binding activity of the transcription factor NFkappaB, but it did inhibit the activity of an [ENTITY_B] reporter construct, suggesting that the mechanism of suppression of microglial iNOS by 15d-PGJ2 may involve interference with NFkappaB transcriptional activity in the nucleus.",INHIBITOR,CPR:4,1,"15d-PGJ2 did not block nuclear translocation or DNA-binding activity of the transcription factor NFkappaB, but it did inhibit the activity of an NFkappaB reporter construct, suggesting that the mechanism of suppression of microglial iNOS by 15d-PGJ2 may involve interference with NFkappaB transcriptional activity in the nucleus."
"In vitro studies, however, revealed that << EO >> inhibits [[ fibrin ]] clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in FPA formation in vitro.","In vitro studies, however, revealed that [ENTITY_A] inhibits [ENTITY_B] clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in FPA formation in vitro.",INHIBITOR,CPR:4,1,"In vitro studies, however, revealed that EO inhibits fibrin clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in FPA formation in vitro."
"The activation may be accelerated by an acute inflammatory process provoked by << oleate >>, which is supported by such clinical manifestations as mild fever, retrosternal pain leukocytosis and an increase in plasma [[ fibrinogen ]] level which was observed in all during the period.","The activation may be accelerated by an acute inflammatory process provoked by [ENTITY_A], which is supported by such clinical manifestations as mild fever, retrosternal pain leukocytosis and an increase in plasma [ENTITY_B] level which was observed in all during the period.",INDIRECT-UPREGULATOR,CPR:3,0,"The activation may be accelerated by an acute inflammatory process provoked by oleate, which is supported by such clinical manifestations as mild fever, retrosternal pain leukocytosis and an increase in plasma fibrinogen level which was observed in all during the period."
OBJECTIVE: Celecoxib and << rofecoxib >> are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the [[ cyclo-oxygenase-2 ]] (COX-2) isoenzyme at therapeutic concentrations.,OBJECTIVE: Celecoxib and [ENTITY_A] are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the [ENTITY_B] (COX-2) isoenzyme at therapeutic concentrations.,INHIBITOR,CPR:4,1,OBJECTIVE: Celecoxib and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 (COX-2) isoenzyme at therapeutic concentrations.
This study was conducted in order to understand the association between acute renal failure and the two << COX-2 >> inhibitors [[ celecoxib ]] and rofecoxib.,This study was conducted in order to understand the association between acute renal failure and the two [ENTITY_A] inhibitors [ENTITY_B] and rofecoxib.,INHIBITOR,CPR:4,1,This study was conducted in order to understand the association between acute renal failure and the two COX-2 inhibitors celecoxib and rofecoxib.
"<< (+)-Tamsulosin >>, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [[ human alpha 1D adrenoceptors ]].","[ENTITY_A], (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [ENTITY_B].",ANTAGONIST,CPR:6,3,"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors."
"The potency of the antipsychotic drug, << risperidone >>, to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and [[ alpha 1B-adrenoceptor ]]-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists.","The potency of the antipsychotic drug, [ENTITY_A], to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and [ENTITY_B]-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists.",ANTAGONIST,CPR:6,3,"The potency of the antipsychotic drug, risperidone, to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists."
"In this article, the action of << dasatinib >> (BMS-354825) is contrasted with that of imatinib, a [[ kinase ]] inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders.","In this article, the action of [ENTITY_A] (BMS-354825) is contrasted with that of imatinib, a [ENTITY_B] inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders.",INHIBITOR,CPR:4,1,"In this article, the action of dasatinib (BMS-354825) is contrasted with that of imatinib, a kinase inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders."
The work of Chen and colleagues shows that << dasatinib >> is a particularly potent inhibitor of [[ PDGFR ]] and that the compound also targets Src kinase.,The work of Chen and colleagues shows that [ENTITY_A] is a particularly potent inhibitor of [ENTITY_B] and that the compound also targets Src kinase.,INHIBITOR,CPR:4,1,The work of Chen and colleagues shows that dasatinib is a particularly potent inhibitor of PDGFR and that the compound also targets Src kinase.
"From these data, it is inferred that both the << SERT >> and NET contribute to the active clearance of exogenously applied [[ 5-HT ]] in the dentate gyrus.","From these data, it is inferred that both the [ENTITY_A] and NET contribute to the active clearance of exogenously applied [ENTITY_B] in the dentate gyrus.",SUBSTRATE,CPR:9,4,"From these data, it is inferred that both the SERT and NET contribute to the active clearance of exogenously applied 5-HT in the dentate gyrus."
"In another experiment, << cyanopindolol >>, an antagonist of the [[ serotonin terminal autoreceptor ]], also prolonged the clearance of 5-HT from the CA3 region.","In another experiment, [ENTITY_A], an antagonist of the [ENTITY_B], also prolonged the clearance of 5-HT from the CA3 region.",ANTAGONIST,CPR:6,3,"In another experiment, cyanopindolol, an antagonist of the serotonin terminal autoreceptor, also prolonged the clearance of 5-HT from the CA3 region."
These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of << 5-HT >> uptake through an effect on the [[ serotonin transporter ]].,These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of [ENTITY_A] uptake through an effect on the [ENTITY_B].,SUBSTRATE,CPR:9,4,These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of 5-HT uptake through an effect on the serotonin transporter.
"The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a << 5-HT1A >>-selective agonist, [[ 8-hydroxy-2-(di-n-propylamino)tetralin ]], was inactive.","The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a [ENTITY_A]-selective agonist, [ENTITY_B], was inactive.",AGONIST,CPR:5,2,"The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a 5-HT1A-selective agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, was inactive."
"The memory-improving effect of minaprine on cycloheximide-induced amnesia was potentiated by a selective << 5-HT2 >> antagonist, [[ ritanserin ]].","The memory-improving effect of minaprine on cycloheximide-induced amnesia was potentiated by a selective [ENTITY_A] antagonist, [ENTITY_B].",ANTAGONIST,CPR:6,3,"The memory-improving effect of minaprine on cycloheximide-induced amnesia was potentiated by a selective 5-HT2 antagonist, ritanserin."
"Even though the activities of << MAT >> and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and [[ S-adenosylhomocysteine ]] increased (113%, p<0.001) in the dwarf mice.","Even though the activities of [ENTITY_A] and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and [ENTITY_B] increased (113%, p<0.001) in the dwarf mice.",PRODUCT-OF,CPR:9,4,"Even though the activities of MAT and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice."
Activation of << alpha 2B-adrenoceptors >> mediates the cardiovascular effects of [[ etomidate ]].,Activation of [ENTITY_A] mediates the cardiovascular effects of [ENTITY_B].,ACTIVATOR,CPR:3,0,Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate.
BACKGROUND: The intravenous anesthetic etomidate exhibits structural similarities to specific << alpha2-adrenoceptor >> agonists of the type such as [[ dexmedetomidine ]].,BACKGROUND: The intravenous anesthetic etomidate exhibits structural similarities to specific [ENTITY_A] agonists of the type such as [ENTITY_B].,AGONIST,CPR:5,2,BACKGROUND: The intravenous anesthetic etomidate exhibits structural similarities to specific alpha2-adrenoceptor agonists of the type such as dexmedetomidine.
"METHODS: Sedative and cardiovascular responses to etomidate and the alpha2-agonist, << dexmedetomidine >>, were determined in mice deficient in [[ alpha2-receptor ]] subtypes.","METHODS: Sedative and cardiovascular responses to etomidate and the alpha2-agonist, [ENTITY_A], were determined in mice deficient in [ENTITY_B] subtypes.",AGONIST,CPR:5,2,"METHODS: Sedative and cardiovascular responses to etomidate and the alpha2-agonist, dexmedetomidine, were determined in mice deficient in alpha2-receptor subtypes."
Inhibition of binding of the << alpha2-receptor >> antagonist [[ [3H]RX821002 ]] to recombinant alpha2-receptors by etomidate was tested in human embryonic kidney (HEK293) cells in vitro.,Inhibition of binding of the [ENTITY_A] antagonist [ENTITY_B] to recombinant alpha2-receptors by etomidate was tested in human embryonic kidney (HEK293) cells in vitro.,ANTAGONIST,CPR:6,3,Inhibition of binding of the alpha2-receptor antagonist [3H]RX821002 to recombinant alpha2-receptors by etomidate was tested in human embryonic kidney (HEK293) cells in vitro.
"In membranes from HEK293 cells transfected with << alpha2-receptors >>, etomidate inhibited binding of the alpha2-antagonist, [[ [3H]RX821002 ]], with higher potency from alpha2B- and alpha2C-receptors than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).","In membranes from HEK293 cells transfected with [ENTITY_A], etomidate inhibited binding of the alpha2-antagonist, [ENTITY_B], with higher potency from alpha2B- and alpha2C-receptors than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).",ANTAGONIST,CPR:6,3,"In membranes from HEK293 cells transfected with alpha2-receptors, etomidate inhibited binding of the alpha2-antagonist, [3H]RX821002, with higher potency from alpha2B- and alpha2C-receptors than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm)."
"In alpha2B-receptor-expressing HEK293 cells, << etomidate >> rapidly increased phosphorylation of the [[ extracellular signal-related kinases ]] ERK1/2.","In alpha2B-receptor-expressing HEK293 cells, [ENTITY_A] rapidly increased phosphorylation of the [ENTITY_B] ERK1/2.",ACTIVATOR,CPR:3,0,"In alpha2B-receptor-expressing HEK293 cells, etomidate rapidly increased phosphorylation of the extracellular signal-related kinases ERK1/2."
"CONCLUSIONS: These results indicate that << etomidate >> acts as an agonist at [[ alpha2-adrenoceptors ]], which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure.","CONCLUSIONS: These results indicate that [ENTITY_A] acts as an agonist at [ENTITY_B], which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure.",AGONIST,CPR:5,2,"CONCLUSIONS: These results indicate that etomidate acts as an agonist at alpha2-adrenoceptors, which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure."
"Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to << SiO(2) >> NPs, the messenger RNA level of apoptotic genes ([[ caspase-3 ]] and caspase-9) were upregulated in a dose-dependent manner.","Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to [ENTITY_A] NPs, the messenger RNA level of apoptotic genes ([ENTITY_B] and caspase-9) were upregulated in a dose-dependent manner.",INDIRECT-UPREGULATOR,CPR:3,0,"Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to SiO(2) NPs, the messenger RNA level of apoptotic genes (caspase-3 and caspase-9) were upregulated in a dose-dependent manner."
"Moreover, activities of << caspase-3 >> and caspase-9 enzymes were also significantly higher in both kinds of cells exposed to [[ SiO(2) ]] NPs.","Moreover, activities of [ENTITY_A] and caspase-9 enzymes were also significantly higher in both kinds of cells exposed to [ENTITY_B] NPs.",ACTIVATOR,CPR:3,0,"Moreover, activities of caspase-3 and caspase-9 enzymes were also significantly higher in both kinds of cells exposed to SiO(2) NPs."
The << CYP2B6*6 >> Allele Significantly Alters the N-demethylation of [[ Ketamine ]] Enantiomers In Vitro.,The [ENTITY_A] Allele Significantly Alters the N-demethylation of [ENTITY_B] Enantiomers In Vitro.,SUBSTRATE,CPR:9,4,The CYP2B6*6 Allele Significantly Alters the N-demethylation of Ketamine Enantiomers In Vitro.
<< Ketamine >> is primarily metabolized to norketamine by hepatic [[ cytochrome P450 (CYP) 2B6 ]] and CYP3A4-mediated N-demethylation.,[ENTITY_A] is primarily metabolized to norketamine by hepatic [ENTITY_B] and CYP3A4-mediated N-demethylation.,SUBSTRATE,CPR:9,4,Ketamine is primarily metabolized to norketamine by hepatic cytochrome P450 (CYP) 2B6 and CYP3A4-mediated N-demethylation.
The << CYP2B6*6 >> allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in [[ ketamine ]] metabolism.,The [ENTITY_A] allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in [ENTITY_B] metabolism.,SUBSTRATE,CPR:9,4,The CYP2B6*6 allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in ketamine metabolism.
"We examined the N-demethylation of individual << ketamine >> enantiomers using human liver microsomes (HLMs) genotyped for the [[ CYP2B6*6 ]] allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant.","We examined the N-demethylation of individual [ENTITY_A] enantiomers using human liver microsomes (HLMs) genotyped for the [ENTITY_B] allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant.",SUBSTRATE,CPR:9,4,"We examined the N-demethylation of individual ketamine enantiomers using human liver microsomes (HLMs) genotyped for the CYP2B6*6 allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant."
"The intrinsic clearance for both << ketamine >> enantiomers by the high affinity enzyme in HLMs with [[ CYP2B6*1 ]]/*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1/*6 genotype and CYP2B6*6/*6 genotype.","The intrinsic clearance for both [ENTITY_A] enantiomers by the high affinity enzyme in HLMs with [ENTITY_B]/*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1/*6 genotype and CYP2B6*6/*6 genotype.",SUBSTRATE,CPR:9,4,"The intrinsic clearance for both ketamine enantiomers by the high affinity enzyme in HLMs with CYP2B6*1/*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1/*6 genotype and CYP2B6*6/*6 genotype."
"<< ThioTEPA >> ([[ CYP2B6 ]] inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations.","[ENTITY_A] ([ENTITY_B] inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations.",INHIBITOR,CPR:4,1,"ThioTEPA (CYP2B6 inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations."
These results indicate a major role of << CYP2B6 >> in [[ ketamine ]] N-demethylation in vitro and a significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity.,These results indicate a major role of [ENTITY_A] in [ENTITY_B] N-demethylation in vitro and a significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity.,SUBSTRATE,CPR:9,4,These results indicate a major role of CYP2B6 in ketamine N-demethylation in vitro and a significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity.
"PURPOSE: Testosterone-to-estradiol ratio levels in infertile men improve during treatment with the << aromatase >> inhibitor, [[ testolactone ]], and resulting changes in semen parameters.","PURPOSE: Testosterone-to-estradiol ratio levels in infertile men improve during treatment with the [ENTITY_A] inhibitor, [ENTITY_B], and resulting changes in semen parameters.",INHIBITOR,CPR:4,1,"PURPOSE: Testosterone-to-estradiol ratio levels in infertile men improve during treatment with the aromatase inhibitor, testolactone, and resulting changes in semen parameters."
"We evaluated the effect of << anastrozole >>, a more selective [[ aromatase ]] inhibitor, on the hormonal and semen profiles of infertile men with abnormal baseline testosterone-to-estradiol ratios.","We evaluated the effect of [ENTITY_A], a more selective [ENTITY_B] inhibitor, on the hormonal and semen profiles of infertile men with abnormal baseline testosterone-to-estradiol ratios.",INHIBITOR,CPR:4,1,"We evaluated the effect of anastrozole, a more selective aromatase inhibitor, on the hormonal and semen profiles of infertile men with abnormal baseline testosterone-to-estradiol ratios."
The results show that CYP2E1 inhibits << CYP2B4 >>-mediated metabolism of [[ benzphetamine ]] (BNZ) with a K(i) of 0.04 µM.,The results show that CYP2E1 inhibits [ENTITY_A]-mediated metabolism of [ENTITY_B] (BNZ) with a K(i) of 0.04 µM.,SUBSTRATE,CPR:9,4,The results show that CYP2E1 inhibits CYP2B4-mediated metabolism of benzphetamine (BNZ) with a K(i) of 0.04 µM.
"However, CYP2B4 is not an inhibitor of << CYP2E1 >>-mediated [[ p-nitrophenol ]] hydroxylation.","However, CYP2B4 is not an inhibitor of [ENTITY_A]-mediated [ENTITY_B] hydroxylation.",SUBSTRATE,CPR:9,4,"However, CYP2B4 is not an inhibitor of CYP2E1-mediated p-nitrophenol hydroxylation."
To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of PSMA a series of << phenylalkylphosphonamidate >> derivatives of glutamic acid were synthesized and evaluated for their inhibitory potencies against [[ PSMA ]].,To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of PSMA a series of [ENTITY_A] derivatives of glutamic acid were synthesized and evaluated for their inhibitory potencies against [ENTITY_B].,INHIBITOR,CPR:4,1,To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of PSMA a series of phenylalkylphosphonamidate derivatives of glutamic acid were synthesized and evaluated for their inhibitory potencies against PSMA.
"In PFC, << DEX >> caused activation of [[ AKT ]], augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2/Bax protein ratio, as well Bcl-2 translocation to mitochondria.","In PFC, [ENTITY_A] caused activation of [ENTITY_B], augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2/Bax protein ratio, as well Bcl-2 translocation to mitochondria.",ACTIVATOR,CPR:3,0,"In PFC, DEX caused activation of AKT, augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2/Bax protein ratio, as well Bcl-2 translocation to mitochondria."
Results of RT-PCR analysis showed decrease of << p53 >> mRNA level and no significant difference in Bcl-2 and Bax mRNA expressions in [[ DEX ]]-treated rats.,Results of RT-PCR analysis showed decrease of [ENTITY_A] mRNA level and no significant difference in Bcl-2 and Bax mRNA expressions in [ENTITY_B]-treated rats.,INDIRECT-DOWNREGULATOR,CPR:4,1,Results of RT-PCR analysis showed decrease of p53 mRNA level and no significant difference in Bcl-2 and Bax mRNA expressions in DEX-treated rats.
Antitumor activity of << sorafenib >> in [[ FLT3 ]]-driven leukemic cells.,Antitumor activity of [ENTITY_A] in [ENTITY_B]-driven leukemic cells.,INHIBITOR,CPR:4,1,Antitumor activity of sorafenib in FLT3-driven leukemic cells.
"We show that << sorafenib >> (BAY 43-9006, Nexavar) potently inhibits [[ FLT3 ]] enzymatic and signaling activities.","We show that [ENTITY_A] (BAY 43-9006, Nexavar) potently inhibits [ENTITY_B] enzymatic and signaling activities.",INHIBITOR,CPR:4,1,"We show that sorafenib (BAY 43-9006, Nexavar) potently inhibits FLT3 enzymatic and signaling activities."
"In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, << sorafenib >> blocked basal and ligand dependent [[ FLT3 ]]-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and Stat5 phosphorylation.","In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, [ENTITY_A] blocked basal and ligand dependent [ENTITY_B]-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and Stat5 phosphorylation.",INHIBITOR,CPR:4,1,"In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, sorafenib blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and Stat5 phosphorylation."
"In leukemia cell lines MV4-11 and EOL-1, << sorafenib >> treatment resulted in decreased cell proliferation and inhibition of [[ FLT3 ]] signaling.","In leukemia cell lines MV4-11 and EOL-1, [ENTITY_A] treatment resulted in decreased cell proliferation and inhibition of [ENTITY_B] signaling.",INHIBITOR,CPR:4,1,"In leukemia cell lines MV4-11 and EOL-1, sorafenib treatment resulted in decreased cell proliferation and inhibition of FLT3 signaling."
The growth of the << FLT3 >>-independent RS4-11 cell line was only weakly inhibited by [[ sorafenib ]].,The growth of the [ENTITY_A]-independent RS4-11 cell line was only weakly inhibited by [ENTITY_B].,INHIBITOR,CPR:4,1,The growth of the FLT3-independent RS4-11 cell line was only weakly inhibited by sorafenib.
The demonstration that << sorafenib >> exhibits potent target inhibition and efficacy in [[ FLT3 ]]-driven models suggests that this compound may have a therapeutic benefit for patients with FLT3-driven leukemias.,The demonstration that [ENTITY_A] exhibits potent target inhibition and efficacy in [ENTITY_B]-driven models suggests that this compound may have a therapeutic benefit for patients with FLT3-driven leukemias.,INHIBITOR,CPR:4,1,The demonstration that sorafenib exhibits potent target inhibition and efficacy in FLT3-driven models suggests that this compound may have a therapeutic benefit for patients with FLT3-driven leukemias.
"<< DBDCT >> up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of [[ Bax ]]/Bcl-2.","[ENTITY_A] up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of [ENTITY_B]/Bcl-2.",INDIRECT-UPREGULATOR,CPR:3,0,"DBDCT up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax/Bcl-2."
"<< DBDCT >> up-regulated the expression of Bax, down-regulated the expression of [[ Bcl-2 ]], and significantly increased the ratio of Bax/Bcl-2.","[ENTITY_A] up-regulated the expression of Bax, down-regulated the expression of [ENTITY_B], and significantly increased the ratio of Bax/Bcl-2.",INDIRECT-DOWNREGULATOR,CPR:4,1,"DBDCT up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax/Bcl-2."
<< DBDCT >> also caused the phosphorylation of [[ JNK ]] and p38(MAPK).,[ENTITY_A] also caused the phosphorylation of [ENTITY_B] and p38(MAPK).,ACTIVATOR,CPR:3,0,DBDCT also caused the phosphorylation of JNK and p38(MAPK).
"Structure-based design of << aliskiren >>, a novel orally effective [[ renin ]] inhibitor.","Structure-based design of [ENTITY_A], a novel orally effective [ENTITY_B] inhibitor.",INHIBITOR,CPR:4,1,"Structure-based design of aliskiren, a novel orally effective renin inhibitor."
"This led to the discovery of << aliskiren >>, a highly potent and selective inhibitor of [[ human renin ]] in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients.","This led to the discovery of [ENTITY_A], a highly potent and selective inhibitor of [ENTITY_B] in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients.",INHIBITOR,CPR:4,1,"This led to the discovery of aliskiren, a highly potent and selective inhibitor of human renin in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients."
<< Aliskiren >> represents the first in a novel class of [[ renin ]] inhibitors with the potential for treatment of hypertension and related cardiovascular diseases.,[ENTITY_A] represents the first in a novel class of [ENTITY_B] inhibitors with the potential for treatment of hypertension and related cardiovascular diseases.,INHIBITOR,CPR:4,1,Aliskiren represents the first in a novel class of renin inhibitors with the potential for treatment of hypertension and related cardiovascular diseases.
"<< Everolimus >> (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of [[ mTOR ]] (mammalian target of rapamycin) to reach the oncology clinic.","[ENTITY_A] (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of [ENTITY_B] (mammalian target of rapamycin) to reach the oncology clinic.",INHIBITOR,CPR:4,1,"Everolimus (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of mTOR (mammalian target of rapamycin) to reach the oncology clinic."
A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the << VEGFR >> tyrosine kinase inhibitors sunitinib and/or [[ sorafenib ]].,A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the [ENTITY_A] tyrosine kinase inhibitors sunitinib and/or [ENTITY_B].,INHIBITOR,CPR:4,1,A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR tyrosine kinase inhibitors sunitinib and/or sorafenib.
Synthesis and structure-activity relationship of << pyripyropene A >> derivatives as potent and selective [[ acyl-CoA:cholesterol acyltransferase 2 ]] (ACAT2) inhibitors: Part 2.,Synthesis and structure-activity relationship of [ENTITY_A] derivatives as potent and selective [ENTITY_B] (ACAT2) inhibitors: Part 2.,INHIBITOR,CPR:4,1,Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors: Part 2.
<< Adrenaline >> inhibits [[ insulin ]] secretion via pertussis toxin-sensitive mechanisms.,[ENTITY_A] inhibits [ENTITY_B] secretion via pertussis toxin-sensitive mechanisms.,INDIRECT-DOWNREGULATOR,CPR:4,1,Adrenaline inhibits insulin secretion via pertussis toxin-sensitive mechanisms.
<< Somatostatin >> which also inhibits [[ insulin ]] secretion was less efficient (inhibition by 20%).,[ENTITY_A] which also inhibits [ENTITY_B] secretion was less efficient (inhibition by 20%).,INDIRECT-DOWNREGULATOR,CPR:4,1,Somatostatin which also inhibits insulin secretion was less efficient (inhibition by 20%).
"In contrast to << adrenaline >> and somatostatin, galanin, another inhibitor of [[ insulin ]] secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner.","In contrast to [ENTITY_A] and somatostatin, galanin, another inhibitor of [ENTITY_B] secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In contrast to adrenaline and somatostatin, galanin, another inhibitor of insulin secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner."
These G-proteins are likely to be involved in the adrenaline-induced inhibition of dihydropyridine-sensitive Ca2+ currents and in other signal transduction pathways contributing to the << adrenaline >>-induced inhibition of [[ insulin ]] secretion.,These G-proteins are likely to be involved in the adrenaline-induced inhibition of dihydropyridine-sensitive Ca2+ currents and in other signal transduction pathways contributing to the [ENTITY_A]-induced inhibition of [ENTITY_B] secretion.,INDIRECT-DOWNREGULATOR,CPR:4,1,These G-proteins are likely to be involved in the adrenaline-induced inhibition of dihydropyridine-sensitive Ca2+ currents and in other signal transduction pathways contributing to the adrenaline-induced inhibition of insulin secretion.
Synthesis and in Vitro Characterisation of << Ifenprodil >>-Based Fluorescein Conjugates as [[ GluN1 ]]/GluN2B N-Methyl-D-aspartate Receptor Antagonists.,Synthesis and in Vitro Characterisation of [ENTITY_A]-Based Fluorescein Conjugates as [ENTITY_B]/GluN2B N-Methyl-D-aspartate Receptor Antagonists.,ANTAGONIST,CPR:6,3,Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B N-Methyl-D-aspartate Receptor Antagonists.
"<< Ifenprodil >>, known as the [[ GluNR2B ]] antagonist of reference, was chosen as the template for the elaboration of probes.","[ENTITY_A], known as the [ENTITY_B] antagonist of reference, was chosen as the template for the elaboration of probes.",ANTAGONIST,CPR:6,3,"Ifenprodil, known as the GluNR2B antagonist of reference, was chosen as the template for the elaboration of probes."
Molecular determinants for the selective inhibition of << cyclooxygenase-2 >> by [[ lumiracoxib ]].,Molecular determinants for the selective inhibition of [ENTITY_A] by [ENTITY_B].,INHIBITOR,CPR:4,1,Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib.
"Lumiracoxib is the first example of a marketed << COX-2 >> inhibitor of the [[ arylacetic acid ]] class, and it is reported to be the most selective COXIB in vivo.","Lumiracoxib is the first example of a marketed [ENTITY_A] inhibitor of the [ENTITY_B] class, and it is reported to be the most selective COXIB in vivo.",INHIBITOR,CPR:4,1,"Lumiracoxib is the first example of a marketed COX-2 inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo."
"Using standard assays, << lumiracoxib >> was found to be a poor inhibitor of purified [[ ovine COX-1 ]] and a relatively weak inhibitor of purified human COX-2.","Using standard assays, [ENTITY_A] was found to be a poor inhibitor of purified [ENTITY_B] and a relatively weak inhibitor of purified human COX-2.",INHIBITOR,CPR:4,1,"Using standard assays, lumiracoxib was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified human COX-2."
Kinetic studies with << lumiracoxib >> demonstrated that it was a time-dependent and slowly reversible inhibitor of [[ human COX-2 ]] that exhibited at least two binding steps during inhibition.,Kinetic studies with [ENTITY_A] demonstrated that it was a time-dependent and slowly reversible inhibitor of [ENTITY_B] that exhibited at least two binding steps during inhibition.,INHIBITOR,CPR:4,1,Kinetic studies with lumiracoxib demonstrated that it was a time-dependent and slowly reversible inhibitor of human COX-2 that exhibited at least two binding steps during inhibition.
Inhibition studies demonstrated that the << methyl >> group on the phenylacetic acid ring is required for [[ COX-2 ]] selectivity.,Inhibition studies demonstrated that the [ENTITY_A] group on the phenylacetic acid ring is required for [ENTITY_B] selectivity.,INHIBITOR,CPR:4,1,Inhibition studies demonstrated that the methyl group on the phenylacetic acid ring is required for COX-2 selectivity.
The chemical identity and position of the substituents on the lower << aniline >> ring were important in determining the potency and extent of [[ COX ]] inhibition as well as COX-2 selectivity.,The chemical identity and position of the substituents on the lower [ENTITY_A] ring were important in determining the potency and extent of [ENTITY_B] inhibition as well as COX-2 selectivity.,INHIBITOR,CPR:4,1,The chemical identity and position of the substituents on the lower aniline ring were important in determining the potency and extent of COX inhibition as well as COX-2 selectivity.
Mutation of Ser-530 to Ala or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type << human COX-2 >> and key [[ lumiracoxib ]] analogs.,Mutation of Ser-530 to Ala or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type [ENTITY_A] and key [ENTITY_B] analogs.,INHIBITOR,CPR:4,1,Mutation of Ser-530 to Ala or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs.
"Interestingly, a << Val-349 to Ile >> mutant was inhibited with equal potency to human COX-2 with [[ 2,6-dichloro ]]-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.","Interestingly, a [ENTITY_A] mutant was inhibited with equal potency to human COX-2 with [ENTITY_B]-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.",INHIBITOR,CPR:4,1,"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency."
"Taken together with a recent crystal structure of a lumiracoxib-COX-2 complex, the kinetic analyses presented herein of the inhibition of mutant << COX-2s >> by [[ lumiracoxib ]] allows the definition of the molecular basis of COX-2 inhibition.","Taken together with a recent crystal structure of a lumiracoxib-COX-2 complex, the kinetic analyses presented herein of the inhibition of mutant [ENTITY_A] by [ENTITY_B] allows the definition of the molecular basis of COX-2 inhibition.",INHIBITOR,CPR:4,1,"Taken together with a recent crystal structure of a lumiracoxib-COX-2 complex, the kinetic analyses presented herein of the inhibition of mutant COX-2s by lumiracoxib allows the definition of the molecular basis of COX-2 inhibition."
"The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on << VMAT2 >> activity by measuring adenosine triphosphate-dependent [[ [(3)H]dopamine ]] uptake into synaptic vesicles prepared from rat striatum.","The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on [ENTITY_A] activity by measuring adenosine triphosphate-dependent [ENTITY_B] uptake into synaptic vesicles prepared from rat striatum.",SUBSTRATE,CPR:9,4,"The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on VMAT2 activity by measuring adenosine triphosphate-dependent [(3)H]dopamine uptake into synaptic vesicles prepared from rat striatum."
"Moreover, kinetic analysis revealed that inhibition by << reserpine >>, a typical [[ VMAT2 ]] inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine.","Moreover, kinetic analysis revealed that inhibition by [ENTITY_A], a typical [ENTITY_B] inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine.",INHIBITOR,CPR:4,1,"Moreover, kinetic analysis revealed that inhibition by reserpine, a typical VMAT2 inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine."
"Moreover, kinetic analysis revealed that inhibition by reserpine, a typical << VMAT2 >> inhibitor, was uncompetitive, decreasing maximum velocity and affinity for [[ dopamine ]].","Moreover, kinetic analysis revealed that inhibition by reserpine, a typical [ENTITY_A] inhibitor, was uncompetitive, decreasing maximum velocity and affinity for [ENTITY_B].",SUBSTRATE,CPR:9,4,"Moreover, kinetic analysis revealed that inhibition by reserpine, a typical VMAT2 inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine."
These results suggest that fluoxetine inhibited the activity of << VMAT2 >> by a mechanism different from that of [[ reserpine ]] and did not directly interact with the active site of VMAT2.,These results suggest that fluoxetine inhibited the activity of [ENTITY_A] by a mechanism different from that of [ENTITY_B] and did not directly interact with the active site of VMAT2.,INHIBITOR,CPR:4,1,These results suggest that fluoxetine inhibited the activity of VMAT2 by a mechanism different from that of reserpine and did not directly interact with the active site of VMAT2.
"<< Betaxolol >>, a [[ beta(1)-adrenoceptor ]] antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.","[ENTITY_A], a [ENTITY_B] antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.",ANTAGONIST,CPR:6,3,"Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists."
"<< Betaxolol >>, a [[ beta(1)-adrenoceptor ]] antagonist used for the treatment of glaucoma, is known to be neuroprotective in paradigms of ischaemia/excitotoxicity.","[ENTITY_A], a [ENTITY_B] antagonist used for the treatment of glaucoma, is known to be neuroprotective in paradigms of ischaemia/excitotoxicity.",ANTAGONIST,CPR:6,3,"Betaxolol, a beta(1)-adrenoceptor antagonist used for the treatment of glaucoma, is known to be neuroprotective in paradigms of ischaemia/excitotoxicity."
"In this study, we examined whether << betaxolol >> and other [[ beta-adrenoceptor ]] antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes.","In this study, we examined whether [ENTITY_A] and other [ENTITY_B] antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes.",ANTAGONIST,CPR:6,3,"In this study, we examined whether betaxolol and other beta-adrenoceptor antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes."
Comparison of all the << beta-adrenoceptor >> antagonists tested revealed a potency order of [[ propranolol ]]>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol>atenolol.,Comparison of all the [ENTITY_A] antagonists tested revealed a potency order of [ENTITY_B]>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol>atenolol.,ANTAGONIST,CPR:6,3,Comparison of all the beta-adrenoceptor antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol>atenolol.
<< Leukotriene D4 >> induces cognitive impairment through enhancement of [[ CysLT₁ R ]]-mediated amyloid-β generation in mice.,[ENTITY_A] induces cognitive impairment through enhancement of [ENTITY_B]-mediated amyloid-β generation in mice.,ACTIVATOR,CPR:3,0,Leukotriene D4 induces cognitive impairment through enhancement of CysLT₁ R-mediated amyloid-β generation in mice.
"The results demonstrated that intracerebral infusions of << LTD4 >> (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of [[ Aβ1-40 ]] and Aβ1-42 in the hippocampus and cortex through increased activity of β- and γ-secretases accompanied with increased expression of amyloid precursor protein (APP).","The results demonstrated that intracerebral infusions of [ENTITY_A] (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of [ENTITY_B] and Aβ1-42 in the hippocampus and cortex through increased activity of β- and γ-secretases accompanied with increased expression of amyloid precursor protein (APP).",INDIRECT-UPREGULATOR,CPR:3,0,"The results demonstrated that intracerebral infusions of LTD4 (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of Aβ1-40 and Aβ1-42 in the hippocampus and cortex through increased activity of β- and γ-secretases accompanied with increased expression of amyloid precursor protein (APP)."
<< LTD4 >> also induced expression of [[ cysteinyl leukotriene receptor 1 ]] (CysLT(1)R) and NF-κB p65 in the hippocampus and cortex.,[ENTITY_A] also induced expression of [ENTITY_B] (CysLT(1)R) and NF-κB p65 in the hippocampus and cortex.,INDIRECT-UPREGULATOR,CPR:3,0,LTD4 also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-κB p65 in the hippocampus and cortex.
"Pretreatment with << pranlukast >> (1.5 ng/mouse, intracerebroventricularly), a [[ CysLT(1)R ]] antagonist, blocked LTD4-induced amyloidogenesis, memory deficits.","Pretreatment with [ENTITY_A] (1.5 ng/mouse, intracerebroventricularly), a [ENTITY_B] antagonist, blocked LTD4-induced amyloidogenesis, memory deficits.",ANTAGONIST,CPR:6,3,"Pretreatment with pranlukast (1.5 ng/mouse, intracerebroventricularly), a CysLT(1)R antagonist, blocked LTD4-induced amyloidogenesis, memory deficits."
"Moreover, << LTD4 >>-induced increases in [[ CysLT(1)R ]] and NF-κB p65 in the brain were also attenuated by pranlukast.","Moreover, [ENTITY_A]-induced increases in [ENTITY_B] and NF-κB p65 in the brain were also attenuated by pranlukast.",INDIRECT-UPREGULATOR,CPR:3,0,"Moreover, LTD4-induced increases in CysLT(1)R and NF-κB p65 in the brain were also attenuated by pranlukast."
"Moreover, LTD4-induced increases in << CysLT(1)R >> and NF-κB p65 in the brain were also attenuated by [[ pranlukast ]].","Moreover, LTD4-induced increases in [ENTITY_A] and NF-κB p65 in the brain were also attenuated by [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, LTD4-induced increases in CysLT(1)R and NF-κB p65 in the brain were also attenuated by pranlukast."
"These results suggest that << LTD4 >> increases Aβ peptide burden via activation of [[ CysLT(1)R ]], which further affects APP levels and activity of β- and γ-secretases via the NF-κB pathway.","These results suggest that [ENTITY_A] increases Aβ peptide burden via activation of [ENTITY_B], which further affects APP levels and activity of β- and γ-secretases via the NF-κB pathway.",ACTIVATOR,CPR:3,0,"These results suggest that LTD4 increases Aβ peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of β- and γ-secretases via the NF-κB pathway."
<< Statins >> increase [[ p21 ]] through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.,[ENTITY_A] increase [ENTITY_B] through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.,INDIRECT-UPREGULATOR,CPR:3,0,Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
<< Statins >> increase p21 through inhibition of [[ histone deacetylase ]] activity and release of promoter-associated HDAC1/2.,[ENTITY_A] increase p21 through inhibition of [ENTITY_B] activity and release of promoter-associated HDAC1/2.,INHIBITOR,CPR:4,1,Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
<< Statins >> are [[ 3-hydroxy-3-methylglutaryl-CoA reductase ]] inhibitors broadly used for the control of hypercholesterolemia.,[ENTITY_A] are [ENTITY_B] inhibitors broadly used for the control of hypercholesterolemia.,INHIBITOR,CPR:4,1,Statins are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors broadly used for the control of hypercholesterolemia.
"In the subsequent enzymatic assay, it was shown that << lovastatin >> inhibited [[ HDAC2 ]] activity competitively with a K(i) value of 31.6 micromol/L.","In the subsequent enzymatic assay, it was shown that [ENTITY_A] inhibited [ENTITY_B] activity competitively with a K(i) value of 31.6 micromol/L.",INHIBITOR,CPR:4,1,"In the subsequent enzymatic assay, it was shown that lovastatin inhibited HDAC2 activity competitively with a K(i) value of 31.6 micromol/L."
"Recent studies have reported that << imatinib mesylate >>, a kinase inhibitor that targets the intracellular [[ tyrosine kinase ]] BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS.","Recent studies have reported that [ENTITY_A], a kinase inhibitor that targets the intracellular [ENTITY_B] BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS.",INHIBITOR,CPR:4,1,"Recent studies have reported that imatinib mesylate, a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS."
"Given that << M-CSF >> signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with [[ imatinib ]] may modulate osteoclast activity.","Given that [ENTITY_A] signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with [ENTITY_B] may modulate osteoclast activity.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Given that M-CSF signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with imatinib may modulate osteoclast activity."
"Imatinib was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that << imatinib >> may affect mature osteoclasts through the inhibition of [[ c-FMS ]].","Imatinib was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that [ENTITY_A] may affect mature osteoclasts through the inhibition of [ENTITY_B].",INHIBITOR,CPR:4,1,"Imatinib was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS."
Structural basis for << LFA-1 >> inhibition upon [[ lovastatin ]] binding to the CD11a I-domain.,Structural basis for [ENTITY_A] inhibition upon [ENTITY_B] binding to the CD11a I-domain.,INHIBITOR,CPR:4,1,Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain.
"We report here that << lovastatin >>, a drug clinically used for lowering cholesterol levels, inhibits the interaction of [[ human LFA-1 ]] with its counter-receptor intercellular adhesion molecule-1.","We report here that [ENTITY_A], a drug clinically used for lowering cholesterol levels, inhibits the interaction of [ENTITY_B] with its counter-receptor intercellular adhesion molecule-1.",INHIBITOR,CPR:4,1,"We report here that lovastatin, a drug clinically used for lowering cholesterol levels, inhibits the interaction of human LFA-1 with its counter-receptor intercellular adhesion molecule-1."
"Particularly, the effects of << doxycycline >> used as a non selective [[ MMP ]] inhibitor in experimental and clinical studies will be discussed.","Particularly, the effects of [ENTITY_A] used as a non selective [ENTITY_B] inhibitor in experimental and clinical studies will be discussed.",INHIBITOR,CPR:4,1,"Particularly, the effects of doxycycline used as a non selective MMP inhibitor in experimental and clinical studies will be discussed."
Time-dependent changes in hepatic and intestinal induction of << cytochrome P450 3A >> after administration of [[ dexamethasone ]] to rats.,Time-dependent changes in hepatic and intestinal induction of [ENTITY_A] after administration of [ENTITY_B] to rats.,ACTIVATOR,CPR:3,0,Time-dependent changes in hepatic and intestinal induction of cytochrome P450 3A after administration of dexamethasone to rats.
"Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal << cytochrome P450 3A >> (CYP3A) in rats using [[ dexamethasone 21-phosphate ]] (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.","Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal [ENTITY_A] (CYP3A) in rats using [ENTITY_B] (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.",ACTIVATOR,CPR:3,0,"Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively."
"Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using << dexamethasone 21-phosphate >> (DEX-P) and midazolam (MDZ) as an inducer and a substrate to [[ CYP3A ]], respectively.","Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using [ENTITY_A] (DEX-P) and midazolam (MDZ) as an inducer and a substrate to [ENTITY_B], respectively.",SUBSTRATE,CPR:9,4,"Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively."
"3. << CYP3A >> induction in the liver increased depending on the dose of [[ DEX-P ]], whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P.","3. [ENTITY_A] induction in the liver increased depending on the dose of [ENTITY_B], whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P.",ACTIVATOR,CPR:3,0,"3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P."
4. Administration of a single dose of << DEX-P >> showed a temporal increase in [[ CYP3A ]] activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration.,4. Administration of a single dose of [ENTITY_A] showed a temporal increase in [ENTITY_B] activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration.,ACTIVATOR,CPR:3,0,4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration.
<< LDH >> is responsible for pyruvate conversion to [[ lactate ]] through glycolysis.,[ENTITY_A] is responsible for pyruvate conversion to [ENTITY_B] through glycolysis.,PRODUCT-OF,CPR:9,4,LDH is responsible for pyruvate conversion to lactate through glycolysis.
Preclinical pharmacokinetics and in vitro metabolism of << dasatinib >> (BMS-354825): a potent oral multi-targeted [[ kinase ]] inhibitor against SRC and BCR-ABL.,Preclinical pharmacokinetics and in vitro metabolism of [ENTITY_A] (BMS-354825): a potent oral multi-targeted [ENTITY_B] inhibitor against SRC and BCR-ABL.,INHIBITOR,CPR:4,1,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
"PURPOSE: << Dasatinib >> (BMS-354825), a potent oral multi-targeted [[ kinase ]] inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.","PURPOSE: [ENTITY_A] (BMS-354825), a potent oral multi-targeted [ENTITY_B] inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.",INHIBITOR,CPR:4,1,"PURPOSE: Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance."
"The results of this study suggest that << noradrenaline >> predominantly, but not exclusively, mediates contraction of rat aorta through the activation of an [[ alphalD-adrenoceptor ]].","The results of this study suggest that [ENTITY_A] predominantly, but not exclusively, mediates contraction of rat aorta through the activation of an [ENTITY_B].",ACTIVATOR,CPR:3,0,"The results of this study suggest that noradrenaline predominantly, but not exclusively, mediates contraction of rat aorta through the activation of an alphalD-adrenoceptor."
"An increase in the << ADP >>/ATP ratio opens [[ K(ATP) channels ]], leading to membrane hyperpolarization.","An increase in the [ENTITY_A]/ATP ratio opens [ENTITY_B], leading to membrane hyperpolarization.",ACTIVATOR,CPR:3,0,"An increase in the ADP/ATP ratio opens K(ATP) channels, leading to membrane hyperpolarization."
"Comparison of the effect of << rofecoxib >> (a [[ cyclooxygenase 2 ]] inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial.","Comparison of the effect of [ENTITY_A] (a [ENTITY_B] inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial.",INHIBITOR,CPR:4,1,"Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial."
"OBJECTIVE: This randomized, double-blind study tested the hypothesis that << rofecoxib >>, a drug that specifically inhibits [[ cyclooxygenase 2 ]], would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design).","OBJECTIVE: This randomized, double-blind study tested the hypothesis that [ENTITY_A], a drug that specifically inhibits [ENTITY_B], would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design).",INHIBITOR,CPR:4,1,"OBJECTIVE: This randomized, double-blind study tested the hypothesis that rofecoxib, a drug that specifically inhibits cyclooxygenase 2, would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design)."
"<< [-]-Huperzine A >> ([-]-Hup A), is a naturally occurring potent reversible [[ AChE ]] inhibitor that penetrates the blood-brain barrier.","[ENTITY_A] ([-]-Hup A), is a naturally occurring potent reversible [ENTITY_B] inhibitor that penetrates the blood-brain barrier.",INHIBITOR,CPR:4,1,"[-]-Huperzine A ([-]-Hup A), is a naturally occurring potent reversible AChE inhibitor that penetrates the blood-brain barrier."
"The synthetic stereoisomer, << [+]-Hup A >>, is less toxic due to poor [[ AChE ]] inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity.","The synthetic stereoisomer, [ENTITY_A], is less toxic due to poor [ENTITY_B] inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity.",INHIBITOR,CPR:4,1,"The synthetic stereoisomer, [+]-Hup A, is less toxic due to poor AChE inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity."
"Also, << vinblastine >> enhances the phosphorylation of [[ Ras homologous protein A ]], the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α.","Also, [ENTITY_A] enhances the phosphorylation of [ENTITY_B], the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α.",ACTIVATOR,CPR:3,0,"Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α."
"In addition, << vinblastine >> induces the DNA-binding activities of the transcription factor [[ NF-κB ]], HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins.","In addition, [ENTITY_A] induces the DNA-binding activities of the transcription factor [ENTITY_B], HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins.",ACTIVATOR,CPR:3,0,"In addition, vinblastine induces the DNA-binding activities of the transcription factor NF-κB, HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins."
Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both << cAMP >> and cGMP ([[ PDE10A ]]).,Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both [ENTITY_A] and cGMP ([ENTITY_B]).,SUBSTRATE,CPR:9,4,Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A).
"Recombinant << PDE10A >> transfected and expressed in COS-7 cells hydrolyzed [[ cAMP ]] and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP.","Recombinant [ENTITY_A] transfected and expressed in COS-7 cells hydrolyzed [ENTITY_B] and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP.",SUBSTRATE,CPR:9,4,"Recombinant PDE10A transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP."
"Of the << PDE >> inhibitors tested, [[ dipyridamole ]] was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively.","Of the [ENTITY_A] inhibitors tested, [ENTITY_B] was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively.",INHIBITOR,CPR:4,1,"Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively."
"Of the << PDE >> inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of [[ cAMP ]] and cGMP hydrolysis, respectively.","Of the [ENTITY_A] inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of [ENTITY_B] and cGMP hydrolysis, respectively.",SUBSTRATE,CPR:9,4,"Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively."
The << cytosine >> analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting [[ DNA methyltransferase ]].,The [ENTITY_A] analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting [ENTITY_B].,INHIBITOR,CPR:4,1,The cytosine analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting DNA methyltransferase.
We examined if subcutaneous << decitabine >> could increase [[ HbF ]] levels and improve SSD pathophysiology without cytotoxicity.,We examined if subcutaneous [ENTITY_A] could increase [ENTITY_B] levels and improve SSD pathophysiology without cytotoxicity.,INDIRECT-UPREGULATOR,CPR:3,0,We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity.
Weekly subcutaneous << decitabine >> produces cumulative increases in [[ HbF ]] and total hemoglobin through a noncytotoxic mechanism of action.,Weekly subcutaneous [ENTITY_A] produces cumulative increases in [ENTITY_B] and total hemoglobin through a noncytotoxic mechanism of action.,INDIRECT-UPREGULATOR,CPR:3,0,Weekly subcutaneous decitabine produces cumulative increases in HbF and total hemoglobin through a noncytotoxic mechanism of action.
"<< Nox4 >> oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific [[ quinone ]] derivatives could modulate this activity.","[ENTITY_A] oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific [ENTITY_B] derivatives could modulate this activity.",ACTIVATOR,CPR:3,0,"Nox4 oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific quinone derivatives could modulate this activity."
"In fact, we demonstrated a significant stimulation of << Nox4 >> activity by 4 [[ quinone ]] derivatives (AA-861, tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx™, and chondrocyte cell lines.","In fact, we demonstrated a significant stimulation of [ENTITY_A] activity by 4 [ENTITY_B] derivatives (AA-861, tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx™, and chondrocyte cell lines.",ACTIVATOR,CPR:3,0,"In fact, we demonstrated a significant stimulation of Nox4 activity by 4 quinone derivatives (AA-861, tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx™, and chondrocyte cell lines."
"Such model of << Nox4 >> activity regulation could provide new insight into the understanding of the molecular mechanism of the electron transfer through the enzyme, i.e., its potential redox regulation, and could also define new therapeutic targets in diseases in which [[ quinones ]] and Nox4 are implicated.","Such model of [ENTITY_A] activity regulation could provide new insight into the understanding of the molecular mechanism of the electron transfer through the enzyme, i.e., its potential redox regulation, and could also define new therapeutic targets in diseases in which [ENTITY_B] and Nox4 are implicated.",ACTIVATOR,CPR:3,0,"Such model of Nox4 activity regulation could provide new insight into the understanding of the molecular mechanism of the electron transfer through the enzyme, i.e., its potential redox regulation, and could also define new therapeutic targets in diseases in which quinones and Nox4 are implicated."
"Although the inhibition of << cyclooxygenases >> by [[ aspirin ]], which leads to its anti-inflammatory/analgesic properties, has been well studied, the mechanisms involved in its chemopreventive effects as well as some of its adverse effects are as yet ill-defined.","Although the inhibition of [ENTITY_A] by [ENTITY_B], which leads to its anti-inflammatory/analgesic properties, has been well studied, the mechanisms involved in its chemopreventive effects as well as some of its adverse effects are as yet ill-defined.",INHIBITOR,CPR:4,1,"Although the inhibition of cyclooxygenases by aspirin, which leads to its anti-inflammatory/analgesic properties, has been well studied, the mechanisms involved in its chemopreventive effects as well as some of its adverse effects are as yet ill-defined."
"In a recent study using protein-specific anti-acetyl lysine antibodies and immunological methods, we demonstrated the ability of << aspirin >> to acetylate the [[ tumor suppressor protein p53 ]].","In a recent study using protein-specific anti-acetyl lysine antibodies and immunological methods, we demonstrated the ability of [ENTITY_A] to acetylate the [ENTITY_B].",ACTIVATOR,CPR:3,0,"In a recent study using protein-specific anti-acetyl lysine antibodies and immunological methods, we demonstrated the ability of aspirin to acetylate the tumor suppressor protein p53."
"Second, << ICRF-187 >>, a [[ Top2 ]] catalytic inhibitor known to deplete Top2β, specifically sensitized MEFs to CPT.","Second, [ENTITY_A], a [ENTITY_B] catalytic inhibitor known to deplete Top2β, specifically sensitized MEFs to CPT.",INHIBITOR,CPR:4,1,"Second, ICRF-187, a Top2 catalytic inhibitor known to deplete Top2β, specifically sensitized MEFs to CPT."
"To explore the molecular basis for CPT hypersensitivity in Top2β-deficient cells, we found that upon << CPT >> exposure, the [[ RNA polymerase II large subunit ]] (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2β-deficient cells.","To explore the molecular basis for CPT hypersensitivity in Top2β-deficient cells, we found that upon [ENTITY_A] exposure, the [ENTITY_B] (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2β-deficient cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"To explore the molecular basis for CPT hypersensitivity in Top2β-deficient cells, we found that upon CPT exposure, the RNA polymerase II large subunit (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2β-deficient cells."
"Altogether, our findings support a model in which Top2β deficiency promotes << CPT >>-induced apoptosis in quiescent non-S-phase cells, possibly due to RNAP LS depletion and [[ p53 ]] accumulation.","Altogether, our findings support a model in which Top2β deficiency promotes [ENTITY_A]-induced apoptosis in quiescent non-S-phase cells, possibly due to RNAP LS depletion and [ENTITY_B] accumulation.",INDIRECT-UPREGULATOR,CPR:3,0,"Altogether, our findings support a model in which Top2β deficiency promotes CPT-induced apoptosis in quiescent non-S-phase cells, possibly due to RNAP LS depletion and p53 accumulation."
"Altogether, our findings support a model in which Top2β deficiency promotes << CPT >>-induced apoptosis in quiescent non-S-phase cells, possibly due to [[ RNAP LS ]] depletion and p53 accumulation.","Altogether, our findings support a model in which Top2β deficiency promotes [ENTITY_A]-induced apoptosis in quiescent non-S-phase cells, possibly due to [ENTITY_B] depletion and p53 accumulation.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Altogether, our findings support a model in which Top2β deficiency promotes CPT-induced apoptosis in quiescent non-S-phase cells, possibly due to RNAP LS depletion and p53 accumulation."
Effects of << felodipine >> (a dihydropyridine [[ calcium channel ]] blocker) and analogues on calmodulin-dependent enzymes.,Effects of [ENTITY_A] (a dihydropyridine [ENTITY_B] blocker) and analogues on calmodulin-dependent enzymes.,INHIBITOR,CPR:4,1,Effects of felodipine (a dihydropyridine calcium channel blocker) and analogues on calmodulin-dependent enzymes.
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine << Ca2+ channel >> blocker [[ felodipine ]] and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine [ENTITY_A] blocker [ENTITY_B] and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.",INHIBITOR,CPR:4,1,"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies."
The << cAMP phosphodiesterase >> was inhibited completely by [[ felodipine ]] and the p-chloro analogue with IC50 values of 3.7 and 1.5 microM respectively.,The [ENTITY_A] was inhibited completely by [ENTITY_B] and the p-chloro analogue with IC50 values of 3.7 and 1.5 microM respectively.,INHIBITOR,CPR:4,1,The cAMP phosphodiesterase was inhibited completely by felodipine and the p-chloro analogue with IC50 values of 3.7 and 1.5 microM respectively.
<< Felodipine >> and the p-chloro analogue inhibited the basal (Ca2+/calmodulin-independent) activity of [[ cAMP phosphodiesterase ]] as well as the calmodulin-stimulated activity.,[ENTITY_A] and the p-chloro analogue inhibited the basal (Ca2+/calmodulin-independent) activity of [ENTITY_B] as well as the calmodulin-stimulated activity.,INHIBITOR,CPR:4,1,Felodipine and the p-chloro analogue inhibited the basal (Ca2+/calmodulin-independent) activity of cAMP phosphodiesterase as well as the calmodulin-stimulated activity.
Calmodulin was relatively ineffective in preventing inhibition of << cAMP phosphodiesterase >> by [[ felodipine ]] and the p-chloro analogue.,Calmodulin was relatively ineffective in preventing inhibition of [ENTITY_A] by [ENTITY_B] and the p-chloro analogue.,INHIBITOR,CPR:4,1,Calmodulin was relatively ineffective in preventing inhibition of cAMP phosphodiesterase by felodipine and the p-chloro analogue.
"<< Felodipine >> and the p-chloro analogue inhibited Ca2+/calmodulin-dependent [[ caldesmon kinase ]] with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition.","[ENTITY_A] and the p-chloro analogue inhibited Ca2+/calmodulin-dependent [ENTITY_B] with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition.",INHIBITOR,CPR:4,1,"Felodipine and the p-chloro analogue inhibited Ca2+/calmodulin-dependent caldesmon kinase with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition."
"Similarly, << felodipine >> and the p-chloro analogue inhibited [[ myosin light chain kinase ]] activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact myosin (IC50 = 11.0 microM) was used as substrate.","Similarly, [ENTITY_A] and the p-chloro analogue inhibited [ENTITY_B] activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact myosin (IC50 = 11.0 microM) was used as substrate.",INHIBITOR,CPR:4,1,"Similarly, felodipine and the p-chloro analogue inhibited myosin light chain kinase activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact myosin (IC50 = 11.0 microM) was used as substrate."
Felodipine and the << p-chloro >> analogue inhibited the actin-activated [[ Mg2+-ATPase ]] activity of smooth muscle myosin (IC50 = 25.1 microM).,Felodipine and the [ENTITY_A] analogue inhibited the actin-activated [ENTITY_B] activity of smooth muscle myosin (IC50 = 25.1 microM).,INHIBITOR,CPR:4,1,Felodipine and the p-chloro analogue inhibited the actin-activated Mg2+-ATPase activity of smooth muscle myosin (IC50 = 25.1 microM).
"Similarly, << felodipine >> and the p-chloro analogue blocked [[ myosin ]] filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not.","Similarly, [ENTITY_A] and the p-chloro analogue blocked [ENTITY_B] filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not.",INHIBITOR,CPR:4,1,"Similarly, felodipine and the p-chloro analogue blocked myosin filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not."
"Again, inhibition of the actin-activated << myosin >> Mg2+-ATPase and myosin filament assembly by [[ felodipine ]] and the p-chloro analogue could be reversed by raising the calmodulin concentration.","Again, inhibition of the actin-activated [ENTITY_A] Mg2+-ATPase and myosin filament assembly by [ENTITY_B] and the p-chloro analogue could be reversed by raising the calmodulin concentration.",INHIBITOR,CPR:4,1,"Again, inhibition of the actin-activated myosin Mg2+-ATPase and myosin filament assembly by felodipine and the p-chloro analogue could be reversed by raising the calmodulin concentration."
These observations suggest that some of the pharmacological actions of << felodipine >> on smooth muscle may involve inhibition of [[ calmodulin-dependent enzymes ]] which are functionally involved in the regulation of smooth muscle contraction.,These observations suggest that some of the pharmacological actions of [ENTITY_A] on smooth muscle may involve inhibition of [ENTITY_B] which are functionally involved in the regulation of smooth muscle contraction.,INHIBITOR,CPR:4,1,These observations suggest that some of the pharmacological actions of felodipine on smooth muscle may involve inhibition of calmodulin-dependent enzymes which are functionally involved in the regulation of smooth muscle contraction.
<< Aldosterone >>-induced [[ ENaC ]] and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells.,[ENTITY_A]-induced [ENTITY_B] and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells.,INDIRECT-UPREGULATOR,CPR:3,0,Aldosterone-induced ENaC and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells.
<< Aldosterone >> also induces the rapid phosphorylation of [[ Protein Kinase D1 ]] (PKD1).,[ENTITY_A] also induces the rapid phosphorylation of [ENTITY_B] (PKD1).,ACTIVATOR,CPR:3,0,Aldosterone also induces the rapid phosphorylation of Protein Kinase D1 (PKD1).
This effect has been attributed to the antagonist effects of << pindolol >> at the [[ 5-HT(1A) ]] receptor.,This effect has been attributed to the antagonist effects of [ENTITY_A] at the [ENTITY_B] receptor.,ANTAGONIST,CPR:6,3,This effect has been attributed to the antagonist effects of pindolol at the 5-HT(1A) receptor.
"In the present study, we compared the pharmacology of << (+/-)pindolol >>, WAY-100635 (a [[ 5-HT(1A) ]] antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.","In the present study, we compared the pharmacology of [ENTITY_A], WAY-100635 (a [ENTITY_B] antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.",ANTAGONIST,CPR:6,3,"In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat."
"In addition, by comparing the combined administration of (+/-)pindolol with either WAY100635, GR127935 or isamoltane, we have determined that << (+/-)pindolol >> produces much of its acute potentiation of fluoxetine-induced increases in extracellular 5-HT via its action at the 5-HT(1B/D) receptor in addition to any activity it has at the presynaptic [[ 5-HT(1A) ]] receptor.","In addition, by comparing the combined administration of (+/-)pindolol with either WAY100635, GR127935 or isamoltane, we have determined that [ENTITY_A] produces much of its acute potentiation of fluoxetine-induced increases in extracellular 5-HT via its action at the 5-HT(1B/D) receptor in addition to any activity it has at the presynaptic [ENTITY_B] receptor.",ANTAGONIST,CPR:6,3,"In addition, by comparing the combined administration of (+/-)pindolol with either WAY100635, GR127935 or isamoltane, we have determined that (+/-)pindolol produces much of its acute potentiation of fluoxetine-induced increases in extracellular 5-HT via its action at the 5-HT(1B/D) receptor in addition to any activity it has at the presynaptic 5-HT(1A) receptor."
"In the local presence into the LC of the << α2-adrenoceptor >> antagonist [[ RS79948 ]] (1 μM), systemic citalopram increased NA in the LC (Emax = 157 ± 25 %) and PFC (Emax = 175 ± 24 %).","In the local presence into the LC of the [ENTITY_A] antagonist [ENTITY_B] (1 μM), systemic citalopram increased NA in the LC (Emax = 157 ± 25 %) and PFC (Emax = 175 ± 24 %).",ANTAGONIST,CPR:6,3,"In the local presence into the LC of the α2-adrenoceptor antagonist RS79948 (1 μM), systemic citalopram increased NA in the LC (Emax = 157 ± 25 %) and PFC (Emax = 175 ± 24 %)."
Local LC citalopram effect was abolished by LC presence of the << 5-HT3 >> receptor antagonist [[ MDL72222 ]] (1 μM) but not the 5-HT1/2 receptor antagonist methiothepin (1 μM).,Local LC citalopram effect was abolished by LC presence of the [ENTITY_A] receptor antagonist [ENTITY_B] (1 μM) but not the 5-HT1/2 receptor antagonist methiothepin (1 μM).,ANTAGONIST,CPR:6,3,Local LC citalopram effect was abolished by LC presence of the 5-HT3 receptor antagonist MDL72222 (1 μM) but not the 5-HT1/2 receptor antagonist methiothepin (1 μM).
alpha(1)-Adrenoceptor antagonists were tested against the << phenylephrine >> ([[ alpha(1)-adrenoceptor ]] agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach.,alpha(1)-Adrenoceptor antagonists were tested against the [ENTITY_A] ([ENTITY_B] agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach.,AGONIST,CPR:5,2,alpha(1)-Adrenoceptor antagonists were tested against the phenylephrine (alpha(1)-adrenoceptor agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach.
"Noradrenaline and << phenylephrine >> ([[ alpha(1)-adrenoceptor ]] agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively.","Noradrenaline and [ENTITY_A] ([ENTITY_B] agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively.",AGONIST,CPR:5,2,"Noradrenaline and phenylephrine (alpha(1)-adrenoceptor agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively."
"Prazosin (nonselective << alpha(1)-adrenoceptor >> antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the [[ phenylephrine ]]-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).","Prazosin (nonselective [ENTITY_A] antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the [ENTITY_B]-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",AGONIST,CPR:5,2,"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)."
"<< Prazosin >> (nonselective [[ alpha(1)-adrenoceptor ]] antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).","[ENTITY_A] (nonselective [ENTITY_B] antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",ANTAGONIST,CPR:6,3,"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)."
"BDZs and other positive GABA(A)R modulators, including << barbiturates >>, ethanol, and neurosteroids, can also inhibit [[ L-type voltage-gated calcium channels ]] (L-VGCCs), which could contribute to reduced neuronal excitability.","BDZs and other positive GABA(A)R modulators, including [ENTITY_A], ethanol, and neurosteroids, can also inhibit [ENTITY_B] (L-VGCCs), which could contribute to reduced neuronal excitability.",INHIBITOR,CPR:4,1,"BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (L-VGCCs), which could contribute to reduced neuronal excitability."
"<< Ca(v)1.3 >> channels were less sensitive to [[ pentobarbital ]] inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists.","[ENTITY_A] channels were less sensitive to [ENTITY_B] inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists.",INHIBITOR,CPR:4,1,"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists."
"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to << dihydropyridine >> (DHP) [[ L-VGCC ]] antagonists.","Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to [ENTITY_A] (DHP) [ENTITY_B] antagonists.",ANTAGONIST,CPR:6,3,"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists."
"All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only << BDZs >> and pentobarbital induced a negative shift in [[ Ca(v)1.2 ]] channel inactivation.","All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only [ENTITY_A] and pentobarbital induced a negative shift in [ENTITY_B] channel inactivation.",INHIBITOR,CPR:4,1,"All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only BDZs and pentobarbital induced a negative shift in Ca(v)1.2 channel inactivation."
"Despite the structural similarity between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency (<< I1150A >>) did not affect [[ diazepam ]] potency.","Despite the structural similarity between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency ([ENTITY_A]) did not affect [ENTITY_B] potency.",INHIBITOR,CPR:4,1,"Despite the structural similarity between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency (I1150A) did not affect diazepam potency."
"Although << L-VGCC >> inhibition by [[ BDZs ]] occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of L-VGCCs during long-term treatment, pentobarbital and ethanol inhibited L-VGCCs at clinically relevant concentrations.","Although [ENTITY_A] inhibition by [ENTITY_B] occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of L-VGCCs during long-term treatment, pentobarbital and ethanol inhibited L-VGCCs at clinically relevant concentrations.",INHIBITOR,CPR:4,1,"Although L-VGCC inhibition by BDZs occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of L-VGCCs during long-term treatment, pentobarbital and ethanol inhibited L-VGCCs at clinically relevant concentrations."
"<< 5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone >> inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and [[ Nrf-2 ]]-dependent heme oxygenase-1 induction.",[ENTITY_A] inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and [ENTITY_B]-dependent heme oxygenase-1 induction.,ACTIVATOR,CPR:3,0,"5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction."
"<< 5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone >> inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via [[ NF-κB ]] suppression and Nrf-2-dependent heme oxygenase-1 induction.",[ENTITY_A] inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via [ENTITY_B] suppression and Nrf-2-dependent heme oxygenase-1 induction.,INHIBITOR,CPR:4,1,"5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction."
"In this study, we found that << 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone >> (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of [[ inducible NO synthase ]] (iNOS) in BV2 microglia.","In this study, we found that [ENTITY_A] (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of [ENTITY_B] (iNOS) in BV2 microglia.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia."
"In addition, << 5HHMF >> blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of [[ nuclear factor-κB ]] (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression.","In addition, [ENTITY_A] blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of [ENTITY_B] (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, 5HHMF blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression."
"<< Pyrrolidine dithiocarbamate >> (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced [[ iNOS ]] expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity.","[ENTITY_A] (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced [ENTITY_B] expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity."
"Thus, we found that << 5HHMF >> enhances heme oxygenase-1 (HO-1) expression via [[ nuclear factor-erythroid 2-related factor 2 ]] (Nrf2) activation.","Thus, we found that [ENTITY_A] enhances heme oxygenase-1 (HO-1) expression via [ENTITY_B] (Nrf2) activation.",ACTIVATOR,CPR:3,0,"Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation."
"In addition, << cobalt protoporphyrin >> (CoPP), a specific [[ HO-1 ]] inducer, predominantly suppressed LPS-induced NO production.","In addition, [ENTITY_A] (CoPP), a specific [ENTITY_B] inducer, predominantly suppressed LPS-induced NO production.",ACTIVATOR,CPR:3,0,"In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production."
"In contrast, << zinc protoporphyrin >> (ZnPP), a specific [[ HO-1 ]] inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production.","In contrast, [ENTITY_A] (ZnPP), a specific [ENTITY_B] inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production.",INHIBITOR,CPR:4,1,"In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production."
"Further, << 5HHMF >> increased specific DNA-binding activity of [[ Nrf2 ]], and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity.","Further, [ENTITY_A] increased specific DNA-binding activity of [ENTITY_B], and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity.",ACTIVATOR,CPR:3,0,"Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity."
"Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced << NO >> inhibition, which was followed by suppression of [[ HO-1 ]] activity.","Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced [ENTITY_A] inhibition, which was followed by suppression of [ENTITY_B] activity.",DOWNREGULATOR,CPR:4,1,"Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity."
"Taken together, our findings indicate that << 5HHMF >> suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of [[ Nrf2 ]]-dependent HO-1 activity.","Taken together, our findings indicate that [ENTITY_A] suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of [ENTITY_B]-dependent HO-1 activity.",ACTIVATOR,CPR:3,0,"Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity."
"Taken together, our findings indicate that 5HHMF suppresses << NO >> production through modulation of iNOS, consequently suppressing [[ NF-κB ]] activity and induction of Nrf2-dependent HO-1 activity.","Taken together, our findings indicate that 5HHMF suppresses [ENTITY_A] production through modulation of iNOS, consequently suppressing [ENTITY_B] activity and induction of Nrf2-dependent HO-1 activity.",DOWNREGULATOR,CPR:4,1,"Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity."
"Synthesis and antitumor activity of << 1,3,4-oxadiazole >> possessing 1,4-benzodioxan moiety as a novel class of potent [[ methionine aminopeptidase type II ]] inhibitors.","Synthesis and antitumor activity of [ENTITY_A] possessing 1,4-benzodioxan moiety as a novel class of potent [ENTITY_B] inhibitors.",INHIBITOR,CPR:4,1,"Synthesis and antitumor activity of 1,3,4-oxadiazole possessing 1,4-benzodioxan moiety as a novel class of potent methionine aminopeptidase type II inhibitors."
"Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of << 2,4,6-trisubstituted 1,3,5-triazines >> as [[ CB2 ]] agonists.",Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of [ENTITY_A] as [ENTITY_B] agonists.,AGONIST,CPR:5,2,"Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of 2,4,6-trisubstituted 1,3,5-triazines as CB2 agonists."
"One of the << CB2 >> agonists, [[ N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine ]] (19, -logEC(50)=7.5, E(max)=255%) was selected for further development.","One of the [ENTITY_A] agonists, [ENTITY_B] (19, -logEC(50)=7.5, E(max)=255%) was selected for further development.",AGONIST,CPR:5,2,"One of the CB2 agonists, N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine (19, -logEC(50)=7.5, E(max)=255%) was selected for further development."
"As far as we are aware, the compound's << 1,3,5-triazine >> scaffold represents a new core structure for [[ CB2 ]] agonists.","As far as we are aware, the compound's [ENTITY_A] scaffold represents a new core structure for [ENTITY_B] agonists.",AGONIST,CPR:5,2,"As far as we are aware, the compound's 1,3,5-triazine scaffold represents a new core structure for CB2 agonists."
The discovery of an inducible << oxidase >> whose apparent substrate preference is [[ spermine ]] indicates that polyamine catabolism is more complex than that originally proposed.,The discovery of an inducible [ENTITY_A] whose apparent substrate preference is [ENTITY_B] indicates that polyamine catabolism is more complex than that originally proposed.,SUBSTRATE,CPR:9,4,The discovery of an inducible oxidase whose apparent substrate preference is spermine indicates that polyamine catabolism is more complex than that originally proposed.
"Purified << PAOh1 >>/SMO oxidizes both [[ spermine ]] (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.","Purified [ENTITY_A]/SMO oxidizes both [ENTITY_B] (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.",SUBSTRATE,CPR:9,4,"Purified PAOh1/SMO oxidizes both spermine (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine."
"The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of << spermine >> by [[ PAOh1 ]]/SMO.","The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of [ENTITY_A] by [ENTITY_B]/SMO.",SUBSTRATE,CPR:9,4,"The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of spermine by PAOh1/SMO."
"The i.c.v. administration of very low doses of << okadaic acid >> (0.001-1 pg/mouse) and cantharidin (0.001-1 ng/mouse), which inhibit [[ PP2A ]], produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.).","The i.c.v. administration of very low doses of [ENTITY_A] (0.001-1 pg/mouse) and cantharidin (0.001-1 ng/mouse), which inhibit [ENTITY_B], produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.).",INHIBITOR,CPR:4,1,"The i.c.v. administration of very low doses of okadaic acid (0.001-1 pg/mouse) and cantharidin (0.001-1 ng/mouse), which inhibit PP2A, produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.)."
"On the other hand, high doses of << okadaic acid >> (10 ng/mouse, i.c.v.) and cantharidin (1 microg/mouse, i.c.v.), which also block [[ PP1 ]], and calyculin-A (0.1 fg/mouse-1 ng/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception.","On the other hand, high doses of [ENTITY_A] (10 ng/mouse, i.c.v.) and cantharidin (1 microg/mouse, i.c.v.), which also block [ENTITY_B], and calyculin-A (0.1 fg/mouse-1 ng/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception.",INHIBITOR,CPR:4,1,"On the other hand, high doses of okadaic acid (10 ng/mouse, i.c.v.) and cantharidin (1 microg/mouse, i.c.v.), which also block PP1, and calyculin-A (0.1 fg/mouse-1 ng/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception."
Inhibition of << mammalian isoforms I-XIV >> with a series of natural product [[ polyphenols ]] and phenolic acids.,Inhibition of [ENTITY_A] with a series of natural product [ENTITY_B] and phenolic acids.,INHIBITOR,CPR:4,1,Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.
"A series of phenolic acids and phenol natural products, such as << p-hydroxybenzoic acid >>, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [[ metalloenzyme ]] carbonic anhydrase (CA, EC 4.2.1.1).","A series of phenolic acids and phenol natural products, such as [ENTITY_A], p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [ENTITY_B] carbonic anhydrase (CA, EC 4.2.1.1).",INHIBITOR,CPR:4,1,"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)."
<< Phenols >> like the ones investigated here possess a [[ CA ]] inhibition mechanism distinct of that of the sulfonamides/sulfamates used clinically or the coumarins.,[ENTITY_A] like the ones investigated here possess a [ENTITY_B] inhibition mechanism distinct of that of the sulfonamides/sulfamates used clinically or the coumarins.,INHIBITOR,CPR:4,1,Phenols like the ones investigated here possess a CA inhibition mechanism distinct of that of the sulfonamides/sulfamates used clinically or the coumarins.
"<< L-serine dehydratase >> (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield [[ pyruvate ]] or 2-oxobutyrate.","[ENTITY_A] (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield [ENTITY_B] or 2-oxobutyrate.",PRODUCT-OF,CPR:9,4,"L-serine dehydratase (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate."
"Synthesis and evaluation of << carbamoylmethylene >> linked prodrugs of BMS-582949, a clinical [[ p38α ]] inhibitor.","Synthesis and evaluation of [ENTITY_A] linked prodrugs of BMS-582949, a clinical [ENTITY_B] inhibitor.",INHIBITOR,CPR:4,1,"Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38α inhibitor."
"A series of << carbamoylmethylene >> linked prodrugs of 1 (BMS-582949), a clinical [[ p38α ]] inhibitor, were synthesized and evaluated.","A series of [ENTITY_A] linked prodrugs of 1 (BMS-582949), a clinical [ENTITY_B] inhibitor, were synthesized and evaluated.",INHIBITOR,CPR:4,1,"A series of carbamoylmethylene linked prodrugs of 1 (BMS-582949), a clinical p38α inhibitor, were synthesized and evaluated."
RESULTS: << Ethanol >> given to rats in drinking water decreased the level of [[ p-CREB ]] protein in the nucleus accumbens (-75 %) at the time of exposure to ethanol.,RESULTS: [ENTITY_A] given to rats in drinking water decreased the level of [ENTITY_B] protein in the nucleus accumbens (-75 %) at the time of exposure to ethanol.,INDIRECT-DOWNREGULATOR,CPR:4,1,RESULTS: Ethanol given to rats in drinking water decreased the level of p-CREB protein in the nucleus accumbens (-75 %) at the time of exposure to ethanol.
"The decrement of << p-CREB >> protein in the nucleus accumbens remained at 24 h (-35 %) and 72 h (-28 %) of [[ ethanol ]] withdrawal, which recovered toward control level after 7 d of ethanol withdrawal.","The decrement of [ENTITY_A] protein in the nucleus accumbens remained at 24 h (-35 %) and 72 h (-28 %) of [ENTITY_B] withdrawal, which recovered toward control level after 7 d of ethanol withdrawal.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The decrement of p-CREB protein in the nucleus accumbens remained at 24 h (-35 %) and 72 h (-28 %) of ethanol withdrawal, which recovered toward control level after 7 d of ethanol withdrawal."
"However, when naloxone was administered concurrently with << ethanol >> treatment, it antagonized the down-regulation of [[ p-CREB ]] protein in the nucleus accumbens (142 %) of rats exposed to ethanol.","However, when naloxone was administered concurrently with [ENTITY_A] treatment, it antagonized the down-regulation of [ENTITY_B] protein in the nucleus accumbens (142 %) of rats exposed to ethanol.",INDIRECT-DOWNREGULATOR,CPR:4,1,"However, when naloxone was administered concurrently with ethanol treatment, it antagonized the down-regulation of p-CREB protein in the nucleus accumbens (142 %) of rats exposed to ethanol."
"CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of << CREB >> in the nucleus accumbens, and those changes can be reversed by [[ naloxone ]], which may be one kind of the molecular mechanisms associated with ethanol dependence.","CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of [ENTITY_A] in the nucleus accumbens, and those changes can be reversed by [ENTITY_B], which may be one kind of the molecular mechanisms associated with ethanol dependence.",UPREGULATOR,CPR:3,0,"CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of CREB in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with ethanol dependence."
"CONCLUSION: A long-term intake of << ethanol >> solution down-regulates the phosphorylation of [[ CREB ]] in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with ethanol dependence.","CONCLUSION: A long-term intake of [ENTITY_A] solution down-regulates the phosphorylation of [ENTITY_B] in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with ethanol dependence.",DOWNREGULATOR,CPR:4,1,"CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of CREB in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with ethanol dependence."
"Adenosine and N(6)-cyclopentyl-adenosine (<< CPA >>, [[ A1R ]] agonist) constricted MVs but not MAs.","Adenosine and N(6)-cyclopentyl-adenosine ([ENTITY_A], [ENTITY_B] agonist) constricted MVs but not MAs.",AGONIST,CPR:5,2,"Adenosine and N(6)-cyclopentyl-adenosine (CPA, A1R agonist) constricted MVs but not MAs."
The << A2A adenosine receptor >> agonist CGS21680 ([[ C23H29N7O6.HCl.xH2O ]]) (0.001-0.1 μM) did not alter NE oxidation currents.,The [ENTITY_A] agonist CGS21680 ([ENTITY_B]) (0.001-0.1 μM) did not alter NE oxidation currents.,AGONIST,CPR:5,2,The A2A adenosine receptor agonist CGS21680 (C23H29N7O6.HCl.xH2O) (0.001-0.1 μM) did not alter NE oxidation currents.
<< Pasireotide >> (Signifor(®)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of [[ corticotropin ]] from the pituitary adenoma in patients with Cushing's disease.,[ENTITY_A] (Signifor(®)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of [ENTITY_B] from the pituitary adenoma in patients with Cushing's disease.,INDIRECT-DOWNREGULATOR,CPR:4,1,Pasireotide (Signifor(®)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease.
"Also, << SB365 >> showed anti-angiogenic activity by decreasing the expression of [[ HIF-1α ]] and VEGF.","Also, [ENTITY_A] showed anti-angiogenic activity by decreasing the expression of [ENTITY_B] and VEGF.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Also, SB365 showed anti-angiogenic activity by decreasing the expression of HIF-1α and VEGF."
"When further examined for its anticancer mechanism, << SB365 >> effectively suppressed the [[ AKT ]]/mTOR pathway both in vitro and in vivo.","When further examined for its anticancer mechanism, [ENTITY_A] effectively suppressed the [ENTITY_B]/mTOR pathway both in vitro and in vivo.",INHIBITOR,CPR:4,1,"When further examined for its anticancer mechanism, SB365 effectively suppressed the AKT/mTOR pathway both in vitro and in vivo."
"Taken together, our study demonstrated that << SB365 >> inhibits the [[ AKT ]]/mTOR pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.","Taken together, our study demonstrated that [ENTITY_A] inhibits the [ENTITY_B]/mTOR pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.",INHIBITOR,CPR:4,1,"Taken together, our study demonstrated that SB365 inhibits the AKT/mTOR pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis."
Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in << SGLT1 >> activity induced by [[ gentamicin C ]].,Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in [ENTITY_A] activity induced by [ENTITY_B].,INHIBITOR,CPR:4,1,Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by gentamicin C.
"Megalin, a family of << endocytic receptors >> related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular [[ aminoglycoside ]] accumulation.","Megalin, a family of [ENTITY_A] related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular [ENTITY_B] accumulation.",SUBSTRATE,CPR:9,4,"Megalin, a family of endocytic receptors related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular aminoglycoside accumulation."
We previously reported that << aminoglycoside >> antibiotics reduce [[ SGLT1 ]]-dependent glucose transport in pig proximal tubular epithelial LLC-PK1 cells in parallel with the order of their nephrotoxicity.,We previously reported that [ENTITY_A] antibiotics reduce [ENTITY_B]-dependent glucose transport in pig proximal tubular epithelial LLC-PK1 cells in parallel with the order of their nephrotoxicity.,DOWNREGULATOR,CPR:4,1,We previously reported that aminoglycoside antibiotics reduce SGLT1-dependent glucose transport in pig proximal tubular epithelial LLC-PK1 cells in parallel with the order of their nephrotoxicity.
"In this study, using a model of << gentamicin C >> (GMC)-induced reduction in [[ SGLT1 ]] activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity.","In this study, using a model of [ENTITY_A] (GMC)-induced reduction in [ENTITY_B] activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity.",INHIBITOR,CPR:4,1,"In this study, using a model of gentamicin C (GMC)-induced reduction in SGLT1 activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity."
"Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the << SGLT1 >>-dependent [[ methyl alpha-D-glucopyranoside ]] (AMG) uptake and levels of SGLT1 expression were determined.","Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the [ENTITY_A]-dependent [ENTITY_B] (AMG) uptake and levels of SGLT1 expression were determined.",SUBSTRATE,CPR:9,4,"Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined."
"Actions of << nizatidine >>, a selective [[ histamine H2-receptor ]] antagonist, on gastric acid secretion in dogs, rats and frogs.","Actions of [ENTITY_A], a selective [ENTITY_B] antagonist, on gastric acid secretion in dogs, rats and frogs.",ANTAGONIST,CPR:6,3,"Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs."
"<< Nizatidine >> (LY139037), a selective [[ histamine H2-receptor ]] antagonist, is a potent inhibitor of gastric acid secretion.","[ENTITY_A] (LY139037), a selective [ENTITY_B] antagonist, is a potent inhibitor of gastric acid secretion.",ANTAGONIST,CPR:6,3,"Nizatidine (LY139037), a selective histamine H2-receptor antagonist, is a potent inhibitor of gastric acid secretion."
3D-QSAR-assisted drug design: identification of a potent << quinazoline >>-based [[ Aurora kinase ]] inhibitor.,3D-QSAR-assisted drug design: identification of a potent [ENTITY_A]-based [ENTITY_B] inhibitor.,INHIBITOR,CPR:4,1,3D-QSAR-assisted drug design: identification of a potent quinazoline-based Aurora kinase inhibitor.
Three different 3D-QSAR models were built and validated by using a set of 66 << pyrazole >> (Model I) and furanopyrimidine (Model II) compounds with IC(50) values toward [[ Aurora kinase A ]] ranging from 33 nM to 10.5 μM.,Three different 3D-QSAR models were built and validated by using a set of 66 [ENTITY_A] (Model I) and furanopyrimidine (Model II) compounds with IC(50) values toward [ENTITY_B] ranging from 33 nM to 10.5 μM.,INHIBITOR,CPR:4,1,Three different 3D-QSAR models were built and validated by using a set of 66 pyrazole (Model I) and furanopyrimidine (Model II) compounds with IC(50) values toward Aurora kinase A ranging from 33 nM to 10.5 μM.
"Based on these suggestions, the rational redesign of << furanopyrimidine >> 24 (clog P=7.41; [[ Aurora A ]] IC(50) =43 nM; HCT-116 IC(50) =400 nM) led to the identification of quinazoline 67 (clog P=5.28; Aurora A IC(50) =25 nM; HCT-116 IC(50) =23 nM).","Based on these suggestions, the rational redesign of [ENTITY_A] 24 (clog P=7.41; [ENTITY_B] IC(50) =43 nM; HCT-116 IC(50) =400 nM) led to the identification of quinazoline 67 (clog P=5.28; Aurora A IC(50) =25 nM; HCT-116 IC(50) =23 nM).",INHIBITOR,CPR:4,1,"Based on these suggestions, the rational redesign of furanopyrimidine 24 (clog P=7.41; Aurora A IC(50) =43 nM; HCT-116 IC(50) =400 nM) led to the identification of quinazoline 67 (clog P=5.28; Aurora A IC(50) =25 nM; HCT-116 IC(50) =23 nM)."
Chelation of calcium ions by BAPTA-AM or blockade of << ERK1/2 >> activation by [[ UO126 ]] also prevented the NMDA effects.,Chelation of calcium ions by BAPTA-AM or blockade of [ENTITY_A] activation by [ENTITY_B] also prevented the NMDA effects.,INHIBITOR,CPR:4,1,Chelation of calcium ions by BAPTA-AM or blockade of ERK1/2 activation by UO126 also prevented the NMDA effects.
Thus prolonged activation of NMDA receptors in hippocampal neurons reduced << GABAR δ subunit >> expression through [[ Ca2+ ]] entry and at least in part by ERK1/2 activation.,Thus prolonged activation of NMDA receptors in hippocampal neurons reduced [ENTITY_A] expression through [ENTITY_B] entry and at least in part by ERK1/2 activation.,DOWNREGULATOR,CPR:4,1,Thus prolonged activation of NMDA receptors in hippocampal neurons reduced GABAR δ subunit expression through Ca2+ entry and at least in part by ERK1/2 activation.
<< Amitriptyline >> is a [[ TrkA ]] and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.,[ENTITY_A] is a [ENTITY_B] and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.,AGONIST,CPR:5,2,Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.
"<< Amitriptyline >>, but not any other tricyclic or selective serotonin reuptake inhibitor antidepressants, promotes [[ TrkA ]] autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells.","[ENTITY_A], but not any other tricyclic or selective serotonin reuptake inhibitor antidepressants, promotes [ENTITY_B] autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells.",ACTIVATOR,CPR:3,0,"Amitriptyline, but not any other tricyclic or selective serotonin reuptake inhibitor antidepressants, promotes TrkA autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells."
"Thus, << amitriptyline >> acts as a TrkA and [[ TrkB ]] agonist and possesses marked neurotrophic activity.","Thus, [ENTITY_A] acts as a TrkA and [ENTITY_B] agonist and possesses marked neurotrophic activity.",AGONIST,CPR:5,2,"Thus, amitriptyline acts as a TrkA and TrkB agonist and possesses marked neurotrophic activity."
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/<< ErbB2 >> kinase inhibitor [[ GW572016 ]].,Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/[ENTITY_A] kinase inhibitor [ENTITY_B].,INHIBITOR,CPR:4,1,Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
"<< GW572016 >>, a reversible small molecule inhibitor of [[ EGFR ]] and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts.","[ENTITY_A], a reversible small molecule inhibitor of [ENTITY_B] and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts.",INHIBITOR,CPR:4,1,"GW572016, a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts."
"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by << GW572016 >> resulted in the inhibition of downstream phospho-[[ Erk1/2 ]], phospho-AKT, and cyclin D steady-state protein levels.","Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by [ENTITY_A] resulted in the inhibition of downstream phospho-[ENTITY_B], phospho-AKT, and cyclin D steady-state protein levels.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by GW572016 resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels."
Increased phosphorylation of << p95ErbB2 >> and AKT in response to HRG was abrogated to varying degrees by [[ GW572016 ]].,Increased phosphorylation of [ENTITY_A] and AKT in response to HRG was abrogated to varying degrees by [ENTITY_B].,INHIBITOR,CPR:4,1,Increased phosphorylation of p95ErbB2 and AKT in response to HRG was abrogated to varying degrees by GW572016.
<< Sulindac sulfide >> inhibited [[ 14-3-3epsilon proteins ]] in HT-29 and DLD-1 cells in a time- and concentration-dependent manner.,[ENTITY_A] inhibited [ENTITY_B] in HT-29 and DLD-1 cells in a time- and concentration-dependent manner.,INDIRECT-DOWNREGULATOR,CPR:4,1,Sulindac sulfide inhibited 14-3-3epsilon proteins in HT-29 and DLD-1 cells in a time- and concentration-dependent manner.
"<< Indomethacin >> and SC-236, a selective [[ cyclooxygenase-2 ]] (COX-2) inhibitor, exerted a similar effect as sulindac.","[ENTITY_A] and SC-236, a selective [ENTITY_B] (COX-2) inhibitor, exerted a similar effect as sulindac.",INHIBITOR,CPR:4,1,"Indomethacin and SC-236, a selective cyclooxygenase-2 (COX-2) inhibitor, exerted a similar effect as sulindac."
<< Sulindac sulfide >> inhibited [[ PPARdelta ]] protein expression and PPARdelta transcriptional activity.,[ENTITY_A] inhibited [ENTITY_B] protein expression and PPARdelta transcriptional activity.,INDIRECT-DOWNREGULATOR,CPR:4,1,Sulindac sulfide inhibited PPARdelta protein expression and PPARdelta transcriptional activity.
"Synergistic cytotoxicity was demonstrated, and << pemetrexed >> significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of [[ dCK ]] in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines.","Synergistic cytotoxicity was demonstrated, and [ENTITY_A] significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of [ENTITY_B] in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines.",INDIRECT-UPREGULATOR,CPR:3,0,"Synergistic cytotoxicity was demonstrated, and pemetrexed significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines."
"Synergistic cytotoxicity was demonstrated, and << pemetrexed >> significantly decreased the amount of [[ phosphorylated Akt ]], enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines.","Synergistic cytotoxicity was demonstrated, and [ENTITY_A] significantly decreased the amount of [ENTITY_B], enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines.",INHIBITOR,CPR:4,1,"Synergistic cytotoxicity was demonstrated, and pemetrexed significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines."
"These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) << pemetrexed >> enhances [[ dCK ]] and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.","These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) [ENTITY_A] enhances [ENTITY_B] and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.",INDIRECT-UPREGULATOR,CPR:3,0,"These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations."
"These data demonstrated that 1) << gemcitabine >> and pemetrexed synergistically interact against NSCLC cells through the suppression of [[ Akt ]] phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.","These data demonstrated that 1) [ENTITY_A] and pemetrexed synergistically interact against NSCLC cells through the suppression of [ENTITY_B] phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.",INHIBITOR,CPR:4,1,"These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations."
<< Kynurenic acid >> (KA) is an endogenous [[ glutamate receptor ]] antagonist at the level of the different ionotropic glutamate receptors.,[ENTITY_A] (KA) is an endogenous [ENTITY_B] antagonist at the level of the different ionotropic glutamate receptors.,ANTAGONIST,CPR:6,3,Kynurenic acid (KA) is an endogenous glutamate receptor antagonist at the level of the different ionotropic glutamate receptors.
"One of the enzymes responsible for the production of << KA >>, [[ kynurenine aminotransferase I ]] (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15).","One of the enzymes responsible for the production of [ENTITY_A], [ENTITY_B] (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15).",PRODUCT-OF,CPR:9,4,"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)."
"Combined treatment of << Mn >> and DA further augments cell toxicity, ROS production and [[ JNK ]] phosphorylation in LRRK2 deficient cells compared to controls.","Combined treatment of [ENTITY_A] and DA further augments cell toxicity, ROS production and [ENTITY_B] phosphorylation in LRRK2 deficient cells compared to controls.",ACTIVATOR,CPR:3,0,"Combined treatment of Mn and DA further augments cell toxicity, ROS production and JNK phosphorylation in LRRK2 deficient cells compared to controls."
"The results showed that IR tyrosine phosphorylation (<< pIR >>) was reduced by 42 % in MSG-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.); control, 11.5 ± 0.4 a.u.); on the other hand, exercise training increased pIR by 76 % in MSG mice without affecting control mice ([[ MSG ]], 11.8 ± 0.3; control, 12.8 ± 0.2 a.u.).","The results showed that IR tyrosine phosphorylation ([ENTITY_A]) was reduced by 42 % in MSG-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.); control, 11.5 ± 0.4 a.u.); on the other hand, exercise training increased pIR by 76 % in MSG mice without affecting control mice ([ENTITY_B], 11.8 ± 0.3; control, 12.8 ± 0.2 a.u.).",DOWNREGULATOR,CPR:4,1,"The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42 % in MSG-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.); control, 11.5 ± 0.4 a.u.); on the other hand, exercise training increased pIR by 76 % in MSG mice without affecting control mice (MSG, 11.8 ± 0.3; control, 12.8 ± 0.2 a.u.)."
"Although the treatment with << MSG >> increased IRS-1 tyrosine phosphorylation ([[ pIRS-1 ]]) by 96 % (MSG, 17.02 ± 0.6; control, 8.7 ± 0.2 a.u.), exercise training also increased it in both groups (control, 13.6 ± 0.1; MSG, 22.2 ± 1.1 a.u.).","Although the treatment with [ENTITY_A] increased IRS-1 tyrosine phosphorylation ([ENTITY_B]) by 96 % (MSG, 17.02 ± 0.6; control, 8.7 ± 0.2 a.u.), exercise training also increased it in both groups (control, 13.6 ± 0.1; MSG, 22.2 ± 1.1 a.u.).",UPREGULATOR,CPR:3,0,"Although the treatment with MSG increased IRS-1 tyrosine phosphorylation (pIRS-1) by 96 % (MSG, 17.02 ± 0.6; control, 8.7 ± 0.2 a.u.), exercise training also increased it in both groups (control, 13.6 ± 0.1; MSG, 22.2 ± 1.1 a.u.)."
"The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of << PDE5 >> that breaks down [[ cGMP ]], the key pathway for the production of erectile function in humans.","The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of [ENTITY_A] that breaks down [ENTITY_B], the key pathway for the production of erectile function in humans.",SUBSTRATE,CPR:9,4,"The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of PDE5 that breaks down cGMP, the key pathway for the production of erectile function in humans."
"Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of << sildenafil >> (Viagra, Pfizer) - the first approved selective [[ PDE ]] inhibitor for the treatment of ED.","Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of [ENTITY_A] (Viagra, Pfizer) - the first approved selective [ENTITY_B] inhibitor for the treatment of ED.",INHIBITOR,CPR:4,1,"Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of sildenafil (Viagra, Pfizer) - the first approved selective PDE inhibitor for the treatment of ED."
"<< Sildenafil >> is inhibitory of [[ PDE5 ]] at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods.","[ENTITY_A] is inhibitory of [ENTITY_B] at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods.",INHIBITOR,CPR:4,1,"Sildenafil is inhibitory of PDE5 at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods."
"With the use of << sildenafil >>, it has been clearly, clinically demonstrated that the selective inhibition of [[ PDE5 ]] is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities.","With the use of [ENTITY_A], it has been clearly, clinically demonstrated that the selective inhibition of [ENTITY_B] is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities.",INHIBITOR,CPR:4,1,"With the use of sildenafil, it has been clearly, clinically demonstrated that the selective inhibition of PDE5 is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities."
"<< cAspAT >> activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the [[ thiazolidinedione ]] (TZD) rosiglitazone.","[ENTITY_A] activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the [ENTITY_B] (TZD) rosiglitazone.",ACTIVATOR,CPR:3,0,"cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone."
"<< RORalpha >> ectopic expression activated the cAspAT gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by [[ rosiglitazone ]] treatment of adipocytes.","[ENTITY_A] ectopic expression activated the cAspAT gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by [ENTITY_B] treatment of adipocytes.",INDIRECT-UPREGULATOR,CPR:3,0,"RORalpha ectopic expression activated the cAspAT gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by rosiglitazone treatment of adipocytes."
"Finally, the amounts of << RORalpha >> and cAspAT mRNAs were similarly increased by [[ TZD ]] treatment of human adipose tissue explants, confirming coordinated regulation.","Finally, the amounts of [ENTITY_A] and cAspAT mRNAs were similarly increased by [ENTITY_B] treatment of human adipose tissue explants, confirming coordinated regulation.",INDIRECT-UPREGULATOR,CPR:3,0,"Finally, the amounts of RORalpha and cAspAT mRNAs were similarly increased by TZD treatment of human adipose tissue explants, confirming coordinated regulation."
"Our data identify << cAspAT >> as a new member of glyceroneogenesis, transcriptionally regulated by [[ TZD ]] via the control of RORalpha expression by PPARgamma in adipocytes.","Our data identify [ENTITY_A] as a new member of glyceroneogenesis, transcriptionally regulated by [ENTITY_B] via the control of RORalpha expression by PPARgamma in adipocytes.",INDIRECT-UPREGULATOR,CPR:3,0,"Our data identify cAspAT as a new member of glyceroneogenesis, transcriptionally regulated by TZD via the control of RORalpha expression by PPARgamma in adipocytes."
"<< ABT-199 >>, a potent and selective [[ BCL-2 ]] inhibitor, achieves antitumor activity while sparing platelets.","[ENTITY_A], a potent and selective [ENTITY_B] inhibitor, achieves antitumor activity while sparing platelets.",INHIBITOR,CPR:4,1,"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets."
"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of << navitoclax >>, a selective inhibitor of both [[ BCL-2 ]] and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers.","The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of [ENTITY_A], a selective inhibitor of both [ENTITY_B] and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers.",INHIBITOR,CPR:4,1,"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers."
"Here we report the re-engineering of << navitoclax >> to create a highly potent, orally bioavailable and [[ BCL-2 ]]-selective inhibitor, ABT-199.","Here we report the re-engineering of [ENTITY_A] to create a highly potent, orally bioavailable and [ENTITY_B]-selective inhibitor, ABT-199.",INHIBITOR,CPR:4,1,"Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2-selective inhibitor, ABT-199."
Suppression of TβR1 by the pharmacological inhibitor (<< SB431542 >>) markedly reduced [[ VEGF ]] release by HFL-1 in response to CSE and this effect was confirmed by TβR1 siRNA.,Suppression of TβR1 by the pharmacological inhibitor ([ENTITY_A]) markedly reduced [ENTITY_B] release by HFL-1 in response to CSE and this effect was confirmed by TβR1 siRNA.,INDIRECT-DOWNREGULATOR,CPR:4,1,Suppression of TβR1 by the pharmacological inhibitor (SB431542) markedly reduced VEGF release by HFL-1 in response to CSE and this effect was confirmed by TβR1 siRNA.
<< NCFP >> binds to the CPPHA site on mGlu5 and potentiates [[ mGlu5 ]]-mediated responses in both recombinant and native systems.,[ENTITY_A] binds to the CPPHA site on mGlu5 and potentiates [ENTITY_B]-mediated responses in both recombinant and native systems.,ACTIVATOR,CPR:3,0,NCFP binds to the CPPHA site on mGlu5 and potentiates mGlu5-mediated responses in both recombinant and native systems.
"Combination treatment with the selective << 5-HT1A >> antagonist [[ WAY100635 ]] produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone.","Combination treatment with the selective [ENTITY_A] antagonist [ENTITY_B] produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone.",ANTAGONIST,CPR:6,3,"Combination treatment with the selective 5-HT1A antagonist WAY100635 produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone."
The beta-adrenergic/<< 5-HT1A >> receptor antagonist [[ (+/-)pindolol ]] and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA.,The beta-adrenergic/[ENTITY_A] receptor antagonist [ENTITY_B] and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA.,ANTAGONIST,CPR:6,3,The beta-adrenergic/5-HT1A receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA.
The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the << GluR5 >> kainate receptor antagonist [[ LY293558 ]].,The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the [ENTITY_A] kainate receptor antagonist [ENTITY_B].,ANTAGONIST,CPR:6,3,The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 kainate receptor antagonist LY293558.
"However, << topiramate >> at low concentrations causes slow inhibition of [[ GluR5 ]] kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses.","However, [ENTITY_A] at low concentrations causes slow inhibition of [ENTITY_B] kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses.",INHIBITOR,CPR:4,1,"However, topiramate at low concentrations causes slow inhibition of GluR5 kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses."
<< Multidrug resistance-associated proteins >> are involved in the transport of the [[ glutathione ]] conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells.,[ENTITY_A] are involved in the transport of the [ENTITY_B] conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells.,SUBSTRATE,CPR:9,4,Multidrug resistance-associated proteins are involved in the transport of the glutathione conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells.
"The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide (BPDE) can be detoxified by << glutathione >> conjugate formation catalyzed by [[ glutathione S-transferases ]].","The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide (BPDE) can be detoxified by [ENTITY_A] conjugate formation catalyzed by [ENTITY_B].",PRODUCT-OF,CPR:9,4,"The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide (BPDE) can be detoxified by glutathione conjugate formation catalyzed by glutathione S-transferases."
Inhibition studies revealed that the << multidrug resistance-associated proteins >> (ABCCs) are involved in the transport of [[ BPDE glutathione ]] conjugates.,Inhibition studies revealed that the [ENTITY_A] (ABCCs) are involved in the transport of [ENTITY_B] conjugates.,SUBSTRATE,CPR:9,4,Inhibition studies revealed that the multidrug resistance-associated proteins (ABCCs) are involved in the transport of BPDE glutathione conjugates.
"Stable << ABCC1 >>, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of [[ BPDE glutathione ]] conjugates.","Stable [ENTITY_A], ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of [ENTITY_B] conjugates.",SUBSTRATE,CPR:9,4,"Stable ABCC1, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of BPDE glutathione conjugates."
"Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean << isoflavone >> increased gene expression of [[ heme oxygenase-1 ]] (HO-1), a major antioxidative stress enzyme.","Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean [ENTITY_A] increased gene expression of [ENTITY_B] (HO-1), a major antioxidative stress enzyme.",INDIRECT-UPREGULATOR,CPR:3,0,"Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean isoflavone increased gene expression of heme oxygenase-1 (HO-1), a major antioxidative stress enzyme."
Comparison of << cyclooxygenase >> inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and [[ bromfenac sodium ]].,Comparison of [ENTITY_A] inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and [ENTITY_B].,INHIBITOR,CPR:4,1,Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium.
METHODS: << Cyclooxygenase >> activity and selectivity was determined in vitro by measuring [[ prostaglandin E(2) ]] (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid.,METHODS: [ENTITY_A] activity and selectivity was determined in vitro by measuring [ENTITY_B] (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid.,PRODUCT-OF,CPR:9,4,METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid.
RESULTS: << Ketorolac >> was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against [[ COX-2 ]] (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).,RESULTS: [ENTITY_A] was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against [ENTITY_B] (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).,DOWNREGULATOR,CPR:4,1,RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).
Tumor-growth-promoting << cyclooxygenase-2 >> [[ prostaglandin E2 ]] pathway provides medulloblastoma therapeutic targets.,Tumor-growth-promoting [ENTITY_A] [ENTITY_B] pathway provides medulloblastoma therapeutic targets.,PRODUCT-OF,CPR:9,4,Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets.
<< PGE(2) >> is synthesized from arachidonic acid by [[ cyclooxygenases ]] (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).,[ENTITY_A] is synthesized from arachidonic acid by [ENTITY_B] (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).,PRODUCT-OF,CPR:9,4,PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).
"<< EP(1) >> and EP(3) receptor antagonists [[ ONO-8713 ]] and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.","[ENTITY_A] and EP(3) receptor antagonists [ENTITY_B] and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",ANTAGONIST,CPR:6,3,"EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth."
"Inhibitors of << PDE4 >> ([[ rolipram ]]; 0.1-10 microM) and PDE3 (cilostazol; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively.","Inhibitors of [ENTITY_A] ([ENTITY_B]; 0.1-10 microM) and PDE3 (cilostazol; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively.",INHIBITOR,CPR:4,1,"Inhibitors of PDE4 (rolipram; 0.1-10 microM) and PDE3 (cilostazol; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively."
Inhibitor of << cGMP-specific PDE5 >> ([[ zaprinast ]]; 0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis.,Inhibitor of [ENTITY_A] ([ENTITY_B]; 0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis.,INHIBITOR,CPR:4,1,Inhibitor of cGMP-specific PDE5 (zaprinast; 0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis.
"<< GW9662 >>, a PPARgamma antagonist, prevented (P < 0.01) the lutein-induced [[ iNOS ]] mRNA downregulation in HD11 cells.","[ENTITY_A], a PPARgamma antagonist, prevented (P < 0.01) the lutein-induced [ENTITY_B] mRNA downregulation in HD11 cells.",INDIRECT-UPREGULATOR,CPR:3,0,"GW9662, a PPARgamma antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells."
"<< GW9662 >>, a [[ PPARgamma ]] antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells.","[ENTITY_A], a [ENTITY_B] antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells.",ANTAGONIST,CPR:6,3,"GW9662, a PPARgamma antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells."
Stereospecific inhibition of << monoamine uptake transporters >> by [[ meta-hydroxyephedrine ]] isomers.,Stereospecific inhibition of [ENTITY_A] by [ENTITY_B] isomers.,INHIBITOR,CPR:4,1,Stereospecific inhibition of monoamine uptake transporters by meta-hydroxyephedrine isomers.
"To extend structure-activity analyses of binding sites within << monoamine transporters >> and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the [[ HED ]] compounds for their abilities to inhibit [(3)H]neurotransmitter uptake into platelets, transfected cells, and chromaffin vesicles.","To extend structure-activity analyses of binding sites within [ENTITY_A] and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the [ENTITY_B] compounds for their abilities to inhibit [(3)H]neurotransmitter uptake into platelets, transfected cells, and chromaffin vesicles.",INHIBITOR,CPR:4,1,"To extend structure-activity analyses of binding sites within monoamine transporters and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the HED compounds for their abilities to inhibit [(3)H]neurotransmitter uptake into platelets, transfected cells, and chromaffin vesicles."
We hypothesized that the << HED >> compounds would be most potent at the [[ norepinephrine transporter ]] (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers.,We hypothesized that the [ENTITY_A] compounds would be most potent at the [ENTITY_B] (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers.,INHIBITOR,CPR:4,1,We hypothesized that the HED compounds would be most potent at the norepinephrine transporter (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers.
<< TCDD >> inhibition of canonical [[ wnt ]] signaling disrupts prostatic bud formation in mouse urogenital sinus.,[ENTITY_A] inhibition of canonical [ENTITY_B] signaling disrupts prostatic bud formation in mouse urogenital sinus.,INDIRECT-DOWNREGULATOR,CPR:4,1,TCDD inhibition of canonical wnt signaling disrupts prostatic bud formation in mouse urogenital sinus.
"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of << TCDD >> on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of [[ Lgr5 ]], a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of [ENTITY_A] on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of [ENTITY_B], a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD."
"Thus, the << TCDD >>-induced reduction in canonical Wnt signaling is associated with a decrease in activators ([[ Rspo2 ]] and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway.","Thus, the [ENTITY_A]-induced reduction in canonical Wnt signaling is associated with a decrease in activators ([ENTITY_B] and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway.",DOWNREGULATOR,CPR:4,1,"Thus, the TCDD-induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway."
This study focuses on determining whether treatment of TCDD-exposed UGS organ cultures with RSPO2 and/or RSPO3 is capable of rescuing the inhibitory effects of << TCDD >> on canonical [[ Wnt ]] signaling and prostatic bud formation.,This study focuses on determining whether treatment of TCDD-exposed UGS organ cultures with RSPO2 and/or RSPO3 is capable of rescuing the inhibitory effects of [ENTITY_A] on canonical [ENTITY_B] signaling and prostatic bud formation.,INDIRECT-DOWNREGULATOR,CPR:4,1,This study focuses on determining whether treatment of TCDD-exposed UGS organ cultures with RSPO2 and/or RSPO3 is capable of rescuing the inhibitory effects of TCDD on canonical Wnt signaling and prostatic bud formation.
We discovered that each RSPO alone or in combination partially rescues << TCDD >> inhibition of both canonical [[ Wnt ]] signaling and prostatic bud formation.,We discovered that each RSPO alone or in combination partially rescues [ENTITY_A] inhibition of both canonical [ENTITY_B] signaling and prostatic bud formation.,INDIRECT-DOWNREGULATOR,CPR:4,1,We discovered that each RSPO alone or in combination partially rescues TCDD inhibition of both canonical Wnt signaling and prostatic bud formation.
"<< Cytochrome P450 epoxygenase 2J2 >> (CYP2J2) metabolizes arachidonic acids to form epoxyeicosatrienoic acids ([[ EETs ]]), which possess various beneficial effects on the cardiovascular system.","[ENTITY_A] (CYP2J2) metabolizes arachidonic acids to form epoxyeicosatrienoic acids ([ENTITY_B]), which possess various beneficial effects on the cardiovascular system.",PRODUCT-OF,CPR:9,4,"Cytochrome P450 epoxygenase 2J2 (CYP2J2) metabolizes arachidonic acids to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system."
"However, whether increasing << EETs >> production by [[ CYP2J2 ]] overexpression in vivo could prevent abdominal aortic aneurysm (AAA) remains unknown.","However, whether increasing [ENTITY_A] production by [ENTITY_B] overexpression in vivo could prevent abdominal aortic aneurysm (AAA) remains unknown.",PRODUCT-OF,CPR:9,4,"However, whether increasing EETs production by CYP2J2 overexpression in vivo could prevent abdominal aortic aneurysm (AAA) remains unknown."
"In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and << EETs >> markedly suppressed Ang II-induced inflammatory [[ cytokine ]] expression.","In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and [ENTITY_A] markedly suppressed Ang II-induced inflammatory [ENTITY_B] expression.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and EETs markedly suppressed Ang II-induced inflammatory cytokine expression."
"Moreover, overexpressed CYP2J2 and << EETs >> inhibited [[ Ang II ]]-induced macrophage migration in a VSMC-macrophage coculture system.","Moreover, overexpressed CYP2J2 and [ENTITY_A] inhibited [ENTITY_B]-induced macrophage migration in a VSMC-macrophage coculture system.",INHIBITOR,CPR:4,1,"Moreover, overexpressed CYP2J2 and EETs inhibited Ang II-induced macrophage migration in a VSMC-macrophage coculture system."
"A decrease in << ADA >> activity was observed when the slices were exposed to [[ organoselenium ]] at the concentrations of 1, 10 and 30 µM.","A decrease in [ENTITY_A] activity was observed when the slices were exposed to [ENTITY_B] at the concentrations of 1, 10 and 30 µM.",INHIBITOR,CPR:4,1,"A decrease in ADA activity was observed when the slices were exposed to organoselenium at the concentrations of 1, 10 and 30 µM."
"Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with << aflatoxin B(1) >> decreased the frequencies of SCE and the malondialdehyde level and increased amount of [[ superoxide dismutase ]], glutathione and glutathione peroxidase which were decreased by aflatoxin.","Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with [ENTITY_A] decreased the frequencies of SCE and the malondialdehyde level and increased amount of [ENTITY_B], glutathione and glutathione peroxidase which were decreased by aflatoxin.",INDIRECT-UPREGULATOR,CPR:3,0,"Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and glutathione peroxidase which were decreased by aflatoxin."
"Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and << glutathione peroxidase >> which were decreased by [[ aflatoxin ]].","Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and [ENTITY_A] which were decreased by [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and glutathione peroxidase which were decreased by aflatoxin."
"<< Phenobarbital >> (PB), a typical [[ CAR ]] activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a.","[ENTITY_A] (PB), a typical [ENTITY_B] activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a.",ACTIVATOR,CPR:3,0,"Phenobarbital (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a."
"<< Cobalt chloride >>, a typical [[ HIF ]] activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.","[ENTITY_A], a typical [ENTITY_B] activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.",ACTIVATOR,CPR:3,0,"Cobalt chloride, a typical HIF activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver."
"BACKGROUND & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes << S-adenosylmethionine >>, [[ MAT1A ]], is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues.","BACKGROUND & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes [ENTITY_A], [ENTITY_B], is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues.",PRODUCT-OF,CPR:9,4,"BACKGROUND & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes S-adenosylmethionine, MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues."
The beta subunit has been cloned and shown to lower the K(m) of << methionine adenosyltransferase II alpha2 >> (the MAT2A product) for methionine and to render the enzyme more susceptible to [[ S-adenosylmethionine ]] inhibition.,The beta subunit has been cloned and shown to lower the K(m) of [ENTITY_A] (the MAT2A product) for methionine and to render the enzyme more susceptible to [ENTITY_B] inhibition.,INHIBITOR,CPR:4,1,The beta subunit has been cloned and shown to lower the K(m) of methionine adenosyltransferase II alpha2 (the MAT2A product) for methionine and to render the enzyme more susceptible to S-adenosylmethionine inhibition.
The beta subunit has been cloned and shown to lower the K(m) of << methionine adenosyltransferase II alpha2 >> (the MAT2A product) for [[ methionine ]] and to render the enzyme more susceptible to S-adenosylmethionine inhibition.,The beta subunit has been cloned and shown to lower the K(m) of [ENTITY_A] (the MAT2A product) for [ENTITY_B] and to render the enzyme more susceptible to S-adenosylmethionine inhibition.,SUBSTRATE,CPR:9,4,The beta subunit has been cloned and shown to lower the K(m) of methionine adenosyltransferase II alpha2 (the MAT2A product) for methionine and to render the enzyme more susceptible to S-adenosylmethionine inhibition.
Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific << CB1 >> antagonist [[ SR 141716A ]].,Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific [ENTITY_A] antagonist [ENTITY_B].,ANTAGONIST,CPR:6,3,Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A.
The channel activators << avermectin >> and moxidectin usually retain their inhibitory potency in the [[ Rdl ]] subunit mutants.,The channel activators [ENTITY_A] and moxidectin usually retain their inhibitory potency in the [ENTITY_B] subunit mutants.,INHIBITOR,CPR:4,1,The channel activators avermectin and moxidectin usually retain their inhibitory potency in the Rdl subunit mutants.
"At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas << mifepristone >> and its monodemethylated metabolite manifested slight [[ glucocorticoid ]] agonist activity.","At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas [ENTITY_A] and its monodemethylated metabolite manifested slight [ENTITY_B] agonist activity.",AGONIST,CPR:5,2,"At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas mifepristone and its monodemethylated metabolite manifested slight glucocorticoid agonist activity."
"5-Fluorouracil (<< 5-FU >>), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of [[ thymidylate synthase ]] (TS).","5-Fluorouracil ([ENTITY_A]), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of [ENTITY_B] (TS).",INHIBITOR,CPR:4,1,"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (TS)."
"When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to << F3(d)Thd >> is due to a mechanism other than [[ TS ]] inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure.","When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to [ENTITY_A] is due to a mechanism other than [ENTITY_B] inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure.",INHIBITOR,CPR:4,1,"When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to F3(d)Thd is due to a mechanism other than TS inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure."
"In conclusion, << F3(d)Thd >>, an antimetabolite that inhibits [[ TS ]] activity, may be effective against 5-FU and/or FdUrd-resistance in colorectal cancer cells caused by amplification of TS and/or deletion of orotate phosphoribosyltransferase.","In conclusion, [ENTITY_A], an antimetabolite that inhibits [ENTITY_B] activity, may be effective against 5-FU and/or FdUrd-resistance in colorectal cancer cells caused by amplification of TS and/or deletion of orotate phosphoribosyltransferase.",INHIBITOR,CPR:4,1,"In conclusion, F3(d)Thd, an antimetabolite that inhibits TS activity, may be effective against 5-FU and/or FdUrd-resistance in colorectal cancer cells caused by amplification of TS and/or deletion of orotate phosphoribosyltransferase."
The failure of the myometrium to respond to << ritodrine >> (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and [[ beta 2-adrenergic receptor ]] concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls.,The failure of the myometrium to respond to [ENTITY_A] (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and [ENTITY_B] concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls.,INDIRECT-DOWNREGULATOR,CPR:4,1,The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls.
"Antiarrhythmic effects of << (-)-epicatechin-3-gallate >>, a novel [[ sodium channel ]] agonist in cultured neonatal rat ventricular myocytes.","Antiarrhythmic effects of [ENTITY_A], a novel [ENTITY_B] agonist in cultured neonatal rat ventricular myocytes.",AGONIST,CPR:5,2,"Antiarrhythmic effects of (-)-epicatechin-3-gallate, a novel sodium channel agonist in cultured neonatal rat ventricular myocytes."
<< Choline dehydrogenase >> (CHDH) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in [[ choline ]] oxidation.,[ENTITY_A] (CHDH) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in [ENTITY_B] oxidation.,SUBSTRATE,CPR:9,4,Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in choline oxidation.
"Liver << BHMT >> activity was 1.3-fold higher in rats fed the Met deficient diet containing [[ choline ]], which was reflected in corresponding increases in mRNA content and immunodetectable protein.","Liver [ENTITY_A] activity was 1.3-fold higher in rats fed the Met deficient diet containing [ENTITY_B], which was reflected in corresponding increases in mRNA content and immunodetectable protein.",ACTIVATOR,CPR:3,0,"Liver BHMT activity was 1.3-fold higher in rats fed the Met deficient diet containing choline, which was reflected in corresponding increases in mRNA content and immunodetectable protein."
"Independent of dietary << choline >>, supplemental Met increased hepatic [[ BHMT ]] activity approximately 30%.","Independent of dietary [ENTITY_A], supplemental Met increased hepatic [ENTITY_B] activity approximately 30%.",ACTIVATOR,CPR:3,0,"Independent of dietary choline, supplemental Met increased hepatic BHMT activity approximately 30%."
"The << calcium >> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban ([[ PLB ]]), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.","The [ENTITY_A] homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban ([ENTITY_B]), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.",SUBSTRATE,CPR:9,4,"The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation."
<< DNA methyltransferase 3a >> expression was increased in all [[ BPA ]] males and BPA 0.5 females and reduced in BPA 200 females.,[ENTITY_A] expression was increased in all [ENTITY_B] males and BPA 0.5 females and reduced in BPA 200 females.,INDIRECT-UPREGULATOR,CPR:3,0,DNA methyltransferase 3a expression was increased in all BPA males and BPA 0.5 females and reduced in BPA 200 females.
<< DNA methyltransferase 3a >> expression was increased in all BPA males and BPA 0.5 females and reduced in [[ BPA ]] 200 females.,[ENTITY_A] expression was increased in all BPA males and BPA 0.5 females and reduced in [ENTITY_B] 200 females.,INDIRECT-DOWNREGULATOR,CPR:4,1,DNA methyltransferase 3a expression was increased in all BPA males and BPA 0.5 females and reduced in BPA 200 females.
The results showed that << wogonoside >> promotes the expression of [[ LC3-II ]] and Beclin-1.,The results showed that [ENTITY_A] promotes the expression of [ENTITY_B] and Beclin-1.,INDIRECT-UPREGULATOR,CPR:3,0,The results showed that wogonoside promotes the expression of LC3-II and Beclin-1.
<< Wogonoside >> also suppressed the activation of mammalian target of rapamycin (mTOR) and [[ p70-S6 kinase ]] (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.,[ENTITY_A] also suppressed the activation of mammalian target of rapamycin (mTOR) and [ENTITY_B] (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.,INHIBITOR,CPR:4,1,Wogonoside also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.
"The << mitochondrial respiratory chain complex IV >> (cytochrome c oxidase) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular [[ oxygen ]], yielding water.","The [ENTITY_A] (cytochrome c oxidase) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular [ENTITY_B], yielding water.",SUBSTRATE,CPR:9,4,"The mitochondrial respiratory chain complex IV (cytochrome c oxidase) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular oxygen, yielding water."
<< Pelargonidin >> activates the [[ AhR ]] and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T.,[ENTITY_A] activates the [ENTITY_B] and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T.,ACTIVATOR,CPR:3,0,Pelargonidin activates the AhR and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T.
<< AhR >>-dependent reporter gene expression in transfected HepG2 cells was increased by [[ pelargonidin ]] in a concentration-dependent manner at 24h.,[ENTITY_A]-dependent reporter gene expression in transfected HepG2 cells was increased by [ENTITY_B] in a concentration-dependent manner at 24h.,INDIRECT-UPREGULATOR,CPR:3,0,AhR-dependent reporter gene expression in transfected HepG2 cells was increased by pelargonidin in a concentration-dependent manner at 24h.
"Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM << 2,3,7,8-tetrachlorodibenzodioxin >> (TCDD), the most potent activator of [[ AhR ]].","Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM [ENTITY_A] (TCDD), the most potent activator of [ENTITY_B].",ACTIVATOR,CPR:3,0,"Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (TCDD), the most potent activator of AhR."
<< CYP1A1 >> and CYP1A2 mRNAs were also increased by [[ pelargonidin ]] in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.,[ENTITY_A] and CYP1A2 mRNAs were also increased by [ENTITY_B] in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.,INDIRECT-UPREGULATOR,CPR:3,0,CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.
Enzyme kinetic analyses using human liver microsomes revealed inhibition of << CYP1A1 >> activity by [[ delphinidin ]] (IC50 78 μM) and pelargonidin (IC50 33 μM).,Enzyme kinetic analyses using human liver microsomes revealed inhibition of [ENTITY_A] activity by [ENTITY_B] (IC50 78 μM) and pelargonidin (IC50 33 μM).,INHIBITOR,CPR:4,1,Enzyme kinetic analyses using human liver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM).
"Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, << pelargonidin >> can bind to and activate the [[ AhR ]] and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity.","Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, [ENTITY_A] can bind to and activate the [ENTITY_B] and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity.",ACTIVATOR,CPR:3,0,"Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity."
"Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and << pelargonidin >> and delphinidin inhibit the [[ CYP1A1 ]] catalytic activity.","Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and [ENTITY_A] and delphinidin inhibit the [ENTITY_B] catalytic activity.",INHIBITOR,CPR:4,1,"Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity."
"In HEK-293 cells stably transfected with this receptor, << serotonin >> elicits a potent stimulation of [[ adenylyl cyclase ]] activity, which is blocked by antipsychotic and antidepressant drugs.","In HEK-293 cells stably transfected with this receptor, [ENTITY_A] elicits a potent stimulation of [ENTITY_B] activity, which is blocked by antipsychotic and antidepressant drugs.",ACTIVATOR,CPR:3,0,"In HEK-293 cells stably transfected with this receptor, serotonin elicits a potent stimulation of adenylyl cyclase activity, which is blocked by antipsychotic and antidepressant drugs."
"A head-to-head comparison between insulin detemir and NPH insulin in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma << glucose >> improved with [[ insulin ]] detemir without an increased incidence of hypoglycaemia.","A head-to-head comparison between insulin detemir and NPH insulin in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma [ENTITY_A] improved with [ENTITY_B] detemir without an increased incidence of hypoglycaemia.",INDIRECT-UPREGULATOR,CPR:3,0,"A head-to-head comparison between insulin detemir and NPH insulin in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma glucose improved with insulin detemir without an increased incidence of hypoglycaemia."
OBJECTIVE: The aim was to test whether the common deletion [T/-] in the promoter of << FADS2 >> affects the [[ PUFA ]] biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid (ALA) on myocardial infarction (MI).,OBJECTIVE: The aim was to test whether the common deletion [T/-] in the promoter of [ENTITY_A] affects the [ENTITY_B] biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid (ALA) on myocardial infarction (MI).,PRODUCT-OF,CPR:9,4,OBJECTIVE: The aim was to test whether the common deletion [T/-] in the promoter of FADS2 affects the PUFA biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid (ALA) on myocardial infarction (MI).
We evaluated the effects of << angiotensin II >> and an angiotensin-converting enzyme inhibitor ([[ cilazapril ]]) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.,We evaluated the effects of [ENTITY_A] and an angiotensin-converting enzyme inhibitor ([ENTITY_B]) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.,INHIBITOR,CPR:4,1,We evaluated the effects of angiotensin II and an angiotensin-converting enzyme inhibitor (cilazapril) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.
"We topically applied the nitric oxide synthase (<< NOS >>) inhibitor, [[ NG-nitro-L-arginine ]], on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet.","We topically applied the nitric oxide synthase ([ENTITY_A]) inhibitor, [ENTITY_B], on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet.",INHIBITOR,CPR:4,1,"We topically applied the nitric oxide synthase (NOS) inhibitor, NG-nitro-L-arginine, on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet."
<< Cadmium >> activates [[ NADPH oxidase ]].,[ENTITY_A] activates [ENTITY_B].,ACTIVATOR,CPR:3,0,Cadmium activates NADPH oxidase.
"However, after 12h << CdCl2 >> treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in [[ p53 ]] activation and the pro-apoptotic protein Bax.","However, after 12h [ENTITY_A] treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in [ENTITY_B] activation and the pro-apoptotic protein Bax.",ACTIVATOR,CPR:3,0,"However, after 12h CdCl2 treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in p53 activation and the pro-apoptotic protein Bax."
"However, after 12h << CdCl2 >> treatment, cell viability diminished in 50%, accompanied by a drastic decrease of [[ metallothionein-II ]] production, and an increase in p53 activation and the pro-apoptotic protein Bax.","However, after 12h [ENTITY_A] treatment, cell viability diminished in 50%, accompanied by a drastic decrease of [ENTITY_B] production, and an increase in p53 activation and the pro-apoptotic protein Bax.",DOWNREGULATOR,CPR:4,1,"However, after 12h CdCl2 treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in p53 activation and the pro-apoptotic protein Bax."
The inhibitory effect of << ginseng saponins >> on the stress-induced plasma [[ interleukin-6 ]] level in mice.,The inhibitory effect of [ENTITY_A] on the stress-induced plasma [ENTITY_B] level in mice.,INDIRECT-DOWNREGULATOR,CPR:4,1,The inhibitory effect of ginseng saponins on the stress-induced plasma interleukin-6 level in mice.
"Ginseng total << saponins >>, ginsenosides Rb2, Rg1 and Rd administered intraperitoneally attenuated the immobilization stress-induced increase in plasma [[ IL-6 ]] level.","Ginseng total [ENTITY_A], ginsenosides Rb2, Rg1 and Rd administered intraperitoneally attenuated the immobilization stress-induced increase in plasma [ENTITY_B] level.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Ginseng total saponins, ginsenosides Rb2, Rg1 and Rd administered intraperitoneally attenuated the immobilization stress-induced increase in plasma IL-6 level."
"Ginsenosides Rb2, Rd and Rg1 significantly decreased << norepinephrine >> and/or epinephrine-induced increase of [[ IL-6 ]] level in macrophage cell line (RAW 264.7).","Ginsenosides Rb2, Rd and Rg1 significantly decreased [ENTITY_A] and/or epinephrine-induced increase of [ENTITY_B] level in macrophage cell line (RAW 264.7).",INDIRECT-UPREGULATOR,CPR:3,0,"Ginsenosides Rb2, Rd and Rg1 significantly decreased norepinephrine and/or epinephrine-induced increase of IL-6 level in macrophage cell line (RAW 264.7)."
"<< Ginsenosides Rb2, Rd and Rg1 >> significantly decreased norepinephrine and/or epinephrine-induced increase of [[ IL-6 ]] level in macrophage cell line (RAW 264.7).",[ENTITY_A] significantly decreased norepinephrine and/or epinephrine-induced increase of [ENTITY_B] level in macrophage cell line (RAW 264.7).,INDIRECT-DOWNREGULATOR,CPR:4,1,"Ginsenosides Rb2, Rd and Rg1 significantly decreased norepinephrine and/or epinephrine-induced increase of IL-6 level in macrophage cell line (RAW 264.7)."
"Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking norepinephrine- and/or << epinephrine >>-induced increase of [[ IL-6 ]] level in macrophage rather than in the brain.","Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking norepinephrine- and/or [ENTITY_A]-induced increase of [ENTITY_B] level in macrophage rather than in the brain.",INDIRECT-UPREGULATOR,CPR:3,0,"Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking norepinephrine- and/or epinephrine-induced increase of IL-6 level in macrophage rather than in the brain."
"Thus, it can be suggested that the inhibitory action of << ginseng saponins >> against the immobilization stress-induced increase of plasma [[ IL-6 ]] level would be in periphery; at least in part, mediated by blocking norepinephrine- and/or epinephrine-induced increase of IL-6 level in macrophage rather than in the brain.","Thus, it can be suggested that the inhibitory action of [ENTITY_A] against the immobilization stress-induced increase of plasma [ENTITY_B] level would be in periphery; at least in part, mediated by blocking norepinephrine- and/or epinephrine-induced increase of IL-6 level in macrophage rather than in the brain.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking norepinephrine- and/or epinephrine-induced increase of IL-6 level in macrophage rather than in the brain."
"Sitagliptin. << Sitagliptin >>, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the [[ incretin hormones ]] glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.","Sitagliptin. [ENTITY_A], an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the [ENTITY_B] glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.",INDIRECT-UPREGULATOR,CPR:3,0,"Sitagliptin. Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide."
"Sitagliptin. << Sitagliptin >>, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting [[ DPP-4 ]] inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.","Sitagliptin. [ENTITY_A], an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting [ENTITY_B] inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.",INHIBITOR,CPR:4,1,"Sitagliptin. Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide."
Improvements from baseline in mean << glycosylated haemoglobin >> (HbA(1c)) were significantly greater with [[ sitagliptin ]] monotherapy than with placebo in patients with type 2 diabetes.,Improvements from baseline in mean [ENTITY_A] (HbA(1c)) were significantly greater with [ENTITY_B] monotherapy than with placebo in patients with type 2 diabetes.,INDIRECT-UPREGULATOR,CPR:3,0,Improvements from baseline in mean glycosylated haemoglobin (HbA(1c)) were significantly greater with sitagliptin monotherapy than with placebo in patients with type 2 diabetes.
"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, << sitagliptin >> improved [[ HbA(1c) ]] to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to metformin.","As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, [ENTITY_A] improved [ENTITY_B] to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to metformin.",INDIRECT-UPREGULATOR,CPR:3,0,"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved HbA(1c) to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to metformin."
"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved << HbA(1c) >> to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to [[ metformin ]].","As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved [ENTITY_A] to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved HbA(1c) to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to metformin."
"In addition, pretreatment with << Z-Val-Ala-Asp-fluoromethylketone >> (Z-VAD-fmk), a broad spectrum of [[ caspase ]] inhibitor, could not rescue apoptotic cells from ClpP toxicity.","In addition, pretreatment with [ENTITY_A] (Z-VAD-fmk), a broad spectrum of [ENTITY_B] inhibitor, could not rescue apoptotic cells from ClpP toxicity.",INHIBITOR,CPR:4,1,"In addition, pretreatment with Z-Val-Ala-Asp-fluoromethylketone (Z-VAD-fmk), a broad spectrum of caspase inhibitor, could not rescue apoptotic cells from ClpP toxicity."
<< Orlistat >> is a new inhibitor of [[ pancreatic lipase ]] enzyme.,[ENTITY_A] is a new inhibitor of [ENTITY_B] enzyme.,INHIBITOR,CPR:4,1,Orlistat is a new inhibitor of pancreatic lipase enzyme.
"In the long term, << orlistat >> has been shown to be more effective than placebo in reducing body weight and serum total and [[ low-density lipoprotein ]] cholesterol levels.","In the long term, [ENTITY_A] has been shown to be more effective than placebo in reducing body weight and serum total and [ENTITY_B] cholesterol levels.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In the long term, orlistat has been shown to be more effective than placebo in reducing body weight and serum total and low-density lipoprotein cholesterol levels."
"<< Genistin >> decreased [[ myosin light chain kinase ]] (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects.","[ENTITY_A] decreased [ENTITY_B] (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Genistin decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects."
It was found that expression of << Sim2 >> protein in cortical neurons was increased in [[ streptozotocin ]]-induced diabetes mellitus rat model.,It was found that expression of [ENTITY_A] protein in cortical neurons was increased in [ENTITY_B]-induced diabetes mellitus rat model.,INDIRECT-UPREGULATOR,CPR:3,0,It was found that expression of Sim2 protein in cortical neurons was increased in streptozotocin-induced diabetes mellitus rat model.
"Moreover, << curcumin >> alleviated [[ Sim2 ]] expression, and reversely raised Drebrin expression in neurons treated with hyperglycaemia.","Moreover, [ENTITY_A] alleviated [ENTITY_B] expression, and reversely raised Drebrin expression in neurons treated with hyperglycaemia.",INDIRECT-UPREGULATOR,CPR:3,0,"Moreover, curcumin alleviated Sim2 expression, and reversely raised Drebrin expression in neurons treated with hyperglycaemia."
Polymorphisms in dopamine transporter (<< SLC6A3 >>) are associated with stimulant effects of [[ D-amphetamine ]]: an exploratory pharmacogenetic study using healthy volunteers.,Polymorphisms in dopamine transporter ([ENTITY_A]) are associated with stimulant effects of [ENTITY_B]: an exploratory pharmacogenetic study using healthy volunteers.,ACTIVATOR,CPR:3,0,Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers.
"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by << cyclopiazonic acid >> (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial [[ SERCA ]] pump.","Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by [ENTITY_A] (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial [ENTITY_B] pump.",INHIBITOR,CPR:4,1,"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump."
"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the << G protein-coupled receptor >> agonist [[ acetylcholine ]] (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump.","Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the [ENTITY_A] agonist [ENTITY_B] (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump.",AGONIST,CPR:5,2,"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump."
"Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic manganese porphyrin and the << NADPH oxidase >> inhibitor [[ apocynin ]].","Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic manganese porphyrin and the [ENTITY_A] inhibitor [ENTITY_B].",INHIBITOR,CPR:4,1,"Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic manganese porphyrin and the NADPH oxidase inhibitor apocynin."
"Our results suggest that arsenite can potentiate EDHF-type relaxations via a mechanism that is dependent on hydrogen peroxide, thus demonstrating that dismutation of the << superoxide >> anion generated by [[ NADPH oxidase ]] can potentially offset loss of NO bioavailability under conditions of reduced eNOS activity.","Our results suggest that arsenite can potentiate EDHF-type relaxations via a mechanism that is dependent on hydrogen peroxide, thus demonstrating that dismutation of the [ENTITY_A] anion generated by [ENTITY_B] can potentially offset loss of NO bioavailability under conditions of reduced eNOS activity.",PRODUCT-OF,CPR:9,4,"Our results suggest that arsenite can potentiate EDHF-type relaxations via a mechanism that is dependent on hydrogen peroxide, thus demonstrating that dismutation of the superoxide anion generated by NADPH oxidase can potentially offset loss of NO bioavailability under conditions of reduced eNOS activity."
"We isolated partial cDNAs that codified for enzymes implicated in the << anthocyanin >> biosynthesis such as [[ l-phenylalanine ammonia-lyase ]] (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX).","We isolated partial cDNAs that codified for enzymes implicated in the [ENTITY_A] biosynthesis such as [ENTITY_B] (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX).",PRODUCT-OF,CPR:9,4,"We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)."
<< Acetaminophen >> (paracetamol) is a selective [[ cyclooxygenase-2 ]] inhibitor in man.,[ENTITY_A] (paracetamol) is a selective [ENTITY_B] inhibitor in man.,INHIBITOR,CPR:4,1,Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man.
The fact that << acetaminophen >> acts functionally as a selective [[ COX-2 ]] inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.,The fact that [ENTITY_A] acts functionally as a selective [ENTITY_B] inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.,INHIBITOR,CPR:4,1,The fact that acetaminophen acts functionally as a selective COX-2 inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.
Ex vivo << COX >> inhibition and pharmacokinetics of [[ acetaminophen ]] were assessed in 5 volunteers receiving single 1000 mg doses orally.,Ex vivo [ENTITY_A] inhibition and pharmacokinetics of [ENTITY_B] were assessed in 5 volunteers receiving single 1000 mg doses orally.,INHIBITOR,CPR:4,1,Ex vivo COX inhibition and pharmacokinetics of acetaminophen were assessed in 5 volunteers receiving single 1000 mg doses orally.
Coagulation-induced << thromboxane B(2) >> and lipopolysaccharide-induced prostaglandin E(2) were measured ex vivo and in vitro in human whole blood as indices of [[ COX-1 ]] and COX-2 activity.,Coagulation-induced [ENTITY_A] and lipopolysaccharide-induced prostaglandin E(2) were measured ex vivo and in vitro in human whole blood as indices of [ENTITY_B] and COX-2 activity.,PRODUCT-OF,CPR:9,4,Coagulation-induced thromboxane B(2) and lipopolysaccharide-induced prostaglandin E(2) were measured ex vivo and in vitro in human whole blood as indices of COX-1 and COX-2 activity.
"In vitro, << acetaminophen >> elicited a 4.4-fold selectivity toward [[ COX-2 ]] inhibition (IC(50)=113.7 micromol/L for COX-1; IC(50)=25.8 micromol/L for COX-2).","In vitro, [ENTITY_A] elicited a 4.4-fold selectivity toward [ENTITY_B] inhibition (IC(50)=113.7 micromol/L for COX-1; IC(50)=25.8 micromol/L for COX-2).",INHIBITOR,CPR:4,1,"In vitro, acetaminophen elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol/L for COX-1; IC(50)=25.8 micromol/L for COX-2)."
<< Acetaminophen >> plasma concentrations remained above the in vitro IC(50) for [[ COX-2 ]] for at least 5 h postadministration.,[ENTITY_A] plasma concentrations remained above the in vitro IC(50) for [ENTITY_B] for at least 5 h postadministration.,INHIBITOR,CPR:4,1,Acetaminophen plasma concentrations remained above the in vitro IC(50) for COX-2 for at least 5 h postadministration.
Ex vivo IC(50) values (<< COX-1 >>: 105.2 micromol/L; COX-2: 26.3 micromol/L) of [[ acetaminophen ]] compared favorably with its in vitro IC(50) values.,Ex vivo IC(50) values ([ENTITY_A]: 105.2 micromol/L; COX-2: 26.3 micromol/L) of [ENTITY_B] compared favorably with its in vitro IC(50) values.,INHIBITOR,CPR:4,1,Ex vivo IC(50) values (COX-1: 105.2 micromol/L; COX-2: 26.3 micromol/L) of acetaminophen compared favorably with its in vitro IC(50) values.
"In contrast to previous concepts, << acetaminophen >> inhibited [[ COX-2 ]] by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors.","In contrast to previous concepts, [ENTITY_A] inhibited [ENTITY_B] by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors.",INHIBITOR,CPR:4,1,"In contrast to previous concepts, acetaminophen inhibited COX-2 by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors."
"In view of its substantial << COX-2 >> inhibition, recently defined cardiovascular warnings for use of COX-2 inhibitors should also be considered for [[ acetaminophen ]].","In view of its substantial [ENTITY_A] inhibition, recently defined cardiovascular warnings for use of COX-2 inhibitors should also be considered for [ENTITY_B].",INHIBITOR,CPR:4,1,"In view of its substantial COX-2 inhibition, recently defined cardiovascular warnings for use of COX-2 inhibitors should also be considered for acetaminophen."
"OBJECTIVES: The alkaloid << galantamine >> (GAL), which exhibits a combined [[ anticholinesterase ]] and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases.","OBJECTIVES: The alkaloid [ENTITY_A] (GAL), which exhibits a combined [ENTITY_B] and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases.",INHIBITOR,CPR:4,1,"OBJECTIVES: The alkaloid galantamine (GAL), which exhibits a combined anticholinesterase and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases."
"RESULTS: Following administration of the highest of the << GAL >> doses used (2.5; 5; 10 mg/kg i.m.), [[ AChE ]] activity decreased mainly in the frontal cortex, hippocampus and hypophysis.","RESULTS: Following administration of the highest of the [ENTITY_A] doses used (2.5; 5; 10 mg/kg i.m.), [ENTITY_B] activity decreased mainly in the frontal cortex, hippocampus and hypophysis.",INHIBITOR,CPR:4,1,"RESULTS: Following administration of the highest of the GAL doses used (2.5; 5; 10 mg/kg i.m.), AChE activity decreased mainly in the frontal cortex, hippocampus and hypophysis."
"In the interaction of << GAL >> and CAR, [[ AChE ]] inhibition was stronger but without any statistical significance.","In the interaction of [ENTITY_A] and CAR, [ENTITY_B] inhibition was stronger but without any statistical significance.",INHIBITOR,CPR:4,1,"In the interaction of GAL and CAR, AChE inhibition was stronger but without any statistical significance."
"<< NaAsO(2) >> increased the mRNA levels of the [[ light and medium subunits of neurofilament ]] and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin.","[ENTITY_A] increased the mRNA levels of the [ENTITY_B] and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin.",INDIRECT-UPREGULATOR,CPR:3,0,"NaAsO(2) increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin."
"<< NaAsO(2) >> increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of [[ tau ]] and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin.","[ENTITY_A] increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of [ENTITY_B] and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin.",INDIRECT-DOWNREGULATOR,CPR:4,1,"NaAsO(2) increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin."
A << naloxone-steroid hybrid azine >> with selective and long-acting opioid antagonism at [[ delta receptors ]] in vitro.,A [ENTITY_A] with selective and long-acting opioid antagonism at [ENTITY_B] in vitro.,ANTAGONIST,CPR:6,3,A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro.
Inhibition of << dipeptidyl peptidase-IV >> (DPP-IV) by [[ atorvastatin ]].,Inhibition of [ENTITY_A] (DPP-IV) by [ENTITY_B].,INHIBITOR,CPR:4,1,Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin.
"In this report, we show that the hypolipidemic agent << atorvastatin >> is a competitive inhibitor of [[ porcine DPP-IV ]] in vitro, with K(i)=57.8+/-2.3 microM.","In this report, we show that the hypolipidemic agent [ENTITY_A] is a competitive inhibitor of [ENTITY_B] in vitro, with K(i)=57.8+/-2.3 microM.",INHIBITOR,CPR:4,1,"In this report, we show that the hypolipidemic agent atorvastatin is a competitive inhibitor of porcine DPP-IV in vitro, with K(i)=57.8+/-2.3 microM."
These results may have implications in the development of novel << DPP-IV >> inhibitors based on the use of [[ atorvastatin ]] as a lead compound for the treatment of type 2 diabetes.,These results may have implications in the development of novel [ENTITY_A] inhibitors based on the use of [ENTITY_B] as a lead compound for the treatment of type 2 diabetes.,INHIBITOR,CPR:4,1,These results may have implications in the development of novel DPP-IV inhibitors based on the use of atorvastatin as a lead compound for the treatment of type 2 diabetes.
<< Neoechinulin A >> suppresses [[ amyloid-β ]] oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity.,[ENTITY_A] suppresses [ENTITY_B] oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity.,INHIBITOR,CPR:4,1,Neoechinulin A suppresses amyloid-β oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity.
"In this study, focus was given to evaluate the ability of << neoechinulin A >>, an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric [[ amyloid-β 1-42 ]] (Aβ42).","In this study, focus was given to evaluate the ability of [ENTITY_A], an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric [ENTITY_B] (Aβ42).",INHIBITOR,CPR:4,1,"In this study, focus was given to evaluate the ability of neoechinulin A, an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-β 1-42 (Aβ42)."
<< Neoechinulin A >> treatment significantly inhibited the generation of reactive oxygen and nitrogen species in [[ Aβ42 ]]-activated BV-2 microglia cells.,[ENTITY_A] treatment significantly inhibited the generation of reactive oxygen and nitrogen species in [ENTITY_B]-activated BV-2 microglia cells.,INHIBITOR,CPR:4,1,Neoechinulin A treatment significantly inhibited the generation of reactive oxygen and nitrogen species in Aβ42-activated BV-2 microglia cells.
"In addition, we found that << neoechinulin A >> significantly suppressed the production of neurotoxic inflammatory mediator [[ tumour necrosis factor-α ]] (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.","In addition, we found that [ENTITY_A] significantly suppressed the production of neurotoxic inflammatory mediator [ENTITY_B] (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells."
"The molecular mechanism studies suggested that << neoechinulin A >> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of [[ nuclear factor-κB ]] (NF-κB) p65 and p50 subunits.","The molecular mechanism studies suggested that [ENTITY_A] may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of [ENTITY_B] (NF-κB) p65 and p50 subunits.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The molecular mechanism studies suggested that neoechinulin A may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-κB (NF-κB) p65 and p50 subunits."
<< Epi >> increased the activity of the [[ human WNT6 promoter ]] through Cav1-dependent binding of β-catenin to the proximal WNT6 promoter.,[ENTITY_A] increased the activity of the [ENTITY_B] through Cav1-dependent binding of β-catenin to the proximal WNT6 promoter.,ACTIVATOR,CPR:3,0,Epi increased the activity of the human WNT6 promoter through Cav1-dependent binding of β-catenin to the proximal WNT6 promoter.
<< Epi >> increased both [[ WNT6 ]]/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg).,[ENTITY_A] increased both [ENTITY_B]/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg).,INDIRECT-UPREGULATOR,CPR:3,0,Epi increased both WNT6/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg).
These results showed that << WNT6 >> and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to [[ anthracycline ]] drugs.,These results showed that [ENTITY_A] and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to [ENTITY_B] drugs.,INDIRECT-UPREGULATOR,CPR:3,0,These results showed that WNT6 and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to anthracycline drugs.
"In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that << TCDD >> up-regulated the expression and secretion of [[ tumor necrosis factor-alpha ]] (TNF-α) in a time-dependent manner in cultured HAPI microglial cells.","In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that [ENTITY_A] up-regulated the expression and secretion of [ENTITY_B] (TNF-α) in a time-dependent manner in cultured HAPI microglial cells.",INDIRECT-UPREGULATOR,CPR:3,0,"In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that TCDD up-regulated the expression and secretion of tumor necrosis factor-alpha (TNF-α) in a time-dependent manner in cultured HAPI microglial cells."
<< TCDD >> also caused a fast (within 30min as judged by the increase in its mRNA level) activation of [[ cytosolic phospholipase A2 ]] (cPLA2).,[ENTITY_A] also caused a fast (within 30min as judged by the increase in its mRNA level) activation of [ENTITY_B] (cPLA2).,INDIRECT-UPREGULATOR,CPR:3,0,TCDD also caused a fast (within 30min as judged by the increase in its mRNA level) activation of cytosolic phospholipase A2 (cPLA2).
"This initial action was accompanied by up-regulation of << cyclooxygenase-2 >> (COX-2), an important inflammation marker within 1h after [[ TCDD ]] treatment.","This initial action was accompanied by up-regulation of [ENTITY_A] (COX-2), an important inflammation marker within 1h after [ENTITY_B] treatment.",INDIRECT-UPREGULATOR,CPR:3,0,"This initial action was accompanied by up-regulation of cyclooxygenase-2 (COX-2), an important inflammation marker within 1h after TCDD treatment."
"Further, << TCDD >> exposure could induce phosphorylation- and ubiquitination-dependent degradation of [[ IкBα ]], and the translocation of NF-κB p65 from the cytosol to the nucleus in this microglial cell line.","Further, [ENTITY_A] exposure could induce phosphorylation- and ubiquitination-dependent degradation of [ENTITY_B], and the translocation of NF-κB p65 from the cytosol to the nucleus in this microglial cell line.",ACTIVATOR,CPR:3,0,"Further, TCDD exposure could induce phosphorylation- and ubiquitination-dependent degradation of IкBα, and the translocation of NF-κB p65 from the cytosol to the nucleus in this microglial cell line."
"Thus, the << NF-κB >> signaling pathway can be activated after [[ TCDD ]] treatment.","Thus, the [ENTITY_A] signaling pathway can be activated after [ENTITY_B] treatment.",ACTIVATOR,CPR:3,0,"Thus, the NF-κB signaling pathway can be activated after TCDD treatment."
"However, Ca(2+) blockers also obviously attenuated << NF-κB >> activation and transnuclear transport induced by [[ TCDD ]].","However, Ca(2+) blockers also obviously attenuated [ENTITY_A] activation and transnuclear transport induced by [ENTITY_B].",ACTIVATOR,CPR:3,0,"However, Ca(2+) blockers also obviously attenuated NF-κB activation and transnuclear transport induced by TCDD."
"In concert with these results, we highlighted that the secretion of pro-inflammatory << cytokine >> and NF-κB activation induced by [[ TCDD ]] can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.","In concert with these results, we highlighted that the secretion of pro-inflammatory [ENTITY_A] and NF-κB activation induced by [ENTITY_B] can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.",ACTIVATOR,CPR:3,0,"In concert with these results, we highlighted that the secretion of pro-inflammatory cytokine and NF-κB activation induced by TCDD can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells."
"The ARB << eprosartan >> is a nonbiphenyl nontetrazole [[ angiotensin II type 1 receptor ]] (AT1) antagonist, which acts to decrease total peripheral resistance.","The ARB [ENTITY_A] is a nonbiphenyl nontetrazole [ENTITY_B] (AT1) antagonist, which acts to decrease total peripheral resistance.",ANTAGONIST,CPR:6,3,"The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance."
"The putative << alpha 1L-adrenoceptor >> antagonist [[ JTH-601 ]], but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA.","The putative [ENTITY_A] antagonist [ENTITY_B], but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA.",ANTAGONIST,CPR:6,3,"The putative alpha 1L-adrenoceptor antagonist JTH-601, but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA."
The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective << alpha 1A-adrenoceptor >> agonist [[ A-61603 ]] (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.,The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective [ENTITY_A] agonist [ENTITY_B] (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.,AGONIST,CPR:5,2,The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.
The potency of the selective << alpha 1D-adrenoceptor >> antagonist [[ BMY 7378 ]] against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.,The potency of the selective [ENTITY_A] antagonist [ENTITY_B] against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.,ANTAGONIST,CPR:6,3,The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.
"Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the << dopamine D1 receptor >> antagonist [[ SCH 39166 ]] ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).","Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the [ENTITY_A] antagonist [ENTITY_B] ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).",ANTAGONIST,CPR:6,3,"Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg)."
"<< Carvedilol >> reduced the risk of death or heart failure in patients with above-median levels of [[ N-BNP ]] or adrenomedullin, or both, to rates not significantly different from those observed in patients with levels below the median value.","[ENTITY_A] reduced the risk of death or heart failure in patients with above-median levels of [ENTITY_B] or adrenomedullin, or both, to rates not significantly different from those observed in patients with levels below the median value.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Carvedilol reduced the risk of death or heart failure in patients with above-median levels of N-BNP or adrenomedullin, or both, to rates not significantly different from those observed in patients with levels below the median value."
<< Carvedilol >> reduced mortality and heart failure in patients with higher pre-treatment plasma [[ N-BNP ]] and adrenomedullin.,[ENTITY_A] reduced mortality and heart failure in patients with higher pre-treatment plasma [ENTITY_B] and adrenomedullin.,INDIRECT-DOWNREGULATOR,CPR:4,1,Carvedilol reduced mortality and heart failure in patients with higher pre-treatment plasma N-BNP and adrenomedullin.
"In combination with << clofarabine >>, the ability of resveratrol to reduce the contents of [[ Sp1 ]] and its target gene products was also evident in a time- and dose-dependent experiment.","In combination with [ENTITY_A], the ability of resveratrol to reduce the contents of [ENTITY_B] and its target gene products was also evident in a time- and dose-dependent experiment.",DOWNREGULATOR,CPR:4,1,"In combination with clofarabine, the ability of resveratrol to reduce the contents of Sp1 and its target gene products was also evident in a time- and dose-dependent experiment."
"The inhibition of phosphoinositide 3-kinase using << Ly294002 >> augmented a decrease in the [[ p21 ]] level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1.","The inhibition of phosphoinositide 3-kinase using [ENTITY_A] augmented a decrease in the [ENTITY_B] level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The inhibition of phosphoinositide 3-kinase using Ly294002 augmented a decrease in the p21 level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1."
"Taken together, the data provide evidence that the synergistic antiproliferative effect of << resveratrol >> and clofarabine is linked to the inhibition of [[ Akt ]] and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.","Taken together, the data provide evidence that the synergistic antiproliferative effect of [ENTITY_A] and clofarabine is linked to the inhibition of [ENTITY_B] and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.",INHIBITOR,CPR:4,1,"Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and clofarabine is linked to the inhibition of Akt and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma."
<< Phillyrin >> attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of [[ LKB1 ]]/AMP-activated protein kinase-dependent signalling.,[ENTITY_A] attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of [ENTITY_B]/AMP-activated protein kinase-dependent signalling.,ACTIVATOR,CPR:3,0,Phillyrin attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/AMP-activated protein kinase-dependent signalling.
Phillyrin strongly inhibited high << glucose >>-induced [[ fatty acid synthase ]] (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.,Phillyrin strongly inhibited high [ENTITY_A]-induced [ENTITY_B] (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.,INDIRECT-UPREGULATOR,CPR:3,0,Phillyrin strongly inhibited high glucose-induced fatty acid synthase (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.
<< Phillyrin >> strongly inhibited high glucose-induced [[ fatty acid synthase ]] (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.,[ENTITY_A] strongly inhibited high glucose-induced [ENTITY_B] (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.,INDIRECT-DOWNREGULATOR,CPR:4,1,Phillyrin strongly inhibited high glucose-induced fatty acid synthase (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.
"Moreover, use of the pharmacological << AMP-activated protein kinase >> (AMPK) inhibitor [[ compound C ]] revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells.","Moreover, use of the pharmacological [ENTITY_A] (AMPK) inhibitor [ENTITY_B] revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells.",INHIBITOR,CPR:4,1,"Moreover, use of the pharmacological AMP-activated protein kinase (AMPK) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells."
"Finally, we found that liver kinase B1 (LKB1) phosphorylation is required for the << phillyrin >>-enhanced activation of [[ AMPK ]] in HepG2 hepatocytes.","Finally, we found that liver kinase B1 (LKB1) phosphorylation is required for the [ENTITY_A]-enhanced activation of [ENTITY_B] in HepG2 hepatocytes.",ACTIVATOR,CPR:3,0,"Finally, we found that liver kinase B1 (LKB1) phosphorylation is required for the phillyrin-enhanced activation of AMPK in HepG2 hepatocytes."
"These results indicate that << phillyrin >> prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through [[ LKB1 ]]/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.","These results indicate that [ENTITY_A] prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through [ENTITY_B]/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.",ACTIVATOR,CPR:3,0,"These results indicate that phillyrin prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity."
"These results indicate that << phillyrin >> prevents lipid accumulation in HepG2 cells by blocking the expression of [[ SREBP-1c ]] and FAS through LKB1/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.","These results indicate that [ENTITY_A] prevents lipid accumulation in HepG2 cells by blocking the expression of [ENTITY_B] and FAS through LKB1/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.",INDIRECT-DOWNREGULATOR,CPR:4,1,"These results indicate that phillyrin prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity."
<< Benzenesulfonamides >> incorporating cyanoacrylamide moieties strongly inhibit [[ Saccharomyces cerevisiae β-carbonic anhydrase ]].,[ENTITY_A] incorporating cyanoacrylamide moieties strongly inhibit [ENTITY_B].,INHIBITOR,CPR:4,1,Benzenesulfonamides incorporating cyanoacrylamide moieties strongly inhibit Saccharomyces cerevisiae β-carbonic anhydrase.
"A series of << benzenesulfonamides >> incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the β-carbonic anhydrase (CA, [[ EC 4.2.1.1 ]]) from Saccharomyces cerevisiae, ScCA.","A series of [ENTITY_A] incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the β-carbonic anhydrase (CA, [ENTITY_B]) from Saccharomyces cerevisiae, ScCA.",INHIBITOR,CPR:4,1,"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the β-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA."
<< Artemisinic acid >> inhibits melanogenesis through downregulation of C/EBP α-dependent expression of [[ HMG-CoA reductase ]] gene.,[ENTITY_A] inhibits melanogenesis through downregulation of C/EBP α-dependent expression of [ENTITY_B] gene.,INDIRECT-DOWNREGULATOR,CPR:4,1,Artemisinic acid inhibits melanogenesis through downregulation of C/EBP α-dependent expression of HMG-CoA reductase gene.
"The mRNA levels of << microphthalmia-associated transcription factor >> (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by [[ artemisinic acid ]] treatment.","The mRNA levels of [ENTITY_A] (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by [ENTITY_B] treatment.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by artemisinic acid treatment."
"Additionally, the mRNA levels of melanogenesis-related genes (<< c-KIT >>, stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by [[ artemisinic acid ]].","Additionally, the mRNA levels of melanogenesis-related genes ([ENTITY_A], stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by artemisinic acid."
"Furthermore, cAMP production and << protein kinase A >> (PKA) activity were suppressed by [[ artemisinic acid ]].","Furthermore, cAMP production and [ENTITY_A] (PKA) activity were suppressed by [ENTITY_B].",INHIBITOR,CPR:4,1,"Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by artemisinic acid."
"Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that << artemisinic acid >> regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the [[ hydroxymethylglutaryl CoA (HMG CoA) reductase ]] gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) α gene.","Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that [ENTITY_A] regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the [ENTITY_B] gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) α gene.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) α gene."
"Taken together, these findings indicate that the inhibition of melanogenesis by << artemisinic acid >> occurs through reduced expression of the [[ HMG CoA reductase ]] gene, which is mediated by C/EBP α inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor.","Taken together, these findings indicate that the inhibition of melanogenesis by [ENTITY_A] occurs through reduced expression of the [ENTITY_B] gene, which is mediated by C/EBP α inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Taken together, these findings indicate that the inhibition of melanogenesis by artemisinic acid occurs through reduced expression of the HMG CoA reductase gene, which is mediated by C/EBP α inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor."
"As determined by Western and Northern blot analyses, << 5 alpha-NET >> inhibited the P4-induced [[ UG ]] gene expression in a dose-dependent manner.","As determined by Western and Northern blot analyses, [ENTITY_A] inhibited the P4-induced [ENTITY_B] gene expression in a dose-dependent manner.",INDIRECT-DOWNREGULATOR,CPR:4,1,"As determined by Western and Northern blot analyses, 5 alpha-NET inhibited the P4-induced UG gene expression in a dose-dependent manner."
"The estrogenic agent << 3 beta,5 alpha-NET >> and estradiol at a dose of 1.0 mg also inhibited the [[ UG ]] gene expression induced by P4.",The estrogenic agent [ENTITY_A] and estradiol at a dose of 1.0 mg also inhibited the [ENTITY_B] gene expression induced by P4.,INDIRECT-DOWNREGULATOR,CPR:4,1,"The estrogenic agent 3 beta,5 alpha-NET and estradiol at a dose of 1.0 mg also inhibited the UG gene expression induced by P4."
"Both << 5 alpha-NET >> and 3 beta,5 alpha-NET blocked the [[ PR ]] down-regulation induced by P4 as assessed by Western and Northern blot methods.","Both [ENTITY_A] and 3 beta,5 alpha-NET blocked the [ENTITY_B] down-regulation induced by P4 as assessed by Western and Northern blot methods.",INDIRECT-UPREGULATOR,CPR:3,0,"Both 5 alpha-NET and 3 beta,5 alpha-NET blocked the PR down-regulation induced by P4 as assessed by Western and Northern blot methods."
"The inhibition of UG synthesis and << PR >> down-regulation by [[ 5 alpha-NET ]] and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties.","The inhibition of UG synthesis and [ENTITY_A] down-regulation by [ENTITY_B] and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties.",INDIRECT-UPREGULATOR,CPR:3,0,"The inhibition of UG synthesis and PR down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties."
"The inhibition of << UG >> synthesis and PR down-regulation by [[ 5 alpha-NET ]] and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties.","The inhibition of [ENTITY_A] synthesis and PR down-regulation by [ENTITY_B] and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The inhibition of UG synthesis and PR down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties."
"Meanwhile, autophagy was detected as early as 12 h after an exposure to low-dose << dioscin >>, as indicated by an up-regulated expression of [[ LC3-II ]] and beclin-1 proteins.","Meanwhile, autophagy was detected as early as 12 h after an exposure to low-dose [ENTITY_A], as indicated by an up-regulated expression of [ENTITY_B] and beclin-1 proteins.",INDIRECT-UPREGULATOR,CPR:3,0,"Meanwhile, autophagy was detected as early as 12 h after an exposure to low-dose dioscin, as indicated by an up-regulated expression of LC3-II and beclin-1 proteins."
"Treatment of A549 and H1299 cells with << dioscin >> caused a dose-dependent increase in ERK1/2 and [[ JNK1/2 ]] activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR.","Treatment of A549 and H1299 cells with [ENTITY_A] caused a dose-dependent increase in ERK1/2 and [ENTITY_B] activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR.",UPREGULATOR,CPR:3,0,"Treatment of A549 and H1299 cells with dioscin caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR."
"Treatment of A549 and H1299 cells with << dioscin >> caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased [[ PI3K ]] expression and decreased phosphorylation of Akt and mTOR.","Treatment of A549 and H1299 cells with [ENTITY_A] caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased [ENTITY_B] expression and decreased phosphorylation of Akt and mTOR.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Treatment of A549 and H1299 cells with dioscin caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR."
"Our results showed that << 2-hydroxy-3-methylanthraquinone >> decreased phosphorylation-ERK1/2 (p-ERK1/2), and increased [[ p-p38MAPK ]], but did not affect expressions of p-JNK1/2 in U937 cells.","Our results showed that [ENTITY_A] decreased phosphorylation-ERK1/2 (p-ERK1/2), and increased [ENTITY_B], but did not affect expressions of p-JNK1/2 in U937 cells.",ACTIVATOR,CPR:3,0,"Our results showed that 2-hydroxy-3-methylanthraquinone decreased phosphorylation-ERK1/2 (p-ERK1/2), and increased p-p38MAPK, but did not affect expressions of p-JNK1/2 in U937 cells."
"Moreover, treatment of U937 cells with << 2-hydroxy-3-methylanthraquinone >> resulted in activation of [[ caspase-3 ]].","Moreover, treatment of U937 cells with [ENTITY_A] resulted in activation of [ENTITY_B].",ACTIVATOR,CPR:3,0,"Moreover, treatment of U937 cells with 2-hydroxy-3-methylanthraquinone resulted in activation of caspase-3."
"Furthermore, PD98059 (ERK1/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or << SB203580 >> ([[ p-p38MAPK ]] inhibitor), decreased apoptosis in U937 cells.","Furthermore, PD98059 (ERK1/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or [ENTITY_A] ([ENTITY_B] inhibitor), decreased apoptosis in U937 cells.",INHIBITOR,CPR:4,1,"Furthermore, PD98059 (ERK1/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or SB203580 (p-p38MAPK inhibitor), decreased apoptosis in U937 cells."
"Taken together, our study for the first time suggests that << 2-hydroxy-3-methylanthraquinone >> is able to enhance apoptosis of U937 cells, at least in part, through activation of [[ p-p38MAPK ]] and downregulation of p-ERK1/2.","Taken together, our study for the first time suggests that [ENTITY_A] is able to enhance apoptosis of U937 cells, at least in part, through activation of [ENTITY_B] and downregulation of p-ERK1/2.",ACTIVATOR,CPR:3,0,"Taken together, our study for the first time suggests that 2-hydroxy-3-methylanthraquinone is able to enhance apoptosis of U937 cells, at least in part, through activation of p-p38MAPK and downregulation of p-ERK1/2."
<< Ribonucleotide reductase >> activity was found to be strongly increased in the [[ gemcitabine ]]-selected line and purine nucleoside phosphorylase was increased in the 2-chlorodeoxyadenosine-selected line.,[ENTITY_A] activity was found to be strongly increased in the [ENTITY_B]-selected line and purine nucleoside phosphorylase was increased in the 2-chlorodeoxyadenosine-selected line.,UPREGULATOR,CPR:3,0,Ribonucleotide reductase activity was found to be strongly increased in the gemcitabine-selected line and purine nucleoside phosphorylase was increased in the 2-chlorodeoxyadenosine-selected line.
A new series of << N2-substituted-5-(p-toluenesulfonylamino)phthalimide >> analogues as [[ α-glucosidase ]] inhibitors.,A new series of [ENTITY_A] analogues as [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,A new series of N2-substituted-5-(p-toluenesulfonylamino)phthalimide analogues as α-glucosidase inhibitors.
"Several members of a new family of non-sugar-type << α-glycosidase >> inhibitors, bearing a [[ 5-(p-toluenesulfonylamino)phthalimide ]] moiety and various substituent at the N2 position, were synthesized and their activities were investigated.","Several members of a new family of non-sugar-type [ENTITY_A] inhibitors, bearing a [ENTITY_B] moiety and various substituent at the N2 position, were synthesized and their activities were investigated.",INHIBITOR,CPR:4,1,"Several members of a new family of non-sugar-type α-glycosidase inhibitors, bearing a 5-(p-toluenesulfonylamino)phthalimide moiety and various substituent at the N2 position, were synthesized and their activities were investigated."
Structure-activity relationship studies indicated that << 5-(p-toluenesulfonylamino)phthalimide >> moiety is a favorable scaffold to exert the [[ α-glucosidase ]] inhibitory activity and substituents at the N2 position have considerable influence on the efficacy of the inhibition activities.,Structure-activity relationship studies indicated that [ENTITY_A] moiety is a favorable scaffold to exert the [ENTITY_B] inhibitory activity and substituents at the N2 position have considerable influence on the efficacy of the inhibition activities.,INHIBITOR,CPR:4,1,Structure-activity relationship studies indicated that 5-(p-toluenesulfonylamino)phthalimide moiety is a favorable scaffold to exert the α-glucosidase inhibitory activity and substituents at the N2 position have considerable influence on the efficacy of the inhibition activities.
"The lysosomal inhibitor << chloroquine >> significantly increased [[ RCAN1 ]] accumulation in +/+ cells, consistent with the hypothesis that higher lysosomal pH impairs RCAN1 degradation, leading to a higher RCAN1/NFATc1 ratio and consequently NFATc1 inhibition.","The lysosomal inhibitor [ENTITY_A] significantly increased [ENTITY_B] accumulation in +/+ cells, consistent with the hypothesis that higher lysosomal pH impairs RCAN1 degradation, leading to a higher RCAN1/NFATc1 ratio and consequently NFATc1 inhibition.",INDIRECT-UPREGULATOR,CPR:3,0,"The lysosomal inhibitor chloroquine significantly increased RCAN1 accumulation in +/+ cells, consistent with the hypothesis that higher lysosomal pH impairs RCAN1 degradation, leading to a higher RCAN1/NFATc1 ratio and consequently NFATc1 inhibition."
"Here, we have now found that activation of << p38 >> MAPK by [[ anisomycin ]] potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.","Here, we have now found that activation of [ENTITY_A] MAPK by [ENTITY_B] potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.",INDIRECT-UPREGULATOR,CPR:3,0,"Here, we have now found that activation of p38 MAPK by anisomycin potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes."
siRNA knockdown of p38 MAPK abrogated the ability of << anisomycin >> to synergistically induce [[ CYP2B6 ]] mRNA.,siRNA knockdown of p38 MAPK abrogated the ability of [ENTITY_A] to synergistically induce [ENTITY_B] mRNA.,INDIRECT-UPREGULATOR,CPR:3,0,siRNA knockdown of p38 MAPK abrogated the ability of anisomycin to synergistically induce CYP2B6 mRNA.
"In addition to << CYP2B6 >>, [[ anisomycin ]] co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs.","In addition to [ENTITY_A], [ENTITY_B] co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs.",INDIRECT-UPREGULATOR,CPR:3,0,"In addition to CYP2B6, anisomycin co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs."
"No effects were observed when << fenclozic acid >> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major [[ human cytochrome P450 ]] enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.","No effects were observed when [ENTITY_A] was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major [ENTITY_B] enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.",INHIBITOR,CPR:4,1,"No effects were observed when fenclozic acid was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells."
"<< Auranofin >>, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of [[ TLR4 ]].","[ENTITY_A], as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of [ENTITY_B].",INHIBITOR,CPR:4,1,"Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4."
"Our results demonstrated that << auranofin >> suppressed TLR4-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of [[ COX-2 ]], a pro-inflammatory enzyme.","Our results demonstrated that [ENTITY_A] suppressed TLR4-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of [ENTITY_B], a pro-inflammatory enzyme.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Our results demonstrated that auranofin suppressed TLR4-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2, a pro-inflammatory enzyme."
This suppression was well correlated with the inhibitory effect of << auranofin >> on the homodimerization of [[ TLR4 ]] induced by an agonist.,This suppression was well correlated with the inhibitory effect of [ENTITY_A] on the homodimerization of [ENTITY_B] induced by an agonist.,INHIBITOR,CPR:4,1,This suppression was well correlated with the inhibitory effect of auranofin on the homodimerization of TLR4 induced by an agonist.
"Furthermore, << auranofin >> inhibited [[ NF-kappaB ]] activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKbeta, and p65.","Furthermore, [ENTITY_A] inhibited [ENTITY_B] activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKbeta, and p65.",INHIBITOR,CPR:4,1,"Furthermore, auranofin inhibited NF-kappaB activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKbeta, and p65."
"<< IRF3 >> activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by [[ auranofin ]].","[ENTITY_A] activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by [ENTITY_B].",DOWNREGULATOR,CPR:4,1,"IRF3 activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by auranofin."
"Our results first demonstrate that << auranofin >> suppresses the multiple steps in [[ TLR4 ]] signaling, especially the homodimerization of TLR4.","Our results first demonstrate that [ENTITY_A] suppresses the multiple steps in [ENTITY_B] signaling, especially the homodimerization of TLR4.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4."
The results suggest that the suppression of << TLR4 >> activity by auranofin may be the molecular mechanism through which [[ auranofin ]] exerts anti-rheumatic activity.,The results suggest that the suppression of [ENTITY_A] activity by auranofin may be the molecular mechanism through which [ENTITY_B] exerts anti-rheumatic activity.,DOWNREGULATOR,CPR:4,1,The results suggest that the suppression of TLR4 activity by auranofin may be the molecular mechanism through which auranofin exerts anti-rheumatic activity.
"<< Vandetanib >> (Caprelsa(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and [[ epidermal growth-factor receptors ]].","[ENTITY_A] (Caprelsa(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and [ENTITY_B].",INHIBITOR,CPR:4,1,"Vandetanib (Caprelsa(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors."
"One exception is << tranexamic acid >> (TXA), which, as a lysine mimetic, inhibits binding of [[ plasminogen ]] to fibrin.","One exception is [ENTITY_A] (TXA), which, as a lysine mimetic, inhibits binding of [ENTITY_B] to fibrin.",INHIBITOR,CPR:4,1,"One exception is tranexamic acid (TXA), which, as a lysine mimetic, inhibits binding of plasminogen to fibrin."
Coupling this computational technique with a high-quality low-throughput screen identified << 5-(4-piperidyl)-3-isoxazolol >> (4-PIOL) as a potent [[ plasminogen ]] binding inhibitor with the potential for the treatment of various bleeding disorders.,Coupling this computational technique with a high-quality low-throughput screen identified [ENTITY_A] (4-PIOL) as a potent [ENTITY_B] binding inhibitor with the potential for the treatment of various bleeding disorders.,INHIBITOR,CPR:4,1,Coupling this computational technique with a high-quality low-throughput screen identified 5-(4-piperidyl)-3-isoxazolol (4-PIOL) as a potent plasminogen binding inhibitor with the potential for the treatment of various bleeding disorders.
"Epididymal tissue from wild-type mice responded in vitro to << noradrenaline >> and isoprenaline with increased glycerol release, reduced [[ IL-6 ]] release, and increased cAMP accumulation.","Epididymal tissue from wild-type mice responded in vitro to [ENTITY_A] and isoprenaline with increased glycerol release, reduced [ENTITY_B] release, and increased cAMP accumulation.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Epididymal tissue from wild-type mice responded in vitro to noradrenaline and isoprenaline with increased glycerol release, reduced IL-6 release, and increased cAMP accumulation."
<< Phospholipase A2 >> inhibitors [[ p-bromophenacyl bromide ]] and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes.,[ENTITY_A] inhibitors [ENTITY_B] and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes.,ACTIVATOR,CPR:3,0,Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes.
Phospholipase A2 inhibitors << p-bromophenacyl bromide >> and arachidonyl trifluoromethyl ketone suppressed [[ interleukin-2 ]] (IL-2) expression in murine primary splenocytes.,Phospholipase A2 inhibitors [ENTITY_A] and arachidonyl trifluoromethyl ketone suppressed [ENTITY_B] (IL-2) expression in murine primary splenocytes.,INDIRECT-DOWNREGULATOR,CPR:4,1,Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes.
"Therefore, the objective of the present study was to investigate the effects of << PLA2 >> inhibitors [[ p-bromophenacyl bromide ]] (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes.","Therefore, the objective of the present study was to investigate the effects of [ENTITY_A] inhibitors [ENTITY_B] (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes.",INHIBITOR,CPR:4,1,"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes."
Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed << phorbol 12-myristate 13-acetate >> plus ionomycin-induced [[ IL-2 ]] secretion in a concentration-dependent manner.,Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed [ENTITY_A] plus ionomycin-induced [ENTITY_B] secretion in a concentration-dependent manner.,UPREGULATOR,CPR:3,0,Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced IL-2 secretion in a concentration-dependent manner.
Pretreatment of the splenocytes with both << BPB >> and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced [[ IL-2 ]] secretion in a concentration-dependent manner.,Pretreatment of the splenocytes with both [ENTITY_A] and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced [ENTITY_B] secretion in a concentration-dependent manner.,INDIRECT-DOWNREGULATOR,CPR:4,1,Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced IL-2 secretion in a concentration-dependent manner.
Inhibition > 90% of << IL-2 >> secretion was observed at 1 microM [[ BPB ]] and 10 microM AACOCF3 compared to the respective vehicle control.,Inhibition > 90% of [ENTITY_A] secretion was observed at 1 microM [ENTITY_B] and 10 microM AACOCF3 compared to the respective vehicle control.,INDIRECT-DOWNREGULATOR,CPR:4,1,Inhibition > 90% of IL-2 secretion was observed at 1 microM BPB and 10 microM AACOCF3 compared to the respective vehicle control.
"Likewise, << IL-2 >> steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM [[ BPB ]] and 20 microM AACOCF3.","Likewise, [ENTITY_A] steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM [ENTITY_B] and 20 microM AACOCF3.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Likewise, IL-2 steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM AACOCF3."
"Taken together, these data demonstrated that PLA2 inhibitors << BPB >> and AACOCF3 are robust inhibitors of [[ IL-2 ]] expression at both the mRNA and protein levels in murine splenocytes.","Taken together, these data demonstrated that PLA2 inhibitors [ENTITY_A] and AACOCF3 are robust inhibitors of [ENTITY_B] expression at both the mRNA and protein levels in murine splenocytes.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes."
"The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and << imatinib >>, a selective [[ tyrosine kinase ]] inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable/metastatic GIST.","The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and [ENTITY_A], a selective [ENTITY_B] inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable/metastatic GIST.",INHIBITOR,CPR:4,1,"The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and imatinib, a selective tyrosine kinase inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable/metastatic GIST."
We have previously reported that << TZDs >> reduce estrogen synthesis by inhibiting [[ aromatase ]] activity in human granulosa cells (HGC).,We have previously reported that [ENTITY_A] reduce estrogen synthesis by inhibiting [ENTITY_B] activity in human granulosa cells (HGC).,INHIBITOR,CPR:4,1,We have previously reported that TZDs reduce estrogen synthesis by inhibiting aromatase activity in human granulosa cells (HGC).
We have previously reported that TZDs reduce << estrogen >> synthesis by inhibiting [[ aromatase ]] activity in human granulosa cells (HGC).,We have previously reported that TZDs reduce [ENTITY_A] synthesis by inhibiting [ENTITY_B] activity in human granulosa cells (HGC).,PRODUCT-OF,CPR:9,4,We have previously reported that TZDs reduce estrogen synthesis by inhibiting aromatase activity in human granulosa cells (HGC).
We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether << TZD >> inhibition of [[ aromatase ]] plays a role in their effects on bone metabolism.,We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether [ENTITY_A] inhibition of [ENTITY_B] plays a role in their effects on bone metabolism.,INHIBITOR,CPR:4,1,We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether TZD inhibition of aromatase plays a role in their effects on bone metabolism.
"<< TZDs >> also inhibited [[ alkaline phosphatase ]] activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031).","[ENTITY_A] also inhibited [ENTITY_B] activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031).",INHIBITOR,CPR:4,1,"TZDs also inhibited alkaline phosphatase activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031)."
"<< TZD >> effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on [[ aromatase ]].","[ENTITY_A] effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on [ENTITY_B].",INHIBITOR,CPR:4,1,"TZD effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on aromatase."
Carnitine acetyltransferases (<< CrAT >>) catalyze the reversible conversion of acetyl-CoA and carnitine to [[ acetylcarnitine ]] and free CoA.,Carnitine acetyltransferases ([ENTITY_A]) catalyze the reversible conversion of acetyl-CoA and carnitine to [ENTITY_B] and free CoA.,PRODUCT-OF,CPR:9,4,Carnitine acetyltransferases (CrAT) catalyze the reversible conversion of acetyl-CoA and carnitine to acetylcarnitine and free CoA.
"The << M564G >> mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, [[ acetyl-CoA ]].","The [ENTITY_A] mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, [ENTITY_B].",SUBSTRATE,CPR:9,4,"The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA."
Kinetic constants of the mutant << CrAT >> showed modification in favor of longer [[ acyl-CoAs ]] as substrates.,Kinetic constants of the mutant [ENTITY_A] showed modification in favor of longer [ENTITY_B] as substrates.,SUBSTRATE,CPR:9,4,Kinetic constants of the mutant CrAT showed modification in favor of longer acyl-CoAs as substrates.
"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in << carnitine octanoyltransferase >> (COT) decreased activity toward its natural substrates, medium- and long-chain [[ acyl-CoAs ]], and increased activity toward short-chain acyl-CoAs.","In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in [ENTITY_A] (COT) decreased activity toward its natural substrates, medium- and long-chain [ENTITY_B], and increased activity toward short-chain acyl-CoAs.",SUBSTRATE,CPR:9,4,"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs."
We conclude that Met564 blocks the entry of medium- and long-chain << acyl-CoAs >> to the catalytic site of [[ CrAT ]].,We conclude that Met564 blocks the entry of medium- and long-chain [ENTITY_A] to the catalytic site of [ENTITY_B].,SUBSTRATE,CPR:9,4,We conclude that Met564 blocks the entry of medium- and long-chain acyl-CoAs to the catalytic site of CrAT.
"Catecholamines (<< adrenaline >>, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase ([[ phenylalanine hydroxylase ]], EC 1.14.16.1).","Catecholamines ([ENTITY_A], noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase ([ENTITY_B], EC 1.14.16.1).",INHIBITOR,CPR:4,1,"Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1)."
Central and peripheral administration of << kisspeptin >> stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a [[ gonadotrophin releasing hormone ]] (GnRH) antagonist abolishes this effect.,Central and peripheral administration of [ENTITY_A] stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a [ENTITY_B] (GnRH) antagonist abolishes this effect.,INHIBITOR,CPR:4,1,Central and peripheral administration of kisspeptin stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a gonadotrophin releasing hormone (GnRH) antagonist abolishes this effect.
"<< Dexamethasone >> (DEX), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either [[ human or rat GR ]].","[ENTITY_A] (DEX), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either [ENTITY_B].",AGONIST,CPR:5,2,"Dexamethasone (DEX), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either human or rat GR."
"The esterified-BM, however, had only partial transactivation agonistic activity in cells transfected with << rat GR >>, whereas [[ BM ]] and esterified-DEX had full transactivation agonistic activity.","The esterified-BM, however, had only partial transactivation agonistic activity in cells transfected with [ENTITY_A], whereas [ENTITY_B] and esterified-DEX had full transactivation agonistic activity.",AGONIST-ACTIVATOR,CPR:5,2,"The esterified-BM, however, had only partial transactivation agonistic activity in cells transfected with rat GR, whereas BM and esterified-DEX had full transactivation agonistic activity."
"Moreover, in rat hepatoma H4-II-E cells, the esterified-<< BM >> failed to induce tyrosine aminotransferase, which is regulated by [[ GR ]]-mediated transactivation activity.","Moreover, in rat hepatoma H4-II-E cells, the esterified-[ENTITY_A] failed to induce tyrosine aminotransferase, which is regulated by [ENTITY_B]-mediated transactivation activity.",AGONIST,CPR:5,2,"Moreover, in rat hepatoma H4-II-E cells, the esterified-BM failed to induce tyrosine aminotransferase, which is regulated by GR-mediated transactivation activity."
"Consistent with the weak transactivation activity of esterified-<< BM >> mediated by [[ rat GR ]], there were few side effects, evaluated by thymus involution and body weight loss, in an antigen-induced asthmatic model in rats.","Consistent with the weak transactivation activity of esterified-[ENTITY_A] mediated by [ENTITY_B], there were few side effects, evaluated by thymus involution and body weight loss, in an antigen-induced asthmatic model in rats.",AGONIST,CPR:5,2,"Consistent with the weak transactivation activity of esterified-BM mediated by rat GR, there were few side effects, evaluated by thymus involution and body weight loss, in an antigen-induced asthmatic model in rats."
"Moreover, << IGFBP-rP2 >> noticeably increased in response to TGF-beta1 and [[ all-trans retinoic acid ]] (atRA) in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC.","Moreover, [ENTITY_A] noticeably increased in response to TGF-beta1 and [ENTITY_B] (atRA) in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC.",INDIRECT-UPREGULATOR,CPR:3,0,"Moreover, IGFBP-rP2 noticeably increased in response to TGF-beta1 and all-trans retinoic acid (atRA) in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC."
"Although the data collected on << IGFBP-rP3 >> in prostate are modest, its role as a growth stimulator and/or protooncogene is supported by its preferential expression in cancerous cells and its down-regulation by [[ atRA ]].","Although the data collected on [ENTITY_A] in prostate are modest, its role as a growth stimulator and/or protooncogene is supported by its preferential expression in cancerous cells and its down-regulation by [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Although the data collected on IGFBP-rP3 in prostate are modest, its role as a growth stimulator and/or protooncogene is supported by its preferential expression in cancerous cells and its down-regulation by atRA."
On the basis of FIP1L1-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-PDGFRa positive cases the << tyrosine kinase >> inhibitor [[ imatinib mesylate ]] (Glivec) would be effective.,On the basis of FIP1L1-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-PDGFRa positive cases the [ENTITY_A] inhibitor [ENTITY_B] (Glivec) would be effective.,INHIBITOR,CPR:4,1,On the basis of FIP1L1-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-PDGFRa positive cases the tyrosine kinase inhibitor imatinib mesylate (Glivec) would be effective.
Transport by << OATP1B1 >> and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several [[ quercetin ]] derivatives.,Transport by [ENTITY_A] and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several [ENTITY_B] derivatives.,SUBSTRATE,CPR:9,4,Transport by OATP1B1 and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several quercetin derivatives.
"Uptake of the radiolabeled model substrates << estradiol 17β-glucuronide >>, estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either [[ OATP1B1 ]] or OATP1B3.","Uptake of the radiolabeled model substrates [ENTITY_A], estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either [ENTITY_B] or OATP1B3.",SUBSTRATE,CPR:9,4,"Uptake of the radiolabeled model substrates estradiol 17β-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or OATP1B3."
Compound 6 stimulated OATP1B3-mediated << estradiol 17β-glucuronide >> uptake by increasing the apparent affinity of [[ OATP1B3 ]] for its substrate.,Compound 6 stimulated OATP1B3-mediated [ENTITY_A] uptake by increasing the apparent affinity of [ENTITY_B] for its substrate.,SUBSTRATE,CPR:9,4,Compound 6 stimulated OATP1B3-mediated estradiol 17β-glucuronide uptake by increasing the apparent affinity of OATP1B3 for its substrate.
Cytotoxicity assays demonstrated that << epigallocatechin 3-O-gallate >> (EGCG) and most of compounds 1-6 killed preferentially [[ OATP ]]-expressing CHO cells.,Cytotoxicity assays demonstrated that [ENTITY_A] (EGCG) and most of compounds 1-6 killed preferentially [ENTITY_B]-expressing CHO cells.,SUBSTRATE,CPR:9,4,Cytotoxicity assays demonstrated that epigallocatechin 3-O-gallate (EGCG) and most of compounds 1-6 killed preferentially OATP-expressing CHO cells.
"EGCG, 1, and 3 were the most potent cytotoxic compounds, with << EGCG >> and 3 selectively killing [[ OATP1B3 ]]-expressing cells.","EGCG, 1, and 3 were the most potent cytotoxic compounds, with [ENTITY_A] and 3 selectively killing [ENTITY_B]-expressing cells.",SUBSTRATE,CPR:9,4,"EGCG, 1, and 3 were the most potent cytotoxic compounds, with EGCG and 3 selectively killing OATP1B3-expressing cells."
"<< Reboxetine >>, a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the [[ human norepinephrine transporter ]].","[ENTITY_A], a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the [ENTITY_B].",INHIBITOR,CPR:4,1,"Reboxetine, a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the human norepinephrine transporter."
"We previously employed a chemical genomic strategy to identify a novel small molecule, << MAC13243 >>, as a likely inhibitor of the [[ bacterial lipoprotein ]] targeting chaperone, LolA.","We previously employed a chemical genomic strategy to identify a novel small molecule, [ENTITY_A], as a likely inhibitor of the [ENTITY_B] targeting chaperone, LolA.",INHIBITOR,CPR:4,1,"We previously employed a chemical genomic strategy to identify a novel small molecule, MAC13243, as a likely inhibitor of the bacterial lipoprotein targeting chaperone, LolA."
"Our results showed that low dose << BPA >> and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of [[ Oct4 ]] and Nanog proteins, while only BPA could downregulate the expression of E-cadherin protein.","Our results showed that low dose [ENTITY_A] and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of [ENTITY_B] and Nanog proteins, while only BPA could downregulate the expression of E-cadherin protein.",INDIRECT-UPREGULATOR,CPR:3,0,"Our results showed that low dose BPA and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only BPA could downregulate the expression of E-cadherin protein."
"Our results showed that low dose BPA and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only << BPA >> could downregulate the expression of [[ E-cadherin ]] protein.","Our results showed that low dose BPA and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only [ENTITY_A] could downregulate the expression of [ENTITY_B] protein.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Our results showed that low dose BPA and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only BPA could downregulate the expression of E-cadherin protein."
"To this end, 158N murine oligodendrocytes were treated with << 7KC >> or 7βOHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving [[ Mcl-1 ]], and caspase-3 activation.","To this end, 158N murine oligodendrocytes were treated with [ENTITY_A] or 7βOHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving [ENTITY_B], and caspase-3 activation.",ACTIVATOR,CPR:3,0,"To this end, 158N murine oligodendrocytes were treated with 7KC or 7βOHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1, and caspase-3 activation."
"Thus, in 158N cells, the ability of << oxysterols >> to trigger a mode of cell death by apoptosis involving [[ GSK-3 ]] and caspase-3 activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains.","Thus, in 158N cells, the ability of [ENTITY_A] to trigger a mode of cell death by apoptosis involving [ENTITY_B] and caspase-3 activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains.",ACTIVATOR,CPR:3,0,"Thus, in 158N cells, the ability of oxysterols to trigger a mode of cell death by apoptosis involving GSK-3 and caspase-3 activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains."
<< Sulindac sulfide >> inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and [[ Bad ]] in human colon cancer cells.,[ENTITY_A] inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and [ENTITY_B] in human colon cancer cells.,INHIBITOR,CPR:4,1,Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells.
<< Sulindac >> and selective [[ cyclooxygenase (COX)-2 ]] inhibitors cause regression of colonic polyps in familial polyposis patients.,[ENTITY_A] and selective [ENTITY_B] inhibitors cause regression of colonic polyps in familial polyposis patients.,INHIBITOR,CPR:4,1,Sulindac and selective cyclooxygenase (COX)-2 inhibitors cause regression of colonic polyps in familial polyposis patients.
<< Sulindac >> metabolites and other nonsteroidal anti-inflammatory drugs selectively inhibit [[ ERK1/2 ]] phosphorylation in human colon cancer cells.,[ENTITY_A] metabolites and other nonsteroidal anti-inflammatory drugs selectively inhibit [ENTITY_B] phosphorylation in human colon cancer cells.,DOWNREGULATOR,CPR:4,1,Sulindac metabolites and other nonsteroidal anti-inflammatory drugs selectively inhibit ERK1/2 phosphorylation in human colon cancer cells.
"EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with << U0126 >>, a selective [[ MAP kinase kinase (MKK)1/2 ]] inhibitor.","EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with [ENTITY_A], a selective [ENTITY_B] inhibitor.",INHIBITOR,CPR:4,1,"EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with U0126, a selective MAP kinase kinase (MKK)1/2 inhibitor."
"Similarly, pretreatment with << sulindac sulfide >> blocks the ability of EGF to induce ERK1/2 and Bad phosphorylation, but also down-regulates total [[ Bad ]] but not ERK1/2 protein levels.","Similarly, pretreatment with [ENTITY_A] blocks the ability of EGF to induce ERK1/2 and Bad phosphorylation, but also down-regulates total [ENTITY_B] but not ERK1/2 protein levels.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Similarly, pretreatment with sulindac sulfide blocks the ability of EGF to induce ERK1/2 and Bad phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels."
The ability of << sulindac >> to block [[ ERK1/2 ]] signaling by the EGF receptor may account for at least part of its potent growth-inhibitory effects against cancer cells.,The ability of [ENTITY_A] to block [ENTITY_B] signaling by the EGF receptor may account for at least part of its potent growth-inhibitory effects against cancer cells.,INDIRECT-DOWNREGULATOR,CPR:4,1,The ability of sulindac to block ERK1/2 signaling by the EGF receptor may account for at least part of its potent growth-inhibitory effects against cancer cells.
"After inflammation was established mice were dosed with the << H4R >> antagonist, [[ JNJ 7777120 ]], or anti-IL-13 antibody for comparison.","After inflammation was established mice were dosed with the [ENTITY_A] antagonist, [ENTITY_B], or anti-IL-13 antibody for comparison.",ANTAGONIST,CPR:6,3,"After inflammation was established mice were dosed with the H4R antagonist, JNJ 7777120, or anti-IL-13 antibody for comparison."
Development and validation of a non-radioactive << DNA polymerase >> assay for studying cytomegalovirus resistance to [[ foscarnet ]].,Development and validation of a non-radioactive [ENTITY_A] assay for studying cytomegalovirus resistance to [ENTITY_B].,INHIBITOR,CPR:4,1,Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet.
"The activity of << polymerases >> containing mutations known to confer resistance to foscarnet (V715M, T700A and N495K) was inhibited by concentrations of [[ foscarnet ]] eight to 14 times higher than those required to inhibit wild-type polymerases.","The activity of [ENTITY_A] containing mutations known to confer resistance to foscarnet (V715M, T700A and N495K) was inhibited by concentrations of [ENTITY_B] eight to 14 times higher than those required to inhibit wild-type polymerases.",INHIBITOR,CPR:4,1,"The activity of polymerases containing mutations known to confer resistance to foscarnet (V715M, T700A and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases."
"Absorption and secretion of << fluoride >> increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/H(+) cotransporter or a [[ F(-)/OH(-) antiporter ]].","Absorption and secretion of [ENTITY_A] increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/H(+) cotransporter or a [ENTITY_B].",SUBSTRATE,CPR:9,4,"Absorption and secretion of fluoride increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/H(+) cotransporter or a F(-)/OH(-) antiporter."
Structure activity relationship studies of << tricyclic bispyran sulfone >> [[ γ-secretase ]] inhibitors.,Structure activity relationship studies of [ENTITY_A] [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Structure activity relationship studies of tricyclic bispyran sulfone γ-secretase inhibitors.
"An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (<< SCH 900229 >>), a potent, [[ PS1 ]]-selective γ-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease.","An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a ([ENTITY_A]), a potent, [ENTITY_B]-selective γ-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease.",INHIBITOR,CPR:4,1,"An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (SCH 900229), a potent, PS1-selective γ-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease."
Culture of HepG2 cells with << griseofulvin >> has now been shown to induce both the formation of intracellular aggregates containing [[ K18 ]] as well as an increase in the abundance of K18 mRNA.,Culture of HepG2 cells with [ENTITY_A] has now been shown to induce both the formation of intracellular aggregates containing [ENTITY_B] as well as an increase in the abundance of K18 mRNA.,INDIRECT-UPREGULATOR,CPR:3,0,Culture of HepG2 cells with griseofulvin has now been shown to induce both the formation of intracellular aggregates containing K18 as well as an increase in the abundance of K18 mRNA.
"Low levels of << serotonin >> may reduce the density of the [[ serotonin transporter ]] (SERT) by either increasing trafficking or reducing synthesis; a ""neuroadaptive response"".","Low levels of [ENTITY_A] may reduce the density of the [ENTITY_B] (SERT) by either increasing trafficking or reducing synthesis; a ""neuroadaptive response"".",DOWNREGULATOR,CPR:4,1,"Low levels of serotonin may reduce the density of the serotonin transporter (SERT) by either increasing trafficking or reducing synthesis; a ""neuroadaptive response""."
"To determine whether << 3,4-methylenedioxymethamphetamine >> (MDMA)-induced reductions in [[ SERT ]] density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.","To determine whether [ENTITY_A] (MDMA)-induced reductions in [ENTITY_B] density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.",DOWNREGULATOR,CPR:4,1,"To determine whether 3,4-methylenedioxymethamphetamine (MDMA)-induced reductions in SERT density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured."
"However, only << MDMA >> reduced [[ SERT ]] density.","However, only [ENTITY_A] reduced [ENTITY_B] density.",DOWNREGULATOR,CPR:4,1,"However, only MDMA reduced SERT density."
"This observation suggests that << MDMA >>-induced reductions in [[ SERT ]] density do not represent neuroadaptive responses to decreased levels of brain serotonin, but may occur in response to some other stimulus or to the neurotoxic effects of MDMA.","This observation suggests that [ENTITY_A]-induced reductions in [ENTITY_B] density do not represent neuroadaptive responses to decreased levels of brain serotonin, but may occur in response to some other stimulus or to the neurotoxic effects of MDMA.",DOWNREGULATOR,CPR:4,1,"This observation suggests that MDMA-induced reductions in SERT density do not represent neuroadaptive responses to decreased levels of brain serotonin, but may occur in response to some other stimulus or to the neurotoxic effects of MDMA."
<< Curcumin >> improves TNBS-induced colitis in rats by inhibiting [[ IL-27 ]] expression via the TLR4/NF-κB signaling pathway.,[ENTITY_A] improves TNBS-induced colitis in rats by inhibiting [ENTITY_B] expression via the TLR4/NF-κB signaling pathway.,INDIRECT-DOWNREGULATOR,CPR:4,1,Curcumin improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the TLR4/NF-κB signaling pathway.
This study explored whether << curcumin >> improves colonic inflammation in a rat colitis model through inhibition of the TLR4/NF-κB signaling pathway and [[ IL-27 ]] expression.,This study explored whether [ENTITY_A] improves colonic inflammation in a rat colitis model through inhibition of the TLR4/NF-κB signaling pathway and [ENTITY_B] expression.,INDIRECT-DOWNREGULATOR,CPR:4,1,This study explored whether curcumin improves colonic inflammation in a rat colitis model through inhibition of the TLR4/NF-κB signaling pathway and IL-27 expression.
"Compared with the untreated colitis group, the << curcumin >>-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of [[ NF-κB ]] mRNA, IL-27 mRNA, TLR4 protein, NF-κB p65 protein, and IL-27 p28 protein (p < 0.05).","Compared with the untreated colitis group, the [ENTITY_A]-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of [ENTITY_B] mRNA, IL-27 mRNA, TLR4 protein, NF-κB p65 protein, and IL-27 p28 protein (p < 0.05).",INDIRECT-DOWNREGULATOR,CPR:4,1,"Compared with the untreated colitis group, the curcumin-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-κB mRNA, IL-27 mRNA, TLR4 protein, NF-κB p65 protein, and IL-27 p28 protein (p < 0.05)."
"There was no significant difference in << TLR4 >>, NF-κB, and IL-27 mRNA and proteins between [[ curcumin ]]-treated and sulfasalazine-treated groups.","There was no significant difference in [ENTITY_A], NF-κB, and IL-27 mRNA and proteins between [ENTITY_B]-treated and sulfasalazine-treated groups.",INDIRECT-DOWNREGULATOR,CPR:4,1,"There was no significant difference in TLR4, NF-κB, and IL-27 mRNA and proteins between curcumin-treated and sulfasalazine-treated groups."
The anti-inflammatory actions of << curcumin >> on colitis may involve inhibition of the TLR4/NF-κB signaling pathway and of [[ IL-27 ]] expression.,The anti-inflammatory actions of [ENTITY_A] on colitis may involve inhibition of the TLR4/NF-κB signaling pathway and of [ENTITY_B] expression.,INDIRECT-DOWNREGULATOR,CPR:4,1,The anti-inflammatory actions of curcumin on colitis may involve inhibition of the TLR4/NF-κB signaling pathway and of IL-27 expression.
A << KCC >> inhibitor-[[ [(dihydroindenyl)oxy] alkanoic acid ]] (DIOA)-blocked RVD more in HCEC than RCEC.,A [ENTITY_A] inhibitor-[ENTITY_B] (DIOA)-blocked RVD more in HCEC than RCEC.,INHIBITOR,CPR:4,1,A KCC inhibitor-[(dihydroindenyl)oxy] alkanoic acid (DIOA)-blocked RVD more in HCEC than RCEC.
"Under isotonic conditions, << N-ethylmaleimide >> (NEM) produced [[ KCC ]] activation and transient cell shrinkage.","Under isotonic conditions, [ENTITY_A] (NEM) produced [ENTITY_B] activation and transient cell shrinkage.",ACTIVATOR,CPR:3,0,"Under isotonic conditions, N-ethylmaleimide (NEM) produced KCC activation and transient cell shrinkage."
Pharmacological properties of << lorglumide >> as a member of a new class of [[ cholecystokinin ]] antagonists.,Pharmacological properties of [ENTITY_A] as a member of a new class of [ENTITY_B] antagonists.,ANTAGONIST,CPR:6,3,Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.
Derivatives of << 5-(dipentylamino)-5-oxo-pentanoic acid >> are a new class of non-peptide cholecystokinin ([[ CCK ]]) antagonists.,Derivatives of [ENTITY_A] are a new class of non-peptide cholecystokinin ([ENTITY_B]) antagonists.,ANTAGONIST,CPR:6,3,Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists.
"The most potent compound, << D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid >> (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent [[ CCK ]] antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.","The most potent compound, [ENTITY_A] (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent [ENTITY_B] antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.",ANTAGONIST,CPR:6,3,"The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini."
In vivo << lorglumide >> antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. [[ CCK-8 ]] or ceruletide (caerulein).,In vivo [ENTITY_A] antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. [ENTITY_B] or ceruletide (caerulein).,ANTAGONIST,CPR:6,3,In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide (caerulein).
"Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual << Aromatase >>-Sulfatase Inhibitor [[ 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate ]].",Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual [ENTITY_A]-Sulfatase Inhibitor [ENTITY_B].,INHIBITOR,CPR:4,1,"Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate."
"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (<< F >>, Cl, Br) derivatives are first-generation dual [[ aromatase ]] and sulfatase inhibitors (DASIs).","4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated ([ENTITY_A], Cl, Br) derivatives are first-generation dual [ENTITY_B] and sulfatase inhibitors (DASIs).",INHIBITOR,CPR:4,1,"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)."
"The most potent in vitro DASI discovered is an << imidazole >> derivative with IC50 values against [[ aromatase ]] and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively.","The most potent in vitro DASI discovered is an [ENTITY_A] derivative with IC50 values against [ENTITY_B] and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively.",INHIBITOR,CPR:4,1,"The most potent in vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively."
The parent << phenol >> of this compound inhibits [[ aromatase ]] with an IC50 value of 0.028 nM in the same assay.,The parent [ENTITY_A] of this compound inhibits [ENTITY_B] with an IC50 value of 0.028 nM in the same assay.,INHIBITOR,CPR:4,1,The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028 nM in the same assay.
"As revealed by glucose oxidase (GOD) and radioimmunoassay (RIA), both << dimethyldiguanide >> (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and [[ insulin ]] levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay.","As revealed by glucose oxidase (GOD) and radioimmunoassay (RIA), both [ENTITY_A] (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and [ENTITY_B] levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay.",INDIRECT-DOWNREGULATOR,CPR:4,1,"As revealed by glucose oxidase (GOD) and radioimmunoassay (RIA), both dimethyldiguanide (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and insulin levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay."
"These findings demonstrate that cinnamon << polyphenols >> can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of [[ iNOS ]], NF-κB activation.","These findings demonstrate that cinnamon [ENTITY_A] can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of [ENTITY_B], NF-κB activation.",INHIBITOR,CPR:4,1,"These findings demonstrate that cinnamon polyphenols can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of iNOS, NF-κB activation."
"These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to << clonidine >> and endogenous clonidine-displacing substance(s), and may serve as markers of [[ imidazoline receptors ]] in humans.","These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to [ENTITY_A] and endogenous clonidine-displacing substance(s), and may serve as markers of [ENTITY_B] in humans.",UPREGULATOR,CPR:3,0,"These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to clonidine and endogenous clonidine-displacing substance(s), and may serve as markers of imidazoline receptors in humans."
"Effects of << ORF 17583 >>, other [[ histamine H2-receptor ]] antagonists and omeprazole on gastric acid secretory states in rats and dogs.","Effects of [ENTITY_A], other [ENTITY_B] antagonists and omeprazole on gastric acid secretory states in rats and dogs.",ANTAGONIST,CPR:6,3,"Effects of ORF 17583, other histamine H2-receptor antagonists and omeprazole on gastric acid secretory states in rats and dogs."
"<< ORF 17583 >>, a [[ histamine H2-receptor ]] antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.).","[ENTITY_A], a [ENTITY_B] antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.).",ANTAGONIST,CPR:6,3,"ORF 17583, a histamine H2-receptor antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.)."
"This study examined the inward transport of << l-[(14)C]alanine >>, an [[ ASCT2 ]] preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats.","This study examined the inward transport of [ENTITY_A], an [ENTITY_B] preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats.",SUBSTRATE,CPR:9,4,"This study examined the inward transport of l-[(14)C]alanine, an ASCT2 preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats."
"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by << alanine >>, serine, and cysteine, which is consistent with amino acid transport through [[ ASCT2 ]].","In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by [ENTITY_A], serine, and cysteine, which is consistent with amino acid transport through [ENTITY_B].",INHIBITOR,CPR:4,1,"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through ASCT2."
"In the presence of the system L inhibitor BCH, Na(+)-dependent << l-alanine >> uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through [[ ASCT2 ]].","In the presence of the system L inhibitor BCH, Na(+)-dependent [ENTITY_A] uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through [ENTITY_B].",SUBSTRATE,CPR:9,4,"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through ASCT2."
"Differences in magnitude of << Na(+) >>-dependent l-alanine uptake through ASCT2 between WKY and SHR PTE cells correlated positively with differences in [[ ASCT2 ]] protein expression, this being more abundant in WKY PTE cells.","Differences in magnitude of [ENTITY_A]-dependent l-alanine uptake through ASCT2 between WKY and SHR PTE cells correlated positively with differences in [ENTITY_B] protein expression, this being more abundant in WKY PTE cells.",UPREGULATOR,CPR:3,0,"Differences in magnitude of Na(+)-dependent l-alanine uptake through ASCT2 between WKY and SHR PTE cells correlated positively with differences in ASCT2 protein expression, this being more abundant in WKY PTE cells."
"Differences in magnitude of Na(+)-dependent << l-alanine >> uptake through [[ ASCT2 ]] between WKY and SHR PTE cells correlated positively with differences in ASCT2 protein expression, this being more abundant in WKY PTE cells.","Differences in magnitude of Na(+)-dependent [ENTITY_A] uptake through [ENTITY_B] between WKY and SHR PTE cells correlated positively with differences in ASCT2 protein expression, this being more abundant in WKY PTE cells.",SUBSTRATE,CPR:9,4,"Differences in magnitude of Na(+)-dependent l-alanine uptake through ASCT2 between WKY and SHR PTE cells correlated positively with differences in ASCT2 protein expression, this being more abundant in WKY PTE cells."
"In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity << Na(+) >>-dependent amino acid transporter, with functional features of [[ ASCT2 ]] transport.","In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity [ENTITY_A]-dependent amino acid transporter, with functional features of [ENTITY_B] transport.",UPREGULATOR,CPR:3,0,"In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity Na(+)-dependent amino acid transporter, with functional features of ASCT2 transport."
"In conclusion, immortalized SHR and WKY PTE cells take up << l-alanine >> mainly through a high-affinity [[ Na(+)-dependent amino acid transporter ]], with functional features of ASCT2 transport.","In conclusion, immortalized SHR and WKY PTE cells take up [ENTITY_A] mainly through a high-affinity [ENTITY_B], with functional features of ASCT2 transport.",SUBSTRATE,CPR:9,4,"In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity Na(+)-dependent amino acid transporter, with functional features of ASCT2 transport."
"The antipsychotic drugs << sertindole >> and pimozide block [[ erg3 ]], a human brain K(+) channel.","The antipsychotic drugs [ENTITY_A] and pimozide block [ENTITY_B], a human brain K(+) channel.",INHIBITOR,CPR:4,1,"The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel."
The antipsychotic drugs << sertindole >> and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the [[ cardiac K(+) channel ]] known as HERG (human ether-a-go-go-related gene; erg1).,The antipsychotic drugs [ENTITY_A] and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the [ENTITY_B] known as HERG (human ether-a-go-go-related gene; erg1).,INHIBITOR,CPR:4,1,The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1).
Block of << erg3 >> by [[ sertindole ]] also displayed a positive voltage-dependence.,Block of [ENTITY_A] by [ENTITY_B] also displayed a positive voltage-dependence.,INHIBITOR,CPR:4,1,Block of erg3 by sertindole also displayed a positive voltage-dependence.
<< Pimozide >> blocked [[ erg3 ]] channel currents with an IC(50) of 103 nM and significant inhibition was noted at concentrations of 10 nM and higher.,[ENTITY_A] blocked [ENTITY_B] channel currents with an IC(50) of 103 nM and significant inhibition was noted at concentrations of 10 nM and higher.,INHIBITOR,CPR:4,1,Pimozide blocked erg3 channel currents with an IC(50) of 103 nM and significant inhibition was noted at concentrations of 10 nM and higher.
We conclude that << erg3 >> can be blocked by certain antipsychotic drugs like [[ sertindole ]] and pimozide.,We conclude that [ENTITY_A] can be blocked by certain antipsychotic drugs like [ENTITY_B] and pimozide.,INHIBITOR,CPR:4,1,We conclude that erg3 can be blocked by certain antipsychotic drugs like sertindole and pimozide.
An amphiphile with branched << poly(ethylene glycol) >> architecture also activated the [[ lectin ]] pathway but only through L-ficolin recognition.,An amphiphile with branched [ENTITY_A] architecture also activated the [ENTITY_B] pathway but only through L-ficolin recognition.,ACTIVATOR,CPR:3,0,An amphiphile with branched poly(ethylene glycol) architecture also activated the lectin pathway but only through L-ficolin recognition.
Conformational variations of both << phosphodiesterase-5 >> and inhibitors provide the structural basis for the physiological effects of vardenafil and [[ sildenafil ]].,Conformational variations of both [ENTITY_A] and inhibitors provide the structural basis for the physiological effects of vardenafil and [ENTITY_B].,INHIBITOR,CPR:4,1,Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.
<< Cucurbitacin I >> inhibits [[ rac1 ]] activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1.,[ENTITY_A] inhibits [ENTITY_B] activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1.,INHIBITOR,CPR:4,1,Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1.
"Here we found that the anticancer agent << cucurbitacin I >>, a [[ Jak2 ]] inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells.","Here we found that the anticancer agent [ENTITY_A], a [ENTITY_B] inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells.",INHIBITOR,CPR:4,1,"Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells."
Subsequent analysis revealed that << cucurbitacin I >> strongly activates [[ RhoA ]] and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers.,Subsequent analysis revealed that [ENTITY_A] strongly activates [ENTITY_B] and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers.,ACTIVATOR,CPR:3,0,Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers.
"Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of << cucurbitacin I >> on [[ Rac1 ]] activation by heregulin.","Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of [ENTITY_A] on [ENTITY_B] activation by heregulin.",INHIBITOR,CPR:4,1,"Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin."
"Lastly, we found that << RhoA >> activation by [[ cucurbitacin I ]] is mediated by reactive oxygen species (ROS).","Lastly, we found that [ENTITY_A] activation by [ENTITY_B] is mediated by reactive oxygen species (ROS).",ACTIVATOR,CPR:3,0,"Lastly, we found that RhoA activation by cucurbitacin I is mediated by reactive oxygen species (ROS)."
The ROS scavenger << N-acetyl l-cysteine >> and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on [[ Rac1 ]] activation.,The ROS scavenger [ENTITY_A] and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on [ENTITY_B] activation.,ACTIVATOR,CPR:3,0,The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on Rac1 activation.
The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of << cucurbitacin I >> on [[ Rac1 ]] activation.,The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of [ENTITY_A] on [ENTITY_B] activation.,INHIBITOR,CPR:4,1,The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on Rac1 activation.
"Moreover, they established that the inhibitory effect of << cucurbitacin I >> on [[ Rac1 ]] activity involves the alteration of the balance between Rho and Rac.","Moreover, they established that the inhibitory effect of [ENTITY_A] on [ENTITY_B] activity involves the alteration of the balance between Rho and Rac.",INHIBITOR,CPR:4,1,"Moreover, they established that the inhibitory effect of cucurbitacin I on Rac1 activity involves the alteration of the balance between Rho and Rac."
"Brain but not spinal << NR2B >> receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist [[ CP-101,606 ]] in a rat chronic constriction injury model.",Brain but not spinal [ENTITY_A] receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist [ENTITY_B] in a rat chronic constriction injury model.,ANTAGONIST,CPR:6,3,"Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model."
"In order to examine the site of action of an << NR2B >> subtype-selective NMDA antagonist [[ CP-101,606 ]], we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.","In order to examine the site of action of an [ENTITY_A] subtype-selective NMDA antagonist [ENTITY_B], we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.",ANTAGONIST,CPR:6,3,"In order to examine the site of action of an NR2B subtype-selective NMDA antagonist CP-101,606, we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration."
"These findings suggest that the anti-allodynia effect of << CP-101,606 >> is ascribable to blockade of [[ NR2B ]] receptors at the brain, but not at the spinal cord.","These findings suggest that the anti-allodynia effect of [ENTITY_A] is ascribable to blockade of [ENTITY_B] receptors at the brain, but not at the spinal cord.",INHIBITOR,CPR:4,1,"These findings suggest that the anti-allodynia effect of CP-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord."
"In contrast, intrathecal injection of a non-selective << NMDA >> antagonist, [[ memantine ]], significantly inhibited CCI-induced mechanical allodynia at a dose of 300 nmol, indicating the difference in the site of action between the non-selective NMDA antagonist and the NR2B-specific NMDA antagonist.","In contrast, intrathecal injection of a non-selective [ENTITY_A] antagonist, [ENTITY_B], significantly inhibited CCI-induced mechanical allodynia at a dose of 300 nmol, indicating the difference in the site of action between the non-selective NMDA antagonist and the NR2B-specific NMDA antagonist.",ANTAGONIST,CPR:6,3,"In contrast, intrathecal injection of a non-selective NMDA antagonist, memantine, significantly inhibited CCI-induced mechanical allodynia at a dose of 300 nmol, indicating the difference in the site of action between the non-selective NMDA antagonist and the NR2B-specific NMDA antagonist."
"<< Rasagiline >> [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible [[ monoamine oxidase ]] (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.","[ENTITY_A] [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible [ENTITY_B] (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.",INHIBITOR,CPR:4,1,"Rasagiline [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible monoamine oxidase (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease."
"Reserpine-induced ptosis was reversed by << rasagiline >> at doses above 2 mg x kg(-1) i.p., which inhibit [[ MAO-A ]] as well as MAO-B, but not at MAO-B-selective doses.","Reserpine-induced ptosis was reversed by [ENTITY_A] at doses above 2 mg x kg(-1) i.p., which inhibit [ENTITY_B] as well as MAO-B, but not at MAO-B-selective doses.",INHIBITOR,CPR:4,1,"Reserpine-induced ptosis was reversed by rasagiline at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as MAO-B, but not at MAO-B-selective doses."
"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both << MAO-A >> and MAO-B by [[ tranylcypromine ]] together with the monoamine precursors.","However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both [ENTITY_A] and MAO-B by [ENTITY_B] together with the monoamine precursors.",INHIBITOR,CPR:4,1,"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and MAO-B by tranylcypromine together with the monoamine precursors."
<< Rasagiline >> does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit [[ MAO-B ]] but not MAO-A.,[ENTITY_A] does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit [ENTITY_B] but not MAO-A.,INHIBITOR,CPR:4,1,Rasagiline does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit MAO-B but not MAO-A.
"<< Omega class GSTs >> have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of [[ monomethylarsonate ]], an intermediate in the pathway of arsenic biotransformation.","[ENTITY_A] have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of [ENTITY_B], an intermediate in the pathway of arsenic biotransformation.",SUBSTRATE,CPR:9,4,"Omega class GSTs have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of monomethylarsonate, an intermediate in the pathway of arsenic biotransformation."
"The latter reaction, catalyzed by << aspartoacylase >> (ASPA), produces [[ acetyl ]] groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter.","The latter reaction, catalyzed by [ENTITY_A] (ASPA), produces [ENTITY_B] groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter.",PRODUCT-OF,CPR:9,4,"The latter reaction, catalyzed by aspartoacylase (ASPA), produces acetyl groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter."
"It is not yet clear whether << tamoxifen >> can reduce breast cancer incidence in women with BRCA1 and [[ BRCA2 ]] mutations, although preliminary evidence favors benefit for at least those with a BRCA2 mutation.","It is not yet clear whether [ENTITY_A] can reduce breast cancer incidence in women with BRCA1 and [ENTITY_B] mutations, although preliminary evidence favors benefit for at least those with a BRCA2 mutation.",DOWNREGULATOR,CPR:4,1,"It is not yet clear whether tamoxifen can reduce breast cancer incidence in women with BRCA1 and BRCA2 mutations, although preliminary evidence favors benefit for at least those with a BRCA2 mutation."
"Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of << zileuton >>, a specific inhibitor of [[ 5-lipoxygenase ]] (5-LOX) and a clinically used anti-asthmatic drug.","Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of [ENTITY_A], a specific inhibitor of [ENTITY_B] (5-LOX) and a clinically used anti-asthmatic drug.",INHIBITOR,CPR:4,1,"Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of zileuton, a specific inhibitor of 5-lipoxygenase (5-LOX) and a clinically used anti-asthmatic drug."
"Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to << zileuton >>, suggesting that troglitazone inhibits LT production by direct inhibition of [[ 5-LOX ]] activity.","Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to [ENTITY_A], suggesting that troglitazone inhibits LT production by direct inhibition of [ENTITY_B] activity.",INHIBITOR,CPR:4,1,"Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to zileuton, suggesting that troglitazone inhibits LT production by direct inhibition of 5-LOX activity."
These findings suggest that << troglitazone >> inhibits antigen-induced LT production in the IgE-sensitized RBL-2H3 cells and A23187-stimulated rat peritoneal neutrophils by direct inhibition of [[ 5-LOX ]] activity.,These findings suggest that [ENTITY_A] inhibits antigen-induced LT production in the IgE-sensitized RBL-2H3 cells and A23187-stimulated rat peritoneal neutrophils by direct inhibition of [ENTITY_B] activity.,INHIBITOR,CPR:4,1,These findings suggest that troglitazone inhibits antigen-induced LT production in the IgE-sensitized RBL-2H3 cells and A23187-stimulated rat peritoneal neutrophils by direct inhibition of 5-LOX activity.
The positive correlation between << vitamin A >> and [[ immunoglobulin A ]] concentrations might be the result of the vitamin A inductive effect during immunoglobulins A synthesis.,The positive correlation between [ENTITY_A] and [ENTITY_B] concentrations might be the result of the vitamin A inductive effect during immunoglobulins A synthesis.,UPREGULATOR,CPR:3,0,The positive correlation between vitamin A and immunoglobulin A concentrations might be the result of the vitamin A inductive effect during immunoglobulins A synthesis.
Experimental as well as clinical reports support the hypothesis that << calcium channel >> blockers such as [[ verapamil ]] may be an appropriate therapeutic approach in LQTS.,Experimental as well as clinical reports support the hypothesis that [ENTITY_A] blockers such as [ENTITY_B] may be an appropriate therapeutic approach in LQTS.,INHIBITOR,CPR:4,1,Experimental as well as clinical reports support the hypothesis that calcium channel blockers such as verapamil may be an appropriate therapeutic approach in LQTS.
"METHODS AND RESULTS: In 8 Langendorff-perfused rabbit hearts, << veratridine >> (0.1 microM), an inhibitor of [[ sodium channel ]] inactivation, led to a marked increase in QT-interval and simultaneously recorded monophasic ventricular action potentials (MAPs) (p < 0.05) thereby mimicking LQT3.","METHODS AND RESULTS: In 8 Langendorff-perfused rabbit hearts, [ENTITY_A] (0.1 microM), an inhibitor of [ENTITY_B] inactivation, led to a marked increase in QT-interval and simultaneously recorded monophasic ventricular action potentials (MAPs) (p < 0.05) thereby mimicking LQT3.",INHIBITOR,CPR:4,1,"METHODS AND RESULTS: In 8 Langendorff-perfused rabbit hearts, veratridine (0.1 microM), an inhibitor of sodium channel inactivation, led to a marked increase in QT-interval and simultaneously recorded monophasic ventricular action potentials (MAPs) (p < 0.05) thereby mimicking LQT3."
"Specificity of << zebrafish retinol saturase >>: formation of [[ all-trans-13,14-dihydroretinol ]] and all-trans-7,8- dihydroretinol.","Specificity of [ENTITY_A]: formation of [ENTITY_B] and all-trans-7,8- dihydroretinol.",PRODUCT-OF,CPR:9,4,"Specificity of zebrafish retinol saturase: formation of all-trans-13,14-dihydroretinol and all-trans-7,8- dihydroretinol."
"Specifically, << all-trans-13,14-dihydroretinol >> is transiently oxidized to all-trans-13,14-dihydroretinoic acid before being oxidized further by [[ Cyp26 ]] enzymes.","Specifically, [ENTITY_A] is transiently oxidized to all-trans-13,14-dihydroretinoic acid before being oxidized further by [ENTITY_B] enzymes.",SUBSTRATE,CPR:9,4,"Specifically, all-trans-13,14-dihydroretinol is transiently oxidized to all-trans-13,14-dihydroretinoic acid before being oxidized further by Cyp26 enzymes."
"Unlike mouse RetSat (mRetSat), << zRetSat A >> had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either [[ all-trans-13,14-dihydroretinol ]] or all-trans-7,8-dihydroretinol, respectively.","Unlike mouse RetSat (mRetSat), [ENTITY_A] had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either [ENTITY_B] or all-trans-7,8-dihydroretinol, respectively.",PRODUCT-OF,CPR:9,4,"Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively."
"<< zRetSat A >> also saturated the 13-14 or 7-8 double bonds of [[ all-trans-3,4-didehydroretinol ]] (vitamin A2), a second endogenous form of vitamin A in zebrafish.","[ENTITY_A] also saturated the 13-14 or 7-8 double bonds of [ENTITY_B] (vitamin A2), a second endogenous form of vitamin A in zebrafish.",SUBSTRATE,CPR:9,4,"zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish."
"<< Rasagiline >> is a novel, potent, and irreversible [[ monoamine oxidase type B ]] (MAO-B) inhibitor which has been approved for treatment of PD.","[ENTITY_A] is a novel, potent, and irreversible [ENTITY_B] (MAO-B) inhibitor which has been approved for treatment of PD.",INHIBITOR,CPR:4,1,"Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD."
<< Rasagiline >> inhibits [[ MAO-B ]] more potently than selegiline and has the advantage of once-daily dosing.,[ENTITY_A] inhibits [ENTITY_B] more potently than selegiline and has the advantage of once-daily dosing.,INHIBITOR,CPR:4,1,Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing.
"Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that << lithium >> produces a large potentiation of the [[ GluR3 flop ]] splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function. J. Neurophysiol., 81 (1999) 1506-1512).","Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that [ENTITY_A] produces a large potentiation of the [ENTITY_B] splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function. J. Neurophysiol., 81 (1999) 1506-1512).",ACTIVATOR,CPR:3,0,"Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function. J. Neurophysiol., 81 (1999) 1506-1512)."
"We now show that mutation of the 769R/ G desensitization site (Lomeli, H.M.J., Melcher, T., Hoger, T., Geiger, J.R., Kuner, T., Monyer, H., Higuchi, M.B.A. and Seeburg, P.H, Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science, 9(266) (1994) 1709-1713) greatly attenuates the << lithium >>-induced potentiation of [[ GluR3 ]].","We now show that mutation of the 769R/ G desensitization site (Lomeli, H.M.J., Melcher, T., Hoger, T., Geiger, J.R., Kuner, T., Monyer, H., Higuchi, M.B.A. and Seeburg, P.H, Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science, 9(266) (1994) 1709-1713) greatly attenuates the [ENTITY_A]-induced potentiation of [ENTITY_B].",ACTIVATOR,CPR:3,0,"We now show that mutation of the 769R/ G desensitization site (Lomeli, H.M.J., Melcher, T., Hoger, T., Geiger, J.R., Kuner, T., Monyer, H., Higuchi, M.B.A. and Seeburg, P.H, Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science, 9(266) (1994) 1709-1713) greatly attenuates the lithium-induced potentiation of GluR3."
"Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the glutamate binding site blocks desensitization of AMPA receptors. Neuron, 21 (1998) 907-918) further confirms that << lithium >> enhances [[ GluR3 ]] responses by reducing desensitization, since lithium's effects are reversed in this mutant.","Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the glutamate binding site blocks desensitization of AMPA receptors. Neuron, 21 (1998) 907-918) further confirms that [ENTITY_A] enhances [ENTITY_B] responses by reducing desensitization, since lithium's effects are reversed in this mutant.",ACTIVATOR,CPR:3,0,"Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the glutamate binding site blocks desensitization of AMPA receptors. Neuron, 21 (1998) 907-918) further confirms that lithium enhances GluR3 responses by reducing desensitization, since lithium's effects are reversed in this mutant."
"Specifically, << aniracetam >>, which potentiates wild-type [[ AMPA receptors ]], is ineffective on the non-desensitizing GluR3(L507Y) mutant, but has synergistic effects with lithium on wild-type receptors.","Specifically, [ENTITY_A], which potentiates wild-type [ENTITY_B], is ineffective on the non-desensitizing GluR3(L507Y) mutant, but has synergistic effects with lithium on wild-type receptors.",ACTIVATOR,CPR:3,0,"Specifically, aniracetam, which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing GluR3(L507Y) mutant, but has synergistic effects with lithium on wild-type receptors."
The << BH(4) >> treatment was associated with a 2-fold increase in [[ eNOS ]] activity as well as a 70% reduction in endothelial O(2)(-) production compared with those in fructose-fed rats.,The [ENTITY_A] treatment was associated with a 2-fold increase in [ENTITY_B] activity as well as a 70% reduction in endothelial O(2)(-) production compared with those in fructose-fed rats.,ACTIVATOR,CPR:3,0,The BH(4) treatment was associated with a 2-fold increase in eNOS activity as well as a 70% reduction in endothelial O(2)(-) production compared with those in fructose-fed rats.
"The << BH(4) >> treatment also partially improved the [[ insulin ]] sensitivity and blood pressure, as well as the serum triglyceride concentration, in the fructose-fed rats.","The [ENTITY_A] treatment also partially improved the [ENTITY_B] sensitivity and blood pressure, as well as the serum triglyceride concentration, in the fructose-fed rats.",INDIRECT-UPREGULATOR,CPR:3,0,"The BH(4) treatment also partially improved the insulin sensitivity and blood pressure, as well as the serum triglyceride concentration, in the fructose-fed rats."
"Moreover, BH(4) treatment of the << fructose >>-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, [[ nuclear factor-kappaB ]] and activating protein-1, which were increased in fructose-fed rats.","Moreover, BH(4) treatment of the [ENTITY_A]-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, [ENTITY_B] and activating protein-1, which were increased in fructose-fed rats.",UPREGULATOR,CPR:3,0,"Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and activating protein-1, which were increased in fructose-fed rats."
"Moreover, << BH(4) >> treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, [[ nuclear factor-kappaB ]] and activating protein-1, which were increased in fructose-fed rats.","Moreover, [ENTITY_A] treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, [ENTITY_B] and activating protein-1, which were increased in fructose-fed rats.",DOWNREGULATOR,CPR:4,1,"Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and activating protein-1, which were increased in fructose-fed rats."
"It has been claimed that << hCTR1 >>, the human high affinity copper transporter, is the major entry pathway for [[ cDDP ]] and related drugs via a mechanism that mimics copper.","It has been claimed that [ENTITY_A], the human high affinity copper transporter, is the major entry pathway for [ENTITY_B] and related drugs via a mechanism that mimics copper.",SUBSTRATE,CPR:9,4,"It has been claimed that hCTR1, the human high affinity copper transporter, is the major entry pathway for cDDP and related drugs via a mechanism that mimics copper."
We confirm the correlation between higher << hCTR1 >> levels and higher [[ Pt ]]-drug uptake in tumor cells sensitive to the drug.,We confirm the correlation between higher [ENTITY_A] levels and higher [ENTITY_B]-drug uptake in tumor cells sensitive to the drug.,SUBSTRATE,CPR:9,4,We confirm the correlation between higher hCTR1 levels and higher Pt-drug uptake in tumor cells sensitive to the drug.
"In the DRN, << brexpiprazole >> completely inhibited the firing of 5-HT neurons via [[ 5-HT1A ]] agonism and was more potent than aripiprazole (ED50 = 230 and 700 mug/kg, respectively).","In the DRN, [ENTITY_A] completely inhibited the firing of 5-HT neurons via [ENTITY_B] agonism and was more potent than aripiprazole (ED50 = 230 and 700 mug/kg, respectively).",AGONIST,CPR:5,2,"In the DRN, brexpiprazole completely inhibited the firing of 5-HT neurons via 5-HT1A agonism and was more potent than aripiprazole (ED50 = 230 and 700 mug/kg, respectively)."
"In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential << 5-HT2A >> receptor agonist [[ DOI ]] (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action.","In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential [ENTITY_A] receptor agonist [ENTITY_B] (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action.",AGONIST,CPR:5,2,"In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential 5-HT2A receptor agonist DOI (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action."
"Brexpiprazole reversed the inhibitory effect of the DA agonist << apomorphine >> on VTA DA neurons (ED50 = 61 mug/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on [[ D2 receptors ]].","Brexpiprazole reversed the inhibitory effect of the DA agonist [ENTITY_A] on VTA DA neurons (ED50 = 61 mug/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on [ENTITY_B].",AGONIST,CPR:5,2,"Brexpiprazole reversed the inhibitory effect of the DA agonist apomorphine on VTA DA neurons (ED50 = 61 mug/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on D2 receptors."
"Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons, << brexpiprazole >> displayed less efficacy at [[ D2 receptors ]].","Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons, [ENTITY_A] displayed less efficacy at [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons, brexpiprazole displayed less efficacy at D2 receptors."
"In the hippocampus, << brexpiprazole >> acted as a full agonist at [[ 5-HT1A ]] receptors on pyramidal neurons.","In the hippocampus, [ENTITY_A] acted as a full agonist at [ENTITY_B] receptors on pyramidal neurons.",AGONIST-ACTIVATOR,CPR:5,2,"In the hippocampus, brexpiprazole acted as a full agonist at 5-HT1A receptors on pyramidal neurons."
"In the lateral geniculate nucleus, << brexpiprazole >> displayed [[ alpha1B-adrenoceptor ]] antagonistic action.","In the lateral geniculate nucleus, [ENTITY_A] displayed [ENTITY_B] antagonistic action.",ANTAGONIST,CPR:6,3,"In the lateral geniculate nucleus, brexpiprazole displayed alpha1B-adrenoceptor antagonistic action."
"For << AII >> and ET1, MAP was also increased for the [[ fenofibrate ]] group but not in a dose-dependent fashion.","For [ENTITY_A] and ET1, MAP was also increased for the [ENTITY_B] group but not in a dose-dependent fashion.",INDIRECT-UPREGULATOR,CPR:3,0,"For AII and ET1, MAP was also increased for the fenofibrate group but not in a dose-dependent fashion."
Nanobody-albumin nanoparticles (NANAPs) for the delivery of a << multikinase >> inhibitor [[ 17864 ]] to EGFR overexpressing tumor cells.,Nanobody-albumin nanoparticles (NANAPs) for the delivery of a [ENTITY_A] inhibitor [ENTITY_B] to EGFR overexpressing tumor cells.,INHIBITOR,CPR:4,1,Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.
Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the << multikinase >> inhibitor [[ 17864 ]]-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment.,Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the [ENTITY_A] inhibitor [ENTITY_B]-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment.,INHIBITOR,CPR:4,1,Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment.
Endogenously produced asymmetrically methylated << arginine >> residues are competitive inhibitors of all three isoforms of [[ nitric oxide synthase ]] (NOS).,Endogenously produced asymmetrically methylated [ENTITY_A] residues are competitive inhibitors of all three isoforms of [ENTITY_B] (NOS).,INHIBITOR,CPR:4,1,Endogenously produced asymmetrically methylated arginine residues are competitive inhibitors of all three isoforms of nitric oxide synthase (NOS).
The enzyme << dimethylarginine dimethylaminohydrolase >> (DDAH) specifically hydrolyzes these asymmetrically methylated [[ arginine ]] residues to citrulline and methylamines.,The enzyme [ENTITY_A] (DDAH) specifically hydrolyzes these asymmetrically methylated [ENTITY_B] residues to citrulline and methylamines.,SUBSTRATE,CPR:9,4,The enzyme dimethylarginine dimethylaminohydrolase (DDAH) specifically hydrolyzes these asymmetrically methylated arginine residues to citrulline and methylamines.
Previously we have proposed that regulation of asymmetric << methylarginine >> concentration by [[ DDAH ]] may provide a novel mechanism for the regulation of NOS activity in vivo.,Previously we have proposed that regulation of asymmetric [ENTITY_A] concentration by [ENTITY_B] may provide a novel mechanism for the regulation of NOS activity in vivo.,SUBSTRATE,CPR:9,4,Previously we have proposed that regulation of asymmetric methylarginine concentration by DDAH may provide a novel mechanism for the regulation of NOS activity in vivo.
Structure-based design of novel << dihydroisoquinoline >> [[ BACE-1 ]] inhibitors that do not engage the catalytic aspartates.,Structure-based design of novel [ENTITY_A] [ENTITY_B] inhibitors that do not engage the catalytic aspartates.,INHIBITOR,CPR:4,1,Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates.
The structure-activity relationship of a series of << dihydroisoquinoline >> [[ BACE-1 ]] inhibitors is described.,The structure-activity relationship of a series of [ENTITY_A] [ENTITY_B] inhibitors is described.,INHIBITOR,CPR:4,1,The structure-activity relationship of a series of dihydroisoquinoline BACE-1 inhibitors is described.
"Tissue-type plasminogen activator (tPA), a << serine >> protease well known for generating plasmin, has been demonstrated to induce [[ matrix metalloproteinase-9 ]] (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts.","Tissue-type plasminogen activator (tPA), a [ENTITY_A] protease well known for generating plasmin, has been demonstrated to induce [ENTITY_B] (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts.",INDIRECT-UPREGULATOR,CPR:3,0,"Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts."
"Furthermore, tPA induced rapid << tyrosine >> phosphorylation on the beta subunit of LRP-1, which was followed by the activation of [[ Mek1 ]] and its downstream Erk-1 and -2.","Furthermore, tPA induced rapid [ENTITY_A] phosphorylation on the beta subunit of LRP-1, which was followed by the activation of [ENTITY_B] and its downstream Erk-1 and -2.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2."
"The data show that << CP[c]Ph >> is less potent at inducing [[ CYP1A ]] gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist.","The data show that [ENTITY_A] is less potent at inducing [ENTITY_B] gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist.",INDIRECT-UPREGULATOR,CPR:3,0,"The data show that CP[c]Ph is less potent at inducing CYP1A gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist."
"Interestingly, the << CP[c]Ph >> dependent up-regulation of [[ CYP1A ]] mRNA is positively correlated with the incidences of clastogenic changes in rainbow trout erythrocytes.","Interestingly, the [ENTITY_A] dependent up-regulation of [ENTITY_B] mRNA is positively correlated with the incidences of clastogenic changes in rainbow trout erythrocytes.",INDIRECT-UPREGULATOR,CPR:3,0,"Interestingly, the CP[c]Ph dependent up-regulation of CYP1A mRNA is positively correlated with the incidences of clastogenic changes in rainbow trout erythrocytes."
"<< CP[c]Ph >> has, comparably to B[a]P, a potential to repress expression of [[ tumor suppressor p53 ]], in the head kidney of rainbow trout.","[ENTITY_A] has, comparably to B[a]P, a potential to repress expression of [ENTITY_B], in the head kidney of rainbow trout.",INDIRECT-DOWNREGULATOR,CPR:4,1,"CP[c]Ph has, comparably to B[a]P, a potential to repress expression of tumor suppressor p53, in the head kidney of rainbow trout."
Identification of << benzofuran >> central cores for the inhibition of [[ leukotriene A(4) hydrolase ]].,Identification of [ENTITY_A] central cores for the inhibition of [ENTITY_B].,INHIBITOR,CPR:4,1,Identification of benzofuran central cores for the inhibition of leukotriene A(4) hydrolase.
Leukotriene A(4) hydrolase (<< LTA(4)H >>) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to [[ LTB(4) ]].,Leukotriene A(4) hydrolase ([ENTITY_A]) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to [ENTITY_B].,PRODUCT-OF,CPR:9,4,Leukotriene A(4) hydrolase (LTA(4)H) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to LTB(4).
This paper describes the identification and synthesis of substituted << benzofurans >> as [[ LTH(4)H ]] inhibitors.,This paper describes the identification and synthesis of substituted [ENTITY_A] as [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,This paper describes the identification and synthesis of substituted benzofurans as LTH(4)H inhibitors.
"<< Benzofuran >> 28 showed dose responsive target engagement and provides a useful tool to explore a [[ LTA(4)H ]] inhibitor for the treatment of inflammatory diseases, such as asthma and inflammatory bowel disease (IBD).","[ENTITY_A] 28 showed dose responsive target engagement and provides a useful tool to explore a [ENTITY_B] inhibitor for the treatment of inflammatory diseases, such as asthma and inflammatory bowel disease (IBD).",INHIBITOR,CPR:4,1,"Benzofuran 28 showed dose responsive target engagement and provides a useful tool to explore a LTA(4)H inhibitor for the treatment of inflammatory diseases, such as asthma and inflammatory bowel disease (IBD)."
"<< Minocycline >> treatment prevents the formation of activated [[ caspase-3 ]], a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic/necrotic cell death.","[ENTITY_A] treatment prevents the formation of activated [ENTITY_B], a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic/necrotic cell death.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Minocycline treatment prevents the formation of activated caspase-3, a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic/necrotic cell death."
Neurochemical effects of the << monoamine oxidase >> inhibitor [[ phenelzine ]] on brain GABA and alanine: A comparison with vigabatrin.,Neurochemical effects of the [ENTITY_A] inhibitor [ENTITY_B] on brain GABA and alanine: A comparison with vigabatrin.,INHIBITOR,CPR:4,1,Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin.
"PURPOSE: To compare << phenelzine >> (PLZ), an antidepressant drug with anxiolytic properties which inhibits [[ monoamine oxidase ]] (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","PURPOSE: To compare [ENTITY_A] (PLZ), an antidepressant drug with anxiolytic properties which inhibits [ENTITY_B] (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).",INHIBITOR,CPR:4,1,"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)."
RESULTS: Both << PLZ >> and VIG inhibited [[ GABA-T ]] and elevated GABA levels.,RESULTS: Both [ENTITY_A] and VIG inhibited [ENTITY_B] and elevated GABA levels.,INHIBITOR,CPR:4,1,RESULTS: Both PLZ and VIG inhibited GABA-T and elevated GABA levels.
Only << PLZ >> inhibited [[ MAO ]] and ALA-T and elevated ALA levels.,Only [ENTITY_A] inhibited [ENTITY_B] and ALA-T and elevated ALA levels.,INHIBITOR,CPR:4,1,Only PLZ inhibited MAO and ALA-T and elevated ALA levels.
The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the << MAO >> inhibitor [[ tranylcypromine ]].,The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the [ENTITY_A] inhibitor [ENTITY_B].,INHIBITOR,CPR:4,1,The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the MAO inhibitor tranylcypromine.
This pretreament had no effect on the inhibition of << GABA-T >> or the elevation of brain GABA levels produced by [[ VIG ]].,This pretreament had no effect on the inhibition of [ENTITY_A] or the elevation of brain GABA levels produced by [ENTITY_B].,INHIBITOR,CPR:4,1,This pretreament had no effect on the inhibition of GABA-T or the elevation of brain GABA levels produced by VIG.
"CONCLUSIONS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike << VIG >>, also inhibited [[ MAO ]] and ALA-T (and increased brain ALA levels).","CONCLUSIONS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike [ENTITY_A], also inhibited [ENTITY_B] and ALA-T (and increased brain ALA levels).",INHIBITOR,CPR:4,1,"CONCLUSIONS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike VIG, also inhibited MAO and ALA-T (and increased brain ALA levels)."
"Pretreatment of rats with the << MAO >> inhibitor [[ tranylcypromine ]] prevented the increase in brain GABA and ALA levels with PLZ, but did not block the effect of VIG on GABA.","Pretreatment of rats with the [ENTITY_A] inhibitor [ENTITY_B] prevented the increase in brain GABA and ALA levels with PLZ, but did not block the effect of VIG on GABA.",INHIBITOR,CPR:4,1,"Pretreatment of rats with the MAO inhibitor tranylcypromine prevented the increase in brain GABA and ALA levels with PLZ, but did not block the effect of VIG on GABA."
"Clinical pharmacology of << enalkiren >>, a novel, dipeptide [[ renin ]] inhibitor.","Clinical pharmacology of [ENTITY_A], a novel, dipeptide [ENTITY_B] inhibitor.",INHIBITOR,CPR:4,1,"Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor."
"<< Enalkiren >> (A-64662), a potent, dipeptide [[ renin ]] inhibitor, mimics the transition state of the human renin substrate, angiotensinogen.","[ENTITY_A] (A-64662), a potent, dipeptide [ENTITY_B] inhibitor, mimics the transition state of the human renin substrate, angiotensinogen.",INHIBITOR,CPR:4,1,"Enalkiren (A-64662), a potent, dipeptide renin inhibitor, mimics the transition state of the human renin substrate, angiotensinogen."
<< Enalkiren >> has been shown to produce dose-related suppression of plasma [[ renin ]] activity (PRA) and angiotensin II when administered intravenously.,[ENTITY_A] has been shown to produce dose-related suppression of plasma [ENTITY_B] activity (PRA) and angiotensin II when administered intravenously.,INHIBITOR,CPR:4,1,Enalkiren has been shown to produce dose-related suppression of plasma renin activity (PRA) and angiotensin II when administered intravenously.
"The results of clinical trials with << enalkiren >> are encouraging, and suggest that [[ renin ]] inhibitors may be safe, useful therapeutic agents in the management of hypertension.","The results of clinical trials with [ENTITY_A] are encouraging, and suggest that [ENTITY_B] inhibitors may be safe, useful therapeutic agents in the management of hypertension.",INHIBITOR,CPR:4,1,"The results of clinical trials with enalkiren are encouraging, and suggest that renin inhibitors may be safe, useful therapeutic agents in the management of hypertension."
"Also in contrast to effects of multiple << METH >> injections, 1) MDMA caused little or no decrease in binding of the [[ DAT ]] ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport.","Also in contrast to effects of multiple [ENTITY_A] injections, 1) MDMA caused little or no decrease in binding of the [ENTITY_B] ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport.",DOWNREGULATOR,CPR:4,1,"Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the DAT ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport."
"Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the << DAT >> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal [[ DA ]] transport.","Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the [ENTITY_A] ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal [ENTITY_B] transport.",SUBSTRATE,CPR:9,4,"Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the DAT ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport."
"In addition to affecting << DAT >> function, MDMA rapidly decreased vesicular [[ DA ]] transport as assessed in striatal vesicles prepared from treated rats.","In addition to affecting [ENTITY_A] function, MDMA rapidly decreased vesicular [ENTITY_B] transport as assessed in striatal vesicles prepared from treated rats.",SUBSTRATE,CPR:9,4,"In addition to affecting DAT function, MDMA rapidly decreased vesicular DA transport as assessed in striatal vesicles prepared from treated rats."
"Concentration-dependent inhibitory effects of << baicalin >> on the metabolism of dextromethorphan, a dual probe of [[ CYP2D ]] and CYP3A, in rats.","Concentration-dependent inhibitory effects of [ENTITY_A] on the metabolism of dextromethorphan, a dual probe of [ENTITY_B] and CYP3A, in rats.",INHIBITOR,CPR:4,1,"Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats."
"Concentration-dependent inhibitory effects of baicalin on the metabolism of << dextromethorphan >>, a dual probe of [[ CYP2D ]] and CYP3A, in rats.","Concentration-dependent inhibitory effects of baicalin on the metabolism of [ENTITY_A], a dual probe of [ENTITY_B] and CYP3A, in rats.",SUBSTRATE,CPR:9,4,"Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats."
"In the current study, we reveal the inhibitory effects of << baicalin >> on the metabolism of dextromethorphan (DXM), a dual probe substrate of [[ CYP2D ]] and CYP3A, in rats.","In the current study, we reveal the inhibitory effects of [ENTITY_A] on the metabolism of dextromethorphan (DXM), a dual probe substrate of [ENTITY_B] and CYP3A, in rats.",INHIBITOR,CPR:4,1,"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats."
"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of << dextromethorphan >> (DXM), a dual probe substrate of [[ CYP2D ]] and CYP3A, in rats.","In the current study, we reveal the inhibitory effects of baicalin on the metabolism of [ENTITY_A] (DXM), a dual probe substrate of [ENTITY_B] and CYP3A, in rats.",SUBSTRATE,CPR:9,4,"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats."
Lineweaver-Burk plots demonstrated that << baicalin >> inhibited the activities of [[ CYP2D ]] and CYP3A in a non-competitive manner in rat liver microsomes (RLMs).,Lineweaver-Burk plots demonstrated that [ENTITY_A] inhibited the activities of [ENTITY_B] and CYP3A in a non-competitive manner in rat liver microsomes (RLMs).,INHIBITOR,CPR:4,1,Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs).
"The activity of << CYP3A >> in excised liver samples from rats following multiple [[ baicalin ]] treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D.","The activity of [ENTITY_A] in excised liver samples from rats following multiple [ENTITY_B] treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D.",INHIBITOR,CPR:4,1,"The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D."
"Taken together, these data demonstrate that << baicalin >> inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic [[ CYP2D ]] and CYP3A activities.","Taken together, these data demonstrate that [ENTITY_A] inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic [ENTITY_B] and CYP3A activities.",INHIBITOR,CPR:4,1,"Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities."
"Taken together, these data demonstrate that baicalin inhibits the metabolism of << DXM >> in a concentration-dependent manner in rats, possibly through inhibiting hepatic [[ CYP2D ]] and CYP3A activities.","Taken together, these data demonstrate that baicalin inhibits the metabolism of [ENTITY_A] in a concentration-dependent manner in rats, possibly through inhibiting hepatic [ENTITY_B] and CYP3A activities.",SUBSTRATE,CPR:9,4,"Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities."
Identification of a novel << benzimidazole >> derivative as a highly potent [[ NPY Y5 receptor ]] antagonist with an anti-obesity profile.,Identification of a novel [ENTITY_A] derivative as a highly potent [ENTITY_B] antagonist with an anti-obesity profile.,ANTAGONIST,CPR:6,3,Identification of a novel benzimidazole derivative as a highly potent NPY Y5 receptor antagonist with an anti-obesity profile.
"We evaluated the clinical effectiveness of << esmolol >>, an ultra-short-acting [[ beta 1-adrenergic receptor ]] blocking drug, to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy (ECT).","We evaluated the clinical effectiveness of [ENTITY_A], an ultra-short-acting [ENTITY_B] blocking drug, to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy (ECT).",INHIBITOR,CPR:4,1,"We evaluated the clinical effectiveness of esmolol, an ultra-short-acting beta 1-adrenergic receptor blocking drug, to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy (ECT)."
The beta(2)-adrenoceptor (<< beta(2)-AR >>) agonists [[ clenbuterol ]] and fenoterol have similar beneficial effects in animal models of heart failure.,The beta(2)-adrenoceptor ([ENTITY_A]) agonists [ENTITY_B] and fenoterol have similar beneficial effects in animal models of heart failure.,AGONIST,CPR:5,2,The beta(2)-adrenoceptor (beta(2)-AR) agonists clenbuterol and fenoterol have similar beneficial effects in animal models of heart failure.
"<< beta(1)-Adrenoceptor >> antagonism (10 mg kg(-1) [[ bisoprolol ]]) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551).","[ENTITY_A] antagonism (10 mg kg(-1) [ENTITY_B]) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551).",ANTAGONIST,CPR:6,3,"beta(1)-Adrenoceptor antagonism (10 mg kg(-1) bisoprolol) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551)."
"The mouse << CYP2J >> subfamily includes members that have wide tissue distribution and are active in the metabolism of [[ arachidonic acid ]] (AA), linoleic acid (LA), and other lipids and xenobiotics.","The mouse [ENTITY_A] subfamily includes members that have wide tissue distribution and are active in the metabolism of [ENTITY_B] (AA), linoleic acid (LA), and other lipids and xenobiotics.",SUBSTRATE,CPR:9,4,"The mouse CYP2J subfamily includes members that have wide tissue distribution and are active in the metabolism of arachidonic acid (AA), linoleic acid (LA), and other lipids and xenobiotics."
"<< CPT I >> (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into [[ palmitoylcarnitine ]] in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.","[ENTITY_A] (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into [ENTITY_B] in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.",PRODUCT-OF,CPR:9,4,"CPT I (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria."
"<< Cholesterol >> uptake from [[ lipoproteins ]], intracellular vesicle transport and lipid transfer are also modified by oxysterols.","[ENTITY_A] uptake from [ENTITY_B], intracellular vesicle transport and lipid transfer are also modified by oxysterols.",SUBSTRATE,CPR:9,4,"Cholesterol uptake from lipoproteins, intracellular vesicle transport and lipid transfer are also modified by oxysterols."
"In addition, the new compound << perviridicin B >> (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant [[ NF-κB ]] (p65) inhibitory activity in an ELISA assay.","In addition, the new compound [ENTITY_A] (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant [ENTITY_B] (p65) inhibitory activity in an ELISA assay.",INHIBITOR,CPR:4,1,"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-κB (p65) inhibitory activity in an ELISA assay."
"In further evaluation, the representative compound << N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium bromide >> (3b) exhibited potent pro-apoptotic activity, through [[ RhoB ]] activation, in HeLa cells.","In further evaluation, the representative compound [ENTITY_A] (3b) exhibited potent pro-apoptotic activity, through [ENTITY_B] activation, in HeLa cells.",ACTIVATOR,CPR:3,0,"In further evaluation, the representative compound N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium bromide (3b) exhibited potent pro-apoptotic activity, through RhoB activation, in HeLa cells."
"Pretreatment of the tissues with combined << 5-HT1 >>/5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of [[ epinastine ]] on the noncholinergic contraction.","Pretreatment of the tissues with combined [ENTITY_A]/5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of [ENTITY_B] on the noncholinergic contraction.",AGONIST-INHIBITOR,CPR:5,2,"Pretreatment of the tissues with combined 5-HT1/5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction."
"Pretreatment of the tissues with combined << 5-HT1 >>/5-HT2 antagonists, [[ methysergide ]] (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.","Pretreatment of the tissues with combined [ENTITY_A]/5-HT2 antagonists, [ENTITY_B] (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.",ANTAGONIST,CPR:6,3,"Pretreatment of the tissues with combined 5-HT1/5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction."
"Pretreatment with << tropisetron >> (1 microM), a [[ 5-HT3 ]] antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.","Pretreatment with [ENTITY_A] (1 microM), a [ENTITY_B] antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.",ANTAGONIST,CPR:6,3,"Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect."
"<< Chlorpheniramine >> (10 microM), another [[ histamine H1 receptor ]] antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction.","[ENTITY_A] (10 microM), another [ENTITY_B] antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction.",ANTAGONIST,CPR:6,3,"Chlorpheniramine (10 microM), another histamine H1 receptor antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction."
"These results suggest that << epinastine >>, although identified as a 5-HT antagonist, acts as a 5-HT1 agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional [[ 5-HT1-like receptor ]], located to sensory nerves.","These results suggest that [ENTITY_A], although identified as a 5-HT antagonist, acts as a 5-HT1 agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional [ENTITY_B], located to sensory nerves.",ACTIVATOR,CPR:3,0,"These results suggest that epinastine, although identified as a 5-HT antagonist, acts as a 5-HT1 agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional 5-HT1-like receptor, located to sensory nerves."
"These results suggest that << epinastine >>, although identified as a 5-HT antagonist, acts as a [[ 5-HT1 ]] agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional 5-HT1-like receptor, located to sensory nerves.","These results suggest that [ENTITY_A], although identified as a 5-HT antagonist, acts as a [ENTITY_B] agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional 5-HT1-like receptor, located to sensory nerves.",AGONIST,CPR:5,2,"These results suggest that epinastine, although identified as a 5-HT antagonist, acts as a 5-HT1 agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional 5-HT1-like receptor, located to sensory nerves."
<< Vitamin C >> forestalls cigarette smoke induced [[ NF-κB ]] activation in alveolar epithelial cells.,[ENTITY_A] forestalls cigarette smoke induced [ENTITY_B] activation in alveolar epithelial cells.,INHIBITOR,CPR:4,1,Vitamin C forestalls cigarette smoke induced NF-κB activation in alveolar epithelial cells.
"It is possible that << vitamin C >>, an antioxidant, may prevent cigarette smoke (CS)-induced NF-κB activation that involves degradation of [[ I-κBε ]] and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.","It is possible that [ENTITY_A], an antioxidant, may prevent cigarette smoke (CS)-induced NF-κB activation that involves degradation of [ENTITY_B] and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.",DOWNREGULATOR,CPR:4,1,"It is possible that vitamin C, an antioxidant, may prevent cigarette smoke (CS)-induced NF-κB activation that involves degradation of I-κBε and nuclear translocation of c-Rel/p50 in alveolar epithelial cells."
"We observed a significant reduction in CSE induced luciferase expression, NF-κB DNA binding, << I-κBε >> degradation and c-Rel nuclear translocation in cells pretreated with [[ vitamin C ]].","We observed a significant reduction in CSE induced luciferase expression, NF-κB DNA binding, [ENTITY_A] degradation and c-Rel nuclear translocation in cells pretreated with [ENTITY_B].",DOWNREGULATOR,CPR:4,1,"We observed a significant reduction in CSE induced luciferase expression, NF-κB DNA binding, I-κBε degradation and c-Rel nuclear translocation in cells pretreated with vitamin C."
Result showed that << vitamin C >> treatment resulted in markedly reduced [[ c-Rel ]] nuclear translocation.,Result showed that [ENTITY_A] treatment resulted in markedly reduced [ENTITY_B] nuclear translocation.,INDIRECT-DOWNREGULATOR,CPR:4,1,Result showed that vitamin C treatment resulted in markedly reduced c-Rel nuclear translocation.
All these results demonstrate that << vitamin C >> prevents CS(E)-induced [[ NF-κB ]] activation and thus it could be used for the prevention of CS-induced inflammatory diseases.,All these results demonstrate that [ENTITY_A] prevents CS(E)-induced [ENTITY_B] activation and thus it could be used for the prevention of CS-induced inflammatory diseases.,INHIBITOR,CPR:4,1,All these results demonstrate that vitamin C prevents CS(E)-induced NF-κB activation and thus it could be used for the prevention of CS-induced inflammatory diseases.
"<< Catalpol >> reduced the expression of pro-inflammatory mediates, such as [[ monocyte chemotactic protein-1 ]] (MCP-1), tumor necrosis factor-α (TNF-α), inducible NO synthase (iNOS), and receptor for AGE (RAGE).","[ENTITY_A] reduced the expression of pro-inflammatory mediates, such as [ENTITY_B] (MCP-1), tumor necrosis factor-α (TNF-α), inducible NO synthase (iNOS), and receptor for AGE (RAGE).",INDIRECT-DOWNREGULATOR,CPR:4,1,"Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), inducible NO synthase (iNOS), and receptor for AGE (RAGE)."
"Promoter and electromobility shift assays showed that transcriptional activation of << NF-κB >> was significantly reduced by [[ catalpol ]] treatment, while AP-1 was not.","Promoter and electromobility shift assays showed that transcriptional activation of [ENTITY_A] was significantly reduced by [ENTITY_B] treatment, while AP-1 was not.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Promoter and electromobility shift assays showed that transcriptional activation of NF-κB was significantly reduced by catalpol treatment, while AP-1 was not."
"<< Catalpol >> also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of IκBα and the nuclear localization of [[ NF-κB ]].","[ENTITY_A] also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of IκBα and the nuclear localization of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Catalpol also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of IκBα and the nuclear localization of NF-κB."
"Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by << catalpol >> treatment, through dual action of reducing ROS itself and inhibiting [[ NADPH oxidase ]] activity.","Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by [ENTITY_A] treatment, through dual action of reducing ROS itself and inhibiting [ENTITY_B] activity.",INHIBITOR,CPR:4,1,"Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by catalpol treatment, through dual action of reducing ROS itself and inhibiting NADPH oxidase activity."
Our findings indicate that << catalpol >> suppresses AGE-mediated inflammation by inhibiting ROS production and [[ NF-κB ]] activity.,Our findings indicate that [ENTITY_A] suppresses AGE-mediated inflammation by inhibiting ROS production and [ENTITY_B] activity.,INHIBITOR,CPR:4,1,Our findings indicate that catalpol suppresses AGE-mediated inflammation by inhibiting ROS production and NF-κB activity.
<< Etoposide >> (VP-16) is a [[ topoisomerase-II ]] (topo II) inhibitor chemotherapeutic agent.,[ENTITY_A] (VP-16) is a [ENTITY_B] (topo II) inhibitor chemotherapeutic agent.,INHIBITOR,CPR:4,1,Etoposide (VP-16) is a topoisomerase-II (topo II) inhibitor chemotherapeutic agent.
<< MXF >> or VP-16 slightly affected cellular topo II activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of [[ topo II ]].,[ENTITY_A] or VP-16 slightly affected cellular topo II activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of [ENTITY_B].,INHIBITOR,CPR:4,1,MXF or VP-16 slightly affected cellular topo II activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of topo II.
Apoptosis studies (DAPI staining and << caspase 3 >> activity) showed a marked increase in the presence of [[ MXF ]] and VP-16 compared to VP-16 alone.,Apoptosis studies (DAPI staining and [ENTITY_A] activity) showed a marked increase in the presence of [ENTITY_B] and VP-16 compared to VP-16 alone.,INDIRECT-UPREGULATOR,CPR:3,0,Apoptosis studies (DAPI staining and caspase 3 activity) showed a marked increase in the presence of MXF and VP-16 compared to VP-16 alone.
"In conclusion, the results suggest that the enhancement in the reduction of << topo II >> activity by the combined [[ MXF ]]/VP-16 treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs.","In conclusion, the results suggest that the enhancement in the reduction of [ENTITY_A] activity by the combined [ENTITY_B]/VP-16 treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs.",INHIBITOR,CPR:4,1,"In conclusion, the results suggest that the enhancement in the reduction of topo II activity by the combined MXF/VP-16 treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs."
"<< TAS-102 >> currently undergoing clinical trials, has been demonstrated to have at least two mechanisms, inhibition of [[ TS ]] and incorporation into DNA.","[ENTITY_A] currently undergoing clinical trials, has been demonstrated to have at least two mechanisms, inhibition of [ENTITY_B] and incorporation into DNA.",INHIBITOR,CPR:4,1,"TAS-102 currently undergoing clinical trials, has been demonstrated to have at least two mechanisms, inhibition of TS and incorporation into DNA."
"In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and << thymidilate synthase >> (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of [[ TAS-102 ]].","In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and [ENTITY_A] (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of [ENTITY_B].",INHIBITOR,CPR:4,1,"In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102."
"Because clinical studies investigating interactions between garlic and << human immunodeficiency virus protease >> inhibitors [[ saquinavir ]] and ritonavir have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes.","Because clinical studies investigating interactions between garlic and [ENTITY_A] inhibitors [ENTITY_B] and ritonavir have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes.",INHIBITOR,CPR:4,1,"Because clinical studies investigating interactions between garlic and human immunodeficiency virus protease inhibitors saquinavir and ritonavir have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes."
"Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the << isoprenaline >> responses of the atria and the pA2 values were 8.60 and 8.98 at the [[ beta 1-adrenoceptors ]] of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.","Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the [ENTITY_A] responses of the atria and the pA2 values were 8.60 and 8.98 at the [ENTITY_B] of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.",AGONIST,CPR:5,2,"Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the beta 1-adrenoceptors of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors."
"<< Labetalol >> (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the [[ beta 1-adrenoceptors ]] of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.","[ENTITY_A] (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the [ENTITY_B] of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.",ANTAGONIST,CPR:6,3,"Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the beta 1-adrenoceptors of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors."
The isoprenaline attenuation responses of the portal vein were inhibited by labetalol and dilevalol (both at > or = 10(-7) M) and the pA2 value for the << labetalol >> at [[ beta 2-adrenoceptors ]] was 7.59.,The isoprenaline attenuation responses of the portal vein were inhibited by labetalol and dilevalol (both at > or = 10(-7) M) and the pA2 value for the [ENTITY_A] at [ENTITY_B] was 7.59.,ANTAGONIST,CPR:6,3,The isoprenaline attenuation responses of the portal vein were inhibited by labetalol and dilevalol (both at > or = 10(-7) M) and the pA2 value for the labetalol at beta 2-adrenoceptors was 7.59.
It is concluded that << labetalol >> and dilevalol are [[ beta 1-adrenoceptor ]] selective antagonists.,It is concluded that [ENTITY_A] and dilevalol are [ENTITY_B] selective antagonists.,ANTAGONIST,CPR:6,3,It is concluded that labetalol and dilevalol are beta 1-adrenoceptor selective antagonists.
<< PR mRNA >> abundance in both myometruim and leiomyomata (center and marginal area) was significantly decreased in 4 patients continuing [[ mifepristone ]] treatment before the operation but not in the other 2 patients stopping RU486 1 month before operation.,[ENTITY_A] abundance in both myometruim and leiomyomata (center and marginal area) was significantly decreased in 4 patients continuing [ENTITY_B] treatment before the operation but not in the other 2 patients stopping RU486 1 month before operation.,INDIRECT-DOWNREGULATOR,CPR:4,1,PR mRNA abundance in both myometruim and leiomyomata (center and marginal area) was significantly decreased in 4 patients continuing mifepristone treatment before the operation but not in the other 2 patients stopping RU486 1 month before operation.
One of the mechanism of << mifepristone >> action on decreasing leiomyomata volume may be related to suppression on expression of [[ PR gene ]].,One of the mechanism of [ENTITY_A] action on decreasing leiomyomata volume may be related to suppression on expression of [ENTITY_B].,INDIRECT-DOWNREGULATOR,CPR:4,1,One of the mechanism of mifepristone action on decreasing leiomyomata volume may be related to suppression on expression of PR gene.
"Experimental cystathioninuria was induced in rats by administration of the << cystathionine gamma-lyase >> inhibitor, [[ D,L-propargylglycine ]].","Experimental cystathioninuria was induced in rats by administration of the [ENTITY_A] inhibitor, [ENTITY_B].",INHIBITOR,CPR:4,1,"Experimental cystathioninuria was induced in rats by administration of the cystathionine gamma-lyase inhibitor, D,L-propargylglycine."
"The concomitant application of subconvulsive dose of pentetrazole (55.0 mg/kg) with low dose of << flumazenil >> (5.0 mg/kg) - a [[ BDZ receptor ]] antagonist, immediately induced BDZ withdrawal signs in these animals.","The concomitant application of subconvulsive dose of pentetrazole (55.0 mg/kg) with low dose of [ENTITY_A] (5.0 mg/kg) - a [ENTITY_B] antagonist, immediately induced BDZ withdrawal signs in these animals.",ANTAGONIST,CPR:6,3,"The concomitant application of subconvulsive dose of pentetrazole (55.0 mg/kg) with low dose of flumazenil (5.0 mg/kg) - a BDZ receptor antagonist, immediately induced BDZ withdrawal signs in these animals."
"The non-selective << adenosine receptor >> antagonist ([[ caffeine ]]), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice.","The non-selective [ENTITY_A] antagonist ([ENTITY_B]), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice.",ANTAGONIST,CPR:6,3,"The non-selective adenosine receptor antagonist (caffeine), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice."
Cross-inhibition of << SR-BI >>- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and [[ glyburide ]].,Cross-inhibition of [ENTITY_A]- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and [ENTITY_B].,INHIBITOR,CPR:4,1,Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide.
Cross-inhibition of << SR-BI >>- and ABCA1-mediated [[ cholesterol ]] transport by the small molecules BLT-4 and glyburide.,Cross-inhibition of [ENTITY_A]- and ABCA1-mediated [ENTITY_B] transport by the small molecules BLT-4 and glyburide.,SUBSTRATE,CPR:9,4,Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide.
<< SR-BI >> is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of [[ cholesteryl esters ]] from lipid-rich HDL to cells and the efflux of unesterified cholesterol from cells to HDL.,[ENTITY_A] is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of [ENTITY_B] from lipid-rich HDL to cells and the efflux of unesterified cholesterol from cells to HDL.,SUBSTRATE,CPR:9,4,SR-BI is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of cholesteryl esters from lipid-rich HDL to cells and the efflux of unesterified cholesterol from cells to HDL.
<< ABCA1 >> mediates the efflux of unesterified [[ cholesterol ]] and phospholipids from cells to lipid-poor apolipoprotein A-I (apoA-I).,[ENTITY_A] mediates the efflux of unesterified [ENTITY_B] and phospholipids from cells to lipid-poor apolipoprotein A-I (apoA-I).,SUBSTRATE,CPR:9,4,ABCA1 mediates the efflux of unesterified cholesterol and phospholipids from cells to lipid-poor apolipoprotein A-I (apoA-I).
"The activities of << ABCA1 >> and other ATP binding cassette superfamily members are inhibited by the drug [[ glyburide ]], and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs.","The activities of [ENTITY_A] and other ATP binding cassette superfamily members are inhibited by the drug [ENTITY_B], and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs.",INHIBITOR,CPR:4,1,"The activities of ABCA1 and other ATP binding cassette superfamily members are inhibited by the drug glyburide, and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs."
"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (<< BLT-4 >>), blocked [[ ABCA1 ]]-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).","Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] ([ENTITY_A]), blocked [ENTITY_B]-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).",INHIBITOR,CPR:4,1,"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)."
"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked << ABCA1 >>-mediated [[ cholesterol ]] efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).","Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked [ENTITY_A]-mediated [ENTITY_B] efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).",SUBSTRATE,CPR:9,4,"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)."
"Reciprocally, << glyburide >> blocked SR-BI-mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of [[ ABCA1 ]] (IC(50) approximately 275-300 microM).","Reciprocally, [ENTITY_A] blocked SR-BI-mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of [ENTITY_B] (IC(50) approximately 275-300 microM).",INHIBITOR,CPR:4,1,"Reciprocally, glyburide blocked SR-BI-mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of ABCA1 (IC(50) approximately 275-300 microM)."
The reciprocal inhibition of << SR-BI >> and ABCA1 by BLT-4 and [[ glyburide ]] raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.,The reciprocal inhibition of [ENTITY_A] and ABCA1 by BLT-4 and [ENTITY_B] raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.,INHIBITOR,CPR:4,1,The reciprocal inhibition of SR-BI and ABCA1 by BLT-4 and glyburide raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.
"The treatment of mice with << Fe-NTA >> alone enhances [[ ornithine decarboxylase ]] activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of [(3)H] thymidine incorporation increased to 3.2 folds, and antioxidants and antioxidant enzymes decreased to 1.8-2.5 folds, compared with the corresponding saline-treated controls.","The treatment of mice with [ENTITY_A] alone enhances [ENTITY_B] activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of [(3)H] thymidine incorporation increased to 3.2 folds, and antioxidants and antioxidant enzymes decreased to 1.8-2.5 folds, compared with the corresponding saline-treated controls.",ACTIVATOR,CPR:3,0,"The treatment of mice with Fe-NTA alone enhances ornithine decarboxylase activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of [(3)H] thymidine incorporation increased to 3.2 folds, and antioxidants and antioxidant enzymes decreased to 1.8-2.5 folds, compared with the corresponding saline-treated controls."
"<< Aldo-keto reductases >> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive [[ oxygen ]] species (ROS), which are capable of initiating and promoting carcinogenesis.","[ENTITY_A] (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive [ENTITY_B] species (ROS), which are capable of initiating and promoting carcinogenesis.",PRODUCT-OF,CPR:9,4,"Aldo-keto reductases (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis."
"Exposure to << PAHs >>, their metabolites, and ROS further increase [[ AKRs ]] isoform expression that may amplify oxidative damage.","Exposure to [ENTITY_A], their metabolites, and ROS further increase [ENTITY_B] isoform expression that may amplify oxidative damage.",INDIRECT-UPREGULATOR,CPR:3,0,"Exposure to PAHs, their metabolites, and ROS further increase AKRs isoform expression that may amplify oxidative damage."
"Despite the importance of << AKRs >> in [[ PAHs ]] metabolism, there are no studies that evaluate, in general human populations, the effect of PAHs on AKRs expression in peripheral blood lymphocytes (PBLs).","Despite the importance of [ENTITY_A] in [ENTITY_B] metabolism, there are no studies that evaluate, in general human populations, the effect of PAHs on AKRs expression in peripheral blood lymphocytes (PBLs).",SUBSTRATE,CPR:9,4,"Despite the importance of AKRs in PAHs metabolism, there are no studies that evaluate, in general human populations, the effect of PAHs on AKRs expression in peripheral blood lymphocytes (PBLs)."
"The pretreatment with 20 mg L(-1) << La(III) >> could alleviate the effects of UV-B radiation on the activities of [[ nitrate reductase ]], glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.","The pretreatment with 20 mg L(-1) [ENTITY_A] could alleviate the effects of UV-B radiation on the activities of [ENTITY_B], glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.",DOWNREGULATOR,CPR:4,1,"The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings."
Inhibition of << monoamine oxidase >> by [[ phthalide ]] analogues.,Inhibition of [ENTITY_A] by [ENTITY_B] analogues.,INHIBITOR,CPR:4,1,Inhibition of monoamine oxidase by phthalide analogues.
"Based on recent reports that the small molecules, << isatin >> and phthalimide, are suitable scaffolds for the design of high potency [[ monoamine oxidase ]] (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues.","Based on recent reports that the small molecules, [ENTITY_A] and phthalimide, are suitable scaffolds for the design of high potency [ENTITY_B] (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues.",INHIBITOR,CPR:4,1,"Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues."
"In most instances, C6-substituted << phthalides >> exhibit [[ MAO-B ]] specific inhibition.","In most instances, C6-substituted [ENTITY_A] exhibit [ENTITY_B] specific inhibition.",INHIBITOR,CPR:4,1,"In most instances, C6-substituted phthalides exhibit MAO-B specific inhibition."
The results also show that the binding modes of representative << phthalides >> are reversible and competitive at both [[ MAO ]] isoforms.,The results also show that the binding modes of representative [ENTITY_A] are reversible and competitive at both [ENTITY_B] isoforms.,INHIBITOR,CPR:4,1,The results also show that the binding modes of representative phthalides are reversible and competitive at both MAO isoforms.
"Binding of the agonist angiotensin II (AngII) and inverse agonist << losartan >> in wild-type [[ AT1R ]] changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific ""lid"" conformations of ECL2.","Binding of the agonist angiotensin II (AngII) and inverse agonist [ENTITY_A] in wild-type [ENTITY_B] changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific ""lid"" conformations of ECL2.",AGONIST-INHIBITOR,CPR:5,2,"Binding of the agonist angiotensin II (AngII) and inverse agonist losartan in wild-type AT1R changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific ""lid"" conformations of ECL2."
"Immunohistochemical characterization of << pyrimidine >> synthetic enzymes, [[ thymidine kinase-1 ]] and thymidylate synthase, in various types of cancer.","Immunohistochemical characterization of [ENTITY_A] synthetic enzymes, [ENTITY_B] and thymidylate synthase, in various types of cancer.",PRODUCT-OF,CPR:9,4,"Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer."
"<< Thymidine kinase-1 >> (TK-1) and thymidylate synthase (TS) are key enzymes for salvage and de novo [[ pyrimidine ]] synthesis, respectively.","[ENTITY_A] (TK-1) and thymidylate synthase (TS) are key enzymes for salvage and de novo [ENTITY_B] synthesis, respectively.",PRODUCT-OF,CPR:9,4,"Thymidine kinase-1 (TK-1) and thymidylate synthase (TS) are key enzymes for salvage and de novo pyrimidine synthesis, respectively."
"<< TAS-102 >> is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit [[ TS ]].","[ENTITY_A] is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"TAS-102 is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit TS."
"<< TAS-102 >> is a novel drug containing trifluorothymidine, which is phosphorylated by [[ TK-1 ]] to its active monophosphated form, that in turn can inhibit TS.","[ENTITY_A] is a novel drug containing trifluorothymidine, which is phosphorylated by [ENTITY_B] to its active monophosphated form, that in turn can inhibit TS.",SUBSTRATE,CPR:9,4,"TAS-102 is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit TS."
"Gastrointestinal adenocarcinomas and squamous cell uterine carcinomas were often accompanied by high << TS >> expression, indicating activation of [[ pyrimidine ]] synthesis through both the salvage and de novo pathways.","Gastrointestinal adenocarcinomas and squamous cell uterine carcinomas were often accompanied by high [ENTITY_A] expression, indicating activation of [ENTITY_B] synthesis through both the salvage and de novo pathways.",PRODUCT-OF,CPR:9,4,"Gastrointestinal adenocarcinomas and squamous cell uterine carcinomas were often accompanied by high TS expression, indicating activation of pyrimidine synthesis through both the salvage and de novo pathways."
"The contractions to 5-HT were inhibited by << ketanserin >> and alosetron indicating involvement of [[ 5-HT(2A) ]] and 5-HT(3) receptors, respectively.","The contractions to 5-HT were inhibited by [ENTITY_A] and alosetron indicating involvement of [ENTITY_B] and 5-HT(3) receptors, respectively.",INHIBITOR,CPR:4,1,"The contractions to 5-HT were inhibited by ketanserin and alosetron indicating involvement of 5-HT(2A) and 5-HT(3) receptors, respectively."
"Regarding << urease >> inhibition, [[ n-butanol ]] was the most potent fraction (IC50: 97 µg/mL).","Regarding [ENTITY_A] inhibition, [ENTITY_B] was the most potent fraction (IC50: 97 µg/mL).",INHIBITOR,CPR:4,1,"Regarding urease inhibition, n-butanol was the most potent fraction (IC50: 97 µg/mL)."
"The current U.S. military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective << acetylcholinesterase >> reactivator, [[ 1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate ]] (MMB-4).","The current U.S. military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective [ENTITY_A] reactivator, [ENTITY_B] (MMB-4).",ACTIVATOR,CPR:3,0,"The current U.S. military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective acetylcholinesterase reactivator, 1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate (MMB-4)."
"Methylation-specific PCR and bisulfite sequencing identified methylation of this << CpG >> ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in [[ DNA methyl transferase 3a ]] concentrations noted with advancing postnatal age (PN14 vs PN3).","Methylation-specific PCR and bisulfite sequencing identified methylation of this [ENTITY_A] ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in [ENTITY_B] concentrations noted with advancing postnatal age (PN14 vs PN3).",INDIRECT-UPREGULATOR,CPR:3,0,"Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3)."
5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that << (m)CpGs >> inhibit [[ glut3 ]] transcription.,5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that [ENTITY_A] inhibit [ENTITY_B] transcription.,INDIRECT-DOWNREGULATOR,CPR:4,1,5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit glut3 transcription.
Separate << 5-aza-2'-deoxycytidine >> pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting [[ Mecp2 ]] and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells.,Separate [ENTITY_A] pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting [ENTITY_B] and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells.,INDIRECT-DOWNREGULATOR,CPR:4,1,Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells.
"A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by << NET >>-inhibiting ADs such as [[ reboxetine ]], desipramine, and imipramine.","A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by [ENTITY_A]-inhibiting ADs such as [ENTITY_B], desipramine, and imipramine.",INHIBITOR,CPR:4,1,"A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by NET-inhibiting ADs such as reboxetine, desipramine, and imipramine."
In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant << human UDP-glucuronosyltransferase 1A9 >>--potent inhibition by [[ niflumic acid ]].,In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant [ENTITY_A]--potent inhibition by [ENTITY_B].,INHIBITOR,CPR:4,1,In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid.
"In conclusion, of the seven NSAIDs investigated, << niflumic acid >> was the most potent inhibitor of recombinant [[ UGT1A9 ]] via 4-MUG in a competitive manner.","In conclusion, of the seven NSAIDs investigated, [ENTITY_A] was the most potent inhibitor of recombinant [ENTITY_B] via 4-MUG in a competitive manner.",INHIBITOR,CPR:4,1,"In conclusion, of the seven NSAIDs investigated, niflumic acid was the most potent inhibitor of recombinant UGT1A9 via 4-MUG in a competitive manner."
"Neither the superoxide radical scavenger, tiron, nor the inhibitor of the << dopamine (DA) transporter >>, [[ GBR 12909 ]], prevented the metabolites' toxicity.","Neither the superoxide radical scavenger, tiron, nor the inhibitor of the [ENTITY_A], [ENTITY_B], prevented the metabolites' toxicity.",INHIBITOR,CPR:4,1,"Neither the superoxide radical scavenger, tiron, nor the inhibitor of the dopamine (DA) transporter, GBR 12909, prevented the metabolites' toxicity."
"Importantly, pre-treatment with buthionine sulfoximine (<< BSO >>), an inhibitor of [[ γ-GCS ]], prevented α-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity.","Importantly, pre-treatment with buthionine sulfoximine ([ENTITY_A]), an inhibitor of [ENTITY_B], prevented α-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity.",INHIBITOR,CPR:4,1,"Importantly, pre-treatment with buthionine sulfoximine (BSO), an inhibitor of γ-GCS, prevented α-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity."
"<< MNU >>-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high [[ MGMT ]] staining.","[ENTITY_A]-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high [ENTITY_B] staining.",INDIRECT-UPREGULATOR,CPR:3,0,"MNU-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high MGMT staining."
"<< MNU >>-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of [[ E-cadherin ]], and high MGMT staining.","[ENTITY_A]-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of [ENTITY_B], and high MGMT staining.",INDIRECT-DOWNREGULATOR,CPR:4,1,"MNU-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high MGMT staining."
"The treatment with << arsenic >> exhibited a significant increase in some serum hepatic and renal biochemical parameters ([[ alanine aminotransferase ]], aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine).","The treatment with [ENTITY_A] exhibited a significant increase in some serum hepatic and renal biochemical parameters ([ENTITY_B], aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine).",INDIRECT-UPREGULATOR,CPR:3,0,"The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)."
"However, recent clinical studies have shown that a single low-dose injection of << ketamine >>, an [[ N-methyl d-aspartate receptor ]] (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting.","However, recent clinical studies have shown that a single low-dose injection of [ENTITY_A], an [ENTITY_B] (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting.",ANTAGONIST,CPR:6,3,"However, recent clinical studies have shown that a single low-dose injection of ketamine, an N-methyl d-aspartate receptor (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting."
<< Doxorubicin >> is mainly excreted into the bile via [[ P-glycoprotein ]] (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.,[ENTITY_A] is mainly excreted into the bile via [ENTITY_B] (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.,SUBSTRATE,CPR:9,4,Doxorubicin is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.
The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic << CYP3A >> subfamily-mediated metabolism (21.9% decrease) of [[ doxorubicin ]].,The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic [ENTITY_A] subfamily-mediated metabolism (21.9% decrease) of [ENTITY_B].,SUBSTRATE,CPR:9,4,The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic CYP3A subfamily-mediated metabolism (21.9% decrease) of doxorubicin.
Activation of << AMP-activated Protein Kinase >> and Phosphorylation of Glycogen Synthase Kinase3 β Mediate [[ Ursolic Acid ]] Induced Apoptosis in HepG2 Liver Cancer Cells.,Activation of [ENTITY_A] and Phosphorylation of Glycogen Synthase Kinase3 β Mediate [ENTITY_B] Induced Apoptosis in HepG2 Liver Cancer Cells.,ACTIVATOR,CPR:3,0,Activation of AMP-activated Protein Kinase and Phosphorylation of Glycogen Synthase Kinase3 β Mediate Ursolic Acid Induced Apoptosis in HepG2 Liver Cancer Cells.
"Interestingly, << ursolic acid >> increased the phosphorylation of [[ AMPK ]] and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells.","Interestingly, [ENTITY_A] increased the phosphorylation of [ENTITY_B] and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells.",ACTIVATOR,CPR:3,0,"Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells."
"Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas << ursolic acid >> attenuated the phosphorylation of [[ AKT ]] and mTOR in HepG2 cells.","Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas [ENTITY_A] attenuated the phosphorylation of [ENTITY_B] and mTOR in HepG2 cells.",INHIBITOR,CPR:4,1,"Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells."
"Conversely, AMPK inhibitor compound C or GSK3β inhibitor SB216763 blocked the cleavages of << PARP >> and caspase 3 induced by [[ ursolic acid ]] in HepG2 cells.","Conversely, AMPK inhibitor compound C or GSK3β inhibitor SB216763 blocked the cleavages of [ENTITY_A] and caspase 3 induced by [ENTITY_B] in HepG2 cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Conversely, AMPK inhibitor compound C or GSK3β inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells."
"Conversely, AMPK inhibitor << compound C >> or GSK3β inhibitor SB216763 blocked the cleavages of PARP and [[ caspase 3 ]] induced by ursolic acid in HepG2 cells.","Conversely, AMPK inhibitor [ENTITY_A] or GSK3β inhibitor SB216763 blocked the cleavages of PARP and [ENTITY_B] induced by ursolic acid in HepG2 cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Conversely, AMPK inhibitor compound C or GSK3β inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells."
"Furthermore, proteosomal inhibitor MG132 suppressed << AMPK >> activation, GSK3β phosphorylation, cleaved PARP and deceased AEG-1 induced by [[ ursolic acid ]] in HepG2 cells.","Furthermore, proteosomal inhibitor MG132 suppressed [ENTITY_A] activation, GSK3β phosphorylation, cleaved PARP and deceased AEG-1 induced by [ENTITY_B] in HepG2 cells.",ACTIVATOR,CPR:3,0,"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3β phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells."
"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3β phosphorylation, cleaved PARP and deceased << AEG-1 >> induced by [[ ursolic acid ]] in HepG2 cells.","Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3β phosphorylation, cleaved PARP and deceased [ENTITY_A] induced by [ENTITY_B] in HepG2 cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3β phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells."
"Overall, our findings suggest that << ursolic acid >> induced apoptosis in HepG2 cells via [[ AMPK ]] activation and GSK3β phosphorylation as a potent chemopreventive agent.","Overall, our findings suggest that [ENTITY_A] induced apoptosis in HepG2 cells via [ENTITY_B] activation and GSK3β phosphorylation as a potent chemopreventive agent.",ACTIVATOR,CPR:3,0,"Overall, our findings suggest that ursolic acid induced apoptosis in HepG2 cells via AMPK activation and GSK3β phosphorylation as a potent chemopreventive agent."
"Using << paraoxon >> as a reference [[ acetylcholinesterase ]] (AChE) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.","Using [ENTITY_A] as a reference [ENTITY_B] (AChE) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.",INHIBITOR,CPR:4,1,"Using paraoxon as a reference acetylcholinesterase (AChE) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis."
"We then showed that static exposure of embryos to << paraoxon >> (31.2-500 nM) from 5 to 96 hpf resulted in significant stage- and concentration-dependent [[ AChE ]] inhibition, albeit these effects were fully reversible within 48 h following transfer to clean water.","We then showed that static exposure of embryos to [ENTITY_A] (31.2-500 nM) from 5 to 96 hpf resulted in significant stage- and concentration-dependent [ENTITY_B] inhibition, albeit these effects were fully reversible within 48 h following transfer to clean water.",INHIBITOR,CPR:4,1,"We then showed that static exposure of embryos to paraoxon (31.2-500 nM) from 5 to 96 hpf resulted in significant stage- and concentration-dependent AChE inhibition, albeit these effects were fully reversible within 48 h following transfer to clean water."
"Based on these studies, the frequency of spontaneous tail contractions at 26 hpf - a developmental stage with minimal << AChE >> expression and activity - was significantly higher following exposure to [[ paraoxon ]] concentrations as low as 31.2 nM.","Based on these studies, the frequency of spontaneous tail contractions at 26 hpf - a developmental stage with minimal [ENTITY_A] expression and activity - was significantly higher following exposure to [ENTITY_B] concentrations as low as 31.2 nM.",ACTIVATOR,CPR:3,0,"Based on these studies, the frequency of spontaneous tail contractions at 26 hpf - a developmental stage with minimal AChE expression and activity - was significantly higher following exposure to paraoxon concentrations as low as 31.2 nM."
"There is, however, much information on the direct (acute and chronic) effects of << alcohol >> on the binding properties of opioid receptors, as well as modulation of opioid peptide synthesis and secretion (e.g. a suggested increase in [[ beta-endorphin ]] release).","There is, however, much information on the direct (acute and chronic) effects of [ENTITY_A] on the binding properties of opioid receptors, as well as modulation of opioid peptide synthesis and secretion (e.g. a suggested increase in [ENTITY_B] release).",INDIRECT-UPREGULATOR,CPR:3,0,"There is, however, much information on the direct (acute and chronic) effects of alcohol on the binding properties of opioid receptors, as well as modulation of opioid peptide synthesis and secretion (e.g. a suggested increase in beta-endorphin release)."
"Conversely, opioid antagonists such as naloxone and << naltrexone >> (which bind to non-selectively [[ opioid receptors ]]) have been shown to decrease alcohol consumption under various experimental conditions.","Conversely, opioid antagonists such as naloxone and [ENTITY_A] (which bind to non-selectively [ENTITY_B]) have been shown to decrease alcohol consumption under various experimental conditions.",ACTIVATOR,CPR:3,0,"Conversely, opioid antagonists such as naloxone and naltrexone (which bind to non-selectively opioid receptors) have been shown to decrease alcohol consumption under various experimental conditions."
"Conversely, opioid antagonists such as << naloxone >> and naltrexone (which bind to non-selectively [[ opioid receptors ]]) have been shown to decrease alcohol consumption under various experimental conditions.","Conversely, opioid antagonists such as [ENTITY_A] and naltrexone (which bind to non-selectively [ENTITY_B]) have been shown to decrease alcohol consumption under various experimental conditions.",ANTAGONIST,CPR:6,3,"Conversely, opioid antagonists such as naloxone and naltrexone (which bind to non-selectively opioid receptors) have been shown to decrease alcohol consumption under various experimental conditions."
"<< Esmolol >>, a unique cardioselective [[ beta 1-adrenergic receptor ]] blocker with a half-life of 9 minutes, can enable some patients with relative contraindications to beta blockers to nevertheless benefit from early beta-blocking therapy.","[ENTITY_A], a unique cardioselective [ENTITY_B] blocker with a half-life of 9 minutes, can enable some patients with relative contraindications to beta blockers to nevertheless benefit from early beta-blocking therapy.",INHIBITOR,CPR:4,1,"Esmolol, a unique cardioselective beta 1-adrenergic receptor blocker with a half-life of 9 minutes, can enable some patients with relative contraindications to beta blockers to nevertheless benefit from early beta-blocking therapy."
"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by << acetazolamide >>, ethoxzolamide, and cyanate, [[ CA V ]] is very similar to CA II.","In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by [ENTITY_A], ethoxzolamide, and cyanate, [ENTITY_B] is very similar to CA II.",INHIBITOR,CPR:4,1,"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II."
"<< Adenylosuccinate synthetase >> (AdSS) catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form [[ adenylosuccinate ]], in a reaction driven by the hydrolysis of GTP to GDP.","[ENTITY_A] (AdSS) catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form [ENTITY_B], in a reaction driven by the hydrolysis of GTP to GDP.",PRODUCT-OF,CPR:9,4,"Adenylosuccinate synthetase (AdSS) catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate, in a reaction driven by the hydrolysis of GTP to GDP."
"<< Phosphate >>, a product of the reaction, was found to be a potent inhibitor of [[ MjAdSS ]] showing biphasic inhibition of enzyme activity.","[ENTITY_A], a product of the reaction, was found to be a potent inhibitor of [ENTITY_B] showing biphasic inhibition of enzyme activity.",INHIBITOR,CPR:4,1,"Phosphate, a product of the reaction, was found to be a potent inhibitor of MjAdSS showing biphasic inhibition of enzyme activity."
"The anti-inflammatory drugs << sodium salicylate >> and aspirin inhibited the activation of [[ NF-kappa B ]], which further explains the mechanism of action of these drugs.","The anti-inflammatory drugs [ENTITY_A] and aspirin inhibited the activation of [ENTITY_B], which further explains the mechanism of action of these drugs.",INHIBITOR,CPR:4,1,"The anti-inflammatory drugs sodium salicylate and aspirin inhibited the activation of NF-kappa B, which further explains the mechanism of action of these drugs."
<< Sodium salicylate >> and aspirin also inhibited [[ NF-kappa B ]]-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.,[ENTITY_A] and aspirin also inhibited [ENTITY_B]-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.,INHIBITOR,CPR:4,1,Sodium salicylate and aspirin also inhibited NF-kappa B-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.
Galanin attenuates << cyclic AMP regulatory element-binding protein >> (CREB) phosphorylation induced by chronic [[ morphine ]] and naloxone challenge in Cath.a cells and primary striatal cultures.,Galanin attenuates [ENTITY_A] (CREB) phosphorylation induced by chronic [ENTITY_B] and naloxone challenge in Cath.a cells and primary striatal cultures.,ACTIVATOR,CPR:3,0,Galanin attenuates cyclic AMP regulatory element-binding protein (CREB) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures.
"The << Na(+)/Ca(2+) exchanger >> (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings [[ Ca(2+) ]] into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization.","The [ENTITY_A] (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings [ENTITY_B] into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization.",SUBSTRATE,CPR:9,4,"The Na(+)/Ca(2+) exchanger (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization."
"The pharmacology of NCX inhibitors has been studied extensively since the development of << KB-R7943 >>, a prototype benzyloxyphenyl [[ NCX ]] inhibitor, in 1996.","The pharmacology of NCX inhibitors has been studied extensively since the development of [ENTITY_A], a prototype benzyloxyphenyl [ENTITY_B] inhibitor, in 1996.",INHIBITOR,CPR:4,1,"The pharmacology of NCX inhibitors has been studied extensively since the development of KB-R7943, a prototype benzyloxyphenyl NCX inhibitor, in 1996."
"Intriguingly, the inhibitory potency of << benzyloxyphenyl >> [[ NCX ]] inhibitors is directly coupled to the rate of Na(+)(i)-dependent inactivation.","Intriguingly, the inhibitory potency of [ENTITY_A] [ENTITY_B] inhibitors is directly coupled to the rate of Na(+)(i)-dependent inactivation.",INHIBITOR,CPR:4,1,"Intriguingly, the inhibitory potency of benzyloxyphenyl NCX inhibitors is directly coupled to the rate of Na(+)(i)-dependent inactivation."
"Existing << ion channel >> blockers, such as amiodarone, dronedarone, bepridil, aprindine, and [[ cibenzoline ]], have been found to have an NCX inhibitory action.","Existing [ENTITY_A] blockers, such as amiodarone, dronedarone, bepridil, aprindine, and [ENTITY_B], have been found to have an NCX inhibitory action.",INHIBITOR,CPR:4,1,"Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action."
"Efficacy and safety of the << dipeptidyl peptidase-4 >> inhibitor, [[ sitagliptin ]], in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.","Efficacy and safety of the [ENTITY_A] inhibitor, [ENTITY_B], in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.",INHIBITOR,CPR:4,1,"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin."
"AIM: To assess the efficacy and safety of a 24-week treatment with << sitagliptin >>, a highly selective once-daily oral [[ dipeptidyl peptidase-4 ]] (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin.","AIM: To assess the efficacy and safety of a 24-week treatment with [ENTITY_A], a highly selective once-daily oral [ENTITY_B] (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin.",INHIBITOR,CPR:4,1,"AIM: To assess the efficacy and safety of a 24-week treatment with sitagliptin, a highly selective once-daily oral dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin."
"<< HSYA >> suppressed the expression of TLR-4, [[ Myd88 ]], ICAM-1, TNFα, IL-1β and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.","[ENTITY_A] suppressed the expression of TLR-4, [ENTITY_B], ICAM-1, TNFα, IL-1β and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"HSYA suppressed the expression of TLR-4, Myd88, ICAM-1, TNFα, IL-1β and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells."
<< HSYA >> treatment also decreased [[ NF-κB ]] p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK).,[ENTITY_A] treatment also decreased [ENTITY_B] p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK).,DOWNREGULATOR,CPR:4,1,HSYA treatment also decreased NF-κB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK).
Synthesis and biological evaluation of << phosphorylated flavonoids >> as potent and selective inhibitors of [[ cholesterol esterase ]].,Synthesis and biological evaluation of [ENTITY_A] as potent and selective inhibitors of [ENTITY_B].,INHIBITOR,CPR:4,1,Synthesis and biological evaluation of phosphorylated flavonoids as potent and selective inhibitors of cholesterol esterase.
A series of << phosphorylated flavonoids >> were synthesized and investigated in vitro as inhibitors of pancreatic [[ cholesterol esterase ]] (CEase) and acetylcholinesterase (AChE).,A series of [ENTITY_A] were synthesized and investigated in vitro as inhibitors of pancreatic [ENTITY_B] (CEase) and acetylcholinesterase (AChE).,INHIBITOR,CPR:4,1,A series of phosphorylated flavonoids were synthesized and investigated in vitro as inhibitors of pancreatic cholesterol esterase (CEase) and acetylcholinesterase (AChE).
"The results showed that most of the synthesized compounds exhibited nanomolar potency against << CEase >>, much better than the parent [[ flavonoids ]].","The results showed that most of the synthesized compounds exhibited nanomolar potency against [ENTITY_A], much better than the parent [ENTITY_B].",INHIBITOR,CPR:4,1,"The results showed that most of the synthesized compounds exhibited nanomolar potency against CEase, much better than the parent flavonoids."
"Furthermore, these << phosphorylated flavonoids >> demonstrated good to high selectivity for [[ CEase ]] over AChE, which only showed micromolar potency inhibition of AChE.","Furthermore, these [ENTITY_A] demonstrated good to high selectivity for [ENTITY_B] over AChE, which only showed micromolar potency inhibition of AChE.",INHIBITOR,CPR:4,1,"Furthermore, these phosphorylated flavonoids demonstrated good to high selectivity for CEase over AChE, which only showed micromolar potency inhibition of AChE."
The structure-activity relationships revealed that the free << hydroxyl >> group at position 5 and phosphate group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of [[ CEase ]].,The structure-activity relationships revealed that the free [ENTITY_A] group at position 5 and phosphate group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of [ENTITY_B].,INHIBITOR,CPR:4,1,The structure-activity relationships revealed that the free hydroxyl group at position 5 and phosphate group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of CEase.
"In healthy rats, << ATB-429 >> dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal [[ c-FOS ]] mRNA, whereas mesalamine had no effect.","In healthy rats, [ENTITY_A] dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal [ENTITY_B] mRNA, whereas mesalamine had no effect.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In healthy rats, ATB-429 dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal c-FOS mRNA, whereas mesalamine had no effect."
"ATB-429-induced antinociception was reversed by << glibenclamide >>, a [[ ATP-sensitive K(+) (K(ATP)) channel ]] inhibitor.","ATB-429-induced antinociception was reversed by [ENTITY_A], a [ENTITY_B] inhibitor.",INHIBITOR,CPR:4,1,"ATB-429-induced antinociception was reversed by glibenclamide, a ATP-sensitive K(+) (K(ATP)) channel inhibitor."
"Colonic << cyclooxygenase-2 >> and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by [[ ATB-429 ]], but not by mesalamine.","Colonic [ENTITY_A] and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by [ENTITY_B], but not by mesalamine.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Colonic cyclooxygenase-2 and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by ATB-429, but not by mesalamine."
Block of human NaV1.5 << sodium channels >> by novel [[ alpha-hydroxyphenylamide ]] analogues of phenytoin.,Block of human NaV1.5 [ENTITY_A] by novel [ENTITY_B] analogues of phenytoin.,INHIBITOR,CPR:4,1,Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin.
Block of human NaV1.5 << sodium channels >>[[ sodium ]] channels by novel alpha-hydroxyphenylamide analogues of phenytoin.,Block of human NaV1.5 [ENTITY_A][ENTITY_B] channels by novel alpha-hydroxyphenylamide analogues of phenytoin.,SUBSTRATE,CPR:9,4,Block of human NaV1.5 sodium channelssodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin.
Block of << human NaV1.5 >> [[ sodium ]] channels by novel alpha-hydroxyphenylamide analogues of phenytoin.,Block of [ENTITY_A] [ENTITY_B] channels by novel alpha-hydroxyphenylamide analogues of phenytoin.,SUBSTRATE,CPR:9,4,Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin.
<< Voltage-gated sodium (Na) channels >>[[ Na ]]) channels are a critical component of electrically excitable cells.,[ENTITY_A][ENTITY_B]) channels are a critical component of electrically excitable cells.,SUBSTRATE,CPR:9,4,Voltage-gated sodium (Na) channelsNa) channels are a critical component of electrically excitable cells.
<< Voltage-gated sodium (Na) channels >>[[ sodium ]] (Na) channels are a critical component of electrically excitable cells.,[ENTITY_A][ENTITY_B] (Na) channels are a critical component of electrically excitable cells.,SUBSTRATE,CPR:9,4,Voltage-gated sodium (Na) channelssodium (Na) channels are a critical component of electrically excitable cells.
"<< Phenytoin >> (diphenylhydantoin, DPH) is an established [[ sodium channel ]] blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain.","[ENTITY_A] (diphenylhydantoin, DPH) is an established [ENTITY_B] blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain.",INHIBITOR,CPR:4,1,"Phenytoin (diphenylhydantoin, DPH) is an established sodium channel blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain."
"Phenytoin (diphenylhydantoin, DPH) is an established << sodium channel >>[[ sodium ]] channel blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain.","Phenytoin (diphenylhydantoin, DPH) is an established [ENTITY_A][ENTITY_B] channel blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain.",SUBSTRATE,CPR:9,4,"Phenytoin (diphenylhydantoin, DPH) is an established sodium channelsodium channel blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain."
"In this study, we have synthesized novel << alpha-hydroxyphenylamide >> analogues of diphenylhydantoin and examined their ability to inhibit [[ human Na(V)1.5 ]] sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells.","In this study, we have synthesized novel [ENTITY_A] analogues of diphenylhydantoin and examined their ability to inhibit [ENTITY_B] sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells.",INHIBITOR,CPR:4,1,"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells."
"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit << human Na(V)1.5 >> [[ sodium ]] channels expressed in Chinese Hamster Ovary (CHO-K1) cells.","In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit [ENTITY_A] [ENTITY_B] channels expressed in Chinese Hamster Ovary (CHO-K1) cells.",SUBSTRATE,CPR:9,4,"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells."
"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 << sodium channels >>[[ sodium ]] channels expressed in Chinese Hamster Ovary (CHO-K1) cells.","In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 [ENTITY_A][ENTITY_B] channels expressed in Chinese Hamster Ovary (CHO-K1) cells.",SUBSTRATE,CPR:9,4,"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 sodium channelssodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells."
"In comparison to << diphenylhydantoin >>, the novel chloro-substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of [[ Na(V)1.5 ]] channels with an IC(50) value of 14.5 microM.","In comparison to [ENTITY_A], the novel chloro-substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of [ENTITY_B] channels with an IC(50) value of 14.5 microM.",INHIBITOR,CPR:4,1,"In comparison to diphenylhydantoin, the novel chloro-substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of Na(V)1.5 channels with an IC(50) value of 14.5 microM."
This information may be useful in the development of more potent << sodium channel >>[[ sodium ]] channel blockers.,This information may be useful in the development of more potent [ENTITY_A][ENTITY_B] channel blockers.,SUBSTRATE,CPR:9,4,This information may be useful in the development of more potent sodium channelsodium channel blockers.
Effects of a << serotonin 5-HT(4) receptor >> antagonist [[ SB-207266 ]] on gastrointestinal motor and sensory function in humans.,Effects of a [ENTITY_A] antagonist [ENTITY_B] on gastrointestinal motor and sensory function in humans.,ANTAGONIST,CPR:6,3,Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans.
METHODS: Part A compared the effects of placebo to four doses of a << 5-HT(4) >> receptor antagonist (SB-207266) on the [[ cisapride ]] mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.,METHODS: Part A compared the effects of placebo to four doses of a [ENTITY_A] receptor antagonist (SB-207266) on the [ENTITY_B] mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.,AGONIST,CPR:5,2,METHODS: Part A compared the effects of placebo to four doses of a 5-HT(4) receptor antagonist (SB-207266) on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.
METHODS: Part A compared the effects of placebo to four doses of a << 5-HT(4) >> receptor antagonist ([[ SB-207266 ]]) on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.,METHODS: Part A compared the effects of placebo to four doses of a [ENTITY_A] receptor antagonist ([ENTITY_B]) on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.,ANTAGONIST,CPR:6,3,METHODS: Part A compared the effects of placebo to four doses of a 5-HT(4) receptor antagonist (SB-207266) on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.
"<< Spermidine/spermine N1-acetyltransferase >> (SSAT) is a key enzyme in the control of [[ polyamine ]] levels in human cells, as acetylation of spermidine and spermine triggers export or degradation.","[ENTITY_A] (SSAT) is a key enzyme in the control of [ENTITY_B] levels in human cells, as acetylation of spermidine and spermine triggers export or degradation.",PRODUCT-OF,CPR:9,4,"Spermidine/spermine N1-acetyltransferase (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and spermine triggers export or degradation."
These unexpected and intriguing complexities seem likely to have some as yet undefined role in regulating << SSAT >> activity or stability as a part of [[ polyamine ]] homeostasis.,These unexpected and intriguing complexities seem likely to have some as yet undefined role in regulating [ENTITY_A] activity or stability as a part of [ENTITY_B] homeostasis.,PRODUCT-OF,CPR:9,4,These unexpected and intriguing complexities seem likely to have some as yet undefined role in regulating SSAT activity or stability as a part of polyamine homeostasis.
Treatment of C57 BL/6 mice with << bleomycin >> increased fibroblast viability and collagen production and significantly downregulated [[ Nrf2 ]].,Treatment of C57 BL/6 mice with [ENTITY_A] increased fibroblast viability and collagen production and significantly downregulated [ENTITY_B].,DOWNREGULATOR,CPR:4,1,Treatment of C57 BL/6 mice with bleomycin increased fibroblast viability and collagen production and significantly downregulated Nrf2.
"In a cell-based model, << bleomycin >> suppressed Nrf2 activation via [[ extracellular signal-related kinase ]] phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.","In a cell-based model, [ENTITY_A] suppressed Nrf2 activation via [ENTITY_B] phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.",ACTIVATOR,CPR:3,0,"In a cell-based model, bleomycin suppressed Nrf2 activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion."
"In a cell-based model, << bleomycin >> suppressed [[ Nrf2 ]] activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.","In a cell-based model, [ENTITY_A] suppressed [ENTITY_B] activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.",INHIBITOR,CPR:4,1,"In a cell-based model, bleomycin suppressed Nrf2 activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion."
"To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative << Nrf2 >> activator, [[ caffeic acid phenethyl ester ]], and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.","To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative [ENTITY_A] activator, [ENTITY_B], and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.",ACTIVATOR,CPR:3,0,"To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester, and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance."
Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor << TAK-441 >> for the inhibition of [[ Gli1 ]] messenger RNA expression and antitumor efficacy in xenografted tumor model mice.,Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor [ENTITY_A] for the inhibition of [ENTITY_B] messenger RNA expression and antitumor efficacy in xenografted tumor model mice.,INDIRECT-DOWNREGULATOR,CPR:4,1,Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.
"6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (<< TAK-441 >>) is a potent, selective [[ hedgehog ]] signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer.","6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide ([ENTITY_A]) is a potent, selective [ENTITY_B] signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer.",INHIBITOR,CPR:4,1,"6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (TAK-441) is a potent, selective hedgehog signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer."
"The IC50 values for << Gli1 >> mRNA inhibition in the tumor and skin by [[ TAK-441 ]] were estimated to be 0.0457 and 0.113 μg/ml, respectively.","The IC50 values for [ENTITY_A] mRNA inhibition in the tumor and skin by [ENTITY_B] were estimated to be 0.0457 and 0.113 μg/ml, respectively.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The IC50 values for Gli1 mRNA inhibition in the tumor and skin by TAK-441 were estimated to be 0.0457 and 0.113 μg/ml, respectively."
"In this report, we evaluated the growth-inhibitory effects of << sulindac sulfide >>, a [[ COX-1 ]] and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines.","In this report, we evaluated the growth-inhibitory effects of [ENTITY_A], a [ENTITY_B] and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines.",INHIBITOR,CPR:4,1,"In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines."
<< Phenothiazines >> inhibit [[ S100A4 ]] function by inducing protein oligomerization.,[ENTITY_A] inhibit [ENTITY_B] function by inducing protein oligomerization.,INHIBITOR,CPR:4,1,Phenothiazines inhibit S100A4 function by inducing protein oligomerization.
"Using a unique biosensor-based assay, << trifluoperazine >> (TFP) was identified as an inhibitor that disrupts the [[ S100A4 ]]/myosin-IIA interaction.","Using a unique biosensor-based assay, [ENTITY_A] (TFP) was identified as an inhibitor that disrupts the [ENTITY_B]/myosin-IIA interaction.",INHIBITOR,CPR:4,1,"Using a unique biosensor-based assay, trifluoperazine (TFP) was identified as an inhibitor that disrupts the S100A4/myosin-IIA interaction."
Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at << TFP >> concentrations that promote [[ S100A4 ]] oligomerization.,Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at [ENTITY_A] concentrations that promote [ENTITY_B] oligomerization.,ACTIVATOR,CPR:3,0,Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization.
Assays examining the ability of << TFP >> to block [[ S100A4 ]]-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization.,Assays examining the ability of [ENTITY_A] to block [ENTITY_B]-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization.,INHIBITOR,CPR:4,1,Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization.
Together these studies support a unique mode of inhibition in which << phenothiazines >> disrupt the [[ S100A4 ]]/myosin-IIA interaction by sequestering S100A4 via small molecule-induced oligomerization.,Together these studies support a unique mode of inhibition in which [ENTITY_A] disrupt the [ENTITY_B]/myosin-IIA interaction by sequestering S100A4 via small molecule-induced oligomerization.,INHIBITOR,CPR:4,1,Together these studies support a unique mode of inhibition in which phenothiazines disrupt the S100A4/myosin-IIA interaction by sequestering S100A4 via small molecule-induced oligomerization.
Cardiac effects of the << beta 3-adrenoceptor >> agonist [[ BRL35135 ]] in man.,Cardiac effects of the [ENTITY_A] agonist [ENTITY_B] in man.,AGONIST,CPR:5,2,Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man.
"The aim of the present study was to evaluate the cardiac effects of the << beta 3-adrenoceptor >> agonist [[ BRL35135 ]], and determine whether beta 3-receptors are involved in mediating chronotropic or inotropic responses in man.","The aim of the present study was to evaluate the cardiac effects of the [ENTITY_A] agonist [ENTITY_B], and determine whether beta 3-receptors are involved in mediating chronotropic or inotropic responses in man.",AGONIST,CPR:5,2,"The aim of the present study was to evaluate the cardiac effects of the beta 3-adrenoceptor agonist BRL35135, and determine whether beta 3-receptors are involved in mediating chronotropic or inotropic responses in man."
"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective << beta 2-adrenoceptor >> agonist [[ salbutamol ]] 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.","Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective [ENTITY_A] agonist [ENTITY_B] 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.",AGONIST,CPR:5,2,"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors."
"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), << bisoprolol >> 5 mg (B5) as a selective [[ beta 1-adrenoceptor ]] antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.","Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), [ENTITY_A] 5 mg (B5) as a selective [ENTITY_B] antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.",ANTAGONIST,CPR:6,3,"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors."
"Both << BRL >> and SAL produced a significant increase in postural finger tremor in keeping with [[ beta 2-adrenoceptor ]] stimulation, and this response was totally abolished by pretreatment with N20.","Both [ENTITY_A] and SAL produced a significant increase in postural finger tremor in keeping with [ENTITY_B] stimulation, and this response was totally abolished by pretreatment with N20.",ACTIVATOR,CPR:3,0,"Both BRL and SAL produced a significant increase in postural finger tremor in keeping with beta 2-adrenoceptor stimulation, and this response was totally abolished by pretreatment with N20."
"Disruption of contact inhibition, which was induced by toxic AhR ligands << 2,3,7,8-tetrachlorodibenzo-p-dioxin >> (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced [[ Cx43 ]] protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.","Disruption of contact inhibition, which was induced by toxic AhR ligands [ENTITY_A] (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced [ENTITY_B] protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner."
"Although both intracellular and membrane Cx43 pools were markedly reduced in cells released from contact inhibition by << TCDD >>, siRNA-mediated [[ Cx43 ]] knock-down was not sufficient to stimulate proliferation in contact-inhibited cells.","Although both intracellular and membrane Cx43 pools were markedly reduced in cells released from contact inhibition by [ENTITY_A], siRNA-mediated [ENTITY_B] knock-down was not sufficient to stimulate proliferation in contact-inhibited cells.",DOWNREGULATOR,CPR:4,1,"Although both intracellular and membrane Cx43 pools were markedly reduced in cells released from contact inhibition by TCDD, siRNA-mediated Cx43 knock-down was not sufficient to stimulate proliferation in contact-inhibited cells."
<< Dexamethasone >> suppresses histamine synthesis by repressing both transcription and activity of [[ HDC ]] in allergic rats.,[ENTITY_A] suppresses histamine synthesis by repressing both transcription and activity of [ENTITY_B] in allergic rats.,INDIRECT-DOWNREGULATOR,CPR:4,1,Dexamethasone suppresses histamine synthesis by repressing both transcription and activity of HDC in allergic rats.
BACKGROUND: << Histamine >> synthesized by [[ histidine decarboxylase ]] (HDC) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.,BACKGROUND: [ENTITY_A] synthesized by [ENTITY_B] (HDC) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.,PRODUCT-OF,CPR:9,4,BACKGROUND: Histamine synthesized by histidine decarboxylase (HDC) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.
However the regulatory mechanism of << histamine >> synthesis by [[ HDC ]] remains to be elucidated.,However the regulatory mechanism of [ENTITY_A] synthesis by [ENTITY_B] remains to be elucidated.,PRODUCT-OF,CPR:9,4,However the regulatory mechanism of histamine synthesis by HDC remains to be elucidated.
"Histamine content, << HDC >> activity and HDC mRNA expression in nasal mucosa were also significantly increased after [[ TDI ]] provocation.","Histamine content, [ENTITY_A] activity and HDC mRNA expression in nasal mucosa were also significantly increased after [ENTITY_B] provocation.",ACTIVATOR,CPR:3,0,"Histamine content, HDC activity and HDC mRNA expression in nasal mucosa were also significantly increased after TDI provocation."
"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, << HDC >> activity and HDC mRNA induced by [[ TDI ]] in TDI-sensitized rats.","Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, [ENTITY_A] activity and HDC mRNA induced by [ENTITY_B] in TDI-sensitized rats.",ACTIVATOR,CPR:3,0,"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and HDC mRNA induced by TDI in TDI-sensitized rats."
"Pretreatment with << dexamethasone >> significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and [[ HDC ]] mRNA induced by TDI in TDI-sensitized rats.","Pretreatment with [ENTITY_A] significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and [ENTITY_B] mRNA induced by TDI in TDI-sensitized rats.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and HDC mRNA induced by TDI in TDI-sensitized rats."
CONCLUSIONS: These findings indicate that increased synthesis of << histamine >> through up-regulation of [[ HDC ]] gene expression and HDC activity in nasal mucosa plays an important role in the development of nasal hypersensitivity.,CONCLUSIONS: These findings indicate that increased synthesis of [ENTITY_A] through up-regulation of [ENTITY_B] gene expression and HDC activity in nasal mucosa plays an important role in the development of nasal hypersensitivity.,PRODUCT-OF,CPR:9,4,CONCLUSIONS: These findings indicate that increased synthesis of histamine through up-regulation of HDC gene expression and HDC activity in nasal mucosa plays an important role in the development of nasal hypersensitivity.
Repression of << HDC >> gene expression and HDC activity by [[ dexamethasone ]] may underlie its therapeutic effect in the treatment of allergy.,Repression of [ENTITY_A] gene expression and HDC activity by [ENTITY_B] may underlie its therapeutic effect in the treatment of allergy.,INDIRECT-DOWNREGULATOR,CPR:4,1,Repression of HDC gene expression and HDC activity by dexamethasone may underlie its therapeutic effect in the treatment of allergy.
CONCLUSIONS A diet that partially replaces << carbohydrate >> with unsaturated fat may improve [[ insulin ]] sensitivity in a population at risk for cardiovascular disease.,CONCLUSIONS A diet that partially replaces [ENTITY_A] with unsaturated fat may improve [ENTITY_B] sensitivity in a population at risk for cardiovascular disease.,INDIRECT-UPREGULATOR,CPR:3,0,CONCLUSIONS A diet that partially replaces carbohydrate with unsaturated fat may improve insulin sensitivity in a population at risk for cardiovascular disease.
"In this study, we assessed the effects of << clopidogrel >> and clarithromycin, known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with [[ CYP2B6 ]] polymorphisms in humans.","In this study, we assessed the effects of [ENTITY_A] and clarithromycin, known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with [ENTITY_B] polymorphisms in humans.",INHIBITOR,CPR:4,1,"In this study, we assessed the effects of clopidogrel and clarithromycin, known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans."
Increased << IL-5 >> activity in the serum was inhibited by both [[ pranlukast ]] and MCI-826 by over 90%.,Increased [ENTITY_A] activity in the serum was inhibited by both [ENTITY_B] and MCI-826 by over 90%.,INHIBITOR,CPR:4,1,Increased IL-5 activity in the serum was inhibited by both pranlukast and MCI-826 by over 90%.
CONCLUSIONS: << CysLTs >> produced after antigen provocation sequentially induced IL-5 production from some immune component cells via [[ CysLT1 ]] receptor activation.,CONCLUSIONS: [ENTITY_A] produced after antigen provocation sequentially induced IL-5 production from some immune component cells via [ENTITY_B] receptor activation.,ACTIVATOR,CPR:3,0,CONCLUSIONS: CysLTs produced after antigen provocation sequentially induced IL-5 production from some immune component cells via CysLT1 receptor activation.
"Extracellular application of meclofenamate (EC(50) = 25 microM) and << diclofenac >> (EC(50) = 2.6 microM) resulted in the activation of [[ KCNQ2/Q3 ]] K(+) currents, heterologously expressed in Chinese hamster ovary cells.","Extracellular application of meclofenamate (EC(50) = 25 microM) and [ENTITY_A] (EC(50) = 2.6 microM) resulted in the activation of [ENTITY_B] K(+) currents, heterologously expressed in Chinese hamster ovary cells.",ACTIVATOR,CPR:3,0,"Extracellular application of meclofenamate (EC(50) = 25 microM) and diclofenac (EC(50) = 2.6 microM) resulted in the activation of KCNQ2/Q3 K(+) currents, heterologously expressed in Chinese hamster ovary cells."
The selective << norepinephrine (NE) transporter >> inhibitor [[ atomoxetine ]] (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD).,The selective [ENTITY_A] inhibitor [ENTITY_B] (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD).,INHIBITOR,CPR:4,1,The selective norepinephrine (NE) transporter inhibitor atomoxetine (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD).
"Lung inflammation, << IL-4 >> production, and airway mast cell activity were also prevented under this early short-term treatment with [[ PGE2 ]].","Lung inflammation, [ENTITY_A] production, and airway mast cell activity were also prevented under this early short-term treatment with [ENTITY_B].",INHIBITOR,CPR:4,1,"Lung inflammation, IL-4 production, and airway mast cell activity were also prevented under this early short-term treatment with PGE2."
Local << PGE2 >> administration prevented the increase of airway [[ IL-13 ]] and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline.,Local [ENTITY_A] administration prevented the increase of airway [ENTITY_B] and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline.,INHIBITOR,CPR:4,1,Local PGE2 administration prevented the increase of airway IL-13 and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline.
"Reactivators showed different activity in the reactivation of << rat brain AChE >> after [[ dichlorvos ]], paraoxon and tabun inhibition.","Reactivators showed different activity in the reactivation of [ENTITY_A] after [ENTITY_B], paraoxon and tabun inhibition.",INHIBITOR,CPR:4,1,"Reactivators showed different activity in the reactivation of rat brain AChE after dichlorvos, paraoxon and tabun inhibition."
<< AChE >> was easier reactivated after [[ paraoxon ]] treatment.,[ENTITY_A] was easier reactivated after [ENTITY_B] treatment.,ACTIVATOR,CPR:3,0,AChE was easier reactivated after paraoxon treatment.
"The reactivation of brain << AChE >> inhibited with tabun demonstrated better activity of new compound [[ BT-07-4M ]], TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure.","The reactivation of brain [ENTITY_A] inhibited with tabun demonstrated better activity of new compound [ENTITY_B], TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure.",ACTIVATOR,CPR:3,0,"The reactivation of brain AChE inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure."
All compounds showed low activity toward inhibition of << AChE >> caused by [[ dichlorvos ]].,All compounds showed low activity toward inhibition of [ENTITY_A] caused by [ENTITY_B].,INHIBITOR,CPR:4,1,All compounds showed low activity toward inhibition of AChE caused by dichlorvos.
State-dependent << mibefradil >> block of [[ Na+ channels ]].,State-dependent [ENTITY_A] block of [ENTITY_B].,INHIBITOR,CPR:4,1,State-dependent mibefradil block of Na+ channels.
"<< Mibefradil >> is a [[ T-type Ca2+ channel ]] antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels.","[ENTITY_A] is a [ENTITY_B] antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels.",ANTAGONIST,CPR:6,3,"Mibefradil is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels."
"Using whole-cell voltage clamp, we examined << mibefradil >> block of four [[ Na+ channel ]] isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve).","Using whole-cell voltage clamp, we examined [ENTITY_A] block of four [ENTITY_B] isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve).",INHIBITOR,CPR:4,1,"Using whole-cell voltage clamp, we examined mibefradil block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)."
"<< Mibefradil >> blocked [[ Nav1.5 ]] in a use/frequency-dependent manner, indicating preferential binding to states visited during depolarization.","[ENTITY_A] blocked [ENTITY_B] in a use/frequency-dependent manner, indicating preferential binding to states visited during depolarization.",INHIBITOR,CPR:4,1,"Mibefradil blocked Nav1.5 in a use/frequency-dependent manner, indicating preferential binding to states visited during depolarization."
"<< Mibefradil >> blocked currents of all [[ Na+ channel ]] isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024/s at -130 mV and 0.007/s at -100 mV for Nav1.5).","[ENTITY_A] blocked currents of all [ENTITY_B] isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024/s at -130 mV and 0.007/s at -100 mV for Nav1.5).",INHIBITOR,CPR:4,1,"Mibefradil blocked currents of all Na+ channel isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024/s at -130 mV and 0.007/s at -100 mV for Nav1.5)."
"In addition, inhibiting the binding of the fast inactivation lid (<< Nav1.5 >> ICM + MTSET) did not alter [[ mibefradil ]] block, confirming that the drug does not preferentially interact with the fast-inactivated state.","In addition, inhibiting the binding of the fast inactivation lid ([ENTITY_A] ICM + MTSET) did not alter [ENTITY_B] block, confirming that the drug does not preferentially interact with the fast-inactivated state.",INHIBITOR,CPR:4,1,"In addition, inhibiting the binding of the fast inactivation lid (Nav1.5 ICM + MTSET) did not alter mibefradil block, confirming that the drug does not preferentially interact with the fast-inactivated state."
"When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV, << mibefradil >> (1 microM) produced 45% fractional block in [[ Nav1.5 ]] and greater block (88%) in an isoform (Nav1.4) that slow-inactivates more completely.","When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV, [ENTITY_A] (1 microM) produced 45% fractional block in [ENTITY_B] and greater block (88%) in an isoform (Nav1.4) that slow-inactivates more completely.",INHIBITOR,CPR:4,1,"When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV, mibefradil (1 microM) produced 45% fractional block in Nav1.5 and greater block (88%) in an isoform (Nav1.4) that slow-inactivates more completely."
Our results suggest that << mibefradil >> blocks [[ Na+ channels ]] in a state-dependent manner that does not depend on fast inactivation but probably involves interaction with one or more slow-inactivated state(s).,Our results suggest that [ENTITY_A] blocks [ENTITY_B] in a state-dependent manner that does not depend on fast inactivation but probably involves interaction with one or more slow-inactivated state(s).,INHIBITOR,CPR:4,1,Our results suggest that mibefradil blocks Na+ channels in a state-dependent manner that does not depend on fast inactivation but probably involves interaction with one or more slow-inactivated state(s).
"<< Docetaxel >> is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of [[ bcl-2 ]] inactivation, which induce apoptosis.","[ENTITY_A] is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of [ENTITY_B] inactivation, which induce apoptosis.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Docetaxel is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of bcl-2 inactivation, which induce apoptosis."
"Risperidone is metabolized to its active metabolite, << 9-hydroxyrisperidone >>, mainly by the [[ cytochrome P450 ]] enzymes CYP2D6 and 3A4.","Risperidone is metabolized to its active metabolite, [ENTITY_A], mainly by the [ENTITY_B] enzymes CYP2D6 and 3A4.",PRODUCT-OF,CPR:9,4,"Risperidone is metabolized to its active metabolite, 9-hydroxyrisperidone, mainly by the cytochrome P450 enzymes CYP2D6 and 3A4."
"Both << risperidone >> and 9-hydroxyrisperidone are substrates of [[ P-glycoprotein ]] (P-gp), a transport protein involved in drug absorption, distribution, and elimination.","Both [ENTITY_A] and 9-hydroxyrisperidone are substrates of [ENTITY_B] (P-gp), a transport protein involved in drug absorption, distribution, and elimination.",SUBSTRATE,CPR:9,4,"Both risperidone and 9-hydroxyrisperidone are substrates of P-glycoprotein (P-gp), a transport protein involved in drug absorption, distribution, and elimination."
"bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of << BW-1 >>, acted as substrate for [[ PAO ]].","bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of [ENTITY_A], acted as substrate for [ENTITY_B].",SUBSTRATE,CPR:9,4,"bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of BW-1, acted as substrate for PAO."
"<< SL-11158 >> inhibited [[ SSAT ]] activity with a mixed type of inhibition in which the analogue had a 70-fold higher affinity for the enzyme than the natural substrate, spermine.","[ENTITY_A] inhibited [ENTITY_B] activity with a mixed type of inhibition in which the analogue had a 70-fold higher affinity for the enzyme than the natural substrate, spermine.",INHIBITOR,CPR:4,1,"SL-11158 inhibited SSAT activity with a mixed type of inhibition in which the analogue had a 70-fold higher affinity for the enzyme than the natural substrate, spermine."
Synthesis and in vitro evaluation of << N-Aryl pyrido-quinazolines >> derivatives as potent [[ EGFR ]] inhibitors.,Synthesis and in vitro evaluation of [ENTITY_A] derivatives as potent [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Synthesis and in vitro evaluation of N-Aryl pyrido-quinazolines derivatives as potent EGFR inhibitors.
"A series of << pyrido-quinazolines >> have been synthesised, characterised and tested for their in vitro [[ EGFR ]] tyrosine kinase inhibitory activity.","A series of [ENTITY_A] have been synthesised, characterised and tested for their in vitro [ENTITY_B] tyrosine kinase inhibitory activity.",INHIBITOR,CPR:4,1,"A series of pyrido-quinazolines have been synthesised, characterised and tested for their in vitro EGFR tyrosine kinase inhibitory activity."
"Exposure to << Cu >> NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of lactate dehydrogenase, intracellular reactive oxygen species and [[ interleukin-8 ]] that mirrored our findings from subacute in vivo inhalation studies in mice.","Exposure to [ENTITY_A] NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of lactate dehydrogenase, intracellular reactive oxygen species and [ENTITY_B] that mirrored our findings from subacute in vivo inhalation studies in mice.",INDIRECT-UPREGULATOR,CPR:3,0,"Exposure to Cu NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of lactate dehydrogenase, intracellular reactive oxygen species and interleukin-8 that mirrored our findings from subacute in vivo inhalation studies in mice."
The Trx mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting << TrxR >> with [[ auranofin ]] (AuF).,The Trx mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting [ENTITY_A] with [ENTITY_B] (AuF).,INHIBITOR,CPR:4,1,The Trx mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting TrxR with auranofin (AuF).
"The TXM peptides were effective in inhibiting << AuF >>-induced [[ MAPK ]], JNK and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.","The TXM peptides were effective in inhibiting [ENTITY_A]-induced [ENTITY_B], JNK and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.",ACTIVATOR,CPR:3,0,"The TXM peptides were effective in inhibiting AuF-induced MAPK, JNK and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation."
Preferential block of late sodium current in the << LQT3 DeltaKPQ mutant >> by the class I(C) antiarrhythmic [[ flecainide ]].,Preferential block of late sodium current in the [ENTITY_A] by the class I(C) antiarrhythmic [ENTITY_B].,INHIBITOR,CPR:4,1,Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.
"<< Flecainide >> block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted ([[ DeltaKPQ ]]) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.","[ENTITY_A] block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted ([ENTITY_B]) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.",DOWNREGULATOR,CPR:4,1,"Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings."
"Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the << long QT syndrome 3 (LQT3) sodium channel alpha >>[[ sodium ]] channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.","Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the [ENTITY_A][ENTITY_B] channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.",SUBSTRATE,CPR:9,4,"Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alphasodium channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings."
"Compared with WT, << DeltaKPQ >> I(Na) was more sensitive to [[ flecainide ]], and flecainide preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na).","Compared with WT, [ENTITY_A] I(Na) was more sensitive to [ENTITY_B], and flecainide preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na).",INHIBITOR,CPR:4,1,"Compared with WT, DeltaKPQ I(Na) was more sensitive to flecainide, and flecainide preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na)."
"We conclude that << DeltaKPQ >> interacts differently with [[ flecainide ]] than with WT, leading to increased block and slowed recovery, especially for late I(Na).","We conclude that [ENTITY_A] interacts differently with [ENTITY_B] than with WT, leading to increased block and slowed recovery, especially for late I(Na).",INHIBITOR,CPR:4,1,"We conclude that DeltaKPQ interacts differently with flecainide than with WT, leading to increased block and slowed recovery, especially for late I(Na)."
"Both << 5'-AMN >> and 5'-MABN had high affinity for κ-receptors (K (i) 1.36 ± 0.98 and 0.27 ± 0.08, respectively) and were revealed as potent κ-antagonists (pA(2) 7.43 and 8.18, respectively) and [[ μ-receptor ]] antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.","Both [ENTITY_A] and 5'-MABN had high affinity for κ-receptors (K (i) 1.36 ± 0.98 and 0.27 ± 0.08, respectively) and were revealed as potent κ-antagonists (pA(2) 7.43 and 8.18, respectively) and [ENTITY_B] antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.",ANTAGONIST,CPR:6,3,"Both 5'-AMN and 5'-MABN had high affinity for κ-receptors (K (i) 1.36 ± 0.98 and 0.27 ± 0.08, respectively) and were revealed as potent κ-antagonists (pA(2) 7.43 and 8.18, respectively) and μ-receptor antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum."
Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of << dihydropteridinone >> based [[ Plk-2 ]] inhibitors.,Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of [ENTITY_A] based [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of dihydropteridinone based Plk-2 inhibitors.
<< Sphingosine-1-phosphate >> promotes the nuclear translocation of β-catenin and thereby induces [[ osteoprotegerin ]] gene expression in osteoblast-like cell lines.,[ENTITY_A] promotes the nuclear translocation of β-catenin and thereby induces [ENTITY_B] gene expression in osteoblast-like cell lines.,INDIRECT-UPREGULATOR,CPR:3,0,Sphingosine-1-phosphate promotes the nuclear translocation of β-catenin and thereby induces osteoprotegerin gene expression in osteoblast-like cell lines.
"<< S1P >> activated [[ phosphatidylinositol 3-kinase ]] (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.","[ENTITY_A] activated [ENTITY_B] (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.",INDIRECT-UPREGULATOR,CPR:3,0,"S1P activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells."
"<< S1P >> activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of [[ glycogen synthase kinase-3β ]] and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.","[ENTITY_A] activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of [ENTITY_B] and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.",INHIBITOR,CPR:4,1,"S1P activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells."
"<< S1P >> increased the amount of [[ osteoprotegerin ]] at both mRNA and protein levels, and increased the activity of alkaline phosphatase, leading to the mineralization.","[ENTITY_A] increased the amount of [ENTITY_B] at both mRNA and protein levels, and increased the activity of alkaline phosphatase, leading to the mineralization.",INDIRECT-UPREGULATOR,CPR:3,0,"S1P increased the amount of osteoprotegerin at both mRNA and protein levels, and increased the activity of alkaline phosphatase, leading to the mineralization."
"These findings suggest that << S1P >> activates the [[ PI3K ]]/Akt signaling pathway leading to the promotion of nuclear translocation of β-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.","These findings suggest that [ENTITY_A] activates the [ENTITY_B]/Akt signaling pathway leading to the promotion of nuclear translocation of β-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.",ACTIVATOR,CPR:3,0,"These findings suggest that S1P activates the PI3K/Akt signaling pathway leading to the promotion of nuclear translocation of β-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively."
"<< Plerixafor >>, a [[ CXCR4 ]] antagonist for the mobilization of hematopoietic stem cells.","[ENTITY_A], a [ENTITY_B] antagonist for the mobilization of hematopoietic stem cells.",ANTAGONIST,CPR:6,3,"Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells."
"<< Plerixafor >> (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine [[ stromal cell-derived factor-1 ]] (SDF-1) to its cognate receptor CXCR4.","[ENTITY_A] (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine [ENTITY_B] (SDF-1) to its cognate receptor CXCR4.",INHIBITOR,CPR:4,1,"Plerixafor (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4."
"This stimulation was attenuated by the << Pak >> inhibitor [[ 2,2'-dihydroxy-1,1'-dinaphthyldisulfide ]] (IPA3) or dominant-negative Pak1.",This stimulation was attenuated by the [ENTITY_A] inhibitor [ENTITY_B] (IPA3) or dominant-negative Pak1.,INHIBITOR,CPR:4,1,"This stimulation was attenuated by the Pak inhibitor 2,2'-dihydroxy-1,1'-dinaphthyldisulfide (IPA3) or dominant-negative Pak1."
Chronic insulin (24 h) activates NHE3 through the classic << phosphatidylinositol 3-kinase >>-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor [[ wortmannin ]] or a dominant-negative SGK1.,Chronic insulin (24 h) activates NHE3 through the classic [ENTITY_A]-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor [ENTITY_B] or a dominant-negative SGK1.,INHIBITOR,CPR:4,1,Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1.
Results showed that neonatal << quinpirole >> treatment induced [[ D2 ]] priming that was eliminated by olanzapine treatment.,Results showed that neonatal [ENTITY_A] treatment induced [ENTITY_B] priming that was eliminated by olanzapine treatment.,INDIRECT-UPREGULATOR,CPR:3,0,Results showed that neonatal quinpirole treatment induced D2 priming that was eliminated by olanzapine treatment.
Results showed that neonatal quinpirole treatment induced << D2 >> priming that was eliminated by [[ olanzapine ]] treatment.,Results showed that neonatal quinpirole treatment induced [ENTITY_A] priming that was eliminated by [ENTITY_B] treatment.,INDIRECT-DOWNREGULATOR,CPR:4,1,Results showed that neonatal quinpirole treatment induced D2 priming that was eliminated by olanzapine treatment.
"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal << NGF >>, BDNF and ChAT that was eliminated by [[ olanzapine ]] treatment.","Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal [ENTITY_A], BDNF and ChAT that was eliminated by [ENTITY_B] treatment.",INDIRECT-UPREGULATOR,CPR:3,0,"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, BDNF and ChAT that was eliminated by olanzapine treatment."
"Brain tissue analyses revealed that neonatal << quinpirole >> treatment produced a significant decrease in hippocampal [[ NGF ]], BDNF and ChAT that was eliminated by olanzapine treatment.","Brain tissue analyses revealed that neonatal [ENTITY_A] treatment produced a significant decrease in hippocampal [ENTITY_B], BDNF and ChAT that was eliminated by olanzapine treatment.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, BDNF and ChAT that was eliminated by olanzapine treatment."
Neonatal << quinpirole >> treatment produced a significant decrease in [[ BDNF ]] and ChAT in the frontal cortex that was unaffected by olanzapine treatment.,Neonatal [ENTITY_A] treatment produced a significant decrease in [ENTITY_B] and ChAT in the frontal cortex that was unaffected by olanzapine treatment.,INDIRECT-DOWNREGULATOR,CPR:4,1,Neonatal quinpirole treatment produced a significant decrease in BDNF and ChAT in the frontal cortex that was unaffected by olanzapine treatment.
These results show that << olanzapine >> eliminates [[ D2 receptor ]] priming and cognitive impairment and also alleviates decreases in neurotrophins and acetylcholinergic markers produced by D2 priming in the hippocampus.,These results show that [ENTITY_A] eliminates [ENTITY_B] priming and cognitive impairment and also alleviates decreases in neurotrophins and acetylcholinergic markers produced by D2 priming in the hippocampus.,INDIRECT-DOWNREGULATOR,CPR:4,1,These results show that olanzapine eliminates D2 receptor priming and cognitive impairment and also alleviates decreases in neurotrophins and acetylcholinergic markers produced by D2 priming in the hippocampus.
Suppression of << Src >>/ERK and GSK-3/β-catenin signaling by [[ pinosylvin ]] inhibits the growth of human colorectal cancer cells.,Suppression of [ENTITY_A]/ERK and GSK-3/β-catenin signaling by [ENTITY_B] inhibits the growth of human colorectal cancer cells.,DOWNREGULATOR,CPR:4,1,Suppression of Src/ERK and GSK-3/β-catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells.
"<< Pinosylvin >> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of [[ p21 ]](WAF1/CIP1) and p53.","[ENTITY_A] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of [ENTITY_B](WAF1/CIP1) and p53.",UPREGULATOR,CPR:3,0,"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53."
"<< Pinosylvin >> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of [[ cyclin D1 ]], cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.","[ENTITY_A] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of [ENTITY_B], cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",DOWNREGULATOR,CPR:4,1,"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53."
"<< Pinosylvin >> was also found to attenuate the activation of proteins involved in f[[ ocal adhesion kinase ]] (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway.","[ENTITY_A] was also found to attenuate the activation of proteins involved in f[ENTITY_B] (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway."
"Subsequently, << pinosylvin >> suppressed the nuclear translocation of [[ β-catenin ]], one of downstream molecules of PI3K/Akt/GSK-3β signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.","Subsequently, [ENTITY_A] suppressed the nuclear translocation of [ENTITY_B], one of downstream molecules of PI3K/Akt/GSK-3β signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Subsequently, pinosylvin suppressed the nuclear translocation of β-catenin, one of downstream molecules of PI3K/Akt/GSK-3β signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc."
"Overall, higher alcohol production was reduced by << ammonium >> supplementation, and this can be correlated with a general downregulation of genes encoding [[ decarboxylases ]] and dehydrogenases of the Ehrlich pathway.","Overall, higher alcohol production was reduced by [ENTITY_A] supplementation, and this can be correlated with a general downregulation of genes encoding [ENTITY_B] and dehydrogenases of the Ehrlich pathway.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Overall, higher alcohol production was reduced by ammonium supplementation, and this can be correlated with a general downregulation of genes encoding decarboxylases and dehydrogenases of the Ehrlich pathway."
"Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as << cyclooxygenase-2 >> inhibiting [[ nitric oxide ]] donors.","Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as [ENTITY_A] inhibiting [ENTITY_B] donors.",INHIBITOR,CPR:4,1,"Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors."
"New classes of << pyrrole >>-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as [[ COX-2 ]] selective inhibitors and NO donors were synthesized and are herein reported.","New classes of [ENTITY_A]-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as [ENTITY_B] selective inhibitors and NO donors were synthesized and are herein reported.",INHIBITOR,CPR:4,1,"New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported."
"<< Nitrooxy >> derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective [[ COX-2 ]] inhibitors in in vitro experimental models.","[ENTITY_A] derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective [ENTITY_B] inhibitors in in vitro experimental models.",INHIBITOR,CPR:4,1,"Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models."
The clinical profile of the << angiotensin II receptor >> blocker [[ eprosartan ]].,The clinical profile of the [ENTITY_A] blocker [ENTITY_B].,INHIBITOR,CPR:4,1,The clinical profile of the angiotensin II receptor blocker eprosartan.
"In clinical trials << eprosartan >> has proven to be at least as effective as the [[ ACE ]] inhibitor enalapril in reducing BP, but with a significantly lower incidence of side effects.","In clinical trials [ENTITY_A] has proven to be at least as effective as the [ENTITY_B] inhibitor enalapril in reducing BP, but with a significantly lower incidence of side effects.",INHIBITOR,CPR:4,1,"In clinical trials eprosartan has proven to be at least as effective as the ACE inhibitor enalapril in reducing BP, but with a significantly lower incidence of side effects."
"A significant decrease of << aspartate aminotransferase >>, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after [[ CCl4 ]] and PC administration alone.","A significant decrease of [ENTITY_A], alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after [ENTITY_B] and PC administration alone.",INHIBITOR,CPR:4,1,"A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone."
"In the CCl4 hepatotoxicity model, pre-treatment with PSM or << silymarin >> resulted in significantly increased activities of [[ ethylmorphine-N-demethylase ]] and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group.","In the CCl4 hepatotoxicity model, pre-treatment with PSM or [ENTITY_A] resulted in significantly increased activities of [ENTITY_B] and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group.",ACTIVATOR,CPR:3,0,"In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group."
In vitro inhibition of << diacylglycerol acyltransferase >> by [[ prenylflavonoids ]] from Sophora flavescens.,In vitro inhibition of [ENTITY_A] by [ENTITY_B] from Sophora flavescens.,INHIBITOR,CPR:4,1,In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens.
"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, << kuraridin >> ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on [[ diacylglycerol acyltransferase ]] (DGAT).","Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, [ENTITY_A] ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on [ENTITY_B] (DGAT).",INHIBITOR,CPR:4,1,"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT)."
"The << flavonoids >> inhibited [[ DGAT ]] activity in a dose-dependent manner with IC50 values of 10.9 microM ( 1), 9.8 microM ( 2), 8.6 microM ( 3), 142.0 microM ( 4) and 250 microM ( 5).","The [ENTITY_A] inhibited [ENTITY_B] activity in a dose-dependent manner with IC50 values of 10.9 microM ( 1), 9.8 microM ( 2), 8.6 microM ( 3), 142.0 microM ( 4) and 250 microM ( 5).",INHIBITOR,CPR:4,1,"The flavonoids inhibited DGAT activity in a dose-dependent manner with IC50 values of 10.9 microM ( 1), 9.8 microM ( 2), 8.6 microM ( 3), 142.0 microM ( 4) and 250 microM ( 5)."
These data suggest that the << lavandulyl >> side chain and the position of the hydroxy group are important for high [[ DGAT ]] inhibitory activity.,These data suggest that the [ENTITY_A] side chain and the position of the hydroxy group are important for high [ENTITY_B] inhibitory activity.,INHIBITOR,CPR:4,1,These data suggest that the lavandulyl side chain and the position of the hydroxy group are important for high DGAT inhibitory activity.
"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while << 1400W dihydrochloride >> (1400W), a selective inhibitor of iNOS, decreased the expression of [[ E-selectin ]], VEGF, and iNOS.","Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while [ENTITY_A] (1400W), a selective inhibitor of iNOS, decreased the expression of [ENTITY_B], VEGF, and iNOS.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS."
"<< DXM >> and 1400W attenuated the mRNA expression of [[ E-selectin ]] and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS.","[ENTITY_A] and 1400W attenuated the mRNA expression of [ENTITY_B] and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS.",INDIRECT-DOWNREGULATOR,CPR:4,1,"DXM and 1400W attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS."
"The beneficial role of << 17beta-estradiol >> on blood pressure, cardiac hypertrophy, vascular [[ osteopontin ]] expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate.","The beneficial role of [ENTITY_A] on blood pressure, cardiac hypertrophy, vascular [ENTITY_B] expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate.",INDIRECT-UPREGULATOR,CPR:3,0,"The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular osteopontin expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate."
"The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular << osteopontin >> expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of [[ medroxyprogesterone acetate ]].","The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular [ENTITY_A] expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular osteopontin expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate."
"At a low pH (pH 7.4), but not pH 7.9, << ifenprodil >> reduces the mean open time of [[ GluN1 ]]/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.","At a low pH (pH 7.4), but not pH 7.9, [ENTITY_A] reduces the mean open time of [ENTITY_B]/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.",DOWNREGULATOR,CPR:4,1,"At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic."
Pharmacological doses of the << mTOR >> inhibitor [[ rapamycin ]] reduce albuminura in diabetes.,Pharmacological doses of the [ENTITY_A] inhibitor [ENTITY_B] reduce albuminura in diabetes.,INHIBITOR,CPR:4,1,Pharmacological doses of the mTOR inhibitor rapamycin reduce albuminura in diabetes.
"High << glucose >> (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates [[ mTOR ]].","High [ENTITY_A] (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates [ENTITY_B].",ACTIVATOR,CPR:3,0,"High glucose (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates mTOR."
"High << glucose >> (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates [[ tuberin ]] and activates mTOR.","High [ENTITY_A] (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates [ENTITY_B] and activates mTOR.",DOWNREGULATOR,CPR:4,1,"High glucose (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates mTOR."
"Inhibition of mTOR by low dose << rapamycin >> decreases HG-induced [[ Nox4 ]] and Nox1, NADPH oxidase activity and podocyte apoptosis.","Inhibition of mTOR by low dose [ENTITY_A] decreases HG-induced [ENTITY_B] and Nox1, NADPH oxidase activity and podocyte apoptosis.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Inhibition of mTOR by low dose rapamycin decreases HG-induced Nox4 and Nox1, NADPH oxidase activity and podocyte apoptosis."
"Inhibition of << mTOR >> by small dose of [[ rapamycin ]] reduces podocyte apoptosis, attenuates glomerular injury and albuminuria.","Inhibition of [ENTITY_A] by small dose of [ENTITY_B] reduces podocyte apoptosis, attenuates glomerular injury and albuminuria.",INHIBITOR,CPR:4,1,"Inhibition of mTOR by small dose of rapamycin reduces podocyte apoptosis, attenuates glomerular injury and albuminuria."
"Systemic administration of << beta2-adrenoceptor >> agonists, [[ formoterol ]] and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.","Systemic administration of [ENTITY_A] agonists, [ENTITY_B] and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.",AGONIST,CPR:5,2,"Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses."
"Two beta(2)-agonists, << formoterol >> and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater [[ beta(2)-adrenoceptor ]] selectivity.","Two beta(2)-agonists, [ENTITY_A] and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater [ENTITY_B] selectivity.",AGONIST,CPR:5,2,"Two beta(2)-agonists, formoterol and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater beta(2)-adrenoceptor selectivity."
"A dose of 25 microg kg(-1) day(-1) of << formoterol >> elicited greater EDL and soleus hypertrophy than salmeterol, but resulted in similar [[ beta-adrenoceptor ]] downregulation.","A dose of 25 microg kg(-1) day(-1) of [ENTITY_A] elicited greater EDL and soleus hypertrophy than salmeterol, but resulted in similar [ENTITY_B] downregulation.",DOWNREGULATOR,CPR:4,1,"A dose of 25 microg kg(-1) day(-1) of formoterol elicited greater EDL and soleus hypertrophy than salmeterol, but resulted in similar beta-adrenoceptor downregulation."
"Clinical utility of << acarbose >>, an [[ alpha-glucosidase ]] inhibitor in cardiometabolic disorders.","Clinical utility of [ENTITY_A], an [ENTITY_B] inhibitor in cardiometabolic disorders.",INHIBITOR,CPR:4,1,"Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders."
"<< Acarbose >>, an [[ alpha-glucosidase ]] inhibitor, delays the absorption of carbohydrate from the small intestine, thereby reducing postprandial hyperglycemia.","[ENTITY_A], an [ENTITY_B] inhibitor, delays the absorption of carbohydrate from the small intestine, thereby reducing postprandial hyperglycemia.",INHIBITOR,CPR:4,1,"Acarbose, an alpha-glucosidase inhibitor, delays the absorption of carbohydrate from the small intestine, thereby reducing postprandial hyperglycemia."
The values of mean corpuscular hemoglobin concentration and mean corpuscular << hemoglobin >> increased in the [[ STX ]] group.,The values of mean corpuscular hemoglobin concentration and mean corpuscular [ENTITY_A] increased in the [ENTITY_B] group.,INDIRECT-UPREGULATOR,CPR:3,0,The values of mean corpuscular hemoglobin concentration and mean corpuscular hemoglobin increased in the STX group.
"First, we showed that intracerebroventricular administration of << glucose >> in rats increases [[ DBI ]] expression in hypothalamic glial-like tanycytes.","First, we showed that intracerebroventricular administration of [ENTITY_A] in rats increases [ENTITY_B] expression in hypothalamic glial-like tanycytes.",INDIRECT-UPREGULATOR,CPR:3,0,"First, we showed that intracerebroventricular administration of glucose in rats increases DBI expression in hypothalamic glial-like tanycytes."
"On phosphorylation of << Ser40 >> by [[ protein kinase A ]], the affinity for H4biopterin increased ([S]0.5 = 11 +/- 2 microM) and the negative cooperativity was amplified (h = 0.27 +/- 0.03).","On phosphorylation of [ENTITY_A] by [ENTITY_B], the affinity for H4biopterin increased ([S]0.5 = 11 +/- 2 microM) and the negative cooperativity was amplified (h = 0.27 +/- 0.03).",SUBSTRATE,CPR:9,4,"On phosphorylation of Ser40 by protein kinase A, the affinity for H4biopterin increased ([S]0.5 = 11 +/- 2 microM) and the negative cooperativity was amplified (h = 0.27 +/- 0.03)."
"Disposition of a specific << cyclooxygenase-2 >> inhibitor, [[ valdecoxib ]], in human.","Disposition of a specific [ENTITY_A] inhibitor, [ENTITY_B], in human.",INHIBITOR,CPR:4,1,"Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human."
"<< Valdecoxib >> is a potent and specific inhibitor of [[ cyclooxygenase-2 ]], which is used for the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain.","[ENTITY_A] is a potent and specific inhibitor of [ENTITY_B], which is used for the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain.",INHIBITOR,CPR:4,1,"Valdecoxib is a potent and specific inhibitor of cyclooxygenase-2, which is used for the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain."
"In mechanistic studies, << Silibinin >> decreased the protein level of [[ p34cdc2 ]], which might be the possible molecular mechanism of Silibinin efficacy on the growth inhibition in SGC-7901 cells.","In mechanistic studies, [ENTITY_A] decreased the protein level of [ENTITY_B], which might be the possible molecular mechanism of Silibinin efficacy on the growth inhibition in SGC-7901 cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In mechanistic studies, Silibinin decreased the protein level of p34cdc2, which might be the possible molecular mechanism of Silibinin efficacy on the growth inhibition in SGC-7901 cells."
"In addition, << Silibinin >> caused an increase in [[ p53 ]] and p21 protein level as well as mRNA levels.","In addition, [ENTITY_A] caused an increase in [ENTITY_B] and p21 protein level as well as mRNA levels.",INDIRECT-UPREGULATOR,CPR:3,0,"In addition, Silibinin caused an increase in p53 and p21 protein level as well as mRNA levels."
"4-Hydroxynonenal (<< 4-HNE >>) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several [[ glutathione S-transferase ]] (GST) isoforms.","4-Hydroxynonenal ([ENTITY_A]) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several [ENTITY_B] (GST) isoforms.",SUBSTRATE,CPR:9,4,"4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (GST) isoforms."
The alpha class << human GSTA4-4 >> enzyme (hGSTA4-4) has a particularly high catalytic efficiency toward [[ 4-HNE ]] conjugation.,The alpha class [ENTITY_A] enzyme (hGSTA4-4) has a particularly high catalytic efficiency toward [ENTITY_B] conjugation.,SUBSTRATE,CPR:9,4,The alpha class human GSTA4-4 enzyme (hGSTA4-4) has a particularly high catalytic efficiency toward 4-HNE conjugation.
"HepG2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high << GST-4 >>[[ 4-HNE ]] catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells.","HepG2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high [ENTITY_A][ENTITY_B] catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells.",SUBSTRATE,CPR:9,4,"HepG2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high GST-44-HNE catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells."
"Specifically, << hGSTA4 >> cells had significantly higher GSH concentrations when exposed to 5-15 microM [[ 4-HNE ]], but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of 4-HNE.","Specifically, [ENTITY_A] cells had significantly higher GSH concentrations when exposed to 5-15 microM [ENTITY_B], but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of 4-HNE.",SUBSTRATE,CPR:9,4,"Specifically, hGSTA4 cells had significantly higher GSH concentrations when exposed to 5-15 microM 4-HNE, but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of 4-HNE."
"In summary, our data indicates that over-expression of hGSTA4 at levels conferring high << GST >>-[[ 4-HNE ]] conjugating activity confers a partial growth advantage to HepG2 cells and protects against 4-HNE oxidative injury.","In summary, our data indicates that over-expression of hGSTA4 at levels conferring high [ENTITY_A]-[ENTITY_B] conjugating activity confers a partial growth advantage to HepG2 cells and protects against 4-HNE oxidative injury.",SUBSTRATE,CPR:9,4,"In summary, our data indicates that over-expression of hGSTA4 at levels conferring high GST-4-HNE conjugating activity confers a partial growth advantage to HepG2 cells and protects against 4-HNE oxidative injury."
"However, the loss of proliferative capacity of << hGSTA4 >> cells challenged with levels of [[ 4-HNE ]] associated with severe oxidative stress indicates a role of other aldehyde metabolizing enzymes, and/or GSH-electrophile transporter proteins, in providing full cellular protection against 4-HNE toxicity.","However, the loss of proliferative capacity of [ENTITY_A] cells challenged with levels of [ENTITY_B] associated with severe oxidative stress indicates a role of other aldehyde metabolizing enzymes, and/or GSH-electrophile transporter proteins, in providing full cellular protection against 4-HNE toxicity.",SUBSTRATE,CPR:9,4,"However, the loss of proliferative capacity of hGSTA4 cells challenged with levels of 4-HNE associated with severe oxidative stress indicates a role of other aldehyde metabolizing enzymes, and/or GSH-electrophile transporter proteins, in providing full cellular protection against 4-HNE toxicity."
"OBJECTIVE: Preclinical evaluation of << DRF 2655 >>, a peroxisome proliferator-activated receptor alpha (PPARalpha) and [[ PPARgamma ]] agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.","OBJECTIVE: Preclinical evaluation of [ENTITY_A], a peroxisome proliferator-activated receptor alpha (PPARalpha) and [ENTITY_B] agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.",AGONIST,CPR:5,2,"OBJECTIVE: Preclinical evaluation of DRF 2655, a peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent."
RESULTS: << DRF 2655 >> showed concentration-dependent transactivation of [[ PPARalpha ]] and PPARgamma.,RESULTS: [ENTITY_A] showed concentration-dependent transactivation of [ENTITY_B] and PPARgamma.,AGONIST-ACTIVATOR,CPR:5,2,RESULTS: DRF 2655 showed concentration-dependent transactivation of PPARalpha and PPARgamma.
"db/db mice treated with << DRF 2655 >> showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes [[ carnitine palmitoyltransferase ]] and carnitine acetyltransferase, respectively.","db/db mice treated with [ENTITY_A] showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes [ENTITY_B] and carnitine acetyltransferase, respectively.",UPREGULATOR,CPR:3,0,"db/db mice treated with DRF 2655 showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively."
"db/db mice treated with << DRF 2655 >> showed 5- and 3.6-fold inhibition in [[ phosphoenolpyruvate carboxykinase ]] and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively.","db/db mice treated with [ENTITY_A] showed 5- and 3.6-fold inhibition in [ENTITY_B] and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively.",INHIBITOR,CPR:4,1,"db/db mice treated with DRF 2655 showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively."
"The enzyme << cyclo-oxygenase >> catalyses the oxygenation of arachidonic acid, leading to the formation of [[ prostaglandins ]].","The enzyme [ENTITY_A] catalyses the oxygenation of arachidonic acid, leading to the formation of [ENTITY_B].",PRODUCT-OF,CPR:9,4,"The enzyme cyclo-oxygenase catalyses the oxygenation of arachidonic acid, leading to the formation of prostaglandins."
"<< hCOX-1 >> had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for [[ arachidonate ]] and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme.","[ENTITY_A] had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for [ENTITY_B] and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme.",SUBSTRATE,CPR:9,4,"hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme."
"<< Indomethacin >> inhibited both [[ hCOX-1 ]] and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2.","[ENTITY_A] inhibited both [ENTITY_B] and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2.",INHIBITOR,CPR:4,1,"Indomethacin inhibited both hCOX-1 and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2."
"Both << NS-398 >> and Dup-697 exhibited time-dependent inactivation of [[ hCOX-2 ]], as did indomethacin on both enzymes.","Both [ENTITY_A] and Dup-697 exhibited time-dependent inactivation of [ENTITY_B], as did indomethacin on both enzymes.",INHIBITOR,CPR:4,1,"Both NS-398 and Dup-697 exhibited time-dependent inactivation of hCOX-2, as did indomethacin on both enzymes."
"The competitive inhibitor of << hCOX-1 >>, [[ mefenamic acid ]], also displayed competitive inhibition of hCOX-2.","The competitive inhibitor of [ENTITY_A], [ENTITY_B], also displayed competitive inhibition of hCOX-2.",INHIBITOR,CPR:4,1,"The competitive inhibitor of hCOX-1, mefenamic acid, also displayed competitive inhibition of hCOX-2."
<< Doxycycline >> was shown to decrease cerebral [[ MMP-9 ]] activities and angiogenesis induced by vascular endothelial growth factor (VEGF).,[ENTITY_A] was shown to decrease cerebral [ENTITY_B] activities and angiogenesis induced by vascular endothelial growth factor (VEGF).,INHIBITOR,CPR:4,1,Doxycycline was shown to decrease cerebral MMP-9 activities and angiogenesis induced by vascular endothelial growth factor (VEGF).
Our results have shown that << MMP-9 >> messenger ribonucleic acid (mRNA) expression was inhibited by [[ doxycycline ]] starting at 10 mg/kg/day (P<0.02).,Our results have shown that [ENTITY_A] messenger ribonucleic acid (mRNA) expression was inhibited by [ENTITY_B] starting at 10 mg/kg/day (P<0.02).,INDIRECT-DOWNREGULATOR,CPR:4,1,Our results have shown that MMP-9 messenger ribonucleic acid (mRNA) expression was inhibited by doxycycline starting at 10 mg/kg/day (P<0.02).
"<< Minocycline >> showed more potent inhibition on [[ MMP-9 ]] mRNA expression, starting at 1 (P<0.005) and further at more than 30 (P<0.001) mg/kg/day.","[ENTITY_A] showed more potent inhibition on [ENTITY_B] mRNA expression, starting at 1 (P<0.005) and further at more than 30 (P<0.001) mg/kg/day.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Minocycline showed more potent inhibition on MMP-9 mRNA expression, starting at 1 (P<0.005) and further at more than 30 (P<0.001) mg/kg/day."
"At the enzymatic activity level, << doxycycline >> started to suppress [[ MMP-9 ]] activity at 5 mg/kg/day (P<0.001), while minocycline had an effect at a lower dose, 1 mg/kg/day (P<0.02).","At the enzymatic activity level, [ENTITY_A] started to suppress [ENTITY_B] activity at 5 mg/kg/day (P<0.001), while minocycline had an effect at a lower dose, 1 mg/kg/day (P<0.02).",INHIBITOR,CPR:4,1,"At the enzymatic activity level, doxycycline started to suppress MMP-9 activity at 5 mg/kg/day (P<0.001), while minocycline had an effect at a lower dose, 1 mg/kg/day (P<0.02)."
We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the << MMP-9 >> inhibition by [[ tetracyclines ]].,We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the [ENTITY_A] inhibition by [ENTITY_B].,INHIBITOR,CPR:4,1,We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the MMP-9 inhibition by tetracyclines.
"In vitro, << minocycline >>, but not doxycycline, inhibits [[ MMP-9 ]], at least in part, via the extracellular signaling-related kinase 1/2 (ERK1/2)-mediated pathway.","In vitro, [ENTITY_A], but not doxycycline, inhibits [ENTITY_B], at least in part, via the extracellular signaling-related kinase 1/2 (ERK1/2)-mediated pathway.",INHIBITOR,CPR:4,1,"In vitro, minocycline, but not doxycycline, inhibits MMP-9, at least in part, via the extracellular signaling-related kinase 1/2 (ERK1/2)-mediated pathway."
"This study provided the evidence that the << tetracyclines >> inhibit stimulated cerebral [[ MMP-9 ]] at multiple levels and are effective at very low doses, offering great potential for therapeutic use.","This study provided the evidence that the [ENTITY_A] inhibit stimulated cerebral [ENTITY_B] at multiple levels and are effective at very low doses, offering great potential for therapeutic use.",INHIBITOR,CPR:4,1,"This study provided the evidence that the tetracyclines inhibit stimulated cerebral MMP-9 at multiple levels and are effective at very low doses, offering great potential for therapeutic use."
"One major route involves the tetrahydrofolate (THF)-dependent activities of the << glycine decarboxylase complex >> (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with [[ glycine ]] (Gly) as one-carbon (1-C) source.","One major route involves the tetrahydrofolate (THF)-dependent activities of the [ENTITY_A] (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with [ENTITY_B] (Gly) as one-carbon (1-C) source.",SUBSTRATE,CPR:9,4,"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source."
An alternative THF-dependent pathway involves the << C1-THF synthase >>/SHMT activities with [[ formate ]] as 1-C source.,An alternative THF-dependent pathway involves the [ENTITY_A]/SHMT activities with [ENTITY_B] as 1-C source.,SUBSTRATE,CPR:9,4,An alternative THF-dependent pathway involves the C1-THF synthase/SHMT activities with formate as 1-C source.
"Firstly, transgenic plants overexpressing << formate dehydrogenase >> (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in [[ formate ]] metabolism.","Firstly, transgenic plants overexpressing [ENTITY_A] (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in [ENTITY_B] metabolism.",SUBSTRATE,CPR:9,4,"Firstly, transgenic plants overexpressing formate dehydrogenase (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in formate metabolism."
We concluded that FDH has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to << CO(2) >> by the [[ FDH ]] reaction is the primary and preferred fate of the organic acid in Arabidopsis.,We concluded that FDH has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to [ENTITY_A] by the [ENTITY_B] reaction is the primary and preferred fate of the organic acid in Arabidopsis.,PRODUCT-OF,CPR:9,4,We concluded that FDH has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to CO(2) by the FDH reaction is the primary and preferred fate of the organic acid in Arabidopsis.
"The ratio between the GDC/<< SHMT >> and C1-THF synthase/SHMT pathways of [[ Ser ]] synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1.","The ratio between the GDC/[ENTITY_A] and C1-THF synthase/SHMT pathways of [ENTITY_B] synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1.",PRODUCT-OF,CPR:9,4,"The ratio between the GDC/SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1."
"On the other hand, the accumulation of << Ser >> through the C1-THF synthase/[[ SHMT ]] pathway in glyD plants was 2.5-fold greater than that in WT plants.","On the other hand, the accumulation of [ENTITY_A] through the C1-THF synthase/[ENTITY_B] pathway in glyD plants was 2.5-fold greater than that in WT plants.",PRODUCT-OF,CPR:9,4,"On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants."
BACKGROUND: << Rivastigmine >> is a carbamate drug designed to inhibit both [[ acetylcholinesterase ]] and butyrylcholinesterase by reversibly covalently bonding to these enzymes.,BACKGROUND: [ENTITY_A] is a carbamate drug designed to inhibit both [ENTITY_B] and butyrylcholinesterase by reversibly covalently bonding to these enzymes.,INHIBITOR,CPR:4,1,BACKGROUND: Rivastigmine is a carbamate drug designed to inhibit both acetylcholinesterase and butyrylcholinesterase by reversibly covalently bonding to these enzymes.
<< Topotecan >> is a [[ topoisomerase I ]] inhibitor which is currently evaluated as an adjuvant agent for malignant glioma.,[ENTITY_A] is a [ENTITY_B] inhibitor which is currently evaluated as an adjuvant agent for malignant glioma.,INHIBITOR,CPR:4,1,Topotecan is a topoisomerase I inhibitor which is currently evaluated as an adjuvant agent for malignant glioma.
"High << p53 >> protein levels, but not genetic or functional p53 status, were associated with increased [[ topotecan ]]-induced DNA/topoisomerase I complex formation.","High [ENTITY_A] protein levels, but not genetic or functional p53 status, were associated with increased [ENTITY_B]-induced DNA/topoisomerase I complex formation.",INDIRECT-UPREGULATOR,CPR:3,0,"High p53 protein levels, but not genetic or functional p53 status, were associated with increased topotecan-induced DNA/topoisomerase I complex formation."
<< Amiloride >> is a specific inhibitor of [[ uPA ]] but does not inhibit tPA.,[ENTITY_A] is a specific inhibitor of [ENTITY_B] but does not inhibit tPA.,INHIBITOR,CPR:4,1,Amiloride is a specific inhibitor of uPA but does not inhibit tPA.
"The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the << endothelin ET(B) receptor >> antagonist [[ RES 701-1 ]], by indomethacin, or by glibenclamide.","The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the [ENTITY_A] antagonist [ENTITY_B], by indomethacin, or by glibenclamide.",ANTAGONIST,CPR:6,3,"The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the endothelin ET(B) receptor antagonist RES 701-1, by indomethacin, or by glibenclamide."
"The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the << thromboxane A2 receptor >> antagonists [[ GR32191 ]] and ridogrel.","The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the [ENTITY_A] antagonists [ENTITY_B] and ridogrel.",ANTAGONIST,CPR:6,3,"The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the thromboxane A2 receptor antagonists GR32191 and ridogrel."
A novel class of << quinoxalines >> has been discovered as antagonists of the [[ IgG ]]:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.,A novel class of [ENTITY_A] has been discovered as antagonists of the [ENTITY_B]:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.,ANTAGONIST,CPR:6,3,A novel class of quinoxalines has been discovered as antagonists of the IgG:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.
"<< Agmatine >>, locally synthesized, is an endogenous agonist at [[ imidazoline receptors ]], a noncatecholamine ligand at alpha 2-adrenergic receptors and may act as a neurotransmitter.","[ENTITY_A], locally synthesized, is an endogenous agonist at [ENTITY_B], a noncatecholamine ligand at alpha 2-adrenergic receptors and may act as a neurotransmitter.",AGONIST,CPR:5,2,"Agmatine, locally synthesized, is an endogenous agonist at imidazoline receptors, a noncatecholamine ligand at alpha 2-adrenergic receptors and may act as a neurotransmitter."
"(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (<< GSK2251052 >>) is a novel boron-containing antibiotic that inhibits [[ bacterial leucyl tRNA synthetase ]], and that has been in development for the treatment of serious Gram-negative infections.","(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole ([ENTITY_A]) is a novel boron-containing antibiotic that inhibits [ENTITY_B], and that has been in development for the treatment of serious Gram-negative infections.",INHIBITOR,CPR:4,1,"(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (GSK2251052) is a novel boron-containing antibiotic that inhibits bacterial leucyl tRNA synthetase, and that has been in development for the treatment of serious Gram-negative infections."
"A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor << 4-methylpyrazole >> provided strong evidence that [[ alcohol dehydrogenase ]], potentially in association with aldehyde dehydrogenase, is the primary enzyme involved in the formation of the M3 metabolite.","A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor [ENTITY_A] provided strong evidence that [ENTITY_B], potentially in association with aldehyde dehydrogenase, is the primary enzyme involved in the formation of the M3 metabolite.",INHIBITOR,CPR:4,1,"A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor 4-methylpyrazole provided strong evidence that alcohol dehydrogenase, potentially in association with aldehyde dehydrogenase, is the primary enzyme involved in the formation of the M3 metabolite."
"In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of << serotonin >>, possibly by facilitating the interaction of serotonin with transport-ready conformations of [[ SERT ]] when concentrations of serotonin were low and rate limiting.","In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of [ENTITY_A], possibly by facilitating the interaction of serotonin with transport-ready conformations of [ENTITY_B] when concentrations of serotonin were low and rate limiting.",SUBSTRATE,CPR:9,4,"In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of serotonin, possibly by facilitating the interaction of serotonin with transport-ready conformations of SERT when concentrations of serotonin were low and rate limiting."
"They display sensitivity to << TK >> inhibitors, including [[ gefitinib ]] and erlotinib.","They display sensitivity to [ENTITY_A] inhibitors, including [ENTITY_B] and erlotinib.",INHIBITOR,CPR:4,1,"They display sensitivity to TK inhibitors, including gefitinib and erlotinib."
"Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme (<< NifS >>) that is involved in the activation of sulphur from [[ l-cysteine ]], and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed.","Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme ([ENTITY_A]) that is involved in the activation of sulphur from [ENTITY_B], and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed.",SUBSTRATE,CPR:9,4,"Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme (NifS) that is involved in the activation of sulphur from l-cysteine, and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed."
"In addition, the number and area of << glutathione S-transferase placental form >> (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg [[ MEG ]] compared with the control animals.","In addition, the number and area of [ENTITY_A] (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg [ENTITY_B] compared with the control animals.",INDIRECT-UPREGULATOR,CPR:3,0,"In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg MEG compared with the control animals."
"Consumption of << alcohol >> for 8weeks induced severe liver damage with increases in prognostic indicators such as [[ aspartate transaminase ]], alanine transaminase in serum whereas co-administration of CNF suppressed their increases.","Consumption of [ENTITY_A] for 8weeks induced severe liver damage with increases in prognostic indicators such as [ENTITY_B], alanine transaminase in serum whereas co-administration of CNF suppressed their increases.",INDIRECT-UPREGULATOR,CPR:3,0,"Consumption of alcohol for 8weeks induced severe liver damage with increases in prognostic indicators such as aspartate transaminase, alanine transaminase in serum whereas co-administration of CNF suppressed their increases."
"Chronic consumption of << alcohol >> also stimulated abrupt increases in pro-inflammatory cytokines such as [[ nuclear factor (NF)-κB ]], tumor necrosis factor (TNF)-α and interleukin (IL)-1β in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently.","Chronic consumption of [ENTITY_A] also stimulated abrupt increases in pro-inflammatory cytokines such as [ENTITY_B], tumor necrosis factor (TNF)-α and interleukin (IL)-1β in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently.",ACTIVATOR,CPR:3,0,"Chronic consumption of alcohol also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-κB, tumor necrosis factor (TNF)-α and interleukin (IL)-1β in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently."
Dietary << EPA >>/DHA treatment restored endogenous biosynthesis of n-3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving [[ insulin ]] sensitivity.,Dietary [ENTITY_A]/DHA treatment restored endogenous biosynthesis of n-3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving [ENTITY_B] sensitivity.,INDIRECT-UPREGULATOR,CPR:3,0,Dietary EPA/DHA treatment restored endogenous biosynthesis of n-3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving insulin sensitivity.
"Notably, << 17-HDHA >> treatment reduced adipose tissue expression of inflammatory cytokines, increased [[ adiponectin ]] expression and improved glucose tolerance parallel to insulin sensitivity in obese mice.","Notably, [ENTITY_A] treatment reduced adipose tissue expression of inflammatory cytokines, increased [ENTITY_B] expression and improved glucose tolerance parallel to insulin sensitivity in obese mice.",INDIRECT-UPREGULATOR,CPR:3,0,"Notably, 17-HDHA treatment reduced adipose tissue expression of inflammatory cytokines, increased adiponectin expression and improved glucose tolerance parallel to insulin sensitivity in obese mice."
"Notably, << 17-HDHA >> treatment reduced adipose tissue expression of inflammatory [[ cytokines ]], increased adiponectin expression and improved glucose tolerance parallel to insulin sensitivity in obese mice.","Notably, [ENTITY_A] treatment reduced adipose tissue expression of inflammatory [ENTITY_B], increased adiponectin expression and improved glucose tolerance parallel to insulin sensitivity in obese mice.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Notably, 17-HDHA treatment reduced adipose tissue expression of inflammatory cytokines, increased adiponectin expression and improved glucose tolerance parallel to insulin sensitivity in obese mice."
"Furthermore, we validated the inhibition of << GSK-3β >>/NF-κB signaling following [[ cinobufagin ]] treatment.","Furthermore, we validated the inhibition of [ENTITY_A]/NF-κB signaling following [ENTITY_B] treatment.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, we validated the inhibition of GSK-3β/NF-κB signaling following cinobufagin treatment."
"Western blots showed a decrease in nuclear p65 protein expression after exposure to different concentrations of << cinobufagin >>, while the phosphorylation of [[ GSK-3β ]] was simultaneously increased.","Western blots showed a decrease in nuclear p65 protein expression after exposure to different concentrations of [ENTITY_A], while the phosphorylation of [ENTITY_B] was simultaneously increased.",ACTIVATOR,CPR:3,0,"Western blots showed a decrease in nuclear p65 protein expression after exposure to different concentrations of cinobufagin, while the phosphorylation of GSK-3β was simultaneously increased."
"Western blots showed a decrease in nuclear << p65 >> protein expression after exposure to different concentrations of [[ cinobufagin ]], while the phosphorylation of GSK-3β was simultaneously increased.","Western blots showed a decrease in nuclear [ENTITY_A] protein expression after exposure to different concentrations of [ENTITY_B], while the phosphorylation of GSK-3β was simultaneously increased.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Western blots showed a decrease in nuclear p65 protein expression after exposure to different concentrations of cinobufagin, while the phosphorylation of GSK-3β was simultaneously increased."
Transduction with constitutively active forms of GSK-3β could protect against the downregulation of p65 and upregulation of cleaved-<< PARP >> that are induced by [[ cinobufagin ]] treatment.,Transduction with constitutively active forms of GSK-3β could protect against the downregulation of p65 and upregulation of cleaved-[ENTITY_A] that are induced by [ENTITY_B] treatment.,INDIRECT-UPREGULATOR,CPR:3,0,Transduction with constitutively active forms of GSK-3β could protect against the downregulation of p65 and upregulation of cleaved-PARP that are induced by cinobufagin treatment.
Transduction with constitutively active forms of GSK-3β could protect against the downregulation of << p65 >> and upregulation of cleaved-PARP that are induced by [[ cinobufagin ]] treatment.,Transduction with constitutively active forms of GSK-3β could protect against the downregulation of [ENTITY_A] and upregulation of cleaved-PARP that are induced by [ENTITY_B] treatment.,INDIRECT-DOWNREGULATOR,CPR:4,1,Transduction with constitutively active forms of GSK-3β could protect against the downregulation of p65 and upregulation of cleaved-PARP that are induced by cinobufagin treatment.
"However, combined treatment with << cinobufagin >> and SB216367 resulted in a significant reduction in p65 and an increase in cleaved-[[ PARP ]] in U2OS cells.","However, combined treatment with [ENTITY_A] and SB216367 resulted in a significant reduction in p65 and an increase in cleaved-[ENTITY_B] in U2OS cells.",INDIRECT-UPREGULATOR,CPR:3,0,"However, combined treatment with cinobufagin and SB216367 resulted in a significant reduction in p65 and an increase in cleaved-PARP in U2OS cells."
"However, combined treatment with << cinobufagin >> and SB216367 resulted in a significant reduction in [[ p65 ]] and an increase in cleaved-PARP in U2OS cells.","However, combined treatment with [ENTITY_A] and SB216367 resulted in a significant reduction in [ENTITY_B] and an increase in cleaved-PARP in U2OS cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"However, combined treatment with cinobufagin and SB216367 resulted in a significant reduction in p65 and an increase in cleaved-PARP in U2OS cells."
<< [6]-gingerol >>: a novel [[ AT₁ ]] antagonist for the treatment of cardiovascular disease.,[ENTITY_A]: a novel [ENTITY_B] antagonist for the treatment of cardiovascular disease.,ANTAGONIST,CPR:6,3,[6]-gingerol: a novel AT₁ antagonist for the treatment of cardiovascular disease.
"<< [6]-Gingerol >> derived from Zingiber officinale Roscoe (ginger) was identified as a novel [[ angiotensin II type 1 receptor ]] antagonist, with an IC50 value of 8.173 µM.","[ENTITY_A] derived from Zingiber officinale Roscoe (ginger) was identified as a novel [ENTITY_B] antagonist, with an IC50 value of 8.173 µM.",ANTAGONIST,CPR:6,3,"[6]-Gingerol derived from Zingiber officinale Roscoe (ginger) was identified as a novel angiotensin II type 1 receptor antagonist, with an IC50 value of 8.173 µM."
"The major ingredient of ginger, << [6]-gingerol >>, could inhibit [[ angiotensin II type 1 receptor ]] activation, which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system.","The major ingredient of ginger, [ENTITY_A], could inhibit [ENTITY_B] activation, which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system.",INHIBITOR,CPR:4,1,"The major ingredient of ginger, [6]-gingerol, could inhibit angiotensin II type 1 receptor activation, which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system."
"In patients who do not reach the LDL-C target, combination therapy with additional << LDL >>-C lowering drugs (e.g. [[ ezetimibe ]], bile acid sequestrants or fibrates) should be considered.","In patients who do not reach the LDL-C target, combination therapy with additional [ENTITY_A]-C lowering drugs (e.g. [ENTITY_B], bile acid sequestrants or fibrates) should be considered.",INHIBITOR,CPR:4,1,"In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered."
"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: << N(5)-methyl >>- and N(5)-hydroxymethyl H(4)biopterin inhibited [[ phenylalanine hydroxylase ]], whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.","N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: [ENTITY_A]- and N(5)-hydroxymethyl H(4)biopterin inhibited [ENTITY_B], whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.",INHIBITOR,CPR:4,1,"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect."
"<< N(5)-Substituted H(4)biopterin >> derivatives were not oxidized to products serving as substrates for [[ dihydropteridine reductase ]] and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.","[ENTITY_A] derivatives were not oxidized to products serving as substrates for [ENTITY_B] and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.",SUBSTRATE,CPR:9,4,"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect."
Our data demonstrate differences in the mechanism of stimulation of << phenylalanine hydroxylase >> and nitric oxide synthase by [[ H(4)biopterin ]].,Our data demonstrate differences in the mechanism of stimulation of [ENTITY_A] and nitric oxide synthase by [ENTITY_B].,INHIBITOR,CPR:4,1,Our data demonstrate differences in the mechanism of stimulation of phenylalanine hydroxylase and nitric oxide synthase by H(4)biopterin.
"Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the << VMAT >> inhibitor [[ reserpine ]] and a proton ionophore, but not by tetrabenazine, which has a high affinity for VMAT-2.","Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the [ENTITY_A] inhibitor [ENTITY_B] and a proton ionophore, but not by tetrabenazine, which has a high affinity for VMAT-2.",INHIBITOR,CPR:4,1,"Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the VMAT inhibitor reserpine and a proton ionophore, but not by tetrabenazine, which has a high affinity for VMAT-2."
<< Mitochondrial arginase II >> modulates [[ nitric-oxide ]] synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells.,[ENTITY_A] modulates [ENTITY_B] synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells.,PRODUCT-OF,CPR:9,4,Mitochondrial arginase II modulates nitric-oxide synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells.
"Reduced synthesis of << nitric oxide >> (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of [[ constitutive nitric-oxide synthase ]] (NOS) and cytosolic arginase I and mitochondrial arginase II.","Reduced synthesis of [ENTITY_A] (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of [ENTITY_B] (NOS) and cytosolic arginase I and mitochondrial arginase II.",PRODUCT-OF,CPR:9,4,"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and mitochondrial arginase II."
"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive << arginase >> inhibitor [[ N(omega)-hydroxy-nor-L-arginine ]] (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive [ENTITY_A] inhibitor [ENTITY_B] (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).",INHIBITOR,CPR:4,1,"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)."
"To determine whether << arginases >> modulate the endothelial [[ NO ]] synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","To determine whether [ENTITY_A] modulate the endothelial [ENTITY_B] synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).",PRODUCT-OF,CPR:9,4,"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)."
"In unstimulated cells, << Nor-NOHA >> dose-dependently reduced the [[ arginase ]] activity with maximal inhibition at 20 microM.","In unstimulated cells, [ENTITY_A] dose-dependently reduced the [ENTITY_B] activity with maximal inhibition at 20 microM.",INHIBITOR,CPR:4,1,"In unstimulated cells, Nor-NOHA dose-dependently reduced the arginase activity with maximal inhibition at 20 microM."
"When HUVECs were stimulated by thrombin without extracellular L-arginine, << Nor-NOHA >> dose-dependently increased the [[ NOS ]] activity and the NO release with maximal effects at 20 microM.","When HUVECs were stimulated by thrombin without extracellular L-arginine, [ENTITY_A] dose-dependently increased the [ENTITY_B] activity and the NO release with maximal effects at 20 microM.",ACTIVATOR,CPR:3,0,"When HUVECs were stimulated by thrombin without extracellular L-arginine, Nor-NOHA dose-dependently increased the NOS activity and the NO release with maximal effects at 20 microM."
Extracellular << L-arginine >> also dose-dependently increased NO release and [[ arginase ]] activity.,Extracellular [ENTITY_A] also dose-dependently increased NO release and [ENTITY_B] activity.,ACTIVATOR,CPR:3,0,Extracellular L-arginine also dose-dependently increased NO release and arginase activity.
"However, despite activation of L-arginine uptake, the inhibition of << arginase >> activity by [[ Nor-NOHA ]] was still significant.","However, despite activation of L-arginine uptake, the inhibition of [ENTITY_A] activity by [ENTITY_B] was still significant.",INHIBITOR,CPR:4,1,"However, despite activation of L-arginine uptake, the inhibition of arginase activity by Nor-NOHA was still significant."
These data suggest that endothelial << NO >> synthesis depends on the activity of [[ arginase II ]] in mitochondria and l-arginine carriers in cell membrane.,These data suggest that endothelial [ENTITY_A] synthesis depends on the activity of [ENTITY_B] in mitochondria and l-arginine carriers in cell membrane.,PRODUCT-OF,CPR:9,4,These data suggest that endothelial NO synthesis depends on the activity of arginase II in mitochondria and l-arginine carriers in cell membrane.
"However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and << RSD1235 >>, a novel mixed [[ ion channel ]] blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3.","However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and [ENTITY_A], a novel mixed [ENTITY_B] blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3.",INHIBITOR,CPR:4,1,"However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and RSD1235, a novel mixed ion channel blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3."
"The << Na channel >> block caused by [[ lidocaine ]] and RSD1235 can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells.","The [ENTITY_A] block caused by [ENTITY_B] and RSD1235 can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells.",INHIBITOR,CPR:4,1,"The Na channel block caused by lidocaine and RSD1235 can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells."
"Depletion of putrescine, spermidine, and spermine by << DL-alpha-difluoromethylornithine >> (DFMO), a specific inhibitor of [[ ornithine decarboxylase ]] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.","Depletion of putrescine, spermidine, and spermine by [ENTITY_A] (DFMO), a specific inhibitor of [ENTITY_B] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.",INHIBITOR,CPR:4,1,"Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index."
"Depletion of << putrescine >>, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of [[ ornithine decarboxylase ]] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.","Depletion of [ENTITY_A], spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of [ENTITY_B] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.",PRODUCT-OF,CPR:9,4,"Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index."
Addition of << putrescine >> restored the induction of apoptosis as indicated by an increase in the number of detached cells and [[ caspase 3 ]] activity.,Addition of [ENTITY_A] restored the induction of apoptosis as indicated by an increase in the number of detached cells and [ENTITY_B] activity.,UPREGULATOR,CPR:3,0,Addition of putrescine restored the induction of apoptosis as indicated by an increase in the number of detached cells and caspase 3 activity.
Inhibition of << S-adenosylmethionine decarboxylase >> by a specific inhibitor [[[ diethylglyoxal bis-(guanylhydrazone) ]]; DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC.,Inhibition of [ENTITY_A] by a specific inhibitor [[ENTITY_B]; DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC.,INHIBITOR,CPR:4,1,Inhibition of S-adenosylmethionine decarboxylase by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC.
Inhibition of << S-adenosylmethionine decarboxylase >> by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of [[ spermidine ]] and spermine with a significant accumulation of putrescine and induction of ODC.,Inhibition of [ENTITY_A] by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of [ENTITY_B] and spermine with a significant accumulation of putrescine and induction of ODC.,PRODUCT-OF,CPR:9,4,Inhibition of S-adenosylmethionine decarboxylase by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC.
"The above results indicate that polyamine depletion delays the onset of apoptosis in IEC-6 cells and confers protection against DNA damaging agents, suggesting that << polyamines >> might be involved in the [[ caspase ]] activating signal cascade.","The above results indicate that polyamine depletion delays the onset of apoptosis in IEC-6 cells and confers protection against DNA damaging agents, suggesting that [ENTITY_A] might be involved in the [ENTITY_B] activating signal cascade.",INDIRECT-UPREGULATOR,CPR:3,0,"The above results indicate that polyamine depletion delays the onset of apoptosis in IEC-6 cells and confers protection against DNA damaging agents, suggesting that polyamines might be involved in the caspase activating signal cascade."
"On the other hand, in patients with a mean serum << carvedilol >> level (Cmin) of less than 2.5 nmol/l up to 2 weeks after the start ofcarvedilol therapy, the degree of reduction in the [[ BNP ]] value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol/l.","On the other hand, in patients with a mean serum [ENTITY_A] level (Cmin) of less than 2.5 nmol/l up to 2 weeks after the start ofcarvedilol therapy, the degree of reduction in the [ENTITY_B] value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol/l.",DOWNREGULATOR,CPR:4,1,"On the other hand, in patients with a mean serum carvedilol level (Cmin) of less than 2.5 nmol/l up to 2 weeks after the start ofcarvedilol therapy, the degree of reduction in the BNP value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol/l."
Two mechanisms of action have been identified for << A77 1726 >>: inhibition of [[ dihydroorotate dehydrogenase ]] (DHODH) and inhibition of tyrosine kinases.,Two mechanisms of action have been identified for [ENTITY_A]: inhibition of [ENTITY_B] (DHODH) and inhibition of tyrosine kinases.,INHIBITOR,CPR:4,1,Two mechanisms of action have been identified for A77 1726: inhibition of dihydroorotate dehydrogenase (DHODH) and inhibition of tyrosine kinases.
<< DHODH >> inhibition occurs at lower concentrations of [[ A77 1726 ]] than that of tyrosine kinases and is currently considered the major mode of action.,[ENTITY_A] inhibition occurs at lower concentrations of [ENTITY_B] than that of tyrosine kinases and is currently considered the major mode of action.,INHIBITOR,CPR:4,1,DHODH inhibition occurs at lower concentrations of A77 1726 than that of tyrosine kinases and is currently considered the major mode of action.
<< L-proline >> accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding [[ gamma-glutamyl kinase ]].,[ENTITY_A] accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding [ENTITY_B].,PRODUCT-OF,CPR:9,4,L-proline accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding gamma-glutamyl kinase.
"Interestingly, the allele of PRO1 was shown to enhance the activities of << gamma-glutamyl kinase >> and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of [[ L-proline ]] synthesis from L-glutamate and which together may form a complex in vivo.","Interestingly, the allele of PRO1 was shown to enhance the activities of [ENTITY_A] and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of [ENTITY_B] synthesis from L-glutamate and which together may form a complex in vivo.",PRODUCT-OF,CPR:9,4,"Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from L-glutamate and which together may form a complex in vivo."
"When cultured in liquid minimal medium, yeast cells expressing the mutated << gamma-glutamyl kinase >> were found to accumulate intracellular [[ L-proline ]] and showed a prominent increase in cell viability after freezing at -20 degrees C compared to the viability of cells harboring the wild-type PRO1 gene.","When cultured in liquid minimal medium, yeast cells expressing the mutated [ENTITY_A] were found to accumulate intracellular [ENTITY_B] and showed a prominent increase in cell viability after freezing at -20 degrees C compared to the viability of cells harboring the wild-type PRO1 gene.",PRODUCT-OF,CPR:9,4,"When cultured in liquid minimal medium, yeast cells expressing the mutated gamma-glutamyl kinase were found to accumulate intracellular L-proline and showed a prominent increase in cell viability after freezing at -20 degrees C compared to the viability of cells harboring the wild-type PRO1 gene."
"These results suggest that the altered << gamma-glutamyl kinase >> results in stabilization of the complex or has an indirect effect on gamma-glutamyl phosphate reductase activity, which leads to an increase in [[ L-proline ]] production in Saccharomyces cerevisiae.","These results suggest that the altered [ENTITY_A] results in stabilization of the complex or has an indirect effect on gamma-glutamyl phosphate reductase activity, which leads to an increase in [ENTITY_B] production in Saccharomyces cerevisiae.",PRODUCT-OF,CPR:9,4,"These results suggest that the altered gamma-glutamyl kinase results in stabilization of the complex or has an indirect effect on gamma-glutamyl phosphate reductase activity, which leads to an increase in L-proline production in Saccharomyces cerevisiae."
"Structural optimization of << 2,5-thiophene amides >> as highly potent and selective [[ 17β-hydroxysteroid dehydrogenase type 2 ]] inhibitors for the treatment of osteoporosis.",Structural optimization of [ENTITY_A] as highly potent and selective [ENTITY_B] inhibitors for the treatment of osteoporosis.,INHIBITOR,CPR:4,1,"Structural optimization of 2,5-thiophene amides as highly potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis."
"We report here the optimization of << human 17β-HSD2 >> inhibitors in the [[ 2,5-thiophene amide ]] class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group.",We report here the optimization of [ENTITY_A] inhibitors in the [ENTITY_B] class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group.,INHIBITOR,CPR:4,1,"We report here the optimization of human 17β-HSD2 inhibitors in the 2,5-thiophene amide class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group."
"While none of the phenethylamides (n = 2) were active, most of the << anilides >> (n = 0) turned out to moderately or strongly inhibit [[ 17β-HSD2 ]].","While none of the phenethylamides (n = 2) were active, most of the [ENTITY_A] (n = 0) turned out to moderately or strongly inhibit [ENTITY_B].",INHIBITOR,CPR:4,1,"While none of the phenethylamides (n = 2) were active, most of the anilides (n = 0) turned out to moderately or strongly inhibit 17β-HSD2."
"Multiple exposure to << theophylline >>, a phosphodiesterase ([[ PDE ]]) inhibitor, induces acinar hypertrophy in the salivary gland.","Multiple exposure to [ENTITY_A], a phosphodiesterase ([ENTITY_B]) inhibitor, induces acinar hypertrophy in the salivary gland.",INHIBITOR,CPR:4,1,"Multiple exposure to theophylline, a phosphodiesterase (PDE) inhibitor, induces acinar hypertrophy in the salivary gland."
"<< Theophylline >> exposure resulted in a sustained increase in mRNA expression for [[ CysS ]] and PDE3A, but PDE4D gene expression was unchanged.","[ENTITY_A] exposure resulted in a sustained increase in mRNA expression for [ENTITY_B] and PDE3A, but PDE4D gene expression was unchanged.",INDIRECT-UPREGULATOR,CPR:3,0,"Theophylline exposure resulted in a sustained increase in mRNA expression for CysS and PDE3A, but PDE4D gene expression was unchanged."
Terbutaline (Bricanyl) and its prodrug << Bambuterol >> (Bambec) are highly potent [[ beta(2)-adrenoceptor ]] agonists often used in asthma patients.,Terbutaline (Bricanyl) and its prodrug [ENTITY_A] (Bambec) are highly potent [ENTITY_B] agonists often used in asthma patients.,AGONIST,CPR:5,2,Terbutaline (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent beta(2)-adrenoceptor agonists often used in asthma patients.
"<< (+/-)-tamsulosin >>, an [[ alpha 1A-adrenoceptor ]] antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart.","[ENTITY_A], an [ENTITY_B] antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart.",ANTAGONIST,CPR:6,3,"(+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart."
"The influence of << (+/-)-tamsulosin >>, a selective [[ alpha 1A-adrenoceptor ]] antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium.","The influence of [ENTITY_A], a selective [ENTITY_B] antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium.",ANTAGONIST,CPR:6,3,"The influence of (+/-)-tamsulosin, a selective alpha 1A-adrenoceptor antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium."
<< Phenylephrine >> elicited a concentration-dependent positive inotropic effect via [[ alpha 1-adrenoceptors ]] in the presence of either (+/-)-bupranolol or S(-)-timolol.,[ENTITY_A] elicited a concentration-dependent positive inotropic effect via [ENTITY_B] in the presence of either (+/-)-bupranolol or S(-)-timolol.,AGONIST-ACTIVATOR,CPR:5,2,Phenylephrine elicited a concentration-dependent positive inotropic effect via alpha 1-adrenoceptors in the presence of either (+/-)-bupranolol or S(-)-timolol.
"(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of << alpha 1B-adrenoceptors >> by treatment with [[ chlorethylclonidine ]], which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.","(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of [ENTITY_A] by treatment with [ENTITY_B], which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.",INHIBITOR,CPR:4,1,"(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine."
"(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of << phenylephrine >> even after inactivation of [[ alpha 1B-adrenoceptors ]] by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.","(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of [ENTITY_A] even after inactivation of [ENTITY_B] by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.",AGONIST,CPR:5,2,"(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine."
"<< (+/-)-Tamsulosin >> effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of [[ alpha 1B-adrenoceptors ]] by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.","[ENTITY_A] effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of [ENTITY_B] by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.",ANTAGONIST,CPR:6,3,"(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine."
"<< (+/-)-Tamsulosin >>, over the range of concentrations at which it antagonized the positive inotropic effect mediated by [[ alpha 1-adrenoceptors ]], did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine.","[ENTITY_A], over the range of concentrations at which it antagonized the positive inotropic effect mediated by [ENTITY_B], did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine.",ANTAGONIST,CPR:6,3,"(+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by alpha 1-adrenoceptors, did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine."
"These results indicate that the positive inotropic effect, mediated via (+/-)-tamsulosin- and << oxymetazoline >>-sensitive subtype of [[ alpha 1-adrenoceptors ]], is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.","These results indicate that the positive inotropic effect, mediated via (+/-)-tamsulosin- and [ENTITY_A]-sensitive subtype of [ENTITY_B], is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.",AGONIST,CPR:5,2,"These results indicate that the positive inotropic effect, mediated via (+/-)-tamsulosin- and oxymetazoline-sensitive subtype of alpha 1-adrenoceptors, is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates."
"These results indicate that the positive inotropic effect, mediated via << (+/-)-tamsulosin >>- and oxymetazoline-sensitive subtype of [[ alpha 1-adrenoceptors ]], is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.","These results indicate that the positive inotropic effect, mediated via [ENTITY_A]- and oxymetazoline-sensitive subtype of [ENTITY_B], is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.",ANTAGONIST,CPR:6,3,"These results indicate that the positive inotropic effect, mediated via (+/-)-tamsulosin- and oxymetazoline-sensitive subtype of alpha 1-adrenoceptors, is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates."
<< Pterostilbene >> exerts antitumor activity against human osteosarcoma cells by inhibiting the [[ JAK2 ]]/STAT3 signaling pathway.,[ENTITY_A] exerts antitumor activity against human osteosarcoma cells by inhibiting the [ENTITY_B]/STAT3 signaling pathway.,INHIBITOR,CPR:4,1,Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway.
"Furthermore, << PTE >> treatment directly inhibited the phosphorylation of JAK2 at Tyr 1007 and the downstream activation of [[ STAT3 ]].","Furthermore, [ENTITY_A] treatment directly inhibited the phosphorylation of JAK2 at Tyr 1007 and the downstream activation of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, PTE treatment directly inhibited the phosphorylation of JAK2 at Tyr 1007 and the downstream activation of STAT3."
"<< PTE >> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins ([[ Bax ]], Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.","[ENTITY_A] also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins ([ENTITY_B], Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.",INDIRECT-UPREGULATOR,CPR:3,0,"PTE also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27."
"<< PTE >> also down-regulated the expression of [[ STAT3 ]] target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.","[ENTITY_A] also down-regulated the expression of [ENTITY_B] target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.",INDIRECT-DOWNREGULATOR,CPR:4,1,"PTE also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27."
"PTE, used in combination with a known << JAK2 >>/STAT3 inhibitor, [[ AG490 ]], further decreased the viability of osteosarcoma cells.","PTE, used in combination with a known [ENTITY_A]/STAT3 inhibitor, [ENTITY_B], further decreased the viability of osteosarcoma cells.",INHIBITOR,CPR:4,1,"PTE, used in combination with a known JAK2/STAT3 inhibitor, AG490, further decreased the viability of osteosarcoma cells."
"Taken together, << PTE >> is a potent inhibitor of osteosarcoma cell growth that targets the [[ JAK2 ]]/STAT3 signaling pathway.","Taken together, [ENTITY_A] is a potent inhibitor of osteosarcoma cell growth that targets the [ENTITY_B]/STAT3 signaling pathway.",INHIBITOR,CPR:4,1,"Taken together, PTE is a potent inhibitor of osteosarcoma cell growth that targets the JAK2/STAT3 signaling pathway."
These data suggest that inhibition of << JAK2 >>/STAT3 signaling is a novel mechanism of action for [[ PTE ]] during therapeutic intervention in osteosarcoma cancers.,These data suggest that inhibition of [ENTITY_A]/STAT3 signaling is a novel mechanism of action for [ENTITY_B] during therapeutic intervention in osteosarcoma cancers.,INHIBITOR,CPR:4,1,These data suggest that inhibition of JAK2/STAT3 signaling is a novel mechanism of action for PTE during therapeutic intervention in osteosarcoma cancers.
"Furthermore, << sinapic acid >> reduced hepatic hydroxyproline content, which correlated with a reduction in the expression of [[ type I collagen ]] mRNA and histological analysis of collagen in liver tissue.","Furthermore, [ENTITY_A] reduced hepatic hydroxyproline content, which correlated with a reduction in the expression of [ENTITY_B] mRNA and histological analysis of collagen in liver tissue.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, sinapic acid reduced hepatic hydroxyproline content, which correlated with a reduction in the expression of type I collagen mRNA and histological analysis of collagen in liver tissue."
"Additionally, the expression of hepatic fibrosis-related factors such as << α-smooth muscle actin >> and transforming growth factor-β1 (TGF-β1), were reduced in rats treated with [[ sinapic acid ]].","Additionally, the expression of hepatic fibrosis-related factors such as [ENTITY_A] and transforming growth factor-β1 (TGF-β1), were reduced in rats treated with [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Additionally, the expression of hepatic fibrosis-related factors such as α-smooth muscle actin and transforming growth factor-β1 (TGF-β1), were reduced in rats treated with sinapic acid."
"In conclusion, we find that << sinapic acid >> exhibits hepatoprotective and antifibrotic effects against DMN-induced liver injury, most likely due to its antioxidant activities of scavenging radicals, its capacity to suppress [[ TGF-β1 ]] and its ability to attenuate activation of hepatic stellate cells.","In conclusion, we find that [ENTITY_A] exhibits hepatoprotective and antifibrotic effects against DMN-induced liver injury, most likely due to its antioxidant activities of scavenging radicals, its capacity to suppress [ENTITY_B] and its ability to attenuate activation of hepatic stellate cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In conclusion, we find that sinapic acid exhibits hepatoprotective and antifibrotic effects against DMN-induced liver injury, most likely due to its antioxidant activities of scavenging radicals, its capacity to suppress TGF-β1 and its ability to attenuate activation of hepatic stellate cells."
<< Thalidomide >> inhibits growth of tumors through [[ COX-2 ]] degradation independent of antiangiogenesis.,[ENTITY_A] inhibits growth of tumors through [ENTITY_B] degradation independent of antiangiogenesis.,INHIBITOR,CPR:4,1,Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis.
"<< Thalidomide >> reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased [[ cytochrome c ]], but had no effect on that of COX-1, in MCF-7 and HL-60.","[ENTITY_A] reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased [ENTITY_B], but had no effect on that of COX-1, in MCF-7 and HL-60.",INDIRECT-UPREGULATOR,CPR:3,0,"Thalidomide reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60."
"<< Thalidomide >> reduced [[ COX-2 ]] expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60.","[ENTITY_A] reduced [ENTITY_B] expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Thalidomide reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60."
These results demonstrated that << thalidomide >> might inhibit growth of tumors through [[ COX-2 ]] degradation independent of antiangiogenesis.,These results demonstrated that [ENTITY_A] might inhibit growth of tumors through [ENTITY_B] degradation independent of antiangiogenesis.,INHIBITOR,CPR:4,1,These results demonstrated that thalidomide might inhibit growth of tumors through COX-2 degradation independent of antiangiogenesis.
"Results: The administration of << prallethrin >> 1.6% w/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, [[ hemoglobin ]], packed cell volume, platelets, mean corpuscular volume, and mean corpuscular hemoglobin in rats after 24, 48, and 72 h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h.","Results: The administration of [ENTITY_A] 1.6% w/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, [ENTITY_B], packed cell volume, platelets, mean corpuscular volume, and mean corpuscular hemoglobin in rats after 24, 48, and 72 h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h.",INDIRECT-UPREGULATOR,CPR:3,0,"Results: The administration of prallethrin 1.6% w/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, hemoglobin, packed cell volume, platelets, mean corpuscular volume, and mean corpuscular hemoglobin in rats after 24, 48, and 72 h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h."
"Gene expression profiling (GEP) of GIST-S, GIST-R cells and two << IM >> resistant GIST patients demonstrated that [[ KIT ]] is downregulated implying a major role in IM resistance.","Gene expression profiling (GEP) of GIST-S, GIST-R cells and two [ENTITY_A] resistant GIST patients demonstrated that [ENTITY_B] is downregulated implying a major role in IM resistance.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Gene expression profiling (GEP) of GIST-S, GIST-R cells and two IM resistant GIST patients demonstrated that KIT is downregulated implying a major role in IM resistance."
"Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to << MP470 >>, a novel [[ c-Kit ]]/AXL kinase inhibitor.","Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to [ENTITY_A], a novel [ENTITY_B]/AXL kinase inhibitor.",INHIBITOR,CPR:4,1,"Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to MP470, a novel c-Kit/AXL kinase inhibitor."
"INTRODUCTION: In this study, we examined the effects of the << alpha-glucosidase >> inhibitors acarbose and [[ voglibose ]] on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus.","INTRODUCTION: In this study, we examined the effects of the [ENTITY_A] inhibitors acarbose and [ENTITY_B] on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus.",INHIBITOR,CPR:4,1,"INTRODUCTION: In this study, we examined the effects of the alpha-glucosidase inhibitors acarbose and voglibose on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus."
"Blockade of << JAK >> and ERK pathways with [[ AG490 ]] and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-α-MSH.","Blockade of [ENTITY_A] and ERK pathways with [ENTITY_B] and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-α-MSH.",INHIBITOR,CPR:4,1,"Blockade of JAK and ERK pathways with AG490 and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-α-MSH."
"The << COX >> pathway generates inflammatory [[ prostaglandins ]], while the 5-LOX pathway generates inflammatory leukotrienes.","The [ENTITY_A] pathway generates inflammatory [ENTITY_B], while the 5-LOX pathway generates inflammatory leukotrienes.",PRODUCT-OF,CPR:9,4,"The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes."
"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the << 5-LOX >> inhibitor [[ REV 5901 ]]; and the 5-LOX activating protein (FLAP) inhibitor MK-886.","They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the [ENTITY_A] inhibitor [ENTITY_B]; and the 5-LOX activating protein (FLAP) inhibitor MK-886.",INHIBITOR,CPR:4,1,"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886."
"Additionally, << MPTP >> significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in [[ Bax ]] expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment.","Additionally, [ENTITY_A] significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in [ENTITY_B] expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment.",INDIRECT-UPREGULATOR,CPR:3,0,"Additionally, MPTP significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment."
"Additionally, << MPTP >> significantly down-regulated [[ Bcl-2 ]] expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment.","Additionally, [ENTITY_A] significantly down-regulated [ENTITY_B] expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Additionally, MPTP significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment."
Add-on therapy with the << DPP-4 >> inhibitor [[ sitagliptin ]] improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.,Add-on therapy with the [ENTITY_A] inhibitor [ENTITY_B] improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.,INHIBITOR,CPR:4,1,Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
"The << hemoglobin A1c >> (HbA1c) of all patients improved significantly from 8.1±1.2% to 7.6±1.1% after 12 weeks of add-on therapy with [[ sitagliptin ]] (p<0.01), and the insulin dosage was reduced from 27.3±15.8 U/day to 24.5±16.5 U/day (p<0.001).","The [ENTITY_A] (HbA1c) of all patients improved significantly from 8.1±1.2% to 7.6±1.1% after 12 weeks of add-on therapy with [ENTITY_B] (p<0.01), and the insulin dosage was reduced from 27.3±15.8 U/day to 24.5±16.5 U/day (p<0.001).",INDIRECT-UPREGULATOR,CPR:3,0,"The hemoglobin A1c (HbA1c) of all patients improved significantly from 8.1±1.2% to 7.6±1.1% after 12 weeks of add-on therapy with sitagliptin (p<0.01), and the insulin dosage was reduced from 27.3±15.8 U/day to 24.5±16.5 U/day (p<0.001)."
"In the present study, we have evaluated possible participation of << monocarboxylate transporters >> (MCTs) responsible for the bidirectional membrane transport of [[ pyruvate ]] in the cytoprotective property in osteoblasts.","In the present study, we have evaluated possible participation of [ENTITY_A] (MCTs) responsible for the bidirectional membrane transport of [ENTITY_B] in the cytoprotective property in osteoblasts.",SUBSTRATE,CPR:9,4,"In the present study, we have evaluated possible participation of monocarboxylate transporters (MCTs) responsible for the bidirectional membrane transport of pyruvate in the cytoprotective property in osteoblasts."
"<< Mammalian ALDH1B1 >>, another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing [[ acetaldehyde ]] but has a tissue distribution and pattern of activity distinct from that of ALDH2.","[ENTITY_A], another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing [ENTITY_B] but has a tissue distribution and pattern of activity distinct from that of ALDH2.",SUBSTRATE,CPR:9,4,"Mammalian ALDH1B1, another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing acetaldehyde but has a tissue distribution and pattern of activity distinct from that of ALDH2."
"<< Aspirin >> (ASA) and other non-steroidal anti-inflammatory drugs, which are [[ cyclooxygenase ]] (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.","[ENTITY_A] (ASA) and other non-steroidal anti-inflammatory drugs, which are [ENTITY_B] (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.",INHIBITOR,CPR:4,1,"Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients."
"However, salicylate moiety appears to interfere with << aspirin >> inhibitory action on platelets and vascular [[ COX ]].","However, salicylate moiety appears to interfere with [ENTITY_A] inhibitory action on platelets and vascular [ENTITY_B].",INHIBITOR,CPR:4,1,"However, salicylate moiety appears to interfere with aspirin inhibitory action on platelets and vascular COX."
"Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between << salicylate >> and ASA on [[ cyclo-oxygenase ]] locus in the respiratory tract in ASA-intolerant patients.","Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between [ENTITY_A] and ASA on [ENTITY_B] locus in the respiratory tract in ASA-intolerant patients.",INHIBITOR,CPR:4,1,"Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between salicylate and ASA on cyclo-oxygenase locus in the respiratory tract in ASA-intolerant patients."
<< Minocycline >> inhibits [[ cytochrome c ]] release and delays progression of amyotrophic lateral sclerosis in mice.,[ENTITY_A] inhibits [ENTITY_B] release and delays progression of amyotrophic lateral sclerosis in mice.,INDIRECT-DOWNREGULATOR,CPR:4,1,Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice.
We find that << minocycline >> inhibits mitochondrial permeability-transition-mediated [[ cytochrome c ]] release.,We find that [ENTITY_A] inhibits mitochondrial permeability-transition-mediated [ENTITY_B] release.,INDIRECT-DOWNREGULATOR,CPR:4,1,We find that minocycline inhibits mitochondrial permeability-transition-mediated cytochrome c release.
"<< Minocycline >>-mediated inhibition of [[ cytochrome c ]] release is demonstrated in vivo, in cells, and in isolated mitochondria.","[ENTITY_A]-mediated inhibition of [ENTITY_B] release is demonstrated in vivo, in cells, and in isolated mitochondria.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Minocycline-mediated inhibition of cytochrome c release is demonstrated in vivo, in cells, and in isolated mitochondria."
"Here we studied the effects of the recently developed << monoacylglycerol lipase >> inhibitor [[ JZL184 ]] on basal and stress-induced corticosterone levels in male CD1 mice, and found that this compound dramatically increased basal levels without affecting stress responses.","Here we studied the effects of the recently developed [ENTITY_A] inhibitor [ENTITY_B] on basal and stress-induced corticosterone levels in male CD1 mice, and found that this compound dramatically increased basal levels without affecting stress responses.",INHIBITOR,CPR:4,1,"Here we studied the effects of the recently developed monoacylglycerol lipase inhibitor JZL184 on basal and stress-induced corticosterone levels in male CD1 mice, and found that this compound dramatically increased basal levels without affecting stress responses."
"Considerable attention has focused on the antitumor effect of << histone deacetylase >> inhibitor ([[ Trichostatin A ]], TSA) as well as the coding gene expression-induced apoptosis of cancer cells.","Considerable attention has focused on the antitumor effect of [ENTITY_A] inhibitor ([ENTITY_B], TSA) as well as the coding gene expression-induced apoptosis of cancer cells.",INHIBITOR,CPR:4,1,"Considerable attention has focused on the antitumor effect of histone deacetylase inhibitor (Trichostatin A, TSA) as well as the coding gene expression-induced apoptosis of cancer cells."
"Among these differentially expressed lncRNAs, the greatest change was noted for << uc002mbe.2 >>, which had more than 300 folds induction upon [[ TSA ]] treatment.","Among these differentially expressed lncRNAs, the greatest change was noted for [ENTITY_A], which had more than 300 folds induction upon [ENTITY_B] treatment.",INDIRECT-UPREGULATOR,CPR:3,0,"Among these differentially expressed lncRNAs, the greatest change was noted for uc002mbe.2, which had more than 300 folds induction upon TSA treatment."
<< TSA >> selectively induced [[ uc002mbe.2 ]] in four studied HCC cell lines.,[ENTITY_A] selectively induced [ENTITY_B] in four studied HCC cell lines.,INDIRECT-UPREGULATOR,CPR:3,0,TSA selectively induced uc002mbe.2 in four studied HCC cell lines.
The << TSA >>-induced [[ uc002mbe.2 ]] expression was positively correlated with the apoptotic effect of TSA in HCC cells.,The [ENTITY_A]-induced [ENTITY_B] expression was positively correlated with the apoptotic effect of TSA in HCC cells.,INDIRECT-UPREGULATOR,CPR:3,0,The TSA-induced uc002mbe.2 expression was positively correlated with the apoptotic effect of TSA in HCC cells.
"<< Orlistat >>, a new [[ lipase ]] inhibitor for the management of obesity.","[ENTITY_A], a new [ENTITY_B] inhibitor for the management of obesity.",INHIBITOR,CPR:4,1,"Orlistat, a new lipase inhibitor for the management of obesity."
"<< Orlistat >> treatment also results in modest improvements in total cholesterol, [[ low-density lipoprotein ]], blood pressure, and fasting glucose and insulin concentrations.","[ENTITY_A] treatment also results in modest improvements in total cholesterol, [ENTITY_B], blood pressure, and fasting glucose and insulin concentrations.",INDIRECT-UPREGULATOR,CPR:3,0,"Orlistat treatment also results in modest improvements in total cholesterol, low-density lipoprotein, blood pressure, and fasting glucose and insulin concentrations."
"Evidence has accumulated in the last few years that the expression of the << microsomal/peroxidase antigen >> (M/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular [[ cAMP ]] accumulation and protein synthesis.","Evidence has accumulated in the last few years that the expression of the [ENTITY_A] (M/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular [ENTITY_B] accumulation and protein synthesis.",UPREGULATOR,CPR:3,0,"Evidence has accumulated in the last few years that the expression of the microsomal/peroxidase antigen (M/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular cAMP accumulation and protein synthesis."
TSH and << cAMP >> also increase the levels of the specific mRNA for [[ TPO ]] in thyroid cells from different species.,TSH and [ENTITY_A] also increase the levels of the specific mRNA for [ENTITY_B] in thyroid cells from different species.,INDIRECT-UPREGULATOR,CPR:3,0,TSH and cAMP also increase the levels of the specific mRNA for TPO in thyroid cells from different species.
A novel << benzo[d]imidazole >> derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of [[ NLRP3 ]] inflammasome.,A novel [ENTITY_A] derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of [ENTITY_B] inflammasome.,INHIBITOR,CPR:4,1,A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome.
"In addition, the disease activity index, histopathologic scores and << myeloperoxidase >> activity were also significantly reduced by [[ Fc11a-2 ]] treatment.","In addition, the disease activity index, histopathologic scores and [ENTITY_A] activity were also significantly reduced by [ENTITY_B] treatment.",INHIBITOR,CPR:4,1,"In addition, the disease activity index, histopathologic scores and myeloperoxidase activity were also significantly reduced by Fc11a-2 treatment."
"Moreover, protein and mRNA levels of DSS-induced proinflammatory << cytokines >> in colon, including TNF-α, IL-1β, IL-18, IL-17A and IFN-γ, were markedly suppressed by [[ Fc11a-2 ]].","Moreover, protein and mRNA levels of DSS-induced proinflammatory [ENTITY_A] in colon, including TNF-α, IL-1β, IL-18, IL-17A and IFN-γ, were markedly suppressed by [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-α, IL-1β, IL-18, IL-17A and IFN-γ, were markedly suppressed by Fc11a-2."
"Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of << caspase-1 >> in peritoneal macrophages were detected in [[ Fc11a ]]-2-treated mice.","Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of [ENTITY_A] in peritoneal macrophages were detected in [ENTITY_B]-2-treated mice.",INHIBITOR,CPR:4,1,"Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice."
"The mechanism of action of << Fc11a-2 >> was related to the inhibition of the cleavage of [[ pro-caspase-1 ]], pro-IL-1β and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome.","The mechanism of action of [ENTITY_A] was related to the inhibition of the cleavage of [ENTITY_B], pro-IL-1β and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The mechanism of action of Fc11a-2 was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1β and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome."
"Taken together, our results demonstrate the ability of << Fc11a-2 >> to inhibit [[ NLRP3 ]] inflammasome activation and its potential use in the treatment of inflammatory bowel diseases.","Taken together, our results demonstrate the ability of [ENTITY_A] to inhibit [ENTITY_B] inflammasome activation and its potential use in the treatment of inflammatory bowel diseases.",INHIBITOR,CPR:4,1,"Taken together, our results demonstrate the ability of Fc11a-2 to inhibit NLRP3 inflammasome activation and its potential use in the treatment of inflammatory bowel diseases."
"At PND35, the medial prefrontal cortex (mPFC) of rats given << MPH >> showed 55% greater immunoreactivity (-ir) for the catecholamine marker [[ tyrosine hydroxylase ]] (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density.","At PND35, the medial prefrontal cortex (mPFC) of rats given [ENTITY_A] showed 55% greater immunoreactivity (-ir) for the catecholamine marker [ENTITY_B] (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density.",INDIRECT-UPREGULATOR,CPR:3,0,"At PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density."
"At PND35, the medial prefrontal cortex (mPFC) of rats given << MPH >> showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less [[ norepinephrine transporter ]] (NET)-ir density.","At PND35, the medial prefrontal cortex (mPFC) of rats given [ENTITY_A] showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less [ENTITY_B] (NET)-ir density.",INDIRECT-DOWNREGULATOR,CPR:4,1,"At PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density."
"In hippocampal dentate gyrus, << MPH >>-receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of [[ neural cell adhesion molecule ]]).","In hippocampal dentate gyrus, [ENTITY_A]-receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of [ENTITY_B]).",INDIRECT-UPREGULATOR,CPR:3,0,"In hippocampal dentate gyrus, MPH-receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule)."
"In hippocampal dentate gyrus, << MPH >>-receiving rats showed a 51% decrease in [[ NET ]]-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule).","In hippocampal dentate gyrus, [ENTITY_A]-receiving rats showed a 51% decrease in [ENTITY_B]-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule).",INDIRECT-DOWNREGULATOR,CPR:4,1,"In hippocampal dentate gyrus, MPH-receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule)."
"In medial striatum, TH-ir decreased by 21%, and in hypothalamus << neuropeptide Y >>-ir increased by 10% in [[ MPH ]]-exposed rats.","In medial striatum, TH-ir decreased by 21%, and in hypothalamus [ENTITY_A]-ir increased by 10% in [ENTITY_B]-exposed rats.",INDIRECT-UPREGULATOR,CPR:3,0,"In medial striatum, TH-ir decreased by 21%, and in hypothalamus neuropeptide Y-ir increased by 10% in MPH-exposed rats."
"In medial striatum, << TH >>-ir decreased by 21%, and in hypothalamus neuropeptide Y-ir increased by 10% in [[ MPH ]]-exposed rats.","In medial striatum, [ENTITY_A]-ir decreased by 21%, and in hypothalamus neuropeptide Y-ir increased by 10% in [ENTITY_B]-exposed rats.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In medial striatum, TH-ir decreased by 21%, and in hypothalamus neuropeptide Y-ir increased by 10% in MPH-exposed rats."
